0000950170-22-005219.txt : 20220331 0000950170-22-005219.hdr.sgml : 20220331 20220331163317 ACCESSION NUMBER: 0000950170-22-005219 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 178 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Connect Biopharma Holdings Ltd CENTRAL INDEX KEY: 0001835268 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-40212 FILM NUMBER: 22793247 BUSINESS ADDRESS: STREET 1: SCIENCE & TECH PARK, EAST R&D BLDG, 3 FL STREET 2: EAST R&D BUILDING, 3RD FLOOR CITY: 6 BEIJING WEST ROAD, TAICANG STATE: F4 ZIP: 215400 BUSINESS PHONE: 86 512 5357 7866 MAIL ADDRESS: STREET 1: SCIENCE & TECH PARK, EAST R&D BLDG, 3 FL STREET 2: EAST R&D BUILDING, 3RD FLOOR CITY: 6 BEIJING WEST ROAD, TAICANG STATE: F4 ZIP: 215400 20-F 1 cntb-20211231.htm 20-F 20-F
falsenonono0001835268FY--12-31nonono0001835268cntb:OfficeEquipmentFurnitureAndOthersMemberifrs-full:GrossCarryingAmountMember2020-12-310001835268ifrs-full:SharePremiumMember2018-12-310001835268cntb:IssuedCapitalAndSharePremiumMember2021-01-012021-12-310001835268ifrs-full:CurrencyRiskMember2021-12-310001835268cntb:DiscountRateForLackOfMarketabilityMeasurementInputMemberifrs-full:TopOfRangeMembercntb:FinancialInstrumentsWithPreferredRightsMember2020-12-310001835268ifrs-full:LeaseLiabilitiesMember2020-01-012020-12-310001835268ifrs-full:ForeignCountriesMember2020-12-310001835268ifrs-full:ParentMember2019-01-012019-12-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMembercntb:OfficeEquipmentFurnitureAndOthersMember2021-12-310001835268ifrs-full:ConstructionInProgressMember2021-12-310001835268country:HK2021-01-012021-12-310001835268ifrs-full:FinancialAssetsAtFairValueMember2020-12-310001835268cntb:ConnectUSMemberstpr:CA2021-01-012021-12-310001835268cntb:IssuedCapitalAndSharePremiumMember2020-01-012020-12-310001835268ifrs-full:CreditRiskMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2021-12-310001835268cntb:LandUseRightsMember2021-12-310001835268cntb:AdministrativeExpensesMember2021-01-012021-12-3100018352682021-03-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMembercntb:LaboratoryEquipmentMember2021-12-310001835268ifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-12-310001835268country:UScntb:ConnectHKMember2019-01-012019-12-310001835268cntb:OtherReceivablesMember2020-12-310001835268cntb:ShanghaiConnectBiopharmaceuticalsLimitedMember2021-01-012021-12-310001835268ifrs-full:OrdinarySharesMembercntb:ConnectUnionMember2021-12-310001835268ifrs-full:GrossCarryingAmountMembercntb:LaboratoryEquipmentMember2021-12-310001835268ifrs-full:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001835268cntb:OtherPayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-12-310001835268ifrs-full:CreditRiskMember2020-12-310001835268ifrs-full:OtherReservesMember2021-01-012021-12-310001835268cntb:RiskFreeInterestRateMeasurementInputMemberifrs-full:TopOfRangeMembercntb:FinancialInstrumentsWithPreferredRightsMember2020-12-310001835268cntb:WealthManagementProductsMember2020-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMemberifrs-full:BottomOfRangeMember2019-12-310001835268cntb:SharePurchaseAgreementMembercntb:SeriesCPreferredSharesMember2020-08-012020-08-310001835268ifrs-full:AccumulatedOtherComprehensiveIncomeMember2019-12-3100018352682021-03-122021-03-120001835268cntb:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostMember2021-12-310001835268cntb:HangzhouTigermedConsultingCompanyLimitedMember2020-01-012020-12-310001835268ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001835268cntb:AfterShareConsolidationMember2021-12-310001835268ifrs-full:ParentMember2020-01-012020-12-310001835268cntb:ConnectUSMember2019-01-012019-12-310001835268cntb:LaboratoryEquipmentMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001835268stpr:CA2021-12-310001835268cntb:ResearchAndDevelopmentExpensesMember2019-01-012019-12-310001835268ifrs-full:OrdinarySharesMembercntb:ConnectUnionMember2018-12-200001835268ifrs-full:GrossCarryingAmountMembercntb:LaboratoryEquipmentMember2020-12-310001835268cntb:ConnectAUMember2021-01-012021-12-310001835268cntb:SharePurchaseAgreementMember2020-01-012020-12-310001835268ifrs-full:AccumulatedOtherComprehensiveIncomeMember2018-12-310001835268ifrs-full:CreditRiskMember2021-12-310001835268ifrs-full:OtherReservesMember2020-12-310001835268ifrs-full:Level3OfFairValueHierarchyMember2021-01-012021-12-310001835268country:CN2020-12-310001835268ifrs-full:OrdinarySharesMembercntb:CoFoundersMember2021-12-310001835268ifrs-full:IssuedCapitalMember2020-12-310001835268cntb:LaboratoryEquipmentMember2021-12-310001835268cntb:TwentyTwentyOneStockIncentivePlanMember2021-01-012021-12-3100018352682020-12-310001835268ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2021-12-310001835268country:AUcntb:ConnectAUMember2020-01-012020-12-310001835268ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2020-12-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMember2021-12-310001835268cntb:SeriesAPreferredSharesMember2021-12-310001835268cntb:OfficeEquipmentFurnitureAndOthersMember2021-01-012021-12-310001835268ifrs-full:SharePremiumMember2019-12-310001835268cntb:SeriesBFinancingMemberifrs-full:OrdinarySharesMembercntb:CoFoundersMember2018-12-200001835268ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2019-12-3100018352682021-03-120001835268cntb:RiskFreeInterestRateMeasurementInputMembercntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:PreferenceSharesMember2020-01-012020-12-310001835268ifrs-full:ConstructionInProgressMember2020-12-310001835268ifrs-full:ConstructionInProgressMember2020-01-012020-12-310001835268ifrs-full:LeaseLiabilitiesMember2018-12-3100018352682021-05-012021-05-310001835268cntb:TwentyTwentyOneEmployeeSharePurchasePlanMember2021-01-012021-12-310001835268cntb:OfficeRentMember2020-12-310001835268ifrs-full:BottomOfRangeMember2019-01-012019-12-310001835268cntb:CashAndCashEquivalentMember2021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2020-12-310001835268ifrs-full:LeaseLiabilitiesMember2019-01-012019-12-310001835268ifrs-full:TreasurySharesMember2021-01-012021-12-310001835268ifrs-full:ParentMember2021-01-012021-12-310001835268ifrs-full:SharePremiumMember2021-12-3100018352682021-03-192021-03-190001835268ifrs-full:GrossCarryingAmountMembercntb:LaboratoryEquipmentMember2019-12-310001835268country:CN2020-01-012020-12-310001835268cntb:AdministrativeExpensesMember2020-01-012020-12-310001835268cntb:LaboratoryEquipmentMember2020-01-012020-12-310001835268country:HK2019-01-012019-12-310001835268country:US2020-12-310001835268ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2020-12-310001835268ifrs-full:FinancialLiabilitiesAtFairValueMember2020-12-310001835268cntb:HangzhouTigermedConsultingCompanyLimitedMember2020-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2020-01-012020-12-310001835268ifrs-full:LeaseholdImprovementsMember2021-01-012021-12-310001835268cntb:OfficeEquipmentAndFurnitureMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001835268cntb:LaboratoryEquipmentMember2020-12-310001835268ifrs-full:OrdinarySharesMember2019-12-310001835268ifrs-full:OtherReservesMember2020-01-012020-12-310001835268cntb:RiskFreeInterestRateMeasurementInputMembercntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:PreferenceSharesMember2020-12-310001835268country:HK2018-04-012018-04-010001835268cntb:FrontageLaboratoriesSuzhouCompanyLimitedMember2020-01-012020-12-310001835268cntb:DiscountRateForLackOfMarketabilityMeasurementInputMemberifrs-full:TopOfRangeMembercntb:FinancialInstrumentsWithPreferredRightsMember2019-12-310001835268ifrs-full:LeaseholdImprovementsMember2021-12-310001835268ifrs-full:OrdinarySharesMember2018-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMemberifrs-full:PreferenceSharesMember2020-12-310001835268cntb:SharePurchaseAgreementMembercntb:SeriesCPreferredSharesMember2020-12-010001835268country:AU2020-12-310001835268cntb:OtherPayablesMember2020-12-3100018352682020-01-012020-12-310001835268cntb:CoFoundersMember2020-01-012020-12-310001835268cntb:OfficeRentMember2021-12-310001835268ifrs-full:GrossCarryingAmountMember2020-12-310001835268cntb:RiskFreeInterestRateMeasurementInputMemberifrs-full:TopOfRangeMembercntb:FinancialInstrumentsWithPreferredRightsMember2019-12-310001835268stpr:CA2021-12-012021-12-310001835268ifrs-full:LeaseLiabilitiesMember2021-01-012021-12-310001835268ifrs-full:ReserveOfSharebasedPaymentsMember2021-12-310001835268ifrs-full:IssuedCapitalMember2020-01-012020-12-310001835268ifrs-full:OtherReservesMember2021-12-310001835268ifrs-full:NotLaterThanOneYearMemberifrs-full:CreditRiskMember2021-12-310001835268ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMemberifrs-full:CreditRiskMember2020-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2019-12-310001835268ifrs-full:GrossCarryingAmountMembercntb:OfficeEquipmentFurnitureAndOthersMember2021-12-310001835268cntb:LaboratoryEquipmentMember2021-01-012021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2021-01-012021-12-310001835268ifrs-full:OtherReservesMember2019-01-012019-12-310001835268ifrs-full:BottomOfRangeMember2021-12-310001835268cntb:SharePurchaseAgreementMembercntb:SeriesCPreferredSharesMember2020-11-302020-12-010001835268cntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:FinancialLiabilitiesAtFairValueMember2020-12-310001835268cntb:OtherPayablesMember2021-12-3100018352682018-12-310001835268ifrs-full:OrdinarySharesMember2021-03-310001835268cntb:DiscountRateForLackOfMarketabilityMeasurementInputMembercntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:BottomOfRangeMember2019-12-310001835268ifrs-full:ReserveOfSharebasedPaymentsMember2020-12-310001835268cntb:OfficeEquipmentFurnitureAndOthersMember2020-12-310001835268cntb:SeriesCPreferredSharesMembercntb:CoFoundersMember2021-03-310001835268ifrs-full:TopOfRangeMember2021-12-310001835268ifrs-full:RecurringFairValueMeasurementMember2020-12-310001835268cntb:HangzhouSimoCompanyLimitedMember2020-12-310001835268cntb:SeriesAPreferredSharesMember2021-01-012021-12-310001835268cntb:BeijingMedicalDevelopmentSuzhouCompanyLimitedMember2019-01-012019-12-310001835268ifrs-full:OrdinarySharesMembercntb:CoFoundersMember2020-01-202020-01-200001835268ifrs-full:AccumulatedDepreciationAndAmortisationMembercntb:OfficeEquipmentFurnitureAndOthersMember2019-12-3100018352682021-12-310001835268ifrs-full:IssuedCapitalMember2021-01-012021-12-310001835268country:AU2021-12-310001835268ifrs-full:LeaseholdImprovementsMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001835268cntb:SeriesPreAPreferredSharesMember2021-01-012021-12-310001835268country:CN2019-01-012019-12-310001835268ifrs-full:LeaseLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-12-310001835268ifrs-full:BottomOfRangeMember2021-01-012021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:PreferenceSharesMember2021-01-012021-12-310001835268cntb:EquipmentAndIntangibleAssetsMember2020-12-310001835268ifrs-full:ParentMember2021-12-310001835268ifrs-full:ReserveOfSharebasedPaymentsMember2021-01-012021-12-310001835268cntb:ShanghaiTigermedConsultingCompanyLimitedMember2019-01-012019-12-310001835268cntb:TwoThousandNineteenStockIncentivePlanMember2021-01-012021-12-310001835268ifrs-full:ConstructionInProgressMember2021-01-012021-12-310001835268ifrs-full:OrdinarySharesMembercntb:CoFoundersMember2019-01-012019-12-310001835268ifrs-full:SharePremiumMember2019-01-012019-12-310001835268ifrs-full:OrdinarySharesMember2021-01-012021-12-310001835268ifrs-full:BottomOfRangeMember2020-12-310001835268ifrs-full:CreditRiskMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2020-12-310001835268ifrs-full:SharePremiumMember2020-01-012020-12-310001835268ifrs-full:ReserveOfSharebasedPaymentsMember2020-01-012020-12-310001835268ifrs-full:ParentMember2018-12-310001835268ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2021-12-310001835268ifrs-full:TopOfRangeMembercntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2020-12-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2020-12-310001835268cntb:TwentyTwentyOneEmployeeSharePurchasePlanMember2021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:PreferenceSharesMember2021-03-180001835268ifrs-full:FinancialAssetsAtFairValueMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2020-12-310001835268ifrs-full:Level3OfFairValueHierarchyMember2019-01-012019-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2020-12-310001835268ifrs-full:TreasurySharesMember2020-12-310001835268cntb:HangzhouTigermedConsultingCompanyLimitedMember2019-01-012019-12-310001835268cntb:IssuedCapitalAndSharePremiumMember2019-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2020-01-012020-12-310001835268cntb:LaboratoryEquipmentMember2019-12-310001835268ifrs-full:ParentMember2019-12-310001835268cntb:IssuedCapitalAndSharePremiumMember2020-12-310001835268cntb:OfficeEquipmentAndFurnitureMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001835268ifrs-full:TopOfRangeMember2020-12-310001835268ifrs-full:NotLaterThanOneYearMemberifrs-full:CreditRiskMember2020-12-310001835268cntb:ResearchAndDevelopmentExpensesMember2021-01-012021-12-310001835268dei:BusinessContactMember2021-01-012021-12-310001835268ifrs-full:TopOfRangeMembercntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2019-12-310001835268ifrs-full:LeaseholdImprovementsMember2019-12-310001835268ifrs-full:GrossCarryingAmountMembercntb:OfficeEquipmentFurnitureAndOthersMember2019-12-310001835268cntb:IssuedCapitalAndSharePremiumMember2021-12-310001835268cntb:TradePayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-12-310001835268cntb:SharePurchaseAgreementMembercntb:SeriesCPreferredSharesMember2020-08-310001835268cntb:EquipmentAndImprovementMembercntb:SuzhouMember2020-12-310001835268cntb:ConnectUSMember2020-01-012020-12-310001835268cntb:SeriesBPreferredSharesMembercntb:FinancialInstrumentsWithPreferredRightsMember2021-01-012021-12-310001835268cntb:TradePayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-12-310001835268cntb:BeijingConnectBiopharmaceuticalsLimitedMember2021-01-012021-12-310001835268ifrs-full:LeaseLiabilitiesMember2020-12-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMembercntb:OfficeEquipmentFurnitureAndOthersMember2020-12-310001835268ifrs-full:ReserveOfSharebasedPaymentsMember2019-01-012019-12-310001835268ifrs-full:ReserveOfSharebasedPaymentsMember2018-12-310001835268ifrs-full:OrdinarySharesMembercntb:CoFoundersMember2020-01-200001835268cntb:RiskFreeInterestRateMeasurementInputMembercntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:BottomOfRangeMember2019-12-310001835268ifrs-full:TopOfRangeMember2021-01-012021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:PreferenceSharesMember2021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2019-01-012019-12-310001835268cntb:ConnectUSMemberstpr:CA2019-01-012019-12-310001835268ifrs-full:TreasurySharesMember2018-12-310001835268ifrs-full:TopOfRangeMember2020-01-012020-12-310001835268cntb:HangzhouSimoCompanyLimitedMember2020-01-012020-12-310001835268cntb:IssuedCapitalAndSharePremiumMember2019-01-012019-12-310001835268country:AUcntb:ConnectAUMember2021-01-012021-12-310001835268ifrs-full:OtherReservesMember2018-12-310001835268cntb:SeriesBPreferredSharesMember2021-01-012021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2018-12-310001835268cntb:TradePayablesMember2020-12-310001835268cntb:OfficeRentMember2019-01-012019-12-310001835268cntb:OtherReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostMember2020-12-310001835268ifrs-full:TopOfRangeMembercntb:LaboratoryEquipmentMember2021-01-012021-12-310001835268ifrs-full:LeaseLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-12-310001835268ifrs-full:ComputerSoftwareMember2021-01-012021-12-310001835268ifrs-full:FinancialAssetsAtAmortisedCostMember2020-12-310001835268cntb:OtherReceivablesMember2021-12-310001835268ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2019-12-310001835268cntb:RiskFreeInterestRateMeasurementInputMembercntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:BottomOfRangeMember2020-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2018-12-310001835268cntb:HangzhouSimoCompanyLimitedMember2019-01-012019-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2021-12-310001835268cntb:OfficeEquipmentFurnitureAndOthersMember2019-12-310001835268cntb:OfficeRentMember2019-12-310001835268country:HK2020-01-012020-12-310001835268ifrs-full:ParentMember2020-12-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2021-12-310001835268ifrs-full:LeaseLiabilitiesMember2019-12-310001835268country:CN2021-01-012021-12-310001835268ifrs-full:IssuedCapitalMember2021-12-310001835268cntb:AdministrativeExpensesMember2019-01-012019-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMemberifrs-full:BottomOfRangeMember2020-12-310001835268cntb:OfficeEquipmentFurnitureAndOthersMember2020-01-012020-12-310001835268ifrs-full:Level3OfFairValueHierarchyMember2020-01-012020-12-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMembercntb:LaboratoryEquipmentMember2020-12-310001835268cntb:IssuedCapitalAndSharePremiumMember2018-12-310001835268cntb:SeriesBPreferredSharesMember2021-12-310001835268cntb:DiscountRateForLackOfMarketabilityMeasurementInputMembercntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:BottomOfRangeMember2020-12-310001835268cntb:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostMember2020-12-310001835268ifrs-full:OrdinarySharesMember2021-03-012021-03-310001835268cntb:EquipmentAndImprovementMember2020-12-310001835268cntb:TradePayablesMember2021-12-310001835268ifrs-full:OrdinarySharesMember2020-01-012020-12-310001835268ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001835268cntb:ConnectUSMemberstpr:CA2020-01-012020-12-310001835268ifrs-full:LeaseholdImprovementsMember2020-01-012020-12-310001835268ifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-12-310001835268ifrs-full:TreasurySharesMember2021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:PreferenceSharesMemberifrs-full:BottomOfRangeMember2021-12-310001835268ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-12-310001835268country:UScntb:ConnectHKMember2020-01-012020-12-3100018352682019-01-012019-12-310001835268cntb:EquipmentAndIntangibleAssetsMember2021-12-310001835268ifrs-full:FinancialAssetsAtAmortisedCostMember2021-12-310001835268ifrs-full:OtherReservesMember2019-12-310001835268ifrs-full:SharePremiumMember2021-01-012021-12-310001835268cntb:SeriesCPreferredSharesMember2021-12-3100018352682020-04-012020-04-300001835268ifrs-full:GrossCarryingAmountMember2019-12-310001835268ifrs-full:TreasurySharesMember2020-01-012020-12-310001835268cntb:SeriesCPreferredSharesMember2020-12-310001835268cntb:ShanghaiTigermedConsultingCompanyLimitedMember2020-01-012020-12-310001835268cntb:SeriesAPreferredSharesMembercntb:FinancialInstrumentsWithPreferredRightsMember2021-01-012021-12-3100018352682021-01-012021-12-310001835268cntb:OfficeRentMember2020-01-012020-12-310001835268cntb:OtherPayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2019-12-310001835268cntb:CashAndCashEquivalentMember2020-12-310001835268ifrs-full:IssuedCapitalMember2019-12-310001835268cntb:ConnectUSMember2021-01-012021-12-310001835268country:CN2021-12-3100018352682021-03-012021-03-310001835268country:US2021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMembercntb:SeriesCPreferredSharesMember2021-01-012021-12-310001835268ifrs-full:Level3OfFairValueHierarchyMember2020-12-3100018352682018-12-192018-12-200001835268cntb:ConnectSzMember2021-01-012021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2021-01-012021-12-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMembercntb:LaboratoryEquipmentMember2019-12-310001835268ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001835268country:AUcntb:ConnectAUMember2019-01-012019-12-310001835268ifrs-full:LeaseholdImprovementsMember2020-12-310001835268cntb:LandUseRightsMember2021-01-012021-12-310001835268ifrs-full:CurrencyRiskMember2020-12-310001835268cntb:SeriesCPreferredSharesMember2021-01-012021-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMember2019-01-012019-12-310001835268cntb:OfficeRentMember2018-12-310001835268cntb:SeriesPreAPreferredSharesMember2021-12-310001835268ifrs-full:IssuedCapitalMember2018-12-310001835268cntb:FinancialInstrumentsWithPreferredRightsMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMemberifrs-full:PreferenceSharesMember2020-01-012020-12-310001835268cntb:OfficeRentMember2021-01-012021-12-310001835268cntb:ConnectHKMember2021-01-012021-12-310001835268ifrs-full:LeaseholdImprovementsMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001835268ifrs-full:BottomOfRangeMember2020-01-012020-12-310001835268cntb:OfficeEquipmentFurnitureAndOthersMember2021-12-310001835268ifrs-full:ReserveOfSharebasedPaymentsMember2019-12-310001835268ifrs-full:ForeignCountriesMember2021-12-310001835268cntb:FrontageLaboratoriesSuzhouCompanyLimitedMember2019-01-012019-12-310001835268ifrs-full:Level3OfFairValueHierarchyMember2018-12-310001835268country:HKifrs-full:BottomOfRangeMember2018-04-012018-04-010001835268ifrs-full:OrdinarySharesMembercntb:ConnectUnionMember2020-01-200001835268cntb:FinancialInstrumentsWithPreferredRightsMember2020-12-310001835268ifrs-full:LeaseLiabilitiesMember2021-12-310001835268ifrs-full:GrossCarryingAmountMember2021-12-310001835268ifrs-full:OrdinarySharesMember2021-12-310001835268cntb:AfterShareConsolidationMember2020-12-310001835268cntb:CoFoundersMember2021-01-012021-12-310001835268ifrs-full:MajorOrdinaryShareTransactionsMember2022-01-012022-03-310001835268cntb:ResearchAndDevelopmentExpensesMember2020-01-012020-12-310001835268cntb:BeijingMedicalDevelopmentSuzhouCompanyLimitedMember2020-01-012020-12-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMember2020-12-310001835268ifrs-full:TopOfRangeMember2019-01-012019-12-310001835268ifrs-full:AccumulatedDepreciationAndAmortisationMember2019-12-310001835268ifrs-full:Level3OfFairValueHierarchyMember2019-12-310001835268ifrs-full:TreasurySharesMember2019-12-310001835268ifrs-full:OrdinarySharesMember2020-12-3100018352682019-12-310001835268ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-12-310001835268ifrs-full:SharePremiumMember2020-12-310001835268cntb:ConnectUSMember2021-01-012021-12-310001835268cntb:OtherReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostMember2021-12-310001835268cntb:ShenzhenConnectBiopharmaceuticalsLimitedMember2021-01-012021-12-310001835268ifrs-full:OrdinarySharesMember2021-03-120001835268cntb:CoFoundersMember2019-01-012019-12-310001835268ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2020-12-310001835268ifrs-full:GovernmentMember2021-01-012021-12-31xbrli:pureutr:sqftxbrli:sharescntb:Segmentiso4217:HKDiso4217:CNYiso4217:USDxbrli:sharesiso4217:CNYiso4217:USDutr:Yiso4217:USDiso4217:CNYxbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

 

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021 OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of event requiring this shell company report

For the transition period from to

Commission file number 001-40212

Connect Biopharma Holdings Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Cayman Islands

(Jurisdiction of incorporation or organization)

Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu, The People’s Republic of China 215400

(Address of principal executive offices)

Dr. Zheng Wei

Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu, 215400

The People’s Republic of China

Tel: +86 512 5357 7866

Fax: +86 (21) 57940050

(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

 

 

 

 

 

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

American Depositary Shares, each representing one Ordinary Share,
par value $0.000174 per Share

 

CNTB

 

The Nasdaq Global Market

 

Securities registered or to be registered pursuant to Section 12(g) of the Act.

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.

None

(Title of Class)

 


 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

55,076,319 Ordinary Shares, par value $0.000174 per Share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or (15) (d) of the Securities Exchange Act of 1934. Yes ☐ No

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

 

 

 

 

 

 

Large Accelerated Filer

 

 

Accelerated Filer

 

 

 

 

 

Non-Accelerated Filer

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company that prepares its financial statements in accordance with U.S.GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.

The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

U.S. GAAP ☐

 

International Financial Reporting Standards as issued

by the International Accounting Standards Board ☒

 

Other ☐

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

 

 


 

 

Table of Contents

 

 

 

ABOUT THIS ANNUAL REPORT

1

 

PRESENTATION OF FINANCIAL INFORMATION

1

 

EXCHANGE RATES

1

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

2

 

PART I

4

 

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS.

4

 

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE.

4

 

ITEM 3. KEY INFORMATION.

4

 

A. [Reserved]

4

 

B. Capitalization and Indebtedness

4

 

C. Reasons for the Offer and Use of Proceeds

4

 

D. Risk Factors

4

 

ITEM 4. INFORMATION ON THE COMPANY.

79

 

A. History and Development of the Company

79

 

B. Business Overview

80

 

C. Organizational Structure

128

 

D. Property, Plants and Equipment

128

 

ITEM 4A. UNRESOLVED STAFF COMMENTS.

129

 

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS.

129

 

A. Operating Results

129

 

B. Liquidity and Capital Resources

136

 

C. Research, Development, Patents and Licenses, Etc.

140

 

D. Trend Information

140

 

E. Critical Accounting Estimates

140

 

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES.

141

 

A. Directors and Senior Management

141

 

B. Compensation

143

 

C. Board Practices

151

 

D. Employees

154

 

E. Share Ownership

155

 

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS.

156

 

A. Major Shareholders

156

 

B. Related Party Transactions

157

 

C. Interests of Experts and Counsel

160

 

ITEM 8. FINANCIAL INFORMATION.

161

 

A. Consolidated Statements and Other Financial Information

161

 

B. Significant Changes

161

 

ITEM 9. THE OFFER AND LISTING.

161

 

A. Offer and Listing Details

161

 

B. Plan of Distribution

161

 

C. Markets

162

 

D. Selling Shareholders

162

 

 

 


 

E. Dilution

162

 

F. Expenses of the Issuer

162

 

ITEM 10. ADDITIONAL INFORMATION.

162

 

A. Share Capital

162

 

B. Memorandum and Articles of Association

162

 

C. Material Contracts

168

 

D. Exchange Controls

169

 

E. Taxation

170

 

F. Dividends on Paying Agents

176

 

G. Statement by Experts

177

 

H. Documents on Display

177

 

I. Subsidiary Information

177

 

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

177

 

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.

178

 

PART II

180

 

ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.

180

 

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.

180

 

ITEM 15. CONTROLS AND PROCEDURES.

180

 

ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT.

181

 

ITEM 16B. CODE OF ETHICS.

181

 

ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

182

 

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES.

182

 

ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS.

182

 

ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT.

182

 

ITEM 16G. CORPORATE GOVERNANCE.

182

 

ITEM 16H. MINE SAFETY DISCLOSURE.

183

 

ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

183

 

PART III

184

 

ITEM 17. FINANCIAL STATEMENTS.

184

 

ITEM 18. FINANCIAL STATEMENTS.

184

 

ITEM 19. EXHIBITS.

185

 

INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS

F-1

 

 

 


 

ABOUT THIS ANNUAL REPORT

 

Except where the context otherwise requires or where otherwise indicated, references to “we” or “us” or “Company” are references to Connect Biopharma Holdings Limited, together with our direct and indirect wholly owned subsidiaries, Connect Biopharma HongKong Limited, Connect Biopharm LLC, Connect Biopharma Australia PTY LTD, Suzhou Connect Biopharma Co., Ltd., Connect Biopharma (Shanghai) Co., Ltd., Connect Biopharma (Beijing) Co., Ltd. and Connect Biopharma (Shenzhen) Co., Ltd.

 

PRESENTATION OF FINANCIAL INFORMATION

 

Our consolidated financial statements included in this annual report have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. None of our consolidated financial statements were prepared in accordance with U.S. GAAP. Our reporting currency is the renminbi. Unless otherwise indicated, all monetary amounts in this annual report are in renminbi. All references in this annual report to “$”, “US$”, “USD”, “U.S. dollars” and “dollars” mean U.S. dollars and all references to “¥” and “RMB” mean renminbi. This annual report contains translations of specific foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations from renminbi to U.S. dollars were made at RMB 6.3757 to $1.00, representing the exchange rate as of December 31, 2021 set forth in the China Foreign Exchange Trade System. We make no representation that the renminbi or U.S. dollar amounts referred to in this annual report could have been or could be converted into U.S. dollars or renminbi, as the case may be, at any particular rate or at all. On March 1, 2022, renminbi to U.S. dollars exchange rate was RMB 6.3014 to $1.00 in the China Foreign Exchange Trade System. We have made rounding adjustments to some of the figures included in this annual report. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.

 

TRADEMARKS, SERVICE MARKS AND TRADE NAMES

 

Solely for convenience, the trademarks, service marks, logos, copyrights and trade names referred to in this annual report are without the ® and ™ symbols. Such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks, logos, copyrights and trade names or that the applicable owner will not assert its rights to these trademarks, service marks, logos, copyrights and trade names. This annual report contains additional trademarks, service marks, logos, copyrights and trade names of others, which are the property of their respective owners. All trademarks, service marks, logos, copyrights and trade names appearing in this annual report are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies’ trademarks, service marks, logos, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

1


 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This annual report includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this annual report, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

 

In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this annual report include, but are not limited to, statements about:

the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;
the timing, progress, focus, and results of our ongoing and future preclinical studies and clinical trials, and the reporting and interpretation of data from those studies and trials;
our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;
the market opportunity and competitive landscape for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;
the success of competing therapies that are or may become available;
our estimates of the number and types of patients that we will enroll in our clinical trials;
the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;
the timing of initiation and completion, and the progress of our drug discovery and research programs;
the timing or likelihood of regulatory filings and approvals for our product candidates for various diseases;
our ability to obtain and maintain regulatory approval of our product candidates;
our plans relating to the further development of our product candidates, including additional indications we may pursue;
existing regulations and regulatory developments in the United States, The People's Republic of China (“PRC”), Europe and other jurisdictions;
risks associated with COVID-19 and other epidemic diseases, which have and may continue to materially and adversely impact our business, preclinical studies and clinical trials;
our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available;
our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;
our plans regarding, and our ability to enter into, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;
the need to hire additional personnel and our ability to attract and retain such personnel;
our plans regarding our growth and expanding our operations, including with respect to expanding our senior management team and constructing facilities;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
our financial performance;
the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;
our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and
our anticipated use of our existing resources.

 

2


 

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this annual report and are subject to a number of risks, uncertainties and assumptions described in the section titled “Item 3. Key Information – Risk Factors” and elsewhere in this annual report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this annual report, whether as a result of any new information, future events or otherwise.

 

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this annual report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.

3


 

PART I

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS.

Not applicable.

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE.

Not applicable.

ITEM 3. KEY INFORMATION.

A. [Reserved]

B. Capitalization and Indebtedness.

Not applicable.

C. Reasons for the Offer and Use of Proceeds.

Not applicable.

D. Risk Factors.

Summary of Risk Factors

An investment in our ADSs is subject to a number of risks, including risks related to doing business in the PRC, risks related to our limited operating history, financial position and capital requirements, risks related to the discovery, development and regulatory approval of our product candidates, risks related to our reliance on third parties, risks related to commercialization of our product candidates, risks related to our business operations and industry, risks related to intellectual property, and risks related to ownership of our ADSs. Investors should carefully consider all of the information in this annual report before making an investment in the ADSs. The following list summarizes some, but not all, of these risks. Please read the information in the section entitled “Risk Factors” for a more thorough description of these and other risks.

Risks Related to Doing Business in the PRC

We could be adversely affected by rising political tensions and any potential conflicts between the United States and the PRC.
Changes in the political and economic policies of the PRC government may materially and adversely affect our business, financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies.
The PRC government may intervene in or influence our operations at any time, which could result in a material change in our operations and significantly and adversely impact the value of our ADSs.
Our ADSs may be delisted and our ADSs and shares prohibited from trading in the over-the-counter market under the Holding Foreign Companies Accountable Act, or the HFCAA, if the PCAOB is unable to inspect or fully investigate auditors located in PRC. Under the current law, delisting and prohibition from over-the-counter trading in the U.S. could take place in 2024. If this happens there is no certainty that we will be able to list our ADSs or shares on a non-U.S. exchange or that a market for our shares will develop outside of the U.S. The delisting of our ADSs or prohibition from trading, or the threat of their being delisted or prohibited from trading, may materially and adversely affect the value of our ADSs.
On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act, which, if enacted, would amend the HFCAA and require the SEC to prohibit an issuer’s securities from trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three. This could have a material and adverse impact on the value of any investment in our ADSs.
Compliance with the PRC’s new Data Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme and any other future laws and regulations may entail significant expenses and could materially affect our business.

4


 

There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations.
The approval of a PRC governmental authority may be required under a PRC regulation in connection with any future offerings of our securities in the U.S. market. The regulation also establishes more complex procedures for acquisitions conducted by non-PRC investors that could make it more difficult for us to grow through acquisitions.
PRC government agencies may exert more oversight and control over offerings that are conducted overseas and non-PRC investment in PRC-based issuers. We face uncertainty about future actions by the PRC government that could significantly affect our ability to offer or continue to offer securities to investors and could significantly negatively affect the value of our ADSs.
Recent litigation, regulatory scrutiny and negative publicity surrounding PRC-based companies listed in the United States may result in increased regulatory scrutiny of us and negatively impact the trading price of our ADSs.
Our business benefits from financial incentives and discretionary policies granted by local governments in the PRC. Expiration, elimination or reduction of these incentives or policies would have an adverse effect on our results of operations.
We may be restricted from transferring our scientific data outside of the PRC.
Additional remedial measures could be imposed on PRC-based accounting firms, including our independent registered public accounting firm, in administrative proceedings instituted by the SEC, as a result of which our consolidated financial statements may be determined to not be in compliance with SEC requirements.

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.
We will require substantial additional financing to achieve our goals.

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur unforeseen costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
We depend on enrollment of patients in our clinical trials for our product candidates and may experience delays or difficulties enrolling patients in our clinical trials.
Our product candidates may be associated with serious adverse events or undesirable side effects or have other properties that could delay or halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
We have conducted and may continue to conduct clinical trials for our product candidates in sites outside the United States, and the FDA may not accept data from trials conducted in foreign locations.
We are early in our development efforts. If we are unable to successfully develop product candidates or experience significant delays in doing so, our business will be materially harmed.
Our approach to the discovery and development of product candidates based on potent T cell modulation activity is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render our approach obsolete.
We have never conducted later-stage clinical trials or submitted a New Drug Application, or NDA, or Biologics License Application, or BLA, and may be unable to do so for any of our product candidates.
The regulatory approval processes of the FDA, the PRC National Medical Products Administration, or NMPA, and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.

5


 

Risks Related to Our Reliance on Third Parties

We rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations, to conduct some aspects of our preclinical studies and clinical trials.
We contract with third parties for the manufacture of our product candidates for preclinical studies and our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately, in some jurisdictions, for commercialization.

Risks Related to Commercialization of Our Product Candidates

The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.
The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies.

Risks Related to Our Business Operations and Industry

We are subject to risks arising from COVID-19 and other epidemic diseases.
We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer.

Risks Related to Intellectual Property

Our success depends on our ability to obtain, maintain, protect and enforce our intellectual property and our proprietary technologies.

Risks Related to Ownership of Our ADSs

An active, liquid trading market for the ADSs may not be maintained, and you may not be able to resell your ADSs at or above the public offering price.

Risks Related to Ownership of Our ADSs

The trading price of our ADSs could be highly volatile, and purchasers of the ADSs could incur substantial losses.
As a foreign private issuer, we are not subject to some U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly available to our shareholders.
Holders of our ADSs have fewer rights than shareholders and must act through the depositary to exercise their rights.
We have identified material weaknesses in our internal control over financial reporting.

Implications of Being an Emerging Growth Company and a Foreign Private Issuer

Emerging Growth Company

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we may take advantage of specific exemptions from various reporting requirements that are applicable to other publicly traded entities that are not emerging growth companies. These exemptions include:

not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002;
not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);

6


 

not being required to submit some executive compensation matters to shareholder advisory votes, such as “say-on-pay,” “say-on-frequency” and “say-on-golden parachutes;” and
not being required to disclose some executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation.

As a result, we do not know if some investors will find our ADSs less attractive. The result may be a less active trading market for our ADSs, and the price of our ADSs may become more volatile.

We will remain an emerging growth company until the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion; (ii) the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering; (iii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common equity held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter; or (iv) the date on which we have issued more than $1 billion in non-convertible debt securities during any three-year period.

Foreign Private Issuer

We report under the Exchange Act as a non-U.S. company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from specific provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:

the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;
the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and
the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specific information, or current reports on Form 8-K, upon the occurrence of specified significant events.

In addition, we will not be required to file annual reports and consolidated financial statements with the SEC as promptly as U.S. domestic companies whose securities are registered under the Exchange Act, and we will not be required to comply with Regulation FD, which restricts the selective disclosure of material information.

Both foreign private issuers and emerging growth companies also are exempt from some more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign private issuer.

RISK FACTORS

Investors should carefully consider the risks and uncertainties described below and the other information in this annual report, including our consolidated financial statements and related notes appearing elsewhere in this annual report and in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest or maintain any investment in our American Depositary Shares, or ADSs. Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our ADSs could decline and some or all of their value may be lost. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.

Risks Related to Doing Business in the PRC

We could be adversely affected by rising political tensions and any potential conflicts between the United States and the PRC.

 

Rising political tensions and any potential conflicts between the United States and the PRC could reduce levels of trade, investments, technological exchanges and other economic activities between the two major economies, which would have a material adverse effect on global economic conditions and the stability of global financial markets. Any of these factors could have a material adverse effect on our business, prospects, financial condition and results of operations. Furthermore, there have been recent media reports on deliberations within the U.S. government regarding potentially limiting or restricting PRC-based companies from accessing U.S.

7


 

capital markets. If any such deliberations were to materialize, the resulting legislation may have a material and adverse impact on the stock performance of PRC-based issuers listed in the United States. It is unclear if this proposed legislation would be enacted.

 

A substantial part of our drug discovery and clinical operations are conducted in the PRC and the United States, and we are required to comply with the PRC, U.S. or other laws and regulations on import and export controls, including the U.S. Department of Commerce’s Export Administration Regulations. Currently, such laws and regulations do not restrict our ability to offer our U.S.-origin drug discovery tools to our subsidiaries in the PRC. However, we may be affected by future changes in U.S. import or export control laws and regulations. If we were unable to transfer our U.S.-origin drug discovery tools to the PRC, source U.S.-origin software and components from third parties or otherwise access U.S. technology as a result of such regulatory changes, our business, results of operations and financial condition would be materially and adversely affected.

 

The PRC and the United States have each imposed tariffs that have adversely affected trade between the two countries. It is not yet clear what impact tariff negotiations between the two countries may have or what further actions the governments may take, and tariffs could potentially increase the price of our clinical supplies and negatively impact our business, results of operations and financial condition.

 

Changes in the political and economic policies of the PRC government may materially and adversely affect our business, financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies.

 

Our financial condition and results of operations are affected to a significant extent by economic, political and legal developments in the PRC, where we have significant operations. The PRC economy differs from the economies of most developed countries in many respects, including the extent of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets, and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in the PRC is still owned by the government. In addition, the PRC government continues to play a significant role in regulating industry development by imposing industrial policies. The PRC government also exercises significant control over the PRC’s economic growth by allocating resources, controlling payment of foreign currency-denominated obligations, setting monetary policy, regulating financial services and institutions and providing preferential treatment to particular industries or companies.

 

While the PRC economy has experienced significant growth in the past three decades, growth has been uneven, both geographically and among various sectors of the economy. The PRC government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may also have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations that are currently applicable to us. In addition, in the past the PRC government implemented some measures, including interest rate increases, to control the pace of economic growth. These measures may cause decreased economic activity in the PRC, which may adversely affect our business and results of operations. In July 2021, the PRC government provided new guidance on PRC-based companies raising capital outside of the PRC, including through arrangements called variable interest entities, or VIEs. In light of such developments, the SEC has imposed enhanced disclosure requirements on PRC-based companies seeking to register securities with the SEC. Although we do not have a VIE structure, due to our operations in the PRC, any future PRC, U.S. or other rules and regulations that place restrictions on capital raising or other activities or require enhanced disclosure by PRC-based companies could adversely affect our business and results of operations. If the business environment in the PRC deteriorates from the perspective of domestic or international investment, the PRC government may intervene with our operations and our business in the PRC and the United States, and the market price of our ADSs could be adversely affected.

 

The PRC government may intervene in or influence our operations at any time, which could result in a material change in our operations and significantly and adversely impact the value of our ADSs.

 

The PRC government has significant oversight and discretion over the conduct of our business and may intervene or influence our operations as the government deems appropriate to further regulatory, political and societal goals. The PRC government has recently published new policies that significantly affected some industries such as the education and internet industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry or us that could require us to seek permission from PRC governmental authorities to continue to operate our business, which may adversely affect our business, financial condition and results of operations. Furthermore, recent statements made by the PRC government have indicated an intent to increase the PRC government’s oversight and control over offerings of companies with significant operations in the PRC that are to be conducted in non-PRC markets, as well as non-PRC investment in PRC-based issuers like us. Any such action, once taken by the PRC government, could significantly limit or completely hinder our ability to offer or continue to offer our securities to investors, and could cause the value of our ADSs to significantly decline or become worthless.

8


 

 

The audit report included in this annual report was prepared by an auditor who is not inspected by the PCAOB and, as such, our investors are deprived of the benefits of such inspection.

 

Our auditor, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, as an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. Since our auditor is located in the PRC, a jurisdiction where the PCAOB has been unable to conduct inspections without the approval of the PRC authorities, our auditor is not currently inspected by the PCAOB.

 

The inability to conduct PCAOB inspections in the PRC prevents the PCAOB from fully evaluating audits and quality control procedures of our independent registered public accounting firm. As a result, we and investors in our ADSs are deprived of the benefits of such PCAOB inspections. Also, the inability of the PCAOB to conduct inspections of auditors in the PRC makes it more difficult to evaluate the effectiveness of our independent registered public accounting firm’s audit procedures or quality control procedures as compared to auditors outside of the PRC that are subject to the PCAOB inspections, which could cause investors in our ADSs and potential investors in our ADSs to lose confidence in our audit procedures and reported financial information and the quality of our financial statements.

 

Our ADSs may be delisted and our ADSs and shares prohibited from trading in the over-the-counter market under the Holding Foreign Companies Accountable Act, or the HFCAA, if the PCAOB is unable to inspect or fully investigate auditors located in the PRC. Under the current law, delisting and prohibition from over-the-counter trading in the U.S. could take place in 2024. If this happens there is no certainty that we will be able to list our ADSs or shares on a non-U.S. exchange or that a market for our shares will develop outside of the U.S. The delisting of our ADSs or prohibition from trading, or the threat of their being delisted or prohibited from trading, may materially and adversely affect the value of our ADSs.

 

As part of a regulatory focus in the United States on access to audit and other information currently protected by foreign national laws, in particular the PRC’s, the Holding Foreign Companies Accountable Act, or HFCAA, was signed into law on December 18, 2020, amending the Sarbanes-Oxley Act of 2002 and directing the SEC to prohibit securities of any registrant from being listed on any of the U.S. securities exchanges or traded “over-the-counter” if the registered public accounting firm of the registrant’s financial statements has not been subject to PCAOB inspection for three consecutive years from the beginning of 2021.

 

On September 22, 2021, the PCAOB adopted a final rule implementing the HFCAA, which provides a framework for the PCAOB to use when determining, as contemplated under the HFCAA, whether the PCAOB is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction.

 

On December 2, 2021 the SEC adopted final rules implementing the HFCAA. As a result, the SEC will identify issuers that have filed an annual report with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and the PCAOB is unable to inspect or investigate completely because of a position taken by an authority taken in that jurisdiction. On December 16, 2021, the PCAOB issued a report on its determinations that it is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in mainland China and in Hong Kong because of positions taken by PRC and Hong Kong authorities in those jurisdictions.

 

In March 2022 the SEC began to identify issuers under the HFCAA. An issuer identified by the SEC will be required to submit documentation to the SEC establishing that it is not owned or controlled by a government entity in that foreign jurisdiction and also will be required to include disclosure in its annual report regarding its audit arrangements and governmental influence on it. If we are so identified, we will be required to comply with the submission and disclosure requirements in our annual report that we file in 2023 for our fiscal year ended December 31, 2022, and if we continue to be so identified for three consecutive years, we may become subject to a trading prohibition on our ADSs by as early as 2024. The trading prohibition could be accelerated to 2023 if the Accelerating Holding Foreign Companies Accountable Act is enacted.

 

If our auditor fails to be inspected or investigated by the PCAOB before the required deadline due to factors beyond our control, we will be de-listed from Nasdaq, deregistered from the SEC and/or face other risks, which may materially and adversely affect the market price and liquidity of our ADSs, or effectively terminate trading of our ADSs in the United States. If this happens there is no certainty that we will be able to list our ADSs or shares on a non-U.S. exchange or that a market for our shares will develop outside of the U.S.

 

Even before the required deadlines to meet the PCAOB inspection requirement, these efforts to increase U.S. regulatory access to audit information could cause investor uncertainty for affected issuers, including us, and the market price of our ADSs could be

9


 

adversely affected. Consequently, we may not be able to raise capital on terms acceptable to us, or at all. While we understand that there has been dialogue among the CSRC, the SEC and the PCAOB regarding the inspection of PCAOB-registered accounting firms in the PRC, there can be no assurance that our auditor will be able to comply with requirements imposed by U.S. regulators. The trading prohibition on our ADSs resulting from such non-compliance could cause holders of our ADSs to sell our ADSs prior to the effective date of such prohibition or to convert them into our Ordinary Shares. Even before such trading prohibition, the market price of our ADSs could be adversely affected as a result of anticipated negative impacts of executive or legislative actions upon, as well as negative investor sentiment towards, companies with significant operations in the PRC that are listed in the United States, regardless of whether these executive or legislative actions become effective or are implemented and regardless of our actual performance. For example, when the SEC began to identify issuers under the HFCAA in March 2022, the trading price of equity securities of PRC-based companies, including our ADSs, declined.

 

On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act, which, if enacted, would amend the HFCAA and require the SEC to prohibit an issuer’s securities from trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three. This could have a material and adverse impact on the value of any investment in our ADSs.

 

On June 22, 2021, the U.S. Senate passed a bill known as the Accelerating Holding Foreign Companies Accountable Act, and on February 4, 2022, the U.S. House of Representatives passed a bill known as the America Competes Act of 2022 which includes the exact same amendments as the bill passed by the Senate, but also includes a broader range of legislation unrelated to the HFCAA. It is unclear when the U.S. Senate and U.S. House of Representatives will resolve the differences in the bills currently passed, or when or whether the U.S. President will sign an agreed bill into law. If enacted, such law would amend the HFCAA and require the SEC to prohibit an issuer’s securities from trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three.

 

Compliance with the PRC’s new Data Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme and any other future laws and regulations may entail significant expenses and could materially affect our business.

 

The PRC has implemented or is implementing rules and is considering a number of additional proposals relating to data protection. The PRC’s new Data Security Law took effect in September 2021. The Data Security Law provides that the data processing activities must be conducted based on “data classification and hierarchical protection system” for the purpose of data protection and prohibits entities in the PRC from transferring data stored in the PRC to foreign law enforcement agencies or judicial authorities without prior approval by the authorized PRC governmental authority.

 

Additionally, the PRC’s Cyber Security Law requires companies to take some organizational, technical and administrative measures and other necessary measures to ensure the security of their networks and data stored on their networks. Specifically, the Cyber Security Law provides that the PRC adopt a multi-level protection scheme, or MLPS, under which network operators are required to perform obligations of security protection to ensure that the network is free from interference, disruption or unauthorized access, and prevent network data from being disclosed, stolen or tampered.

 

Recently, the Cyberspace Administration of China (“CAC”) has taken action against several PRC internet companies in connection with their initial public offerings on U.S. securities exchanges, for alleged national security risks and improper collection and use of the personal information of PRC data subjects. In April 2020, the Chinese government promulgated the Cybersecurity Review Measures (the “2020 Cybersecurity Review Measures”), which came into effect on June 1, 2020. In July 2021, the CAC and other related authorities released a draft amendment to the 2020 Cybersecurity Review Measures for public comments. On December 28, 2021, the Chinese government promulgated amended Cybersecurity Review Measures (the “2022 Cybersecurity Review Measures”), which came into effect and replaced the 2020 Cybersecurity Review Measures on February 15, 2022. According to the 2022 Cybersecurity Review Measures, (i) critical information infrastructure operators that purchase network products and services and internet platform operators that conduct data processing activities shall be subject to cybersecurity review in accordance with the 2022 Cybersecurity Review Measures if such activities affect or may affect national security; and (ii) internet platform operators holding personal information of more than one million users and seeking to have their securities list on a stock exchange in a foreign country shall file for cybersecurity review with the Cybersecurity Review Office. On November 14, 2021, the CAC released the draft Administrative Regulation on Network Data Security for public comments through December 13, 2021 (the “Draft Administrative Regulation”). Under the Draft Administrative Regulation, foreign listed data processors shall carry out annual data security evaluation and submit the evaluation report to the municipal cyberspace administration authority.

 

10


 

It is unclear at the present time how widespread the cybersecurity review requirement and the enforcement action will be and what effect they will have on the life sciences sector generally and on us in particular. Any failure or delay in the completion of the cybersecurity review procedures or any other non-compliance with applicable laws and regulations may result in fines or suspension of operations, and this could lead to us de-listing from the U.S. stock market.

 

Also, recently, the National People’s Congress released the Personal Information Protection Law, which became effective on November 1, 2021. The Personal Information Protection Law provides a comprehensive set of data privacy and protection requirements that apply to the processing of personal information and expands data protection compliance obligations to cover the processing of personal information of persons by organizations and individuals in the PRC, and the processing of personal information of persons in the PRC outside of the PRC if such processing is for purposes of providing products and services to, or analyzing and evaluating the behavior of, persons in the PRC. The Personal Information Protection Law also provides that critical information infrastructure operators and personal information processing entities who process personal information meeting a volume threshold to be set by PRC cyberspace regulators are also required to store in the PRC personal information generated or collected in the PRC, and to pass a security assessment administered by PRC cyberspace regulators for any export of such personal information. Lastly, the Personal Information Protection Law provides for significant fines for serious violations of up to RMB 50 million or 5% of annual revenues from the prior year and may also be ordered to suspend any related activity or be revoked the relevant business permits or business license by competent authorities. We do not maintain, nor do we intend to maintain, personally identifiable health information of patients in the PRC. We do, however, collect and maintain de-identified health data for clinical trials in compliance with local regulations.

 

Interpretation, application and enforcement of these laws, rules and regulations evolve from time to time and their scope may continually change, through new legislation, amendments to existing legislation or changes in enforcement. Compliance with such laws, rules and regulations could significantly increase the cost of our operations, require significant changes to our operations or even prevent us from operating in jurisdictions in which we currently operate or in which we may operate in the future. Despite our efforts to comply with applicable laws, rules, regulations and other obligations relating to privacy, data protection and information security, it is possible that our operations could fail to meet all of the requirements imposed on us. Any failure on our part to comply, or any compromise of security that results in unauthorized access, use or release of personal information or other data, or the perception or allegation that any failure or compromise has occurred, could damage our reputation, discourage new and existing partners, vendors or other parties from contracting with us or result in investigations, fines, suspension or other penalties by governmental authorities and private claims or litigation, any of which could materially adversely affect our business, financial condition and results of operations. Even if our operations are not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm our reputation and adversely affect our business, financial condition and results of operations. Moreover, the legal uncertainty created by such laws, rules and regulations and the recent PRC government actions could materially adversely affect our ability to raise capital, or to do so on favorable terms, including engaging in public or private equity or debt financings in the U.S. market.

 

There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations.

 

Our operations in the PRC are governed by PRC laws, rules and regulations. Our PRC subsidiaries are subject to laws, rules and regulations applicable to foreign investment in the PRC. The PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value.

 

The PRC has not developed a fully integrated legal system, and recently enacted laws, rules and regulations may not sufficiently cover all aspects of economic activities in the PRC or may be subject to significant degrees of interpretation by PRC regulatory agencies. In particular, because these laws, rules and regulations are relatively new, and because of the limited number of published decisions and the non-binding nature of such decisions, and because the laws, rules and regulations often give the relevant regulator significant discretion in how to enforce them, the interpretation and enforcement of these laws, rules and regulations involve uncertainties and can be inconsistent and unpredictable. In addition, the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation.

 

Any administrative and court proceedings in the PRC may be protracted, resulting in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. These uncertainties may impede our ability to enforce the contracts we have entered into and could materially and adversely affect our business, financial condition and results of operations.

 

Recently, PRC regulators have announced regulatory actions aimed at providing the PRC government with greater oversight over sectors of the economy in the PRC, including the for-profit education sector and technology platforms that have a quantitatively significant number of users located in the PRC. Although the biotechnology industry is already highly regulated in the PRC and while

11


 

there has been no indication to date that such actions or oversight would apply to companies like us, the PRC government may in the future take regulatory actions that materially adversely affect the business environment and financial markets in the PRC as they relate to us, our ability to operate our business, our liquidity and our access to capital.

 

The approval of the CSRC may be required under a PRC regulation in connection with any future offerings of our securities in the U.S. market. The regulation also establishes more complex procedures for acquisitions conducted by non-PRC investors that could make it more difficult for us to grow through acquisitions.

 

On August 8, 2006, six PRC regulatory agencies, including the Ministry of Commerce, or MOFCOM, the State-Owned Assets Supervision and Administration Commission, the State Administration of Taxation, or SAT, the State Administration for Industry and Commerce, currently known as the SAMR, the CSRC, and the State Administration of Foreign Exchange, or the SAFE, jointly adopted the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&A Rules, which came into effect on September 8, 2006 and were amended on June 22, 2009. The M&A Rules include, among other things, provisions that purport to require that an offshore special purpose vehicle that is controlled by PRC domestic companies or individuals and that has been formed for the purpose of an overseas listing of securities through acquisitions of PRC domestic companies or assets to obtain the approval of the CSRC prior to the listing and trading of such special purpose vehicle’s securities on an overseas stock exchange. On September 21, 2006, the CSRC published on its official website procedures regarding its approval of overseas listings by special purpose vehicles. However, substantial uncertainty remains regarding the scope and applicability of the M&A Rules to offshore special purpose vehicles.

 

While the application of the M&A Rules remains unclear, we believe, based on our understanding of the current PRC laws and regulations, that the CSRC approval under the M&A Rules would not be required in the context of future offerings of our securities in the U.S. market because Connect SZ was incorporated as a domestic company in May 2012 and became a sino-foreign equity venture on August 23, 2012 in compliance with the M&A Rules, such that the M&A Rules are not applicable to it thereafter; provided that the CSRC has not issued any definitive rule or interpretation concerning whether follow-on offerings of securities in the U.S. market are subject to the M&A Rules. There can be no assurance that the relevant PRC government agencies, including the CSRC, would reach the same conclusion as our PRC legal counsel. If the CSRC or any other PRC regulatory body determines that we need to obtain the CSRC’s approval for follow-on offerings or if the CSRC or any other PRC government authorities promulgates any interpretation or implements rules that would require us to obtain CSRC or other governmental approvals for follow-on offerings, we may be unable to obtain such approvals on a timely basis or at all and we may face adverse actions or sanctions by the CSRC or other PRC regulatory agencies if we proceed with an offering of our securities without first receiving any required approvals. In any such event, these regulatory agencies may impose fines and penalties on our operations in the PRC, limit our operating privileges in the PRC, delay or restrict the repatriation of the proceeds from future offerings into the PRC or take other actions that could have a material adverse effect on our business, financial condition, results of operations, reputation and prospects.

 

These regulations also established additional procedures and requirements that are expected to make merger and acquisition activities in the PRC by non-PRC investors more time-consuming and complex. For example, the M&A rules require that the MOFCOM be notified in advance of any change-of-control transaction in which a non-PRC investor takes control of a PRC domestic enterprise if (i) any important industry is concerned,(ii) such transaction involves factors that have or may have impact on the national economic security, or (iii) such transaction will lead to a change in control of a domestic enterprise which holds a famous trademark or PRC time-honored brand. The approval from the MOFCOM shall be obtained in circumstances where overseas companies established or controlled by PRC enterprises or residents acquire affiliated domestic companies. Mergers, acquisitions or contractual arrangements that allow one market player to take control of or to exert decisive impact on another market player must also be notified in advance to the anti-monopoly authority under the State Council when the threshold under the Provisions on Thresholds for Prior Notification of Concentrations of Undertakings issued by the State Council in August 2008 and amended in September 2018, is triggered. In addition, the security review rules issued by the MOFCOM that became effective in September 2011 specify that mergers and acquisitions by non-PRC investors that raise “national defense and security” concerns and mergers and acquisitions through which non-PRC investors may acquire de facto control over domestic enterprises that raise “national security” concerns are subject to strict review by the MOFCOM, and the rules prohibit any activities attempting to bypass a security review, including by structuring the transaction through a proxy or contractual control arrangement. We may grow our business in part by acquiring other companies operating in our industry. Complying with the requirements of the new regulations to complete such transactions could be time-consuming, and any required approval processes, including approval from the MOFCOM, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share. In addition, as PRC governmental authorities have significant discretion in interpreting and implementing statutory provisions, we cannot assure you that we are not required to obtain such approval or pass such review under PRC laws, regulations or policies if the relevant PRC governmental authorities take a contrary position, nor can we predict whether or how long it will take to obtain such approval or pass such review. Any failure to obtain or delay in obtaining the requisite governmental approval or review would subject us to sanctions imposed by the relevant PRC regulatory authority, including orders to stop the illegal act, confiscation of illegal income and a fine ranging from 1% to 10% of the

12


 

sale amount of the preceding year or not more than 500,000 RMB (the specific amount of fines shall be determined in consideration of the nature of the illegal act, the extent and the period of time during which the act was continuing etc.).

 

Furthermore, on December 24, 2021, the CSRC released the draft Administrative Provisions on the Offshore Listing and Securities Issuance of PRC-Based Companies and the draft Administrative Measures on the Filing of Offshore Listing and Securities Issuance of PRC-Based Companies for public comments through January 23, 2022 (collectively, the “CSRC Draft Rules”). Under the CSRC Draft Rules, the PRC-based companies involved in any of the following circumstances shall not list or offer securities on foreign exchanges: (i) where the circumstances under which listing for financing is expressly prohibited by the laws, regulations and relevant provisions; (ii) the overseas offering and listing threatens or endangers the national security upon examination and verification by the relevant competent department of the PRC State Council; (iii) a major ownership dispute over the equity, main assets, core technology, etc.; (iv) such PRC-based company or its controlling shareholder or actual controller has, in the past three years, committed a criminal offence such as corruption, bribery, encroachment or misappropriation of property or undermined the order of socialist market economy, or is under investigation by the judicial authority for being suspected of committing a crime or being involved in a major violation of laws or regulations; (v) any director, supervisor or senior management personnel of such PRC-based company has been subject to any administrative punishment in the last three years with serious circumstances, or is subject to a case filing and investigation by the judicial authority for being suspected of a crime or a major violation of laws or regulations; and (vi) any other circumstance recognized by the PRC State Council. Where a PRC-based company falls under any of the aforesaid circumstances prior to its overseas listing and offering, the relevant competent authorities shall request such PRC-based company to suspend or terminate its overseas listing and offering. In addition, an overseas listed Chinese Company may be subject to the following obligations of filing or report: (i) an overseas listed Chinese company shall complete a filing for a follow-on offering with the CSRC within three (3) business days upon the completion of the follow-on offering; (ii) an overseas listed Chinese company shall report detailed information to the CSRC within three (3) business days from the occurrence of the following major events after its overseas listing, including the change of such issuer’s control right, investigation and punishment imposed by the overseas regulatory security authority or the relevant competent authority and the termination of listing voluntarily or compulsorily; and (iii) where there is any material change in the major business and operation activities of an overseas listed Chinese company and such change does not fall within the scope of filing requirement, such issuer shall, within three (3) business days from the occurrence of such change, submit a special report and a legal opinion issued by a PRC law firm to the CSRC to explain the relevant information. It is uncertain whether, when and in what form the CSRC Draft Rules will be enacted. If the CSRC Draft Rules are enacted in the current form, we will be required to make such filing or report with respect to offerings we make in the future. However, we cannot assure you that we will be able to complete such filing or comply with any other requirements that may be imposed on us under the Overseas Listing Rules, on a timely basis or at all. Failure to comply with the filing requirements or any other requirements under the CSRC Draft Rules (if enacted) could result in warnings, a fine ranging from RMB 1 million to RMB 10 million, suspension of specific business operations, orders of rectification and revocation of business license.

 

PRC government agencies may exert more oversight and control over offerings that are conducted overseas and non-PRC investment in PRC-based issuers. We face uncertainty about future actions by the PRC government that could significantly affect our ability to offer or continue to offer securities to investors and could significantly negatively affect the value of our ADSs.

 

Recently, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the “Opinions on Severely Cracking Down on Illegal Securities Activities According to Law,” or the Opinions, which was made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen administration over illegal securities activities, and the need to strengthen supervision over overseas listings by PRC companies. Effective measures, such as promoting the construction of relevant regulatory systems will be taken to deal with the risks and incidents of PRC-based overseas listed companies, and cybersecurity and data privacy protection requirements and similar matters. The Opinions and any related implementing rules to be enacted may subject us to compliance requirements in the future.

 

Given the current regulatory environment in the PRC, we are still subject to the uncertainty of interpretation and enforcement of the rules and regulations in the PRC, which can change quickly with little advance notice, and any future actions of the PRC authorities. It is uncertain whether we will be required to obtain permission from the PRC government to maintain our listing on any U.S. exchange (including retroactively), and even if such permission is sought, whether it will be denied or rescinded. As a result, our operations could be adversely affected, directly or indirectly, by existing or future laws and regulations relating to our business or industry.

 

13


 

We may be treated as a resident enterprise for PRC tax purposes under the PRC Enterprise Income Tax Law, and we may therefore be subject to PRC income tax on our global income.

 

Under the PRC Enterprise Income Tax Law and its implementing rules, enterprises established under the laws of jurisdictions outside of the PRC with “de facto management bodies” located in the PRC may be considered PRC tax resident enterprises for tax purposes and may be subject to the PRC enterprise income tax at the rate of 25% on their global income. “De facto management body” refers to a managing body that exercises substantial and overall management and control over the production and operations, personnel, accounting and assets of an enterprise. The SAT issued the Notice Regarding the Determination of Chinese-Controlled Offshore-Incorporated Enterprises as PRC Tax Resident Enterprises on the Basis of De Facto Management Bodies, or Circular 82, on April 22, 2009, which was most recently amended on December 29, 2017. Circular 82 provides specific criteria for determining whether the “de facto management body” of a PRC-controlled offshore-incorporated enterprise is located in the PRC. Although Circular 82 only applies to offshore enterprises controlled by PRC enterprises, not those controlled by non-PRC enterprises or individuals, the determining criteria set forth in Circular 82 may reflect the SAT’s general position on how the “de facto management body” test should be applied in determining the tax resident status of offshore enterprises, regardless of whether they are controlled by PRC enterprises. If we were to be considered a PRC resident enterprise, we would be subject to PRC enterprise income tax at the rate of 25% on our global income. In such case, our cash flow may be materially reduced as a result of our global income being taxed under the Enterprise Income Tax Law. We believe that none of our entities outside of the PRC is a PRC resident enterprise for PRC tax purposes. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term “de facto management body.”

 

Dividends paid to our non-PRC investors (should we ever pay dividends) and gains on the sale of our ADSs by our non-PRC investors may become subject to PRC tax.

 

Under the Enterprise Income Tax Law and its implementation regulations issued by the State Council, a 10% PRC withholding tax is applicable to dividends paid to investors that are non-resident enterprises, which do not have an establishment or place of business in the PRC or which have such establishment or place of business but the dividends are not effectively connected with such establishment or place of business, to the extent such dividends are derived from sources within the PRC. Any gain realized on the transfer of ADSs or ordinary shares by such investors is also subject to PRC tax at a current rate of 10%, if such gain is regarded as income derived from sources within the PRC. If we are deemed a PRC resident enterprise, dividends paid on our ordinary shares or ADSs, and any gain realized from the transfer of our ordinary shares or ADSs, would be treated as income derived from sources within the PRC and would as a result be subject to PRC taxation. Furthermore, if we are deemed a PRC resident enterprise, dividends paid to individual investors who are non-PRC residents and any gain realized on the transfer of ADSs or ordinary shares by such investors may be subject to PRC tax (which in the case of dividends may be withheld at source) at a rate of 20%. Any PRC tax liability may be reduced by an applicable tax treaty. However, if we or any of our subsidiaries established outside the PRC are considered a PRC resident enterprise, it is unclear whether holders of our ADSs would be able to claim the benefit of income tax treaties or agreements entered into between the PRC and other countries or areas. If dividends paid to our non-PRC investors, or gains from the transfer of our ADSs by such investors, are deemed as income derived from sources within the PRC and thus are subject to PRC tax, the value of our ADSs may decline significantly.

 

14


 

We and our shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company, or immovable properties located in the PRC owned by non-PRC companies.

 

On February 3, 2015, the SAT issued the Bulletin on Issues of Enterprise Income Tax on Indirect Transfers of Assets by Non-PRC Resident Enterprises, or Bulletin 7. Pursuant to this Bulletin 7, an “indirect transfer” of assets, including non-publicly traded equity interests in a PRC resident enterprise, by non-PRC resident enterprises may be re-characterized and treated as a direct transfer of PRC taxable assets if such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax. According to Bulletin 7, “PRC taxable assets” include assets attributed to an establishment in the PRC, immovable properties located in the PRC, and equity investments in PRC resident enterprises, in respect of which gains from their transfer by a direct holder, being a non-PRC resident enterprise, would be subject to PRC enterprise income taxes. When determining whether there is a “reasonable commercial purpose” of the transaction arrangement, features to be taken into consideration include, without limitation: whether the main value of the equity interest of the relevant offshore enterprise derives from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consists of direct or indirect investment in the PRC or if its income mainly derives from the PRC; whether the offshore enterprise and its subsidiaries directly or indirectly holding PRC taxable assets have real commercial nature which is evidenced by their actual function and risk exposure; the duration of existence of the business model and organizational structure; the replicability of the transaction by direct transfer of PRC taxable assets; and the tax situation of such indirect transfer and applicable tax treaties or similar arrangements. In respect of an indirect offshore transfer of assets of a PRC establishment, the resulting gain is to be included with the enterprise income tax filing of the PRC establishment or place of business being transferred, and would consequently be subject to PRC enterprise income tax at a rate of 25%. Where the underlying transfer relates to the immovable properties located in the PRC or to equity investments in a PRC resident enterprise, which is not related to a PRC establishment or place of business of a non-resident enterprise, a PRC enterprise income tax of 10% would apply, subject to available preferential tax treatment under applicable tax treaties or similar arrangements, and the party who is obligated to make the transfer payments has the withholding obligation. Bulletin 7 does not apply to transactions of sale of shares by investors through a public stock exchange where such shares were acquired from a transaction through a public stock exchange. On October 17, 2017, the SAT promulgated the Announcement of the SAT on Issues Concerning the Withholding of Non-resident Enterprise Income Tax at Source, or SAT Circular 37, which became effective on December 1, 2017 and was most recently amended on June 15, 2018. SAT Circular 37, among other things, simplified procedures of withholding and payment of income tax levied on non-resident enterprises.

 

We face uncertainties as to the reporting and other implications of past and future transactions where PRC or other taxable assets are involved, such as offshore restructuring, sale of the shares in our offshore subsidiaries or investments. We may be subject to filing obligations, required to obtain independent valuations, or taxed if we are the transferor in such transactions, and may be subject to withholding obligations if we are the transferee in such transactions under Bulletin 7 and SAT Circular 37. If there are transfers of our securities by investors that are non-PRC resident enterprises, our PRC subsidiaries may be requested to assist in the filing under Bulletin 7 and SAT Circular 37. As a result, we may be required to expend valuable resources to comply with Bulletin 7 and SAT Circular 37 or to request the relevant transferors from whom we purchase taxable assets to comply with these publications, or to establish that we should not be taxed under these publications, which may have a material adverse effect on our financial condition and results of operations.

 

We and our shareholders face uncertainties with respect to reorganizations or restructurings that we may undertake.

 

We have historically undertaken various reorganizations and restructurings of our subsidiaries and of intellectual property and other assets. We currently anticipate that we may undertake further reorganizations or restructurings that may, for instance, involve licensing or assigning of intellectual property and other assets, but any further reorganization or restructuring has still to be effected, remains to be fully planned out, would involve complexity, and no assurance can be given that any such reorganization or restructuring would be effective at achieving its intended goals and may result in unintended tax or other consequences that may materially and adversely affect our business, results of operations, financial condition and prospects.

 

PRC regulation of loans to, and direct investments in, PRC entities by offshore holding companies may restrict or prevent us from making loans or additional capital contributions to our PRC subsidiaries.

 

We are permitted under PRC laws and regulations to provide funding to our PRC subsidiaries, which are treated as “foreign-invested enterprises” under PRC laws, through loans or capital contributions. However, loans by us to our PRC subsidiaries to finance their activities cannot exceed statutory limits and must be registered with the local counterpart of SAFE and capital contributions to our PRC subsidiaries are subject to the requirement of making necessary registration with competent governmental authorities in the PRC.

 

15


 

SAFE promulgated the Notice of the SAFE on Reforming the Administration of Foreign Exchange Settlement of Capital of Foreign-invested Enterprises, or Circular 19, effective on June 1, 2015. According to Circular 19, the flow and use of the RMB capital converted from non-PRC currency-denominated registered capital of a non-PRC-invested company is regulated such that RMB capital may not be used for the issuance of RMB entrusted loans, the repayment of inter-enterprise loans or the repayment of banks loans that have been transferred to a third party. Although Circular 19 allows RMB capital converted from non-PRC currency-denominated registered capital of a non-PRC-invested enterprise to be used for equity investments within the PRC, it also reiterates the principle that RMB converted from the non-PRC currency-denominated capital of a non-PRC-invested company may not be directly or indirectly used for purposes beyond its business scope. Thus, it is unclear whether SAFE will permit such capital to be used for equity investments in the PRC in actual practice. SAFE promulgated the Notice of the SAFE on Reforming and Standardizing the Foreign Exchange Settlement Management Policy of Capital Account, or Circular 16, effective on June 9, 2016, which reiterates some of the rules set forth in Circular 19, but changes the prohibition against using RMB capital converted from non-PRC currency-denominated registered capital of a non-PRC-invested company to issue RMB entrusted loans to a prohibition against using such capital to issue loans to non-associated enterprises. Violations of Circular 19 and Circular 16 could result in administrative penalties. Circular 19 and Circular 16 may significantly limit our ability to transfer any non-PRC currency we hold, to our PRC subsidiaries, which may adversely affect our liquidity and our ability to fund and expand our business in the PRC. On October 23, 2019, SAFE promulgated the Circular of the SAFE on Further Promoting the Facilitation of Cross-border Trade and Investment, or Circular 28, which permits non-investment non-PRC-invested enterprises to use their capital funds to make equity investments in the PRC, with genuine investment projects and in compliance with effective non-PRC investment restrictions and other applicable laws. However, as Circular 28 was issued recently, there are still substantial uncertainties as to its interpretation and implementations in practice.

 

In light of the various requirements imposed by PRC regulations on loans to, and direct investments in, our PRC subsidiaries, we cannot assure investors that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans or future capital contributions by us to our PRC subsidiaries. As a result, uncertainties exist as to our ability to provide prompt financial support to our PRC subsidiaries when needed. If we fail to complete such registrations or obtain such approvals, our ability to use non-PRC currency, and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business.

 

Any failure to comply with PRC regulations regarding the registration requirements for employee share incentive plans may subject our equity incentive plan participants or us to fines and other legal or administrative sanctions.

 

In February 2012, SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plan of Overseas Publicly Listed Company, replacing earlier rules promulgated in 2007. Pursuant to these rules, PRC citizens and non-PRC citizens who reside in the PRC for a continuous period of not less than one year and participate in any share incentive plan of an overseas publicly listed company are required to register with the SAFE through a domestic qualified agent, which could be the PRC subsidiaries of such overseas-listed company, and complete other procedures, unless some exceptions are available. In addition, an overseas-entrusted institution must be retained to handle matters in connection with the exercise or sale of share options and the purchase or sale of shares and interests. We and our executive officers and other employees who are PRC citizens or non-PRC citizens living in the PRC for a continuous period of not less than one year and have been granted options are subject to these regulations. Failure to complete SAFE registrations may subject them to fines of up to RMB300,000 for entities and up to RMB50,000 for individuals and may also limit our ability to contribute additional capital into our PRC subsidiaries and our PRC subsidiaries’ ability to distribute dividends to us. We also face regulatory uncertainties that could restrict our ability to adopt additional incentive plans for our directors, executive officers and employees under PRC law. See Item 6. “Directors, Senior Management and – Compensation.”

 

In addition, the SAT has issued some circulars concerning employee share options and restricted shares. Under these circulars, our employees working in the PRC who exercise share options or are granted restricted shares will be subject to PRC individual income tax. Our PRC subsidiaries have obligations to file documents related to employee share options or restricted shares with relevant tax authorities and to withhold individual income taxes for those employees who exercise their share options. If our employees fail to pay or we fail to withhold their income taxes according to relevant laws and regulations, we may face sanctions imposed by the tax authorities or other PRC government authorities. See Item 6. “Directors, Senior Management and – Compensation.”

 

16


 

PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries’ ability to change their registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws.

 

In July 2014, SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents’ Offshore Investment and Financing and Roundtrip Investment Through Special Purpose Vehicles, or Circular 37. Circular 37 requires PRC residents (including PRC individuals and PRC corporate entities as well as non-PRC individuals that are deemed as PRC residents for foreign exchange administration purposes) to register with SAFE or its local branches in connection with their direct or indirect offshore investment activities. Circular 37 further requires amendment to the SAFE registrations in the event of any changes with respect to the basic information of the offshore special purpose vehicle, such as change of a PRC individual shareholder, name and operation term, or any significant changes with respect to the offshore special purpose vehicle, such as increase or decrease of capital contribution, share transfer or exchange, or mergers or divisions. Circular 37 is applicable to our shareholders or beneficial owners who are PRC residents and may be applicable to any offshore acquisitions that we make in the future. According to the Notice on Further Simplifying and Improving Policies for the Foreign Exchange Administration of Direct Investment released on February 13, 2015 by the SAFE, local banks will examine and handle foreign exchange registration for overseas direct investment, including the initial foreign exchange registration and amendment registration, under Circular 37 from June 1, 2015.

 

If our shareholders or beneficial owners who are PRC residents or entities do not complete their registration with the local SAFE branches or qualified local banks, our PRC subsidiaries may be prohibited from distributing to us its profits and proceeds from any reduction in capital, share transfer or liquidation, and we may be restricted in our ability to contribute additional capital to our PRC subsidiaries. Moreover, failure to comply with the SAFE registration described above could result in liability under PRC laws for evasion of applicable foreign exchange restrictions.

 

We may not be informed of the identities of all the PRC residents or entities holding direct or indirect interest in our securities, nor can we compel our shareholders or beneficial owners to comply with SAFE registration requirements. We cannot assure investors that all shareholders or beneficial owners of ours who are PRC residents or entities have complied with, and will in the future make, obtain or update any applicable registrations or approvals required by, SAFE regulations.

 

The failure or inability of such shareholders or beneficial owners to comply with SAFE regulations, or failure by us to amend the foreign exchange registrations of our PRC subsidiaries, could subject us or the non-compliant shareholders or beneficial owners to fines or legal sanctions, restrict our overseas or cross-border investment activities, limit our PRC subsidiaries’ ability to make distributions or pay dividends to us or affect our ownership structure. As a result, our business operations and our ability to distribute any future profits to investors could be materially and adversely affected.

 

Governmental control of currency conversion may limit our ability to remit funds out of the PRC and utilize our capital or future revenues effectively and could affect the value of any investment in our ADSs.

 

The PRC government imposes controls on the convertibility of the renminbi into non-PRC currencies and, in some cases, the remittance of currency out of the PRC. We fund our PRC operations and expect to receive some of our future revenues in renminbi. Approval from or registration with appropriate PRC governmental authorities is required where renminbi is to be converted into non-PRC currency and remitted out of the PRC to pay capital expenses such as the repayment of loans denominated in non-PRC currencies. As a result, we need to obtain SAFE approval to use cash generated from the operations of our PRC subsidiaries to pay off their respective debt in a currency other than renminbi owed to entities outside the PRC, or to make other capital expenditure payments outside the PRC in a currency other than renminbi.

 

In light of the flood of capital outflows of the PRC in 2016 due to the weakening renminbi, the PRC government has imposed more restrictive foreign exchange policies and stepped-up scrutiny of major outbound capital movement including overseas direct investment. More restrictions and a substantial vetting process have been put in place by SAFE to regulate cross-border transactions falling under the capital account. If any of our shareholders regulated by such policies fails to satisfy the applicable overseas direct investment filing or approval requirement timely or at all, it may be subject to penalties from the relevant PRC authorities. The PRC government may at its discretion further restrict access in the future to non-PRC currencies for current account transactions. If the foreign exchange control system prevents us from obtaining sufficient non-PRC currencies to satisfy our non-PRC currency demands, we may not be able to pay dividends in non-PRC currencies to our shareholders, including holders of our ADSs.

 

17


 

Recent litigation, regulatory scrutiny and negative publicity surrounding PRC-based companies listed in the United States may result in increased regulatory scrutiny of us and negatively impact the trading price of our ADSs.

 

We believe that litigation, regulatory scrutiny and negative publicity surrounding PRC-based companies that are listed in the United States have negatively impacted stock prices for such companies. U.S.-listed public companies that have substantially all of their operations in the PRC have been the subject of intense scrutiny by investors, equity-based research organizations and regulatory agencies, such as the SEC and PCAOB. Some of these companies have become subject to shareholder litigation or are conducting internal or external investigations into allegations of, among other things, accounting irregularities and mistakes, a lack of effective internal controls over financial accounting and inadequate corporate governance policies. Any similar scrutiny of us, regardless of its lack of merit, could result in a diversion of management resources and energy, potential costs to defend ourselves against rumors or litigation, decreases and volatility in our ADS trading price, and increased directors and officers insurance premiums, and could have a material adverse effect upon our business, results of operations and financial condition.

 

The enforcement of the PRC Labor Law, Labor Contract Law, and other labor-related regulations in the PRC may increase our labor costs and limit our flexibility to use labor. If we fail to comply with PRC labor-related laws, we may be exposed to penalties.

 

According to the PRC Labor Contract Law, an employer is obliged to sign an unfixed-term labor contract with any employee who has worked for the employer for 10 consecutive years. Further, if an employee requests or agrees to renew a fixed-term labor contract that has already been entered into twice consecutively, the resulting contract must have an unfixed term, with some exceptions. The employer must pay economic compensation to an employee where a labor contract is terminated or not renewed upon expiration in accordance with the PRC Labor Contract Law, except for some situations which are specifically regulated. As a result, our ability to terminate employees is significantly restricted. In addition, the PRC government has issued various labor-related regulations to further protect the rights of employees. According to such laws and regulations, employees who have worked continuously for not less than 12 months are entitled to annual leave ranging from five to 15 days and are able to be compensated for any untaken annual leave days in the amount of three times their daily salary, subject to some exceptions. In the event that we decide to change our employment or labor practices, the PRC Labor Contract Law and its implementation rules may also limit our ability to effect those changes in a manner that we believe to be cost-effective. In addition, as the interpretation and implementation of these new regulations are still evolving, our employment practices may not be at all times deemed in compliance with the new regulations. If we are subject to severe penalties or incur significant liabilities in connection with labor disputes or investigations, our business and financial conditions may be adversely affected.

 

Companies operating in the PRC are required to participate in various government sponsored employee benefit plans, including social insurance, housing funds and other welfare-oriented payment obligations, and contribute to the plans in amounts equal to specific percentages of salaries, including bonuses and allowances, of their employees up to a maximum amount specified by the local government from time to time. The requirement to maintain employee benefit plans has not been implemented consistently by local governments in the PRC given the different levels of economic development in different locations. We may not pay social security and housing fund contributions in strict compliance with the relevant PRC regulations for and on behalf of our employees due to differences in local regulations and inconsistent implementation or interpretation by local authorities in the PRC and varying levels of acceptance of the housing fund system by our employees. We may be subject to fines and penalties for any such failure to make payments in accordance with the applicable PRC laws and regulations. We may be required to make up the contributions for these plans as well as to pay late fees and fines. If we are subject to penalties, late fees or fines in relation to any underpaid employee benefits, our financial condition and results of operations may be adversely affected.

 

Some of our leasehold interests in leased properties have not been registered with the relevant PRC governmental authorities as required by relevant PRC laws. The failure to register leasehold interests may expose us to potential fines.

 

We have not registered some of our lease agreements with the relevant government authorities. Under the relevant PRC laws and regulations, we may be required to register and file with the relevant government authority executed leases. The failure to register the lease agreements for our leased properties will not affect the validity of these lease agreements, but the competent housing authorities may order us to register the lease agreements in a prescribed period of time and impose a fine ranging from RMB1,000 to RMB10,000 for each non-registered lease if we fail to complete the registration within the prescribed timeframe.

 

18


 

Our business benefits from tax benefits or financial incentives and discretionary policies granted by governmental authorities in the PRC. Expiration, elimination or reduction of these incentives or policies would have an adverse effect on our results of operations.

 

Governmental authorities in the PRC have granted tax benefits or financial incentives to our PRC subsidiaries as part of their efforts to encourage the development of PRC businesses, including in connection with our land use and investment agreements with governmental authorities in the PRC. We are undertaking various obligations and responsibilities under such agreements. We have not obtained necessary permits in connection with the construction of our PRC facilities and the construction project is currently put on hold, with no assurance that the construction can be completed on time or at all or that we will be able to meet all obligations and responsibilities under such agreements, which may result in the loss of financial incentives, deny access to future opportunities, and jeopardize or damage our relationships from or with governmental authorities in the PRC, which in turn would negatively affect our financial condition and results of operations.

 

The timing, amount and criteria of tax benefits or governmental financial incentives are determined within the sole discretion of the local government authorities and cannot be predicted with certainty before we actually receive any financial incentive. We do not have the ability to influence government authorities in making these decisions. Governmental authorities may decide to reduce or eliminate tax benefits or incentives at any time. In addition, some of the governmental tax benefits or financial incentives are granted on a project or milestone basis and subject to the satisfaction of some conditions, including compliance with the applicable investment or financial incentive agreements and completion of the specific project or milestone therein. We cannot guarantee that we will satisfy all relevant conditions, and if we fail, we may be deprived of the relevant tax benefits or incentives. We cannot assure investors of the continued availability of governmental tax benefits or incentives currently enjoyed by us. Any elimination or reduction of tax benefits or financial or other incentives granted to us would have an adverse effect on our results of operations.

 

The pharmaceutical industry in the PRC is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs.

 

Most of our research and development operations and facilities are in the PRC, which we believe confers clinical, commercial and regulatory advantages. The pharmaceutical industry in the PRC is subject to comprehensive government regulation and supervision encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. See Item 4. Business Overview—Government Regulation and Product Approval—PRC Regulation” for a discussion of the regulatory requirements that are applicable to our current and planned business activities in the PRC. In recent years, the regulatory framework in the PRC regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development or commercialization of our product candidates in the PRC and reduce the current benefits we believe are available to us from developing and manufacturing product candidates in the PRC. PRC authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry and any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in the PRC. We believe our strategy and approach are aligned with the PRC government’s regulatory policies, but we cannot ensure that our strategy and approach will remain so aligned.

 

We may be restricted from transferring our scientific data outside of the PRC.

 

On May 28, 2019, the State Council promulgated the Regulation on the Administration of Human Genetic Resources, or the Regulation, which became effective on July 1, 2019. Under this Regulation, provision of human genetic resources materials (“HGR Materials”) and human genetic resources information (“HGR Information”) to non-PRC parties is subject to different forms of review and pre-approval. HGR Materials refers to genetic materials, such as organs, tissues or cells, which contain the human genome, genes and their products, and HGR Information refers to genetic information or data generated by using the HGR Materials. Only in order to obtain marketing authorization for relevant drugs and medical devices in the PRC and in the event without export, no approval is required in international clinical trial cooperation using the PRC’s HGR Materials and HGR Information at clinical institutions. However, the type, quantity and usage of the HGR Materials and HGR Information to be used shall be filed with the Ministry of Science and Technology, or the MOST, before clinical trials. Otherwise, international cooperation in scientific research carried out by utilization of the PRC’s HGR Materials and HGR Information shall meet specified conditions, and the two cooperative parties shall jointly submit an application, which shall be approved by the MOST. In addition, delivery, mailing or carrying out of HGR Materials outside of the PRC shall be subject to the approval of the MOST, and an export certificate shall be obtained. The provision of HGR Information to non-PRC parties or permitting uses of HGR Information by non-PRC parties requires a record filing with MOST and submission of that corresponding information’s copy. If such provision or permitting uses could impact the public health, national security or public interest of the PRC, an additional security review will be conducted.

 

19


 

If we are unable to obtain the necessary approvals or complete the necessary filing process in a timely manner, or at all, our research and development of product candidates may be hindered, which may materially and adversely affect our business, results of operations, financial conditions and prospects. If relevant PRC governmental authorities consider the transmission of our materials, data or information to be in violation of relevant regulations, we may be subject to specific administrative penalties imposed by those government authorities, including warnings, orders to make corrections, confiscation of illegal gains as well as the HGR Materials and HGR Information illegally collected and preserved, fines of not less than one million RMB but not more than 10 million RMB (if the illegal gains are more than one million RMB, the fine shall be more than 5 times and less than 10 times the illegal gains), and temporary (1-5 years) or permanent debarment of companies, institutions and responsible persons from further human genetic resources projects, or even criminal liability.

 

The ability of U.S. authorities to bring actions for violations of U.S. securities law and regulations against us, our directors, executive officers or the expert named in this annual report may be limited. Therefore, investors may not be afforded the same protection as provided to investors in U.S. domestic companies.

 

The SEC, the U.S. Department of Justice, or the DOJ, and other U.S. authorities often have substantial difficulties in bringing and enforcing actions against non-U.S. companies such as us, and non-U.S. persons, such as our directors and officers in the PRC. Due to jurisdictional limitations, matters of comity and various other factors, the SEC, the DOJ and other U.S. authorities may be limited in their ability to pursue bad actors, including in instances of fraud, in emerging markets such as the PRC. With respect to our operations and assets in the PRC, there are significant legal and other obstacles for U.S. authorities to obtain information needed for investigations or litigation against us or our directors, executive officers or other gatekeepers in case we or any of these individuals engage in fraud or other wrongdoing. In addition, local authorities in the PRC may be constrained in their ability to assist U.S. authorities and overseas investors in connection with legal proceedings. As a result, if we, our directors, executive officers or other gatekeepers commit any securities law violation, fraud or other financial misconduct, the U.S. authorities may not be able to conduct effective investigations or bring and enforce actions against us, our directors, executive officers or other gatekeepers. Therefore, investors may not be able to enjoy the same protection provided by various U.S. authorities as it is provided to investors in U.S. domestic companies.

 

Investors may experience difficulties in effecting service of legal process, enforcing non-PRC judgments or bringing original actions in the PRC, based on United States or other non-PRC laws, against us, our directors, executive officers or the expert named in this annual report. Therefore, investors may not be able to enjoy the protection of such laws in an effective manner.

 

With respect to our operations and assets in the PRC, it may not be possible to effect service of process upon us, our directors and officers, including with respect to matters arising under U.S. federal securities laws or applicable state securities laws. Even if an investor obtains a judgment against us, our directors or officers, or the expert named in this annual report in a U.S. court or other court outside the PRC, an investor may not be able to enforce such judgment against us or them in the PRC. The PRC does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts in the United States or most other western countries. Therefore, recognition and enforcement in the PRC of judgments of a court in any of these jurisdictions may be difficult or impossible. In addition, investors may not be able to bring original actions in the PRC based on the U.S. or other non-PRC laws against us, our directors or officers, or the expert named in this annual report. As a result, shareholder claims that are common in the United States, including class actions based on securities law and fraud claims, are difficult or impossible to pursue as a matter of law and practicality in the PRC.

 

For example, in the PRC, there are significant legal and other obstacles to obtaining information needed for shareholder investigations or litigation outside the PRC or otherwise with respect to non-PRC entities. Although the local authorities in the PRC may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such regulatory cooperation with the securities regulatory authorities in the Unities States have not been efficient in the absence of mutual and practical cooperation mechanism. According to Article 177 of the PRC Securities Law which became effective in March 2020, no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory of the PRC. Accordingly, without the consent of the competent PRC securities regulators and relevant authorities, no organization or individual may provide the documents and materials relating to securities business activities to overseas parties. While detailed interpretation of or implementation rules under Article 177 of the PRC Securities Law is not yet available, the inability for an overseas securities regulator to directly conduct investigation or evidence collection activities within the PRC may further increase difficulties faced by investors in protecting the interests of investors. Therefore, investors may not be able to effectively enjoy the protection offered by the U.S. laws and regulations that are intended to protect public investors in the U.S.

 

20


 

Additional remedial measures could be imposed on PRC-based accounting firms, including our independent registered public accounting firm, in administrative proceedings instituted by the SEC, as a result of which our consolidated financial statements may be determined to not be in compliance with the requirements of the Exchange Act, if at all.

 

In December 2012, the SEC brought administrative proceedings against the PRC-based “big four” accounting firms, including our independent registered public accounting firm, alleging that they had violated U.S. securities laws by failing to provide audit work papers and other documents related to some other PRC-based companies under investigation by the SEC. In February 2015, each of the four PRC-based accounting firms agreed to a censure and to pay a fine to the SEC to settle the dispute and avoid suspension of their ability to practice before the SEC and to audit U.S.-listed companies. The settlement required the firms to follow detailed procedures to seek to provide the SEC with access to such firms’ audit documents via the CSRC. If the firms did not follow these procedures or if there is a failure in the process between the SEC and the CSRC, the SEC could impose penalties such as suspensions, or it could restart the administrative proceedings. If our independent registered public accounting firm is subject to additional legal challenges or penalties such as suspensions, our ability to file our consolidated financial statements in compliance with SEC requirements could be impacted. A determination that we have not timely filed consolidated financial statements in compliance with SEC requirements could ultimately lead to our de-listing from Nasdaq or deregistration from the SEC, or both, which would substantially reduce or effectively terminate the trading of our ADSs in the United States.

 

In the event that the PRC-based “big four” accounting firms become subject to additional legal challenges by the SEC or the PCAOB depending upon the final outcome, listed companies in the United States with major PRC operations may find it difficult or impossible to retain auditors in respect of their operations in the PRC, which could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act, including possible de-listing. Moreover, any negative news about any such future proceedings against these audit firms may cause investor uncertainty regarding PRC-based, U.S.-listed companies such as us and the market price of our ADSs may be adversely affected.

 

If our independent registered public accounting firm were denied, even temporarily, the ability to practice before the SEC and we were unable to timely find another registered public accounting firm to audit and issue an opinion on our consolidated financial statements, our consolidated financial statements could be determined not to be in compliance with the requirements of the Exchange Act. Such a determination could ultimately lead to the de-listing of our ADSs from Nasdaq or deregistration from the SEC, or both, which would substantially reduce or effectively terminate the trading of our ADSs in the United States.

 

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

 

We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.

 

Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage biopharmaceutical company with a limited operating history upon which investors can evaluate our business and prospects. We commenced operations in 2012, and to date, we have focused primarily on organizing and staffing our company, business planning, raising capital, performing research and development activities, establishing our intellectual property portfolio, discovering potential product candidates and conducting preclinical studies and clinical trials. Our approach to the discovery and development of product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value. We only have CBP-201, CBP-307, and CBP-174 in clinical development. There is no guarantee that we will be able to continue the development of or advance any product candidate into further clinical trials, including to meet the capital requirements for such activities. We have not yet demonstrated an ability to successfully obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.

 

21


 

We have incurred significant operating losses since our inception. If our product candidates are not successfully developed and approved, we may never generate any revenue. Our net losses were RMB 1,306.8 million (USD 205.0 million) and RMB 779.2 million (USD 119.4 million) for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of RMB 2.4 billion (USD 373.0 million). Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Our product candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we conduct our ongoing and planned preclinical studies and clinical trials, continue our research and development activities, increase our production capacity, and seek regulatory approvals for our product candidates, as well as hire additional personnel, obtain and protect our intellectual property and incur additional costs for commercialization or to expand our pipeline of product candidates.

 

To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability. If we fail to become and remain profitable, the value of our ADSs could be depressed and our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations could be impaired, and some or all of the value of our ADSs could be lost.

 

We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Our existing capital will not be sufficient for us to fund our product candidates through regulatory approval, and we will need to raise additional capital to complete their development and commercialization.

 

The development of biopharmaceutical product candidates is capital-intensive. Since our inception, we have used substantial amounts of cash to fund our operations and we expect our expenses to increase in connection with our ongoing activities during the next few years, particularly as we conduct our ongoing and planned clinical trials of CBP-201, CBP-307 and CBP-174, continue research and development for any additional product candidates, and seek regulatory approval for our current product candidates and any future product candidates we may develop. In addition, as our product candidates progress through development and toward commercialization, we may need to make royalty or other payments to our licensors and other third parties. Furthermore, if and to the extent we seek to acquire or in-license additional product candidates or rights in the future, we may be required to make significant upfront payments, milestone payments, licensing payments, royalty payments and/or other types of payments. If we obtain regulatory approval for any of our product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, we have incurred and expect to continue to incur significant costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital or find alternative sources of financing when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. The impact of the COVID-19 pandemic or other unexpected events on the capital markets may affect the availability, amount and type of financing available to us in the future. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates.

 

Our future financing requirements will depend on many factors, including:

 

the type, number, scope, progress, expansions, results, costs and timing of our clinical trials (especially if and as we move into Phase 3 clinical trials) and preclinical studies of our product candidates which we are pursuing or may choose to pursue in the future;

22


 

safety concerns related to the use of our product candidates;
adverse findings regarding the efficacy of our product candidates as additional information is acquired;
the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any product candidate is approved;
the costs, timing and outcome of regulatory review of our product candidates;
the costs of obtaining, maintaining, enforcing and defending our patents and other intellectual property and proprietary rights and resolving disputes related to third parties’ intellectual property and proprietary rights;
our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;
the costs associated with hiring additional personnel and consultants as our clinical activities increase;
the timing and amount of the royalty or other payments we must make to our licensors and other third parties;
the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved;
our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;
the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and
costs associated with any product candidates, products or technologies that we may in-license or acquire.

 

Conducting clinical trials (especially if and as we move into Phase 3 clinical trials which are typically substantially more expensive and of longer duration) and preclinical studies is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.

 

Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs, future commercialization efforts or other operations.

 

Raising additional capital may cause dilution to our shareholders, including holders of our ADSs, restrict our operations or require us to relinquish rights to our technologies or product candidates.

 

Until such time, if ever, as we can generate substantial revenues, we expect to finance our business and operational needs through equity offerings, debt financings or other financing sources, including potentially collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, investors’ ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect investors’ rights as a holder of our ADSs. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our ADSs. We may also lose control of the development of our products or product candidates, such as the pace and scope of clinical trials, as a result of such third-party arrangements. If we are unable to raise funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.

 

23


 

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

 

Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur unforeseen costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

 

All jurisdictions in which we intend to conduct our clinical drug development activities regulate these activities in great depth and detail. We intend to focus our activities on major markets, including the United States and the PRC. We currently conduct clinical trials, including in the United States, the PRC, Australia and New Zealand and must comply with the numerous and varying regulatory requirements of each jurisdiction. Before obtaining marketing approval from the FDA, the NMPA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the efficacy and safety of our product candidates. Clinical testing is expensive, time-consuming and subject to uncertainty. A failure of one or more clinical trials can occur at any stage of the process, and the outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.

 

To date, we have not completed any pivotal clinical trials for any of our product candidates. We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at all. We also cannot be sure that submission of an IND or similar application will result in the FDA, the NMPA or another regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. For example, we initiated in the second half of 2021 a PRC specific pivotal trial evaluating CBP-201 for moderate-to-severe atopic dermatitis, and in light of recent PRC governmental guidelines, we are now expanding that clinical trial in number and types of patients, so that enrollment and availability of data will take longer than originally anticipated. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include:

 

inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;
delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials;
delays or failure in obtaining regulatory authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a study;
delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;
delays in identifying, recruiting and training suitable clinical investigators;
delays in obtaining required ethics committee or institutional review board, or IRB, approval at each clinical trial site;
delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing;
insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;
imposition of a temporary or permanent clinical hold by regulatory authorities for a number of reasons, including after review of an IND or amendment or equivalent foreign application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; or a negative finding from an inspection of our clinical trial operations or study sites;
developments in trials conducted by competitors for related technology that raises FDA, NMPA or foreign regulatory authority concerns about risk to patients of the technology broadly, or findings by the FDA, the NMPA or a foreign regulatory authority that an investigational protocol or plan is clearly deficient to meet its stated objectives;
delays or failure in recruiting, screening and enrolling suitable patients and delays or failure caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up;
difficulty collaborating with patient groups and investigators;
failure by our CROs, other third parties or us to adhere to clinical trial protocols;
failure to perform clinical trials in accordance with the FDA’s, the NMPA’s or any other regulatory authority’s good clinical practice requirements, or GCPs, or applicable regulatory guidelines in other countries;

24


 

occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits, or occurrence of adverse events in trials of the same class of agents conducted by other companies;
changes to clinical trial protocols;
clinical sites deviating from trial protocol or dropping out of a trial;
changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;
selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data;
the cost of clinical trials of our product candidates being greater than we anticipate;
clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates;
transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization, or CMO, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing processes; and
third parties being unwilling or unable to satisfy their contractual obligations to us.

 

In addition, disruptions caused by the COVID-19 pandemic increased and may continue to increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing preclinical and clinical trials. For example, enrollment of our Phase 2 clinical trial of CBP-307 in patients with CD in the PRC was prematurely terminated due to challenges in recruitment caused by the COVID-19 pandemic. Additionally, enrollment in one Phase 1 clinical trial of CBP-307 and the Phase 1 clinical trial of CBP-174 in Australia have been slow due to the COVID-19 pandemic. Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue from product sales. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays or failure could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may seriously harm our business.

 

Clinical trials must be conducted in accordance with the FDA, the NMPA and other applicable regulatory authorities’ requirements, regulations or guidelines, which can change unexpectedly and significantly, and are subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions where the clinical trials are conducted. We could encounter delays or failure in the development of our product candidates if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA, the NMPA or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, the NMPA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

 

Further, conducting clinical trials in foreign countries for our product candidates, as in our ongoing clinical trials, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services, languages or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries, including war. For example, we have engaged CROs to conduct clinical trials outside of the U.S., including in Ukraine for our ongoing CBP-307 and CBP-201 trials. Russia’s invasion of Ukraine in February 2022 may impact our ability to conduct some of our trials in Ukraine and the surrounding region and may prevent us from obtaining data on patients already enrolled at sites in these countries. This could hinder the completion of our clinical trials and/or analyses of clinical results, which could materially harm our business.

 

25


 

Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under some circumstances, we may be required to report some of these relationships to the FDA, the NMPA or comparable foreign regulatory authorities. The FDA, the NMPA or a comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA, the NMPA or a comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA, the NMPA or a comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our product candidates.

 

Delays or failure in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate product revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to or failure in our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.

 

We depend on enrollment of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected.

 

Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. These trials and other trials we conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, patient withdrawal or adverse events. These types of developments could cause us to delay the trial or halt further development.

 

Our clinical trials will compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. In addition, there may be limited patient pools from which to draw for clinical studies. The eligibility criteria of our clinical studies will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a study.

 

Patient enrollment also depends on many other factors, including:

the size and nature of the patient population;
the severity of the disease under investigation;
eligibility criteria for the trial;
the proximity of patients to clinical sites;
the design of the clinical protocol;
the ability to obtain and maintain patient consents;
the ability to recruit clinical trial investigators with the appropriate competencies and experience;
the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion;
the availability of competing clinical trials;
the availability of new drugs approved or drug candidates under investigation for the indication the clinical trial is investigating; and
clinicians’ and patients’ perceptions as to the potential risks and advantages of the drug being studied in relation to other available therapies.

 

These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner, or may require us to abandon one or more clinical trials altogether. For example, enrollment of our Phase 2 clinical trial of CBP-307 in patients with CD in the PRC was prematurely terminated due to challenges in recruitment caused by the COVID-19

26


 

pandemic and enrollment in one Phase 1 clinical trial of CBP-307 and the Phase 1 clinical trial of CBP-174 in Australia have been slow due to the COVID-19 pandemic. In addition, we have engaged CROs to conduct clinical trials outside of the U.S., including in Ukraine for our ongoing CBP-307 and CBP-201 trials. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

 

Our product candidates may be associated with serious adverse events or undesirable side effects or have other properties that could delay or halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.

 

Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the NMPA or other comparable foreign regulatory authorities for such product candidates.

 

During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in previous trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale clinical trials or, in some cases, after they are made available to patients on a commercial scale following approval. In the single-dose regimen of our Phase 1 trial of CBP-307, one healthy adult treated with 2.5mg of CBP-307 experienced bradycardia associated with transient asystole, which was deemed a treatment-related serious adverse event. The subject was treated with high-flow oxygen and fully recovered.

 

If any serious adverse events occur, clinical trials or commercial distribution of any product candidates or products we develop or commercialize could be suspended or terminated, and our business could be seriously harmed. Treatment-related side effects could also affect patient recruitment and the ability of enrolled patients to complete the trial or result in potential liability claims. Regulatory authorities could order us to cease further development of, deny approval of, or require us to cease selling any product candidates or products for any or all targeted indications. If we are required to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be harmed, and our ability to generate product revenues from them or other product candidates that we develop may be delayed or eliminated. Additionally, if one or more of our product candidates receives marketing approval and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:

 

regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution;
regulatory authorities may require additional warnings on the label, including “boxed” warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;
we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies;
we may be required to create a risk evaluation and mitigation strategy, or REMS, which could include a medication guide outlining the risks of such side effects for distribution to patients;
we may be subject to fines, injunctions or the imposition of criminal penalties;
we could be sued and held liable for harm caused to patients; and
our reputation may suffer.

 

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could seriously harm our business.

 

27


 

We have conducted and may continue to conduct clinical trials for our product candidates in international sites, and the applicable regulatory authority may not accept data from trials conducted in foreign locations.

 

We have conducted, and may in the future choose to conduct, clinical trials outside the United States for our product candidates. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to specific conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well designed, conducted, performed, monitored, audited, recorded, analyzed, and reported in a way that provides assurance that the data and reported results are credible and accurate and that the rights, safety, and well-being of trial subjects are protected, in accordance with GCP requirements. FDA must also be able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, NMPA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, NMPA or any similar foreign regulatory authority does not accept the data from our clinical trials of our product candidates, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our product candidates.

 

Interim, “top-line” or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

 

From time to time, we may publicly disclose top-line or preliminary data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Moreover, caution should be exercised in drawing any conclusions from a comparison of data that does not come from head-to-head analysis. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line or preliminary data should be viewed with caution until the final data are available.

 

From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Disclosure of interim data by us or by our competitors could also result in volatility in the price of our ADSs.

 

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our ADSs. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and investors or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

 

28


 

We may attempt to secure approval from the FDA, the NMPA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, the NMPA or comparable foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, the NMPA or comparable foreign regulatory authorities may seek to withdraw accelerated approval.

 

We may in the future seek an accelerated approval for one or more of our product candidates. Under the accelerated approval program in the United States, for example, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verity and describe the drug’s clinical benefit. If such post-approval studies fail to confirm the drug’s clinical benefit, the FDA, the NMPA, or comparable foreign regulatory authorities may withdraw approval of the drug.

 

Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA, the NMPA, or comparable foreign regulatory authorities and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA or BLA, for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent regulatory feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA, the NMPA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type.

 

Further, there have been recent regulatory initiatives in the PRC in relation to clinical trial approvals, the evaluation and approval of some drugs and medical devices and the simplification and acceleration of the clinical trial process. As a result, the regulatory process in the PRC is evolving and subject to change.

 

A failure to obtain accelerated approval or any other form of expedited development, review or approval for one of our product candidates would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.

 

We are early in our development efforts and have only three product candidates, CBP-201, CBP-307, and CBP-174, in clinical development. If we are unable to successfully develop product candidates or experience significant delays in doing so, our business will be materially harmed.

 

We are in the early stages of our development efforts and have only three product candidates, CBP-201, CBP-307 and CBP-174, in clinical development. Any additional product candidates will need to progress through IND-enabling studies prior to clinical development. We have invested substantially all of our efforts and financial resources into developing our current product candidates, identifying potential product candidates and conducting preclinical studies and clinical trials. As a result, we have limited infrastructure and experience in conducting clinical trials as a company and in engaging in regulatory interactions, and cannot be certain that our ongoing or planned clinical trials will be initiated or completed on time, if at all, that our planned development programs would be acceptable to the FDA, the NMPA or other comparable foreign regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized.

 

Because of the early stage of our development and clinical programs, the success of our product candidates will depend on several factors, including the following:

 

successful enrollment in clinical trials and completion of clinical trials and preclinical studies with favorable results;

29


 

submission of and authorization to proceed with clinical trials under INDs by the FDA or similar regulatory filing by the NMPA or comparable foreign regulatory authorities for the conduct of clinical trials of our preclinical product candidates and our proposed design of future clinical trials;
demonstrating safety, purity, potency and/or efficacy of our product candidates to the satisfaction of applicable regulatory authorities;
receipt of marketing approvals from applicable regulatory authorities, including NDAs or BLAs from the FDA or similar regulatory filings from the NMPA or comparable foreign regulatory authorities, and maintaining such approvals;
making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing capabilities;
establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;
establishment, maintenance, enforcement and defense of patent, trade secret and other intellectual property and proprietary protection or regulatory exclusivity for our product candidates;
maintaining an acceptable safety profile of our products following approval, if any;
the impact of the COVID-19 pandemic on our current or future clinical trials, including any enrollment delays; and
maintaining and growing an organization of people who can develop our products and technology.

 

The success of our business, including our ability to finance our business and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates, which may never occur. We may not succeed in demonstrating the safety or efficacy for any product candidates in clinical trials or in obtaining marketing approval thereafter. Given our early stage of development, it may be several years, if at all, before we have demonstrated the safety or efficacy of any of our product candidates sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.

 

Our approach to the discovery and development of product candidates based on potent T cell modulation activity is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render our approach obsolete.

 

The success of our business depends primarily upon our ability to identify, develop and commercialize products based on the rapid identification of molecules with potent T cell modulation activity, which is a novel and unproven approach. Our drug screening approach is designed to enable us to identify and develop product candidates targeting multiple allergic and autoimmune diseases.

 

While we believe our preclinical, Phase 1 and/or Phase 2 results for each of CBP-201, CBP-307, and CBP-174 were supportive of further clinical development, we have not yet succeeded and may never succeed in demonstrating the safety and efficacy of any of our product candidates in later stage clinical trials or in obtaining marketing approval thereafter. We do not have any other product candidates in clinical development.

 

Our approach to targeting molecules that we believe have potent T cell modulation activity may be unsuccessful in identifying additional product candidates, and any product candidates based on our technology may be shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing or make the product candidates unmarketable or unlikely to receive marketing approval. Further, adverse developments with respect to any of our CBP-201, CBP-307 and CBP-174 programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our future product candidates based on our drug-screening approach.

 

In addition, the biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies. Our future success will depend in part on our ability to maintain a competitive position with our T cell modulating activity approach. If we fail to stay at the forefront of technological change in utilizing this technology and approach to create and develop product candidates, we may be unable to compete effectively. Our competitors may render our approach obsolete, or limit the commercial value of our product candidates, by advancing existing technological approaches or developing new or different approaches (including, for example, using different targeting approaches from ours), potentially eliminating the advantages that we believe we derive from our targeting of molecules with potent T cell modulation activity. By contrast, adverse developments with respect to other companies that attempt to use a similar T cell modulation approach to ours may adversely impact the actual or perceived value of and potential of our product candidates.

 

If any of these events occur, we may be forced to abandon our development efforts for one or more programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.

30


 

 

We have never conducted later-stage clinical trials or submitted an NDA or BLA, and may be unable to do so for any of our product candidates.

 

We are early in our development efforts for our product candidates, and we will need to successfully complete pivotal clinical trials in order to obtain FDA, NMPA or comparable foreign regulatory approval to market any of our current or future product candidates. Carrying out later-stage clinical trials and the submission of a successful NDA or BLA is a complicated and expensive time-consuming process. We have not previously conducted any pivotal clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted an IND or an NDA or BLA or other comparable foreign regulatory submission for any product candidate. We also plan to conduct a number of clinical trials for multiple product candidates in parallel over the next several years, which may be a difficult process to manage with our limited resources and which may divert the attention of management. In addition, we have had limited interactions with the FDA, the NMPA, and comparable foreign regulatory authorities and cannot be certain how many additional clinical trials of CBP-201, CBP-307, CBP-174 or any of our other product candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that will support regulatory submissions and lead to approval of any of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in submitting NDAs or BLAs for and commercializing our product candidates.

 

The regulatory approval processes of the FDA, the NMPA and comparable foreign authorities are lengthy, time consuming and unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

 

The time required to obtain approval by the FDA, the NMPA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary unexpectedly and significantly among jurisdictions. We have not obtained regulatory approval for any product candidate in the United States, the PRC or any other jurisdiction, and it is possible that any product candidates we may seek to develop in the future will never obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States or any other jurisdiction until we receive regulatory approval of an NDA or BLA from the FDA or the comparable foreign regulatory submission from a foreign regulatory authority.

 

Prior to obtaining approval to commercialize a product candidate in the United States, the PRC or elsewhere, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, the NMPA or foreign regulatory agencies, as applicable, that such product candidates are safe and effective, or in the case of biologics, safe, pure, and potent, for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the NMPA or other regulatory authorities. The FDA, the NMPA or other foreign regulatory authorities may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program.

 

The FDA, the NMPA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates, or require us to conduct additional nonclinical or clinical testing or abandon a program for many other reasons, including the following:

 

the FDA, the NMPA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
we may be unable to demonstrate to the satisfaction of the FDA, the NMPA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;
the results of our clinical trials may not meet the level of statistical significance required for approval by the FDA, the NMPA or comparable foreign regulatory authorities;
serious and unexpected drug or biologic-related side effects experienced by participants in our clinical trials or by individuals using drugs or biologics similar to our product candidates;
we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
the FDA, the NMPA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

31


 

the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of a BLA or NDA or other submission or to obtain regulatory approval in the United States, the PRC or elsewhere;
the FDA, the NMPA or applicable foreign regulatory authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;
our clinical sites, investigators or other participants in our clinical trials may deviate from a trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial;
the FDA, the NMPA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of ours or third-party manufacturers with which we contract for clinical and commercial supplies; and
the approval policies or regulations of the FDA, the NMPA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

 

Of the large number of drugs in development, only a small percentage successfully complete the FDA, the NMPA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.

 

Even if we eventually complete clinical trials and receive approval of an NDA, BLA or foreign marketing application for our product candidates, the FDA, the NMPA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or the implementation of a REMS, which may be required to ensure safe use of the drug after approval. The FDA, the NMPA or the comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested. Any delay in obtaining, or inability to obtain, the applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.

 

Disruptions at the FDA, the NMPA, comparable foreign regulatory authorities, and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.

 

The ability of the FDA, the NMPA, comparable foreign regulatory authorities and other government agencies to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the regulatory authority’s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the regulatory authority’s ability to perform routine functions. For example, average review times at the FDA and the NMPA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA, the NMPA and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and some regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities.

 

32


 

Separately, in response to the COVID-19 pandemic, in March 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020 the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed some on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 14 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of some drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA, the NMPA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA, the NMPA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

 

Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.

 

The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or “biosimilar” product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.

 

We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

33


 

Risks Related to Our Reliance on Third Parties

We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct some aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

 

We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct some aspects of our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only some aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors, including our CROs, are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the NMPA and comparable foreign regulatory authorities for our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties, including our CROs, fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the NMPA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure investors that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under Current Good Manufacturing Practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal, state or foreign fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.

 

Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if they do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised or incorrect due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be unproductive and may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely.

 

Our clinical sites and CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our clinical sites and CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.

 

Furthermore, U.S. export control laws and economic sanctions prohibit the provision of some products and services to countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed as a result of military conflicts in other countries may impact CROs’ ability to continue activities at clinical trial sites within regions covered by such sanctions. For example, as a result of the military conflict between Russia and Ukraine, the United States and its European allies have recently announced the imposition of sanctions on specific industry sectors and parties in Russia and the regions of Donetsk and Luhansk in Ukraine, as well as enhanced export controls on some products and industries. These and any additional sanctions and export controls, as well as any economic countermeasures by the governments of Russia or other jurisdictions, could adversely impact our ability to continue activities at clinical trial sites within regions covered by such sanctions or directly or indirectly disrupt our supply chain. If we or our third-party contractors, including our CROs, fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of some export privileges.

 

34


 

If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative sites or CROs or to do so on commercially reasonable terms. Switching or adding additional sites and CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new site or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, clinical sites and CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs and through them clinical sites, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.

 

We contract with third parties for the manufacture of our product candidates for preclinical studies and our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately, in some jurisdictions, for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

 

We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We are planning to construct facilities to be used to develop and manufacture preclinical and clinical material for future clinical trials for some product candidates and to build commercial supply in some jurisdictions, including the PRC. However, we rely, and we expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials. We do not have long-term supply agreements. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example, the extent to which the continuing COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our product candidates will depend on the severity and duration of the spread of the virus and variants of the virus, and the actions undertaken to contain COVID-19 or treat its effects.

 

We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We are continuously evaluating multiple vendors both in the PRC and outside of the PRC to ensure that we have a continuous supply of product candidates for global studies and trials. However, we may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

 

the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;
the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;
the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;
the breach by the third-party contractors of our agreements with them;
the failure of the third-party contractors to comply with applicable regulatory requirements;
the failure of the third party contractors to manufacture our product candidates according to our specifications;
the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or study drug or placebo not being properly identified;
clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and
the misappropriation of our proprietary information, including our trade secrets and know-how.

 

35


 

We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States or successfully manufacture material that conforms to our specifications. If our contract manufacturers cannot comply with the strict regulatory requirements of the FDA, the NMPA or other comparable foreign regulatory authorities, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, the NMPA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. If we, or if our third-party manufacturers, fail to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.

 

Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.

 

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third party will discover them or that our trade secrets will be misappropriated or disclosed.

 

Because we currently rely on other third parties to manufacture our product candidates and to perform development, quality testing and other services, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements are intended to limit the rights of the third parties to use or disclose our confidential information, but such agreements could be breached, and we might not enter into such agreements with all applicable parties. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors or other third parties, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, the discovery by a competitor or other third party of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.

 

We expect to seek to enter into collaborations, licenses and other similar arrangements and may not be successful in doing so, and even if we are, we may not realize the benefits of such relationships.

 

We expect to seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product candidates, due to capital costs or other reasons affecting our ability to develop or commercialize the product candidates or manufacturing constraints in some or all jurisdictions. We may not be successful in our efforts to establish other such collaborations for our product candidates because our research and development pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. We cannot be certain that, following a strategic transaction or license, we will achieve an economic benefit that justifies such transaction.

Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned or sales of an approved product candidate are unsatisfactory.

 

36


 

In addition, any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for some rights to control decisions regarding the development and commercialization of our product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.

 

If the custodians or authorized users of our controlling non-tangible assets, including chops and seals, fail to fulfill their responsibilities, or misappropriate or misuse these assets, our business and operations may be materially and adversely affected.

 

Under PRC law, legal documents for corporate transactions are executed using the chop or seal of the signing entity or with the signature of a legal representative whose designation is registered and filed with the relevant local branch of the State Administration for Market Regulation, or the SAMR. We generally execute legal documents by affixing chops or seals, rather than having the designated legal representatives sign the documents. The chops of our subsidiaries are generally held by the relevant entities so that documents can be executed locally. Although we usually utilize chops to execute contracts, the registered legal representatives of our subsidiaries have the apparent authority to enter into contracts on behalf of such entities without chops, unless such contracts set forth otherwise.

 

In order to maintain the physical security of our chops, we generally have them stored in secured locations accessible only to the designated key employees of our legal, administrative or finance departments. Our designated legal representatives generally do not have access to the chops. Although we have approval procedures in place and monitor our key employees, including the designated legal representatives of our subsidiaries, the procedures may not be sufficient to prevent all instances of abuse or negligence. There is a risk that our key employees or designated legal representatives could abuse their authority, for example, by binding our subsidiaries with contracts against our interests, as we would be obligated to honor these contracts if the other contracting party acts in good faith in reliance on the apparent authority of our chops or signatures of our legal representatives. If any designated legal representative obtains control of the chop in an effort to obtain control over the relevant entity, we will need to have a shareholder or board resolution to designate a new legal representative and to take legal action to seek the return of the chop, apply for a new chop with the relevant authorities, or otherwise seek legal remedies for the legal representative’s misconduct. If any of the designated legal representatives obtains and misuses or misappropriates our chops and seals or other controlling intangible assets for whatever reason, we could experience disruption to our normal business operations. We may have to take corporate or legal action, which could involve significant time and resources to resolve while distracting management from our operations, and our business and operations may be materially and adversely affected.

 

Risks Related to Commercialization of Our Product Candidates

 

Even if our product candidates receive regulatory approval, they will be subject to ongoing regulatory review and significant post-marketing regulatory requirements and oversight.

 

Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidates, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, the NMPA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, sampling, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMP and GCPs for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA, the NMPA and other regulatory authorities to ensure compliance with cGMP or similar regulations and standards. If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.

 

37


 

In addition, failure to comply with FDA, NMPA and other comparable foreign regulatory requirements may subject us to administrative or judicially imposed sanctions, including:

delays in reviewing or the rejection of product applications or supplements to approved applications;
require us to change the way a product is distributed, conduct additional clinical trials, change the labeling of a product or require us to conduct additional post-marketing studies or surveillance;
restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
restrictions on the products, manufacturers or manufacturing process;
warning or untitled letters;
civil and criminal penalties;
injunctions;
suspension or withdrawal of regulatory approvals;
product seizures, detentions or import bans;
voluntary or mandatory product recalls and publicity requirements;
total or partial suspension of production; and
imposition of restrictions on operations, including costly new manufacturing requirements.

 

The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.

 

The FDA’s, the NMPA’s and other regulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.

 

The FDA, the NMPA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability.

 

If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA, the NMPA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA, the NMPA or such other regulatory agencies as reflected in the product’s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.

 

The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.

 

Our product candidates may not be commercially successful. Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or others in the medical community. The commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products, if approved for commercial sale, will depend on a number of factors, including:

 

demonstration of clinical efficacy and safety compared to other more established products;
the indications for which our product candidates are approved;
the limitation of our targeted patient population and other limitations or warnings contained in any regulatory authority-approved labeling;
acceptance of a new drug or biologic for the relevant indication by healthcare providers and their patients;

38


 

the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;
our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;
the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in absence of sufficient either with or without third-party coverage and adequate reimbursement;
any restrictions on the use of our products, and the prevalence and severity of any adverse effects;
potential product liability claims;
the timing of market introduction of our products as well as competitive drugs;
the effectiveness of our or any of our potential future collaborators’ sales and marketing strategies; and
unfavorable publicity relating to the product.

 

If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, patients, healthcare payors or others in the medical community, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and healthcare payors regarding the benefits of our products may require significant resources and may never be successful.

 

The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.

 

The availability of coverage and the adequacy of reimbursement by governmental healthcare programs, such as Medicare and Medicaid in the U.S., private health insurers, and other third-party payors are essential for most patients to be able to access and afford prescription medications such as our product candidates, if approved. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize our products. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or coverage policies may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the PRC, the European Union, or EU, or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.

 

In the United States, governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered and reimbursed. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage processes may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage will be applied consistently or obtained in the first instance. It is possible that a third-party payor may consider our products as substitutable and only offer to provide coverage for a less expensive product.

 

Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. These payors may deny or revoke the reimbursement amount of a given product at any time. If reimbursement is not available or is available at only limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement of our products.

 

Third-party payors increasingly are challenging prices paid for pharmaceutical products and services and requesting discounts or rebates through pharmacy benefit managers. Even if we are successful in demonstrating improved efficacy or safety with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. As a result, market prices, including discounts we may be required to provide, for our products may be too low to enable us to realize an appropriate return on our investment in product development. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, including the PRC, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

39


 

 

In the PRC, the National Healthcare Security Administration of the PRC, or the NHSA, or provincial or local healthcare security authorities, together with other government authorities, review the inclusion or removal of drugs from the PRC’s National Drug Catalog for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, or the National Reimbursement Drug List, or the NRDL, or provincial or local medical insurance catalogues for the National Medical Insurance Program regularly, and the tier under which a drug will be classified, both of which affect the amounts reimbursable to program participants for their purchases of those drugs. There can be no assurance that any of our product candidates will be included in the NRDL after initial approval for commercial sale. Historically, pharmaceutical products included in the NRDL are typically generic and essential drugs, while innovative drugs similar to our product candidates have been more limited on their inclusion in the NRDL due to cost constraints. Since 2019, innovative drugs similar to ours are subject to pricing negotiation with the NHSA for the NRDL inclusion, potentially with significant price reduction. If we were to successfully launch commercial sales of our products but fail in our efforts to have our products included in the NRDL, our revenue from commercial sales will be highly dependent on patient self-payment, which can make our products less competitive.

 

Moreover, increasing efforts by governmental and third-party payors in the United States, the PRC and other jurisdictions to cap or reduce healthcare costs may cause payors to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the overall rising costs of healthcare, the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

 

Outside the United States and the PRC, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.

 

We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected.

 

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products or product candidates competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition in the fields of immunology and inflammation. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling patients for clinical trials and in identifying, in-licensing and establishing intellectual property and proprietary protection for new product candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

We expect to face competition from existing products and products in development for each of our product candidates as described in the section titled “Business—Competition” elsewhere in this annual report.

 

40


 

We have competitors in the United States, the PRC and elsewhere, including major multinational pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies. Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.

 

If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.

 

The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases.

 

The total addressable market across our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States, the PRC and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.

 

We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.

 

We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.

 

Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.

 

Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product candidates. To obtain

41


 

separate regulatory approval in many other countries or areas we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our product candidates.

If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:

 

efforts to enter into collaboration or licensing arrangements with third parties in connection with our international sales, marketing and distribution efforts may increase our expenses or divert our management’s attention from the acquisition or development of product candidates;
different regulatory requirements for approval of drugs in foreign countries;
reduced protection for intellectual property and other proprietary rights;
the existence of additional third-party patent rights of potential relevance to our business;
unexpected changes in tariffs, trade barriers and regulatory requirements;
the effects of applicable non-PRC tax structures and potentially adverse tax consequences;
changes in a specific country’s or region’s political and cultural climate or economic condition;
economic weakness, including inflation, or political instability in particular foreign economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;
foreign reimbursement, pricing and insurance regimes;
difficulty of effective enforcement of contractual provisions in local jurisdictions;
workforce uncertainty in countries where labor unrest is common;
failure of our employees and contracted third parties to comply with rules and regulations of the U.S. Treasury Department’s Office of Foreign Assets Controls and the U.S. Foreign Corrupt Practices Act of 1977, as amended, and other applicable rules and regulations;
the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from an international market with low or lower prices rather than buying them locally;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;
the illegal importation of competing products from countries where government price controls or other market dynamics result in lower prices; and
business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters, including earthquakes, typhoons, floods and fires, or public health epidemics, including the COVID-19 pandemic.

 

Risks Related to Our Business Operations and Industry

 

We are subject to risks arising from COVID-19 and other epidemic diseases.

 

In December 2019, a novel strain of coronavirus, COVID-19, was first reported in Wuhan, PRC and has since become a global pandemic. In an effort to contain the spread of COVID-19 and variants of the virus (when we refer to COVID-19 in this annual report we include its variants), many countries, including the PRC, the United States and most other jurisdictions around the world, have imposed unprecedented restrictions on travel, business closures, quarantines and lock-downs, resulting in a substantial reduction in economic activity.

 

As COVID-19 has continued to evolve, it has resulted in adverse effects in the global economy and financial markets, such as significant volatility in the global stock markets. The effects of government actions and our own policies and those of third parties to reduce the spread of COVID-19 have and may continue to negatively impact productivity and slow down or delay our ongoing and future clinical trials, preclinical studies and research and development activities, and have caused, and may further cause, disruptions to our supply chain and may impair our ability to execute our business development strategy. For example, enrollment of our Phase 2 clinical trial of CBP-307 in patients with CD in the PRC was prematurely terminated due to challenges in recruitment caused by the COVID-19 pandemic. Additionally, enrollment in one Phase 1 clinical trial of CBP-307 and the Phase 1 clinical trial of CBP-174 in Australia have been slow due to the COVID-19 pandemic. In response to the COVID-19 pandemic, we have transitioned to a hybrid model with some of our employees generally working both remotely and onsite, and we anticipate we will continue to use this model

42


 

going forward. In the event that government authorities were to enhance current restrictions, our employees who currently are working onsite may no longer be able to access our facilities, and our operations may be limited or curtailed.

 

COVID-19’s continuing impact and any future epidemic diseases may cause disruptions that could severely impact our business, preclinical studies and clinical trials, including:

 

delays in receiving authorizations from local regulatory authorities to initiate our planned clinical trials;
delays or additional difficulties in enrolling and retaining patients in our clinical trials;
risk that patients may withdraw from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine, which could adversely influence the results of a clinical trial by increasing the number of adverse events or patients lost to follow-up;
delays or difficulties in clinical site initiation or expansion, including difficulties in recruiting clinical site investigators and clinical site staff;
delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruptions in global shipping that may affect the transport of clinical trial materials;
changes in regulations as part of a response to the COVID-19 outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;
diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;
delays in necessary interactions with regulators, ethics committees and other agencies and contractors due to limitations in employee resources or forced furloughs of government or contractor personnel;
interruption or delays in the operations of the FDA, the NMPA or other regulatory authorities, which may adversely affect review and approval timelines; and
refusal of a regulatory authority to accept data from clinical trials in affected geographies outside its jurisdiction.

 

These and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial condition.

 

Our clinical trials have been, and may in the future be, affected by COVID-19. For example, some of our clinical trial sites experienced slow-down of enrollment of new patients in clinical trials, denied access to site monitors and were otherwise impacted in some of their operations. Similarly, our ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may be adversely impacted. We and our CROs have also made some adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA on March 18, 2020 and most recently updated on January 27, 2021, and may need to make further adjustments in the future. Many of these adjustments are new and untested, may not be effective in mitigating risks, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials. These events could delay our clinical trials, increase the cost of completing our clinical trials and negatively impact the integrity, reliability or robustness of the data from our clinical trials.

 

In addition, quarantines, shelter-in-place and similar government orders related to COVID-19 or other epidemic or infectious diseases, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, could adversely affect personnel at third-party manufacturing facilities upon which we rely, or the availability or cost of materials, which could disrupt the supply chain for our product candidates. To the extent our suppliers and service providers are unable to comply with their obligations under our agreements with them or they are otherwise unable to deliver or are delayed in delivering goods and services to us due to the COVID-19 pandemic, our ability to continue meeting clinical supply demand for our product candidates or otherwise advancing development of our product candidates may become impaired.

 

The spread of COVID-19 and actions taken to reduce its spread may also materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, it has already caused, and could result in further, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our ADSs or other securities and such sales may be on unfavorable terms.

 

43


 

COVID-19 and other epidemic or infectious diseases, as well as actions taken to reduce their spread continue to rapidly evolve. The extent to which COVID-19 and other epidemic or infectious diseases may impede the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the PRC, the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section, such as those relating to the timing and results of our clinical trials and our financing needs.

 

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.

 

Our operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:

 

the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our product candidates, which may change from time to time;
coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products;
the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with third-party manufacturers;
the timing and amount of the royalty or other payments we must make to the licensors and other third parties from whom we have in-licensed our acquired our product candidates, including payments due upon a change in control of our subsidiaries;
expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;
the level of demand for any approved products, which may vary significantly;
future accounting pronouncements or changes in our accounting policies; and
the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.

 

The cumulative effects of these factors could result in large fluctuations and unpredictability in our operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.

 

This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our ADSs could decline substantially. Such an ADS price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.

 

We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer.

 

Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon our senior management, particularly our Chief Executive Officer and our President and Chairman, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will and, therefore, we may not be able to retain their services as expected. We do not currently maintain “key person” life insurance on the lives of our executives or any of our employees, except for our Chief Executive Officer and our President and Chairman. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.

 

We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We compete for qualified management and scientific personnel with

44


 

other life science and technology companies, universities, and research institutions in the United States, the PRC and other countries. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.

 

We may encounter difficulties in managing our growth and expanding our operations successfully, including with respect to expanding our senior management team and constructing facilities.

 

We had 108 full-time employees as of December 31, 2021. We have been experiencing challenges in attracting and retaining qualified personnel, including with respect to expanding our senior management team. We expect to continue to hire, but could encounter difficulties in finding and securing sufficient candidates that meet our needs in a timely manner and on favorable terms.

 

We plan to expand our facilities in the United States and the PRC to support our growth, including the clinical development and potential commercialization of our product candidates. However, if we are unable to obtain adequate committed third party financing or if there are otherwise delays in bringing the facilities on-line, we may not have sufficient capacity to meet our long-term requirements. In addition, we are making significant investments and undertaking various obligations and responsibilities, including in connection with our land use and investment agreements with governmental authorities in the PRC. We face challenges in meeting timelines in connection with the construction of our PRC facilities, including having not obtained necessary permits, with no assurance that this investment can be recouped or that we will be able to meet all obligations and responsibilities under such agreements, which may result in land retrieval, penalties and/or fines, the loss of financial incentives, or the loss of access to future opportunities, and jeopardize or damage our relationships, from or with governmental authorities in the PRC, which in turn would have a negative effect on our financial condition and results of operations.

As we continue development and pursue the potential commercialization of our product candidates, as well as function as a public company, we will need to continue to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.

 

Because we have multiple product candidates in our clinical pipeline and are considering a variety of target indications, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

 

Because we have limited financial and managerial resources, we focus on specific product candidates, indications and development programs. We also plan to conduct several clinical trials for multiple product candidates in parallel over the next several years, which may make our decision as to which product candidates to focus on more difficult. As a result, we may forgo or delay pursuit of opportunities with other product candidates that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

 

Additionally, we may pursue additional in-licenses or acquisitions of development-stage assets or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a particular product candidate, potentially resulting in a diversion of our management’s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment.

 

45


 

We have incurred and may continue to incur significant costs for our clinical trials for CBP-201 and CBP-307.

 

The majority of our third-party expenses have been related to the development of CBP-201 and CBP-307. During the years ended December 31, 2020 and 2021, we spent RMB 58.5 million and RMB 349.5 million (USD 54.8 million), respectively, in clinical trial related expenses relating to CBP-201, and RMB 46.5 million and RMB 112.3 million (USD 17.6 million), respectively, in clinical trial related expenses relating to CBP-307. Product candidates in a later-stage of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our costs to increase as we continue clinical trials (especially if and as we move into Phase 3 clinical trials) and, if we manufacture or have manufactured, CBP-201 and CBP-307.

 

We cannot determine with certainty the timing or costs or probability of success of current or future clinical trials of CBP-201 and CBP-307 due to the inherently unpredictable nature of clinical development. We anticipate that we will make determinations as to which indications to pursue, as well as how much funding is needed to direct to each indication on an ongoing basis in response to the results of clinical trials, regulatory developments and our assessments as to each product candidate’s commercial potential. It is likely that we will need to raise additional capital in the future for clinical development of CBP-201 and CBP-307 and if either or both of CBP-201 and CBP-307 can be commercialized.

 

Our clinical development costs for CBP-201 and CBP-307 are highly uncertain and may vary significantly based on factors such as:

per patient trial costs;
the number of trials required for approval;
the number of sites included in the trials;
the countries in which the trials are conducted;
the length of time required to enroll eligible patients;
the number of patients that participate in the trials;
the drop-out or discontinuation rates of patients;
potential additional safety monitoring requested by regulatory agencies;
the duration of patient participation in the trials and follow-up;
the cost and timing of manufacturing our product candidates;
the phase of development of our product candidates; and
the efficacy and safety profile of our product candidates.

 

Any of these variables with respect to the development of CBP-201 and CBP-307 could result in a significant change in the costs and timing associated with their development. Despite our efforts and the costs incurred and to be incurred, we may never succeed in obtaining regulatory approval for either or both of CBP-201 and CBP-307, which could significantly harm our business, operating results, prospects or financial condition.

 

We may be exposed to liabilities under the Foreign Corrupt Practices Act, or FCPA, and Chinese anti-corruption laws, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.

 

We are subject to the FCPA. The FCPA generally prohibits us from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We are also subject to the anti-bribery laws of other jurisdictions, particularly mainland China. As our business continues to expand, the applicability of the FCPA and other anti-bribery laws to our operations will continue to increase. Our procedures and controls to monitor anti-bribery compliance may fail to protect us from reckless or criminal acts committed by our employees or agents. If we, due to either our own deliberate or inadvertent acts or those of others, fail to comply with applicable anti-bribery laws, our reputation could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.

 

46


 

We are subject to various foreign, federal, and state healthcare laws and regulations, and failure to comply with these laws and regulations could harm our results of operations and financial condition.

 

Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:

 

the U.S. Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. A conviction for violation of the federal Anti-Kickback Statute can result in criminal fines and/or imprisonment and requires mandatory exclusion from participation in federal health care programs. Exclusion from the federal healthcare programs may also be imposed if the government determines that an entity has committed acts that are prohibited by the federal Anti-Kickback Statute;

 

the U.S. false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the U.S. government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false or fraudulent claim or statement for violations;

 

the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

 

the U.S. Physician Payments Sunshine Act, which requires some manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with some exceptions) to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related to payments and other “transfers of value” made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), some non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse-midwives) and teaching hospitals as well as ownership and investment interests held by the physicians described above and their immediate family members; and analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or paid for by the patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives; state and foreign laws governing the collection, processing, distribution, use, privacy, security, storage and other use of health information and other personally identifiable information and other data relating to individuals (including the EU General Data Protection Regulation 2016/679, or EU GDPR, and the California Consumer Protection Act, or CCPA), many of which differ from each other in significant ways and often are not preempted by HIPAA.

 

47


 

Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.

 

The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Complying with such requirements can be difficult, time-consuming, expensive, and could require us to change our business practices and put in place additional compliance mechanisms. Failure to comply with laws, regulations and contractual and other obligations governing personal or other sensitive information could result in enforcement actions against us, including fines, public censure, processing penalties, claims for damages by affected individuals, damage to our reputation and loss of goodwill. It is possible that new and existing laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful.

 

In the United States., HIPAA imposes, among other things, specific standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted under HIPAA’s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA’s requirements for disclosure of individually identifiable health information.

 

Some states have also adopted comparable privacy and security laws and regulations, which govern the privacy, processing and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, California Consumer Privacy Act of 2018, or the CCPA, went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling specific personal information. It also provides a private right of action for data breaches that is expected to increase data breach litigation and creates a statutory damages framework. In addition, on November 3, 2020, California voters approved a new privacy law, the California Privacy Rights Act, or CPRA, which significantly amends the CCPA, including by expanding consumers’ rights with respect to personal information and creating a new state agency to oversee implementation and enforcement efforts. Many of the CPRA’s provisions will become effective on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.

48


 

Our operations in Europe may also be subject to increased scrutiny or attention from data protection authorities. For example, the General Data Protection Regulation, or GDPR, went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area, or EEA. The GDPR increases our obligations with respect to clinical trials conducted in the EU by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. Failure to comply with the requirements of GDPR may result in fines of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. In addition, the GDPR confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States; in July 2020, the Court of Justice of the EU (CJEU) limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses (SCCs). The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the United Kingdom, or the UK; the UK’s Information Commissioner’s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021 and laid its proposal before Parliament, with the UK SCCs expected to come into force in March 2022, with a two-year grace period. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.

 

Since the beginning of 2021, after the end of the transition period following the UK’s departure from the EU, we are also subject to the UK data protection regime, which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to £17.5 million or 4% of a noncompliant company’s global annual revenue for the preceding financial year, whichever is greater. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.

 

Regulatory authorities in the PRC have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, the PRC’s Cyber Security Law, which became effective in June 2017, created the PRC’s first national-level data protection for “network operators,” which may include all organizations in the PRC that provide services over the internet or another information network. Numerous regulations, guidelines and other measures are expected to be adopted under the umbrella of the Cyber Security Law. Drafts of some of these measures have now been published, including the draft rules on cross-border transfers published by the China Cyberspace Administration in 2017, which may, upon enactment, require security review before transferring human health-related data out of the PRC. In addition, some industry-specific laws and regulations affect the collection and transfer of personal data in the PRC. For example, on June 10, 2019 the PRC State Council promulgated the Regulation on the Administration of Human Genetic Resources which became effective on July 1, 2019. Under the Regulation, international collaborative projects involving human genetic resources or HGR are subject to approval by the PRC Ministry of Science and Technology ("MOST"), except for international collaborations on clinical trials intended to support marketing approval of drugs and devices in the PRC that do not transfer HGR Materials abroad. This HGR regulatory regime is further confirmed by the Biosecurity Law of the PRC published by the Standing Committee of the NPC of the PRC in October 2020. The PRC has established a record-filing procedure for such exceptions. To comply with such record-filing procedure, the parties must submit information as to the types, quantities and purposes of the HGR used prior to the commencement of the trials. As for cross-border transfer of the HGR samples or associated data, they are subject to different forms of review and pre-approval respectively. Any export or cross-border transfer of the HGR samples shall be subject to the approval of the MOST, and an export certificate shall be obtained. The provision of HGR associated data to non-PRC parties or permitting uses of HGR associated data by non-PRC parties requires a record filing with MOST and submission of that corresponding information’s copy. If such provision or permitting uses could impact the public health, national security or public interest of the PRC, an additional security review will be conducted. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices, potentially resulting in disgorgement of illegal gains, confiscation of HGR samples and associated data, administrative fines, temporary (1-5 years) or permanent disbarment of companies and responsible persons from further HGR projects, or even criminal liability.

 

The PRC’s new Data Security Law took effect in September 2021. The Data Security Law provides that the data processing activities must be conducted based on a “data classification and hierarchical protection system” for the purpose of data protection and that the provision of “important data” outside of the PRC should comply with security management measures for cross-border transfer of data

49


 

and fulfill risk assessment. In addition, entities in the PRC are prohibited from transferring data stored in the PRC to foreign law enforcement agencies or judicial authorities without prior approval by the PRC government. The Personal Information Protection Law, which took effect on November 1, 2021, includes biometric and medical health information in the scope of "sensitive personal information", and the cross-border transfer of personal information should also comply with the relevant assessment requirements. The relevant specific interpretative and implementation rules are still under development.

 

Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.

 

Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.

 

In the United States, the PRC and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.

 

For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, or ACA, was enacted in the United States. Among the provisions of the ACA of importance to our potential product candidates, the ACA: established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expands eligibility criteria for Medicaid programs; expanded the entities eligible for discounts under the 340B Drug Discount Pricing program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; created a new Medicare Part D coverage gap discount program; established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.

 

Since its enactment, there have been executive, judicial and Congressional challenges to some aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the U.S. Supreme Court’s decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed some governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the healthcare reform measures of the Biden administration, if any, will impact our business.

 

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 and a 1% reduction from April 1, 2022 through June 30, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price, beginning January 1, 2024.

 

Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, by way of example, the Biden Administration has supported legislation including substantial drug pricing reforms, including the

50


 

establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated “maximum fair price” for specific selected drugs or pay an excise tax for noncompliance, and the establishment of rebate payment requirements on manufacturers of specific drugs payable under Medicare Parts B and D, as seen in the Build Back Better Act. Similar or other drug pricing proposals could appear in future legislation. Further, it is possible that additional governmental action will be taken in response to the COVID-19 pandemic.

 

At the state level, legislatures have increasingly passed legislation and implemented regulations designed to address pharmaceutical and biological product pricing, including transparency measures that require the disclosure of prices, including price changes, marketing costs, and research costs, among others. Price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects.

 

Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or Right to Try Act, was signed into law. The law, among other things, provides a federal framework for some patients with life-threatening diseases or conditions to access some investigational new drug products that have completed a Phase 1 clinical trial. Under some circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.

 

We expect that healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we may charge for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.

 

Some of our investments may be subject to review from the Committee on Foreign Investment in the United States, or CFIUS, which may delay or block a transaction from closing.

 

The Committee on Foreign Investment in the United States, or CFIUS, has jurisdiction over investments in which a foreign person acquires control over a U.S. company, as well as some non-controlling investments in U.S. businesses that deal in critical technology, critical infrastructure, or sensitive personal data. Some transactions involving U.S. businesses that deal in critical technology are subject to a mandatory filing requirement. Accordingly, to the extent the U.S. portion of our business decides to take investments from foreign persons, or we decide to invest in or acquire, in whole or in part, a U.S. business, such investments could be subject to CFIUS’ jurisdiction. To date, none of our investments have been subject to CFIUS review but, depending on the particulars of ongoing or future investments, we may be obligated to secure CFIUS approval before closing, which could delay the time period between signing and closing. If we determine that a CFIUS filing is not mandatory (or otherwise advisable), there is a risk that CFIUS could initiate its own review, if it determines that the transaction is subject to its jurisdiction. If an investment raises significant national security concerns, CFIUS has the authority to impose mitigation conditions or recommend that the President block a transaction.

 

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.

 

We face an inherent risk of product liability as a result of the clinical trials of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability or a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.

 

If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

decreased demand for our products;
injury to our reputation and significant negative media attention;
difficulty attracting or withdrawal of clinical trial participants;
costs to defend the related litigation;

51


 

a diversion of management’s time and our resources;
substantial monetary awards to trial participants, patients or other claimants;
product recalls, withdrawals or labeling, marketing or promotional restrictions;
significant negative financial impact;
the inability to commercialize our product candidates; and
a decline in our ADS price.

 

We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.

 

Our information technology systems, or those of our CROs, manufacturers, other contractors or consultants or collaborators, may fail or suffer system failures, security breaches or deficiencies in cyber-security, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or trigger contractual and legal obligations.

 

We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information.

 

Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants, vendors and collaborators may fail and are vulnerable to attack, breakdown, breach, interruption or damage from computer viruses, cybersecurity threats, computer hackers, malicious code, human error or malfeasance, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, fire and telecommunication and electrical failures. Our information technology and other internal infrastructure systems, including corporate firewalls, servers and connection to the Internet, face the risk of systemic failure that could disrupt our operations.

 

Cyber-based attacks, security breaches, computer viruses, malware and other incidents could cause misappropriation, loss or other unauthorized disclosure of clinical or other confidential data, materials or information. Increasingly complex methods have been used in cyberattacks, including ransomware, phishing, structured query language injections and distributed denial-of-service attacks. We have, for instance, experienced unauthorized access to our systems in May 2021 due to phishing, as a result of which we incurred a loss of RMB 7.0 million (USD 1.1 million). The risk of a security breach or disruption has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. As such, we may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.

 

We and some of our contractors or CROs are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations or result in the unauthorized use, disclosure of or access to personally identifiable information or individually identifiable health information (potentially violating privacy laws such as the GDPR), it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions cause us to breach our contractual obligations, subject us to mandatory corrective action, and otherwise subject us to liability under laws, regulations and contracts that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages. Some applicable federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have

52


 

formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure or use of confidential or proprietary information, we could incur liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance with privacy and security laws. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.

 

Further, the costs of attempting to protect against the foregoing risks and the costs of responding to a cyber-attack are significant. Large scale data breaches at other entities increase the challenge we and our contractors or CROs face in maintaining the security of our systems and networks. Following a cyber-attack, our and/or our contractors or CROs’ remediation efforts may not be successful, and a cyber-attack could result in interruptions, delays or cessation of business. In addition, breaches of our and/or our contractors or CROs’ security measures and the unauthorized dissemination of clinical or other confidential data or information could expose us to the risk of financial or medical identity theft, or expose us or other third parties to a risk of loss or misuse of this information, and result in investigations, regulatory enforcement actions, material fines and penalties, loss of business, litigation or other actions which could have a material adverse effect on our business, prospects, reputation, results of operations and financial condition. In addition, if we fail to adhere to our policies and other published statements or applicable laws concerning our processing, use, transmission and disclosure of protected information, or if our statements or practices are found to be deceptive or misrepresentative, we could face regulatory actions, fines and other liability.

 

Any breach or interruption of our security measures or information technology infrastructure could compromise our networks, and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach, or other loss of information could result in legal claims or proceedings, and liability under federal, state or foreign laws that protect the privacy of personal information, and could give rise to regulatory penalties. Notice of breaches may need to be made to affected individuals, federal, state, or foreign regulators, and the media. Such a notice could harm our reputation and our ability to compete.

 

We have insurance coverage generally for potential claims, liabilities, and costs relating to security incidents that may arise from our business or operations; however, the coverage may not be sufficient to cover all claims, liabilities, and costs arising from the incidents, including fines and penalties. For example, in connection with the unauthorized access to our systems in May 2021, we incurred a loss of RMB 7.0 million (USD 1.1 million), of which RMB 1.0 million was recovered from our cyber insurance provider. In addition, we cannot be certain that insurance for cybersecurity incidents will continue to be available to us on commercially reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. It could be difficult to predict the ultimate resolution of any such incidents or to estimate the amounts or ranges of potential loss, if any, that could result therefrom. If we cannot successfully resolve a security incident or contain any potential loss, it could materially impact our ability to operate our business as well as our results of operations and financial position.

 

Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or trigger contractual and legal obligations.

 

The United States federal and various state government, the PRC government and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data. Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants, vendors and collaborators may fail and are vulnerable to breakdown, breach, interruption or damage from computer viruses, cybersecurity threats, computer hackers, malicious code, employee error or malfeasance, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, fire and telecommunication and electrical failures. The risk of a security breach or disruption has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. Our information technology and other internal infrastructure systems, including corporate firewalls, servers and connection to the Internet, face the risk of systemic failure that could disrupt our operations.

53


 

If such an event were to occur and cause interruptions in our operations or result in the unauthorized use, disclosure of or access to personally identifiable information or individually identifiable health information (potentially violating privacy laws such as the GDPR), it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions cause us to breach our contractual obligations, subject us to mandatory corrective action, and otherwise subject us to liability under laws, regulations and contracts that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages. Some applicable federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Any costs might not be covered by insurance, in whole or in part. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure or use of confidential or proprietary information, we could incur liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance with privacy and security laws. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.

 

Cyber-based attacks (including ransomware, phishing, etc.), security breaches, loss of data and other disruptions in relation to our systems and networks could compromise clinical or other confidential data or information related to our business, prevent us from accessing it, and expose us to substantial liability, which could adversely affect our business and reputation.

 

Cyber-based attacks, security breaches, computer viruses, malware and other incidents could cause misappropriation, loss or other unauthorized disclosure of clinical or other confidential data, materials or information. Increasingly complex methods have been used in cyber-attacks, including ransomware, phishing, structured query language injections and distributed denial-of-service attacks. A cyber-attack can also be in the form of unauthorized access or a blocking of authorized access. We have, for instance, experienced unauthorized access to our systems in May 2021 due to a phishing scam, as a result of which we incurred a loss of RMB 7.0 million (USD 1.1 million), although we implemented mitigating steps, similar or worse incidents could occur in the future. We can provide no assurance that we or our contractors or CROs will be able to detect, prevent or contain the effects of such attacks or other information security risks or threats in the future.

 

The costs of attempting to protect against the foregoing risks and the costs of responding to a cyber-attack are significant. Large scale data breaches at other entities increase the challenge we and our contractors or CROs face in maintaining the security of our systems and networks. Following a cyber-attack, our and/or our contractors or CROs’ remediation efforts may not be successful, and a cyber-attack could result in interruptions, delays or cessation of business. In addition, breaches of our and/or our contractors or CROs’ security measures and the unauthorized dissemination of clinical or other confidential data or information could expose us to the risk of financial or medical identity theft, or expose us or other third parties to a risk of loss or misuse of this information, and result in investigations, regulatory enforcement actions, material fines and penalties, loss of business, litigation or other actions which could have a material adverse effect on our business, prospects, reputation, results of operations and financial condition. In addition, if we fail to adhere to our policies and other published statements or applicable laws concerning our processing, use, transmission and disclosure of protected information, or if our statements or practices are found to be deceptive or misrepresentative, we could face regulatory actions, fines and other liability.

 

The secure processing, storage, maintenance and transmission of information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive data from unauthorized access, use, modification or disclosure, no security measures can be perfect and our information technology infrastructure could be vulnerable to hackers, phishing scams, malware, viruses, security flaws, employee errors, and other malfeasance or inadvertent disruptions. Any breach or interruption of our security measures or information technology infrastructure could compromise our networks, and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach, or other loss of information could result in legal claims or proceedings, and liability under federal, state or foreign laws that protect the privacy of personal information, and could give rise to regulatory penalties. Notice of breaches may need to be made to affected individuals, federal, state, or foreign regulators, and the media. Such a notice could harm our reputation and our ability to compete.

 

Although we have implemented security measures to prevent unauthorized access to data, such data is currently accessible through multiple channels, and there is no guarantee we can protect all data from breach. Unauthorized access, loss or dissemination could disrupt our operations (including our ability to perform our analysis, provide clinical data, conduct research and development, develop

54


 

intellectual property, collect, process and prepare financial information, and manage our business) and damage our reputation, any of which could adversely affect our business and financial condition. As cyber threats evolve, we may be required to expend significant additional resources to continue to modify or enhance our practices and controls to protect our systems or to investigate and remediate any information security vulnerabilities, and these efforts may not be successful.

 

We have insurance coverage generally for potential claims, liabilities, and costs relating to security incidents that may arise from our business or operations; however, the coverage may not be sufficient to cover all claims, liabilities, and costs arising from the incidents, including fines and penalties. In addition, we cannot be certain that insurance for cybersecurity incidents will continue to be available to us on commercially reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. It could be difficult to predict the ultimate resolution of any such incidents or to estimate the amounts or ranges of potential loss, if any, that could result therefrom. If we cannot successfully resolve a security incident or contain any potential loss, it could materially impact our ability to operate our business as well as our results of operations and financial position.

 

Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

 

We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (1) the laws and regulations of the FDA, the NMPA or other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, including cGMP requirements, (3) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (4) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.

 

In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

 

We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.

 

From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies. In addition, we have, and may have, arrangements with governmental authorities that have obligations or responsibilities that we cannot successfully fulfill with potentially significant adverse consequences to us. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our ADSs, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our financial condition, liquidity and results of operations.

 

Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any such transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.

 

55


 

Risks Related to Intellectual Property

 

Our success depends on our ability to obtain, maintain, protect and enforce our intellectual property and our proprietary technologies.

 

Our success depends in part on our ability to obtain and maintain patent, trade secret and other intellectual property and proprietary protection for our current and any future product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon, misappropriating or otherwise violating the intellectual property and proprietary rights of others. If we are unable to protect our intellectual property and proprietary rights or if our intellectual property and proprietary rights are inadequate for our current or any future product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States, the PRC and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. We also seek to protect our proprietary position by acquiring or in-licensing relevant issued patents, pending patent applications and other intellectual property from third parties. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.

 

Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover such technology. There can be no assurance that our current or future patent applications or the patent applications of our current and future licensors will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States, the China National Intellectual Property Administration, or NIPA, courts in the PRC or by the patent offices and courts in other jurisdictions or will result in patents being issued. In addition, there can be no assurance that any issued patents will afford sufficient protection against competitors or other third parties with similar technology, or will not be infringed, designed around or invalidated. Even issued patents may later be found invalid or unenforceable, in whole or in part, or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. In addition, under PRC patent law, any organization or individual that applies for a patent in a foreign country for an invention or utility model accomplished in the PRC is required to report to NIPA for confidentiality examination.

 

Otherwise, if an application is later filed in the PRC, the patent right will not be granted. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to our current and any future product candidates could have a material adverse effect on our financial condition and results of operations.

 

The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our current and any future product candidates by obtaining, maintaining, defending and enforcing patents. These risks and uncertainties include the following:

the USPTO, NIPA and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other obligations during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
patent applications may not result in any patents being issued;
patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;
our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our current and any future product candidates;
there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and
countries other than the United States may have patent laws less favorable to patentees than those of the United States, allowing foreign competitors a better opportunity to create, develop and market competing products.

 

The patent prosecution process is also expensive and time consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We and our current and future licensors may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of the patent applications, which may result in such patents being narrowed, invalidated or held

56


 

unenforceable. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license to or from third parties. We may also require the cooperation of our licensors, licensees or other collaborators in order to enforce or defend the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.

 

In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospect.

 

If we fail to comply with our obligations under any license, collaboration or other agreements, or otherwise experience disruptions to our business relationships with our collaborators or licensors, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our current and future product candidates.

 

We have in-licensed some intellectual property rights, including specific intellectual property rights relating to H3R antagonists, and we may license other intellectual property rights in the future. If, for any reason, any license agreement is terminated or we otherwise lose the rights associated with such license, it could adversely affect our business. Any collaboration agreement or license agreement we have entered into, or are likely to enter into, imposes or is likely to impose, various development, commercialization, funding, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us, as well as milestone, royalty, annual maintenance and other payment obligations. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, or if, in spite of our efforts, a collaborator or licensor concludes that we have materially breached our obligations under such agreement, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, have manufactured, and commercialize products that are covered by the licensed technology or having to negotiate new or reinstated licenses on less favorable terms, or enable a competitor or other third party to gain access to the licensed technology. Additionally, if any future license agreement includes a sublicense from a third party who is not the original licensor of the intellectual property at issue, then we must rely on our direct licensor to comply with its obligations under the primary license agreements under which such licensor obtained rights in the applicable intellectual property, where we may have no relationship with the original licensor of such rights. If such a licensor fails to comply with its obligations under its upstream license agreement, including due to the impact of the COVID-19 pandemic on its business operations, the original third-party licensor may have the right to terminate the original license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms or at all, or such license may be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. Any such events may impact our ability to continue to develop and commercialize our current and any future product candidates incorporating the relevant intellectual property.

 

We may need to obtain further licenses from third parties to advance our research or allow commercialization of our current and any future product candidates, and we cannot provide any assurances that third-party patents or other intellectual property or proprietary rights do not exist which might be enforced against our current and any future product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation.

 

Licensing of intellectual property is of high importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:

 

the scope of rights granted under the license agreement and other interpretation-related issues;
whether and the extent to which our technology and processes infringe on, misappropriate or otherwise violate intellectual property of the licensor that is not subject to the license agreement;

57


 

our right to sublicense patents and other intellectual or proprietary rights to third parties;
our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our current and any future product candidates, and what activities satisfy those diligence obligations;
our right to transfer or assign the license; and
the ownership of patents, inventions, know-how and other intellectual property and proprietary rights resulting from activities performed by our licensors, us and our partners.

 

These agreements may be complex, and some provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates. In addition, some of our agreements may limit or delay our ability to consummate some transactions, may impact the value of those transactions, or may limit our ability to pursue some activities. Any of the foregoing would have a material adverse effect on our business, financial conditions, results of operations and prospects.

 

If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors and other third parties from commercializing product candidates similar or identical to ours would be adversely affected.

 

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.

 

Similarly, in the PRC, intellectual property laws are constantly evolving, with efforts being made to improve intellectual property protection in the PRC. For example, PRC Patent Law was amended on October 17, 2020 and became effective on June 1, 2021. It provides that in order to compensate for the time taken up by the review and approval of new drugs for marketing, the patent administrative department shall grant compensation for the duration of patent rights for invention patents related to new drugs that have been granted a marketing license in the PRC. The compensation period shall not exceed five years, and the total valid patent right period shall not exceed fourteen years after the new drug is approved for marketing. Therefore, the terms of our PRC patents will be eligible for extension and allow us to extend patent protection of our products, and the terms of the patents owned by third parties may also be extended, which may in turn affect our ability to commercialize our products candidates without facing infringement risks. If we are required to delay commercialization for an extended period of time, technological advances may develop and new competitor products may be launched, which may render our product non-competitive. We also cannot guarantee that other changes to PRC intellectual property laws would not have a negative impact on our intellectual property protection.

 

The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. During the patent examination process, we or our licensors may be required to narrow the pending claims to overcome prior art, a process that may limit the scope of patent protection. Even if patent applications we own or license issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any future patents that we own or license, now or in the future, may be challenged or circumvented by third parties or may be narrowed, modified, invalidated or revoked as a result of challenges by third parties. Consequently, we do not know whether our current or any future product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our future patents or the patents of our current and future licensors by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.

 

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States, the PRC or elsewhere. The inventorship and ownership rights for patents that we own or in-license or may own or in-license in the future may be challenged by third parties. Such challenges could

58


 

result in loss of exclusive rights to such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or require us to obtain a license from such third parties on commercially reasonable terms to secure exclusive rights. If any such challenges to inventorship or ownership were asserted, there is no assurance that a court would find in our favor or that, if we choose to seek a license, such license would be available to us on acceptable terms or at all. Moreover, we may be subject to a third-party submission of prior art to the USPTO challenging the priority of an invention claimed within one of our patents or patent applications (which submissions may be made prior to a patent’s issuance) or otherwise become involved in pre- and post-issuance proceedings, including opposition, derivation, re-examination, revocation, inter partes review, post-grant review, interference or other proceedings challenging our patent rights or the patent rights of others from whom we have obtained licenses to such rights. For example, if we or a licensor or other collaborator initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, in whole or in part, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture, have manufactured, or commercialize products without infringing third-party patent rights.

 

Any loss of patent rights, loss of exclusivity or patent claims being narrowed, invalidated or held unenforceable, in whole or in part, could limit our ability to stop others from using or commercializing similar or identical technology and products, without payments to us, limit the duration of the patent protection of our current or any future product candidates, or result in our inability to manufacture, have manufactured, and commercialize our product candidates, which could materially and adversely impact our business. Proceedings relating to intellectual property also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of our current and future licensors is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize our current or any future product candidates. Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations and prospects.

 

The patent protection and patent prosecution for our current or any future product candidates may be dependent on third parties.

 

We may in the future rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect and enforce the licensed intellectual property under some current and future license agreements. Under such arrangements, we may not have sufficient control over these activities for some licensed patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. In addition, our current and future licensors or licensees may not be fully cooperative or disagree with us as to the prosecution, maintenance, enforcement or defense of any patent rights, which could compromise such patent rights. Therefore, we cannot be certain that such patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business.

 

We may in the future enter into license agreements where the licensors or licensees may have the right to control enforcement of the licensed patents or defense of any claims asserting the invalidity of these patents, and even if we are permitted to pursue such enforcement or defense, it might require the cooperation of our licensors or licensees. We cannot be certain that our licensors or licensees will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business or result in invalidation or limitation of the scope of the licensed patents or other intellectual property rights. If any of our current or future licensors, licensees or collaborators fail to appropriately prosecute and maintain patent protection for patents covering our current or any future product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors or other third parties from making, using and selling competing products.

 

In addition, even where we have the right to control prosecution, maintenance, enforcement and defense of patent applications or patents we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of prior owners, licensors and/or their counsel that took place prior to us assuming control over such activities.

 

Licensors may retain rights to the technology that they license to us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether such licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to the licensed technology in the event of misuse.

 

59


 

If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

If we are not successful in obtaining patent term extensions for our current and future product candidates, our business may be harmed, and the lack of effective enforcement of patent linkage and the absence of patent term extension and data and market exclusivity for product candidates approved by the NMPA could increase the risk of early generic competition with our products in the PRC.

 

Patents have a limited lifespan. In the United States, for example, the natural expiration of a patent is generally 20 years after the filing of the earliest non-provisional application to which the patent claims priority. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. We may be required to disclaim a portion of patent term in order to overcome double patenting rejections from the applicable patent office, thus potentially shortening our exclusivity period. Without patent protection for our current or future product candidates, we may be open to competition, including from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Hence, we expect to seek extensions of patent terms in the United States and abroad.

 

Depending upon the timing, duration and specifics of FDA marketing approval of our current and future product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during drug development and the FDA regulatory review process, which is limited to the approved indication (or any additional indications approved during the period of extension). This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in some foreign countries upon obtaining the applicable regulatory approval for our current and any future product candidates. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries or areas, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request.

 

If we or our licensors are unable to extend the expiration date of our or their existing patents or obtain new patents with longer expiry dates, as applicable, our competitors and other third parties may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case.

 

The Hatch-Waxman Amendments also provide a process for patent linkage, pursuant to which the FDA will stay approval of some follow-on applications during the pendency of litigation between the follow-on applicant and the patent holder or licensee, generally for a period of 30 months. Finally, the Hatch-Waxman Amendments provide for statutory exclusivities that can prevent submission or approval of some follow-on marketing applications. For example, federal law provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of a new chemical entity and three years of exclusivity protecting some innovations to previously approved active ingredients where the applicant was required to conduct new clinical investigations to obtain approval for the modification. Similarly, the U.S. Orphan Drug Act provides seven years of market exclusivity for some drugs to treat rare diseases, where the FDA designates the product candidate as an orphan drug and the drug is approved for the designated orphan disease or condition. These provisions, designed to promote innovation, can prevent competing products from entering the market for a period of time after the FDA grants marketing approval for the innovative product.

 

60


 

In the PRC, however, due to the lack of effective law or regulation providing for patent linkage or data exclusivity (referred to as regulatory data protection), historically a lower-cost generic drug could emerge onto the market much more quickly. PRC regulators published regulations in 2021 for a patent dispute early resolution mechanism, which may be comparable to the patent linkage system in the U.S. PRC regulators have also set forth a legislative framework for data exclusivity and patent term extension. To be implemented, this framework will require adoption of regulations. To date, no regulations have been issued for data exclusivity and patent term extension. These factors result in weaker protection for us against generic competition in the PRC than could be available to us in the United States. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.

 

Periodic maintenance fees on any issued patent are due to be paid to the USPTO, NIPA and other foreign patent agencies in several stages over the lifetime of the patent. In addition, the USPTO, NIPA and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on an international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain patents and patent applications, whether owned or in-licensed now or in the future, covering any of our current or future product candidates and technologies, our competitors might be able to enter the market, which would have an adverse effect on our business, financial condition, results of operations and prospects.

 

Third-party claims or litigation alleging infringement, misappropriation or other violation of, or seeking to invalidate, patents or other intellectual and proprietary rights, may delay or prevent the development and commercialization of any of our current or future product candidates.

 

Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates without infringing, misappropriating, or otherwise violating the intellectual property and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the pharmaceutical and biotechnology industries, including patent infringement lawsuits and interference, derivation, inter partes review and post-grant review proceedings before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Litigation or other proceedings relating to intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management’s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our current and future product candidates.

 

One or more third parties may challenge our current or future patents, which could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims, or a finding of non-infringement. For example, if a third party files an Abbreviated New Drug Application, or ANDA, for a generic copy of one of our products, and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1) there is no patent information listed in the FDA’s Orange Book, or Orange Book, with respect to our NDA for the applicable approved product candidate; (2) the patents listed in the Orange Book have expired; (3) the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party’s generic drug. A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved product candidate, or that such patents are invalid, is called a paragraph IV certification. If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third party’s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third party’s ANDA until the earliest of 30 months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file a patent infringement lawsuit within the required 45-day period, the third party’s ANDA will not be subject to the 30-month stay of FDA approval. Grounds for an unenforceability assertion includes an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Any challenge to our current or future patents could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third party successfully challenges all of the patents

61


 

that might otherwise be eligible for listing in the Orange Book for one of our products, we will not be entitled to the 30-month stay of FDA approval upon the filing of an ANDA for a generic copy of our product.

 

We cannot provide any assurances that third-party patents do not exist which might be enforced against our current and future product candidates. Numerous U.S., PRC and other foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are or may in the future be developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties.

 

Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current and future product candidates. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be currently pending patent applications—including ones we are unaware of—that may later result in issued patents that our current and future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.

 

Even if we believe that such claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. In order to successfully challenge the validity of a U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If any third-party patents were held by a court of competent jurisdiction to be valid and enforceable and cover the manufacturing process of any of our current and future product candidates, any molecules formed during such manufacturing process, any final products resulting from such manufacturing process, or our formulations or methods of use thereof, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire. Such a license would likely include significant payment and other obligations, or may not be available on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on non-exclusive terms, thereby providing our competitors and other third parties access to the same technologies licensed to us. In addition, we may be subject to claims that we are infringing, misappropriating or otherwise violating others’ intellectual property rights, such as trademarks, copyrights or trade secrets, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.

 

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our current and future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we also may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our current and future product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. As a result, we might be unable to further develop and commercialize any affected product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our ADSs or ordinary shares. Any of the foregoing would have a material adverse effect on our business, financial condition, results of operations and prospects.

 

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.

 

We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration dates of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, the PRC and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction.

62


 

 

The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively affect our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the PRC or elsewhere that we consider relevant may be incorrect, and if we fail to identify and correctly interpret relevant patents our ability to develop and market our products may be negatively affected.

 

We may need to acquire or license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.

 

Because our development programs may require the use of intellectual property rights held by other parties, the growth of our business may depend in part on our ability to acquire, in-license or use such third-party intellectual property rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our current and any future product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the applicable program and/or develop alternative approaches that do not infringe, misappropriate or otherwise violate such intellectual property rights. This could entail additional costs and development delays, and the development of such alternatives may not be feasible. Any of the foregoing could prevent us from developing or commercializing one or more of our product candidates, force us to modify such product candidates, or cease some aspect of our business operations, and our business, financial condition, results of operations and prospects could suffer.

 

We may become involved in lawsuits to protect or enforce our or our licensors’ patents or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

 

Competitors may infringe, misappropriate or otherwise violate our or our licensors’ patents or other intellectual property rights. To counter infringement or unauthorized use, we or our licensors may be required to file legal claims, which can be expensive and time-consuming. In addition, in such a proceeding, a court may decide that an asserted patent is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that the asserted patent or other intellectual property right does not cover the third-party technology in question. An adverse result in any litigation or defense proceedings could put one or more asserted patents at risk of being invalidated or interpreted narrowly and could put related patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us, such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, the PRC and elsewhere, defendant counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, NIPA or any other applicable patent office, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte re-examinations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. For patents and patent applications that we license in the future, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.

 

We may not be able to detect or prevent, alone or with our licensors, infringement, misappropriation or other violation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there

63


 

is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our ADSs or ordinary shares. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

Derivation, interference or other proceedings may be necessary to determine priority of inventions relating to our current or future product candidates, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.

 

Derivation, interference or other proceedings provoked by third parties or brought by us or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our current or future patents or patent applications or those of our current and future licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all. Our defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our current and any future product candidates to market.

 

Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.

 

Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing, misappropriating or otherwise violating our owned or in-licensed patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing a claim or action against such third party may be too high or not in the best interest of our shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.

 

Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our current and future patent applications or those of our current and future licensors and the enforcement or defense of our current and future issued patents or those of our current and future licensors.

 

Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and are therefore costly, time-consuming and inherently uncertain. Recent patent reform legislation in the United States and other countries could increase those uncertainties and costs.

 

On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act made a number of significant changes to United States patent laws. These include provisions that affect the way patent applications are prosecuted and challenged at the USPTO and may also affect patent litigation. The USPTO has developed and continues to develop new regulations and procedures to govern administration of the Leahy-Smith Act.

 

The Leahy-Smith Act established a “first-to-file” system, under which, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. This will require us to be cognizant of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. Therefore, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition. Similarly, the PRC also adopted a “first-to-file” system.

 

The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include limiting where a patentee may file a patent infringement suit, allowing third-party submission of prior art to the USPTO during patent prosecution and providing for additional procedures to attack the validity of a patent at the USPTO by post-grant review, inter partes review and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, in whole or in part, which could adversely affect our competitive position.

 

64


 

Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our future patent applications or those of our current and future licensors and the enforcement or defense of our future issued patents or those of our current and future licensors, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

Changes in U.S. patent law, PRC patent law or patent laws in other countries could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.

 

Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States, the PRC and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our future patents or in third-party patents. In addition, there are periodic proposals for changes to the patent laws of the PRC, the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology.

 

In the PRC, intellectual property laws are constantly evolving, with efforts being made to improve intellectual property protection in the PRC. For example, PRC Patent Law was amended on October 17, 2020 and became effective on June 1, 2021. It provides that in order to compensate for the time taken up by the review and approval of new drugs for marketing, the patent administrative department shall grant compensation for the duration of patent rights for invention patents related to new drugs that have been granted a marketing license in the PRC. The compensation period shall not exceed five years, and the total valid patent right period shall not exceed fourteen years after the new drug is approved for marketing. Therefore, the terms of our PRC patents will be eligible for extension and allow us to extend patent protection of our products, and the terms of the patents owned by third parties may also be extended, which may in turn affect our ability to commercialize our products candidates without facing infringement risks. If we are required to delay commercialization for an extended period of time, technological advances may develop and new competitor products may be launched, which may render our product non-competitive. We also cannot guarantee that other changes to PRC intellectual property laws would not have a negative impact on our intellectual property protection.

 

Evolving judicial interpretation of patent law could also adversely affect our business. The U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have issued numerous precedential opinions in recent years narrowing the scope of patent protection available in some circumstances or weakening the rights of patent owners in some situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on future actions by the U.S. Congress, the U.S. federal courts, the USPTO or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce or defend patents that we have licensed or that we might own or license in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce our current and future owned and licensed patents.

 

We may not be able to protect our intellectual property rights throughout the world, including in the PRC.

 

Filing, prosecuting and defending patents for our current and future product candidates in all relevant jurisdictions throughout the world could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability differ in some jurisdictions, particularly developing countries. For example, the PRC has a heightened requirement for patentability and, specifically, requires a detailed description of medical uses of a claimed drug. In addition, the laws of some foreign countries, including the PRC, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our current or any future product candidates, and our patents, the patents of our current and future licensors or other intellectual property rights may not be effective or sufficient to prevent them from competing. Additionally, some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Many countries also limit the enforceability of patents against

65


 

government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent.

 

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement, misappropriation or other violation of our intellectual property rights or the marketing of competing products in violation of our intellectual property or proprietary rights. In particular, the validity, enforceability and scope of protection available under the relevant laws in the PRC are uncertain and still evolving. Implementation and enforcement of PRC intellectual property-related laws have historically been deficient and ineffective. Accordingly, intellectual property and confidentiality legal regimes in the PRC may not afford protection to the same extent as in the United States or other countries. Policing unauthorized use of intellectual property or proprietary technology in foreign jurisdictions is difficult and expensive, and we may need to resort to litigation to enforce or defend patents issued to us or our current or future licensors or to determine the enforceability, scope and validity of our proprietary rights or those of others. Such litigations and proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our current and future licensors at risk of being invalidated or interpreted narrowly and our patent applications or the patent applications of our current and future licensors at risk of not issuing and could provoke third parties to assert claims against us. Moreover, the experience and capabilities of courts in foreign jurisdictions, including PRC courts, in handling intellectual property litigation varies, and outcomes are unpredictable. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. An adverse determination in any such proceeding or litigation could materially impair our intellectual property rights and may harm our business, prospects and reputation.

 

In addition, as permitted by the PRC laws, other parties may register trademarks which may look similar to our registered trademarks under some circumstances, which may cause confusion among consumers. We may not be able to prevent other parties from using trademarks that are similar to ours and our consumers may confuse our treatment centers with others using similar trademarks. In such case, the goodwill and value of our trademarks and the public perception of our brand and our image may be adversely affected. A negative perception of our brand and image could have a material and adverse effect on our sales, and therefore on our business, financial condition, results of operations and prospects. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, and any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

Compulsory standards for remuneration to creators or inventors of the patents they contribute to our business could be considerable.

 

Under PRC laws, we are required to remunerate inventors or creators of patents they create for our business during the course of their employment. In the event of a dispute between an inventor or creator and us, there is a risk that the compulsory standards for remuneration, as set forth in relevant laws and regulations, may apply. Our policies do not include any rules regarding a predetermined lump sum or proportion of profits to award inventors as remuneration for the patents they contribute to our business and in the potential event of a dispute between us and an inventor, there is a potential risk that the compulsory standard for remuneration, as set forth in relevant laws and regulations, may apply. Such compulsory standards for remuneration could be considerable and could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

 

We also rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants, CROs and advisors, we cannot provide any assurances that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information and that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose or use our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of trade secrets and other confidential information is difficult, and we do not know whether the steps we have taken to protect our trade secrets or confidential information will be effective. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these security measures, they may be breached.

 

66


 

Moreover, third parties may still lawfully obtain our trade secrets or proprietary information or may develop or otherwise come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to protect our trade secret information may be jeopardized. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.

 

We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we endeavor to ensure that our employees, consultants and independent contractors do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of a former employer or another third party. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these claims, and there is no guarantee of success. If we fail in defending these claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property, if such intellectual property rights are found to incorporate or be derived from the trade secrets or other proprietary information of third parties. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition.

 

In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property on our behalf to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Such agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.

 

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

 

We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. We may design or create new trademarks and apply to register them, but our trademark applications may not be approved in the United States, the PRC or any other relevant jurisdiction. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our drugs, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Competitors or other parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, they may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.

 

We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.

Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.

 

67


 

Any collaboration arrangements that we have or may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products.

 

The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators and partners. Collaborations and partnerships are subject to numerous risks, which may include that:

 

collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;
collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;
a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;
we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
collaborators may not properly maintain, protect, enforce and defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;
collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability;
disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our current or future product candidates or that result in costly litigation or arbitration that diverts management attention and resources;
collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future products;
collaborators may own or co-own intellectual property covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and
a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws which may result in civil or criminal proceedings involving us.

 

Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.

 

Intellectual property rights do not necessarily address all potential threats.

 

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

 

others may be able to make products that are similar to our product candidates or utilize similar technologies that are not covered by the claims of the patents that we own or license now or in the future;
we or our licensors or collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or license now or in the future;
we or our licensors or collaborators might not have been the first to file patent applications covering some of our or their inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;
it is possible that there are prior public disclosures that could invalidate our or our licensors’ or collaboration partners’ patents;
issued patents that we hold rights to may fail to provide us with any competitive advantage, or may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;
our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

68


 

we may not develop additional proprietary technologies that are patentable;
the ownership, validity or enforceability of our or our licensors’ or collaboration partners’ patents or patent applications may be challenged by third parties;
the patents or pending or future applications of others, if issued, may harm our business; and
we may choose not to file a patent in order to maintain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

 

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

Risks Related to Ownership of Our ADSs

 

The trading price of our ADSs could be highly volatile, and purchasers of our ADSs could incur substantial losses.

 

The trading price of our ADSs has been and may continue to be volatile. The stock market in general and the market for shares of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, some or all of the value of our ADSs may be lost. The market price for our ADSs may be influenced by those factors discussed in this “Risk Factors” section and many others, including:

 

political tensions between the United States and the PRC;
our ability to enroll subjects in our ongoing and planned clinical trials;
results (and interpretations of results) of our clinical trials and preclinical studies, and the results (and interpretations of results) of trials of our competitors or those of other companies in our market sector;
regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;
regulatory developments in the United States, the PRC and foreign countries;
changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;
the success or failure of our efforts to acquire, license or develop additional product candidates;
innovations or new products developed by us or our competitors;
announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
manufacturing, supply or distribution delays or shortages;
any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners;
achievement of expected product sales and profitability;
variations in our financial results or those of companies that are perceived to be similar to us;
market conditions in the biopharmaceutical sector and issuance of securities analysts’ reports or recommendations;
trading volume of our ADSs;
an inability to obtain additional funding;
sales of our securities by insiders and shareholders;
general economic, industry and market conditions other events or factors, many of which are beyond our control;
additions or departures of key personnel;
the ongoing and future impact of the COVID-19 pandemic and actions taken to slow its spread; and
intellectual property, product liability or other litigation against us.

 

In addition, in the past, shareholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies’ shares. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management’s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.

 

69


 

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations and the price of our ADSs.

 

From time to time, the global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that future deterioration in credit and financial markets and confidence in economic conditions will not occur. Our business strategy and performance may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the conflict in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our business, financial condition and results of operations and the price of our ADSs.

 

If we fail to meet the continued listing requirements of Nasdaq, it could result in a de-listing of our ADSs.

 

If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our ADSs. Such a de-listing would likely have a negative effect on the price of our ADSs and would impair the ability of investors to sell or purchase our ADSs when any investor may wish to do so. In the event of a de-listing, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our ADSs to become listed again, stabilize the market price or improve the liquidity of our ADSs, prevent our ADSs from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

 

An active, liquid trading market for our ADSs may not be maintained.

 

We can provide no assurance that we will be able to maintain an active trading market for our ADSs. The lack of an active market may impair the ability of any investor to sell our ADSs at the time an investor may wish to sell them or at a price that an investor may consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business.

 

Our executive officers, directors and principal shareholders, if they choose to act together, will have the ability to control or significantly influence all matters submitted to shareholders for approval. Furthermore, many of our current directors were appointed by our principal shareholders.

 

Our executive officers, directors and greater than 5% shareholders, in the aggregate, own approximately 78.8% of our outstanding ordinary shares (including 43,434,363 ordinary shares represented by ADSs and assuming no exercise of outstanding options). Furthermore, many of our current directors were appointed by our principal shareholders. As a result, such persons or their appointees to our board of directors, acting together, have and will continue to have the ability to control or significantly influence all matters submitted to our board of directors or shareholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other shareholders.

 

We do not currently intend to pay dividends on our securities, and, consequently, the ability to achieve a return on investment in our ADSs will depend on appreciation, if any, in the price of our ADSs.

 

We have never declared or paid any cash dividend on our securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends.

 

70


 

Our board of directors has complete discretion as to whether to distribute dividends, subject to the requirements of Cayman Islands law. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit or its share premium account, provided that in no circumstances may a dividend be paid if this would result in its being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on any investment in our ADSs will depend on any future price appreciation of our ADSs. There is no guarantee that our ADSs will appreciate in value or even maintain the price at which our ADSs were or are purchased. Some or all of any investment in our ADSs may be lost.

 

Sales of a substantial number of our ADSs or ordinary shares by our existing shareholders in the public market could cause the price of our ADSs to fall.

 

Sales of a substantial number of our ADSs or ordinary shares in the public market or the perception that these sales might occur could significantly reduce the market price of our ADSs and impair our ability to raise adequate capital.

 

We have a total of 49,429,019 ordinary shares represented by ADSs outstanding, assuming no exercise of outstanding options, which are freely tradable, without restriction, in the public market, unless they are held or purchased by one of our affiliates. ADSs held by our affiliates are eligible for sale in the public market and will be subject to volume limitations under Rule 144 under the Securities Act.

 

The holders of approximately 18.9 million of our outstanding ordinary shares, or approximately 34.3% of our total outstanding ordinary shares, are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares (including, in the case of affiliates, for resale) under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act. Any sales of securities by these shareholders could have a material adverse effect on the trading price of our ADSs.

 

We are an emerging growth company, and the reduced disclosure requirements applicable to emerging growth companies may make our ADSs less attractive to investors.

 

We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our IPO. However, if specific events occur prior to the end of such five-year period, including if we become a “large accelerated filer,” our annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from some disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:

 

not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;
not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements; and
reduced disclosure and other obligations regarding executive compensation.

 

We have taken advantage of reduced reporting burdens in this annual report. Our ADSs may be less attractive by relying on these exemptions, and as a result, there may be a less active trading market for our ADSs and the trading price of our ADSs may be reduced or more volatile.

 

71


 

As a foreign private issuer, we are not subject to some U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly available to our shareholders.

 

As a foreign private issuer, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act and therefore there may be less publicly available information about us than if we were a U.S. domestic issuer. For example, we currently report financial information on a six-monthly basis and have no current plans to report financial information on a quarterly basis, as a U.S. domestic issuer would be required to do. Also, we are not subject to the proxy rules in the United States and disclosure with respect to our annual general meetings will be governed by the Cayman Islands’ requirements. In addition, our officers, directors and principal shareholders are exempt from reporting (i.e., will not file Forms 3, 4, or 5 when they trade) and are not subject to the “short-swing” profit recovery provisions of Section 16 of the Exchange Act and the rules thereunder. Therefore, our shareholders may not have timely information and may not, for instance, know when our officers, directors and principal shareholders purchase or sell our ordinary shares or ADSs.

 

As a foreign private issuer, we are permitted to adopt some home country practices in relation to corporate governance matters that differ significantly from the Nasdaq corporate governance listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing standards.

 

As a foreign private issuer, we are permitted to take advantage of some provisions in the Nasdaq listing rules that allow us to follow Cayman Islands law for some governance matters. Corporate governance practices in the Cayman Islands may differ significantly from corporate governance listing standards as, except for general fiduciary duties and duties of care, Cayman Islands law has no corporate governance regime which prescribes specific corporate governance standards. Cayman Islands law does not impose a requirement that our board of directors consist of a majority of independent directors. Nor does Cayman Islands law impose specific requirements on the establishment of a compensation committee or nominating committee or nominating process. To the extent we choose to follow home country practice in the future, our shareholders may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers.

 

Under our amended and restated memorandum and articles of association, investors do not have the same rights with respect to shareholder meetings and voting that shareholders of some U.S. corporations have.

 

Our holding company is incorporated under the laws of the Cayman Islands. Our amended and restated memorandum and articles of association provides that a quorum required for the transaction of business at any general meeting of shareholders shall consist of one or more shareholders present in person or by proxy, holding shares which carry in aggregate not less than one-third of all votes attaching to all of our shares in issue and entitled to vote. Additionally, our amended and restated memorandum and articles of association provides that any voting at any shareholders’ meeting shall be decided by a show of hands unless a poll is demanded (before or on the declaration of the result of the show of hands) by the chairman of such meeting or by any one or more shareholders who together hold not less than 10% of the votes attaching to the total number of ordinary shares which are present in person or by proxy at the meeting. Although our minority quorum provisions satisfy the requirements applicable to Nasdaq-listed companies, some U.S. corporations have stricter quorum requirements than these. Additionally, shareholder votes of some U.S. corporations, such as corporations incorporated under the laws of the State of Delaware, must be in written form and cannot be conducted by a show of hands. Therefore, as a result of our amended and restated memorandum and articles of association, investors do not have the benefit of the procedural protections relating to shareholder meetings and voting that shareholders of some U.S. corporations enjoy.

 

We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.

 

As discussed above, we are a foreign private issuer, and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act. The determination of foreign private issuer status is made annually on the last business day of an issuer’s most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our ordinary shares are directly or indirectly held by residents of the United States and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from specific corporate governance requirements under the Nasdaq listing rules. As a U.S.-listed public company that is not a foreign private issuer, we will incur significant additional legal, accounting and other expenses that we will not incur as a foreign private issuer, and accounting, reporting and other expenses in order to maintain a listing on a U.S. securities exchange.

 

72


 

Fluctuations in currency exchange rates may have a material adverse effect on our results of operations and the value of any investment in our ADSs.

 

The value of the renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions. On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of the renminbi to the U.S. dollar, and the renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted, and the exchange rate between the renminbi and U.S. dollar remained within a narrow band. In June 2010, the People’s Bank of China, or PBOC, announced that the PRC government would increase the flexibility of the exchange rate, and thereafter allowed the renminbi to appreciate slowly against the U.S. dollar within the narrow band fixed by the PBOC. However, more recently, on August 11, 12 and 13, 2015, the PBOC significantly devalued the renminbi by fixing its price against the U.S. dollar 1.9%, 1.6%, and 1.1% lower than the previous day’s value, respectively. On October 1, 2016, the renminbi joined the International Monetary Fund’s basket of currencies that make up the Special Drawing Right, or SDR, along with the U.S. dollar, the Euro, the Japanese yen and the British pound. In the fourth quarter of 2016, the renminbi depreciated significantly while the U.S. dollar surged and the PRC experienced persistent capital outflows. With the development of the foreign exchange market and progress towards interest rate liberalization and renminbi internationalization, the PRC government may in the future announce further changes to the exchange rate system. There is no guarantee that the renminbi will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces, PRC and U.S. government’s policies and regulations may impact the exchange rate between the renminbi and the U.S. dollar in the future.

 

Significant revaluation of the renminbi may have a material adverse effect on any investment in our ADSs. For example, to the extent that we need to convert U.S. dollars into renminbi for our operations, appreciation of the renminbi against the U.S. dollar would have an adverse effect on the renminbi amount we would receive from the conversion. Conversely, if we decide to convert our renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against the renminbi would have a negative effect on the U.S. dollar amount available to us. In addition, appreciation or depreciation in the value of the renminbi relative to U.S. dollars would affect our financial results reported in U.S. dollar terms regardless of any underlying change in our business or results of operations.

 

Very limited hedging options are available in the PRC to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert renminbi into non-PRC currency.

 

73


 

Holders of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.

 

Holders of our ADSs do not have the same rights as our registered shareholders. As a holder of our ADSs, an investor will not have any direct right to attend general meetings of our shareholders or to cast any votes at such meetings. As a holder of our ADSs, an investor will only be able to exercise the voting rights carried by the underlying ordinary shares which are represented by our ADSs indirectly by giving voting instructions to the depositary in accordance with the provisions of the deposit agreement. Upon receipt of voting instructions from any investor, the depositary will try, as far as is practicable, to vote the ordinary shares underlying our ADSs in accordance with investor instructions. If we ask for investor instructions, then upon receipt of investor voting instructions, the depositary will try to vote the underlying ordinary shares in accordance with these instructions. If we do not instruct the depositary to ask for investor instructions, the depositary may still vote in accordance with instructions the investor gives, but it is not required to do so. An investor will not be able to directly exercise any right to vote with respect to the underlying ordinary shares unless the investor withdraws the shares, and becomes the registered holder of such shares prior to the record date for the general meeting. When a general meeting is convened, an investor may not receive sufficient advance notice of the meeting to withdraw the shares underlying our ADSs and become the registered holder of such shares to allow the investor to attend the general meeting and to vote directly with respect to any specific matter or resolution to be considered and voted upon at the general meeting. In addition, under our amended and restated memorandum and articles of association, for the purposes of determining those shareholders who are entitled to attend and vote at any general meeting, our directors may close our register of members and/or fix in advance a record date for such meeting, and such closure of our register of members or the setting of such a record date may prevent an investor from withdrawing the ordinary shares underlying our ADSs and becoming the registered holder of such shares prior to the record date, so that an investor would not be able to attend the general meeting or to vote directly. If we ask for instructions from investors, the depositary will notify investors of the upcoming vote and will arrange to deliver our voting materials to investors. We have agreed to give the depositary notice of shareholder meetings sufficiently in advance of such meetings. Nevertheless, we cannot assure investors that investors will receive the voting materials in time to ensure that investors can instruct the depositary to vote the underlying ordinary shares represented by our ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out voting instructions. This means that investors may not be able to exercise any right to direct how the shares underlying our ADSs are voted and investors may have no legal remedy if the shares underlying our ADSs are not voted as requested. In addition, in an investor’s capacity as an ADS holder, the investor will not be able to call a shareholders’ meeting.

 

Except in limited circumstances, the depositary for our ADSs will give us a discretionary proxy to vote the ordinary shares underlying our ADSs if investors do not vote at shareholders’ meetings, which could adversely affect the interests of investors.

 

Under the deposit agreement for our ADSs, if investors do not vote, the depositary will deem that investors have instructed the depositary to give us a discretionary proxy to vote the ordinary shares underlying our ADSs at shareholders’ meetings unless:

 

we have instructed the depositary that we do not wish a discretionary proxy to be given;
we have informed the depositary that there is substantial opposition as to a matter to be voted on at the meeting;
a matter to be voted on at the meeting would have a material adverse impact on shareholders; or
the voting at the meeting is to be conducted via a show of hands unless voting by poll is required by the applicable listing rules or our articles of association.

 

The effect of this discretionary proxy is that investors cannot prevent our ordinary shares underlying our ADSs from being voted, except under the circumstances described above. This may make it more difficult for shareholders to influence our management. Holders of our ordinary shares are not subject to this discretionary proxy.

 

74


 

Investors may not receive distributions on our ADSs or any value for them if such distribution is illegal or impractical or if any required government approval cannot be obtained in order to make such distribution available to any investor.

 

Although we do not have any present plan to pay any dividends, the depositary of our ADSs has agreed to pay to investors the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities underlying our ADSs, after deducting its fees and expenses and any applicable taxes and governmental charges. Investors will receive these distributions in proportion to the number of ordinary shares our ADSs represent. However, the depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities whose offering would require registration under the Securities Act but are not so properly registered or distributed under an applicable exemption from registration. The depositary may also determine that it is not reasonably practicable to distribute some property. In these cases, the depositary may determine not to distribute such property. We have no obligation to register under the U.S. securities laws any offering of ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that investors may not receive distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to investors. These restrictions may cause a material decline in the value of our ADSs.

 

Investors’ right to participate in any future rights offerings may be limited, which may cause dilution to holdings in our ADSs.

 

We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights available to investors in the United States unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Also, under the deposit agreement, the depositary bank will not make rights available to investors unless either both the rights and any related securities are registered under the Securities Act, or the distribution of them to ADS holders is exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. If the depositary does not distribute the rights, it may, under the deposit agreement, either sell them, if possible, or allow them to lapse. Accordingly, investors may be unable to participate in our rights offerings and may experience dilution in holdings in our ADSs.

 

We may be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences to U.S. Holders of our ADSs or ordinary shares.

 

We would be classified as a passive foreign investment company, or PFIC, for any taxable year if, after the application of specific look-through rules, either: (i) 75% or more of our gross income for such year is “passive income” (as defined in the relevant provisions of the U.S. Internal Revenue Code of 1986, as amended (the income test), or (ii) 50% or more of the value of our assets (generally determined on the basis of a quarterly average) during such year is attributable to assets that produce or are held for the production of passive income (the asset test). Based on the value of our assets, including goodwill, and the composition of our income and assets, we do not believe we were a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2021. However, the application of the PFIC rules is subject to uncertainty in several respects, and we cannot assure investors that we will not be a PFIC for any taxable year. Adverse U.S. federal income tax consequences could apply to a U.S. Holder (as defined in “Taxation—United States Federal Income Taxation Considerations”) if we are treated as a PFIC for any taxable year during which such U.S. Holder holds our ADSs or ordinary shares.

 

Investors may be subject to limitations on transfers of our ADSs.

 

Our ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason.

 

75


 

Investors’ rights to pursue claims against the depositary as a holder of ADSs are limited by the terms of the deposit agreement.

 

Under the deposit agreement, any action or proceeding against or involving the depositary, arising out of or based upon the deposit agreement or the transactions contemplated thereby or by virtue of owning our ADSs may only be instituted in a state or federal court in New York, New York, and any investor, as a holder of our ADSs, will have irrevocably waived any objection which the investor may have to the laying of venue of any such proceeding, and irrevocably submitted to the exclusive jurisdiction of such courts in any such action or proceeding. The depositary may, in its sole discretion, require that any dispute or difference arising from the relationship created by the deposit agreement be referred to and finally settled by an arbitration conducted under the terms described in the deposit agreement. These arbitration provisions govern such dispute or difference and do not, in any event, preclude investors from pursuing claims under the Securities Act or the Exchange Act in state or federal courts.

 

ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.

 

The deposit agreement governing our ADSs representing our ordinary shares provides that, subject to the depositary’s right to require a claim to be submitted to arbitration, the federal or state courts in the City of New York have exclusive jurisdiction to hear and determine claims arising under the deposit agreement and in that regard, to the fullest extent permitted by law, ADS holders, including purchasers of ADSs in secondary transactions, waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, our ADSs or the deposit agreement, including any claim under the U.S. federal securities laws.

 

If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the U.S. Supreme Court. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement. We believe that this is the case with respect to the deposit agreement and our ADSs. It is advisable that investors consult legal counsel regarding the jury waiver provision before investing in our ADSs.

 

If an investor or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or our ADSs, including claims under federal securities laws, an investor or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action.

 

Nevertheless, if this jury trial waiver provision is not enforced, to the extent a court action proceeds, it would proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.

 

Investors may face difficulties in protecting the interests of investors, and the ability to protect the rights of investors through U.S. courts may be limited, because we are incorporated under Cayman Islands law.

 

Our holding company is an exempted company incorporated under the laws of the Cayman Islands. Our corporate affairs are governed by our amended and restated memorandum and articles of association, the Companies Law (2020 Revision) of the Cayman Islands and the common law of the Cayman Islands. The rights of shareholders to take action against our directors and the fiduciary duties of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the decisions of whose courts are of persuasive authority, but are not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedents in some jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have the standing to initiate a shareholder derivative action in a federal court of the United States.

76


 

 

Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records (other than the memorandum and articles of association and any special resolutions passed by such companies, and the registers of mortgages and charges of such companies) or to obtain copies of lists of shareholders of these companies. Under Cayman Islands law, the names of our current directors can be obtained from a search conducted at the Registrar of Companies. Our directors have discretion under our amended and restated articles of association, to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for investors to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.

 

As a result of all of the above, our public shareholders may have more difficulty in protecting their interests in the face of actions taken by management or members of our board of directors than they would as public shareholders of a company incorporated in the United States.

 

We have identified material weaknesses in our internal control over financial reporting. If our remediation of the material weaknesses is not effective, or if we experience additional material weaknesses in the future or otherwise fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely consolidated financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our ADSs may decline.

 

Pursuant to Section 404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning with the annual report for our fiscal year ending December 31, 2022. When we lose our status as an “emerging growth company” and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to upgrade our information technology systems, implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff. If we or, if required, our auditor is unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our ADSs may decline.

 

In connection with the audit of our consolidated financial statements, as of and for the years ended December 31, 2019, 2020 and 2021, we and our independent registered public accounting firm identified two material weakness in our internal control over the financial statement closing process. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. The material weaknesses that have been identified relate to (i) our lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of IFRS and reporting requirements set forth by the SEC to address complex IFRS technical accounting issues, and to prepare and review consolidated financial statements and related disclosures in accordance with IFRS and SEC reporting requirements; and (ii) our lack of formal and effective financial closing policies and procedures, specifically those related to period end expenses cut-off and accruals.

 

We are working to remediate these material weaknesses and are taking steps to strengthen our internal control over financial reporting through the development and implementation of processes and controls over the financial reporting process. Specifically, we are working to implement the newly established period-end financial closing policies and procedures, including expense reconciliation between finance and operation departments, execute the developed staffing plan for hiring additional accounting and finance personnel in 2022, hire additional qualified resources with appropriate knowledge and expertise to handle complex accounting issues and effectively prepare financial statements and conduct regular and continuous IFRS accounting and financial reporting training programs for our financial reporting and accounting personnel. However, we cannot assure investors that these measures will significantly improve or remediate the material weaknesses described above.

 

We cannot assure investors that there will not be additional material weaknesses or any significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our ADSs could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

 

77


 

Our amended and restated memorandum and articles of association contain anti-takeover provisions that could discourage a third party from acquiring us, which could limit our shareholders’ opportunity to sell their shares, including ordinary shares represented by our ADSs, at a premium.

 

Our amended and restated memorandum and articles of association contain provisions to limit the ability of others to acquire control of us or cause us to engage in change-of-control transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to obtain control of us in a tender offer or similar transaction. For example, our board of directors has the authority, without further action by our shareholders, to issue preferred shares in one or more series and to fix their designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares, in the form of ADS or otherwise. Preferred shares could be issued quickly with terms calculated to delay or prevent a change in control of us or make removal of management more difficult. If our board of directors decides to issue preferred shares, the price of our ADSs may fall and the voting and other rights of the holders of our ordinary shares and ADSs may be materially and adversely affected.

 

Our amended and restated memorandum and articles of association provide that the courts of the Cayman Islands and the U.S. federal courts will be the exclusive forums for substantially all disputes between us and our shareholders, which could limit our shareholders’ ability to obtain a favorable judicial forum for complaints against us or our directors, officers or employees.

 

Our amended and restated memorandum and articles of association provide that, unless otherwise agreed by us, (i) the federal courts of the United States shall have exclusive jurisdiction to hear, settle and/or determine any dispute, controversy or claim arising under the provisions of the Securities Act or the Exchange Act, which are referred to as the “U.S. Actions;” and (ii) save for such U.S. Actions, the courts of the Cayman Islands shall have exclusive jurisdiction to hear, settle and/or determine any dispute, controversy or claim whether arising out of or in connection with our articles of association or otherwise, including without limitation:

any derivative action or proceeding brought on behalf of our shareholders;
any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to our shareholders;
any action asserting a claim under any provision of the Companies Law (Revised) of the Cayman Islands or our articles of association; or
any action asserting a claim against us which if brought in the United States would be a claim arising under the internal affairs doctrine (as such concept is recognized under the laws of the United States).

 

These exclusive-forum provisions may increase a shareholder’s cost and limit the shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any of our shares or other security, such as our ADSs, whether by transfer, sale, operation of law or otherwise, shall be deemed to have notice of and have irrevocably agreed and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies’ charter documents has been challenged in legal proceedings. It is possible that a court could find this type of provisions to be inapplicable or unenforceable, and if a court were to find this provision in our amended and restated memorandum and articles of association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could have adverse effect on our business and financial performance.

 

We could be subject to securities class action litigation.

 

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us, because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

 

78


 

If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, the market price for our ADSs and trading volume could decline.

 

The trading market for our ADSs relies in part on the research and reports that equity research analysts publish about us or our business. We do not control these analysts. If research analysts do not maintain adequate research coverage or if one or more of the analysts who covers us downgrades our ADSs or publishes inaccurate or unfavorable research about our business, the market price for our ADSs would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our ADSs to decline significantly.

 

The increasing use of social media platforms presents new risks and challenges.

 

Social media is increasingly being used to communicate about us and the diseases our products are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend ourselves or the public’s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Further, there is a risk that unmerited or unsupported claims about our products may circulate on social media. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions, or incur other harm to us and our business, including damage to the reputation of our products.

ITEM 4. INFORMATION ON THE COMPANY.

A. History and Development of the Company

General Information

We are a Cayman Islands exempted company incorporated with limited liability and were incorporated in November 2015. Our legal name is Connect Biopharma Holdings Limited and our commercial name is Connect Biopharma. Prior to this, our business was conducted by Suzhou Connect Biopharma Co., Ltd., or Connect SZ, which was incorporated in May 2012 in Suzhou in the PRC. Our registered office in the Cayman Islands is at the offices of Maples Corporate Services Limited at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. Our administration office and agent for service of process in the United States is located at 12265 El Camino Real, Suite 350, San Diego, California 92130. Our principal executive office and PRC research, development and administration facility is located at Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu, China 215400, and its telephone number is +86 512 5357 7866. Our website address is www.connectbiopharm.com. The information contained on, or accessible through, our website does not constitute a part of this annual report. We have included our website address in this annual report solely as an inactive textual reference. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.

We are a holding company, and we may rely on dividends and other distributions on equity paid by our subsidiaries for our cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders or holders of our ADSs or to service any debt we may incur. If any of our subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may restrict its ability to pay dividends to us. To date, there have not been any such dividends or other distributions from our subsidiaries. In addition, none of our subsidiaries have ever issued any dividends or distributions to us or to U.S. investors. In the future, cash proceeds raised from overseas financing activities may be transferred by us to our subsidiaries via capital contribution or shareholder loans, as the case may be.

Under PRC laws and regulations, there are restrictions on the Company’s PRC subsidiaries with respect to transferring some of their net assets to the Company either in the form of dividends, loans, or advances. Restricted net assets including paid-in capital and statutory reserve funds of the Company’s PRC subsidiaries was RMB 137.7 million as of December 31, 2020 and RMB 288.9 million as of December 31, 2021.

For a description of our principal capital expenditures and divestitures for the three years ended December 31, 2021 and for those currently in progress, see Item 5. “Operating and Financial Review and Prospects.”

79


 

Corporate Establishment

In May 2012, Connect SZ was incorporated as a limited liability under the laws of the PRC. At such time, Connect SZ held 100% of the equity interests of Connect Biopharm LLC, or Connect US, a single member LLC incorporated under the laws of the State of California. Connect US commenced its operations in January 2012.
In July 2014, Connect Biopharma Australia PTY LTD, or Connect AU, was formed as a limited liability company incorporated under the laws of Australia.
In October 2015, Connect Biopharma (Shanghai) Co., Ltd., or Connect SH, was formed as a limited liability company incorporated under the laws of the PRC.
In November 2015, Connect Biopharma Holdings Limited was formed as a Cayman Islands exempted company with limited liability, and in December 2015, Connect HK was formed as a limited liability company under the laws of Hong Kong. Connect Biopharma Holdings Limited and Connect HK were formed for the purpose of effecting the reorganization described below as holding companies for the majority shareholders of Connect SZ.
Connect Biopharma (Beijing) Co., Ltd., or Connect BJ, was formed subsequent to the reorganization and restructuring described below in July 2019 as a limited liability company incorporated under the laws of the PRC.
In November, 2021, Connect Biopharma (Shenzhen), Co. Ltd., or Connect SE, was formed as a limited liability company incorporated under the laws of the PRC.

The Reorganization and the Restructuring

In January 2016, the Company and its subsidiaries underwent a reorganization, or the Reorganization, pursuant to which Connect Biopharma Holdings Limited issued ordinary shares to Dr. Wei and Dr. Pan, each of whom were founders of the company group, in exchange for their equity interests held in Connect SZ. As a result of issuance of the ordinary shares, Dr. Wei and Dr. Pan held 100% of the equity interests in the Company and Connect HK and retained joint control over the Company and its subsidiaries.
Following the issuance of equity interests in the Company to Dr. Wei and Dr. Pan, the remaining 30% of the equity interests in Connect SZ were held by an existing investor. These interests are referred to as the Non-Controlling Interests.
In October 2018, we underwent a restructuring, pursuant to which we transferred 100% of the outstanding shares of our subsidiaries Connect US and Connect AU (which were then held by Connect SZ) to Connect HK. Following such transfer, Connect US and Connect AU become wholly owned subsidiaries of Connect HK. Also in October 2018, we issued ordinary shares of Connect Biopharma Holdings Limited to the holders of Non-Controlling Interests in Connect SZ in exchange for such Non-Controlling Interests and Connect Biopharma Holdings Limited issued Series Pre-A convertible preferred shares, par value $0.0001 per share, or the Series Pre-A Preferred Shares, and Series A convertible preferred shares, par value $0.0001 per share, or the Series A Preferred Shares, to the preferred shareholders of Connect SZ as consideration for the same equity interests they held in Connect SZ, respectively. Following these transactions, the shareholders of Connect SZ became shareholders of our company and Connect SZ became a wholly owned subsidiary of Connect HK. We refer to the 2018 events described above as the Restructuring.
Connect SZ continues to hold 100% of the equity interest in Connect SH, Connect BJ and Connect SE.

Following the Reorganization and the Restructuring, each as described above, Connect Biopharma Holdings Limited became the ultimate parent of the Company and all its subsidiaries. On March 23, 2021, we completed our initial public offering, or IPO, for a total cash consideration of $219.9 million, before netting underwriting discounts and commissions of $15.4 million.

B. Business Overview

We are a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis, or AD, and asthma. The estimated global market for AD was approximately $7.6 billion in 2021 and is expected to grow to $12.1 billion by 2025, a compound annual growth rate, or CAGR, of 12.4%. Based on observed results in preclinical studies and clinical trials, CBP-201 has the potential to be differentiated from dupilumab, an antibody that also targets IL-4Ra, which is now approved by the U.S. Food and Drug Administration, or FDA. We recently completed a Phase 2b trial of CBP-201 in the United States, Australia and New Zealand in adult patients with moderate-to-severe AD, in which primary and key secondary endpoints were met, and plan to initiate a global Phase 3 program in adult patients with moderate-to-severe AD in the second half of 2022. We are also currently conducting a Phase 2b trial

80


 

evaluating CBP-201 in Type 2 inflammatory asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, and a pivotal trial in moderate-to-severe AD patients in the PRC. Furthermore, we are developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, or S1P1, for the treatment of inflammatory bowel disease, or IBD. Specifically, we are developing CBP-307 for two types of IBD, ulcerative colitis, or UC, and Crohn’s disease, or CD. We anticipate reporting top-line results from a global Phase 2 trial in UC in the second quarter of 2022, while we will determine whether to initiate further clinical trials in CD after evaluating the Phase 2 UC data.

Our immune modulator product candidates originate from our approach to drug discovery based on using biologically relevant functional cellular assays to conduct primary drug screens instead of high-throughput biochemical assays. The clinical and preclinical results we have observed for our product candidates support the potential for this physiologically relevant methodology to yield highly differentiated solutions, in a more efficient manner. Our approach is agnostic to drug modalities and has been used to identify both small molecule and antibody product candidates.

We are advancing CBP-201, an investigational anti-IL-4Ra antibody, for the treatment of inflammatory allergic diseases such as AD, asthma and CRSwNP. Inhibition of IL-4Ra blocks the action of two inflammatory cytokines: interleukin- 4, or IL-4, and interleukin-13, or IL-13. In a randomized, placebo-controlled Phase 1a trial in healthy volunteers, administration of a single dose of CBP-201 was well-tolerated and led to suppression of a serum biomarker of inflammation. In a randomized, double-blinded placebo-controlled Phase 2b trial in adult AD patients, we observed significant improvements in primary and key secondary endpoints on skin clearance, disease severity, and itch, and CBP-201 was generally well-tolerated. Although no head-to-head trials have been conducted, we believe that CBP-201 has two potential advantages over the current standard of care: (1) in preclinical studies CBP-201 bound to a region of IL-4Ra that is distinct from that bound by dupilumab and associated with high binding affinity and potency for IL-4Ra, which we believe may lead to improved clinical response; and (2) a more convenient proposed dosing regimen in adult patients with moderate to severe AD, as evidenced by our Phase 2b trial data showing positive results with our Q4W (300 mg dose every four weeks) results, which is a less frequent dosing schedule than the Q2W (300 mg dose every two weeks) dose for duplimab for adult patients with moderate to severe AD.

CBP-307 is an investigational, small molecule modulator of S1P1, a regulator of T cell mobilization out of lymph nodes into the periphery. Inhibiting S1P1 leads to reduction in the levels of these T cells in circulation and a reduction in autoimmune-related inflammation. S1P1 is a validated therapeutic target with three drugs approved to treat multiple sclerosis: fingolimod, marketed as Gilenya® by Novartis, siponimod, marketed as Mayzent® by Novartis, and ozanimod, marketed as Zeposia®, by Bristol Myers Squibb. Evidence from third-party clinical trials suggests that the potential of S1P1 modulators is far broader than multiple sclerosis and includes highly prevalent diseases with unmet need such as UC and CD, and Zeposia received approval for the treatment of adults with moderately to severely active UC from the FDA and EMA in 2021. The estimated global market for UC was approximately $5.4 billion in 2021, and the estimated global market for CD was approximately $5.4 billion in 2020. We believe that CBP-307 is well-positioned to potentially address these diseases due to the potency, specificity and pharmacokinetics observed in our preclinical studies and early clinical trials. We are conducting a global Phase 2 trial in UC and anticipate reporting top-line results before the end of the second quarter of 2022. In addition, we intend to initiate a global clinical trial in CD based on the preliminary clinical responses observed in a limited number of patients in an earlier CD clinical trial.

We are developing CBP-174, a peripherally acting, small molecule H3R antagonist, for oral administration to treat chronic itch associated with skin inflammation. We have exclusively licensed global rights to CBP-174 from Arena Pharmaceuticals, Inc., or Arena, to complement our CBP-201 program in AD. We believe that the ability to quickly alleviate itch in the setting of AD has the potential to complement the anti-pruritic effect of disease-modifying IL-4Ra antagonists such as our CBP-201 product candidate or dupilumab. In clinical trials, these IL-4Ra targeted products required weeks of treatment for many AD patients to obtain significant relief of itching, or pruritus. Our preclinical mouse model study has indicated that CBP-174 led to reductions in scratching within the first 30 minutes of dosing, which could potentially translate to rapid reduction in pruritus in the clinic. We expect to complete our Phase 1 dose escalation study with CBP-174 in healthy adults in the first half of 2022 and anticipate reporting top-line results in the first half of 2022.

We are building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting other aspects of T cell biology.

We are a global company with clinical development activities in the United States, the PRC, Europe, and Australia and operations in those geographies as well as Hong Kong. We intend to continue recruiting top talent and operating in these geographies for the foreseeable future.

We were founded by a team with broad knowledge of the drug discovery industry and domain expertise in targeting immunological pathways. Zheng Wei, Ph.D., our Chief Executive Officer, has over 25 years of experience at drug discovery organizations including Arena and was a scientist and program leader at ChemoCentryx. Wubin Pan, Ph.D., our President and Chairman, was a co-founder, the PRC President, and Chief Operation Officer of Crown Bioscience. We believe that our experience and professional networks in

81


 

both the drug discovery and contract research industry provide us with critical insights on best practices to optimally build a highly efficient and cost-effective discovery and development organization. Our physical presence in the United States and the PRC enables us to take advantage of high-quality local talent while facilitating access to other global resources. We have raised approximately $440 million to date and are supported by top tier investors including RA Capital Management, Fidelity, BlackRock, Lilly Asia Ventures, Boxer Capital, HBM Healthcare, Qiming Venture Partners, Wellington, Janus Henderson Investors, and Octagon Capital Advisors.

Our Pipeline

img67639792_0.jpg 

Connect Biopharma Has Global Development & Commercialization Rights to All Product Candidates

* Phase 2 trial ended early due to COVID-19-related enrolment challenges. Future clinical development plans to be determined upon completion of Phase 2 UC trial

Our Strategy

Our goal is to become a global biopharmaceutical company developing and commercializing therapies for patients suffering from inflammatory diseases. Our strategy to achieve this goal is as follows:

Discover and develop product candidates targeting inflammatory diseases with significant unmet medical need. We specialize in designing and developing product candidates that modulate the immune system, with a particular focus on T cells. By leveraging our internal expertise and unique insights in therapeutic targeting of the immune system, our goal is to identify highly differentiated, potentially best-in-class product candidates against validated targets as well as potential first-in-class molecules against novel targets. We will continue to focus on the discovery and development of product candidates targeting inflammatory diseases with significant unmet medical need and affecting millions of patients worldwide.
Continue development of our three most advanced product candidates. We believe CBP-201, CBP-307 and CBP-174 each have the potential to provide significant therapeutic benefit to patients suffering from inflammatory disorders, such as AD, IBD, asthma and CRSwNP, and pruritus associated with inflammatory skin diseases. We plan to advance these product candidates into and through clinical trials in the indications currently being investigated. In addition, we plan to expand the development of our product candidates into other indications.
Advance our earlier stage programs and continue to invest in R&D to expand and enhance our pipeline. We are continuing to expand our pipeline of product candidates by applying our expertise in immunology to select targets, design assays, and execute preclinical drug discovery programs.
Leverage our core strengths in the United States and the PRC and expand our operations globally. We currently have operations in the United States, the PRC, Australia, Europe, and Hong Kong. Globally, we leverage our relationships with clinical research organizations, large patient population and local infrastructure in ways that we believe provide us with a competitive advantage. In addition, we plan to leverage our expertise and relationships regarding drug development in the United States and the PRC. We currently intend to retain significant commercial rights to our product candidates globally and will consider high-value commercial partnerships in select territories.

82


 

Dysregulation of T Cells in Inflammatory Diseases

T cells are a type of lymphocyte, or white blood cell, responsible for controlling and shaping the immune response to foreign substances such as pathogens and allergens. Dysregulation of T cells often leads to the development of multiple diseases related to autoimmunity and inflammation. These diseases include respiratory diseases such as asthma, dermatological diseases such as AD, gastrointestinal diseases such as IBD and neurodegenerative diseases such as multiple sclerosis. As understanding of the details of T cell biology has evolved over the last two decades, a number of targeted drugs have been developed for these diseases that directly modulate T cell biology.

A subclass of T cells called T helper cells assists in determining the appropriate immune response based on the nature of the attack on the body. T helper cells themselves belong to two major subcategories, leading to two types of immune responses known as Th1 and Th2 immune responses.

Broadly speaking, Th1 immune responses are pro-inflammatory in nature. When the body needs to respond to pathogens inside the cell, it triggers a Th1 response. Dysregulation of this Th1 response is also associated with pathologies such as autoimmune diseases, including multiple sclerosis, psoriasis and IBD. In those cases, the body reacts to a part of itself as if it is a threat, and the inflammation that results is part of the Th1 response. Therapies that interfere with Th1 signaling include glucocorticoids, inhibitors of TNFa and inhibitors of interleukin 12 and interleukin 23, or IL-12/IL-23. These therapies have been approved to treat multiple diseases such as rheumatoid arthritis, psoriasis and IBD.

Th2 immune responses help the body attack extracellular pathogens and drive allergic reactions. Diseases caused by Th2 dysregulation include asthma, AD and allergies. Dupilumab, which blocks the activity of Th2 cytokines by inhibiting IL-4 and IL-13, has been approved to treat AD and asthma.

Previously approved modulators of the Th1 and Th2 immune responses have illustrated both the broad therapeutic potential and the sizeable commercial market associated with targeted T cell therapies. We believe, however, that there exist multiple opportunities to develop next-generation therapeutics directed against clinically validated as well as novel targets that regulate Th1 and Th2 immune responses.

Our Approach

Our differentiated approach is designed to specifically identify product candidates based on our deep understanding of the immune system, particularly T cell biology, and ability to develop sophisticated functional assays using T cells. In contrast to traditional drug discovery approaches, which often begin with high throughput screening based on biochemical properties, we directly screen our molecules with these functional assays. We believe our approach leads to more rapid identification of relevant molecules and avoids the elimination of attractive molecules that could fail to advance through traditional screening assays.

We apply our approach to develop product candidates against targets in T cell modulation related to inflammatory diseases with large unmet need. Our goal is to produce first-in-class or best-in-class product candidates to address these targets.

img67639792_1.jpg 

 

Figure 1. Our drug screening approach

83


 

Our Product Candidates

CBP-201, an Anti-IL-4Ra Antibody

We are advancing CBP-201, an investigational, an anti-IL-4Ra antibody, for the treatment of inflammatory allergic diseases such as AD, asthma and CRSwNP. Inhibition of IL-4Ra blocks the action of two inflammatory cytokines: IL-4 and IL-13. Dupilumab, marketed as Dupixent® by Sanofi and Regeneron, an antibody that also targets IL-4Ra, has been demonstrated to lead to significant therapeutic benefit in patients with these diseases. Despite being on the market for only four years, sales of dupilumab were over €5.2 billion in 2021, representing +48.5% growth over 2020 and are expected to grow to over €10 billion according to Sanofi’s estimates.

Atopic dermatitis disease overview

Atopic dermatitis, or AD, also referred to as eczema, is one of the most commonly diagnosed chronic inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. Chronically inflamed skin lesions cause persistent itch, which is the primary symptom associated with the disease, as well as localized pain and sleep disturbances. According to the National Eczema Association, 26.1 million people in the United States have AD. Of these, 6.6 million adults have moderate-to-severe disease. Globally, prevalence of AD is increasing and, as of 2018, had an estimated lifetime prevalence of up to 20%. In the PRC, the prevalence of clinically diagnosed AD in children aged one to seven is estimated to be approximately 13% as of 2016. Although AD prevalence is stabilizing in high-income nations, it has historically increased two- to three-fold in industrialized nations since the 1970s. The estimated global market for AD was approximately $7.6 billion in 2021 and is expected to grow to $12.1 billion by 2025, a compound annual growth rate, or CAGR, of 12.4%.

Topical anti-inflammatory agents, such as corticosteroids and calcineurin inhibitors, are routinely used to manage skin health and to reduce skin inflammation in patients with mild-to-moderate AD. Patients whose disease flares despite topical treatments may be prescribed systemic agents such as oral corticosteroids or oral cyclosporine to rapidly relieve severe signs and symptoms of the disease. While these are effective as temporary treatments of flare-ups, extended use has been associated with many potential side effects or adverse events. Systemic steroids, such as prednisone, can lead to symptom relief but their use is not recommended to induce stable remission due to numerous side effects associated with steroids and the propensity of severe disease flares upon abrupt treatment cessation. Cyclosporine is also generally not recommended for use lasting longer than one to two years, as it has been associated with renal toxicity, hirsutism, nausea and lymphoma. Based on data from the 2014 Adelphi US AD Disease Specific Program over 58% of adults with moderate-to-severe AD have disease which physicians consider to be inadequately controlled by these therapeutic modalities.

To address the shortcomings of traditional therapies for AD, specific biologic targets implicated in the pathogenesis of AD have been explored, a key focus of which has been interleukin-4, or IL-4 and interleukin-13, or IL-13. IL-4 production leads to increased levels of immunoglobulin E, or IgE, and eosinophils in the peripheral blood and tissue. IL-13 is a Th2-related cytokine that affects B cells and monocytes thereby regulating inflammatory and immune responses. Both cytokines exert their effects via IL-4Ra, which is expressed on the surface of T cells, B cells and macrophages amongst others and is involved in activation of the inflammatory immune response to allergens. IL-4Ra can form a heterodimer with the IL-13 receptor, or IL-13Ra, and can thus be activated by binding of either IL-4 or IL-13. IL-4 and IL-13 have redundant activities and both serve as the main drivers of allergic inflammation in the body. Activation of IL-4Ra leads to cytokine production, macrophage activation, IgE production by B cells, mucus production by airway epithelial cells, and dermal inflammation and remodeling.

In 2017, dupilumab, marketed as Dupixent® by Sanofi and Regeneron, was approved as an alternative treatment for patients with moderate-to-severe AD. Dupilumab blocks signaling through IL-4Ra, preventing IL-4 and IL-13 from binding and reducing levels of serum cytokines and IgE levels. Treatment with dupilumab has been shown to alleviate symptoms in patients suffering from AD and other inflammatory diseases such as asthma, CRSwNP and in Phase 3 clinical trials for other type 2 inflammatory diseases, such as eosinophilic esophagitis (EoE), prurigo nodularis (PN) and chronic spontaneous urticaria (CSU). Dupilumab has been approved by the FDA for the treatment of AD that is not adequately controlled with topical prescription therapies and as an add-on maintenance treatment for moderate-to-severe asthma and inadequately controlled CRSwNP. Despite being on the market for only four years, sales of dupilumab were over €5.2 billion in 2021 and are expected to grow to over €10 billion according to Sanofi’s estimates, highlighting the high demand for effective treatments for AD. The global market opportunity for asthma biologics is likewise growing rapidly, with a total market size of approximately $1.8 billion in 2015 and projected growth to $6.1 billion by 2024, a CAGR of 14.5%.

84


 

Limitations of dupilumab

Despite the impressive results, a significant number of patients treated with dupilumab continue to have significant active uncontrolled disease. In SOLO 1 and SOLO 2, two Phase 3 clinical trials in moderate-to-severe AD patients whose disease was not adequately controlled with topical prescription therapies, both of which were conducted by Sanofi and Regeneron, a 75% reduction in the Eczema Area and Severity Index score, or EASI-75, was achieved at week 16 by 44 to 51% of patients receiving dupilumab every two weeks and, in another long-term efficacy study conducted by Sanofi and Regeneron, LIBERTY AD CHRONOS, 39% of patients in the dupilumab plus topical corticosteroids groups achieved the Investigator’s Global Assessment endpoint of a score of zero or one, with at least a two point or greater reduction from baseline, at weeks 16 and 52. These results indicate that up to 60% of patients do not achieve sufficient control of disease. Further, even for patients that respond to treatment with dupilumab, it can take 12 to 16 weeks to achieve adequate control. Lastly, dupilumab is not approved for dosing less frequently than every two weeks for adults.

Our solution, CBP-201

CBP-201 is an investigational, human monoclonal antibody targeting IL-4Ra. As an inhibitor of IL-4Ra, CBP-201 blocks inflammatory signaling by both IL-4 and IL-13. CBP-201 binds to a region of IL-4Ra that is distinct from that bound by dupilumab and associated with high binding affinity and potency for IL-4Ra, which we believe may lead to improved clinical response. Our clinical development program is focused on the potential for differentiating CBP-201 from dupilumab in the degree of clinical response and with less frequent dosing.

img67639792_2.jpg 

 

Figure 2. CBP-201 is an anti-IL-1Ra antibody designed to block the signaling of both IL-4 and IL-13.

We have completed a Phase 2b trial of CBP-201 in adult patients with moderate-to-severe AD, that was conducted in 59 trial sites across the United States, the PRC, Australia and New Zealand, and was designed to assess efficacy, safety, pharmacokinetics and pharmacodynamics with longer term, alternate dosing schedules (CBP-201 WW001). The prolonged pharmacodynamic TARC response following a single dose of CBP-201 observed in our initial Phase 1a trial suggests that it may be possible to achieve suppression of IL-4Ra on a once every two weeks or once every four weeks dosing schedule, following a loading dose.

85


 

Key inclusion criteria for the WW001 trial were moderate-to-severe AD adult patients that were inadequately controlled with topical corticosteroids and calcineurin inhibitors, AD duration of at least one year, an EASI score of at least 16, and IGA score of at least 3 and at least 10% BSA involvement. This trial enrolled a total of 226 patients across three cohorts of CBP-201 and a placebo control. The first cohort received one loading dose of 600 mg of CBP-201 followed by 150 mg every two weeks (Q2W). The second cohort received one loading dose of 600 mg, then 300 mg Q2W. The third CBP-201 cohort received one loading dose of 600mg followed by 300 mg every four weeks (Q4W). All patients were dosed for a total of 16 weeks followed by an 8 week safety follow-up period. The primary endpoint was the percentage change in EASI from baseline to week 16. Key secondary endpoints included the proportion of patients achieving IGA 0,1, EASI-75, EASI-90 and the change in PNRS from baseline to week 16.

img67639792_3.jpg  

 

Figure 3. Design of the Phase 2b trial of CBP-201 in moderate-to-severe AD

The results from the WW001 trial detailing the primary and key secondary endpoints were presented at the Maui Derm 2022 Scientific Meeting, including the following:

CBP-201 successfully met both primary and key secondary endpoints, demonstrating significant improvements in skin clearance, disease severity and itch, compared to placebo, and suggesting a potential dose response between CBP-201 300mg and CBP-201 150mg.
CBP-201 was generally well tolerated, with a similar incidence of Treatment-Emergent Adverse Events, or TEAEs, Serious Adverse Events, or SAEs and TEAEs leading to study drug discontinuation between the active and placebo arms. For AEs of special interest, or AESIs among patients receiving CBP-201, there were low reported incidences of injection site reactions (1.8%) and conjunctivitis (3.5%). The WW001 trial occurred during the COVID-19 pandemic and the patient population recruited had a markedly lower AD disease severity and higher patient discontinuation rate relative to previous third-party IL-4Rα antibody Phase 3 trials. We believe these factors contributed to a higher placebo response rate and lower active group response rate in our trial than observed in third-party trials with a higher baseline disease severity and fewer patient discontinuations. As such, we conducted post-hoc analyses from the trial to evaluate the effects of these factors on the magnitude of the efficacy results observed with CBP-201. These analyses demonstrated that with an increasing baseline disease severity, CBP-201 efficacy results improved across all doses, with placebo responses trending lower, supporting our plans for further development of CBP-201 300mg administered Q2W and also when administered Q4W.

86


 

img67639792_4.jpg 

EASI, Eczema Area and Severity Index score. FAS, full analysis set. LOCF, last observation carried forward. LS, least squares. Q2W, every 2 weeks. Q4W, every 4 weeks. *P<0.05 vs placebo. **P<0.01 vs placebo. ***P<0.001 vs placebo.

Figure 4. Primary Endpoint – EASI % change from baseline at Week 16

img67639792_5.jpg 

EASI-50/75/90, Eczema Area and Severity Index score percentage improvement. FAS, full analysis set. IGA, Investigator’s Global Assessment. NRI, non-responder imputation. Q2W, every 2 weeks. Q4W, every 4 weeks. *P<0.05 vs placebo. **P<0.01 vs placebo. ***P<0.001 vs placebo

Figure 5. Key Secondary Endpoints – % patients with IGA 0/1, and ≥2-point reduction / EASI-50, -75 or -90 % response vs. baseline at Week 16

87


 

img67639792_6.jpg 

PP-NRS, Peak Pruritus Numerical Rating Scale. FAS, full analysis set. LS, least squares. LOCF, last observation carried forward. Q2W, every 2 weeks. Q4W, every 4 weeks. *P<0.05 vs placebo. **P<0.01 vs placebo.

Figure 6. Key Secondary Endpoints – Change in weekly average PP-NRS at Week 16

 

n (%) patients with…

CBP-201 300 mg Q2W

N=57

CBP-201 150 mg Q2W

N=57

CBP-201 300 mg Q4W

N=56

All CBP-201

N=170

Placebo
N=56

Any TEAE

26 (46%)

24 (42%)

32 (57%)

82 (48%)

30 (54%)

Serious TEAE

0

1 (1.8%)

2 (3.6%)

3 (1.8%)

2 (3.6%)

Grade ≥3 TEAE

1 (1.8%)

1 (1.8%)

4 (7.1%)

6 (3.5%)

1 (1.8%)

Discontinuation due to TEAE

0

1 (1.8%)

1 (1.8%)

2 (1.2%)

1 (1.8%)

Treatment-related TEAE

6 (10.5%)

6 (10.5%)

8 (14.2%)

20 (11.7%)

5 (8.9%)

COVID-19 infections

2 (3.5%)

4 (7.0%)

1 (1.8%)

7 (4.1%)

4 (7.1%)

Conjunctivitis

Conjunctivitis allergic

2 (3.5%)

0

2 (3.5%)

0

1 (1.8%)

1 (1.8%)

5 (2.9%)

1 (0.6%)

0

0

Injection site reaction

1 (1.8%)

1 (1.8%)

1 (1.8%)

3 (1.8%)

1 (1.8%)

Herpes virus infections

Oral herpes

Ophthalmic herpes simplex

0

0

0

0

0

1 (2%)

0

1 (1%)

1 (1.8%)

0

Table 1. Safety Summary to Week 24

We believe the results from the WW001 trial were adversely affected by enrolled patients having less severe disease and a relatively high rate of treatment discontinuations.

88


 

To evaluate these hypotheses, we conducted post-hoc analyses to examine the impact of baseline disease severity on the magnitude of the observed treatment effect, including:

 

Post-hoc analyses

Issue that the analysis was conducted to evaluate

The PRC Subgroup (n=32)

Conducted to evaluate the outcomes for the Chinese patient population in the trial , which showed disease severity higher than the global population (Higher baseline EASI / baseline TARC) and appeared to show a reduced impact from discontinuations.

Median Results (n=226)

Conducted to account for non-normal distribution of baseline EASI reflecting low disease severity

EASI baseline (n=216)

Conducted to stratify efficacy responses by baseline EASI score (disease severity)

TARC baseline (n=212)

Conducted to stratify efficacy responses by baseline levels of an inflammatory biomarker of disease activity

Table 2. Additional post-hoc analyses performed to evaluate impact of baseline severity on CBP-201 response

These analyses demonstrated that with an increasing baseline disease severity, CBP-201 efficacy results improved across all doses, with placebo responses trending lower, supporting our plans for further development of CBP-201 300mg administered Q2W and also when administered Q4W.

img67639792_7.jpg 

EASI, Eczema Area and Severity Index score. EASI-50/75/90, Eczema Area and Severity Index score percentage improvement PP-NRS, Peak Pruritus Numerical Rating Scale. IGA, Investigator’s Global Assessment. NRI, non-responder imputation FAS, full analysis set. LOCF, last observation carried forward. LS, least squares. Q2W, every 2 weeks. Q4W, every 4 weeks. *P<0.05 vs placebo.

Figure 7. WW001 Additional analyses - the PRC sub-group (Post-hoc)

89


 

img67639792_8.jpg 

EASI, Eczema Area and Severity Index score. FAS, full analysis set. LOCF, last observation carried forward. LS, least squares. Q2W, every 2 weeks. Q4W, every 4 weeks. CFB, change from baseline

Figure 8. WW001 Additional analyses – Median Changes for continuous variables at Week 16 (Post-Hoc)

img67639792_9.jpg 

EASI, Eczema Area and Severity Index score. FAS, full analysis set. LOCF, last observation carried forward. LS, least squares. Q2W, every 2 weeks. Q4W, every 4 weeks. CFB, change from baseline. Tertiles defined as Low (≤ 18.4), Mid (>18.4 to 26.4) and High (≥ 26.4). *P<0.05 vs placebo. ***P<0.001 vs placebo.

Figure 9. WW001 Additional analyses – EASI % change from baseline at Week 16 by baseline EASI tertiles (Post-hoc)

90


 

img67639792_10.jpg 

^Serum TARC quantified via Luminex (WW001) and ELISA (SOLO 1 & 2) technologies. EASI, Eczema Area and Severity Index score. FAS, full analysis set. LOCF, last observation carried forward. LS, least squares. Q2W, every 2 weeks. Q4W, every 4 weeks. CFB, change from baseline. Tertiles defined as Low (≤ 116.74 pg/mL), Mid (>116.74 to ≤ 291 pg/mL) and High (≥ 291 pg/mL).*P<0.05 vs placebo. **P<0.01 vs placebo. ***P<0.001 vs placebo

Figure 10. WW001 Additional analyses – EASI % change from baseline at Week 16 by baseline TARC tertiles (Post-hoc)

Ongoing clinical trials

We initiated a PRC-specific pivotal trial to evaluate CBP-201 in adult patients with moderate-to-severe AD, in the second half of 2021. We initially designed the trial to enroll 255 patients, but have decided to expand the trial to include a target enrollment of approximately 500 patients.

As a result with respect to the PRC specific pivotal trial of CBP-201:

enrollment is being continued into the second half of 2022;
the expanded patient population will now include both adult and adolescent patients; and
the expanded patient numbers will also now include greater exposure to 300mg Q2W and 300mg Q4W.

Pending agreement with the Center for Drug Evaluation of the National Medical Products Administration, or NMPA, as to the required patient numbers for this PRC-specific pivotal trial and also for the ability to disclose the data from stage 1 of the trial (Baseline to week 16, the primary endpoint timing), top-line data readout is currently expected to be available as early as in the first half of 2023.

We are conducting clinical trials to assess the potential of CBP-201 in other diseases driven by dysregulation of the Th2 immune response, including global Phase 2 trials of CBP-201 in patients with Type 2 inflammatory asthma and CRSwNP, both of which were initiated in 2021.

Planned clinical trials

Based on the successful results from the phase 2b trial in moderate-to-severe AD adult patients, we plan to initiate a phase 3 program in both adults and adolescents (12 years to 17 years of age) in this same population, subject to positive meetings with regulatory authorities in both USA and ex-USA, with target first patient enrolled in the second half of 2022.

CBP-307, a Sphingosine 1-Phosphate Receptor 1 Modulator

CBP-307 is an investigational, selective modulator of sphingosine 1-phosphate receptor 1, or S1P1, which we are developing for the treatment of UC and CD. Modulation of S1P1 activity has been shown to suppress T cell migration and reduce inflammation and approved S1P1 modulators such as fingolimod, siponimod, and ozanimod are used to treat multiple sclerosis. We have observed in vitro potency, selectivity and pharmacokinetics for CBP-307 that we believe suggest advantages over other S1P1 modulators. Based on the accumulating clinical evidence seen with other S1P1 modulators, and the class mechanism of preventing T cells from entering

91


 

circulation and therefore reducing the likelihood of their migration into inflamed gastrointestinal parenchymal tissue, we believe that CBP-307 has potential to address unmet needs in UC and CD. We have completed a Phase 1 trial in healthy volunteers in which CBP-307 was generally well-tolerated. Administration of CBP-307 led to reductions in circulating lymphocytes, which recovered within one week of treatment completion. We anticipate reporting top-line results from a global Phase 2 trial in UC before the end of the second quarter of 2022. Our Phase 2 trial in CD ended early in 2021 due to COVID-19 enrollment challenges. We will determine whether to initiate future trials in CD based on Phase 2 UC trial data.

Ulcerative colitis and Crohn’s disease overview

UC and CD are forms of IBD that are distinguished by the portion of the intestinal tract that is affected. In CD, segments of local inflammation can be found anywhere along the digestive tract, whereas UC is characterized by inflammation and ulceration of just the inner lining of the colon and rectum. Both diseases are associated with symptoms, that dependent upon the extent and severity of the disease, include abdominal pain, bloody diarrhea, rectal bleeding, urgency, fecal incontinence, and fatigue. Both UC and CD are diseases that undergo cycles of remissions and relapses.

Approximately 1.3% of adults in the United States, or approximately three million people, were estimated to be diagnosed with UC or CD in 2015. Worldwide in 2017, there were approximately 6.8 million people affected by IBD, and the majority of IBD patients had UC. The estimated global market for UC was approximately $5.4 billion in 2020, and the estimated global market for CD was approximately $7.4 billion in 2019. The UC market is estimated to grow at a CAGR of 6.8% to $7.5 billion in 2025. The CD market is estimated to reach $12.6 billion in 2029, a CAGR of 5.5%.

Mesalamine is typically used for first-line treatment and maintenance of remission in mild-to-moderate active UC and CD and can be supplemented with oral corticosteroids for disease flares. Patients who have moderate-to-severe disease or are refractory to mesalamine and oral corticosteroids may be treated with intravenous steroids, or biologics, including anti-TNFa, anti-integrin a4ß7, anti-IL-12/23, or small molecule inhibitors of JAK.

Limitations of Existing Therapies

Despite the multiple therapeutic options available for IBD, significant unmet medical need remains due to the tolerability, inadequate clinical responses and remissions, speed of action and burden of administration associated with existing therapies. Prolonged exposure to intravenous steroids is associated with a side effect profile that may outweigh clinical benefit. Anti-TNFa agents have been associated with a risk of infection or malignancy, while the approved labeling for specific JAK inhibitors includes a “black box” warning for risks including serious infections, mortality, malignancy and thrombosis. Beyond the safety concerns associated with existing therapies, clinical management of UC and CD remains unsatisfactory, with one 2013 study reporting that less than half of patients achieved long-term remissions. Further, some advanced therapies have a delay in onset of up to three months, and maximal clinical remission may require up to one year of treatment. Some therapies also involve complicated administration regimens, with biologics requiring either regular subcutaneous injections or intravenous infusions. There is therefore an unmet medical need for novel oral agents with an enhanced risk-benefit profile and more convenient administration for the treatment of moderate-to-severe active IBD.

Role of S1P1 in inflammation

S1P1 is a clinically validated anti-inflammatory target with three marketed drugs directed against it: fingolimod, marketed as Gilenya® by Novartis, siponimod, marketed as Mayzent® by Novartis, and ozanimod, marketed as Zeposia®, by Bristol Myers Squibb. All three drugs are approved to treat multiple sclerosis. Sales of fingolimod were $3.2 billion in 2019.

There are five sphingosine 1-phosphate receptors: S1P1-S1P5. S1P1, in particular, is expressed on lymphocytes that are associated with the underlying inflammation of autoimmune diseases. Importantly, modulation of the S1P1 receptor causes selective and reversible sequestration of circulating lymphocytes in the thymus and peripheral lymphoid tissues. This sequestration is achieved through changes in the trafficking of lymphocytes. These changes, in turn, prevent the migration of autoreactive lymphocytes to sites of inflammation, including the central nervous system in multiple sclerosis and the gastrointestinal tract in IBD. It is exactly this reduction in the migration of potentially damaging lymphocytes that is a desirable result of intervention in S1P1 signaling.

Other sphingosine 1-phosphate receptors have physiological roles that do not involve inflammation. Inhibition of S1P3, for example, with poorly selective S1P1 modulators, such as fingolimod, is associated with fibrosis in mice models. S1P2 and S1P3 are also expressed on myofibroblasts and their modulation leads to vasoconstriction and an increase in blood pressure. The clinical relevance of S1P4 and S1P5 is currently unknown. Fingolimod, which lacks high selectivity, has been associated with significant AEs and is contraindicated for patients with a history of cardiac disease.

92


 

We believe that this lack of selectivity can be overcome with a more targeted approach to drug discovery. Furthermore, we believe that S1P1 modulation of lymphocyte trafficking may have utility in other autoimmune diseases, including highly prevalent diseases with unmet need such as UC and CD. S1P1 modulators with high specificity for S1P1 may lead to reductions in those cardiovascular effects that limit the potential of less selective modulators to be used in broad populations. Prior clinical trials of second generation S1P1 modulators, ozanimod and etrasimod, demonstrated results in IBD, but are not yet approved for any IBD indication. Further optimization of pharmacokinetics and pharmacodynamics of a highly selective S1P1 modulator has the potential to lead to a best-in-class agent for autoimmune diseases, particularly in UC and CD.

Our solution CBP-307

CBP-307 is an orally available, next generation, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells or targeting a specific cytokine. By design, CBP-307 is highly selective for S1P1 without significant activity for S1P2 and S1P3 receptor subtypes allowing it to potentially have an optimized effect on circulating T lymphocytes, which we believe may result in significant anti-inflammatory activity. In preclinical studies, CBP-307 demonstrated strong pharmacokinetics and pharmacodynamics, with rapid onset of action and rapid recovery of T lymphocytes. These enhanced characteristics were evidenced by CBP-307’s short half-life as well as ability to rapidly induce an absolute lymphocyte reduction to ~400 to ~750 cells per µL and >60-70% reduction in lymphocyte count from baseline, which compares favorably to targets achieved by approved S1P1 modulators. Further, its pharmacokinetics characteristics could allow CBP-307 to be dosed once daily orally. CBP-307 is not a pro-drug and does not require in vivo conversion to produce its effects. We believe these characteristics position CBP-307 to potentially address the unmet efficacy, safety and convenience needs of currently approved agents in UC and CD.

img67639792_11.jpg 

 

Figure 11. Mechanism of CBP-307

We discovered CBP-307 by running a functional screen for the desired biological property, which in this case was the ability of a small molecule to cause internalization of S1P1 from its native location on the surface of T cells. It is because of this internalization that T cells are not able to leave the lymph node and enter circulation. By focusing our discovery efforts on this desired result, we were able to identify CBP-307 as a highly potent S1P1 modulator while avoiding false positive results for compounds that bound tightly to S1P1 but did not cause internalization and false negative results for compounds that failed to bind tightly to recombinant S1P1.

93


 

CBP-307 is a highly potent and selective modulator of S1P1, which in preclinical studies has shown selectivity of over 80,000-fold in S1P1 versus S1P3. Furthermore, in preclinical studies, 10 µM of CBP-307 did not show meaningful interactions in a broad receptor panel screen against other G-protein-coupled receptors and ion channels that have important physiologic functions in the body except for an inhibition effect of 57% on the histamine receptor H1. In preclinical studies, CBP-307 was only significantly inhibited by two of the seven major cytochrome P450 metabolizing enzymes that were profiled.

 

img67639792_12.jpg 

 

(i)
cAMP Assay
(ii)
ß-Arrestin Assay

Figure 12. CBP-307 potently and selectively modulated S1P1 in vitro. Information provided in the table above is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies.

We have completed a Phase 1 trial of CBP-307 in 44 healthy adults in Australia, which consisted of a 7-day single ascending dose regimen and a 28-day multiple ascending dose regimen, and another in 30 healthy adults in the PRC. The single dose regimen in the trial in Australia included 0.1 mg, 0.25 mg, 0.5 mg, 2.5 mg and placebo cohorts. The multiple dose regimen in the trial in Australia included 0.15 mg, 0.25 mg and placebo cohorts. In the trial in the PRC, the single and multiple dose regimens included 0.1 mg, 0.2 mg and placebo cohorts, and the multiple dose regimen also included a 0.3 mg cohort. Once daily doses of up to 0.25 mg of CBP-307 were generally well-tolerated. The most frequent AEs observed across all regimens included low white blood cells and headache. Most AEs were mild or moderate. There were no clinically significant changes in lung function, a range of ophthalmological tests, blood pressure, or liver enzyme levels. Consistent with observations from clinical trials of other S1P1 modulators, a dose-dependent decrease in heart rate was observed early in all regimens. One healthy adult treated with a single dose of 2.5mg of CBP-307 experienced bradycardia associated with transient asystole, which was deemed to be a treatment-related serious adverse event. The healthy adult was treated with high-flow oxygen and fully recovered.

Sequestration of lymphocytes in the lymphoid tissues results in decreased lymphocyte count in peripheral circulation, which can be measured through blood sampling and thereby provide a robust mechanistic pharmacodynamic biomarker for preclinical and clinical studies. Although our trials were not powered to achieve statistical significance, in six healthy adults, CBP-307 at 0.25 mg led to a

94


 

75% decrease in number of circulating lymphocytes by day 14 of dosing and this level of lymphocyte suppression was maintained for the rest of the daily dosing period. Upon completion of dosing, the levels of lymphocytes returned to baseline within one week.

 

img67639792_13.jpg 

 

Figure 13. CBP-307 led to a reduction in the level of circulating lymphocytes in healthy volunteers.

Data from a separately conducted Phase 1 clinical trial in healthy adults showed a median reduction of 65% with a 1 mg dose of ozanimod after 28 days, while a 2 mg dose of etrasimod in a Phase 1 trial was associated with a mean reduction of 69% at steady state from days seven to 21. We believe that the comparison of the reduction in circulating lymphocytes across our trials and these independent clinical trials is meaningful because all were conducted in healthy volunteers using a 21-day or 28-day multiple-dose regimen. Healthy individuals share the same normal range of absolute lymphocyte count, or ALC, and the percentage of lymphocytes as a proportion of total white blood cells. Like our trial, the Phase 1 clinical trial of ozanimod and Phase 1 clinical trial of etrasimod required the healthy volunteers to have normal hematology. Consequently, we believe these subjects have similar baseline levels of circulating lymphocytes. Based on their known and validated pharmacological mode of action, S1P1 modulators reduce circulating lymphocyte counts, and as such, the reduction of circulating lymphocytes seen across trials in these healthy subjects are believed to be due to the effect of the investigational drugs studied, including, in the case of our trial, CBP-307.

We hypothesize that the selectivity and potency of CBP-307 observed in healthy adults will translate into similar effects on lymphocyte levels in UC patients. Independent clinical trials of ozanimod and etrasimod in UC patients have shown weaker activity on reductions in circulating lymphocytes compared to healthy volunteers of 49% and 40%, for ozanimod 1 mg at eight weeks and etrasimod 2 mg at steady state of four weeks, respectively. We believe the lower ALC reductions seen in these Phase 2 trials potentially reflect sub-optimal dosing. It has been confirmed by Arena that they intend to test a dose of 3 mg of etrasimod in the CULTIVATE trial in CD, which is greater than the 2 mg of etrasimod previously tested in UC and AD. Arena has also confirmed that it intends to apply the higher 3 mg dose of etrasimod to clinical programs other than UC.In addition, we observed the restoration of lymphocyte levels upon completion of dosing with CBP-307, which was faster than that reported for other S1P1 modulators. We attribute these results to the shorter half-life of CBP-307 of approximately 25 hours observed in healthy subjects. This is in contrast to fingolimod, which reported a half-life of six to nine days and a lymphocyte recovery time of 30 days to 60 days. We believe the ability to rapidly restore lymphocyte levels is important as it could minimize the length of time that a patient treated with CBP-307 may have

95


 

compromised immunity, which may lower the risk of patients developing infections. Patients treated with fingolimod may be at risk of developing infections for up to two months beyond completion of dosing.

img67639792_14.jpg 

 

Figure 14. The shorter half-life of CBP-307 compared to other S1P1 modulators correlates with a shorter lymphocyte recovery time. Information provided in the table above is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies.

Clinical Development of CBP-307 in Patients with IBD

We have initiated and fully enrolled a double-blind, placebo-controlled global Phase 2 trial of CBP-307 in 134 adult patients with moderate-to-severe UC. The primary endpoint of this trial is the clinical response at week 12 in the 0.2 mg CBP-307 group versus the placebo group, as measured by the modified Mayo score, an objective measure of disease severity based on stool frequency, rectal bleeding, endoscopic findings, and physician overall evaluation. Specifically, clinical response is defined as a decrease of at least 3 points and at least 30% from baseline in the complete Mayo score, accompanied by a decrease of at least 1 point from baseline in the rectal bleeding subscore or an absolute rectal bleeding subscore of at least 1 point. This trial is still ongoing. We anticipate reporting top-line results from this trial before the end of the second quarter of 2022.

img67639792_15.jpg 

 

 

 

Figure 15. Design of the Phase 2 trial of CBP-307 in UC

In parallel, we initiated a Phase 2 trial of CBP-307 in patients with moderate-to-severe CD in the PRC. The primary endpoint of this trial was the clinical response, as measured by the Crohn’s Disease Activity Index, or CDAI. Enrollment in this trial was ended prematurely with only 22 patients completing 12 weeks of dosing due to challenges in recruitment caused by the COVID-19 pandemic.

96


 

Nevertheless, from this limited number of patients who were able to complete 12 weeks of dosing, CBP-307 was generally well-tolerated and the safety profile was consistent with our earlier CBP-307 phase 1 studies as well as with the safety profiles seen with emerging data from other second generation S1P1 modulators currently in clinical development in IBD. Although this trial ended prematurely and thus was not powered to show statistically significant treatment group differences, exploratory efficacy assessments in the per protocol dataset of 18 patients suggested clear evidence of biological activity of CBP-307, with all patients on the 0.2 mg dose showing benefits on biomarkers of disease at week 12, such as reductions compared to baseline in ALC and reductions compared to baseline in Fecal Calprotectin, or FCP. In addition, all patients on the 0.2 mg dose had a reduction in the key clinical endpoint of the CDAI score at week 12, an efficacy parameter accepted by the FDA in trials of other drugs approved to date. In contrast, in the placebo group, changes in the ALC, FCP and CDAI score at week 12 compared to baseline were variable, with the majority of these placebo patients showing worsening of these markers.

img67639792_16.jpg 

 

Figure 16. We observed evidence of biological activity in CD patients treated with 0.2 mg doses of CBP-307.

Based on this data, and the evidence of CBP-307’s biological effect, we are continuing the development of CBP-307 in IBD with our ongoing UC clinical trial and will determine whether to initiate further clinical trials of CBP-307 in CD upon the completion of the Phase 2 UC trial.

Planned clinical trials

S1P1 modulators have demonstrated clinical efficacy in a number of Th1-related immune diseases including multiple sclerosis, psoriasis and IBD. We chose to focus our initial development resources on IBD, where we believe CBP-307 has the highest potential to demonstrate superior clinical response and safety as compared to existing products. If we observe clinical activity in IBD, we will consider investigating the potential of CBP-307 in other immune diseases.

CBP-174, a Histamine Receptor 3 Antagonist

We are developing CBP-174 as a rapid acting therapy for the alleviation of pruritus in AD. CBP-174 is an antagonist of histamine receptor 3, or H3R, that was observed to reduce scratching after injection in a mouse model of pruritus. It was designed not to penetrate the blood brain barrier and has been well-tolerated in multiple preclinical studies. We obtained global rights to CBP-174 from Arena. We initiated a Phase 1 trial with CBP-174 in the first half of 2021 and expect to have topline results in first half of 2022.

Chronic inflammatory pruritus overview

AD is often accompanied by chronic inflammatory pruritus, or an unpleasant and often persistent itch that can last over six weeks in duration and is often caused by inflamed skin lesions. Due to the significant impact chronic inflammatory pruritus has on AD patients’ quality of life, AD severity is often measured by patients based on intensity of pruritus rather than skin lesions themselves. The effect on patients experiencing this symptom contributes to additional comorbidities in some, such as hyperactivity, generalized anxiety and major depressive disorders. Of those with AD, prevalence of chronic pruritus was estimated to range from 58 to 91% in 2015. Despite currently available treatments for AD, an estimated 40 to 50% of AD patients have inadequate relief of their pruritus and are in need of new, efficacious pruritus therapies.

97


 

The role of histamine receptors in pruritus

Histamine is a small molecule that is released by inflammatory immune cells leading to multiple effects including dilation of local blood vessels and the facilitation of immune cells to leave the bloodstream and migrate to areas of tissue damage or infection. In diseases such as AD, this can lead to exacerbation of inflammatory conditions such as pruritus. Histamine and acetylcholine provoke itch by direct binding to ‘itch receptors’ and several mediators such as neuropeptides, proteases or cytokines indirectly via histamine release. The direct role of histamines in inducing pruritus has been demonstrated in mice, where injections of histamines or other agonists of histamine receptors induced strong itch.

There are four types of histamine receptors, H1R, H2R, H3R, and H4R. H2R is involved in gastric acid secretion and is the target of drugs such as famotidine and ranitidine which are used to treat conditions such as peptic ulcers and gastroesophageal reflux. H3R is highly expressed in the central nervous system where it has been targeted by a number of product candidates intended to treat cognitive disorders such as Alzheimer’s and Parkinson’s diseases. H3R is also expressed in the peripheral tissues, including nerve cells.

Common antihistamine drugs, or molecules that block histamine receptors, primarily target the histamine 1 receptor, or H1R, and lead to alleviation of itch in part by blocking H1R on peripheral nerves. Antihistamines are commonly used in clinical practice and as over-the-counter therapies for the alleviation of histamine-driven allergic reactions. However, many types of chronic itch cannot be relieved by current antihistamine treatments that target H1R. Many of these antihistamines have significant activity in the central nervous system leading to undesirable side effects such as drowsiness, rapid heart rate, and dizziness. In our preclinical research we observed that inhibition of H3R significantly reduced itch in a mouse model of allergen-induced chronic skin inflammation, indicating inhibition of pruritus in skin inflammation by an H3R antagonist is not limited to acute itch induced by direct pruritogen injection.

Our solution, CBP-174, a peripherally acting H3R antagonist

We are developing CBP-174, a peripherally acting H3R antagonist, for oral administration to treat chronic pruritus associated with skin inflammation. We believe that the ability to quickly alleviate itch in the setting of AD has the potential to complement the anti-pruritic effect of disease-modifying IL-4Ra antagonists such as our CBP-201 product candidate or dupilumab. In clinical trials, these currently approved IL-4Ra targeted products required weeks of treatment for many AD patients to obtain significant relief of pruritus.

In a preclinical model of histamine-induced pruritus in mice, CBP-174 at an oral dose of 0.1 mg/kg led to significant reductions in scratching. We observed that CBP-174 had a strong anti-itch effect in mice with a rapid onset of action, within the first 30 minutes of dosing.

img67639792_17.jpg 

 

Figure 17. CBP-174 reduced scratching in a histamine-induced pruritus mouse model at doses of 0.1 mg/kg, 0.3 mg/kg and 1 mg/kg

We have developed a topical 0.01% ointment formulation of CBP-174 that led to similar reductions in scratching frequency in these mice. We observed that the slow release of CBP-174 from the topical ointment led to prolonged exposure while simultaneously increasing the local concentration of drug at skin lesions.

98


 

Administration of CBP-174 orally was well-tolerated with no clinical signs of toxicity in a 28-day multiple-dose study of up to 5 mg/kg in rats. Single doses of up to 3 mg/kg were well-tolerated in dogs with no toxicologically significant changes in heart rate or hematology. In mice, brain exposure of CBP-174 was between three and five percent of levels in plasma. These preclinical data supported advancing CBP-174 into clinical studies.

We initiated a Phase 1 trial of CBP-174 in the first half of 2021. This is a single ascending dose double-blind trial of CBP-174 in a total of 48 healthy adults. We enrolled six cohorts of eight volunteers with six in each cohort receiving one of six oral doses of CBP-174 and two placebo. The primary endpoints of this trial are safety and tolerability as well as pharmacokinetics changes. We believe that the oral formulation would work best for pruritus caused by chronic inflammatory diseases, such as AD, due to the large body surfaces that can be affected.

Our Preclinical Programs

We are building a rich pipeline of internally designed, wholly owned small molecules and antibodies leveraging our expertise in T cell biology and sophisticated functional assays. Consistent with our clinical-stage candidates, our preclinical programs are focused on targets, both novel and clinically validated, with strong biological rationale in immunology indications with high unmet medical need and sizable commercial potential.

Commercialization

Given the stage of development of our lead product candidates, we have not yet invested in a commercial infrastructure or distribution capabilities. While we currently plan to establish our own commercial organization in the United States, the PRC and potentially in other selected markets, we continue to consider and evaluate in each market the potential advantages and enhancements of our commercial capabilities that may be realized as a result of a collaboration between us and a pharmaceutical or other company.

Competition

The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition and an emphasis on intellectual property. We face potential competition from many different sources, including major and specialty pharmaceutical, biopharmaceutical, therapeutics and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective or more convenient or have fewer or less severe side effects than any products that we may develop. Our competitors also may obtain FDA, NMPA or other regulatory approval for their products more rapidly than we do. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, convenience, cost, market access and reimbursement by payors, level of promotional activity devoted to them and intellectual property protection.

We expect to face competition from existing products and products in development for each of our product candidates. In addition to those described below, there may be other earlier stage clinical programs that, if approved, would compete with our product candidates. Many of our competitors have substantially greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances made in the commercial applicability of technologies and greater availability of capital for investment in these fields. Our success will be based in part on our ability to build and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy.

We expect CBP-201, if approved, to primarily compete across several targeted indications with dupilumab, marketed as Dupixent® by Sanofi and Regeneron, and another IL-4Ra antibody currently in development for moderate-to-severe AD by Sunshine Guojian Pharmaceutical, a subsidiary of 3SBio Inc., which recently announced approval of an IND application in June 2020.

If approved for the treatment of moderate-to-severe AD, CBP-201 would also compete directly with a number of other approved systemically administered products, such as JAK inhibitors, baricitinib marketed as Olumiant® by Eli Lilly, upadacitinib marketed as RINVOQ® by AbbVie, abrocitinib marketed as CIBINQO® by Pfizer) and tralokinumab marketed as Adbry® / Adtrlaza®, an anti-IL-13 neutralizing monoclonal antibody, or mAb. Other systemic product candidates in clinical development with which CBP-201 could compete in the treatment of moderate-to-severe AD include lebrikizumab (anti-IL-13 neutralizing mAb; Eli Lilly and Almirall S.A.), risankizumab (anti-IL-23 mAb; AbbVie), amlitelimab (anti-OX40 mAb; Sanofi), GBR 830 (anti-OX40 mAb; Glenmark Pharmaceuticals), KHK4083 (anti-OX40 mAb; Kyowa Kirin / Amgen), , etrasimod (S1P1, S1P4 and S1P5 modulator; Arena), and RPT193 (C-C chemokine receptor type 4, or CCR4, antagonist; RAPT Therapeutics). If approved for the treatment of moderate-to-severe asthma, CBP-201 would compete directly with a number of approved antibodies, including dupilumab, as well as omalizumab

99


 

marketed as Xolair® by Genentech/Roche and Novartis, an anti-IgE mAb, benralizumab marketed as Fasenra® by AstraZeneca, an anti-IL-5 mAb, mepolizumab marketed as Nucala® by GlaxoSmithKline, an anti-IL-5 mAb, and resalizumab, marketed as Cinqair® by Teva Pharmaceuticals, an anti-IL-5 mAb, and Tezepelumab marketed as Tezspire® by Amgen / AstraZeneca. CBP-201 would also face competition from RPT193 in the treatment of asthma.

We would expect to face similar competition if CBP-201 was approved for the treatment of CRSwNP. The majority of products or product candidates currently marketed for asthma with a type 2 inflammatory phenotype are also the agents either currently approved (dupilumab and omalizumab) or in clinical development (mepolizumab and benralizumab) for CRSwNP.

If approved for the treatment of UC and CD, we would expect CBP-307 to compete with a number of systemically administered antibodies and oral immunotherapies approved for the treatment of UC, including infliximab marketed as Remicade® by Janssen Pharmaceuticals, an anti-TNFa neutralizing mAb, adalimumab marketed as Humira® by AbbVie, an anti-TNFa neutralizing mAb, golimumab marketed as Simponi® by Janssen Pharmaceuticals, an anti-TNFa neutralizing mAb, vedolizumab marketed as Entyvio® by Takeda Pharmaceuticals, an anti-a4ß7 integrin mAb, and ustekinumab marketed as Stelara® by Janssen Pharmaceuticals, an anti-IL-12/23 mAb. We would also expect CBP-307 to compete with certolizumab marketed as Cimzia® by UCB S.A., an anti-TNFa neutralizing mAb Fab fragment approved for the treatment of CD, tofactinib marketed as Xeljanz® by Pfizer, an oral reversible JAK1 and JAK3 inhibitor, currently marketed for the treatment of UC, and ozanimod marketed as Zeposia® for the treatment of UC (S1P1, S1P4 and S1P5 modulator; Bristol Myers Squibb).

Other product candidates in clinical development with which CBP-307 could compete in the treatment of UC and CD include risankizumab (anti-IL-23 mAb; AbbVie), guselkumab (anti-IL-23 mAb; Janssen Pharmaceuticals), brazikumab (anti-IL-23 mAb; AstraZeneca) mirikizumab (anti-IL-23 mAb; Eli Lilly), filgotinib (reversible JAK1 inhibitor; Gilead Sciences), upadacitinib (reversible JAK1 inhibitor; AbbVie), and etrasimod (S1P1, S1P4 and S1P5 modulator; Arena).

If approved for treatment of chronic pruritus associated with inflammatory skin disease, CBP-174 could compete with current treatment options available for the treatment of acute pruritus of non-inflammatory origin, including topical and oral anti-histamines and would also face competition from other therapies in development for chronic inflammatory pruritus.

 

Intellectual property, including patents, trade secrets, trademarks and copyrights, is important to our business. Our commercial success depends in part on our ability to obtain and maintain proprietary intellectual property protection for our current and future product candidates and novel discoveries, product development technologies, and know-how. In general, to protect our product candidates and related technologies, we seek patent protection by licensing relevant patent rights from third parties or by filing Patent Cooperation Treaty, or PCT, applications and national stage patent applications throughout the world, including in the United States, the PRC, Europe and other major markets, in each case on subject matter relating to our technology, inventions, and improvements that are important to the development and implementation of our business. We also rely on know-how, confidential methodologies and processes and continuing technological innovation to develop and maintain our proprietary positions, in addition to trademarks, copyrights and trade secret laws, and employee disclosure and invention assignment agreements. Our commercial success also depends in part on our ability to operate without infringing, misappropriating or otherwise violating the proprietary rights of others and to prevent others from infringing, misappropriating or otherwise violating our proprietary rights.

 

We own or exclusively license more than 50 issued U.S. or foreign patents and have more than 60 pending patent applications in multiple jurisdictions, including in the United States, the PRC, the United Kingdom, France, Germany, Switzerland, the Netherlands, Sweden, Spain, Belgium, Italy, Japan, Australia, and Hong Kong.

 

These issued patents and patent applications include:

 

With respect to the composition of matter of CBP-201, we have a patent family with an issued U.S. patent, issued foreign patents, including in the PRC, and pending patent applications in various jurisdictions, where the issued patents and the patent applications, if issued, are expected to expire between 2036 and 2037, without accounting for any available patent term adjustments or extensions. We also have two other patent families that relate to our CBP-201 program, which include pending patent applications in various jurisdictions, including in the United States, where the patent applications, if issued, are expected to expire between 2039 and 2041, without accounting for any available patent term adjustments or extensions.
With respect to the composition of matter of CBP-307, we have a patent family that includes issued U.S. and foreign patents, including in the PRC, and pending patent applications in various jurisdictions, where the issued patents and the pending patent applications, if issued, are expected to expire between 2033 and 2034, without accounting for any available patent term adjustments or extensions. We further have one issued patent in the PRC, and pending U.S. and foreign patent applications, related to additional salts and crystal forms of CBP-307, where the issued patent and the patent applications, if issued, are expected to expire between 2037 and 2038, without accounting for any available patent term adjustments or extensions.

100


 

With respect to the composition of matter of CBP-174 and methods of making and using the same, we have issued U.S. and foreign patents, including in the PRC, where the patents and pending patent applications, if issued, are expected to expire in 2034, without accounting for any available patent term adjustments or extensions, which we exclusively licensed from Arena.

 

The term of individual patents depends upon the legal term of patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent may be eligible for patent term adjustment, which permits patent term restoration as compensation for delays incurred at the USPTO during the patent prosecution process. In addition, for patents that cover an FDA-approved drug, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. While the length of the patent term extension is related to the length of time the drug is under regulatory review, patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent per approved drug—and only those claims covering the approved drug, a method for using it, or a method for manufacturing it—may be extended under the Hatch-Waxman Act. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval or applicable approval in other jurisdictions, we expect to apply for patent term extensions on issued patents covering those products in the United States and other jurisdiction where such extensions are available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. We also may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements.

 

Our patent positions are generally uncertain and involve complex legal and factual questions. The relevant patent laws and their interpretation, both inside and outside of the United States, is also uncertain. Changes in either the patent laws or their interpretation in the United States and other jurisdictions may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe, misappropriate or otherwise violate our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, product candidates, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our owned or licensed pending patent applications or with respect to any patent applications we may file or license in the future, nor can we be sure that any patents that may be granted to us or our licensors in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, issued patents do not guarantee the right to practice our technology in relation to the commercialization of our products. Issued patents only allow us to block—in some cases—potential competitors from practicing the claimed inventions of the issued patents.

 

Further, patents and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and any future product candidates and practicing our proprietary technology, and any issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidate and any future product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors or other parties with similar technology. Furthermore, our competitors or other parties may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates and any future product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product candidate may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.

 

We also rely on protections under trade secret laws, and seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Our trade secrets include, for example, some program specific synthesis, formulations, patient selection strategies and some aspects of our research. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us, and for employees and consultants to enter into invention assignment agreements with us. These agreements are intended to provide that all confidential information developed or made known to the individual during the course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Where applicable, the agreements would also provide that all inventions to which the individual contributed as an inventor shall be assigned to us, and as such, will become our property. There can be no assurance, however, that these agreements and our policies will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. We also may be unsuccessful in executing such agreements with each party who, in fact, conceives or develops intellectual property that we regard as our own or receives access

101


 

to our confidential information. The assignment of intellectual property rights may not be self-executing, or the agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. Further, we have filed for and are pursuing trademark protection for our company name “Connect Biopharmaceuticals” in the United States, the PRC and some other jurisdictions.

 

In June 2012, we and Arena entered into an exclusive license agreement, or the Arena Agreement. Pursuant to the Arena Agreement, as subsequently amended, Arena granted us an exclusive (even as to Arena, except for internal research purposes), worldwide, royalty-bearing, sublicensable (subject to some conditions) license to identify, research, develop, make, have made, use, sell, offer for sale, have sold and import products under some patents and know how relating to H3R antagonists and methods of making and using such H3R antagonists. Under the Arena Agreement, we are obligated to use commercially reasonable efforts to conduct and complete clinical trials, other development work and commercialization activities in order to achieve the goal of commercialization of the licensed products worldwide. If we desire to sublicense or otherwise transfer any rights under the Arena Agreement to a third party or otherwise enter into a commercialization agreement with a third party with respect to selling a licensed product in a specific country, Arena has the right to first negotiation with respect to such transaction pursuant to which we must negotiate in good faith for a specified period to reach an agreement with Arena before we are able to enter into such an agreement with a third party.

 

Pursuant to the Arena Agreement, we are obligated to pay Arena royalties of a high single-digit percentage on net sales of all licensed products sold by us anywhere in the world. If we grant any third party a sublicense to market, distribute, or otherwise commercialize a licensed product, we are obligated to pay Arena royalties of the greater of (a) low double-digit percentage of all royalty payments, on a licensed product-by-licensed product and country-by-country basis, received from such sublicensee based on the sales of all licensed products sold by such sublicensees anywhere in the world, and (b) a royalty of a mid-single-digit percentage on the net sales of all licensed products sold anywhere in the world by such sublicensee, provided that, in the latter case, to the extent such sublicense is granted by us after a licensed product is launched for commercial sale in a particular country, the applicable rate for the royalty based on net sales of all licensed products sold in such country by such sublicensee will be reduced. After our aggregate royalty payments based on the foregoing reach a specific low single-digit million threshold, the royalty rate with respect to licensed products sold by us for end use in the PRC shall reduce to a mid-single-digit percentage, while the same high single-digit percentage royalty rate will continue to apply to licensed products sold by us for end use in the rest of the world. In addition, we are obligated to pay Arena sublicense fees of a low double-digit percentage on our sublicense revenues. Similarly, if we sell or otherwise grant any rights with respect to marketing, distribution or other commercialization of any licensed products to any third party (including by sale of all or substantially all of our assets or of our assets that relate to the Arena Agreement), we are obligated to pay Arena a low double-digit percentage of all consideration received by us pursuant to such transaction (even consideration that is attributed to assets other than a licensed product or the Arena Agreement). Lastly, we are required to pay Arena an annual license maintenance fee in the low five-figures. Royalties will be payable on a licensed product-by-licensed product and country-by-country basis from the first commercial sale of such licensed product in such country, until the later of (x) 12 years following such first commercial sale in such country, or (y) the expiration of the last to expire licensed patent in such country covering such licensed product or its manufacture or use. We have the sole responsibility to file, prosecute and maintain patents licensed under the Arena Agreement and the first right to enforce any such patents. The Arena Agreement will continue until the expiration of our obligation to pay royalties. We and Arena may each terminate the Arena Agreement upon a material breach by the other party that is not cured within 60 days after receiving written notice of breach. We may terminate the Arena Agreement without cause upon 60 days’ prior written notice. Arena may terminate the Arena Agreement upon our bankruptcy or other insolvency-related events.

Government Regulation and Product Approval

U.S. Regulations

As a biopharmaceutical company with operations in the United States, we are subject to extensive regulation. Among others, the FDA, the EMA, U.S. Department of Health and Human Services Office of Inspector General, the Centers for Medicare and Medicaid Services, or CMS, and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs and biologics such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.

102


 

U.S. Regulation of Drugs and Biologics

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations, and biologics under the FDCA and the Public Health Service Act, or PHSA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning or other enforcement letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. FDA approval is required before a drug or biological product may be marketed in the United States and they are also subject to other federal, state, and local statutes and regulations. The process required by the FDA before product candidates may be marketed in the United States generally involves the following:

 

completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the Good Laboratory Practices, or GLP, regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;
submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical studies may begin and must be updated annually;
approval by an independent IRB or ethics committee at each clinical site before each clinical study may be initiated;
performance of adequate and well-controlled human clinical studies in accordance with Good Clinical Practice, or GCP, requirements to establish the safety and efficacy, or with respect to biologics, the safety, purity and potency of the product candidate for each proposed indication;
preparation of and submission to the FDA of a new drug application, or NDA, or biologics license application, or BLA, after completion of all pivotal clinical studies that include substantial evidence of safety, purity, and potency of the drug from analytical (CMC) studies and from results of nonclinical testing and clinical trials;
satisfactory completion of an FDA advisory committee review, where appropriate and if applicable;
a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;
satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the proposed product is produced to assess compliance with current Good Manufacturing Practices, or cGMP, and potential FDA inspection of nonclinical study and clinical trial sites that generated the data in support of the NDA or BLA to ensure compliance with GCP; and
FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the drug in the United States.

An IND is a request for authorization from the FDA to administer an investigational new drug or biological product to humans. The central focus of an initial IND submission is on the general investigational plan and the protocol or protocols for clinical trials. The IND submission also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls, or CMC, information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.

103


 

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP, which includes the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, dosing procedures, subject selection and exclusion criteria, and the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to some data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.

The clinical investigation of a drug is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined.

Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution and excretion of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.
Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.
Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.

In some cases, the FDA may condition approval of an NDA or BLA for a product candidate on the sponsor’s agreement to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after approval to gain more information about the drug. Such post-approval studies are typically referred to as Phase 4 clinical studies.

During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and to investigators for serious and unexpected adverse events, findings from other studies that suggest a significant risk in humans exposed to the drug, laboratory animal testing or in vitro testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over the rate listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor’s initial receipt of the information and/or if Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the product has been associated with unexpected serious harm to patients.

Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

104


 

NDA and BLA Review Process

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. The NDA or BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s CMC and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of an NDA or BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.

In addition, under the Pediatric Research Equity Act, or PREA, an NDA or BLA or supplement to an NDA or BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, requires that a sponsor who is planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any drug or biological product for an indication for which orphan designation has been granted.

Within 60 days following submission of the application, the FDA reviews the submitted BLA or NDA to determine if the application is substantially complete before the agency accepts it for filing. The FDA may refuse to file any NDA or BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the NDA or BLA must be resubmitted with the additional information. Once an NDA or BLA has been accepted for filing, the FDA’s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is sufficient to assure and preserve the product’s identity, strength, quality and purity. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product’s continued safety, purity and potency. When reviewing an NDA or BLA, the FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

Before approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.

After the FDA evaluates the NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the NDA or BLA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the CRL may include recommended actions that the applicant take. If a CRL is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, withdraw the application, or request an opportunity for a hearing.

If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA or BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.

105


 

Expedited Development and Review Programs

The FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the fast track program is intended to expedite or facilitate the process for reviewing new products that meet specific criteria. Specifically, product candidates are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the review team during product development and, once an NDA or BLA is submitted, the application may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.

A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.

Any marketing application for a drug or biologic submitted to the FDA for approval, including a product candidate with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product candidate is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For new-molecular-entity NDAs and original BLAs, priority review designation means the FDA’s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review).

Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.

Fast track designation, breakthrough therapy designation, priority review, and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.

If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA or BLA, to market the same drug or biologic for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the

106


 

FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug or biologic was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for some research and a waiver of the NDA or BLA application user fee.

A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.

Post-Approval Requirements

Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Drug and biologic manufacturers and their subcontractors are required to register their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs, which impose some procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.

The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;
fines, warning letters or holds on post-approval clinical studies;
refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;
product seizure or detention, or refusal of the FDA to permit the import or export of products;
consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
mandated modification of promotional materials and labeling and the issuance of corrective information;
the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or
injunctions or the imposition of civil or criminal penalties.

The FDA closely regulates the marketing, labeling, advertising and promotion of drug products and biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products.

107


 

Drug Product Marketing Exclusivity

Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of some marketing applications. For example, the FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.

The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b) (2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in some circumstances.

Biosimilars and Reference Product Exclusivity

The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that are highly similar, or “biosimilar,” to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA’s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.

Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created some exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.

A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued “Written Request” for such a study.

108


 

U.S. Healthcare Laws

Pharmaceutical and medical device manufacturers are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, federal and state anti-kickback, fraud and abuse, false claims, price reporting, and transparency laws and regulations, as well as similar foreign laws in the jurisdictions outside the United States, including but not limited to those discussed below.

The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program. A person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. A conviction for violation of the federal Anti-Kickback Statute can result in criminal fines and/or imprisonment and requires mandatory exclusion from participation in federal health care programs. Exclusion from the federal healthcare programs may also be imposed if the government determines that an entity has committed acts that are prohibited by the federal Anti-Kickback Statute.

The federal civil monetary penalties and false claims laws, including the civil False Claims Act, or FCA, prohibit individuals or entities from, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The FCA also permits a private individual acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false or fraudulent claim or statement for violations.

The federal civil monetary penalties laws authorize the imposition of substantial civil fines for monetary penalties against an entity that engages in activities including, among other things, (1) knowingly presenting, or causing to be presented, a claim for services not provided as claimed or is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable by Medicare or a federal healthcare program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment.

The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity need not have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

The Physician Payments Sunshine Act imposes annual reporting requirements for some manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program, for some payments and “transfers of value” provided to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), specific non-physician providers including physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members.

Moreover, analogous state and foreign laws and regulations may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, many of which differ from each other in significant ways, thus further complicating compliance efforts; and restrict marketing practices or require disclosure of marketing expenditures and pricing information, including notice of price increases.

Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, significant administrative, civil and criminal penalties, damages, fines, additional reporting obligations and oversight if a manufacturer becomes subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and imprisonment.

109


 

PRC Regulations

We are subject to a variety of PRC laws, rules and regulations affecting many aspects of our business. This section sets out a summary of the major relevant laws, regulations, rules and policies which may have material impact on our business and operations.

Regulations on Company Establishment and Foreign Investment

The establishment, operation and management of corporate entities in the PRC are governed by the Company Law of the PRC, or the PRC Company Law, which was promulgated by the Standing Committee of the National People’s Congress, or the NPC, in December 1993 and further amended in December 1999, August 2004, October 2005, December 2013 and October 2018, respectively. According to the PRC Company Law, companies are generally classified into two categories: limited liability companies and companies limited by shares. The PRC Company Law also applies to non-PRC-invested limited liability companies. According to the PRC Company Law, where laws on foreign investment have other stipulations, such stipulations shall prevail.

Investment activities in the PRC by non-PRC investors are governed by the Guiding Foreign Investment Direction, which was promulgated by the State Council in February 2002 and came into effect in April 2002, and the Special Administrative Measures for the Access of Foreign Investment (Negative List), or the Negative List, which was recently updated by MOFCOM and the National Development and Reform Commission in December 2021 and came into effect in January 2022. The Negative List sets out the restrictive measures in a unified manner, such as the requirements on shareholding percentages and management, for the access of non-PRC investments, and the industries that are prohibited from receiving non-PRC investment. The Negative List covers 12 industries, and any field not falling under the Negative List shall be administered under the principle of equal treatment to PRC and non-PRC investment.

Foreign Investment Law of the PRC, or the Foreign Investment Law, was promulgated by the NPC in March 2019 and came into effect in January 2020. When the Foreign Investment Law came into effect, the Law on Wholly Foreign-owned Enterprises of the PRC, the Law on Sino-foreign Equity Joint Ventures of the PRC and the Law on Sino-foreign Cooperative Joint Ventures of the PRC were repealed simultaneously. The investment activities of non-PRC natural persons, enterprises or other organizations (collectively, the “non-PRC investors”) directly or indirectly within the territory of the PRC shall comply with and be governed by the Foreign Investment Law. Such activities include: (1) establishing by non-PRC investors of non-PRC-invested enterprises in the PRC alone or jointly with other investors; (2) acquiring by non-PRC investors of shares, equity, property shares, or other similar interests of PRC enterprises; (3) investing by non-PRC investors in new projects in the PRC alone or jointly with other investors; and (4) other forms of investment prescribed by laws, administrative regulations or the State Council.

In December 2019, the State Council promulgated the Regulations on Implementing the Foreign Investment Law of the PRC, which came into effect in January 2020. When the Regulations on Implementing the Foreign Investment Law of the PRC came into effect, the Regulation on Implementing the Sino-Foreign Equity Joint Venture Enterprise Law of the PRC, Provisional Regulations on the Duration of Sino-Foreign Equity Joint Venture Enterprise, the Regulations on Implementing the Wholly Foreign-Invested Enterprise Law of the PRC and the Regulations on Implementing the Sino-Foreign Cooperative Joint Venture Enterprise Law of the PRC were repealed simultaneously.

In December 2019, the MOFCOM and the State Administration for Market Regulation, or the SAMR promulgated the Measures on Reporting of Foreign Investment Information, which came into effect in January 2020. When the Measures on Reporting of Foreign Investment Information came into effect, the Interim Measures for the Administration of Filing for Establishment and Changes in Foreign Investment Enterprises were repealed simultaneously. Since January 1, 2020, for non-PRC investors carrying out investment activities directly or indirectly in the PRC, the non-PRC investors or non-PRC-invested enterprises shall submit investment information to the relevant commerce administrative authorities according to the Measure on Reporting of Foreign Investment Information.

110


 

Cybersecurity Measures

In April 2020, the Chinese government promulgated the 2020 Cybersecurity Review Measures, which came into effect on June 1, 2020. On July 10, 2021, the Cyberspace Administration of China published the draft amendment to the 2020 Cybersecurity Review Measures (Revised Draft for Public Consultation), which is expected to replace the 2020 Cybersecurity Review Measures after it is adopted and becomes effective. On December 28, 2021, the PRC government promulgated the 2022 Cybersecurity Review Measures, which came into effect and replaced the 2020 Cybersecurity Review Measures on February 15, 2022. According to the 2022 Cybersecurity Review Measures, (i) critical information infrastructure operators that purchase network products and services and internet platform operators that conduct data processing activities shall be subject to cybersecurity review in accordance with the 2022 Cybersecurity Review Measures if such activities affect or may affect national security; and (ii) internet platform operators holding personal information of more than one million users and seeking to have their securities list on a stock exchange in a country outside the PRC shall file for cybersecurity review with the Cybersecurity Review Office. Under the Regulation on Protecting the Security of Critical Information Infrastructure promulgated by the State Council on July 30, 2021, effective September 1, 2021, “critical information infrastructure” is defined as important network facilities and information systems in important industries and fields, such as public telecommunication and information services, energy, transportation, water conservancy, finance, public services, e-government and national defense, science, technology and industry, as well as other important network facilities and information systems that, in case of destruction, loss of function or leak of data, may severely damage national security, the national economy and the people's livelihood and public interests. Compared with the 2020 Cybersecurity Review Measures, the 2022 Cybersecurity Review Measures contain the following key changes: (i) internet platform operators who are engaged in data processing are also subject to the regulatory scope; (ii) the CSRC is included as one of the regulatory authorities for purposes of jointly establishing the state cybersecurity review mechanism; (iii) internet platform operators holding personal information of more than one million users and seeking to have their securities list on a stock exchange in a country outside of PRC shall file for cybersecurity review with the Cybersecurity Review Office; (iv) the risks of core data, material data or large amounts of personal information being stolen, leaked, destroyed, damaged, illegally used or illegally transmitted to non-PRC parties and the risks of critical information infrastructure, core data, material data or large amounts of personal information being influenced, controlled or used maliciously by non-PRC governments and any cybersecurity risk after a company’s listing on a stock exchange shall be collectively taken into consideration during the cybersecurity review process; and (v) critical information infrastructure operators and internet platform operators covered by the 2022 Cybersecurity Review Measures shall take measures to prevent and mitigate cybersecurity risks in accordance with the requirements therein. On November 14, 2021, the CAC released the Draft Administrative Regulation, under which, (i) data processors, i.e., individuals and organizations who can decide on the purpose and method of their data processing activities at their own discretion, that process personal information of more than one million individuals shall apply for cybersecurity review before listing in a country outside the PRC; (ii) non-PRC listed data processors shall carry out annual data security evaluation and submit the evaluation report to the municipal cyberspace administration authority; and (iii) where the data processor undergoes merger, reorganization and subdivision that involves important data and personal information of more than one million individuals, the recipient of the data shall report the transaction to the in-charge authority at the municipal level. The Draft Administrative Regulation was released for public comment only, and the draft provisions and anticipated adoption or effective date are subject to changes and thus its interpretation and implementation remain substantially uncertain. We cannot predict the impact of the Draft Administrative Regulation, if any, on the operations of our Company at this stage, and we will closely monitor and assess any development in the rule-making process.

Currently, the 2022 Cybersecurity Review Measures and the Draft Administrative Regulation have not materially affected our business and operations, and as we do not maintain, nor do we intend to maintain in the future, personally identifiable health information of patients in the PRC, we do not believe our business activities affect or may be interpreted to affect national security. As of the date of this annual report, we have not been informed by any relevant PRC governmental authorities that we are identified as or considered a “critical information infrastructure operator” or “data processors”. We are also not aware of any requirement that we should file for a cybersecurity review or annual data security evaluation, nor have we received any inquiry, notice, warning, sanction in such respect. However, as PRC governmental authorities have significant discretion in interpreting and implementing statutory provisions and there remains significant uncertainty in the interpretation and enforcement of relevant PRC cybersecurity laws and regulations, in anticipation of the strengthened implementation of cybersecurity laws and regulations and if the PRC regulatory authorities take a position contrary to ours, there can be no assurance that we will not be deemed as a critical information infrastructure operator or data processor under the PRC cybersecurity laws and regulations in the future, or that the Draft Administrative Regulation will not be further amended or other laws or regulations will not be promulgated to subject us to the cybersecurity review or other compliance requirements. In such case, we may face challenges in addressing such enhanced regulatory requirements.

111


 

Regulation on Pharmaceutical Product Development, Approval and Registration

Drug Regulatory Regime

The Drug Administration Law of the PRC, or the Drug Administration Law, was promulgated by the Standing Committee of the NPC, in September 1984. The two latest amendments to the Drug Administration Law were the amendment promulgated in April 2015 and in August 2019. The Regulations for the Implementation of the Drug Administration Law were promulgated by the State Council in August 2002, and were last amended in March 2019. The Drug Administration Law and the Regulations for the Implementation of the Drug Administration Law have jointly established the legal framework for the administration of pharmaceutical products in the PRC, including the research, development and manufacturing of new drugs. The Drug Administration Law applies to entities and individuals engaged in the development, production, trade, application, supervision and administration of pharmaceutical products. It regulates and provides for a framework for the administration of pharmaceutical manufacturers, pharmaceutical trading companies and medicinal preparations of medical institutions, and the development, research, manufacturing, distribution, packaging, pricing and advertisements of pharmaceutical products. The Regulations for the Implementation of the Drug Administration Law, at the same time, provide the detailed implementation regulations for the Drug Administration Law.

In 2017, the drug regulatory system entered a new and significant period of reform. The General Office of the State Council and the General Committee of the China Communist Party jointly issued Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices, or the Innovation Opinions. The expedited programs, the record-filing system, the prioritized review mechanism, the acceptance of non-PRC clinical data under the Innovation Opinions and other recent reforms encourage drug manufacturers to seek marketing approval in the PRC first for the development of drugs in highly prioritized therapeutic areas, such as oncology or rare diseases.

To implement the regulatory reform introduced by the Innovation Opinions, the Standing Committee of the NPC, the National Medical Products Administration, or the NMPA, a newly formed government authority as well as other authorities, are currently responsible for revising the laws, regulations and rules governing the pharmaceutical products and the industry.

In August 2019, the Standing Committee of the NPC promulgated the new Drug Administration Law, or the 2019 Amendment, which came into effect in December 2019. The 2019 Amendment contains many of the major reform initiatives implemented by the Chinese government since 2015, including but not limited to the Marketing Authorization Holder, or the MAH, system, conditional approvals of drugs, traceability system of drugs, and the cancellation of relevant certification according to Good Manufacturing Practice and Good Supply Practice.

Regulatory Authorities

Pharmaceutical products in the PRC are monitored and supervised on a national scale by the NMPA. The local provincial medical products administrative authorities are responsible for supervision and administration of drugs within their respective administrative regions. The NMPA was newly formed under the SAMR. The NMPA’s predecessor, the State Drug Administration was replaced by the State Food and Drug Administration, or the SFDA, which was later reorganized into the China Food and Drug Administration, or the CFDA, as part of the institutional reforms implemented by the State Council.

The primary responsibilities of the NMPA include:

monitoring and supervising the administration of pharmaceutical products, medical appliances and equipment as well as cosmetics in the PRC;
formulating administrative rules and policies concerning the supervision and administration of pharmaceutical, medical devices, and cosmetics industry;
evaluating, registering and approving new drugs, generic drugs, imported drugs and traditional Chinese medicine;
approving and issuing permits for the manufacture and export/import of pharmaceutical products, medical appliances and equipment;
approving the establishment of enterprises to be engaged in the manufacture and distribution of pharmaceutical products;
examining and evaluating the safety of pharmaceutical products, medical devices, and cosmetics; and
managing significant accidents involving pharmaceutical products, medical devices and cosmetics.

112


 

In 2013, the Ministry of Health, or the MOH, and the National Population and Family Planning Commission were integrated into the National Health and Family Planning Commission of the PRC, or the NHFPC. In March 2018, the First Session of the Thirteenth NPC approved the State Council Institutional Reform Proposal, according to which, NHFPC and some other governmental authorities were consolidated into the National Health Commission, or the NHC. The responsibilities of the NHC include coordinating the formulation of national drug policies, the national essential medicine system and the National Essential Medicines List and drafting the administrative rules for the procurement, distribution and use of national essential medicines.

According to the Decision of the CFDA on Adjusting the Approval Procedures under the Administrative Approval Items for Certain Drugs, which was promulgated by the CFDA in March 2017 and came into effect in May 2017, an IND approval should be issued by the Center for Drug Evaluation, or the CDE, on behalf of the CFDA.

Regulations on Clinical Trials and Registration of Drugs

Administrative Measures for Drug Registration

In July 2007, the SFDA promulgated the amended version of the Administrative Measures for Drug Registration, or the Registration Measures, which became effective in October 2007. The Registration Measures mainly cover: (1) definitions of drug registration applications and regulatory responsibilities of drug administration; (2) general requirements for drug registration, including application for registration of new drugs, generic drugs, imported drugs and supplemental application, as well as application for re-registration; (3) clinical trials; (4) application, examination and approval of new drugs, generic drugs and imported drugs; (5) supplemental applications and re-registrations of drugs; (6) inspections; (7) registration standards and specifications; (8) time limit; (9) re-examination; and (10) liabilities and other supplementary provisions.

According to the Registration Measures, drug registration applications are divided into three different types, namely Domestic New Drug Application, Domestic Generic Drug Application and Imported Drug Application. Drugs which fall into one of three general types are divided according to the drug’s working mechanism, namely whether the drug is classified as a chemical medicine, a biological product, a traditional Chinese medicine or a natural medicine. A Domestic New Drug Application, or Domestic NDA, refers to an application for registration of a drug that has not yet been marketed for sale in the PRC. In addition, the registration of drugs that change the dosage form of the marketed drugs, change the route of administration and increase the new indications shall be reported in accordance with the application procedures for new drugs. Under the Registration Measures, a Category 1 drug refers to a new drug that has never been marketed in any country, and such drug is eligible for special review or fast track approval by the NMPA.

In January 2020, the SAMR released the amended Administrative Measures for Drug Registration, or the Amended Registration Measures, which came into effect in July 2020. The Amended Registration Measures provide detailed procedural and substantive requirements for the key regulatory concepts established by the Drug Administration Law, and confirms a number of reform actions that have been taken in the past years, including but not limited to: (i) the full implementation of the MAH system and implied approval of the commencement of clinical trial; (ii) the implementation of associated review of drugs, excipients and packaging materials; and (iii) the introduction of four procedures for expedited registration of drugs, which are procedures for ground-breaking therapeutic drugs, procedures for conditional approval, procedures for prioritized reviews and approval, and procedures for special examination and approval. Detailed implementation rules for drug classification and requirements for corresponding application materials will be promulgated by the NMPA.

In March 2016, the CFDA issued the Reform Plan for Registration Category of Chemical Medicine, which outlined the reclassifications of drug applications under the Registration Measures. According to the Reform Plan for Registration Category of Chemical Medicine, Category 1 drugs refer to innovative new drugs that have not been marketed anywhere in the world. Improved new drugs that are not marketed anywhere in the world fall into Category 2 drugs. Generic drugs, that have equivalent quality and efficacy to the originator’s drugs and have been marketed outside of the PRC but not yet in the PRC, can be classified as Category 3 drugs. Generic drugs, that have equivalent quality and efficacy to the originator’s drugs and have been marketed in the PRC, fall into Category 4 drugs. Category 5 drugs are drugs which have already been marketed outside of the PRC, but are not yet approved in the PRC. Category 1 drugs and Category 5 drugs can be registered through the Domestic New Drug Application and the Imported Drug Application Procedures under the Registration Measures, respectively.

The SFDA promulgated the Administrative Provisions on Special Examination and Approval of Registration of New Drugs in January 2009, according to which, the SFDA conducts special examination and approval for new drug registration applications when: (1) the effective constituent of drug extracted from plants, animals, minerals, etc., as well as the preparations thereof have never been marketed in the PRC, and the material medicines and the preparations thereof are newly discovered; (2) the chemical raw material medicines as well as the preparations thereof and the biological product have not been approved for marketing at home and outside of the PRC; (3) the new drugs have obvious clinical treatment advantages for such diseases as AIDS, malignant tumors and orphan diseases, etc. or (4) the new drugs treat diseases currently with no effective methods of treatment.

113


 

The Special Examination and Approval of Registration of New Drugs provides that the applicant may file for special examination and approval at the clinical trial application stage if the product candidate falls within items (1) or (2). The provisions provide that for product candidates that fall within items (3) or (4), the application for special examination and approval cannot be made until filing for production.

Accelerated Approval for Clinical Trial and Registration

The Innovation Opinions established a framework for reforming the evaluation and approval system for drugs, medical devices and equipment. The Innovation Opinions enhanced the standard of approval for drug registration and accelerated the evaluation and approval process for innovative drugs as well as drug clinical trials.

The CFDA released the Circular Concerning Several Policies on Drug Registration Review and Approval in November 2015, which further clarified the measures and policies for simplifying and accelerating the approval process of clinical trials, including:

a one-time umbrella approval procedure allowing the overall approval of all phases of a new drug’s clinical trials, replacing the current phase-by-phase application and approval procedure; and
a fast track drug registration or clinical trial approval pathway for the following applications: (1) registration of innovative new drugs for treating HIV, cancer, serious infectious diseases and orphan diseases, etc.; (2) registration of pediatric drugs; (3) registration of geriatric drugs and drugs treating PRC-prevalent diseases in elders; (4) registration of drugs listed in national major science and technology projects or national key research and development plan; (5) registration of clinical urgently needed drugs using advanced technology, using innovative treatment methods, or having distinctive clinical benefits; (6) registration of non-PRC innovative drugs to be manufactured locally in the PRC; (7) concurrent applications for new drug clinical trials which are already approved in the United States or EU or concurrent drug registration applications for drugs which have applied to the competent drug approval authorities for marketing authorization and passed such authorities’ onsite inspections in the United States or EU and are manufactured using the same production line in the PRC; and (8) clinical trial applications for drugs with urgent clinical need and patent expiry within three years, and manufacturing authorization applications for drugs with urgent clinical need and patent expiry within one year.

The NMPA released the Circular on Adjusting Evaluation and Approval procedures for Clinical Trials for Drugs in July 2018, according to which, within 60 working days after the acceptance of and the fees paid for the IND application, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any negative or questioning opinion from the CDE. Such approval process has been further enacted into the 2019 Amendment.

Trial Exemptions and Acceptance of Foreign Data

The NMPA issued the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data in July 2018, as one of the implementing rules for the Innovation Opinions, which provides that overseas clinical data can be submitted for the drug registration applications in the PRC. Such applications can be in the form of waivers to PRC-based clinical trials, bridging trials and direct Domestic NDAs. According to the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data, sponsors may use the data of non-PRC clinical trials to support drug registration in the PRC, provided that the sponsors must ensure the authenticity, completeness, accuracy and traceability of non-PRC clinical trial data and such data must be obtained consistent with the relevant requirements under the Good Clinical Trial Practice of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, or the ICH. Sponsors must also comply with other relevant sections of the Registration Measures when applying for drug registrations in the PRC using non-PRC clinical trial data.

The NMPA now officially permits, and its predecessor agencies have permitted on a case-by-case basis in the past, drugs approved outside of the PRC to be approved in the PRC on a conditional basis without pre-approval clinical trials being conducted in the PRC. Specifically, the NMPA and the NHC released the Procedures for Reviewing and Approval of Clinical Urgently Needed Overseas New Drugs in October 2018, permitting drugs that have been approved within the last ten years in the United States, the EU or Japan and that prevent or treat orphan diseases, or prevent or treat serious life-threatening illnesses for which there is either no effective therapy in the PRC, or for which the non-PRC-approved drug would have clear clinical advantages. Applicants will be required to establish a risk mitigation plan and may be required to complete trials in the PRC after the drug has been marketed. The CDE has developed a list of qualifying drugs that meet the foregoing criteria.

114


 

Clinical Trial Process and Good Clinical Practices

According to the Registration Measures, a clinical trial consists of Phases I, II, III and IV. Phase I refers to the initial clinical pharmacology and safety evaluation studies in humans. Phase II refers to the preliminary evaluation of a product candidate’s therapeutic effectiveness and safety for particular indications in patients, to provide evidence and support for the design of Phase III clinical trials and to settle the administrative dose regimen. Phase III refers clinical trials undertaken to confirm the therapeutic effectiveness and safety on patients with target indications, to evaluate the overall benefit-risk relationships of the drug, and ultimately to provide sufficient evidence for the review of drug registration application. Phase IV refers to a new drug’s post-marketing study to assess therapeutic effectiveness and adverse reactions when the drug is widely used, to evaluate the overall benefit-risk relationships of the drug when used among the general population or specific groups and to adjust the administration dose.

To improve the quality of clinical trials, the SFDA promulgated the Good Clinical Trial Practice for Drugs in August 2003, or the GCP Rules, which was replaced by the revised Good Clinical Trial Practice for Drugs, or the Revised GCP Rules, promulgated by the NMPA and the NHC in April 2020 and coming into effect in July 2020. According to the Administration of Quality of Drug Clinical Practice, clinical trial means systematical investigation of drugs conducted on human subjects (patients or healthy volunteers) to prove or reveal the function, adverse reactions and/or absorption, distribution, metabolism and excretion of the drug being investigated. The purpose of a clinical trial is to determine the therapeutic efficacy and safety of the drug. The Revised GCP Rules provide comprehensive and substantive requirements on the design and conduct of clinical trials in the PRC. In particular, the Revised GCP Rules enhance the protection for study subjects and tighten the control over bio-samples collected under clinical trials.

The Revised GCP Rules also set out the qualifications and requirements for the investigators and centers participating in clinical trial, who must:

have professional certification at a clinical trial center, professional knowledge, training experience and capability of clinical trial, and be able to provide the latest resume and relevant qualification documents per request; (ii) be familiar with the trial protocol, investigator’s brochure and relevant information of the trial drug provided by the applicant; (iii) be familiar with and comply with the Revised GCP Rules and relevant laws and regulations relating to clinical trials; (iv) keep a copy of the authorization form on work allocation signed by investigators; (v) accept supervision and inspection organized by the applicant and inspection by the drug regulatory authorities; and (vi) in the case of investigators and clinical trial centers authorizing other individuals or institutions to undertake some responsibilities and functions relating to clinical trial, they shall ensure such individuals or institutions are qualified and establish complete procedures to ensure the responsibilities and functions are fully performed and generate reliable data.

Communication with the CDE

According to the Circular on Adjusting Evaluation and Approval Procedures for Clinical Trials for Drugs, where the application for clinical trial of a new investigational drug has been approved, upon the completion of Phases I and II clinical trials and prior to Phase III clinical trial, the applicant shall submit the application for Communication Session to the CDE to discuss the key technical questions including the design of Phase III clinical trial protocol. Within 60 days after the acceptance of and the fees paid for the IND application, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any negative or questioning opinion from the CDE.

The NMPA promulgated the Administrative Measures for Communication on the Research, Development and Technical Evaluation of Drugs in September 2018, according to which, during the research and development periods and in the registration applications of, among others, innovative new drugs, the applicants may propose to conduct communication meetings with the CDE. The communication meetings can be classified into three types. Type I meetings are convened to address key safety issues in clinical trials of drugs and key technical issues in the research and development of breakthrough therapeutic drugs. Type II meetings are held during the key research and development periods of drugs, mainly including meetings before the IND application, meetings upon the completion of Phase II trials and before the commencement of Phase III trials, meetings before submitting a marketing application for a new drug, and meetings for risk evaluation and control. Type III meetings refer to meetings not classified as Type I or Type II.

115


 

Drug Clinical Trial Registration

According to the Registration Measures, upon obtaining the approval of its IND applications and before conducting a clinical trial, an applicant shall file a registration form with the SFDA containing various details, including the clinical trial protocol, the name of the principal researcher of the leading institution, the names of participating institutions and researchers, an approval letter from the ethics committee, and a sample of the informed consent form, with a copy sent to the competent provincial administration departments where the trial institutions will be located. The CFDA released the Announcement on Drug Clinical Trial Information Platform in September 2013, according to which, instead of the aforementioned registration filed with the CFDA, all clinical trials approved by the CFDA and conducted in the PRC shall complete a clinical trial registration and publish trial information through the Drug Clinical Trial Information Platform. The applicant shall complete the trial pre-registration within one month after obtaining the approval of the clinical trial approval in order to obtain the trial’s unique registration number and complete registration of some follow-up information before the first subject’s enrollment in the trial. If the registration is not completed within one year after the approval of the IND applications, the applicant shall submit an explanation, and if the first submission is not completed within three years, the approval of the IND applications shall automatically expire.

New Drug Application

According to the Registration Measures, drug registration applications include Domestic NDAs, domestic generic drug application and imported drug application. Drugs are classified into chemical drugs, biological products and traditional Chinese medicine or natural drugs. When Phases I, A and III clinical trials have been completed, the applicant may apply to the SFDA for approval of a Domestic NDA. The SFDA then determines whether to approve the application according to the comprehensive evaluation opinion provided by the CDE.

Pilot Plan for the MAH System

The Innovation Opinions provide a pilot plan for the MAH system.

Under the authorization of the Standing Committee of the NPC, the General Office of the State Council issued the Pilot Plan for the Drug Marketing Authorization Holder Mechanism in May 2016, which provides a detailed pilot plan for the MAH system in ten Chinese provinces. Under the MAH system, domestic drug research and development institutions and individuals in the pilot regions are eligible to be holders of drug registrations without having to become drug manufacturers. The marketing authorization holders may engage contract manufacturers for manufacturing, provided that the contract manufacturers are licensed and located within the pilot regions. Drugs that qualify for the MAH system are: (1) new drugs (including but not limited to drugs under category I to category IV of chemical drugs, and targeted preparation, sustained release preparation, controlled release preparation under category V of chemical drugs, biological products approved as category I and VII drugs and biosimilars under the Registration Measures) approved after the implementation of the MAH system; (2) generic drugs approved as category III or IV drugs under the Reform Plan for Registration Category of Chemical Medicine; (3) previously approved generics that have passed equivalence assessments against original drugs; and (4) previously approved drugs whose licenses were held by drug manufacturers originally located within the pilot regions, but which have moved out of the pilot regions due to corporate mergers or other reasons.

The CFDA promulgated the Circular on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System in August 2017. It clarified the legal liability of the MAH, who is responsible for managing the whole manufacturing and marketing chain and the whole life cycle of drugs and legally liable for preclinical drug study, clinical trials, manufacturing, marketing, distribution and adverse drug reaction monitoring. According to the Circular on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System, the MAH shall submit a report of drug manufacturing, marketing, prescription, techniques, pharmacovigilance, quality control measures and other situations to the CFDA within 20 working days after the end of each year.

According to the Pilot Plan for the Drug Marketing Authorization Holder Mechanism, the pilot plan was originally set for a three-year period and was scheduled to expire in November 2018. The Standing Committee of the NPC promulgated the Decision of Extending the Pilot Period of Authorizing the State Council to Carry Out the Pilot Plan for the Drug Marketing Authorization Holder Mechanism in Certain Places in October 2018, which extended the term of the MAH system to November 4, 2019.

According to the 2019 Amendment, which came into effect on December 1, 2019, the MAH system will be applicable throughout the country and the legal representative and the key person-in-charge of a drug MAH shall be fully responsible for the quality of drugs.

116


 

International Multi-Center Clinical Trials

The International Multi-Center Clinical Trial Guidelines (Trial), or the Multi -Center Clinical Trial Guidelines, which was promulgated by the CFDA in January 2015 and came into effect in March 2015, provided guidance on the implementation of Multi-Regional Clinical Trials, or the MRCT, in the PRC. According to the Multi-Center Clinical Trial Guidelines, international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicants plan to implement the international multi-center clinical trials in the PRC, the applicants shall comply with relevant laws and regulations, such as the Drug Administration Law, the Implementing Regulations of the Drug Administration Law and the Registration Measures, execute the GCP Rules, make reference to universal international principles such as the ICH-GCP and comply with the laws and regulations of the countries involved in the international multi-center clinical trials. Where the applicants plan to use the data derived from the international multi-center clinical trials for approval of a drug registration in the PRC, it shall involve at least two countries, including the PRC, and shall satisfy the requirements for clinical trials set forth in the Multi-Center Clinical Trial Guidelines, Registration Measures and other related laws and regulations.

In April 2020, the NMPA and the NHC promulgated the Revised GCP Rules, which came into effect in July 2020. The Revised GCP Rules summarize the requirements for initiating an MRCT, that is, before initiating an MRCT: (i) the applicant shall ensure that all the centers participating in the clinical trial comply with the trial protocol; (ii) the applicant shall provide each center with the same trial protocol, and each center shall comply with the same unified evaluation criterion for clinical trial and laboratory data and the same guidance for case report form; (iii) each center shall use the same case report form to record the data of each human subject obtained during the trial; (iv) before initiating a clinical trial, a written document is required to specify the responsibilities of the investigators of each center; and (v) the applicant shall ensure the communication among the investigators of each center.

Data derived from international multi-center clinical trials can be used for the new drug applications with the NMPA. When using international multi-center clinical trial data to support new drug applications in the PRC, applicants shall submit the completed global clinical trial report, statistical analysis report and database, along with relevant supporting data in accordance with the content and format requirements under the International Conference on Harmonization-Common Technical Document; subgroup research results summary and comparative analysis shall also be conducted concurrently. Leveraging the clinical trial data derived from international multi-center clinical trials conducted by our partners, we may avoid unnecessarily repetitive clinical trials and thus further accelerate the Domestic NDA process.

The CFDA released the Decision on Adjusting Items concerning the Administration of Imported Drug Registration in October 2017, which includes the following key points:

If the International Multicenter Clinical Trial, or the IMCCT, of a drug is conducted in the PRC, Phase I clinical trial of the drug is allowed simultaneously. The IMCCT drug does not need to be approved or to enter into either a Phase II or III clinical trial in a country outside of the PRC, except for preventive biological products;
If the IMCCT is conducted in the PRC, the application for drug marketing authorization can be submitted directly after the completion of the IMCCT. The Registration Measures and relevant laws and regulations shall be complied with for registration application;
With respect to applications for clinical trial and marketing of the imported innovative chemical drugs and therapeutic biological products, the marketing authorization in the country or region where the non-PRC drug manufacturer is located will not be required; and
With respect to drug applications that have been accepted before the release of the Decision on Adjusting Items concerning the Administration of Imported Drug Registration, if relevant requirements are met, importation permission can be granted if such applications request exemption of clinical trials for the imported drugs based on the data generated from the IMCCT.

Approval of Human Genetic Resources

The Interim Administrative Measures on Human Genetic Resources, promulgated by the Ministry of Science and Technology and the MOH in June 1998, aimed at protecting and fairly utilizing human genetic resources in the PRC. The Ministry of Science and Technology promulgated the Service Guide for Administrative Licensing Items concerning Examination and Approval of Sampling, Collecting, Trading or Exporting Human Genetic Resources, or Taking Such Resources out of the PRC in July 2015, according to which, the sampling, collection or research activities of human genetic resources by a non-PRC-invested sponsor fall within the scope of international cooperation, and the cooperating Chinese organization shall apply for approval of the China Human Genetic Resources Management Office through an online system. The Ministry of Science and Technology further promulgated the Circular on Optimizing the Administrative Examination and Approval of Human Genetic Resources in October 2017, which became effective in December 2017 and simplified the approval of sampling and collecting human genetic resources for listing a drug in the PRC.

117


 

The Regulations of the PRC on the Administration of Human Genetic Resources, which was promulgated by the State Council in May 2019 and came into effect in July 2019, further stipulates that, in order to obtain marketing authorization for relevant drugs and medical devices in the PRC, no approval is required in international clinical trial cooperation using the PRC’s human genetic resources at clinical institutions without export of human genetic resource materials. However, the type, quantity and usage of the human genetic resource to be used shall be filed with the administrative department of science and technology under the State Council before clinical trials.

The regulatory framework laid out by the above regulation over is confirmed by the Law of Biosecurity of the PRC, which was promulgated by the Standing Committee of the NPC in October 2020 and came into effect in April 2021.

Regulations on Drug Manufacturing and Distribution

Drug Manufacturing

According to the Drug Administration Law and the Implementing Regulations of the Drug Administration Law, a drug manufacturing enterprise is required to obtain a drug manufacturing license from the relevant provincial drug administration authority of the PRC. The grant of such license is subject to an inspection of the manufacturing facilities, and an inspection to determine whether the sanitary condition, quality assurance systems, management structure and equipment meet the required standards. According to the Implementing Regulations of the Drug Administration Law and the Measures on the Supervision and Administration of the Manufacture of Drugs, which was promulgated in August 2004, amended in November 2017 and January 2020 and came into effect in July 2020, the drug manufacturing license is valid for five years and shall be renewed at least six months prior to its expiration date upon a re-examination by the relevant authority. In addition, the name, legal representative, registered address and type of the enterprise specified in the drug manufacturing certificate shall be identical to that set forth in the business license as approved and issued by the industrial and commercial administrative department. To the extent the MAH does not manufacture the drug internally but through a contract manufacturing organization, the MAH shall apply for drug manufacturing license with the provincial counterpart of the NMPA, subject itself to inspections and other regulatory oversight by the agency.

The Good Manufacturing Practice for Drugs was promulgated in March 1988 and was amended in December 1992 and June 1999 and January 2011. The latest amendment was in June 2020 and came into effect in October 2020. The Good Manufacturing Practice for Drugs comprises a set of detailed standard guidelines governing the manufacture of drugs, which include institution and staff qualifications, production premises and facilities, equipment, hygiene conditions, production management, quality controls, product operation, raw material management, maintenance of sales records, management of customer complaints and adverse event reports.

Drug Distribution

According to the Drug Administration Law, its implementing regulations and the Measures for the Supervision and Administration of Circulation of Pharmaceuticals, which was promulgated by the SFDA in January 2007 and came into effect in May 2007, pharmaceutical enterprises shall be responsible for the quality of the pharmaceuticals that they manufacture, distribute, use, purchase, sell, transport, or store.

According to the Measures for the Administration of Drug Distribution License, which was promulgated in February 2004 and amended in November 2017 by the CFDA, a Drug Distribution License is valid for five years. Each holder of the Drug Distribution License must apply for an extension of its permit six months prior to expiration. The establishment of a wholesale pharmaceutical distribution company requires the approval of provincial medicine administrative authorities. Upon approval, the authority will grant a Drug Distribution License in respect of the wholesale pharmaceutical product distribution company. The establishment of a retail pharmacy store requires the approval of the local medicine administrative authorities at or above the county level. Upon approval, the authority will grant a Drug Distribution License in respect of the retail pharmacy store.

 

Other PRC Government Regulations

Regulations on Intellectual Property Rights

In terms of international conventions, the PRC has entered into (including but not limited to) the Agreement on Trade-Related Aspects of Intellectual Property Rights, the Paris Convention for the Protection of Industrial Property, the Madrid Agreement Concerning the International Registration of Marks and the Patent Cooperation Treaty.

118


 

Patents

According to the Patent Law of the PRC, which was promulgated by the Standing Committee of the NPC in March 1984, amended in September 1992, August 2000, December 2008 and October 2020, and came into effect in June 2021, and the Implementation Rules of the Patent Law of the PRC, which was promulgated by the State Council in June 2001 and amended in December 2002 and January 2010, there are three types of patents in the PRC: invention patents, utility model patents and design patents. The protection period is 20 years for an invention patent and 10 years for a utility model patent and a design patent, commencing from their respective application dates. Any individual or entity that utilizes a patent or conducts any other activities that infringe a patent without prior authorization of the patent holder shall pay compensation to the patent holder and is subject to a fine imposed by relevant administrative authorities and, if constituting a crime, shall be held criminally liable in accordance with the law. According to the Patent Law of the PRC, any organization or individual that applies for a patent in a country outside the PRC for an invention or utility model patent established in the PRC is required to report to the NIPA for confidentiality examination.

 

The Patent Law of the PRC amended in October 2020 creates a patent dispute early resolution mechanism that may be comparable to the patent linkage system in the United States. This mechanism is further defined by an implementing rule jointly published by the NMPA and the China National Intellectual Property Administration, or the CNIPA, and a judicial interpretation published by the People’s Supreme Court of the PRC, both of which became effective from July 2021. Under this mechanism, genetic drug applicants are required to, at the time of their drug applications, make one of four types of announcements on the patent information registration platform established by the NMPA with regard to their generic drugs and the relevant patents, for instance, whether the generic drug could infringe any patent registered on the platform. The patent right holders may, within 45 days upon the NMPA’s publication of its acceptance of the generic drug applications, bring a judicial action before the competent court or an administrative proceeding with the CNIPA for determination whether the generic drugs fall into the scope of their patents. The NMPA will provide a 9-month waiting period not to approve the generic drug applications once it is duly notified of such action or proceeding, but the NMPA will not stop its technical review on these generic applications within this waiting period.

Trade Secrets

According to the PRC Anti-Unfair Competition Law, which was promulgated by the Standing Committee of the NPC in September 1993 and amended in November 2017 and April 2019, respectively, the term “trade secrets” refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others’ trade secrets by: (1) obtaining the trade secrets from the legal owners or holders by any unfair methods such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2) disclosing, using or permitting others to use the trade secrets obtained illegally under item (1) above; (3) disclosing, using or permitting others to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to keep such trade secrets in confidence; or (4) instigating, inducing or assisting others to violate a confidentiality obligation or to violate a rights holder’s requirements on keeping confidentiality of trade secrets, disclosing, using or permitting others to use the trade secrets of the rights holder. If a third party knows or should have known of the above-mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third party may be deemed to have committed a misappropriation of the others’ trade secrets. The parties whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may stop any illegal activities and fine infringing parties.

Trademarks

According to the Trademark Law of the PRC promulgated by the Standing Committee of the NPC in August 1982, and amended in February 1993, October 2001, August 2013 and April 2019, respectively, the period of validity for a registered trademark is ten years, commencing on the date of registration. The registrant shall go through the formalities for renewal within twelve months prior to the expiry date of the trademark if continued use is intended. Where the registrant fails to do so, a grace period of six months may be granted. The validity period for each renewal of registration is ten years, commencing on the day immediately after the expiry of the preceding period of validity for the trademark. In the absence of a renewal upon expiry, the registered trademark shall be cancelled. Industrial and commercial administrative authorities have the authority to investigate any behavior that infringes the exclusive right under a registered trademark in accordance with the law. In case of a suspected criminal offense, the case shall be timely referred to a judicial authority and decided according to the law.

119


 

Domain Names

Domain names are protected under the Administrative Measures on the Internet Domain Names, which was promulgated by the Ministry of Industry and Information Technology in August 2017, and the Implementing Rules on Registration of National Top-level Domain Names, which was promulgated by China Internet Network Information Center in and came into effect in June 2019. The Ministry of Industry and Information Technology is the main regulatory body responsible for the administration of PRC internet domain names. Domain name registrations are handled through domain name service agencies established under the relevant regulations, and the applicants become domain name holders upon successful registration.

Regulations on Product Liability

In addition to the strict new drug approval process, PRC laws have been promulgated to protect the rights of consumers and to strengthen the control of medical products in the PRC. Under current PRC laws, manufacturers and vendors of defective products in the PRC may incur liability for loss and injury caused by such products. According to the General Principles of the Civil Law of the PRC promulgated in April 1986 and amended in August 2009, General Rules of the Civil Law of the PRC promulgated and amended in October 2017, and the Civil Code of the PRC promulgated in May 2020, collectively, the PRC Civil Law, the manufacturer or vendor of a defective product which causes property damage or physical injury to any person may be subject to civil liability for such damage or injury.

In February 1993, the Product Quality Law of the PRC, or the Product Quality Law, was promulgated to supplement the PRC Civil Law, aiming to protect the legitimate rights and interests of the end-users and consumers and to strengthen the supervision and control of the quality of products. The Product Quality Law was last revised in December 2018. According to the revised Product Quality Law, manufacturers who produce defective products may be subject to civil or criminal liability and have their business licenses revoked.

The Law of the PRC on the Protection of the Rights and Interests of Consumers was promulgated in October 1993 and amended in October 2013 to protect consumer rights when they purchase or use goods and services. According to which, all business operators must comply with this law when they manufacture or sell goods and/or provide services to customers. Under the latest amendment, all business operators shall protect the customers’ privacy and keep any consumer information they obtain during the business operation strictly confidential. In addition, in extreme situations, pharmaceutical product manufacturers and operators may be subject to criminal liability if their goods or services lead to the death or injuries of customers or other third parties.

Regulations on Tort

According to the Civil Code of the PRC published by the NPC in May 2020, if damages to other persons are caused by defective products due to the fault of third parties, such as the parties providing transportation or warehousing, the producers and the sellers of the products have the right to recover their respective losses from such third parties. If defective products are identified after they have been put into circulation, the producers or the sellers shall take remedial measures such as issuance of a warning, recall of products, etc., in a timely manner. The producers or the sellers shall be liable under tort if they fail to take remedial measures in a timely manner or have not made efforts to take remedial measures, thus causing damages. If the products are produced or sold with known defects, causing deaths or severe adverse health issues, the infringed party has the right to claim punitive damages in addition to compensatory damages.

Regulations on Environment Protection

Pursuant to the Environmental Protection Law of the PRC promulgated by the Standing Committee of the NPC, in December 1989, amended in April 2014 and effective in January 2015, any entity which discharges or will discharge pollutants during its course of operations or other activities must implement effective environmental protection safeguards and procedures to control and properly treat waste gas, waste water, waste residue, dust, malodorous gases, radioactive substances, noise vibrations, electromagnetic radiation and other hazards produced during such activities. According to the provisions of the Environmental Protection Law, in addition to other relevant laws and regulations of the PRC, the Ministry of Environmental Protection and its local counterparts take charge of administering and supervising said environmental protection matters.

Pursuant to the Environmental Protection Law, the environmental impact statement on any construction project must assess the pollution that the project is likely to produce and its impact on the environment, and stipulate preventive and curative measures; the statement shall be submitted to the competent administrative department of environmental protection for approval. Installations for the prevention and control of pollution in construction projects must be designed, built and commissioned together with the principal part of the project.

120


 

Pursuant to the Law of the People’s Republic of China on Environment Impact Assessment, which was promulgated in October 2002 and most recently amended in December 2018, the government of the PRC implements a classification-based management on the environmental impact assessment of construction projects according to the impact of the construction projects on the environment. Construction units shall prepare an Environmental Impact Report or an Environmental Impact Statement, or fill out the Environmental Impact Registration Form.

Pursuant to the Regulations on Urban Drainage and Sewage Disposal, which was promulgated in October 2013 and came into effect in January 2014, and the Measures for the Administration of Permits for the Discharge of Urban Sewage into the Drainage Network, which was promulgated in January 2015 and came into effect in March 2015, drainage entities covered by urban drainage facilities shall discharge sewage into urban drainage facilities in accordance with the relevant government regulations. Where a drainage entity needs to discharge sewage into urban drainage facilities, it shall apply for a drainage license in accordance with the provisions of these measures. The drainage entity that has not obtained the drainage license shall not discharge sewage into urban drainage facilities.

Regulations on Fire Protection

The Fire Prevention Law of the PRC, or the Fire Prevention Law, was adopted in April 1998 and last amended in April 2021. The Fire Prevention Law provides that fire control design and construction of a construction project shall comply with PRC’s fire control technical standards. Developers, designers, builders and project supervisors shall be responsible for the quality of the fire control design and construction of the construction project pursuant to the law. Development project fire safety design examinations and acceptance systems shall be implemented for development projects which are required to have fire safety design in accordance with the national fire protection technical standards. The Interim Provisions on the Administration of Fire Protection Design Examination and Acceptance of Construction Projects which came into effect on June 1, 2020, provides that the fire safety design examination and acceptance systems shall be implemented for special construction projects subject to the standards and restrictions of the specific building area and use. Other construction projects shall be subject to the filing and selective examination systems.

According to the Eight Measures for the Public Security Fire Department to Deepen Reform and Serve Economic and Social Development promulgated by the Ministry of Public Security of the PRC in August 2015, the fire protection design and completion acceptance fire protection record of construction projects with an investment of less than RMB300,000 or a building area of less than 300 square meters (or below the limit set by the housing and urban construction department of the provincial people’s government) was no longer required.

Regulations on Foreign Exchange and Dividend Distribution

Foreign Exchange Control

According to the PRC Regulation for the Foreign Exchange promulgated by the State Council in January 1996, which was amended in January 1997 and August 2008, and the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment promulgated by the People’s Bank of China in June 1996, foreign exchanges required for distribution of profits and payment of dividends may be purchased from designated foreign exchange banks in the PRC upon presentation of a board resolution authorizing distribution of profits or payment of dividends.

According to the Circular of the State Administration of Foreign Exchange, or the SAFE, on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment and its appendix promulgated in November 2012 and amended in May 2015, October 2018 and December 2019 by the SAFE, (1) the opening of and payment into foreign exchange accounts under direct investment accounts are no longer subject to approval by the SAFE; (2) reinvestment with legal income of non-PRC investors in the PRC is no longer subject to approval by SAFE; (3) the procedures for capital verification and confirmation that non-PRC-funded enterprises need to go through are simplified; (4) purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by SAFE; (5) domestic transfer of foreign exchange under direct investment account is no longer subject to approval by SAFE; and (6) the administration over the conversion of foreign exchange capital of non-PRC-invested enterprises is improved. Later, the SAFE promulgated the Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment in February 2015, which was further amended in December 2019 and prescribed that the bank instead of the SAFE can directly handle the foreign exchange registration and approval under foreign direct investment while the SAFE and its branches indirectly supervise the foreign exchange registration and approval under foreign direct investment through the bank.

The Provisions on the Administration of Foreign Exchange in Foreign Direct Investments by Foreign Investors, which were promulgated by the SAFE in May 2013 and amended in October 2018 and December 2019, regulate and clarify the administration over foreign exchange administration in foreign direct investments.

121


 

According to the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises promulgated by the SAFE in Mach 2015 and amended in December 2019, and the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects promulgated by the SAFE in June 2016, the settlement of foreign exchange by non-PRC invested enterprises shall be governed by the policy of foreign exchange settlement on a discretionary basis. However, the settlement of foreign exchange shall only be used for their own operational purposes within the business scope of the non-PRC invested enterprises and follow the principles of authenticity.

Dividend Distribution

The SAFE promulgated the Notice on Improving the Check of Authenticity and Compliance to Further Promote Foreign Exchange Control in January 2017, which stipulates several capital control measures with respect to outbound remittance of profits from PRC entities to offshore entities, including the following: (1) under the principle of genuine transaction, banks shall check board resolutions regarding profit distribution, the original version of tax filing records and audited financial statements; and (2) PRC entities shall hold income to account for previous years’ losses before remitting the profits. Moreover, PRC shall make detailed explanations of sources of capital and utilization arrangements, and provide board resolutions, contracts and other proof when completing the registration procedures in connection with an outbound investment. Restrictions on our PRC subsidiaries’ ability to pay dividends to an offshore entity primarily include: (i) the PRC subsidiaries may pay dividends only out of their accumulated after-tax profits upon satisfaction of relevant statutory conditions and procedures, if any, determined in accordance with PRC accounting standards and regulations; (ii) each of the PRC subsidiaries is required to set aside at least 10% of its after-tax profits each year, if any, to fund reserve funds until the total amount set aside reaches 50% of its registered capital; (iii) the PRC subsidiaries are required to complete procedural requirements related to foreign exchange control in order to make dividend payments in non-PRC currency; and (iv) a withholding tax, at the rate of 10% or lower, is payable by the PRC subsidiary upon dividend remittance. Such restrictions could have a material and adverse effect on our ability to distribute profits to our investors.

Foreign Exchange Registration of Offshore Investment by PRC Residents

The SAFE promulgated the SAFE Circular 37 in July 2014. The SAFE Circular 37 requires PRC residents (including PRC institutions and individuals) to register with local branches of SAFE in connection with their direct or indirect offshore investment in an overseas special purpose vehicle, or the SPV, directly established or indirectly controlled by PRC residents for offshore investment and financing with their legally owned assets or interests in domestic enterprises, or their legally owned offshore assets or interests. Such PRC residents are also required to amend their registrations with the SAFE when there is a change to the basic information of the SPV, such as changes of a PRC resident individual shareholder, the name or operating period of the SPV, or when there is a significant change to the SPV, such as changes of the PRC individual resident’s increase or decrease of its capital contribution in the SPV, or any share transfer or exchange, merger, division of the SPV.

The Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, which was promulgated in February 2015 and effective in June 2015 and further amended in December 2019, provides that PRC residents may register with qualified banks instead of the SAFE in connection with their establishment or control of an offshore entity established for the purpose of overseas direct investment. The SAFE and its branches shall implement indirect supervision over foreign exchange registration of direct investment via the banks.

Failure to comply with the registration procedures set forth in the SAFE Circular 37 may result in restrictions on the foreign exchange activities of the relevant onshore company, including the payment of dividends and other distributions to its offshore parent or affiliate, the capital inflow from the offshore entities and settlement of foreign exchange capital, and may also subject relevant onshore company or PRC residents to penalties under PRC foreign exchange administration regulations.

Regulations on Labor

Labor Law and Labor Contract Law

According to the PRC Labor Law, which was promulgated by the Standing Committee of the NPC in July 1994 and amended in August 2009 and December 2018, respectively, the PRC Labor Contract Law, which was promulgated by the Standing Committee of the NPC in June 2007 and amended in December 2012 and came into effect July 2013, and the Implementing Regulations of the Employment Contracts Law of the PRC, which was promulgated by the State Council in September 2008, labor contracts in written form shall be executed to establish labor relationships between employers and employees. In addition, wages cannot be lower than the local minimum wage. The employers must establish a system for labor safety and sanitation, strictly abide by PRC rules and standards, provide education regarding labor safety and sanitation to its employees, provide employees with labor safety and sanitation

122


 

conditions and necessary protection materials in compliance with PRC rules, and carry out regular health examinations for employees engaged in work involving occupational hazards.

Social Insurance and Housing Provident Funds

According to the Social Insurance Law of PRC, which was promulgated by the Standing Committee of the NPC in October 2010 and came into effect in July 2011, and further amended in December 2018, and the Interim Regulations on the Collection and Payment of Social Security Funds, which was promulgated by the State Council in January 1999 and amended in March 2019, and the Regulations on the Administration of Housing Provident Funds, which was promulgated by the State Council in April 1999 and amended in March 2002 and March 2019, employers are required to contribute, on behalf of their employees, to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational injury insurance, maternity insurance and to housing provident funds. Any employer who fails to contribute may be fined and ordered to make good the deficit within a stipulated time limit.

Regulations on Taxation and Withholding Tax

Enterprise Income Tax and Withholding Tax

According to the Enterprise Income Tax Law promulgated by the NPC in March 2007 and amended in February 2017 and December 2018, and the Implementation Rules of the Enterprise Income Tax Law of the PRC promulgated by the State Council in December 2007 and amended in April 2019, other than a few exceptions, the income tax rate for both domestic enterprises and non-PRC-invested enterprises is 25%. Enterprises are classified as either “resident enterprises” or “non-resident enterprises”. Besides enterprises established within the PRC, enterprises established outside the PRC whose “de facto management bodies” are located in the PRC are considered “resident enterprises” and subject to the uniform 25% enterprise income tax rate for their global income. A non-resident enterprise refers to an entity established under non-PRC law whose “de facto management bodies” are not within the PRC but which have an establishment or place of business in the PRC, or which do not have an establishment or place of business in the PRC but have income sourced within the PRC. An income tax rate of 10% will normally be applicable to dividends declared to non-PRC resident enterprise investors that do not have an establishment or place of business in the PRC, or that have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived from sources within the PRC.

According to the Notice on Promoting the Implementation of Corporate Income Tax Policies for Advanced Technology Service Enterprises Nationwide, or the Notice, effective in January 2017, an enterprise which is recognized as an “Advanced Technology Service Enterprises” under the Notice enjoys a reduced enterprise income tax rate of 15%.

According to the Arrangement Between the Mainland of China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Prevention of Fiscal Evasion with Respect to Taxes on Income, or the Double Tax Avoidance Arrangement, which was promulgated and came into effect in August 2006, and other applicable PRC laws, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied the relevant conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax on the dividends the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5%. However, based on the Circular on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties which was promulgated by the State Administration of Taxation, or the SAT, in February 2009, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential tax treatment. Based on the Announcement on Certain Issues with Respect to the “Beneficial Owner” in Tax Treaties, which was promulgated by the SAT in February 2018 and came into effect in April 2018, if an applicant’s business activities do not constitute substantive business activities, it could result in the negative determination of the applicant’s status as a “beneficial owner”, and consequently, the applicant could be precluded from enjoying the above-mentioned reduced income tax rate of 5% under the Double Tax Avoidance Arrangement.

Value Added Tax

According to the Provisional Regulations of the PRC on Value-Added Tax, effective in January 1994 and further amended in November 2008, February 2016, and November 2017, and its implementation rules effected in January 1994 and amended in December 2008 and October 2011, except stipulated otherwise, taxpayers who sell goods, labor services or tangible personal property leasing services or import goods shall be subject to a 17% tax rate; taxpayers who sell transport services, postal services, basic telecommunications services, construction services, or real property leasing services, sell real property, transfer the land use right shall be subject to an 11% tax rate, and taxpayers who sell services or intangible assets shall be subject to a 6% tax rate.

123


 

According to the Circular of the Ministry of Finance and the State Administration of Taxation on Adjusting Value-added Tax Rates adopted in April 2018, as of May 2018, where a taxpayer engages in a taxable sales activity for the value-added tax purpose or imports goods, the previous applicable 17% and 11% rates are adjusted to 16% and 10%.

According to the Announcement on Relevant Policies for Deepening Value-Added Tax Reform, effective in April 2019, the 16% VAT tax rate, which applies to the sales or imported goods of a VAT general taxpayer, will be lowered to 13%; and the 10% VAT tax rate will be lowered to 9%.

According to the Measures for the Exemption of Value-Added Tax from Cross-Border Taxable Activities in the Collection of Value-Added Tax in Lieu of Business Tax (for Trial Implementation) revised in June 2018, if domestic enterprises provide cross-border taxable activities such as professional technical services, technology transfer, software services, the above-mentioned cross-border taxable activities are exempt from VAT.

Tax on Indirect transfer

On February 3, 2015, the SAT issued the Bulletin on Issues of Enterprise Income Tax on Indirect Transfers of Assets by Non-PRC Resident Enterprises, or Bulletin 7. Pursuant to Bulletin 7, an “indirect transfer” of assets, including equity interests in a PRC resident enterprise, by non-PRC resident enterprises, may be recharacterized and treated as a direct transfer of PRC taxable assets, if such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax. When determining whether there is a “reasonable commercial purpose” of the transaction arrangement, features to be taken into consideration include, inter alia, whether the main value of the equity interest of the relevant offshore enterprise derives directly or indirectly from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consists of direct or indirect investment in the PRC or if its income is mainly derived from the PRC; and whether the offshore enterprise and its subsidiaries directly or indirectly holding PRC taxable assets have a real commercial nature which is evidenced by their actual function and risk exposure. According to Bulletin 7, where the payer fails to withhold any or sufficient tax, the transferor shall declare and pay such tax to the tax authority by itself within the statutory time limit. Late payment of applicable tax will subject the transferor to default interest. Bulletin 7 does not apply to transactions of sale of shares by investors through a public stock exchange where such shares were acquired on a public stock exchange. On October 17, 2017, the SAT issued the Announcement of the SAT on Issues Concerning the Withholding of Non-resident Enterprise Income Tax at Source, or SAT Circular 37, which was amended by the Announcement of the State Administration of Taxation on Revising Certain Taxation Normative Documents issued on June 15, 2018 by the SAT. The SAT Circular 37 further elaborates the relevant implemental rules regarding the calculation, reporting and payment obligations of the withholding tax by the non-resident enterprises. Nonetheless, there remain uncertainties as to the interpretation and application of Bulletin 7. Bulletin 7 may be determined by the tax authorities to be applicable to our offshore transactions or sale of our shares or those of our offshore subsidiaries where non-resident enterprises, being the transferors, were involved.

European Regulations

Our product candidates will be subject to similar laws and regulations imposed by jurisdictions outside of the United States, in particular in Europe, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.

In order to market our future product candidates in the European Economic Area (which is comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), or the EEA, and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal product candidates can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations:

the “Community MA,” which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Product candidates for Human Use, or CHMP, of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for some types of product candidates, such as biotechnology medicinal product candidates, orphan medicinal product candidates and medicinal product candidates indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for product candidates containing a new active substance not yet authorized in the EEA, or for product candidates that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and
“National MAs,” which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for product candidates not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be

124


 

recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.

Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.

Data and marketing exclusivity. In the EEA, new product candidates authorized for marketing, or reference product candidates, qualify for eight years of data exclusivity and an additional two years of market exclusivity from the initial authorization of a medicine. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period can be extended by one more year (for a maximum of 11 years) in the event of authorization of new therapeutic indications provided that (i) the new application represents a significant clinical benefit in comparison with existing therapies and (ii) the new indication is granted during the first eight years since the initial MA.

Pediatric investigation plan. In the EEA, MA applications for new medicinal product candidates not authorized have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA’s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all Member States of the EEA and study results are included in the product information, even when negative, the product is eligible for a six-month supplementary protection certificate extension or, in the case of orphan medicinal products, a two-year extension of orphan market exclusivity.

Orphan drug designation. In the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically-debilitating condition affecting not more than five in 10,000 persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.

In the EEA, an application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, the EMA or the competent authorities of the Member States, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar medicinal product for the same indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP.

This period of orphan market exclusivity may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan drug destination, i.e., the prevalence of the condition has increased above the threshold or it is judged that the product is sufficiently profitable not to justify maintenance of market exclusivity. Granting of an authorization for another similar orphan medicinal product where another product has market exclusivity can happen only in selected cases, such as, for example, demonstration of “clinical superiority” by a similar medicinal product, inability of a manufacturer to supply sufficient quantities of the first product or where the manufacturer itself gives consent. A company may voluntarily remove a product from the orphan register. Medicinal products or medicinal product candidates designated as orphan are eligible for incentives made available by the EU and its Member States to support research into, development and availability of orphan medicinal products. In March 2016, we obtained orphan drug designation for setrusumab for the treatment of OI in the EU. We intend to pursue orphan designation for alvelestat and for future, eligible rare disease programs.

125


 

Adaptive pathways. The EMA has an adaptive pathways program which allows for early and progressive patient access to a medicine. The adaptive pathways concept is an approach to medicines approval that aims to improve patients’ access to medicines in cases of high unmet medical need. To achieve this goal, several approaches are envisaged: identifying small populations with severe disease where a medicine’s benefit-risk balance could be favorable; making more use of real-world data where appropriate to support clinical trial data; and involving health technology assessment bodies early in development to increase the chance that medicines will be recommended for payment and ultimately covered by national healthcare systems. The adaptive pathways concept applies primarily to treatments in areas of high medical need where it is difficult to collect data via traditional routes and where large clinical trials would unnecessarily expose patients who are unlikely to benefit from the medicine. The approach builds on regulatory processes already in place within the existing EU legal framework. These include: scientific advice; compassionate use; the conditional approval mechanism (for medicines addressing life-threatening conditions); patient registries and other pharmacovigilance tools that allow collection of real-life data and development of a risk-management plan for each medicine.

The adaptive pathways program does not change the standards for the evaluation of benefits and risks or the requirement to demonstrate a positive benefit-risk balance to obtain marketing authorization. In February 2017, setrusumab was accepted into the adaptive pathways program.

PRIME scheme. In July 2016, the EMA launched the PRIME scheme. PRIME is a voluntary scheme aimed at enhancing the EMA’s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is however not guaranteed. The benefit of a PRIME designation include the appointment of a rapporteur from the CHMP before submission of a MA Application, early dialogue and scientific advice at key development milestones, and the potential to qualify product candidates for accelerated review earlier in the application process. In November 2017, the EMA granted PRIME designation for setrusumab for the treatment of OI.

U.S. Healthcare Coverage and Reimbursement

Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor’s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage processes of a payor may require manufactures to provide scientific and clinical support for the use of a product to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.

Third-party payors are also increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are more and more challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.

In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors’ reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.

126


 

U.S. Healthcare Reform

In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system. In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell some “branded prescription drugs” to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for covered outpatient drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

Since its enactment, there have been judicial and Congressional challenges to some aspects of the ACA.

On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. It is unclear how other healthcare reform measures enacted by Congress or implemented by the Biden administration, if any, will impact our business.

 

Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2031 absent additional congressional action, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 and a reduction to 1% from April 1, 2022 through June 30, 2022 due to the COVID-19 pandemic. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. In addition, individual states in the United States have also become increasingly active in implementing regulations designed to address pharmaceutical product pricing, such as transparency measures that require the disclosure of prices, including price or patient reimbursement constraints, discounts, restrictions on specific product access and changes, marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing costs, and research costs, among others. Furthermore, there has been increased interest by third party payors and governmental authorities as to pricing systems and publication of discounts and list prices for drug spending.

Data Privacy and Security Laws

Numerous state, federal and foreign laws govern the collection, dissemination, use, access to, confidentiality and security of health-related information and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, some foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.

127


 

C. Organizational Structure.

The following diagram illustrates our corporate structure as of the date of this annual report:

 

img67639792_18.jpg 

 

The following table illustrates the principal activities and percentage equity interest as of December 31, 2020 and 2021 for each of our subsidiaries:

 

 

 

 

 

 

 

As of December 31,

Name

 

Principal activities

 

Country of incorporation

 

2020

 

 

2021

Connect Biopharma HongKong Limited

 

Investment holding

 

PRC

 

100%

 

 

100%

Connect Biopharm LLC

 

Pharmaceutical R&D

 

U.S.

 

 

100%

 

 

100%

Connect Biopharma Australia PTY LTD

 

Pharmaceutical R&D

 

Australia

 

 

100%

 

 

100%

Suzhou Connect Biopharma Co., Ltd.

 

Pharmaceutical R&D

 

PRC

 

 

100%

 

 

100%

Connect Biopharma (Shanghai) Co., Ltd

 

Pharmaceutical R&D

 

PRC

 

 

100%

 

 

100%

Connect Biopharma (Beijing) Co., Ltd

 

Pharmaceutical R&D

 

PRC

 

 

100%

 

 

100%

Connect Biopharma (Shenzhen) Co., Ltd

 

Dormant

 

PRC

 

 

—%

 

 

100%

The Company was formed to acquire Connect Biopharma HongKong Limited. As the sole holder of equity in Connect Biopharma HongKong Limited, the Company operates the business and controls the strategic decisions and day-to-day operations of Connect Biopharma HongKong Limited. We have six (6) wholly owned subsidiaries.

D. Property, Plant and Equipment.

We have a research, development and administration facility in Taicang, Jiangsu Province, The People’s Republic of China, where we lease approximately 25,476 square feet of office and laboratory space under leases that expire on April 30, 2023, and an executive and administration office in San Diego, California, where we lease approximately 3,600 square feet of office space under a lease that expires in April 2025. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.

 

In May 2021, we entered into the Land Use Agreement. Pursuant to this agreement, we obtained the right to use approximately 70,400 square meters of state-owned land located in the Taicang High-Tech Industrial Development Zone for a period of fifty years. We acquired the land use rights to build a research and development laboratory, manufacturing facility and office. As of December 31, 2021, we have paid an aggregate of approximately RMB 22.3 million ($3.5 million) for the land use rights and an additional RMB 7.0 million ($1.1 million) for related construction costs and have recorded those amounts in right-of-use assets and property, plant, and equipment, respectively in our Consolidated Balance Sheets. This construction project is currently on hold until we can obtain the necessary construction permits and therefore are not expecting a significant increase to our capital commitments related to this project during 2022.

 

In connection with the Land Use Agreement, we entered into an Investment Agreement with the Jiangsu Taicang High-tech Industrial Development Zone Management Committee (the “Jiangsu Taicang HIDC”), a local government authority in Taicang. Pursuant to this

128


 

agreement, the Jiangsu Taicang HIDC has agreed to provide specific financial support and incentives in connection with the development of our facilities contemplated by the Land Use Agreement. As of December 31, 2021, we have provided pursuant to this agreement approximately RMB 356.2 million ($55.9 million) of cash into our Connect Suzhou research and development operations to fund research, development, and administration expenses at our Taicang facility.

ITEM 4A. UNRESOLVED STAFF COMMENTS.

Not applicable.

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS.

You should read the following discussion and analysis in conjunction with our audited financial statements, in each case, together with the accompanying notes included elsewhere in this Annual Report. Our audited financial statements have been prepared in accordance with IFRS, as issued by the International Accounting Standards Board. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under “Item 3. Key Information—D. Risk Factors” and elsewhere in this Annual Report.

We have omitted a discussion of the operating results comparing the year ended December 31, 2019 and 2020 which was previously included in Management’s Discussion and Analysis of Financial Condition and Results of Operations of our prospectus filed with the SEC on March 19, 2021.

Our consolidated financial statements are presented in Renminbi, or RMB. For the convenience of the reader, we have translated information in the tables below presented in RMB into U.S. dollars at the rate of RMB 6.3757 to $1.00, the exchange rate set forth in the China Foreign Exchange Trade System on December 31, 2021. These translations should not be considered representations that any such amounts have been, could have been, or could be converted into U.S. dollars at that or any other exchange rate as of that or any other date.

Upon approval of shareholders of the Company on March 12, 2021, every 1.74 ordinary shares were consolidated into one ordinary share (the “Share Consolidation”) (Note 19).

A. Operating Results

Overview

We are a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Our lead product candidate, CBP-201, is an antibody designed to target IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as AD and asthma. The estimated global market for AD was approximately $7.6 billion in 2021 and is expected to grow to $12.1 billion by 2025, a CAGR of 12.4%. We recently completed a Phase 2b trial of CBP-201 in the United States, Australia and New Zealand in adult patients with moderate-to-severe AD, in which primary and key secondary endpoints were met, and will be initiating a global Phase 3 program in adult patients with moderate-to-severe AD in the second half of 2022. Furthermore, we are developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, or S1P1, for the treatment of IBD. Specifically, we are developing CBP-307 for two types of IBD, UC and CD. We anticipate reporting top-line results from a global Phase 2 trial in UC before the end of the second quarter of 2022. Our global clinical trial in CD ended early due to enrollment challenges during the pandemic and we will determine future clinical plans for CD upon the completion of the Phase 2 UC trial.

Since our inception, we have devoted our resources to developing a differentiated drug discovery approach based on our deep understanding of the immune system and conducting preclinical studies and clinical trials, as well as protecting our intellectual property estate comprising multiple patent families. Additionally, we have applied resources to business planning and capital raising to develop a pipeline of product candidates. We have funded our operations primarily through equity and preferred shares financing. On March 23, 2021, we completed our initial public offering (“IPO”) for a total cash consideration of USD 219.9 million, before netting underwriting discounts and commissions of USD 15.4 million. As of December 31, 2021, we had RMB 1,706.9 million (USD 267.7 million) in cash and cash equivalents.

As a research intensive, innovation-focused entity, we have also incurred losses and experienced negative operating cash flows since inception. Our net losses were RMB 779.2 million and RMB 1,306.8 million (USD 205.0 million) for the years ended December 31,

129


 

2020 and 2021, respectively. As of December 31, 2021, we had an accumulated loss of RMB 2.4 billion (USD 373.0 million). We expect to continue to incur significant expenses and operating losses for the foreseeable future as we conduct our ongoing and planned preclinical studies and clinical trials, continue our research and development activities, build our facilities, increase our production capacity, and seek regulatory approvals for our product candidates, as well as hire additional personnel, obtain and protect our intellectual property and incur additional costs for commercialization or to expand our pipeline of product candidates.

 

As our product candidates move further into clinical development stages, we may receive milestone and other payments from third parties with whom we may choose to collaborate. In addition, we may also receive revenues from product commercialization if we obtain regulatory approval for any of our product candidates. However, even with these sources of revenue and income, we may continue to experience losses and negative operating cash flows and may not be able to fund our late stage programs without additional fundraisings, licensing or partnership proceeds. We believe that our existing cash and cash equivalents noted above will be sufficient to meet our anticipated daily operation needs for at least the next 12 months.

Key Factors and Trends Affecting Our Business

 

The future success of our business is predicated on the continuation of our research and development programs, initially by advancing CBP-201 and CBP-307 through Phase 2 and Phase 3 clinical trials and then seeking regulatory approval in the United States, the PRC, Europe, Australia and other jurisdictions. We may advance CBP-174 into additional clinical trials after evaluating results of our Phase 1 trial in healthy volunteers. We do not currently have sufficient capital resources to complete late stage clinical trials of all our product candidates or in all planned indications.

Impact of COVID-19

In December 2019, a novel strain of coronavirus was reported in Wuhan, China and on March 11, 2020 the WHO declared COVID-19 a pandemic. The COVID-19 pandemic has resulted in a widespread health crisis and numerous disease control measures being taken to limit its spread. As the pandemic continues its impact throughout the world, the healthcare systems of the various countries in which we are conducting ongoing clinical trials of CBP-201 and CBP-307 have and may continue to experience great disruption. Enrollment in our Phase 2 clinical trial of CBP-307 in patients in the PRC was prematurely terminated due to challenges in recruitment caused by the COVID-19 pandemic. Additionally, enrollment in one phase 1 clinical trial of CBP-307 and the phase 1 clinical trial of CBP-174 in Australia have been slow due to the COVID-19 pandemic.

We will continue to monitor and assess the impact of the ongoing development of the pandemic on our clinical trials and for any impact to our financial position and operating results.

Key Components of Our Results of Operations

Revenue

We do not currently have any approved products. Accordingly, we have not generated any revenue and do not expect to do so unless we obtain regulatory approval and commercialize any of our product candidates or until we receive revenues from collaborations or other arrangements with third parties, neither of which may occur.

Operating Expenses

Research and Development Expenses

Research and development expenses are primarily related to third-party clinical trial costs, drug manufacturing costs, and other preclinical research for our product candidates and discovery efforts, along with payroll and related expenses and share-based compensation costs.

Elements of research and development expenses primarily include (1) expenses related to preclinical testing of our technologies under development and clinical trials such as payments to CROs, investigators and clinical trial sites that conduct the clinical studies; (2) consultant service related to the design of clinical trials and data analysis, (3) payroll and other related expenses of personnel engaged in research and development activities, (4) expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility-related expenses, and (5) other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to our research and development services and have no alternative future uses.

130


 

The majority of our third-party expenses have been related to the development of CBP-201 and CBP-307. During the years ended December 31, 2020 and 2021, we spent RMB 58.5 million and RMB 349.5 million (USD 54.8 million), respectively, in clinical trial related expenses relating to CBP-201, RMB 46.5 million and RMB 112.3 million (USD 17.6 million), respectively, in clinical trial related expenses relating to CBP-307. We deploy our personnel and facility-related resources across all of our research and development activities. We have substantially increased our research and development expenditures as we continue the development of our product candidates and conduct discovery and research activities for our preclinical programs. Product candidates in a later stage of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. We expect that our research and development costs will continue to increase as we conduct ongoing, and plan and conduct new, preclinical studies and clinical trials and manufacture our product candidates.

We cannot determine with certainty the timing of initiation, the duration, or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical and clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate’s commercial potential. It is likely that we will need to raise additional capital in the future for commercialization of our products, assuming that we obtain regulatory approval.

Our clinical development costs are highly uncertain and may vary significantly based on factors such as:

(a)
per patient trial costs;
(b)
the number of trials required for approval;
(c)
the number of sites included in the trials;
(d)
the countries in which the trials are conducted;
(e)
the length of time required to enroll eligible patients;
(f)
the number of patients that participate in the trials;
(g)
the drop-out or discontinuation rates of patients;
(h)
potential additional safety monitoring requested by regulatory agencies;
(i)
the duration of patient participation in the trials and follow-up;
(j)
the cost and timing of manufacturing our product candidates;
(k)
the phase of development of our product candidates; and
(l)
the efficacy and safety profile of our product candidates.

Any of these variables with respect to the development of our product candidates or any other future candidate that we may develop could result in a significant change in the costs and timing associated with their development. For example, if the FDA, the NMPA, or another regulatory authority were to require us to conduct preclinical studies and clinical trials beyond those we currently anticipate will be required for the completion of clinical development or if we experience significant delays in enrollment in any clinical trials, we could be required to expend significant additional financial resources and time on the completion of our clinical development programs. We may never succeed in obtaining regulatory approval for any of our product candidates.

Administrative Expenses

Administrative expenses primarily include payroll and related expenses for employees involved in general corporate functions including finance, legal, information technology, business development, and human resources, share-based compensation costs, insurance costs, third-party audit and accounting fees, legal fees, rental and depreciation expenses related to facilities and equipment used by these functions, professional service expenses and other general corporate related expenses.

We expect our administrative expenses to increase in the future to support our public company infrastructure and, if any of our product candidates receive marketing approval, commercialization activities. We also anticipated increased expenses related to professional fees, including audit, legal, regulatory and tax-related services, associated with maintaining compliance with Nasdaq listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.

 

Other Income

Other income consists of government grants received by us. Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received and we will comply with all attached conditions. Government grants received

131


 

in advance of costs being incurred are deferred until the associated costs are recognized. Grants that compensate us for the cost of an asset initially are presented as deferred income and are recognized as income in consolidated statements of loss on a straight-line basis over the useful life of the associated asset.

Other Income (Losses)—Net

Other gains or losses consist of the foreign exchange gains and losses resulting from the settlement of foreign exchange transactions, most of which were denominated in U.S. dollars for the subsidiaries that have functional currency in RMB, and the short-term investments in wealth management products with various maturities which bear floating interest rates. The fair value of short-term investments in wealth management products is based on discounted cash flows using their expected returns. Changes in fair value of these financial assets are recorded in other income (losses)—net.

Finance Income

Finance income is comprised primarily of interest income earned from bank and term deposits that are held for cash management purposes.

Finance Cost

Finance cost is mainly comprised of issuance costs for our financial instruments with preferred rights and interests for lease liabilities.

Fair Value Loss of Financial Instruments with Preferred Rights

The fair value of financial instruments with preferred rights that are not traded in an active market is determined using valuation techniques. We first determine the equity value and then allocated the equity value to each element of our capital structure using either an option pricing back-solve method, or OPM, or a hybrid method, which employs the concepts of the OPM and the probability-weighted expected return method, or PWERM, that merged into a single framework. The fair value difference is accounted for as fair value loss of financial instruments with preferred rights within the consolidated statements of loss.

Income Taxes

Income tax expense is recognized based on the income tax rates in the following main tax jurisdictions where we operate. We are incorporated in the Cayman Islands with subsidiaries in Hong Kong, China (PRC), Australia and the United States and is exempt from income tax in the Cayman Islands. Our United States entity is a service provider for the Hong Kong entity and as a result its cost-plus income is subject to taxation in the United States. There is no tax expense in Hong Kong, PRC or Australia as there was no estimated assessable profit that was subject to tax during the years ended December 31, 2020 and 2021.

132


 

Results of Operations

Comparison of the Years Ended December 31, 2020 and 2021

The following table summarizes key components of our results of operations for the periods indicated:

 

 

 

Year Ended December 31,

 

 

2020

 

2021

 

2021

 

Change

 

 

 

RMB’000

 

RMB’000

 

USD’000(1)

 

RMB’000

 

Research and development expenses

 

 

(150,932)

 

 

(518,021)

 

 

(81,249)

 

 

(367,089)

 

Administrative expenses

 

 

(47,720)

 

 

(122,445)

 

 

(19,205)

 

 

(74,725)

 

Other income

 

 

6,989

 

 

18,996

 

 

2,979

 

 

12,007

 

Other losses—net

 

 

(6,100)

 

 

(9,966)

 

 

(1,563)

 

 

(3,866)

 

Operating loss

 

 

(197,763)

 

 

(631,436)

 

 

(99,038)

 

 

(433,673)

 

Finance income

 

 

717

 

 

622

 

 

98

 

 

(95)

 

Finance cost

 

 

(2,893)

 

 

(44)

 

 

(7)

 

 

2,849

 

Finance (cost)/income—net

 

 

(2,176)

 

 

578

 

 

91

 

 

2,754

 

Fair value loss of financial instruments with preferred rights

 

 

(579,286)

 

 

(674,269)

 

 

(105,756)

 

 

(94,983)

 

Loss before income tax

 

 

(779,225)

 

 

(1,305,127)

 

 

(204,703)

 

 

(525,902)

 

Income tax expense

 

 

 

 

(1,697)

 

 

(266)

 

 

(1,697)

 

Loss for the year

 

 

(779,225)

 

 

(1,306,824)

 

 

(204,969)

 

 

(527,599)

 

(1) USD 1.00 = RMB 6.3757.

Research and Development Expenses

Research and development expenses increased by RMB 367.1 million from RMB 150.9 million for the year ended December 31, 2020 to RMB 518.0 million (USD 81.2 million) for the year ended December 31, 2021, primarily due to an increase of RMB 323.6 million in third-party clinical trial costs for advancing our lead product candidates further into later clinical trial phases. Specifically, we completed a Phase 2b clinical trial of CBP-201 in the United States, the PRC, Australia and New Zealand in adult AD patients with moderate-to-severe AD, which significantly increased clinical trial related expenses in 2021. In addition, in 2021, we incurred additional drug supply and clinical expenses related to the initiation of global Phase 2 clinical trials of CBP-201 for asthma and CSwNP indications and the initiation of a global Phase 2 trial for CBP-307 in UC and CD indications.

Administrative Expenses

Administrative expenses increased by RMB 74.7 million from RMB 47.7 million for the year ended December 31, 2020 to RMB 122.4 million (USD 19.2 million) for the year ended December 31, 2021. The increase in administrative expenses was primarily due to (i) a RMB 43.1 million increase in payroll and related expenses for additional headcount, including share-based compensation expense, and resources needed in support of the growth of our business operations, and (ii) a RMB 26.6 million increase in professional fees including accounting and audit fees, legal fees, insurance costs, and other costs required for a public company infrastructure.

Other Income

Other income increased by RMB 12.0 million from RMB 7.0 million for the year ended December 31, 2020 to RMB 19.0 million (USD 3.0 million) for the year ended December 31, 2021. This increase was primarily related to a total of RMB 17.2 million of government grants for completing its IPO milestone and for conducting research and development activities in the PRC and a RMB 1.6 million R&D tax incentive in Australia.

Other Losses—Net

Other losses—net, increased by RMB 3.9 million from RMB 6.1 million of net losses for the year ended December 31, 2020 to RMB 10.0 million (USD 1.6 million) of net losses for the year ended December 31, 2021. The increase was primarily attributable to fluctuations in foreign exchange rates in 2021 and 2020. During 2021, the USD exchange rates against RMB were declining, leading to higher foreign exchange losses in 2021.

133


 

Finance Income

Finance income decreased by RMB 0.1 million from RMB 0.7 million for the year ended December 31, 2020 to RMB 0.6 million (USD 0.1 million) for the year ended December 31, 2021. The decrease is considered insignificant.

Finance Costs

Finance costs decreased by RMB 2.8 million from RMB 2.9 million for the year ended December 31, 2020 to less than RMB 0.1 million (less than USD 0.1 million) for the year ended December 31, 2021. This decrease in finance costs was primarily due to issuance costs related to the Series C Preferred Shares issued in August and December 2020.

Fair Value Loss of Financial Instruments with Preferred Rights

Fair value loss of financial instruments with preferred rights increased by RMB 95.0 million from RMB 579.3 million for the year ended December 31, 2020 to RMB 674.3 million (USD 105.8 million) for the year ended December 31, 2021. The increase was primarily related to the issuance of Series C Preferred Shares in August and December 2020, and higher fair value of preferred shares during 2021 prior to the Company’s IPO. The impact resulting from the higher fair value of preferred shares was partially offset by the foreign currency translation, because preferred shares were valued in USD, which is different from the reporting currency of RMB.

Income Tax Expense

Income tax expense increased by RMB 1.7 million from nil for the year ended December 31, 2020 to RMB 1.7 million (USD 0.3 million) for the year ended December 31, 2021. The increase is mainly related to higher activity during the year ended December 31, 2021 in Connect US, which for income tax purposes is a service provider for Connect HK and as a result its cost-plus income is taxed for federal and state income tax purposes in the United States.

Critical Accounting Policies and Estimates

Our consolidated financial statements were prepared in accordance with IFRS issued by the IASB. Our consolidated financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through profit or loss and financial instruments with preferred rights.

The preparation of financial statements requires the use of accounting estimates which, by definition, may not equal the actual results.

Management also needs to exercise judgment in applying the accounting policies.

Estimates and judgments are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact and that are believed to be reasonable under the circumstances. These estimates may not equal actual results.

(a)
Research and development expenses

We incur costs and effort on research and development activities. Research expenditures are charged to the profit or loss as an expense in the period the expenditure is incurred. Development costs are recognized as assets if they can be directly attributable to a newly developed service or product and all the following can be demonstrated:

the technical feasibility to complete the development project so that it will be available for use or sale;
the intention to complete the development project to use or sell the product;
the ability to use or sell the product;
the manner in which the development project will generate probable future economic benefits for us;
the availability of adequate technical, financial and other resources to complete the development project and use or sell the product; and
the expenditure attributable to the asset during its development can be reliably measured.

Elements of research and development expenses primarily include (1) expenses related to preclinical testing of our technologies under development and clinical trials such as payments to clinical trial related investigators and clinical trial sites that conduct the clinical studies; (2) consultant service related to the design of clinical trials and data analysis, (3) payroll and other related expenses of

134


 

personnel engaged in research and development activities, (4) expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5) other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to our research and development services and have no alternative future uses.

(b)
Fair value of financial instruments with preferred rights

Financial instruments with preferred rights issued by us will be convertible into ordinary shares upon the closing of a qualified initial public offering or at the option of the holders and redeemable upon occurrence of specific future events. Financial instruments with preferred rights are compound instruments with discretionary dividend right. The Company elected to designate the entire hybrid contracts that include a host contract and embedded derivatives as financial liabilities at fair value through profit or loss considering the fact that the instruments also have contingent settlement provisions. Our preferred shares are not traded in an active market and the respective fair value is determined by using valuation techniques. We first determined the equity value and then allocated the equity value to each element of our capital structure using either an OPM or a hybrid method. We make assumptions and estimates concerning variables such as discount rate for lack of marketability, or DLOM, expected volatility and risk-free interest rates.

(c)
Recognition of share-based compensation expenses

In order to attract and retain the right talent, we offer share-based compensation incentives to our employees, directors and consultants. We used a Binomial Option Pricing model to determine the total fair value of the awarded options, which is to be expensed over the vesting period. Significant estimate on assumptions, such as the grant date share price, expected volatility, expected early exercise multiple, option life, risk-free interest rate and dividend yield, are required to derive such expense amounts. As we continue to grow and move into key stages of product development, we expect to continue offering share-based incentives to our employees, directors and consultants and the amount of expenses may increase in future.

Key assumptions are set forth as follows (after Share Consolidation):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2021

 

Weighted average exercise price during the year

 

USD 6.6

 

 

USD 13.8

 

Grant date share price

 

USD2.1~USD11.1

 

 

USD 4.3~USD 23.3

 

Risk-free interest rate

 

0.8%~1.1%

 

 

1.2%~1.7%

 

Expected volatility

 

61.8%~77.4%

 

 

60.5%~62.2%

 

Option life

 

10 years

 

 

10 years

 

Expected early exercise multiple

 

 

2.2

 

 

 

2.2

 

Dividend yield

 

Nil

 

 

Nil

 

Forfeiture rate

 

 

9.5%

 

 

 

3.0~9.6%

 

Weighted average fair value of options granted during the year

 

USD 4.2

 

 

USD 10.6

 

 

1.
Grant date share price—Because our ordinary shares are not yet publicly traded, we are required to estimate the fair value of our ordinary shares, as discussed in “—Ordinary Share Valuation” below.
2.
Risk-free interest rate—The risk-free rate is based on the U.S. Treasury yield for our risk-free interest rate that corresponds with the expected term.
3.
Expected volatility—We adopted the average volatility of the comparable companies as the proxy of the expected volatility of the underlying share. The volatility of each comparable company was based on the historical daily stock prices for a period with length commensurate to the remaining maturity life of the stock options.
4.
Option life—We adopted option life in accordance with the contractual terms of the options.
5.
Expected early exercise multiple—We estimated expected early exercise multiple for employee grantees and senior management grantees respectively by making reference to academic research.
6.
Dividend yield—We have no history of paying cash dividends on our ordinary shares and do not expect to pay dividends in the foreseeable future.
7.
Forfeiture rate—We estimated the probability of employee grantees exit based on the historical records.
(d)
Ordinary Share Valuation

Before IPO the fair value of the ordinary shares underlying our share options has been determined by us, with input from management and contemporaneous third-party valuations, as there has been no public market for our ordinary shares. Given the absence of a public trading market of our ordinary shares at then, and in accordance with the American Institute of Certified Public Accountants Practice

135


 

Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, the management exercised reasonable judgement and considered numerous objective and subjective factors to determine the best estimate of the fair value of our ordinary shares at each grant date for the reporting period. These factors include important developments in our operations, including research and development activities, sales of preferred shares, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general and the stock price performance and volatility of comparable public companies used to determine our total equity value, which is allocated to our different classes of ordinary and preferred shares. In addition, the valuation of our ordinary shares considers the lack of liquidity of our ordinary shares. Our ordinary shares were valued under a hybrid framework which includes a OPM valuation model and an analysis assuming an initial public offering as a possible future event, or the IPO Scenario.

The OPM valuation model utilized the following inputs to determine the fair value of our ordinary shares:

(i)
Term to exit—The term to exit considered market conditions and our estimate of when an exit would most likely occur by sale.
(ii)
Risk-free rate—The rates were based on the yield of US Treasury Strips with a maturity life equal to the expected terms for a liquidation event.
(iii)
Volatility—Expected volatility is based on daily stock prices of comparable companies for a period equal to the expected terms for a liquidation event. The comparable companies were selected based on operational similarities to us as well as other qualitative considerations.

The IPO Scenario utilized the following assumptions to determine the fair value of our ordinary shares:

(a)
Pre-money equity value on expected IPO Date—This value estimation was based on the guideline public company method under market approach, recently completed life sciences and biotechnology sectors IPO pricing by underwriter, as well as the expected capital market sentiment.
(b)
Cost of equity—The cost of equity is based on comparable companies selected based on operational similarities to us as well as other qualitative considerations.
(c)
Expected term for IPO Event—The expected term for IPO Event considered market conditions and our estimate of when an IPO would most likely occur.

Under both methods, we considered an adjustment to recognize the lack of marketability and liquidity since stockholders of private companies do not have access to trading markets similar to public companies. We used methodologies consistent with those used for financial instruments with preferred rights to determine DLOM for our ordinary shares.

To estimate the fair value of our ordinary shares, we probability weighted the fair value as determined under the OPM valuation model and the IPO Scenario. Subsequent to the closing of our IPO, the fair value of each ordinary share is determined based on the closing price of our ordinary shares on the date of grant.

(e)
Current and deferred income taxes

We recognize deferred tax assets based on estimates that it is probable to generate sufficient taxable profits in the foreseeable future against which the deductible losses and temporary differences will be utilized. The recognition of deferred tax assets mainly involves management’s judgments and estimations about the timing and the amount of taxable profits of the companies which have tax losses. As we expect continued operating losses in the near future, we do not expect to utilize historical tax losses. We have not recognized deferred income assets as of December 31, 2020 and 2021.

Recently Issued and Adopted Accounting Pronouncement

For information on the standards applied for the first time as of January 1, 2021, please refer to our consolidated financial statements as of December 31, 2021.

B. Liquidity and Capital Resources

Overview

We are a clinical development stage company that has generated no revenues and are exposed to a variety of financial risks including liquidity risks. We have incurred significant losses and negative cash flows from operations since our inception. As of December 31, 2021, we had an accumulated losses of RMB 2.4 billion (USD 373.0 million), and we expect to continue to incur significant losses for the foreseeable future. As of December 31, 2021, we had cash and cash equivalents of RMB 1.7 billion (USD 267.7 million). Our

136


 

principal sources of funding have historically been continuous cash contributions from common equity holders and preferred shareholders, including our IPO that we completed on March 23, 2021 for total cash consideration of USD 219.9 million before underwriting discounts and commissions. We believe, based on our current operating plan and expected expenditures, that our existing cash, and cash equivalents will be sufficient to meet our anticipated operating cash expenditures for at least the next 12 months from the issuance date of our financial statements as of and for the year ended December 31, 2021 and meet the requirements of a going concern. We will continue to seek additional fundraisings, licensing, or partnership proceeds to sufficiently fund our late-stage clinical trials for our product candidates.

We have funded our operations primarily through equity financing. Proceeds from those financings are initially held in the bank accounts of Connect Biopharma Holdings Limited and used to fund the operations of our subsidiaries.

In addition, we have received development incentives and subsidies from the PRC government. During the years ended December 31, 2021 and 2020, we received approximately RMB 22.2 million ($3.5 million) and RMB 2.2 million ($0.3 million) respectively.

The following table summarizes the cash transferred from our holding company to our operating subsidiaries:

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2021

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

USD’000

 

Cash Flow from Connect Biopharma Holdings Limited to:

 

 

 

 

 

 

 

 

Connect Biopharma HongKong Limited

 

202,497

 

 

672,529

 

105,483

 

Total cash transferred to operating subsidiaries

 

202,497

 

 

672,529

 

105,483

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2021

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

USD’000

 

Connect Biopharma HongKong Limited to:

 

 

 

 

 

 

 

 

Connect Biopharm LLC

 

83,981

 

 

309,287

 

48,510

 

Suzhou Connect Biopharma Co., Ltd.

 

134,521

 

 

356,218

 

55,871

 

Connect Biopharma Australia PTY LTD

 

30,017

 

 

 

 

Total cash transferred to operating subsidiaries

 

248,519

 

 

665,505

 

104,381

 

 

The amounts funded from Suzhou Connect Biopharma Co., Ltd to other the PRC subsidiaries were insignificant. There were no distributions, dividends or any other transfers out from any of the PRC entities to any of our entities outside of the PRC.

Cash Flows for the Years Ended December 31, 2020 and 2021

The following table summarizes our cash flows for the periods indicated:

 

 

 

Year Ended December 31,

 

 

 

2020

 

2021

 

2021

 

 

 

RMB’000

 

RMB’000

 

USD’000

 

Cash Flow Data:

 

 

 

 

 

 

 

Net cash used in operating activities

 

(167,161)

 

(544,926)

 

(85,469)

 

Net cash generated from/(used in) investing activities

 

2,932

 

(34,025)

 

(5,338)

 

Net cash generated from financing activities

 

918,761

 

1,316,100

 

206,424

 

Net increase in cash and cash equivalents

 

754,532

 

737,149

 

115,617

 

 

137


 

Operating Activities

During the year ended December 31, 2021, net cash used in operating activities was RMB 544.9 million (USD 85.5 million), primarily due to net loss before tax of RMB 1,305.1 million (USD 204.7 million), offset by certain adjustments of RMB 739.4 million (USD 116.0 million) and a positive working capital change in our operating assets and liabilities of RMB 20.8 million (USD 3.3 million). These adjustments consisted primarily of the fair value changes in financial instruments with preferred rights of RMB 674.3 million (USD 105.8 million), share-based compensation expense of RMB 57.9 million (USD 9.1 million), the net foreign exchange differences of RMB 3.3 million (USD 0.5 million), and depreciation and amortization expense of RMB 4.1 million (USD 0.6 million). The positive working capital change in operating assets and liabilities was primarily due to an increase in trade payables of RMB 56.6 million (USD 8.9 million) due to timing of payments on outstanding payables, offset by an increase in other receivables and prepayments of RMB 16.1 million (USD 2.5 million) driven by clinical trial prepayments to CROs for CBP-201 and CBP-307 and an increase in other non-current assets of RMB 8.2 million (USD 1.3 million) due to higher deductible value-added tax, or VAT, balances which can offset against future VAT payables as well as a decrease in other payables and accruals of RMB 11.5 million (USD 1.8 million) due to timing of payments on outstanding payables.

During the year ended December 31, 2020, net cash used in operating activities was RMB 167.2 million, primarily due to our net loss of RMB 779.2 million, offset by some adjustments of RMB 614.9 million and negative working capital change in our operating assets and liabilities of RMB 2.8 million. These adjustments consisted primarily of the fair value changes of financial instruments with preferred rights of RMB 579.3 million, share-based compensation expense of RMB 25.2 million, the net foreign exchange differences of RMB 6.8 million, and depreciation and amortization expense of RMB 1.4 million. The negative working capital change in operating assets and liabilities was primarily due to an increase in other receivables and prepayments of RMB 9.4 million driven by prepayments to the clinical trials related vendors for CBP-307 and CBP-201 and preparation for the production of CBP-201 to be used in future clinical trials and an increase in other non-current assets of RMB 3.9 million due to higher deductible value-added tax, or VAT, balances which can offset against future VAT payables. These decreases in working capital were offset by an increase in trade payables and an increase in other payables and accruals of RMB 10.4 million due to timing of payments on outstanding payables and increases in research and development activities related to clinical trials for CBP-307 and CBP-201.

Investing Activities

During the year ended December 31, 2021, net cash used in investing activities of RMB 34.0 million (USD 5.3 million) was primarily related to the proceeds from sale of financial assets of RMB 128.0 million (USD 20.1 million) and investment income of RMB 0.4 million (less than USD 0.1 million), partially offset by the purchase of financial assets of RMB 114.5 million (USD 18.0 million), the purchase of property, plant and equipment of RMB 24.9 million (USD 3.9 million), the lease payments of RMB 22.3 million (USD 3.5 million) and the purchase of intangible assets of RMB 0.3 million (less than USD 0.1 million).

During the year ended December 31, 2020, net cash generated from investing activities of RMB 2.9 million was primarily related to the proceeds from disposal of financial assets of RMB 124.8 million, offset by the purchase of financial assets of RMB 106.6 million, the purchase of property, plant and equipment of RMB 15.0 million and the purchase of intangible assets of RMB 0.3 million.

Financing Activities

During the year ended December 31, 2021, net cash generated from financing activities was RMB 1,316.1 million (USD 206.4 million), primarily resulting from the receipt of RMB 1,431.8 million (USD 224.6 million) of gross proceeds from the sales of ordinary shares, partially offset by the payments made to repurchase treasury shares of RMB 3.7 million (USD 0.6 million), the payments in relation to listing expenses of RMB 111.4 million (USD 17.5 million) and the payments of lease liabilities of RMB 0.8 million (USD 0.1 million).

During the year ended December 31, 2020, net cash generated from financing activities was RMB 918.8 million, primarily resulting from the receipt of RMB 923.2 million of proceeds from the issuance of Series C redeemable convertible preferred shares in August and December 2020, partially offset by the related issuance costs related to the Series C Preferred Shares of RMB 2.9 million, the payments in relation to listing expenses of RMB 1.1 million and the principal payments of lease liabilities of RMB 0.5 million.

Material Cash Requirements

As discussed below, our material cash requirements as of December 31, 2021 and any subsequent interim period primarily include our capital expenditures and operating lease obligations. We intend to fund our existing and future material cash requirements with our existing cash balance. We will continue to make cash commitments, including capital expenditures, to support the growth of our business.

138


 

In May 2021, we entered into a Contract for the Transfer of the Right to Use State-Owned Construction Land with the Natural Resources and Planning Bureau of Taicang (the “Land Use Agreement”). Pursuant to this agreement, we obtained the right to use approximately 70,400 square meters of state-owned land located in the Taicang High-Tech Industrial Development Zone for a period of fifty years. We acquired the land use rights to build a research and development laboratory, manufacturing facility and office. As of December 31, 2021, we have paid an aggregate of approximately RMB 22.3 million ($3.5 million) for the land use rights and an additional RMB 7.0 million ($1.1 million) for related construction costs and have recorded those amounts in right-of-use assets and property, plant, and equipment, respectively in our Consolidated Balance Sheets. This construction project is currently on hold until we can obtain the necessary construction permits and therefore are not expecting a significant increase to our capital commitments related to this project during 2022.

In connection with the Land Use Agreement, we entered into Investment Agreement with the Jiangsu Taicang High-tech Industrial Development Zone Management Committee (the “Jiangsu Taicang HIDC”), a local government authority in Taicang. Pursuant to this agreement, the Jiangsu Taicang HIDC has agreed to provide certain financial support and incentives in connection with the development of our facilities contemplated by the Land Use Agreement. As of December 31, 2021, we have provided in pursuant to this agreement approximately RMB 356.2 million ($55.9 million) of cash into its Connect Suzhou research and development operations to fund research, development, and administration expenses at our Taicang facility.

Capital commitments

 

 

Year Ended December 31,

 

 

 

2020

 

2021

 

 

 

RMB’000

 

RMB’000

 

Equipment and intangible assets:

 

 

 

 

 

— Contracted but not provided for

 

23,243

 

146,878

 

 

As of December 31, 2021, we had capital commitments of approximately RMB 146.9 million (USD 23.0 million), primarily in connection with the construction of a campus in Taicang, a project that is currently on hold until we can obtain the necessary construction permits and therefore are not expecting a significant increase to our capital commitments related to this project during 2022. As of December 31, 2020, we had capital commitments of approximately RMB 23.2 million (USD 3.6 million), primarily in connection with the purchase of equipment and improvement of our laboratory in Suzhou.

Other commitments

In December 2021, we entered into the office lease agreement for approximately 3,600 square feet in San Diego, California, and the lease commenced in March 2022. The aggregate lease obligation over the three-year lease term is approximately $0.6 million.

Tabular Disclosure of Contractual Obligations

The table below summarizes our financial liabilities into relevant maturity groupings based on the remaining period at each year-end date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows except for financial instruments with preferred rights, which are presented on a fair value basis. The maturity dates are determined by the terms in financing agreements.

 

 

 

As of December 31, 2020

 

 

 

 

 

 

Between

 

 

Between

 

 

More

 

 

 

 

 

 

Less Than

 

 

1 and

 

 

2 and

 

 

Than

 

 

 

 

 

 

1 Year

 

 

2 Years

 

 

5 Years

 

 

5 Years

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Financial instruments with preferred rights

 

 

 

 

 

 

 

 

2,071,508

 

 

 

 

 

 

2,071,508

 

Trade payables

 

 

24,638

 

 

 

 

 

 

 

 

 

 

 

 

24,638

 

Other payables

 

 

8,631

 

 

 

 

 

 

 

 

 

 

 

 

8,631

 

Lease liabilities

 

 

633

 

 

 

225

 

 

 

94

 

 

 

 

 

 

952

 

Total

 

 

33,902

 

 

 

225

 

 

 

2,071,602

 

 

 

 

 

 

2,105,729

 

 

139


 

 

 

As of December 31, 2021

 

 

 

 

 

 

Between

 

 

Between

 

 

More

 

 

 

 

 

 

Less Than

 

 

1 and

 

 

2 and

 

 

Than

 

 

 

 

 

 

1 Year

 

 

2 Years

 

 

5 Years

 

 

5 Years

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Trade payables

 

 

81,195

 

 

 

 

 

 

 

 

 

 

 

 

81,195

 

Other payables

 

 

21,456

 

 

 

 

 

 

 

 

 

 

 

 

21,456

 

Lease liabilities

 

 

653

 

 

 

186

 

 

 

 

 

 

 

 

 

839

 

Total

 

 

103,304

 

 

 

186

 

 

 

 

 

 

 

 

 

103,490

 

Holding Company Structure

 

We are a holding company that conducts its operations primarily through our various subsidiaries. As a result, our ability to pay dividends depends upon dividends paid to us by our subsidiaries. If our existing subsidiaries or any newly formed subsidiaries of our company incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us. In addition, our PRC subsidiaries are permitted to pay dividends to us only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. Under the PRC law, each of our PRC subsidiaries, and their subsidiaries are required to set aside at least 10% of its after-tax profits each year, if any, to fund specific statutory reserve funds until such reserve funds reach 50% of its registered capital. In addition, each of our PRC subsidiaries may allocate a portion of its after-tax profits based on PRC accounting standards to staff welfare and bonus funds, a discretionary surplus fund and an enterprise expansion fund at its discretion or in accordance with its articles of association. These reserve funds and staff welfare and bonus funds are not distributable as cash dividends. Remittance of dividends by a wholly foreign-owned company out of the PRC is subject to examination by the banks designated by SAFE. Our PRC subsidiaries have not paid dividends and will not be able to pay dividends until they generate accumulated profits and meet the requirements for statutory reserve funds. As of December 31, 2021, the amount restricted, including paid-in capital, as determined in accordance with PRC accounting standards and regulations, was RMB 288.9 million.

C. Research and Development, Patents and Licenses, etc.

 

See “Item 4. Information on the Company—B. Business Overview” and “Item 5. Operating and Financial Review and Prospects—A. Operating Results.”

 

D. Trend Information

See “Item 5. Operating and Financial Review and Prospects—A. Operating Results.”

E. Critical Accounting Estimates

Not Applicable

Safe Harbor

See “Cautionary Statement Regarding Forward-Looking Statements.”

 

140


 

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES.

A. Directors and Senior Management.

Executive Officers and Directors

The following table presents information about our current executive officers and directors, including their ages as of the date of this annual report:

 

Name

 

Age

 

Position

 

Executive Officers

 

 

 

 

 

Zheng Wei, Ph.D. (3)

 

58

 

Chief Executive Officer and Director

 

Wubin Pan, Ph.D.

 

57

 

President and Chairman of the Board of Directors

 

Selwyn Ho, MB BS

 

51

 

Chief Business Officer

 

Steven Chan

 

50

 

Chief Financial Officer

 

Chin Lee, M.D.

 

52

 

Chief Medical Officer

 

 

 

 

 

 

 

Non-Executive Directors

 

 

 

 

Kleanthis G. Xanthopoulos, Ph.D. (1)(2)

 

63

 

Lead Independent Director

 

Derek DiRocco, Ph.D. (2)

 

41

 

Director

 

Kan Chen, Ph.D. (3)

 

40

 

Director

 

Jean Liu (1)(3)

 

53

 

Director

 

Karen J. Wilson (1)(2)

 

58

 

Director

 

 

(1)
Audit committee member
(2)
Compensation committee member
(3)
Nominating and Corporate Governance committee member

The current business address for our executive officers and board of directors is c/o Connect Biopharma Holdings Limited, Science and Technology Park, East R&D Building, 3rd Floor 6 Beijing West Road, Taicang, Jiangsu Province, The People’s Republic of China.

The following are brief biographies of our executive officers and directors:

Executive Officers

Zheng Wei, Ph.D. Dr. Wei is a co-founder of the company and has served as our Chief Executive Officer and a member of our board of directors since our inception in 2012. Prior to that, Dr. Wei was Director of Immunology at Arena Pharmaceuticals, Inc. from December 2007 to March 2011, where he oversaw its immunology discovery programs. Prior to this role, Dr. Wei was a scientist and program leader at ChemoCentryx, Inc. from April 1998 to September 2007. Prior to this role, Dr. Wei was a scientist at Glycomed, Inc. (acquired by Ligand Pharmaceuticals Incorporated) from September 1992 to November 1995. Before joining Glycomed, Inc., Dr. Wei also conducted immunology research at Stanford University School of Medicine. Dr. Wei received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis and his bachelor’s degree in Biology from South China Normal University. We believe that Dr. Wei is qualified to serve as a member of our board of directors based on his deep knowledge of our business and his extensive development, commercial and executive management experience.

Wubin Pan, Ph.D. Dr. Pan is a co-founder of the company and has served as our President and Chairman of our board of directors since May 2012. Previously, Dr. Pan co-founded and led Crown Bioscience Inc., a venture-backed contract research organization, from June 2006 to October 2011. During this tenure, he served in various executive leadership positions at the company, including PRC President, Chief Operation Officer and Executive Vice President. Prior to this role, Dr. Pan was the Vice President at TsingHuaYuanXing Biopharmaceutical Co. Ltd. from November 2000 to May 2006. Prior to that, Dr. Pan worked as a research scientist with TerraGen Discovery Inc. (acquired by Cubist Pharmaceuticals) from October 1996 to October 2000. Dr. Pan obtained his Ph.D. in Biochemistry from University of Sussex and completed postdoctoral training at the University of California at Berkeley. He holds an M.B.A. from Tsing-Hua University and an M.S. in Pharmacology and a B.S. in Zoology, both from Sun Yat-sen University. We believe that Dr. Pan is qualified to serve as Chairman of our board of directors based on his extensive knowledge of our business and his senior executive and board-level experience at biopharmaceutical companies.

141


 

Selwyn Ho, MB BS. Dr. Ho has served as our Chief Business Officer since January 2021 and previously as an adviser to our company since May 2019 in his capacity as Consultant and Managing Director of Artemis Catalyst Ltd., a U.K.-based management consulting firm. Dr. Ho has served in this role at Artemis Catalyst Ltd. since he founded the company in October 2017. In his capacity as a consultant, Dr. Ho has served as an advisor to several biopharmaceutical companies and private capital markets firms including: Boerhinger Ingelheim, from October 2020 to January 2021; Oculis S.A., from February 2020 to October 2020; New Rhein Healthcare Investors, from December 2019 to December 2020; Pharming NV, from February 2020 to April 2020; Argenx S.A., from May 2019 to November 2019; Dermira Inc., a biopharmaceutical company acquired by Eli Lilly in Jan 2020, from February 2019 to April 2019; UCB S.A., from October 2018 to March 2020; Kala Pharmaceuticals, from December 2017 to February 2018; and Oxular Ltd., from October 2017 to May 2019. Dr. Ho has been an Executive-In-Residence at New Rhein Healthcare Investors, a venture capital and growth stage fund manager focused on healthcare therapeutics and medical devices since July 2020. Prior to his consulting work, Dr. Ho held several leadership positions at biopharmaceutical companies. He was Vice President, Head of Market Access and Vice President, Head of Strategic Marketing, at Dermira Inc. from September 2016 to September 2017. Prior to this role, Dr. Ho served as Vice President, Head of International Markets, from March 2015 to September 2016, and Vice President, Global Missions Lead, Cimzia, from March 2013 to March 2015, at UCB S.A. Dr. Ho has been a qualified Medical Doctor since 1994. He obtained his Bachelor of Medicine and Bachelor of Surgery (MB BS) and his BSc in Pharmacology with Basic Medical Sciences from Imperial College of Science, Technology & Medicine, University of London.

Steven Chan. Mr. Chan has served as our Chief Financial Officer since November 2021. Previously, Mr. Chan served as Chief Financial Officer at Delphon Industries LLC, a global materials manufacturer, from April 2019 to November 2021. Prior to this role, from April 2017 to April 2019, Mr. Chan was Vice-President, Finance and Corporate Controller at Arcus Biosciences, Inc. Mr. Chan also served as Vice-President, Finance and Corporate Controller at MyoKardia, Inc. from November 2014 to March 2017 and as Vice-President, Corporate Controller at Solta Medical, Inc. from June 2010 to November 2014. Mr. Chan received a B.S. in Business Administration from the University of California at Berkeley, Haas School of Business and is a Certified Public Accountant in California (inactive status).

Chin Lee, M.D., M.P.H., Dr. Lee has served as our Chief Medical Officer since March 1, 2022. Previously, Dr. Lee had served as Vice President, Head of Clinical Science, and Chief Medical Officer at Theravance Biopharma, Inc., since April 2021. Prior to this role, from January 2018 to April 2021, Dr. Lee was Lead Group Medical Director within the Genentech Research & Early Development group at Genentech, Inc. Previously, Dr. Lee held roles of increasing responsibility at Eli Lilly & Company from January 2010 to January 2018, serving most recently as Global Senior Medical Director, Immunology Therapeutic Area within the Bio-medicines Business Unit, and he also served as Associate Medical Director, Immunoscience Group, at Abbott Laboratories from September 2006 to January 2010. Dr. Lee received a B.S. in Biology and an M.D. from the University of North Carolina at Chapel Hill and an M.P.H. from Northwestern University Feinberg School of Medicine.

Non-Executive Directors

Kleanthis G. Xanthopoulos, Ph.D. Dr. Xanthopoulos has served as a member of our board of directors since December 2020 and as our Lead Independent Director since January 2022. Dr. Xanthopoulos is currently the Chairman and Chief Executive Officer of Shoreline Biosciences Inc., and Chairman of Stork Capital Life Sciences which focuses on building and investing in innovative biotechnology companies. Dr. Xanthopoulos was Chief Executive Officer of IRRAS AB a publicly traded medical technology company from 2015 to 2021. He was a Managing General Partner at Cerus DMCC, from 2015 to 2020. Previously, he served as President and Chief Executive Officer of Regulus Therapeutics Inc. from the time of its formation in 2007 until June of 2015. Prior to that, he was a Managing Director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. from its inception in 2000 to 2006 and remained a director until its acquisition by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals, Inc.) from 1997 to 2000. Dr. Xanthopoulos also co-founded and served as the first President and Chief Executive Officer of Sente Labs, and a member of the board of Shoreline Biosciences, a cell therapy company, and IRRAS AB. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Prior to this, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. In addition to being a director at Shoreline Biosciences and IRRAS AB, Dr. Xanthopoulos is also a member of the board of directors of Zosano Pharma, Inc and Sente Labs. Dr. Xanthopoulos received his B.S. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos has over 45 peer review publications and several issued patents. We believe that Dr. Xanthopoulos’s senior executive experience managing and developing a major biotechnology company and his extensive industry knowledge and leadership experience in the life sciences industry qualify him to serve as a member of our board of directors.

 

142


 

Derek DiRocco, Ph.D. Dr. DiRocco has served as a member of our board of directors since August 2020. Dr. DiRocco has been a principal at RA Capital Management since December 2017 and was previously an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco has served on the boards of directors of iTeos Therapeutics, Inc., CANbridge Pharmaceuticals Inc., Achilles Therapeutics Ltd. and 89bio, Inc. since March 2020, February 2020, September 2019 and May 2018, respectively. Dr. DiRocco holds a B.A. in Biology from College of the Holy Cross and a Ph.D. in Pharmacology from the University of Washington. We believe that Dr. DiRocco is qualified to serve as a member of our board of directors because of his experience as an investor in biopharmaceutical companies and his roles in early-stage companies.

Kan Chen, Ph.D. Dr. Chen has served as a member of our board of directors since December 2020. Dr. Chen is currently a partner and previously a principal at Qiming Weichuang Venture Capital Management (Shanghai) Co. Ltd., where he has served with a focus on healthcare investment since February 2016. Dr. Chen has also served on the boards of directors of Zion Pharma Limited, Kira Pharmaceuticals and Abbisko Therapeutics since August 2020, April 2020 and February 2020, respectively. From October 2014 to January 2016, Dr. Chen was a senior scientist at Johnson & Johnson, where he focused on cancer medicine. Prior to that, Dr. Chen was a group leader at Jiangsu Hengrui Medicine, where he specialized in cancer immunotherapies. Dr. Chen completed his postdoctoral training in immunology at Harvard Medical School, earned his Ph.D. in Cell Biology from Case Western Reserve University and earned his B.S. in Biological Sciences from Fudan University. We believe that Dr. Chen is qualified to serve as a member of our board of directors because of his experience as an investor in biopharmaceutical companies and his expertise in immunology and drug discovery.

Jean Liu. Ms. Liu has served as a member of our board of directors since August 2021. Ms. Liu is the Chief Legal Officer at Seagen Inc., a global, multi-product biotechnology company, where she has served since 2014. Previously, Ms. Liu served as the Vice President of General Counsel at Halozyme Therapeutics, Inc. and as the Chief Legal Officer and Corporate Secretary at Durect Corporation. Earlier in her career, Ms. Liu was an attorney at Pillsbury, Madison & Sutro LLP (now Pillsbury Winthrop Shaw Pittman LLP) and Venture Law Group, where she advised on technology transfer, licensing, patents, and copyright and trademark litigation. Ms. Liu holds a B.S. in Cellular and Molecular Biology from the University of Michigan, an M.S. in Biology from Stanford University, and a J.D. from Columbia University. We believe Ms. Liu is qualified to serve as a member of our board of directors because of her legal expertise and senior executive experience in biopharmaceutical companies.

Karen J. Wilson. Ms. Wilson has served as a member of our board of directors since December 2020. Ms. Wilson is also currently a member of the boards of directors of Angion Biomedica, LAVA Therapeutics B.V. and Vaxart, Inc. Ms. Wilson served as Senior Vice President of Finance at Jazz Pharmaceuticals plc until September 2020 after serving as Vice President of Finance and Principal Accounting Officer. Prior to joining the Jazz Pharmaceuticals organization in February 2011, Ms. Wilson served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc. from 2009 to January 2011. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley. We believe that Ms. Wilson is qualified to serve as a member of our board of directors because of her expertise in finance and accounting and her senior executive experience in the pharmaceutical industry.

Family Relationships

There are no family relationships among any of our executive officers or directors.

B. Compensation

The aggregate compensation awarded to, earned by and paid to our current directors and executive officers who were employed by or otherwise performed services for us for the fiscal year ended December 31, 2021 was approximately $7.3 million (using an exchange rate of RMB 6.3757 to $1.00, which represents the exchange rate as of December 31, 2021 set forth in the China Foreign Exchange Trade System, for RMB denominated compensation). Our PRC subsidiaries are required by law to make contributions equal to specific percentages of each employee’s salary for his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing provident fund. The total amount set aside or accrued by us to provide pension, retirement or similar benefits to our current directors and executive officers who were employed by or otherwise performed services for us with respect to the fiscal year ended December 31, 2021 was $0.1 million (using an exchange rate of RMB 6.3757 to $1.00, which represents the exchange rate as of December 31, 2021 set forth in the China Foreign Exchange Trade System, for RMB denominated compensation).

 

In 2021, our executive officers had the opportunity to earn annual cash bonuses to compensate them for attaining company and individual performance goals. Each officer had an annual target bonus for 2021 that is expressed as a percentage of his or her annual base salary. Awards under the bonus plan for 2021 were generally based on company-wide objectives related to our clinical

143


 

development programs and individual contributions and were determined by our Compensation Committee. Amounts paid in respect of these annual bonuses are included in the aggregate compensation amount shown in the paragraph above.

 

Our board of directors has adopted a non-employee director compensation program, or the Director Compensation Program, which became effective as of January 1, 2022. The Director Compensation Program is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our directors’ interests with those of our stockholders. Directors who are also employees of our Company or our significant investors do not receive compensation for their service on our board of directors. We have reimbursed, and will continue to reimburse, our non-employee directors for their actual out-of-pocket costs and expenses incurred in connection with attending board meetings.

 

Under the Director Compensation Program, non-employee directors receive a cash retainer for service on our board of directors and for service on each committee of which the director is a member. Our Lead Independent Director and the Chairperson of each committee of our board receive a higher retainer for such service. Cash retainers are payable quarterly in arrears. Annual cash retainers will be pro-rated for any partial calendar quarter of service. In addition, under this program, each of our non-employee directors receives an annual grant of options vesting on the first anniversary of the grant date or upon a change of control of our Company (as defined in our 2021 Stock Incentive Plan). Under the Director Compensation Program, the annual fees and equity awards for our non-employee directors are as follows:

 

Role

 

Annual retainer

 

Annual option award

Non-employee Director

 

$35,000

 

21,269 shares

Lead Independent Director

 

$17,500

 

7,090 shares

Audit Committee Chair

 

$15,000

 

Audit Committee Member

 

$7,500

 

Compensation Committee Chair

 

$10,000

 

Compensation Committee Member

 

$7,500

 

Nominating Committee Chair

 

$10,000

 

Nominating Committee Member

 

$7,500

 

 

As of December 31, 2021, options to purchase 1,890,232 ordinary shares granted to our executive officers and directors were outstanding under our equity incentive plans at a weighted average exercise price of $8.99 per ordinary share. In addition, thus far in 2022, we have approved the grant of additional options to purchase 800,800 ordinary shares at a weighted average exercise price of $4.12 per ordinary share, in the aggregate, to our executive officers and directors. Options under our equity incentive plans expire no later than ten years following the date of grant.

Employment Agreements with Executive Officers

We have entered into employment agreements with each of our executive officers. Under these agreements, some of our executive officers are employed for specified time periods. We may terminate employment for cause, at any time, for specific acts of the executive officer.

 

Each executive officer has agreed to hold, both during and after the termination or expiry of his or her employment agreement, in strict confidence and not to use, except as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential information or trade secrets of our business partners, or the confidential or proprietary information of any third party received by us and for which we have confidential obligations. The executive officers have also agreed to disclose in confidence to us all inventions, designs and trade secrets which they conceive, develop or reduce to practice during the executive officer’s employment with us and to assign all right, title and interest in them to us, and assist us in obtaining and enforcing patents, copyrights and other legal rights for these inventions, designs and trade secrets.

Employment Agreement with Wubin Pan

 

Effective January 1, 2021, Connect Biopharma HongKong Limited and its affiliates entered into an employment agreement with Dr. Wubin Pan setting forth the terms of his employment as the President and Chairman of Connect Biopharma HongKong Limited and our company. Pursuant to the agreement, Dr. Pan is entitled to an annual base salary of $495,000 ($512,000 effective from January 1, 2022), which amount may not be reduced but is subject to annual review by and at the sole discretion of our board of directors or its designee. Dr. Pan’s employment agreement provides that he may be eligible to earn an annual performance-based bonus with a target amount equal to 50% of his annual base salary.

 

144


 

Pursuant to his employment agreement, if we terminate Dr. Pan’s employment other than for cause or Dr. Pan terminates his employment for good reason (each as defined in his employment agreement), he is entitled to the following payments and benefits, subject (except for item below) to his timely execution and non-revocation of a general release of claims in favor of the company: (1) his fully earned but unpaid base salary and accrued and unused paid time off through the date of termination at the rate then in effect, any annual bonus payable for any prior calendar year (to the extent not previously paid), plus all other amounts under any compensation plan or practice to which he is entitled; (2) a payment equal to 12 months of his then-current base salary, payable in a lump sum payment 60 days following the termination date; (3) a payment equal to his prorated target annual bonus for the calendar year in which the termination date occurs, payable in a lump sum payment 60 days following the termination; and (4) payment of the health insurance premiums for him and his eligible dependents until the earliest of (a) the expiration of 18 months following his termination date or (b) the date he becomes eligible for health insurance coverage in connection with his new employment. In the event that such termination occurs during the period beginning two (2) months prior to and ending twelve (12) months following a change in control of our company (or with respect to equity awards granted under the 2019 Stock Incentive Plan, the corporate transaction) (as defined in his employment agreement) (or with respect to equity awards granted under the 2019 Stock Incentive Plan, the corporate transaction (as defined therein)), in addition to the severance benefits provided above, all of Dr. Pan’s equity awards will vest on an accelerated basis as of the later of the date of termination or the date of the change in control (provided that if any equity award is subject to more favorable vesting conditions, such more favorable provisions shall apply).

 

In the event we terminate Dr. Pan’s employment for cause, he terminates his employment without good reason, or upon his death or permanent disability, he is entitled to receive only his fully earned but unpaid base salary and accrued and unused paid time off through the date of termination at the rate then in effect, any annual bonus payable for any prior calendar year (to the extent not previously paid), plus all other amounts under any compensation plan or practice to which he is entitled.

 

Pursuant to his employment agreement, Dr. Pan is subject to a one-year post-termination non-solicitation covenant and a perpetual non-disparagement covenant, in addition to a noncompetition covenant that applies during the employment term and his obligations under the Company’s standard proprietary information and inventions assignment agreement.

 

Employment Agreement with Zheng Wei

 

Effective January 1, 2021, Connect Biopharm LLC and its affiliates entered into an employment agreement with Dr. Zheng Wei setting forth the terms of his employment as the Chief Executive Officer of Connect Biopharm LLC and our company. Pursuant to the agreement, Dr. Wei is entitled to an annual base salary of $495,000 ($539,000 effective from January 1, 2022), which amount may not be reduced but is subject to annual review by and at the sole discretion of our board of directors or its designee. Dr. Wei’s employment agreement provides that he may be eligible to earn an annual performance-based bonus with a target amount equal to 50% of his annual base salary.

 

Pursuant to his employment agreement, if we terminate Dr. Wei’s employment other than for cause or Dr. Wei terminates his employment for good reason (each as defined in his employment agreement), he is entitled to the following payments and benefits, subject (except for item below) to his timely execution and non-revocation of a general release of claims in favor of the company: (1) his fully earned but unpaid base salary and accrued and unused paid time off through the date of termination at the rate then in effect, any annual bonus payable for any prior calendar year (to the extent not previously paid), plus all other amounts under any compensation plan or practice to which he is entitled; (2) a payment equal to 12 months of his then-current base salary, payable in a lump sum payment 60 days following the termination date; (3) a payment equal to his prorated target annual bonus for the calendar year in which the termination date occurs, payable in a lump sum payment 60 days following the termination date; and (4) payment of the COBRA premiums for him and his eligible dependents until the earliest of (a) the expiration of 18 months following his termination date, (b) expiration of his eligibility for continuation coverage under COBRA, or (c) the date he becomes eligible for health insurance coverage in connection with his new employment. In the event that such termination occurs during the period beginning two (2) months prior to and ending twelve (12) months following a change in control of our company (as defined in his employment agreement) (or with respect to equity awards granted under the 2019 Stock Incentive Plan, the corporate transaction (as defined therein)), in addition to the severance benefits provided above, all of Dr. Wei’s equity awards will vest on an accelerated basis as of the later of the date of termination or the date of the change in control (or with respect to equity awards granted under the 2019 Stock Incentive Plan, the corporate transaction) (provided that if any equity award is subject to more favorable vesting conditions, such more favorable provisions shall apply).

 

In the event we terminate Dr. Wei’s employment for cause, he terminates his employment without good reason, or upon his death or permanent disability, he is entitled to receive only his fully earned but unpaid base salary and accrued and unused paid time off through the date of termination at the rate then in effect, any annual bonus payable for any prior calendar year (to the extent not previously paid), plus all other amounts under any compensation plan or practice to which he is entitled.

 

145


 

Pursuant to his employment agreement, Dr. Wei is subject to a one-year post-termination non-solicitation covenant and a perpetual non-disparagement covenant, in addition to a noncompetition covenant that applies during the employment term and his obligations under the Company’s standard proprietary information and inventions assignment agreement.

 

Employment Arrangements with Selwyn Ho

 

U.S. Employment Offer Letter. On January 19, 2021, Connect Biopharm LLC entered into an offer letter with Dr. Selwyn Ho setting forth the terms of his employment as the Senior Vice President of Corporate Development and Chief Business Officer of Connect Biopharm LLC. Pursuant to the offer letter, prior to his relocation to the Unites States, Dr. Ho will be employed full-time under a UK employment contract through Globalization Partners Limited for up to twelve months, on substantially the same financial terms as the offer letter. The terms of the UK employment contract are summarized below under the heading “UK Contract of Employment”.

 

Pursuant to the offer letter, Dr. Ho will be entitled to an annual base salary of $350,000 ($385,000 effective from January 1, 2022) and an annual performance-based bonus with a target amount equal to 40% of his annual base salary. Dr. Ho’s employment in the US will be at-will. Dr. Ho will also be eligible to receive a relocation lump sum payment equal to $100,000 USD and reimbursement of some expenses in connection with his relocation to the US.

 

Pursuant to the offer letter, if Dr. Ho’s employment (including under the UK contract) is terminated without cause, as a result of a change in control of our company, or as a result of a constructive termination (each as defined in his offer letter), he will be entitled to the following payments and benefits, subject to his execution of a general release of claims in favor of the company: (1) a payment equal to 9 months of his then-current base salary plus his prorated target annual bonus for the calendar year in which the termination date occurs, payable in a lump sum payment within 5 days following the expiration of the release revocation period (subject to Section 409A of the Code); and (2) payment of COBRA premiums until the earliest of (a) the expiration of 9 months following his termination date, (b) expiration of his eligibility for continuation coverage under COBRA, or (c) the date he becomes eligible for health insurance coverage in connection with his new employment. In the event that Dr. Ho’s employment (including under the UK contract) is terminated without cause during the period beginning two (2) months prior to and ending twelve (12) months following a change in control or corporate transaction of our company (as defined in his offer letter), subject to his execution of a release, all of Dr. Ho’s outstanding equity awards will become fully vested. Any severance amounts payable under the offer letter will be reduced by the amount of any notice, severance, redundancy pay or payment in lieu of notice to which Dr. Ho is entitled under English employment law or other applicable law at the time of termination.

 

The employment agreement also includes a “best pay” provision under Section 280G of the Code, pursuant to which any “parachute payments” that become payable to Dr. Ho will either be paid in full or reduced so that such payments are not subject to the excise tax under Section 4999 of the Code, whichever results in the better after-tax treatment to Dr. Ho.

 

Dr. Ho was also required to execute the Company’s confidential information and invention assignment agreement as a condition to his employment under the offer letter.

 

UK Contract of Employment. On January 20, 2021, Globalization Partners Limited (GPL) entered into a contract of employment with Dr. Ho, pursuant to which Dr. Ho will serve as Senior Vice President of Corporate Development and Chief Business Officer of Connect Biopharm LLC while based in the UK. Pursuant to the contract of employment, Dr. Ho is entitled to an annual base salary of £257,000 GBP, and is eligible to earn an annual bonus with a target amount equal to 40% of his annual base salary. Unless he opts out, Dr. Ho will be contractually enrolled in GPL’s workplace pension scheme, under which GPL will make a pension contribution equal to four percent of his base salary and Dr. Ho must make a contribution equal to five percent of his base salary during each year of employment. Under the contract of employment, Dr. Ho’s employment may be terminated by him or by GPL with one week’s notice in writing (or, for GPL, payment in lieu of notice). Under the contract, Dr. Ho is subject to a three-month post-termination non-competition covenant applying to Connect Biopharm LLC, a twelve-month service provider non-solicitation covenant applying to both GPL and Connect Biopharm LLC, and a twelve-month customer non-solicitation covenant applying to Connect Biopharm LLC, in addition to an indefinite confidentiality provision and intellectual property rights and inventions provisions.

 

Offer Letters with Steven Chan and Chin Lee

Connect Biopharm LLC entered into an offer letter with each of Steven Chan and Chin Lee, dated October 11, 2021 and October 28, 2021, respectively, setting forth the terms of employment as the Chief Financial Officer and Chief Medical Officer, respectively, of Connect Biopharm LLC and its affiliates. Pursuant to the offer letters, of Mr. Chan and Dr. Lee is entitled to receive (i) an annual base salary ($410,000 for Mr. Chan and $440,000 for Dr. Lee), (ii) an annual discretionary bonus with a target amount equal to 40% of his annual base salary, (iii) an option to purchase 310,000 ordinary shares of Connect Biopharma Holdings Limited, (v) for Mr. Chan, a

146


 

one-time sign-on bonus of $75,000 (subject to full or partial repayment in the event of his voluntary termination of employment within two years of his start date), and (vi) for Mr. Chan, reimbursement of moving expenses up to $50,000.

Pursuant to an addendum to each offer letter, if we terminate Mr. Chan or Dr. Lee’s employment without cause or the executive terminates his employment as a result of a constructive termination (each as defined in the applicable offer letter), he is entitled to the following payments and benefits, subject to his timely execution and non-revocation of a general release of claims in favor of the company and continued compliance with the CIIA (as defined below): (1) a payment equal to (A) nine months of his then-current base salary plus (B) 75% of his target annual bonus for the applicable year, payable in a lump sum payment five days following the effectiveness of the release; and (2) payment of the COBRA premiums for him and his eligible dependents for up to nine months following his termination date. In the event that such termination occurs during the period beginning two months prior to and ending 12 months following a change in control of our company (as defined in the applicable offer letter), in addition to the severance benefits provided above, all of the executive’s outstanding equity awards will vest on an accelerated basis as of the later of the date of termination or the date of the change in control (provided that if any equity award is subject to more favorable vesting conditions, such more favorable provisions shall apply).

Mr. Chan and Dr. Lee entered into our standard employee confidential information and inventions assignment agreement, or CIIA, in connection with the commencement of his employment with us.

 

Limitations on Liability and Indemnification Matters

Cayman Islands law does not limit the extent to which a company’s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our articles of association provide that we shall indemnify our officers and directors against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such directors or officer, other than by reason of such person’s dishonesty, willful default or fraud, in or about the conduct of our company’s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his or her duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.

 

In addition, we have entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers against specific liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of our company.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

 

2021 Stock Incentive Plan

 

Our board of directors and our shareholders have approved our 2021 Stock Incentive Plan, or the 2021 Plan, to provide additional incentives to our employees, directors and consultants and to promote our business.

 

The following paragraphs describe the principal terms of the 2021 Plan.

 

Shares Available for Issuance. The maximum aggregate number of ordinary shares which may be issued pursuant to all awards under the 2021 Plan is (1) 6,000,000 ordinary shares, plus (2) any ordinary shares that are, as of the effective date of the 2021 Plan, (i) available for issuance under the 2019 Plan or (ii) subject to outstanding awards under the 2019 Plan that become available for issuance under the 2021 Plan thereafter in accordance with its terms. The number of ordinary shares initially available for issuance will be increased on the first day of each of our fiscal years during the term of the 2021 Plan commencing with the fiscal year beginning January 1, 2022, by an amount equal to the least of (i) 5% of the total number of ordinary shares issued and outstanding on the last day of the immediately preceding fiscal year; or (ii) such lesser number of shares as may be determined by our board of directors. In no event will more than 60,000,000 shares be issuable upon the exercise of incentive share options (within the meaning of Section 422 of the U.S. Internal Revenue Code) under the 2021 Plan.

 

147


 

As of the effective date of the 2021 Plan, no further grants will be made under the 2019 Plan. However, the 2019 Plan will continue to govern the terms and conditions of the outstanding awards granted under it.

 

Types of Awards. The 2021 Plan will permit the awards of options, share appreciation rights, restricted shares, restricted share units, dividend equivalent rights or other stock- or cash-based awards that the plan administrator determines to award under the 2021 Plan.

 

Plan Administration. Our board of directors or a committee designated by the board of directors will administer the 2021 Plan. The committee or the full board of directors, as applicable, will have the authority to (i) determine whether and the total number of awards to be granted in any fiscal year; (ii) determine the fair market value and exercise price set forth in the notice of stock option award and the award agreements; (iii) approve forms of award agreements for use under the 2021 Plan and amend terms of the award agreements, (iv) amend the terms of any outstanding awards granted under the 2021 Plan, provided that any amendment that would adversely affect a grantee’s rights under an outstanding award in material aspects will not be made without the grantee’s written consent, (v) construe and interpret the terms of the 2021 Plan and awards, including any notice of award or award agreement and (vi) exercise such other powers provided by the 2021 Plan, any award agreement or notice of award. In addition, our board of directors may authorize one or more officers of directors to grant awards under the 2021 Plan, and delegate authority under the 2021 Plan to such officers. We expect that our compensation committee will administer the 2021 Plan generally, other than awards to non-employee directors, which shall continue to be administered by our board of directors.

 

Award Agreement. Awards granted under the 2021 Plan will be evidenced by an award agreement that sets forth terms, conditions and limitations for each award, which may include the term of the award, the provisions applicable in the event of the grantee’s employment or service terminates, and our authority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind the award.

 

Eligibility. We may grant awards to employees, directors and consultants of our company and its related entities. However, we may grant options that are intended to qualify as incentive share options only to our employees and employees of our parent companies and subsidiaries.

 

Vesting Schedule. In general, the plan administrator will determine the vesting schedule, which will be specified in the relevant award agreement.

 

Exercise of Awards. The plan administrator will determine the exercise price or purchase price, as applicable, for each award, which will be stated in the award agreement. The vested portion of option will expire if not exercised prior to the time as the plan administrator determines at the time of its grant. However, the maximum exercisable term is ten years from the date of grant.

 

Transfer Restrictions. Awards may not be transferred in any manner by the recipient other than by will or the laws of descent and distribution, except as otherwise provided by the plan administrator.

 

Termination and Amendment of the 2021 Plan. Unless terminated earlier, the 2021 Plan has a term of ten years from the date of our board of directors’ initial adoption of the 2021 Plan. Our board of directors or the compensation committee has the authority to amend or terminate the plan, subject to shareholder approval to the extent necessary to comply with applicable law. However, no such action may adversely affect in any material way any awards previously granted unless agreed by the recipient.

2019 Stock Incentive Plan

Our shareholders and our board of directors adopted our 2019 Stock Incentive Plan, or the 2019 Plan, in November 2019 to provide additional incentives to our employees, directors and consultants and to promote our business. As of the date of this annual report, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards under the 2019 Plan is 2,570,864 ordinary shares.

 

The following paragraphs describe the principal terms of the 2019 Plan.

 

Types of Awards. The 2019 Plan permits the awards of options, share appreciation rights, restricted shares, restricted share units, dividend equivalent rights or any other type of awards that the plan administrator determines to award under the 2019 Plan.

 

Plan Administration. Our board of directors or a committee designated by the board of directors, constituted of one or more members of the board of directors, administers the 2019 Plan. The committee or the full board of directors, as applicable, has the authority to (i) determine whether and the total number of awards to be granted in any fiscal year; (ii) determine the fair market value and exercise price set forth in the notice of stock option award and the award agreements; (iii) approve forms of award agreements for use under the 2019 Plan and amend terms of the award agreements, (iv) amend the terms of any outstanding awards granted under the 2019 Plan, provided that any amendment that would adversely affect a grantee’s rights under an outstanding award in material aspects will not be

148


 

made without the grantee’s written consent, (v) construe and interpret the terms of the 2019 Plan and awards, including any notice of award or award agreement and (vi) exercise such other powers provided by the 2019 Plan, any award agreement or notice of award. In addition, our board of directors may authorize one or more officers of directors to grant awards under the 2019 Plan, and delegate authority under the 2019 Plan to such officers.

 

Award Agreement. Awards granted under the 2019 Plan are evidenced by an award agreement that sets forth terms, conditions and limitations for each award, which may include the term of the award, the provisions applicable in the event of the grantee’s employment or service terminates, and our authority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind the award.

 

Eligibility. We may grant awards to employees, directors and consultants of our company and its related entities. However, we may grant options that are intended to qualify as incentive share options only to our employees and employees of our parent companies and subsidiaries.

 

Vesting Schedule. In general, the plan administrator determines the vesting schedule, which is specified in the relevant award agreement.

 

Exercise of Awards. The plan administrator determines the exercise price or purchase price, as applicable, for each award, which is stated in the award agreement. The vested portion of option will expire if not exercised prior to the time as the plan administrator determines at the time of its grant. However, the maximum exercisable term is ten years from the date of grant.

 

Transfer Restrictions. Awards may not be transferred in any manner by the recipient other than by will or the laws of descent and distribution, except as otherwise provided by the plan administrator.

 

Termination and Amendment of the 2019 Plan. Unless terminated earlier, the 2019 Plan has a term of ten years from the date of our board of directors’ initial adoption of the 2019 Plan. Our board of directors has the authority to amend or terminate the plan, subject to shareholder approval to the extent necessary to comply with applicable law. However, no such action may adversely affect in any material way any awards previously granted unless agreed by the recipient.

 

ESOP Entity. Due to regulatory and practical administration issues relating to equity awards in the PRC, we formed Connect Union as a means of facilitating the issuance and delivery of ordinary shares under the 2019 Plan to our employees in the PRC. In connection therewith, we issued 2,570,864 ordinary shares to Connect Union, to hold for the 2019 Plan. Connect Union held the ordinary shares issued by us as a nominee structure, and the ordinary shares of our company to be obtained by employees, directors and consultants upon exercise of the options will come from the ordinary shares of our company held by Connect Union. In September 2021, Connect Union surrendered 2,570,864 ordinary shares to us and ceased holding ordinary shares issued by us under the nominee structure.

 

2021 Employee Share Purchase Plan

Effective the day prior to the first public trading date of our ordinary shares, we adopted and our shareholders approved the 2021 Employee Share Purchase Plan, or the 2021 ESPP, the material terms of which are summarized below.

 

The 2021 ESPP is comprised of two distinct components in order to provide increased flexibility to grant options to purchase shares under the 2021 ESPP to U.S. and to non-U.S. employees. Specifically, the 2021 ESPP authorizes (1) the grant of options to U.S. employees that are intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Code (the “Section 423 Component”) and (2) the grant of options that are not intended to be tax-qualified under Section 423 of the Code to facilitate participation for employees located outside of the U.S. who do not benefit from favorable U.S. federal tax treatment and to provide flexibility to comply with non-U.S. law and other considerations (the “Non-Section 423 Component”). Where permitted under local law and custom, we expect that the Non-Section 423 Component will generally be operated and administered on terms and conditions similar to the Section 423 Component.

 

Shares Available for Awards; Administration. A total of 600,000 ordinary shares are initially reserved for issuance under the 2021 ESPP. In addition, the number of shares available for issuance under the 2021 ESPP will be annually increased on January 1 of each calendar year beginning in 2022 and ending in and including 2031, by an amount equal to the lesser of (A) 1% of the ordinary shares outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares as is determined by our board of directors, provided that no more than 12,000,000 ordinary shares may be issued under the Section 423 Component. Our board of directors or a committee of our board of directors administers and have authority to interpret the terms of the 2021 ESPP and determine eligibility of participants. The compensation committee is the initial administrator of the 2021 ESPP.

 

149


 

Eligibility. All of our employees will be eligible to participate in the 2021 ESPP. However, an employee may not be granted rights to purchase shares under our 2021 ESPP if the employee, immediately after the grant, would own (directly or through attribution) shares possessing 5% or more of the total combined voting power or value of all classes of our shares.

 

Grant of Rights. Shares will be offered under the 2021 ESPP during offering periods. The length of the offering periods under the 2021 ESPP will be determined by the plan administrator and may be up to twenty-seven months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The purchase dates for each offering period will be the final trading day in the offering period. Offering periods under the 2021 ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. In non-U.S. jurisdictions where participation in the 2021 ESPP through payroll deductions is prohibited, the plan administrator may provide that an eligible employee may elect to participate through contributions to the participant’s account under the 2021 ESPP in a form acceptable to the 2021 ESPP administrator in lieu of or in addition to payroll deductions.

 

The 2021 ESPP permits participants to purchase ordinary shares through payroll deductions of up to a specified percentage of their eligible compensation. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period. In addition, no employee will be permitted to accrue the right to purchase shares under the Section 423 Component at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our ordinary shares as of the first day of the offering period).

 

On the first trading day of each offering period, each participant will automatically be granted an option to purchase our ordinary shares. The option will expire at the end of the applicable offering period, and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of our ordinary shares on the first trading day of the offering period or on the purchase date. Participants may voluntarily end their participation in the 2021 ESPP at any time during a specified period prior to the end of the applicable offering period, and will be paid their accrued payroll deductions that have not yet been used to purchase ordinary shares. Participation ends automatically upon a participant’s termination of employment.

 

A participant may not transfer rights granted under the 2021 ESPP other than by will or the laws of descent and distribution, and options under the 2021 ESPP are generally exercisable only by the participant.

 

Certain Transactions. In the event of specific non-reciprocal transactions or events affecting our ordinary shares, the plan administrator will make equitable adjustments to the 2021 ESPP and outstanding rights. In the event of specific unusual or non-recurring events or transactions, including a change in control, the plan administrator may provide for (1) either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (2) the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (3) the adjustment in the number and type of shares subject to outstanding rights, (4) the use of participants’ accumulated payroll deductions to purchase shares on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (5) the termination of all outstanding rights.

 

Plan Amendment. The plan administrator may amend, suspend or terminate the 2021 ESPP at any time. However, shareholder approval will be obtained for any amendment that increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the 2021 ESPP or changes the corporations or classes of corporations whose employees are eligible to participate in the 2021 ESPP.

 

Code of Business Conduct and Ethics

Our board of directors has adopted a Code of Business Conduct and Ethics that is applicable to all of our employees, executive officers and directors. The Code of Conduct is available under the “Corporate Governance” section of our website at www.connectbiopharm.com. Our board of directors is responsible for overseeing the Code of Conduct and is required to approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this annual report.

 

150


 

C. Board Practices.

Board Composition

Under our amended and restated memorandum and articles of association, or articles of association, our board of directors must be composed of at least three members, the exact number of members to be determined from time to time by our board of directors. Our directors may be elected by a resolution of our board of directors, or by an ordinary resolution of our shareholders, which requires approval by a simple majority of the votes which are cast at a general meeting by those of our shareholders who, being entitled to do so, attend and vote at such meeting or by the unanimous written consent of our shareholders entitled to vote at such meeting. Our amended and restated memorandum and articles also provide that our directors may be removed with or without cause by the affirmative vote of the holders of at least a majority of the votes of the shareholders present, represented by a proxy or voting by mail at the relevant ordinary shareholders’ meeting, and that any vacancy on our board resulting from the death or resignation of a director may be filled by vote of a majority of our directors then in office. Directors chosen or appointed to fill a vacancy shall be elected by the board for the remaining duration of the current term of the replaced director (if any).

We currently have seven directors. The following table sets forth the names of our directors and the years of their initial appointment as directors.

 

Name

 

Current position

 

      Year of appointment

Wubin Pan, Ph.D.

 

Chairman

 

 2015 (1)

Kleanthis G. Xanthopoulos, Ph.D.

 

Lead Independent Director

 

 2020

Derek DiRocco, Ph.D.

 

Director

 

 2020

Kan Chen, Ph.D.

 

Director

 

 2020

Jean Liu

 

Director

 

 2021

Zheng Wei, Ph.D.

 

Director

 

 2015 (1)

Karen J. Wilson

 

Director

 

 2020

 

 

(1)
Served as a director of Connect SZ since 2012 and continued to serve as a director of our Company following the Reorganization in 2015. See Item 4. “Information on the Company.” for more information.

Wubin Pan, Ph.D., leads our board of directors as the Chairman. The Chairman is primarily responsible for ensuring that the board provides effective governance to the Company. In doing so, the Chairman presides over meetings of the board and of our shareholders. The Chairman takes a lead role in managing the board and facilitates effective communication among directors. He is responsible for overseeing matters pertaining to governance, including the organization, composition and effectiveness of the board and its committees. The Chairman oversees the management of the board’s administrative activities, such as meetings, schedules, agendas, communication and documentation.

Kleanthis G. Xanthopoulos, Ph.D., serves as our Lead Independent Director. The Lead Independent Director provides leadership to the independent directors, liaises on behalf of the independent directors and ensures board effectiveness to maintain high-quality governance of our company and the effective functioning of the board.

Director Independence

As a foreign private issuer, under the listing requirements and rules of Nasdaq, we are not required to have independent directors on our board of directors, except with respect to our audit committee, for which the Nasdaq listing requirements permit specified phase-in schedules.

Our board of directors has determined that, applying the applicable rules and regulations of the SEC and the Nasdaq listing standards, all of our directors, except Dr. Pan and Zheng Wei, Ph.D., qualify as “independent directors.” In making such determination, our board considered the relationships that each non-employee director has with us and all other facts and circumstances our board of directors deemed relevant in determining the director’s independence, including the number of ordinary shares beneficially owned by the director and his or her affiliated entities.

151


 

Role of the Board in Risk Oversight

One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee also monitors compliance with legal and regulatory requirements. Our nominating and corporate governance committee monitors the effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our compensation committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. While each committee is responsible for evaluating some risks and overseeing the management of such risks, our entire board of directors is regularly informed through committee reports about such risks.

Corporate Governance Practices

As a Cayman Islands exempted company incorporated with limited liability, we are subject to various corporate governance requirements under Cayman Islands law. In addition, as a foreign private issuer listed on Nasdaq, we are subject to the Nasdaq corporate governance listing standards. However, Nasdaq’s listing standards provide that foreign private issuers are permitted to follow home country corporate governance practices in lieu of the Nasdaq rules, with some exceptions. Some corporate governance practices in Cayman Islands may differ significantly from corporate governance listing standards. For example, neither the corporate laws of the Cayman Islands nor our amended and restated memorandum and articles require that (i) a majority of our directors be independent, (ii) our compensation committee include only independent directors, or (iii) our independent directors hold regularly scheduled meetings at which only independent directors are present. Other than as set forth below, we currently intend to comply with the corporate governance listing standards of Nasdaq to the extent possible under Cayman Islands law. However, we may choose to change such practices to follow home country practice in the future.

Although we are a foreign private issuer, we are required to comply with Rule 10A-3 of the Exchange Act, relating to audit committee composition and responsibilities. Rule 10A-3 provides that the audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control over the performance of their duties, management of complaints made, and selection of consultants. Under Rule 10A-3, if the laws of a foreign private issuer’s home country require that any such matter be approved by the board of directors or the shareholders of the Company, the audit committee’s responsibilities or powers with respect to such matter may instead be advisory.

In addition, Nasdaq rules require that a listed company specify that the quorum for any meeting of the holders of share capital be at least 33 1/3% of the outstanding shares of the company’s common voting stock. As provided under our post-listing amended and restated memorandum and articles of association, and as permitted by Cayman Islands law, a quorum required for and throughout a meeting of shareholders consists of one or more shareholders entitled to vote and present in person or by proxy or (in the case of a shareholder being a corporation) by its duly authorized representative holding shares which carry in aggregate not less than one-third of all votes attaching to all of our shares in issue and entitled to vote.

Additionally, Nasdaq rules require that the independent directors of listed companies hold regularly scheduled meetings at which only independent directors are present. We intend to follow our Cayman Islands home country practice, rather than complying with this Nasdaq rule.

Further, Nasdaq rules require that listed companies have a nominations committee comprised solely of independent directors. We intend to follow our Cayman Islands home country practice, as described under “—Board Composition,” rather than complying with this Nasdaq rule.

Committees of our Board of Directors

Our board of directors has the following standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and functioning of all of our committees complies with the Cayman Islands Companies Act, the Exchange Act, Nasdaq, and SEC rules and regulations.

 

152


 

Audit Committee of the Board

The audit committee, which consists of Ms. Wilson, Ms. Liu, and Dr. Xanthopoulos, assists the board in overseeing our accounting and financial reporting processes and the audits of our consolidated financial statements. Ms. Wilson serves as Chairman of the committee. The audit committee consists exclusively of members of our board who are financially literate, and Ms. Wilson is considered an “audit committee financial expert” as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations. Our board has determined that all of the members of the audit committee satisfy the “independence” requirements set forth in Rule 10A-3 under the Exchange Act. The audit committee is governed by a charter that complies with Nasdaq rules.

The audit committee’s responsibilities include:

recommending the appointment of the independent auditor to the general meeting of shareholders;
the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit services;
pre-approving the audit services and non-audit services to be provided by our independent auditor before the auditor is engaged to render such services;
evaluating the independent auditor’s qualifications, performance and independence, and presenting its conclusions to the full board on at least an annual basis;
reviewing and discussing with the executive officers, the board and the independent auditor our consolidated financial statements and our financial reporting process; and
approving or ratifying any related person transaction (as defined in our related person transaction policy) in accordance with our related person transaction policy.

The audit committee meets as often as one or more members of the audit committee deem necessary, but in any event will meet at least four times per year. The audit committee meets at least once per year with our independent accountant, without our executive officers being present.

 

Compensation Committee of the Board

The compensation committee, which consists of Dr. Xanthopoulos, Dr. DiRocco, and Ms. Wilson, assists the board in determining executive officer compensation. Dr. Xanthopoulos serves as Chairman of the committee. Under SEC and Nasdaq rules, there are heightened independence standards for members of the compensation committee, including a prohibition against the receipt of any compensation from us other than standard board member fees. Although foreign private issuers are not required to meet this heightened standard, all of our compensation committee members meet this heightened standard.

The compensation committee’s responsibilities include:

identifying, reviewing and proposing policies relevant to executive officer compensation;
evaluating each executive officer’s performance in light of such policies and reporting to the board;
analyzing the possible outcomes of the variable compensation components and how they may affect the compensation of the executive officers;
recommending any equity long-term incentive component of each executive officer’s compensation in line with the compensation policy and reviewing our executive officer compensation and benefits policies generally; and
reviewing and assessing risks arising from our compensation policies and practices.

 

Nominating and Corporate Governance Committee of the Board

The nominating and corporate governance committee, which consists of Ms. Liu, Dr. Wei, and Dr. Chen, assists our board in identifying individuals qualified to become members of our board and executive officers consistent with criteria established by our board and in developing our corporate governance principles. Ms. Liu serves as Chairman of the nominating and corporate governance committee.

The nominating and corporate governance committee’s responsibilities include:

drawing up selection criteria and appointment procedures for board members;
reviewing and evaluating the size and composition of our board and making a proposal for a composition profile of the board at least annually;

153


 

recommending nominees for election to our board and its corresponding committees;
assessing the functioning of individual members of board and executive officers and reporting the results of such assessment to the board; and
developing and recommending to the board rules governing the board, reviewing and reassessing the adequacy of such rules governing the board and recommending any proposed changes to the board.

Duties of Directors

Under Cayman Islands law, our directors owe fiduciary duties to our company, including a duty of loyalty, a duty to act honestly, and a duty to act in what they consider in good faith to be in our best interests. Our directors must also exercise their powers only for a proper purpose. Our directors also owe to our company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree of skill than may reasonably be expected from a person of his or her knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands. In fulfilling their duty of care to us, our directors must ensure compliance with our articles of association, as amended and restated from time to time, and the class rights vested thereunder in the holders of the shares. In some limited exceptional circumstances, a shareholder may have the right to seek damages in our name if a duty owed by our directors is breached. Our board of directors has all the powers necessary for managing, and for directing and supervising, our business affairs. The functions and powers of our board of directors include, among others:

convening shareholders’ annual and extraordinary general meetings and reporting its work to shareholders at such meetings;
declaring dividends and distributions;
appointing officers and determining the term of office of the officers;
exercising the borrowing powers of our company and mortgaging the property of our company; and
approving the transfer of shares in our company, including the registration of such shares in our share register.

 

Terms of Directors and Officers

Our directors may be appointed by a resolution of our board of directors, or by an ordinary resolution of our shareholders. Our directors are not subject to a term of office and hold office until such time as they are removed from office by resolution of the shareholders. A director will cease to be a director if, among other things, the director (i) becomes bankrupt or makes any arrangement or composition with his creditors; (ii) dies or is found to be or becomes of unsound mind, (iii) resigns his or her office by notice in writing to our company, or (iv) without special leave of absence from our board, is absent from three consecutive board meetings and our directors resolve that his or her office be vacated. Our officers are elected by and serve at the discretion of our board of directors. We have entered into employment agreements with our executive officers.

 

D. Employees.

As of December 31, 2021, 2020, and 2019 we had 108, 53 and 26 full-time employees, respectively.

 

The following table shows the approximate number of employees we had at the end of the last two years by the principal business function they performed:

 

 

 

As of December 31,

 

 

2021

 

2020

Research and development

 

69

 

38

General and administrative

 

39

 

15

Total

 

108

 

53

 

 

 

 

 

 

154


 

The following table sets forth the number of employees we had at the end of the last two years by geography:

 

 

 

As of December 31,

 

 

2021

 

2020

 PRC and Hong Kong

 

82

 

49

 United States

 

25

 

3

 Other

 

1

 

1

Total

 

108

 

53

 

None of our employees work under a collective bargaining agreement. We have never experienced labor-related work stoppages or strikes and believe that our relations with our employees are satisfactory.

 

E. Share Ownership.

For information regarding the share ownership of directors and officers, see Item 7.A. “Major Shareholders and Related Party Transactions—Major Shareholders.” For information as to our equity incentive plans, see Item 6.B. “Director, Senior Management and Employees—Compensation—Incentive Programs.”

 

155


 

A. Major Shareholders.

The following table sets forth information relating to the beneficial ownership of our ordinary shares as of March 1, 2022 by:

each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares; and
each member of our board of directors and each of our executive officers.

The number of ordinary shares beneficially owned by each entity, person, board member or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days of March 1, 2022 through the exercise of any option or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person.

The percentage of ordinary shares beneficially owned is computed on the basis of 55,076,319 ordinary shares outstanding as of December 31, 2021 on an as-converted basis. Ordinary shares that a person has the right to acquire within 60 days of March 1, 2022 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all board members and executive officers as a group. Unless otherwise indicated below, the address for each beneficial owner listed is c/o Connect Biopharma Holdings Limited, Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu, The People’s Republic of China 215400.

 

 

 

Name and Address of Beneficial Owner

 

Number of
Shares Beneficially

Owned

 

Percentage of
Shares Beneficially Owned

5% or Greater Shareholders:

 

 

 

 

Entities affiliated with RA Capital Management (1)

 

    6,991,003

 

12.7%

BioFortune Inc. (2)

 

   5,948,929

 

10.8%

Shanghai Minhui Enterprise Management Consulting Partnership (Limited Partnership) (3)

 

   5,306,149

 

9.6%

Entities affiliated with Qiming Venture Partners (4)

 

   4,840,898

 

8.8%

Advantech Capital II Connect Partnership L.P. (5)

 

   4,762,185

 

8.6%

FMR LLC (6)

 

   3,417,564

 

6.2%

 

 

 

 

 

Executive Officers and Directors:

 

 

 

 

Zheng Wei, Ph.D. (7)

 

    6,070,761

 

11.0%

Wubin Pan, Ph.D. (1) (8)

 

    6,135,908

 

11.1%

Selwyn Ho, MB BS (9)

 

       143,674

 

      *

Steven Chan

 

                —

 

      *

Chin Lee, MD, MPH

 

               —

 

     *

Derek DiRocco, Ph.D.

 

                —

 

      *

Kan Chen, Ph.D.

 

                —

 

      *

Jean Liu

 

                —

 

      *

Karen J. Wilson (10)

 

         52,105

 

      *

Kleanthis G. Xanthopoulos, Ph.D. (11)

 

         42,105

 

      *

All directors and executive officers as a group (ten (10) persons)

 

  12,444,553

 

 22.6%

 

* Indicates beneficial ownership of less than 1% of the total outstanding ordinary shares.

(1)
Consists of (i) 5,988,348 ordinary shares held by RA Capital Healthcare Fund, L.P., or RA Capital, and (ii) 1,002,655 ordinary shares held by RA Capital Nexus Fund, L.P., or Nexus Fund. RA Capital Management, L.P. is the investment manager for RA Capital and Nexus Fund. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are managing members. RA Capital Management, L.P., RA Capital Management GP, LLC, Mr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the shares held by RA Capital and Nexus Fund. RA Capital Management, L.P., RA Capital Management GP, LLC, Mr. Kolchinsky and Mr. Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the RA Capital entities is 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116.
(2)
Includes 5,948,929 ordinary shares held by BioFortune Inc., a company limited by shares organized under the laws of the British Virgin Islands. Wubin Pan, Ph.D., our President and Chairman of our board of directors, is the sole shareholder of BioFortune Inc. and may be

156


 

deemed to have voting and investment power over such shares. Dr. Pan disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The registered address of BioFortune Inc. is Coastal Building, Wickham’s Cay II, P. O. Box 2221, Road Town, Tortola, British Virgin Islands.
(3)
Consists of 5,306,149 ordinary shares held by Shanghai Minhui Enterprise Management Consulting Partnership (Limited Partnership), a limited partnership formed under the laws of the PRC. Suzhou Xiangtang Venture Investment Limited, a limited liability company organized under the laws of the PRC and the ultimate shareholders of which are Mr. Gu Zhenqi and Mr. Gu Jianping, is the general partner of Shanghai Minhui Enterprise Management Consulting Partnership (Limited Partnership). The registered address of Shanghai Minhui Enterprise Management Consulting Partnership (Limited Partnership) is 1/F, Block 1, No. 251, Yao Hua Road, Pilot Free Trade Zone, Shanghai, PRC.
(4)
Consists of 4,762,185 ordinary shares held by Advantech Capital II Connect Partnership L.P., a Cayman Islands exempted limited partnership, or Advantech. Advantech Capital II Investment Partners Limited, an exempted company organized under the laws of the Cayman Islands, is the general partner of Advantech and may be deemed to beneficially own specific shares held by Advantech. Advantech Capital II Investment Partners Limited is beneficially owned and controlled by Advantech Capital Partners II Limited, which in turn is ultimately controlled by Hebert Pang Kee Chan. Mr. Chan disclaims beneficial ownership of the shares held by Advantech, except to the extent of any pecuniary interest therein. The registered address of Advantech is 190 Elgin Avenue, George Town, Grand Cayman KY1-9005, Cayman Islands.
(5)
Represents (i) 96,285 ordinary shares held by Qiming Managing Directors Fund V, L.P., a Cayman Islands exempted limited partnership, (ii) 3,102,470 ordinary shares held by Qiming Venture Partners V, L.P., a Cayman Islands exempted limited partnership, (iii) 14,993 ordinary shares held by Qiming VII Strategic Investors Fund, L.P., a Cayman Islands exempted limited partnership, and (iv) 1,627,150 ordinary shares held by Qiming Venture Partners VII, L.P., a Cayman Islands exempted limited partnership. The general partner of Qiming Venture Partners V, L.P. is Qiming GP V, L.P., whose general partner is Qiming Corporate GP V, Ltd., a Cayman Islands exempted company. Qiming Corporate GP V, Ltd. is also the general partner of Qiming Managing Directors Fund V, L.P. The voting and investment power of the shares held by Qiming Managing Directors Fund V, L.P. and Qiming Venture Partners V, L.P. in our company is exercised by Qiming Corporate GP V, Ltd., which is beneficially owned by Messrs. Duane Kuang, Gary Rieschel, and Nisa Leung. The general partner of Qiming Venture Partners VII, L.P. and Qiming VII Strategic Investors Fund, L.P. is Qiming GP VII, LLC, a Cayman Islands limited liability company. The voting and investment power of the shares held by Qiming Venture Partners VII, L.P. and Qiming VII Strategic Investors Fund, L.P. in our company are exercised by Qiming GP VII, LLC, which is beneficially owned by Messrs. Duane Kuang, Gary Rieschel, and Nisa Leung. Messrs. Duane Kuang, Gary Rieschel, and Nisa Leung disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The registered address of each of Qiming Managing Directors Fund V, L.P., Qiming Venture Partners V, L.P., Qiming Venture Partners VII, L.P. and Qiming VII Strategic Investors Fund, L.P. is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.
(6)
Consists of 3,417,564 ordinary shares held by FMR LLC. Abigail P. Johnson is Director, Chairman and Chief Executive Officer of FMR LLC. Members of the Johnson family, including Ms. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The address of FMR LLC and Ms. Johnson is 245 Summer Street, Boston, Massachusetts 02210.
(7)
Includes 142,597 ordinary shares underlying options held by Dr. Wei that are exercisable as of March 1, 2022 or that will become exercisable within 60 days after such date.
(8)
Includes (i) 142,597 Ordinary Shares underlying stock options held of record by Dr. Pan that are exercisable as of March 1, 2022; (ii) 39,382 Ordinary Shares held of record by Dr. Pan’s spouse; and (iii) 5,000 Ordinary Shares held of record by Dr. Pan’s sister.
(9)
Includes 143,674 ordinary shares underlying options held by Dr. Ho that are exercisable within 60 days after March 1, 2022.
(10)
Includes 42,105 ordinary shares underlying options held by Ms. Wilson that are exercisable within 60 days after March 1, 2022.
(11)
Represents 42,105 ordinary shares underlying options held by Dr. Xanthopoulos that are exercisable within 60 days after March 1, 2022.

 

Some of our directors are associated with our principal shareholders as indicated in the table below:

 

Director

 

Principal shareholder

Derek DiRocco, Ph.D.

 

Entities affiliated with RA Capital Management

Kan Chen, Ph.D.

 

Entities affiliated with Qiming Venture Partners

The following is a description of material related party transactions we have entered into since January 1, 2018 with any members of our board of directors or executive officers and the holders of more than 5% of our ordinary shares.

 

Preferred Share Private Placements

 

The following is a summary of our securities issuances in the past three years. The history of securities issuances set forth below does not give effect to the 1-for-1.74 share consolidation of our ordinary shares effected prior to our IPO.

Ordinary Shares

On November 20, 2015, we issued (i) one ordinary share to N.D. Nominees Ltd., which was immediately transferred to BioFortune Inc. (ii) 4,999 ordinary shares to BioFortune Inc., and (iii) 5,000 ordinary shares to Zheng Wei, Ph.D. On October 30, 2018, each of BioFortune Inc. and Zheng Wei, Ph.D. surrendered 4,000 Ordinary Shares.

157


 

 

On October 30, 2018, in connection with the Restructuring, we issued 92,327 ordinary shares to Shanghai Minhui Enterprise Management Consulting Partnership (Limited Partnership), which was later sub-divided into 9,232,700 ordinary shares on December 20, 2018.

 

On April 14, 2020, we issued 245,798 ordinary shares to each of BioFortune Inc. and Zheng Wei, Ph.D.

 

From December 2018 through December 2020, we issued 4,473,305 ordinary shares to Connect Union as nominee for purposes of the implementation of awards issue or to be issued to employees, directors and consultants of our company pursuant to the 2019 Plan. In September 2021, Connect Union surrendered all such ordinary shares to us and ceased to hold ordinary shares issued by us as a nominee structure.

 

Upon the closing of our IPO, we issued (i) 12,937,500 ordinary shares represented by the ADSs purchased in the offering, (ii) 121,080 ordinary shares to our founders immediately after the closing of the offering as a result of the achievement of the Financing Condition, and (iii) 46,232 ordinary shares to the holders of Series C Preferred Shares pursuant to the anti-dilution provisions contained in the Shareholders Agreement.

 

Preferred Shares

Series Pre-A Preferred Shares Financing. In connection with the Restructuring, on October 30, 2018, we issued and sold to existing shareholders of Connect SZ an aggregate of 31,090 Series Pre-A Preferred Shares (which were split into 3,109,000 Series Pre-A Preferred Shares in December 2018) as consideration and in exchange for the same equity interests they held in Connect SZ. The equity interest held in Connect SZ was originally purchased for aggregate consideration of USD5 million.

 

Series A Preferred Shares Financing. In connection with the Restructuring, on October 30, 2018, we issued and sold to existing shareholders of Connect SZ an aggregate of 84,712 Series A Preferred Shares (which were split into 8,471,200 Series A Preferred Shares in December 2018) as consideration and in exchange for the same equity interests they held in Connect SZ. The equity interest held in Connect SZ was originally purchased for aggregate consideration of USD20 million.

 

Series B Preferred Shares Financing. On December 20, 2018, we issued and sold to investors in private placements an aggregate of 10,127,579 Series B Preferred Shares at a subscription price of $5.4307 per share, for aggregate consideration of $55 million.

 

Series C Preferred Shares Financing. On August 21, 2020, we issued and sold to investors in private placements an aggregate of 16,605,196 Series C Preferred Shares at a subscription price of $6.3233 per share, for aggregate consideration of $105 million. On December 1, 2020, we issued and sold to investors in private placements an aggregate of 4,744,341 Series C Preferred Shares at a subscription price of $6.3233 per share, for aggregate consideration of $30 million.

 

The following table sets forth the aggregate number of our ordinary shares and Preferred Shares acquired by holders of more than 5% of our ordinary shares in the financing transactions described above. Each Preferred Share identified in the following table converted into one ordinary share upon the completion of our IPO.

 

Participants

 

Ordinary shares

 

 

Series A Preferred shares

 

 

Series B Preferred shares

 

 

Series C Preferred shares

 

5% or Greater Shareholders (1)

 

 

 

 

 

 

 

 

 

 

 

 

Entities affiliated with Qiming Venture

 

 

 

 

 

 

 

 

 

 

 

 

Partners (2)

 

 

 

 

 

4,235,600

 

 

 

1,012,758

 

 

 

3,162,895

 

Advantech Capital II Connect

 

 

 

 

 

 

 

 

 

 

 

 

Partnership L.P.

 

 

 

 

 

 

 

 

8,286,202

 

 

 

 

Entities affiliated with RA Capital

 

 

 

 

 

 

 

 

 

 

 

 

Management (3)

 

 

 

 

 

 

 

 

 

 

 

6,325,789

 

Shanghai Minhui Enterprise

 

 

 

 

 

 

 

 

 

 

 

 

Management Consulting

 

 

 

 

 

 

 

 

 

 

 

 

Partnership (Limited Partnership)

 

 

9,232,700

 

 

 

 

 

 

 

 

 

 

 

(1)
Additional details regarding these shareholders and their equity holdings are provided in this annual report under the caption “Principal Shareholders.”

158


 

(2)
Represents shares acquired by Qiming Managing Directors Fund V, L.P., Qiming Venture Partners V, L.P., Qiming VII Strategic Investors Fund, L.P. and Qiming Venture Partners VII, L.P.
(3)
Represents shares acquired by RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P. and Blackwell Partners LLC—Series A.

 

Shareholders Agreement

We entered into a Second Amended and Restated Shareholders Agreement, or Shareholders Agreement, on December 1, 2020, by and among us and some of our shareholders, including each of the holders of more than 5% of our ordinary shares identified above. The Shareholders Agreement, as amended, imposes some affirmative obligations on us and also grants specific rights to holders, including registration rights with respect to the securities held by them, preemptive rights, co-sale and drag-along rights and some information and inspection rights. Pursuant to the Shareholders Agreement, we issued 121,080 ordinary shares to our founders immediately after the closing of our IPO as a result of the achievement of the Financing Condition. As a result of the issuance of ordinary shares to our founders, we have also issued an additional 46,232 ordinary shares to the holders of Series C Preferred Shares pursuant to the anti-dilution provisions contained in the Shareholders Agreement.

Except for Ms. Liu, each of our current directors was designated to serve on our board of directors under the Shareholders Agreement. Dr. Wei, Dr. Pan, Ms. Wilson and Dr. Xanthopoulos were designated by our founders to serve on our board of directors as their representatives. Dr. DiRocco, designated by RA Capital Management, was selected to serve on our board of directors as a representative of our Series C Preferred Shares. Dr. Chen, designated by Qiming, was selected to serve on our board of directors as a representative of our Series A Preferred Shares.

The rights of our shareholders under the Shareholders Agreement, except the registration rights discussed below terminated immediately prior to the completion of our IPO, and members previously elected to our board of directors pursuant to this agreement will continue to serve as directors until they resign, are removed or their successors are duly elected by the holders of our ordinary shares. The composition of our board of directors is described in more detail under “Management—Board Composition.”

Arrangements with Our Executive Officers and Directors

Agreements with Our Executive Officers and Directors

We have entered into employment agreements with each of our executive officers.

In March 2021, we repurchased 20,765 ordinary shares from Zheng Wei, Ph.D., for consideration of RMB 2.5 million (USD 0.4 million) for the payment of employee withholding taxes related to share-based awards. Following the repurchase, such shares were cancelled.

 

Indemnification Agreements

We have entered into indemnification agreements with each of our directors and executive officers. See “Management—Limitations on Liability and Indemnification Matters.”

Consulting Arrangement with Artemis Catalyst

We have previously entered into a consulting agreement with Artemis Catalyst Ltd., a management consulting firm which is wholly owned by Selwyn Ho, MB BS, our Chief Business Officer. The consulting agreement was terminated in January 2021 upon the commencement of full time employment by Dr. Ho with us on such date. For the year ended December 31, 2021, the total amount payable under the consulting agreement was USD 0.3 million.

159


 

Contract Research Organization Services

In the ordinary course of business, we have entered into transactions with the below entities, which are affiliated with Ye Linlu, who was a director of our company until November 2020, and Ye Xiaoping, who was a member of the board of directors of Connect SZ until February 2021.

 

 

 

Year Ended December 31,

 

 

 

2021

 

2020

 

 

 

RMB’000

 

RMB’000

 

Purchase of CRO Services

 

 

 

 

 

Hangzhou Simo Company Limited

 

 —

 

 

5,948

 

Frontage Laboratories (Suzhou) Company Limited

 

 

 

2,157

 

Shanghai Tigermed Consulting Company Limited

 

 

 

34

 

Hangzhou Tigermed Consulting Company Limited

 

 

 

1,069

 

Beijing Medical Development (Suzhou) Company Limited

 

 

 

301

 

Total

 

 

 

9,509

 

 

2019 Stock Incentive Plan

See “Management—2019 Stock Incentive Plan.”

 

Related Person Transaction Policy

Our board of directors has adopted a written related person transaction policy setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers any transaction or proposed transactions between us and a related person that are material to us or the related person, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction and the extent of the related person’s interest in the transaction.

 

C. Interests of Experts and Counsel.

Not applicable.

160


 

ITEM 8. FINANCIAL INFORMATION.

A. Consolidated Statements and Other Financial Information.

Please see Item 18. “Financial Statements” for our audited consolidated financial statements filed as part of this annual report.

Litigation

We are, from time to time, party to various claims and legal proceedings arising out of our ordinary course of business, but we do not believe that any of these existing claims or proceedings will have a material effect on our business, consolidated financial condition or results of operations. We are not currently a party to any material legal proceedings, including any such proceedings that are pending or threatened, of which we are aware.

Dividend Policy

Since our incorporation, we have never paid or declared any dividend on our ordinary shares, and we do not anticipate paying dividends on our ordinary shares in the foreseeable future. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business. As a result, investors in our ordinary shares or ADSs will benefit in the foreseeable future only if such ordinary shares or ADSs appreciate in value.

Any dividend on our ordinary shares will be paid to the depositary bank, as the registered holder of those ordinary shares, and the depositary bank will then pay such amounts to the holders of ADSs, subject to the terms of the deposit agreement. Holders of our ADSs will receive any dividend to the same extent as holders of our ordinary shares, to the extent permitted by applicable law and regulations, less the fees and expenses payable under the deposit agreement.

Any future determination to pay a dividend will be made at the discretion of our board of directors, and subject to Cayman Islands Law. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our board of directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit or its share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will be based upon conditions then existing, including our results of operations, financial condition, current and anticipated capital requirements, business prospects, contractual restrictions and other factors our board of directors deems relevant, and subject to the restrictions contained in any future financing instruments and our memorandum and articles of association, as amended from time to time. Any profits or share premium we declare as dividends will not be available to be reinvested in our operations.

Moreover, we are a holding company that does not conduct any business operations of our own. As a result, we are dependent upon cash dividends, distributions and other transfers from our subsidiaries to make dividend payments.

In the year ended December 31, 2021, we did not declare or pay any dividends.

B. Significant Changes.

No significant change has occurred since the date of the financial statements included in this annual report.

ITEM 9. THE OFFER AND LISTING.

A. Offer and Listing Details

Our ADSs commenced trading on the Nasdaq Global Market on March 19, 2021. Prior to this, no public market existed for our ADSs.

B. Plan of Distribution

Not applicable.

161


 

C. Markets

Our ADSs are listed on Nasdaq under the symbol “CNTB.”

D. Selling Shareholders

Not applicable.

E. Dilution

Not applicable.

F. Expenses of the Issuer

Not applicable.

ITEM 10. ADDITIONAL INFORMATION.

A. Share Capital

Not applicable.

B. Memorandum and Articles of Association.

We are a Cayman Islands exempted company incorporated with limited liability and our affairs are governed by our memorandum and articles of association, as amended from time to time, the Companies Act (As Revised) of the Cayman Islands, which we refer to as the Companies Act below and the common law of the Cayman Islands.

Our shareholders adopted our amended and restated memorandum and articles of association, which became effective and replaced our fourth amended and restated memorandum and articles of association in its entirety immediately prior to the completion of our IPO. The following are summaries of some material provisions of our amended and restated memorandum and articles of association, and of the Companies Act, insofar as they relate to the material terms of our ordinary shares.

Objects of Our Company. Under our amended and restated memorandum and articles of association, the objects of our company are unrestricted and we have the full power and authority to carry out any object not prohibited by the law of the Cayman Islands.

Ordinary Shares. Our ordinary shares are issued in registered form and are issued when registered in our register of members (shareholders). We may not issue shares to bearer. Our shareholders who are nonresidents of the Cayman Islands may freely hold and vote their shares. Each ordinary share shall entitle the holder thereof to one vote on all matters subject to vote at our general meetings.

Dividends. The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors. In addition, our shareholders may declare dividends by ordinary resolution, but no dividend shall exceed the amount recommended by our directors. Our amended and restated memorandum and articles of association provide that our directors may, before recommending or declaring any dividend, set aside out of the funds legally available for distribution such sums as they think proper as a reserve or reserves which shall, in the absolute discretion of the directors, be applicable for meeting contingencies or for equalizing dividends or for any other purpose to which those funds may be properly applied. Under the laws of the Cayman Islands, our company may pay a dividend out of either profit or our share premium account, provided that in no circumstances may a dividend be paid if this would result in our company being unable to pay its debts as they fall due in the ordinary course of business.

Voting Rights. Each ordinary share shall be entitled to one vote on all matters subject to a vote at general meetings of our company. Voting at any shareholders’ meeting is by show of hands unless a poll is demanded (before or on the declaration of the result of the show of hands). A poll may be demanded by the chairman of such meeting or by any one or more shareholders who together hold not less than 10% of the votes attaching to the total number of ordinary shares which are present in person or by proxy at the meeting.

An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares which are cast at a meeting, while a special resolution requires the affirmative vote of no less than two-thirds of the votes attaching to the ordinary shares which are cast at a meeting. A special resolution will be required for important

162


 

matters such as a change of name or making changes to our amended and restated memorandum and articles of association. Our company may, among other things, divide or combine our ordinary shares, by an ordinary resolution of our shareholders.

General Meetings of Shareholders. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders’ annual general meetings. Our amended and restated memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we shall specify the meeting as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by our directors.

Shareholders’ general meetings may be convened by the chairman of our board of directors or by a majority of our directors (acting by a resolution of the board). Advance notice of at least ten calendar days is required for the convening of our annual general shareholders’ meeting (if any) and any other general meeting of our shareholders. A quorum required for any general meeting of shareholders consists of one or more shareholders present in person or by proxy, holding shares which carry in aggregate not less than one-third of all votes attaching to all of our shares in issue and entitled to vote at such general meeting.

The Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company’s articles of association. Our amended and restated memorandum and articles of association provide that upon the requisition of shareholders holding shares which carry in aggregate not less than one-third of the votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings, our board will convene an extraordinary general meeting and put the resolutions so requisitioned to a vote at such meeting. However, our amended and restated memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders.

Transfer of Ordinary Shares. Subject to the restrictions set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors.

Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which is not fully paid up or on which we have a lien. Our board of directors may also decline to register any transfer of any ordinary share unless:

the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;
the instrument of transfer is in respect of only one class of ordinary shares;
the instrument of transfer is properly stamped, if required;
in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be transferred does not exceed four; and
a fee of such maximum sum as the Nasdaq Global Market may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof.

If our directors refuse to register a transfer they shall, within three months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal.

The registration of transfers may, after compliance with any notice required of the Nasdaq Global Market, be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine, provided, however, that the registration of transfers shall not be suspended nor the register closed for more than 30 calendar days in any calendar year.

Liquidation. On the winding up of our company, if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay the whole of the share capital, the assets will be distributed so that the losses are borne by our shareholders in proportion to the par value of the shares held by them.

Calls on Shares and Forfeiture of Shares. Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their shares in a notice served to such shareholders at least 14 days prior to the specified time and place of payment. The shares that have been called upon and remain unpaid are subject to forfeiture.

Redemption, Repurchase and Surrender of Shares. We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders of these shares, on such terms and in such manner as may be determined by our board of directors. Our company may also repurchase any of our shares on such terms and in such manner as have been approved by our board

163


 

of directors or by an ordinary resolution of our shareholders. Under the Companies Act, the redemption or repurchase of any share may be paid out of our profits or out of the proceeds of a new issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if our company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a) unless it is fully paid up, (b) if such redemption or repurchase would result in there being no shares outstanding or (c) if our company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.

Variations of Rights of Shares. If at any time, our share capital is divided into different classes or series of shares, the rights attached to any class or series of shares (unless otherwise provided by the terms of issue of the shares of that class or series), whether or not our company is being wound-up, may be varied with the consent in writing of the holders of two-thirds of the issued shares of that class or series or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class or series. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not, subject to any rights or restrictions for the time being attached to the shares of that class, be deemed to be varied by the creation, allotment or issue of further shares ranking pari passu with or subsequent to such existing class of shares or the redemption or purchase of any shares of any class by our company. The rights of the holders of shares shall not be deemed to be materially adversely varied by the creation or issue of shares with preferred or other rights including, without limitation, the creation of shares with enhanced or weighted voting rights.

Issuance of Additional Shares. Our amended and restated memorandum of association authorizes our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares.

Our amended and restated memorandum of association also authorizes our board of directors to establish from time to time one or more series of preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including:

the designation of the series;
the number of shares of the series;
the dividend rights, dividend rates, conversion rights, voting rights; and
the rights and terms of redemption and liquidation preferences.

Our board of directors may issue preference shares without action by our shareholders to the extent authorized but unissued. Issuance of these shares may dilute the voting power of holders of ordinary shares.

Inspection of Books and Records. Holders of our ordinary shares have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records (except for the amended and restated memorandum and articles of association, special resolutions which have been passed by our shareholders, our register of mortgages and charges and a list of our current directors). However, we will provide our shareholders with annual audited consolidated financial statements. See “Where You Can Find Additional Information.”

Anti-Takeover Provisions. Some provisions of our amended and restated memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that:

authorize our board of directors to issue preference shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preference shares without any further vote or action by our shareholders; and
limit the ability of shareholders to requisition and convene general meetings of shareholders.

However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our amended and restated memorandum and articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company.

Exempted Company. We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company:

does not have to file an annual return of its shareholders with the Registrar of Companies;
the statutory provisions as to the required majority vote have been met;
is not required to open its register of members for inspection;

164


 

does not have to hold an annual general meeting;
may issue shares with no par value;
may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance);
may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;
may register as a limited duration company; and
may register as a segregated portfolio company.

“Limited liability” means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).

Our fiscal year is the calendar year ending December 31.

 

Differences in Corporate Law

 

The Companies Act of the Cayman Islands is derived, to a large extent, from the older Companies Acts of England but does not follow recent English statutory enactments and accordingly there are significant differences between the Companies Act of the Cayman Islands and the current Companies Act of England. In addition, the Companies Act differs from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of some significant differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in the United States and their shareholders.

 

Mergers and Similar Arrangements. The Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes, (i) “merger” means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company, and (ii) a “consolidation” means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then be authorized by (a) a special resolution of the shareholders of each constituent company, and (b) such other authorization, if any, as may be specified in such constituent company’s articles of association. The written plan of merger or consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a list of the assets and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures.

 

A merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders of that Cayman subsidiary if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member agrees otherwise. For this purpose a company is a “parent” of a subsidiary if it holds issued shares that together represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary.

 

The consent of each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived by a court in the Cayman Islands.

 

Save in some limited circumstances, a shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled to payment of the fair value of his shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or consolidation, provide the dissenting shareholder complies strictly with the procedures set out in the Companies Act. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful.

 

165


 

Separate from the statutory provisions relating to mergers and consolidations, the Companies Act also contains statutory provisions that facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the arrangement is approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made, and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that:

the statutory provisions as to the required majority vote have been met;
the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests adverse to those of the class;
the arrangement is such that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and
the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act.

 

The Companies Act also contains a statutory power of compulsory acquisition which may facilitate the “squeeze out” of dissentient minority shareholders upon a tender offer. When a tender offer is made and accepted by holders of 90.0% of the shares affected within four months, the offeror may, within a two-month period commencing on the expiration of such four month period, require the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion.

 

If an arrangement and reconstruction by way of scheme of arrangement is thus approved and sanctioned, or if a tender offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares.

 

Shareholders’ Suits. In principle, we will normally be the proper plaintiff to sue for a wrong done to us as a company, and as a general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands court can be expected to follow and apply the common law principles (namely the rule in Foss v. Harbottle and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action against or derivative actions in the name of the company to challenge actions where:

the act complained of, although not ultra vires, could only be effected duly if authorized by more than a simple majority vote that has not been obtained; and
those who control the company are perpetrating a “fraud on the minority.”

 

Indemnification of Directors and Executive Officers and Limitation of Liability. Cayman Islands law does not limit the extent to which a company’s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our amended and restated memorandum and articles of association provide that we shall indemnify our officers and directors against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such directors or officer, other than by reason of such person’s dishonesty, willful default or fraud, in or about the conduct of our company’s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his or her duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.

 

In addition, we have entered into indemnification agreements with our directors and specific executive officers that provide such persons with additional indemnification beyond that provided in our amended and restated memorandum and articles of association.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

 

166


 

Directors’ Fiduciary Duties. Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director acts in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use their corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.

 

As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that he or she owes the following duties to the company—a duty to act bona fide in the best interests of the company, a duty not to make a profit based on his or her position as director (unless the company permits them to do so), a duty not to put himself or herself in a position where the interests of the company conflict with his or personal interest or his duty to a third party, and a duty to exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands.

 

Shareholder Action by Written Resolution. Under the Delaware General Corporation Law, a corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. Cayman Islands law and our amended and restated articles of association provide that our shareholders may approve corporate matters by way of a unanimous written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held.

 

Shareholder Proposals. Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.

 

The Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company’s articles of association. Our amended and restated articles of association allow our shareholders holding shares which carry in aggregate not less than one-third of all votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. Other than this right to requisition a shareholders’ meeting, our amended and restated articles of association do not provide our shareholders with any other right to put proposals before annual general meetings or extraordinary general meetings. As an exempted Cayman Islands company, we may but are not obliged by law to call shareholders’ annual general meetings.

 

Cumulative Voting. Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation’s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single director, which increases the shareholder’s voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under the laws of the Cayman Islands but our amended and restated articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation.

 

167


 

Removal of Directors. Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our amended and restated articles of association, directors may be removed with or without cause, by an ordinary resolution of our shareholders. In addition, a director’s office shall be vacated if the director (i) becomes bankrupt or makes any arrangement or composition with his creditors; (ii) is found to be or becomes of unsound mind or dies; (iii) resigns his or her office by notice in writing to the company; (iv) without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves that his or her office be vacated; or (v) is removed from office pursuant to any other provisions of our amended and restated memorandum and articles of association.

 

Transactions with Interested Shareholders. The Delaware General Corporation Law contains a business combination statute applicable to Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in various business combinations with an “interested shareholder” for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target’s outstanding voting share within the past three years. This has the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target’s board of directors.

 

Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the company and not with the effect of constituting a fraud on the minority shareholders.

 

Dissolution; Winding up. Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.

 

Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.

 

Variation of Rights of Shares. Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under Cayman Islands law and our amended and restated articles of association, if our share capital is divided into more than one class of shares, we may vary the rights attached to any class with the written consent of the holders of two-thirds of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class.

 

Amendment of Governing Documents. Under the Delaware General Corporation Law, a corporation’s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under the Companies Act and our amended and restated memorandum and articles of association, our memorandum and articles of association may only be amended by a special resolution of our shareholders.

 

Rights of Non-resident or Foreign Shareholders. There are no limitations imposed by our amended and restated memorandum and articles of association on the rights of non-resident or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our amended and restated memorandum and articles of association governing the ownership threshold above which shareholder ownership must be disclosed.

C. Material Contracts.

Except as otherwise disclosed in this Annual Report (including the exhibits thereto), we are not currently, and have not been in the last two years, party to any material contract, other than contracts entered into in the ordinary course of business.

168


 

D. Exchange Controls.

According to the PRC Regulation for the Foreign Exchange promulgated by the State Council in January 1996, which was amended in January 1997 and August 2008, and the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment promulgated by the People’s Bank of China in June 1996, foreign exchanges required for distribution of profits and payment of dividends may be purchased from designated foreign exchange banks in the PRC upon presentation of a board resolution authorizing distribution of profits or payment of dividends.

According to the Circular of the State Administration of Foreign Exchange, or the SAFE, on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment and its appendix promulgated in November 2012 and amended in May 2015, October 2018 and December 2019 by the SAFE, (1) the opening of and payment into foreign exchange accounts under direct investment accounts are no longer subject to approval by the SAFE; (2) reinvestment with legal income of non-PRC investors in the PRC is no longer subject to approval by SAFE; (4) the procedures for capital verification and confirmation that non-PRC-funded enterprises need to go through are simplified; (4) purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by SAFE; (5) domestic transfer of foreign exchange under direct investment account is no longer subject to approval by SAFE; and (6) the administration over the conversion of foreign exchange capital of foreign-invested enterprises is improved. Later, the SAFE promulgated the Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment in February 2015, which was further amended in December 2019 and prescribed that the bank instead of the SAFE can directly handle the foreign exchange registration and approval under foreign direct investment while the SAFE and its branches indirectly supervise the foreign exchange registration and approval under foreign direct investment through the bank.

The Provisions on the Administration of Foreign Exchange in Foreign Direct Investments by Foreign Investors, which were promulgated by the SAFE in May 2013 and amended in October 2018 and December 2019, regulate and clarify the administration over foreign exchange administration in foreign direct investments.

According to the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises promulgated by the SAFE in Mach 2015 and amended in December 2019, and the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects promulgated by the SAFE in June 2016, the settlement of foreign exchange by foreign invested enterprises shall be governed by the policy of foreign exchange settlement on a discretionary basis. However, the settlement of foreign exchange shall only be used for their own operational purposes within the business scope of the non-PRC invested enterprises and follow the principles of authenticity.

During the years presented in our consolidated balance sheets, we have not transferred cash out from our PRC entities so therefore experienced no foreign exchange control related issues.

Dividend Distribution

The SAFE promulgated the Notice on Improving the Check of Authenticity and Compliance to Further Promote Foreign Exchange Control in January 2017, which stipulates several capital control measures with respect to outbound remittance of profits from domestic entities to offshore entities, including the following: (1) under the principle of genuine transaction, banks shall check board resolutions regarding profit distribution, the original version of tax filing records and audited financial statements; and (2) domestic entities shall hold income to account for previous years’ losses before remitting the profits. Moreover, domestic entities shall make detailed explanations of sources of capital and utilization arrangements, and provide board resolutions, contracts and other proof when completing the registration procedures in connection with an outbound investment. Restrictions on our PRC subsidiaries’ ability to pay dividends to an offshore entity primarily include: (i) the PRC subsidiaries may pay dividends only out of their accumulated after-tax profits upon satisfaction of relevant statutory conditions and procedures, if any, determined in accordance with Chinese accounting standards and regulations; (ii) each of the PRC subsidiaries is required to set aside at least 10% of its after-tax profits each year, if any, to fund reserve funds until the total amount set aside reaches 50% of its registered capital; (iii) the PRC subsidiaries are required to complete procedural requirements related to foreign exchange control in order to make dividend payments in non-PRC currency; and (iv) a withholding tax, at the rate of 10% or lower, is payable by the PRC subsidiary upon dividend remittance. Such restrictions could have a material and adverse effect on our ability to distribute profits to our investors.

Since our inception, we have not distributed any dividends from our PRC entities.

 

169


 

Foreign Exchange Registration of Offshore Investment by PRC Residents

 

The SAFE promulgated the SAFE Circular 37 in July 2014. The SAFE Circular 37 requires PRC residents (including PRC institutions and individuals) to register with local branches of SAFE in connection with their direct or indirect offshore investment in an overseas special purpose vehicle, or the SPV, directly established or indirectly controlled by PRC residents for offshore investment and financing with their legally owned assets or interests in domestic enterprises, or their legally owned offshore assets or interests. Such PRC residents are also required to amend their registrations with the SAFE when there is a change to the basic information of the SPV, such as changes of a PRC resident individual shareholder, the name or operating period of the SPV, or when there is a significant change to the SPV, such as changes of the PRC individual resident’s increase or decrease of its capital contribution in the SPV, or any share transfer or exchange, merger, division of the SPV.

 

The Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, which was promulgated in February 2015 and effective in June 2015 and further amended in December 2019, provides that PRC residents may register with qualified banks instead of the SAFE in connection with their establishment or control of an offshore entity established for the purpose of overseas direct investment. The SAFE and its branches shall implement indirect supervision over foreign exchange registration of direct investment via the banks.

 

Failure to comply with the registration procedures set forth in the SAFE Circular 37 may result in restrictions on the foreign exchange activities of the relevant onshore company, including the payment of dividends and other distributions to its offshore parent or affiliate, the capital inflow from the offshore entities and settlement of foreign exchange capital, and may also subject relevant onshore company or PRC residents to penalties under PRC foreign exchange administration regulations.

 

Since our inception, none of our PRC entities have direct or indirect offshore investments in any SPVs.

 

Capital expenses

 

Approval from or registration with appropriate PRC governmental authorities is required where Renminbi is to be converted into non-PRC currency and remitted out of the PRC to pay capital expenses, such as the repayment of loans denominated in non-PRC currencies. As a result, our PRC subsidiaries are required to obtain approval from SAFE or complete a specific registration process in order to use cash generated from their operations to pay off their respective debt in a currency other than Renminbi owed to entities outside the PRC, or to make other capital expenditure payments outside the PRC in a currency other than Renminbi.

E. Taxation

 

The following discussion of Cayman Islands, PRC and United States federal income tax consequences relevant to the acquisition, ownership and disposition of our ADSs or ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this annual report, all of which are subject to change or different interpretation, possibly with retroactive effect. This summary does not deal with all possible tax consequences relating to an investment in our ADSs or ordinary shares, such as the tax consequences under U.S. state and local tax laws or under the tax laws of jurisdictions other than the Cayman Islands, the PRC and the United States. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.

 

Cayman Islands Taxation

 

The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or, after execution, brought within the jurisdiction of the Cayman Islands. The Cayman Islands is not party to any double tax treaties that are applicable to any payments made to or by our company. There are no exchange control regulations or currency restrictions in the Cayman Islands.

Payments of dividends and capital in respect of our ordinary shares or ADSs will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of our ordinary shares or ADSs, nor will gains derived from the disposal of our ordinary shares or ADSs be subject to Cayman Islands income or corporation tax.

 

170


 

PRC Taxation

 

Enterprise Income Tax and Withholding Tax

 

Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside the PRC with “de facto management body” within the PRC is considered as a Tax Resident Enterprise for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. The implementation rules of the PRC Enterprise Income Tax Law define the term “de facto management body” as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties of an enterprise. In April 2009, the SAT issued Circular 82, which provides specific criteria for determining whether the “de facto management body” of a PRC-controlled enterprise that is incorporated offshore is located in the PRC. Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or non-PRC, the criteria set forth in the circular may reflect the SAT’s general position on how the “de facto management body” text should be applied in determining the tax resident status of all non-PRC enterprises. According to Circular 82, a non-PRC incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its “de facto management body” in the PRC if all of the following conditions are met: (i) the primary location of the day-to-day operational management is in the PRC; (ii) decisions relating to the enterprise’s financial and human resource matters are made or are subject to approval by organizations or personnel located in the PRC; (iii) the enterprise’s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in the PRC; and (iv) at least 50% of board members with voting rights or senior executives habitually reside in the PRC.

 

We believe that we should not be considered as a PRC resident enterprise for PRC tax purposes as (i) we are incorporated outside of the PRC and not controlled by a PRC enterprise or PRC enterprise group; and (ii) we do not meet all of the conditions above. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term “de facto management body.” There can be no assurance that PRC tax authorities will ultimately not take a different view.

 

If the PRC tax authorities determine that we are a PRC resident enterprise for enterprise income tax purposes, our worldwide income could be subject to 25% enterprise income tax; and any dividends payable to non-resident enterprise holders of our ordinary shares or ADSs may be treated as income derived from sources within the PRC and therefore, subject to a 10% withholding tax (or 20% in the case of non-resident individual holders) unless an applicable income tax treaty provides otherwise. In addition, capital gains realized by non-resident enterprise shareholders (including our ADS holders) upon the disposition of our ordinary shares or ADSs may be treated as income derived from sources within PRC and therefore, subject to 10% income tax (or 20% in the case of non-resident individual shareholders or ADS holders) unless an applicable income tax treaty provides otherwise. It is unclear whether non-PRC shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. See “Risk Factors—Risks Related to Doing Business in the PRC—We may be treated as a resident enterprise for PRC tax purposes under the PRC Enterprise Income Tax Law, and we may therefore be subject to PRC income tax on our global income.”

 

Provided that we are not deemed to be a PRC resident enterprise, holders of our ordinary shares or ADSs who are not PRC residents will not be subject to PRC income tax on dividends distributed by us or gains realized from the sale or other disposition of our ordinary shares or ADSs. However, under the Bulletin 7, where a non-resident enterprise conducts an “indirect transfer” by transferring taxable assets, including, in particular, equity interests in a PRC resident enterprise, indirectly by disposing of the equity interests of an overseas holding company, the non-resident enterprise, being the transferor, or the transferee or the PRC entity which directly owned such taxable assets may report to the relevant tax authority such indirect transfer. Using a “substance over form” principle, the PRC tax authority may disregard the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of reducing, avoiding or deferring PRC tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax, and the transferee or other person who is obligated to pay for the transfer is obligated to withhold the applicable taxes, currently at a rate of 10% for the transfer of equity interests in a PRC resident enterprise. We and our non-PRC resident investors may be at the risk of being required to file a return and being taxed under Bulletin 7, and we may be required to expend valuable resources to comply with Bulletin 7, or to establish that we should not be taxed under these regulations.

 

171


 

Value Added Tax

 

According to the Provisional Regulations of the PRC on Value-Added Tax, effective in January 1994 and further amended in November 2008, February 2016, and November 2017, and its implementation rules effected in January 1994 and amended in December 2008 and October 2011, except stipulated otherwise, taxpayers who sell goods, labor services or tangible personal property leasing services or import goods shall be subject to a 17% tax rate; taxpayers who sell transport services, postal services, basic telecommunications services, construction services, or real property leasing services, sell real property, transfer the land use right shall be subject to an 11% tax rate, and taxpayers who sell services or intangible assets shall be subject to a 6% tax rate.

According to the Circular of the Ministry of Finance and the State Administration of Taxation on Adjusting Value-added Tax Rates adopted in April 2018, as of May 2018, where a taxpayer engages in a taxable sales activity for the value-added tax purpose or imports goods, the previous applicable 17% and 11% rates are adjusted to 16% and 10%.

According to the Announcement on Relevant Policies for Deepening Value-Added Tax Reform, effective in April 2019, the 16% VAT tax rate, which applies to the sales or imported goods of a VAT general taxpayer, will be lowered to 13%; and the 10% VAT tax rate will be lowered to 9%.

According to the Measures for the Exemption of Value-Added Tax from Cross-Border Taxable Activities in the Collection of Value-Added Tax in Lieu of Business Tax (for Trial Implementation) revised in June 2018, if domestic enterprises provide cross-border taxable activities such as professional technical services, technology transfer, software services, the above-mentioned cross-border taxable activities are exempt from VAT.

 

Tax on Indirect transfer

 

On February 3, 2015, the SAT issued the Bulletin on Issues of Enterprise Income Tax on Indirect Transfers of Assets by Non-PRC Resident Enterprises, or Bulletin 7. Pursuant to Bulletin 7, an “indirect transfer” of assets, including equity interests in a PRC resident enterprise, by non-PRC resident enterprises, may be recharacterized and treated as a direct transfer of PRC taxable assets, if such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax. When determining whether there is a “reasonable commercial purpose” of the transaction arrangement, features to be taken into consideration include, inter alia, whether the main value of the equity interest of the relevant offshore enterprise derives directly or indirectly from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consists of direct or indirect investment in the PRC or if its income is mainly derived from the PRC; and whether the offshore enterprise and its subsidiaries directly or indirectly holding PRC taxable assets have a real commercial nature which is evidenced by their actual function and risk exposure. According to Bulletin 7, where the payer fails to withhold any or sufficient tax, the transferor shall declare and pay such tax to the tax authority by itself within the statutory time limit. Late payment of applicable tax will subject the transferor to default interest. Bulletin 7 does not apply to transactions of sale of shares by investors through a public stock exchange where such shares were acquired on a public stock exchange. On October 17, 2017, the SAT issued the Announcement of the SAT on Issues Concerning the Withholding of Non-resident Enterprise Income Tax at Source, or SAT Circular 37, which was amended by the Announcement of the State Administration of Taxation on Revising Certain Taxation Normative Documents issued on June 15, 2018 by the SAT. The SAT Circular 37 further elaborates the relevant implemental rules regarding the calculation, reporting and payment obligations of the withholding tax by the non-resident enterprises. Nonetheless, there remain uncertainties as to the interpretation and application of Bulletin 7. Bulletin 7 may be determined by the tax authorities to be applicable to our offshore transactions or sale of our shares or those of our offshore subsidiaries where non-resident enterprises, being the transferors, were involved.

 

United States Federal Income Taxation Considerations

 

The following discussion describes some material United States federal income tax consequences to U.S. Holders (defined below) of an investment in the ADSs or ordinary shares. This summary applies only to investors that hold the ADSs or ordinary shares as capital assets (generally, property held for investment) and that have the U.S. dollar as their functional currency. This discussion is based on the United States Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, as in effect on the date of this annual report and on United States Treasury regulations in effect or, in some cases, proposed, as of the date of this annual report, as well as judicial and administrative interpretations thereof available on or before such date. All of the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences described below. The summary below does not discuss some United States federal tax consequences that may be relevant to a particular U.S. Holder’s particular circumstances, such as consequences relating to the Medicare contribution tax on net investment income or the alternative minimum tax.

 

172


 

The following discussion neither deals with the tax consequences to any particular investor nor describes all of the tax consequences applicable to persons in special tax situations such as:

banks;
some financial institutions;
insurance companies;
regulated investment companies;
real estate investment trusts;
broker dealers;
United States expatriates;
traders that elect to use the mark-to-market method of tax accounting;
tax-exempt entities;
persons holding an ADS or ordinary share as part of a straddle, hedging, conversion or integrated transaction;
persons that actually or constructively own 10% or more of our stock, by total combined voting power or by value;
persons who acquired ADSs or ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation; or
persons holding ADSs or ordinary shares through partnerships or other pass-through entities.

 

A “U.S. Holder,” for purposes of this discussion, means a beneficial owner of ADSs or ordinary shares that is, for United States federal income tax purposes,

an individual who is a citizen or resident of the United States;
a corporation (or other entity taxable as a corporation for United states federal income tax purposes) created or organized in the United States or under the laws of the United States, any state thereof or the District of Columbia;
an estate, the income of which is subject to United States federal income taxation regardless of its source; or
a trust (a) that is subject to the supervision of a court within the United States and the control of one or more United States persons as described in Internal Revenue Code Section 7701(a)(30), or (b) that has a valid election in effect under applicable U.S. Treasury regulations to be treated as a United States person.

 

If an entity or arrangement treated as a partnership for United States federal income tax purposes holds ADSs or ordinary shares, the tax treatment of a partner will generally depend upon the status and the activities of the partnership. A U.S. Holder that is a partner in a partnership holding ADSs or ordinary shares is urged to consult its tax advisor.

 

The discussion below assumes that the representations contained in the deposit agreement are true and that the obligations in the deposit agreement and any related agreement will be complied with in accordance with their terms. Based on such assumptions, if you hold ADSs, you should generally be treated as the holder of the underlying ordinary shares represented by those ADSs for United States federal income tax purposes.

 

The United States Treasury has expressed concerns that intermediaries in the chain of ownership between the holder of an ADS and the issuer of the underlying ordinary shares may be taking actions that are inconsistent with the beneficial ownership of the underlying ordinary shares. Accordingly, the creditability of foreign tax credits by U.S. Holders of ADSs or the availability of the reduced tax rate for dividends received by some non-corporate U.S. Holders could be affected by actions taken by intermediaries in the chain of ownership between the holder of an ADS and the Company.

 

173


 

Taxation of Dividends and Other Distributions on the ADSs or Ordinary Shares

 

Subject to the PFIC rules discussed below, the gross amount of any distributions we make to you with respect to the ADSs or ordinary shares (without reduction for any amounts withheld) generally will be includible in your gross income as foreign source dividend income on the date of receipt by the depository, in the case of ADSs, or by you, in the case of ordinary shares, but only to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under United States federal income tax principles). Any such dividends will not be eligible for the dividends received deduction allowed to corporations in respect of dividends received from other United States corporations. To the extent that the amount of the distribution exceeds our current and accumulated earnings and profits (as determined under United States federal income tax principles), such excess amount will be treated first as a tax-free return of your tax basis in your ADSs or ordinary shares, and then, to the extent such excess amount exceeds your tax basis in your ADSs or ordinary shares, as capital gain. However, we currently do not, and we do not intend to, calculate our earnings and profits under United States federal income tax principles. Therefore, a U.S. Holder should expect that any distribution will generally be reported as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above.

 

With respect to some non-corporate U.S. Holders, including individual U.S. Holders, dividends may be taxed at the lower capital gains rate applicable to “qualified dividend income,” provided that (1) the ADSs or ordinary shares, as applicable, are readily tradable on an established securities market in the United States or we are eligible for the benefits of a qualifying income tax treaty with the United States, (2) we are neither a PFIC nor treated as such with respect to you (as discussed below) for the taxable year in which the dividend is paid or the preceding taxable year, and (3) the ADSs or ordinary shares are held for a holding period of more than 60 days during the 121-day period beginning 60 days before the ex-dividend date. Ordinary shares or ADSs will generally be considered for the purpose of clause (1) above to be readily tradable on an established securities market in the United States if they are listed on Nasdaq, as our ADSs are currently. If we are treated as a “resident enterprise” for PRC tax purposes (see “Taxation—People’s Republic of China Taxation”), we may be eligible for the benefits of the income tax treaty between the United States and the PRC, or the Treaty. You should consult your tax advisors regarding the availability of the lower capital gains rate applicable to qualified dividend income for any dividends paid with respect to our ADSs or ordinary shares.

 

Any non-U.S. withholding tax (including any PRC withholding tax (see “Taxation—PRC”) paid (or deemed paid) by a U.S. Holder at the rate applicable to such U.S. Holder may be eligible for foreign tax credits (or deduction in lieu of such credits) for U.S. federal income tax purposes, subject to applicable limitations. Any dividends will constitute foreign source income for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend income (as discussed above), the amount of the dividend taken into account for purposes of calculating the foreign tax credit limitation will in general be limited to the gross amount of the dividend, multiplied by the reduced tax rate applicable to qualified dividend income and divided by the highest tax rate normally applicable to dividends. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, any dividends distributed by us with respect to ADSs or ordinary shares will generally constitute “passive category income.”

 

The rules relating to the determination of the foreign tax credit are complex, and U.S. Holders should consult their tax advisors to determine whether and to what extent a credit would be available in their particular circumstances, including the effects of any applicable income tax treaties.

 

Taxation of a Disposition of ADSs or Ordinary Shares

 

Subject to the PFIC rules discussed below, upon a sale or other disposition of ADSs or ordinary shares, a U.S. Holder will generally recognize a capital gain or loss for United States federal income tax purposes in an amount equal to the difference between the amount realized for the ADS or ordinary share and such U.S. Holder’s tax basis in such ADSs and ordinary shares. Any such gain or loss will be treated as long-term capital gain or loss if the U.S. Holder’s holding period in the ADSs or ordinary shares at the time of the disposition exceeds one year. Long-term capital gain of individual U.S. Holders generally will be subject to United States federal income tax at reduced tax rates. The deductibility of capital losses is subject to limitations.

 

Any such gain or loss that you recognize generally will be treated as United States source income or loss for foreign tax credit limitation purposes. However, if we are treated as a “resident enterprise” for PRC tax purposes, we may be eligible for the benefits of the Treaty. In such event, if PRC tax were to be imposed on any gain from the disposition of the ADSs or ordinary shares, a U.S. Holder that is eligible for the benefits of the Treaty may elect to treat the gain as PRC source income for foreign tax credit purposes. U.S. Treasury regulations, however, may impose additional restrictions on the creditability of any PRC taxes on disposition gains. U.S. Holders should consult their tax advisors regarding the proper treatment of gain or loss in their particular circumstances, including the effects of any applicable income tax treaties.

 

174


 

Passive Foreign Investment Company

 

A non-United States corporation will be a PFIC for United States federal income tax purposes for any taxable year if, after applying some look-through rules, either:

at least 75% of its gross income for such taxable year is passive income (the income test), or
at least 50% of the total value of its assets (generally based on an average of the quarterly values of the assets during such year) is attributable to assets, including cash, that produce passive income or are held for the production of passive income (the asset test).

 

For this purpose, we will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other corporation in which we own, directly or indirectly, 25% (by value) of the stock.

Based on the value of our assets, including goodwill, and the composition of our income and assets, we do not believe we were a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2021. However, the application of the PFIC rules is subject to uncertainty in several respects, and we cannot assure investors that we will not be a PFIC for any taxable year.

 

If we are a PFIC for any taxable year during which you hold ADSs or ordinary shares, we generally will continue to be treated as a PFIC with respect to you for all succeeding years during which you hold our ordinary shares or ADSs, unless we cease to be a PFIC and you make a “deemed sale” election with respect to the ordinary shares or ADSs. If such election is timely made, you will be deemed to have sold the ADSs and ordinary shares you hold at their fair market value on the last day of the last taxable year in which we were as a PFIC and any gain from such deemed sale would be subject to the consequences described in the following two paragraphs. In addition, a new holding period would be deemed to begin for the ordinary shares and ADSs for purposes of the PFIC rules. After the deemed sale election, your ordinary shares or ADSs with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently become a PFIC.

 

For each taxable year that we are treated as a PFIC with respect to you, you will be subject to special tax rules with respect to any “excess distribution” that you receive and any gain you recognize from a sale or other disposition (including a deemed sale discussed in the preceding paragraph and a pledge) of the ADSs or ordinary shares, unless you make a “mark-to-market” election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable years or your holding period for the ADSs or ordinary shares will be treated as an excess distribution. Under these special tax rules:

the excess distribution or gain will be allocated ratably over your holding period for the ADSs or ordinary shares;
the amount allocated to the current taxable year, and any taxable year in your holding period prior to the first taxable year in which we were a PFIC, will be treated as ordinary income; and
the amount allocated to each other year will be subject to the highest tax rate in effect for individuals or corporations, as applicable, for each such year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.

 

In addition, non-corporate U.S. Holders will not be eligible for reduced rates of taxation on any dividends received from us (as described above under “—Taxation of Dividends and Other Distributions on the ADSs or Ordinary Shares”) if we are a PFIC in the taxable year in which such dividends are paid or in the preceding taxable year.

The tax liability for amounts allocated to taxable years prior to the year of disposition or “excess distribution” cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale or other disposition of the ADSs or ordinary shares cannot be treated as capital, even if you hold the ADSs or ordinary shares as capital assets.

 

If we are treated as PFIC with respect to you for any taxable year, to the extent any of our subsidiaries are also PFICs or we make direct or indirect equity investments in other entities that are PFICs, you may be deemed to own shares in such lower-tier PFICs that are directly or indirectly owned by us in that proportion which the value of the ADSs and ordinary shares you own bears to the value of all of the ADSs and ordinary shares, and you may be subject to the adverse tax consequences described in the preceding paragraphs with respect to the shares of such lower-tier PFICs that you would be deemed to own. You should consult your tax advisor regarding the applicability of the PFIC rules to any of our subsidiaries.

 

A U.S. Holder of “marketable stock” (as defined below) in a PFIC may make a mark-to-market election for such stock to elect out of the PFIC rules described above regarding excess distributions and recognized gains. If you make a valid mark-to-market election for the ADSs or ordinary shares, you will include in income for each year that we are a PFIC an amount equal to the excess, if any, of the fair market value of the ADSs or ordinary shares as of the close of your taxable year over your adjusted basis in such ADSs or ordinary shares. You will be allowed a deduction for the excess, if any, of the adjusted basis of the ADSs or ordinary shares over their

175


 

fair market value as of the close of the taxable year. However, deductions are allowable only to the extent of any net mark-to-market gains on the ADSs or ordinary shares included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition of the ADSs or ordinary shares, will be treated as ordinary income. Ordinary loss treatment will also apply to the deductible portion of any mark-to-market loss on the ADSs or ordinary shares, as well as to any loss realized on the actual sale or other disposition of the ADSs or ordinary shares, to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such ADSs or ordinary shares. Your basis in the ADSs or ordinary shares will be adjusted to reflect any such income or loss amounts. If you make a mark-to-market election, any distributions that we make would generally be subject to the tax rules discussed above under “—Taxation of Dividends and Other Distributions on the ADSs or Ordinary Shares,” except that the lower rate applicable to qualified dividend income (discussed above) would not apply.

 

The mark-to-market election is available only for “marketable stock,” which is other than de minimis quantities on at least 15 days during each calendar quarter (“regularly traded”) on a qualified exchange or other market, as defined in the applicable United States Treasury regulations. Nasdaq is a qualified exchange. Our ADSs are currently listed on Nasdaq and, consequently, if you are a holder of ADSs and the ADSs are regularly traded, the mark-to-market election may be available to you if we become a PFIC. Because a mark-to-market election may not be made for equity interests in any lower-tier PFICs we own, a U.S. Holder may continue to be subject to the PFIC rules with respect to its indirect interest in any investments held by us that are treated as an equity interest in a PFIC for United States federal income tax purposes. You should consult your tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such election on interests in any lower-tier PFICs.

 

Alternatively, if a non-United States corporation is a PFIC, a holder of shares in that corporation may avoid taxation under the PFIC rules described above regarding excess distributions and recognized gains by making a “qualified electing fund” election (a “QEF Election”) to include in income its share of the corporation’s income on a current basis. However, you may make a qualified electing fund election with respect to our ADSs or ordinary shares only if we agree to furnish you annually with some tax information. If we determine we are a PFIC for any taxable year, we intend to provide the information necessary for you to make a QEF Election with respect to us and intend to cause each lower-tier PFIC which we control to provide such information with respect to such lower-tier PFIC.

 

A U.S. Holder of a PFIC is generally required to file an annual report with the U.S. Internal Revenue Service. If we are or become a PFIC, you should consult your tax advisor regarding any reporting requirements that may apply to you.

 

You should consult your tax advisor regarding the application of the PFIC rules to your investment in ADSs or ordinary shares.

 

Information Reporting and Backup Withholding

 

Any dividend payments with respect to ADSs or ordinary shares and proceeds from the sale, exchange, redemption or other disposition of ADSs or ordinary shares may be subject to information reporting to the U.S. Internal Revenue Service and possible United States backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from backup withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification on Internal Revenue Service Form W-9. U.S. Holders should consult their tax advisors regarding the application of the United States information reporting and backup withholding rules.

 

Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your United States federal income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the U.S. Internal Revenue Service and furnishing any required information.

 

Additional Reporting Requirements

 

Some U.S. Holders who are individuals (and some entities) are required to report information relating to an interest in our ADSs or ordinary shares, subject to some exceptions (including an exception for ADSs and ordinary shares held in accounts maintained by some financial institutions). U.S. Holders should consult their tax advisors regarding the effect, if any, of these rules on the ownership and disposition of our ADSs or ordinary shares.

F. Dividends and Paying Agents.

Not applicable.

176


 

G. Statement by Experts.

Not applicable.

H. Documents on Display.

We are subject to the periodic reporting and other informational requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Under the Exchange Act, we are required to file reports and other information with the SEC. Specifically, we are required to file annually a Form 20-F containing financial statements audited by an independent registered public accounting firm no later than 120 days after the close of each fiscal year, which is December 31 of each year. The SEC also maintains a web site at www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of quarterly reports and proxy statements, and officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.

We also make available on our website, free of charge, our Annual Report and the text of our reports on Form 6-K, including any amendments to these reports, as well as some other SEC filings, as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Our website address is www.connectbiopharm.com. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated into this Annual Report.

I. Subsidiary Information.

Not applicable.

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Market risk is the risk that the fair value of, or future cash flows from, a financial instrument will vary due to changes in market prices. The type of market risk that primarily impacts us is foreign currency risk.

Interest rate risk

Our interest rate risk primarily arises from short-term investments in wealth management products measured at fair value through profit or loss and cash and cash equivalents. Those carried at variable rates expose us to cash flow interest rate risk whereas those at fixed rates expose us to fair value interest rate risk. We believe we did not have significant interest rate risk during the periods presented.

Exchange risk

As discussed above, we operate internationally and can be exposed to foreign exchange risk, primarily the USD. Foreign exchange risk arises from future commercial transactions and recognized assets and liabilities denominated in a currency that is not the functional currency of the relevant group entity. See detail to our potential exposure to foreign currency risk at the end of the reporting periods in the consolidated financial statements and the related footnote disclosure.

 

Most foreign exchange transactions were denominated in USD for the subsidiaries that have functional currency in RMB. For the years ended December 31, 2021 and 2020, if the USD strengthened/weakened by 5% against the RMB with all other variables held constant, net loss for the years then ended would have been RMB 1.6 million ($0.3 million) lower/higher and RMB 3.3 million ($0.5 million) lower/higher, respectively. We plan to monitor the exchange rate movement between USD and RMB to minimize potential risks.

Credit risk

Credit risk primarily arises from cash and cash equivalents, financial assets at fair value through profit or loss, and other receivables. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the balance sheets.

The credit risk of cash and cash equivalents and financial assets at fair value through profit or loss is limited because the counterparties are mainly state-owned or reputable commercial institutions located in the PRC and other reputable financial institutions located in Australia and the United States.

177


 

For other receivables, management makes periodic as well as individual assessments on the recoverability based on historical settlement records and past experience and adjusts for forward looking information based on macroeconomic factors affecting the ability of the debtors to settle the receivables.

We apply the expected credit loss model to financial assets measured at amortized cost. Impairment on other receivables is measured as either 12-month expected credit losses or lifetime expected credit losses, depending on whether there has been a significant increase in credit risk since initial recognition. To assess whether there is a significant increase in credit risk, we compare the risk of default occurring on the asset as of the reporting date with the risk of default as of the date of initial recognition by considering available, reasonable and supportive forwarding-looking information.

In view of the history of cooperation with debtors, the sound collection history of other receivables as well as forward-looking factors, we believe that the credit risk inherent in these outstanding receivables is not significant.

Liquidity risk

We aim to maintain sufficient cash, cash equivalents and short-term investments in wealth management products to meet obligations coming due as well as future operating and capital requirements.

 

Inflation Risk

 

We do not believe that inflation has had a material effect on our business, financial condition, or results of operations. If our costs become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition, and operating results.

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.

A. Debt Securities.

Not applicable.

B. Warrants and Rights.

Not applicable.

C. Other Securities.

Not applicable.

D. American Depositary Shares.

Deutsche Bank Trust Company Americas, as depositary, will register and deliver the ADSs. Each ADS will represent ownership of one ordinary share, deposited with Deutsche Bank AG, Hong Kong Branch, as custodian for the depositary. Each ADS will also represent ownership of any other securities, cash or other property which may be held by the depositary. The depositary’s corporate trust office at which the ADSs will be administered is located at 60 Wall Street, New York, NY 10005, USA. The principal executive office of the depositary is located at 60 Wall Street, New York, NY 10005, USA.

 

The Direct Registration System, or DRS, is a system administered by The Depository Trust Company, or DTC, pursuant to which the depositary may register the ownership of uncertificated ADSs, which ownership shall be evidenced by periodic statements issued by the depositary to the ADS holders entitled thereto.

 

We do not treat ADS holders as our shareholders and accordingly, you, as an ADS holder, will not have shareholder rights. Cayman Islands law governs shareholder rights. The depositary will be the holder of the ordinary shares underlying your ADSs. As a holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary and you, as an ADS holder, and the beneficial owners of ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. The laws of the State of New York govern the deposit agreement and the ADSs.

178


 

Fees and Expenses

As an ADS holder, an investor will be required to pay the following service fees to the depositary bank and specific taxes and governmental charges (in addition to any applicable fees, expenses, taxes and other governmental charges payable on the deposited securities represented by any of your ADSs):

 

 

Service

 

Fees

To any person to which ADSs are issued or to any person to which a distribution is made in respect of ADS distributions pursuant to stock dividends or other free distributions of stock, bonus distributions, stock splits or other distributions (except where converted to cash)

 

Up to US$0.05 per ADS issued

Cancellation of ADSs, including the case of termination of the deposit agreement

 

Up to US$0.05 per ADS cancelled

Distribution of cash dividends

 

Up to US$0.05 per ADS held

Distribution of cash entitlements (other than cash dividends) and/or cash proceeds from the sale of rights, securities and other entitlements

 

Up to US$0.05 per ADS held

Distribution of ADSs pursuant to exercise of rights.

 

Up to US$0.05 per ADS held

Distribution of securities other than ADSs or rights to purchase

additional ADSs

 

Up to US$0.05 per ADS held

Depositary services

 

Up to US$0.05 per ADS held on the applicable record date(s) established by the depositary bank

The depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

179


 

PART II

ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.

None.

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.

On March 18, 2021, the SEC declared effective our registration statement on Form F-1 (File No. 333-253631), as amended, filed in connection with our IPO (the “Registration Statement”). Pursuant to the Registration Statement, we registered the offer and sale of 12,937,500 of our ADSs, including up to 1,687,500 ADSs pursuant to the underwriters’ option to purchase additional ADSs. Jefferies LLC, SVB Leerink LLC, Piper Sandler & Co. and China International Capital Corporation Hong Kong Securities Limited acted as representatives of the underwriters for the offering.

On March 23, 2021, we issued and sold 12,937,500 of our ADSs, at a price to the public of $17.00 per share. The aggregate offering price of the shares sold was approximately $219.9 million. Upon completion of the IPO on March 23, 2021, we received net proceeds of $202.8 million, after deducting underwriting discounts, commissions and offering expenses of $17.1 million. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates.

The offering terminated after the sale of all securities registered pursuant to the Registration Statement. As of December 31, 2021, none of our IPO proceeds have been used.

 

Below is a summary of the currently expected use of the net proceeds from our IPO:

approximately $120 million to fund the clinical development of our product candidates;
approximately $20 million to fund the research and preclinical development program; and
the remainder to fund other current and future research and development activities and for working capital and other general corporate purposes, which may include capital projects.

ITEM 15. CONTROLS AND PROCEDURES.

(a) Disclosure Controls and Procedures.

As required by Rule 13a-15 under the Exchange Act, management, including our chief executive officer and our chief financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitations, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding our required disclosures.

Based on the foregoing, our chief executive officer and our chief financial officer have concluded that, as of December 31, 2021, our disclosure controls and procedures were not effective due to two material weaknesses in our internal control over financial reporting.

(b) Management’s Report on Internal Control over Financial Reporting.

This Annual Report does not include a report of management’s assessment regarding internal control over financial reporting due to a transition period established by rules of the SEC for newly public companies.

Material Weaknesses in Internal Control over Financial Reporting

In connection with the preparation and audit of our consolidated financial statements, as of and for the years ended December 31, 2021, we and our independent registered public accounting firm identified two material weaknesses in our internal control over the financial statement closing process. The material weaknesses that have been identified relate to (i) our lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of IFRS and the reporting and compliance requirements of the SEC to address complex IFRS technical accounting issues, and to prepare and review consolidated financial statements and related

180


 

disclosures in accordance with IFRS and SEC reporting requirements; and (ii) our lack of formal and effective financial closing policies and procedures, specifically those related to period-end expenses cut-off and accruals.

Remediation Plan for Material Weaknesses

We are working to remediate these material weaknesses and are taking steps to strengthen our internal control over financial reporting through the development and implementation of processes and controls over the financial reporting process. Specifically, we are working to:

implement the newly established period-end financial closing policies and procedures, including expense reconciliation between finance and operation departments;
execute the developed staffing plan for hiring additional accounting and finance personnel in 2022;
hire additional qualified resources with appropriate knowledge and expertise to handle complex accounting issues and effectively prepare financial statements; and
conduct regular and continuous IFRS accounting and financial reporting training programs for our financial reporting and accounting personnel.

 

(c) Report of Independent Registered Public Accounting Firm.

This Annual Report does not include an attestation report of the company’s registered public accounting firm due to a transition period established by rules of the SEC for newly public companies and because we are an emerging growth company under the JOBS Act.

(d) Changes in Internal Control over Financial Reporting.

This Annual Report does not include disclosure of changes in control over financial reporting due to a transition period established by rules of the SEC for newly public companies.

ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT.

The audit committee, which consists of Ms. Wilson, Dr. Xanthopoulos and Dr. Chen, assists the board in overseeing our accounting and financial reporting processes and the audits of our consolidated financial statements. Ms. Wilson serves as Chairman of the committee. The audit committee consists exclusively of members of our board who are financially literate, and Ms. Wilson is considered an “audit committee financial expert” as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations. Our board has determined that all of the members of the audit committee satisfy the “independence” requirements set forth in Rule 10A-3 under the Exchange Act. The audit committee is governed by a charter that complies with Nasdaq rules.

ITEM 16B. CODE OF ETHICS.

Our board of directors has adopted, a Code of Business Conduct and Ethics (the “Code of Conduct”) that is applicable to all of our employees, executive officers and directors. The Code of Conduct is available under the “Corporate Governance” section of our website at www.connectbiopharm.com. Our board of directors is responsible for overseeing the Code of Conduct and is required to approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this annual report.

181


 

ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

The following table sets forth the aggregate fees by categories specified below in connection with certain professional services rendered by PricewaterhouseCoopers Zhong Tian LLP, our principal external auditors, for the periods indicated.

 

 

 

Year Ended December 31,

 

 

2021

 

 

2020

 

 

USD’000

 

 

USD’000

Audit fees (1)

 

 

1,393

 

 

 

1,000

All other fees (2)

 

 

 

 

 

Total

 

 

1,393

 

 

 

1,000

 

(1)
“Audit fees” means the aggregate fees billed in each of the fiscal years listed for professional services rendered by our principal auditors for the audit of our consolidated and subsidiary financial statements and other audit or interim review services provided in connection with statutory and regulatory filings or engagements.
(2)
“All other fees” means the aggregate fees billed in each of the fiscal years listed for products and services provided by our principal auditors, other than the services reported under audit fees, audit-related fees and tax fees.

 

Audit Committee Pre-approval Policies and Procedures

Our audit committee has adopted procedures which set forth the manner in which the committee will review and approve all audit and non-audit services to be provided by PricewaterhouseCoopers Zhong Tian LLP. The pre-approval procedures are as follows:

Any audit or non-audit service to be provided to us by the independent accountant must be (i) pre-approved by the audit committee; or (ii) pre-approved by one or several committee members designated by the committee and ratified by the audit committee.

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES.

Not applicable.

ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS.

None.

ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT.

Not applicable.

ITEM 16G. CORPORATE GOVERNANCE.

As a Cayman Islands exempted company incorporated with limited liability, we are subject to various corporate governance requirements under Cayman Islands law. In addition, as a foreign private issuer listed on Nasdaq, we are subject to the Nasdaq corporate governance listing standards. However, Nasdaq’s listing standards provide that foreign private issuers are permitted to follow home country corporate governance practices in lieu of the Nasdaq rules, with some exceptions. Some corporate governance practices in Cayman Islands may differ significantly from corporate governance listing standards. For example, neither the corporate laws of the Cayman Islands nor our amended and restated memorandum and articles require that (i) a majority of our directors be independent, (ii) our compensation committee include only independent directors, or (iii) our independent directors hold regularly scheduled meetings at which only independent directors are present. Other than as set forth below, we currently comply with the corporate governance listing standards of Nasdaq to the extent possible under Cayman Islands law. However, we may choose to change such practices to follow home country practice in the future.

Although we are a foreign private issuer, we are required to comply with Rule 10A-3 of the Exchange Act, relating to audit committee composition and responsibilities. Rule 10A-3 provides that the audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control over the performance of their duties, management of complaints made, and selection of consultants. Under Rule 10A-3, if the laws of a foreign private issuer’s home country require that any such matter be approved by the board of directors or the shareholders of the Company, the audit committee’s responsibilities or powers with respect to such matter may instead be advisory.

182


 

In addition, Nasdaq rules require that a listed company specify that the quorum for any meeting of the holders of share capital be at least 33 1/3% of the outstanding shares of the company’s common voting stock. As provided under our post-listing amended and restated memorandum and articles of association, and as permitted by Cayman Islands law, a quorum required for and throughout a meeting of shareholders consists of one or more shareholders entitled to vote and present in person or by proxy or (in the case of a shareholder being a corporation) by its duly authorized representative holding shares which carry in aggregate not less than one-third of all votes attaching to all of our shares in issue and entitled to vote.

Additionally, Nasdaq rules require that the independent directors of listed companies hold regularly scheduled meetings at which only independent directors are present. We intend to follow our Cayman Islands home country practice, rather than complying with this Nasdaq rule.

Further, Nasdaq rules require that listed companies have a nominations committee comprised solely of independent directors. We intend to follow our Cayman Islands home country practice, as described in the section titled Item 6. “Directors, Senior Management and Employees – Board Practices,” rather than complying with this Nasdaq rule.

Also, the Nasdaq rules require each issuer to hold an annual meeting of shareholders no later than one year after the end of the issuer’s fiscal year. We intend to follow our home country practice with respect to annual meetings of shareholders and did not hold an annual meeting of shareholders in the year ended December 31, 2021. We may, however, hold annual meetings of shareholders in the future if there are significant issues that require approval of shareholders.

ITEM 16H. MINE SAFETY DISCLOSURE.

Not applicable.

ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

Not applicable.

183


 

PART III

ITEM 17. FINANCIAL STATEMENTS.

We have elected to furnish financial statements and related information specified in Item 18.

ITEM 18. FINANCIAL STATEMENTS.

Financial statements are filed as part of this Annual Report beginning on page F-1.

184


 

ITEM 19. EXHIBITS.

List all exhibits filed as part of the registration statement or annual report, including exhibits incorporated by reference.

 

 

Incorporation by Reference

Exhibit No.

Description

Form

File No.

Exhibit No.

Filing Date

Filed / Furnished

1.1

Fifth Amended and Restated Memorandum and Articles of Association of Connect Biopharma Holdings Limited

 

 

 

 

*

2.1

Specimen Certificate for Ordinary Shares

F-1/A

333-253631

4.1

3/12/2021

 

2.2

Deposit Agreement, among Connect Biopharma Holdings Limited, the depositary, and the holders and beneficial owners of American Depositary Shares issued thereunder

S-8

333-254524

4.3

3/19/2021

 

2.3

Specimen American Depositary Receipt (included in Exhibit 2.2)

S-8

333-254524

4.3

3/19/2021

 

2.4

Second Amended and Restated Shareholders Agreement, dated as of December 1, 2020, between Connect Biopharma Holdings Limited, its subsidiaries and certain of its shareholders

F-1

333-253631

4.4

2/26/2021

 

2.5

Description of Securities

 

 

 

 

*

4.1

Form of Indemnification Agreement

F-1/A

333-253631

10.2

3/17/2021

 

4.2†

Connect Biopharma Holdings Limited 2019 Stock Incentive Plan

F-1

333-253631

10.1

2/26/2021

 

4.3†

2021 Incentive Award Plan and form of share option grant notice and share option agreement thereunder

F-1/A

333-253631

10.3

3/12/2021

 

4.4†

2021 Employee Share Purchase Plan

F-1/A

333-253631

10.4

3/12/2021

 

4.5†

Non-Employee Director Compensation Program

 

 

 

 

*

4.6†

Employment Agreement, effective as of January 1, 2021, between Connect Biopharm LLC and Zheng Wei, Ph.D.

F-1

333-253631

10.11

2/26/2021

F-1

4.7†

Employment Agreement, effective as of January 1, 2021, between Connect Biopharma HongKong Limited and Wubin Pan, Ph.D.

F-1

333-253631

10.12

2/26/2021

F-1

4.8†

Employment Letter, dated January 19, 2021, between Connect Biopharm LLC and Selwyn Ho, MB BS, as amended

F-1

333-253631

10.14

2/26/2021

F-1

4.9†

Contract of Employment, dated January 20, 2021, between Globalization Partners Limited and Selwyn Ho, MB BS

F-1

333-253631

10.15

2/26/2021

F-1

4.10†

Employment Letter, dated October 13, 2021, between Connect Biopharm LLC and Steven Chan

 

 

 

 

*

4.11†

Employment Letter, dated November 2, 2021, between Connect Biopharm LLC and Chin Lee, M.D.

 

 

 

 

*

4.12

English translation of House Lease Contract, dated April 9, 2021, between Suzhou Connect Biopharma Co., Ltd. and Taicang Science and Technology Venture Park Co., Ltd.

 

 

 

 

*

4.13

Lease Contract, effective as of December 22, 2021, between Connect Biopharm LLC and Paseo Del Mar LLC

 

 

 

 

*

8.1

List of Subsidiaries

 

 

 

 

*

12.1

Principal Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

*

12.2

Principal Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

*

13.1

Principal Executive Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

**

13.2

Principal Financial Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

**

15.1

Consent of PricewaterhouseCoopers Zhong Tian LLP, an independent registered public accounting firm.

 

 

 

 

*

 

185


 

101.INS

Inline XBRL Instance Document.

 

 

 

 

*

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

 

*

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

 

*

101.DEF

Inline XBRL Taxonomy Definition Linkbase Document.

 

 

 

 

*

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

 

 

 

*

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

*

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

 

* Filed herewith.

** Furnished herewith.

† Indicates management contract or compensatory plan or arrangement.

Some agreements filed as exhibits to this Annual Report contain representations and warranties that the parties thereto made to each other. These representations and warranties have been made solely for the benefit of the other parties to such agreements and may have been qualified by specific information that has been disclosed to the other parties to such agreements and that may not be reflected in such agreements. In addition, these representations and warranties may be intended as a way of allocating risks among parties if the statements contained therein prove to be incorrect, rather than as actual statements of fact. Accordingly, there can be no reliance on any such representations and warranties as characterizations of the actual state of facts. Moreover, information concerning the subject matter of any such representations and warranties may have changed since the date of such agreements.

186


 

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

 

 

 

Connect Biopharma Holdings Limited

 

 

 

Date: March 31, 2022

 

/s/ Steven Chan

 

 

Steven Chan, Chief Financial Officer

 

187


 

CONNECT BIOPHARMA HOLDINGS LIMITED

 

INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Audited consolidated financial statements:

PAGE

 

 

 

 

 

Report of Independent Registered Public Accounting Firm (PCAOB ID 1424 )

F-2

 

Consolidated Statements of Loss for the Years Ended December 31, 2019, 2020 and 2021

F-3

 

Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2019, 2020 and 2021

F-4

 

Consolidated Balance Sheets as of December 31, 2020 and 2021

F-5

 

Consolidated Statements of Changes in Shareholders’ (Deficit)/Equity for the Years Ended December 31, 2019, 2020 and 2021

F-6

 

Consolidated Statements of Cash Flows for the Years Ended December 31, 2019, 2020 and 2021

F-8

 

Notes to Consolidated Financial Statements

F-9

 

 

 

 

 

 

F-1


 

Report of Independent Registered Public Accounting Firm

 

To the Board of Directors and Shareholders of Connect Biopharma Holdings Limited

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Connect Biopharma Holdings Limited and its subsidiaries (the “Company”) as of December 31, 2021 and 2020, and consolidated statements of loss, comprehensive loss, changes in shareholders’ (deficit)/equity and cash flows for each of the three years in the period ended December 31, 2021, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/PricewaterhouseCoopers Zhong Tian LLP

 

Beijing, the People’s Republic of China

March 31, 2022

 

We have served as the Company’s auditor since 2020.

F-2


 

CONNECT BIOPHARMA HOLDINGS LIMITED

 

Consolidated Statements of Loss

 

 

 

 

 

Year Ended December 31,

 

 

 

Notes

 

2019

 

 

2020

 

 

2021

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

USD’000
Note 2.5

 

Research and development expenses

 

5

 

 

(106,414

)

 

 

(150,932

)

 

 

(518,021

)

 

 

(81,249

)

Administrative expenses

 

5

 

 

(9,713

)

 

 

(47,720

)

 

 

(122,445

)

 

 

(19,205

)

Other income

 

7

 

 

2,836

 

 

 

6,989

 

 

 

18,996

 

 

 

2,979

 

Other gains/(losses)—net

 

8

 

 

3,050

 

 

 

(6,100

)

 

 

(9,966

)

 

 

(1,563

)

Operating loss

 

 

 

 

(110,241

)

 

 

(197,763

)

 

 

(631,436

)

 

 

(99,038

)

Finance income

 

9

 

 

1,066

 

 

 

717

 

 

 

622

 

 

 

98

 

Finance cost

 

9

 

 

(53

)

 

 

(2,893

)

 

 

(44

)

 

 

(7

)

Finance income/(cost)—net

 

9

 

 

1,013

 

 

 

(2,176

)

 

 

578

 

 

 

91

 

Fair value loss of financial instruments with preferred rights

 

24

 

 

(59,397

)

 

 

(579,286

)

 

 

(674,269

)

 

 

(105,756

)

Loss before income tax

 

 

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,305,127

)

 

 

(204,703

)

Income tax expense

 

10

 

 

 

 

 

 

 

 

(1,697

)

 

 

(266

)

Net loss

 

 

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,306,824

)

 

 

(204,969

)

Loss attributable to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Owners of the Company

 

 

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,306,824

)

 

 

(204,969

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RMB

 

 

RMB

 

 

RMB

 

 

USD

 

Loss per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

11

 

 

(10.0

)

 

 

(45.6

)

 

 

(25.0

)

 

 

(3.9

)

 

The accompanying notes are an integral part of these consolidated financial statements.

F-3


 

CONNECT BIOPHARMA HOLDINGS LIMITED

 

Consolidated Statements of Comprehensive Loss

 

 

 

 

 

Year Ended December 31,

 

 

 

Notes

 

2019

 

 

2020

 

 

2021

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

USD’000
Note 2.5

 

Net loss

 

 

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,306,824

)

 

 

(204,969

)

Other comprehensive (loss)/income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Items that may be reclassified to profit or loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exchange differences on translation of foreign operations

 

 

 

 

(6,027

)

 

 

34,655

 

 

 

20,426

 

 

 

3,204

 

Items that will not be reclassified to profit or loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exchange differences on translation of foreign operations

 

 

 

 

(466

)

 

 

12,377

 

 

 

(57,464

)

 

 

(9,013

)

Other comprehensive (loss)/income for the year, net of tax

 

 

 

 

(6,493

)

 

 

47,032

 

 

 

(37,038

)

 

 

(5,809

)

Total comprehensive loss for the year

 

 

 

 

(175,118

)

 

 

(732,193

)

 

 

(1,343,862

)

 

 

(210,778

)

Total comprehensive loss attributable to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Owners of the Company

 

 

 

 

(175,118

)

 

 

(732,193

)

 

 

(1,343,862

)

 

 

(210,778

)

 

The accompanying notes are an integral part of these consolidated financial statements.

F-4


 

CONNECT BIOPHARMA HOLDINGS LIMITED

 

Consolidated Balance Sheets

 

 

 

 

 

As of December 31,

 

 

 

Notes

 

2020

 

 

2021

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

USD’000
Note 2.5

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

 

 

 

 

 

Property, plant and equipment

 

12

 

 

6,939

 

 

 

59,337

 

 

 

9,307

 

Right-of-use assets

 

14

 

 

929

 

 

 

22,821

 

 

 

3,579

 

Other non-current assets

 

13

 

 

19,860

 

 

 

18,806

 

 

 

2,950

 

Intangible assets

 

 

 

 

342

 

 

 

560

 

 

 

88

 

Total non-current assets

 

 

 

 

28,070

 

 

 

101,524

 

 

 

15,924

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

Other receivable and prepayments

 

16

 

 

33,655

 

 

 

47,255

 

 

 

7,412

 

Financial assets at fair value through profit or loss

 

17

 

 

13,068

 

 

 

 

 

 

 

Cash and cash equivalents

 

18

 

 

1,010,076

 

 

 

1,706,880

 

 

 

267,716

 

Total current assets

 

 

 

 

1,056,799

 

 

 

1,754,135

 

 

 

275,128

 

Total assets

 

 

 

 

1,084,869

 

 

 

1,855,659

 

 

 

291,052

 

LIABILITIES

 

 

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

 

 

 

Lease liabilities

 

14

 

 

309

 

 

 

163

 

 

 

26

 

Financial instruments with preferred rights

 

24

 

 

2,071,508

 

 

 

 

 

 

 

Deferred income

 

 

 

 

 

 

 

5,000

 

 

 

784

 

Total non-current liabilities

 

 

 

 

2,071,817

 

 

 

5,163

 

 

 

810

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

 

Trade payables

 

 

 

 

24,638

 

 

 

81,195

 

 

 

12,735

 

Other payables and accruals

 

23

 

 

12,755

 

 

 

32,840

 

 

 

5,152

 

Lease liabilities

 

14

 

 

604

 

 

 

630

 

 

 

98

 

Total current liabilities

 

 

 

 

37,997

 

 

 

114,665

 

 

 

17,985

 

Total liabilities

 

 

 

 

2,109,814

 

 

 

119,828

 

 

 

18,795

 

Net (liabilities)/assets

 

 

 

 

(1,024,945

)

 

 

1,735,831

 

 

 

272,257

 

SHAREHOLDERS’ (DEFICIT)/EQUITY

 

 

 

 

 

 

 

 

 

 

 

Share capital

 

19

 

 

24

 

 

 

66

 

 

 

10

 

Share premium

 

19

 

 

41,466

 

 

 

4,094,434

 

 

 

642,194

 

Treasury shares

 

20

 

 

(3

)

 

 

(1,164

)

 

 

(183

)

Share-based compensation reserves

 

21(a)

 

 

6,602

 

 

 

61,904

 

 

 

9,709

 

Other reserves

 

21(b)

 

 

(1,693

)

 

 

(41,244

)

 

 

(6,469

)

Accumulated losses

 

 

 

 

(1,071,341

)

 

 

(2,378,165

)

 

 

(373,004

)

Total shareholders’ (deficit)/equity

 

 

 

 

(1,024,945

)

 

 

1,735,831

 

 

 

272,257

 

Total liabilities and shareholders’ (deficit)/equity

 

 

 

 

1,084,869

 

 

 

1,855,659

 

 

 

291,052

 

 

The accompanying notes are an integral part of these consolidated financial statements.

F-5


 

CONNECT BIOPHARMA HOLDINGS LIMITED

 

Consolidated Statements of Changes in Shareholders’ (Deficit)/Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-Based

 

 

 

 

 

 

 

 

Total

 

 

 

 

 

Share

 

 

Share

 

 

Treasury

 

 

Compensation

 

 

Other

 

 

Accumulated

 

 

Shareholders’

 

 

 

Notes

 

Capital

 

 

Premium

 

 

Shares

 

 

Reserves

 

 

Reserves

 

 

Losses

 

 

Deficit

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Balance at January 1, 2019

 

 

 

 

21

 

 

 

38,074

 

 

 

(1

)

 

 

584

 

 

 

(42,280

)

 

 

(123,491

)

 

 

(127,093

)

Comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(168,625

)

 

 

(168,625

)

Exchange differences

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6,493

)

 

 

 

 

 

(6,493

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6,493

)

 

 

(168,625

)

 

 

(175,118

)

Transactions with owners

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock options

 

22

 

 

 

 

 

49

 

 

 

 

 

 

(48

)

 

 

48

 

 

 

 

 

 

49

 

Share-based compensations

 

6

 

 

 

 

 

 

 

 

 

 

 

3,875

 

 

 

 

 

 

 

 

 

3,875

 

 

 

 

 

 

 

 

 

49

 

 

 

 

 

 

3,827

 

 

 

48

 

 

 

 

 

 

3,924

 

Balance at December 31, 2019

 

 

 

 

21

 

 

 

38,123

 

 

 

(1

)

 

 

4,411

 

 

 

(48,725

)

 

 

(292,116

)

 

 

(298,287

)

Comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(779,225

)

 

 

(779,225

)

Exchange differences

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

47,032

 

 

 

 

 

 

47,032

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

47,032

 

 

 

(779,225

)

 

 

(732,193

)

Transactions with owners

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of shares to co-founders

 

22

 

 

1

 

 

 

3,343

 

 

 

 

 

 

(3,344

)

 

 

 

 

 

 

 

 

 

Issuance of treasury shares

 

20

 

 

2

 

 

 

 

 

 

(2

)

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensations

 

6

 

 

 

 

 

 

 

 

 

 

 

5,535

 

 

 

 

 

 

 

 

 

5,535

 

 

 

 

 

 

3

 

 

 

3,343

 

 

 

(2

)

 

 

2,191

 

 

 

 

 

 

 

 

 

5,535

 

Balance at December 31, 2020

 

 

 

 

24

 

 

 

41,466

 

 

 

(3

)

 

 

6,602

 

 

 

(1,693

)

 

 

(1,071,341

)

 

 

(1,024,945

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6


 

CONNECT BIOPHARMA HOLDINGS LIMITED

 

Consolidated Statements of Changes in Shareholders’ (Deficit)/Equity

 

 

 

 

 

 

 

 

 

Notes

 

Share Capital

 

 

Share Premium

 

 

Treasury Shares

 

 

Share-Based Compensation Reserves

 

 

Other Reserves

 

 

Accumulated Losses

 

 

Total Shareholders’ (Deficit)/Equity

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Balance at January 1, 2021

 

 

 

 

24

 

 

 

41,466

 

 

 

(3

)

 

 

6,602

 

 

 

(1,693

)

 

 

(1,071,341

)

 

 

(1,024,945

)

Comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,306,824

)

 

 

(1,306,824

)

Exchange differences

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(37,038

)

 

 

 

 

 

(37,038

)

.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(37,038

)

 

 

(1,306,824

)

 

 

(1,343,862

)

Transactions with owners

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of ordinary shares, net of issuance costs

 

19

 

 

14

 

 

 

1,305,805

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,305,819

 

Conversion from preferred shares to ordinary shares

 

19

 

 

28

 

 

 

2,743,597

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,743,625

 

Repurchase of ordinary shares

 

20

 

 

 

 

 

 

 

 

(1,161

)

 

 

 

 

 

(2,513

)

 

 

 

 

 

(3,674

)

Issuance of shares to co-founders

 

22

 

 

 

 

 

1,417

 

 

 

 

 

 

(1,417

)

 

 

 

 

 

 

 

 

 

Exercise of stock options

 

22

 

 

 

 

 

2,149

 

 

 

 

 

 

(1,144

)

 

 

 

 

 

 

 

 

1,005

 

Share-based compensations

 

6

 

 

 

 

 

 

 

 

 

 

 

57,863

 

 

 

 

 

 

 

 

 

57,863

 

.

 

 

 

 

42

 

 

 

4,052,968

 

 

 

(1,161

)

 

 

55,302

 

 

 

(2,513

)

 

 

 

 

 

4,104,638

 

Balance at December 31, 2021

 

 

 

 

66

 

 

 

4,094,434

 

 

 

(1,164

)

 

 

61,904

 

 

 

(41,244

)

 

 

(2,378,165

)

 

 

1,735,831

 

 

The accompanying notes are an integral part of these consolidated financial statements.

F-7


 

CONNECT BIOPHARMA HOLDINGS LIMITED

 

Consolidated Statements of Cash Flows

 

 

 

Notes

 

Year Ended December 31,

 

 

 

 

 

2019

 

 

2020

 

 

2021

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash used in operations

 

25(a)

 

 

(90,256

)

 

 

(167,161

)

 

 

(544,926

)

 

 

(85,469

)

Net cash used in operating activities

 

 

 

 

(90,256

)

 

 

(167,161

)

 

 

(544,926

)

 

 

(85,469

)

Cash flows from investing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

 

 

(1,072

)

 

 

(14,955

)

 

 

(24,941

)

 

 

(3,912

)

Purchase of financial assets at fair value through profit or loss

 

 

 

 

(163,000

)

 

 

(106,600

)

 

 

(114,500

)

 

 

(17,959

)

Proceeds from disposal of financial assets at fair value through profit or loss

 

 

 

 

160,731

 

 

 

124,836

 

 

 

128,004

 

 

 

20,076

 

Payment for right-of-use assets

 

 

 

 

 

 

 

 

 

 

(22,284

)

 

 

(3,495

)

Purchase of intangible assets

 

 

 

 

 

 

 

(349

)

 

 

(304

)

 

 

(48

)

Net cash (used in)/generated from investing activities

 

 

 

 

(3,341

)

 

 

2,932

 

 

 

(34,025

)

 

 

(5,338

)

Cash flows from financing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from exercise of options

 

 

 

 

49

 

 

 

 

 

 

243

 

 

 

38

 

Proceeds from issuance of ordinary shares

 

 

 

 

 

 

 

 

 

 

1,431,775

 

 

 

224,567

 

Proceeds from issuance of financial instruments with preferred rights

 

24,25(c)

 

 

 

 

 

923,247

 

 

 

 

 

 

 

Payment for lease liabilities

 

25(c)

 

 

(445

)

 

 

(538

)

 

 

(805

)

 

 

(126

)

Payment for repurchase of ordinary shares

 

 

 

 

 

 

 

 

 

 

(3,674

)

 

 

(576

)

Issuance cost of financial instruments with preferred rights

 

9

 

 

 

 

 

(2,851

)

 

 

 

 

 

 

Payment in relation to listing expenses

 

 

 

 

 

 

 

(1,097

)

 

 

(111,440

)

 

 

(17,479

)

Net cash (used in)/generated from financing activities

 

 

 

 

(396

)

 

 

918,761

 

 

 

1,316,099

 

 

 

206,424

 

Net (decrease) increase in cash and cash equivalents

 

 

 

 

(93,993

)

 

 

754,532

 

 

 

737,148

 

 

 

115,617

 

Cash and cash equivalents at the beginning of year

 

 

 

 

401,597

 

 

 

308,972

 

 

 

1,010,076

 

 

 

158,426

 

Effects of exchange rate changes on cash and cash equivalents

 

 

 

 

1,368

 

 

 

(53,428

)

 

 

(40,344

)

 

 

(6,327

)

Cash and cash equivalents at end of year

 

 

 

 

308,972

 

 

 

1,010,076

 

 

 

1,706,880

 

 

 

267,716

 

 

The accompanying notes are an integral part of these consolidated financial statements.

F-8


 

CONNECT BIOPHARMA HOLDINGS LIMITED

 

Notes to the Consolidated Financial Statements

1. General Information, Reorganization and Basis of Presentation

1.1 General information

 

Connect Biopharma Holdings Limited (the “Company”) was incorporated on November 23, 2015 in the Cayman Islands as an exempted company with limited liability. The address of the Company’s registered office is P.O. Box 613, Harbour Centre, George Town, Grand Cayman KY1-1107, Cayman Islands. The Company completed its initial public offering (“IPO”) in March 2021 and the Company’s American Depositary Shares (“ADSs”) have been listed on the Nasdaq Global Market (“Nasdaq”) since then. Each ADS of the Company represents one ordinary share, par value USD 0.000174 per share.

 

The Company and its subsidiaries (collectively the “Group”) is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. The Group has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. The Group currently carries out clinical trials on its product candidates in the United States, People’s Republic of China (“PRC”), Australia, Europe, and other jurisdictions.

 

As of December 31, 2021, the Group had direct or indirect interests in the following principal subsidiaries:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Company name

 

Principal activities

 

Place and date of incorporation

 

Attributable equity interest to the Group

 

Directly Held:

 

 

 

 

 

 

 

Connect Biopharma HongKong Limited (“Connect HK”)

 

Investment holding

 

Hong Kong/December 1, 2015

 

 

100

%

Indirectly held:

 

 

 

 

 

 

 

Connect Biopharm LLC (“Connect US”)

 

Pharmaceutical R&D

 

San Diego, United States of America January 24, 2012

 

 

100

%

Connect Biopharma Australia PTY LTD (“Connect AU”)

 

Pharmaceutical R&D

 

Prahran, Australia/July 18, 2014

 

 

100

%

Suzhou Connect Biopharma Co., Ltd. (“Connect SZ”)

 

Pharmaceutical R&D

 

Suzhou, PRC/May 2, 2012

 

 

100

%

Connect Biopharma (Shanghai) Co., Ltd

 

Pharmaceutical R&D

 

Shanghai, PRC/October 23, 2015

 

 

100

%

Connect Biopharma (Beijing) Co., Ltd

 

Pharmaceutical R&D

 

Beijing, PRC/July 9, 2019

 

 

100

%

Connect Biopharma (Shenzhen) Co., Ltd

 

Dormant

 

Shenzhen, PRC/November 15, 2021

 

 

100

%

 

2. Summary of Significant Accounting Policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

2.1 Basis of preparation

The Group’s consolidated financial statements were prepared in accordance with International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”). The Group adopted and transitioned to IFRS issued by IASB on January 1, 2018. The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through profit or loss and financial instruments with preferred rights. In preparing its consolidated financial statements prepared under IFRS, the Group early adopted IFRS 9 Financial Instruments (“IFRS 9”) and IFRS 16 Leases (“IFRS 16”) on January 1, 2018.

The Group has applied the following standards and amendments for the first time for their annual reporting period commencing January 1, 2021, which did not have any material impact on the consolidated financial statements:

Amendment to IFRS 16, ‘Leases’ – COVID-19 related rent concessions – Extension of the practical expedient.

F-9


 

The consolidated financial statements for the years ended December 31, 2019, 2020 and 2021 were authorized for issue by the Company’s board of directors (the “Board”) on March 31, 2022.

Liquidity

As of December 31, 2021, the Group had net assets of RMB 1,735.8 million, and accumulated losses of RMB 2,378.2 million. For the year ended December 31, 2021, the Group had net operating loss of RMB 631.4 million and net operating cash outflow of RMB 544.9 million. The principal sources of funding have historically been continuous cash contributions from equity holders and preferred shareholders. The cumulative contributions up through December 31, 2021 approximated USD 440.1 million, among which included USD 219.9 million of proceeds from issuance of ordinary shares in connection with the IPO or RMB 1,431.8 million based on the exchange rate as of the date of the IPO. As of December 31, 2021, the Group had a cash and cash equivalents balance of RMB 1,706.9 million, which it believes to be sufficient available financial resources to meet its obligations becoming due and working capital requirements in the next twelve months from the date of issuance of these financial statements. Accordingly, the Group considers that it is appropriate to prepare the consolidated financial information on a going concern basis.

Impact of COVID-19

In December 2019, a novel strain of coronavirus was reported in Wuhan, China and on March 11, 2020 the WHO declared COVID-19 a pandemic. The COVID-19 pandemic has resulted in a widespread health crisis and numerous disease control measures being taken to limit its spread. As the pandemic continues its impact throughout the world, the healthcare systems of the various countries in which the Group is conducting ongoing clinical trials of CBP-201 and CBP-307 have and may continue to experience great disruption. Enrollment of the Group’s Phase 2 clinical trial of CBP-307 in patients in China was prematurely terminated due to challenges in recruitment caused by the COVID-19 pandemic.

The Group will continue to monitor and assess the impact of the ongoing development of the pandemic on the Group’s clinical trials and for any impact to its financial position and operating results.

2.2 New and amended standards and interpretations not yet adopted by the Group

The Group has not applied the following new and revised IFRSs that have been issued but are not yet effective in the consolidated financial statements.

 

 

 

Effective for annual periods beginning on or after

 

Scope amendments to IFRS 3, IAS 16, IAS 37 and some annual improvements on IFRS 1, IFRS 9, IAS 41 and IFRS 16

 

January 1, 2022

 

Narrow scope amendments to IAS 1, Practice statement 2 and IAS 8

 

January 1, 2023

 

Amendment to IAS 12 – Deferred tax related to assets and liabilities arising from a single transaction

 

 January 1, 2023

 

Amendments to IAS 1, Presentation of financial statements’, on classification of liabilities

 

January 1, 2024

 

 

The Group expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a material impact on disclosures or amounts reported in the Group’s consolidated financial statements in the period of initial application and future reporting periods.

 

2.3 Principles of consolidation

Subsidiaries

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

Intra-group transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group’s accounting policies.

2.4 Separate financial statements

F-10


 

Investments in subsidiaries are accounted for at cost less impairment. Cost includes direct attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividends received and receivable.

Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee’s net assets including goodwill.

2.5 Foreign currency translation

(a) Functional and presentation currency

 

The consolidated financial statements of the Group are presented in RMB as the historical records for its entities were set-up for consolidations in RMB.

 

The functional currency of the Company is USD. Other subsidiaries have functional currencies in USD, RMB and Australian dollars.

 

(b) Transactions and balances

 

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.

 

Since the Group has no borrowings, all foreign exchange gains or losses are presented in the consolidated statements of loss on a net basis within other gains/(losses)-net.

 

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income.

(c) Group companies

 

The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

 

assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;
income and expenses for each statement of loss and comprehensive income/(loss) are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions); and
all resulting currency translation differences are recognized in other comprehensive income/loss.

 

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.

 

(d) Convenience translation

 

Translations of the consolidated balance sheet, the consolidated statement of loss, consolidated statement of comprehensive loss and consolidated statement of cash flows from RMB into USD as of and for the year ended December 31, 2021 are solely for the convenience of the readers and calculated at the rate of USD1.00=RMB 6.3757, representing the exchange rate as of December 31, 2021 set forth in the China Foreign Exchange Trade System. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into USD at that rate, or at any other rate, on December 31, 2021.

 

2.6 Property, plant and equipment

F-11


 

Property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

 

Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

 

The Group’s assets under construction represents buildings and equipment under construction and pending installation, and is stated at cost less accumulated impairment losses, if any. Costs include construction and acquisition costs. No provision for depreciation is made on assets under construction until such time as the assets are completed and ready for its intended use. Once the asset becomes available for use, it is transferred to the appropriate category of assets.

 

Depreciation is calculated using the straight-line method to allocate the cost, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements, the shorter lease term as follows:

 

Assets

 

Useful life

Laboratory equipment

 

5-10 years

Leasehold improvements

 

Shorter of lease term or 5 years

Office equipment and furniture

 

3-5 years

 

The assets’ residual values and useful lives are reviewed and adjusted if appropriate at the end of each reporting period.

 

An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount (Note 2.8).

 

Gains and losses on disposals are determined by comparing proceeds with carrying amount and are recognized within other gains/(losses)—net in the statements of loss.

 

2.7 Intangible assets

 

Software

 

Acquired software licenses are capitalized on the basis of the costs incurred to acquire and bring the specific software into usage. These costs are amortized using the straight-line method over their estimated useful lives of approximately 10 years. Costs associated with maintaining software programs are recognized as expense as incurred.

 

2.8 Impairment of non-financial assets

 

Non-financial assets other than goodwill and intangible assets that have an indefinite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

 

2.9 Investments and other financial assets

 

(a) Classification

 

The Group classifies its financial assets in the following measurement categories:

 

those to be measured subsequently at fair value (either through other comprehensive income (“OCI”) or through profit or loss), and
those to be measured at amortized cost.

 

F-12


 

The classification depends on the entity’s business model for managing the financial assets and the contractual terms of the cash flows.

 

For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through OCI (“FVOCI”).

 

The Group reclassifies debt investments when and only when its business model for managing those assets changes.

 

(b) Recognition and derecognition

 

Regular way purchases and sales of financial assets are recognized on trade date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

 

(c) Measurement

 

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (“FVPL”), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial asset carried at FVPL are expensed in profit or loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

(i)
Debt instruments

 

Subsequent measurement of debt instruments depends on the Group’s business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the Group classifies its debt instruments:

Amortized cost: Assets that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortized cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains/(losses), together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the statements of loss.
FVOCI: Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets’ cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses which are recognized in profit or loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains/(losses). Interest income from these financial assets is included in finance income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains/(losses) and impairment expenses are presented as a separate line item in the statements of loss.
FVPL: Assets that do not meet the criteria for amortized cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured at FVPL is recognized in profit or loss and presented net within other gains/(losses) in the period in which it arises.
(ii)
Equity instruments

 

The Group subsequently measures all equity investments at fair value. Where the Group’s management has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognized in profit or loss as other income when the Group’s right to receive payments is established.

 

Changes in the fair value of financial assets at FVPL are recognized in other gains/(losses) in the statements of loss as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.

 

There were no equity investments during the reporting periods.

 

F-13


 

(d) Impairment

 

The Group assesses on a forward-looking basis the expected credit loss associated with its debt instruments carried at amortized cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk refer to Note 3.1(b) for further details.

 

2.11 Cash and cash equivalents

 

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

 

2.12 Share capital

 

Ordinary shares are classified as equity. Mandatorily redeemable preferred shares are classified as liabilities. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

 

Where any Group company purchases the Company’s equity instruments, for example as the result of a share buy-back or a share-based payment plan, the consideration paid, including any directly attributable incremental costs (net of income taxes), is deducted from equity attributable to the owners of the Group as treasury shares until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the owners of the Group.

 

Shares held by Connect Union, which was established for the purpose of holding shares for the share incentive plans are disclosed as treasury shares and deducted from contributed equity.

 

2.13 Trade and other payables

 

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.

 

2.14 Financial instruments with preferred rights

 

Financial instruments with preferred rights are compound instruments with discretionary dividend right. The Company elected to designate the entire hybrid contracts that include host contract and embedded derivatives as financial liabilities at fair value through profit or loss considering the fact that the instruments also have contingent settlement provisions. They are initially recognized at fair value. Any directly attributable transaction costs are expensed in the consolidated statements of loss.

 

Subsequent to initial recognition, the amount of change in the fair value of the financial instruments with preferred rights that is attributable to changes in the credit risk of that liability shall be presented in OCI with the remaining changes in fair value recognized as “fair value loss of financial instruments with preferred rights” in profit or loss.

 

As of December 31, 2020, management believed that there were no triggering events resulting in redemption in 12 months from the end of the reporting period and so the financial instruments with preferred rights were classified as non-current liabilities unless the Group had an obligation to settle the liabilities within 12 months after the end of the reporting period.

 

Dividends on financial instruments with preferred rights classified as financial liabilities are normally included in financial costs.

 

On March 19, 2021, upon completion of the IPO, all issued and outstanding preferred shares were converted to ordinary share on a one-for-one basis.

 

F-14


 

2.15 Current and deferred income tax

 

The income tax expense or credit for the period is the tax payable on the taxable income of current period based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

 

Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively.

 

(a) Current income tax

 

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

 

Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.

 

(b) Deferred income tax

 

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

 

Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.

 

Deferred tax liabilities and assets are not recognized for temporary differences between the carrying amount and tax bases of investments in foreign operations where the Group is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

 

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.

Investment allowances and similar tax incentives

 

Companies within the Group may be entitled to claim special tax deductions for investments in qualifying assets or in relation to qualifying expenditure (e.g. the research and development tax incentive or other investment allowances). The Group accounts for such allowances as tax credits, which means that the allowance reduces income tax payable and current tax expense. A deferred tax asset is recognized for unclaimed tax credits that are carried forward as deferred tax assets.

 

2.16 Employee benefits

 

(a) Short-term obligations

 

Liabilities for wages and salaries, including non-monetary benefits and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in other payables and accruals in the balance sheet.

 

F-15


 

(b) Defined benefit plans

 

The liability or asset recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method.

 

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms approximating to the terms of the related obligation. In countries where there is no deep market in such bonds, the market rates on government bonds are used.

 

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of loss.

 

Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income. They are included in retained earnings in the statement of changes in equity and in the balance sheet.

 

Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognized immediately in profit or loss as past service costs.

 

(c) Defined contribution plans

 

For defined contribution plans, including those under Section 401(k) of the U.S. Internal Revenue Code, the Group pays contributions to publicly administered pension insurance plans on a mandatory, contractual or voluntary basis. The Group has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.

 

The members of the Group incorporated in the PRC contribute based on a certain percentage of the salaries of their employees to a defined contribution retirement benefit plan organized by relevant government authorities in the PRC on a monthly basis. The government authorities undertake to assume the retirement benefit obligations payable to all existing and further retired employees under these plans and the Group has no further obligation for post-retirement benefits beyond the contributions made. Contributions to these plans are expensed as incurred. Assets of the plans are held and managed by government authorities and are separate from those of the Group.

 

(d) Housing funds and medical insurance

 

The PRC employees of the Group are entitled to participate in various government-supervised housing funds and medical insurance. The Group contributes on a monthly basis to these funds based on a certain percentage of the salaries of the employees, subject to certain ceilings. The Group’s liability in respect of these funds is limited to the contribution payable in each period and recognized as employee benefit expense when they are due.

 

2.17 Share-based compensation

 

The Group operates an equity-settled share-based compensation plan, under which the Group receives services from employees, directors and consultants. The consultants’ work for the Group is under the Group’s direction in the same way as employees and the services rendered by the consultants are similar to those rendered by the Group’s employees.

 

The fair value of options granted under the share incentive plans is recognized as an employee benefits expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:

 

including any market performance conditions (e.g. the entity’s share price);

 

excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the entity over a specified time period); and

 

including the impact of any non-vesting conditions (e.g. the requirement for employees to save or hold shares for a specific period of time).

 

F-16


 

The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. The Group recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.

 

2.18 Research and development expenses

 

The Group incurs costs and efforts on research and development activities. Research expenditures are recorded as an expense in the period the expenditure is incurred. Elements of research and development expenses primarily include (1) expenses related to preclinical testing of the Group’s technologies under development and clinical trials such as payments to CRO investigators and clinical trial sites that conduct the clinical studies; (2) consultant service related to the design of clinical trials and data analysis, (3) payroll and other related expenses of personnel engaged in research and development activities, (4) expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5) other research and development expenses.

 

The Group estimates preclinical and clinical study and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. The Group estimates these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Group will adjust the accrual accordingly. Payments made in advance for the related services are recorded as prepayments in the consolidated balance sheets until the services are rendered.

 

Development costs are recognized as assets if they can be directly attributable to a newly developed service or product and all the following criteria are met or exist:

 

the technical feasibility to complete the development project so that it will be available for use or sale;
the intention to complete the development project to use or sell the product;
the ability to use or sell the product;
the manner in which the development project will generate probable future economic benefits for the Group;
the availability of adequate technical, financial and other resources to complete the development project and use or sell the product; and
the expenditure attributable to the asset during its development can be reliably measured.

 

Research and development expenses are charged to expense as incurred for all periods presented because they have not met all of the criteria stated above.

 

2.19 Administrative expenses

 

Administrative expenses primarily include payroll and related expenses for employees involved in general corporate functions including finance, legal and human resources, rental and depreciation expenses related to facilities and equipment used by these functions, professional service expenses and other general corporate related expenses.

 

2.20 Interest income

 

Interest income from financial assets at FVPL is included in the net fair value gains/(losses) on these assets, see Note 9 below. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset except for financial assets that subsequently become credit-impaired. For credit-impaired financial assets, the effective interest rate is applied to the net carrying amount of the financial asset (after deduction of the loss allowance). Interest income is presented as finance income where it is earned from financial assets that are held for cash management purposes.

 

F-17


 

2.21 Government grants

 

Grants from the government are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group is expected to comply with all required conditions. Government grants received in advance of costs being incurred are deferred until the associated costs are recognized. Grants that compensate the Group for the cost of an asset initially are presented as deferred income and are recognized as income in consolidated statements of loss on a straight-line basis over the useful life of the associated asset.

 

2.22 Leases

 

The Group leases offices and the rental contracts are typically made for fixed periods of approximately 2 to 4 years. All land in the PRC is owned by the mainland PRC government. The PRC government may sell land use rights for a specified period of time. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as right-of-use assets on the balance sheet. The right-of-use assets are amortized over the remaining lease term. In 2021, the Group acquired a land use right from the PRC government for 50 years.

 

Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. However, for leases of real estate for which the Group is a lessee, it has elected not to separate lease and non-lease components and instead accounts for these as a single lease component.

 

Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.

 

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:

 

fixed payments (including in-substance fixed payments), less any lease incentives receivable;
variable lease payment that are based on an index or a rate, initially measured using the index or rate as of the commencement date;
amounts expected to be payable by the Group under residual value guarantees;
the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and
payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option.

 

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

 

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee’s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

 

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

 

Right-of-use assets are measured at cost comprising the following:

 

the amount of the initial measurement of lease liability;

 

any lease payments made at or before the commencement date less any lease incentives received;

 

any initial direct costs; and

 

restoration costs.

 

Right-of-use assets are generally depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset’s useful life.

 

Payments associated with short-term leases and all leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less without a purchase option.

 

2.23 Segment information

F-18


 

 

Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Group are the Co-Founders of the Company. The Group does not divide its operations into different segments and the CODM operates and manages the Group’s entire operations as one segment, which is consistent with the Group’s internal organization and reporting system. The Group does not have any revenue and substantially all non-current assets outside of the country of domicile are in China.

 

2.24 Loss per share

 

(i)
Basic loss per share

 

Basic loss per share is calculated by dividing:

 

the loss attributable to owners of the Company, excluding any costs of servicing equity other than ordinary shares;
by the weighted average number of ordinary shares outstanding during the financial year and excluding treasury shares

 

(ii)
Diluted loss per share

 

Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account:

 

the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and

 

the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares. 

3. Financial Instruments and Risk Management

3.1 Financial risk factors

 

The Group’s activities expose it to a variety of financial risks: market risk (including interest rate risk and exchange risk), credit risk and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group’s financial performance. Risk management is carried out by the senior management of the Group.

(a)
Market risk
(i)
Interest rate risk

The Group’s interest rate risk primarily arises from wealth management products investments measured at fair value through profit or loss (Note 17) and cash and cash equivalents (Note 18). Those carried at variable rates expose the Group to cash flow interest rate risk whereas those at fixed rates expose the Group to fair value interest rate risk. The Group did not have significant interest rate risk during the periods presented.

(ii)
Exchange risk

The Group operates internationally and is exposed to foreign exchange risk, primarily the USD. Foreign exchange risk arises from future commercial transactions and recognized assets and liabilities denominated in a currency that is not the functional currency of the relevant group entity. The Group’s exposure to foreign currency risk at the end of the reporting periods, expressed in RMB, was as follows:

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Cash and cash equivalents

 

 

65,791

 

 

 

150,640

 

 

F-19


 

The aggregate net foreign exchange gains/(losses) recognized in profit or loss were:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Net foreign exchange gains/(losses) included in other gains/(losses)—net

 

 

2,252

 

 

 

(6,772

)

 

 

(3,309

)

 

Most foreign exchange transactions were denominated in USD for the subsidiary that has functional currency in RMB. For the years ended December 31, 2019, 2020 and 2021, if the USD strengthened/weakened by 5% against the RMB with all other variables held constant, net loss for the years then ended would have been RMB 1.6 million lower/higher, RMB 3.3 million lower/higher and RMB 7.5 million lower/higher, respectively.

(b)
Credit risk

Credit risk primarily arises from cash and cash equivalents, financial assets at fair value through profit or loss, and other receivables. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the balance sheets.

The credit risk of cash and cash equivalents and financial assets at fair value through profit or loss is limited because the counterparties are reputable commercial institutions located in the Cayman Islands, the U.S., PRC and Australia.

For other receivables, management makes periodic as well as individual assessments on the recoverability based on historical settlement records and past experience and adjusts for forward looking information based on macroeconomic factors affecting the ability of the debtors to settle the receivables.

The Group applies the expected credit loss model to financial assets measured at amortized cost. Impairment on other receivables is measured as either 12-month expected credit losses or lifetime expected credit losses, depending on whether there has been a significant increase in credit risk since initial recognition. To assess whether there is a significant increase in credit risk, the Group compares the risk of default occurring on the asset as of the reporting date with the risk of default as of the date of initial recognition by considering available, reasonable and supportive forwarding-looking information.

(c)
Liquidity risk

The Group aims to maintain sufficient cash to meet obligations coming due as well as operating and capital requirements.

The table below analyzes the Group’s financial liabilities into relevant maturity groupings based on the remaining period at each year-end date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows except for financial instruments with preferred rights, which are presented on a fair value basis. The maturity dates are determined by the terms in financing agreements presented in Note 24(c) as management considers the other redemption terms are not probable to occur.

 

 

 

As of December 31, 2020

 

 

 

 

 

 

Between

 

 

Between

 

 

More

 

 

 

 

 

 

Less Than

 

 

1 and

 

 

2 and

 

 

Than

 

 

 

 

 

 

1 Year

 

 

2 Years

 

 

5 Years

 

 

5 Years

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Financial instruments with preferred rights

 

 

 

 

 

 

 

 

2,071,508

 

 

 

 

 

 

2,071,508

 

Trade payables

 

 

24,638

 

 

 

 

 

 

 

 

 

 

 

 

24,638

 

Other payables

 

 

8,631

 

 

 

 

 

 

 

 

 

 

 

 

8,631

 

Lease liabilities

 

 

633

 

 

 

225

 

 

 

94

 

 

 

 

 

 

952

 

Total

 

 

33,902

 

 

 

225

 

 

 

2,071,602

 

 

 

 

 

 

2,105,729

 

 

 

 

As of December 31, 2021

 

 

 

 

 

 

Between

 

 

Between

 

 

More

 

 

 

 

 

 

Less Than

 

 

1 and

 

 

2 and

 

 

Than

 

 

 

 

 

 

1 Year

 

 

2 Years

 

 

5 Years

 

 

5 Years

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Trade payables

 

 

81,195

 

 

 

 

 

 

 

 

 

 

 

 

81,195

 

Other payables

 

 

21,456

 

 

 

 

 

 

 

 

 

 

 

 

21,456

 

Lease liabilities

 

 

653

 

 

 

186

 

 

 

 

 

 

 

 

 

839

 

Total

 

 

103,304

 

 

 

186

 

 

 

 

 

 

 

 

 

103,490

 

 

F-20


 

 

 

3.2 Capital management

The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

The Group monitors capital by regularly reviewing the capital structure and the overall capital markets. The Group may seek additional financing or debt at terms satisfactory to the Group in order to maintain adequate resources.

As of December 31, 2020 and 2021, the Group had no debt outstanding.

3.3 Fair value estimation

As of December 31, 2021 the Group does not have any financial instruments measured at fair value. The table below analyzes the Group’s financial instruments carried at fair value as of December 31, 2020 by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorized into three levels within a fair value hierarchy as follows:

(i)
Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).
(ii)
Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).
(iii)
Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Financial assets at fair value through profit or loss

 

 

 

 

 

 

 

 

13,068

 

 

 

13,068

 

Total assets

 

 

 

 

 

 

 

 

13,068

 

 

 

13,068

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Financial instruments with preferred rights

 

 

 

 

 

 

 

 

2,071,508

 

 

 

2,071,508

 

Total liabilities

 

 

 

 

 

 

 

 

2,071,508

 

 

 

2,071,508

 

 

There were no transfers between levels 1, 2 and 3 during the years.

Financial instruments in Level 3

If one or more of the significant inputs are not based on observable market data, the instrument is included in level 3.

Specific valuation techniques used to value financial instruments include:

Quoted market prices or dealer quotes for similar instruments;
A combination of observable and unobservable inputs, including risk-free rate, expected volatility, discount rate for lack of marketability (“DLOM”), etc.

Level 3 instruments within the Group’s assets and liabilities include short-term investment in wealth management products measured at fair value through profit or loss and financial instruments with preferred rights.

F-21


 

The following table presents the changes in level 3 instruments of short-term investment in wealth management products for the years ended December 31, 2019, 2020 and 2021.

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Financial assets at fair value through profit or loss

 

 

 

 

 

 

 

 

 

Opening balance

 

 

27,565

 

 

 

30,632

 

 

 

13,068

 

Additions

 

 

163,000

 

 

 

106,600

 

 

 

114,500

 

Settlements

 

 

(160,731

)

 

 

(124,836

)

 

 

(128,004

)

Investment income credited to profit or loss (Note 8)*

 

 

798

 

 

 

672

 

 

 

436

 

Closing balance

 

 

30,632

 

 

 

13,068

 

 

 

 

*Includes unrealized gains recognized in profit or loss attributable to balances held at the end of the reporting period

 

 

132

 

 

 

68

 

 

 

 

 

The valuation of level 3 instruments of wealth management products and financial instruments with preferred rights is set out in Note 17 and Note 24.

The changes in level 3 instruments with preferred rights for the years ended December 31, 2019, 2020 and 2021 are presented in Note 24.

The carrying amounts of the Group’s other financial assets and liabilities, including cash and cash equivalents, other receivables, trade payable and other payables, approximate their fair values.

4. Critical Accounting Estimates and Judgements

The preparation of financial statements requires the use of accounting estimates which, by definition, may not equal the actual results. Management also needs to exercise judgment in applying the Group’s accounting policies. Estimates and judgments are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Group and that are believed to be reasonable under the circumstances.

a) Fair value of financial assets

The fair value of financial assets that are not traded in an active market is determined using valuation techniques. The Group uses its judgement to select a variety of methods and make assumptions that are mainly based on market conditions existing at the end of each reporting period.

b) Fair value of financial instruments with preferred rights

The fair value of financial instruments with preferred rights that are not traded in an active market is determined using valuation techniques. The Group first determined the equity value and then allocated the equity value to each element of the Group’s capital structure using either an option pricing backsolve method (“OPM”), or a hybrid method, which employs the concepts of the OPM and the probability-weighted expected return method (“PWERM”) that merged into a single framework.

Key assumptions such as risk-free interest rate, DLOM and expected volatility are disclosed in Note 24.

c) Recognition of share-based compensation expenses

As mentioned in Note 22, the equity-settled share-based compensation plan was granted to employees and consultants. The Group has used the Binomial option-pricing model to determine the total fair value of the awarded options, which is to be expensed over the vesting period. Significant estimates on assumptions, such as the fair value of underlying shares, risk-free interest rate, expected volatility and dividend yield, are required to be made by the management.

For the details of the key assumptions and estimates used by management in determining the fair values of share based compensation, refer to Note 22.

F-22


 

d)
Current and deferred income taxes

(i) Deferred income tax

The Group recognizes deferred tax assets based on estimates that it is probable to generate sufficient taxable profits in the foreseeable future against which the deductible losses and temporary differences will be utilized. The recognition of deferred tax assets mainly involves management’s judgments and estimations about the timing and the amount of taxable profits of the companies which have tax losses, refer to Note 10 for details.

5. Expenses by Nature

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Clinical trials related expenses

 

 

82,046

 

 

 

107,440

 

 

 

424,724

 

Employee benefit expenses (Note 6)

 

 

15,098

 

 

 

27,243

 

 

 

120,173

 

Consultancy fee (i)

 

 

12,011

 

 

 

31,784

 

 

 

69,498

 

R&D materials and consumable supplies

 

 

988

 

 

 

2,127

 

 

 

13,718

 

Depreciation and amortization

 

 

790

 

 

 

1,436

 

 

 

4,082

 

Office expenses

 

 

2,424

 

 

 

3,052

 

 

 

3,653

 

Expense related to Series C financing (ii)

 

 

 

 

 

19,655

 

 

 

 

Others

 

 

2,770

 

 

 

5,915

 

 

 

4,618

 

 

 

 

116,127

 

 

 

198,652

 

 

 

640,466

 

 

(i)
The Company exclusively licenses CBP-174 from a third-party licensor. Such license is worldwide and royalty-bearing. As of December 31, 2021, CBP-174 has not yet been commercialized, the Company is only subject to a non-refundable, non-creditable license maintenance fee, which is paid to the third-party licensor on an annual basis and recorded as a consultancy fee within research and development expense.
(ii)
Represents a share-based compensation to additional Series C preferred shareholder, which was recognized as an administrative expense as set forth in Note 22. 

6. Employee Benefit Expenses

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Share-based compensation expenses (Note 22)

 

 

3,875

 

 

 

5,535

 

 

 

57,863

 

Wages, salaries and bonuses

 

 

8,628

 

 

 

19,527

 

 

 

56,122

 

Welfare expenses

 

 

964

 

 

 

520

 

 

 

4,820

 

Housing funds

 

 

491

 

 

 

690

 

 

 

1,368

 

Contributions to defined benefit plan (Note 27(d))

 

 

1,140

 

 

 

971

 

 

 

 

 

 

 

15,098

 

 

 

27,243

 

 

 

120,173

 

 

(i) The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder. The Company does not have any further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk.

 

Employee benefit expenses were charged in the following line items in the consolidated statements of loss:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Research and development expenses

 

 

11,496

 

 

 

18,405

 

 

 

68,225

 

Administrative expenses

 

 

3,602

 

 

 

8,838

 

 

 

51,948

 

 

 

 

15,098

 

 

 

27,243

 

 

 

120,173

 

 

F-23


 

7. Other Income

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Government grants

 

 

2,836

 

 

 

6,989

 

 

 

18,996

 

 

Government grants are mainly related to cash incentives from the China government based on specific milestones or operating expenses incurred in China and tax incentives from the Australian government for conducting clinical research and development activities in Australia. In 2021, the Group received a one-time award of RMB 11.0 million for its successful IPO listing, other subsidies of RMB 6.2 million from China local government, RMB 1.6 million from the Australian government as an incentive for research and development activities.

8. Other Gains/(losses)—net

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Net foreign exchange gains/(losses)

 

 

2,252

 

 

 

(6,772

)

 

 

(3,309

)

Investment income from wealth management products

 

 

798

 

 

 

672

 

 

 

436

 

Other loss (i)

 

 

 

 

 

 

 

 

(7,093

)

 

 

 

3,050

 

 

 

(6,100

)

 

 

(9,966

)

 

(i) The Group incurred a loss of RMB 7.0 million (USD 1.1 million) due to a phishing scam experienced in May 2021 which resulted in the Company remitting such amount to an account set up by the phishers rather than to one of the Company’s vendors. No loss of company data nor any loss or compromise of third-party information has been discovered. The Company filed a claim and partially recovered RMB 1.0 million losses from its cyber insurance provider.

9. Finance Income/(cost) —net

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Finance income

 

 

 

 

 

 

 

 

 

Interest from bank deposits and term deposits

 

 

1,066

 

 

 

717

 

 

 

622

 

Finance cost

 

 

 

 

 

 

 

 

 

Issuance cost of financial instruments with preferred rights

 

 

 

 

 

(2,851

)

 

 

 

Interest for lease liabilities

 

 

(53

)

 

 

(42

)

 

 

(44

)

 

 

 

(53

)

 

 

(2,893

)

 

 

(44

)

Finance income/(cost)—net

 

 

1,013

 

 

 

(2,176

)

 

 

578

 

 

10. Income Taxes

 

Income tax expense is recognized based on the income tax rates in the following main tax jurisdictions where the Group operates for the years ended December 31, 2019, 2020 and 2021.

a) Cayman Islands

 

The Company is incorporated in the Cayman Islands as an exempted company with limited liabilities under the Companies Law of the Cayman Islands and accordingly, is exempted from Cayman Islands income tax.

b)
Hong Kong

 

Hong Kong profits tax rate was 16.5% as of April 1, 2018 when the two-tiered profits tax regime took effect, under which the tax rate is 8.25% for assessable profits on the first HK$ 2 million and 16.5% for any assessable profits in excess. No Hong Kong profit tax was provided for as there was no estimated assessable profit that was subject to Hong Kong profits tax during the years ended December 31, 2019, 2020 and 2021.

F-24


 

c)
United States

 

Connect US is incorporated in the U.S. and is a single member Limited Liability Company that is disregarded for US income tax purposes wholly owned by Connect SZ (before September 2018) and then Connect HK from a tax perspective. During the years ended December 31, 2019 and 2020, from a U.S. tax perspective, Connect HK is subject to US federal corporate income tax at a rate of 21% and state income tax in California at a rate of 8.84% to the extent of the income apportionable to Connect US. No provision for income taxes was made for the years ended December 31, 2019 and 2020. The provision for income taxes for the year ended December 31, 2021 was RMB 1.7 million.

d)
Australia

 

Connect AU is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is 30%. Connect AU has no taxable income for all periods presented, therefore, no provision for income taxes has been provided.

e)
PRC

 

Provision for PRC corporate income tax is calculated based on the statutory income tax rate of 25% on the assessable income of respective PRC Group entities during the years ended December 31, 2019, 2020 and 2021 in accordance with relevant PRC enterprise income tax rules and regulations.

 

No provision for PRC corporate income tax has been made for the years ended December 31, 2019, 2020 and 2021 as the Group had no such taxable profit for the years then ended.

 

The reconciliation between the Group’s actual tax charge and the amount that is calculated based on the statutory income tax rate of 25% in the PRC is as follows:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Loss from operations in the PRC

 

 

(73,741

)

 

 

(85,788

)

 

 

(233,382

)

Loss from overseas entities

 

 

(94,884

)

 

 

(693,437

)

 

 

(1,071,745

)

Loss before income tax

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,305,127

)

Tax expense at PRC enterprise income tax rate of 25%

 

 

(42,156

)

 

 

(194,806

)

 

 

(326,282

)

Expenses not deductible for income tax purpose

 

 

799

 

 

 

3,185

 

 

 

13,663

 

Super deduction of research and development expenses (i)

 

 

(9,529

)

 

 

(13,341

)

 

 

(35,523

)

Tax losses and deductible temporary differences for which no deferred income tax assets were recognized

 

 

33,956

 

 

 

40,865

 

 

 

114,121

 

Effect of income tax in jurisdictions other than the PRC

 

 

16,930

 

 

 

164,097

 

 

 

235,718

 

Income tax expense

 

 

 

 

 

 

 

 

1,697

 

 

(i)
According to policies promulgated by the State Tax Bureau of the PRC, certain of the Group's subsidiaries are entitled to tax incentives for research and development expenses at 175% of tax-deductible research and development expenses in 2019, 2020 and 2021.

 

For the year ended December 31, 2021, the Group’s income tax expense of RMB 1.7 million is due primarily to income tax expense for Connect US, which is treated for income tax purposes as a service provider for Connect HK and earns service fee income on a cost-plus basis.

 

The Group did not recognize deferred income tax assets for the tax losses and deductible temporary differences that amounted to approximately RMB 284 million, RMB 582 million and RMB 1,327 million as of December 31, 2019, 2020 and 2021, respectively. The balance of research and development tax credits for Connect US as of December 31, 2021 is RMB 13.74 million, which can be carried forward against future tax liabilities.

 

As of December 31, 2019, 2020 and 2021, the Group did not have any significant unrecognized uncertain tax positions.

F-25


 

11. Net Loss Per Share

 

Upon approval of shareholders of the Company on March 12, 2021, every 1.74 ordinary shares were consolidated into one ordinary share (the “Share Consolidation”) (Note 19). To calculate net loss per share, the number of shares used reflects such Share Consolidation retrospectively as of January 1, 2019 in the calculation of the weighted average number of ordinary shares outstanding.

Basic and diluted net losses per share reflecting the effect of the issuance of ordinary shares by the Company are presented as follows.

 

Basic net loss per share is calculated by dividing the net loss attributable to owners of the Company by the weighted average number of ordinary shares outstanding.

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

Net loss attributable to owners of the Company (RMB’000)

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,306,824

)

Weighted average number of ordinary shares outstanding (in thousands)

 

 

16,875

 

 

 

17,090

 

 

 

52,177

 

Basic net loss per share (RMB)

 

 

(10.0

)

 

 

(45.6

)

 

 

(25.0

)

 

Share options and preferred shares are considered as potential dilutive shares throughout the reporting period. However, since the Group had incurred losses for the years ended December 31, 2019, 2020 and 2021, the potential dilutive shares have anti-dilutive effect on loss per share if they are converted to ordinary shares. Thus, diluted loss per share is equivalent to the basic loss per share.

12. Property, Plant and Equipment

 

 

 

 

 

 

 

 

 

Office
equipment,

 

 

 

 

 

 

 

 

 

Laboratory
equipment

 

 

Leasehold
improvements

 

 

furniture
and others

 

 

Assets under
construction

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of January 1, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

 

3,059

 

 

 

628

 

 

 

582

 

 

 

 

 

 

4,269

 

Accumulated depreciation

 

 

(1,121

)

 

 

(234

)

 

 

(375

)

 

 

 

 

 

(1,730

)

Net book value

 

 

1,938

 

 

 

394

 

 

 

207

 

 

 

 

 

 

2,539

 

Year ended December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Opening net book value

 

 

1,938

 

 

 

394

 

 

 

207

 

 

 

 

 

 

2,539

 

Additions

 

 

2,613

 

 

 

833

 

 

 

3

 

 

 

1,906

 

 

 

5,355

 

Depreciation

 

 

(339

)

 

 

(574

)

 

 

(42

)

 

 

 

 

 

(955

)

Closing net book value

 

 

4,212

 

 

 

653

 

 

 

168

 

 

 

1,906

 

 

 

6,939

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

 

5,672

 

 

 

1,461

 

 

 

585

 

 

 

1,906

 

 

 

9,624

 

Accumulated depreciation

 

 

(1,460

)

 

 

(808

)

 

 

(417

)

 

 

 

 

 

(2,685

)

Net book value

 

 

4,212

 

 

 

653

 

 

 

168

 

 

 

1,906

 

 

 

6,939

 

Year ended December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Opening net book value

 

 

4,212

 

 

 

653

 

 

 

168

 

 

 

1,906

 

 

 

6,939

 

Additions

 

 

30,440

 

 

 

793

 

 

 

422

 

 

 

24,121

 

 

 

55,776

 

Disposals

 

 

(234

)

 

 

 

 

 

(14

)

 

 

 

 

 

(248

)

Depreciation

 

 

(2,142

)

 

 

(813

)

 

 

(175

)

 

 

 

 

 

(3,130

)

Transfers

 

 

 

 

 

2,449

 

 

 

 

 

 

(2,449

)

 

 

 

Closing net book value

 

 

32,276

 

 

 

3,082

 

 

 

401

 

 

 

23,578

 

 

 

59,337

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

 

35,878

 

 

 

4,703

 

 

 

993

 

 

 

23,578

 

 

 

65,152

 

Accumulated depreciation

 

 

(3,602

)

 

 

(1,621

)

 

 

(592

)

 

 

 

 

 

(5,815

)

Net book value

 

 

32,276

 

 

 

3,082

 

 

 

401

 

 

 

23,578

 

 

 

59,337

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

F-26


 

13. Other non-current Assets

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Deductible value-added tax

 

 

10,260

 

 

 

18,045

 

Prepayments for purchase of non-current assets (i)

 

 

9,600

 

 

 

341

 

Others

 

 

 

 

 

420

 

 

 

 

19,860

 

 

 

18,806

 

 

(i)
As of December 31, 2020, the Group had prepayment balances of approximately RMB 9.6 million, primarily due to the purchase of laboratory equipment for Connect SZ. 

14. Leases

 

Amounts recognized in the consolidated balance sheets are as follows:

 

(i) Right-of-use assets

 

 

 

Land use rights

 

 

Office rent

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Net book amount-as of January 1, 2019

 

 

 

 

 

1,290

 

 

 

1,290

 

Depreciation

 

 

 

 

 

(407

)

 

 

(407

)

Net book amount-as of December 31, 2019

 

 

 

 

 

883

 

 

 

883

 

Additions

 

 

 

 

 

527

 

 

 

527

 

Depreciation

 

 

 

 

 

(481

)

 

 

(481

)

Net book amount-as of as of December 31, 2020

 

 

 

 

 

929

 

 

 

929

 

Additions

 

 

22,284

 

 

 

517

 

 

 

22,801

 

Depreciation

 

 

(297

)

 

 

(612

)

 

 

(909

)

Net book amount-as of as of December 31, 2021

 

 

21,987

 

 

 

834

 

 

 

22,821

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

Cost

 

 

22,284

 

 

 

2,607

 

 

 

24,891

 

Accumulated depreciation

 

 

(297

)

 

 

(1,773

)

 

 

(2,070

)

Net Book value

 

 

21,987

 

 

 

834

 

 

 

22,821

 

 

During the year ended December 31, 2021, the addition of land use rights was related to payments to acquire long-term interest in the usage of land in the PRC over the period of 50 years as stated in the land use right certificate. The land is expected to be used for the construction of production, research and office facilities.

 

(ii) Lease liabilities

 

 

 

As of December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Non-current

 

 

470

 

 

 

309

 

 

 

163

 

Current

 

 

412

 

 

 

604

 

 

 

630

 

.

 

 

882

 

 

 

913

 

 

 

793

 

 

F-27


 

Amounts recognized in the consolidated statements of loss in addition to depreciation presented above are as follows:

 

 

 

As of December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Interest expense

 

 

53

 

 

 

42

 

 

 

44

 

Expense relating to short-term leases (included in administrative expenses and research and development expenses)

 

 

98

 

 

 

45

 

 

 

12

 

Expense relating to leases of low-value assets that are not shown above as short-term leases (included in administrative expenses and research and development expenses)

 

 

58

 

 

 

30

 

 

 

58

 

 

 

 

209

 

 

 

117

 

 

 

114

 

 

The total cash outflow for leases for the years ended December 31, 2019, 2020 and 2021 was RMB 0.4 million, RMB 0.5 million and RMB 0.8 million, respectively.

15. Financial Instruments by Category

 

 

 

Financial assets

 

 

Financial assets

 

 

 

 

Financial assets

 

at FVPL

 

 

at amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

Other receivables

 

 

 

 

 

5,612

 

 

 

5,612

 

Financial assets at fair value through profit or loss

 

 

13,068

 

 

 

 

 

 

13,068

 

Cash and cash equivalents

 

 

 

 

 

1,010,076

 

 

 

1,010,076

 

 

 

 

13,068

 

 

 

1,015,688

 

 

 

1,028,756

 

 

 

 

Financial assets

 

 

Financial assets

 

 

 

 

Financial assets

 

at FVPL

 

 

at amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

Other receivables

 

 

 

 

 

6,423

 

 

 

6,423

 

Cash and cash equivalents

 

 

 

 

 

1,706,880

 

 

 

1,706,880

 

 

 

 

 

 

 

1,713,303

 

 

 

1,713,303

 

 

 

 

Financial

 

 

Financial

 

 

 

 

 

 

liabilities at

 

 

liabilities at

 

 

 

 

Financial Liabilities

 

FVPL

 

 

amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

Financial instruments with preferred rights

 

 

2,071,508

 

 

 

 

 

 

2,071,508

 

Other payables

 

 

 

 

 

8,631

 

 

 

8,631

 

Trade payables

 

 

 

 

 

24,638

 

 

 

24,638

 

Lease liabilities

 

 

 

 

 

913

 

 

 

913

 

 

 

 

2,071,508

 

 

 

34,182

 

 

 

2,105,690

 

 

 

 

Financial

 

 

Financial

 

 

 

 

 

 

liabilities at

 

 

liabilities at

 

 

 

 

Financial Liabilities

 

FVPL

 

 

amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

Other payables

 

 

 

 

 

21,456

 

 

 

21,456

 

Trade payables

 

 

 

 

 

81,195

 

 

 

81,195

 

Lease liabilities

 

 

 

 

 

793

 

 

 

793

 

.

 

 

 

 

 

103,444

 

 

 

103,444

 

 

F-28


 

16. Other Receivables and Prepayments

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Prepayment for clinical trials related services

 

 

28,043

 

 

 

36,879

 

Deposits(ii)

 

 

3,881

 

 

 

4,312

 

Prepaid expenses(i)

 

 

 

 

 

3,953

 

Others

 

 

1,731

 

 

 

2,111

 

 

 

 

33,655

 

 

 

47,255

 

 

(i)
In March 2021, the Group made payments to purchase director and officer liability insurance. Such expenses are amortized over one year.
(ii)
Deposits held by CRO suppliers are refundable upon the completion of related services. 

17. Financial Assets at Fair Value Through Profit or Loss

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Wealth management products

 

 

13,068

 

 

 

 

 

The returns on these wealth management products were not guaranteed, hence their contractual cash flows did not qualify solely as payments of principal and interest. Therefore, they were measured at fair value through profit or loss. Wealth management products held by the Group with various maturities bear floating interest rates of 1.6%-3.4% and 1.48%-3.44% per annum for the years ended December 31, 2020 and 2021, respectively.

The fair value of wealth management products is based on discounted cash flows using their expected returns. Changes in fair value of these financial assets are recorded in other gains/(losses) – net in the consolidated statements of loss.

18. Cash and Cash Equivalents

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Cash at bank

 

 

 

 

 

 

-USD deposits

 

 

975,810

 

 

 

1,645,948

 

-RMB deposits

 

 

28,113

 

 

 

57,595

 

-Australian Dollar deposit

 

 

6,153

 

 

 

3,337

 

 

 

 

1,010,076

 

 

 

1,706,880

 

 

Cash at bank located in the PRC earns interest at floating rates based on daily bank deposit rates, while deposits in banks outside the PRC are with interest rate of nil.

 

Cash at banks denominated in RMB are deposited with banks in the PRC. The conversion of these RMB-denominated balances into foreign currencies and the remittance of funds out of China are subject to the rules and regulations of foreign exchange control promulgated by the Government of the PRC. As of December 31, 2020 and 2021, RMB 932.8 million and RMB 1,501.8 million of cash and cash equivalents were held in banks outside the PRC, respectively.

F-29


 

19. Share Capital

Upon approval of shareholders of the Company on March 12, 2021, every 1.74 ordinary shares with a par value of USD 0.0001 each in the authorized share capital of the Company (including all issued and unissued shares) were consolidated into one share with a par value of USD 0.000174 each. Therefore, the authorized share capital of the Company was changed from USD 50,000 into USD 76,560. The authorized share capital of the Company as of December 31, 2021 was USD 76,560. The number of ordinary shares below are presented retrospectively as if such Share Consolidation took place as of January 1, 2019.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number of Ordinary Shares

 

 

Share Capital

 

 

Share Premium(i)

 

 

Total

 

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of January 1, 2019

 

 

17,684,770

 

 

 

21

 

 

 

38,074

 

 

 

38,095

 

Exercise of stock options

 

 

 

 

 

 

 

 

49

 

 

 

49

 

As of December 31, 2019

 

 

17,684,770

 

 

 

21

 

 

 

38,123

 

 

 

38,144

 

Issuance of shares to Co-Founders (iv, Note 22)

 

 

282,526

 

 

 

1

 

 

 

3,343

 

 

 

3,344

 

Issuance of treasury shares

 

 

1,686,495

 

 

 

2

 

 

 

 

 

 

2

 

As of December 31, 2020

 

 

19,653,791

 

 

 

24

 

 

 

41,466

 

 

 

41,490

 

Issuance of ordinary shares (ii)

 

 

12,937,500

 

 

 

14

 

 

 

1,305,805

 

 

 

1,305,819

 

Conversion from preferred shares to ordinary shares (Note 24)

 

 

24,791,804

 

 

 

28

 

 

 

2,743,597

 

 

 

2,743,625

 

Repurchase of ordinary shares (iii)

 

 

(20,765

)

 

 

 

 

 

 

 

 

 

Issuance of shares to Co-Founders (iv, Note 22)

 

 

121,080

 

 

 

 

 

 

1,417

 

 

 

1,417

 

Exercise of stock options

 

 

 

 

 

 

 

 

2,149

 

 

 

2,149

 

As of December 31, 2021

 

 

57,483,410

 

 

 

66

 

 

 

4,094,434

 

 

 

4,094,500

 

 

(i)
Share premium mainly arose from the contributions to the Company by its holders of ordinary shares and the conversion from preferred shares.
(ii)
In March 2021, 12,937,500 ADSs (representing 12,937,500 ordinary shares, including the exercise of the option by the underwriters in full to purchase additional ADSs) were offered by the Company in connection with its listing on Nasdaq, and the proceeds received were USD 219.9 million or RMB 1,431.8 million based on the exchange rate as of the date of the IPO. The Company incurred issuance costs of USD 19.3 million in connection with this offering.
(iii)
In March 2021, at the request of one co-founder the Group repurchased 20,765 ordinary shares from him for a consideration of RMB 2.5 million (USD 0.4 million) for the payment of employee withholding taxes related to share-based awards, then such shares were cancelled accordingly.
(iv)
Pursuant to the Company’s shareholder agreement in effect as of the completion of the Series C financing (see Note 22), each of the Company’s founders is entitled to two or more votes to ensure the Co-Founders control the majority of the votes under certain circumstances.

20. Treasury Shares

 

Treasury shares were previously held by Connect Union for the purpose of issuing shares under 2019 Stock Incentive Plan in 2019 and 2020. All the Company’s ordinary shares held by Connect Union were surrendered to the Company in September 2021. As of December 31, 2019, 2020 and 2021, there were 877,066, 2,563,563 and 2,407,091 treasury shares, respectively.

 

21. Reserves

(a) Share-based compensation reserves

The share-based compensation reserves represent the fair value of unexercised options granted to employees recognized in accordance with the accounting policy adopted for equity-settled share-based payments described in Note 2.17 to the financial statements.

(b) Other reserves

Other reserves mainly represent the reserve transferred from share-based compensation reserve upon exercise of share options and foreign currency translation reserve described in Note 2.5(c).

F-30


 

(c) Statutory reserves

In accordance with the PRC regulations and the articles of association of the PRC companies now included in the Group, before annual profit distribution, companies registered in the PRC are required to set aside 10% of their net profit for the year after offsetting any prior year losses as determined under relevant PRC accounting standards to the statutory surplus reserve fund. When the balance of such reserve reaches 50% of the entity’s registered capital, any further appropriation is optional. No profit appropriation to the reserve fund was made for those Group entities for the reporting periods as they were in accumulated loss positions.

Under PRC laws and regulations, there are restrictions on the Company’s PRC subsidiaries with respect to transferring certain of their net assets to the Company either in the form of dividends, loans, or advances. Restricted net assets including paid-in capital and statutory reserve funds of the Company’s PRC subsidiaries was RMB 137.7 million as of December 31, 2020 and RMB 288.9 million as of December 31, 2021.

22. Share-Based Compensation

 

2019 Stock Incentive Plan

 

The Group adopted the 2019 stock incentive plan ("2019 Plan") and obtained Board’s approval on November 1, 2019, under which the Group may grant various awards such as options, restricted shares or restricted share units to employees, directors, and consultants for services rendered. As of December 31, 2020 and 2021 the Group has reserved 4,460,600 (after the Share Consolidation 2,563,563) and 2,407,091 ordinary shares (after the Share Consolidation).

 

Pursuant to the plan, a grantee has the right to subscribe for the ordinary shares at a price determined by the Board. The options granted can only vest if the service conditions are met. Options granted under the plan are valid and effective for 10 years from the date of grant and vest over a service period which is generally four years; 25% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next 36 months. Some options are vested in equal monthly installments or annual installments over the entire service period or vested immediately upon the grant date in instances where services had already been performed in their entirety.

 

The Chinese grantees are entitled to subscribe for underlying shares only if an IPO is achieved, provided that the service condition is also met. As of each grant date during the year ended December 31, 2020, management believed achievement of the IPO was probable.

 

The grant date of certain grantees occurred after the date they had begun rendering services to satisfy the condition attached to the share option award, the management estimated the grant date fair value in each reporting period for the purpose of recognizing the expense during the period between the service commencement date and the grant date. Once the grant date has been established, the recognized expense is based on the actual grant date fair value of the share option in the period of change.

 

Grantees who leave the Group other than for certain causes will lose their entitlement to the vested options if not exercised within three months of their termination date (or within three months after the IPO kick-off date for certain option holders).

 

2021 Stock Incentive Plan

 

The Group adopted 2021 Stock Incentive Plan (“2021 Plan”) effective on the day of effectiveness of its IPO. Awards granted under the 2021 Plan may be either stock options, stock appreciation rights (“SARs”), restricted stock units (“RSUs”), restricted stock awards (“RSA”) or dividend equivalent right ("DER”).

 

Pursuant to the plan, a grantee has the right to subscribe for the ordinary shares at a price determined by the Board. The options granted can only vest if the service conditions are met. Options granted under the plan are valid and effective for 10 years from the date of grant and vest over a service period which is generally four years; 25% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next 36 months.

 

Grantees who leave the Group other than for certain causes will lose their entitlement to the vested options if not exercised within three months of their termination date.

 

In 2021, the Company granted a total of 2,403,660 options which contain 897,660 options from the 2019 Plan and 1,506,000 options from the 2021 Plan.

 

F-31


 

2021 Employee Share Purchase Plan

 

The Group adopted but have not yet implemented the 2021 Employee Share Purchase Plan (“2021 ESPP”). A total of 600,000 ordinary shares were initially reserved for issuance under the 2021 ESPP Plan. On the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031, the number of shares available for issuance under the 2021 ESPP Plan shall be increased by that number of shares equal to the lesser of 1% of the aggregate number of ordinary shares of the Group outstanding on the final day of the immediately preceding calendar year or such smaller number of shares as determined by the Groups board of directors. No offering has been made under the 2021 ESPP Plan in the period from the adoption of the 2021 ESPP Plan to December 31, 2021.

The options activities under 2019 and 2021 Plans (after the Share Consolidation) for the year ended December 31, 2019, 2020 and 2021 were as follows:

 

 

 

Number of options

 

 

Weighted average
exercise price per
share option

Options outstanding as of January 1, 2019

 

 

 

 

 

Granted

 

 

198,064

 

 

USD 0.9

Forfeited (i)

 

 

(7,302

)

 

USD 0.9

Options outstanding as of December 31, 2019

 

 

190,762

 

 

 

Granted

 

 

1,500,887

 

 

USD 6.6

Forfeited (i)

 

 

(25,766

)

 

USD 0.9

Options outstanding as of December 31, 2020

 

 

1,665,883

 

 

 

Granted

 

 

2,403,660

 

 

USD 13.8

Exercised

 

 

(163,773

)

 

USD 0.9

Forfeited (i)

 

 

(157,381

)

 

USD 14.7

Options outstanding as of December 31, 2021

 

 

3,748,389

 

 

 

Options exercisable as of December 31, 2021

 

 

485,324

 

 

 

 

The weighted average remaining contractual life of options outstanding as of December 31, 2019, 2020 and 2021 was 7.6, 9.3 and 9.2 years, respectively.

 

(i)
The options were forfeited when the employment terminated.

Fair value of options granted

 

Prior to the completion of the IPO, the Group determined its equity value which was estimated using the hybrid method and adopted the allocation model to determine the fair value of its underlying ordinary shares. After the completion of the IPO, the fair value of the share options is estimated based on the fair market value of the Company’s underlying ordinary shares at the grant date.

 

Based on the fair value of underlying ordinary shares, the Group used the Binomial option-pricing model to determine the fair value of options as of the grant date. Key assumptions (after the Share Consolidation) for the options granted are set forth below:

 

 

 

Year Ended December 31

 

 

2019

 

 

2020

 

 

2021

Weighted average exercise price during the year

 

USD 0.9

 

 

USD 6.6

 

 

USD 13.8

Grant date share price

 

USD 1.9~USD 2.1

 

 

USD 2.1~USD 11.1

 

 

USD 4.3~USD 23.3

Risk-free interest rate

 

1.7%~2.1%

 

 

0.8%~1.1%

 

 

1.2%~1.7%

Expected volatility

 

56.6%~77.4%

 

 

61.8%~77.4%

 

 

60.5%~62.2%

Option life

 

10 years

 

 

10 years

 

 

10 years

Expected early exercise multiple

 

 

2.2

 

 

 

2.2

 

 

2.2

Dividend yield

 

Nil

 

 

Nil

 

 

Nil

Forfeiture rate

 

 

9.5

%

 

 

9.5

%

 

*3.0%-9.6%

Weighted average fair value of options granted during the year

 

USD 1.2

 

 

USD 4.2

 

 

USD 10.6

 

* Forfeiture rates for executives and all other employees in the year ended December 31, 2021, were 3.0% and 9.6%,

respectively.

 

F-32


 

The Company adopted the average volatility of the comparable companies as the proxy of the expected volatility of the underlying share. The volatility of each comparable company was based on the historical daily stock prices for a period with length commensurate to the remaining maturity life of the share options.

Share-based compensation to Co-Founders

On December 20, 2018, pursuant to the shareholders agreement entered into among the Company and all its shareholders in connection with its Series B financing, up to 702,278 and 1,140,474 ordinary shares (before Share Consolidation) will be issued to the Co-Founders and Connect Union, respectively, for no consideration, contingent on achieving of various R&D milestones as non-market performance conditions. Under such agreement, the ordinary shares may also be issued in a lump sum immediately after the closing of new financing that meets several requirements including, among others, the pre-money valuation of the Group exceeding USD 600,000,000 (“Financing Condition”). Such shares to be issued to Connect Union were reserved for future issuance of options.

 

Upon achievement of certain R&D milestones, 351,140 ordinary shares (before Share Consolidation) were vested and yet to be issued to the Co-Founders as of December 31, 2019. In January 2020, another 140,456 ordinary shares (before Share Consolidation) were vested to the Co-Founders. Accordingly, the Company issued 491,596 ordinary shares (before Share Consolidation) to the Co-Founders and 798,330 ordinary shares (before Share Consolidation) to Connect Union, respectively, for no consideration in April 2020. The Company recognized the related share-based compensation expenses in the amounts of RMB 2.7 million and RMB 1.2 million for the years ended December 31, 2019 and 2020, respectively. Unless otherwise waived by the Company and the investors party to the shareholders agreement, 210,682 ordinary shares (before Share Consolidation) are potentially issuable to the Co-Founders and 342,144 ordinary shares (before Share Consolidation) are potentially issuable to Connect Union upon achievement of the Financing Condition.

 

Pursuant to the shareholders agreement entered into in connection with the Company’s Series C financing in August and December 2020, upon the issuance of the remaining ordinary shares issuable upon achievement of the Financing Condition (i.e. 210,682 ordinary shares (before Share Consolidation) to be issued to the Co-Founders and 342,144 ordinary shares (before Share Consolidation) to be issued to Connect Union), the Company will be obligated to issue additional Series C preferred shares at par value to each of the Series C shareholders so that the shareholdings of the Series C preferred shares obtained by such Series C shareholders will not be diluted. As of December 31, 2020, the Company has not yet issued the above ordinary shares to Co-Founders and Connect Union, so no additional Series C preferred shares are issued.

 

Pursuant to the shareholders agreement, upon achievement of certain R&D milestones, 210,682 ordinary shares were issued to the Co-Founders for the year ended December 31, 2021. After the Share Consolidation, these have become 121,080 ordinary shares.


In March 2021, based on the anti-dilutive obligation of the Company to issue additional Series C preferred shares, the Company also issued additional
80,457 Series C preferred shares. After the Share Consolidation, these have become 46,232 preferred shares. Upon completion of the IPO, such preferred shares were converted to ordinary shares on a one-for-one basis.

 

The Group determined its equity value which was estimated using the hybrid method and adopted the allocation model to determine the fair value of this share-based payment as USD 0.9 per share before the Share Consolidation (USD 1.57 after the Share Consolidation) on the grant date. Key assumptions included risk-free interest rate of 2.5%, expected volatility of 60.0%, dividend yield of nil and were based on the management’s best estimates.

Share-based compensation to additional Series C preferred shareholder

 

In August 2020, the Company entered into a Series C preferred share purchase agreement with certain investors to issue 18,186,643 shares (10,452,094 after the Share Consolidation) of Series C preferred shares for a cash consideration of USD 115.0 million. Subsequent to the completion of the Series C financing in August 2020, the Company negotiated with another investor for an additional round of Series C financing. On December 1, 2020, the Company issued 3,162,894 (1,817,755 after the Share Consolidation) additional Series C preferred shares to such investor for a cash consideration of USD 20.0 million with the same subscription price and similar terms as Series C preferred shares issued in August 2020 (“Additional Series C Preferred Shares”).

 

According to the relevant guidance under IFRS 2, when the Group receives identifiable consideration that is less than the fair value of the equity instruments granted or liability incurred, the Group measures the identifiable goods or services received. The Group shall measure the unidentifiable goods or services received (or to be received) as the difference between the fair value of the share-based payment and the fair value of any identifiable goods or services received (or to be received) on the grant date.

 

F-33


 

Therefore, the Group recognized the difference between the cash consideration received from and the fair value of the Additional Series C Preferred Shares on the issuance date as a share-based compensation in the amount of approximately RMB 19.7 million for the year ended December 31, 2020.

 

Share-based compensation expenses included in the consolidated statements of loss for the years ended December 31, 2019, 2020 and 2021 is as follows:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Research and development expenses (Note 6)

 

 

3,635

 

 

 

3,523

 

 

 

26,532

 

Administrative expenses (Note 5(ii), Note 6)

 

 

240

 

 

 

21,667

 

 

 

31,331

 

 

 

 

3,875

 

 

 

25,190

 

 

 

57,863

 

 

Upon completion of the IPO, all issued and outstanding Additional Series C Preferred Shares were converted to ordinary share on a one-for-one basis.

23. Other Payables and Accruals

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Construction payables

 

 

 

 

 

16,576

 

Payroll, welfare and bonus payables

 

 

4,124

 

 

 

11,384

 

Accrued professional service fee

 

 

8,090

 

 

 

2,318

 

Others

 

 

541

 

 

 

2,562

 

 

 

 

12,755

 

 

 

32,840

 

 

24. Financial Instruments with Preferred Rights

The Group has completed a series of financings by issuing preferred shares with the following details:

 

 

 

 

 

 

 

 

Subscription

 

 

 

 

 

Number of

 

 

consideration

 

Date of subscription

 

Round

 

preferred shares

 

 

RMB’000

 

March 3, 2016

 

Series Pre-A

 

 

3,109,000

 

 

 

33,110

 

January 3, 2017

 

Series A

 

 

8,471,200

 

 

 

137,868

 

December 20, 2018

 

Series B

 

 

10,127,579

 

 

 

379,148

 

August 21, 2020/December 1, 2020

 

Series C

 

 

21,349,537

 

 

 

923,247

 

 

 

 

 

 

43,057,316

 

 

 

1,473,373

 

 

After the Share Consolidation, the above number of preferred shares were changed to 24,745,572 and together with additional 46,232 preferred shares as disclosed in the Note 22, the Company’s issued and outstanding preferred shares were 24,791,804 prior to March 19, 2021. Upon completion of the IPO, such preferred shares were converted to ordinary share on a one-for-one basis.

 

The key preferred rights of the preferred shares are summarized as follows:

 

(a) Conversion feature

 

i) Optional conversion

 

Each holder of preferred share shall be entitled to exercise its right to convert any of its preferred shares, at any time after the date of issuance of such shares, and each preferred share may be convertible into a certain number of fully paid and non-assessable ordinary shares at a ratio calculated by dividing the Series Pre-A issue price, the Series A issue price, the Series B issue price, or the Series C issue price, as applicable, by the then applicable conversion price (the “Conversion Price”). The Conversion Price is initially equal to the Series Pre-A issue price, the Series A issue price, the Series B issue price, or the Series C issue price, as applicable, and is subject to adjustment from time to time to reflect stock dividends, stock splits and other events. For the avoidance of doubt, no payment shall

F-34


 

be made by the holders of preferred shares to the Company upon or in connection with the conversion of the preferred shares into ordinary shares.

 

ii) Automatic conversion

 

The preferred shares held by each holder shall be, at the applicable Conversion Price in effect at the time of conversion, without the payment of any additional consideration, converted into fully-paid and non-assessable ordinary shares upon the closing of a Qualified initial public offering (“QIPO”).

 

(b) Liquidation preferences

 

In the event of (i) any liquidation, dissolution or termination event, whether voluntary or involuntary, or (ii) unless waived by the holders of at least a majority of ordinary shares and the holders of at least two thirds of the preferred shares (calculated on a fully-diluted and as-converted basis), any deemed liquidation event as defined in the Company’s shareholders agreement, such as a merger, consolidation, sale, transfer, lease, exclusive license or other disposal of all or substantially all of the assets or intellectual property of the Company or of all of its subsidiaries as a whole (“Deemed Liquidation Event”), all assets and funds legally available for distribution shall be distributed to the holders of preferred shares in preference to the holders of ordinary shares, in an amount per share equal to the applicable series issue price plus any declared but unpaid dividends (the “Preference Amount”).

 

The full preference amount is first paid to the holders of the series of preferred shares that was most recently issued then to the holders of the next level of preference in order (Series C preferred shares, Series B preferred shares, Series A preferred shares, and Series Pre-A preferred shares (ranked pari passu), which are listed in order of highest liquidation preference to lowest).

 

If there are any assets or funds remaining after the aggregate Series Pre-A Preference Amount, Series A Preference Amount, Series B Preference Amount and Series C Preference Amount have been distributed or paid in full to the applicable holders of the preferred shares, the remaining assets and funds of the Company available for distribution shall be distributed ratably among all shareholders (including the preferred shareholders) according to the relative number of ordinary shares of the Company held by such shareholder (on an as-converted basis).

 

If the available funds and assets become insufficient to satisfy the full preferential payment to the holders of a particular series of preferred shares, then such assets shall be distributed among the holders of that particular series of preferred shares, ratably in proportion to the full amounts to which they would otherwise be respectively entitled thereon.

 

(c) Redemption rights

 

Upon the occurrence of any of the following events, any holder of any other series of preferred shares is entitled to request a redemption of any of its shares.

 

(i)
the Company fails to consummate a QIPO on or before December 31, 2024 (the “Target QIPO Date”), such Target QIPO Date shall be postponed reasonably if any force majeure event adversely affects the process of the QIPO of the Company and the postponement arising therefrom is agreed by all the parties (including the preferred shareholders);

 

(ii)
the Company or any of the Co-Founders or the other group companies materially breaches its or his representations, warranties, covenants or obligations under any transaction document.

 

With the written consent of the holder(s) of more than fifty percent (50%) of the voting power of the aggregate number of a particular series of issued and outstanding preferred shares, the Company shall redeem such particular series of preferred shares, out of funds legally available therefor including the capital.

 

The redemption price for each issued and outstanding Series B and Series C preferred share (the “Series B and Series C Redemption Price”) shall be the amount equal to the sum of (i) an amount that would give an internal rate of return that equals to eight percent (8%) per annum on such Series B preferred share and Series C preferred share in respect of the Series B and Series C issue price, respectively, calculated for a period of time commencing from the Series B and Series C issue date and ending on the date that the Series B and Series C Redemption Price is paid in full by the Company, and (ii) any declared but unpaid dividends thereupon.

 

Series A Redemption Price is the amount equal to 150% of the Series A issue Price and any declared but unpaid dividends thereupon.

 

Pre-A shareholders do not have redemption rights, although they have a liquidation preference upon occurrence of any Deemed Liquidation Events.

F-35


 

 

(d) Dividends

 

Dividends are payable when and if declared by the Board out of funds legally available, and such dividends are not cumulative. Holders of the shares shall be entitled to receive out of any funds legally available therefor, when, as and if declared by the Board, non-cumulative dividends, as well as any non-cash dividends when, as and if declared by the Board. In the event the Company shall declare a distribution other than in cash, the holders of shares shall be entitled to a proportionate share of any such distribution when, as and if declared by the Board.

 

The Group designates the entire instruments with preferred rights described above as financial liabilities at fair value through profit or loss with the changes in the fair value recorded in the consolidated statements of loss, except for the changes in the fair value due to own credit risk, which are recorded in other comprehensive income/(loss).

 

Movements of financial instruments with preferred rights during the years ended December 31, 2019, 2020 and 2021 were as follows:

 

 

 

Fair value

 

 

 

RMB’000

 

As of January 1, 2019

 

 

573,499

 

Change in fair value recognized in profit or loss

 

 

59,397

 

Change in fair value due to foreign currency translation recognized in other comprehensive income

 

 

10,112

 

As of December 31, 2019

 

 

643,008

 

Issuance of Series C Preferred Shares

 

 

923,247

 

Change in fair value recognized in profit or loss

 

 

579,286

 

Share-based compensation to additional Series C preferred shareholder

 

 

19,655

 

Change in fair value due to foreign currency translation recognized in other comprehensive income

 

 

(93,688

)

As of December 31, 2020

 

 

2,071,508

 

Change in fair value recognized in profit or loss

 

 

674,269

 

Change in fair value due to foreign currency translation recognized in other comprehensive income

 

 

(2,152

)

Converted to ordinary shares upon IPO

 

 

(2,743,625

)

As of December 31, 2021

 

 

 

 

The Group first determined the equity value and then allocated the equity value to each element of the Group’s capital structure using either the option pricing back-solve method (“OPM”) or a hybrid method.

 

Key valuation assumptions used to determine the fair value of the financial instruments with preferred rights are as follows:

 

 

 

Year ended December 31,

 

 

2019

 

2020

DLOM

 

25.8% ~ 30.7%

 

14.0% ~ 25.8%

Expected volatility

 

55.0% ~ 60.0%

 

64.0% ~ 75.1%

Risk-Free interest rate

 

1.7% ~ 2.3%

 

0.1% ~ 0.2%

 

DLOM was estimated based on OPM. Under OPM, the cost of put option, which can hedge price changes before the privately held shares are sold, was considered as a basis to determine the DLOM.

 

Expected volatility was estimated based on the annualized standard deviation of daily stock price return of comparable companies for periods from respective valuation dates and with similar span as time to exit.

 

Risk-free interest rates were estimated based on the yield of U.S. Treasury strips as of each valuation date.

 

Sensitivity to changes in fair value

 

The Company performed sensitivity test to changes in unobservable inputs in determining the fair value of preferred shares issued by the Company. The changes in unobservable inputs risk-free interest rate and expected volatility will result in a higher or lower fair value measurement. The increase in the fair value of financial instruments with preferred rights would increase the fair value loss in the consolidated statements of loss. When performing the sensitivity test, management applied an increase or decrease to each unobservable input, which represents management’s assessment of reasonably possible change to these unobservable inputs, and effect of those changes to the fair value of financial instruments with preferred rights is as set forth below:

F-36


 

 

If the volatility had increased/decreased 5%, the loss before income tax for the year ended December 31, 2020 would have been approximately RMB 18.0 million lower/RMB 18.1 million higher.

 

If the risk-free interest rate had increased/decreased 1%, the loss before income tax for the year ended December 31, 2020 would have been approximately RMB 887,000 higher/RMB 1,712,000 lower.

 

The Group used the IPO price (USD 17) to determine the fair value of the financial instruments with preferred rights on March 19, 2021. Upon completion of the IPO, such preferred shares were converted to ordinary share on a one-for-one basis.

25. Cash Flow Information

 

(a) Cash used in operations

 

 

 

 

 

Year Ended December 31,

 

 

 

Notes

 

2019

 

 

2020

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Loss before income tax

 

 

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,305,127

)

Adjustments for:

 

 

 

 

 

 

 

 

 

 

 

—Interest for lease liabilities

 

9

 

 

53

 

 

 

42

 

 

 

44

 

—Investment income from wealth management products

 

8

 

 

(798

)

 

 

(672

)

 

 

(436

)

—Amortization of intangible assets

 

 

 

 

 

 

 

7

 

 

 

43

 

—Depreciation of property, plant and equipment

 

12

 

 

383

 

 

 

955

 

 

 

3,130

 

—Depreciation of rights-of-use assets

 

14

 

 

407

 

 

 

481

 

 

 

909

 

—Share-based compensation expenses

 

22

 

 

3,875

 

 

 

25,190

 

 

 

57,863

 

—Net foreign exchange differences

 

 

 

 

(1,368

)

 

 

6,772

 

 

 

3,309

 

—Fair value changes of financial instruments with preferred rights

 

24

 

 

59,397

 

 

 

579,286

 

 

 

674,269

 

—Issuance cost of financial instruments with preferred rights

 

9

 

 

 

 

 

2,851

 

 

 

 

—Loss on disposal of property, plant and equipment

 

 

 

 

 

 

 

 

 

 

250

 

Changes in working capital

 

 

 

 

 

 

 

 

 

 

 

—Other receivables and prepayments

 

 

 

 

(3,026

)

 

 

(9,350

)

 

 

(16,116

)

—Other non-current assets

 

 

 

 

(1,603

)

 

 

(3,906

)

 

 

(8,206

)

—Other payables and accruals

 

 

 

 

1,698

 

 

 

8,558

 

 

 

(11,459

)

—Trade payables

 

 

 

 

19,351

 

 

 

1,850

 

 

 

56,601

 

Net cash used in operations

 

 

 

 

(90,256

)

 

 

(167,161

)

 

 

(544,926

)

 

(b) Non-cash investing and financing activities

 

 

 

 

 

Year Ended December 31,

 

 

 

Notes

 

2019

 

 

2020

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Construction payables

 

 

 

 

 

 

 

 

16,576

 

Fair value changes of financial instruments with preferred rights

 

24

 

 

59,397

 

 

 

579,286

 

 

 

674,269

 

Share-based compensation to additional Series C preferred shareholder

 

22

 

 

 

 

 

19,655

 

 

 

 

 

 

 

 

 

59,397

 

 

 

598,941

 

 

 

690,845

 

 

 

F-37


 

(c) Reconciliation of liabilities arising from financing activities

 

 

 

Financial

 

 

 

 

 

 

instruments with

 

 

 

 

 

 

preferred rights

 

 

Lease liability

 

 

 

RMB’000

 

 

RMB’000

 

At January 1, 2019

 

 

573,499

 

 

 

1,274

 

Cash flows

 

 

 

 

 

(445

)

Interest expenses

 

 

 

 

 

53

 

Differences of foreign currency translation

 

 

10,112

 

 

 

 

Changes in fair value

 

 

59,397

 

 

 

 

At December 31, 2019

 

 

643,008

 

 

 

882

 

Cash flows

 

 

923,247

 

 

 

(538

)

New leases

 

 

 

 

 

527

 

Interest expenses

 

 

 

 

 

42

 

Differences of foreign currency translation

 

 

(93,688

)

 

 

 

Changes in fair value

 

 

579,286

 

 

 

 

Share-based compensation to additional Series C preferred shareholder

 

 

19,655

 

 

 

 

At December 31, 2020

 

 

2,071,508

 

 

 

913

 

Cash flows

 

 

 

 

 

(805

)

New leases

 

 

 

 

 

641

 

Interest expenses

 

 

 

 

 

44

 

Differences of foreign currency translation

 

 

(2,152

)

 

 

 

Changes in fair value

 

 

674,269

 

 

 

 

Conversion to ordinary shares

 

 

(2,743,625

)

 

 

 

At December 31, 2021

 

 

 

 

 

793

 

 

26. Commitments

 

Capital commitments

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Equipment and intangible assets

 

 

 

 

 

 

- Contracted but not provided for

 

 

23,243

 

 

 

146,878

 

 

As of December 31, 2021, the Group had capital commitments of approximately RMB 146.9 million, primarily in connection with the construction of campus in Taicang in the PRC. As of December 31, 2020, the Group had capital commitments of approximately RMB 23.2 million, primarily in connection with the purchase of equipment and improvement of the Group’s laboratory in Suzhou in the PRC.

 

Other commitments

 

In December 2021, the Company entered into the office lease agreement for approximately 3,600 square feet in San Diego, California, and the lease commenced in March 2022. The aggregate lease obligation over the three-year lease term is approximately $0.6 million.

27. Related Party Transactions

 

Parties are considered to be related if one party has the ability, directly or indirectly, to control or exercise significant influence over the other party. Parties are also considered to be related if they are subject to common control. Members of key management of the Group and their close family members are also considered as related parties.

 

Names of related parties

 

Nature of relationship

Hangzhou Simo Company Limited

 

Entity controlled by a director of the Company

Frontage Laboratories (Suzhou) Company Limited

 

Entity controlled by a director of the Company

Shanghai Tigermed Consulting Company Limited

 

Entity controlled by a director of the Company

Hangzhou Tigermed Consulting Company Limited

 

Entity controlled by a director of the Company

Beijing Medical Development (Suzhou) Company Limited

 

Entity controlled by a director of the Company

 

F-38


 

 

As the former director Xiaoping Ye resigned on February 2, 2021, the above companies were no longer considered as related parties for the year ended December 31, 2021.

 

In addition to other related party transactions and balances disclosed elsewhere in this financial information, the following is a summary of significant transactions and balances with related parties during the years ended December 31, 2019, 2020 and 2021 and at each year end.

 

(a)
Interests in subsidiaries of the Company are set out in Note 1.1.

 

(b)
Significant transactions with related parties

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Purchase of clinical trials related services

 

 

 

 

 

 

 

 

 

Hangzhou Simo Company Limited

 

 

5,601

 

 

 

5,948

 

 

 

 

Frontage Laboratories (Suzhou) Company Limited

 

 

2,346

 

 

 

2,157

 

 

 

 

Hangzhou Tigermed Consulting Company Limited

 

 

810

 

 

 

1,069

 

 

 

 

Beijing Medical Development (Suzhou) Company Limited

 

 

186

 

 

 

301

 

 

 

 

Shanghai Tigermed Consulting Company Limited

 

 

891

 

 

 

34

 

 

 

 

 

(c)
Balances with related parties

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

(i) Prepayments

 

 

 

 

 

 

Hangzhou Tigermed Consulting Company Limited

 

 

850

 

 

 

 

Hangzhou Simo Company Limited

 

 

507

 

 

 

 

 

All the above balances with related parties were unsecured, interest-free and had no fixed repayment terms.

 

(d)
Key management personnel compensation

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Wages, salaries and bonuses

 

 

3,358

 

 

 

8,013

 

 

 

18,100

 

Share-based compensation expenses

 

 

2,749

 

 

 

1,148

 

 

 

28,266

 

Contributions to defined benefit plan (i)

 

 

1,140

 

 

 

971

 

 

 

 

Welfare, housing funds and other

 

 

216

 

 

 

180

 

 

 

308

 

 

 

 

7,463

 

 

 

10,312

 

 

 

46,674

 

 

(i)
The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder following termination. The Company will have no further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk. The benefit obligation was determined using certain assumptions, including life annuity factor and specified interest rate, which were published by the U.S. Internal Revenue Service.

(e) Shares repurchase from key management personnel

 

In March 2021, the Group repurchased 20,765 ordinary shares from one of the co-founders (see Note 19).

28. Events After the Reporting Period

In addition to those disclosed elsewhere in these financial statements, the following events occurring after the reporting periods are noted.

F-39


 

From January to March 2022, the Group granted 2,044,741 ordinary share options to its employees and directors with service based vesting conditions and weighted average exercise price of USD 4.45.

29. Restricted net Assets and Parent Company only Condensed Financial Information

The Company’s ability to pay dividends is primarily dependent on the Company receiving distributions of funds from its subsidiaries. Relevant PRC statutory laws and regulations permit payments of dividends by the Company’s subsidiaries in the PRC only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations.

In accordance with the PRC laws and regulations, statutory reserve funds shall be made and can only be used for specific purposes and are not distributable as cash dividends. As a result of these PRC laws and regulations that require annual appropriation of 10% of net after-tax profits to be set aside prior to payment of dividends as statutory surplus fund, unless such reserve fund reaches 50% of the entity’s registered capital, the Group’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.

The Company performs a test on the restricted net assets of its consolidated subsidiaries (the “Restricted Net Assets”) in accordance with Securities and Exchange Commission Regulation S-X Section 4-08 (e) (3) “General Notes to Financial Statements” and concluded that the condensed financial information for the parent company is required to be presented as of December 31, 2020 and 2021 and for the years ended December 31, 2019, 2020 and 2021.

 

Furthermore, cash transfers from the Company’s PRC subsidiaries to their parent companies outside of China are subject to PRC government control of currency conversion. Shortages in the availability of foreign currency may restrict the ability of the PRC subsidiaries and consolidated affiliated entities to remit sufficient foreign currency to pay dividends or other payments to the Company, or otherwise satisfy their foreign currency denominated obligations.

(a) Condensed balance sheets

 

 

As of December 31,

 

 

2020

 

 

2021

 

 

2021

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

ASSETS

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

 

 

Interest in a subsidiary

 

472,273

 

 

 

1,177,380

 

 

 

184,667

 

Total non-current assets

 

472,273

 

 

 

1,177,380

 

 

 

184,667

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

885,611

 

 

 

1,464,637

 

 

 

229,722

 

Other receivables

 

84,278

 

 

 

86,352

 

 

 

13,544

 

Other current assets

 

1,097

 

 

 

 

 

 

 

Total current assets

 

970,986

 

 

 

1,550,989

 

 

 

243,266

 

Total assets

 

1,443,259

 

 

 

2,728,369

 

 

 

427,933

 

LIABILITIES

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

Financial instruments with preferred rights

 

2,071,508

 

 

 

 

 

 

 

Total non-current liabilities

 

2,071,508

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Trade payables

 

 

 

 

49

 

 

 

7

 

Other payables and accruals

 

6,864

 

 

 

34,190

 

 

 

5,364

 

Total current liabilities

 

6,864

 

 

 

34,239

 

 

 

5,371

 

Total liabilities

 

2,078,372

 

 

 

34,239

 

 

 

5,371

 

Net (liabilities)/assets

 

(635,113

)

 

 

2,694,130

 

 

 

422,562

 

SHAREHOLDERS’ (DEFICIT)/EQUITY

 

 

 

 

 

 

 

 

Share capital

 

24

 

 

 

66

 

 

 

10

 

Share premium

 

41,466

 

 

 

4,094,434

 

 

 

642,194

 

Treasury shares

 

(3

)

 

 

(1,164

)

 

 

(183

)

Other reserves

 

(5,732

)

 

 

(10,359

)

 

 

(1,625

)

Accumulated losses

 

(670,868

)

 

 

(1,388,847

)

 

 

(217,834

)

Total shareholders’ (deficit)/equity

 

(635,113

)

 

 

2,694,130

 

 

 

422,562

 

 

F-40


 

(b) Condensed statements of loss

 

 

Year Ended December 31,

 

 

2019

 

 

2020

 

 

2021

 

 

2021

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

Administrative expenses

 

(23

)

 

 

(29,540

)

 

 

(43,710

)

 

 

(6,856

)

Operating loss

 

(23

)

 

 

(29,540

)

 

 

(43,710

)

 

 

(6,856

)

Finance income/(costs)—net

 

335

 

 

 

(2,758

)

 

 

 

 

 

 

Fair value loss of financial instruments with preferred rights

 

(59,397

)

 

 

(579,286

)

 

 

(674,269

)

 

 

(105,756

)

Loss before income tax

 

(59,085

)

 

 

(611,584

)

 

 

(717,979

)

 

 

(112,612

)

Income tax expense

 

 

 

 

 

 

 

 

 

 

 

Loss for the year

 

(59,085

)

 

 

(611,584

)

 

 

(717,979

)

 

 

(112,612

)

 

(c) Condensed statements of cash flows

 

 

Year Ended December 31,

 

 

2019

 

 

2020

 

 

2021

 

 

2021

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

Net cash from/(used in) operating activities

 

249

 

 

 

(4,766

)

 

 

(31,025

)

 

 

(4,866

)

Net cash used in investing activities

 

(159,057

)

 

 

(204,170

)

 

 

(672,529

)

 

 

(105,483

)

Net cash generated from financing activities

 

99,990

 

 

 

934,284

 

 

 

1,319,418

 

 

 

206,945

 

Net (decrease)/increase in cash and cash equivalents

 

(58,818

)

 

 

725,348

 

 

 

615,864

 

 

 

96,596

 

Cash and cash equivalents at the beginning of year

 

267,665

 

 

 

213,253

 

 

 

885,611

 

 

 

138,904

 

Effects of exchange rate changes on cash and cash equivalents

 

4,406

 

 

 

(52,990

)

 

 

(36,838

)

 

 

(5,778

)

Cash and cash equivalents at end of year

 

213,253

 

 

 

885,611

 

 

 

1,464,637

 

 

 

229,722

 

 

F-41


EX-1.1 2 cntb-ex1_1.htm EX-1.1 EX-1.1

 

Exhibit 1.1

 

THE COMPANIES ACT (AS REVISED)
OF THE CAYMAN ISLANDS
COMPANY LIMITED BY SHARES

FIFTH AMENDED AND RESTATED
MEMORANDUM OF ASSOCIATION
OF
CONNECT BIOPHARMA HOLDINGS LIMITED

(adopted by a Special Resolution passed on March 12, 2021 and effective immediately
prior to the completion of the initial public offering of the Company’s American Depositary
Shares representing its Ordinary Shares)

1.
The name of the Company is Connect Biopharma Holdings Limited.
2.
The Registered Office of the Company will be situated at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands, or at such other location within the Cayman Islands as the Directors may from time to time determine.
3.
The objects for which the Company is established are unrestricted and the Company shall have full power and authority to carry out any object not prohibited by the Companies Act or any other law of the Cayman Islands.
4.
The Company shall have and be capable of exercising all the functions of a natural person of full capacity irrespective of any question of corporate benefit as provided by the Companies Act.
5.
The Company will not trade in the Cayman Islands with any person, firm or corporation except in furtherance of the business of the Company carried on outside the Cayman Islands; provided that nothing in this section shall be construed as to prevent the Company effecting and concluding contracts in the Cayman Islands, and exercising in the Cayman Islands all of its powers necessary for the carrying on of its business outside the Cayman Islands.
6.
The liability of each Shareholder is limited to the amount, if any, unpaid on the Shares held by such Shareholder.
7.
The authorised share capital of the Company is US$76,560 divided into (i) 400,000,000 Ordinary Shares of a par value of US$0.000174 each, and (ii) 40,000,000 Preferred Shares of a par value of US$0.000174f each of such class or classes (however designated) as the board of directors may determine in accordance with Article 9 of the Articles. Subject to the Companies Act and the Articles, the Company shall have power to redeem or purchase any of its Shares and to increase or reduce its authorised share capital and to sub-divide or consolidate the said Shares or any of them and to issue all or any part of its capital whether original, redeemed, increased or reduced with or without any preference, priority, special privilege or other rights or subject to any postponement of rights or to any conditions or restrictions whatsoever and so that unless the conditions of issue shall otherwise expressly provide every issue of shares whether stated to be ordinary, preference or otherwise shall be subject to the powers on the part of the Company hereinbefore provided.
8.
The Company has the power contained in the Companies Act to deregister in the Cayman Islands and be registered by way of continuation in some other jurisdiction.

 


 

9.
Capitalised terms that are not defined in this Memorandum of Association bear the same meanings as those given in the Articles of Association of the Company.

 


 

THE COMPANIES ACT (AS REVISED)
OF THE CAYMAN ISLANDS
COMPANY LIMITED BY SHARES

FIFTH AMENDED AND RESTATED
MEMORANDUM OF ASSOCIATION
OF
CONNECT BIOPHARMA HOLDINGS LIMITED

(adopted by a Special Resolution passed on March 12, 2021 and effective immediately prior to
the completion of the initial public offering of the Company’s American Depositary Shares
representing its Ordinary Shares)

TABLE A

The regulations contained or incorporated in Table ‘A’ in the First Schedule of the Companies Act shall not apply to the Company and the following Articles shall comprise the Articles of Association of the Company.

INTERPRETATION

1.
In these Articles the following defined terms will have the meanings ascribed to them, if not inconsistent with the subject or context:

ADS

means an American Depositary Share representing Ordinary Shares;

Affiliate

means in respect of a Person, any other Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person, and (i) in the case of a natural person, shall include, without limitation, such person’s spouse, parents, children, siblings, mother-in-law, father-in-law, brothers-in-law and sisters-in-law, a trust for the benefit of any of the foregoing, and a corporation, partnership or any other entity wholly or jointly owned by any of the foregoing, and (ii) in the case of an entity, shall include a partnership, a corporation or any other entity or any natural person which directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such entity. The term “control” shall mean the ownership, directly or indirectly, of shares possessing more than fifty per cent (50%) of the voting power of the corporation, partnership or other entity (other than, in the case of a corporation, securities having such power only by reason of the happening of a contingency), or having the power to control the management or elect a majority of members to the board of directors or equivalent decision-making body of such corporation, partnership or other entity;

Articles

means these articles of association of the Company, as amended or substituted from time to time;

Board and Board of Directors and Directors

means the directors of the Company for the time being, or as the case may be, the directors assembled as a board or as a committee thereof;

 

 


 

Chairman

means the chairman of the Board of Directors;

Class or Classes

means any class or classes of Shares as may from time to time be issued by the Company;

Commission

means the Securities and Exchange Commission of the United States of America or any other federal agency for the time being administering the Securities Act;

Communication Facilities

means video, video-conferencing, internet or online conferencing applications, telephone or tele-conferencing and/or any other video‑communications, internet or online conferencing application or telecommunications facilities by means of which all Persons participating in a meeting are capable of hearing and being heard by each other;

Company

means Connect Biopharma Holding Limited, a Cayman Islands exempted company;

Companies Act

means the Companies Act (As Revised) of the Cayman Islands and any statutory amendment or re-enactment thereof;

Company’s Website

means the main corporate/investor relations website of the Company, the address or domain name of which has been disclosed in any registration statement filed by the Company with the Commission in connection with its initial public offering of ADSs, or which has otherwise been notified to Shareholders;

Designated Stock Exchange

means the Nasdaq Global Market and any other stock exchange in the United States on which any Shares or ADSs are listed for trading;

Designated Stock Exchange Rules

means the relevant code, rules and regulations, as amended, from time to time, applicable as a result of the original and continued listing of any Shares or ADSs on the Designated Stock Exchange;

electronic

has the meaning given to it in the Electronic Transactions Act and any amendment thereto or re-enactments thereof for the time being in force and includes every other law incorporated therewith or substituted therefor;

electronic communication

means electronic posting to the Company’s Website, transmission to any number, address or internet website or other electronic delivery methods as otherwise decided and approved by not less than two-thirds of the vote of the Board;

Electronic Transactions Act

means the Electronic Transactions Act (As Revised) of the Cayman Islands and any statutory amendment or re-enactment thereof;

electronic record

has the meaning given to it in the Electronic Transactions Act and any amendment thereto or re-enactments thereof for the time being in force and includes every other law incorporated therewith or substituted therefor;

Memorandum of Association

means the memorandum of association of the Company, as amended or substituted from time to time;

 

 


 

Ordinary Resolution

1.
means a resolution:
a.
passed by a simple majority of the votes cast by such Shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy or, in the case of corporations, by their duly authorised representatives, at a general meeting of the Company held in accordance with these Articles; or
b.
approved in writing by all of the Shareholders entitled to vote at a general meeting of the Company in one or more instruments each signed by one or more of the Shareholders and the effective date of the resolution so adopted shall be the date on which the instrument, or the last of such instruments, if more than one, is executed;

Ordinary Share

means an Ordinary Share of a par value of US$0.000174 in the capital of the Company, having the rights provided for in these Articles;

paid up

means paid up as to the par value in respect of the issue of any Shares and includes credited as paid up;

Person

means any natural person, firm, company, joint venture, partnership, corporation, association or other entity (whether or not having a separate legal personality) or any of them as the context so requires;

Preferred Share

means a Preferred Share of a par value of US$0.000174 in the capital of the Company, having the rights provided for in these Articles;

Present

means, in respect of any Person, such Person’s presence at a general meeting of Shareholders, which may be satisfied by means of such Person or, if a corporation or other non-natural Person, its duly authorized representative (or, in the case of any Shareholder, a proxy which has been validly appointed by such Shareholder in accordance with these Articles), being: (a) physically present at the meeting; or (b) in the case of any meeting at which Communications Facilities are permitted in accordance with these Articles, including any Virtual Meeting, connected by means of the use of such Communication Facilities;

Register

means the register of Members of the Company maintained in accordance with the Companies Act;

Registered Office

means the registered office of the Company as required by the Companies Act;

Seal

means the common seal of the Company (if adopted) including any facsimile thereof;

Secretary

means any Person appointed by the Directors to perform any of the duties of the secretary of the Company;

Securities Act

means the Securities Act of 1933 of the United States of America, as amended, or any similar federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time;

 

 


 

Share

means a share in the capital of the Company. All references to “Shares” herein shall be deemed to be Shares of any or all Classes as the context may require. For the avoidance of doubt in these Articles the expression “Share” shall include a fraction of a Share;

Shareholder or Member

means a Person who is registered as the holder of one or more Shares in the Register;

Share Premium Account

means the share premium account established in accordance with these Articles and the Companies Act;

signed

means bearing a signature or representation of a signature affixed by mechanical means or an electronic symbol or process attached to or logically associated with an electronic communication and executed or adopted by a Person with the intent to sign the electronic communication;

Special Resolution

2.
means a special resolution of the Company passed in accordance with the Companies Act, being a resolution:
a.
passed by not less than two-thirds of the votes cast by such Shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy or, in the case of corporations, by their duly authorised representatives, at a general meeting of the Company of which notice specifying the intention to propose the resolution as a special resolution has been duly given; or
b.
approved in writing by all of the Shareholders entitled to vote at a general meeting of the Company in one or more instruments each signed by one or more of the Shareholders and the effective date of the special resolution so adopted shall be the date on which the instrument or the last of such instruments, if more than one, is executed;

Treasury Share

means a Share held in the name of the Company as a treasury share in accordance with the Companies Act;

United States

means the United States of America, its territories, its possessions and all areas subject to its jurisdiction; and.

Virtual Meeting

means any general meeting of the Shareholders at which the Shareholders (and any other permitted participants of such meeting, including without limitation the chairman of the meeting and any Directors) are permitted to attend and participate solely by means of Communications Facilities.

 

2.
In these Articles, save where the context requires otherwise
(a)
words importing the singular number shall include the plural number and vice versa;
(b)
words importing the masculine gender only shall include the feminine gender and any Person as the context may require;
(c)
the word “may” shall be construed as permissive and the word “shall” shall be construed as imperative;

 


 

(d)
reference to a dollar or dollars (or US$) and to a cent or cents is reference to dollars and cents of the United States of America;
(e)
reference to a statutory enactment shall include reference to any amendment or re‑enactment thereof for the time being in force;
(f)
reference to any determination by the Directors shall be construed as a determination by the Directors in their sole and absolute discretion and shall be applicable either generally or in any particular case;
(g)
reference to “in writing” shall be construed as written or represented by any means reproducible in writing, including any form of print, lithograph, email, facsimile, photograph or telex or represented by any other substitute or format for storage or transmission for writing including in the form of an electronic record or partly one and partly another;
(h)
any requirements as to delivery under the Articles include delivery in the form of an electronic record or an electronic communication;
(i)
any requirements as to execution or signature under the Articles, including the execution of the Articles themselves, can be satisfied in the form of an electronic signature as defined in the Electronic Transaction Law; and
(j)
Sections 8 and 19(3) of the Electronic Transactions Act shall not apply.
3.
Subject to the last two preceding Articles, any words defined in the Companies Act shall, if not inconsistent with the subject or context, bear the same meaning in these Articles.

PRELIMINARY

4.
The business of the Company may be conducted as the Directors see fit.
5.
The Registered Office shall be at such address in the Cayman Islands as the Directors may from time to time determine. The Company may in addition establish and maintain such other offices and places of business and agencies in such places as the Directors may from time to time determine.
6.
The expenses incurred in the formation of the Company and in connection with the offer for subscription and issue of Shares shall be paid by the Company. Such expenses may be amortised over such period as the Directors may determine and the amount so paid shall be charged against income and/or capital in the accounts of the Company as the Directors shall determine.
7.
The Directors shall keep, or cause to be kept, the Register at such place as the Directors may from time to time determine and, in the absence of any such determination, the Register shall be kept at the Registered Office.

SHARES

8.
Subject to these Articles, all Shares for the time being unissued shall be under the control of the Directors who may, in their absolute discretion and without the approval of the Members, cause the Company to:
(a)
issue, allot and dispose of Shares (including, without limitation, Preferred Shares) (whether in certificated form or non-certificated form) to such Persons, in such manner, on such terms and having such rights and being subject to such restrictions as they may from time to time determine;

 


 

(b)
grant rights over Shares or other securities to be issued in one or more classes or series as they deem necessary or appropriate and determine the designations, powers, preferences, privileges and other rights attaching to such Shares or securities, including dividend rights, voting rights, conversion rights, terms of redemption and liquidation preferences, any or all of which may be greater than the powers, preferences, privileges and rights associated with the then issued and outstanding Shares, at such times and on such other terms as they think proper; and
(c)
grant options with respect to Shares and issue warrants or similar instruments with respect thereto.
9.
The Directors may authorise the division of Shares into any number of Classes and the different Classes shall be authorised, established and designated (or re-designated as the case may be) and the variations in the relative rights (including, without limitation, voting, dividend and redemption rights), restrictions, preferences, privileges and payment obligations as between the different Classes (if any) may be fixed and determined by the Directors or by an Ordinary Resolution. The Directors may issue Preferred Shares with such preferred or other rights, all or any of which may be greater than the rights of Ordinary Shares, at such time and on such terms as they may think appropriate. Notwithstanding Article 12, the Directors may issue from time to time, out of the authorised share capital of the Company (other than the authorised but unissued Ordinary Shares), series of Preferred Shares in their absolute discretion and without approval of the Members; provided, however, before any Preferred Shares of any such series are issued, the Directors shall by resolution of Directors determine, with respect to any series of Preferred Shares, the terms and rights of that series, including:
(a)
the designation of such series, the number of Preferred Shares to constitute such series and the subscription price thereof if different from the par value thereof;
(b)
whether the Preferred Shares of such series shall have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights, which may be general or limited;
(c)
the dividends, if any, payable on such series, whether any such dividends shall be cumulative, and, if so, from what dates, the conditions and dates upon which such dividends shall be payable, and the preference or relation which such dividends shall bear to the dividends payable on any shares of any other class or any other series of shares;
(d)
whether the Preferred Shares of such series shall be subject to redemption by the Company, and, if so, the times, prices and other conditions of such redemption;
(e)
whether the Preferred Shares of such series shall have any rights to receive any part of the assets available for distribution amongst the Members upon the liquidation of the Company, and, if so, the terms of such liquidation preference, and the relation which such liquidation preference shall bear to the entitlements of the holders of shares of any other class or any other series of shares;
(f)
whether the Preferred Shares of such series shall be subject to the operation of a retirement or sinking fund and, if so, the extent to and manner in which any such retirement or sinking fund shall be applied to the purchase or redemption of the Preferred Shares of such series for retirement or other corporate purposes and the terms and provisions relative to the operation thereof;
(g)
whether the Preferred Shares of such series shall be convertible into, or exchangeable for, shares of any other class or any other series of Preferred Shares or any other securities and, if so, the price or prices or the rate or rates of conversion or exchange and the method,

 


 

if any, of adjusting the same, and any other terms and conditions of conversion or exchange;
(h)
the limitations and restrictions, if any, to be effective while any Preferred Shares of such series are outstanding upon the payment of dividends or the making of other distributions on, and upon the purchase, redemption or other acquisition by the Company of, the existing shares or shares of any other class of shares or any other series of Preferred Shares;
(i)
the conditions or restrictions, if any, upon the creation of indebtedness of the Company or upon the issue of any additional shares, including additional shares of such series or of any other class of shares or any other series of Preferred Shares; and
(j)
any other powers, preferences and relative, participating, optional and other special rights, and any qualifications, limitations and restrictions thereof;

and, for such purposes, the Directors may reserve an appropriate number of Shares for the time being unissued. The Company shall not issue Shares to bearer.

10.
The Company may insofar as may be permitted by law, pay a commission to any Person in consideration of his subscribing or agreeing to subscribe whether absolutely or conditionally for any Shares. Such commissions may be satisfied by the payment of cash or the lodgement of fully or partly paid-up Shares or partly in one way and partly in the other. The Company may also pay such brokerage as may be lawful on any issue of Shares.
11.
The Directors may refuse to accept any application for Shares, and may accept any application in whole or in part, for any reason or for no reason.

MODIFICATION OF RIGHTS

12.
If at any time the capital of the Company is divided into different Classes or series of shares, the rights attached to any such Class or series (unless otherwise provided by the terms of issue of the shares of that Class or series), whether or not the Company is being wound-up, may be varied with the consent in writing of the holders of two-thirds of the issued Shares of that Class or series, or with the sanction of a Special Resolution passed at a separate meeting of the holders of the Shares of that Class or series. To every such separate meeting all the provisions of these Articles relating to general meetings of the Company or to the proceedings thereat shall, mutatis mutandis, apply, except that the necessary quorum shall be one or more Persons holding or representing by proxy at least one-third in nominal or par value amount of the issued Shares of the relevant Class (but so that if at any adjourned meeting of such holders a quorum as above defined is not present, those Shareholders who are present shall form a quorum) and that, subject to any rights or restrictions for the time being attached to the Shares of that Class, every Shareholder of the Class shall on a poll have one vote for each Share of the Class held by him. For the purposes of this Article the Directors may treat all the Classes or any two or more Classes as forming one Class if they consider that all such Classes would be affected in the same way by the proposals under consideration, but in any other case shall treat them as separate Classes.
13.
The rights conferred upon the holders of the Shares of any Class issued with preferred or other rights shall not, subject to any rights or restrictions for the time being attached to the Shares of that Class, be deemed to be varied by, inter alia, the creation, allotment or issue of further Shares ranking pari passu with or subsequent to them or the redemption or purchase of any Shares of any Class by the Company. The rights of the holders of Shares shall not be deemed to be materially adversely varied by the creation or issue of Shares with preferred or other rights including, without limitation, the creation of Shares with enhanced or weighted voting rights.

 


 

CERTIFICATES

14.
Every Person whose name is entered as a Member in the Register may, without payment and upon its written request, request a certificate within two calendar months after allotment or lodgement of transfer (or within such other period as the conditions of issue shall provide) in the form determined by the Directors. All certificates shall specify the Share or Shares held by that Person, provided that in respect of a Share or Shares held jointly by several Persons the Company shall not be bound to issue more than one certificate, and delivery of a certificate for a Share to one of several joint holders shall be sufficient delivery to all. All certificates for Shares shall be delivered personally or sent through the post addressed to the Member entitled thereto at the Member’s registered address as appearing in the Register.
15.
Every share certificate of the Company shall bear such legends as may be required under applicable laws, including the Securities Act.
16.
Any two or more certificates representing Shares of any one Class held by any Member may at the Member’s request be cancelled and a single new certificate for such Shares issued in lieu on payment (if the Directors shall so require) of one dollar (US$1.00) or such smaller sum as the Directors shall determine.
17.
If a share certificate shall be damaged or defaced or alleged to have been lost, stolen or destroyed, a new certificate representing the same Shares may be issued to the relevant Member upon request, subject to delivery up of the old certificate or (if alleged to have been lost, stolen or destroyed) compliance with such conditions as to evidence and indemnity and the payment of out‑of‑pocket expenses of the Company in connection with the request as the Directors may think fit.
18.
In the event that Shares are held jointly by several Persons, any request may be made by any one of the joint holders and if so made shall be binding on all of the joint holders.

FRACTIONAL SHARES

19.
The Directors may issue fractions of a Share and, if so issued, a fraction of a Share shall be subject to and carry the corresponding fraction of liabilities (whether with respect to nominal or par value, premium, contributions, calls or otherwise), limitations, preferences, privileges, qualifications, restrictions, rights (including, without prejudice to the generality of the foregoing, voting and participation rights) and other attributes of a whole Share. If more than one fraction of a Share of the same Class is issued to or acquired by the same Shareholder such fractions shall be accumulated.

LIEN

20.
The Company has a first and paramount lien on every Share (whether or not fully paid) for all amounts (whether presently payable or not) payable at a fixed time or called in respect of that Share. The Company also has a first and paramount lien on every Share registered in the name of a Person indebted or under liability to the Company (whether he is the sole registered holder of a Share or one of two or more joint holders) for all amounts owing by him or his estate to the Company (whether or not presently payable). The Directors may at any time declare a Share to be wholly or in part exempt from the provisions of this Article. The Company’s lien on a Share extends to any amount payable in respect of it, including but not limited to dividends.
21.
The Company may sell, in such manner as the Directors in their absolute discretion think fit, any Share on which the Company has a lien, but no sale shall be made unless an amount in respect of which the lien exists is presently payable nor until the expiration of fourteen calendar days after a notice in writing, demanding payment of such part of the amount in respect of which the lien exists

 


 

as is presently payable, has been given to the registered holder for the time being of the Share, or the Persons entitled thereto by reason of his death or bankruptcy.
22.
For giving effect to any such sale the Directors may authorise a Person to transfer the Shares sold to the purchaser thereof. The purchaser shall be registered as the holder of the Shares comprised in any such transfer and he shall not be bound to see to the application of the purchase money, nor shall his title to the Shares be affected by any irregularity or invalidity in the proceedings in reference to the sale.
23.
The proceeds of the sale after deduction of expenses, fees and commissions incurred by the Company shall be received by the Company and applied in payment of such part of the amount in respect of which the lien exists as is presently payable, and the residue shall (subject to a like lien for sums not presently payable as existed upon the Shares prior to the sale) be paid to the Person entitled to the Shares immediately prior to the sale.

CALLS ON SHARES

24.
Subject to the terms of the allotment, the Directors may from time to time make calls upon the Shareholders in respect of any moneys unpaid on their Shares, and each Shareholder shall (subject to receiving at least fourteen calendar days’ notice specifying the time or times of payment) pay to the Company at the time or times so specified the amount called on such Shares. A call shall be deemed to have been made at the time when the resolution of the Directors authorising such call was passed.
25.
The joint holders of a Share shall be jointly and severally liable to pay calls in respect thereof.
26.
If a sum called in respect of a Share is not paid before or on the day appointed for payment thereof, the Person from whom the sum is due shall pay interest upon the sum at the rate of eight percent per annum from the day appointed for the payment thereof to the time of the actual payment, but the Directors shall be at liberty to waive payment of that interest wholly or in part.
27.
The provisions of these Articles as to the liability of joint holders and as to payment of interest shall apply in the case of non-payment of any sum which, by the terms of issue of a Share, becomes payable at a fixed time, whether on account of the amount of the Share, or by way of premium, as if the same had become payable by virtue of a call duly made and notified.
28.
The Directors may make arrangements with respect to the issue of partly paid Shares for a difference between the Shareholders, or the particular Shares, in the amount of calls to be paid and in the times of payment.
29.
The Directors may, if they think fit, receive from any Shareholder willing to advance the same all or any part of the moneys uncalled and unpaid upon any partly paid Shares held by him, and upon all or any of the moneys so advanced may (until the same would, but for such advance, become presently payable) pay interest at such rate (not exceeding without the sanction of an Ordinary Resolution, eight percent per annum) as may be agreed upon between the Shareholder paying the sum in advance and the Directors. No such sum paid in advance of calls shall entitle the Member paying such sum to any portion of a dividend declared in respect of any period prior to the date upon which such sum would, but for such payment, become presently payable.

FORFEITURE OF SHARES

30.
If a Shareholder fails to pay any call or instalment of a call in respect of partly paid Shares on the day appointed for payment, the Directors may, at any time thereafter during such time as any part of such call or instalment remains unpaid, serve a notice on him requiring payment of so much of the call or instalment as is unpaid, together with any interest which may have accrued.

 


 

31.
The notice shall name a further day (not earlier than the expiration of fourteen calendar days from the date of the notice) on or before which the payment required by the notice is to be made, and shall state that in the event of non-payment at or before the time appointed, the Shares in respect of which the call was made will be liable to be forfeited.
32.
If the requirements of any such notice as aforesaid are not complied with, any Share in respect of which the notice has been given may at any time thereafter, before the payment required by notice has been made, be forfeited by a resolution of the Directors to that effect.
33.
A forfeited Share may be sold or otherwise disposed of on such terms and in such manner as the Directors think fit, and at any time before a sale or disposition the forfeiture may be cancelled on such terms as the Directors think fit.
34.
A Person whose Shares have been forfeited shall cease to be a Shareholder in respect of the forfeited Shares, but shall, notwithstanding, remain liable to pay to the Company all moneys which at the date of forfeiture were payable by him to the Company in respect of the Shares forfeited, but his liability shall cease if and when the Company receives payment in full of the amount unpaid on the Shares forfeited.
35.
A certificate in writing under the hand of a Director that a Share has been duly forfeited on a date stated in the certificate shall be conclusive evidence of the facts in the declaration as against all Persons claiming to be entitled to the Share.
36.
The Company may receive the consideration, if any, given for a Share on any sale or disposition thereof pursuant to the provisions of these Articles as to forfeiture and may execute a transfer of the Share in favour of the Person to whom the Share is sold or disposed of and that Person shall be registered as the holder of the Share and shall not be bound to see to the application of the purchase money, if any, nor shall his title to the Shares be affected by any irregularity or invalidity in the proceedings in reference to the disposition or sale.
37.
The provisions of these Articles as to forfeiture shall apply in the case of non-payment of any sum which by the terms of issue of a Share becomes due and payable, whether on account of the amount of the Share, or by way of premium, as if the same had been payable by virtue of a call duly made and notified.

TRANSFER OF SHARES

38.
The instrument of transfer of any Share shall be in writing and in any usual or common form or such other form as the Directors may, in their absolute discretion, approve and be executed by or on behalf of the transferor and if in respect of a nil or partly paid up Share, or if so required by the Directors, shall also be executed on behalf of the transferee and shall be accompanied by the certificate (if any) of the Shares to which it relates and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer. The transferor shall be deemed to remain a Shareholder until the name of the transferee is entered in the Register in respect of the relevant Shares.
39.
The Directors may in their absolute discretion decline to register any transfer of Shares which is not fully paid up or on which the Company has a lien.
(a)
The Directors may also decline to register any transfer of any Share unless:
(i)
the instrument of transfer is lodged with the Company, accompanied by the certificate for the Shares to which it relates and such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer;

 


 

(ii)
the instrument of transfer is in respect of only one Class of Shares;
(iii)
the instrument of transfer is properly stamped, if required;
(iv)
in the case of a transfer to joint holders, the number of joint holders to whom the Share is to be transferred does not exceed four; and
(v)
a fee of such maximum sum as the Designated Stock Exchange may determine to be payable, or such lesser sum as the Board of Directors may from time to time require, is paid to the Company in respect thereof.
40.
The registration of transfers may, after compliance with any notice required by the Designated Stock Exchange, be suspended and the Register closed at such times and for such periods as the Directors may, in their absolute discretion, from time to time determine, provided always that such registration of transfer shall not be suspended nor the Register closed for more than thirty calendar days in any calendar year.
41.
All instruments of transfer that are registered shall be retained by the Company. If the Directors refuse to register a transfer of any Shares, they shall within three calendar months after the date on which the transfer was lodged with the Company send notice of the refusal to each of the transferor and the transferee.

TRANSMISSION OF SHARES

42.
The legal personal representative of a deceased sole holder of a Share shall be the only Person recognised by the Company as having any title to the Share. In the case of a Share registered in the name of two or more holders, the survivors or survivor, or the legal personal representatives of the deceased survivor, shall be the only Person recognised by the Company as having any title to the Share.
43.
Any Person becoming entitled to a Share in consequence of the death or bankruptcy of a Shareholder shall, upon such evidence being produced as may from time to time be required by the Directors, have the right either to be registered as a Shareholder in respect of the Share or, instead of being registered himself, to make such transfer of the Share as the deceased or bankrupt Person could have made; but the Directors shall, in either case, have the same right to decline or suspend registration as they would have had in the case of a transfer of the Share by the deceased or bankrupt Person before the death or bankruptcy.
44.
A Person becoming entitled to a Share by reason of the death or bankruptcy of a Shareholder shall be entitled to the same dividends and other advantages to which he would be entitled if he were the registered Shareholder, except that he shall not, before being registered as a Shareholder in respect of the Share, be entitled in respect of it to exercise any right conferred by membership in relation to meetings of the Company, provided however, that the Directors may at any time give notice requiring any such Person to elect either to be registered himself or to transfer the Share, and if the notice is not complied with within ninety calendar days, the Directors may thereafter withhold payment of all dividends, bonuses or other monies payable in respect of the Share until the requirements of the notice have been complied with.

REGISTRATION OF EMPOWERING INSTRUMENTS

45.
The Company shall be entitled to charge a fee not exceeding one U.S. dollar (US$1.00) on the registration of every probate, letters of administration, certificate of death or marriage, power of attorney, notice in lieu of distringas, or other instrument.

 


 

ALTERATION OF SHARE CAPITAL

46.
The Company may from time to time by Ordinary Resolution increase the share capital by such sum, to be divided into Shares of such Classes and amount, as the resolution shall prescribe.
47.
The Company may by Ordinary Resolution:
(a)
increase its share capital by new Shares of such amount as it thinks expedient;
(b)
consolidate and divide all or any of its share capital into Shares of a larger amount than its existing Shares;
(c)
subdivide its Shares, or any of them, into Shares of an amount smaller than that fixed by the Memorandum, provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced Share shall be the same as it was in case of the Share from which the reduced Share is derived; and
(d)
cancel any Shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken by any Person and diminish the amount of its share capital by the amount of the Shares so cancelled.
48.
The Company may by Special Resolution reduce its share capital and any capital redemption reserve in any manner authorised by the Companies Act.

REDEMPTION, PURCHASE AND SURRENDER OF SHARES

49.
Subject to the provisions of the Companies Act and these Articles, the Company may:
(a)
issue Shares that are to be redeemed or are liable to be redeemed at the option of the Shareholder or the Company. The redemption of Shares shall be effected in such manner and upon such terms as may be determined by the Board;
(b)
purchase its own Shares (including any redeemable Shares) on such terms and in such manner as have been approved by the Board or by the Members by Ordinary Resolution, or are otherwise authorised by these Articles; and
(c)
make a payment in respect of the redemption or purchase of its own Shares in any manner permitted by the Companies Act, including out of capital.
50.
The purchase of any Share shall not oblige the Company to purchase any other Share other than as may be required pursuant to applicable law and any other contractual obligations of the Company.
51.
The holder of the Shares being purchased shall be bound to deliver up to the Company the certificate(s) (if any) thereof for cancellation and thereupon the Company shall pay to him the purchase or redemption monies or consideration in respect thereof.
52.
The Directors may accept the surrender for no consideration of any fully paid Share.

TREASURY SHARES

53.
The Directors may, prior to the purchase, redemption or surrender of any Share, determine that such Share shall be held as a Treasury Share.

 


 

54.
The Directors may determine to cancel a Treasury Share or transfer a Treasury Share on such terms as they think proper (including, without limitation, for nil consideration).

GENERAL MEETINGS

55.
All general meetings other than annual general meetings shall be called extraordinary general meetings.
56.
The Company may (but shall not be obliged to) in each calendar year hold a general meeting as its annual general meeting and shall specify the meeting as such in the notices calling it. The annual general meeting shall be held at such time and place as may be determined by the Directors.
(a)
At these meetings the report of the Directors (if any) shall be presented.
57.
The Chairman or a majority of the Directors (acting by a resolution of the Board) may call general meetings, and they shall on a Shareholders’ requisition forthwith proceed to convene an extraordinary general meeting of the Company.
(a)
A Shareholders’ requisition is a requisition of Members holding at the date of deposit of the requisition Shares which carry in aggregate not less than one-third (1/3rd) of all votes attaching to all issued and outstanding Shares of the Company that as at the date of the deposit carry the right to vote at general meetings of the Company.
(b)
The requisition must state the objects of the meeting and must be signed by the requisitionists and deposited at the Registered Office, and may consist of several documents in like form each signed by one or more requisitionists.
(c)
If there are no Directors as at the date of the deposit of the Shareholders’ requisition, or if the Directors do not within twenty-one (21) calendar days from the date of the deposit of the requisition duly proceed to convene a general meeting to be held within a further twenty-one (21) calendar days, the requisitionists, or any of them representing more than one-half of the total voting rights of all of them, may themselves convene a general meeting, but any meeting so convened shall not be held after the expiration of three calendar months after the expiration of the said twenty-one (21) calendar days.
(d)
A general meeting convened as aforesaid by requisitionists shall be convened in the same manner as nearly as possible as that in which general meetings are to be convened by Directors.

NOTICE OF GENERAL MEETINGS

58.
At least ten (10) calendar days’ notice shall be given for any general meeting. Every notice shall be exclusive of the day on which it is given or deemed to be given and of the day for which it is given and shall specify the place, the day and the hour of the meeting and the general nature of the business and shall be given in the manner hereinafter mentioned or in such other manner if any as may be prescribed by the Company, provided that a general meeting of the Company shall, whether or not the notice specified in this Article has been given and whether or not the provisions of these Articles regarding general meetings have been complied with, be deemed to have been duly convened if it is so agreed:
(a)
in the case of an annual general meeting, by all the Shareholders (or their proxies) entitled to attend and vote thereat; and

 


 

(b)
in the case of an extraordinary general meeting, by two-thirds (2/3rd) of the Shareholders having a right to attend and vote at the meeting, Present at the meeting.
59.
The accidental omission to give notice of a meeting to or the non-receipt of a notice of a meeting by any Shareholder shall not invalidate the proceedings at any meeting.

PROCEEDINGS AT GENERAL MEETINGS

60.
No business except for the appointment of a chairman for the meeting shall be transacted at any general meeting unless a quorum of Shareholders is Present at the time when the meeting proceeds to business. One or more Shareholders holding Shares which carry in aggregate not less than one-third of all votes attaching to all Shares in issue and entitled to vote at such general meeting, Present at the meeting, shall be a quorum for all purposes.
61.
If within half an hour from the time appointed for the meeting a quorum is not Present, the meeting shall be dissolved.
62.
If the Directors wish to make this facility available for a specific general meeting or all general meetings of the Company, attendance and participation in any general meeting of the Company may be by means of Communications Facilities. Without limiting the generality of the foregoing, the Directors may determine that any general meeting may be held as a Virtual Meeting. The notice of any general meeting at which Communications Facilities will be utilized (including any Virtual Meeting) must disclose the Communications Facilities that will be used, including the procedures to be followed by any Shareholder or other participant of the Meeting who wishes to utilize such Communications Facilities for the purposes of attending and participating in such meeting, including attending and casting any vote thereat.
63.
The Chairman, if any, of the Board of Directors shall preside as chairman at every general meeting of the Company. If there is no such Chairman of the Board of Directors, or if at any general meeting he is not Present within fifteen minutes after the time appointed for holding the meeting or is unwilling to act as chairman of the meeting, any Director or Person nominated by the Chairman (or, in the absence of such Chairman nomination, the Directors) shall preside as chairman of that meeting, failing which the Shareholders Present shall choose any Person Present to be chairman of that meeting.
64.
The chairman of any general meeting shall be entitled to attend and participate at any such general meeting by means of Communication Facilities, and to act as the chairman of such general meeting, in which event the following provisions shall apply:
(a)
The chairman of the meeting shall be deemed to be Present at the meeting; and
(b)
If the Communication Facilities are interrupted or fail for any reason to enable the chairman of the meeting to hear and be heard by all other Persons participating in the meeting, then the other Directors Present at the meeting shall choose another Director Present to act as chairman of the meeting for the remainder of the meeting; provided that if no other Director is Present at the meeting, or if all the Directors Present decline to take the chair, then the meeting shall be automatically adjourned to the same day in the next week and at such time and place as shall be decided by the board of Directors.
65.
The chairman may with the consent of any general meeting at which a quorum is Present (and shall if so directed by the meeting) adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place. When a meeting, or adjourned meeting, is adjourned for fourteen calendar days or more, notice of the adjourned meeting shall be

 


 

given as in the case of an original meeting. Save as aforesaid it shall not be necessary to give any notice of an adjournment or of the business to be transacted at an adjourned meeting.
66.
The Directors may cancel or postpone any duly convened general meeting at any time prior to such meeting, except for general meetings requisitioned by the Shareholders in accordance with these Articles, for any reason or for no reason, upon notice in writing to Shareholders. A postponement may be for a stated period of any length or indefinitely as the Directors may determine.
67.
At any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands, unless a poll is (before or on the declaration of the result of the show of hands) demanded by the chairman of the meeting or by any one of more Shareholders Present at the meeting who together hold not less than 10% of the votes attaching to the total number of Ordinary Shares which are Present at the meeting. Unless a poll is so demanded, a declaration by the chairman of the meeting that a resolution has, on a show of hands, been carried, or carried unanimously, or by a particular majority, or lost, and an entry to that effect in the book of the proceedings of the Company, shall be conclusive evidence of the fact, without proof of the number or proportion of the votes recorded in favour of, or against, that resolution.
68.
If a poll is duly demanded it shall be taken in such manner as the chairman of the meeting directs, and the result of the poll shall be deemed to be the resolution of the meeting at which the poll was demanded.
69.
All questions submitted to a meeting shall be decided by an Ordinary Resolution except where a greater majority is required by these Articles or by the Companies Act. In the case of an equality of votes, whether on a show of hands or on a poll, the chairman of the meeting at which the show of hands takes place or at which the poll is demanded, shall be entitled to a second or casting vote.
70.
A poll demanded on the election of a chairman of the meeting or on a question of adjournment shall be taken forthwith. A poll demanded on any other question shall be taken at such time as the chairman of the meeting directs.

VOTES OF SHAREHOLDERS

71.
Subject to any rights and restrictions for the time being attached to any Share, on a show of hands every Shareholder Present at the meeting shall, at a general meeting of the Company, each have one vote and on a poll every Shareholder Present at the meeting shall have one (1) vote for each Ordinary Share of which he is the holder.
72.
In the case of joint holders the vote of the senior who tenders a vote whether in person or by proxy (or, if a corporation or other non-natural person, by its duly authorised representative or proxy) shall be accepted to the exclusion of the votes of the other joint holders and for this purpose seniority shall be determined by the order in which the names stand in the Register.
73.
Shares carrying the right to vote that are held by a Shareholder of unsound mind, or in respect of whom an order has been made by any court having jurisdiction in lunacy, may be voted, whether on a show of hands or on a poll, by his committee, or other Person in the nature of a committee appointed by that court, and any such committee or other Person may vote in respect of such Shares by proxy.
74.
No Shareholder shall be entitled to vote at any general meeting of the Company unless all calls, if any, or other sums presently payable by him in respect of Shares carrying the right to vote held by him have been paid.
75.
On a poll votes may be given either personally or by proxy.

 


 

76.
Each Shareholder, other than a recognised clearing house (or its nominee(s)) or depositary (or its nominee(s)), may only appoint one proxy on a show of hand. The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorised in writing or, if the appointor is a corporation, either under Seal or under the hand of an officer or attorney duly authorised. A proxy need not be a Shareholder.
77.
An instrument appointing a proxy may be in any usual or common form or such other form as the Directors may approve.
78.
The instrument appointing a proxy shall be deposited at the Registered Office or at such other place as is specified for that purpose in the notice convening the meeting, or in any instrument of proxy sent out by the Company:
(a)
not less than 48 hours before the time for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote; or
(b)
in the case of a poll taken more than 48 hours after it is demanded, be deposited as aforesaid after the poll has been demanded and not less than 24 hours before the time appointed for the taking of the poll; or
(c)
where the poll is not taken forthwith but is taken not more than 48 hours after it was demanded be delivered at the meeting at which the poll was demanded to the chairman or to the secretary or to any director;

provided that the Directors may in the notice convening the meeting, or in an instrument of proxy sent out by the Company, direct that the instrument appointing a proxy may be deposited at such other time (no later than the time for holding the meeting or adjourned meeting) at the Registered Office or at such other place as is specified for that purpose in the notice convening the meeting, or in any instrument of proxy sent out by the Company. The Chairman may in any event at his discretion direct that an instrument of proxy shall be deemed to have been duly deposited. An instrument of proxy that is not deposited in the manner permitted shall be invalid.

79.
The instrument appointing a proxy shall be deemed to confer authority to demand or join in demanding a poll.
80.
A resolution in writing signed by all the Shareholders for the time being entitled to receive notice of and to attend and vote at general meetings of the Company (or being corporations by their duly authorised representatives) shall be as valid and effective as if the same had been passed at a general meeting of the Company duly convened and held.

CORPORATIONS ACTING BY REPRESENTATIVES AT MEETINGS

81.
Any corporation which is a Shareholder or a Director may by resolution of its directors or other governing body authorise such Person as it thinks fit to act as its representative at any meeting of the Company or of any meeting of holders of a Class or of the Directors or of a committee of Directors, and the Person so authorised shall be entitled to exercise the same powers on behalf of the corporation which he represents as that corporation could exercise if it were an individual Shareholder or Director.

DEPOSITARY AND CLEARING HOUSES

82.
If a recognised clearing house (or its nominee(s)) or depositary (or its nominee(s)) is a Member of the Company it may, by resolution of its directors or other governing body or by power of attorney, authorise such Person(s) as it thinks fit to act as its representative(s) at any general meeting of the Company or of any Class of Shareholders provided that, if more than one Person is so authorised,

 


 

the authorisation shall specify the number and Class of Shares in respect of which each such Person is so authorised. A Person so authorised pursuant to this Article shall be entitled to exercise the same powers on behalf of the recognised clearing house (or its nominee(s)) or depositary (or its nominee(s)) which he represents as that recognised clearing house (or its nominee(s)) or depositary (or its nominee(s)) could exercise if it were an individual Member holding the number and Class of Shares specified in such authorisation, including the right to vote individually on a show of hands.

DIRECTORS

83.
Unless otherwise determined by the Company in general meeting, the Board of Directors shall comprise not less than three (3) Directors, with the exact number of Directors to be determined from time to time by the Board of Directors.
(a)
The Board of Directors shall elect and appoint a Chairman by a majority of the Directors then in office. The period for which the Chairman will hold office will also be determined by a majority of all of the Directors then in office. The Chairman shall preside as chairman at every meeting of the Board of Directors. To the extent the Chairman is not present at a meeting of the Board of Directors within fifteen minutes after the time appointed for holding the same, the attending Directors may choose one of their number to be the chairman of the meeting.
(b)
The Company may by Ordinary Resolution appoint any person to be a Director.
(c)
The Board may, by the affirmative vote of a simple majority of the Directors present and voting at a Board meeting, appoint any person as a Director, to fill a casual vacancy on the Board or as an addition to the Board. A Director appointed to fill a vacancy shall continue in office for the remaining duration of the current term of the replaced Director (if any).
(d)
An appointment of a Director may be on terms that the Director shall automatically retire from office (unless he has sooner vacated office) at the next or a subsequent annual general meeting or upon any specified event or after any specified period in a written agreement between the Company and the Director, if any; but no such term shall be implied in the absence of express provision. Each Director whose term of office expires shall be eligible for re-election at a meeting of the Shareholders or re-appointment by the Board.
84.
A Director may be removed from office with or without cause by an Ordinary Resolution, notwithstanding anything in these Articles or in any agreement between the Company and such Director (but without prejudice to any claim for damages under such agreement). A vacancy on the Board created by the removal of a Director under the previous sentence may be filled by an Ordinary Resolution or by the affirmative vote of a simple majority of the remaining Directors present and voting at a Board meeting. The notice of any meeting at which a resolution to remove a Director shall be proposed or voted upon must contain a statement of the intention to remove that Director and such notice must be served on that Director not less than ten (10) calendar days before the meeting. Such Director is entitled to attend the meeting and be heard on the motion for his removal.
85.
The Board may, from time to time, and except as required by applicable law or Designated Stock Exchange Rules, adopt, institute, amend, modify or revoke the corporate governance policies or initiatives of the Company and determine on various corporate governance related matters of the Company as the Board shall determine by resolution of Directors from time to time.
86.
A Director shall not be required to hold any Shares in the Company by way of qualification. A Director who is not a Member of the Company shall nevertheless be entitled to attend and speak at general meetings.

 


 

87.
The remuneration of the Directors may be determined by the Directors or by Ordinary Resolution.
88.
The Directors shall be entitled to be paid their travelling, hotel and other expenses properly incurred by them in going to, attending and returning from meetings of the Directors, or any committee of the Directors, or general meetings of the Company, or otherwise in connection with the business of the Company, or to receive such fixed allowance in respect thereof as may be determined by the Directors from time to time, or a combination partly of one such method and partly the other.

ALTERNATE DIRECTOR OR PROXY

89.
Any Director may in writing appoint another Person to be his alternate and, save to the extent provided otherwise in the form of appointment, such alternate shall have authority to sign written resolutions on behalf of the appointing Director, but shall not be required to sign such written resolutions where they have been signed by the appointing director, and to act in such Director’s place at any meeting of the Directors at which the appointing Director is unable to be present. Every such alternate shall be entitled to attend and vote at meetings of the Directors as a Director when the Director appointing him is not personally present and where he is a Director to have a separate vote on behalf of the Director he is representing in addition to his own vote. A Director may at any time in writing revoke the appointment of an alternate appointed by him. Such alternate shall be deemed for all purposes to be a Director and shall not be deemed to be the agent of the Director appointing him. The remuneration of such alternate shall be payable out of the remuneration of the Director appointing him and the proportion thereof shall be agreed between them.
90.
Any Director may appoint any Person, whether or not a Director, to be the proxy of that Director to attend and vote on his behalf, in accordance with instructions given by that Director, or in the absence of such instructions at the discretion of the proxy, at a meeting or meetings of the Directors which that Director is unable to attend personally. The instrument appointing the proxy shall be in writing under the hand of the appointing Director and shall be in any usual or common form or such other form as the Directors may approve, and must be lodged with the chairman of the meeting of the Directors at which such proxy is to be used, or first used, prior to the commencement of the meeting.

POWERS AND DUTIES OF DIRECTORS

91.
Subject to the Companies Act, these Articles and to any resolutions passed in a general meeting, the business of the Company shall be managed by the Directors, who may pay all expenses incurred in setting up and registering the Company and may exercise all powers of the Company. No resolution passed by the Company in general meeting shall invalidate any prior act of the Directors that would have been valid if that resolution had not been passed.
92.
Subject to these Articles, the Directors may from time to time appoint any natural person or corporation, whether or not a Director to hold such office in the Company as the Directors may think necessary for the administration of the Company, including but not limited to, chief executive officer, one or more other executive officers, president, one or more vice presidents, treasurer, assistant treasurer, manager or controller, and for such term and at such remuneration (whether by way of salary or commission or participation in profits or partly in one way and partly in another), and with such powers and duties as the Directors may think fit. Any natural person or corporation so appointed by the Directors may be removed by the Directors. The Directors may also appoint one or more of their number to the office of managing director upon like terms, but any such appointment shall ipso facto terminate if any managing director ceases for any cause to be a Director, or if the Company by Ordinary Resolution resolves that his tenure of office be terminated.
93.
The Directors may appoint any natural person or corporation to be a Secretary (and if need be an assistant Secretary or assistant Secretaries) who shall hold office for such term, at such remuneration and upon such conditions and with such powers as they think fit. Any Secretary or

 


 

assistant Secretary so appointed by the Directors may be removed by the Directors or by the Company by Ordinary Resolution.
94.
The Directors may delegate any of their powers to committees consisting of such member or members of their body as they think fit; any committee so formed shall in the exercise of the powers so delegated conform to any regulations that may be imposed on it by the Directors.
95.
The Directors may from time to time and at any time by power of attorney (whether under Seal or under hand) or otherwise appoint any company, firm or Person or body of Persons, whether nominated directly or indirectly by the Directors, to be the attorney or attorneys or authorised signatory (any such Person being an “Attorney” or “Authorised Signatory”, respectively) of the Company for such purposes and with such powers, authorities and discretion (not exceeding those vested in or exercisable by the Directors under these Articles) and for such period and subject to such conditions as they may think fit, and any such power of attorney or other appointment may contain such provisions for the protection and convenience of Persons dealing with any such Attorney or Authorised Signatory as the Directors may think fit, and may also authorise any such Attorney or Authorised Signatory to delegate all or any of the powers, authorities and discretion vested in him.
96.
The Directors may from time to time provide for the management of the affairs of the Company in such manner as they shall think fit and the provisions contained in the three next following Articles shall not limit the general powers conferred by this Article.
97.
The Directors from time to time and at any time may establish any committees, local boards or agencies for managing any of the affairs of the Company and may appoint any natural person or corporation to be a member of such committees or local boards and may appoint any managers or agents of the Company and may fix the remuneration of any such natural person or corporation.
98.
The Directors from time to time and at any time may delegate to any such committee, local board, manager or agent any of the powers, authorities and discretions for the time being vested in the Directors and may authorise the members for the time being of any such local board, or any of them to fill any vacancies therein and to act notwithstanding vacancies and any such appointment or delegation may be made on such terms and subject to such conditions as the Directors may think fit and the Directors may at any time remove any natural person or corporation so appointed and may annul or vary any such delegation, but no Person dealing in good faith and without notice of any such annulment or variation shall be affected thereby.
99.
Any such delegates as aforesaid may be authorised by the Directors to sub-delegate all or any of the powers, authorities, and discretion for the time being vested in them.

BORROWING POWERS OF DIRECTORS

100.
The Directors may from time to time at their discretion exercise all the powers of the Company to raise or borrow money and to mortgage or charge its undertaking, property and assets (present and future) and uncalled capital or any part thereof, to issue debentures, debenture stock, bonds and other securities, whether outright or as collateral security for any debt, liability or obligation of the Company or of any third party.

THE SEAL

101.
The Seal shall not be affixed to any instrument except by the authority of a resolution of the Directors provided always that such authority may be given prior to or after the affixing of the Seal and if given after may be in general form confirming a number of affixing of the Seal. The Seal shall be affixed in the presence of a Director or a Secretary (or an assistant Secretary) or in the presence

 


 

of any one or more Persons as the Directors may appoint for the purpose and every Person as aforesaid shall sign every instrument to which the Seal is so affixed in their presence.
102.
The Company may maintain a facsimile of the Seal in such countries or places as the Directors may appoint and such facsimile Seal shall not be affixed to any instrument except by the authority of a resolution of the Directors provided always that such authority may be given prior to or after the affixing of such facsimile Seal and if given after may be in general form confirming a number of affixing of such facsimile Seal. The facsimile Seal shall be affixed in the presence of such Person or Persons as the Directors shall for this purpose appoint and such Person or Persons as aforesaid shall sign every instrument to which the facsimile Seal is so affixed in their presence and such affixing of the facsimile Seal and signing as aforesaid shall have the same meaning and effect as if the Seal had been affixed in the presence of and the instrument signed by a Director or a Secretary (or an assistant Secretary) or in the presence of any one or more Persons as the Directors may appoint for the purpose.
103.
Notwithstanding the foregoing, a Secretary or any assistant Secretary shall have the authority to affix the Seal, or the facsimile Seal, to any instrument for the purposes of attesting authenticity of the matter contained therein but which does not create any obligation binding on the Company.

DISQUALIFICATION OF DIRECTORS

104.
The office of Director shall be vacated, if the Director:
(a)
becomes bankrupt or makes any arrangement or composition with his creditors;
(b)
dies or is found to be or becomes of unsound mind;
(c)
resigns his office by notice in writing to the Company;
(d)
without special leave of absence from the Board, is absent from meetings of the Board for three consecutive meetings and the Board resolves that his office be vacated; or
(e)
is removed from office pursuant to any other provision of these Articles.

PROCEEDINGS OF DIRECTORS

105.
The Directors may meet together (either within or outside the Cayman Islands) for the despatch of business, adjourn, and otherwise regulate their meetings and proceedings as they think fit. Questions arising at any meeting shall be decided by a majority of votes. At any meeting of the Directors, each Director present in person or represented by his proxy or alternate shall be entitled to one vote. In case of an equality of votes the Chairman shall have a second or casting vote. A Director may, and a Secretary or assistant Secretary on the requisition of a Director shall, at any time summon a meeting of the Directors.
106.
A Director may participate in any meeting of the Directors, or of any committee appointed by the Directors of which such Director is a member, by means of telephone or similar communication equipment by way of which all Persons participating in such meeting can communicate with each other and such participation shall be deemed to constitute presence in person at the meeting.
107.
The quorum necessary for the transaction of the business of the Board may be fixed by the Directors, and unless so fixed, the quorum shall be a majority of Directors then in office. A Director represented by proxy or by an alternate Director at any meeting shall be deemed to be present for the purposes of determining whether or not a quorum is present.

 


 

108.
A Director who is in any way, whether directly or indirectly, interested in a contract or transaction or proposed contract or transaction with the Company shall declare the nature of his interest at a meeting of the Directors. A general notice given to the Directors by any Director to the effect that he is a member of any specified company or firm and is to be regarded as interested in any contract or transaction which may thereafter be made with that company or firm shall be deemed a sufficient declaration of interest in regard to any contract so made or transaction so consummated. A Director may vote in respect of any contract or transaction or proposed contract or transaction notwithstanding that he may be interested therein and if he does so his vote shall be counted and he may be counted in the quorum at any meeting of the Directors at which any such contract or transaction or proposed contract or transaction shall come before the meeting for consideration.
109.
A Director may hold any other office or place of profit under the Company (other than the office of auditor) in conjunction with his office of Director for such period and on such terms (as to remuneration and otherwise) as the Directors may determine and no Director or intending Director shall be disqualified by his office from contracting with the Company either with regard to his tenure of any such other office or place of profit or as vendor, purchaser or otherwise, nor shall any such contract or arrangement entered into by or on behalf of the Company in which any Director is in any way interested be liable to be avoided, nor shall any Director so contracting or being so interested be liable to account to the Company for any profit realised by any such contract or arrangement by reason of such Director holding that office or of the fiduciary relation thereby established. A Director, notwithstanding his interest, may be counted in the quorum present at any meeting of the Directors whereat he or any other Director is appointed to hold any such office or place of profit under the Company or whereat the terms of any such appointment are arranged and he may vote on any such appointment or arrangement.
110.
Any Director may act by himself or through his firm in a professional capacity for the Company, and he or his firm shall be entitled to remuneration for professional services as if he were not a Director; provided that nothing herein contained shall authorise a Director or his firm to act as auditor to the Company.
111.
The Directors shall cause minutes to be made for the purpose of recording:
(a)
all appointments of officers made by the Directors;
(b)
the names of the Directors present at each meeting of the Directors and of any committee of the Directors; and
(c)
all resolutions and proceedings at all meetings of the Company, and of the Directors and of committees of Directors.
112.
When the chairman of a meeting of the Directors signs the minutes of such meeting the same shall be deemed to have been duly held notwithstanding that all the Directors have not actually come together or that there may have been a technical defect in the proceedings.
113.
A resolution in writing signed by all the Directors or all the members of a committee of Directors entitled to receive notice of a meeting of Directors or committee of Directors, as the case may be (an alternate Director, subject as provided otherwise in the terms of appointment of the alternate Director, being entitled to sign such a resolution on behalf of his appointer), shall be as valid and effectual as if it had been passed at a duly called and constituted meeting of Directors or committee of Directors, as the case may be. When signed a resolution may consist of several documents each signed by one or more of the Directors or his duly appointed alternate.

 


 

114.
The continuing Directors may act notwithstanding any vacancy in their body but if and for so long as their number is reduced below the number fixed by or pursuant to these Articles as the necessary quorum of Directors, the continuing Directors may act for the purpose of increasing the number, or of summoning a general meeting of the Company, but for no other purpose.
115.
Subject to any regulations imposed on it by the Directors, a committee appointed by the Directors may elect a chairman of its meetings. If no such chairman is elected, or if at any meeting the chairman is not present within fifteen minutes after the time appointed for holding the meeting, the committee members present may choose one of their number to be chairman of the meeting.
116.
A committee appointed by the Directors may meet and adjourn as it thinks proper. Subject to any regulations imposed on it by the Directors, questions arising at any meeting shall be determined by a majority of votes of the committee members present and in case of an equality of votes the chairman shall have a second or casting vote.
117.
All acts done by any meeting of the Directors or of a committee of Directors, or by any Person acting as a Director, shall notwithstanding that it be afterwards discovered that there was some defect in the appointment of any such Director or Person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such Person had been duly appointed and was qualified to be a Director.

PRESUMPTION OF ASSENT

118.
A Director who is present at a meeting of the Board of Directors at which an action on any Company matter is taken shall be presumed to have assented to the action taken unless his dissent shall be entered in the minutes of the meeting or unless he shall file his written dissent from such action with the person acting as the chairman or secretary of the meeting before the adjournment thereof or shall forward such dissent by registered post to such person immediately after the adjournment of the meeting. Such right to dissent shall not apply to a Director who voted in favour of such action.

DIVIDENDS

119.
Subject to any rights and restrictions for the time being attached to any Shares, the Directors may from time to time declare dividends (including interim dividends) and other distributions on Shares in issue and authorise payment of the same out of the funds of the Company lawfully available therefor.
120.
Subject to any rights and restrictions for the time being attached to any Shares, the Company by Ordinary Resolution may declare dividends, but no dividend shall exceed the amount recommended by the Directors.
121.
The Directors may, before recommending or declaring any dividend, set aside out of the funds legally available for distribution such sums as they think proper as a reserve or reserves which shall, in the absolute discretion of the Directors, be applicable for meeting contingencies or for equalising dividends or for any other purpose to which those funds may be properly applied, and pending such application may in the absolute discretion of the Directors, either be employed in the business of the Company or be invested in such investments (other than Shares of the Company) as the Directors may from time to time think fit.
122.
Any dividend payable in cash to the holder of Shares may be paid in any manner determined by the Directors. If paid by cheque it will be sent by mail addressed to the holder at his address in the Register, or addressed to such person and at such addresses as the holder may direct. Every such cheque or warrant shall, unless the holder or joint holders otherwise direct, be made payable to the order of the holder or, in the case of joint holders, to the order of the holder whose name stands first on the Register in respect of such Shares, and shall be sent at his or their risk and payment of

 


 

the cheque or warrant by the bank on which it is drawn shall constitute a good discharge to the Company.
123.
The Directors may determine that a dividend shall be paid wholly or partly by the distribution of specific assets (which may consist of the shares or securities of any other company) and may settle all questions concerning such distribution. Without limiting the generality of the foregoing, the Directors may fix the value of such specific assets, may determine that cash payment shall be made to some Shareholders in lieu of specific assets and may vest any such specific assets in trustees on such terms as the Directors think fit.
124.
Subject to any rights and restrictions for the time being attached to any Shares, all dividends shall be declared and paid according to the amounts paid up on the Shares, but if and for so long as nothing is paid up on any of the Shares dividends may be declared and paid according to the par value of the Shares. No amount paid on a Share in advance of calls shall, while carrying interest, be treated for the purposes of this Article as paid on the Share.
125.
If several Persons are registered as joint holders of any Share, any of them may give effective receipts for any dividend or other moneys payable on or in respect of the Share.
126.
No dividend shall bear interest against the Company.
127.
Any dividend unclaimed after a period of six calendar years from the date of declaration of such dividend may be forfeited by the Board of Directors and, if so forfeited, shall revert to the Company.

ACCOUNTS, AUDIT AND ANNUAL RETURN AND DECLARATION

128.
The books of account relating to the Company’s affairs shall be kept in such manner as may be determined from time to time by the Directors.
129.
The books of account shall be kept at the Registered Office, or at such other place or places as the Directors think fit, and shall always be open to the inspection of the Directors.
130.
The Directors may from time to time determine whether and to what extent and at what times and places and under what conditions or regulations the accounts and books of the Company or any of them shall be open to the inspection of Shareholders not being Directors, and no Shareholder (not being a Director) shall have any right to inspect any account or book or document of the Company except as conferred by law or authorised by the Directors or by Ordinary Resolution.
131.
The accounts relating to the Company’s affairs shall be audited in such manner and with such financial year end as may be determined from time to time by the Directors or failing any determination as aforesaid shall not be audited.
132.
The Directors may appoint an auditor of the Company who shall hold office until removed from office by a resolution of the Directors and may fix his or their remuneration.
133.
Every auditor of the Company shall have a right of access at all times to the books and accounts and vouchers of the Company and shall be entitled to require from the Directors and officers of the Company such information and explanation as may be necessary for the performance of the duties of the auditors.
134.
The auditors shall, if so required by the Directors, make a report on the accounts of the Company during their tenure of office at the next annual general meeting following their appointment, and at any time during their term of office, upon request of the Directors or any general meeting of the Members.

 


 

135.
The Directors in each calendar year shall prepare, or cause to be prepared, an annual return and declaration setting forth the particulars required by the Companies Act and deliver a copy thereof to the Registrar of Companies in the Cayman Islands.

CAPITALISATION OF RESERVES

136.
Subject to the Companies Act, the Directors may:
(a)
resolve to capitalise an amount standing to the credit of reserves (including a Share Premium Account, capital redemption reserve and profit and loss account), which is available for distribution;
(b)
appropriate the sum resolved to be capitalised to the Shareholders in proportion to the nominal amount of Shares (whether or not fully paid) held by them respectively and apply that sum on their behalf in or towards:
(i)
paying up the amounts (if any) for the time being unpaid on Shares held by them respectively, or
(ii)
paying up in full unissued Shares or debentures of a nominal amount equal to that sum,

and allot the Shares or debentures, credited as fully paid, to the Shareholders (or as they may direct) in those proportions, or partly in one way and partly in the other, but the Share Premium Account, the capital redemption reserve and profits which are not available for distribution may, for the purposes of this Article, only be applied in paying up unissued Shares to be allotted to Shareholders credited as fully paid;

(c)
make any arrangements they think fit to resolve a difficulty arising in the distribution of a capitalised reserve and in particular, without limitation, where Shares or debentures become distributable in fractions the Directors may deal with the fractions as they think fit;
(d)
authorise a Person to enter (on behalf of all the Shareholders concerned) into an agreement with the Company providing for either:
(i)
the allotment to the Shareholders respectively, credited as fully paid, of Shares or debentures to which they may be entitled on the capitalisation, or
(ii)
the payment by the Company on behalf of the Shareholders (by the application of their respective proportions of the reserves resolved to be capitalised) of the amounts or part of the amounts remaining unpaid on their existing Shares,

and any such agreement made under this authority being effective and binding on all those Shareholders; and

(e)
generally do all acts and things required to give effect to the resolution.
137.
Notwithstanding any provisions in these Articles, the Directors may resolve to capitalise an amount standing to the credit of reserves (including the Share Premium Account, capital redemption reserve and profit and loss account) or otherwise available for distribution by applying such sum in paying up in full unissued Shares to be allotted and issued to:
(a)
employees (including Directors) or service providers of the Company or its Affiliates upon exercise or vesting of any options or awards granted under any share incentive scheme or

 


 

employee benefit scheme or other arrangement which relates to such persons that has been adopted or approved by the Directors or the Members;
(b)
any trustee of any trust or administrator of any share incentive scheme or employee benefit scheme to whom shares are to be allotted and issued by the Company in connection with the operation of any share incentive scheme or employee benefit scheme or other arrangement which relates to such persons that has been adopted or approved by the Directors or Members; or
(c)
any depositary of the Company for the purposes of the issue, allotment and delivery by the depositary of ADSs to employees (including Directors) or service providers of the Company or its Affiliates upon exercise or vesting of any options or awards granted under any share incentive scheme or employee benefit scheme or other arrangement which relates to such persons that has been adopted or approved by the Directors or the Members.

SHARE PREMIUM ACCOUNT

138.
The Directors shall in accordance with the Companies Act establish a Share Premium Account and shall carry to the credit of such account from time to time a sum equal to the amount or value of the premium paid on the issue of any Share.
139.
There shall be debited to any Share Premium Account on the redemption or purchase of a Share the difference between the nominal value of such Share and the redemption or purchase price provided always that at the discretion of the Directors such sum may be paid out of the profits of the Company or, if permitted by the Companies Act, out of capital.

NOTICES

140.
Except as otherwise provided in these Articles, any notice or document may be served by the Company or by the Person entitled to give notice to any Shareholder either personally, or by posting it by airmail or a recognised courier service in a prepaid letter addressed to such Shareholder at his address as appearing in the Register, or by electronic mail to any electronic mail address such Shareholder may have specified in writing for the purpose of such service of notices, or by facsimile to any facsimile number such Shareholder may have specified in writing for the purpose of such service of notices, or by placing it on the Company’s Website should the Directors deem it appropriate. In the case of joint holders of a Share, all notices shall be given to that one of the joint holders whose name stands first in the Register in respect of the joint holding, and notice so given shall be sufficient notice to all the joint holders.
141.
Notices sent from one country to another shall be sent or forwarded by prepaid airmail or a recognised courier service.
142.
Any Shareholder Present at any meeting of the Company shall for all purposes be deemed to have received due notice of such meeting and, where requisite, of the purposes for which such meeting was convened.
143.
Any notice or other document, if served by:
(a)
post, shall be deemed to have been served five calendar days after the time when the letter containing the same is posted;
(b)
facsimile, shall be deemed to have been served upon production by the transmitting facsimile machine of a report confirming transmission of the facsimile in full to the facsimile number of the recipient;

 


 

(c)
recognised courier service, shall be deemed to have been served 48 hours after the time when the letter containing the same is delivered to the courier service; or
(d)
electronic means, shall be deemed to have been served immediately (i) upon the time of the transmission to the electronic mail address supplied by the Shareholder to the Company or (ii) upon the time of its placement on the Company’s Website.

In proving service by post or courier service it shall be sufficient to prove that the letter containing the notice or documents was properly addressed and duly posted or delivered to the courier service.

144.
Any notice or document delivered or sent by post to or left at the registered address of any Shareholder in accordance with the terms of these Articles shall notwithstanding that such Shareholder be then dead or bankrupt, and whether or not the Company has notice of his death or bankruptcy, be deemed to have been duly served in respect of any Share registered in the name of such Shareholder as sole or joint holder, unless his name shall at the time of the service of the notice or document have been removed from the Register as the holder of the Share, and such service shall for all purposes be deemed a sufficient service of such notice or document on all Persons interested (whether jointly with or as claiming through or under him) in the Share.
145.
Notice of every general meeting of the Company shall be given to:
(a)
all Shareholders holding Shares with the right to receive notice and who have supplied to the Company an address for the giving of notices to them; and
(b)
every Person entitled to a Share in consequence of the death or bankruptcy of a Shareholder, who but for his death or bankruptcy would be entitled to receive notice of the meeting.

No other Person shall be entitled to receive notices of general meetings.

INFORMATION

146.
Subject to the relevant laws, rules and regulations applicable to the Company, no Member shall be entitled to require discovery of any information in respect of any detail of the Company’s trading or any information which is or may be in the nature of a trade secret or secret process which may relate to the conduct of the business of the Company and which in the opinion of the Board would not be in the interests of the Members of the Company to communicate to the public.
147.
Subject to due compliance with the relevant laws, rules and regulations applicable to the Company, the Board shall be entitled to release or disclose any information in its possession, custody or control regarding the Company or its affairs to any of its Members including, without limitation, information contained in the Register and transfer books of the Company.

INDEMNITY

148.
Every Director (including for the purposes of this Article any alternate Director appointed pursuant to the provisions of these Articles), Secretary, assistant Secretary, or other officer for the time being and from time to time of the Company (but not including the Company’s auditors) and the personal representatives of the same (each an “Indemnified Person”) shall be indemnified and secured harmless against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such Indemnified Person, other than by reason of such Indemnified Person’s own dishonesty, wilful default or fraud, in or about the conduct of the Company’s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the

 


 

foregoing, any costs, expenses, losses or liabilities incurred by such Indemnified Person in defending (whether successfully or otherwise) any civil proceedings concerning the Company or its affairs in any court whether in the Cayman Islands or elsewhere.
149.
No Indemnified Person shall be liable:
(a)
for the acts, receipts, neglects, defaults or omissions of any other Director or officer or agent of the Company; or
(b)
for any loss on account of defect of title to any property of the Company; or
(c)
on account of the insufficiency of any security in or upon which any money of the Company shall be invested; or
(d)
for any loss incurred through any bank, broker or other similar Person; or
(e)
for any loss occasioned by any negligence, default, breach of duty, breach of trust, error of judgement or oversight on such Indemnified Person’s part; or
(f)
for any loss, damage or misfortune whatsoever which may happen in or arise from the execution or discharge of the duties, powers, authorities, or discretions of such Indemnified Person’s office or in relation thereto;

unless the same shall happen through such Indemnified Person’s own dishonesty, wilful default or fraud.

FINANCIAL YEAR

150.
Unless the Directors otherwise prescribe, the financial year of the Company shall end on December 31st in each calendar year and shall begin on January 1st in each calendar year.

NON-RECOGNITION OF TRUSTS

151.
No Person shall be recognised by the Company as holding any Share upon any trust and the Company shall not, unless required by law, be bound by or be compelled in any way to recognise (even when having notice thereof) any equitable, contingent, future or partial interest in any Share or (except only as otherwise provided by these Articles or as the Companies Act requires) any other right in respect of any Share except an absolute right to the entirety thereof in each Shareholder registered in the Register.

WINDING UP

152.
If the Company shall be wound up the liquidator may, with the sanction of a Special Resolution of the Company and any other sanction required by the Companies Act, divide amongst the Members in species or in kind the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and may for that purpose value any assets and determine how the division shall be carried out as between the Members or different classes of Members. The liquidator may, with the like sanction, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the Members as the liquidator, with the like sanction, shall think fit, but so that no Member shall be compelled to accept any asset upon which there is a liability.
153.
If the Company shall be wound up, and the assets available for distribution amongst the Members shall be insufficient to repay the whole of the share capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by the Members in proportion to the par value of the Shares held by them. If in a winding up the assets available for distribution amongst the

 


 

Members shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst the Members in proportion to the par value of the Shares held by them at the commencement of the winding up subject to a deduction from those Shares in respect of which there are monies due, of all monies payable to the Company for unpaid calls or otherwise. This Article is without prejudice to the rights of the holders of Shares issued upon special terms and conditions.

AMENDMENT OF ARTICLES OF ASSOCIATION

154.
Subject to the Companies Act, the Company may at any time and from time to time by Special Resolution alter or amend these Articles in whole or in part.

CLOSING OF REGISTER OR FIXING RECORD DATE

155.
For the purpose of determining those Shareholders that are entitled to receive notice of, attend or vote at any meeting of Shareholders or any adjournment thereof, or those Shareholders that are entitled to receive payment of any dividend, or in order to make a determination as to who is a Shareholder for any other purpose, the Directors may provide that the Register shall be closed for transfers for a stated period which shall not exceed in any case thirty calendar days in any calendar year.
156.
In lieu of or apart from closing the Register, the Directors may fix in advance a date as the record date for any such determination of those Shareholders that are entitled to receive notice of, attend or vote at a meeting of the Shareholders and for the purpose of determining those Shareholders that are entitled to receive payment of any dividend the Directors may, at or within ninety calendar days prior to the date of declaration of such dividend, fix a subsequent date as the record date for such determination.
157.
If the Register is not so closed and no record date is fixed for the determination of those Shareholders entitled to receive notice of, attend or vote at a meeting of Shareholders or those Shareholders that are entitled to receive payment of a dividend, the date on which notice of the meeting is posted or the date on which the resolution of the Directors declaring such dividend is adopted, as the case may be, shall be the record date for such determination of Shareholders. When a determination of those Shareholders that are entitled to receive notice of, attend or vote at a meeting of Shareholders has been made as provided in this Article, such determination shall apply to any adjournment thereof.

REGISTRATION BY WAY OF CONTINUATION

158.
The Company may by Special Resolution resolve to be registered by way of continuation in a jurisdiction outside the Cayman Islands or such other jurisdiction in which it is for the time being incorporated, registered or existing. In furtherance of a resolution adopted pursuant to this Article, the Directors may cause an application to be made to the Registrar of Companies to deregister the Company in the Cayman Islands or such other jurisdiction in which it is for the time being incorporated, registered or existing and may cause all such further steps as they consider appropriate to be taken to effect the transfer by way of continuation of the Company.

DISCLOSURE

159.
The Directors, or any service providers (including the officers, the Secretary and the registered office provider of the Company) specifically authorised by the Directors, shall be entitled to disclose to any regulatory or judicial authority any information regarding the affairs of the Company including without limitation information contained in the Register and books of the Company.

 


EX-2.5 3 cntb-ex2_5.htm EX-2.5 EX-2.5

Exhibit 2.5

Description of rights of securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”)

 

American Depositary Shares (“ADSs”), each of which represents one ordinary share of Connect Biopharma Holdings Limited (“we,” “us,” “our company,” or “our”), are listed and traded on the on the Nasdaq Global Market and, in connection with this listing (but not for trading), the ordinary shares are registered under Section 12(b) of the Exchange Act. This exhibit contains a description of the rights of (1) the holders of ordinary shares, and (2) the holders of ADSs. Ordinary shares underlying the ADSs are held by the Deutsche Bank Trust Company Americas, as depositary, and holders of ADSs will not be treated as holders of ordinary shares.

 

Description of Ordinary Shares (Items 9.A.3, 9.A.5, 9.A.6, 9.A.7, 10.B.3, 10.B.4, 10.B.6, 10.B.7, 10.B.8, 10.B.9 and 10.B.10 of Form 20-F)

 

The following are summaries of certain material provisions of the 5th amended and restated memorandum and articles of association of our company, and of the Cayman Islands Companies Act (As Revised) (the “Companies Act”), insofar as they relate to the material terms of our ordinary shares.

Objects of Our Company. Under our amended and restated memorandum and articles of association, the objects of our company are unrestricted and we have the full power and authority to carry out any object not prohibited by the law of the Cayman Islands.

Ordinary Shares. Our ordinary shares are issued in registered form and are issued when registered in our register of members (shareholders). We may not issue shares to bearer. Our shareholders who are nonresidents of the Cayman Islands may freely hold and vote their shares. Each ordinary share shall entitle the holder thereof to one vote on all matters subject to vote at our general meetings.

Dividends. The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors. In addition, our shareholders may declare dividends by ordinary resolution, but no dividend shall exceed the amount recommended by our directors. Our amended and restated memorandum and articles of association provide that our directors may, before recommending or declaring any dividend, set aside out of the funds legally available for distribution such sums as they think proper as a reserve or reserves which shall, in the absolute discretion of the directors, be applicable for meeting contingencies or for equalizing dividends or for any other purpose to which those funds may be properly applied. Under the laws of the Cayman Islands, our company may pay a dividend out of either profit or our share premium account, provided that in no circumstances may a dividend be paid if this would result in our company being unable to pay its debts as they fall due in the ordinary course of business.

Voting Rights. Each ordinary share shall be entitled to one vote on all matters subject to a vote at general meetings of our company. Voting at any shareholders’ meeting is by show of hands unless a poll is demanded (before or on the declaration of the result of the show of hands). A poll may be demanded by the chairman of such meeting or by any one or more shareholders who together hold not less than 10% of the votes attaching to the total number of ordinary shares which are present in person or by proxy at the meeting.

An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares which are cast at a meeting, while a special resolution requires the affirmative vote of no less than two-thirds of the votes attaching to the ordinary shares which are cast at a meeting. A special resolution will be required for important matters such as a change of name or making changes to our amended and restated memorandum and articles of association. Our company may, among other things, divide or combine our ordinary shares, by an ordinary resolution of our shareholders.

1

 


General Meetings of Shareholders. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders’ annual general meetings. Our amended and restated memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we shall specify the meeting as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by our directors.

Shareholders’ general meetings may be convened by the chairman of our board of directors or by a majority of our directors (acting by a resolution of the board). Advance notice of at least ten calendar days is required for the convening of our annual general shareholders’ meeting (if any) and any other general meeting of our shareholders. A quorum required for any general meeting of shareholders consists of one or more shareholders present in person or by proxy, holding shares which carry in aggregate not less than one-third of all votes attaching to all of our shares in issue and entitled to vote at such general meeting.

The Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company’s articles of association. Our amended and restated memorandum and articles of association provide that upon the requisition of shareholders holding shares which carry in aggregate not less than one-third of the votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings, our board will convene an extraordinary general meeting and put the resolutions so requisitioned to a vote at such meeting. However, our amended and restated memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders.

Transfer of Ordinary Shares. Subject to the restrictions set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors.

Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which is not fully paid up or on which we have a lien. Our board of directors may also decline to register any transfer of any ordinary share unless:

the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;
the instrument of transfer is in respect of only one class of ordinary shares;
the instrument of transfer is properly stamped, if required;
in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be transferred does not exceed four; and
a fee of such maximum sum as the Nasdaq Global Market may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof.

If our directors refuse to register a transfer they shall, within three months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal.

The registration of transfers may, after compliance with any notice required of the Nasdaq Global Market, be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine, provided, however, that the registration of transfers shall not be suspended nor the register closed for more than 30 calendar days in any calendar year.

Liquidation. On the winding up of our company, if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are

2

 


insufficient to repay the whole of the share capital, the assets will be distributed so that the losses are borne by our shareholders in proportion to the par value of the shares held by them.

Calls on Shares and Forfeiture of Shares. Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their shares in a notice served to such shareholders at least 14 days prior to the specified time and place of payment. The shares that have been called upon and remain unpaid are subject to forfeiture.

Redemption, Repurchase and Surrender of Shares. We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders of these shares, on such terms and in such manner as may be determined by our board of directors. Our company may also repurchase any of our shares on such terms and in such manner as have been approved by our board of directors or by an ordinary resolution of our shareholders. Under the Companies Act, the redemption or repurchase of any share may be paid out of our profits or out of the proceeds of a new issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if our company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a) unless it is fully paid up, (b) if such redemption or repurchase would result in there being no shares outstanding or (c) if our company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.

Variations of Rights of Shares. If at any time, our share capital is divided into different classes or series of shares, the rights attached to any class or series of shares (unless otherwise provided by the terms of issue of the shares of that class or series), whether or not our company is being wound-up, may be varied with the consent in writing of the holders of two-thirds of the issued shares of that class or series or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class or series. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not, subject to any rights or restrictions for the time being attached to the shares of that class, be deemed to be varied by the creation, allotment or issue of further shares ranking pari passu with or subsequent to such existing class of shares or the redemption or purchase of any shares of any class by our company. The rights of the holders of shares shall not be deemed to be materially adversely varied by the creation or issue of shares with preferred or other rights including, without limitation, the creation of shares with enhanced or weighted voting rights.

Issuance of Additional Shares. Our amended and restated memorandum of association authorizes our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares.

Our amended and restated memorandum of association also authorizes our board of directors to establish from time to time one or more series of preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including:

the designation of the series;
the number of shares of the series;
the dividend rights, dividend rates, conversion rights, voting rights; and
the rights and terms of redemption and liquidation preferences.

Our board of directors may issue preference shares without action by our shareholders to the extent authorized but unissued. Issuance of these shares may dilute the voting power of holders of ordinary shares.

Inspection of Books and Records. Holders of our ordinary shares have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records (except for the amended and restated memorandum and articles of association, special resolutions which have been passed by our shareholders, our register of mortgages and charges and a list of our current directors). However, we will provide our shareholders with annual audited consolidated financial statements.

3

 


Anti-Takeover Provisions. Some provisions of our amended and restated memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that:

authorize our board of directors to issue preference shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preference shares without any further vote or action by our shareholders; and
limit the ability of shareholders to requisition and convene general meetings of shareholders.

However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our amended and restated memorandum and articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company.

Exempted Company. We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company:

does not have to file an annual return of its shareholders with the Registrar of Companies;
the statutory provisions as to the required majority vote have been met;
is not required to open its register of members for inspection;
does not have to hold an annual general meeting;
may issue shares with no par value;
may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance);
may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;
may register as a limited duration company; and
may register as a segregated portfolio company.

“Limited liability” means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).

 

Differences in Corporate Law

 

The Companies Act of the Cayman Islands is derived, to a large extent, from the older Companies Acts of England but does not follow recent English statutory enactments and accordingly there are significant differences between the Companies Act of the Cayman Islands and the current Companies Act of England. In addition, the Companies Act differs from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of some significant differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in the United States and their shareholders.

 

Mergers and Similar Arrangements. The Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes, (i) “merger” means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company, and (ii) a “consolidation” means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the

4

 


directors of each constituent company must approve a written plan of merger or consolidation, which must then be authorized by (a) a special resolution of the shareholders of each constituent company, and (b) such other authorization, if any, as may be specified in such constituent company’s articles of association. The written plan of merger or consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a list of the assets and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures.

 

A merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders of that Cayman subsidiary if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member agrees otherwise. For this purpose a company is a “parent” of a subsidiary if it holds issued shares that together represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary.

 

The consent of each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived by a court in the Cayman Islands.

 

Save in some limited circumstances, a shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled to payment of the fair value of his shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or consolidation, provide the dissenting shareholder complies strictly with the procedures set out in the Companies Act. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful.

 

Separate from the statutory provisions relating to mergers and consolidations, the Companies Act also contains statutory provisions that facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the arrangement is approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made, and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that:

• the statutory provisions as to the required majority vote have been met;

• the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests adverse to those of the class;

• the arrangement is such that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and

• the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act.

 

The Companies Act also contains a statutory power of compulsory acquisition which may facilitate the “squeeze out” of dissentient minority shareholders upon a tender offer. When a tender offer is made and accepted by holders of 90.0% of the shares affected within four months, the offeror may, within a two-month period commencing on the expiration of such four month period, require the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion.

5

 


 

If an arrangement and reconstruction by way of scheme of arrangement is thus approved and sanctioned, or if a tender offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares.

 

Shareholders’ Suits. In principle, we will normally be the proper plaintiff to sue for a wrong done to us as a company, and as a general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands court can be expected to follow and apply the common law principles (namely the rule in Foss v. Harbottle and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action against or derivative actions in the name of the company to challenge actions where:

• the act complained of, although not ultra vires, could only be effected duly if authorized by more than a simple majority vote that has not been obtained; and

• those who control the company are perpetrating a “fraud on the minority.”

 

Indemnification of Directors and Executive Officers and Limitation of Liability. Cayman Islands law does not limit the extent to which a company’s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our amended and restated memorandum and articles of association provide that we shall indemnify our officers and directors against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such directors or officer, other than by reason of such person’s dishonesty, willful default or fraud, in or about the conduct of our company’s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his or her duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.

 

In addition, we have entered into indemnification agreements with our directors and specific executive officers that provide such persons with additional indemnification beyond that provided in our amended and restated memorandum and articles of association.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

 

Directors’ Fiduciary Duties. Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director acts in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use their corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a

6

 


director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.

 

As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that he or she owes the following duties to the company—a duty to act bona fide in the best interests of the company, a duty not to make a profit based on his or her position as director (unless the company permits them to do so), a duty not to put himself or herself in a position where the interests of the company conflict with his or personal interest or his duty to a third party, and a duty to exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands.

 

Shareholder Action by Written Resolution. Under the Delaware General Corporation Law, a corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. Cayman Islands law and our amended and restated articles of association provide that our shareholders may approve corporate matters by way of a unanimous written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held.

 

Shareholder Proposals. Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.

 

The Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company’s articles of association. Our amended and restated articles of association allow our shareholders holding shares which carry in aggregate not less than one-third of all votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. Other than this right to requisition a shareholders’ meeting, our amended and restated articles of association do not provide our shareholders with any other right to put proposals before annual general meetings or extraordinary general meetings. As an exempted Cayman Islands company, we may but are not obliged by law to call shareholders’ annual general meetings.

 

Cumulative Voting. Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation’s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single director, which increases the shareholder’s voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under the laws of the Cayman Islands but our amended and restated articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation.

 

Removal of Directors. Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our amended and restated articles of association, directors may be removed with or without cause, by an ordinary resolution of our shareholders. In addition, a director’s office shall be vacated if the director (i) becomes bankrupt or makes any arrangement or composition with his creditors; (ii) is found to be or becomes of unsound mind or dies; (iii) resigns his or her office by notice in writing to the company; (iv) without special leave of absence from our board of directors, is absent from three

7

 


consecutive meetings of the board and the board resolves that his or her office be vacated; or (v) is removed from office pursuant to any other provisions of our amended and restated memorandum and articles of association.

 

Transactions with Interested Shareholders. The Delaware General Corporation Law contains a business combination statute applicable to Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in various business combinations with an “interested shareholder” for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target’s outstanding voting share within the past three years. This has the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target’s board of directors.

 

Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the company and not with the effect of constituting a fraud on the minority shareholders.

 

Dissolution; Winding up. Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.

 

Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.

 

Variation of Rights of Shares. Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under Cayman Islands law and our amended and restated articles of association, if our share capital is divided into more than one class of shares, we may vary the rights attached to any class with the written consent of the holders of two-thirds of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class.

 

Amendment of Governing Documents. Under the Delaware General Corporation Law, a corporation’s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under the Companies Act and our amended and restated memorandum and articles of association, our memorandum and articles of association may only be amended by a special resolution of our shareholders.

 

Rights of Non-resident or Foreign Shareholders. There are no limitations imposed by our amended and restated memorandum and articles of association on the rights of non-resident or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our amended and restated memorandum and articles of association governing the ownership threshold above which shareholder ownership must be disclosed.

 

8

 


Transfer Agent and Registrar

Our ordinary share register is maintained by Maples Fund Services (Cayman) Limited. Holders of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our share register.

 

Description of Debt Securities, Warrants and Rights and Other Securities (Items 12.A, 12.B and 12.C of Form 20-F)

Not applicable.

 

Description of American Depositary Shares (Items 12.D.1 and 12.D.2 of Form 20-F)

 

Each ADS represents ownership of one ordinary share, deposited with Deutsche Bank AG, Hong Kong Branch, as custodian for the depositary. Each ADS also represents ownership of any other securities, cash or other property which may be held by the depositary. The depositary’s corporate trust office at which the ADSs are administered is located at 60 Wall Street, New York, NY 10005, USA. The principal executive office of the depositary is located at 60 Wall Street, New York, NY 10005, USA.

The Direct Registration System, or DRS, is a system administered by The Depository Trust Company, or DTC, pursuant to which the depositary may register the ownership of uncertificated ADSs, which ownership is evidenced by periodic statements issued by the depositary to the ADS holders entitled thereto.

We do not treat ADS holders as our shareholders and accordingly, you, as an ADS holder, do not have shareholder rights. Cayman Islands law governs shareholder rights. The depositary is the holder of the ordinary shares underlying your ADSs. As a holder of ADSs, you have ADS holder rights. A deposit agreement among us, the depositary and you, as an ADS holder, and the beneficial owners of ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. The laws of the State of New York govern the deposit agreement and the ADSs.

The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of American Depositary Receipt.

Dividends and Other Distributions

How will you receive dividends and other distributions on the ordinary shares?

The depositary has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities, after deducting its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent as of the record date (which will be as close as practicable to the record date for our ordinary shares) set by the depositary with respect to the ADSs.

Cash. The depositary will convert or cause to be converted any cash dividend or other cash distribution we pay on the ordinary shares or any net proceeds from the sale of any ordinary shares, rights, securities or other entitlements under the terms of the deposit agreement into U.S. dollars if it can do so on a practicable basis, and can transfer the U.S. dollars to the United States and will distribute promptly the amount thus received. If the depositary shall determine in its judgment that such conversions or transfers are not practical or lawful or if any government approval or license is needed and cannot be obtained at a reasonable cost within a reasonable period or otherwise sought, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold or cause the custodian to hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid and such funds will be held for the respective accounts of the ADS holders. It will not invest the foreign currency and it will not be liable for any interest for the respective accounts of the ADS holders.

Before making a distribution, any taxes or other governmental charges, together with fees and expenses of the depositary, that must be paid, will be deducted. It will distribute only whole U.S. dollars and cents and

9

 


will round down fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.

Shares. For any ordinary shares we distribute as a dividend or free distribution, either (1) the depositary will distribute additional ADSs representing such ordinary shares or (2) existing ADSs as of the applicable record date will represent rights and interests in the additional ordinary shares distributed, to the extent reasonably practicable and permissible under law, in either case, net of applicable fees, charges and expenses incurred by the depositary and taxes and/or other governmental charges. The depositary will only distribute whole ADSs. It will try to sell ordinary shares which would require it to deliver a fractional ADS and distribute the net proceeds in the same way as it does with cash. The depositary may sell a portion of the distributed ordinary shares sufficient to pay its fees and expenses, and any taxes and governmental charges, in connection with that distribution.
Elective Distributions in Cash or Shares. If we offer holders of our ordinary shares the option to receive dividends in either cash or shares, the depositary, after consultation with us and having received timely notice as described in the deposit agreement of such elective distribution by us, has discretion to determine to what extent such elective distribution will be made available to you as a holder of the ADSs. We must timely first instruct the depositary to make such elective distribution available to you and furnish it with satisfactory evidence that it is legal to do so. The depositary could decide it is not legal or reasonably practicable to make such elective distribution available to you. In such case, the depositary shall, on the basis of the same determination as is made in respect of the ordinary shares for which no election is made, distribute either cash in the same way as it does in a cash distribution, or additional ADSs representing ordinary shares in the same way as it does in a share distribution. The depositary is not obligated to make available to you a method to receive the elective dividend in shares rather than in ADSs. There can be no assurance that you will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of ordinary shares.
Rights to Purchase Additional Shares. If we offer holders of our ordinary shares any rights to subscribe for additional shares, the depositary shall having received timely notice as described in the deposit agreement of such distribution by us, consult with us, and we must determine whether it is lawful and reasonably practicable to make these rights available to you. We must first instruct the depositary to make such rights available to you and furnish the depositary with satisfactory evidence that it is legal to do so. If the depositary decides it is not legal or reasonably practicable to make the rights available but that it is lawful and reasonably practicable to sell the rights, the depositary will endeavor to sell the rights and in a riskless principal capacity or otherwise, at such place and upon such terms (including public or private sale) as it may deem proper distribute the net proceeds in the same way as it does with cash. The depositary will allow rights that are not distributed or sold to lapse. In that case, you will receive no value for them.

If the depositary makes rights available to you, it will establish procedures to distribute such rights and enable you to exercise the rights upon your payment of applicable fees, charges and expenses incurred by the depositary and taxes and/or other governmental charges. The Depositary shall not be obliged to make available to you a method to exercise such rights to subscribe for ordinary shares (rather than ADSs).

U.S. securities laws may restrict transfers and cancellation of the ADSs represented by shares purchased upon exercise of rights. For example, you may not be able to trade these ADSs freely in the United States. In this case, the depositary may deliver restricted depositary shares that have the same terms as the ADSs described in this section except for changes needed to put the necessary restrictions in place.

There can be no assurance that you will be given the opportunity to exercise rights on the same terms and conditions as the holders of ordinary shares or be able to exercise such rights.

Other Distributions. Subject to receipt of timely notice, as described in the deposit agreement, from us with the request to make any such distribution available to you, and provided the depositary has determined such distribution is lawful and reasonably practicable and feasible and in accordance with the terms of the deposit agreement, the depositary will distribute to you anything else we distribute on deposited securities by any means it may deem practicable, upon your payment of applicable fees, charges and expenses

10

 


incurred by the depositary and taxes and/or other governmental charges. If any of the conditions above are not met, the depositary will endeavor to sell, or cause to be sold, what we distributed and distribute the net proceeds in the same way as it does with cash; or, if it is unable to sell such property, the depositary may dispose of such property in any way it deems reasonably practicable under the circumstances for nominal or no consideration, such that you may have no rights to or arising from such property.

The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make on our shares or any value for them if we and/or the depositary determines that it is illegal or not practicable for us or the depositary to make them available to you.

 

Deposit, Withdrawal and Cancellation

How are ADSs issued?

The depositary will deliver ADSs if you or your broker deposit ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons entitled thereto.

How do ADS holders cancel an American Depositary Share?

You may turn in your ADSs at the depositary’s corporate trust office or by providing appropriate instructions to your broker. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the ordinary shares and any other deposited securities underlying the ADSs to you or a person you designate at the office of the custodian. Or, at your request, risk and expense, the depositary will deliver the deposited securities at its corporate trust office, to the extent permitted by law.

How do ADS holders interchange between Certificated ADSs and Uncertificated ADSs?

You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send you a statement confirming that you are the owner of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to you an ADR evidencing those ADSs.

 

Voting Rights

How do you vote?

You may instruct the depositary to vote the ordinary shares or other deposited securities underlying your ADSs at any meeting at which you are entitled to vote pursuant to any applicable law, the provisions of our memorandum and articles of association, and the provisions of or governing the deposited securities. Otherwise, you could exercise your right to vote directly if you withdraw the ordinary shares. However, you may not know about the meeting sufficiently enough in advance to withdraw the ordinary shares.

If we ask for your instructions and upon timely notice from us by regular, ordinary mail delivery, or by electronic transmission, as described in the deposit agreement, the depositary will notify you of the upcoming meeting at which you are entitled to vote pursuant to any applicable law, the provisions of our memorandum and articles of association, and the provisions of or governing the deposited securities, and arrange to deliver our voting materials to you. The materials will include or reproduce (a) such notice of meeting or solicitation of consents or proxies; (b) a statement that the ADS holders at the close of business on the ADS record date will be entitled, subject to any applicable law, the provisions of our memorandum and articles of association, and the provisions of or governing the deposited securities, to instruct the depositary as to the exercise of the voting rights, if any, pertaining to the ordinary shares or other deposited securities represented by such holder’s ADSs; and (c) a brief statement as to the manner in which such instructions may be given to the depositary or deemed given in accordance with the second to last

11

 


sentence of this paragraph if no instruction is received by the depositary to give a discretionary proxy to a person designated by us. Voting instructions may be given only in respect of a number of ADSs representing an integral number of ordinary shares or other deposited securities. For instructions to be valid, the depositary must receive them in writing on or before the date specified. The depositary will try, as far as practical, subject to applicable law and the provisions of our memorandum and articles of association, to vote or to have its agents vote the ordinary shares or other deposited securities (in person or by proxy) as you instruct. The depositary will only vote or attempt to vote as you instruct. If we timely requested the depositary to solicit your instructions but no instructions are received by the depositary from an owner with respect to any of the deposited securities represented by the ADSs of that owner on or before the date established by the depositary for such purpose, the depositary shall deem that owner to have instructed the depositary to give a discretionary proxy to a person designated by us with respect to such deposited securities, and the depositary shall give a discretionary proxy to a person designated by us to vote such deposited securities. However, no such instruction shall be deemed given and no such discretionary proxy shall be given with respect to any matter if we inform the depositary we do not wish such proxy given, substantial opposition exists or the matter materially and adversely affects the rights of holders of the ordinary shares.

We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the ordinary shares underlying your ADSs. In addition, there can be no assurance that ADS holders and beneficial owners generally, or any holder or beneficial owner in particular, will be given the opportunity to vote or cause the custodian to vote on the same terms and conditions as the holders of our ordinary shares.

The depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote and you may have no recourse if the ordinary shares underlying your ADSs are not voted as you requested.

In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary to act, we will give the depositary notice of any such meeting and details concerning the matters to be voted at least 30 business days in advance of the meeting date.

 

Compliance with Regulations

Information Requests

Each ADS holder and beneficial owner shall (a) provide such information as we or the depositary may request pursuant to law, including, without limitation, relevant Cayman Islands law, any applicable law of the United States of America, our memorandum and articles of association, any resolutions of our Board of Directors adopted pursuant to such memorandum and articles of association, the requirements of any markets or exchanges upon which the ordinary shares, ADSs or ADRs are listed or traded, or to any requirements of any electronic book-entry system by which the ADSs or ADRs may be transferred, regarding the capacity in which they own or owned ADRs, the identity of any other persons then or previously interested in such ADRs and the nature of such interest, and any other applicable matters, and (b) be bound by and subject to applicable provisions of the laws of the Cayman Islands, our memorandum and articles of association, and the requirements of any markets or exchanges upon which the ADSs, ADRs or ordinary shares are listed or traded, or pursuant to any requirements of any electronic book-entry system by which the ADSs, ADRs or ordinary shares may be transferred, to the same extent as if such ADS holder or beneficial owner held ordinary shares directly, in each case irrespective of whether or not they are ADS holders or beneficial owners at the time such request is made.

Disclosure of Interests

Each ADS holder and beneficial owner shall comply with our requests pursuant to Cayman Islands law, the rules and requirements of the Nasdaq Global Market and any other stock exchange on which the ordinary shares are, or will be, registered, traded or listed or our memorandum and articles of association, which requests are made to provide information, inter alia, as to the capacity in which such ADS holder or beneficial owner owns ADS and regarding the identity of any other person interested in such ADS and the nature of such interest and various other matters, whether or not they are ADS holders or beneficial owners at the time of such requests.

 

Fees and Expenses

12

 


As an ADS holder, you are required to pay the following service fees to the depositary bank and certain taxes and governmental charges (in addition to any applicable fees, expenses, taxes and other governmental charges payable on the deposited securities represented by any of your ADSs):

 

 

 

 

Service

 

Fees

•   To any person to which ADSs are issued or to any person to which a distribution is made in respect of ADS distributions pursuant to stock dividends or other free distributions of stock, bonus distributions, stock splits or other distributions (except where converted to cash)

 

Up to US$0.05 per ADS issued

•   Cancellation of ADSs, including the case of termination of the deposit agreement

 

Up to US$0.05 per ADS cancelled

•   Distribution of cash dividends

 

Up to US$0.05 per ADS held

•   Distribution of cash entitlements (other than cash dividends) and/or cash proceeds from the sale of rights, securities and other entitlements

 

Up to US$0.05 per ADS held

•   Distribution of ADSs pursuant to exercise of rights.

 

Up to US$0.05 per ADS held

•   Distribution of securities other than ADSs or rights to purchase additional ADSs

 

Up to US$0.05 per ADS held

•   Depositary services

 

Up to US$0.05 per ADS held on the applicable record date(s) established by the depositary bank

As an ADS holder, you are also responsible for paying certain fees and expenses incurred by the depositary bank and certain taxes and governmental charges (in addition to any applicable fees, expenses, taxes and other governmental charges payable on the deposited securities represented by any of your ADSs) such as:

Fees for the transfer and registration of ordinary shares charged by the registrar and transfer agent for the ordinary shares in the Cayman Islands (i.e., upon deposit and withdrawal of ordinary shares).
Expenses incurred for converting foreign currency into U.S. dollars.
Expenses for cable, telex and fax transmissions and for delivery of securities.
Taxes and duties upon the transfer of securities, including any applicable stamp duties, any stock transfer charges or withholding taxes (i.e., when ordinary shares are deposited or withdrawn from deposit).
Fees and expenses incurred in connection with the delivery or servicing of ordinary shares on deposit.
Fees and expenses incurred in connection with complying with exchange control regulations and other regulatory requirements applicable to ordinary shares, deposited securities, ADSs and ADRs.
Any applicable fees and penalties thereon.

The depositary fees payable upon the issuance and cancellation of ADSs are typically paid to the depositary bank by the brokers (on behalf of their clients) receiving the newly issued ADSs from the depositary bank and by the brokers (on behalf of their clients) delivering the ADSs to the depositary bank for cancellation. The brokers in turn charge these fees to their clients. Depositary fees payable in connection with distributions of cash or securities to ADS holders and the depositary services fee are charged by the depositary bank to the holders of record of ADSs as of the applicable ADS record date.

The depositary fees payable for cash distributions are generally deducted from the cash being distributed or by selling a portion of distributable property to pay the fees. In the case of distributions other than cash (i.e., share dividends, rights), the depositary bank charges the applicable fee to the ADS record date holders concurrent with the distribution. In the case of ADSs registered in the name of the investor (whether certificated or uncertificated in direct registration), the depositary bank sends invoices to the applicable record date ADS holders. In the case of ADSs held in brokerage and custodian accounts (via DTC), the depositary bank generally collects its fees through the systems provided by DTC (whose nominee is the registered holder of the ADSs held in DTC) from the brokers

13

 


and custodians holding ADSs in their DTC accounts. The brokers and custodians who hold their clients’ ADSs in DTC accounts in turn charge their clients’ accounts the amount of the fees paid to the depositary banks.

In the event of refusal to pay the depositary fees, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder.

The depositary may make payments to us or reimburse us for certain costs and expenses, by making available a portion of the ADS fees collected in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary bank agree from time to time.

 

Payment of Taxes

You are responsible for any taxes or other governmental charges payable, or which become payable, on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register or transfer your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to you any net proceeds, or send to you any property, remaining after it has paid the taxes. You are required to indemnify us, the depositary, the custodian and each of our and their respective agents, directors, employees and affiliates for, and hold each of them harmless from, any claims with respect to taxes (including applicable interest and penalties thereon) arising from any refund of taxes, reduced rate of withholding at source or other tax benefit obtained for you. Your obligations under this paragraph shall survive any transfer of ADRs, any surrender of ADRs and withdrawal of deposited securities or the termination of the deposit agreement.

 

Reclassifications, Recapitalizations and Mergers

 

 

 

If we:

 

Then:

Change the nominal or par value of our ordinary shares

 

The cash, shares or other securities received by the depositary will become deposited securities.

Reclassify, split up or consolidate any of the deposited securities

 

Each ADS will automatically represent its equal share of the new deposited securities.

Distribute securities on the ordinary shares that are not distributed to you, or

Recapitalize, reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action

 

The depositary may distribute some or all of the cash, shares or other securities it received. It may also deliver new ADSs or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities.

 

 

 

Amendment and Termination

How may the deposit agreement be amended?

We may agree with the depositary to amend the deposit agreement and the form of ADR without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, including expenses incurred in connection with foreign exchange control regulations and other charges specifically payable by ADS holders under the deposit agreement, or materially prejudices a substantial existing right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended. If any new laws are adopted which would require the deposit agreement to be amended in order to comply therewith, we and the depositary may amend the deposit agreement in accordance with such laws and such amendment may become effective before notice thereof is given to ADS holders.

How may the deposit agreement be terminated?

14

 


The depositary will terminate the deposit agreement if we ask it to do so, in which case the depositary will give notice to you at least 90 days prior to termination. The depositary may also terminate the deposit agreement if the depositary has told us that it would like to resign, or if we have removed the depositary, and in either case we have not appointed a new depositary within 90 days. In either such case, the depositary must notify you at least 30 days before termination.

After termination, the depositary and its agents will do the following under the deposit agreement but nothing else: collect distributions on the deposited securities, sell rights and other property and deliver ordinary shares and other deposited securities upon cancellation of ADSs after payment of any fees, charges, taxes or other governmental charges. Six months or more after the date of termination, the depositary may sell any remaining deposited securities by public or private sale. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and has no liability for interest. After such sale, the depositary’s only obligations will be to account for the money and other cash. After termination, we shall be discharged from all obligations under the deposit agreement except for our obligations to the depositary thereunder.

 

15

 


Books of Depositary

The depositary will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the Company, the ADRs and the deposit agreement.

The depositary will maintain facilities in the Borough of Manhattan, The City of New York to record and process the issuance, cancellation, combination, split-up and transfer of ADRs.

These facilities may be closed at any time or from time to time when such action is deemed necessary or advisable by the depositary in connection with the performance of its duties under the deposit agreement or at our reasonable written request.

 

Limitations on Obligations and Liability

Limits on our Obligations and the Obligations of the Depositary and the Custodian; Limits on Liability to Holders of ADSs

The deposit agreement expressly limits our obligations and the obligations of the depositary and the custodian. It also limits our liability and the liability of the depositary. The depositary and the custodian:

are only obligated to take the actions specifically set forth in the deposit agreement without gross negligence or willful misconduct;
are not liable if any of us or our respective controlling persons or agents are prevented or forbidden from, or subjected to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement and any ADR, by reason of any provision of any present or future law or regulation of the United States or any state thereof, the Cayman Islands or any other country, or of any other governmental authority or regulatory authority or stock exchange, or on account of the possible criminal or civil penalties or restraint, or by reason of any provision, present or future, of our memorandum and articles of association or any provision of or governing any deposited securities, or by reason of any act of God or war or other circumstances beyond its control (including, without limitation, nationalization, expropriation, currency restrictions, work stoppage, strikes, civil unrest, revolutions, rebellions, explosions and computer failure);
are not liable by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement or in our memorandum and articles of association or provisions of or governing deposited securities;
are not liable for any action or inaction of the depositary, the custodian or us or their or our respective controlling persons or agents in reliance upon the advice of or information from legal counsel, any person presenting ordinary shares for deposit or any other person believed by it in good faith to be competent to give such advice or information;
are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement;
are not liable for any special, consequential, indirect or punitive damages for any breach of the terms of the deposit agreement, or otherwise;
may rely upon any documents we believe in good faith to be genuine and to have been signed or presented by the proper party;
disclaim any liability for any action or inaction or inaction of any of us or our respective controlling persons or agents in reliance upon the advice of or information from legal counsel, accountants, any person presenting ordinary shares for deposit, holders and beneficial owners (or authorized representatives) of ADSs, or any person believed in good faith to be competent to give such advice or information; and

16

 


disclaim any liability for inability of any holder to benefit from any distribution, offering, right or other benefit made available to holders of deposited securities but not made available to holders of ADS.

The depositary and any of its agents also disclaim any liability (i) for any failure to carry out any instructions to vote, the manner in which any vote is cast or the effect of any vote or failure to determine that any distribution or action may be lawful or reasonably practicable or for allowing any rights to lapse in accordance with the provisions of the deposit agreement, (ii) the failure or timeliness of any notice from us, the content of any information submitted to it by us for distribution to you or for any inaccuracy of any translation thereof, (iii) any investment risk associated with the acquisition of an interest in the deposited securities, the validity or worth of the deposited securities, the credit-worthiness of any third party, (iv) for any tax consequences that may result from ownership of ADSs, ordinary shares or deposited securities, or (v) for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the depositary or in connection with any matter arising wholly after the removal or resignation of the depositary, provided that in connection with the issue out of which such potential liability arises the depositary performed its obligations without gross negligence or willful misconduct while it acted as depositary.

In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.

 

Jurisdiction and Arbitration

The laws of the State of New York govern the deposit agreement and the ADSs and we have agreed with the depositary that the federal or state courts in the City of New York shall have exclusive jurisdiction to hear and determine any dispute arising from or in connection with the deposit agreement and that the depositary will have the right to refer any claim or dispute arising from the relationship created by the deposit agreement (including those purchasers of ADSs in a secondary market transaction) to arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The arbitration provisions of the deposit agreement govern such dispute or difference and do not, in any event, preclude you from pursuing claims under the Securities Act or the Exchange Act in federal or state courts.

 

Jury Trial Waiver

The deposit agreement provides that each party to the deposit agreement (including each holder, beneficial owner and holder of interests in the ADRs) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any lawsuit or proceeding against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable law.

 

Requirements for Depositary Actions

Before the depositary will issue, deliver or register a transfer of an ADS, split-up, subdivide or combine ADSs, make a distribution on an ADS, or permit withdrawal of ordinary shares, the depositary may require:

payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any ordinary shares or other deposited securities and payment of the applicable fees, expenses and charges of the depositary;
satisfactory proof of the identity and genuineness of any signature or any other matters contemplated in the deposit agreement; and
compliance with (A) any laws or governmental regulations relating to the execution and delivery of ADRs or ADSs or to the withdrawal or delivery of deposited securities and (B) such reasonable regulations and procedures as the depositary may establish, from time to time, consistent with the deposit agreement and applicable laws, including presentation of transfer documents.

17

 


The depositary may refuse to issue and deliver ADSs or register transfers of ADSs generally when the register of the depositary or our transfer books are closed or at any time if the depositary or we determine that it is necessary or advisable to do so.

 

Your Right to Receive the Shares Underlying Your ADSs

You have the right to cancel your ADSs and withdraw the underlying ordinary shares at any time except:

when temporary delays arise because: (1) the depositary has closed its transfer books or we have closed our transfer books; (2) the transfer of ordinary shares is blocked to permit voting at a shareholders’ meeting; or (3) we are paying a dividend on our ordinary shares;
when you owe money to pay fees, taxes and similar charges;
when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities, or other circumstances specifically contemplated by Section I.A.(l) of the General Instructions to Form F-6 (as such General Instructions may be amended from time to time); or
for any other reason if the depositary or we determine, in good faith, that it is necessary or advisable to prohibit withdrawals.

The depositary shall not knowingly accept for deposit under the deposit agreement any ordinary shares or other deposited securities required to be registered under the provisions of the Securities Act, unless a registration statement is in effect as to such ordinary shares.

This right of withdrawal may not be limited by any other provision of the deposit agreement.

 

Direct Registration System

In the deposit agreement, all parties to the deposit agreement acknowledge that the DRS and Profile Modification System, or Profile, will apply to uncertificated ADSs upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC pursuant to which the depositary may register the ownership of uncertificated ADSs, which ownership shall be evidenced by periodic statements issued by the depositary to the ADS holders entitled thereto. Profile is a required feature of DRS which allows a DTC participant, claiming to act on behalf of an ADS holder, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register such transfer.

18

 


EX-4.5 4 cntb-ex4_5.htm EX-4.5 EX-4.5

 

Exhibit 4.5

connect biopharma holdings limited

NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM

 

Eligible Directors (as defined below) on the board of directors (the “Board”) of Connect Biopharma Holdings Limited (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically as set forth herein and without further action of the Board, to each member of the Board who is not an employee of the Company or any of its parents or subsidiaries and who is determined by the Board to be eligible to receive compensation under this Program (each, an “Eligible Director”), unless such Eligible Director declines the receipt of such cash or equity compensation by written notice to the Company. Notwithstanding the foregoing, unless otherwise determined by the Board, any member of the Board who is representing, designated by or affiliated with an investor or a group of investors that owns beneficially 5% or more of outstanding ordinary shares of the Company shall not be an Eligible Director for purposes of this Program.

This Program shall become effective January 1, 2022 (the “Effective Date”) and shall remain in effect until it is revised or rescinded by further action of the Board. This Program may be amended, modified or terminated by the Board at any time in its sole discretion. No Eligible Director shall have any rights hereunder, except with respect to equity awards granted pursuant to Section 2 of this Program.

1.
Cash Compensation.
a.
Annual Retainers. Each Eligible Director shall be eligible to receive an annual cash retainer of $35,000 for service on the Board.
b.
Additional Annual Retainers. An Eligible Director shall be eligible to receive the following additional annual retainers, as applicable:
(i)
Lead Independent Director. An Eligible Director serving as Lead Independent Director of the Board shall be eligible to receive an additional annual retainer of $17,500 for such service.
(ii)
Audit Committee. An Eligible Director serving as Chairperson of the Audit Committee shall be eligible to receive an additional annual retainer of $15,000 for such service. An Eligible Director serving as a member of the Audit Committee (other than the Chairperson) shall be eligible to receive an additional annual retainer of $7,500 for such service.
(iii)
Compensation Committee. An Eligible Director serving as Chairperson of the Compensation Committee shall be eligible to receive an additional annual retainer of $10,000 for such service. An Eligible Director serving as a member of the Compensation Committee (other than the Chairperson) shall be eligible to receive an additional annual retainer of $7,500 for such service.
(iv)
Nominating and Corporate Governance Committee. An Eligible Director serving as Chairperson of the Nominating and Corporate Governance Committee shall be eligible to receive an additional annual retainer of $10,000 for such service. An Eligible Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall be eligible to receive an additional annual retainer of $7,500 for such service.

 

 

 


 

c.
Payment of Retainers. The annual cash retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than 30 days following the end of each calendar quarter. In the event an Eligible Director does not serve as a director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, the retainer paid to such Eligible Director shall be prorated for the portion of such calendar quarter actually served as a director, or in such position, as applicable.
2.
Equity Compensation.
a.
General. Eligible Directors shall be granted the equity awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Company’s 2021 Stock Incentive Plan or any other applicable Company equity incentive plan then-maintained by the Company (such plan, as may be amended from time to time, the “Equity Plan”) and may be granted subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms approved by the Board prior to or in connection with such grants. All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of equity awards hereby are subject in all respects to the terms of the Equity Plan. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Equity Plan.
b.
Initial Awards. Each Eligible Director who is initially elected or appointed to serve on the Board after the Effective Date shall be granted such equity awards as determined by the Board at the time of such initial election or appointment.
c.
Annual Awards. An Eligible Director who is serving on the Board as of the first trading day of March each calendar year beginning with calendar year 2022 shall be automatically granted on such date a stock option to purchase 21,269 ordinary shares of the Company (an “Annual Award”). Each Annual Award shall vest in full on the one-year anniversary of the applicable grant date, subject to continued service through the applicable vesting date. In addition, each Annual Award shall vest upon a Change in Control (as defined in the Equity Plan).
d.
Annual Award for Lead Independent Director. An Eligible Director who is serving as Lead Independent Director of the Board as of the first trading day of March each calendar year beginning with calendar year 2022 shall be automatically granted on such date an additional stock option to purchase 7,090 ordinary shares of the Company (a “Lead Independent Director Annual Award”). Each Lead Independent Director Annual Award shall vest in full on the one-year anniversary of the applicable grant date, subject to continued service through the applicable vesting date. In addition, each Lead Independent Director Annual Award shall vest upon a Change in Control (as defined in the Equity Plan).
e.
Terms of Awards Granted to Eligible Directors.
(i)
Purchase Price. The per share exercise price of each stock option granted to an Eligible Director shall equal the Fair Market Value (as defined in the Equity Plan) of an ordinary share on the date the option is granted.
(ii)
Term. The term of each stock option granted to an Eligible Director shall be ten years from the date the option is granted.
3.
Compensation Limits. Notwithstanding anything to the contrary in this Program, all compensation payable under this Program will be subject to any limits on the maximum amount of non-employee Director compensation set forth in the Equity Plan, as in effect from time to time.

*****

 

 


EX-4.10 5 cntb-ex4_10.htm EX-4.10 EX-4.10

 

Exhibit 4.10

 

img21858020_0.jpg 

 

October 13, 2021

 

Steven Chan

Via Electronic Mail

 

Re: Employment Terms

Dear Steven:

Connect Biopharm LLC (the “Company” or “Connect”) is pleased to offer you the position of Chief Financial Officer of the Company and its affiliates, on the following terms. As applicable, references to Company or Connect also include its affiliated entities.

You will be responsible for fully contributing to the development of the Company strategy and the successful planning and execution of corporate goals. You will lay the foundations for long term growth and success by delivering functional excellence, leading areas of responsibility with vision, and by developing high performing and accountable teams. Key responsibilities include, but are not limited to driving financing strategy, providing financial insight for strategic planning and managing the corporatewide financial planning, budgeting and forecasting, and general risk analysis. This position will report to Zheng Wei, Chief Executive Officer and you will work at our facility located at San Diego. Of course, the Company may change your position, duties, and work location from time to time in its discretion.

Your base salary will be paid at the rate of $34,166.66 per month ($410,000.00 on an annualized basis), less payroll deductions and withholdings, paid on the Company’s normal payroll schedule.

As part of your offer, you will be eligible for a one-time sign-on bonus of $75,000.00 (subject to applicable taxes and withholdings), payable within the first 60 days of your date of hire. Upon acceptance of this offer, you will also be required to sign and return a Bonus Repayment Agreement in the form attached to this offer letter prior to any sign-on bonus payment being issued. Sign-on bonus payments are recoverable and due back to Connect should you voluntarily leave the Company within two (2) years of your start date, per the following schedule:

 

If you voluntarily terminate your employment for any reason with Connect within the first 12 months of your start date, you will repay 100% of the sign-on bonus provided to you within 30 days following your resignation.

 

If you voluntarily terminate your employment for any reason with Connect within the 13th month through the 24th month from your start date, you will repay 50% of the sign-on bonus provided to you within 30 days following your resignation.

 

By signing this offer letter, you will indicate your agreement to the foregoing repayment provisions.

 


 

You will be expected to relocate to San Diego within twelve (12) months of joining the Company, as long as COVID-19 conditions permit. However, if your circumstances do not allow you to relocate after one year, you would be expected to be present at the San Diego office consistent with what is expected of employees who are located in San Diego. You will be reimbursed for actual moving costs for packing and shipping your personal belongings to San Diego upon submitting corresponding receipt of payment, up to $50,000.

You will be eligible to receive a target discretionary annual bonus of up to 40% of your base salary, based or the Company’s performance and your individual performance. Whether the Company awards bonuses for any given year, the allocation of the bonuses for Company and individual performance, and the amounts of such bonuses, if awarded, will be in the sole discretion of the Company as determined by the Board of Directors of Connect Biopharma Holdings Limited (the “Board”). If the Board approves payment of bonuses for any given year, the bonus amounts generally will be determined and paid within the first calendar quarter of the year based on the prior year’s performance. To incentivize you to remain employed with the Company, you must be employed on the date any bonus is paid in order to earn the bonus. If your employment terminates for any reason prior to the payment of the bonus, then you will not have earned the bonus and will not receive any portion of it, except as set forth in the Addendum to Employment Offer Letter for Severance Benefits attached hereto.

During your employment, you will be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company from time to time, subject to plan terms and generally applicable Company policies. Exempt employees do not accrue vacation, and there is no set guideline as to how much vacation each employee will be permitted to take. Supervisors will approve paid vacation requests based on the employee’s progress on work goals or milestones, status of projects, fairness to the working team, and productivity and efficiency of the employee. Since vacation is not allotted or accrued, “unused” vacation time will not be carried over from one year to the next nor paid out upon termination.

A full description of these benefits is available for your review. The Company may change compensation and benefits from time to time in its discretion.

Subject to approval by the Board of Directors of Connect Biopharma Holdings Limited, the Company anticipates granting you an option to purchase 310,000 ordinary shares of the Connect Biopharma Holdings Limited with an exercise price equal to the fair market value as of the date of grant (the “Option”). The anticipated Option will be governed by the terms and conditions of Connect Biopharma Holdings Limited’s

2021 Stock Incentive Plan (the “Plan”) and your grant agreement, and will include a four year vesting schedule, under which 25% of your Option will vest 12 months after your start date, and 1/48th of the total shares will vest at the end of each month thereafter, until either the Option is fully vested or your continuous service (as defined in the Plan) terminates, whichever occurs first.

As a Company employee, you will be expected to abide by Company rules and policies. As a condition of employment, you must sign and comply with the attached Employee Confidential Information and Inventions Assignment Agreement which prohibits unauthorized use or disclosure of the Company’s proprietary information, among other obligations.

In your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company.

 


 

Normal business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional hours as required by the nature of your work assignments.

Your employment with the Company will be “at-will.” You may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. Your employment at-will status can only be modified in a written agreement signed by you and by an officer of the Company.

Under certain circumstances, you may be entitled to receive severance benefits upon termination of your employment, as further described in the Addendum to Employment Offer Letter for Severance Benefits attached hereto.

This offer is contingent upon a reference and background check satisfactory to the Company and satisfactory proof of your right to work in the United States. You agree to assist as needed and to complete any documentation at the Company’s request to meet these conditions.

To the extent permissible by applicable law, to ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. § 1-16, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS’ then applicable rules and procedures for employment disputes (available upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/). You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law(s) to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the “Excluded Claims”). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. You will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent either you

 


 

or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.

This letter, together with your Employee Confidential Information and Inventions Assignment Agreement, forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the Company’s discretion in this letter, require a written modification signed by an officer of the Company. If any provision of this offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This letter may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

This offer letter, the Employee Confidential Information and Inventions Assignment Agreement, the SignOn Bonus Repayment Agreement and the Addendum to Employment Offer Letter for Severance Benefits constitute the complete, final and exclusive embodiment of the entire agreement between you and the Company with respect to the terms and conditions of your employment specified herein and therein, and supersede any other such promises, warranties, representations or agreements between you and the Company. This offer letter may not be amended or modified except by a written instrument signed by you and a duly authorized officer of the Company.

This offer letter will be governed by and construed in accordance with the laws of the State of California without regard to the conflicts of law provisions thereof.

Please sign and date this letter, and the enclosed Employee Confidential Information and Inventions Assignment Agreement and return them to me by October 14, 2021, if you wish to accept employment at the Company under the terms described above. If you accept our offer, we would like you to start on November 22, 2021.

We look forward to your favorable reply and to a productive and enjoyable work relationship. Sincerely,

/s/ Zheng Wei

 

 

Zheng Wei, Chief Executive Officer

 

 

 

 

 

Understood and Accepted:

 

 

/s/ Steve Chan

 

10/14/2021

Steven Chan

 

Date:

 

Chansteven93@gmail.com

 

Attachments: Employee Confidential Information and Inventions Assignment Agreement

Addendum to Employment Offer Letter for Severance Benefits

Sign-On Bonus Repayment Agreement

 

 


 

Addendum To Employment Offer Letter For Severance Benefits

 

The provisions of this Addendum to Employment Offer Letter for Severance Benefits

(the “Addendum”) are incorporated into, and are made a part of, the employment offer letter (the “Offer Letter”) by and between you, Steven Chan, and Connect Biopharm LLC (“Company”) to which this Addendum is attached. Capitalized terms used in this Addendum are either defined herein or in Appendix A.

 

1.
Severance Benefits.

 

(a)
Subject to Section 1(b) below and your continued compliance with the Employee Confidential Information and Inventions Assignment Agreement executed by you in connection with your commencement of employment, if your employment is terminated by the Company without Cause or is terminated by you as a result of a Constructive Termination, then you shall be entitled to the following severance benefits in lieu of any severance benefits to which you may otherwise be entitled under any severance plan or program of the Company:

 

(i)
Payment of a lump sum amount equivalent to (A) nine (9) months of your Base Salary plus (B) 75% of your target bonus for the applicable year as determined by the Board, in each case less applicable withholding. Such amount shall be payable in a lump sum no later than five (5) days following the effective date of your Release; and

 

(ii)
Payment for your premiums for health (i.e., medical, vision and dental) continuation coverage under COBRA; provided, however, that (A) you are eligible for COBRA on the Termination Date and (B) you elect continuation coverage pursuant to COBRA, within the required time period. The Company shall continue to provide you with health coverage pursuant to this paragraph until the earliest of (1) the date you are no longer eligible to receive continuation coverage pursuant to COBRA, (2) nine (9) months from the Termination Date, or (3) the date on which you obtain comparable health coverage (such period, the “COBRA Coverage Period”). If any of the Company’s health benefits are self-funded as of your Termination Date, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A of the Code or that is otherwise compliant with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to you the foregoing monthly amount as a taxable monthly payment (grossed up to account for taxes) for the COBRA Coverage Period (or any remaining portion thereof). You shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums. You agree to notify Company promptly after you obtain alternative health coverage; and
(iii)
If your employment is terminated by the Company without Cause or is terminated by you as a result of a Constructive Termination, in each case during the Relevant Period, then each of your outstanding stock awards (including any stock options, restricted stock or other awards granted to you by the Parent) shall automatically become fully vested and exercisable and be released from any repurchase or forfeiture rights for all of the shares you receive as a result of exercise on the later of

 


 

(A) the date of such termination or (B) the date of the Change in Control. The foregoing provisions are hereby deemed to be a part of each stock award (and, for the avoidance of doubt, if any stock award is subject to more favorable vesting pursuant to any agreement or plan regarding such stock award, such more favorable provisions shall continue to apply and shall not be limited by this clause (iii)).

 

(b)
As a condition to your receipt of any post-termination benefits pursuant to Section 1(a) above, you shall execute and not revoke a general release of all claims in favor of the Company and its affiliates in a form reasonably acceptable to and provided by the Company in compliance with applicable law (the “Release”). In the event the Release does not become effective within the fifty-five (55) day period following the date when your employment is terminated by the Company without Cause or is terminated by you as a result of a Constructive Termination, you shall not be entitled to the aforesaid payments and benefits.

 

2.
Successors.

 

(a)
Company’s Successors. Any successor to Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of Company’s business and/or assets shall assume Company’s obligations under this Addendum and perform Company’s obligations under this Addendum in the same manner and to the same extent as Company would be required to perform such obligations in the absence of a succession. For all purposes under this Addendum, the term “Company” shall include any successor to Company’s business and/or assets which acknowledges it will be bound by the terms of this Addendum or which becomes bound by the terms of this Addendum by operation of law.

 

(b)
Your Successors. Without the written consent of Company, you shall not assign or transfer this Addendum or any right or obligation under this Addendum to any other person or entity. Notwithstanding the foregoing, the terms of this Addendum and all you rights hereunder shall inure to the benefit of, and be enforceable by, your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.

 

3.
Code Section 409A.
(a)
This Addendum is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the severance payments payable under Section 1(a) shall be paid no later than the later of: (A) the fifteenth (15th) day of the third month following your first taxable year in which such amounts are no longer subject to a substantial risk of forfeiture, and (B) the fifteenth (15th) day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as determined in accordance with Code Section 409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Addendum shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Addendum is hereby designated as a series of “separate payments” within the meaning of Section 409A of the Code. For purposes of this Addendum, to the extent required to ensure the payments hereunder are exempt from or comply with Section 409A of the Code, all references to your “termination of employment” shall mean your “separation from service” as defined in Treasury Regulation Section 1.409-A-1(h).

 


 

(b)
If you are a “specified employee” (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of your Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section 409A of the Code and the delayed payment or distribution of all or any portion of such amounts to which you are entitled under this Addendum is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to this Section 9(o)(ii) shall be paid or distributed to you in a lump sum on the earlier of (A) the date that is six (6)-months following your Separation from Service, (B) the date of your death or (C) the earliest date as is permitted under Section 409A of the Code. Any remaining payments due under the Addendum shall be paid as otherwise provided herein.
(c)
To the extent applicable, this Addendum shall be interpreted in accordance with the applicable exemptions from Section 409A of the Code. If you and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3) and (4) of the Code do not comply with Section 409A of the Code, you and the Company agree to amend this Addendum, or take such other actions as you and the Company deem reasonably necessary or appropriate, to comply with the requirements of Section 409A of the Code and the Treasury Regulations thereunder (and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Addendum is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner that no payments payable under this Addendum shall be subject to an “additional tax” as defined in Section 409A(a)(1)(B) of the Code.
(d)
Any reimbursement of expenses or in-kind benefits payable under this Addendum shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of your taxable year following the taxable year in which you incurred the expenses. The amount of expenses reimbursed or in-kind benefits payable during any taxable year of yours shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of yours, and your right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit.
(e)
In the event that the amounts payable under Section 1(a) are subject to Section 409A of the Code and the timing of the delivery of your Release could cause such amounts to be paid in one or another taxable year, then notwithstanding the payment timing set forth in such sections, such amounts shall not be payable until the later of (A) the payment date specified in such section or (B) the first business day of the taxable year following your Separation from Service.

 

4.
Miscellaneous Provisions.

 

a.
Integration. This Addendum represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements and provisions in other agreements related to severance benefits, whether written or oral. With respect to any conflict between this Addendum and the Offer Letter or any other employment related agreement, this Addendum shall prevail. For the avoidance of doubt, this Addendum does not change your employment at-will status.

 

b.
Choice of Law. The validity, interpretation, construction and performance of this Addendum shall be governed by the internal substantive laws, but not the conflicts of law rules, of the State of California.

 

c.
Employment Taxes. All payments made pursuant to this Addendum shall be subject to withholding of applicable income and employment taxes.

 


 

 

IN WITNESS WHEREOF, each of the parties has executed this Addendum, in the case of Company by its duly authorized officer, as of the day and year first above written.

 

 

CONNECT BIOPHARM LLC:

EXECUTIVE:

By: /s/ Zheng Wei

By: /s/ Steven Chan

Title: Chief Executive Officer

Name: Steven Chan

Date: 10/13/2021

Date: 10/14/2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

APPENDIX A

 

The following definitions shall be in effect under the severance benefits letter:

 

(a)
Base Salary. “Base Salary” means your annual base salary as in effect during the last regularly scheduled payroll period immediately preceding the effective date of your termination without Cause or due to a Constructive Termination.

 

(b)
Board. “Board” means the Board of Directors of Parent.

 

(c)
Cause. “Cause” means any of the following:
(i)
Your unauthorized use or disclosure of any proprietary information of the Company or its affiliates or any material breach of a written agreement between you and any member of the Company or any affiliate, including without limitation a material breach of any employment, confidentiality, non-compete, non-solicit or similar agreement executed by you;
(ii)
Your conviction by a court of competent jurisdiction of, or your pleading “guilty” or “no contest” to, a felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof;
(iii)
Your gross negligence or willful misconduct or your willful or repeated failure or refusal to substantially perform assigned duties;
(iv)
the commission of an act of fraud, embezzlement or dishonesty by you, or the commission of some other illegal act by you, that causes material harm to the Company or any successor or affiliate thereof; or
(v)
Your ongoing and repeated failure or refusal to perform or neglect of your duties as required by your offer letter, which failure, refusal or neglect continues for thirty (30) days following your receipt of written notice from the Board stating with specificity the nature of such failure, refusal or neglect; provided, however, that prior to the determination that “Cause” under clauses (i), (iii), or (v) of this Section (c) has occurred, the Company shall (A) provide to you in writing, in reasonable detail, the reasons for the determination that such “Cause” exists, (B) afford you a reasonable opportunity to remedy any such breach (if it is capable of being cured), and (C) provide you an opportunity to be heard prior to the final decision to terminate your employment hereunder for such “Cause”. The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge or dismiss you for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Addendum, to constitute grounds for termination for Cause.

 

(d)
Change in Control. “Change in Control” shall have the meaning given to such term in the Stock Incentive Plan. Notwithstanding the foregoing, if a Change in Control would give rise to a payment or settlement event with respect to any amount hereunder that constitutes “nonqualified deferred compensation,” the transaction or event constituting the Change in Control must also constitute a “change in control event” (as defined in Treasury Regulation §1.409A3(i)(5)) in order to give rise to the payment or settlement event for such Award, to the extent required by Section 409A.

 

 


 

(e)
COBRA. “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.

 

(f)
Code. “Code” means the Internal Revenue Code of 1986, as amended.

 

(g)
Constructive Termination. “Constructive Termination” means your voluntary resignation following the occurrence of any of the following events or conditions without your prior written consent:

 

(i)
a material diminution in your title, authority, duties, or responsibilities;

 

(ii)
a material diminution in your base compensation, unless such a reduction is imposed across-the-board to senior management of the Company;

 

(iii)
a material change in the geographic location at which you must perform your duties that increases your one-way commute by more than thirty (30) miles as compared to your then-current principal place of employment immediately prior to such relocation (provided that the requirement that you relocate to the San Diego, California area and work from the Company’s San Diego, California facility shall not constitute grounds for a Constructive Termination); or

 

(iv)
any other action or inaction that constitutes a material breach by the Company or any successor or affiliate of its obligations to you under your offer letter or this Addendum.

 

You must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without your written consent within sixty (60) days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30) days to cure such event or condition after receipt of written notice of such event from you. Your resignation by reason of Constructive Termination must occur within thirty (30) days following the expiration of the foregoing thirty (30) day cure period.

 

(h)
Parent. “Parent” shall mean Connect Biopharma Holdings Limited.

 

(i)
Relevant Period. “Relevant Period” shall mean the period beginning two (2) months prior to the effective date of a Change in Control and ending twelve (12) months after the effective date of a Change in Control.

 

(j)
Section 409A. “Section 409A” shall mean Section 409A of the Code.

 

(k)
Stock Incentive Plan. “Stock Incentive Plan” shall mean Parent’s 2021 Stock Incentive Plan, as amended from time to time.
(l)
Termination Date. “Termination Date” shall mean the effective date of your termination of employment.

 

 

 

 

 

 


 

 

 

 

 

CONNECT BIOPHARM LLC SIGN-ON BONUS REPAYMENT AGREEMENT

 

As part of my employment offer, I am eligible to receive a one-time sign on bonus of $75,000 subject to applicable taxes and withholdings. Prior to receiving any bonus payment, I agree to and understand the following:

If I voluntarily terminate my employment for any reason with Connect within the first 12 months from my start date, I will repay 100% of the sign-on bonus provided to me within 30 days following my resignation.

If I voluntarily terminate my employment for any reason with Connect within the 13th month through the 24th month from my start date, I will repay 50% of the sign-on bonus provided to me within 30 days following my resignation.

This repayment provision does not constitute a contract of employment or a guarantee of employment. This Agreement does not alter or amend the employment-related agreements I have executed. I understand that employment with Connect is at-will.

 

CONNECT BIOPHARM LLC:

EXECUTIVE:

By: /s/ Zheng Wei

By: /s/ Steven Chan

Title: Chief Executive Officer

Name: Steven Chan

Date: 10/13/2021

Date: 10/14/2021

 

 

 


EX-4.11 6 cntb-ex4_11.htm EX-4.11 EX-4.11

 

Exhibit 4.11

img22781541_0.jpg 

 

November 2, 2021

 

Chin Lee

Via Electronic Mail

 

Re: Employment Terms

Dear Chin:

Connect Biopharm LLC (the “Company” or “Connect”) is pleased to offer you the position of Chief Medical Officer of the Company and its affiliates, on the following terms. As applicable, references to Company or Connect also include its affiliated entities.

You will be responsible for providing medical and trial execution expertise to craft Company strategy, advance the Company’s pipeline, and oversee the conduct of clinical trials. You will also oversee the teams responsible for monitoring and analyzing clinical trials for safety, efficacy, and assisting with the generation, analysis, and presentation of clinical data, including authoring documents and slide presentations. As one of the Company’s most senior and visible executives, your responsibilities will also include communication and interactions with key opinion leaders, regulatory agencies, patient associations, advocacy groups, and investors, while pushing our programs through quickly and expertly and building the future state of the Clinical Development and regulatory organization. This position will report to Zheng Wei, Chief Executive Officer and you will work remotely until our office in the San Francisco Bay Area has been secured and work in the San Francisco Bay Area office consistent with the designated company hybrid model. Additionally, you would be expected to travel to the San Diego office, as needed. Of course, the Company may change your position, duties, and work location from time to time in its discretion.

Your base salary will be paid at the rate of $35,833.33 per month ($440,000.00 on an annualized basis), less payroll deductions and withholdings, paid on the Company’s normal payroll schedule.

You will be eligible to receive a target discretionary annual bonus of up to 40% of your base salary, based or the Company’s performance and your individual performance. Whether the Company awards bonuses for any given year, the allocation of the bonuses for Company and individual performance, and the amounts of such bonuses, if awarded, will be in the sole discretion of the Company as determined by the Board of Directors of Connect Biopharma Holdings Limited (the “Board”). If the Board approves payment of bonuses for any given year, the bonus amounts generally will be determined and paid within the first calendar quarter of the year based on the prior year’s performance. To incentivize you to remain employed with the Company, you must be employed on the date any bonus is paid in order to earn the bonus. If your employment terminates for any reason prior to the payment of the bonus, then you will not have earned the bonus and will not receive any portion of it, except as set forth in the Addendum to Employment Offer Letter for Severance Benefits attached hereto.

During your employment, you will be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company from time to time, subject to plan terms and generally applicable Company policies. Exempt employees do not accrue vacation, and there is no set guideline as

 


 

to how much vacation each employee will be permitted to take. Supervisors will approve paid vacation requests based on the employee’s progress on work goals or milestones, status of projects, fairness to the working team, and productivity and efficiency of the employee. Since vacation is not allotted or accrued, “unused” vacation time will not be carried over from one year to the next nor paid out upon termination.

A full description of these benefits is available for your review. The Company may change compensation and benefits from time to time in its discretion.

Subject to approval by the Board of Directors of Connect Biopharma Holdings Limited, the Company anticipates granting you an option to purchase 310,000 ordinary shares of the Connect Biopharma Holdings Limited with an exercise price equal to the fair market value as of the date of grant (the “Option”). The anticipated Option will be governed by the terms and conditions of Connect Biopharma Holdings Limited’s

2021 Stock Incentive Plan (the “Plan”) and your grant agreement, and will include a four year vesting schedule, under which 25% of your Option will vest 12 months after your start date, and 1/48th of the total shares will vest at the end of each month thereafter, until either the Option is fully vested or your continuous service (as defined in the Plan) terminates, whichever occurs first.

As a Company employee, you will be expected to abide by Company rules and policies. As a condition of employment, you must sign and comply with the attached Employee Confidential Information and Inventions Assignment Agreement which prohibits unauthorized use or disclosure of the Company’s proprietary information, among other obligations.

In your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company.

Normal business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional hours as required by the nature of your work assignments.

Your employment with the Company will be “at-will.” You may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. Your employment at-will status can only be modified in a written agreement signed by you and by an officer of the Company.

Under certain circumstances, you may be entitled to receive severance benefits upon termination of your employment, as further described in the Addendum to Employment Offer Letter for Severance Benefits attached hereto.

This offer is contingent upon a reference and background check satisfactory to the Company and satisfactory proof of your right to work in the United States. You agree to assist as needed and to complete any documentation at the Company’s request to meet these conditions.

 


 

To the extent permissible by applicable law, to ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the

Federal Arbitration Act, 9 U.S.C. § 1-16, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS’ then applicable rules and procedures for employment disputes (available upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/). You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law(s) to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the “Excluded Claims”). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. You will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.

This letter, together with your Employee Confidential Information and Inventions Assignment Agreement, forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the Company’s discretion in this letter, require a written modification signed by an officer of the Company. If any provision of this offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This letter may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,

 


 

Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

This offer letter, the Employee Confidential Information and Inventions Assignment Agreement, the Sign On Bonus Repayment Agreement and the Addendum to Employment Offer Letter for Severance Benefits constitute the complete, final and exclusive embodiment of the entire agreement between you and the Company with respect to the terms and conditions of your employment specified herein and therein, and supersede any other such promises, warranties, representations or agreements between you and the Company. This offer letter may not be amended or modified except by a written instrument signed by you and a duly authorized officer of the Company.

This offer letter will be governed by and construed in accordance with the laws of the State of California without regard to the conflicts of law provisions thereof.

Please sign and date this letter, and the enclosed Employee Confidential Information and Inventions Assignment Agreement and return them to me by November 4, 2021, if you wish to accept employment at the Company under the terms described above.

If you accept our offer, we would like you to start on March 1, 2022.

We look forward to your favorable reply and to a productive and enjoyable work relationship. Sincerely,

 

By: /s/ Zheng Wei

 

Zheng Wei, Chief Executive Officer

 

 

Understood and Accepted:

 

/s/ Chin Lee

Name: Chin Lee

 

Date: 11/3/2021

 

 

Chinster158@gmail.com

 

Attachments: Employee Confidential Information and Inventions Assignment Agreement

Addendum to Employment Offer Letter for Severance Benefits

 

 

 

 


 

 

 

Addendum To Employment Offer Letter For Severance Benefits

 

The provisions of this Addendum to Employment Offer Letter for Severance Benefits (the “Addendum”) are incorporated into, and are made a part of, the employment offer letter (the “Offer Letter”) by and between you, Chin Lee, and Connect Biopharm LLC (“Company”) to which this Addendum is attached. Capitalized terms used in this Addendum are either defined herein or in Appendix A.

 

1. Severance Benefits.

(a)
Subject to Section 1(b) below and your continued compliance with the Employee Confidential Information and Inventions Assignment Agreement executed by you in connection with your commencement of employment, if your employment is terminated by the Company without Cause or is terminated by you as a result of a Constructive Termination, then you shall be entitled to the following severance benefits in lieu of any severance benefits to which you may otherwise be entitled under any severance plan or program of the Company:

 

(i)
Payment of a lump sum amount equivalent to (A) nine (9) months of your Base Salary plus (B) 75% of your target bonus for the applicable year as determined by the Board, in each case less applicable withholding. Such amount shall be payable in a lump sum no later than five (5) days following the effective date of your Release; and

 

(ii)
Payment for your premiums for health (i.e., medical, vision and dental) continuation coverage under COBRA; provided, however, that (A) you are eligible for COBRA on the Termination Date and (B) you elect continuation coverage pursuant to COBRA, within the required time period. The Company shall continue to provide you with health coverage pursuant to this paragraph until the earliest of (1) the date you are no longer eligible to receive continuation coverage pursuant to COBRA, (2) nine (9) months from the Termination Date, or (3) the date on which you obtain comparable health coverage (such period, the “COBRA Coverage Period”). If any of the Company’s health benefits are self-funded as of your Termination Date, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A of the Code or that is otherwise compliant with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to you the foregoing monthly amount as a taxable monthly payment (grossed up to account for taxes) for the COBRA Coverage Period (or any remaining portion thereof). You shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums. You agree to notify Company promptly after you obtain alternative health coverage; and

 

 


 

(iii)
If your employment is terminated by the Company without Cause or is terminated by you as a result of a Constructive Termination, in each case during the Relevant Period, then each of your outstanding stock awards (including any stock options, restricted stock or other awards granted to you by the Parent) shall automatically become fully vested and exercisable and be released from any repurchase or forfeiture rights for all of the shares you receive as a result of exercise on the later of (A) the date of such termination or (B) the date of the Change in Control. The foregoing provisions are hereby deemed to be a part of each stock award (and, for the avoidance of doubt, if any stock award is subject to more favorable vesting pursuant to any agreement or plan regarding such stock award, such more favorable provisions shall continue to apply and shall not be limited by this clause (iii)).

 

(b)
As a condition to your receipt of any post-termination benefits pursuant to Section 1(a) above, you shall execute and not revoke a general release of all claims in favor of the Company and its affiliates in a form reasonably acceptable to and provided by the Company in compliance with applicable law (the “Release”). In the event the Release does not become effective within the fifty-five (55) day period following the date when your employment is terminated by the Company without Cause or is terminated by you as a result of a Constructive Termination, you shall not be entitled to the aforesaid payments and benefits.

 

2. Successors.

 

(a)
Company’s Successors. Any successor to Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of Company’s business and/or assets shall assume Company’s obligations under this Addendum and perform Company’s obligations under this Addendum in the same manner and to the same extent as Company would be required to perform such obligations in the absence of a succession. For all purposes under this Addendum, the term “Company” shall include any successor to Company’s business and/or assets which acknowledges it will be bound by the terms of this Addendum or which becomes bound by the terms of this Addendum by operation of law.

 

(b)
Your Successors. Without the written consent of Company, you shall not assign or transfer this Addendum or any right or obligation under this Addendum to any other person or entity. Notwithstanding the foregoing, the terms of this Addendum and all you rights hereunder shall inure to the benefit of, and be enforceable by, your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.

 

3.
Code Section 409A.
(a)
This Addendum is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the severance payments payable under Section 1(a) shall be paid no later than the later of: (A) the fifteenth (15th) day of the third month following your first taxable year in which such amounts are no longer subject to a substantial risk of forfeiture, and (B) the fifteenth (15th) day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as determined in accordance with Code Section 409A and any Treasury

 


 

Regulations and other guidance issued thereunder. To the extent applicable, this Addendum shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Addendum is hereby designated as a series of “separate payments” within the meaning of Section 409A of the Code. For purposes of this Addendum, to the extent required to ensure the payments hereunder are exempt from or comply with Section 409A of the Code, all references to your “termination of employment” shall mean your “separation from service” as defined in Treasury Regulation Section 1.409-A-1(h).

 

(b)
If you are a “specified employee” (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of your Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section 409A of the Code and the delayed payment or distribution of all or any portion of such amounts to which you are entitled under this Addendum is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to this Section 9(o)(ii) shall be paid or distributed to you in a lump sum on the earlier of (A) the date that is six (6)-months following your Separation from Service, (B) the date of your death or (C) the earliest date as is permitted under Section 409A of the Code. Any remaining payments due under the Addendum shall be paid as otherwise provided herein.
(c)
To the extent applicable, this Addendum shall be interpreted in accordance with the applicable exemptions from Section 409A of the Code. If you and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3) and (4) of the Code do not comply with Section 409A of the Code, you and the Company agree to amend this Addendum, or take such other actions as you and the Company deem reasonably necessary or appropriate, to comply with the requirements of Section 409A of the Code and the Treasury Regulations thereunder (and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Addendum is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner that no payments payable under this Addendum shall be subject to an “additional tax” as defined in Section 409A(a)(1)(B) of the Code.
(d)
Any reimbursement of expenses or in-kind benefits payable under this Addendum shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of your taxable year following the taxable year in which you incurred the expenses. The amount of expenses reimbursed or in-kind benefits payable during any taxable year of yours shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of yours, and your right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit.
(e)
In the event that the amounts payable under Section 1(a) are subject to Section 409A of the Code and the timing of the delivery of your Release could cause such amounts to be paid in one or another taxable year, then notwithstanding the payment timing set forth in such sections, such amounts shall not be payable until the later of (A) the payment date specified in such section or (B) the first business day of the taxable year following your Separation from Service.

 

4.
Miscellaneous Provisions.

 

 


 

(a)
Integration. This Addendum represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements and provisions in other agreements related to severance benefits, whether written or oral. With respect to any conflict between this Addendum and the Offer Letter or any other employment related agreement, this Addendum shall prevail. For the avoidance of doubt, this Addendum does not change your employment at-will status.

 

(b)
Choice of Law. The validity, interpretation, construction and performance of this Addendum shall be governed by the internal substantive laws, but not the conflicts of law rules, of the State of California.

 

(c)
Employment Taxes. All payments made pursuant to this Addendum shall be subject to withholding of applicable income and employment taxes.

 

 

 

 

 


 

 

IN WITNESS WHEREOF, each of the parties has executed this Addendum, in the case of Company by its duly authorized officer, as of the day and year first above written.

 

CONNECT BIOPHARM LLC:

EXECUTIVE:

By: /s/ Zheng Wei

By: /s/ Chin Lee

Title: Chief Executive Officer

Name: Chin Lee

Date: 11/2/2021

Date: 11/3/2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

APPENDIX A

 

The following definitions shall be in effect under the severance benefits letter:

 

(a)
Base Salary. “Base Salary” means your annual base salary as in effect during the last regularly scheduled payroll period immediately preceding the effective date of your termination without Cause or due to a Constructive Termination.
(b)
Board. “Board” means the Board of Directors of Parent.

 

(c)
Cause. “Cause” means any of the following:
(i)
Your unauthorized use or disclosure of any proprietary information of the Company or its affiliates or any material breach of a written agreement between you and any member of the Company or any affiliate, including without limitation a material breach of any employment, confidentiality, non-compete, non-solicit or similar agreement executed by you;
(ii)
Your conviction by a court of competent jurisdiction of, or your pleading “guilty” or “no contest” to, a felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof;
(iii)
Your gross negligence or willful misconduct or your willful or repeated failure or refusal to substantially perform assigned duties;
(iv)
the commission of an act of fraud, embezzlement or dishonesty by you, or the commission of some other illegal act by you, that causes material harm to the Company or any successor or affiliate thereof; or
(v)
Your ongoing and repeated failure or refusal to perform or neglect of your duties as required by your offer letter, which failure, refusal or neglect continues for thirty (30) days following your receipt of written notice from the Board stating with specificity the nature of such failure, refusal or neglect;

provided, however, that prior to the determination that “Cause” under clauses (i), (iii), or (v) of this Section (c) has occurred, the Company shall (A) provide to you in writing, in reasonable detail, the reasons for the determination that such “Cause” exists, (B) afford you a reasonable opportunity to remedy any such breach (if it is capable of being cured), and (C) provide you an opportunity to be heard prior to the final decision to terminate your employment hereunder for such “Cause”.

 

The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge or dismiss you for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Addendum, to constitute grounds for termination for Cause.

(a)
Change in Control. “Change in Control” shall have the meaning given to such term in the Stock Incentive Plan. Notwithstanding the foregoing, if a Change in Control would give rise to a payment or settlement event with respect to any amount hereunder that constitutes “nonqualified deferred compensation,” the transaction or event constituting the Change in Control must also constitute a “change in control event” (as defined in Treasury Regulation §1.409A3(i)(5)) in order to give rise to the payment or settlement event for such Award, to the extent required by Section 409A.

 


 

 

(b)
COBRA. “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.

 

(c)
Code. “Code” means the Internal Revenue Code of 1986, as amended.

 

(d)
Constructive Termination. “Constructive Termination” means your voluntary resignation following the occurrence of any of the following events or conditions without your prior written consent:

 

(i)
a material diminution in your title, authority, duties, or responsibilities;

 

(ii)
a material diminution in your base compensation, unless such a reduction is imposed across-the-board to senior management of the Company;
(iii)
a material change in the geographic location at which you must perform your duties that increases your one-way commute by more than thirty (30) miles as compared to your then-current principal place of employment immediately prior to such relocation (provided that the requirement that you work remotely until the Company’s office in the San Francisco Bay Area, California, has been secured, work in the Company’s San Francisco Bay Area office consistent with the designated company hybrid model, and travel to the Company’s San Diego, California office as needed shall not constitute grounds for a Constructive Termination); or
(iv)
any other action or inaction that constitutes a material breach by the Company or any successor or affiliate of its obligations to you under your offer letter or this Addendum.

You must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without your written consent within sixty (60) days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30) days to cure such event or condition after receipt of written notice of such event from you. Your resignation by reason of Constructive Termination must occur within thirty (30) days following the expiration of the foregoing thirty (30) day cure period.

Parent. “Parent” shall mean Connect Biopharma Holdings Limited.

 

(e)
Relevant Period. “Relevant Period” shall mean the period beginning two (2) months prior to the effective date of a Change in Control and ending twelve (12) months after the effective date of a Change in Control.

 

(f)
Section 409A. “Section 409A” shall mean Section 409A of the Code.

 

(g)
Stock Incentive Plan. “Stock Incentive Plan” shall mean Parent’s 2021 Stock Incentive Plan, as amended from time to time.

 

(h)
Termination Date. “Termination Date” shall mean the effective date of your termination of employment.

 


EX-4.12 7 cntb-ex4_12.htm EX-4.12 EX-4.12

Exhibit 4.12

House Lease Contract

Lessor: Taicang Science and Technology Venture Park Co., Ltd. (hereinafter referred to as “Party A”)

Lessee: Suzhou Connect Biopharmaceuticals, Ltd. (hereinafter referred to as “Party B”)

 

In accordance with the “Civil Code of the People's Republic of China” and relevant provisions, in order to define the rights and obligations of the Lessor and the Lessee, Party A and Party B hereby sign this Contract upon negotiated consensus.

 

Article 1 Party A will lease the 3rd and the 4th floors of the R&D Building (East) at No. 6 West Beijing Road, Taicang City, to Party B for the company’s office use. Both parties confirm that the building area of the house is 2366.81 m2 (including but not limited to stairs, elevators, emergency passages, public passages and other public parts), and all expenses shall be calculated based on the said area. Unless otherwise agreed by both parties, the charged area of the house during the contract period will not be adjusted, to which Party B has no objection.

 

Article 2 Lease period: from May 1, 2021 to April 30, 2023.

When the lease contract is terminated upon expiration, if Party B proposes the renewal of the Contract, it shall notify Party A of its intention to renew the Contract in writing one month before the expiration of the Contract. Party A shall decide whether to renew the Contract according to the actual situation. If Party A agrees to renew the Contract, both parties shall sign a separate house lease agreement.

 

Article 3 House rent, enterprise management service fee and the content of enterprise management service

1. The unit rent will be RMB 23/m2•month, so the total rent will be RMB 54,436.63/month. The enterprise management service fee will be RMB 7100/month. The total amount will be RMB 61536.63/month


2. In order to facilitate Party B to enter the Taicang Science and Technology Venture Park & Overseas Students Venture Park for development, Party A may provide Party B with the following additional services. Nevertheless, regardless of whether Party A provides such services or not, it will not affect the normal collection of enterprise management service fee:

(1) Provide "one-stop" services such as the registration of establishment of a domestic company with the market regulation authority and the opening of a bank account;

(2) Provide consulting services related to annual inspection of enterprises;

(3) Provide policy-related consulting services and assist the resident enterprise in obtaining policy-based preferences;

(4) Assist the resident enterprise in applying for various scientific research projects and funds;

(5) Provide management-related consulting services such as corporate structure and governance model;

(6) Provide services to support the market development, assist the business negotiation, enterprise and product promotion, etc., to promote the connection between products and channels and between enterprises and markets;

(7) Provide services such as investors recommendation, the selection of investment scheme to promote the connection between capital and projects;

(8) Provide services such as new product development consulting, project evaluation, follow-up technical assistance, and the promotion of industry-university-research cooperation;

(9) Relevant services specified in the “Interim Regulations on Park Management”.

3. Party A is a private enterprise. If the government introduces a policy of granting a rent reduction to resident enterprises in state-owned parks only under certain circumstances (such as the epidemic), Party A will not grant such rent reduction since it is not a state-owned park, and Party B has no objection with respect thereto.

 

Article 4 Mode of payment of house rent and enterprise management service fee

Mode of payment: quarterly payment; the rent and enterprise management service fee for three months


shall be paid within five working days from the signing date of the Contract (subsequently, every three months shall be a payment cycle). The rent and enterprise management service fee for the next cycle, i.e., three months, shall be paid 15 days before the expiration of the 3rd month of the first cycle, and the rest may be deduced by analogy. After Party B’s payment, Party A shall issue an invoice.

During the lease period, Party B shall not deduct any rent, enterprise management service fee and other expenses that it must pay to Party A in advance for any reason.

Party B shall remit the rent and other expenses to the following account before the payment date as agreed in this Contract, and shall not delay or refuse the payment on the grounds that it has not received a reminder notice.

Information of Party A’s account for collection of rent, enterprise management service fee and other expenses:

Account Name: Taicang Science and Technology Venture Park Co., Ltd

Opening Bank: Taicang Branch of China CITIC Bank

Account No.: 7324710182800018835

Party A’s act or factual state of accepting Party B’s rent and other expenses shall not be interpreted as a waiver of the legal liability arising from Party B’s breach of contract. Party B shall not use this as a defense for exemption from the liability for breach of contract.

When Party B makes payment, if there is a previous arrear of water & electricity fee, overdue fine, enterprise management service fee, and rent, Party A may first deduct the above-mentioned arrear in the above order.

 

Article 5 Security deposit

1. In order to ensure that Party B fully fulfills the lease contract, the leased house and its auxiliary facilities are safe and intact, Party B returns the house and handles the relocation of business license on time (after the expiration of the Contract or the cancellation of the Contract), Party B shall agree to pay Party A the rent and enterprise management service fee for one month as a security deposit at the time of signing this contract. During the lease period, before the termination of this Contract and the completion of house return


procedures, the security deposit shall not be required to cover the payable expenses such as rent, enterprise management service fee, water & electricity fee, etc., and Party A shall issue a receipt to Party B after receiving the security deposit.

2. If Party B has one of the following circumstances, Party A shall have the right to directly make a deduction from the security deposit:

(1) If Party B has any act of infringing rights or violating administrative laws and regulations, causing losses to Party A or any third party, Party A may withhold part or all of the security deposit to cover the economic losses suffered by Party A or any third party;

(2) Party B’s leasing act must meet the relevant property management requirements; otherwise, Party A shall have the right to deduct the security deposit based on the severity of the circumstances.

3. Where it is stipulated in this Contract that Party A has the right to deduct the above-mentioned security deposit, resulting in the insufficient part of the security deposit, Party B must make a supplement within seven days after receiving Party A’s written notice; otherwise, for each day of delay, Party B shall pay Party A 0.1% of the amount payable as liquidated damages; if the supplement is not completed after 30 days, it shall be deemed that Party B is in breach of this Contract, and Party A shall have the right to terminate this Contract without assuming any liability.

4. If Party B has one of the following circumstances, the security deposit shall not be refunded:

(1) Party B damages the leased house, or its auxiliary facilities and equipment, and refuses to compensate according to the price;

(2) This Contract is cancelled due to Party B’s breach of contract, or Party B unilaterally cancels this Contract in advance;

(3) Party B has a third-party debt during its operations, and the debt affects the lease or use of Party A’s house.

5. Upon the expiration of lease period, Party B shall settle the arrears. If no loss has been caused to Party A, no third party has filed a lawsuit or arbitration and other outstanding matters, and Party B has moved out all movable items (with no damage to the renovation state of the house upon return, or restoration to the original state according to Party A’s requirements), completed the house return procedures, water, electricity,


business license and other item hand-over and move-out procedures, and settled the relevant expenses, Party A shall refund the security deposit (in the event of any deduction, it shall be the remaining security deposit after deduction) to Party B in a lump sum, without interest, within 15 working days.

6. The security deposit shall have nothing to do with the rent, enterprise management service fee, water & electricity fee and other expenses paid by Party B during the performance of this Contract, which shall only be used as a guarantee for the safety and intactness of the leased house and equipment and facilities, and Party B’s return of the house and completion of the house handover procedures on time. Party B shall not invoke the security deposit to evade the obligation for the payment of rent, enterprise management service fee, and water & electricity fee, and shall not use the above-mentioned security deposit for external guarantees or transfer the security deposit.

 

Article 6 Party A’s rights and obligations

1. Party A shall provide intact office house, and guarantee the supply of water and electricity. In case of any failure, Party A shall solve it in a timely manner. The water & electricity fee shall be borne by Party B and withheld and paid by Party A, and Party B shall make payment in a timely manner according to Party A’s provisions. In the event of any breach of contract by Party B during the lease period, or when this Contract is cancelled or terminated, Party A shall have the right to stop the supply of water & electricity and other service guarantees, and Party B shall solely bear the losses caused thereby. Party B shall hereby agree not to claim against Party A for compensation in connection therewith from Party A.

2. Party A shall be responsible for the repair of the house to ensure Party B’s normal and safe use. Party A’s responsibility for the repair of the house shall be limited to the original structure of the house, and the power supply lines and public parts that have not been modified by Party B; Party A shall be responsible for the management services of public areas.

3. If there are the factors beyond Party A’s control that cause the instability or interruption of services such as water, electricity, network, etc., Party A need not assume any responsibility, but shall try its best to take effective measures to reduce the impact and losses caused thereby.

4. In the event of any factual state caused by Party B’s act or breach of contract, resulting in that Party


A pays fees, fines, etc. to any third party, Party B shall pay the full amount within ten days after receiving Party A’s written notice; otherwise, Party A shall have the right to make a deduction directly from the security deposit.

 

Article 7 Party B’s rights and obligations

1. Party B shall not sublease, transfer, or lend the house arbitrarily, and shall not use the house for non-office use (warehouse, dormitory, etc.).

2. Party B shall not use the leased house to conduct illegal activities and harm public interests.

3. Party B shall guarantee to comply with the “Interim Regulations on Park Management”, the “Interim Regulations on Renovation Management” and other relevant provisions on management formulated by Party A; the text of the above-mentioned regulations shall be an appendix to the Contract, and Party B shall confirm the receipt of the text, read it carefully, and promise to comply with relevant regulations.

4. If Party B renovates the house due to business needs, it shall not damage the structure and appearance of the house, and the outdoor unit of air conditioner shall not be hung outdoors without authorization and shall be placed at a location designated by the park. If the renovation involves the construction and modification of fire safety, it needs to declare to the relevant management department by itself according to national provisions. Party B shall submit a plan to Party A in writing before the renovation, which may be implemented only after Party A gives its consent; otherwise, Party B must bear the economic losses caused thereby. Party B needs to comply with the relevant regulations on renovation management formulated by Party A.

5. The elevators, stairs, passages, and other public spaces on this floor shall be shared by all users, and Party B shall not hinder the use of others.

6. Party B shall pay house rent, enterprise management service fee and other expenses on time.

7. Party B shall comply with other provisions of Party A’s management department.

8. Party B shall strictly abide by the Chinese laws and regulations on the protection of intellectual property rights, and solely assume the legal liability for any infringement or violation of intellectual property rights.


9. When this Contract is cancelled or terminated, or when Party B leaves the park in advance due to various reasons, Party B must settle the house rent and enterprise management service fee in a timely manner. Party B shall promise that all items in the offices will not be removed before all expenses have been settled. In the event of forcible removal, Party A shall have the right to interfere. If any material losses and personal injuries of either party are caused due to this reason, Party B shall assume the economic and legal liabilities.

10. When this Contract is cancelled or terminated, in addition to removing all detachable and removable equipment belonging to Party B in the leased site, in order to reduce dismantlement and renovation time, save social costs, and reduce the interference to the surrounding enterprises, Party B shall agree to give up the residual value of renovation and leave it for free use by any future enterprise, and Party A need not pay any form of compensation or indemnification to Party B. If Party A requires Party B to dismantle the renovation, Party B must dismantle the renovation completely, restore the leased site to its original state, and clean it up. The expenses of dismantlement and garbage transportation shall be solely borne by Party B, and it also needs to pay rent and management fee within time required for dismantlement and cleaning work.

11. When this Contract is cancelled or terminated, if Party B is unable to return the leased site in a timely manner, from the next day until the return date of the leased site, Party B shall pay Party A liquidated damages equivalent to two times of the monthly rent and other expenses. At the same time, if Party A suffers other losses, Party B shall also pay compensation. If Party B still fails to evacuate and return the house for more than 15 days, it shall be deemed that Party B has given up all items in the leased site. Party A shall have the right to clear the site and recover the house by itself, and Party B shall agree not to claim against Party A for compensation. The reasonable expenses for site clearance and house restoration to its original state shall be paid by Party B or deducted from the security deposit paid by Party B.

12. When Party B returns the leased site, it shall not require Party A to purchase the interior renovation and various equipment funded by Party B.

13. Party B shall agree to pay attention to relevant notices of municipal construction, water & power outages, etc. by itself, and shall not file any claims against Party A in this regard.

14. The ownership, use right, and publishing right of the public areas, exterior elevations of the houses (including the spaces of exterior elevations) and outdoor advertising spaces in the property project where the


leased house is located shall belong to Party A. Without the written consent of Party A, Party B shall not post, hang, and install any pictures, light boxes, posters, etc. that contain advertising contents outdoors independently. Party B shall have the right to publish all kinds of advertisements in the leased house, but all kinds of commercial advertisements and service information shall be published with healthy and true contents, and comply with the requirements of the “Advertising Law of the People’s Republic of China” and relevant laws and regulations. Party A shall have the right to exercise supervision and require rectification within a prescribed period.

15. Party B shall assist Party A in the management work and publicity, education, and cultural activities of the venture park, cooperate on the statistical work of the venture park, and report the relevant statistics of technological enterprise incubator required by the relevant national and local departments to the venture park in a timely manner.

16. If Party B is an enterprise involved in biological and chemical research and development (non-production type; for a production type, it needs to go through the relevant procedures for project establishment and pass the environmental assessment), except for research and development experiments, it is not allowed to produce or prepare hazardous chemicals (including but not limited to the chemicals such as sulfuric acid, perchloric acid, benzene, methanol, etc.) and contrabands (including but not limited to detonators, gun powders, medicines and intermediates, pharmaceutical raw materials, drugs, etc., and the products that may be produced only after a production license has been obtained according to the express provisions of the state) in the leased site. If Party A finds that Party B has the above-mentioned acts, Party A shall have the right to cancel this Contract and recover the house at any time.

If Party B produces or prepares the above-mentioned contrabands privately, all legal consequences caused thereby shall be solely borne by Party B; Party B shall also bear the losses suffered by Party A for this reason.

 

Article 8 If Party B has one of the following circumstances, Party A may confiscate the security deposit, terminate the Contract, stop the supply of water & electricity and other service guarantees, and recover the house (Party B shall bear and be responsible for all losses caused thereby, including Party B’s


renovation, etc.):

1. Party B subleases, transfers, or lends the house arbitrarily, or changes the purpose of the house arbitrarily;

2. Party B uses the leased house to conduct illegal activities;

3. Party B delays the payment of rent and enterprise management service fee for two months (in the event of Party B’s delay in the payment of rent, enterprise management service fee, etc., causing Party A’s losses, Party B agrees that Party A is free to dispose the office furniture, office supplies and other assets left by Party B in the house to cover the arrears owed by Party B, and Party A shall reserve the right to pursue the legal liability of Party B);

4. Without the written consent of Party A, Party B dismantles and changes the load-bearing structure of the leased house arbitrarily, or damages the leased house intentionally;

5. Party B is confronting a financial crisis or will confront liquidation or bankruptcy;

6. Any assets of Party B in the house are attached or seized.

 

Article 9 Change of the Lessor and the Lessee

1. If Party A transfers the ownership of the house to any third party, this Contract shall continue to be valid for the new owner of the house.

2. If Party A sells the house, it must notify Party B three months in advance.

3. If Party B terminates this Contract in advance, it shall notify Party A in writing one month in advance.

 

Article 10 Special provisions

1. Party B’s legal representative and shareholders shall provide Party A with a joint and several liability guarantee for all expenses and liabilities incurred under this Contract (including but not limited to rent, enterprise management service fee, water & electricity fee, communication fee, liquidated damage, attorney fee, etc.), and the guarantee period shall be two years from the expiration date of the performance period of the last installment of expenses.

2. Party B shall not present properties, pay rebates or give other illegitimate benefits to the employees


of Party A. Otherwise, once it is verified, Party A shall have the right to unilaterally increase the rent standard as agreed in this Contract by 20% - 30%, and Party B shall give its approval for this.

3. Party B shall confirm that during the lease period, the leased site is also the effective notification address of Party B. Party A shall have the right to choose to post the notices under this Contract on the doors, windows, or walls of the leased site; once posted, such notices shall be deemed to have been served on Party B, and shall be deemed to have already been known to Party B.

 

Article 11 Liability for breach of contract

1. If either party terminates this Contract in advance without justifiable reasons and causes economic losses to the other party, it shall pay compensation.

2. If the Lessee delays the payment of rent, in addition to making up the payment in a timely manner, it shall pay the liquidated damages at a daily rate of 0.05% from the date when the payment is delayed.

 

Article 12 Conditions for disclaimer of liability

Party B shall hereby expressly agree and declare that, unless the following accidents and losses are caused by Party A’s willful acts or gross negligence, Party A need not be liable to Party B or any third party in any of the following circumstances; if the following losses are caused by any third party, Party A shall assist B to claim against the third party for compensation from the third party:

1. Any economic losses or damages to Party B caused by the defects or malfunctions of the public facilities (including but not limited to fire protection, security equipment, air-conditioning equipment) or other equipment in the property where the house is located;

2. Any economic losses or damages to Party B caused by the failure, malfunction, or suspension of the electricity, tap water, and other supplies in the property where the house is located;

3. Any economic losses or damages to Party B caused by the theft or robbery of the property where the house is located or of the house;

4. Any economic losses or damages to Party B caused by Party A’s restriction on the use of water, electricity, central air-conditioning, etc. according to the circumstances due to the government’s rationing of


water, electricity, and other public resources;

5. The necessary impacts caused by the normal maintenance of public facilities in the property where the house is located;

6. The house is damaged or causes losses to Party B due to other force majeure events.

 

Article 13 Conditions for dispute resolution

1. If there is any dispute arising during the performance of this Contract, both parties shall resolve it through consultations, failing which, they may file a lawsuit with the Taicang People’s Court.

2. If Party A files a lawsuit due to Party B’s breach of contract, Party A shall have the right to claim against Party B for the attorney fee incurred thereby.

 

Article 14 The matters not covered in this Contract shall be subject to the relevant provisions of the “Civil Code of the People’s Republic of China”, and supplementary provisions shall be made after the mutual consultations between both parties to this Contract. The supplementary provisions shall have the same effect as this Contract.

 

Article 15 This Contract shall be made in quadruplicate, and both parties shall hold two copies respectively.

 

 

 


Party A: Taicang Science and Technology Venture Park Co., Ltd.

Agent (Signature): /s/ Hu Yutian (胡雨田)

 

(Month) (Day) (Year)

[seal:] Taicang Science and Technology Venture Park Co., Ltd.

3205850937840 (太仓市科技创业园有限公司)

Party B: Suzhou Connect Biopharmaceuticals, Ltd.

Guarantor (signature): /s/ [STAMPED]

[seal:] Suzhou Connect Biopharmaceuticals, Ltd. 3205851965705

 

April 9, 2021

(Month) (Day) (Year)

[seal:] Suzhou Connect Biopharmaceuticals, Ltd.

3205851965705 (苏州康乃德生物医药有限公司)


EX-4.13 8 cntb-ex4_13.htm EX-4.13 EX-4.13

 

 

Exhibit 4.13

 

LEASE

BETWEEN

PASEO DEL MAR LLC

AND

CONNECT BIOPHARM LLC

LEASE

(Short Form)

 

 

THIS LEASE is made as of December 22, 2021 , by and between PASEO DEL MAR LLC, a Delaware limited liability company, hereafter called “Landlord,” and CONNECT BIOPHARM LLC, a California limited liability company hereafter called “Tenant.”

 

 

ARTICLE 1. BASIC LEASE PROVISIONS

 

 

Each reference in this Lease to the “Basic Lease Provisions” shall mean and refer to the following collective terms, the application of which shall be governed by the provisions in the remaining Articles of this Lease.

 

1.
Tenant’s Trade Name: N/A

 

2.
Premises: Suite No. 350 (The Premises are more particularly described in Section 2.1.)

 

Address of Building: 12265 El Camino Real, San Diego, CA 92130

 

Project: Paseo Del Mar

 

3.
Permitted Use: General office and for no other use.

 

4.
Estimated Commencement Date: March 1, 2022

 

5.
Lease Term: 36 months, plus such additional days as may be required to cause this Lease to expire on the final day of the calendar month.

 

6.
Basic Rent:

 

Months of Term or Period

Monthly Rate Per Rentable Square Foot

Monthly Basic Rent

1 to 12

$4.30

$15,600.40

13 to 24

$4.49

$16,289.72

25 to 36

$4.69

$17,015.32

 

Notwithstanding the above schedule of Basic Rent to the contrary, as long as Tenant is not in Default (as defined in Section 14.1) under this Lease, Tenant shall be entitled to an abatement of 1 full calendar month of Basic Rent in the amount of $15,600.40 (the “Abated Basic Rent”) for the 2nd full calendar month of the Term (the “Abatement Period”).

 


 

In the event Tenant Defaults at any time during the Term, all unamortized Abated Basic Rent shall immediately become due and payable. The payment by Tenant of the Abated Basic Rent in the event of a Default shall not limit or affect any of Landlord's other rights, pursuant to this Lease or at law or in equity. Only Basic Rent shall be abated during the Abatement Period and all other additional rent and other costs and charges specified in this Lease shall remain as due and payable pursuant to the provisions of this Lease.

 

7.
Property Tax Base: The Property Taxes per rentable square foot incurred by Landlord and attributable to the twelve month period ending June 30, 2023 (the "Base Year").

 

Project Cost Base: The Project Costs per rentable square foot incurred by Landlord and attributable to the Base Year.

 

Expense Recovery Period: Every twelve month period during the Term (or portion thereof during the first and last Lease years) ending June 30.

 

8.
Floor Area of Premises: approximately 3,628 rentable square feet

 

Floor Area of Building: approximately 75,957 rentable square feet

 

9.
Security Deposit: $34,317.40

Guarantor: Connect Biopharma Holdings Limited

 

10.
Broker(s): Irvine Management Company ("Landlord's Broker") is the agent of Landlord exclusively and Hughes Marino, Inc. ("Tenant's Broker") is the agent of Tenant exclusively.

 

11.
Parking: Up to 13 unreserved parking passes in accordance with the provisions set forth in Exhibit F to this Lease.

 

12.
Address for Payments and Notices:

 

 

LANDLORD

 

Payment Registration Address:

 

Email tenantportal@irvinecompany.com to request an account for the Tenant Payment Portal.

TENANT

 

CONNECT BIOPHARM LLC

12265 El Camino Real, Suite 350 San Diego, CA 92130

 

Notice Address:

 

PASEO DEL MAR LLC

12275 El Camino Real, Suite 130 San Diego, CA 92130

Attn: Property Manager with a copy of notices to:

THE IRVINE COMPANY LLC

550 Newport Center Drive Newport Beach, CA 92660

Attn: Senior Vice President, Operations Irvine Office Properties

Notice Address:

 

Prior to the Commencement Date:

 

12707 High Bluff Drive, Suite 20 San Diego, CA 92130

 

After the Commencement Date:

 


 

At the address above with a copy to: Shartsis Friese LLP

One Maritime Plaza, Suite 1800

San Francisco, CA 94111

Attn: P. Rupert Russell/ Thomas D. Morell

 

 

13.
List of Lease Exhibits (all exhibits, riders and addenda attached to this Lease are hereby incorporated into and made a part of this Lease):

 

Exhibit A Description of Premises Exhibit B Operating Expenses

Exhibit C Utilities and Services Exhibit D Tenant’s Insurance

Exhibit E Rules and Regulations Exhibit F Parking

Exhibit G Guarantee

Exhibit X Work Letter Exhibit X-1 Plan

 

 

 

ARTICLE 2. PREMISES

 

1.1.
LEASED PREMISES. Landlord leases to Tenant and Tenant leases from Landlord the Premises shown in Exhibit A (the “Premises”), containing approximately the floor area set forth in Item 8 of the Basic Lease Provisions (the “Floor Area”). The Premises are located in the building identified in Item 2 of the Basic Lease Provisions (the “Building”), which is a portion of the project described in Item 2 (the “Project”). Landlord and Tenant stipulate and agree that the Floor Area of Premises set forth in Item 8 of the Basic Lease Provisions is correct.

 

1.2.
ACCEPTANCE OF PREMISES. Subject to Sections 2.3 and 2.4 below, Tenant acknowledges that neither Landlord nor any representative of Landlord has made any representation or warranty with respect to the Premises, the Building or the Project or the suitability or fitness of either for any purpose, except as set forth in this Lease. The taking of possession or use of the Premises by Tenant for any purpose other than construction shall conclusively establish that the Premises and the Building were in satisfactory condition and in conformity with the provisions of this Lease in all respects. Nothing contained in this Section 2.2 shall affect the commencement of the Term or the obligation of Tenant to pay rent.

 

1.3.
GOOD WORKING ORDER WARRANTY. Landlord warrants to Tenant that the fire sprinkler system, lighting, heating, ventilation and air conditioning systems, plumbing (if any) and electrical systems serving the Premises shall be in good operating condition as of the day the Premises are delivered to Tenant.

 

1.4.
LATENT DEFECTS. Landlord shall be responsible for latent defects in the Tenant Improvements of which Tenant notifies Landlord to the extent that the correction of such defects is covered under valid and enforceable warranties given Landlord by contractors or subcontractors performing the Tenant Improvements. Landlord, at its option, may pursue such claims directly or assign any such warranties to Tenant for enforcement.

 

 

ARTICLE 3. TERM

 

1.1.
GENERAL. The term of this Lease (“Term”) shall be for the period shown in Item 5 of the Basic Lease Provisions. The Term shall commence (“Commencement Date”) on the earlier of (a) the date the Premises are deemed “ready for occupancy” (as hereinafter defined) and possession thereof is delivered to Tenant, or (b) the date Tenant commences its regular business activities within the Premises. Promptly following request by Landlord, the parties shall memorialize on a form provided by Landlord (the "Commencement Memorandum") the actual Commencement Date and the expiration date (“Expiration Date") of this Lease; should either Landlord fail to prepare or Tenant fail to execute and return the Commencement Memorandum to Landlord within 5 business days (or provide specific written objections thereto within that period), then the Commencement and Expiration Dates as set forth in the Basic Lease Provisions shall be conclusive. The Premises shall be deemed “ready for occupancy” when Landlord, to the extent applicable, has substantially completed all the work required to be completed by Landlord pursuant to the Work Letter attached to this Lease but for minor fit and finish

 


 

punch list matters, and has obtained the requisite governmental approvals for Tenant’s occupancy in connection with such work.

 

1.2.
DELAY IN POSSESSION. If Landlord, for any reason whatsoever, cannot deliver possession of the Premises to Tenant on or before the Estimated Commencement Date set forth in Item 4 of the Basic Lease Provisions, this Lease shall not be void or voidable nor shall Landlord be liable to Tenant for any resulting loss or damage. However, Tenant shall not be liable for any rent until the Commencement Date occurs as provided in Section 3.1 above, except that if Landlord’s failure to substantially complete all work required of Landlord pursuant to Section 3.1 above is attributable to any action or inaction by Tenant (including without limitation any Tenant Delay described in the Work Letter attached to this Lease), then the Premises shall be deemed ready for occupancy, and Landlord shall be entitled to full performance by Tenant (including the payment of rent), as of the date Landlord would have been able to substantially complete such work and deliver the Premises to Tenant but for Tenant’s delay(s). Landlord shall use commercially reasonable efforts to provide at least twenty

(20) days prior written notice of the date upon which, in Landlord’s judgment, the Premises shall be “ready for occupancy”.

 

ARTICLE 4. RENT AND OPERATING EXPENSES

 

1.1.
BASIC RENT. From and after the Commencement Date, Tenant shall pay to Landlord without deduction or offset (except as expressly provided in this Lease) Basic Rent for the Premises in the total amount shown (including subsequent adjustments, if any) in Item 6 of the Basic Lease Provisions (the “Basic Rent”). If the Commencement Date is other than the first day of a calendar month, any rental adjustment shown in Item 6 shall be deemed to occur on the first day of the next calendar month following the specified monthly anniversary of the Commencement Date. The Basic Rent shall be due and payable in advance commencing on the Commencement Date and continuing thereafter on the first day of each successive calendar month of the Term, as prorated for any partial month. No demand, notice or invoice shall be required. An installment in the amount of 1 full month’s Basic Rent at the initial rate specified in Item 6 of the Basic Lease Provisions shall be delivered to Landlord concurrently with Tenant’s execution of this Lease.

 

1.2.
OPERATING EXPENSES. Tenant shall pay Tenant’s Share of Operating Expenses in accordance with Exhibit B of this Lease.

 

1.3.
SECURITY DEPOSIT. Concurrently with Tenant’s delivery of this Lease, Tenant shall deposit with Landlord the sum, if any, stated in Item 9 of the Basic Lease Provisions (the “Security Deposit”), to be held by Landlord as security for the full and faithful performance of Tenant’s obligations under this Lease, to pay any rental sums, including without limitation such additional rent as may be owing under any provision hereof, and to maintain the Premises as required by this Lease. Upon any breach of the foregoing obligations by Tenant, Landlord may apply all or part of the Security Deposit as full or partial compensation. If any portion of the Security Deposit is so applied, Tenant shall within 5 days after written demand by Landlord deposit cash with Landlord in an amount sufficient to restore the Security Deposit to its original amount. Landlord shall not be required to keep this Security Deposit separate from its general funds, and Tenant shall not be entitled to interest on the Security Deposit. In no event may Tenant utilize all or any portion of the Security Deposit as a payment toward any Rent due under this Lease. Any unapplied balance of the Security Deposit shall be returned to Tenant or, at Landlord’s option, to the last assignee of Tenant’s interest in this Lease within 30 days following the termination of this Lease and Tenant's vacation of the Premises. Tenant hereby waives the provisions of Section 1950.7 of the California Civil Code, or any similar or successor laws now or hereafter in effect.

 

ARTICLE 5. USES

 

1.1.
USE. Tenant shall use the Premises only for the purposes stated in Item 3 of the Basic Lease Provisions and for no other use whatsoever. The uses prohibited under this Lease shall include, without limitation, use of the Premises or a portion thereof for (i) offices of any agency or bureau of the United States or any state or political subdivision thereof;

(ii) offices or agencies of any foreign governmental or political subdivision thereof; or (iii) schools, temporary employment agencies or other training facilities which are not ancillary to corporate, executive or professional office use. Tenant shall not do or permit anything to be done in or about the Premises which will in any way interfere with the rights or quiet enjoyment of other occupants of the Building or the Project, or use or allow the Premises to be used for any unlawful purpose, nor shall Tenant permit any nuisance or commit any waste in the Premises or the Project. Tenant shall not perform any work or conduct any business whatsoever in the Project other than inside the Premises. Tenant shall comply at its expense with all present and future laws, ordinances and requirements of all governmental authorities that pertain to Tenant or its use of the Premises, and with all energy usage reporting requirements of Landlord. Pursuant to California Civil Code § 1938, Landlord hereby states that the Premises have not undergone inspection by a Certified Access Specialist (CASp) (defined in California Civil Code § 55.52(a)(3)). Pursuant to Section 1938 of the California Civil Code, Landlord hereby provides the following notification to Tenant: “A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor

 


 

may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction related accessibility standards within the premises.”

 

1.2.
SIGNS. Landlord shall, at Landlord’s cost and expense, affix and maintain a sign (restricted solely to Tenant’s name as set forth herein or such other name as Landlord may consent to in writing) adjacent to the entry door of the Premises, together with a directory strip listing Tenant's name as set forth herein in the lobby directory of the Building. Tenant shall not place or allow to be placed any other sign, decoration or advertising matter of any kind that is visible from the exterior of the Premises.

 

1.3.
HAZARDOUS MATERIALS. Tenant shall not generate, handle, store or dispose of hazardous or toxic materials (as such materials may be identified in any federal, state or local law or regulation) in the Premises or Project without the prior written consent of Landlord.

 

ARTICLE 6. LANDLORD SERVICES

 

1.1.
UTILITIES AND SERVICES. Landlord and Tenant shall be responsible to furnish those utilities and services to the Premises to the extent provided in Exhibit C, subject to the conditions and payment obligations and standards set forth in this Lease. Landlord’s failure to furnish, or any interruption, diminishment or termination of, services due to the application of laws, the failure of any equipment, the performance of repairs, improvements or alterations, utility interruptions or the occurrence of an event of force majeure (defined in Section 20.8) shall not render Landlord liable to Tenant, constitute a constructive eviction of Tenant, give rise to an abatement of Rent, nor relieve Tenant from the obligation to fulfill any covenant or agreement. Electricity used by Tenant in the Premises shall be paid for by Tenant by separate charge billed by the applicable utility company and payable directly by Tenant. However, if the Premises, or a material portion of the Premises, are made untenantable for a period in excess of 5 consecutive business days as a result of a service interruption that is reasonably within the control of Landlord to correct and through no fault of Tenant and for reasons other than as contemplated in Article 11, then Tenant, as its sole remedy, shall be entitled to receive an abatement of Rent payable hereunder during the period beginning on the 6th consecutive business day of the service interruption and ending on the day the service has been restored.

 

1.2.
OPERATION AND MAINTENANCE OF COMMON AREAS. During the Term, Landlord shall operate all Common Areas within the Building and the Project. The term “Common Areas” shall mean all areas within the Building, Project and other buildings in the Project which are not held for exclusive use by persons entitled to occupy space.

 

1.3.
COMMON AREAS The occupancy by Tenant of the Premises shall include the use of the Common Areas in common with Landlord and with all others for whose convenience and use the Common Areas may be provided by Landlord, subject, however, to compliance with Rules and Regulations set forth in Exhibit E. Landlord shall at all times during the Term have exclusive control of the Common Areas, and may restrain or permit any use or occupancy. Landlord may temporarily close any portion of the Common Areas for repairs, remodeling and/or alterations, to prevent a public dedication or the accrual of prescriptive rights, or for any other reasonable purpose.

 

ARTICLE 7. REPAIRS AND MAINTENANCE

 

1.1.
TENANT’S MAINTENANCE AND REPAIR. Subject to Articles 11 and 12 and Section 7.2, Tenant at its sole expense shall make all repairs necessary to keep the interior, non-structural components of the Premises and all improvements and fixtures therein in good condition and repair. Tenant’s maintenance obligation shall include without limitation all appliances, interior glass, doors, door closures, hardware, fixtures, non-building standard electrical, non- building standard plumbing, fire extinguisher equipment and other equipment installed in the Premises, together with any supplemental HVAC equipment servicing only the Premises. Should Landlord or its management agent agree to make a repair on behalf of Tenant and at Tenant’s request, Tenant shall promptly reimburse Landlord as additional rent for all reasonable costs incurred (including the standard supervision fee) upon submission of an invoice.

 

1.2.
LANDLORD’S MAINTENANCE AND REPAIR. Subject to Articles 11 and 12, Landlord shall provide service, maintenance and repair with respect to the heating, ventilating and air conditioning (“HVAC”) equipment of the Building (exclusive of any supplemental HVAC equipment servicing only the Premises) and shall maintain in good repair the Common Areas, roof, foundations, footings, the exterior surfaces of the exterior walls of the Building (including exterior glass), and the structural, electrical, mechanical and plumbing systems of the Building (including elevators, if any, serving the Building), except to the extent provided in Section 7.1 above. Notwithstanding any provision of the California Civil Code or any similar or successor laws to the contrary, Tenant understands that it shall not make repairs at Landlord’s expense or by rental

 


 

offset. Except as provided in Section 11.1 and Article 12 below, there shall be no abatement of rent and no liability of Landlord by reason of any injury to or interference with Tenant’s business arising from the making of any repairs, alterations or improvements to any portion of the Building, including repairs to the Premises, nor shall any related activity by Landlord constitute an actual or constructive eviction provided, however, that in making repairs, alterations or improvements, Landlord shall use reasonable efforts to minimize interference with Tenant’s business operations in the Premises. Tenant hereby waives any and all rights under and benefits of subsection 1 of Section 1932, and Sections 1941 and 1942 of the California Civil Code, or any similar or successor laws now or hereafter in effect.

 

1.3.
ALTERATIONS. Except for cosmetic alteration projects that do not exceed $18,140.00 during each calendar year and that satisfy the criteria in the next following sentence (which work shall require notice to Landlord but not Landlord’s consent), Tenant shall make no alterations, additions, decorations or improvements (collectively referred to as “Alterations”) to the Premises without the prior written consent of Landlord. Landlord may impose, as a condition to its consent, any reasonable requirements. Tenant shall use Landlord’s designated mechanical and electrical contractors, obtain all required permits for the Alterations and shall perform the work in compliance with all applicable laws, regulations and ordinances with contractors reasonably acceptable to Landlord. Except for cosmetic Alterations not requiring a permit, Landlord shall be entitled to a supervision fee in the amount of 5% of the cost of the Alterations. Landlord may elect to cause its architect to review Tenant’s architectural plans, and the reasonable cost of that review shall be reimbursed by Tenant. Should the Alterations proposed by Tenant and consented to by Landlord change the floor plan of the Premises, then Tenant shall, at its expense, furnish Landlord with as-built drawings and CAD disks compatible with Landlord’s systems. Unless Landlord otherwise agrees in writing, all Alterations affixed to the Premises, including without limitation all Tenant Improvements constructed pursuant to the Work Letter (except as otherwise provided in the Work Letter), but excluding moveable trade fixtures and furniture, shall become the property of Landlord and shall be surrendered with the Premises at the end of the Term, except that Landlord may, by notice to Tenant given at the time of Landlord’s approval, require Tenant to remove by the Expiration Date or sooner termination date of this Lease, all or any Alterations (including without limitation any Tenant Improvements constructed pursuant to the Work Letter) installed either by Tenant or by Landlord at Tenant’s request (collectively, the “Required Removables”). In connection with its removal of Required Removables, Tenant shall repair any damage to the Premises arising from that removal and shall restore the affected area to its pre-existing condition, reasonable wear and tear excepted.

 

1.4.
MECHANIC’S LIENS. Tenant shall keep the Premises free from any liens arising out of any work performed, materials furnished, or obligations incurred by or for Tenant. In the event that Tenant shall not, within 15 days following the imposition of any lien, cause the lien to be released of record by payment or posting of a proper bond in accordance with California Civil Code Section 8424 or any successor statute, Landlord shall have, in addition to all other available remedies, the right to cause the lien to be released by any means it deems proper, including payment of or defense against the claim giving rise to the lien. All expenses so incurred by Landlord shall be reimbursed by Tenant promptly following Landlord’s demand. Tenant shall give Landlord no less than 20 days’ prior notice in writing before commencing construction of any kind on the Premises.

 

1.5.
ENTRY AND INSPECTION. Landlord shall at all reasonable times and with at least 24 hours prior verbal notice, except in emergencies or to provide Building services, have the right to enter the Premises to inspect them, to supply services in accordance with this Lease, to make repairs and renovations as reasonably deemed necessary by Landlord, and to submit the Premises to prospective or actual purchasers or encumbrance holders (or, during the final twelve months of the Term or when an uncured Default exists, to prospective tenants), all without being deemed to have caused an eviction of Tenant and without abatement of rent except as provided elsewhere in this Lease. Notwithstanding the foregoing, Tenant may, at its own expense, provide its own locks to an area within the Premises ("Secured Area"). Tenant need not furnish Landlord with a key but upon the Expiration Date, or earlier termination of the Lease, Tenant shall surrender all such keys to Landlord. If Landlord must gain access to a Secured Area in a non-emergency situation, Landlord shall contact Tenant and Landlord and Tenant shall arrange a mutually agreed upon time for Landlord to do so. Landlord shall comply with all reasonable security measures pertaining to the Secured Area and Tenant shall be entitled to have an employee of Tenant accompany the person(s) entering the Premises, provided Tenant makes such employee available at the time Landlord or such other party desires to enter the Premises. If Landlord determines in its sole discretion that an emergency in the Building or the Premises, including, without limitation, a suspected fire or flood, requires Landlord to gain access to the Secured Area, Tenant hereby authorizes Landlord to forcibly enter the Secured Area. In such event, Landlord shall have no liability whatsoever to Tenant, and Tenant shall pay all reasonable expenses incurred by Landlord in repairing or reconstructing any entrance, corridor, door or other portions of the Premises damaged as a result of a forcible entry by Landlord. Landlord shall have no obligation to provide either janitorial service or cleaning in the Secured Area.

 

 

ARTICLE 8. SPACE PLANNING AND SUBSTITUTION

 

 


 

Landlord shall have the right, upon providing not less than 90 days written notice, to move Tenant to other space of comparable size in the Building or in the Project. The new space shall be provided with improvements of comparable quality to those within the Premises and shall contain similar finishes as the Premises, approximately the same rentable square footage as the Premises and approximately the same number of work stations, offices, breakrooms and reception areas as are contained in the Premises as of the date Tenant receives Landlord’s notice of relocation. Landlord shall pay the reasonable out-of-pocket costs to relocate and reconnect Tenant’s personal property and equipment within the new space. Landlord shall also reimburse Tenant for such other reasonable out-of-pocket costs that Tenant may incur in connection with the relocation. The total monthly Basic Rent for the new space shall in no event exceed the total monthly Basic Rent for the Premises prior to the relocation and Tenant’s Share for the new space shall in no event exceed Tenant’s Share for the Premises prior to the relocation. Within 10 days following request by Landlord, Tenant shall execute an amendment to this Lease prepared by Landlord to memorialize the relocation. No rent shall be payable during the period in which Tenant is unable to operate as a result of the relocation and reconstruction as provided herein. Notwithstanding the foregoing, in the event the relocation space designated by Landlord is not acceptable to Tenant, then Tenant may, by written notice to Landlord within 5 business days following delivery of Landlord’s relocation notice, elect to terminate this Lease by written notice to Landlord (the "Termination Notice"); in such event, unless Landlord revokes in writing its relocation election within three business days thereafter (in which case the Termination Notice shall be null and void), this Lease shall terminate 60 days following delivery of the Termination Notice.

 

 

ARTICLE 9. ASSIGNMENT AND SUBLETTING

 

1.1.
RIGHTS OF PARTIES. Tenant shall not, directly or indirectly, assign, sublease, transfer or encumber any interest in this Lease or allow any third party to use any portion of the Premises (collectively or individually, a “Transfer”) without the prior written consent of Landlord, which consent shall not be unreasonably withheld if Landlord does not exercise its recapture rights. Notwithstanding the foregoing, a Transfer shall not include the infusion of additional equity capital in Tenant, or any affiliated entity including Tenant’s parent entity Connect Biopharma Holdings Limited (NASDAQ: CNTB). Tenant agrees that it is not unreasonable for Landlord to withhold consent to a Transfer to a proposed assignee or subtenant who is an existing tenant or occupant of the Building or Project or to a prospective tenant with whom Landlord or Landlord's affiliate has been actively negotiating within the prior 6 months. Within 20 days after receipt of executed copies of the transfer documentation and such other information as Landlord may request, Landlord shall either: (a) consent to the Transfer by execution of a consent agreement in a form reasonably designated by Landlord; (b) refuse to consent to the Transfer; or (c) recapture the portion of the Premises that Tenant is proposing to Transfer. Tenant hereby waives the provisions of Section 1995.310 of the California Civil Code, or any similar or successor Laws, now or hereinafter in effect, and all other remedies at law or equity to terminate this Lease, on its own behalf and, to the extent permitted under all applicable laws, on behalf of the proposed transferee. In no event shall any Transfer release or relieve Tenant from any obligation under this Lease, as same may be amended. Tenant shall pay Landlord a review fee of $1,000.00 for Landlord’s review of any requested Transfer. Tenant shall pay Landlord, as additional Rent, 50% of all rent and other consideration which Tenant actually receives as a result of a Transfer that is in excess of the Rent payable to Landlord for the portion of the Premises and Term covered by the Transfer after deducting Tenant’s transfer costs. For purposes herein, such transfer costs shall include all reasonable and customary expenses directly incurred by Tenant attributable to the Transfer, including brokerage fees, legal fees, construction costs, and Landlord’s review fee. If Tenant is in Default, Landlord may require that all sublease payments be made directly to Landlord, in which case Tenant shall receive a credit against Rent in the amount of Tenant’s share of payments received by Landlord.

 

1.2.
PERMITTED TRANSFER. Notwithstanding the foregoing, Tenant may assign this Lease to a successor to Tenant by merger, consolidation or the purchase of substantially all of Tenant’s assets, or assign this Lease or sublet all or a portion of the Premises to an Affiliate (defined below), without the consent of Landlord, provided that all of the following conditions are satisfied (a “Permitted Transfer”): (i) Tenant is not then in Default hereunder; (ii) Tenant gives Landlord written notice prior to such Permitted Transfer or as soon thereafter as required to comply with any confidentiality obligation or legal requirement; and (iii) if Tenant ceases to exist as a going concern as a result of any merger or consolidation of Tenant or the sale of all or substantially all of the assets of Tenant, the resulting successor entity has a tangible net worth not less than the tangible net worth of Tenant immediately before the Permitted Transfer. “Affiliate” shall mean an entity controlled by, controlling or under common control with Tenant, including without limitation to any parent or subsidiary of Tenant, or a subsidiary of Tenant's parent. Tenant shall not be obligated to pay Landlord a review fee nor any “excess” or Additional Rent or other consideration which Tenant receives as a result of a Permitted Transfer.

 

ARTICLE 10. INSURANCE AND INDEMNITY

 

1.1.
TENANT’S INSURANCE. Tenant, at its sole cost and expense, shall provide and maintain in effect the insurance described in Exhibit D. Evidence of that insurance must be delivered to Landlord prior to the Commencement Date.

 


 

 

1.2.
TENANT’S INDEMNITY. To the fullest extent permitted by law, but subject to Section 10.4 below, Tenant shall defend, indemnify and hold harmless Landlord and Landlord’s agents, employees, lenders, and affiliates, from and against any and all negligence, claims, liabilities, damages, costs or expenses arising either before or after the Commencement Date which arise from or are caused by Tenant’s use or occupancy of the Premises, the Building or the Common Areas of the Project, or from the conduct of Tenant’s business, or from any activity, work, or thing done, permitted or suffered by Tenant or Tenant’s agents, employees, subtenants, vendors, contractors, invitees or licensees in or about the Premises, the Building or the Common Areas of the Project, or from any Default in the performance of any obligation on Tenant’s part to be performed under this Lease, or from any act, omission or negligence on the part of Tenant or Tenant’s agents, employees, subtenants, vendors, contractors, invitees or licensees. Landlord may, at its option, require Tenant to assume Landlord’s defense in any action covered by this Section 10.2 through counsel reasonably satisfactory to Landlord. Notwithstanding the foregoing, Tenant shall not be obligated to indemnify Landlord against any liability or expense to the extent it is ultimately determined that the same was caused by the gross negligence or willful misconduct of Landlord, its agents, contractors or employees.

 

1.3.
WAIVER OF CLAIMS. Unless caused by the negligence or intentional misconduct of Landlord, its agents, employees or contractors but subject to Section 10.4 below, Landlord shall not be liable to Tenant, its employees, agents and invitees, and Tenant hereby waives all claims against Landlord, its employees and agents for loss of or damage to any property, or any injury to any person, resulting from any condition including, but not limited to, acts or omissions (criminal or otherwise) of third parties and/or other tenants of the Project, or their agents, employees or invitees, fire, explosion, falling plaster, steam, gas, electricity, water or rain which may leak or flow from or into any part of the Premises or from the breakage, leakage, obstruction or other defects of the pipes, sprinklers, wires, appliances, plumbing, air conditioning, electrical works or other fixtures in the Building, whether the damage or injury results from conditions arising in the Premises or in other portions of the Building, regardless of the negligence of Landlord, its agents or any and all affiliates of Landlord in connection with the foregoing. Notwithstanding anything to the contrary contained in this Lease, in no event shall Landlord be liable for Tenant’s loss or interruption of business or income (including without limitation, Tenant’s consequential damages, lost profits or opportunity costs), or for interference with light or other similar intangible interests.

 

1.4.
WAIVER OF SUBROGATION. Landlord and Tenant waive all rights of recovery against the other on account of loss and damage to the property of such waiving party to the extent that the waiving party is entitled to proceeds for such loss and damage under any property insurance policies carried or otherwise required to be carried by this Lease; provided however, that the foregoing waiver shall not apply to the extent of Tenant’s obligation to pay deductibles under any such policies and this Lease.

 

1.5.
LANDLORD’S INSURANCE. Landlord shall provide the following types of insurance, with or without deductible and in amounts and coverages as may be reasonably determined by Landlord: (i) property insurance, subject to standard exclusions (such as, but not limited to, earthquake and flood exclusions), covering the full replacement cost of the Building and Project (the “Property Policy”), and (ii) liability insurance in amounts of at least $2,000,000. In addition, Landlord may, at its election, obtain insurance for such other risks as Landlord or its mortgagees may from time to time deem appropriate in its sole discretion, including without limitation, coverage for earthquake, flood, and commercial general liability in the amounts in excess of the amount required above.

 

 

ARTICLE 11. DAMAGE OR DESTRUCTION

 

1.1.
RESTORATION.

 

(a)
If the Building of which the Premises are a part is damaged as the result of an event of casualty, then subject to the provisions below, Landlord shall repair that damage as soon as reasonably possible unless Landlord reasonably determines that: (i) the Premises have been materially damaged and there is less than 1 year of the Term remaining on the date of the casualty; (ii) any Mortgagee (defined in Section 13.1) requires that the insurance proceeds be applied to the payment of the mortgage debt; or (iii) proceeds necessary to pay the full cost of the repair are not available from Landlord’s insurance, including without limitation earthquake insurance. Should Landlord elect not to repair the damage for one of the preceding reasons, Landlord shall so notify Tenant in the “Casualty Notice” (as defined below), and this Lease shall terminate as of the date of delivery of that notice.

 

(b)
As soon as reasonably practicable following the casualty event but not later than 60 days thereafter, Landlord shall notify Tenant in writing (“Casualty Notice”) of Landlord’s election, if applicable, to terminate this Lease. If this Lease is not so terminated, the Casualty Notice shall set forth the anticipated period for repairing the casualty damage. If the anticipated repair period exceeds 210 days and if the damage is so extensive as to reasonably prevent Tenant’s

 


 

substantial use and enjoyment of the Premises, then either party may elect to terminate this Lease by written notice to the other within 10 days following delivery of the Casualty Notice.

 

(c)
In the event that neither Landlord nor Tenant terminates this Lease pursuant to Section 11.1(b), Landlord shall repair all material damage to the Premises or the Building as soon as reasonably possible and this Lease shall continue in effect for the remainder of the Term. Upon notice from Landlord, Tenant shall assign or endorse over to Landlord (or to any party designated by Landlord) all property insurance proceeds payable to Tenant under Tenant's insurance with respect to any Alterations. Within 15 days of demand, Tenant shall also pay Landlord for any additional excess costs that are determined during the performance of the repairs to such Alterations. However, notwithstanding the foregoing, if Tenant has maintained the insurance required to be maintained by Tenant pursuant to the terms of Exhibit D of this Lease throughout the Term, and if the proceeds from the insurance required to be maintained by Tenant with respect to the Tenant Installations have been paid to Landlord prior to Landlord commencing repair of the Tenant Installations, then Landlord agrees Tenant shall not be required to pay any deficiency between the estimated or actual Tenant Installation repair costs and the insurance proceeds received by Landlord from Tenant’s insurance until after substantial completion of the repairs to the Tenant Installations, and such sums shall be payable by Tenant within 15 days after demand of Landlord.

 

(d)
From and after the casualty event, the rental to be paid under this Lease shall be abated in the same proportion that the Floor Area of the Premises that is rendered unusable by the damage from time to time bears to the total Floor Area of the Premises.

 

(e)
Notwithstanding the provisions of subsections (a), (b) and (c) of this Section 11.1, but subject to Section 10.4, the cost of any repairs shall be borne by Tenant, and Tenant shall not be entitled to rental abatement or termination rights, if the damage is due to the fault or neglect of Tenant or its employees, subtenants, contractors, invitees or representatives.

 

1.2.
LEASE GOVERNS. Tenant agrees that the provisions of this Lease, including without limitation Section 11.1, shall govern any damage or destruction and shall accordingly supersede any contrary statute or rule of law.

 

ARTICLE 12. EMINENT DOMAIN

 

Either party may terminate this Lease if any material part of the Premises is taken or condemned for any public or quasi-public use under Law, by eminent domain or private purchase in lieu thereof (a “Taking”). Landlord shall also have the right to terminate this Lease if there is a Taking of any portion of the Building or Project which would have a material adverse effect on Landlord’s ability to profitably operate the remainder of the Building or Project. The termination shall be effective as of the effective date of any order granting possession to, or vesting legal title in, the condemning authority. All compensation awarded for a Taking shall be the property of Landlord provided that Tenant may file a separate claim seeking redress from the Taking party, agency or entity so long as it does not diminish the award otherwise receivable by Landlord. Tenant agrees that the provisions of this Lease shall govern any Taking and shall accordingly supersede any contrary statute or rule of law.

ARTICLE 13. SUBORDINATION; ESTOPPEL CERTIFICATE

 

1.1.
SUBORDINATION. Tenant accepts this Lease subject and subordinate to any mortgage(s), deed(s) of trust, ground lease(s) or other lien(s) now or subsequently arising upon the Building or the Project, and to renewals, modifications, refinancings and extensions thereof (collectively referred to as a “Mortgage”). The party having the benefit of a Mortgage shall be referred to as a “Mortgagee”. This clause shall be self-operative, but upon request from a Mortgagee, Tenant shall execute a commercially reasonable subordination and attornment agreement in favor of the Mortgagee, provided such agreement provides a non-disturbance covenant benefitting Tenant. Alternatively, a Mortgagee shall have the right at any time to subordinate its Mortgage to this Lease. Upon request, Tenant, without charge, shall attorn to any successor to Landlord’s interest in this Lease in the event of a foreclosure of any Mortgage. Tenant agrees that any purchaser at a foreclosure sale or lender taking title under a deed in lieu of foreclosure shall not be responsible for any act or omission of a prior landlord, shall not be subject to any offsets or defenses Tenant may have against a prior landlord, and shall not be liable for the return of the Security Deposit not actually recovered by such purchaser nor bound by any rent paid in advance of the calendar month in which the transfer of title occurred; provided that the foregoing shall not release the applicable prior landlord from any liability for those obligations. Tenant acknowledges that Landlord’s Mortgagees and their successors-in- interest are intended third party beneficiaries of this Section 13.1.

 

1.2.
ESTOPPEL CERTIFICATE. Tenant shall, within 10 days after receipt of a written request from Landlord, execute and deliver a commercially reasonable estoppel certificate in favor of those parties as are reasonably requested by Landlord (including a Mortgagee or a prospective purchaser of the Building or the Project).

 

 


 

ARTICLE 14. DEFAULTS AND REMEDIES

 

1.1.
TENANT’S DEFAULTS. In addition to any other event of default set forth in this Lease, the occurrence of any one or more of the following events shall constitute a “Default” by Tenant:

 

(a)
The failure by Tenant to make any payment of Rent required to be made by Tenant, as and when due, where the failure continues for a period of 3 business days after written notice from Landlord to Tenant. The term “Rent” as used in this Lease shall be deemed to mean the Basic Rent and all other sums, including but not limited to parking charges, required to be paid by Tenant to Landlord pursuant to the terms of this Lease.

 

(b)
Except where a specific time period is otherwise set forth for Tenant’s performance in this Lease (in which event the failure to perform by Tenant within such time period shall be a Default), the failure or inability by Tenant to observe or perform any of the covenants or provisions of this Lease to be observed or performed by Tenant, other than as specified in any other subsection of this Section 14.1, where the failure continues for a period of 30 days after written notice from Landlord to Tenant; provided, however, that if the nature of Tenant’s obligation is such that more than 30 days are required for its performance, then Tenant shall have up to an additional thirty (30) days to satisfy Tenant’s obligation.

 

The notice periods provided herein are in lieu of, and not in addition to, any notice periods provided by law, and Landlord shall not be required to give any additional notice under California Code of Civil Procedure Section 1161, or any successor statute, in order to be entitled to commence an unlawful detainer proceeding.

 

1.2.
LANDLORD’S REMEDIES. In addition to all other rights or remedies of Landlord set forth in this Lease, if a Default occurs, Landlord shall have all rights available to Landlord under California law, without further notice or demand to Tenant, including, without limitation, the right to terminate this Lease. In addition, Landlord has the remedy described in California Civil Code Section 1951.4 (Landlord may continue this Lease in effect after Tenant's breach and abandonment and recover Rent as it becomes due, if Tenant has the right to sublet or assign, subject only to reasonable limitations). In any case in which Landlord re-enters and occupies the Premises, by unlawful detainer proceedings or otherwise, Landlord, at its option, may repair, alter, subdivide or change the character of the Premises as Landlord deems best, relet all or any part of the Premises and receive the rents therefor, and none of these actions shall constitute a termination of this Lease, a release of Tenant from any liability, or result in the release of any Guarantor. Landlord shall not be deemed to have terminated this Lease or the liability of Tenant to pay any Rent or other charges later becoming due by any re-entry of the Premises pursuant to this Section 14.2, or by any action in unlawful detainer or otherwise to obtain possession of the Premises, unless Landlord has first given Tenant notice that it is terminating this Lease. Any notice given by Landlord pursuant to Section 14.1 shall be in lieu of, and not in addition to, any notice required by Section 1161 of the California Code of Civil Procedure or superseding statute. Any payment of Rent following Landlord’s delivery of notice to Tenant pursuant to Section 14.1 shall not constitute acceptance of Rent. If Landlord elects to terminate this Lease pursuant to the provisions of this Section 14.2, damages shall include, without limitation, the remedy and measure of damages specified pursuant to California Civil Code Section 1951.2, which shall include the worth at the time of award of the amount by which the unpaid Rent for the balance of the Term after the time of award exceeds the amount of Rent loss Tenant proves could have been reasonably avoided.

 

1.3.
LATE PAYMENTS. Any Rent due under this Lease that is not paid to Landlord within 5 business days of the date when due shall bear interest at the maximum rate permitted by law from the date due until fully paid and if any Rent due from Tenant shall not be received by Landlord or Landlord’s designee within 5 days after the date due, then Tenant shall pay to Landlord, in addition to the interest, a late charge for each delinquent payment equal to the greater of (i) 5% of that delinquent payment or (ii) $100.00. Notwithstanding the foregoing, Tenant shall not be obligated to pay such late charge for the first delinquency in a calendar year.

 

1.4.
DEFAULT BY LANDLORD. Landlord shall not be deemed to be in default in the performance of any obligation under this Lease unless and until it has failed to perform the obligation within 30 days after written notice by Tenant to Landlord specifying in reasonable detail the nature and extent of the failure; provided, however, that if the nature of Landlord’s obligation is such that more than 30 days are required for its performance, then Landlord shall not be deemed to be in default if it commences performance within the 30 day period and thereafter diligently pursues the cure to completion.

 

1.5.
EXPENSES AND LEGAL FEES. Should either Landlord or Tenant bring any action in connection with this Lease, the prevailing party shall be entitled to recover as a part of the action its reasonable attorneys’ fees, and all other reasonable costs. The prevailing party for the purpose of this paragraph shall be determined by the trier of the facts.

 

1.6.
JUDICIAL REFERENCE/WAIVER OF JURY TRIAL. Landlord and Tenant agree that any disputes arising in

 


 

connection with this Lease (including but not limited to a determination of any and all of the issues in such dispute, whether of fact or of law) shall be resolved (and a decision shall be rendered) by way of a general reference as provided for in Part 2, Title 8, Chapter 6 (§§ 638 et. seq.) of the California Code of Civil Procedure, or any successor California statute governing resolution of disputes by a court appointed referee. Nothing within this Section 14.6 shall apply to an unlawful detainer action. Any fee to initiate the judicial reference proceedings shall be paid by the party initiating such procedure; provide d however, that the costs and fees, including any initiation fee, of such proceeding shall ultimately be borne in accordance this Section 14.6. LANDLORD AND TENANT EACH ACKNOWLEDGES THAT IT IS AWARE OF AND HAS HAD THE ADVICE OF COUNSEL OF ITS CHOICE WITH RESPECT TO ITS RIGHT TO TRIAL BY JURY, AND, TO THE EXTENT PERMITTED BY LAW, EACH PARTY DOES HEREBY EXPRESSLY AND KNOWINGLY WAIVE AND RELEASE ALL SUCH RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE.

 

1.7.
SATISFACTION OF JUDGMENT. The obligations of Landlord and Tenant do not constitute the personal obligations of the individual partners, trustees, directors, officers, members or shareholders of Landlord or Tenant or their constituent partners or members. Should Tenant recover a money judgment against Landlord, such judgment shall be satisfied only from the interest of Landlord in the Project and out of the rent or other income from such property receivable by Landlord, and no action for any deficiency may be sought or obtained by Tenant.

 

ARTICLE 15. END OF TERM

 

1.1.
HOLDING OVER. If Tenant holds over for any period after the Expiration Date (or earlier termination of the Term), such tenancy shall constitute a tenancy at sufferance only and possession shall be subject to all of the terms of this Lease, except that the monthly rental shall be 200% of the total monthly rental for the month immediately preceding the date of termination, except that during the first 60 days of such holdover, the monthly rental shall be 150% of Rent for the month immediately preceding the date of termination. After the initial 60 days of such holdover, the monthly rental shall be increased to 200% of the total monthly Rent for the month immediately preceding the date of termination. The acceptance by Landlord of monthly hold-over rental in a lesser amount shall not constitute a waiver of Landlord's right to recover the full amount due unless otherwise agreed in writing by Landlord. If Tenant fails to vacate the Premises within 15 days after Landlord notifies Tenant that Landlord has entered into a lease for the Premises or has received a bona fide offer to lease the Premises and that Landlord will be unable to deliver possession or perform improvements due to Tenant’s holdover, and if Landlord is unable to deliver possession of the Premises to a new tenant or to perform improvements for a new tenant as a result of Tenant’s holdover, then Tenant shall be liable for all damages that Landlord suffers from the holdover. Tenant shall also indemnify and hold Landlord harmless from all loss or liability, including without limitation, any claims made by any succeeding tenant relating to such failure to surrender. The foregoing provisions of this Section 15.1 are in addition to and do not affect Landlord’s right of re-entry or any other rights of Landlord under this Lease or at law.

 

1.2.
SURRENDER OF PREMISES; REMOVAL OF PROPERTY. Upon the Expiration Date or upon any earlier termination of this Lease, Tenant shall quit and surrender possession of the Premises to Landlord in as good order, condition and repair as when received or as hereafter may be improved by Landlord or Tenant, reasonable wear and tear and repairs which are Landlord’s obligation excepted, and shall remove or fund to Landlord the cost of removing all wallpapering, voice and/or data transmission cabling installed by or for Tenant and Required Removables, together with all personal property and debris, and shall perform all work required under Section 7.3 of this Lease. If Tenant shall fail to comply with the provisions of this Section 15.2 and remove any personal property within 10 days following the expiration or earlier termination of this Lease, such personal property shall be conclusively deemed to have been abandoned, then Landlord may effect the removal and/or make any repairs, without notice and without incurring any liability to Tenant, and the cost to Landlord shall be additional rent payable by Tenant upon demand. Tenant hereby waives all rights under and benefits of Section 1993.03 of the California Civil Code, or any similar or successor laws now or hereafter in effect and authorizes Landlord to dispose of any personal property remaining at the Premises following the expiration or earlier termination of this Lease without further notice to Tenant.

 

ARTICLE 16. PAYMENTS AND NOTICES

 

All sums payable by Tenant to Landlord shall be paid, without deduction or offset, in lawful money of the United States to Landlord at its address set forth in Item 12 of the Basic Lease Provisions, or at any other place as Landlord may designate in writing. Unless this Lease expressly provides otherwise, all payments shall be due and payable within 30 days after written demand. All payments requiring proration shall be prorated on the basis of the number of days in the pertinent calendar month or year, as applicable. Any notice, election, demand, consent or approval to be given or other document to be delivered by either party to the other may be delivered to the other party, at the address set forth in Item 12 of the Basic Lease Provisions, by personal service or by any courier or “overnight” express mailing service. Either party may, by written notice to the other, served in the manner provided in this Article, designate a different address. The refusal to accept delivery

 


 

of a notice, or the inability to deliver the notice (whether due to a change of address for which notice was not duly given or other good reason), shall be deemed delivery and receipt of the notice as of the date of attempted delivery.

 

ARTICLE 17. RULES AND REGULATIONS

 

Tenant agrees to comply with the Rules and Regulations attached as Exhibit E, and any reasonable and nondiscriminatory amendments, modifications and/or additions as may be adopted by Landlord from time to time. The rules and regulations shall be generally applicable, and generally applied in the same manner, to all tenants of the Building.

 

ARTICLE 18. BROKER’S COMMISSION

 

The parties recognize as the broker(s) who negotiated this Lease the firm(s) whose name(s) is (are) stated in Item 10 of the Basic Lease Provisions, and agree that Landlord shall be responsible for the payment of brokerage commissions to those broker(s) unless otherwise provided in this Lease. Tenant agrees to indemnify and hold Landlord harmless from any cost, expense or liability (including reasonable attorneys’ fees) for any compensation, commissions or charges claimed by any other real estate broker or agent employed or claiming to represent or to have been employed by Tenant in connection with the negotiation of this Lease.

 

ARTICLE 19. TRANSFER OF LANDLORD’S INTEREST

 

Landlord shall have the right to transfer and assign, in whole or in part, all of its ownership interest, rights and obligations in the Building, Project or Lease, including the Security Deposit, and upon transfer Landlord shall be released from any further obligations hereunder, and Tenant agrees to look solely to the successor in interest of Landlord for the performance of such obligations and the return of any Security Deposit.

 

ARTICLE 20. INTERPRETATION

 

1.1.
NUMBER. Whenever the context of this Lease requires, the words “Landlord” and “Tenant” shall include the plural as well as the singular.

 

1.2.
JOINT AND SEVERAL LIABILITY. If more than one person or entity is named as Tenant, the obligations imposed upon each shall be joint and several and the act of or notice from, or notice or refund to, or the signature of, any one or more of them shall be binding on all of them with respect to the tenancy of this Lease, including, but not limited to, any renewal, extension, termination or modification of this Lease.

 

1.3.
SUCCESSORS. The expiration of the Term, whether by lapse of time, termination or otherwise, shall not relieve either party of any obligations which accrued prior to or which may continue to accrue after the expiration or termination of this Lease.

 

1.4.
TIME OF ESSENCE. Time is of the essence with respect to the performance of every provision of this Lease in which time of performance is a factor.

 

1.5.
CONTROLLING LAW. This Lease shall be governed by and interpreted in accordance with the laws of the State of California.

 

1.6.
SEVERABILITY. If any term or provision of this Lease, the deletion of which would not adversely affect the receipt of any material benefit by either party or the deletion of which is consented to by the party adversely affected, shall be held invalid or unenforceable to any extent, the remainder of this Lease shall not be affected and each term and provision of this Lease shall be valid and enforceable to the fullest extent permitted by law.

 

1.7.
WAIVER. One or more waivers by Landlord or Tenant of any breach of any term, covenant or condition contained in this Lease shall not be a waiver of any subsequent breach of the same or any other term, covenant or condition. Consent to any act by one of the parties shall not be deemed to render unnecessary the obtaining of that party’s consent to any subsequent act. No breach of this Lease shall be deemed to have been waived unless the waiver is in a writing signed by the waiving party.

 

1.8.
INABILITY TO PERFORM. In the event that either party shall be delayed or hindered in or prevented from the performance of any work or in performing any act required under this Lease by reason of any cause beyond the reasonable control of that party, then the performance of the work or the doing of the act shall be excused for the period of the delay and the time for performance shall be extended for a period equivalent to the period of the delay. The provisions of this

 


 

Section 20.8 shall not operate to excuse Tenant from the prompt payment of Rent or Landlord from any claim arising out of a financial inability to perform.

 

1.9.
ENTIRE AGREEMENT. This Lease constitutes the entire agreement between the parties and supersedes all prior agreements and understandings related to the Premises. This Lease may be modified only by a written agreement signed by Landlord and Tenant.

 

1.10.
QUIET ENJOYMENT. Upon the observance and performance of all the covenants, terms and conditions on Tenant’s part to be observed and performed, and subject to the other provisions of this Lease, Tenant shall have the right of quiet enjoyment and use of the Premises for the Term without hindrance or interruption by Landlord or any other person claiming by or through Landlord.

 

1.11.
SURVIVAL. All covenants of Landlord or Tenant which reasonably would be intended to survive the expiration or sooner termination of this Lease, including without limitation any warranty or indemnity hereunder, shall so survive and continue to be binding upon and inure to the benefit of the respective parties and their successors and assigns.

 

 

 

ARTICLE 21. EXECUTION

 

1.1.
COUNTERPARTS; DIGITAL SIGNATURES. This Lease may be executed in one or more counterparts, each of which shall constitute an original and all of which shall be one and the same agreement. The parties agree to accept a digital image (including but not limited to an image in the form of a PDF, JPEG, GIF file, or other e-signature) of this Lease, if applicable, reflecting the execution of one or both of the parties, as a true and correct original.

 

1.2.
CORPORATE AND PARTNERSHIP AUTHORITY. Tenant represents and warrants to Landlord, and agrees, that each individual executing this Lease on behalf of Tenant is authorized to do so on behalf of Tenant.

 

1.3.
EXECUTION OF LEASE; NO OPTION OR OFFER. The submission of this Lease to Tenant shall be for examination purposes only, and shall not constitute an offer to or option for Tenant to lease the Premises unless and until Landlord has executed and delivered this Lease to Tenant.

 

1.4.
BROKER DISCLOSURE. By the execution of this Lease, each of Landlord and Tenant hereby acknowledge and confirm (a) receipt of a copy of a Disclosure Regarding Real Estate Agency Relationship conforming to the requirements of California Civil Code 2079.16, and (b) the agency relationships specified in Item 10 of the Basic Lease Provisions, which acknowledgement and confirmation is expressly made for the benefit of Tenant’s Broker identified in Item 10 of the Basic Lease Provisions. If there is no Tenant’s Broker so identified in Item 10 of the Basic Lease Provisions, then such acknowledgement and confirmation is expressly made for the benefit of Landlord’s Broker. By the execution of this Lease, Landlord and Tenant are executing the confirmation of the agency relationships set forth in Item 10 of the Basic Lease Provisions.

 

ARTICLE 22. MISCELLANEOUS

 

1.1.
MORTGAGEE PROTECTION. No act or failure to act on the part of Landlord which would otherwise entitle Tenant to be relieved of its obligations hereunder or to terminate this Lease shall result in such a release or termination unless (a) Tenant has given notice by registered or certified mail to any Mortgagee of a Mortgage covering the Building whose address has been furnished to Tenant and (b) such Mortgagee is afforded a reasonable opportunity to cure the default by Landlord. Tenant shall comply with any written directions by any Mortgagee to pay Rent due hereunder directly to such Mortgagee without determining whether a default exists under such Mortgagee’s Mortgage.

 

1.2.
SDN LIST. Tenant hereby represents and warrants that neither Tenant nor any officer, director, employee, partner, member or other principal of Tenant (collectively, "Tenant Parties") is listed as a Specially Designated National and Blocked Person ("SDN") on the list of such persons and entities issued by the U.S. Treasury Office of Foreign Assets Control (OFAC). In the event Tenant or any Tenant Party is or becomes listed as an SDN, Tenant shall be deemed in breach of this Lease and Landlord shall have the right to terminate this Lease immediately upon written notice to Tenant.

 

1.3
APPROVALS GENERALLY. Except (i) for matters for which there is a standard of consent or discretion specifically set forth in this Lease; (ii) matters which could have an adverse effect on the Building Structure or the Building Systems, or which could affect the exterior appearance of the Building, or (iii) matters covered by Article 14 (Defaults and Remedies) of this Lease (the "Excepted Matters"), any time the consent of Landlord or Tenant is required under this Lease,

 


 

such consent shall not be unreasonably withheld, conditioned or delayed, and, except with regard to the Excepted Matters, whenever this Lease grants Landlord or Tenant the right to take action, exercise discretion, establish rules and regulations or make an allocation or other determination, Landlord and Tenant shall act reasonably and in good faith.

 

 

IN WITNESS WHEREOF, the parties have executed this Lease as of the day and year first above written.

 

 

 

 

 

 

 

 

 

 

 

LANDLORD:

TENANT:

 

PASEO DEL MAR LLC,

a Delaware limited liability company

 

CONNECT BIOPHARM LLC

a California limited liability company

 

By: /s/ Steven M. Chase

By: /s/ Zheng Wei

Steven M. Case

Executive Vice President, Leasing & Marketing Office Properties

 

 

Zheng Wei, Ph.D.

CEO

By: /s/ Christopher Gash

By: /s/ Steven Chan

Christopher Gash

Vice President, Operations Office Properties

 

Steven Chan

Chief Financial Officer

 

 

 

 

EXHIBIT A

DESCRIPTION OF PREMISES

12265 El Camino Real, Suite 350

 

 

 

 


 

img24628583_0.jpg 

 

 

 

 

EXHIBIT B

 

OPERATING EXPENSES AND TAXES

(Base Year)

 

 

(a)
Following the Base Year, Tenant shall pay Landlord, as additional rent, for Tenant’s Share of the amount, if any, by which “Project Costs” (defined below) for each Expense Recovery Period during the Term exceed Project Costs for the Project Cost Base and the amount, if any, by which “Property Taxes” (defined below) for each Expense Recovery Period during the Term exceed Property Taxes for the Property Tax Base. Property Taxes and Project Costs are mutually exclusive and may be billed separately or in combination as determined by Landlord. “Tenant’s Share” shall mean that portion of any Operating Expenses determined by multiplying the cost of such item by a fraction, the numerator of which is the Floor Area of Premises and the denominator of which is the total rentable square footage, as determined from time to time by Landlord, of (i) the Floor Area of Building as defined in Item 8 of the Basic Lease Provisions, for expenses determined by Landlord to benefit or relate substantially to the Building rather than the entire Project, or (ii) all or some of the buildings in the Project, for expenses determined by Landlord to benefit or relate substantially to all or some of the buildings in the Project rather than any specific building. Tenant acknowledges Landlord’s rights to make changes or additions to the Building and/or Project from time to time, in which event the total rentable square footage within the Building and/or Project may be adjusted. For convenience of reference, Property Taxes and Project Costs may sometimes be collectively referred to as “Operating Expenses.”

 

(b)
Commencing prior to the start of the first full “Expense Recovery Period” of the Lease (as defined in Item 7 of the Basic Lease Provisions) following the Base Year, and prior to the start of each full or partial Expense Recovery Period thereafter, Landlord shall give Tenant a written estimate of the amount of Tenant’s Share of Project Costs and Property Taxes for the Expense Recovery Period or portion thereof. Tenant shall pay the estimated amounts to Landlord in equal monthly installments, in advance, with Basic Rent. Landlord may from time to time change the Expense Recover y Period to reflect a calendar year or a new fiscal year of Landlord, as applicable, in which event Tenant’s Share of Operating Expenses shall be equitably prorated for any partial year. From time to time during an Expense Recovery Period, Landlord may revise the estimate based on increases in any of the Operating Expenses.

 

(c)
Within 180 days after the end of each Expense Recovery Period, Landlord shall furnish to Tenant a statement setting forth the actual or prorated Property Taxes and Project Costs attributable to that period, and the parties shall within 30 days thereafter make any payment or allowance necessary to adjust Tenant’s estimated payments, if any, to Tenant’s actual Tenant’s Share as shown by the annual statement. If actual Property Taxes or Project Costs allocable to Tenant during any Expense Recovery Period are less than the Property Tax Base or the Project Cost Base, respectively, Landlord shall not be required to pay that differential to Tenant, although Landlord shall refund any applicable estimated payments collected from Tenant. Should Tenant fail to object in writing to Landlord’s determination of actual Operating

 


 

Expenses within 90 days following delivery of Landlord’s expense statement, Landlord’s determination of actual Operating Expenses for the applicable Expense Recovery Period shall be conclusive and binding on Tenant.

 

(d)
Even though the Lease has terminated and the Tenant has vacated the Premises, when the final determination is made of Tenant’s share of Property Taxes and Project Costs for the Expense Recovery Period in which the Lease terminates, Tenant shall upon notice pay the entire increase due over the estimated expenses paid; conversely, any overpayment made in the event expenses decrease shall be rebated by Landlord to Tenant.

 

(e)
The term “Project Costs” shall include all charges and expenses pertaining to the operation, management, maintenance and repair of the Building and the Project, together with all Common Areas (as defined in Section 6.2), and shall include the following charges by way of illustration but not limitation: water and sewer charges; insurance premiums and deductibles and/or reasonable premium equivalents and deductible equivalents should Landlord elect to self-insure any risk that Landlord is authorized to insure hereunder to the extent attributable to an expense which is included in Project Costs hereunder [such that any deductible which funds a cost item shall be amortized if amortization would be required by the terms of this Lease, and shall be excluded from costs passed through to Tenant if the exclusions set forth below in this Exhibit B would operate to exclude such costs]; license, permit, and inspection fees; heat; light; power; janitorial services; the cost of equipping, staffing and operating an on-site and/or off-site management office for the Building and Project; all labor and labor-related costs for personnel applicable to the Building and Project, including both Landlord's personnel and outside personnel; a commercially reasonable Landlord overhead/management fee; reasonable fees for consulting services; access control/security costs, inclusive of the reasonable cost of improvements made to enhance access control systems and procedures; repairs; air conditioning; supplies; materials; equipment; tools; tenant services; programs instituted to comply with transportation management requirements; any expense incurred pursuant to Sections 6.1, 6.2, 7.2, and 10.2 and Exhibits C and F below; costs incurred (capital or otherwise) on a regular recurring basis every 3 or more years for normal maintenance projects (e.g., parking lot slurry coat or replacement of lobby, corridor and elevator cab carpets and coverings); and the amortized cost of capital improvements (as distinguished from replacement parts or components installed in the ordinary course of business) which are intended to reduce other operating costs or increases thereof, or upgrade Building and/or Project security, or which are required to bring the Building and/or Project into compliance with applicable laws and building codes first imposed after the Commencement Date. Landlord shall amortize the cost of such permitted capital improvements on a straight-line basis over the lesser of the Payback Period (as defined below) or the useful life of the capital improvement as reasonably determined by Landlord. Any amortized Project Costs item may include, at Landlord's option, an actual or imputed interest rate that Landlord would reasonably be required to pay to finance the cost of the item, applied on the unamortized balance. "Payback Period" shall mean the reasonably estimated period of time that it takes for the cost savings, if any, resulting from a capital improvement item to equal the total cost of the capital improvement. It is understood that Project Costs shall include competitive charges for direct services provided by any subsidiary or division of Landlord. If any Project Costs are applicable to one or more buildings or properties in addition to the Building, then that cost shall be equitably prorated and apportioned among the Building and such other buildings or properties. The term “Property Taxes” shall include the following: (i) all real estate taxes or personal property taxes, as such property taxes may be increased from time to time due to a reassessment or otherwise; and (ii) other taxes, charges and assessments which are levied with respect to this Lease or to the Building and/or the Project, and any improvements, fixtures and equipment and other property of Landlord located in the Building and/or the Project, except that general net income and franchise taxes imposed against Landlord shall be excluded; and (iii) any tax, surcharge or assessment which shall be levied in addition to or in lieu of real estate or personal property taxes; and (iv) costs and expenses incurred in contesting the amount or validity of any Property Tax by appropriate proceedings. A copy of Landlord’s unaudited statement of expenses shall be made available to Tenant upon request. The Project Costs that vary based upon occupancy, inclusive of those for the Base Year, shall be extrapolated by Landlord to reflect at least 95% occupancy of the rentable area of the Building. If other than as a result of any legal or governmental requirements or other occurrence(s) beyond the reasonable control of Landlord (the parties agreeing that requirements of Landlord's lenders or investors shall not be deemed to be beyond the reasonable control of Landlord for purposes of this sentence), following the Base Year any new category of operating expense is added to Operating Expenses, then during such time as the costs relating to such new category are included in the Building's expenses, the calculation of the Base Year Operating Expenses shall be increased to reflect such Operating Expenses as would have been incurred had such new category item been included in the Base Year, giving due consideration to what the costs for such new category would have been in the Base Year.

 

(f)
Notwithstanding the foregoing, Operating Expenses shall exclude the following:

 

(1)
Any ground lease rental;

 

(2)
Costs incurred by Landlord with respect to goods and services (including utilities sold and supplied to tenants and occupants of the Building) to the extent that Landlord is reimbursed for such costs other than through the Operating Expense pass-through provisions of such tenants' lease;

 

 


 

(3)
Costs incurred by Landlord for repairs, replacements and/or restoration to or of the Building to the extent that Landlord is reimbursed by insurance or condemnation proceeds or by tenants (other than through Operating Expense pass- throughs), warrantors or other third persons;

 

(4)
Costs, including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for other tenants in the Building or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants or other occupants of the Building;

 

(5)
Costs arising from Landlord's charitable or political contributions;

 

(6)
Attorneys' fees and other costs and expenses incurred in connection with negotiations or disputes with present or prospective tenants or other occupants of the Building, except those attorneys' fees and other costs and expenses incurred in connection with negotiations, disputes or claims relating to items of Operating Expenses, enforcement of rules and regulations of the Building and such other matters relating to the maintenance of standards required of Landlord under this Lease;

 

(7)
Capital expenditures as determined in accordance with generally accepted accounting principles, consistently applied, and as generally practiced in the real estate industry (“GAAP”), except as otherwise provided above;

 

(8)
Brokers commissions, finders' fees, attorneys' fees, entertainment and travel expenses and other costs incurred by Landlord in leasing or attempting to lease space in the Building;

 

(9)
Expenses in connection with services or other benefits which are not offered to Tenant or for which Tenant is charged for directly but which are provided to another tenant or occupant of the Building;

 

(10)
Costs incurred by Landlord due to the violation by Landlord of any law, code, regulation, or ordinance;

 

(11)
Overhead and profit increments paid to subsidiaries or affiliates of Landlord for services provided to the Building to the extent the same exceeds the costs that would generally be charged for such services if rendered on a competitive basis (based upon a standard of similar office buildings in the general market area of the Premises) by unaffiliated third parties capable of providing such service;

 

(12)
Interest or other charges on debt or amortization on any mortgage or mortgages encumbering the Building;

 

(13)
Landlord's general corporate overhead, except as it relates to the specific management, operation, repair, replacement and maintenance of the Building or Project;

 

(14)
Costs of installing the initial landscaping and the initial sculpture, paintings and objects of art for the Building and Project;

 

(15)
Advertising expenditures;

 

(16)
Any bad debt loss, rent loss, or reserves for bad debts or rent loss;

 

(17)
Costs associated with the operation of the business of the partnership or entity which constitutes the Landlord, as the same are distinguished from the costs of the operation, management, repair, replacement and maintenance of the Project, including partnership accounting and legal matters, costs of defending any lawsuits with any mortgagee (except as the actions of Tenant may be in issue), costs of selling, syndicating, financing, mortgaging or hypothecating any of Landlord's interest in the Project, and costs incurred in connection with any disputes between Landlord and its employees, between Landlord and Project management, or between Landlord and other tenants or occupants;

 

(18)
The wages and benefits of any employee who does not devote substantially all of his or her employed time to the Project unless such wages and benefits are prorated to reflect time spent on operating and managing the Project vis- à-vis time spent on matters unrelated to operating and managing the Project; provided that in no event shall Project Costs include wages and/or benefits attributable to personnel above the level of portfolio property manager or chief engineer;

 

(19)
Costs incurred by Landlord for improvements or replacements (including structural additions), repairs, equipment and tools which are of a “capital” nature and/or which are considered “capital” improvements or replacements under GAAP, except to the extent included in Project Costs pursuant to the definition above or by other express terms of this Lease; and

 


 

 

(20)
Legal fees and costs, settlements, judgments or awards paid or incurred because of disputes between Landlord and other tenants or prospective occupants or prospective tenants/occupants or providers of goods and services to the Project.

 

 

 

EXHIBIT C

UTILITIES AND SERVICES

 

The following standards for utilities and services shall be in effect at the Building. Landlord reserves the right to adopt nondiscriminatory modifications and additions to these standards. In the case of any conflict between these standards and the Lease, the Lease shall be controlling. Subject to all of the provisions of the Lease, the following shall apply:

 

1.
Landlord shall make available to the Premises during the hours of 8:00 a.m. to 6:00 p.m., Monday through Friday, and upon request, from 9:00 a.m. to 1:00 p.m. on Saturday ("Building Hours"), generally recognized national holidays excepted, reasonable HVAC services. Subject to the provisions set forth below, Landlord shall also furnish the Building with elevator service (if applicable), reasonable amounts of electric current for normal lighting by Landlord’s standard overhead fluorescent and incandescent fixtures and for the operation of office equipment consistent in type and quantity with that utilized by typical office tenants of the Building and Project, and water for lavatory purposes. Tenant will not, without the prior written consent of Landlord, connect any apparatus, machine or device with water pipes or electric current (except through existing electrical outlets in the Premises) for the purpose of using electric current or water.

 

2.
Upon written request from Tenant delivered to Landlord at least 24 hours prior to the period for which service is requested, but during normal business hours, Landlord will provide any of the foregoing building services to Tenant at such times when such services are not otherwise available. Tenant agrees to pay Landlord for those after-hour services at rates that Landlord may establish from time to time. If Tenant requires electric current in excess of that which Landlord is obligated to furnish under this Exhibit C, Tenant shall first obtain the consent of Landlord, and Landlord may cause an electric current meter to be installed in the Premises to measure the amount of electric current consumed. The cost of installation, maintenance and repair of the meter shall be paid for by Tenant, and Tenant shall reimburse Landlord promptly upon demand for all electric current consumed for any special power use as shown by the meter.

 

3.
Landlord shall furnish water for drinking, personal hygiene and lavatory purposes only.

 

4.
In the event that any utility service to the Premises is separately metered or billed to Tenant, Tenant shall pay all charges for that utility service to the Premises and the cost of furnishing the utility to tenant suites shall be excluded from the Operating Expenses as to which reimbursement from Tenant is required in the Lease.

 

5.
Landlord shall provide janitorial services 5 days per week, equivalent to that furnished in comparable buildings, and window washing as reasonably required; provided, however, that Tenant shall pay for any additional or unusual janitorial services.

 

6.
Subject to temporary closures, Tenant shall have access to the Building, Common Area, Premises and Parking Area 24 hours per day, 7 days per week, 52 weeks per year; provided that Landlord may install access control systems as it deems advisable for the Building. Landlord may impose a reasonable charge for access control cards and/or keys issued to Tenant.

 

7.
The costs of operating, maintaining and repairing any supplemental air conditioning unit serving only the Premises shall be borne solely by Tenant. Such installation shall be subject to Landlord’s prior written approval, at Tenant's sole expense and shall include installation of a separate meter for the operation of the unit. Landlord may require Tenant to remove at Lease expiration any such unit installed by or for Tenant and to repair any resulting damage to the Premises or Building.

 

 


 

EXHIBIT D

TENANT’S INSURANCE

 

 

The following requirements for Tenant’s insurance shall be in effect during the Term, and Tenant shall also cause any subtenant to comply with the requirements. Landlord reserves the right to adopt reasonable nondiscriminatory modifications and additions to these requirements.

 

1.
Tenant shall maintain, at its sole cost and expense, during the entire Term: (i) commercial general liability insurance with respect to the Premises and the operations of Tenant in, on or about the Premises, on a policy form that is at least as broad as Insurance Service Office (ISO) CGL 00 01 (if alcoholic beverages are sold on the Premises, liquor liability shall be explicitly covered), which policy(ies) shall be written on an “occurrence” basis and for not less than

$2,000,000 combined single limit per occurrence for bodily injury, death, and property damage liability; (ii) workers’ compensation insurance coverage as required by law, together with employers’ liability insurance coverage of at least

$1,000,000 each accident and each disease; (iii) with respect to Alterations constructed by Tenant under this Lease, builder’s risk insurance, in an amount equal to the replacement cost of the work; and (iv) insurance against fire, vandalism, malicious mischief and such other additional perils as may be included in a standard “special form” policy, insuring all Alterations, trade fixtures, furnishings, equipment and items of personal property in the Premises, in an amount equal to not less than 90% of their replacement cost (with replacement cost endorsement), which policy shall also include business interruption coverage in an amount sufficient to cover 1 year of loss. In no event shall the limits of any policy be considered as limiting the liability of Tenant under this Lease.

 

2.
All policies of insurance required to be carried by Tenant pursuant to this Exhibit D shall be written by insurance companies authorized to do business in the State of California and with a general policyholder rating of not less than “A-” and financial rating of not less than “VIII” in the most current Best’s Insurance Report. The deductible or other retained limit under any policy carried by Tenant shall be commercially reasonable, and Tenant shall be responsible for payment of such deductible or retained limit with waiver of subrogation in favor of Landlord. Any insurance required of Tenant may be furnished by Tenant under any blanket policy carried by it or under a separate policy. A certificate of insurance, certifying that the policy has been issued, provides the coverage required by this Exhibit and contains the required provisions, together with endorsements acceptable to Landlord evidencing the waiver of subrogation and additional insured provisions required below, shall be delivered to Landlord prior to the date Tenant is given the right of possession of the Premises. Proper evidence of the renewal of any insurance coverage shall also be delivered to Landlord prior to the expiration of the coverage. In the event of a loss covered by any policy under which Landlord is an additional insured, Landlord shall be entitled to review a copy of such policy.

 

3.
Tenant’s commercial general liability insurance shall contain a provision that the policy shall be primary to and noncontributory with any policies carried by Landlord, together with a provision including Landlord and any other parties in interest designated by Landlord as additional insureds. Tenant’s policies described in Subsections 1 (ii), (iii) and (iv) above shall each contain a waiver by the insurer of any right to subrogation against Landlord, its agents, employees, contractors and representatives. Tenant also waives its right of recovery for any deductible or retained limit under same policies enumerated above. To the extent such a provision is available, the insurance coverage shall provide that it may not be canceled or modified without at least thirty (30) days prior written notice to Landlord. In any event Tenant shall not modify or cancel such insurance coverage except upon thirty (30) days prior notice to Landlord and shall promptly notify Landlord of any notice of cancellation received by Tenant. Tenant shall also name Landlord as an additional insured on any excess or umbrella liability insurance policy carried by Tenant.

 

 

NOTICE TO TENANT: IN ACCORDANCE WITH THE TERMS OF THIS LEASE, TENANT MUST PROVIDE EVIDENCE OF THE REQUIRED INSURANCE TO LANDLORD’S MANAGEMENT AGENT PRIOR TO BEING AFFORDED ACCESS TO THE PREMISES.

 

 


 

 

 

EXHIBIT E

 

RULES AND REGULATIONS

 

 

The following Rules and Regulations shall be in effect at the Building. Landlord reserves the right to adopt reasonable nondiscriminatory modifications and additions at any time. In the case of any conflict between these regulations and the Lease, the Lease shall be controlling.

 

1.
The sidewalks, halls, passages, elevators, stairways, and other common areas shall not be obstructed by Tenant or used by it for storage, for depositing items, or for any purpose other than for ingress to and egress from the Premises. Should Tenant have access to any balcony or patio area, Tenant shall not place any furniture other personal property in such area without the prior written approval of Landlord.

 

2.
Neither Tenant nor any employee or contractor of Tenant shall go upon the roof of the Building without the prior written consent of Landlord.

 

3.
Tenant shall, at its expense, be required to utilize the third party contractor designated by Landlord for the Building to provide any telephone wiring services from the minimum point of entry of the telephone cable in the Building to the Premises.

 

4.
No antenna or satellite dish shall be installed by Tenant without the prior written agreement of Landlord.

 

5.
The sashes, sash doors, windows, glass lights, solar film and/or screen, and any lights or skylights that reflect or admit light into the halls or other places of the Building shall not be covered or obstructed. If Landlord, by a notice in writing to Tenant, shall object to any curtain, blind, tinting, shade or screen attached to, or hung in, or used in connection with, any window or door of the Premises, the use of that curtain, blind, tinting, shade or screen shall be immediately discontinued and removed by Tenant. Interior of the Premises visible from the exterior must be maintained in a visually professional manner and consistent with a first class office building. Tenant shall not place any unsightly items (as determined by Landlord in its reasonable discretion) along the exterior glass line of the Premises including, but not limited to, boxes, and electrical and data cords. No awnings shall be permitted on any part of the Premises.

 

6.
The installation and location of any unusually heavy equipment in the Premises, including without limitation file storage units, safes and electronic data processing equipment, shall require the prior written approval of Landlord. The moving of large or heavy objects shall occur only between those hours as may be designated by, and only upon previous notice to, Landlord. No freight, furniture or bulky matter of any description shall be received into or moved out of the lobby of the Building or carried in any elevator other than the freight elevator (if available) designated by Landlord unless approved in writing by Landlord.

 

7.
Any pipes or tubing used by Tenant to transmit water to an appliance or device in the Premises must be made of copper or stainless steel, and in no event shall plastic tubing be used for that purpose.

 

8.
Tenant shall not place any lock(s) on any door in the Premises or Building without Landlord’s prior written consent, which consent shall not be unreasonably withheld. Upon the termination of its tenancy, Tenant shall deliver to Landlord all the keys to offices, rooms and toilet rooms and all access cards which shall have been furnished to Tenant or which Tenant shall have had made.

 

9.
Tenant shall not install equipment requiring electrical or air conditioning service in excess of that to be provided by Landlord under the Lease without prior written approval from Landlord.

 

10.
Tenant shall not use space heaters within the Premises.

 

11.
Tenant shall not do or permit anything to be done in the Premises, or bring or keep anything in the Premises, which shall in any way increase the insurance on the Building, or on the property kept in the Building, or interfere with the rights of other tenants, or conflict with any government rule or regulation.

 

12.
Tenant shall not use or keep any foul or noxious gas or substance in the Premises.

 

 


 

13.
Tenant shall not permit the Premises to be occupied or used in a manner offensive or objectionable to Landlord or other occupants of the Building by reason of noise, odors and/or vibrations, or interfere in any way with other tenants or those having business with other tenants.

 

14.
Tenant shall not permit any pets or animals in or about the Building. Bona fide service animals are permitted provided such service animals are pre-approved by Landlord, remain under the direct control of the individual they serve at all times, and do not disturb or threaten others.

 

15.
Neither Tenant nor its employees, agents, contractors, invitees or licensees shall bring any firearm, whether loaded or unloaded, into the Project at any time.

 

16.
Smoking tobacco, including via personal vaporizers or other electronic cigarettes, anywhere within the Premises, Building or Project is strictly prohibited except that smoking tobacco may be permitted outside the Building and within the Project only in areas designated by Landlord. Smoking, vaping, distributing, growing or manufacturing marijuana or any marijuana derivative anywhere within the Premises, Building or Project is strictly prohibited.

 

17.
Tenant shall not install an aquarium of any size in the Premises unless otherwise approved by Landlord.

 

 


 

18.
Tenant shall not utilize any name selected by Landlord from time to time for the Building and/or the Project as any part of Tenant’s corporate or trade name. Landlord shall have the right to change the name, number or designation of the Building or Project without liability to Tenant. Tenant shall not use any picture of the Building in its advertising, stationery or in any other manner.

 

19.
Tenant shall, upon request by Landlord, supply Landlord with the names and telephone numbers of personnel designated by Tenant to be contacted on an after-hours basis should circumstances warrant.

 

20.
Landlord may from time to time grant tenants individual and temporary variances from these Rules, provided that any variance does not have a material adverse effect on the use and enjoyment of the Premises by Tenant.

 

 

 


 

EXHIBIT F PARKING

 

The following parking regulations shall be in effect at the Building In the case of any conflict between these regulations and the Lease, the Lease shall be controlling.

 

1.
Landlord agrees to maintain, or cause to be maintained, an automobile parking area (“Parking Area”) in reasonable proximity to the Building for the benefit and use of the visitors and patrons and, except as otherwise provided, employees of Tenant, and other tenants and occupants of the Building. Landlord shall have the right to determine the nature and extent of the automobile Parking Area, and of making such changes to the Parking Area from time to time which in its opinion are desirable. Landlord shall not be liable for any damage to motor vehicles of visitors or employees, for an y loss of property from within those motor vehicles, or for any injury to Tenant, its visitors or employees, unless ultimately determined to be caused by the sole active negligence or willful misconduct of Landlord. Landlord shall also have the right to establish, and from time to time amend, and to enforce against all users of the Parking Area all reasonable rules and regulations (including the designation of areas for employee parking) as Landlord may deem necessary and advisable for the proper and efficient operation and maintenance of the Parking Area.

 

2.
Landlord may, if it deems advisable in its sole discretion, charge for parking and may establish for the Parking Area a system or systems of permit parking for Tenant, its employees and its visitors. In no event shall Tenant or its employees park in reserved stalls leased to other tenants or in stalls within designated visitor parking zones, nor shall Tenant or its employees utilize more than the number of Parking Passes (defined below) allotted in this Lease to Tenant. Tenant shall, upon request of Landlord from time to time, furnish Landlord with a list of its employees’ names and of Tenant’s and its employees’ vehicle license numbers. Parking access devices, if applicable, shall not be transferable. Landlord may impose a reasonable fee for access devices and a replacement charge for devices which are lost or stolen. Each access device shall be returned to Landlord promptly following the Expiration Date or sooner termination of this Lease.

 

3.
Washing, waxing, cleaning or servicing of vehicles, or the parking of any vehicle on an overnight basis, in the Parking Area (other than emergency services) by any parker or his or her agents or employees is prohibited unless otherwise authorized by Landlord.

 

4.
It is understood that the employees of Tenant and the other tenants of Landlord within the Building and Project shall not be permitted to park their automobiles in the portions of the Parking Area which may from time to time be designated for patrons of the Building and/or Project. Tenant shall have the right, but not the obligation, to purchase from Landlord for the Term of this Lease, the total number of parking passes set forth in Item 11 of the Basic Lease Provisions (the "Parking Passes") for unreserved parking, at no charge during the initial Term. Thereafter, the stall charge shall be at Landlord’s scheduled parking rates from time to time.

 

5.
Landlord shall be entitled to pass on to Tenant its proportionate share of any charges or parking surcharge or transportation management costs levied by any governmental agency and Tenant shall cooperate in any voluntary or mandated transportation management programs.

 

6.
Tenant shall not assign or sublet any of the Parking Passes, either voluntarily or by operation of law, without the prior written consent of Landlord, except in connection with an authorized assignment of this Lease or subletting of the Premises.

 

 

 


 

EXHIBIT G

GUARANTEE OF LEASE

 

ARTICLE 1. PARTIES

 

The undersigned (hereinafter collectively "Guarantor"), whose address is hereinafter set forth, as a material inducement to and in consideration of PASEO DEL MAR LLC], a Delaware limited liability company (hereinafter "Landlord") entering into a written lease (hereinafter, the "Lease") with CONNECT BIOPHARM LLC, a Cayman Islands corporation (hereinafter "Tenant"), of approximately even date herewith, for lease of that certain space located at 12265 El Camino Real, Suite 350, San Diego, California, and more particularly described in the Lease, pursuant to the provisions of this Guarantee of Lease (the "Guarantee") unconditionally guarantees and promises to and for the benefit of Landlord full payment and performance of each and all of the terms, covenants and conditions of the Lease by Tenant, all as more specifically set forth hereinafter.

 

ARTICLE 2. GUARANTOR'S DUTIES

 

Section 2.1. Guarantee of Tenant's Performance

 

Guarantor hereby unconditionally guarantees to Landlord the full and complete performance of each and all of the terms, covenants and conditions of the Lease as required to be performed by Tenant, including, but not limited to, the payment of all rental, property taxes, operating expenses, and any and all other charges or sums, or any portion thereof, to accrue or become due from Tenant to Landlord pursuant to the terms of the Lease.

 

Section 2.2. Tenant's Failure to Perform

 

1.1.1.
Payment of Rental and Other Sums. In the event that Tenant shall fail to pay any rental, property taxes, operating expenses, or any other sums or charges, or any portion thereof, accrued or due pursuant to the terms of said Lease, including without limitation any obligations incurred by Tenant as a result of a hold-over beyond the term of the Lease, then upon written notice to Guarantor by Landlord as herein provided, Guarantor shall within 5 business days pay to Landlord or Landlord’s designated agent any and all such amounts as may be due and owing from Tenant to Landlord by reason of Tenant’s failure to perform.

 

1.1.2.
Other Provisions. In the event that Tenant shall fail to perform any covenants, terms or conditions of the Lease as required to be performed, other than as provided for in Section 2.2.1. above, then upon written notice to Guarantor by Landlord, as provided herein, Guarantor shall commence and complete performance of such conditions, covenants and terms within 5 business days after the date of Landlord's notice to Guarantor of such failure by Tenant to so perform, and in the event such performance by Guarantor cannot be completed within said 5 business days, Guarantor shall commence performance within said time and shall diligently pursue completion thereof within a reasonable time duly set forth hereinafter.

 

1.1.3.
Interest and Additional Damages. In addition to the payment of rental and other sums, and the performance of any and all other provisions, conditions and terms of the Lease which may be required of Guarantor by reason of Tenant's failure to perform, Guarantor agrees to pay to Landlord any and all reasonable and necessary incidental damages and expenses incurred by Landlord as a direct and proximate result of Tenant's failure to perform. Guarantor further agrees to pay to Landlord interest on any and all sums due and owing Landlord, by reason of Tenant's failure to pay same, at the highest rate as allowed by law at the time of payment thereof.

 

Section 2.3. Statements of Guarantor.

 

Guarantor shall deliver to Landlord, prior to the execution of this Guarantee and thereafter at any time upon Landlord’s request, Guarantor’s current financial statements, certified true, accurate and complete by the chief financial officer of Guarantor, including a balance sheet and profit and loss statement for the most recent prior year (collectively, the “Statements”), which Statements shall accurately and completely reflect the financial condition of Guarantor. Landlord agrees that it will keep the Statements confidential, except that Landlord shall have the right to deliver the same to any proposed purchaser or encumbrancer of the premises described in the Lease. Notwithstanding the foregoing, so long as Guarantor remains a public company on a stock exchange in the United States with Guarantor’s English language financial statements publicly available for review by Landlord, Guarantor’s obligations under this Section 2.3 shall be satisfied by providing a link to such publicly available information that is currently available.

 

 

 


 

ARTICLE 3. LANDLORD'S RIGHTS

 

Section 3.1. Enforcement

 

Notwithstanding the provisions of Section 2.2.1. above, Landlord reserves the right, in the event of any failure of Tenant to pay rental, property taxes, operating expenses and other sums which may become due and owing pursuant to the terms of the Lease, to proceed against Tenant or Guarantor, or both, and to enforce against Guarantor or Tenant, or both, any and all rights that Landlord may have to said rental, property taxes, operating expenses and other sums accrued pursuant to the terms of the Lease, without giving prior notice to Tenant or Guarantor, and without making demands therefor on either of them. Guarantor understands and agrees that its liability under this Guarantee shall be primary (and joint and several with Tenant) and that, in any right of action which may accrue to Landlord under the Lease or this Guarantee, Landlord at its option may proceed against Guarantor without having taken any action or obtained any judgment against Tenant.

 

Section 3.2. Guarantor's Waivers

 

In addition to any other waiver herein and except as otherwise specifically provided in this Guarantee, Guarantor hereby waives:

 

(a)
any and all notices, presentments, notice of nonpayment or nonperformance;

 

(b)
all defenses by reason of any disability of Tenant;

 

(c)
any and all rights it may have now or in the future, whether pursuant to Section 2845 of the California Civil Code or otherwise, to require or demand that Landlord pursue any right or remedy Landlord may have against Tenant or any other third party;

 

(d)
until such time as all obligations of Tenant under the Lease have been satisfied in full, any and all rights it may have for subrogation against, or reimbursement from, Tenant with respect to any sums paid hereunder; and

 

(e)
any and all right to the benefit of, or to participate in, any security held by Landlord now or in the future, or to require that such security be applied by Landlord either (i) prior to any action against Guarantor hereunder or (ii) as a credit or offset against sums owing hereunder.

 

ARTICLE 4. ALTERATION, MODIFICATION, OR ASSIGNMENT

 

Section 4.1. Effect of Extension, Modification, or Alteration of Lease

 

Guarantor understands and agrees that notwithstanding the provisions of Section 2819 of the California Civil Code, the obligations of Guarantor under this Guarantee shall in no way be affected by any extension, modification or alteration of the Lease, including, but not limited to, Tenant entering into any sublease thereunder, or Tenant's obligations under the Lease and each of its provisions, and any such extension, modification or alteration of the Lease, including Tenant entering into any sublease thereunder, shall in no way release or discharge Guarantor from any obligations accruing under this Guarantee. The term "Lease" shall include all amendments, modifications, alterations and extensions of the Lease.

 

Section 4.2. Assignment

 

Guarantor understands and agrees that any assignment of the Lease, or any rights or obligations accruing thereunder, shall in no way affect Guarantor's obligations under this Guarantee.

 

Section 4.3. Delay in Enforcement/Settlements

 

Guarantor understands and agrees that any failure or delay of Landlord to enforce any of its rights under the Lease or this Guarantee shall in no way affect Guarantor's obligations under this Guarantee, nor shall any settlement or release with Tenant or any third party release or discharge Guarantor from its obligations hereunder.

 

ARTICLE 5. TENANT'S INSOLVENCY

 

Section 5.1. Liability upon Tenant's Insolvency

 

Guarantor understands and agrees that in the event Tenant shall become insolvent or be adjudicated bankrupt,

 

 


 

whether by voluntary or involuntary petition, or shall a petition for organization, arrangement, or similar relief be filed against it, or if a receiver of any part of its property or assets is appointed by any court, Guarantor will remain obligated to pay to Landlord the amount of all unpaid rent, property taxes, operating expenses, and any other sums accrued and thereafter accruing under the Lease.

 

Section 5.2. Effect of Operation of Law

 

Any operation of any present or future debtor's relief act or similar act or law, or decision of any court, shall in no way abrogate or otherwise limit the obligation of Guarantor to perform any of the terms, covenants or conditions of this Guarantee.

 

ARTICLE 6. MISCELLANEOUS

 

Section 6.1. Notices

 

Any and all notices required under this Guarantee shall be made in writing, and shall be personally delivered, sent by reputable courier or overnight delivery service, or mailed, first-class mail, postage prepaid, to the party who is designated to receive such notice at the address set forth after their respective signatures on this Guarantee, or at such other place as may be designated by said party upon written notice from time to time hereafter.

 

Section 6.2. Extent of Obligations

 

Notwithstanding anything to the contrary in this Guarantee, it is understood and agreed that this Guarantee shall extend to any and all obligations of Tenant under the Lease.

 

Section 6.3. Assignability

 

This agreement may be assigned in whole or in part by Landlord at any time to any successor to Landlord's interest in the leased premises and/or to any lender of Landlord.

 

Section 6.4. Successors and Assigns

 

The terms and provisions of this Guarantee shall be binding upon and inure to the benefit of the successors and assigns of the parties hereto.

 

Section 6.5. Modification of Guarantee

 

This Guarantee constitutes the full and complete agreement between the parties hereto, and it is understood and agreed that the provisions hereof may only be modified by a writing executed by both parties hereto.

 

Section 6.6. Number and Gender

 

As used herein the singular shall include the plural, and as used herein the masculine shall include the feminine and neuter genders.

 

Section 6.7. Captions/Headings

 

Any captions or headings used in this Guarantee are for reference purposes only and are in no way to be construed as part of this Guarantee.

 

Section 6.8. Invalidity

 

If any term, provision, covenant or condition of this Guarantee is held to be void, invalid, or unenforceable, the remainder of the provisions shall remain in full force and effect and shall in no way be affected, impaired, or invalidated.

 

Section 6.9. Jurisdiction

 

The validity of this agreement and of any of its terms or provisions, as well as the rights and duties of the parties hereunder, shall be interpreted and construed pursuant to and in accordance with the laws of the State of California. Guarantor consents to the jurisdiction of any competent state or federal court in California where Landlord may elect to

 

 


 

initiate an action to enforce its rights hereunder.

 

Section 6.10. Joint and Several

 

Should more than one party execute this instrument as Guarantor, then the obligations of each such party shall be joint and several.

 

Section 6.11. Attorney's Fees

 

In the event it becomes necessary to enforce any of the terms and provisions of this Guarantee, whether or not suit be instituted, the prevailing party shall be entitled to its reasonable costs and expenses incurred with respect thereto, including, but not limited to, reasonable attorney's fees, and such other costs and expenses as may be allowed by law.

 

Section 6.12. Guarantee of Payment and Performance

 

It is understood and agreed that this Guarantee is unconditional and continuing, and a guarantee of payment and performance and not of collection.

 

Section 6.13. WAIVER OF JURY TRIAL/JUDICIAL REFERENCE LANDLORD AND GUARANTOR HEREBY ACKNOWLEDGE AND AGREE THAT THE PROVISIONS OF SECTION 14.6 OF THE LEASE SHALL BE INCORPORATED BY REFERENCE INTO THIS GUARANTEE, AND THAT ALL REFERENCES TO “TENANT” IN THAT SECTION SHALL BE DEEMED TO REFER TO GUARANTOR FOR PURPOSES HEREOF.

 

Section 6.14. COUNTERPARTS; DIGITAL SIGNATURES. This Guarantee may be executed in one or more counterparts, if applicable, each of which shall constitute an original and all of which shall be one and the same agreement. The parties agree to accept a digital image (including but not limited to an image in the form of a PDF, JPEG, GIF file, or other e-signature) of this Guarantee, if applicable, reflecting the execution of one or both of the parties, as a true and correct original.

 

[SIGNATURES ON FOLLOWING PAGE]

 

ARTICLE 7. EXECUTION

 

IN WITNESS WHEREOF, the undersigned have executed this Guarantee and made it effective as of December 22, 2021.

 

 

 

 

 

 


 

 

Connect Biopharma Holdings Limited a Cayman Islands corporation

 

By: /s/ Zheng Wei

 

Printed Name: Zheng Wei

 

Title: CEO

Address: 12265 El Camino Real, Suite 350 San Diego, CA 92130

 

 

 

 


 

EXHIBIT X

 

WORK LETTER BUILD TO SUIT

 

Landlord shall cause its contractor to construct the tenant improvements (the “Tenant Improvements”) for the Premises as shown in the space plan (the “Plan”) prepared by Gensler and dated October 13, 2021 (attached hereto as Exhibit X-1). Tenant acknowledges that Landlord has delivered an estimated schedule for construction of the Tenant Improvements. Landlord shall use commercially reasonable efforts to achieve substantial completion of the Tenant Improvements in accordance with such schedule, but makes no representations or warranties with respect thereto and shall not be liable to Tenant for any damages if the Tenant Improvements are not complete by the time periods set forth in such schedule. Tenant shall be invited to weekly construction meetings and will be notified of any potential delays. Any additional cost resulting from changes requested by Tenant shall be borne solely by Tenant and paid to Landlord prior to the commencement of construction. Unless otherwise specified in the Plan or hereafter agreed in writing by Landlord, all materials and finishes utilized in constructing the Tenant Improvements shall be Landlord's building standard. Should Landlord submit any additional plans, equipment specification sheets, or other matters to Tenant for approval or completion, Tenant shall respond in writing, as appropriate, within 5 business days unless a shorter period is provided herein. Tenant shall not unreasonably withhold its approval of any matter, and any disapproval shall be limited to items not previously approved by Tenant in the Plan or otherwise.

 

In the event that Tenant requests in writing a revision in the Plan or in any other plans hereafter approved by Tenant, then provided such change request is reasonably acceptable to Landlord, Landlord shall advise Tenant by written change order of any additional cost and/or prospective Tenant Delay (as defined below) such change would cause. Tenant shall approve or disapprove such change order in writing within 2 business days following its receipt. Tenant's approval of a change order shall not be effective unless accompanied by payment in full of the additional cost of the tenant improvement work resulting from the change order. It is understood that Landlord shall have no obligation to interrupt or modify the tenant improvement work pending Tenant's approval of a change order to the extent such change order impacts a critical path item or would delay Landlord’s timely completion of the Tenant Improvements.

 

Notwithstanding any provision in the Lease to the contrary, if Tenant fails to comply with any of the time periods specified in this Work Letter, requests any changes to the work, fails to make timely payment of any sum due hereunder, furnishes inaccurate or erroneous specifications or other information, or otherwise delays in any manner the completion of the Tenant Improvements or the issuance of an occupancy certificate (any of the foregoing being referred to in this Lease as a “Tenant Delay”), then Tenant shall bear any resulting increase in the construction cost or other expenses and the Commencement Date shall be deemed to have occurred for all purposes, including Tenant's obligation to pay Rent, as of the date Landlord reasonably determines that it would have been able to deliver the Premises to Tenant but for the collective Tenant Delays. Notwithstanding the foregoing, Landlord shall deliver written notice of the Tenant Delay within three (3) business days after becoming aware of the act or omission which will or may form the basis of a claim for Tenant Delay (the “Tenant Delay Notice”); provided, however, if Landlord does not deliver the Tenant Delay Notice within such three (3) Business Day period, such act or omission shall not constitute a Tenant Delay until the date that is three (3) Business Days following Tenant’s receipt of the Tenant Delay Notice.

 

Landlord shall permit Tenant and its agents to enter the Premises up to 5 days prior to the Commencement Date of the Lease in order that Tenant may perform any work to be performed by Tenant hereunder through its own contractors, subject to Landlord's prior written approval, and in a manner and upon terms and conditions and at times satisfactory to Landlord's representative. The foregoing license to enter the Premises prior to the Commencement Date is, however, conditioned upon Tenant's contractors and their subcontractors and employees working in harmony and not interfering with the work being performed by Landlord. If at any time that entry shall cause disharmony or interfere with the work being performed by Landlord, this license may be withdrawn by Landlord upon 24 hours written notice to Tenant. That license is further conditioned upon the compliance by Tenant's contractors with all requirements imposed by Landlord on third party contractors, including without limitation the maintenance by Tenant and its contractors and subcontractors of workers' compensation and public liability and property damage insurance in amounts and with companies and on forms satisfactory to Landlord, with certificates of such insurance being furnished to Landlord prior to proceeding with any such entry. The entry shall be deemed to be under all of the provisions of the Lease except as to the covenants to pay Rent unless Tenant commences business activities within the Premises. Landlord shall not be liable in any way for any injury, loss or damage which may occur to any such work being performed by Tenant, the same being solely at Tenant's risk. In no event shall the failure of Tenant's contractors to complete any work in the Premises extend the Commencement Date.

 

 

 


 

Tenant hereby designates Leeza Argier (largier@connectpharm.com), as its representative, agent and attorney-in-fact for the purpose of receiving notices, approving submittals and issuing requests for changes, and Landlord shall be entitled to rely upon authorizations and directives of such person(s) as if given by Tenant. Tenant may amend the designation of its construction representative(s) at any time upon delivery of written notice to Landlord.

 

 


 

EXHIBIT X-1

 

img24628583_1.jpg 

 

img24628583_2.jpg 

 

 

 


 

 

img24628583_3.jpg 

 

 


EX-8.1 9 cntb-ex8_1.htm EX-8.1 EX-8.1

Exhibit 8.1

List of Principal Subsidiaries of the Registrant

 

 

 

 

Wholly Owned Subsidiary

 

Place of Incorporation

Connect Biopharma HongKong Limited

 

Hong Kong

Connect Biopharm LLC

 

United States

Connect Biopharma Australia PTY LTD

 

Australia

Suzhou Connect Biopharma Co., Ltd.

 

People’s Republic of China

Connect Biopharma (Beijing), Ltd

 

People’s Republic of China

Connect Biopharma (Shanghai), Ltd

 

People’s Republic of China

Connect Biopharma (Shenzhen), Ltd

 

People’s Republic of China

 

 

Affiliated Entity Consolidated in the Registrant’s Financial Statements

 

 

Connect Union Inc.

 

British Virgin Islands

 


EX-12.1 10 cntb-ex12_1.htm EX-12.1 EX-12.1

 

Exhibit 12.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Zheng Wei, certify that:

1.
I have reviewed this annual report on Form 20-F of Connect Biopharma Holdings Limited;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
4.
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
[Paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];
c.
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
5.
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial re-porting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

 

 


 

 

 

 

Date: March 31, 2022

 

 /s/ Zheng Wei

 

 

Zheng Wei

 

 

Chief Executive Officer and Director

(Principal Executive Officer)

 

 

 


EX-12.2 11 cntb-ex12_2.htm EX-12.2 EX-12.2

 

Exhibit 12.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven Chan, certify that:

1.
I have reviewed this annual report on Form 20-F of Connect Biopharma Holdings Limited;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
4.
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
[Paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];
c.
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
5.
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial re-porting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

 

 

 

Date: March 31, 2022

 

 /s/ Steven Chan

 

 

Steven Chan

 

 

Chief Financial Officer

(Principal Financial Officer)

 

 

 


EX-13.1 12 cntb-ex13_1.htm EX-13.1 EX-13.1

 

Exhibit 13.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Connect Biopharma Holdings Limited (the “Company”) on Form 20-F for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Zheng Wei, Chief Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1.
The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

Date: March 31, 2022

 

 /s/ Zheng Wei

 

 

Zheng Wei

 

 

Chief Executive Officer and Director

(Principal Executive Officer)

 

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 

 


EX-13.2 13 cntb-ex13_2.htm EX-13.2 EX-13.2

 

Exhibit 13.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Connect Biopharma Holdings Limited (the “Company”) on Form 20-F for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Chan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1.
The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

Date: March 31, 2022

 

 /s/ Steven Chan

 

 

Steven Chan

 

 

Chief Financial Officer

(Principal Financial Officer)

 

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 

 


EX-15.1 14 cntb-ex15_1.htm EX-15.1 EX-15.1

 

Exhibit 15.1

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-254524) of Connect Biopharma Holdings Limited of our report dated March 31, 2022 relating to the financial statements, which appears in this Form 20-F.

 

 

/s/ PricewaterhouseCoopers Zhong Tian LLP
Beijing, the People’s Republic of China
March 31, 2022

 

 


GRAPHIC 15 img21858020_0.jpg GRAPHIC begin 644 img21858020_0.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBFR2)% M&TDCJB*,LS' ]2: '45PFO?$NQLB\&E1B\F&1YI.(P?;NWZ#WKS_4_%VN:L M6%Q?R+&W'E0G8N/3 Z_CFO0HY;6J*[T7F>7B,VH4G:/O/R_S/;KK6-,L<_:M M0M82.TDJ@_EFLI_'7AJ,X.J(?]V-S_(5X717='**?VI,\V>>U7\,4OQ_R/Y?\)]X9_Z"0_[]/\ _$T?\)]X:/\ S$A_WY?_ .)KRSP[X1U'Q')N MA7R;4'#W#CY1]!_$:]"33_"O@.!)KDK+>XRK. \K'U5>BCKSQ]:XZV%PU-\D M6Y2[*W^1W8?&XNK'VDE&,>[O_F=997\&H0>=;^:8ST+Q,F?IN S4TLL<*%Y9 M$C4?Q.P KR76/B9JEXS1ZE>5[Z17X_YGNL7CCPW*P5=4C!_VU9?U(K7M M=1LKT9M+RWG'_3*0-_(U\YTJLR.'1BK Y!!P0:F640^S)E0SVHOC@GZ:?YGT MI17B6C^/M;TME624N#DX]FZC]?I7J'A[Q9IWB*+%NYBN5&7MY/O#W'J M/UB+0='GU"5=^P (F<;V/ ' M^>V:Y8Q0H^JQ,1_S MS5G'Y@$5XWK&O:CKMR9KZX9QG*QCA$^@_P FLVO:I92K?O):^1\]6SR5[4HZ M>9[Q;>-/#MU((X]5A#'IY@*#\V %;B.LB!T8,I&00<@U\UUU'A+QC<^';@03 M%IM.<_/%U*?[2_X=ZBOE5HWI.[[,O#9WS2Y:RLNZ/;J*@L[RWU"TBNK6598) M5W(Z]ZGKQVFG9GOIIJZ"BBN&\>^,)M&*Z;IYVWY_3\>-*-& M5::A'%"FZD]CK;[5M/TQ=U[>P0>@D< GZ#J:QSX]\- X_M,?A$_^%>( MS3RW$S332/)*YRSNQ))]R:CKV8913M[TG<^?GGM5OW(JWG_2/H/3_$.D:JVV MRU""5_[F[#?]\GFM.OFM69&#*Q5E.00<$&O5?!/CH7WEZ7JLF+K[L,['B3V/ M^U_/Z]>7%9:Z4>>F[H[,%F\:TN2JK/\ [^BBBO+/:"LG4O$VC:1/Y%]?QQR MXSL +,/J #BM.:58())G^[&I8_0#-?.=W9F6/>%4>57;/:CX_\,C_ )B7_D&3_P")H'C[PR?^8E_Y!?\ ^)KP^BO2 M_LFCW?X?Y'D_VYB/Y5^/^9[C_P )]X:_Z"0_[]/_ /$T?\)]X:_Z"0_[]/\ M_$UX=11_9-'N_P /\@_MS$?RK\?\SWJW\6Z)=6EU=0WH:"U"F9_+8;=QP.W- M5O\ A/O#7_02'_?I_P#XFO-;*46OPZU-L?->7L=OGV4;_P#/UKF*RIY92DY7 M;T=OP7D:U'M-$^?-^S1[\]<[1U]ZY,=@X8=)Q>YW9;F%3%.49I:=C0HHKD]?\ 'VEZ M*S00_P"FW:\%(VPJGW;^@S7%3I3JRY8*[/1JUJ=&/-4=D=95>YO[.R&;J[@@ M'K+(%_G7B^J>.]>U-B!=FUBSPEM\GZ]3^=-6SR"=J<;^NA[K+XV\.0L5;58B1_<5F'Y@5%_PGWAK_H)#_OT__P 37AU% M="RFCW?X?Y'(\\K](K\?\SW'_A/O#7_02'_?I_\ XFC_ (3[PU_T$A_WZ?\ M^)KPZBG_ &31[O\ #_(/[[_ _R#^W,1_*OQ_S/[_#_(/[ MDZ_IFN&8:=<^=Y.-_P C+C.<=0/0UI5P?PKMU30KRXQ\TEQM)]E48_\ 0C7> M5XN)IQIU7".R/H,)5E6HQJ3W84445@=(4444 5K^_MM,LI;R[E$<$0RS'^0] M37B_BCQC>^(IFB4F"P4_)"I^][MZGVZ#]:TOB1K[7^K_ -EPR?Z+:'YPIX:3 MOGZ=/SKB*^@R_!QA%59K5_@?+9IF$JDW1IOW5OY_\ ****]0\4Z+PEX5F\37 MS L8K.+'G2@<^RCW/Z5ZY8>%=#TV(1P:;;GU>5 ['\3FH/!>F+I7A6RCV@23 M)Y\A ZEN>?H,#\*WZ^:QN+G4J-)^ZC[#+\#3HTE*2O)E/^R-,_Z!UI_WX7_" MC^R-,_Z!UI_WX7_"KE9/B765T+0KB^X,BC;$IZ%ST_Q_"N2#G.2BGJSNFJ<( MN61BSLQY)/4U'7T^&PL*$;+?JSXW&8R>)G=Z+H@I0"S!5!))P M .])75?#W35U#Q7"T@REJIG(]2, ?J0?PK:K45.#F^AA0I.K4C375G7^&/AW M9VUM'=:Q']HNF ;R6/R1^QQ]X^O:NN_L72MFS^S++;_=\AQ\YG.'A2JJ4%:Z"I+>XFM;A)[>1HY8S MN5U."#4=%>DU?1GD)M.Z/;_!GB@>(]-(FVK?08$RC@,.S#Z_SK&^*TP71K&# M/+W!?'^ZI'_LU<9X%OWL?%UEM/RSMY#CU#=/UP?PK>^*]P6U+3K;M'"TG_?1 MQ_[+7BK"JECHJ.VY]"\8ZV72G^TOH?YU[78:A:ZI91W=G*LL,@R&'\CZ&OG*MWPQXHN_#=[OC)DM7 M(\Z GAAZCT->;C<"JRYX?%^9Z^79DZ#]G4UC^7_ />:\+\1 MVO/\ [\'_ .*KJI?& MNGI(52&>11_$ #^9IG_ G%C_SZW'_CO^-> ^(+?\O5]W_ /7_LW!?R_B_\ MS-F^'KOX9MM(34$5H[AKB27RC\Y(P.,\<5E?\*GF_P"@O'_WX/\ \5797_BB MUT]H%D@F9I85E 7' /8\]>*J?\)Q8_\ /K7X M.3]Y;:;LR=(^&%K9WD=Q?WANU0[A"(MJD^_)R/:N\9ECC+NP5%&23P *R-+\ M2V6JW'V>-9(I2,JK@?-],5RWQ-UY[:VBT>W/9M2DDL-*D:*R!VM*O#3?X+_/]*X6BBOIZ-&% M&/+!'R6(Q%2O/GJ,*T=#T6ZU[5([&U&"W+N1PB]V-9U>L_"[3!;Z+/J#IA[F M3:C>J+Q_Z%G\JSQE?V%)S6_0UP&&^L5U![;LVM(\$Z'I,2C[''M>G5Y+\4[AGU^TM\_+%;;L>[,<_P A7=ESE+$+7N>=FJA'"RTW MM^9PE%%%?2'R 5[QH7AW3;/1+.)]/MC+Y*F5FB#%G(Y))YZYKPZR@^TW]O ! MDRRJGYD"OHZO'S:HTHQ3[GOY'2C)SFUV*?\ 9&F?] ZT_P"_"_X4?V1IG_0. MM/\ OPO^%7**\7GEW/H?9P[$<%O#;1^7!#'$F<[8U"C/T%2445-[EI6V"BBB M@ HHHH ^;KJ=KJ[FN'^_+(SM]2[LI%*F&5E&>XSP?Q&#^-4J M^SBTXIK8_/IIJ34MPJ2")KBXCA7[TCA!]2<5'5W1G6/7-/=R JW,9)/8;A1) MV3:""3DDSZ'CC6*)(T&%4!0/84ZBBOC#]!"O.?BO=.MKIMH#^[D=Y&'NH '_ M *$:]&K@?BGI[3Z1:7ZY/V:4HP_V7QS^:@?C77@&EB(W.#,U)X2?+_6IY111 M17U)\6%>F?">!=FJ7!'S9C0'T'S$_P!*\SKU3X4,/[+U!<\B921_P'_ZU<.9 M.V&E\OS/2RE)XN/S_(]!HHHKYD^Q,CQ5,L'A35'8X!MG7\6&!_.O :]=^)VI M);>'X[ -^]NI!E?]A>3^NVO(J^ARJ#C1I.G*E@%?[4K M_*QC5JZ3X?OM:M;V:R3S&M%5FC'5@<]/4\=*RJ]3^%%N5T[4;G'#S+&/^ C/ M_LPK;%UG1I.<=]#GP.'CB*ZIRVU_(\L(()!&".H-%>M>-? JZD)-2TN,+>#F M6$<"7W'^U_/ZUY,RLCLCJ593@@C!!IX;$PKQYH_<+%X2IAI\LMNC[B4445T' M(:NA^(+[0+B22T<&.5=LL3?=8?T([&LJBBDH13Z#?6&E MV>I2QYM;I=R./X3Z'T]1ZUEU]"V>G0-X=M=.N(EDA%LD3(XX("@5QXS%/#\K MM>YW9?@EBN=-VLM/4^>Z*ZOQ?X-G\/3&YMM\VG.>'QDQGT;^AKE*ZJ56-6*G M!Z''6HSHS<)JS"BBBK,C4N?$%]=Z#!I%PXDMX) \3'[R@ C;GN.>/2LNBBE& M,8_"BYSE-WD[FQX5@^T^*]+CQD?:$8C_ '3N_I7K/C6:2/1XT4D+)* _N "< M?F/TKSKX0_EM_\ 9J]AO;*#4+5K>X3=&WX$'U%?-9]%U;TH MO6Q]+DU-_5Y/NSR6@ DX'4UWG_"$:?\ \_%U_P!]+_A3X?!EA#/'*)KABC!L M,5P<'OQ7Q*RG$7U2^\]'V,CE_$SEM=F3^&)4C7V 4?US617H5WX1LKR[EN9+ MBX#R,6(!7 _2H?\ A"-/_P"?BZ_-?\*TK9;B)U)226K?4DQE;:,[F^\['+-7D/ MQ"L9+/Q="?3!1110 4444 %>(_$"Y^T^,KP9RL02,?@H)_4FO;J M^??$4XN?$FIS*KE,;U92[(\3/)VHQCW9F4445[Y\N;G@ZW M%SXOTR,]!,)/^^06_I7O->-_#2U%QXL$I_Y=X'D'U.%_]F->R5\]FLKUDNR/ MJLDA;#N7=A1117F'LA1110 4444 %%%% '"?$#PB^JQ_VK8)NNXEQ+$HYE4= MQ[C]?P%>2D%20001P0:^E:Y3Q)X$T_7F:YA/V2]/61%RK_[P]??K7K8+,%37 MLZFW<\/,#];T.]/U&QB@U"Y2VOD4*QE.U9,?Q!CQSZ5TXU33R,B_ MM2/^NR_XU\Z45YE3*JZ%?K>6,FUQPRMRKCT([BLY92TKPG MJ;1SQ2=IPTZZEOQ)X!CF&8#AQ_0^HK%KV;2_$VA>,K'[!?1QI M/(,-;3'J?5&[GZ(]V7X M,Y,1EUU[7"OFB_O7]?>#/$P\.:JS3AFL[@!9@O5<=&QWQD_G6%=V-W8 M2^5=VTL$G]V5"I/YU!7;.$*L'%ZIGG4ZDZ%13CHT?0=KX@T>]A66#4K5E89P M90"/J#R/QJEJOC+1-)A+/>QSRX^6*!@[$_AP/QKPFBO-64TU*[D['KRSRJXV M45ZBC0Z>#D*>& MF^GH/?\ +UKL=!^'FEZ2RSW?^G7*\@R+A%^B]_QS785Y.*S.ZY:/W_Y'MX+) MK-3Q'W?YD:1QVT"QQJJ11KA5' 4 =*^<;B4SW,LS')D_>%;9;3PKID2C'^CJY^K#_P"==K17B4:TZ4N>#U/HZ]"%>#A46A\UR1O#*T4J,DB$ MJRL,$'T(IM>S^,O!46O1->686+44'7H)@.Q]_0_G[>.W%O-:7#P7$3Q2H<,C MC!!KZ;"XJ&(C=;]4?'XS!3PL[2U71D5%%* 6( !)/ KI.(M:5:K?:O9VC9V MS3I&V/0L :^BZ\Q\">"KJ.^BU?5(FA6([H(7&&9O[Q';';_.?3J^>S.M&I44 M8N]CZO)L/.E2/^,O!4FAR->V2M)IS M'IG+0D]C[>A_/W]DILD:2QM'(JNC AE89!'H:Y<-BIX>5UMU1V8S!PQ4.66_ M1GS917;^-/ [Z2SZAIJ,]B3EXQR8?_L??M7$5]/1K0K1YX,^/KX>=";A-:A1 M15JPTZ\U2Y6VLK>2>4_PH.GN3V'N:T;25V8QBY.R6IV_PIMB^J:A==HX5C_% MCG_V6NTU_P 41:-(+>*(37)&2"DF*1P]U,0\S#H#CA1 M[#^IKBO$BR+XBO?,!R9,C/ICC],5\#Q'F$Z=ZE'J[7^1^B\.X!."IUNBO;YF MK_PGFI?\^UI_WRW_ ,56CHGBV\U&]>.XAMTACA:5V0'.!]37"5N:$FS3=9NR M--VC9[?>[%[_ (3S4O\ GVM/ M^^6_^*H'CS4C:K'K&G+=(A0Y* MNF<[6'^16;XP\,IXCTL+'M2\ART+GH?53['^>*D\(6,MCH2B92KS.9=IZ@$ M#]!FMZOM\#6JJG"K+25D?)8VA2G*=+>)\WW-M/9W,EMQ]1[?RKR_6/ .MZ4[-% ;V#/$D R<>Z]1^OUK MZO#9A2JJTG9GQN+RNM0=XKFC_6YRU>E>!?&UG:Z>FDZI*(?*.(9F^Z5)SACV MQGKTQ^OFS*R,592K X((P0:2NBO0A7ARR.7"XF>&J<\#Z)75M-==RZA:,#W$ MRG^M._M/3_\ G^MO^_R_XU\Z45YO]D1_G_ ];^WI?R?B?1?]IZ?_ ,_UM_W^ M7_&C^T]/_P"?ZV_[_+_C7SI11_9$?Y_P#^WI?R?C_P ^C8KZSFD$<5U!(YZ M*D@)/X58KQKX:0&;Q:K_ //&!W_DO_LU>RUYF+PZH5.1.Y[&!Q3Q-+VC5M2. MXE$%M+*3@(A8GZ#-?-Y))))R3UKWOQ9<&V\)ZI(#@FW9!_P+Y?ZUX'7J91'W M92/'SV=YPCY/^OP"BBBO7/ /1?A/!F[U.XQ]U$0'ZDG_ -EKU"N%^%D.SP_= M38YDN2,^H"C_ !-=U7R^/ES8B1]IED.7"P_KJ%%%%<9WA1110 4444 %%%% M!1110 50N]$TN_S]JTZUF)_B>($_GUJ_134G%W3)E&,E:2N=F_F:Z&BK^L5O MYW][,EA*"^PON15M=,L+$?Z)96\'_7*)5_D*M445DVWJS=))604444AE>^LK M?4;*6TNDWP2C#KN(R/J.:P?^%?\ AG_H&_\ D:3_ .*KIJ*TA5J05HR:^9E. MA2J.\XI^J.9_X5_X9_Z!O_D:3_XJNCAB2"&.&-=L<:A5'H!P*?11.K.?QML= M.C3I_!%+T04445F:!5#4=$TS5E O[*&:TJ*TE7JR5I2; M^9G'#T8.\8)/T04445D;!1110 $9)>>#_ _?2F6?2X=YZF/*9_[Y(K;H MJHSE!WB[$3IPJ*TTGZG.1^ _#4;!AIBD@Y^:5R/U-;MK9VUE$(K6WB@C'\,: M!1^E3454ZLY_%)LF%&G3^"*7H@JG>:58Z@RM=6L,I1=XNS,K_ (1K1O\ H'Q?K_C4R:)IL5M+;I:1K#+@R(,X;'(J_16:PU%; M07W(MUZKWD_O,K_A&M&_Z!\7Z_XU)#H.E6\HDBL80XZ$C./SK1HI+#44[J"^ MY Z]5Z.3^]A1116YD%%%% %6ZTVQOAB[L[>?_KK&&_G61)X&\-RL6.EQ@G^Z M[*/R!KH:*TC5J0^&37S,IT:4_CBGZHYG_A7_ (9_Z!W_ )&D_P#BJ/\ A7_A MG_H'?^1I/_BJZ:BK^LUOYW][(^J8?_GVON1S/_"O_#/_ $#O_(TG_P 51_PK M_P ,_P#0._\ (TG_ ,57344?6:W\[^]A]4P__/M?3)( MNUF\QFR,Y[DUK445E*<4WYHYG_A7_ (9_ MZ!W_ )&D_P#BJ/\ A7_AG_H'?^1I/_BJZ:BK^LUOYW][(^J8?_GVON14TW3+ M/2+-;2QA\J $L%W$\GKR>:MT45BVY.[-XQ459*R"BBBD,**** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;Q7JD*^/K: MVO=0N;73HH!YWDNXY(8CA>>ZUZ37 06VJV/CS4]9ET:ZN8I 8H3$5Z?* >3Z M+^M=F#LI2D^W>WYG!C^9QC&/5J^C>GG8@?4?!6QL:[JF<<8FN,_J*T/ DU_< MSWTHU![G2=Q%N+B423 YXS@G;QV/Y5JR:_J;(1'X7OGV@X[=; M)Q^^[=_0JZU=3W'Q-TBPBN94A2,221HY )&YN0.O05>\1>(KV+6;70-&1#J% MP-S2R#*Q+R,96TC\K^8[5N2$C)F34-:U2ZF;[Q6X,2?@J]*J:KX;N]-M);_1M:U"*:!#)Y,\QEC< 9(PW M]OR17!F(1&U$Q$+@I/Y5UM_HS:5X'N=+T M>!Y9#$8U&1N<\]ZZ*'1=*MGWP:99Q-_>C@ M53^@JCXPMKN\\+7MM8PM+/*%547J1N&?TS6?MHU+4WU:U?0U]A.GS55I9/17 MU_KT.3\%>+]+T[1'CU?5)#=/,S8D620A< #D ^AKHC\0/# '_(3S_P!L)/\ MXFM#PQ8/IGAJPM)$*2)%EU/9B6!HU1>IWK[K_(5*&(I8=>\M%MRN__ *5^ASGPUFN;S3+^\N9YI2]QM7S'+8P M>,_[U:GB;Q%)IQBTW3(_M&KW7$48&=@_OM^OY>@JGHT&I>'? L$5OIDDVI$L M3"".&+'!;GH!CI3-(\#V\L!O=?$ESJEP?,E<3,FS/\(VD?YZ<5<_9.M*K/:^ MB[_\ BG[94(48+WK7;>EK_K^1EM_:7@C6M.N;^_N+RQNT\JZ:1V94D)R2,^G M4=R :]%#!E# @J1D$>EQX^F*FLX5H*<7[RT>ROV9=!5*%1TY+W7JMW;N MKVZ[G+Z'J%AJVKZOM[!3Y4Y/75._Y_P"1E>!9]6FU"^S- M=W&B,$]1C.>W3I6?X@&I:]XXO-.L+N> 6=GN"QR%0S ;AT/&;[69[4V^MV#P7,7 F&-DH]>#P?TK-\,Z5?Q^+M=U6]MVA69MD!8CYUW' MG\E7\ZE5%&I.H[72TZ]OO*=)SI4Z2;:;UW5M]/(T?!FL'6O#=O-(Q:XB_\]/*^]_3H7S5IT73DG[J=WWMM;UZ_<1?#G[3)X9-S=3 MRS-/.S*9'+$*,+CGW!I?$6MW5W??\([H1S?2#_2)QTMT[G/8_P LCN:B2'6M M$\%Z?INE6+R:A)'AWR-L!8Y).>IR3 MT(XHDZ2J2K3?5V6_S?E^8159THT*:V2NWI\D[/7\O4S=-N+KPGXN_LF_O)[B MPOE7[//.Q.'Z8_/C\5KOJXOQ#X"L)](E;3(9$OHQOB+3N^<=5^8D<_SQ6]X< MN-1GT6'^U;9X+R,;) W\>.C?C_/-9XCDJ152+UV?3YV-<*JE*;HS6FZZ_*YK M4445QG>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 %44 ?_]D! end GRAPHIC 16 img22781541_0.jpg GRAPHIC begin 644 img22781541_0.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBFR2)% M&TDCJB*,LS' ]2: '45PFO?$NQLB\&E1B\F&1YI.(P?;NWZ#WKS_4_%VN:L M6%Q?R+&W'E0G8N/3 Z_CFO0HY;6J*[T7F>7B,VH4G:/O/R_S/;KK6-,L<_:M M0M82.TDJ@_EFLI_'7AJ,X.J(?]V-S_(5X717='**?VI,\V>>U7\,4OQ_R/Y?\)]X9_Z"0_[]/\ _$T?\)]X:/\ S$A_WY?_ .)KRSP[X1U'Q')N MA7R;4'#W#CY1]!_$:]"33_"O@.!)KDK+>XRK. \K'U5>BCKSQ]:XZV%PU-\D M6Y2[*W^1W8?&XNK'VDE&,>[O_F=997\&H0>=;^:8ST+Q,F?IN S4TLL<*%Y9 M$C4?Q.P KR76/B9JEXS1ZE>5[Z17X_YGNL7CCPW*P5=4C!_VU9?U(K7M M=1LKT9M+RWG'_3*0-_(U\YTJLR.'1BK Y!!P0:F640^S)E0SVHOC@GZ:?YGT MI17B6C^/M;TME624N#DX]FZC]?I7J'A[Q9IWB*+%NYBN5&7MY/O#W'J M/UB+0='GU"5=^P (F<;V/ ' M^>V:Y8Q0H^JQ,1_S MS5G'Y@$5XWK&O:CKMR9KZX9QG*QCA$^@_P FLVO:I92K?O):^1\]6SR5[4HZ M>9[Q;>-/#MU((X]5A#'IY@*#\V %;B.LB!T8,I&00<@U\UUU'A+QC<^';@03 M%IM.<_/%U*?[2_X=ZBOE5HWI.[[,O#9WS2Y:RLNZ/;J*@L[RWU"TBNK6598) M5W(Z]ZGKQVFG9GOIIJZ"BBN&\>^,)M&*Z;IYVWY_3\>-*-& M5::A'%"FZD]CK;[5M/TQ=U[>P0>@D< GZ#J:QSX]\- X_M,?A$_^%>( MS3RW$S332/)*YRSNQ))]R:CKV8913M[TG<^?GGM5OW(JWG_2/H/3_$.D:JVV MRU""5_[F[#?]\GFM.OFM69&#*Q5E.00<$&O5?!/CH7WEZ7JLF+K[L,['B3V/ M^U_/Z]>7%9:Z4>>F[H[,%F\:TN2JK/\ [^BBBO+/:"LG4O$VC:1/Y%]?QQR MXSL +,/J #BM.:58())G^[&I8_0#-?.=W9F6/>%4>57;/:CX_\,C_ )B7_D&3_P")H'C[PR?^8E_Y!?\ ^)KP^BO2 M_LFCW?X?Y'D_VYB/Y5^/^9[C_P )]X:_Z"0_[]/_ /$T?\)]X:_Z"0_[]/\ M_$UX=11_9-'N_P /\@_MS$?RK\?\SWJW\6Z)=6EU=0WH:"U"F9_+8;=QP.W- M5O\ A/O#7_02'_?I_P#XFO-;*46OPZU-L?->7L=OGV4;_P#/UKF*RIY92DY7 M;T=OP7D:U'M-$^?-^S1[\]<[1U]ZY,=@X8=)Q>YW9;F%3%.49I:=C0HHKD]?\ 'VEZ M*S00_P"FW:\%(VPJGW;^@S7%3I3JRY8*[/1JUJ=&/-4=D=95>YO[.R&;J[@@ M'K+(%_G7B^J>.]>U-B!=FUBSPEM\GZ]3^=-6SR"=J<;^NA[K+XV\.0L5;58B1_<5F'Y@5%_PGWAK_H)#_OT__P 37AU% M="RFCW?X?Y'(\\K](K\?\SW'_A/O#7_02'_?I_\ XFC_ (3[PU_T$A_WZ?\ M^)KPZBG_ &31[O\ #_(/[[_ _R#^W,1_*OQ_S/[_#_(/[ MDZ_IFN&8:=<^=Y.-_P C+C.<=0/0UI5P?PKMU30KRXQ\TEQM)]E48_\ 0C7> M5XN)IQIU7".R/H,)5E6HQJ3W84445@=(4444 5K^_MM,LI;R[E$<$0RS'^0] M37B_BCQC>^(IFB4F"P4_)"I^][MZGVZ#]:TOB1K[7^K_ -EPR?Z+:'YPIX:3 MOGZ=/SKB*^@R_!QA%59K5_@?+9IF$JDW1IOW5OY_\ ****]0\4Z+PEX5F\37 MS L8K.+'G2@<^RCW/Z5ZY8>%=#TV(1P:;;GU>5 ['\3FH/!>F+I7A6RCV@23 M)Y\A ZEN>?H,#\*WZ^:QN+G4J-)^ZC[#+\#3HTE*2O)E/^R-,_Z!UI_WX7_" MC^R-,_Z!UI_WX7_"KE9/B765T+0KB^X,BC;$IZ%ST_Q_"N2#G.2BGJSNFJ<( MN61BSLQY)/4U'7T^&PL*$;+?JSXW&8R>)G=Z+H@I0"S!5!))P M .])75?#W35U#Q7"T@REJIG(]2, ?J0?PK:K45.#F^AA0I.K4C375G7^&/AW M9VUM'=:Q']HNF ;R6/R1^QQ]X^O:NN_L72MFS^S++;_=\AQ\YG.'A2JJ4%:Z"I+>XFM;A)[>1HY8S MN5U."#4=%>DU?1GD)M.Z/;_!GB@>(]-(FVK?08$RC@,.S#Z_SK&^*TP71K&# M/+W!?'^ZI'_LU<9X%OWL?%UEM/RSMY#CU#=/UP?PK>^*]P6U+3K;M'"TG_?1 MQ_[+7BK"JECHJ.VY]"\8ZV72G^TOH?YU[78:A:ZI91W=G*LL,@R&'\CZ&OG*MWPQXHN_#=[OC)DM7 M(\Z GAAZCT->;C<"JRYX?%^9Z^79DZ#]G4UC^7_ />:\+\1 MVO/\ [\'_ .*KJI?& MNGI(52&>11_$ #^9IG_ G%C_SZW'_CO^-> ^(+?\O5]W_ /7_LW!?R_B_\ MS-F^'KOX9MM(34$5H[AKB27RC\Y(P.,\<5E?\*GF_P"@O'_WX/\ \5797_BB MUT]H%D@F9I85E 7' /8\]>*J?\)Q8_\ /K7X M.3]Y;:;LR=(^&%K9WD=Q?WANU0[A"(MJD^_)R/:N\9ECC+NP5%&23P *R-+\ M2V6JW'V>-9(I2,JK@?-],5RWQ-UY[:VBT>W/9M2DDL-*D:*R!VM*O#3?X+_/]*X6BBOIZ-&% M&/+!'R6(Q%2O/GJ,*T=#T6ZU[5([&U&"W+N1PB]V-9U>L_"[3!;Z+/J#IA[F M3:C>J+Q_Z%G\JSQE?V%)S6_0UP&&^L5U![;LVM(\$Z'I,2C[''M>G5Y+\4[AGU^TM\_+%;;L>[,<_P A7=ESE+$+7N>=FJA'"RTW MM^9PE%%%?2'R 5[QH7AW3;/1+.)]/MC+Y*F5FB#%G(Y))YZYKPZR@^TW]O ! MDRRJGYD"OHZO'S:HTHQ3[GOY'2C)SFUV*?\ 9&F?] ZT_P"_"_X4?V1IG_0. MM/\ OPO^%7**\7GEW/H?9P[$<%O#;1^7!#'$F<[8U"C/T%2445-[EI6V"BBB M@ HHHH ^;KJ=KJ[FN'^_+(SM]2[LI%*F&5E&>XSP?Q&#^-4J M^SBTXIK8_/IIJ34MPJ2")KBXCA7[TCA!]2<5'5W1G6/7-/=R JW,9)/8;A1) MV3:""3DDSZ'CC6*)(T&%4!0/84ZBBOC#]!"O.?BO=.MKIMH#^[D=Y&'NH '_ M *$:]&K@?BGI[3Z1:7ZY/V:4HP_V7QS^:@?C77@&EB(W.#,U)X2?+_6IY111 M17U)\6%>F?">!=FJ7!'S9C0'T'S$_P!*\SKU3X4,/[+U!<\B921_P'_ZU<.9 M.V&E\OS/2RE)XN/S_(]!HHHKYD^Q,CQ5,L'A35'8X!MG7\6&!_.O :]=^)VI M);>'X[ -^]NI!E?]A>3^NVO(J^ARJ#C1I.G*E@%?[4K M_*QC5JZ3X?OM:M;V:R3S&M%5FC'5@<]/4\=*RJ]3^%%N5T[4;G'#S+&/^ C/ M_LPK;%UG1I.<=]#GP.'CB*ZIRVU_(\L(()!&".H-%>M>-? JZD)-2TN,+>#F M6$<"7W'^U_/ZUY,RLCLCJ593@@C!!IX;$PKQYH_<+%X2IAI\LMNC[B4445T' M(:NA^(+[0+B22T<&.5=LL3?=8?T([&LJBBDH13Z#?6&E MV>I2QYM;I=R./X3Z'T]1ZUEU]"V>G0-X=M=.N(EDA%LD3(XX("@5QXS%/#\K MM>YW9?@EBN=-VLM/4^>Z*ZOQ?X-G\/3&YMM\VG.>'QDQGT;^AKE*ZJ56-6*G M!Z''6HSHS<)JS"BBBK,C4N?$%]=Z#!I%PXDMX) \3'[R@ C;GN.>/2LNBBE& M,8_"BYSE-WD[FQX5@^T^*]+CQD?:$8C_ '3N_I7K/C6:2/1XT4D+)* _N "< M?F/TKSKX0_EM_\ 9J]AO;*#4+5K>X3=&WX$'U%?-9]%U;TH MO6Q]+DU-_5Y/NSR6@ DX'4UWG_"$:?\ \_%U_P!]+_A3X?!EA#/'*)KABC!L M,5P<'OQ7Q*RG$7U2^\]'V,CE_$SEM=F3^&)4C7V 4?US617H5WX1LKR[EN9+ MBX#R,6(!7 _2H?\ A"-/_P"?BZ_-?\*TK9;B)U)226K?4DQE;:,[F^\['+-7D/ MQ"L9+/Q="?3!1110 4444 %>(_$"Y^T^,KP9RL02,?@H)_4FO;J M^??$4XN?$FIS*KE,;U92[(\3/)VHQCW9F4445[Y\N;G@ZW M%SXOTR,]!,)/^^06_I7O->-_#2U%QXL$I_Y=X'D'U.%_]F->R5\]FLKUDNR/ MJLDA;#N7=A1117F'LA1110 4444 %%%% '"?$#PB^JQ_VK8)NNXEQ+$HYE4= MQ[C]?P%>2D%20001P0:^E:Y3Q)X$T_7F:YA/V2]/61%RK_[P]??K7K8+,%37 MLZFW<\/,#];T.]/U&QB@U"Y2VOD4*QE.U9,?Q!CQSZ5TXU33R,B_ MM2/^NR_XU\Z45YE3*JZ%?K>6,FUQPRMRKCT([BLY92TKPG MJ;1SQ2=IPTZZEOQ)X!CF&8#AQ_0^HK%KV;2_$VA>,K'[!?1QI M/(,-;3'J?5&[GZ(]V7X M,Y,1EUU[7"OFB_O7]?>#/$P\.:JS3AFL[@!9@O5<=&QWQD_G6%=V-W8 M2^5=VTL$G]V5"I/YU!7;.$*L'%ZIGG4ZDZ%13CHT?0=KX@T>]A66#4K5E89P M90"/J#R/QJEJOC+1-)A+/>QSRX^6*!@[$_AP/QKPFBO-64TU*[D['KRSRJXV M45ZBC0Z>#D*>& MF^GH/?\ +UKL=!^'FEZ2RSW?^G7*\@R+A%^B]_QS785Y.*S.ZY:/W_Y'MX+) MK-3Q'W?YD:1QVT"QQJJ11KA5' 4 =*^<;B4SW,LS')D_>%;9;3PKID2C'^CJY^K#_P"==K17B4:TZ4N>#U/HZ]"%>#A46A\UR1O#*T4J,DB$ MJRL,$'T(IM>S^,O!46O1->686+44'7H)@.Q]_0_G[>.W%O-:7#P7$3Q2H<,C MC!!KZ;"XJ&(C=;]4?'XS!3PL[2U71D5%%* 6( !)/ KI.(M:5:K?:O9VC9V MS3I&V/0L :^BZ\Q\">"KJ.^BU?5(FA6([H(7&&9O[Q';';_.?3J^>S.M&I44 M8N]CZO)L/.E2/^,O!4FAR->V2M)IS M'IG+0D]C[>A_/W]DILD:2QM'(JNC AE89!'H:Y<-BIX>5UMU1V8S!PQ4.66_ M1GS917;^-/ [Z2SZAIJ,]B3EXQR8?_L??M7$5]/1K0K1YX,^/KX>=";A-:A1 M15JPTZ\U2Y6VLK>2>4_PH.GN3V'N:T;25V8QBY.R6IV_PIMB^J:A==HX5C_% MCG_V6NTU_P 41:-(+>*(37)&2"DF*1P]U,0\S#H#CA1 M[#^IKBO$BR+XBO?,!R9,C/ICC],5\#Q'F$Z=ZE'J[7^1^B\.X!."IUNBO;YF MK_PGFI?\^UI_WRW_ ,56CHGBV\U&]>.XAMTACA:5V0'.!]37"5N:$FS3=9NR M--VC9[?>[%[_ (3S4O\ GVM/ M^^6_^*H'CS4C:K'K&G+=(A0Y* MNF<[6'^16;XP\,IXCTL+'M2\ART+GH?53['^>*D\(6,MCH2B92KS.9=IZ@$ M#]!FMZOM\#6JJG"K+25D?)8VA2G*=+>)\WW-M/9W,EMQ]1[?RKR_6/ .MZ4[-% ;V#/$D R<>Z]1^OUK MZO#9A2JJTG9GQN+RNM0=XKFC_6YRU>E>!?&UG:Z>FDZI*(?*.(9F^Z5)SACV MQGKTQ^OFS*R,592K X((P0:2NBO0A7ARR.7"XF>&J<\#Z)75M-==RZA:,#W$ MRG^M._M/3_\ G^MO^_R_XU\Z45YO]D1_G_ ];^WI?R?B?1?]IZ?_ ,_UM_W^ M7_&C^T]/_P"?ZV_[_+_C7SI11_9$?Y_P#^WI?R?C_P ^C8KZSFD$<5U!(YZ M*D@)/X58KQKX:0&;Q:K_ //&!W_DO_LU>RUYF+PZH5.1.Y[&!Q3Q-+VC5M2. MXE$%M+*3@(A8GZ#-?-Y))))R3UKWOQ9<&V\)ZI(#@FW9!_P+Y?ZUX'7J91'W M92/'SV=YPCY/^OP"BBBO7/ /1?A/!F[U.XQ]U$0'ZDG_ -EKU"N%^%D.SP_= M38YDN2,^H"C_ !-=U7R^/ES8B1]IED.7"P_KJ%%%%<9WA1110 4444 %%%% M!1110 50N]$TN_S]JTZUF)_B>($_GUJ_134G%W3)E&,E:2N=F_F:Z&BK^L5O MYW][,EA*"^PON15M=,L+$?Z)96\'_7*)5_D*M445DVWJS=))604444AE>^LK M?4;*6TNDWP2C#KN(R/J.:P?^%?\ AG_H&_\ D:3_ .*KIJ*TA5J05HR:^9E. MA2J.\XI^J.9_X5_X9_Z!O_D:3_XJNCAB2"&.&-=L<:A5'H!P*?11.K.?QML= M.C3I_!%+T04445F:!5#4=$TS5E O[*&:TJ*TE7JR5I2; M^9G'#T8.\8)/T04445D;!1110 $9)>>#_ _?2F6?2X=YZF/*9_[Y(K;H MJHSE!WB[$3IPJ*TTGZG.1^ _#4;!AIBD@Y^:5R/U-;MK9VUE$(K6WB@C'\,: M!1^E3454ZLY_%)LF%&G3^"*7H@JG>:58Z@RM=6L,I1=XNS,K_ (1K1O\ H'Q?K_C4R:)IL5M+;I:1K#+@R(,X;'(J_16:PU%; M07W(MUZKWD_O,K_A&M&_Z!\7Z_XU)#H.E6\HDBL80XZ$C./SK1HI+#44[J"^ MY Z]5Z.3^]A1116YD%%%% %6ZTVQOAB[L[>?_KK&&_G61)X&\-RL6.EQ@G^Z M[*/R!KH:*TC5J0^&37S,IT:4_CBGZHYG_A7_ (9_Z!W_ )&D_P#BJ/\ A7_A MG_H'?^1I/_BJZ:BK^LUOYW][(^J8?_GVON1S/_"O_#/_ $#O_(TG_P 51_PK M_P ,_P#0._\ (TG_ ,57344?6:W\[^]A]4P__/M?3)( MNUF\QFR,Y[DUK445E*<4WYHYG_A7_ (9_ MZ!W_ )&D_P#BJ/\ A7_AG_H'?^1I/_BJZ:BK^LUOYW][(^J8?_GVON14TW3+ M/2+-;2QA\J $L%W$\GKR>:MT45BVY.[-XQ459*R"BBBD,**** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;Q7JD*^/K: MVO=0N;73HH!YWDNXY(8CA>>ZUZ37 06VJV/CS4]9ET:ZN8I 8H3$5Z?* >3Z M+^M=F#LI2D^W>WYG!C^9QC&/5J^C>GG8@?4?!6QL:[JF<<8FN,_J*T/ DU_< MSWTHU![G2=Q%N+B423 YXS@G;QV/Y5JR:_J;(1'X7OGV@X[=; M)Q^^[=_0JZU=3W'Q-TBPBN94A2,221HY )&YN0.O05>\1>(KV+6;70-&1#J% MP-S2R#*Q+R,96TC\K^8[5N2$C)F34-:U2ZF;[Q6X,2?@J]*J:KX;N]-M);_1M:U"*:!#)Y,\QEC< 9(PW M]OR17!F(1&U$Q$+@I/Y5UM_HS:5X'N=+T M>!Y9#$8U&1N<\]ZZ*'1=*MGWP:99Q-_>C@ M53^@JCXPMKN\\+7MM8PM+/*%547J1N&?TS6?MHU+4WU:U?0U]A.GS55I9/17 MU_KT.3\%>+]+T[1'CU?5)#=/,S8D620A< #D ^AKHC\0/# '_(3S_P!L)/\ MXFM#PQ8/IGAJPM)$*2)%EU/9B6!HU1>IWK[K_(5*&(I8=>\M%MRN__ *5^ASGPUFN;S3+^\N9YI2]QM7S'+8P M>,_[U:GB;Q%)IQBTW3(_M&KW7$48&=@_OM^OY>@JGHT&I>'? L$5OIDDVI$L M3"".&+'!;GH!CI3-(\#V\L!O=?$ESJEP?,E<3,FS/\(VD?YZ<5<_9.M*K/:^ MB[_\ BG[94(48+WK7;>EK_K^1EM_:7@C6M.N;^_N+RQNT\JZ:1V94D)R2,^G M4=R :]%#!E# @J1D$>EQX^F*FLX5H*<7[RT>ROV9=!5*%1TY+W7JMW;N MKVZ[G+Z'J%AJVKZOM[!3Y4Y/75._Y_P"1E>!9]6FU"^S- M=W&B,$]1C.>W3I6?X@&I:]XXO-.L+N> 6=GN"QR%0S ;AT/&;[69[4V^MV#P7,7 F&-DH]>#P?TK-\,Z5?Q^+M=U6]MVA69MD!8CYUW' MG\E7\ZE5%&I.H[72TZ]OO*=)SI4Z2;:;UW5M]/(T?!FL'6O#=O-(Q:XB_\]/*^]_3H7S5IT73DG[J=WWMM;UZ_<1?#G[3)X9-S=3 MRS-/.S*9'+$*,+CGW!I?$6MW5W??\([H1S?2#_2)QTMT[G/8_P LCN:B2'6M M$\%Z?INE6+R:A)'AWR-L!8Y).>IR3 MT(XHDZ2J2K3?5V6_S?E^8159THT*:V2NWI\D[/7\O4S=-N+KPGXN_LF_O)[B MPOE7[//.Q.'Z8_/C\5KOJXOQ#X"L)](E;3(9$OHQOB+3N^<=5^8D<_SQ6]X< MN-1GT6'^U;9X+R,;) W\>.C?C_/-9XCDJ152+UV?3YV-<*JE*;HS6FZZ_*YK M4445QG>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 %44 ?_]D! end GRAPHIC 17 img24628583_0.jpg GRAPHIC begin 644 img24628583_0.jpg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img24628583_1.jpg GRAPHIC begin 644 img24628583_1.jpg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end GRAPHIC 19 img24628583_2.jpg GRAPHIC begin 644 img24628583_2.jpg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end GRAPHIC 20 img24628583_3.jpg GRAPHIC begin 644 img24628583_3.jpg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end GRAPHIC 21 img67639792_0.jpg GRAPHIC begin 644 img67639792_0.jpg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end GRAPHIC 22 img67639792_1.jpg GRAPHIC begin 644 img67639792_1.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" #[ ET# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@#\ M?? /_!4#4?B1\=/%'P\\._ 6*X^'7@OXW>-_@;XS\;VWQH\':G\6? NH> KS MQ'I'B'XC>.?V(_#/P?_ +9\.;/^$Q/B)?$/@?QG\2_A/HWADK M\//AWXSL=(C"^(?^$W\4_P#"*_\ "1>%QXP72S+F/P#Q]_P3'^+GQ8^.'ACQ M9\3O''[/WB;PAX0^.2_%JP^,\'P1/AO]LO7? UIJQ\1#]G[Q%\0?#6N^&_#N ML^%CG_A$/^$O.)#X4^4Z.2NT>T?!O]C+]J_X46GPP^"I_:PT!_V6_@=:ZAI? M@+P_H'PJ:Q^,7Q!\(?V!K7AKP1\.OC9XU_X2K_A#[SPMX-76+8$^"O OA8^* MQX;L W_"+@ ^??AO\ \%A]1\5>'_A3XJ\7_LSZ-X1\(?&KP9XYUGX>WOA+ M]IGX=?$7QT+[P)\,?'OQ6.E>-?AMHOA?PWXB\%Z*_ACP-KK3>(69U\-;/G3+ MDC>T7_@J]XYU#X!^*_VB=7_9E^&^G> ?#?P-?XY6VF^&OVQ_AUXY\=WFC,NC MWN@:#J_@K1/AU_;_ (8WMKR-)J,@9/#13#HQ(KGOA[_P2)/P?\#_ %N/@[X MC^'/@GXS^&?@=XW_ &GQYKW]D GP_X7\+*VC!,DH"<^)\?(RA01W^O_P#!5'P)9_%W3/ 7@OP* M/'OA+7-?_9>TCP]\2-/\:VEC8:]I_P"U1\+_ (P?%7P_KZZ2=$9E&@6/PGRX M9F\S_A(DYTHJQ?@-,_X)^_'_ %?2O"GASQ?IO[!G@30?"_Q?_9W^+5U,OAGXI\8CX$_%OPUX\&A^.-4O/%?B4ZTK:'I&L;'*C'BCQ [ A/F;SOPY M_P $;+WX?_&CQMXP^'WQ3T32OA3K/[2/PA^-/@/P!J>BZ]<7O@3POX"\&_M! M^&_$/POTJ\./^)&VM_&X'PF>5'A;1RI;=C< >H?!G_@LM\'?B_\ "WX"?%]O M >H^"=.^)_C;XH>"?BAI>L^)-NJ_!!OA9\$O'GQZ.JZN4\+ >,M#\1_#KPX? M$/A;Y/#"L=;T\C(WJ?=O@W^VI\?_ (HZU\&M;UW]B?QKX*^ WQ]?[5X$^*%O M\4/!WCGQOH/AGQ'H0\3?#[QC\6/A/X9T)E\ :'XQT48W#QSXI/A)E*>+\,I M^+/#W_!%'1K'5?V1[W6OB'IXL?A=\$?$'P;_ &F=#T>PU32M+^.=A=_!'Q]\ M'O#_ (RT@#(T;Q3X=T/XL>(/"*MX@)9O";[2@9"#V^@?\$S?CMK/Q4_9.UWX MO?%GX%>(_"W[$^I^ %^'/Q(T#X2>,-+_ &DO'7P_^%5W=?\ "$_#SQMXBUCX MB2?#[0]&=9 _C[7/"'AC=XMV@[%^=B ?I3\//V@QX^_:(_:-^ ,/AJ\L9?V? M],^".JW/B>34Q>?\)3_PNO0_$NMV>-*.C*=&/AY?#NURS.'*O"_@+X=?LV>&-?UG7?#GQV\573^/\ ]J'P9\(M*TVR^"7[1?B/ M]FZ[M[;5O$_P[QK>M^,?%.CIK\8P&1=5 9G(!'O/C']G3]L[P?\ M1_'OX^? MLU?$G]FNPT#X^:%\']%\0^'OC9X)^)WB/5=/_P"%0:'XDT2/^R&\ >*_#2DO M_P )%JA0%LY90?FKXL?_ ()*?&+1_$_@KQ;I>L?L6?%^X\->$_CQX?'L:II.D+XK+:-KGAX^(?^$>_M[!+?\3Y2&5N0#T^ MR_X*Y:]XPU#X5:9\+_V;M)U:Y^(_[/ _:#OS\5/VF/AQ\%M,T32%^+?CSX1: MMH6@:OXFT'4= \9XU[P1:^(?"?BY"L?BKPGK']J[=+4E*]+\7?\ !6CX3^%? M@I^QS\8V^'7CE]$_:ENTUK4M)%^D%]\&_A=H^O:/X;\<_&'QO=E&.L>%?!VN M>(/#R/M4-XJ365,;J^0OA_@/_@BG\/KE;#PW^T!X@\(?&3PI;_LGZC\ [4/X M-&G^(OAMXY\2?'CQ_P#%]?&?P3D\2GQ.GP_T/P;_ ,)G_P (_P##[89'1?#N MFLZ*IQ6O;_\ !)KQI\8)-8OOVN_VE_%VNWVG_LX^$?V6_!,O[/ER_P (]*U+ MX8Z,VJGQLOQ,TEAXC3Q1_P )KK;^']?\5Z 9%\*AM%L%56VOL /:_P!H?_@I M)XN^"GQH^,WPG\*_ 3PAX^M/@3\-/ WQ+\9>+O%G[37@+X'SZAI_CO0O$VLV M>D^"?#OC_P ,2)K3*/!&JJ[KXGPS#@XVJO.:=_P5AT+4-%DL[;X)^,+/XP_$ M&3]G>Z_9C^">L^(A8ZO^T'X(_:0T*TUGP5X[TG5SX7QX97P9P?\$@?^%D^&/BE;_M1^,? /Q&^)OBW]GS]GGX3?#KXQ MZ'X,5?&'PW\<_ ?3?'6CZ3\4-*\0:X-XD\1CQ%X*/BKP]M"^*O\ A&7\Q@=K M5]MV?[+/CO7OC?\ L5?'[XH:_P##C5_'_P"SA\'/C!\/_B!>^'_"YTL>*O%7 MQ5T/P)HYUWP222="T-&\.^(2?#[ !1XD 0$KMH ^];?SFBB\Z*"&X(_TF""4 M8&<]",9[=2>#U]-"BB@ HHHH **** "BBB@#E?$$A@\.Z\\3B*7^S+^09 .& M&FL1@8ZCJ..V3Q7D_A+XE^>8M+\2Y3S1_HVI]G MX5\B^$O'FI>&,6O3I7!C\OQ6#>U^J>^CMN^CN_S/4R_.,-F2UDE)6NGH[KO=KK MLW^9O+W/J3Z=!D=N#Z_CU-5W12P.T$#)Z].1U&.HY/.",=^*HW-U#902W#2L M(H,"3. ?QSC\1SWP !7Y]P_\%(_V:)?%D?@QO$HK: MG6?[ T>ZT?6-3%[XI_L3.O\ ]A*$?^RKL-U ^2S#/\ *3EG![=?3)Z\U\T? ;]I;P-\?X];' MA?3-:TNZT/3M UJ[LM?CTJ&\-AXD_M@:/J"_V-K/B%!@>O?/'H8''8;,\-#&9?C.?#5+GV\VIPR:K<7U_'#>_\ M>L$%S]B6SL?4@8R01DG/^(T/[%M?^?S6_P#PHM4_^3J7PY_R M(_Z\1_(5T% M>@9G/_V%;?\ /YK'_@]U7_Y-JK<66EQPFXFU/4(;<#/G_P!NZKQ_P(WN .G> MOF;]MGQ]\1/A[^S3\2]5^#^BZUXF^+/B/2].\"?#+3O#J?;-4@\;&,Z-X/O?$"^+6Z@Q:*Z@J,*?P@TOX"?&]/V:]#_8:\:>!OBSX#\.?"_] MN3]G?6O"^C7-IX.^,&E:]^SQ\;/&?]L_\5%K^M>$O&O@'QF?A7\1O^$W\0,& M_P"*70V/A(>, "S5VX;!JO%UW*,7=)JZYN5VO)*][)M7:5DWTMIPUZSH=&]> ME]=K:*_?9_EJ?TZ1V&G7#RQ0ZCJ$LUO@7(@UW5I_P"Q M[,_\ONK_ (^(=5_K>U_+%\-_!'[2?[,O@/QQX\^%>A?$"X^*^J?"S_@H!XH_ MX3B\^ _@W5?'!\<:/^VA\'_ ?@D?VMHWPX'B#6_^$S^'.D^(?$)\'^,B>!_Q M1_\ Q1WAKP(O@/U[]J0?MBW_ (Q^*GPI37OBWX_M?ANW[5UE\+_B_!\)O!LW MC[^S_$G_ 3^T?XBZ1I7ASQOHWPY T3=\5?$/B#X7)J/@O'Q!;(\(CQ9D[1U MO)H_6=,8G&S=W)O6/+=62MHVENG:[5[&?U^?52\O=>]UY>GSL?T@IHMJ>EYK M) ZD>(M5SS[_ &WGZ?RJ3^PK/_G]UG_PH=5_^3:_$C]E;XR?M(:E\?O@[^SA M_P +*\<>.OAO;?#/PO\ M,W?C_Q3X*\(>&_$&H_!W_A6'_"H?^%.ZNH^''@F M,/\ \-$C5O$(9O#"_$#_ (1;PV$:9%;>?W3+G' Q[]?Z5YV+P?U::IIQD]+N M-^JV:=FI/=JUULU??JH5W6M>^NU_O^[\[F'_ &+:_P#/YK?_ (46J?\ R=5? M2YKA;Z^T^YG%[)"+&\M+@X&=/U8W2XXXX;2[KH1R!MSGGJ:YZ+_D8=4_[ WA MC_TZ>)*P.@Z&N*LK"VU.2_NK[%Q_Q,+^.UM"?]"M/[(+:20 ,?,2"22!R2<< M8KM:Y[0O^/&Y_P"PWXF_]/\ K% $W_"/:)_T"[+_ ,!A6=D^(^/!S #LP>"_M"LJ$Y*-KN\GI=6>[:TOO9ZI:V.?$5I4% MIOW5^]G\OQ_$_HK30?#[]-+T\?@#^7'/_P"OTJ7_ (1[0O\ H&:?_P" H_\ MBJ_FU\:_'O\ :@^#FA?&.*WU?XG_ .\,:7J'_!2CXE^ [WX:?L^Z9XA/CKX MG>!/C;K!^$^A?%8?\*W\<'1?AT?AS_:NOGXG'_A%/^$_&?%__"PP?#(#>M^$ M?CQ^VY=:=X?^,6I>+/C!XMT2U_:8\+?#0_"GP_\ "'P=>:5XJ^#^K_L6^'/B MGK_C+P\P^'0\0ZSKO_"XF;_A$O$(\=#P /%7_%NP>>.QY/5C;WXV;48NZY7S M)6LU=/?6S:23;?0R^O>4O_)OZZK[S]Z9-"\/Q_\ ,+L,]N /Z'_]1R*/[!\/ M./\ D&:>>#U..._;'Y_RK^8SX;?%/]K7XY^.?A/#\2X?BMXV\'>#_P!I#]G? MXA>$]8\6>!#]NLCX\_9]_:_T?XK#Q#JNB_LY_ +P\=#\.^*=*\$^'VT'_A!_ M$_A;PKX_\1#PA_PL+Q3QM],^#/Q#_;IT+X4>"]4TO5OB'X2TSX0>&_\ @F3H M_ASX,Z7\%_!GAOP1XJL?BI_PC7AK]H_0=5_XMS_PD!T/PZNJL=W@S_A%_P#A M7_V$ ]5/[$;7^^1YKQBX\S2N^5)*6SU<5=>ZO>]ZRN'UY>?X^7^:^]=T?T6 MC0-#/!TNR/\ VZYS_P".BG_\(_H?_0+LO_ 85^&O[%?[3?[17C_]IWX0^!OB MA\2/B9JU_P"./@1^T-X]^*OPX\;_ UTVM=+:69K0K^W?Y7NM[/S[WZO5G,:7#]CO[S3DFN) MK06MC^'/ =MX\\6:=X!\)3>(+ MH6']O>*=8)_LG0=*)QEVYQV&T9*DY+5V[1NW?9:N_P NH'I'_"/Z+_T#;/\ M\ __ *U?GZG[1/Q=?]K2;]F7_AE7P>FFVWAU?B6?B-_PO/3&/_"H&\9'P$/& M(\$#X M,?@]JFG:-\3]#TB\%Y?>"M9UC^V/[*TKQ #D)>N-'U4@%B?]$R=I!KRSQOX3 M^'GPQ^,OB[]M'Q]X\'A/0/"_[/@^%OB4ZQ\GAO2?"^C^.KSQX?%[ZIN+A@^K M&P.$*A-OS,PP-Z/M;VK)N7+HO>O=VY4UN[WU6O32UD\,0T[>\G[SZK7_ (<\ M4^(/[3OC6S^)_P 4_AO\#?V6KCX[6/P(C\$Z=\6M6L?'^@^"==TS6?'?A\^. MQX/^&>@:UH7E^/M>'PZU_2O$3;_&OAA _B33X\9(WL^*_P"WE^S/\.]!^-R: M==)XF^(_P@^'_P 4/&-WX!CT7Q/X;TKQ3K'PJ\'GQ'XX^'?A_P"*_P#PC3?# M#Q-\1/""A3XI\/\ @SQ-XJ\6>$P29=(4C:(?CU^R;8S>(/C+\:-+_:F^*7[- MW@?XD:/H^M_M*P>!O^$0MUU[3?A9H)T=?&6D>-]:T)M?^$^N+\.=)3P]XM\1 M>'& ;PKI .U#IRZH?G_Q!_P2]^!>L1_&GXC1?%BUT[X'=#\0^-=?\ "B[O"YQXE8>,?%GB MA5W-V8?#X!V^L\'>!O$JZ[N.C1 MI@_\)J(44*S;M)1F<_,1]4G0-# /_$KL_P#P%Q_,8KY&_91\ ?"[X7GXQ^'/ MA]\2(_B'?^,?B#IOQR\4VY^S$Z#_ ,+3\"^&](\/84#']C>(M$\$#7XF5BQ9 MK\A> K?:3,"G.,G''OG_ #C\*X<1"E'$MT(RBDWRNS6FF[?7;?J;T)*S]Y?$ MK:K?_AVOO\S(_P"$>T3_ *!=E_X#"LW3K<6>J7UCYT]U:FPTZXMFN;C[7]DR MVJAMH8$X. %Y(("X)X-=;7,P_P#(RW__ &!=&_\ 3MK%8G0=-1110 4444 % M%8TFJVENXA'GW,Q&?(L\WK8Z^Q_#@#V[4FGUZYB AT^"UD'?4-3Z_P#@HW^O M,>O_ M "%PGIV(/>@#IJ*R8]1LW'D_\>TH'_'O<9LS[]1^&!G/IBM:@ HHHH *9O'H M?T_QI]5Y^WX?UH /-A]?U/\ C2?:X?4_D/\ &J%5ZUY%W?X?Y'/[?R_#_@E_ M[?;_ /3?_OG_ .O3/[4M_P"[-^1_QK+K/G[?A_6M/J[\_P ?_D3F^N/R^Y_Y M&W_;%C_TW_+_ .O1_;%C_P!-_P O_KURMQU_'^K56^V0S27,4,UO/TKH^K+^:?WO_/S7WG-_:.*_E_'T\O-?>NYUG]O6']VX_+_ .R^ MO^1R?V]8?W;C\O\ [+Z_Y'/%7'3\/Z-4-QU_'^K5JL%A=/>N_P Q?VEBOY5] MZ.S_ .$LTW^_5]_P" K?X_Y_$TO_"9Z3_SSU#_ , F M_P#BO;^?J:\RJM<=/P_HU:?V5AN_X>GEY?CZWYUFV.5O=T36GI;_ "7]7/3O M^$[T3^[J/_@O/^%,_P"$_P!%_P">6H?^ 7_V5>2U7J_[*PW67X1#^U\5V_%> M7]?\.SV+_A8.C_\ /+4/_ 5O\?;_ #DU!_PLC1/^>>H?^ S?Y[?S]37CE5Z? M]E83O^7EYVZ=OS9@LZQVFUOE?IW].OZL]L_X6/X?_N:A_P" #?XTS_A9F@>E M_P#^ A_QKPZJ]=*R3!634G*]M;JW2_;M][?=]_X"4W_A:?A_\ N:A_X"G_ !KP67_7'\?Y&L^G_8>"[O[UY>?E^+[G.^(\ M;Y>5V_+^ODOE]%?\+0\/_P#/+4/_ #_ /KU5_X6QX;_ .>6K?\ @"U> 7'7 M\?ZM5:?M^']:U618"R^/;>V^W=?\'5WZ6C_6/,^R^Y>7EY?AYL]OU[XGZ!>: M1J=I:QW_ )]QIFHVUN/LC9)^RDG'.<$D'!X( ['%> 58JO7J9=@L-@T_J[;> MG,G=VLEY6M?MHV>/C\PQ68V^L67+M9;;/37357_IE>M32M;U'09_M>G2^5-T MQU_M+M[G/&.WZUET5O**KIJ2NG=.Z3M=):JSTU5]MD<$9UJ+3C*SWC9[6MM: MU]D^K=CVCQ/XN3QU\-?'6C:5I\DGBB?PCKL%AH N%#:OJ*Z#>$Z;IN7"L&(P M=B KNR00"1_(K\4_#?B70?&MWXJT3PM?ZWKG@_XBZAXR^*GPZN]/TS5?#NNZ MSJ_@YO#?@EO!/PSR?$'B@>#1XW&T?\)(NW!^9L@+_3SYTT,GG0S?9KFW XQC M/T_E_P#7Z>K^$/&6@W>IVLOB[2=*.N0V'V>V\3FP NKBQW!_[.8JN_)8<_,5 MR Q7/-?@WB=X._ZX5L'C\/CITXY>KM1O:SM>T;J]GKV;LKJQ_1OA'XU1X(AB M\'CL!#,YX]+D'_DQI.23E0?WJ*_ M><9XQWZ#^1^N/3@XJE:0Q6\>(TB@3TAB SCU(&<'WP.>N:T#TX3X/*I8MXUX#1MI)O9V[Z=+O_)1Q5Q-_K;GN-SU8..7_ -H-25.G M*ZARJ*5M$KM*^B7WZF%X:_Y FE?]>0_D:Z"3&,^A_3!_PKGO#?\ R ]*_P"O M-/YUC^.=:F\-^#_%>NVL:2W.B^'M7U>VMYG1+?OH>#AE+$UZ>'3]Z4H03E:SWY=>_3OFF;U.2I$BK_SS/1OP_$=< G)('-?R4:K^VY^ MTWX7^*]A',M)U;6O^ M$U_L/6_#VN>'-*"?\(;\I'B,J>A _3[_ ()4_'GQU\9]2^.=IXK\3W7BG2/" M-WX(T32[^?QOKGC=M2O%TK6&U?7U76@&\,CQ!(T>?#X&$_LK'OCIX^M; M+_A8%MXPLM4\4:+\!_ _A31CXYU;4M8T;QE_PC?_ !=GP23GPS\.?&>A^(-) M_P"%>_\ "/>&B/%?_%)>+N?B1_R/GZL?E"BNR^2MM;_*/W+RM_2+X>^$?PQ\ M*>-/&?Q'\.>!_#VB>/\ XC_V'_$FGVWAR]\0:#KW@[5/%>H M:P=8\1^(?&!\$ZWK>IZ_HFALVL67AX#Q$0Q/AOY>AQ^R?FQYQO7/IGFE*26L MI)=$Y/\ #4:CVCMV733_ ('X>0^N>B_Y&'5/^P-X8_\ 3IXDK>\Q,XW#/IW_ M "K!B_Y&'5/^P-X8_P#3IXCH4HRUBTUW33_(+-;JQT-<]H7_ !XW/_8;\3?^ MG_6*Z&N>T+_CQN?^PWXF_P#3_K%,#H:*** /G/XN_LT_ GX]76AWWQF^%'@O MXB7/ANSUC3]&N?%&C+JDVEZ;XB-L/$.F+O9Q>:-XA_LK1Q)H3!@Y0?("0%]Y ML[&WL[>*SLH8+.VMK<6]M;P ?Z*,= <\8P,<9X.3DYKRCQ]\:_A9\+[^&S\< M>+]$T;69]/O;ZRT!KD'6[W3EW,;FTTO.]AC3&P>,%3R.<\/^SS^U/\*/VEM/ MUJ_^&E_.TVBD_P!HZ9JDNA'5+/\ XGOB/PYEQHFM^(UQ_;7AS5U#N<*0@^;= MMI.LVK-RMT5V_P WIV]%YNZLNR_K_AE]Q]18'H..GM28'H/RI:*8R^Y>7 M^2^Y=D?-7PO_ &7_ ( _!OQ1KOCKX7_"3P+X*\8>(K74+#6_$'AW0+;2+^?3 MM9URU\3:KI@"X&DZ*^M$:]_PCZG89/F15*;1]*TP..<\>G7G]./UI]1[=UG[ MSDVM;MW>R>M_3^E89SO_ #,'_<%_]R==%7._\S!_W!?_ ')UT56!SNB?\>-Q M_P!ACQ!_Z?M7K\Q/^"I?[*OQ'_:R\$?!OPA\/---Y<^%?''Q&\3W>H#5=#TL MZ#K+_LZ?&+1?ACJN=9R&Q\8-5\"ABH/EJI>0A>1^GNA_\>,OOK/B$_\ E>U4 M>ASQG''&#@5>'K/#XA8BBDVGL_AZ=.MUVZZW.:O05?]QK:.K:Z MJ_5WTO;\6NI_,U\+/V$?VO?!TNK^.?B+\+K_ .(5I\4/'OP@^+/[4?P?\#_% M/P;X=\2?&;6?[1_:U\3^./!>C^(!\1O#?A'6S\*_B'\5_A.__".^,?$WA?P# MXL31@1XLQX+_@YXE\"^)_AKXY^+>H>)?V?]9\)? [1D_:)T MQ=*_9AUJ\^/WQ)\>GP9XTU;7/B+X;'Q$(^#?B#X9?#'_ (3&+_A*?^1!/A') M\'@^*J_IWI^P^H_7_"O0_MNNZGME&GS*2O:+23223LG=;6=]X^Z]#!9=1_FF M^NK?]V^[\O577D?SV_$S]F?]MGQC'X^^&EG\//%%YX>_X6C_ ,%%O%%KXSU# MXL>#AX<\;^%_VCO@!\8O#7P1T/2=)_X2@>(-O@_Q5XV\/>$%;QGX8V^%U4NN MY 6'D/B?]B#]M_QS\0[^VU#X8W^B>'/^$ ^,'PUUF\T_XOG_ (1;QMX.\2?L MF:QX%^%/_"0C6/C?XC\0AO\ A;^D^'_^$K\/>'?#/ACPKX .#X0_X3T!OB#7 M].>]?7]#_A1\G^S^E.CG.)HW4(P\]- M+WTTLEMIT6A_.SX>_91_:GTS1-$FN_@Q\2K[X*:5J'[-"^-?V8KGXS^#K'Q? M\2/#'@3X-?%[P+XW\/Z/JY^(P\'N-/\ C#XB\#?%'_A$?&'CGP)X3\??8&#N MK*?"M4IOV%?VQ]9\!^.KG5[;QQ<>/=#^ 'PQL/@#;_\ "^]>^V_#GX@>&_VL M?CQX]T#P:WB)OB,!XF\5_"KX(^(OAYX>/Q0\0;CN#+\./%F1)M_HSW+Z_H?\ M/8?E1N3V_(_X>P_*I>,$\@< GGG@5@&/4-1SG[1IMB M0!Y.";R[&TX/8Z1V^4'<"\G)_W>W8GGH3G MP/X^_'/2_@-HWA">;PEXL^(OBKXD>,]/^'WPY^'/@"TT ^*_%_C?6-,\2>)A MIJ_\)1K7AOP]HFBKHOA[Q#X@\4^(/$7B?3-)TG2='OG8D_*%/VIOCY\)?@-=:WXI_X5/XH^!]M\._@5HG[+7C M'QKX=\>6'CWP;X#\2>-[7QO^T=H8/AWX2X;Q#X@U\:_XS(^7!W,02??M$_X* M(^*O%VJ6&A>"OV:?&.JZUXV^+/QJ^&OPABU?XH>#=$LOB>/V?->\>^&_BOXG M&J,'/@O0_#A\$:4=''B!=WBIO$FGK'A"?$[>C^"_VA/V:/AQ;^-_C)\7]-U' M]DCXA?%?QPWAWX@:;^T3XAT'PYXD\6>)OA5X?T7PVNNZ"?\ A*_$7P_\4>%O M#WA9M* \7_"S4I?"C(FZ1_,(SS^K^&_^"=7B:[T']FK5_'7PTA\;^'_B)XX\ M8^'/!&@?&W5O WQ.T+XH>.[;Q+X\\::II6J>%?B+X>^)^BZAXCT/XB>(?$$F MA)XD&[PMJX(0*%"^VHT5"/-@6VDDY6DE=))MV:35TK-W2UVT/-T3_P!]MM=6 MV?N76MMK6Z=-#YV\>?\ !4?Q#XW^',_B7]G/X6^);:T\.^+?V4=&^)?Q \:7 M?AG[/\/=1^-GQF\.>'/$?@ZZ\$L2_B;4#X5;5_#Z:]X=?$?BCQ'X?6/A&8^S M^*?^"G7@;PAX!\$_$34?AIXVNM/^(4?[3T6C:7IFIZ%<:K_:_P"SA\;=&^!% MMI3+E3N^(7BGQ!I7ENKX\+!\2(YCW-\]2Z[_ ,$L_&7Q5\,^ /AM\/O#WQ&D M\&^'?V8;73_$'PE^+&B:!\',C]H%_ WPFT+Q%Y?QL\,Z!X^^(OPK\3J/&!3Q M%X9\3>/CX"\1!/!K>*I?$Y\+2;UY>?\ !)B#XP>*/ Z)\//$;ZAX$_:(\9?$ M7Q'<_%[4O$7PE^&VBZOXT\ ^&_BSI9TK6_B/)X.\ 7_C7XB^-M,_Y$OPRN?' MWA[75_=>,UWCI5'!-12P-6Z=VE=RY7%+5\ZM)3M-/E6BY4FKR>:JSV^N)_\ M#QZ)=D]+]5V/H.']J3]H"[_:6_9V^!_BW]GNQ\"Z3\5M&^.VJ>-[?6?'GA;Q MA?:+6PJ^"-M?I_\ "WXR?"OXX>')/%GP@^(OA3XD>&[?5+_2KKQ! MX,UK3->TNSU"RP;O3#=V>1NR<9PQ.-Q8XP/*QM)KE;PDXQ7\ZE&UWI?F=T]' MI=6:6IVX=W5[WTWO?I$]8BF2:-9D/R<_X?H>OXX]YZP/W=A<]C9W=S[8M;\_ MT;'TR._??KD6RTMIMV\CI"J\_;\/ZU8JO/V_#^M,#/JO5BJ]=!Y_6W7MU^XK MU@:SK%AH^EW^JZK-]FL-+M?M]U>>V"#Q_/!Q[]ZWZ\Z^('A*?QQX4U/P]:Z] MJ'A6_N6T^[TCQ!IF/[6T&_T;7/[6TG4U_MG'.X G))QD$C"@=!SG@7B+]H31 M-9TOQAX.T234/"7C_P#L=='\.?VP- XUCQWH/B3_ (0C703XI'&><_\ "3$] M<8P /C'7_&FJ^ _".L?&G5;_ ,-^ /$^EZSJ'P]^(UYH^LZ]_P *Q\*^%]8U M['_"9'^Q?^$)\0:UKG@SPK_PCWB#_A,/^$Y_Z&T>@KP?PK\&? '@_0?']K\? M?'^G_$BP\0>+-1_X6_HWQ _M[X(M%\5?\270S_Q3 MW_")_P#"&8S_ ,4E_P 7"\4?\)K7YH:Q\,?BK\0OVJO#W[!'C#2M0T3X(?'# MQ']@UGX@?#/XO:KXX\<>%=/_ .%7^)/$GA[0/$/A[6O%6/\ D5O#OA[_ (2S M_A,_ V/^*;\7A!W;Y?FE_=OT]/PUV/WX_91_;8T'X\?&[ MXD? ;P?K9^,>@_"?P9I^LW7QX\/VO_%.7FL:Q_S -6\0Z+GP_P#VW_V)E=]\ M?OVS/ /P+NO&%A/#8>)-8\!#PO8:SHP\1Z#XT'2<_>.?$/A[ MTP#BNM^%OPH^!?["/[/7_"->%;73_!WPW\!6VH^*/$NL7EKH.E:KKNH:Q\WB M'5/$7]C?\(UX?.NG(Z @8T+)..?YJ_VP/)\8?&3XW^-KGX.?&SXM?!#XR> ] M0\9> [SX-W6@^(_B;\-_B!HVO?\ "1_\)EXW.BC_ (DOA4^*O^13_P"I ^HK M9XA4+:77;7\'Z6[ZZ]&CRFKV=GL]4[?COU/Z9_!_[17PZ\2:?X M8GU:_M_!-QXPM?M^C6?BS6=!THWE^>N@_P#(U#DG&!W/ KW&OXT/@#\3_AU> M?"OX4:K\)?\ A;'Q:_:?\/\ ]HV'QX\)^+-%_M75? >CZQ_R,.@'P]K7_%/_ M ^P!_Q2?_0U<8Z9K^J_]E_7QXJ^ ?PNUO[!JFF:;<>&_P#B3:/K-W]NU2RT M_P#Y%OP_H/B+_J.#^??.:[88?V"TU7KYK3OV1 M[Q5:XZ?A_1JLU6N.GX?T:O5Z7Z=^GWGAE"J]6*KUT)J7POF]-?R.=IK1JS[/ M3\RO5>K%5Z#G*]5Z_.#]MZ3X_>%?'G[/%_\ "O\ :8\?%#2!X$']O>( M?#Q\*^&QHH\:>%?$)\0X\%^!O%&./"/PW^'OB@'GOP^"3H1ZW::Z/6UM6TVW MKI>]OD!^H\O^N/X_R-9]?EAX;_X*/^)?C!X3\/0_!SX#ZIXD\?ZIX"^,'C+Q MEH__ L;0=*TKP'X8^%?C(^ _P"WO#WB'6O"O_%P=<\:>*L?\(EX/_X0;PN, MG'Q(_P"$6ZM\N:/^WK^TG9^ _ %_X:^T?$CQSX@\&_\ !.;_ (23_A*[GP;X M<\.G4?VD/^$D'C?_ (1[^Q?AS_Q)=<\9^*?#O_"/=/%'A7PK_P )(/\ A6_P M]XKTHX'$M+EZ6Z:K:WY_E9NYSG[Y57G[?A_6OS&\$_MI?$74M>\3_#+P?\,= M<^,7Q@N/C3^U!HUKX3\0?$?P=X'\.>%?A_\ ?7O#?AOQ"?^$VT7X<_]#5XW M\/\ A_PG_P 4SXH\?\_\7(^(>:Y[6/\ @IW_ &EX2UCQ]\,O@#KGC;P?X7_9 M^\,?M(^/+S6/B-H/@?5=!\+_ /"9>// GC70?^$>_P"$5\2?\)-KO@SQ3X(\ M0\_\S5VXY\43]3Q.CMIWT2UY;;V6K>_W7N[!^J55Z_-R]_X*$:5-^T#H_P " MH? VA?9_&%UXH\+>'?%FC_&#P;XC\<6>H:/\+_$GCPZ]XW^$^B_\)&?A_H?_ M !3QQ_PF?CG_ (2K_JGHKZ+_ &.?'OBKXJ?LJ_L__$7QSJIUOQCXP^%7A;Q1 MXCU@6N@Z5]LU#6-!_P"H+W^F/Z4*AB*%M7:Z;\E\M+VZ=-.YS/9ZVTW[>9]( M5SWBKQ)8>#_"_B'Q5JOVC[!X8T;4=9NOL=KG5/L&C:#_ &OW_3\>U=#7AO[2 M&C^*M>^ _P 5]$\#:5_;?B?5/!M_8:-H_P!I_P"/WK_GD]#7DYQB,1@\MS'$ MX!.4U"3@E'F;FHII)=;M726^VBL=_#N'P&,SK*<%F#Y:%K_[38W%UJ%A_P ?6?\ MB8:/_3/'O]>G\\'B#]GOXJ:#IW@#1/&'@#Q)J7P_^&_AO[?K-I>>'->^'.J^ M/-8\>:#XD\-^(/V?=)U;13_PD';P]XA_XK/_ (I7Q5_PC><\ M"?A78:)XSAN+:Y^U'[+]LM?[+U7^S_[!\-\^(?3_ )F'ZU^ ^&O'GB-G_%]3 M*L]P,XY4LNDE*66O#1TEH^9I&OACP_P12S7AG,5+/'F4)2C M',TVKQC=**=[)MJU[:[Z(^U/"'Q#U+PO-]CF)U'2,_\ 'N"1]CQG']E8P"O) M^4Y&>P.*^I]%\0Z5X@M$O]-N?M$!YS_SR/H1C@^V2<#C&*^'/+N?^>7ZFNN\ M/OX@T.0ZEITUQILW<7@']E7G;GU]/Z],?N^:9'AJM)8FDU";6JV3:2T>S7R] M=EK_ #MD>>8JB_JU5MI.]WJNEM7Y?@?6WAK_ ) 6E?\ 7KG]1_0?C5+Q-X:T M[Q1X>\0>&-5B>;2O%&F:AH>IP0RF&8V&L::=*NQD'(_T)V ;&5W9"G %<5\. M/'FG:WI5CITT?]G:U!:X_LR<"W^U#!W'3"6&Y<@+A1D$YP1\R^P.PR/IUP<= M3WP!_P#7XYKX/%X2,H2PN)3E!Q<7HM5)6M?;5/1_+?0_1,%B?;2CB<-)*2<6 MM=5)6?-9VLU9?CH?AMX__P""//A_QOJ^MR7GQ2U2#0=0O#J^E3VFB!?&O@/4 M0=(^UGX?ZSJ^MR:#H:^(UL[H^+#_ &0?[4+ $ [MOUE\$OV5?AW^R)K7Q(^, MUSXEU3Q7XB\?Q>&-!U"R%MX8T'2PUF+'1M'TSP]IJ^6L;:^XTU67Q!XEE)&Q MM\98J?L'XKZSJ/ASP!XIUG2]-UC4=5M[ "U'AC1AXD\261.IVEB-5TGP^>=9 M;PZ+PZ]]@R ?LA&"37XGZ]^T7\9/B+\/_BC?ZW\*=;\6> +?4-1UJ_\ A/\ M%C6->^'&K?\ "K_#NA>&W\/^,M)U;6O"OAG^VMVN_P#%1-X?'CD GD_\(N?^ M$IKXW*> >'S7/@W4M.U?2-+T_ M_A*C]@L?$W]LZ&=:TO4O#VIE@FLZ*5&JJ'+CYM)D.(QU_*S]MK]@W]HWXX_M M13>./@?I/PH\/Z)XB/P_\4ZC\=]7@TT?$WPMJ/@;0?\ A'O^%8KE?[??PJQT MKP_XARNX%_$GB!<[U8#XPC_:?_:0_:?UCX;^&_V(? ?ASQ#XP'@S4/A+\7_B M!=_V%\1_ _PET_6/^1>_M4:(,_#_ "-)U;Q!X3'C+J?[>&#QG]MO WC#X-?L M(_!7X6_!OXG_ !JF\4:MX-L'T>^UM?"]Y?\ B77=0U:[D\1:KJMUX)\ :)XA MO]&T>7_A(8]1 V!8Q_8Z^:ZLK-]HK:=M/N^7Z?(^'>SL[Z.SZOL_F>>?L-?L MB?%']F>75==^*WCSPG\0/%.J:-K6CW^M>&-'UW2+C41J_C!O%P?7K;5]:ET# M?H"?\2!/^$;0Y4G<-=-T9 _@W7OBD=4U4I)_PD@((5L \#]K=7_;&_ M9:T9EB\1?';X9Z/:VVEMJ5WJFL>*=+L-$T[&F6.L%=5\0WK)H.CZRVB:OI=^ M^@O)'JO_ !-$"Q,K%C^>?QC_ ."<=O\ '?Q3=>,_AQ\4=!\2?"7XI:QK/C/5 M;&[UG4CI.IW^KZJOB+2?&7A_Q)\/RJZPW@[6R'\**3TL=# \6-M!;\N\2,#Q M3B\!@EPS)QG_ &HN:S:O%I==+*^_2]C]4\*L=P5A,PQW^N2C*D\JM!.*FE.\ M>:R46^=I^[:[:YMVT<]^QU^UE\8/B3^V#)\,_%>O7'B;PV/#WC76+K5=-\1: M#XA\.#?>A/#VA-I.C:*G]C;?[,\0O_PD#,"&4>$QEU6OW 3CQ#JHSR-$\/CK MW_M/Q#TK\I_V:/\ @F+'\ _BQ\)_B9JGQ;D\5WWPH\&:OX6MI='\$/X/OO&S M:PX#ZGXUU[_A*O$,FL@$?)HN%0';+T #?JH)%3Q#JI?C=HOA_P#74?$7X<$9 MZ]B*]?PZP/$& R9X?B*5\QYF[N7-HW%_%KU3O>S?S=O.\3,=PMC\[^L<)Q4, ML654X\JING:<7>H[-)MM6ULM>O;K4PR#/?K^?^-8&C ?890./^)WXESU[:_J M^/S_ /U]ZR)?%EA9:C]@OY1;12 ?9K@Y )QSDX)]<''X=A?\/C_09S_U&/$( M_/7=8_P%?=.A9)MNVFNJ5]/+]=MS\SP^(I5THW5U9:/71*_G?9^9U5%%%!U' M\V'_ 5D\(_$#P[\1=4\877AZV\6>$_B1I^C> _ GA[7_ FN^,[#7O%'B30O M$G_"0Z]I&K_#Y5\8>&/B-\*O"OA_Q#XA\)_*!_PBV<>*QC_B@_F[_@G%\:_" M?[-?Q9T/PAIOQ$^'_P 4_$/CWP9X'T;Q%X>\.:$?AA_8/AC1]4T?PYK^E^"/ M!2^*?$K:O\1Q\2/$(\0>*W4%OC.0&0>%V K^F']H3X%Z/^T!\-]5\"7FOZ[X M(U?!NO"?C_PG<_8?%7@GQ !_HFO^'KSHM\IR.>".H)QCR3]DK]B#X)_LE^#] M.T7P-I%MK_BNW_M%=8^(^OV /BO6&U;5K[Q$P)W,NC8.J$;=. *D'>,Y" 'V MU61JNL:5H5C<:KJMW;V%A;C-S=3_ "J.@ 8@9_#!QSP,&M>OQ^_X*P?%36?" M_P "I],^&GBB]O?'?@_Q#X8^('B/P/H%KJVJ^)%\#Z/=WAU_7E/AM2[_ /"' M+M\0/H32EOJ MMGJZ\#2_[)/S;\8P,')) W8KUROX?_@S^T@?[8_:9\-^%?VTM/\ ^$/\+W6G M_$'PY9WFBZ]X&^,7Q)U#Q[KW_"2?V#_PD.M<#7/!GBK_ (I__A,/!G/KFOZ? MOV /C9K7QK^"?_"2:G<^)+V*P\0ZEH\%SXJL]=M_$FF[;E?^*/UA];/]NZU? M>'5NMIUYP=RXY"(V0#[@_P"9@_[@O_N3K=V'U'Z_X5A?\S!_W!?_ ')TVY\2 M6-GJ!L+MQ#D8$Y(QGK@X!Q@\'K]/5I-[)OT39FZD5OIZV7ZC]"_X\;G_ +#? MB;_T_P"L5T-<_HG_ !X3?]AKQ3_ZD&KUT%(T*^<+'ZD$?ES_ %KE?%7B73O" M&AZIX@U:86VGZ3:FZNI6Z!0.3W[8'4#/(PS&W.HC2=4L]5_LULD837!IGV-R2 J.[C)RI\[,YXC#8#'5\ M(KUX0E.*>MY**;2Z:[;]5W.O+8X6MF&7T,5*U*=:G"I):6A*I3C-_*,F_):G MYH?$+_@JWX1@BG\/_#3POK3?$4O?W=AH_CC0+O[)>:%H^NV6C>(M;\.-HMZ- M/^(.LQC5%*>$O!OB9IG8DAH0@$GU7^PM^U;9?M1?#C6-=OG9?$_A+Q7K7AS5 M/MND?\(]?7NG)J6?#^O#2#N:RL=?L54*JL QTQS@E21_,7>?"CQ39>/_ A! M\+_[7\)?%?[5\4-;M?"?B'Q'J>D^!]>_X6GH)\!^'O!W@C2B"=%UL:V=*_XK M!2O/_"6,3_Q40K]MO^"=W[&WQE^"'Q'U+XK^)XM6^'/A/QSX&T_1O$7P;UKQ M:/&UT_C2T.?^$@WZ-O\ #^C:-Y;ZK&@CRT\IP!'&97\1?@W _%W&>?\ %,OK M\)QRU*4&G3E!)IV24FK.ZBFWHW?2Q_1W'W OA_D/"F(J8+&0P>:\E.IE;E.- M669JT'*+2=X[NSC9)V!GK[4#.@/3[A'ODUDZI<-' M (H?DN+N46T+9S@G.3^I_/L:P+SQA:6%_P"3= ):'_E\[?C[?J<<8K3BEAO] M4A$7EM%;V!OPO(/!/CFW^'/Q8^"'Q&_P"%D_#;Q/J'AAO&/AT:Q_PC^M^!M7T7Q5X3LO%7 M@J77=%\2>%_$/B'PZR#Q3X9(%X&1]RLK?7M%94JOLFFM'&^C3M9[]+:K37[C MH/QO^.__ 3Z_:;^.W@=?#GC;]LZ36;_ ,3Z9\:-&\>6=M\/_&/@[P/9Z?\ M%30?#>C^'O\ A!_#WP]^.'@KQ!_8?PK_ .$>'_%'_%7QS\8_ 'Q _P"$EUX^ M,/">VB3WLE?9WM8XG@<+9ODWQ3TH: ML+WXD>)<:YXQT,?V _&^T\/>!M$\,_M2>&?#6F_!CX M1^)_@;\()] ^$VN>%?%-WX'UCXV?#_XI9\:^-]%^(R^(K3Q3_8?P^_X1#_A( M?A4/ 9!U=_%O@\:4=J']N0=JKR<16X[R_"8J&78C-:;5GJ[MVO9KU\!P7F^98)YM@\DSBI@$VI58TYRA>%G)\T M5M;5M:73BW<^!O\ AT7XUF\->(?"DW[06A/;>//!O[4'@WQY=?\ "O/&=]JO MV']I'QGX!^*8UWP]JGB?XW^)?$?]M^#?B+X+#"3QAXW\4IXH\*!A*R>,E/CV MOT%_8_\ V9M2_9QTKXA3>*/$FG>*O'_Q7\>6/C/QCK&EWWQAO[2:31_!GAOP M)I$"ZK\7?BE\7/%VLNFA^'K4B34_$^T9*%&_X1Y2/MI9%>-98L,&&X-NSP1D M$>N01V_QIW'5_D]AG';VQG_'\_6JYM7QJ]C5DIIVFW!)K1*UFDO)I:;ZWNT> M=0P]/#O[6CM9IW3TTWWOU6SZ::036\-U#-#+^\AN!^'TS]1T],U7TR5IK?RI MFS=6I$%SC^^,D>O:M6N6-]#INJ7YF4);W4%C,",'.H W:W8.?XA9_P!E9]B. M]ZMKNOZ+J=IKD7@J\TK2]3TR]U?1&;P_8-J][K$>H*S MA=2=AX>+[&4X8X8GYCBGB7!<)Y1C,SQ%W))[:V6VO37WN%N&< MQXLS[ Y3@)*//I*3U4()1O4DUO96=M+MKHV?IG8>(?#FJW-]8:=K>DW]_8XB MU&TT^^T^[O;4X/&JCYG3_=8#CL1FMSM]S\/TSZY_#WS7\=O[/G[57Q0^&/QQ M^'FGR:]/<>-_"'Q$\4>"/'/PAN=7_LS5/ /P*T;0?[83Q#\3=?\ ^*D\/>&] M$\8:]I"O_P 5$PY\1^$?^%;XZC^DO]G3]L/PA\>YK#2I_#VJ>#?$FJ?VQ<^' M;36/]-TWQ5I&CD#5-3\/ZJH 90"Q.<;<=&R2OR_!GBIEG$ML+C%]0S"33C%O M247R\MM&GS:?\!,^PX_\),ZX+7UG"0_M'+4HN><*/NQD[<\;7;7(UJW%*W5V M;5#]KO\ ; \(?LEZ!H]_XDB-S?ZYH7Q!U_3S>_VE_94X\!Z$=870OEP/[;\1 M9&!U*V>N[OFSC@_@A_P4,^!7QCM='BE\3>&['Q%<>'-/U_6;/P]K6N^,=+T+ M4=6U3^QQH.JZL?"H71F)U4 $D*!WQFOQS_;$_:@\*_&GXX^#[7XB_&G0_@GK M'PWUGX@>*/ =YX(.A>)/$GPW\+:-_P ))X"\0Z#XX\/ZWX5)UOQ7XS_Z%]LG MPL>ISFO"/V,_A[\8_B1K'A#X%>&]5US^V/@/=:=XI^'-GHWPJTOX2:5X\^%_ MCS7O#?\ PG'C+QOXW_Y%[Q/H?@S_ (2#_A'O^+5=<^$L9YK]76J5M=M>]]O2 MY^4?5[X6^_GWZ=^O;\>I_09^U?\ \$Z_V7OVRK._'Q@\*ZQ;:]J=K86%UXL\ M#>,=>\-^(@NCYVC5N3X?UO PI_X3+P/XHY&1M! K*_9K_P"":7[(7[(_BA_B M+\)?AOJ!^)U[HW]CZS\3/''CSQEXY\1ZEZZ[_P 5/XJ/@_1=;Q_T)GAGPN1G MBOOKR?)A$)'!_#Z>OH?ZYHN.OX_U:NZ*TLFGTZ6VM:VUCQ?K,EU:7S\O[O\ MA_#R/D7]KSX9_$7XC^!O!_\ PK2P\)^)/$/@/Q[I_C*Z\#^.+K[#X<\>:?H^ MA>)-&&@>(<\9SJ__ D'&\ /BW#<6OAXYUD>(-*NQI6J^%=0TF<<\\URXZ&&P\74Q%2,(15Y3;225M[MV]U6=G\SMR^IB8SC#"P=2I) MI**3DVVTK::N^A^!O[)?[*^MWG[0%MX:T3X_7'C?X/?&3X(Z??\ Q>T?PG@^ M(] T_1]!(\$9\;_\(K_PCXT/G_A'_P#H:NF<_P#"$U_1CX/\'^&_ ?A?P[X/ M\*Z5!HGACPO:?V-HNCV9_P"8?G_)'KDYQQ7P+^S6O[&W[&'A_P#X9[^%^J^) M+:_U0:Q\0=9UC7_#NOWVJZ]G&=>U;Q"/"J^'NV?[ /(YZ9-?HE%>6&I6MK?V M$UO75G^4YQE\85\WP#RVG42<9RA)*:=M4VE>_WWZ;7*_/+XU_M\> /A_KU_ MX?T2+6+F/3-9U"PU/QQ_8Q\2>'=-.CZ$>O\ 8OBD>(,#6R/^)^1_PBR\@DGF MOT-K^9/]LRP^*G[/GQ0\=>-E\5GPWXP^)'CR_P# 'P@\/^+?"1\;>"/&7@?5 M]>!!TK_A%POB$:YX,T0#(/B7Q.I&5*[3BOS[QKS[B;(#:2GK#276S3>EK6=];67VY^R[_P M44U;XL>./#'A7Q)?Z%KEAXP\>>)_!MKX@TC1SI.E7NG?V$?^$?U[P]CQ3_Q. M_P#BJ1X?\/\ BL9Y/!V]:_7"OY+O@]#:?!_4?@EXPNOCGXK\6>.?!1_X5]X! MM_%=MX-^'7AWX2^)O'FNKI!W>'O#/A,?VS_PF;;O#V/&;,"OB)6W9.T?TS_ M/XD3?%7X9Z/K]_-I=SXATNZU#POXCO-(_P"05>>*-'_Y&+7O#W!Z=??&,]J\ MCP*X^Q6>1QF5YQBIYACNDY*7*G>.BDU;37T^\][Z1?AQAN&\1@\URC*8Y=@- M$XWC&3M;WDM'>7FK/2Q[%5>K%5Z_HQ=.FWR^[L?RJ?&'QF^*'[,OB']H_P" M/[,WQ3GU"Y^,QUJP_:"^$.D?8=>TG2O[0\-Z#X\'A[7?[6T7_BG^-#\/>-_^ M*0\9D8]N37BOP?TW]A[]L#X>?$[5?A@/$@\,P?M5:Q\4/$?BVS\1?%#X<^([ M/]HA="\-_P#%9>"?$0\4^"?$&B_\4J?#Q \&G_A%>21WSXM_P4 _9'_:3^+/ MQTOOC?\ '1;>Y\8?#CX#_"_3_@]K'_"1:%X<_XNCH_QD\>?\)QH)_MGQ5@9 M^!_C?Q"J'QYIQ_9?^ _PK\#_ !0_X1[XN ?##63X,^(W@CQOQXS!^( _X23_ (2[ MX;YS7N8:CA7AXWQR4TUH[733CHE>]FI.W\MUNWJ'V1\6_A+_ ,$]/@SI?B?2 MO%7_ E?ANY^#?AS4?B#XRL_"?Q&^,G_ G ^'_[2'C/_A&_$&A>(O$.B^*O M^$AUG0_BKXI\/8_X1#QGXYR3SVX]YF_8A_97_P"$8O\ 1(/#^H:9H]OHOP?\ M+C6-+^(OC+2M5T'3_P!F_P#Y)/\ \(_JW_"5?\2;7/!G!'C#(S@\YZ?E?X\_ MX)U_&F#PWXYT32O@A_PFWB?XD?LE_ ?X?6OC_6/B+\+]5\1^#_''@/XH>)/$ MGC?0?$/C?6O^$)U_6O\ BW)\#^'_ /A,/!G@_P#AU\%O#?B3]F$_&[]G#XGC]G#2-9\&>'?#GQ9T[1_@WX\\!^-_^*>U MKQ3_ ,(\-;\&?$;Q!X'\0'P=XS_X1?PIXJ_X1L#)P#78K;+'/[*=W:RBH:A6U_-I7BSPW=6_BWX@?$"U\;>'_B_\3_#G MCC_A*/BISXX(\;Z+XI_X2 _\)I_PCX'_ AX)Q@=PO MU"_8_P#AWXK^$O[+?[/WPQ\!/A5X8\+^(]'-UH.J_8M1\-Z"!C_A M(=%Y&<=..>O)K&L_84%;'\SYEJGTYMMV[Z-=KVLDUH6?]?+_ #1Q^F_L1?LY M:#XRMO'.E>&O%=KK&E^/+_X@Z-;_ /"U?BA_PCF@_$#6-!_X1OQ#XS\/>"/^ M$J_X1_\ MSQGX5S_ ,)7S7O'P]^'_A7X2> _#'PQ\#:2=$\'^ M&T_PMX;TO M[5KVJ_8]/T?'_,PZU^./RKT"J]ZU* M.DEM);_?N5ZKU8JO6L:=.$N:$(1E;EYHQ47;LVDG;U9S3Q&*G'EJ5:DH)WM* M.]ICC)/? P/8=.,5 M\\F\FA_(G_\ 5U_SQZUV&G^)-4N[6QT2&$7$V/\ 1=+@P/MG/KZ 9YZ=QWK@ MS6BVHVE9;[Z6MKVVTU?X['K957P]*[BE*4GI:[UT5_5;>EM5N6;.STJ;0;": M_F^S?9[7_1=8/_(4_P _3D>N*](T3XAS>&?"%]XF\?N--T* V%OH^L7%HT&I MZP+ME_LW.EJ"%$4\ M$\?Q< C&",D?EA_P5"^,MOK>F67[/&@W.E>&M1M/'OPNO_\ A-_%&LF'P]_P MG-IGQYI7@3Q'X?.NZ;X@'A3Q%X(^UKXK\7+]U?$/_$F)\7^' B_'X_$867[B M*6ETY^::O9Z-M;7OMJK[GV^48#$^W^L-M1:UB]%K;HTT_P#AK^?ZO?#+XX?# M#XMZ-I^M^ /$R:O9ZJ;\6 GM=3LKW4?[)/+:5::RJ9 Z\=<@D @D?FM^TU^Q M]^VQJOB'2'_9=^)OP 3X=67B0ZQ%\._COHWC)AING;=P\&G5M$'B0ZQHAUH@ MX<*03M7<-K-^+_[(=OXMM?B=8?#3P'IOA>_\;_#_ ,>?V]:R>"_&7Q&^(U]K MWPO\>>,SH^D_\*RTGQ/X5\$^(?#'A7X5?\(]X>\8'Q@/'/\ T*7_ LCCQ)_ MQ2_]FY=5CRQ &,&VT_PYKGCO6?#W_%/'[VM#_A. M-5W,!C(P-V&4?B'^TA\0M5\'_$#Q%XP^(OCGXH?#?]H?PO\ #G4-0_9]T?2/ M#G_"QO\ A;7BC6/^*D_Z%7.M:'XS\5>'O#O_ !1V!XJ[=Q7]?DFK:7'-]D>^ MMA="+_4_:E^UX!_WLXSW[FOP^_:G_P""=_Q3\8?&*R^,_P (-?U/4O%6G^,K M_6? EQK6J>#KCPY\,+#Q)IH7Q'_Q3^M*#K6M(VK^(O\ A%F(\3[!JY+A0#6, M<1AZ[E[.<)N+LU"<7;1)I\KTW5[V6NIM.G7@HRG3G"+MRN44D]-XN2BFM=UZ M(_ 227XQ^'/V-_'/Q4L=:\)W/@;]K2UT_P 9?%^\UBUT#5?$=GXH_L+_ (1O MQQ_Q1'/]B9\5>'O$.?!__"Z!.N_\)+XR\2>(QX@T@G@>%_&+:M_PD7A,D$?\(IJ^A?*3@CX" M\+?\$DH/!'@OX8^'DOOA1\0=-\+VNL>(OB?!\6=%&?$OQ \>#Q%K'Q"U4:IH MOA8LNA+XLUC^WO"H=5*D-N4+M+:'[.O[A:3H_B?PM_R PWB+^P/A]X?4HQ\*>&@-PP,;_YW M^??U\S'SZVM?R[>GD?NJGWA^/\C7)7W_ "&=8_[ VG_R\25X[\'/VC_A1\=# MJ,/@;Q38:EK6F7.L6&IZ792W$W/AS5/['U6ZTC5\#3]:T07V -0\/Y'3.2#7 MMQC$NN:K%*>/[&\,9(Z$_P!J>)!]>HY'..O)IQ^*-]KK\S.ILETLU;I;33T/ M%O%7_+;_ #Z5G_![5O$PDFTZ&'[?H?\ ;.LBYDN#@Z=C4V.T=-V 6(!R,^EMM7J>)A\!B5B%B+ MM*^U]+>[KVO^6UNIV%%%%>.>^%%?,WBKX_>#H(M1\/\ @S54N?B!<^#]1UOP M1IMWI6J#3-=Y71M'N3JAL74Z(?$NK:5&\F\-_<4!B%^//^%[?$SP7+H_BC7O M%EEX;M_&FL_\(%K'A[XGZG_PD7@;P%XHQ_:^DZ[X@\;:*0/^$IQ\O_"/>#/^ M$7\*8\2^$A@C_BJBVFMTUZJP'ZM;%]/U/^-?S5?\%#?@_P#M9>!_'9^+/AKX M2>$_B+X8F^,&H7_B7XF6_C$#Q5>> =; ?P5X.U?2=8&W1_"W@[?_ ,(BQ7*E MO#K)_AIJEY!)/#]IJL6CWFK:3;ZG?6_F6VFW6IHM]=* M-[?V7(PRH'WF7)X.,X.,)XBC"SG.,$]$Y2C&[T5E=ZZ_UVN%*O-\M.,YR:YK M1C.3LK:V3;25UY)/HC^,/X;W'Q+_ &K/BIX)_:'T3Q5\/],^-_A?X\?\(O:_ M!_Q!X#/CCQQ>Z/\ V"? ?B'^R0(+@'5-?U_6F3-VS!VP0BZ7H0!*Y&F*K*6&:\[^$G[ M$W[-'P8^+7B[XY?#?X8Z=H/Q-\<6FKZ3K?B9M7U35;J'3=9U4>(]5T[2!JUT MZ^&K%];^8#PXJ*> 0JDA?LFM%.$FU&49-;I--KU2)::T::?9IK\SDKC_ )#- MQ_V#/_WH]'WTZ^7<\/-L/BJ]E1;3LK-/M9?E MK?7IWN><_#CQGK4-];:$+.XU?3Y[G6)?,Z7NG :FPPWJHW$XZ \Y%?3CY&", MX'7!QZ?Y[UPG@S0M.T33YX;.((?[4UG[1<%1FZ/]NZOSUY()Z#@ X/2N\WKZ M_H:YL=B*%?$IX>/+VTW:L[VVW6VNGF['5EU'$8?#*&)=VMFV[ZK;]-/EU'4F M!C&!CTQQ^5+29&,Y&/7/'YURRY4G?E2Z\UK:][Z?>>AI?I>WSM^=KG/QZ'I, MSCKC& <= MY''_ +)A:,Z\(THJG%RG**AH[)N[BM'U;>K.ARQ.+KTZ4I5)RDXPIJ;5H MQC!2>UVDDE;1=RY>>)-#L[Y-+NM1M8]1\H7'V'[0/M8!X!P&R%['\.V,[L?E MG$D?S+)R)5).3U_/IVX&<\<5_'O^T3^T5XWN_CXWQ1UG5?&5O\,)OBMXF^S> M,C\/-+\<^%-"\$ZQX"\.:OSI6B:POB#1?B+X-/AP^#O["$7B;[I^(P0'Y1^[ M?_!.?XM_%7XF> _%MM\4I?$36<+IED[6;'1 6+A7TZ M11X@ \4,VL.)6!*&OS#AKQ.P^?\ $.*R5X.5H3?U6:V2C92YGT3Z:N]D]F?J M?%'A-C^&^%\%Q'+&+EJQ@\53DN6<95.1)0775V:T<=7J?IX"#R*Y2X_Y#NJ? M]@;1O_3IK%=77,HGF>(-10\9T;1_PQJFLU^O1WCS;75U^9^2=-^F^_S/'?%7 M_+;_ #Z5D?#F\\3?\)! M#_[5U$^;BWTL?ZV('/VO/KGIGWZ#/7OMV=G9:7J<-M;0B&.YTK XX$.CW.,= M<\MJWIZY Q7L5\=A_JL<.DE.RUTW?)J[:Z6M;N[;7/F,/E.*^O/%7:C?75[. MVEM4]-^K.JH(S^8/Y'-%(3@$^@S7C;'U"OHNNGWD7R1\<_@>1D\=.Y\,:H MVC>(;&%GM;S2-0 YM;S375&5L$D;@,C."2,5\Q2XJX?Q&8SRG#X^#S%)^YS* M[:LN5W?1IJRV:U9[E;AK/\'@(YKB*QH^M^%M(MM"9O^$8UC0O#S>-]1_M4AO$" MZRFAOXBV*K':&(P,9;\BM4^-WAKP[\3OB;X1_9HMM/\ B%X1O_A18^*/&.N^ M/K[4[)?!OQ,UC^RU\.?V6SKGQ/KGC/PKL9@F&/AGPWM\PHK;_P!LOVY_V OB M#XZ\67WQ#\#?#;P/X^N-2\<7WB/R[W5M3-_>:OJJYT#_ (37P6?^$:T#Q/H7 MAO6QNQ)XWC8H P0 .%_.>;X4_&GX,>.OC=-\4-$\*>,/CI\=YO#.G^,OAGX MT61-+L_#'ACP>9W MG^9X&I-?VLXT9KG:M)6RYQY7M%6>CM=+F35XO^U_#;/N$ZO#O"7#>4X^E&)?Z0;4 MK$[72_$NIZEX=L[KQ)I'_"!:I]@&@:3XJ,7B7149M?=1(DGA61=4D5 M8G(;;_5HD"*BJH^55"K@ $A<=>.O&,GW[8K^C/"9\15LACB<^Q3DY-L>)S(@_LQ/L9.AF3 M][)_8CJB(?$A?]AB00$;H>N>^3V_#^?3I44@ 4D]"1D'D=^,>YYQ^-?-\2\- MY=Q/EO\ 9V:?"_>O>SN[.]TWJOQ^\]WA?B7->$,XP^<9395X])*Z:ERIQ=VE M9JUFM4U=Z73_ (F-5\'?%W]G2/\ :KUV32=;\/:E8>/?(\0:;\6+K0-6^)OQ M8L-8&DIX>8>(QG&B%79/"?/*EEZ$U^UW_!)7]F"7P3\.[_\ :"\:ZIX@U?Q3 M\1KK6;KP+_PD.I'[#X6\$>)AX<&JZ!X?\/GQ5XD\/Z,/$.NZ3EE1@^=G1&PW MZ/?&G]F+X"_'P12?%KX6^&/&5Y8@7&GZM>Z6UGX@LR%R1I7BG1@/$$1&<[=, M="QP&RQ&?A']K+]NO0?V0[JX^$'PQT/P9H5MX \*> +;1;?4O#NI'PYIW]KZ M]_PC?]@@Z-K?AT:*OA[PM_9# 9Z>(]!!.PE:_'H>(]>/AP+KQ.!H[-KH509'4?\3<%B>6K] M*7^:,21X*,>./7!Z%^(N$<0\!G>!EERNFI;J5E%>[+5-:KONEV/RNG_X*"Z+XK\8?$GP-X)U[ MP=X;\5?"_P",)^"]_P##_P 07./B9XPU G^Q_P"WM)\/?V'DZ&<_\)"Q_P"$ M9Y\+>&R> 0!Z9\-_B9XD^'_C*_\ #?B2;Q)XD\ >'[7_ (1?4_B!K'B,>(_$ M=Y\0,^&]8\/:#JW@C_F6/%7_ !4/B'D_\C5_Q27_ %(9KPC_ (*=?L8?"KXA M>"_%7[7^E>%O%%K^T%^SE\./%'Q!\&W_ ,/K_0?#>J^.]7\":$WB/2- \;^( M#H?_ F.LZ%E3C_A'?$WA?Q3@?*7QBOS&_8S\>>#_$FE_P#"R_VA/%_[/^B? M%_Q[XRU#1O =GH_Q?\9>.-+\!^*/ G_%-^(?^$A\/:UXJ_XG6N?\(J/#W3_H M6\5]!U\_+]+'AX=86MAM;:;K:]K;NR6O6UEMT/Z7O!?Q(\*?$C3[#5?"E_<7 M-MJFC:?K-K]HT_[$;S3]8_Y%[7OQX[_R&?R8_P""I?B'7I-0^&GA.T\.ZYXR ML-7L-0UFU\)Z5_9=]_9JC4_[)\1>,1X>_P"8WK?]B>(V_P"$3/A]?$Y'_%6G M'][ZC_8I^$=MX/TSQ%XO\-_$7QQXD^&^J:UXGL/AUX?\0:-I5CI=G8?\4W_P MD.IZ3JV?^$AUOPM_PE.D>(#X4SQ@@_\ 0L8]P_:0^!6B_&WX?Z];V\?]G?$C M3/#GB=?ACXVL[G^R_$'A7Q1JV@L- VZMD88L=)!R6&$"X.9)-J32:=KI]59=M;/H?5^'&=O\ Q5WS'Q>N\_T^_L>?%KPK MX\^%>A>"=(OKG_A,?A?X;\,>&/&6CZJ=!&JVA'_$H_M[_B2ZV0-#_P"*>\0_ M\(GWYXS7\W.F^'/%WA_X@>&/@7\#)_B=XC\<7&C^*/"WQ?M_'7AS7M4U6S^( M&D:#XC\1^(,^'C@:T26\0!?^$+)_Y&3/6OW5_8K_ &7_ (E?LY>%-!\8?'[X MG>$[G6/#'@34-'_L?0/#K>'=*T"PU?7?[8QJNK'Q41K&M>#0OA_P^2 %SG 9 MV)K\!\&,+Q9EG$:AANE>+EIT35N9[I^7],>/<^#,TX.P> M(K9W1EF,E"64933Y'))I.\W&[?J[+TM9_97CKXY?"SX:6FH7_COQ5_8EMX?N MM'T_6;RTT77=5%GJ&L$_\(]H?B#^Q/"S_*W# $].HR:\A_:%\!?\-#_#J/5? MA-XJTBV^)'@_/BCX)/#?B'_A'O[:/_(# M_P"$5/\ PCW_ !1A_P"1JKZ)T?X_>.?AOX;_ &>/BU\6OVD].U+_ (6AX,U# M1?#EGX'\9_\ ".>'/AO_ &Q_PC7B3_BH>?\ B=YS^>>_%?U3FM##9]AL7EN: M8*^!:2BVTY:\NJ;MHM[W3LD]7J?Q_D4\5P]B<%FV5XUQQ\&I*-WI:SL_RMU? MW'V+^S?_ ,$M=*.JW_Q%_:MT_P )^-O$^J^/#XR/@C^QM!U;PV-0\,G&,?\ M"+#_ (D;>*O#QQX?' QST"G]@=!T'1/"NCV'AOPWHFA^&_#VEVWV#1M'\/VO MV'2K+K@Z3X?T7T],#UKGOAYXH_X2GX?^%_%4U_\ :+;5-&T^Z&J7EJ+$7F/^ M8_[?\)E_R,'\^F1P'B3]I;X2^%=8L-$U3Q)_X2'_ )C?_?*E*[Y6KRW>[6FFFB2L5QE MQOQ7QUC5_:U2;C!YMKC_3[ M6]L\?Z9[Y_\ UX[ 56K[1.Z3[I/]?U/S2UG9]'9KT>IS&I>*/"NG:Q;>&K_Q M)H=MXAU/_3[71[S6L:K><]N>>XXS]:UZ\'^*GPKT7XD:IK&G_P#"*_#GA+M@5P]G^ MS??Z#)X8_L3Q!X;_ .)7XRT_Q1]LO/#FO?VK9_V/_P )+XD.@>'O^*J_Y)R/ M%7_,GCJ?$GB[/;+OZ^G_ WY_?L;I82RNM?GOI_FOO/J#[1YTEUY'2W'^E'U MSQSZ=NGOFBOCZ[_9*AO+6Z_M7QA_:5_&R=*']L>#?$O@/_BH0/%1/B?\ Y&'_ (2 >,/&?.FG?7;3 MN1;#O9-_+T_S7WKN?15QU_'^K56G[?A_6ODB\_9Z\*WG_"3_ &#QSX;MO#^J M7^G^%_\ D7-!_P"*5U#1]"_X0/Q#H/A[5O\ A*O^)+_PFGBK_DH0_P"9I/YG MIX?V>K.'0_&WA^'7M/\ ^*O\1V&L_P"F:-JFJZ59_P!D:]XD\3>'O^$A\/?\ M)4= SGQ!ZX/_ C9R"0/"RG-=)KWKV:OVTUL^RMI;L@Y:'\K^[^NZ^\^@89H M9HQ\\._V5I7_( MY>)/$GB'_BGM%\5?\(__ ,S#XA],?\(WX2X;K7<^'/A1_P ('K%]K(]''ALV/VS^V/#_AOPYX>T'P]_P 55@#_ (2D>'O#_A/P@'O$/UZX]/ MD>']E^_U\^'M:\0^.;@^(1HWV#6;.\M=4U7[9J']O_VQ_;W_ D/_"5'_B>> M#/"O_"/: #C''L!75?\ #.HA\46OB2'Q)X;MKFWUGPOJ'/@+_B:WG]C^,O$G MB0?VM_Q56/[+T:::V7SMIW[7ML<[H85;W7JFOU/IB MJ]6*[_PYX%%QI\_B'Q3-_9/AVPMC=//<-_KK #=@D<+@#J>,GIDC.^+Q^$P& M#GCL:XIPC>W,E9)7=UTM;^M3GPF4XK-\9##8.+]^45%6?O7:7*K:R;O;1OOJKPMX'T?PG;[+.$379 M%S?W !GF)[D\C'3C&.O7.*^#? O_ 42_9PU75=1\,:?=7GA[2M$BTTMKE_+ MID>E9\1&Q_LFS .M2>(&UAEU;3,JVF,P#X$G0K^@GAWQ)HGB_1+'Q#H6IV&K MZ)JUJ+K3=2L+K[;8WEB<,+A&^ZP.XC(+#)*DC!%?D]'CC+N*9XBGD^.BW"33 MIIZVC*,6G%O9ZIZ>>I^Q3\/\.?\@+2/^O$?R%;Y&01 MZC_]?^'XUT]KZOOY]7Y7.B-DU;96^[Y>1^;/[$'[#]]^R9HDMMK_ ,4KSXIZ MIIVC:CX-\"3KX=L_!UGX6^'!UW_A)%T"[M;(_P#%3ZT-;)!? ?B73;[5]1\'^ M)_#D?V+4-M[H/B6]TEUTH:MM U[1]8C+(V'VNJQN^6*A6\3B3"8G&9'C\/AN M=R4)-.#?-=)-*+6MWI;\[7/;X8Q-# Y]E.(QL(SP"S>DYJ?P*_A9XQ\2-:?$_1]-?#W[,OP%\ M<^#O#0M/#/AFYMOB[XIU/2M6L_'^C%=6=M4\09\2''APNJ$XZNJ_Q '^DS]C MCX;^/?A?\*[CP]\1=-E\/7,VNW^HZ9X?N?$0\8WF@Z&_A_X3NAXCU7X M2^%SI@']F:KJ^BD>']%T+Q%K9SXM_B/C_P#X1/ S@'^B6+_D8=4_[ WAC_TZ M>)*^2OV+?V8-#_9-^!_AOX96&C^&M%U.*]UG6=4LO"MN3IEE_;6J-JYT&TU7 M6A_;VKZ)X>^T[4=V!+%U7&,-]:Q?\C#JG_8&\,?^G3Q)3 Z&N>T+_CQN?^PW MXF_]/^L5T-<]H7_'C<_]AOQ-_P"G_6* .@X4>WZD_P"/^>EWJ,#(QY^*Q>%P.&>*Q$ZDY-)1A&4Y2;LTE&*?>Y^!_Q;^'?PW^#OQ#^- M-W^T?\9+?Q%IMS?^%[P:/\4AIG@?5;OP0=*SX(U[X4^-?A[M;X?8\5?\)#_P MEOB_P;X&7Q8#X;VG!&!^>?P=^"E_^U5^T_XJ_8?\7^++#Q!^S]X?O]0^)5UX M_P#A-\9-2^(NK'4? FF> M7\/>#?&_A[XAMXT\._V(3XB\.GQ9X@_P"$''_% M?\8K^BS4I?V-OVZK"7P/XV\+^"/C;::-_:4$4'C3P'J1N[4Z1J>D'7O[!U76 MM#T$H%OSH'F2^'G0;U4L7# +[9\$OV8?@!^SEIVHV'P-^#_P]^%D.KVMC;:O M_P (-X7TG1-4UC^RN$_M;5HT636-AX5K]@=N2S$_=>79C@\RPSQ.&QJS%)_9 MDFMHNUUU7G:UOF=&+H8K 8CZOF."G2GRIVJ1E&<4TK-QDNM]W;LFT='\.?AK MX#^!GPN\,_#'X:^&]/\ #/@/P!X:L=&\.:%IML+>"VT_1[-44 #&Z\)MR6+9 M&[/(!7;_ "S?M8_M ZQXB^+UVFN_$O\ M#X2>(_$?_"1_$7Q9I>C?VKX=^#6 MG_V%C26;Q$/^0,WAXZ3I)8GDDY/+&OZO/'GAH^+/ OBOPA#=3Z=/XF\.Z[X? M.I6C^3?6(U33KK3!J5J0?DE0,KQX8$.JL..*_EM^.O[-'QDTKQ)XT_9T\7R^ M)/ _PX^+O@TZ?:WGACP-IOB[6/&NH'0/$FC^(D\&+HX\1:#X7!_LKPZ3'(/^ M$I/_ DBO@'81^%>-M+/JTLD668:K]2C43J.AS*2:<6N;EVZ]U:[\G^]^ M3 MARCB,\K9UBJ,<=*FHY2JSBO<;_>OWDT[)JR44[I)V5FH_A;^W1^TAHGP,^'? MC[XD_%'XD>'O!.GZAK$^F>,?#7@/2S<:Y\(]'\7ZI:^!_&)TG6_^$D.K-XR\ M*"P\0D^( ,>%L2+X38D,?Z&OV,/BMXO^-'[/'@CXG>-)#:[X+O=>U=O!&J:IX?RHT:^U#PI_8[NJG(+9R"Y(_D2\=Z/XJB^"]K%XU MUNX^''C[PY\1O^%?_P#"B?$'AT%?^$7T?QD/#8_XI\>*_FT-O^$>\0X*@K_Q M-^6'R@_V$_L>Z=;Z'^S/\%[*/2-3\.7ESX&T;5=1TC6C_P 36RUKQ#:)XB\0 M+=XR=PUS5+O.>F<'T$>#V,XCQ.;YQ_;&(JJFDE2ISY^6*3BDH^TN[);:WV;W MU]+QQRS@_+\BR6KP]A:#JXJHYULTI?S.>T+_CQN?^PWXF_P#3 M_K%=">AZ].W7\/>N>T+_ (\;G_L-^)O_ $_ZQ70T <7XC\0:9X8T&_UO5KBW ML-)TBU-]J5Y>8%G%9 -NRQ8!0 26^[TR<@#\4OBI_P4XUF:XOK'2/!_B?PY MX7M]#O\ 5AXE\/W'_"1>(;+_ (F0T?3?^$J\/:/HCR^&1(PWD22R'A5R<$G] M@_BMH[>)_AKXZT"TTTZS=:UX5UZRMM&75FT;[7?OII%KI?\ :B _V1YF2"^/ MW8)D;C-?R#^/=7^.GP&TO7/$^G>*O#E[\5OB#K0\#^-/#/QPL/\ A'+W0FPZ M_P!O :)X6R=$48.64KXJR"OS*2O\]^-.?<492L%1RK&O+\OQZM4J1C=Q:Y=> M9Z16U]>K;N?T%X#\-\+9[4S>OGV"_M/,,O=/V%&4E&$HM)R_=I-RD]=91<;J M'+9W9]+_ !_X*(>-+#68O%FI^*/B3XZ\-2?%2RL-/UKQ1XYUV'PYXIL&);Q MOX/\.Z3K17P_K1\&:-_PD+\,-S9;(/@G(_I3^)7@'0?C%\/KKPCK,FHVVGZ\ M^C:COL+O[%>6M_H^MZ5XBTO44<8(;3M;TO2G#8..5(()(_C2^#_@'5O!_A'X M0^-/'_[3VN_%'PY\(O$5_J/ASP%X3T;P_I2^!?%.D%AX?U/51G=K14+JN[P> M55<.FUG;>$_J(_8N_:"\8?$G0;[P9\5UL;3XEZ3H^C^(;1;&[TV=_$7@K6-- MTA?[>CCT:]*)=+XI&K^'BJ; %L]%D(8ZE\WB>#W%=''5L=PWF>/GF;QZ;4I< MSCJESQYN9V;5TDNO9JY]!XU\(/ /+^*CD>&P#C&5ERN4H./)/E:2=I)^ M\[:6W31^5GQD_P""5'Q@T3X@Z1X>\)2ZC^T/\'/B$/'%CXE_X67XFT+P[JGP MYUCQUJGVQ_&>I^(?# \.>,/%()U6\RGAT"919C**60M^^WPC^%GA7X/> ?#O M@#P?98TSP]I&G6\5[* =5U>^33K6TGUO5=7"!M9UO75!?5->8;FE9RVTY"^T M9B('?.<$@_A^?& .2*8",?UY_H*_;\AX*R'AO&8S&Y?@DIYA)-^[ M=PUC=)MWMHWWT7DC\/XFX^XEXMP. P&:XYNEEB2C%+EC+2*YI15HMJ*<5IHF M^]BS7,P_\C+?_P#8%T;_ -.VL5TU&[B_P!;87/VK9ZC'((^AZ3)G'7&PY_3-8EMC3W^QDC[)/SIN2 !SC^S>_P!K?VX-6T3Q4GB#X?ZTHTK_ (1\ M>(#X#\4 X\(L%#8V_JS_ ,$A_!-YM^(7BJ]U#3]&LX+/2M.TSX:67C77?B+? M: /%NE>&?$?]J>(O&FM-ODUUSH 4!49 -V\JWEK)ZIX\_P""0GP.^(GCGQ]X MYU#XB_&'3[CQAXAU+Q%H]G8>*3;?\(5=^(]>&L^-+7P^0&5!J.L@L?E()9?[ M7_X2;@-]E?LP_LQ:!^S5X8D\/:)XDU3Q)8RV.@Z+I]SJ]CIEF]EH/AT_\2JT MNFT=8_[8UC;J=UG7R#YA(W!!&/,_G_AWP[XBR_CFIG./PN6/+G*4HM2][5\R MMK=ZV;73J]4C^D^-?$OA'.O#VED.65\TCFD897%J=-*'N*FJGO*/*M+K5WNN MVI]>87&#'N&.YUO3+C2?%%J/*TGQSX9_L[3/ M'&@\]='\1&RDDL3UXRPZ\9KZ1PO]\GZAC_,TO Z.1^!K]QQ^6X#,L.Z&-P\) M)N,FG%/6-K26]]%HUMTM<_G+ 8['9?B%B,+BI0DE92BY1EK:ZTM=66J>YXC\ M%_@KX.^!O@:Q\"^"8K\:;!_\ +UX?TX'X#..G7G/O_GFM M,-AL-@\,L-A5:*M9+R5DEKLK*QE7KXC$XF6)Q#YI2.6:;]U%;]3VYZD8[9[>GZTM'C*6[W4\8@N;^0W,\?HQ&!^G/U-5[G.H3F MV3'V.W_X^CQBZ//_ !+#G&?4\\< 9.:Z&NX@*K^1[_K_ /6JQ12:4E9I->8' MB/QC^(&C?"?X>ZY\0=<69[#P^EK^YAMS /B7I'P[\4_##QY9V?@_P;XR\#ZQH MVMMX;UGP_P"#?[ 9AX@76E+'&N^(O^$H"IXCV(H 51_7-KNB:-XFT35/#WB. MQL-:T+6[6^TK5-)U*U6]L-1T[51]ENM,U*T8,&#AO+;MMW $8)/X2?MB_P#! M'[PUJEIKWQ$_9-T'3O"'CBXU3PQK]_X&L2=*L=8U'1B2HTW5-9UO_A'TL=HT MK.A;M+0O8L&\5QDK&?Q;Q8X4XBX@PV#J95B_]@P&LLIY5[[22YF]7IT\MC]M M\$^*N$N&-!XH8KX5!VK\J M@#PL_AUF/BO>,O&WA;X>:/\ M$?$ M32?#WA^X\'Z9*WASP[IO@OP[KLB-H6I^-M%_X3B?%#4_\ A*/%'AS_ (5]X-\&_$;P M/X[_ +8T'PWX;\/?"_P]_P B5X@T76S_ ,(]I/\ Q6'_ %,G_)/>U>GX2\'8 MGAK*O;XZZQ^86?*_LK2RM=VM%W>B]+6.+QCXSP/&G$#PV!Y?[,RV\*44D];ZN[N?I5I?[2=O;W.MZ)\0?#FH0M;Z+K/BB[GT#2SXCTNT^& M *[?&?B$AN!@'=X?/B1OB 21_P 6^7!!^4?B/^S'_P $G_ %QX2^.6K?L[_ M^6?5?#>L?$#PO<^'?!.@Z?I>H:,5_P")MKZ^"?[:\&>'M<*GQ$.!X9/BC.=!^-G_!3[Q7%X=TSXL>,O@K\-?@#:Z-\+OVFK.'PKKWPD^,/CO3_ M !+KZAM"T!C_ ,)&OB70O&.A^"=6;^W_ !&WA9O"P\1GQ;&K. M:/[6&E>'_ M (TWWPZ\'_!#P'H_A[X4?"?X+^*/!OASX??&3Q;XQ\#_ /"4?!;^P/$8\$?& M,>-\>-O$'AC_ (GGATGPG_PFG@8G)/\ PL<^%QX; '[![>2TU7X:]]]_P\C\ M7]AY_C_P#^DKX;>+?AKXSTO3;;P3KMA;0P:-8'2] &F_\(]>Z;I[$-I7_$J8 M@X!TL[0. J\;1M6O5/\ A&?^GX_^ H]_]K_.?KC^1/\ 8;UCQ+J6O?!;_A#_ M K;Z;XA\/\ BWX?_"7XJW@^+_\ PL;QQX\^*'_(R?\ "T/!']C?\RKX,\*^ M(?$/B#'C/_A%\=:_L;WGT'Z_XUG]:Q2T=DGI:RU6F]_3S^8OJ&'3B[*Z:>K6 MC37KU_(\:A^$?@^R\2W_ (PL- \-VOC#4[ :?K/BR#PYI8\5ZG8$?*NJ>(2! MKYR,YPW&,'V^*_V]]%\30>#?!-M+HGQ(\5?"*X\1:@?BKIWP?TK5=4\<@:1_ MQ4G@B[:R\,@>(AX5_P"$J'_%6#P\ 1C0O0U^AGB3Q3X5\*VEM<>*/$NC^&+" MYN1;6UUK^J:;I-M>7S XME;6< LTW]KOP?XJ\#^, M/ WCKX9:AJ7CGQA=?\*O\!V7Q8\!?VK_ ,('X7_M[_BGM>\/>'M:'_$FUSP9 M_P 4]X@[_P#%5>'!GM7TA^PY^Q?\5-+^-/QI^ /_ ISX7_!RY^*'AS1_BUX M<^*__$T\1_\ "!^%_P#BF_#GB'P;X(TG_P N#_A#_P#BE_"O_%2>AK]HOV]? M^"97@7]JSPD]]X _L;X??%VR\6+XSE\3W]UKMOX=UW6'T'6M'U(ZM::,<:+K M'O#0U8R68&"'.SW?\ 8@_9.NOV8/A]#'X[\:W/Q9^-?B&T\KQY M\5=8MKJWN+NRLF(TKP9X?W$G1O"_AX,H1 @/B>16\6.69ECTN;ON_O\ Z[+[ MC2UNEK:>GEY'R_\ MQ_#CQ3\)/V;_A'X&^'5V=6.CZ]X6^&&C:OXMF6R\+66 MH'0/['\.Z_XW 8^'\?\ $I/AW=_P@P\*;O$1V_\ ",#!/\\__"$ZM\5/'GQ1 MF^&/@?0_!&C^ _ >G_#ZZO?'/QW_ .$X/A7Q1HWC+_A&_BQ\4/A/\)]%_P"0 MU_Q2OAW_ )$_QI_PB_\ R+?BW/\ PB__ FN*_M[\37?A^XMV\.Z]J%C:6WB M.WOM,-O<7ZV-[=AK;#C2LR!B50M(V Q'RG#?=;^:[6/^"3?QL\8_'?PY\+-( M\/\ P_\ A)^S'\.[?Q.MI\6_A]71O#.B:EK^N^)M>\1ZOJ-AXM.-'L5/]K$:%X?01!6#,KA01]9% .2WZ?\ UZ]/Z_B$E[UDK?G3\ M_-W\QY1ESDW;5N[]79NWSV]%VU^$?BO^RAJ'Q$U=];TCQ?;^&+[[-I&C2WFG MZ7;_ -K:EHVCCQ[G2VU9U7:/[>\;:5XO&"V?%/AM3QJ[_P#"5#@M5_8O\8:Q M)<7=K\<=7:RM+[5HK;PU)8_;O#?V#Y='\/Z7JAUT>,V=?#GA;P_X&7<%&?%F MDZ[XL.&\2,J_5OB_X8WGBOX@Z=X@OO$FOVWA^"R\/VAT/1_&7C'PW]M>TTSX MJ)JX'_",ZW%D:@WB#PG? MAF'AH"M_P!B[Q3!;[;C MXIVD6K9(T>Q@T;_0/[."^/3J^ADZ&?!:KH/C(>-M 'BUM \-+\VBX_B4GZ!\ M6_!OQSXG@U*[M_B)K6FZW?:9K-KHNH6'BWXB:3I6GW][\.])T?P]J:Z38^*B M"-,^(@/B+'W]F,@OG'EFN?L[_&75X]#N%^*.LZ5/$/C'_ (2'6=#\2-\/?^$A\5+I/B)O"'A[PQXH\)J/#>@DD#.#^T<5 MW?XC65X9=.W1=.7_ .1_JQQ]Y^P]XI30_$$*?$CPQ8OJGB.^\4:-/_PBNK?8 MOAMNU\^)!_PA2CQ3N0'!Y< #O@@U7L_V&/%4']G30?$[2[:Z^W_:M3N-'\+: M78_;&_X3+QYK&D9.& _X0W0_$/AWP_X3_P"$=7PN,>' 0?#&:]8U'X-_&9[1 M]-T_Q5:H;^U70?$=WJ_Q%^(MZ/$ELWC+P)J_B'QX-*;0@/#.M^(-#TCQ%H+> M#?#C?\(P!JX_XJO#!2:!\"/C#H>OZ-J=U\1_$.L6VG^,K#69'U/XEZH-+O-. M_M+1^O@K1?AWX;4$Z&+W0!H1\3II(!53CP@/^$ )_:.*[O\ $%E^$22MY;=K M>6G]>9YIXD_9+\;:1\-I=#M?B9IMC?:9K6H:S:ZE_P (X/LVF Z =)\/'2-Q M!.M_\)4!X@RH;Q5F]X^(1\7A_B!XE\KT?X&S6)-/UNV\/W7A>_NKR\ MM?\ F:/ >O> _P#A(=>\/?\ %59_MSQF/!&K?\)9U_Y&3C_J:/HCXJ?L_?%# MQ3HGQ/@N?BUK3Z%XG_X26YT^P_MCQ-8_V1H\FOKJ^DZ#\N?E70]6\;>'W(PH M5?"97<$;'SO9_"OQCX;\+ZQ8:7?_ &F_\0>(]/O[KP_9^//&6E:5_P ED\2> M//$/_%0G_D"?\4MXA_X1_N/%7':OHLCQ+KZUG]^B4=-+?HWKN?-YWAL/A+?5 ME[UEHDWKI;T_+IW+6I_ V_F_X2&_L/$EO;>(=4NM0U#^V+VUS_R&->\>>_\ MT*OC?P]X?/\ V(?A(=\UJ?!_X8^,/#?B+5X=5U_4=;L!IXM?#EN?^@AK&/\ MA(?^$?/?0_\ A%?#W@GP_P"$P?\ A%\G_A+?^AUKG=)_9E^+_C>"PLXO'4_V M_2O]+/BT^,O&0^Q:QCPW_P (^?[)_P"J4_\ %0_\*].?^*_&/^$P_P"$7/3W MK3OV2_%UEX42PG\7:M=ZQ_;.CW5U::K\5?&&K6-[I^D7>M:O_9?]K:'X6\%# MG7+KPZV3X9''AP;L-\HZL5FN&P_PVWOARTT#2-++:KH1DL="\1*=>\0AMG MA;3-1TZ1=6 UQB4_L\I7Z)#&'._>#GN>.<#@#IG@Y[X. :^&?VU?BI;>$=$^ M%WPEM?LUYXC_ &C?BEX5^%-K93D';X)U;7-''Q*U3:%.%7PO=-H*G.X2^(K MCD),'C\#A\8\-B<="2BU=J"LG9=DUOY6=['WV0X_*>$L=E./QN! MCC\#E]6#E%NSD[QT=K.ZE[RT;TM:VW\IW@O1-0LO'O@NS\"ZK?>._"GB^U\ M?!O6/%MO\(O^$X\<> [[6%\1^)/!!TOQMHJKX@UC7 3I7AX^+_&9/'B-69L^ M"]J_V"?LL> O$WPZ^ 'PW\'^-7E'BC1/#EM%X@82:8-FJB.E)I6DW%Q36MGU?R:L[]E^R^*GB9E_&N&RC!91AO9Y="$) M/FBN?F\\Q+3 M2[&_OKL6]N;R\FL=)!:3;C)9@ 7P<]>6'S,)/#G_ " M(_Z\1_(5QOC_ .*/ MA'X>0VY\4W.J6<5R.'L]&U75 01T;^QE8C/.>#].U?K:?,D^ZO\ ?J?CFQ_) MY^W%\0W_ &HOB%XV\:0>*/AQX9\0^'O"?@BUM? %[=>,?$>K7@.OZ/X]\#ZG MX>U?X?>*O^$@\,_$4>%#JR^*\^!CX6P,-X4)_P"$]8_HY_P2>M_'7C35]>^* MVG^'].\(?"3Q9X3OM1T_P]X1M/$#>'/ GC9?$ \.>(_A>-?\9Z@I\::Z=;TG MQ%K_ ,0-2'ADA?%A5F\5./D;ZE_:+_X)U?L__M0/I'Q ^%E]X<^!WQ?T+QE8 M:[8?%KP#X.T*^U8:CX:75O#P_M7P^3X*8IAX:^&'@GQ-XUU]= M/M=U_=:;X//%.LZS\*-8\&_P#"1V/P9^#_ /S)'@W5?^*5\$^(-9\5'OXP M_P"$Y \5=<5_4)\;OACH7QF^%GC+X8^(_*.D^--'_LKSR0HM-0+"[TG5!A26 M,>M+IC;0"6( X)R/Q:\;:;\5/B'XR\<_"6_^$OB2V^#_ (.\9?"^U_MCPG=> M#?\ A%?%7BCX5^,O#?B3QOH/A[P]K7_"$^(-:\*_\)5_Q3__ #+ QU_X2BI4 M8Q^&,5Z)+\O1?<8MN3NVV^C;;:^;/"/@_P# O]I_Q1XRT?X@?M-?M/\ [1'Q M(\4^(/['\4? >S^$_CS7M*^&6@ZAK&@^)/\ A(?^$A\/?\)7_P (_P#VY_PB MO'KC_DFU?U 5\):!^RQJMGXHN9_$7B-=4\'_ /"9^"?&6C>'K#^TK'2_"E_X M9'APC3/#^DYP _BG2/\ A(DU]B& 8;@I#!?NVJ$%<]%_R,.J?]@;PQ_Z=/$E M=#7/1?\ (PZI_P!@;PQ_Z=/$E '0USVA?\>-S_V&_$W_ *?]8KH:Y[0O^/&Y M_P"PWXF_]/\ K% &K*K.J@=,GZ>A^O/X ^E?S,?\%"?'&M:#^T9\1]6\86/Q M'U/P9X!TSPM<75Q\/M4O'\5:'>:SI@'@T^"- 81,^[7-4*^*)/#Z^)@5"L(P MH\41U_3-([;7."0#@=\9/)Z8XZGIBOS\_;N_9BT_]HOX8V!T[PKIWB7QA\/O M$FG>/M#T._N1IB>-7\-VFLW8^'SZRS#[)8^(S<>2YOQ)X:W,C2#R@'C_ #KQ M-X=S#B+AR>#R^4E.*YN6#:.[O^R#_ ,(]X>^'_A5L:'X-\*>'?#P&@%?# M/_"3L?"+;'VE#_7+H>O:;KVCV&N:7(->\&?#+PK MK0LM8TLWNED*3MT3>1NU7Q#_ '$QN \+F3;XG/\ 1-X,\):#X)\+:)X0T"U% MEH?AC1]/T71[99/-"Z?I"*MJ%R,D#:"RCB/)\!BZ&;X18'!7 M]Q3?OR:Y4VKZI/H]3ZWQNS7A3-LZP5?(,7]>QSI1CFSBDJ*NU)*%E9N.OPWT MM=MK3N@ 0..,<9J-H(7^_%&_^\H;^8-<+X[\<:)\.]'_ +;UOS_LV1:V]O;# MG.!Z=#C SS@?F/B;QM^TA8_$/5O#EG\)OB+9:-I6L6U_8?VQ9:IH/_"566O_ M -@_\))MN_!.M\'&B?V5@^(E48O0-N02?VJ4(32YHQG;9R2EZ/7?OV9^()N/ MPMQ]&U^1^@1TZR=G+VMNWF$')C4D[0/5>/7Y35Q411M555?[H ].G2OS8_9 M8_;R\/\ Q[^)/_"H["30_&7BK2_#OB'Q%X\UCX<3Z]XD\*?"O4=*\0#PX/ ? MC;Q$_A7PYH(\5;B BJ1_R!]=4#A /TQ.>PS[=*(TX0OR0A%_W8J-_FD7.K4F ME&T M+_CQN?\ L-^)O_3_ *Q70USVA?\ 'C<_]AOQ-_Z?]8KH: *Y&00>AX-?C7_P M4P_9OTO5KSP-^U?:?#>#XM7GP*TWQ1;^(/!-KI5KJWB&\\/^)4"/J7AT8"C4 M/#9U(ZE('Y_X1A]1W#FOV3+\+QU]!T[D]/8#CMTJ,QJZR1R+F/C //3KD$>N M>AXSQQQ7S_$&18'B;+L9E6*BG=6C*RNM8ZK[FM&KK2Y[?#?$F.X7SC 9O@5> M4))RIW:51:)QE;3WDWK9ZVWV?\8_[.W[%/Q;_;@\3?$.Z9=2\#?!S6_$>GVM MS,FOO:-H6CZQIFJJ=,(4$:QK8_LKPX"V@%54>),LP4$C^H?]FG]DOX8_LP:+ M>VG@2?Q5KFJ7NGZ=I=WXF\>>(F\1^)[O2=' 72]-.L.NX:,A+%$&T@$%E)QL M^I[:"*.*39Y"@]## $(R3R<*" M'61\)P4\+0B\?:_M&DGJUL[:)KS>][V/L^/O%GB+CRLEBJG]GY;'EC')X2DX MOE45S2>TYQ^3,F^(]1^'KS[>]8_VJ73S MLOL2V( _XF0.<87'_$S!QCJ!G&.@(';HZ* (8Y$FCWQ8P?8=NWI]*EP/0?D* MY^;3(O,,UGM'_$^\K_F'7;G_ *^=+ _]2/J? MIT['J =#161YFL_\^=A_X-KK_P"455?^)]Y7_,.M''_7SJ@/_J.=#]>O<] # M:FFAMXS+-((HP!EC@=?H"^EQP;C& !GL !C\0.V.U;= %.VCALX?(AB\FW@& .3^74G MWY-7*** "BBB@ KPSQG\I:-:>'_#']G:KK O_#I' M]O@V9"L#X>7&\.00PVE2/F'R/_P4BO?VG/#_ ,)_#_CC]G70X_&NA>"/$_\ MPD/QT^&>C7ATOQOX\^%HMG;7[3P1=$ WFH;;:[)\.X'_ E!;8&8*#7Y=_!/ M]NKX#_$CPG\>?%5M(?\ A(!GZ>] ;;']*.@ZWI7B32[?5=*F%Q87&3$0._N#^G\^M?FE M^T?_ ,$ROAG^T'X_L?B%I_QA_:+^!VNVWB#_ (2*ZM_@A\0%\-^'=3U@[?[> MU0:1K7A;Q*-%UOQ&2ZMJ/A\H5D0^*U635B)#X%X _;N\%_#SX4>(KKX=^*?$ M/B[X<>#_ !9IVE>,OCA\0-,U^_%EXI\=Z_XE/B J"<:P?!A/A[Y@!X6_XFXR M3M7'ZO\ PI^(_P#PG^B27-T;?[7;C3Y0;0_->:?JRDZ5J7V/EM*W*"2IS]TM M]\"B_+K>W+KZ6U_R!=UUZ[W_ ,^AY-^R/^QW\*/V-?A]J?@7X97/C35DUO5& MUWQ'XG^(WBAO%GC?7]9.,76K^( JE\8. .2>I&1^:O[:_\ P2"\+?$#1-=^ M('[+]WXA\$?$^W\)?V!;>#_^$\\9W^D>*;#1]?O/$>DZ#I#>*/B*N@>&4W:K MJZ)H+(GA5Q>!E'A@9:OOC]H/]N3X3_ /5[_PWKVG:_XDU^PGT&TN]'\-_P!@ M'5/MNK6QU320%UOQ-X=X=1OYQR1_"2*]1^&W[3/PL^(^J1>'=/\ $VCZ;XTN M;6PO]-\(ZIK.EVGB+4+"]T[^U4U+2](_MAFUBQ"FY9FL R*;63)"(I/RZXRX M=J9J\G>9Q68IQCR2DHMR5ERZVL[JUM7I;4^@EPQQ)2RY9Y5RJK++FHR]HJP:5JFF6?A[P(UW8Z5J^OZQHY5-:USQ?G_A(F&&/A8;5 +-XF5][_@H M?^U?XI_9-\._##Q>NBZU;_!_Q#XS/ASXT?%31M"NO$0^$&D7?]E1Z5K][:IM M&D6)%Y=[M=(*(ZJP175#7Z85QGB[PQX?\<^%M=\'^)=-M]:\-^)](U#POKVF MW/\ J+_2-84Z1J]J>./W9(.?7@@D$?4?B?/GXE?#?XV>!OC!X3\?_&3X=?$: MW^*/AWP?#?'WCZWUD6U]J_@_4]!TOP19MX[U;Q) MK/AUB22-&T0$#0!QN4@G<3T_GM_:_P#V>/\ ACS]L/P]^SA\%]:\$?#[X#_% MS1O _P 0?$GQ _:-\1CQ)?V?Q \>?%#Q+H^?!!'A8KR/#V?^$?\ &1_YEO/_ M EF?&QK[K_L']E?XD?"OQ#\'/!^M^!_"5MI=W_PB_B/X?\ P'M= U;Q'XJ^ M/'_(M^']>\/":667RXX!F>4X'(P<=<#''I@D#OBO ?V=_A M7U3Q#XY\7>*;JTL-5\5ZW\2-:ST#[*/#Z#P]X:"E!9/RBDOW_Q:\'7/Q%^''C?P58:U<^'[SQAX;U?0+76 M[+FXTW^UM-:S^UK]-S#KTZ DD>+3?^ /#] MAX!\2_#K5SX$\8^)O!'C'^QCXD\,^-O![:QHFBO_ ,(P?#R:J/&(\0!W\+>* M =@9MN?"_P!G_L&_M6>,-8^,NA?"^S^*.F?%;P7XK@%_87'@_1%L_AY/J0TU M#KR^"=5)9=)?PXWAS5=>\4^'QXF9L^)CY7A4,P:OBS]IGX)_M4?LN>)-8U'Q MP?#]Q\%_B1X\\,:/?^,?AQHW]DVF@>%UTL:N="TKPX,D$?V#JP)!(PPYPXK] M2/\ @F+^R5HG@;X>>&_BCXG?4?%4%MKGBG6/V>+CQ%H.A:/JGA3X:>.+/=_: M)TS14 6^U\ZMXA;S'VG_ (1?553:&.*_E;(\JXLS'Q'^LUL+6RZ,:DL5FNLW M3G!22BHJ]FFDK[W^2M_6W$>/X&R[POIQBJ&9494%EF42BJ?M5FG)!2J3Y5&: MY&[MIQTO;9(_:$'(!]0#2T45_5L=$E=.R2^Y+^OF?R">1:WX T36/B'X3\>7 M>@Z!>ZCX8T3Q-8#5;O35F\0PW#:IX=O-)_LA@0Z\:1JF3R?F4IN.0/F+7_@I M\??$-G+I4_C/%A<>&/%&EZR)?B?XQOM*U?Q5J^E[3XQ_LG_A%CG1/$.2/^%7 MC/A7P#D_\(<2#S]]450'RGIWP8\5-:^#=,U+Q3K>FZ9X8\)>!_#%S8>$OB#X MQ\-V-T/#>E^.[+5,_P#",-X;)9SJOA8J0 ,:-A@&4[O(;OX)_M#ZOH6H:1XA M\66NKG6-$\3V'B&QC^+/Q%L=+USQ/JUWJQT?QEA?"A_L70?#6B,N@#X8#_BD M_'OVT'Q@0/#8/BC]"J*!77=?U_PZ^\_.GQ7\'/VH-=NK'5;#Q3X?M-8T3P5K M/@>VO9OB?XRTC5KYO[+T@@>*00 M,*2!@;8^"/QZM+?5+;PKXO;2;:YU3Q1?^'+S4OB?\1QJN@'5_&9U?2M3U?\ MXD9'Q!_XI4'P^N@^,SCPN,%&8 =2T7PKXI+36^LZA MJ=A<^)?B/\13JEGIP\':1C_B:AF_MG/C>SU9CH'C(>)_"S:1K*[B-H5?GGPQ M^S'\;-,=5_M_6/^$/ TK7SI6N>%U7^P_$' MQ&!9AG=_PBBG"L< _JT!&Y/;_'GZ8_KZYI^ %'8GD?3T]/>MKO M?>W??UZV/-KX!5\2JE=+E5K-;):6T]5;IM;4_/>R^!GQ?\&^(FO-.\9ZG>W/ MC?4/A_X8U.32/%OC+[!8^'_[!UBS^)NJ_P#"/$'P_P"%[[&K:OXP\)^(!_S- M7ASPEX1Y_P"$D(K]"W P3CGCG\:?D'H0:1NA^A_E65[ZWO?K>]_F>A%1BE%6 M273[O\U]Z*#&-5;<>,9&3R<#D?7C\.HXK^8;Q]^T'/\ M!_\%,_!^MZ#?M<^ M"OAAK6H^'?!'D$?8O[/\":#XEUGQ#KOO_P )EKAQ[^%1X3)R2:_6O_@H_P#M M#W'P _9OU^YT.]-MX[\>D^ /!?D*#?6<^L KX@UQ<:@FT^'?#"ZI,CXD'_"3 M'1$(594*_P \W[ 6C_VE^T%83>1_R"_!NH7_ *_]"WX;YZ_]##].PP,5^A\* MY)"ED^\GR\\D];Z*,5;5/G[L_'^,L]5?B+AWAW#/5YK&4^ M5MIQBU922Z=-=.A_7C\+(I8? OA[S_\ 77%H;D\XQN(&/?L/H?>O1JYCPK;_ M &/PSH-M_P ^^EZ?^MJ/IZ]^/>NGK\^F^:4G?=M_*Y^P1CRQC&UK12M:UK+: MW0^)?VG/&/Q1\%_!*VU3X5^$/%_CK68BVEG1O"VJ:#X;!)']CZ3_ &OXA.N^ M"?$.CZ&-9*#/@UCXIP JA!D'\H/V@_VNO%7[/=UX/^)W[0#-9 M\?ZI<_%#2?'%F?[!/AK^P?$/A[1?AQXV&B:'XS^(V?\ A$_^$,_Y&HZ>;;:5Z^GS \X.&/I7YB>)/^"3/@ M;QCXDUZ\\7?M/_M6>)? WB'6=.U2_P#AIJ'C/P8?#EY_9&@_\(W::7JNJCX= M?\)"=#&A_P!J:"=/_M-?EO$ M/^$ ^$WP*^'^E^#;'PH/A\QM/$>D>,O'&K:)XI\2GQ/XJU(W+ <>%\[3XO(! M\2?V5X7^SOVPOVG]*_93\!^%?'GB+1;VY\,:OX]T?PAXC\9SVVJS^%?AQINM M&14\8^.?['LFD7PL+Y;/068%,RZM8,&Y<5]=VEG;:=:VUG9Q"&VMK?[-;6_0 M!5P<<^N!DDCJ3CI7,^,?"7AGQ[X8UWP7XQT2P\1^$_%&D:AH/B/0-4MOMVEZ MQH^L?Z'JNEW:GY65QN5AU&*M/\(?$6P^*7AKQ)8^*= M:'A?1[T>(1I7PSO?"_@$_P#$_P#BCDCG_A,B/E\'D8'_ DGA''Q"K[-\"?& M'X'_ !1\;WB^'M-L+[Q%I6LG1M/\5SZ-I0-[?_V -8(TG5LC7'8Z+JA 8A MQ4%?F+?S3?'?X8:#^Q#^UYXVMO%OPJ\6ZE^Q_P"#K$^)_@/\/]'_ &8M6^-W MPQO=1\1Z%X$7Q%H7C?XKZX/&WB'^V_&>NCQP0?$60WBGPV&4E2"?V>_8K^#F MA^)?%>N_M*+X7^,G@^Z\4V'A>71H/BA=>,/!%_X@U : 2-1'PS8>'0OA;P_H MGB'_ (1'PH?$4T+_CQN?\ L-^) MO_3_ *Q0!T-)@<\#GKQU^OK2T4 ,"JHP$ 'H O\ C3MJ^@_*EHH#K?KWZ_>? M.'[1GP?TCXY?"[Q/X'U6RU;5VN-*U;[!I&G^+?$O@>WUV^_LUP="U?5O#3B3 M^Q->!7S=P(&5*#.\+_,K^U3I_C7X@ZH/AK\"?V9_VF/A]\=/A_JGA>U\(^.= M7_8S'Q&#:-K(_L<:%XA\<>)_"Q\/'X<>#/"H_P"$?\)XX([XYK^OFB@#Y&_9 M%_9H\!?LP?"'0? W@KPEIOA'4]5T_2?$7Q'_ +/U75-477?B3=Z5T- '/:%_QXW/\ V&_$W_I_UBNAKGM"_P"/&Y_[#?B;_P!/^L5T- !1110 MF!Z#\A2T44 %%%% !7,P_P#(RW__ &!=&_\ 3MK%=-7+0_\ (U:E_P!B]IG_ M *=?$- '4T444 %%%% !1110 4444 %%%% !1110 445^8WQ@_X*/? _P#K& MF:+%XHL-#AU#1?%&O:+XW\::+KL'@G73HZA1IGA^3/AY]9<:UOCW(X^72GR2 MQ#* ?IOPX[]?\^OK7\F?_!6KX%V_[/\ ^T/\&/B%X(/C']GC]F'QKI?A<_$; MP]^RW\.?[*/CSXH:1\1L^(=2\;CPPJ>'QKB_#GQ%_;P\7ZBN[;X:!8^*&\.& MOLSX.?\ !6Y/$/BS6=)\;:WI&MQ:/\9/"WA.Z/A/PH1X=_X0?Q'R-=&2?$'] MM^'" 2.58:.=RG+9_?WB2/\ R.G^?IGVIJZ:MO?3U _F)^"O[7G[._[5DC_! MGP'IWQ(_:$F\%V&G_#3P1;R:-KVE>%?%6CZQ_P Q[Q#_ &+X5P?"AZ?\)AXS M&3_PC?BW'M^XGA/PS\.OV2?V?$L],T/PQH6D>#?#ZZGX@B\%Z59^'[#Q!XHL M])LQ>'2](!C']K>(;X8\,6!=GD9M%A1LB.O=_#7A'P?X/M[^/PIX5T#PJ-4N M3?ZQ%X?T?2]#_M'42H']I:F-&1 QP#AG!92S@$*6%D:CI.J6FLZ5K.EW:HVR^36;2-P_(8?*5&1GSLP M6*E@\:L#;^T'"7(]+][7 MUUU^%7LC^2K]L!_B%\:/%_QR^)WP_P#AUH_BS3-;\.G5D\+WGQ8U/P+XJ^#7 MC;PWKS,/&.E:KK'A8#6F\8IJHU\^#P /"^UFPO\ PFP%=)^S9KVHW_C/X.>) M? 'PL\5^ O!NJ>//#'P_\63>,?$1'C>\^)W]ICPU_;NE'1-W]M#P<022/$GA M?Y?#F/ANI(R>W_;!_8'^/'[+,FK_ !'T_P ;^,/C9\*?$_Q?_P"$H\5RZPVD MMXCTW1]8_P"$DU<:;JK:)X5P4/BH:3H"DJOA@KXD&Y8WR!^HG_!+S]E7PAX* MT+Q7^T1/X U/P=!\:F\,Z_X!\%^,;O[;K?@K1TTHI)J6E:0"^G^#1XR9AK[Z M7X?90,C)X(/\CY5P3Q7CN.EA,ZP,X1C56;2SE75USJ2A=:1OM9>7<_MK.N-^ M$+O)MQ;4E9N^I^IGCSXK_#[ MX6: ==^(OB_1/"=D+*^U"W&M:OIMA<7BZ3:F]NAI5L[9O7"J=ZDLX8@LHW#/ MR-9_\%$_@5=_%:3X2W=S<:+J1DG& #D$GY0_X*G>'OB!)?>!/$NG7VG:3\//#OA3Q1J_COQ;XP MT?7M0\$'3O#FI6.M7G@[Q;XAT3"> ?#'B/13K!=M?3Q(GBISH2",'PR<_@;\ M&?L%QJ&L?M)W^J_!+X2>!KCXO^%_BU_PK_P/HWC+5?'%GI_]@Y\/>#?^$WUK M_A"/^+._\)5XA_XJSP?X,[CQ;S_Q1//]C4X\L(1WY(15]]DE>_GIKYG\/R?- M*32Y=6^6]^6[V^5S^R'XW?LL_LZ_M*6&BZ5\>O@UX"^*UIH'V_\ L+_A,_#M MMJQT@ZLH75#I;,#)I+LH568OD;54$G+'Q?\ 9]_X)P?L1?LJZLWB+X&_L\>" M_"OB?[9]OL?%.IG5O&_BK1[E;4:6O_"/^(/'U_XE\0>&5. '70'C5P6#*RR! M3ZO^SC\:KOXX_#^3Q!K_ (:M/"_BWP_XIO\ P=XM\.VVM:7XCL=,U?2!I6KX MTO7](8K?+)H>K:!KH('(;;@;-X]W\2:TGA_0=:UMK.>__LC3-0U/[':1>=>W M@TA2QV@#YCE0<'D*6.< K5?Y7^7?T(NNZWM\^WJ=37R1>_M%Z+8^,]!T@>'+ MV\\,^+I1:Z9XITZ\&J 3FZU;/_"0:4$ T;1--%E\I?Q(9/\ B;D#PLF>/SZM M_P!O'Q9XQ\?_ !$\-_ OQ5;_ !1U+POX-UC[7+I>H:%_PA&N_%#_ (IO^R?! MO@@^)^?[=_XFV?\ A'\@G\Z^9-8_:$^%?A7P;^T/X.F^$OQ0^$NC:IX<_P"$ MI\2>![SPY_Q-=!\4:Q_R,1U;P]_Q6WA_1?\ F7O&'_%&#_F9*!G[\Z#XK^&W MQIT'41HM_P"'_%^D1:@;#5-.G^RWOV&_T?5 AT_5=+;>NY-8TQL!QAV!P"!F MO5!'%$HAABCC'10 H '7H/IZ]?>OYU?^";&O_M3?MD_$3X>?M>_$'3/!G[/G M[/'PL\'_ /"#>#?"?@;_ $Z_^,VH?\(\[#7O$-UK9!\->%?!O]OD 1AW'BS2 M/%GA(J%W,/Z+5N+>4$I+&X'HZD9';.<5S_[.IO\ AQG+1[*;6EKN]VO7RV-F MZ_(E+VCIQDVD^9P4]%>WP\VD=7KHAN_<1WSD9Z8P,^GO7YO_ +;_ .WYX2_9 M%32O#]IX??QQ\2O$NFSZMI'AQ;I=+L=-T^SG*-KVOZJ5/EV!^RL,JQ8C27&5 M! /Z/E5XD')YP?3N.??KQCGFOY*/^"M$DLG[9WBV&6;RQ;^#O )M>YR=$)/K MU)/7GKWQ7VO V2X3/L_C@L3K3<')VENERI>5FG=M-:Q2V;O^>>(N>XW(* MR_W<0VH\UK6>C=[]M=+.[ZZ'N7_#[/X__P#1*OA-_P!]>,/?_J-^_P#+TIG_ M ^Q^/\ _P!$R^$O_?CQC_\ -17Y0>#YM*A^W^=-X;MK_P#MG3_],\66O]JZ M5_PB_P#Q4G_"1=^G_(O#MXJ-=S#IGPM?MG^HO"T7;ZE)V=G[TM;/7[7EZ'\X?Z_\82VS MIJ^MNU^7\K]NFQ^DW_#['X__ /1+_A+_ -]>,?\ Y=U'_P /L/VAO^B5_"D_ M6+Q?_P#-17Y_P_\ "I8)/ $W_%)_:=+NM0_X2.TQKVJZ5_9__"9?\A[/']M: MY_PBO_"/?YZ)_8_P0AS8?VKI]R?LNGW]K>?\3_C4/[>\>8T'_D:O^0&/"O\ MPCWB ]/^*J_Z%<_\4K6/^J'"^W]CR[?'4_N^?G^?D0N-^-+I_P!N:73W7]WI M;[_1]U?]!O\ A]E\?_\ HF7PD_\ ?QA_P#-/2?\/L/VAO\ HEGPE_[]>+O_ M )IZ_+C68?AU9R:/+I/V?4[7^QM0O_L=Y=:]F\U#^P?^*?\ ^$A[?\AS_A(> M<>%NY_ZFKQ1W,.A_!:\U"Y^P:A<7-M]JU"PM=&LO[>U7Q'>?\3[Q)_PCO]D? M]1SQGX5_LG/_ +J]:K@;A71O!2Z77-/[OC*_U^XQ32_UA[:_Z#7_"9^*O_ "U?$G&:Q[/3?A6/$FL6%_-]EL/M6G_V->>Y\&^)/^$A)_XJ MK/\ R4;_ (1[P_\ \CR1_P (KGU/BHO_ %,X5M;^QI-?]?)Z[?WK?\-Z%?Z_ M<8/_ )G;N[*^ZUY=>KZO[M4['Z8_\/L/VAO^B6?"G_OUXN_^:>I#_P %L?C\ M<_\ %K_A+R,?>\8__+NOSQU+PW\'--_M"'[?%QBH9[/X(7EKYTTUOIMS_QX?8]'&O?V4.?#>-> MU;Q#K7_0Y_\ %0_\)9GP-_T*0'_"+CBL?]4.%O\ H3RZ?;J?W?[WG^?D9KC7 MC73_ (6[[:7U?P^6^OY]U?J/VK?VO?B5^UQXG\+^(/'=AH_ARW\'Z6-&TO0/ M"@UW^R[3^V->QX@UXCQ,JC^V\?\ "/ +@#'AL #C%>>? ?X\:W\ ?%E_XP\- MZ)H>N7]QHW]C?\5 =>_Z#W_"2>O;_A'NG7G\*TK/3/A+J6HW_P#;=_;Z;_R3 M^P^QZ/\ \@JS_P")#X;_ .$A_LG_ +FKU_X2GIUQ_P 556Q'H/PBU+5)O"NE M7]N+;5/#FGW]UXA^RZ]_Q(=0_L#_ (23Q#[_ -A^#.Y[_P#10J]^&#RR&6K) MXX'ERUNR5]=6FV[WV?B#2U^)/PB\,R>%)2+;4#X,U#7[/Q#9X U,IXI)765./FV;';D[ MP3NK^@GP%X[\+?$WP=X>\>>#M1M];\->)],T_6-%U.W.5N-/U8[D<9Y&>-PX MP00"RC$,HR?#8+'96N7FLFNCD^6^ M^S3OS>KZG[7X5<99UG>8XS+\UQJQ_(KIM+1>[MULMMK+34_44:/J5I)/]@U2 M&WLY[DW,=O+IGVTPY X5MRD'T.1CC!YJ_P#9?$G_ $%-'_\ !+J7_P U%= # MD ^HS17Y ?OIS_V7Q)_T%-'_ /!+J7_S44?9?$G_ $%-'_\ !+J7_P U%=!1 M0!S_ -E\2?\ 04T?_P $NI?_ #44?9?$G_04T?\ \$NI?_-17044 <_]E\2? M]!31_P#P2ZE_\U%'V7Q)_P!!31__ 2ZE_\ -17044 <_P#9?$G_ $%-'_\ M!+J7_P U%3Z;IZ67G32S>=>7'[VYGZ9_H /0#CMP3LT4 %7'_'Y=DW _''!K:HH **** "BBB@ HHHH **** " MBBB@ HHHH XKQMI?]K^$/%^E^=/:_;]"U6U^T6.!>C=IC+E6P_X1O^PO\ A'OB#_S*I\5<^+/&&?QK^T&OP9_X*C?LI?!N77_A[^TC\2?! M7B'_ (4U\-SK5U\7H/AO+CA_"P4D MY +4 ?B;\#?@G\:='^%_[-^K?%K_ (9O\ ? ;X;^//%'C*TL_AG:Z]XX\1^* MOB!_R+?]@?%CGP3_ ,6Y\9X\0^'_ !9_Q7/_ !57_"-$CG_D5_ZTOV6/VDW^ M/?A34O[?\+WG@GX@>&!I UGPI>(;(G0-9P-)\8Z4"?\ D!ZB!J@5MQ)_LAEP MO!/\BWP;_9Y_:%_;9O\ XT_#[]G_ %7Q)X1^!L>NZ?:Z-JD6BZ9966A:1K \ M2^'/#VNZK9+K?APZ.3H6DGQ ,DX P:_J[_9U_9R@_93M->\:?%#XVZQ\5_$ M=[X<\'^![CQQXITG0_!]CH>@Z-<_8]*T'2O#^B8TR,>(-=U93N9BSE=%5$R M6QE*.&BYUY148I-RD[))7U;>BNM.M^PXJ4VHQ3E)V22U;OHK)=^GW'W;L&,I MR/3H>_8X_IV[5X7^T)\=/ G[-_PF\6_&3XF2W]KX/\%G1SJ4NF6#:I?9UG7M M&\-Z5MM!C+'6_$&E#.Y<$J^&X4R>%/VA?@UXWUC4] \,?$+POJNM:5J;:1J& MFVNHVINX+\ G^S67@ENIPH<\G!YR>/\ VM_AMX=^,?[,'QW^&OB/6?#>@>'? M&GPO\7Z-JGB+Q5:_;?#>@:>VDN?^$@U<9Y7P]@:@ 2^#:#CC(X\'F&7YA)RP M6.A-WM)0E&2W5XNSOIHNGY&N)P&+P5J>*P,Z5U>/M(2INSY7S1YTK^35UH8- MI^UQ\+QI\=YXGTSQ;X,SX;\*^*!9^)-+TV_U>;3_ !UJAT;P\5\/>&-<\2Z[ MJVZ^^5C'&&(^8'=MV_4V@:YHWB/2[;5M#N[>]TNY'[F>( #' (],^OUR#C@? MR2_L+?M7>#[/X(^'O VK?$;7/BUXA-KJ/@WXC?'CPG=>,O''_"*_#_\ XJ71 M_P"P?^$>UK/B Z'X,/T_X17PK_Q<;_A85?T+?LK_ !5\,^(O"UKX(E\5^(/$ MGC[1[L'Q)X@U30=5TH^)=8UG3/\ A)%U(8T5/#_A@#1""W@YB?%7A=04U=7+ M_P#"5>)O1LK\UES6M>RO;M?>QES2LHWE9;+7E3TVZ7VV/I;XH_#[0?BGX$\1 M_#WQ2D\V@>*]';1M0%L,7L*78*_: <_*RG:22<<,. 21_/1K/_!-'08/C!KO MQ4_X*&^,?A]XI\#:KJ&G?#_X9>"/A)X=UZW'CK1?#84^'QXV\$Z)X49='=M" MT #Q4O@QE4CIZ5XAU.YT5M,TB\_XFECDKHHT+Q'J@#O!6HW M6H:?X8\%^"/">NB^N]8ZZKY?@?0]#?Q!GFVWEM*R?7:%Q]G>"_'/A[Q]HL.N M>&M4BU/36N;VP^T0YB_T[2KIENK?E5P00V>2H"L,KBT\9?&32/"MA MJMO\/=0_X5'XE^%WCKQ/\2=/U3Q%JWPP\2Z1XR\->.] T+3/$;28^'^N_%+P MOXA\1/QXX&Y/#>U$9T'F?TK_ /!+6=/^%&:[9P:1_84=CXJ$&H6YOOMB:GXG M&BZ)_:VOVKX).CZ^#IS1)ZE_N9W'\LX*\3\RXDS[!Y=B< E''96I*:O:,H6W M71Z/1I-Z6T=S];\1O!K+N"^&L1G>&S?ZU..;1@Z;<4^65DG%QT:32;6_*M5= MI/A/VT=/^(GP%N_'7Q)^'?[-/B']H#0=;^W?$'1CX T72[[QM\./'&DY'B J MW_(WMHGB(@Z\5\.X<'6/%A90'0G\1;;X!_%G_@H9^TA\ ?BOX>_8]_:?^"5_ M9^(O"_BCQ[\>/'&LZ]X<\#CQ1X<\9^&_$>O_ /%/:U_R,^?"ND_\(]X2\8=" M?#?A(5_:4#GFOB_X1_MO?LR?&SXK>.?@G\./B99ZY\1O 4TXUG1Y[37;$W0M M&%GJG_"*:IK"A?$RQ$_>\.;O+"[V)^9A^\QV731:?(_GV_6_G?\ 6Y\/_P#! M87Q?X0L_ OP9^%OCKX@:M\+O WCWQMJ%WJ>M>'HR-4UV_P# ^FE])\'O\N!H MTLFO/XB)VM\OAK(&68-^0'P8^*/[:_P]TKP++X0^//B[PY\,H/'NH>'9[S^Q M5\)%&FZ7I.MCQ)X?T4^#4&W/@WP-@IX;VGY&O'^H M_%6_TF1O[8\ _$+P9H'A;4KWS?/\1> /##+XC?QM>>!])_L:0_VWLTM=?&OE MLH5VJ H6OQ^TSP%K=I\1=6\(>!?'W[3OBWP_<>(]-_X41XVN/B-K[>!KNQ&@ M@^-M!U7P457^W-!\9-_PD/A\>,"OB@]"%!S7\<%QE7+J6!E" M%HN7+45XK1+1W7,XV6MTKJQ_;_A?PSD;\.,-2Q^!PV95:<87@XJRC) MS]Y2BK*2;5U%\JMH?U]_LC^+/%GC_P"!7A;Q-XPU>;Q'JVH:AXGMX-?O=&T_ MP[J>NZ1I.O:MH^E:EJ>E:5F'1=6:.RQ)'"5V;F^7S)=R_P Z/_!6;_D]3QKC M_H3O!?\ ZB#U_2[^S9J4VM? ?X5:Q-I-CX?N=4\%>&=1N=$TO3VTNRTS[?I2 MR"TM-*R#I,2%BB*"-H'E@Y''\T7_ 5FX_;4\;?]B?X+_P#40>O[W\$Y2GF. M6RG)SG+)DY3=[RE)49-N]W=WZNY_FK]()*.!S%48*G%9U-*G"W+""E524;>[ MRI::66FB1^<6F0V$VH6$-_-]EL+BZ_TJ\/\ RYZ?C_/T_#CZ!A\'_"6\M?#Q MU7Q)_P (W]GM=8_X2*SL_&7@WQ'JHSXR\-_\(]V_XG7_ !2OB'5^YY\.=N:\ MN^&^F^%-2\66%AXP-O\ V/\ 9=0_X_-9_P"$>,O!N-!U#^WO^$;\/:#XB_['/Z_\4M@?C_2^(Z?X6?R;A[: M7MUW^?\ P/P(1H/PQFM?$,%A-J%S?Z7K.G_V-_;'C+P9X6EUH.E:K>:=_Q4G_" M/:__ ,(]K7_(:USQGCP]W_XI7&>W%ZS^'O@?1]'N=;U75;?6_L_@W[?=?8_& M7@TBS\4:QX.\2?\ $A]/^1J\/?YS6/9^&_AC#]OLYM5^T_\ %9>*/"]KX@_X M2/0>=/.O> _^$>UX^'O^Q5\0^(0,CZ]<'&S[?U_37WA]77E]_P#]MYK[PE\- M_#'3=>L+#2O$A\76UQHWQ &L_;-9T'PYI0U#1_!O_"-^'O\ BH=:_P"AS\5> M'O$/B#PGG_F5?$GA+CM2:EX;^$O]L7^E:5K>H:E;6]KJ%_HUX?$>@V.E7F1X M;/A[0?\ D5?^QA_XK#_Z]1>*O ?@;3='UC5=$\8?VE_PC]KI_P#H?VK2]6_M M[4/$FO>)/^$>_P"$>_L3M_Q3W_"8?\(?G_ [UY\-_A79W5A#<^/[>Y%Q:ZA? MW7V/QEX-_P"0AHY\2?\ $A_X2'_N7O#WB#TX],U'UA^?W?\ VOFOO']6\OZ_ M\"'ZQX;^%>I:Q8:?I5_J'VG5+K4+ 6>CZSH/]E6>/&7AO1_#V@C_ (I7_F<_ M"O\ PD0_X3'J>U9I\%^!M-U_Q#9^)+_5--&EZ-X7O_L?_"1Z"?\ B8:QX-_X M23Q#H(Z?VU_Q57_%/G_A#,>O.:H6?AOP-K&CZ/I^GZII^FW]OX\U#^V=9UCQ M'H.E?;/"^?#G_$^X]#^9-;'_ A/PJA\26'_ !4EQK>C_P#"1_8-9_XKSP;I M7V/1]&\9>)/#?]O?]1G_ (3/PKI'?_D5>U67HNR7W&]K%G\%M>DL/]/_ +$M MO[0^P75IH]UH.E&S_P"$D\99_M[_ )%7G_BE?$.KPKI MX? ?PET?_A)QJOC#3];L+?1OB ;46?B/0;[5;S4/^9=U[P]X>R/^)[USS[U/ M\#SOZVM^+W_JV^UU7UNE;K?2UUZ/>WWKN8-YX/\ @A_:MS##XP\2?8+%;_7+G M6#=:?]JL]9UG0=6[>//^@)_V+W@C_F>?^9D]N-BR^'O@^'Q9K'A7Q'XYM]-M M?#^L^%[#6-8%UH..?^*;\0_\(][>"_%7_"/<<8\*_P#"6^+O7%_5_ ?PZA_M M#^Q/$FJ7/]E^#?\ A,[J\_MG0=5_ZEO_ (0T?V+_ ,QS_A*O^$>(]?\ A(_^ M2>BK5;5>[I==-.GGZ?AY&7[W^N8\'K^H#_@DE_R1+PG_ -@_Q1_ZF7B2OY?Z M_J _X))?\D2\)_\ 8/\ %'_J9>)*^!\5/^2]K0W\OB\MS]/\%K? MZTXS:_\ 9O\ [?#\=_/N?K'<7M]?WDMKI;VMO%;QM;W5]-$+S%_D;M-(+#[H M8%SDC)/<@&[Y/B3_ *"FC_\ A.ZE_P#-/4.@?\@^7_L->*/_ $_:Q7.>//$6 MO^$?!^L>(= \!>*/BCKNG6I-KX)\'W?@[2_$>OJ9U_T?27^('BGPSX<1CN8' M^WO$VG)MS\X+8'\^']41V7HOR.H^S^)/^@OHW_A.ZK_\U%'V?Q'_ -!?1O\ MPG=5_P#FHKXT_9\_;(T[XZ_"#Q?\>=1^%/Q'^!WPN\+Z9XJUD^*/B9?_ OO MH->T?P)J7B71O&NIZ6GP]^(GC@V?_"/-X*U4N?$+1\;3@J&!S/AE^VY:>-!_ M;_Q&^"/QB_9]^%^H?#K4OBUX7^,WQ7M/!MA\-+KX>Z61>_VIXW\1:)XK\1K\ M)=<'A?5-+\0'0/BLGA9F47X&YXR'M8>L]M?11>KM^.O2_4P^L8?3WM]]%Y/_ M #W\NS/M[R?$O_05T;_PG-2_^:F@P^)1_P Q71?Q\.:D/_=HK\__ (M_\%+? MV<_AAX;TGQIH.IR?&/P?KWPT^/'Q,M/$'PHUGPAXDTK[-^SD/ __ F^@[_[ M=56UL'QQI0$8.4"AL@O&5[CX]_MG_#K]GKXO?LU_"7QKX6\63W_[3_B34O"_ MASQ%I%KII\/>%=3M-4\"^'+,>-2=60@:_P")_'/AO0$9/,&YI(SG9E]%@\3[ MONM\S=E9)NSU7=6W=[:)VO8?UC#7W73HEVN]]WKITONK'V)Y7B/_ *"FB?\ MA.:G_P#-/1Y7B/\ Z"FB?^$YJ?\ \T]?GO\ !O\ X*?_ ++7Q8\ ^.?B7KOB MJS^"_A/PA\7=;^#>G:O\8];\'^$D\=ZOXE_%/\ ;N_9T^%&O^ /!5Q\1/"'C'Q_\1/'?P@\$^'/A]X+ M\7^&-0\5_P!G_&OQ!I'AOPEXS/A\:SN_X18KJR^(6U!21_PBW_$U0R1Y)KZC MC%6='ZG+1:O2]THMW=MK.]_-[7']:P^GO+77XM]4NW]7\M/KWR/$G_03T;_P MG-5_^:>CR/$G_03T;_PG-5_^:>OE#XO_ +:7P&^$_P -;/XH+XMT3XA:;J%M MHNK>'=!\ :[H>K>(O%?A[5OB?X#^%FK>(/#P&MHFLZ+X/USQSH \5LI* !5= M@X$0Y_XI_P#!0W]D'X4Z7\0[_7/CS\.=3U?X477V3QEX/\->.- U7QQI>KGQ MY8> FTL^'C>F0-IWB?53H/BK?SX7;6Q]I^1XC_P"@KI'_ (3VI_\ S44GD>(O^@OH?_A- MZG_\U%?)$/[;W[/6G>&/$'C#QS\3/ /P^\+:/\1]1^&^E^(O%'Q&^'/]D^*M M2TC0M(\1_P!H^';W1O%6O@L=#U8^(%\/Z^?^$J4#=+I4>^+?W+?M8_LT)XWT MSX:Q_M ?!]?'GB2_\,6.@^#/^%A>#I?$6I:CXZTO2?$7A)+;P^M[]O;_ (3# M1=?T#7O"G)/BH:NG]DACR9^K8GJFM&[M:*UK].BM?[MM1^WI/:1] >3XD_Z" MFC_^$[J7_P T]0Z9J$SS36E_"(KNWS@P'%E>6)*A=24GH&Y!R>"0 .1CIJP) M?^0U8?\ 8,U;^>BUF;&_1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,:SH^E^(=+U#1=')?Q2WAY_"!4?\)(V?U_D&00QP>F!_B%X*-8(M_&;?$JS\*ZKI>!I)TO1]"\:G6M M%\/:U:Z2X7P\"2MEHA_X11BC$?G/B/B,[7#N-IY3@WF,FM>6_,E:/-:S5[*Z MTOWTLC]&\*L)D&+XOR]9]CXY=AHRBXN7PRJ\T5"+;32O)K=IO3=7/R1\ _&Z MPTKQE\;?"L7[0'Q'\+QPZA8>,OAUX(\8>#O&/PZ^+?CKQ/XDU)_$?]@LOBC/ MB#Q-_P (]XK!']O^#<,5;<Z1X_^ M%EQK&O6&J+XP\'#6-#>QU+3-57Q.1KFLW_A\^('4MXA^9\(K'"J1^$OP4L_% M?[3WQ3^'>JV?Q+U#PU^T%X?^+VG_ -E^!K+PU_PD=]_PK\_\2CQ#KQ&L_P#( M&\+'PJ3_ ,5@JG)]=W']:'P:^"W@CX&^#_\ A"_ ^GC3=,-]?:S?SRW7VR\U M76-6._5=3U,ORSL=N\GY6"+\@V_/^4>#&1Y[_:.-S/$1JY;@59.G4;?-4T;L MI*VKOI9N-EJS]D\>LUR"AE^$R2BJ&8YA>,E5HQBW"DE%?'&S7-[N]^9&C>*/"UK^UQ^SGX-^W:K\9=/UC7 M0VD_\)%X>^'Q_P"+>_*01_PD7_(JC!Z'-?JG^S1^S!XX\#_$SQO\4M>\47%M MX?\ B)XET[QC%\/O&%@;SXC>%M8TC05\-'^U/$6B^*O^$/OO^$A_LM?$!9/# M. Q*Y# X_2SY!^;'J>F,XR<=SZ<=Z_#S_@H#^VE\7/A+\2/$'PN^%K:[9:OI M_P *?^$WTV+0--TW5?$5P!KVSQ%XMTGPYJ'AGQ,GB;1O#ND/IJC:D1;Q(=8A M9"(E-?O/%/%6%X9RU9CB5=65M4N:UK*.VCZZ_P#!_G;AKAS,>*\RCE.6\JE) M7Y7[J2M&[;5]%IHKV=KL_;AI&3RPJ*[9).#D#N/Z^O;KUKP;XP_L_?"/X])X M#_$7C;PYXJTNQF_X2S77TSPMXBU,-J6D*-3\*>' M%T51XG']C>($8;$1H1YTE:I@IIV;T3:=IK^./#MCX@ M\1_\)3\1-*TKQ/=^3\4K\1K9_P#%;7>L?VEX@;.CJVA?;O#NJ^&&VEOWGW57 M[R^''PU\)_##P^OAWPE816&E_:#<&,2>8'G;&XC<6))PN#GL/E'./G#]I_XI MWFBZ9X?\.>"FN-*#KXT=AXW_ +:_X23_ (JDGQ!I&?\ D5_"A(7()Q7TF5\+9)EV)6)P&"AE M\U%+F44GT5DVFXKNEVMJ>7C^),\S3#1PV;9M5JY#?[?S_P (]HG_ !2HTM5\/^(O^1I'B-D!*I@?A9\-_&W_ ICXM_#_P"& M/P6^+6H?$CP]X6^(W_#2/Q?UCX?_ Y_X3CQSX5&C_\ "2?\)#_PF_B'/@HZ M+_Q5/_"/>'_%G@_P9R*_K_7P?XA^(_P-TWP=\7]'\-6GC;Q/\.M/T[QU;VEA MIOB+PMH_C;5]#(\0C21J\:KK$<6N-(L8*%) (W\TD[Z_!+X/_P#!+'XX:9X\ M\/:3KGB#QGX1\%^#O@AJ'PUT>]\&ZSI?AKPYH'_$]\2GQ#X-(//C_P#X3,?\ M(\W_ F#>!A@$=:U&QUS4A:O;:-K=E:ZGI)!_X1WQGI6B^*,>(?#. MC>,=#!D&@ZB/F^97)4!:]DL_V/?V>[;5?#NI'X?Z=?R^#XL>$K*ZN-3FT701 MSFWTK09+W_A'ER3@@1<$],98=K\#_@KX:^!_A ^$/#,^HWWG737.J7>H#3K> M:]U#^SBH.-&PNDYPIX#%<_(SAU+>\?=_N#\AU/X8'Y]/6O QW#F2YCCEC<3E M."=31IRIQESU"/_ %#F'/7^9^M?UQYC*^OKCD\Y]!TQ^'XU^27_ 4%_P"">MS^ MU#)-0 ML!K%Y_R+F@C^P?#8&O>(O^QS_P"1?_IVKH1\,?"LVCW-_P#VK?Z)?V_]H_:M M'UC_ (FNJV7_ !(?#?\ T!?"O_,F?\)#CL.W_%+UZO\ \,'_ +1OE^3_ &5H M7V;_ +&,_P"/3_9Z^U0?\,$_M"_] GPY_P"#?_Z]#S)I^B6&K:SJ5MS9^ _ &O1W.MPS6^AZ?I?AO3[^ZL_ M[9_XE5WXI_X0WPWXD\0_GXJ\V>L\^N,>U= M$?73-_X5+X; ML[2_O]6O]1Q_8QO[71_M8TK5?[0'PO\ $GCWP]H)_P"*5Y_XJK_A'A[?\))C M_A7GA:H;WX;^%=-D\0ZK8>.=.N?^$>_M#6=&L[(Z[_R#Q_PDO'_$E_ZFOP]X MA\/_ /,KX_X23PEXN/Q#]-Z\_9=^--Y=7-_?PZ?J5S2/S M.#GB&']E?XQPRVTT.GZ?;7(.?MG]L@G\OR_SBA9GEB2;QUTK-NZMTZ^OR3]0 MCDV;M*V3-7M:RUV5K67W==$>#^*K.'3?%'B?2X>;?2_$>H6%KUX/]O>WMU_S MC'^T7,*7,,$W^C7'_'U9_IZ]?\GJ:^P(?V%?C]J4?V^&P\-7-M\?/\%W0 M+A#B>5G')$L\C[)XH'IQ_PF?B3 M_.:_''PI_P $]OC3J6J6T/B2;PWX:T?C[5>6=U]NU3M_R+OA[GC_ #]/Z./V M0/@K#\*?!^GZ?86=QIND:5HPT?3+:Y/_ !]C.<]& MP>&P6+YNO*NK5O\ *]]VV[^7ZSX1<*9[EN8XW'YK@GEUUM+>2T]-;;KOMU/L MC0O^0;-_V&O$_P#Z?]8KH*Y_0O\ D&S?]AKQ/_Z?]8KH*_'C^ASXL^$G[)VD M> _V5;S]ECQGKG_"=>&]'/$.IV]B=$FU3P]\5?&/CO6?$-H!GQ"MDP MT3QJV@C.\@6C$$!]H^8?$G[ ?Q\^)OP=UCX&_$_]L+^T_AY8?#"P^'/PYT/P MS\(!X.GFU#PYK_@36O!/COXQ:O8_$9M?^(.N^'AX'TG0BO@L_!HD7FO%@/[1 MR/ULPGJ?\_A1A/4_Y_"MXXBI'9JZ:ELK7NFFDT[?#WMWN%_@CX?0G7O%,@\5,",^%\-M^E/VX/V!Y_VOG\(? MV?\ $]?AOJ/@CX8?$#PIX;UF+PNWB/5=,\4^)?'OP%\>>#/&>F%?$OAQ$?P9 MK?P44JI?,@\2$C:%8C]+?NGLCOIY^*'PZ_X):>*O@=K/A[Q;\#OC M-X1TOQ?X5F\3Z+X!_P#A$/%_[/WP%^"FK'5?#VB?$;P1J)\4 MA_@-I7B__A(3XF&[_A(]>\)!61U9JGA7_@E7XA^&47@[P;X)^.VC'X1^&?C' M^R=\;-3T_P 3?"R[\2?$W4_&W[+>A> / 0TW2?&__"Q4\/Z+H?C/POX(/RKX M')\! '2(RWA(F-?V\\SV_7_ZU'F>WZ__ %JUGG>83=VE?W;OEC=\MI1N^6]D M]8]KW6YFL!AUL]UIJM=5MKKTOOYGX:2?\$G?B1J?A7PWX"\0?M#>#[GPI\// MA_XI^&OP\FTSX,Z]8>(ET#Q'^T]\'_VCO[4\;ZL/BH?[;UQ6^$J^'F_X0[_A M E UAGW$H :?BK_@E'\7/&OB3QUXN\4_M/6GB'5]>T'XH>'/"E[X@\&_$75C M9:1X[^._@/X[:!=>(])UGXW_ /"/:,/#@\#+X/'A#X4^&O@]X68./%W'BT G M]VL@=3^>/_K4<# ]][VM M?5;*VGDMC\?HOV ?B[H7C5OC#X*^.7PYC^-$_P 2_C_XSOSXG^"6KZU\)8=( M_:+\(?!W2/B%I>E>"A\4UU\ZWX?\4_"<>(O">OGQT!-#K&H>$_%JR1/DP_#? M_@EC9_#+P_9^%M'^+,E]8Z5\:/V&/BSI^H:QX/!OQ8?L:>&/AMX:_L$E?%.0 MOC3_ (0C5&5PO_%*+XD^8>)2,']A-O\ L?\ CU &>B?^/5S_ -I8YI0<8\MD MK>2=UNOLO;HK]C2.%P\;/72W5=TW]^OW+Y25@2_\AJP_[!FK?ST6M^L"7_D- M6'_8,U;^>BUD=6QOT444 %%%% !1110 4444 1 KGE\/?!KP'\4%^)7P(\,? C0?$?B7P]JOB+Q!\ M0/%7_"L-:_X3(^'1X?\ ^9"SXI\2^$QQDUO2PE;%*3P[3Y4FT[-VT?EUNNET MM%=HPKUX4$M'K;T5[;V2VOK\C]_/[:TSR\VM_P#;QZV%L=4.<],:,OIT![>^ M>N9_[%W7O_ )2>Q_*OS=?_ (*3_#2QTT:KK'P5_:+\/^'= \.> M"?&?Q@\0:UX2\&Z7:? KP1\5/&6L^&OA[XR^)VF-\1SX@">(3H,GC$)X)TGQ MYXJ\)^ "/%GQ&TKPJ@9&\S\<_P#!5+P[HGBC0/$&G_"WXD0_L]#P'^U;XXU; MXE:GX8\/F]^(UC^S==:-I/\ :?P4 ^(Q*A];.JAU^*OAKPMO0Z#@Z66)(LLS M"]FU>^G6]DG9:V;<6FEV3;5D0L=AVEK:Z71*VW7Y/7S/UZBU+3[Q_*M[JWN) MAG]W!=+G'K\I(YQ^)ZUHW3\ /T]*_.OXA?M\_"OPO\1M7^#4'PP^*WQ3^ M*^EZSX6T[1_ /@71/ =]JWB\^)OACXB^*7]I>'3XH^(GAOP_CP=X(TG[?XL/ MC/5/"K$W:_\ "'#Q06^74_9[_:C\1?&OXW_M!_#%/A5\0_ .A?""W^#U]H^K M>.O[+LK[4C\2?AYX;\=-H'B'P\FM-X@\%ZW&?$14Z"P^1-&9G90'\+U,L%7B MW.2M:-WS:*UTKI/5[VTWVO?4M8G#-JUM;*UK[VUNGT[===>B_0:BLFTO8;O, M/,4UOC[5;S8W#MGDX(!&<\8!P0:UJR-PHHHH **** "BBB@ HHHH **** "B MBB@ HHHH *KS]OP_K5BJ\_;\/ZT 9]5R >",CT-?BM_P4Q_:U^+7PK\?VGP? M^%6JVUOKE[\$?%'Q,M[/2_'G_"$>(L^&_&7AK_A(0-7.MKG7!H7'A/0-H+#Q M&,XQBKO[-7_!0_XB>*_$GPM\._%/P+_8EA\5_!W@#Q3X2_X2#Q'H(\<7OA?6 M/?B1X<^#Z:M\7/$_A+4/%^O7G@S3-" MTO5;S3SJ9PNK:MK.N)N7Q!KC$ :"K,2 [8=58_G-\4/^"M]M%\8_ACX8\!?$ MOQ!J6B:QK/\ 8OC+P/I?@W0;'QN,:$3XAU['B?PK_;VB_P#"&DYX.3QDGC'6 M?\%)O!?Q"\;?M%^'O!^@^,M#\$:5<^#;#XEZ9;^.-&QX<\5>*?#9/AOQ'H(\ M;D*=&T,^%O\ A'S\0M QXFW9\), 17Y*^ _%7[47[5W[2'CGXJ> ?$G[,_[ M,WB&X^''BCX7VMGK.C?\+;\1Z]IW@37O^$;_ +>\/?V*?!./^$TUS'3/7C!X MKE]G##JV&A&SM>*2L[VOHE9]?3[[;/$8O$?[1BG*;2BHMRE.32LDO>;WM96T MUZ[G],_P/_:UE^+/[+/BOXVV>B:KK6O^!5\4Z?/-"\.9\&^'M5_X2KG0S_Q3W_%'G[WBHDD9K]*O^"?' MQ;A_9^\*^$_@MH-CKFM? OPWJFD>%O'GQ \0:9X.@\1^ _B?K!Y/C?Q#X7(_ MMO0_$6N?V20?^*G/A7PKK'##X;^"LC[F_;#_ &!OAC^U%X9UVZM;:V\+?%&\ MET@6WB:R.J:59ZQJ&D,/[)/C;^QVQK*J-*.@?V]@X&%3A0K?EOBGP-F7%V&P M6(R['./]G6D\H6BFWRJ[:M=WU6E[).Y^M>$G'O#G!>:>PSW .7]IK_D;W?-E MMFG:UKNZ=F]VWWM;^?W]F3X ?%CXR>)+OX#2ZI\7]2\4?"C1O#/BKX+WGC76 M!X<\$>!?ACJX_P"$:_MWQ#XWT+/_ L,A4VD;?%! "^$_\ F::_JR\9Z5K> MG?#F^T7PWI-QJ5_I>C:?:6OA_0+_ $SPZ;TZ/@?V#I1/_$@T8^F3QC'2OG3] MCO\ 98UO]G#PG'[7^V=9TO_A+=!U75;+3Q_P!2\/\ MB?XSCC''.2O=;6Z:-;6U[:'B^,?B$^,LZ]A@&Y MY;E^F52U:FFX\\F^TGKK:]KV=S\B8? >M7GAKXD>*OVA;^X^&_\ Q7GQ \4: MS9_#_P"+_P#P@^J^%#_Q3?AOP]H/C?\ L7_BG_$^A_\ "*^'O#OB#Q9[=N#7 MQ)^PQX/N?$G_ 48A^&/Q0/[._QMT'X'> ]1UGP%>>![#7M5\1_";6/^*#\2 M>'M=&K'U_P"$A_X1[KXH'A7_ (1ODXK]J?&GPQ_8>_;ZT34+?7(=$^)*W%H= M'UJRT;Q'XS^'?B/^S\D_V#XV\.Z+XJ\%>(O[$/( \9;@O_"1@+_R,@S[Q\#_ M -F_X$_LT^%[?P?\"/A7X3^''AU?^/K_ (1^S)U6]X_YF'Q#C_A(-;Z?\SD? M;!.:_5,/@KXB[>DMN9W5VE;?YNUM;>1^28C'OZJDUKIS:;/KIT[]E\SVCSKC M_GO/_G\:SYII_P#GM(;C.H6NCW'C+0?[5ZCIX>_'Z^U=A#>33QVT MT-U_HQ_Z>L?ACI[\#W[\_P AOQ._:+FT+XM?8(?C[X<\?7_@+X0G6? =E\/_ M ;J6J^(_'OBC6-!\2>&_#WPQSX6+>'M%# ;EY!VD;E5LJ/Z2/V.?&UGXH^! M'@#1)M:N;GQAX"\.:/X7\8Z/>Z-KNE:KX5&,>'M \0?VT?\ B=?\(9C_ (1# M_A(,X\5?V1WY _,O#3Q5_P!=^WGKT_ Y^;1]*S_Q MX6_]#_+ZCMUQZ5!_8^E?] ^V_(?XUOR_ZX_C_(UGT6MT\]NFEG^7W(Y5-N]I M-ZVW>^EE^7X%#^Q]*_Z!]M^0_P :KS:/I7_/A;=N/_K=.NCE:TM:_2UKG*Y1E>\HNV]VG:W?MTW.?_X1K0_^@3I_ M_@,:K?\ "-:)_P! JP_\!1_A70T3]OP_K5)2ZJ26E]'HM-^FUOP\CGYHJUI1 M\M5^&OH3>%]2A\,7$DVGZ782V!S]JTNXM0?M?'8'()![G(]<\@_3_AR]\%>+ M[7[38Z?8),!BZM+BU47MJQYP1CCG^[@#IVKY2JQ9ZC=V%Q#>63F&4T,0DZ,I1E;OI?31VLK77176FMCV.^"_B?::WY>FZT8+' M5,#$V1]BNR 0-C' Y]"<# Y&!GV4 !/E[GG'/K_@*^*Q&&Q-"K[+$I[Z-ZZ. MUM7=/IM:WX'Z)@LQPN,PRQ&&=Y-*Z6CNTKZ=;:W72R]3%T+_ )!LW_8:\3_^ MG_6*Z"N?T,XTV;_L-^)A^?B#5Q705@=JU2??_@?YA111VXQTX]/;\*5U:]U; MOT H,Z#>VS9@-DY('?I[Y..,+3X:F MTO5?AAI$OBOQO6\>8 MS&K,\?[-9>H/V4;*I43=]5HC^MS]GK]I'P!^T1HTU]X/N)X+ MC3]-T'5-3TR]N=,-_9KXDTS[=9K(=(O9%.4&&;(^;[A&1CZ5_=!Y?+R'_B). M0![8SG()SG/'KT/\PW["'Q'\0_LO?&+QU=_$+3? ]IX9US2](T:Y\)_#>[U7 MQ%I/P:^%_AO2?#J_\)BWCCQ*?#3ZSH1#'Q!XK:/P.KJP5LD8#?T\ATGC#+\J M%%(('9L$8P.>HZ>A/J:]OPWXLJ<5Y+]8Q-9?74^65H[)*/D^96W22_!7^?\ M$W@Y\%<05,#2PDW@&N?*G-IN4;14MW=6;=T[6NK+M/L1BF<<=\\9X]Q[G'U. M>34H8!N.G3N>/4^GKV_G7P_^U#^V!X/_ &8KOPGIGB>R2ZG\5:5XGUJR%UXB MT'P]%.OA!M'%UIFD+K3J=9\3.==TOR]#L 2XW,&P&#?-%W_P5A^#B>(;7P]! MX0\(>+]#\=>&M"\7^&+VVU?P_XBTS3]6TC4K8DP7ECJZ+(MPI.W(* M,'Z9&2#W [-FQQW_ ,_G^%?6TJBKQIUX:QJ0C*+337*TFG]S3O?TN?+U*;P\ MI4*MXRA)PDFK.,HO6+6CNGHU:Z=[^3JP)?\ D-6'_8,U;^>BUOU@2_\ (:L/ M^P9JW\]%JQF_1110 4444 %%%% !7-_\A)_[FF1C_=-]S^*MHVT_\"(_NCY9 M[R67,-G#DRWQ^8@?\>MB!@L<8]<'GJ2.P-:<4<5O'Y,7[F* #Z8Y_3@Y_#B@ M#X]^./[6GP^^"WBO3? %SX:^+GQ(\?3^%;_Q_?>"?@W\-==^(OB;1O .BZ]; M:)=>,?$**/+T?0OMSFQ56#>)_%+'/@^+4WTT[>)\$>#/V1]=_9QTO]D_P]XU MTM?AO\:/@YXIN_"_@C6?&*V7Q-U[X8?%1?$GB+Q#KMII/B8+XA*D>(-3=7_X M1MCX6&Z-MFU57/\ C5\"_P!HO3OCUK'[0/[,OBOX4VGBOQW\&-#^#OC3PY\9 M-.\97'AV,>#_ !IXB\1^"_%^DZIX,\UO[:\./XY\0:=+H6H(J>)(I$VR*T;. MGQ_XV_X)\?M3>/?VC/ 7Q6\4?$WX0^*;/PAXS^"?C/4?$[:2WPY\4^(M1\ ? M##_A O'-SXB\$^ /ASM\3:YXS\5-JOB#PAXO\1?& _\ "!^$KW_A7L7A)X@7 M'J8:CAW&+>*4%:,N:[O=F[2XFL2[[O?1\KLKK1ZZWW:OM\K? M3?C']GS]BOXMZMK7C+6/B7;'P_X<\(?#;1OC-I'AGX]6FE_#+QOX \"@ZS\* M/^%U>'=&UL: ?"Z?:VU#2\_\(L/%<8;2]7/B?P<6C7YL\!_!'_@GO\7]?\:^ M'M'U'XJ:WX)M[7]LWX>_9=3^(>N_\*3\#>&?$EYX"/[00\%X\4-X=T30?$6M M^-_#^O\ A?Q"$SB1F7R=@)XF/_@E/\2/#_A3X#6OA6\^"*:U\'?@1^S=X(\5 MZ1<6FJ67@?XR_%#X*_'CPY\7O$ \:6:^%"S>!_$3)J[GQ"5/BD>*'WGPKL'R MY=Q_P2J^.&MZ!X_L;_Q%\#O"=WXON/VL/$5IX:\,+XSU;P-::S\=OC-^S)\7 M?!7@,Z1_8?AMC\.Q_P *%U7PC\0AM'F>%?$^8O"D@WE/0H+#-O\ X5I02O:V MC3C:*LDV_A6C224;1W;2Y/WZ_P"8);I=N9>[=_*^V^GFCT_PW\&_V!/%&K_$ M35K3X_?$/2_&GPW^)?PSTO7OVD=>_:(_L_Q%J7BC6/V?E_X1U?!/Q9?7?[!U MK1_$/P>\;'0/%.B>'"D;K:/NC!\.1N/I[X,:?^QI\'_BK\=?$_PZ^,L?AW5/ M FD?"_X.?&OP_P"+OB;=CPAX?U#P'X*\-Z3\/=3U>\\:L1K&O'X=V>@: ?$3 M>)M2!%IKD3#_ (3$^*7;\_/B%_P2^_:D\?W_ ,6KZTG_ &7? &C?&?QCXY\1 M:GX"\$G4[*Q\%+X[^"/@3X5&\T#QQK/P0;Q>!_;?AWQ#XB\7>$/#P\!#Q]_; M8SXL\+,65;NK?\$J?CW;FV31=3^"-RVE_$+X0_$L?\51XF\.GQ5J_AK]DOPY M^SAXVT+5=GP0\3?V,O\ PE.D:M\0/"7C#_BJ#_Q4NN@^$O"[DT5HX6M%*6:- MMI7BU=*R@N5[V7-HD[*]WO>[_?[_ %-636JO=7M9K[_R[H_?K=8:S;6E]87% MOB\\V&;]UF >]? M/_[+WPEF^ OP ^$OP9O[ZTOKSX<^!]%\+ZI<:9)J9TK^T+0N+K^QVUQ_[>&B M+>;[+PQ@!_*M5&"V!7N^I;;62'4A\@MO^/HCG_0,G/'3C\QDU\U626B=TFK/ MNK/7ROO8]:.RTMHM.VFQO4444QA1110 4444 %%%% !1110 4444 %%%% !7 M/ZO]LDT^_BTJ:"&_-C?Q6,\^/EU CC(XXR,Y7&#@YP*Z"LZXZ?A_1J /X[?V MN-0\<_!/Q)K>B?M.?LTZQXQ\,:QX2T^ZM?$'Q@UGP;\6]*O/BQX]_P"$D\!^ M-_B-I/\ Q5?_ " _^*A_XI,>'?\ A%_^$ _X23_F0^M?5O\ P3,_8P_M#QAJ M-_J1\!_\(Q\%/B9\/_'?@+XB?#NZU[Q&;W3_ .RCK ^#7AW5=:UPGX?:)X,' M_"/$^'_#F<>%?$9)X\:DU^[?[1VB?!SQ%\(O%6E?M!Z1I^O?"V\MK?\ X2*P MU>+5#OF355_LK^R3X9(U]==_MK^R1X3/A_'B@3%1HY_M8KG\IM(_X*!_L]_L MXZ%\//@I^SKX*\#>#?A_8>+=8\,6NBWVH:\;WPR6UW5\ZD/!11?$.H#Q"\8\/<.NG',\:E4FTH0;5[Z626C:;^6CU1]+DG"?$W$\)R MR7 2Q\*R/U0_:1^#FE_'SX+>/_A-JVEZ/TK=?GH?)XE8G*\4\)BK*4 M)3C-=8RC+E:>FEFFOU/QD_8U_P""3TWPGCOO%?QF^,?Q%?[?P/\ A'SGP?X+\3_\(!@8 )-?M7<= M?Q_JU?*GQ@_:J^''PM\477@S7/&'@OPCK&E_\(O6WAN_\07^GZ>/#^J?\ M2L_VAK [_P#4#)_XJ ^(,G/45W1^JK?RTO;7W;O;573=V^B5NWEXCZUB]DEM MT]%K?;HE\O*WJ7Q:\*_\)M\+_B1X,,VH6P\8> _%'A<7GA^Z&E:K9_VQH/B/ M1_\ BGM6X_XG@YP>OM7\5'A74O%7_#/OB>_\-?$7X?\ ANY_9#\>?%#Q1\$; MS1[70?#GCB]^*'_%2> _#V@_V3K1\;?VUC7/$)(_X3,]J_L_\!?%/0_B3J_C M#P_:?9_M_@X:.-9L[/6?[5TN[T[6@^+;3_@F MK\&1'J7AOQ5K?B#Q;\-+CP)_PKZU^'X&E^'+#_A%O[4'B0?\)%JVB@>(/B!K MN>WB+/ SGK_PDY7H>W2?16LD]EIV;27GKNF=.&JK"N*Q*WM:_1MI:7\[>OY? MG7_P3_UC_A(/VAO[*L+/X@>&-9\'ZSX7'Q?\/_%CQY_:WBO7OC#_ ,(;_P 5 M#_PA']B_\4?_ &&/"OB$#S7ZT?M=?M1:)^R[X?\ 'B3Q5]GT3PQ MXQ\>:?X-UGX@:Q:Z]JOASP'_ ,))C&O>(?[%_P#U5F? ']ASX5_L]Z\WB31) MKCQ'K%M=:A?^'-8\06NF'Q5H'_%/CPY_R.__ ",&M'_A%O[5_P"1R+#_ (J3 M&1R!]->//!/A7XD>#?%'@#QSHEOXD\'^,-%U#POXCT>]_P"05J6GZS_//?C/ M].W#T;8=N]I*UF]&K.RMJWNEZO1,\W$5L-+$V4;I]+.S;MOTUTOZV;3/SH\* M_&SQ)\1?"_\ PLWPKX_\)^-K_7/$>L?#[X57FC^/->\.?"3QY_8W_"2>)/\ MA,N>=%\5$Y]?"O\ PBOAL_CTOQAU#X??M%:1;?V3K%_;_%/X7Z/K.L^$]4/] M@WVE_P!H>),>&\ZMI7_"5^)!K7A7Q%KOAX\># !X6_X1LC'XM^ M'^+%UKWB/Q'\3]0_L'PWXD\;Z%XA M\0_\B_HFA^,_%?\ PD/A_C_J;:_3C]G7P_\ LX_M1>//!_Q.^"'C#QQ]@\/^ M#=0T^Z/PSNM!\#^!_"OP_P!8R?#WPN\0_P#%*_\ "0$?E_W*_./#S+*<-FF MQ^4YA?'_ -HQ:C=/W$^5;:?#H[=.MCZW*,UCD.+R_/]K>;;6A^0NCZEXD^!.H:-X;T;Q#X3\;_$#XQW_ ,01\4] \*>'/^$(TO0? M%.KZWXD\1>(3JO\ Q2Q\0Z'_ ,522@_X3,#@;_Y@G_ AGA7CC MM]*^]H_V;_@A9_%K4/CK%\.=#MOB=>\77BS_ (FA_P")AC^Q_P"WO^$=/_%/ M_P!N8S_Q4'Y^I]JK\RX&\$2?;N_,_2 M?$KQ]Q'&'"T.&\#@(X&34?[7J\TK1+;Q)XN\87.H6'ARSUC_ M )!5F='(_P"$AU[5CD _P!GWPQ^T?X^^-__ M ".&G^&=0T7X9^$OAAX-TKGQTPU70- _X3;6CXV/&B'!/3=UZYK] _C=\"OA MW\?O"8\(?$/3+C4;"VNOM6D:Q9W1LM4T+4!D?V]X?\0[@.#DA@>.0<@X'SS; M_L66$WABW\ :U\:/B=XV^%UO:G1K7X?^+!X-U72O[.TCCPZ?^$A_X14>(-%_ MX0X\ G SC)XX^WR/$Y#3R_+76IOZ[&HGFTG!352"Y;*#UY5RJTN91?-:2DHN M\OS;/L)Q+5S/&JA-+!2M_9,>=1E?3FO:S5WJG]_E\M'X[?M6:Q^S=J_[5'+S_8WPRL_AUH6K:5=Z>/&2^!!G5M:_XJ#)UO)!ZGIDCKY5X[_P"" MB?QJ\2> /AQ=?#O2]/\ #?C75+KQP?'8LO#@\1_:_P#A QX;\1_V[X>&L\G0 M\_VNP)_Z%S'9<_;T/_!/SP%;Z##X&O\ XL_&;4_A?;ZD-7MOAS<>(M!_X1[[ M>&R%!'A7=MR=P7<1W['/I>F_LF_##PY\4_ /Q-\-P7'ART^&'A/4/!OAWP-9 M\^%2-8/B/_B>XP=?_MO_ (FOB$'CIDG)R:^BCG'"N%+_8G%^*4;8]9>XQ5T\Q3;>EZ]MK-[16OD M?GIK'_!23Q?KOP1TR'PKI]OHOQ]N/$=AX8N[?^QS>Z7=:>/[6_XK#P\ /FS_ M ,2O0/[ SD'Q'C R"(O"O_!1KQ7+\'?'VB>-A;:;\;O#^C'_ (1/Q =&']EZ M[J']O'']J>'@,Z+KG@P[<@G&/FSQMK[(O/V _@6/B[8_%K2XM;<".'LZ.55(RE^_4[J].HE M&4&4<>^T526;QY7)0E9MODO%2??9[[NW??P/1O' M/[2M>%_LOA_1_$8_LNST M[^WO^$;\/Z#COH8Z>@KY]\2? SX/W/CB_P#C'\.O$GQ7^#OC#5+;^V=9N/ ] MAH(^U_VQSX@SX>\4>%B,@X_X2P^# .QQBOS[@S,\RQV/XBJ\0X!0IQE4CD<8 MX?#QBHNW+S1I:2V2NXRE>]U9MGU'$64PR:&4RR7.9YE.44\Z2>(34I*+:3J] MM4FM%TV3.Y\?>%OVC?!'@?Q?XYE_:H^U6WA#PGXG\3_8_P#A2WPY'VS^Q]!_ MMCW/J._UYKP?]DKQW^TS^T3H?B'Q5JOQO_X1NP\+^(]/T;[-9_"KP;JO]NX' M]K^(>I.3Z8&/H>ON[>#;:X\!_$?X>>./B;\;/$UOX[T8:*;OQ7X=_P")KH(. MA^(Q_8/A[^QO"H!_X3#^R2WJ%_L(+\QVD^ 'A[X=?L[^$=9\(>')O'^MV%QX MC/B?6-4U_P .G/V_^P_#>CG0>G_,FX\.CH<;>K9KZ[ZQ@_J&-P[5/Z_)PY/] MGC:--VN_:-'#8K^TL%B%SK+]')?V@[M^[O!?)6??9GV' M5>N-T?QYHFO:A;6%A#KG^F?VA_IEYHVO:7I7_$GX_L'^UL_\ASC_ (2#_L5< MYYKLJ^0^K^P>FKTN_3^M5T^\^W]O[?2/DE=]%KO]UWM]XMQU_'^K5[#X(^(V MI:5&;#6O/U'2X 1]L(SJ=IQCYE!&X=.X] 1GCRV"&&;_ )8@?Y_7Z_6O7]&\ M.0WFB6%]80_9K[@CC O/;TYX/;\N:\O,H86>%2Q"U;5I*R:>EG=Z]D_G?0]O M)7B:&(]O0;Y-K7M'5QVC_73:Y[-X7O;;4=*^T6<\%S;7&L^(?](M^A U[5P2 M.O3..><[L#'!Z[&(B!UQ_7 _E7RAX:76M %U=^'LH?[3U@7/A^?BRN_^)]XE MS@C!!Z#7OWAGQAI7B.WE:TF\F[M5)U#3+@D7MH IR&7O\ D>_W<<_# M8S!?5&Y-KE:O=7LDDGK?;?IIIKJ?H6 S'ZY;#_;T7G>R6G^3UU['#_%#XQ^! MO@]IUAJOCC47M8M3OK^QTVWM[8WC7-[::'K'B+ *@G)T31KXCD E0F0#E?/_ M (._M5_"/XX:)I>M>%M3U#3!K]L+G3['Q+I;Z+>W:X(^SA+U=UT!G!V^9@=< M\X_&7_@IG\5[KXY_$+X>>$_A;X?T3Q;IGPR\1WUMJ=CX@\3Z]X4L_C)H^L*/ M#?CC0O!>K?\ "+-H#2>#@,'Q /$P50NMQHGR-))^6OPKO-;M-!UCPK<_"OX@ M6WC_ .'?B/Q/K/C+_A8'Q&T'Q'X'L_A?_;WB3PWX>T'2?$.>=<_X18$C_BAA MG_A&\_$C'_(TU_,G$7BUG&7<38C+\K65YE@<%4A3Y8M^T?-*"ERVTR9_57"W@AE^;<&8?-SBDKP1_<)$ MR3!"A#H1SR"&!Z\=#Z^G;J,5^*G_ 4=_9+U[Q+XH?XZ?!KX,:;\3_B+XB\+ MM\+O$,,,26.O^'--:VUJ\TKX@:2<9UB^B+#P^J?(1'>1[6=$E5/U;^#3:Z/A M9\/Y/%-R;[Q#/X4T"36;OIYVI-I=FUXV!U+/OYYW=2#FO4=P;?E,[.V >#D= M]W:OV#..'L%QGDE'#YM2M[2$*BT7-"4HQ;2=K[2>RVZ[)?BV1\0YAP5G\\;E M&(MB,MJ3I\RYN6I&$^6\[;QE;F2UOINKI_@O^R#_ ,$A=%\-VGA_X@_M(^*? M&?BGQE>> X-$U#P5#XB\0>'-)TP:QJ*ZUX@T/5!X7\4E?$^6TK25.]@/]!.% M8]/WI5?+C1(AOVJ!SP>,#@#CIDXZ#&.XQAZUXBTC0+(WFM:A8Z99>9Y8GOKI M;"'/;:78*/Q(XZ\X-<+X(^+?PN^),$EQ\/\ XC^#?&B1#_2F\*^*- \1):,DT\ARSASAA1RG SIX644KIRBG)JU[J]WZ67EH/BCB'BG MC'$2SO,XULRA%I1DH2]E33Y?=BXQY8I65[MMNUWLS\4_^"L?A'QWXY^.7[/4 M>F^&!I'A/PCIOB?6O^%N:QHNN>(_"&C7PLM675?#]X=%/_%,7V=&\/L"QSXJ M%^ #_$FF^(?BAXC\+W_P .?">CZS_PCG_" M*_$#P'H/B3PW_P +0\;_ GUH@_\5G\.?#W_ !2GC#&/%?@#C_BE_P#A-J_M MAD@@N8D\R*&ZB;@%AS[\_P!",=<@9.<#_A#?"G]K_P!MC1-'_MH6PLO[8_LN MU&I_8MV_^S?[4^_MW<[-^PGJF[YJ_.>*/"&/$6:XK-XYW**QTZC25NFC/TOA'QOK\.9!A>'O["IM8&-1*IS/FYJEG>5X-J*E)ZJ6EOA/+_V M;M/\0Z=\$?AW:^*;0Z;XF7PII#ZQ9C3[K2EM-0%I'O4:23C20"1NT3_EFV8C MT>OH' R&QQ]W.><8_P#K GU]:CB1;<)&!@ ' Z\ ^OKCZ9P>F: ]?L.6X3^S\!@,%*3E[.G"GS.[T7.?.U&ZNDKI+T\D64Z#_/L?^E/AO_ US0P_-972YE?;?WE^'2W_ M YYM?$>SU[ZZ:[ZO[OZ\O2_^!G\C2^:OK^H_P :\;N[R_'2_N!SVNL#GKT[ M_P#UL=JYB;4K_G_3Y^O_ #]G/)&>@[&OE>?4M5_Z"NH=_^7KU M_P \X_#O6#>:QJO4:KJ'_@5Z<_K^GX"NQ9+5=KM*]GL]%=7ZOH^U^QYW^M%* MW6]M_P#@?/;U[,^L]"\0:5X@L_MFFW N(<_0QG'<'/(Q[],XQFMO=@9<^W!_ M(#(/YO#=Z=-Y,Q'(]>W3N"!_'%OXOMYD>WDMM0L M_P#CZM\?N@3QD9X/T/?)SUKGS#*)X-K$/56WN[IZ+5+?M=;:=KOJRC/:&-?L M))N6R=KKH^U];J_FK:'60 7.J7=RT8DDLB-,!_YXY']K$D C=E3I6.V<5T=8 M.D "VF8?QZIJ#?GJ9'H/6MXG )]!FO*/HC)O;R#3-/FU"[<0Q6T375QSZ@9& M>2.@S@9SCU-?E78_\%,8;Q/"FNQ_!W6W\'^/+F]'AS6+3Q*M_>_V=9G)U/5O M#ZZ(LFBAB,_,['@X+#-?HM\2=:_L+P%XTU9-2T?1I]'\*:_J\>I^([HV7A_3 M!I.FSNVI:NRLKQZ)IY*/JKCB.,[P1\C#^)C]G_6/AYX8\?>+1K%WX_\ %>B> M'_%?V_3O$4-SKS7OA^Q.N^&PNAZ4@9?['4$Y*^"W7+_ /@K#\(9/B1J?@;X:65OX]@\.SZ-:>(O$LGBBU\,Z5H. MJZIHHU>ZTW59/[%U%LZ$FJ:3N+[B-4;7AM1_#;M)^B/P,^,7A?XW^#YO%_A^ M2U+1:GJ&B:O;6NLZ;JOV*^TB[*?9FU71R4RUI]FUU5#$A=8 R,X7^+/X<>"O MB5\4]'^-OPK\'WW@ ?#?X _M):Q\2OMOBOQ'_P 5%X\_MC=X]&A>./$/;_A# M3XVQ_P )CTW>' H&2,_TG?\ !+/5=!U/P+XK;P?H.K>'-((\.?\ "1V_B!&T MW5!X_&DV1\1;]+ 8%?[$'AP'7,AY6((#")C7RW 7B?GV=<8QRG%*,\!F-)3M M%)_57RQFG=)O56TD[K[24MOH/$GPCR+AG@E9O@I3689?4A"3FY?O%*2CJFTK MNZDK+=62[?L ,]QCVZT4PMC;G\?4<=Q]3G\*<&!R 1QU]OK7],:)+71[-]?1 M]?D?S$G==-%[WEZ]OF+4$L*31M"X^3C_ !_0]/PS[ST4QG/Z.2+"&&;B:V"V M) '?2F*@D]R2N2??\*Z"L33?^/OQ!_V&4_\ 3%H];= !1110 4444 %%%% ! M1110 4444 %%%% !5>?M^']:L57G[?A_6@#XM_;=^''C+XF_L^^,?#/P\L;C M4?%[W6CWNCP6=[H-AJG&IK_:I\/GQ.O]@#6_[#.KX_X2 K$,MN.\J%_E9U4: MW?\ Q*U#1/%'Q?\ $O@3P%\,+;QO\%O WCC3?A'H7ASQ%KVH:QH*CQ%H/C7Q MM\01XX_MC;K7_$@V>"_ V&?/*LS-7]L4I&"I&5 )((R#QR.G/TYZ]*_)WXX_ M\$U_#_QK^-OA_P 3:OXZN[#X+)XA'C?7?@U]@SI.I>-LO_:6J:9JYDWZ1_;R M_8Q)H._YS?:\Z%=Y5?Q?Q/\ #C$\48C!8_*VXXUS22<7==FE9O9V\FS] MS\'_ !,R[A7#X[),\BGE\XO,XN*:GS]G: "Z.T@G4R!G6 ?5F+8^7=D**[R?M^']:_3>"LIS+(TO M9R:YGJ[-O5ML_&;]J'Q'\!_$G[2'CGP=\79O#6B?%KPN?A>?@CK'BS1M!U75 M?^$7UC0?#GB/Q#H/@C^V\?\ $C\9^*?^$@\/>+#Z=.V/D&\_:$\ ?#?]HSXT M_"N;QAJ%Q\*+KQ'X6^+7Q&^'_C?PYX-TKQ'X5_L?P;X#_P"$AU[P_P"'_P#A M%?\ B=?#D#_A'O3_ (13/B[_ +E?]8?VT/\ @G_\(/VV$^&^M^,]?\:> /B/ M\)M8.L?"KXI?#2ZT+2_%?A;6>'OVH?B3X/T;Q3X8\+ZOK7@W2QI7BK3O$9\1Z.=5^+&D:WD MZWK8\*ZN/!_A70!QX4_LC'?%?2>PU\]=ODFOA\TK'AX?$898=7O?I?I:UM_3 M33Y-L\Z^'W_!3']GKQ+XH\3_ !$TO]I+0OM^E?%7PMX8T;X9G1M!TK5?'?A< M:"/#@U[_ (2'_JI_KBOF+P'^Q9^R M7\,GT^;P?^SQ\(]-O_#X_P")-X@U3PCH7B/Q59G_ )A7]D^-_$X\2>(!G^RA MQDG Z<$M].5Z&&I*CUNFEJVKWVVW5K+Y-6\_%Q^(]M9]M=ET:T[]$5ZS9M_M M_D\9QV].^>O:OE7]KG]HG5?V??!=AJGANTTF76-4_M"__M3Q4!JGAS0M-T(-=_LK_ (2KPWX@UK']K:2/E(91@YY%?BAXX_:?_:>U'XH_#*+6M-US1=0T MOPGK'COQ)K/_ L74])\#Z]X7!/_ D.I_\ "/#Q2#_;@)\/_P#%'G/)/:OR MGC7QHR?@_,8Y0\$\?CG*"EH[03<;/96WNM?^#^M<$>!_$''.6O/5C8X#+XQ? M+JO?Y;;*]Y-.R>N[/Z,O$G@_PKXVTNYT/QAX5\-^+='N+7[#=:/X@T;0?$>E M76G_ /<:_#\SD5S$.L?#KP1)I_@;3YO"?A(_\>&C:!9_V#X/!X\\ M-^'O&7B'P]K7A7_BWW_(O>(?^1,_X2C_ )%L]O\ D:/TC 9O0QV5X#-\+;_A M1A"3M[W+S)-Q36JY?-]NMS\UQ_#D\!G.-RC&8V5\MDU&Z:YVI6V=G):)+?U/ MH?7?B%XC\8>-_$'AO1+[Q9X(OO"__$ZT;Q7K-M_Q;/Q3I^/#>1X>QD:W_P ) ME_PD./\ BLB1Z5C6?[7.BZ#8>!?%7Q%L=.\)?#OXL>(K#PO\.M7N]9T(>+"< MCPV#XVT '_A'L#Q3N!!\;DY*D?#X;2&_)C]I?]HKQU^P?JGA>_O_ (B_&SXD M> -*\.?\(;X-\6WGP1_X2,>%?[8T'_A)!X-P/^$).M?\(9X4\/?Y_P"$)KV[ M]@/_ ()V:@/%.C_M;_M,^,-#^,?B'Q!_9_Q:^ ^C^'_$?C+5?AEX"_X3W'CS M_A,O^$'UL_\ "/Z+KG]A^(?#W/\ Q5!.?^$NZUOAZV)Q&)5U:,=/2UKI-*VW M7I?;HI^X55Y^WX?UJQ5>OIE=6ZO3[SXO MKI??3OY?,_/?_@H%X;U7QAX8^#^B:)-<6OB&X\>>*-0\.&S[^*-'^#?CWQ)X M>'_A5>'O#V<=SC%?$'AOXU^.+/Q]\5OVG-!M3!K'Q-^%:ZQX>^W$ZKI?A7PN M/C%X#^%:Z\^D\;O^$._X1_Q!XQ/9CQW93^[$UE#-]FFFAM[G[-FZM?MG'V/@ M?YZ\CI6;#H.B6\?DP:5I]K;?9?L'_'I_S#_^@#_^L_RK['*^(,!A, L!7RJ$ MYOW7.2;;C)Q;C?16;C'I)-)JVK:^%S7AO,,PS%9AA(?BG8Z=X9TOXP?$#PN-?L[KX<_P!E^*K#_A6 M\2#0?&__ @/BKQ)X>&N*?\ A(= Z #_ (23PD-;#Q/^S]XX\3^&_"G_".G2AX7OO FO>&3_;W]JC_B?ZU_Q2WB(Z_X ML!&<^&R5ZDG];9O#?ALVUAI7]B:']@TNZ%_:V?\ 8VE_V59ZAUYX_P Y]N"' M3;!/LWDZ?;VPTNU^P6OV.U_X]/QZ?Y/.:MYY@W/V/U*$8Z>XH1Y$DY6=^7F5 M^=2]UIJ47RNSE=KAO'Z8AXY\RM=-MO[.B5[:-;-/2Y^;.L?M%?$72'U?PMI7 MQ8\*>/=!&L?""QN?C]9>'=!'AWX;GXIZYXD_X2$>(=K?\(\?^03X=QV_XJ3_ M (J_!YKUO]C[4IM2T[X_7\WB#3_&G_&2'B@_\)7IEJ-)TO7/^*,\!XU,8W*< M G)#$ ],YS7US_8&B0:?K%5Z\A2E'X9->C:_(]_EB]XQ M=][I:^NA7HG[?A_6BB?M^']:?-*^\K][N_\ GT7W'/R0VY(V[@SZ<]\]>?%8#'V;1SG%V""A[^21Q6(Q/[B+<.KLTDEND]E9?=IKU.7\)Z9X@\90W-O MI1_LW0?[9UDW.H?\MY@=?\1Y..N 2,]AG/!QGZ/\-^%=)\,:=]BT^$*#"PN9 MNM[=C!R200222.X&"!C))J?PS;P6FD&&UA%O#;ZQX@\J =O^)_J_ ^O)_3M7 M5=/G?IQ]3]0.,8_/^?PV-QSQMXRBN2UK:ZK3>_>W2UMM=#]!R[*J.$?UI2:F M[6M?1JW?S2=]S\&OVOO^"7'B37II?B5\ ?B?X_L==T+0_'ZZ=\.M^*7Q M2^"/B#P'=?"3P[J/@F[U'QWH^I:5_P +=U[5UCT1+TR2H.>2#T.>O.37Y#BO#_A>CG,N)Y067O+VYU4TN2; MNFY2OI>ZTW6V^J/VO"^+'&57AG_4JG.>81S!QA1:O[6,7RP]G&2UV=DVW+>V MMFN[A5=BJ2F%[@X'! Z#@'C^8Z<4,0"=BG+<=QCV[#L>3T['J*_%_P 6_P#! M6_X>:-XYTOPUX?T33M1T35-/U^Z:\U'5]5TGQ%IQ\.?\))YEWJOAYO"[.NB- M_96E[65]R_VR,[\<_KAX2\4:7X[\(Z'XMT"X$^D^)]'L=7TRY7/[VPU:V6]C M8(L1C%_"'@_ M3/$DOBF35"AB*[)3^-?P<^/6M^";7Q!X*\/_ !=^)4GC#X>?$6^MO"OPEM_ M?C+X7?$J\\$\:1_PF.K>'F4>(&VG5N-RKX6R.5!.!^J_[9'["W[3I\9P?%/X M1^+O#?CG2#\0_'WC#4?#5_X5%EXULQXO^W:O\WB,ZXO]L:+X=%H- \+Z>T:< MG0@NY48K\>?L&_"J\_:B^*G@KQ'K.O\ C^'7M$M?%$_[26@'%CX>)_%A_GS_ )QVQ7*> M&O#6C^#M"TOP[H=I;Z9I&BV%AI>FV-L ++3K#2E5;6W09& JJ%[L% YXR>I! M!D?&.<$_C]/3O^%?U1EM"6#R_ 83$R4JT*<8RN[WG&,4WWUEW[Z]3^/,PKX? M%YGC\5A8?P M!J,O_+_8?]^6_P /U'.?QSZ]A_?\_P#Z]&']_P __KUT_P!H8C37;\=M]/+^ MKG%_9.&>Z>N__#W\K?\ #L\)F^&&MS?\OFGX[?N#_0'IT_PKGK_X4>(8XYIO MM^D#R+4 P$=/7(!'3J< ]L5]*[&]3_X[_A1L;U/_CO^%:K.<GO]T_A M_.LL?F&)QS2D[+1*-[)=->^G_ 1I@,GPV6MNGOWZO9W=NB?3[_/!TD(DFI6N M!OM]9U 9_P"OO_B<#)YQ_P A8^GH?2N@KFODAUB:3$7V>_MO0-C4-'//7HS( M<>H.DFNEKA/8/&?C/\+](^-/PQ\&?BS\.[[1/&T_B:YNOB5/X M3U;P]XM\.'6_MI(L?#YO_&D6N;&U0CS-3\3*P7G@,<_T->6A&SOR >XSCKCU M[] ?3KEP.$8 Y&"/?CMG..>WMQW-?)\0\)Y)Q+]4_M3"*3B[;VY=M&O-NUI6 MU[V/K>%./.)N$(XRAD^.Y,/BK.<>5/F:2MTNY*VEO=32T[_S#7G_ 2W^,D/ MB'POX%\+?#GPEHIX5885FR"W[>?LL_LYV/[/^A^(-VH2ZMXB\6MI']JWDMPUV;2P\/:9 M::/H6@:8I(QH?AY1J?E@JKC[9(6ZA1]=S,B??E6,D]695)^N3CTZ9P#T]'Q% M60$2 CLPP?RQZ?Y &*\+A_PYX7XJTMOO9+0] MGB;Q3XMXMRF&3YK7_P"$^/*]()?%GBIEM=&6ZU,65G::C>;;;2MX=2=6#WC!3'C>%^;>I*X_-7X(_ M\%%OCEKW[0%GX2\::?XAD\*^,?C-IWPLT'0=>L_"&DW>GZV-!\1^)_$&EJFD M:2=>U>/P]X7&D^(?[<\P)C275GPSD_U%UC1A_PEOAO65.D*L6N>&GWJ')*D8)_FW^ M%GPOUJQ\6_\ "K?@[\)]/^-?Q574_"Y\1_%CX?ZS_:WBG7=.\> _\)SIFK>. M/B#XJ!X'A[_A(#_Q7)_X17''&[=^8\>9AQCE?&^ JQQF;SRMSA]6RK*HMQ:< MHI\[5[KO?\;QM^O^&>0_]NMM+Y\$,N02R@D#L2,D?^/5,!RWID$<]^,^_X>_IQ7S_ /L\:?XY MT3X4^%-+^(J0VOBC3H&L)H&U ZK=Z?8KJ+#2M-U36-S+JFL#1?[,620(NYP3 MSD,_N]Y=0V=O<7DYV06\7FGWSDYQCV_7BOZ,R^N\3@\-B)J46X1;C-6DO=B[ M2_O*[OMK>Y_,&.H1P^+QV'C*%2$)M1J0=X2C&<4G'RLDUJ_)O M5O-2SCW4C1<]._\ 97T^E=%6-IEO+;6,,4OE?:?*'V@C!S?8!SD'IZ8QQR." M*V:ZS!:)+LD%%%% PHHHH **** "BBB@ HHHH **** "J\_;\/ZU8JO/V_#^ MM %"XZ_C_5J^6?VL_P!I+1?V4_@IXG^-WB32;G5]&\,7.G6MU9P\6>F_VQKJ MZ/\ V[JVK')T?0QG+OD*"50;CN*_5OD>_P"O_P!:N2\0^']&\6:+K'A_Q#I% MAK?A[6["_P!(U31-4M/[4L=7T[60?[6TS5-**D<]&Y. 3TKH//\ S:MZKMZ> M1^6&E?&^Y^/]Y_PB0^+N@>,?#'C#P=8?%&_O/A"Q)\!Z>S>'#X?\&^(=)/\ MPDWA\:%XRR<:]XB\38 'BQ5VKT]N^"WQXM-#\$ZMJOQ3T_3?AQX>^QMK7@*S MM-;/C?[9X9T<>&O[?UW2?[%4_P!B!O%7B'P_N\(\E< A6SQ^$7[9_P"RP?\ M@E7X[M_B)^RQI_Q \2>'?VG]8\?:-:_"#P/H^E^!O#G@0^'-!\2^/#KOB'QM MQ_;6/^$A\0?\4@#X7'_" ^',#GPT:^L_A7\ 89O!-S8>,/[0TWX\>(/!NH^% M_$EG\0/BK_PG'ASPI\+]8Q_R)'A[1?%6/[<'A4^'O^$L_P"$,_Y&H_B:#T/J MW^S?\'R_Q'[K>%/&VE>,-/\ -LX;_3=0M_[/-_H^L#&JV?\ ;&?^$?\ H#G/ MKG//>NKN.OX_U:OA']AKX:?$3PU\-HM<\7_$D>/]+']L:+X#N+/PE_PCGVSP MQ_;V1KOB+5AKA/Q )_LH?\(EXOQX8;_A%", @XK[TGLYN-7P]VE;1M;;*[^7;^NOY(_\%//VA/$/P?T?X4:5X5\ M8:'X;MO$'BW4-&\>:QX@M?[5\*^%=/\ $F@_\(WX>U[XL_\ 0%T/^W/$.,8_ MY&K_ (1(U\#?LO\ _!0;XM:'X ^%&K>)?&'PGN?#.O:UXH^%]J;CXC:_\1M6 MU[4/ >O9.O>(?$.?^)+H?_$I\0D^,,D9\1CC(S7=_MS_ H_:T^!WQ,\1?M M^%OAEX?^(O@&?6?''Q!\9>(+?6O&.K>)->&C'2-7^'C>-])'A9O!^BK\*_"H M_P"$?\) D^%@/#>#A@0/$?\ @GG^S-X:^/GQ)\8>+]+U[P=K?@GXD?#.PO\ MX\:/\/\ X8:#X<\5> _'W]OAO#W@[5O&_P#PBO3QGH?]J_\ "6^$/^1J_P"$ M5([D5QW?UG=_>^YWK#85X6SMKHTK7].M_O/V;_:Z_9ZE_:;^'?@8B#0\^%[H M>,;KP/XXM?[5TK7P-";&@>(?^@+K8)XU\_=YP.:_E[T[X;^!M$U2U^*/[0GP M+N/$>E?%"Z\4>%_A7X3^)GBW5/B-JO@3PMR/#N@>'_#Q!XX)P",?\))P<9!_ MM8MM%FM+.UM;/3;BUMK*P^S6MG]FXQ^'Z\]F!R.GYM>-_P#@F)\&/''Q[TWX MOZI<:^/#-OK&G^)[KX0_9M2_X0@>*1KW_"2'Q!X>R"-%/C+7!I1\6>'RI4D' M( R:_'/$[PJJ<58_+\QRC&1IX]R2S2:M\%XJZ3Z_B_NM^[^#OB[@N#L!F&2< M1PE4R^*;RB*35Y))J+M:[;ZMV?SU^/\ _@F7\2/&'C;QQ_:NE>#_ (DZ;H^J M:UX_\+^/+S6? ?\ P@_PRL].T?0?^*>U[P]XA_X1;P3_ ,3W^W!X>\/_ /"/ MDX'_ DGBX]J_4#X_? ?_AHKZ(T'P?#X5TC3_#?AOP\-$\/:7:_V?H^CZ/HW M]EZ59Z?@$#MSR,\YJS<:?JO(_LJ__P# 7GMQ^G^?FK]3X&X4H<)9!3RC$9@L MQ<;/WGS6NTVEKI9Z77R6B/QOQ%XKK<9\3SSO 9?_ &=3YMHQ24DFE%MV:;:U M^_:Y^"'A?_@D[^T;KVGZ;X5^.O[?GBSQ;X \/^(_%%_:^!_ _P .=!TK^WM/ M\=_\))X;\0CQ#XBUH9_Y%7Q"?#_W?% \*[>OB@XQ^W^FZ;8:!I>CZ)I4/V:P MTNUT_1K6RQC['I^CXY]2/;IFNG_L;5?^@7J/_@&?\*J_V1JG_0+U'_P%'^-? M;X66$H;-:VOM9;+7LM=7T_$^!Q-;%XM6:;;TV;]=_EZ=S*JO6G_9.J?] N__ M / 85!_9&K?] K4/_ ;_ .M6_MH=U]Z_S\U]YYOU/%=W]S_R/GOXYWGQ.M-' MT@?#+^W/M_VKQ1?W?]C_ -@_VK>?V/X-\2^)/#P(UKPKXVSGQ5_PCP[=LUX_ M-\?/B+_PGESX/A\*?Z-;VNH7^C7EYX#\9:5_PE7]C^,O#?AO^P?#Q'BOV_X2 M ^,/^ID\)'_A7M?2'Q4C^+-AH_G?#;P^+J_M[7Q3?W5OK'A/7?$9O/[%T(>( M] T'_D:O!(/_ F.N_\ %/$]B<$]J\-\2:I^TS#_ *-9^ [C4O$&E^,OL%K_ M &/X#U32O[>\#:/XRYU4>-_^$J_X1_1?^$S_ .$>\/>'SX/SC_FHV.><'CGY M?.7IY]G^*[G30P3W::^3ZV[KS6F^JWLCSK_A=GQCL_L'BG7-$U"V\/:!;>%] M9\=^'_\ A ]>_M6S\+C0?C ?&W_%0GC6M<_X17P]X>\0?\49R#_PB7A'_F=J M[;XD?$+XQ^&[SP]8:7X;^TZA<6OP_O\ 6;/1_#FO>(]*O-0_X3+PYX;\;^#? M#WB'IHO_ !2O_"0D>,/&8'_(MUJ6&N_'N_BL#XF\"1:G86^M>%[K['HWPA^( MQ_M/PM_PF(.K:H/[:_Y OBGP8.?^$/\ ^$&Z$G.,5A?\)+^TV-4U*:S\"7&F MZ-JEKHVLVG_"0^ _B-JNJX_X0W&K?V3_ &+X5SHO_"/>*_\ F3_&?7_A)/%H MZUJL;3;YERW:WYE>U[]^C?WB^JRM;EE;M9V_]),&\^+7QXU'0-8O])\*Z=IG MV?PY]OM;R\^&GC*^U6\U@Z#X]\2?\B]_PE>?^*,_X0?P]H!\'^OB0Y'A?_D5 M31U+XG?&_P /ZIXAO_[%U#Q)87'B/4-&\-VG_"!Z]_96@Z?H_@WP'XD\/:]_ MU&O^$S\5>(?$7A_]?^*H_P"$)KV+4==_:)C@\('2/AK<78UOPC876M7ESX2U M.P&F>*-7SX;)/A[_ (2K_B2_\55XA\$>(&)QCPKX:^)?;FN2\!VW[3-QK-O? M>*=%U?[#]E\#V%WX>N/ >O6)L_[9S_PD)\/>(?\ A*NG@S^U2!XA]1QT--8V M&RY>UE)>6F_H<_U&7\C^]^5NGFOP*%Y\8/B+9^ _$^MGP?<7/B'2_$?]C6ME M9^ _&6JZ5_R ?^$DX\/?\)5_PD&M_P#0O_\ "8?\4MCQ7T^'OKW_ ,,=8\8: MQ'X_F\50ZA;?9_B+J%AX<%Y:?V5GPO\ V#X;Y_#_ (J'GIR:\]T'QM^T!XDM M/#]]#X3G&D>(-+\*ZS_;_P#PJ_QE_9?]K^)CX<'B#0>?%>?["\&Z)X@.OCXH M?\BKXKP0/^1(_P"*HP=!\:_M&WF@VWV_1-#_ +8M]&^WW0O/ ?C+^UKS4/\ MA#?$GB4EFO[KZ]-ENU=]- M5YG+B<,UNFNBNK/IWMY?-6Z:_6-$_;\/ZUX/INC^.=>M? $WB35O$G]L6_CS MX@VOB/\ X1_^W? ^E7GA?_BO/^$>_P"*>]/^*>\$<5CZQXV^-,/B3[)I.B:? M]@_X2/4=/^V:QX-\9$6FG_V\?^$>_P"*AT7_ (3;^VO^$S\*Y\0?\)AC_A%? M"I]Z]/ZPUWLNFVB_[>/,^K>7]?\ @1]$5/8:5JFMW<5IIUI<2RS\L3@ 8QDY M)X QUSQ6#^S[X(\>>*? 'A@^,QJ%M?\ _$P_M34]8(&JECKVL *"2!SH9 ^8 MXR>F.:^YO#_A/3/#-DEKI\(RP)N+@C-W=,,D,S#YCUZ @ #@9.1Y.9YYAZ&E M%7E9:;I2:TOIW>FS=[=+GIY=PWB:[YJNB;5[Z75TWOT_+IN'%AU M"[%O?:IC/V@C%I:>OV16&0.,#.TDYX'#'UH',6<8S_\ %8_I05C/]/O'CA\ M/%*V[TN[I)ZMMVOJV]=>YAZ%_P @V;_L->)__3_K%= 1D$>HQ7/Z'_R#9O\ ML->)_P#T_P"L5T (/(K,Z[:6Z;%39@H<\C"[Y;+Q1J:V*Z;>_:?L1A7^T[-M647:@X_M#0EU70]Q!.+HH< DC MZSSCC/WO;TY_SR*C*QR121$9R-K=N&^4X]".<]_KFO(S'+Z&8Y?CLNKMQ68P ME%N]^5-)))]]=-NOE?JRG'5\JS/ 9AA[<^7U(33DG;FA*$E?5-IVNTK779'\ M.'C'0;X^)-)]$\9>*?#VJ Z_X,\<^ _^8"V>1XJK^DK_ ()D?&OQ#\7/@W"- M2@OKC1=)T7POJ'A'46\-ZEHECIOAG5SJZZ7\/4N]9^;Q.W@VQT)4?Q!R6_MB M-05)._N->_X)U_ WQ7^T'IOQ]UR77[_^S1K-S<_#*ZO+:Y^&EYX@UK0=7T74 M]?/AYEQ::^UCJSAM0#C.!C[_ ,GW+9V6B>&K"TTRQ&F:+9P6ZVVFV-O]FL[. M*SM553;VZX "*FW(4@ X4 #'Y'P;X=X[A'.*F+Q&/C'+IMV5U'F7-'E4I:) MO97;.,&\U<^6 TKEF=@$9F8H!Z&VHV$0 ENX$]1]I3DGIPS+[8XYY] M.<'Q1H5MXF\/:[X?NU3[-K>D7^CW F3[5E=5TXV3;@6.5*M@Y&TD6KSW6I:)JITCQ3J_@U7U71/[2T71D#ZTA5?$$@W M>)24\2+'Y@7:A_"S]IG]E+Q#\+O&VI_#37- \6S?#3X;>%M'^*'Q9F\*_$S4 MO#G@GXF_\3X_\(]KK:2C'7M%U[PZ/#I)VL>__(T8KLOV,O&\5E\:C-^R]\*O M']G,UCIWBBTU+PU\.?$OB.S\52>.=2\-R:GX1^)?Q+9&UUM'C9!,/&'C/Q'\ MNPR 83%?RQPWQ;Q3E_',Z.=RSC,,3*JXQRE7=-0*C%6EIOTV;/Z^XDX M#X3S#PWQ&*X=P62Y=AHT:51YS)Q5:53EIR<'*4E44ZDOQSUR= MLZ_\L^/3U.1S]?KBKU95Q;S1R_:[0 ]3

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end GRAPHIC 23 img67639792_2.jpg GRAPHIC begin 644 img67639792_2.jpg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img67639792_3.jpg GRAPHIC begin 644 img67639792_3.jpg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end GRAPHIC 25 img67639792_4.jpg GRAPHIC begin 644 img67639792_4.jpg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end GRAPHIC 26 img67639792_5.jpg GRAPHIC begin 644 img67639792_5.jpg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ⅅ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img67639792_6.jpg GRAPHIC begin 644 img67639792_6.jpg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end GRAPHIC 28 img67639792_7.jpg GRAPHIC begin 644 img67639792_7.jpg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end GRAPHIC 29 img67639792_8.jpg GRAPHIC begin 644 img67639792_8.jpg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end GRAPHIC 30 img67639792_9.jpg GRAPHIC begin 644 img67639792_9.jpg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ⅅ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end GRAPHIC 31 img67639792_10.jpg GRAPHIC begin 644 img67639792_10.jpg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end GRAPHIC 32 img67639792_11.jpg GRAPHIC begin 644 img67639792_11.jpg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end GRAPHIC 33 img67639792_12.jpg GRAPHIC begin 644 img67639792_12.jpg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end GRAPHIC 34 img67639792_13.jpg GRAPHIC begin 644 img67639792_13.jpg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end GRAPHIC 35 img67639792_14.jpg GRAPHIC begin 644 img67639792_14.jpg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웾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img67639792_15.jpg GRAPHIC begin 644 img67639792_15.jpg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img67639792_16.jpg GRAPHIC begin 644 img67639792_16.jpg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end GRAPHIC 38 img67639792_17.jpg GRAPHIC begin 644 img67639792_17.jpg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end GRAPHIC 39 img67639792_18.jpg GRAPHIC begin 644 img67639792_18.jpg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end EX-101.SCH 40 cntb-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Consolidated Statements of Loss link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Balance Sheets (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Consolidated Statements of Changes in Shareholders' (Deficit)/Equity link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - General Information, Reorganization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Financial Instruments and Risk Management link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Critical Accounting Estimates and Judgements link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Expenses by Nature link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Employee Benefit Expenses link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Other Income link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Other Gains/(losses) Net link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Finance Income/(cost) Net link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Other non-current Assets link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Financial Instruments by Category link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Other Receivables and Prepayments link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Financial Assets at Fair Value Through Profit or Loss link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Share Capital link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Treasury Shares link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Reserves link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Other Payables and Accruals link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Financial Instruments with Preferred Rights link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Events After the Reporting Period link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - General Information, Reorganization and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Financial Instruments and Risk Management (Tables) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Expenses by Nature (Tables) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Employee Benefit Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Other Income (Tables) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Other Gains/(losses) Net (Tables) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Finance Income/(cost) Net (Tables) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Other non-current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Financial Instruments by Category (Tables) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Other Receivables and Prepayments (Tables) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Financial Assets at Fair Value Through Profit or Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 100550 - Disclosure - Share Capital (Tables) link:presentationLink link:calculationLink link:definitionLink 100560 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100570 - Disclosure - Other Payables and Accruals (Tables) link:presentationLink link:calculationLink link:definitionLink 100580 - Disclosure - Financial Instruments with Preferred Rights (Tables) link:presentationLink link:calculationLink link:definitionLink 100590 - Disclosure - Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 100600 - Disclosure - Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 100610 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 100620 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 100630 - Disclosure - General Information, Reorganization and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100640 - Disclosure - General Information, Reorganization and Basis of Presentation - Summary of Direct or Indirect Interests in Principal Subsidiaries (Details) link:presentationLink link:calculationLink link:definitionLink 100650 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100660 - Disclosure - Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100670 - Disclosure - Financial Instruments and Risk Management - Summary of Exposure to Foreign Currency Risk (Details) link:presentationLink link:calculationLink link:definitionLink 100680 - Disclosure - Financial Instruments and Risk Management - Summary of Aggregate Net Foreign Exchange Gains/(Losses) Recognized in Profit or Loss (Details) link:presentationLink link:calculationLink link:definitionLink 100690 - Disclosure - Financial Instruments and Risk Management - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100700 - Disclosure - Financial Instruments and Risk Management - Summary of Financial Liabilities into Maturity Groupings Based on Remaining Period to Contractual Maturity Date (Details) link:presentationLink link:calculationLink link:definitionLink 100710 - Disclosure - Financial Instruments and Risk Management - Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques (Details) link:presentationLink link:calculationLink link:definitionLink 100720 - Disclosure - Financial Instruments and Risk Management - Summary of Changes in Level 3 Instruments of Short-term Investment (Details) link:presentationLink link:calculationLink link:definitionLink 100730 - Disclosure - Expenses by Nature - Summary of Expenses by Nature (Details) link:presentationLink link:calculationLink link:definitionLink 100740 - Disclosure - Employee Benefit Expenses - Schedule of Employee Benefit Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 100750 - Disclosure - Employee Benefit Expenses - Schedule of Employee Benefit Expenses Included in Consolidated Statements of Loss (Details) link:presentationLink link:calculationLink link:definitionLink 100760 - Disclosure - Other Income - Summary of Other Income (Details) link:presentationLink link:calculationLink link:definitionLink 100770 - Disclosure - Other Income - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100780 - Disclosure - Other Gains/(losses) Net - Schedule of Other gains/ (losses) - Net (Details) link:presentationLink link:calculationLink link:definitionLink 100790 - Disclosure - Other Gains/(losses)-Net - Other gains/ (losses)-Net (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 100800 - Disclosure - Finance Income/(cost) Net - Summary of Finance income/(cost) Net (Details) link:presentationLink link:calculationLink link:definitionLink 100810 - Disclosure - Income taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100820 - Disclosure - Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 100830 - Disclosure - Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 100840 - Disclosure - Net Loss Per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100850 - Disclosure - Net Loss Per Share - Schedule of Net Basic Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 100860 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100870 - Disclosure - Other non-current Assets - Schedule of Other Non-current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 100880 - Disclosure - Other non-current Assets - Schedule of Other Non-current Assets (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 100890 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets (Details) link:presentationLink link:calculationLink link:definitionLink 100900 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100910 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 100920 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 100930 - Disclosure - Financial Instruments by Category - Schedule of Financial Instruments by Category (Details) link:presentationLink link:calculationLink link:definitionLink 100940 - Disclosure - Other Receivables and Prepayments - Schedule of Other Receivables and Prepayments (Details) link:presentationLink link:calculationLink link:definitionLink 100950 - Disclosure - Other Receivables and Prepayments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100960 - Disclosure - Financial Assets At Fair Value Through Profit or Loss - Summary of Returns on Wealth Management Products (Details) link:presentationLink link:calculationLink link:definitionLink 100970 - Disclosure - Financial Assets At Fair Value Through Profit or Loss - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100980 - Disclosure - Cash and Cash Equivalents - Schedule of Cash And Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 100990 - Disclosure - Cash and Cash Equivalents - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 101000 - Disclosure - Share Capital - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 101010 - Disclosure - Share Capital - Schedule of Share Capital and Share Premium (Details) link:presentationLink link:calculationLink link:definitionLink 101020 - Disclosure - Share Capital - Schedule of Share Capital and Share Premium (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 101030 - Disclosure - Treasury Shares - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 101040 - Disclosure - Reserves - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 101050 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 101060 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 101070 - Disclosure - Share-Based Compensation - Summary of Key Assumptions for Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 101080 - Disclosure - Share-Based Compensation - Summary of Key Assumptions for Options Granted (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 101090 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 101100 - Disclosure - Other Payables and Accruals - Schedule of Other Payables and Accruals (Details) link:presentationLink link:calculationLink link:definitionLink 101110 - Disclosure - Financial Instruments with Preferred Rights - Summary of Series of Financings by Issuing Preferred Shares (Details) link:presentationLink link:calculationLink link:definitionLink 101120 - Disclosure - Financial Instruments with Preferred Rights - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 101130 - Disclosure - Financial Instruments with Preferred Rights - Movements of Financial Instruments with Preferred Rights (Details) link:presentationLink link:calculationLink link:definitionLink 101140 - Disclosure - Financial Instruments with Preferred Rights - Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights (Details) link:presentationLink link:calculationLink link:definitionLink 101150 - Disclosure - Cash Flow Information - Summary of Cash Used in Operations (Details) link:presentationLink link:calculationLink link:definitionLink 101160 - Disclosure - Cash Flow Information - Summary of Non-cash Investing and Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 101170 - Disclosure - Cash Flow Information - Summary of Reconciliation of Liabilities Arising from Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 101180 - Disclosure - Commitments - Schedule of Capital Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 101190 - Disclosure - Commitments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 101200 - Disclosure - Related Party Transactions - Schedule of Significant Transactions with Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 101210 - Disclosure - Related Party Transactions - Schedule of Balances with Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 101220 - Disclosure - Related Party Transactions - Summary of Key Management Personnel Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 101230 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 101240 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 101250 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 101260 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Loss (Details) link:presentationLink link:calculationLink link:definitionLink 101270 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 101280 - Disclosure - Events After the Reporting Period - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 41 cntb-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Disclosure Of Income Tax Explanatory Income Taxes Disclosure of finance income expense. Disclosure Of Finance Income Expense [Abstract] Ordinary shares reserved. Ordinary Shares Reserved Ordinary shares reserved Disclosure Of Initial Application Of Standards Or Interpretations [Abstract] Financial Assets Category [Member] Financial assets, category [member] Converted to ordinary shares upon IPO Gains Losses on Conversion to Ordinary Shares Upon Initial Public Offering Gains losses on conversion to ordinary shares upon initial public offering. Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques Disclosure of fair value of financial instruments [text block] Expense relating to short-term leases (included in administrative expenses and research and development expenses) Expense relating to short-term leases for which recognition exemption has been used Non-cash investing and financing activities Non-cash investing and financing activities Non-cash investing and financing activities. Disclosure Of Attribution Of Expenses By Nature To Their Function [Abstract] Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount [Axis] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Disclosure Of Financial Instruments [Abstract] Document Information [Line Items] Consideration, contingent on achieving of research and development milestones. Consideration Contingent On Achieving Of Research And Development Milestones Consideration, contingent on achieving of R&D milestones Auditor Location Construction payables Construction Payables Non-Cash Investing and Financing Activities Construction payables non-cash investing and financing activities Other receivables and prepayments. Other Receivables And Prepayments [Abstract] Weighted Average Exercise Price Of Share Options In Sharebased Payment Arrangement Exercised During Period At Date Of Exercise2019 Weighted average exercise price during the year Types Of Sharebased Payment Arrangements [Axis] Types of share-based payment arrangements [axis] Total cash outflow for leases Total cash outflow for leases Payment for land use rights Cash outflow for leases Less than 1 Year Not later than one year [member] Financial Assets At Fair Value Through Profit Or Loss [Abstract] Assets Current liabilities Current Liabilities Total current liabilities Total interest expense amount recognized Interest expense Total shareholders' (deficit)/equity Equity Balance Balance Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax [Abstract] Items that will not be reclassified to profit or loss Entity Emerging Growth Company Entity Emerging Growth Company Entity's total for subsidiaries [member] Disclosure of income taxes. Disclosure Of Income Taxes [Line Items] Disclosure Of Income Taxes [Line Items] Summary of Cash and Cash Equivalents Disclosure of Summary of Cash and Cash Equivalents Explanatory Disclosure of summary of cash and cash equivalents explanatory. Disclosure Of Initial Application Of Standards Or Interpretations [Table] Disclosure Of Initial Application Of Standards Or Interpretations [Table] Description Of Useful Life Property Plant And Equipment Useful life Credit Risk [Member] Credit Risk Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation Disclosure of Quantitative Information About Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation Explanatory [Text Block] Disclosure of quantitative information about amounts recognized in consolidated statements of loss in addition to depreciation explanatory. Description of accounting policy for investment and other financial assets explanatory. Description Of Accounting Policy For Investment And Other Financial Assets Explanatory Investments and other financial assets Date of subscription Preferred shares, subscription date. Preferred Shares Subscription Date Disclosure Of Treasury Shares Explanatory Treasury shares Financial Assets At Amortised Cost [Member] Financial Assets at Amortized Cost Aggregate lease obligation Operating Lease Costs Operating lease costs. Transactions with owners. Transactions With Owners [Abstract] Transactions with owners Document Shell Company Report Document Shell Company Report Financial assets measured at fair value Financial assets, at fair value Liabilities [Abstract] LIABILITIES Disclosure of credit risk exposure [line items] Other receivables. Other Receivables [Member] Other Receivables Purchase of clinical trials related services Purchases of goods, related party transactions Loss from operations in the PRC Profit Loss From Continuing Operations Before Tax Profit (loss) from continuing operations before tax. Outside of PRC Foreign countries [member] Classes Of Financial Assets [Axis] Classes of financial assets [axis] Expense related to Series C financing. Expense Related To Series C Financing Expense related to Series C financing Financial Liabilities at FVPL Financial Liabilities At Fair Value [Member] Financial Liabilities at Amortized Cost Disclosure Of Property Plant And Equipment [Table] Disclosure Of Property Plant And Equipment [Table] Maturity [Axis] Maturity [axis] Trade And Other Payables [Abstract] Others Other Non-current Assets Other Other non-current assets other. Ranges [member] Schedule of Significant Transactions and Balances with Related Parties Disclosure Of Transactions Between Related Parties Explanatory Disclosure Of Initial Application Of Standards Or Interpretations [Line Items] Disclosure Of Initial Application Of Standards Or Interpretations [Line Items] Legal Entity [Axis] Legal Entity Owners of the Company Comprehensive Income Attributable To Owners Of Parent Owners of the Company Redemption price percentage Redemption price percentage. Financial Liabilities [Member] Financial liabilities, class [member] Description Of Accounting Policy For Financial Instruments Explanatory Financial instruments with preferred rights Disclosure Of Related Party Explanatory Related Party Transactions Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax [Abstract] Items that may be reclassified to profit or loss Finance Income/(cost) Net Disclosure Of Finance Income Expense Explanatory Schedule disclosing information related to details of financial information. Disclosure Of Financial Information [Table] Disclosure Of Financial Information [Table] Other Income Other income Entity Address Country Entity Address, Country Other Noncurrent Assets Other non-current assets Other non-current assets Financial Instruments by Category Disclosure Of Financial Instruments Explanatory Description of accounting policy for standards issued but not yet adopted explanatory. Description Of Accounting Policy For Standards Issued But Not Yet Adopted Explanatory New and amended standards and interpretations not yet adopted by the Group Non-current Noncurrent Lease Liabilities Lease liabilities Aggregate lease obligation over lease term Total lease liabilities Lease Liabilities Lease liabilities Net cash generated from financing activities Net cash flows from (used in) financing activities Cash Flows From Used In Financing Activities Cash flows Net cash (used in)/ generated from financing activities City Area Code City Area Code Disclosure of reconciliation of liabilities arising from financing activities [table] Statement Of Financial Position [Abstract] Summary of Key Assumptions for Options Granted Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period Explanatory Hangzhou Simo Company Limited. Hangzhou Simo Company Limited [Member] Hangzhou Simo Company Limited Disclosure of cash flow information. Disclosure Of Cash Flow Information [Abstract] Cash and cash equivalents [abstract] Fair value of share based payment on grant date at consolidation Weighted Average Share Price Share Options Granted At Consolidation Weighted average share price share options granted at consolidation. Classes Of Share Capital [Axis] Classes of share capital [axis] Investment income credited to profit or loss (Note 8) Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets Total gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets Conversion to ordinary shares Increase (decrease) through Conversion to ordinary shares, liabilities arising from financing activities. Increase (decrease) through conversion to ordinary shares, liabilities arising from financing activities. Connect Biopharm LLC Connect US. Connect U S [Member] Equity [Member] Equity [member] Noncurrent Assets 1 Total non-current assets Summary of Aggregate Net Foreign Exchange Gains/(Losses) Recognized in Profit or Loss Disclosure of aggregate net foreign exchange gains/(losses) recognized in profit or loss explanatory. Disclosure Of Aggregate Net Foreign Exchange Gains Losses Recognized In Profit Or Loss Explanatory Recurring Recurring Fair Value Measurement [Member] Payments of lease liabilities Payments Of Lease Liabilities Classified As Financing Activities Payment for lease liabilities Cash Flows From Used In Investing Activities [Abstract] Cash flows from investing activities Subscription consideration Preferred shares, subscription consideration. Preferred Shares Subscription Consideration Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill Intangible assets estimated useful lives Categories Of Financial Assets [Axis] Categories of financial assets [axis] Miscellaneous Noncurrent Assets [Abstract] Prepaid expenses Current prepaid expenses Fair value changes of financial instruments with preferred rights. Fair Value Changes Of Financial Instruments With Preferred Rights Fair value changes of financial instruments with preferred rights Financial Assets At Fair Value Through Profit Or Loss Category [Member] Financial Assets at Fair Value through Profit or Loss Grants received from other subsidies Revenue from government grants from other subsidies. Critical Accounting Estimates and Judgements Disclosure Of Accounting Judgements And Estimates Explanatory 2021 Stock Incentive Plan Twenty twenty one stock incentive plan. weighted average exercise price Weighted Average Exercise Price per Share Option, Granted during the year Weighted Average Exercise Price Of Share Options Granted In Sharebased Payment Arrangement2019 Shanghai Tigermed Consulting Company Limited. Shanghai Tigermed Consulting Company Limited [Member] Shanghai Tigermed Consulting Company Limited Carrying Amount [Member] Carrying amount [member] Schedule of Employee Benefit Expenses Disclosure Of Detailed Information About Employee Benefit Expenses Explanatory Disclosure of detailed information about employee benefit expenses. Disclosure Of Cash And Cash Equivalents Explanatory Cash and Cash Equivalents Unobservable Inputs [Axis] Unobservable inputs [axis] Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised Deductible temporary differences for which no deferred tax asset is recognized Statement Of Changes In Equity [Line Items] Statement Of Changes In Equity [Line Items] Conversion from preferred shares to ordinary shares, shares Conversion from Preferred Shares to Ordinary Shares Conversion from preferred shares to ordinary shares. Applicable Tax Rate Tax rate Disclosure Of Quantitative Information About Rightofuse Assets [Table] Disclosure Of Quantitative Information About Rightofuse Assets [Table] Other comprehensive income, net of tax, exchange differences on translation of foreign operations Other Comprehensive Income Net Of Tax Exchange Differences On Translation Exchange differences on translation of foreign operations Other Gains/(losses)-Net Disclosure of Other income (losses) net explanatory Disclosure of Other income (losses) net. 2019 Stock Incentive Plan Two Thousand Nineteen Stock Incentive Plan [Member] 2019 Stock Incentive Plan. Disclosure of condensed financial information for the parent company. Disclosure Of Condensed Financial Information For Parent Company Explanatory Schedule of Condensed Financial Information For the Parent Company Weighted Average Fair Value At Measurement Date Share Options Granted Weighted average fair value of options granted during the year Connect Union Connect Union Incorporation. Connect Union Incorporation [Member] Connect Union Inc. (Note) Additions Other Than Through Business Combinations Property Plant And Equipment Additions Disclosure Of Classes Of Share Capital [Table] Disclosure Of Classes Of Share Capital [Table] Security Exchange Name Security Exchange Name Number of shares issued at consolidation Number of shares issued at consolidation. Other Income (Losses) Net [Abstract] Other income losses net. Employee benefit expenses Employee benefit expenses Employee benefits expense Employee Benefits Expense Employee benefit expenses (Note 6) Disclosure of non-adjusting events after reporting period [line items] Current Liabilities [Abstract] Current liabilities -Other receivables and prepayments Adjustments for decrease (increase) in other operating receivables Total shareholders' (deficit)/equity Equity Attributable To Owners Of Parent Net liabilities Document Period End Date Document Period End Date Total issued capital Issued Capital Share capital Issued capital and share premium. Issued Capital And Share Premium [Member] Share Capital and Share Premium Series c preferred shares. Series C Preferred Shares [Member] Series C Preferred Shares Series C Preferred Shares Disclosure of general information, reorganization and basis of presentation. Disclosure Of General Information Reorganization And Basis Of Presentation [Table] Disclosure Of General Information Reorganization And Basis Of Presentation [Table] Disclosure Of Financial Instruments [Table] Disclosure Of Financial Instruments [Table] Corporate income tax rate Corporate Income Tax Rate Corporate income tax rate. Land of use rights Net Book value Net book amount, Ending balance Net book amount. Beginning balance Rightofuse Assets Right-of-use assets Options outstanding at December 31, 2021 Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period Weighted Average Exercise Price Of Share Options Outstanding In Sharebased Payment Arrangement2019 Equity investment Investments accounted for using equity method Total investments accounted for using equity method Disclosure of financial liabilities into maturity groupings based on remaining period to contractual maturity date explanatory. Disclosure Of Financial Liabilities Into Maturity Groupings Based On Remaining Period To Contractual Maturity Date Explanatory Summary of Financial Liabilities into Maturity Groupings Based on Remaining Period to Contractual Maturity Date Share options granted Number of Options, Granted during the year Number Of Share Options Granted In Sharebased Payment Arrangement Finance Income Finance income Effect of income tax in jurisdictions other than the PRC Tax Effect Of Foreign Tax Rates Disclosure of significant unobservable inputs used in fair value measurement of assets [line items] Disclosure Of Property Plant And Equipment [Line Items] Disclosure Of Property Plant And Equipment [Line Items] Financial Assets [Member] Financial assets, class [member] Accumulated losses Total accumulated other comprehensive income Accumulated Other Comprehensive Income Accumulated losses Beijing Medical Development (Suzhou) Company Limited. Beijing Medical Development Suzhou Company Limited [Member] Beijing Medical Development (Suzhou) Company Limited Disclosure Of Expenses Explanatory Summary of Expenses by Nature Interest from bank deposits and term deposits Interest income on deposits Classes Of Employee Benefits Expense [Abstract] Date of subscription Preferred Shares Subscription Date One Preferred Shares Subscription Date One Net loss attributable to owners of the Company (RMB'000) Profit Loss Attributable To Owners Of Parent Owners of the Company Percentage of reserve fund of registered capital Percentage of Entitys Reserve Registered Capital Percentage of entity's reserve registered capital. Statement Of Comprehensive Income [Abstract] Disclosure of cash used in operations. Disclosure Of Cash Used In Operations Explanatory Summary of Cash Used in Operations Document Accounting Standard Document Accounting Standard Other Income Disclosure Of Government Grants Explanatory Disclosure of general information, reorganization and basis of presentation. Disclosure Of General Information Reorganization And Basis Of Presentation [Abstract] Level1 Of Fair Value Hierarchy [Member] Level 1 Accumulated deprecation Right of use Assets Accumulated Depreciation Right of use assets accumulated depreciation. Aggregate amount paid Cost Right-of-use assets, revalued assets, at cost Disclosure Of Financial Assets [Line Items] Disclosure Of Financial Assets [Line Items] Unobservable Inputs [Member] Unobservable inputs [member] Address Type [Domain] Entity Address, Address Line Two Current Fiscal Year End Date Current Fiscal Year End Date Issuance of treasury shares Sale or issue of treasury shares HONG KONG Hong Kong Parent [Member] Parent Document Information [Table] Total cash and cash equivalents Cash And Cash Equivalents Cash and cash equivalents at end of year Cash and cash equivalents at the beginning of year Cash and cash equivalents Disclosure of income taxes. Disclosure Of Income Taxes [Table] Disclosure Of Income Taxes [Table] More than 5 Years Later than five years [member] Place of incorporation Country Of Incorporation Country of incorporation Non-adjusting events after reporting period [axis] -Investment income from wealth management products -Investment income from wealth management products Adjustments for investment income from wealth management products. Adjustments For Investment Income From Wealth Management Products Loss before income tax Profit Loss Before Tax Loss before income tax Loss before income tax Customers [member] Number of shares represented by one depositary shares Number of Shares Represented by One Depositary Shares Number of shares represented by one depositary shares. Effect Of Exchange Rate Changes On Cash And Cash Equivalents Effects of exchange rate changes on cash and cash equivalents Payment for right-of-use assets Payment For Right Of Use Assets Payment for right of use assets. Percentage of voting equity interests acquired Percentage of foreign exchange transactions Percentage Of Foreign Exchange Transaction Percentage of foreign exchange transaction. Disclosure Of Quantitative Information About Rightofuse Assets [Line Items] Disclosure Of Quantitative Information About Rightofuse Assets [Line Items] Key Management Personnel Compensation Postemployment Benefits Contributions to defined benefit plan Lease Liabilities [Member] Lease Liabilities Disclosure Of Number And Weighted Average Exercise Prices Of Share Options Explanatory Summary of Options Outstanding Other comprehensive (loss)/income for the year, net of tax Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax Issued Capital [Member] Share Capital Key Management Personnel Compensation Sharebased Payment Share-based compensation expenses Series A preferred shares. Series A Preferred Shares [Member] Series A Preferred Shares Income Statement [Abstract] Net cash used in operations Net operating cash outflow Net operating cash outflow Net cash flows from (used in) operations Cash Flows From Used In Operations Cash used in operations Classes Of Intangible Assets Other Than Goodwill [Axis] Classes of intangible assets other than goodwill [axis] Basic and diluted earnings loss per share. Basic And Diluted Earnings Loss Per Share Basic and diluted Transfers Increase (decrease) through transfers from construction in progress, property, plant and equipment Adjustments For Reconcile Profit Loss [Abstract] Adjustments for: Welfare, housing funds and other Key management personnel compensation, other long-term employee benefits Liabilities [Member] Liabilities [member] Disclosure of financial information. Disclosure Of Financial Information [Line Items] Disclosure Of Financial Information [Line Items] Document Type Document Type Total retained earnings Retained Earnings Accumulated losses Classes Of Financial Liabilities [Axis] Financial Liabilities at Amortized Cost Disclosure of restricted net assets and parent company condensed financial information. Disclosure Of Restricted Net Assets And Parent Company Condensed Financial Information Explanatory Restricted Net Assets and Parent Company Only Condensed Financial Information Prepayments Prepayments Prepayment for clinical trials related services Expected early exercise multiple Expected Early Exercise Multiple Expected early exercise multiple. Weighted Average Exercise Price Of Share Options Exercisable In Sharebased Payment Arrangement2019 Options exercisable at December 31, 2021 Intangible assets Intangible assets and goodwill Intangible assets and goodwill at beginning of period Intangible assets and goodwill at end of period Total intangible assets and goodwill Share-based payment award, award vesting period. Share Based Payment Award Vesting Period Vesting period Total gains (losses) on financial liabilities at fair value through profit or loss Gains Losses On Financial Liabilities At Fair Value Through Profit Or Loss Fair value loss of financial instruments with preferred rights Treasury Shares Treasury shares Treasury shares Proceeds from disposal of financial assets at fair value through profit or loss Proceeds from disposal or maturity of available-for-sale financial assets Increase Decrease Through Exercise Of Options Exercise of stock options Clinical trials related expenses. Clinical Trials Related Expenses Clinical trials related expenses Entity Incorporation Date Of Incorporation Date of incorporation Issuance cost of financial instruments with preferred rights Payments for share issue costs Liabilities Arising From Financing Activities [Axis] Liabilities arising from financing activities [axis] All Levels Of Fair Value Hierarchy [Member] All levels of fair value hierarchy [member] Attribution Of Expenses By Nature To Their Function [Axis] Attribution of expenses by nature to their function [axis] Comprehensive loss Other comprehensive loss Other Comprehensive Income [Abstract] Number of Options, Forfeited during the year Number Of Share Options Forfeited In Sharebased Payment Arrangement Forfeited during the year Related Party Transactions [Abstract] Issuance of treasury shares. Issuance Of Treasury Shares Issuance of treasury shares, shares Disclosure Of Reserves Within Equity [Abstract] Interest in a subsidiary, Interest In Subsidiary Interest in a subsidiary Restricted net assets and parent company condensed financial information. Restricted Net Assets And Parent Company Condensed Financial Information [Abstract] China Government Government [member] Conversion from preferred shares to ordinary shares Conversion from preferred shares Increase (decrease) through conversion of convertible instruments, equity Principal activities Description of nature of entity's operations and principal activities After Share Consolidation After Share Consolidation [Member] After share consolidation. Number of shares issued for pre money valuation amount. Number Of Shares Issued For Pre Money Valuation Amount Number of shares issued for pre money valuation amount Other Income Expense [Abstract] Other income expense. Profit Loss From Operating Activities Operating loss Net operating loss -Share-based compensation expenses Adjustments For Sharebased Payments Share-based compensation expenses Weighted Average Exercise Price per Share Option, Exercised during the year Weighted average exercise price of share options exercised in share-based payment arrangement Cash Flows From Used In Operating Activities [Abstract] Cash flows from operating activities Bottom Of Range [Member] Bottom of range Interest for lease liabilities Interest expense Interest for lease liabilities Interest expense on lease liabilities Welfare expenses Welfare Expenses Welfare expenses. Disclosure Of Classes Of Share Capital Explanatory Schedule of Share Capital and Share Premium Disclosure Of Transactions Between Related Parties [Line Items] Disclosure Of Transactions Between Related Parties [Line Items] Disclosure Of Summary Of Significant Accounting Policies Explanatory Summary of Significant Accounting Policies Loss from overseas entities Profit (loss) from overseas entities Profit (loss) from overseas entities -Other non-current assets Adjustments for decrease (increase) in other assets Summary of Non-cash Investing and Financing Activities Disclosure Of Non Cash Investing and Financing Activities Explanatory Disclosure of non cash investing and financing activities explanatory. Description Of Accounting Policy For Cash Flows Explanatory Cash and cash equivalents Measurement [Axis] Measurement [axis] Beginning balance Ending balance Liabilities arising from financing activities Share-based compensation to additional Series C preferred shareholder Increase (decrease) through Share-based compensation to additional Series C preferred shareholder, liabilities arising from financing activities Increase (decrease) through share-based compensation to additional Series C preferred shareholder, liabilities arising from financing activities. Document Fiscal Period Focus Document Fiscal Period Focus Top Of Range [Member] Top of range 2021 Employee Share Purchase Plan Twenty Twenty One Employee Share Purchase Plan [Member] Twenty twenty one employee share purchase plan. Percentage of annual require net after tax profits. Percentage Of Annual Require Net After Tax Profits Percentage of annual require net after tax profits -Net foreign exchange differences Adjustments For Unrealised Foreign Exchange Losses Gains Entity Address Address Line1 Entity Address, Address Line One Land use Rights Land use Rights [Member] Land use rights. Lease liabilities [abstract] Categories Of Related Parties [Axis] Categories of related parties [axis] Computer Software [Member] Software Contributions to defined benefit plan (Note 27(d)) Post-employment benefit expense in profit or loss, defined benefit plans Total post-employment benefit expense in profit or loss, defined benefit plans Disclosure Of Defined Benefit Plans [Line Items] Disclosure Of Defined Benefit Plans [Line Items] Initial public offering price Initial Public Offering Price Initial Public Offering Price Entity Address Postal Zip Code Entity Address, Postal Zip Code Classes Of Property Plant And Equipment [Axis] Classes of property, plant and equipment [axis] Description Of Accounting Policy For Intangible Assets Other Than Goodwill Explanatory Intangible assets Internal rate of return Internal Rate of Return Internal Rate of Return Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability Disclosure of Quantitative Information about Lease Liabilities Explanatory [Text Block] Disclosure of quantitative information about lease liabilities explanatory. Depreciation Depreciation Depreciation, right-of-use assets Administrative expenses. Administrative Expenses [Member] Administrative Expenses Number of preferred shares NUMBER OF PREFERRED SHARES Total number of shares issued Number of shares issued Comprehensive Income Total comprehensive loss for the year Other loss Other loss Other Non Operating Incomes Expenses Other non-operating incomes (expenses). Financial Liabilities At Amortised Cost [Member] Financial Liabilities at Amortized Cost Disclosure Of Financial Liabilities Explanatory Movements of Financial Instruments with Preferred Rights Loss before income tax lower due to change in unobservable input Options granted vesting term Description of vesting requirements for share-based payment arrangement Categories Of Financial Liabilities [Axis] Categories of financial liabilities [axis] Comprehensive Income Attributable To [Abstract] Total comprehensive loss attributable to: Liabilities [Abstract] 1 LIABILITIES -Issuance cost of financial instruments with preferred rights Adjustments for issuance cost of financial instruments with preferred rights. Adjustments For Issuance Cost Of Financial Instruments With Preferred Rights Entity Registrant Name Entity Registrant Name Noncurrent Prepayments Prepayments -Loss on disposal of property, plant and equipment -(Gain)/Loss on disposal of PPE (Gain)/Loss on disposal of PPE Gains (losses) on disposals of property, plant and equipment Net gains (losses) on disposals of property, plant and equipment Summary of Series of Financings by Issuing Preferred Shares Disclosure Of Summary of Financial Instruments With Preferred Rights Explanatory Disclosure of summary of financial instruments with preferred rights. Other Receivables Others Total liabilities and shareholders' (deficit)/equity Equity And Liabilities Disclosure Of Commitments Explanatory Commitments Entity Interactive Data Current Entity Interactive Data Current Tax losses and deductible temporary differences for which no deferred income tax assets were recognized. Tax Losses And Deductible Temporary Differences For Which No Deferred Income Tax Assets Recognized Tax losses and deductible temporary differences for which no deferred income tax assets were recognized Entity Address City Or Town Entity Address, City or Town Treasury Shares Held For Issuance Consolidated Treasury shares held for issuance consolidated Line Items By Function [Member] Line items by function [member] Description Of Accounting Policy For Leases Explanatory Leases Statement Of Cash Flows [Abstract] Schedule of Other Gains/ (Losses) Net Disclosure Of Detailed Information About Schedule Of Other Gains Losses Net Explanatory Disclosure of detailed information about schedule of other gains/(losses) - net. Depreciation and amortization Depreciation and amortisation expense Depreciation and amortisation expense Total depreciation and amortisation expense Cash Flows From Used In Financing Activities [Abstract] Cash flows from financing activities Trading Symbol Trading Symbol Description Of Accounting Policy For Issued Capital Explanatory Share capital Statement Of Changes In Equity [Table] Statement Of Changes In Equity [Table] Disclosure Of General Information About Financial Statements Explanatory General Information, Reorganization and Basis of Presentation Interest expenses Increase (decrease) through Interest Expense, liabilities arising from financing activities Increase (decrease) through interest expense, liabilities arising from financing activities. Local Phone Number Local Phone Number Noncurrent Liabilities [Abstract] Non-current liabilities Total cash Cash Cumulative cash contributions Unrecognized uncertain tax positions Unrecognized uncertain tax positions. Investment income from wealth management products Investment income Recovery from Insurance Amount Recovery from insurance amount. Other Payables Other payables Total financial liabilities at fair value through profit or loss Financial Liabilities At Fair Value Through Profit Or Loss Financial instruments with preferred rights Depreciation Property Plant And Equipment Depreciation Housing funds Housing Funds Housing funds. Noncurrent Assets [Abstract] Non-current assets Noncurrent Liabilities Total non-current liabilities Office Equipment and Furniture Office equipment and furniture. Revenue from government as an incentive for research and development Revenue from government as an incentive for research and development. Non-adjusting events after reporting period [member] SHAREHOLDERS' (DEFICIT)/EQUITY Equity [Abstract] 1 SHAREHOLDERS’ DEFICIT Other Current Assets Other current assets PRC RMB deposits CHINA Description Of Accounting Policy For Interest Income And Expense Explanatory Interest Income Disclosure Of Information About Key Management Personnel Explanatory Summary of Key Management Personnel Compensation Entity [Domain] Entity Construction in Progress Assets Under Construction Construction in progress [member] Tax Effect Of Expense Not Deductible In Determining Taxable Profit Tax Loss Expenses not deductible for income tax purpose Office Rent Office Rent [Member] Office rent. Disclosure of significant unobservable inputs used in fair value measurement of assets [table] Description Of Accounting Policy For Income Tax Explanatory Current and deferred income tax Loss before income tax Accounting Profit Assessable profits Cash flows Increase (decrease) through financing cash flows, liabilities arising from financing activities Description Of Option Life Share Options Granted Option life Research and development tax credits Share Premium Share premium Place of incorporation Principal place of business of subsidiary Shares reserved for future issuance under 2019 Stock Incentive plan Shares Reserved for Future Issuance under Two Thousand Nineteen Stock Incentive Plan Shares reserved for future issuance under 2019 stock incentive plan. Issuance of shares to Co-Founders Issuance of shares to Co-founders Increase Decrease In Value Of Ordinary Shares Issued To Co-founders Increase decrease in value of ordinary shares issued to co-founders. Weighted Average Remaining Contractual Life Of Outstanding Share Options2019 Weighted average remaining contractual life of options outstanding Capital commitments Equipment and intangible assets - Contracted but not provided for Contractual capital commitments Finance Costs Finance cost Finance costs Proceeds from issuance of ordinary shares Proceeds From Issuing Shares Cash consideration Provision for income taxes Tax income (expense) Income Tax Expense Continuing Operations Income tax expense Income tax expense Income tax expense Share based compensation Increase Decrease Through Sharebased Payment Transactions Share-based compensations Summary of Finance Income/(Cost) Net Disclosure of Detailed Information about Finance Income/(Cost) Net Disclosure of detailed information about finance income/(cost) net. Weighted Average Shares Weighted average number of ordinary shares outstanding (in thousands) Forfeiture rate for executives and all other employees Forfeiture rate, share options granted. Forfeiture Rate Share Options Granted Forfeiture rate Description Of Accounting Policy For Sharebased Payment Transactions Explanatory Share-based compensation Disclosure Of Share Capital Reserves And Other Equity Interest Explanatory Share Capital Other Reserves [Member] Other Reserves Number of Options, Options outstanding, Ending Balance Number of Options, Options outstanding, Beginning Balance Number Of Outstanding Share Options Number of segments. Number Of Segments Number of segments Disclosure of schedule of other payables and accruals. Disclosure Of Schedule Of Other Payables And Accruals Schedule of Other Payables and Accruals Share-based payment award, vesting rights, percentage. Share Based Payment Award Vesting Rights Percentage Vesting rights percentage Wealth management products Opening balance Closing balance Financial Assets Liabilities At Fair Value Through Profit Or Loss Financial assets (liabilities) at fair value through profit or loss. Administrative Expense Administrative expenses Description Of Accounting Policy For Government Grants Government grants Percentage of assessable profits Percentage of assessable profits Attributable equity interest to the Group Proportion of ownership interest in subsidiary San Diego, California State Income Tax in California Summary of Changes in Level 3 Instruments of Short-term Investment Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities [Text block] Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities. Critical accounting estimates and judgements. Critical Accounting Estimates And Judgements [Abstract] Changes in fair value Increase (decrease) through changes in fair values, liabilities arising from financing activities Disclosure Of Transactions Between Related Parties [Table] Disclosure Of Transactions Between Related Parties [Table] Trade payables. Trade Payables [Member] Trade Payables Expense By Nature [Abstract] -Fair value changes of financial instruments with preferred rights Adjustments For Fair Value Gains Losses Date of subscription Preferred Shares Subscription Date Two Preferred shares subscription date two. Net (liabilities)/assets Net assets Net assets (liabilities) Net Assets Liabilities Major customers [axis] Equity Attributable To Owners Of Parent [Member] Total Summary of Reconciliation of Liabilities Arising from Financing Activities Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities Explanatory Description Of Accounting Policy For Subsidiaries Explanatory Separate financial statements Wealth Management Products Wealth Management Products. Key Management Personnel Compensation Key management personnel compensation Connect Biopharma (Shenzhen) Co., Ltd Shenzhen Connect Biopharmaceuticals, Limited [Member] Shenzhen Connect Biopharmaceuticals, Limited. Payment for repurchase of ordinary shares Payments to acquire or redeem entity's shares -Amortization of intangible assets Adjustments for amortisation expense Par Value Per Share Par value per share Par value Losses partially recovered from cyber insurance Losses Partially Recovered from Cyber Insurance Losses partially recovered from cyber insurance. Other Payables and Accruals [Abstract] Other payables and accruals. Issuance of Ordinary Shares Increase Decrease in Value of Ordinary Shares Issued increase decrease in value of ordinary shares issued. Total expenses, by nature Expense By Nature Total expenses by nature Deferred income Non Current Deferred Revenue Non current deferred revenue. Accumulated depreciation Accumulated depreciation and amortisation [member] Historical Volatility For Shares Measurement Input [Member] Expected Volatility Volatility Loss before income tax higher due to change in unobservable input Disclosure Of Prepayments And Other Assets Explanatory Other Receivables and Prepayments Lease term Operating Lease Period Operating lease period. Entitys Total For Related Parties [Member] Entity's total for related parties [member] Disclosure Of Financial Instruments [Line Items] Disclosure Of Financial Instruments [Line Items] Discount rate for lack of marketability, measurement input. Discount Rate For Lack Of Marketability Measurement Input [Member] DLOM Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract] Depreciation method Security12b Title Title of 12(b) Security Percentage of shares equal to lesser of aggregate number of ordinary shares Percentage of Shares Equal to Lesser of Aggregate Number of Ordinary Shares Percentage of shares equal to lesser of aggregate number of ordinary shares. Laboratory equipment. Laboratory Equipment [Member] Laboratory Equipment Disclosure Of Nonadjusting Events After Reporting Period [Abstract] Connect Biopharma (Shanghai) Co., Ltd Shanghai Connect Biopharmaceuticals, Limited [Member] Shanghai Connect Biopharmaceuticals, Limited. Entity Well Known Seasoned Issuer Entity Well-known Seasoned Issuer Square feet of operating lease area Square Feet Of Operating Lease Area Square feet of operating lease area. Wages, salaries and bonuses Wages and salaries Issuance of value of treasury shares. Issuance Of Value Of Treasury Shares Issuance of treasury shares Other Current Receivables Other receivables Between 1 and 2 Years Later than one year and not later than two years [member] Types Of Risks [Axis] Types of risks [axis] Issuance costs Share issue related cost Purchase of property, plant and equipment Purchase Of Property Plant And Equipment Classified As Investing Activities Purchase of property, plant and equipment Disclosure of non-adjusting events after reporting period [table] Schedule of Financial Instruments by Category Disclosure Of Detailed Information About Financial Instruments Explanatory Leasehold Improvements [Member] Leasehold Improvements Leases Disclosure of leases [text block] -Other payables and accruals Adjustments for increase (decrease) in other operating payables Description Of Accounting Policy For Research And Development Expense Explanatory Research and development expenses Description of accounting policy for principles of consolidation explanatory. Description Of Accounting Policy For Principles Of Consolidation Explanatory Principles of consolidation Number of share options vested in share-based payment arrangement Number Of Share Options Vested In Share Based Payment Arrangement Number of shares vested Assets at beginning of period Assets at end of period Assets 1 Total assets Co-Founders. Co Founders [Member] Co-Founders Tax expense at PRC enterprise income tax rate of 25% Tax calculated at statutory tax rate of 25% Tax expenses (income) Tax Expense Income At Applicable Tax Rate Net cash flows from (used in) investing activities Cash Flows From Used In Investing Activities Net cash used in investing activities Net cash (used in)/ generated from investing activities Preferred shares conversion ratio Preferred Shares Conversion Ratio Preferred shares conversion ratio. Noncurrent Value Added Tax Receivables Deductible value-added tax Entity Current Reporting Status Entity Current Reporting Status Net Loss Per Share Disclosure Of Earnings Per Share Explanatory Issuance cost of financial instruments with preferred rights. Issuance Cost Of Financial Instruments With Preferred Rights Issuance cost of financial instruments with preferred rights Entity Voluntary Filers Entity Voluntary Filers Super deduction of research and development expenses Income Tax Super Deduction Of Research And Development Expenses Income tax super deduction of research and development expenses. Percentage of tax deductible research and development expense. Percentage Of Tax Deductible Research And Development Expense Percentage of tax-deductible research and development expenses Shares reserved for future issuance Shares Reserved For Issue Under Options And Contracts For Sale Of Shares Number of shares potentially issuable Other Reserves Other reserves Payroll, welfare and bonus payables. Payroll Welfare And Bonus Payables Payroll, welfare and bonus payables Research And Development Expense Research and development expenses Government Grants Government grants Level2 Of Fair Value Hierarchy [Member] Level 2 Equipment and Intangible Assets - Contracted but not provided for Equipment And Intangible Assets [Member] Equipment and intangible assets. Financial Liabilities Category [Member] Financial liabilities, category [member] Auditor Firm ID Issuance of Ordinary Shares, shares Increase Decrease In Number Of Ordinary Shares Issued Issuance of shares to Co-founders, shares Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table] Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table] Weighted Average Exercise Price per Share Option, Forfeited during the year Weighted Average Exercise Price Of Share Options Forfeited In Sharebased Payment Arrangement2019 Number of ADSs issued Number of American Depositary Shares Issued Number of American depositary shares issued. Capital Commitments [Abstract] USD deposits UNITED STATES US Federal Corporate Income Tax Summary of Direct or Indirect Interests in Principal Subsidiaries Disclosure of interests in subsidiaries [text block] Loss per share Earnings Per Share [Abstract] -Depreciation of property, plant and equipment Adjustments for depreciation of property, plant and equipment. Adjustments For Depreciation Of Property Plant And Equipment Geographical Areas [Member] Geographical areas [member] Auditor Name Expense relating to leases of low-value assets that are not shown above as short-term leases (included in administrative expenses and research and development expenses) Expense relating to leases of low-value assets for which recognition exemption has been used -Depreciation of rights-of-use assets Adjustments for depreciation of rights of use assets. Adjustments For Depreciation Of Rights Of Use Assets Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill Explanatory Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights Financial Assets at Fair Value Through Profit or Loss Disclosure Of Financial Instruments At Fair Value Through Profit Or Loss Explanatory Purchase of financial assets at fair value through profit or loss Purchase of available-for-sale financial assets Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate Disclosure Of Detailed Information About Schedule Of Income Tax Expense Reconciliation Explanatory Disclosure of detailed information about schedule of income tax expense reconciliation. Phone Fax Number Description Reserve Of Sharebased Payments [Member] Share-Based Compensation Reserves Schedule of Capital Commitments Disclosure Of Detailed Information About Schedule Of Capital Commitments Explanatory Disclosure of detailed information about schedule of capital commitments. Cash And Cash Equivalents [Abstract] Suzhou. Suzhou [Member] Suzhou Sharebased Payment Arrangements [Member] Share-based payment arrangements [member] Statement Of Changes In Equity [Abstract] Intangible Assets Other Than Goodwill [Member] Intangible assets other than goodwill [member] Currency Risk [Member] Foreign Currency Risk Ordinary shares consolidation Conversion Of Ordinary Shares Converted Conversion of ordinary shares converted. Summary of returns on wealth management products. Summary Of Returns On Wealth Management Products Table [Text Block] Summary of Returns on Wealth Management Products Financial instruments with preferred rights. Financial Instruments With Preferred Rights Financial instruments with preferred rights Treasury Shares [Member] Treasury Shares Description Of Accounting Policy For Trade And Other Payables Explanatory Trade and other payables Other receivable and prepayments Other receivables and prepayments Other receivables and prepayments. Other Receivables And Prepayments Share-Based Compensation Disclosure Of Sharebased Payment Arrangements Explanatory Gross Carrying Amount [Member] Cost Document Annual Report Document Annual Report Other gains/(losses)-net Other gains/(losses) - net Other Gains Losses Series B financing. Series B Financing [Member] Series B Financing Total assets FINANCIAL ASSETS Financial Assets Financial assets at beginning of period Financial assets at end of period Financial Assets Disclosure of general information, reorganization and basis of presentation. Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items] Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items] Basic net loss per share (RMB) Total basic earnings (loss) per share Basic Earnings Loss Per Share Government grants received Share purchase agreement. Share Purchase Agreement [Member] Share Purchase Agreement Classes of assets [axis] Entity Filer Category Entity Filer Category Disclosure Of Classes Of Share Capital [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Treasury shares held for issuance Treasury Shares held for Issuance Treasury shares held for issuance. Office expenses. Office Expenses Office expenses Period of grant of share-based payment arrangement. Period Of Grant Of Share Based Payment Arrangement Period of grant of share-based payment arrangement Subsidiaries [axis] Between 2 and 5 Years Later than two years and not later than five years [member] Financial liabilities Total liabilities Total Total liabilities Description Of Accounting Policy For Expenses Explanatory Administrative expenses Repurchase of ordinary shares value Repurchase Of Ordinary Shares Value Repurchase of ordinary shares value. Total financial assets at fair value through profit or loss Financial Assets At Fair Value Through Profit Or Loss Closing balance Opening balance Financial assets at fair value through profit or loss Types Of Risks [Member] Risks [member] Entity Ex Transition Period Entity Ex Transition Period Change in fair value due to foreign currency translation recognized in other comprehensive income Gains Losses On Exchange Differences On Translation Net Of Tax Exchange differences Share capital Classes Of Share Capital [Member] Share capital [member] State income tax rate Average effective tax rate Total average effective tax rate Components Of Equity [Axis] Components of equity [axis] Entity Central Index Key Entity Central Index Key Increase Decrease Through New Transactions Aggregate Difference Between Fair Value At Initial Recognition And Amount Determined Using Valuation Technique Yet To Be Recognised Issuance of Series C Preferred Shares Proceeds from issuance of financial instruments with preferred rights. Proceeds From Issuance Of Financial Instruments With Preferred Rights Proceeds from issuance of financial instruments with preferred rights Number Of Shares Authorised Authorized shares Authorized share capital Percentage of net profit to offset prior losses Percentage of Entity Profit to Offset Prior Losses Percentage of entity profit to offset prior losses Liabilities Liabilities 1 At December 31, 2021 At January 1, 2021 Net liabilities Total liabilities Prepayments for purchase of non-current assets. Prepayments For Purchase Of Non Current Assets Prepayments for purchase of non-current assets Disclosure of credit risk exposure [table] Cash and cash equivalent. Cash And Cash Equivalent [Member] Cash and Cash Equivalents Total expense from share-based payment transactions Expense From Sharebased Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets Share-based compensation expenses Current Current Lease Liabilities Lease liabilities Consultancy fee Professional fees expense Share-based compensation expenses (Note 22) Share-based compensation expenses Expense From Sharebased Payment Transactions With Employees Other Payables and Accruals Disclosure Of Other Payables and Accruals Explanatory Disclosure Of other payables and accruals explanatory. Repurchase of ordinary shares Repurchase of ordinary shares, shares Repurchase of ordinary shares, shares Repurchase of Ordinary Shares Repurchase of ordinary shares. Classes Of Financial Instruments [Axis] Classes of financial instruments [axis] Profit Loss Attributable To [Abstract] Loss attributable to: Other non-current Assets Disclosure Of Other Non Current Asset Explanatory Disclosure of other non-current assets explanatory. R&D materials and consumable supplies Raw materials and consumables used Raw materials and consumables used Statutory Reserve Statutory reserve Contact Personnel Name Contact Personnel Name Purchase of intangible assets Purchase Of Intangible Assets Classified As Investing Activities Purchase of intangible assets Description Of Accounting Policy For Impairment Of Nonfinancial Assets Explanatory Impairment of non-financial assets Classes Of Liabilities [Axis] Classes of liabilities [axis] Schedule of Net Basic Loss Per Share Earnings Per Share Explanatory Aggregated Measurement [Member] Aggregated measurement [member] -Trade payables Adjustments For Increase Decrease In Trade Account Payable Property, plant and equipment at beginning of period Property, plant and equipment at end of period Total property, plant and equipment Property Plant And Equipment Property, plant and equipment Net book value Net (decrease) increase in cash and cash equivalents Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes Suzhou Connect Biopharma Co., Ltd. Connect SZ [Member] Connect SZ [Member] Reserves Disclosure of Share Capital Reserves Explanatory Disclosure of share capital reserves explanatory. Entity File Number Entity File Number Treasury shares. Treasury Shares [Abstract] Entity Addresses, Address Type [Axis] Address Of Registered Office Of Entity Address of registered office Ordinary Share Options Major ordinary share transactions [member] Disclosure Of Financial Assets [Table] Disclosure Of Financial Assets [Table] Accumulated Other Comprehensive Income [Member] Accumulated Losses Proceeds from issuance of ordinary shares Proceeds from issue of ordinary shares Series B preferred shares. Series B Preferred Shares [Member] Series B Preferred Shares Major Components Of Tax Expense Income [Abstract] Profit Loss [Abstract] Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Table] Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Table] Description Of Expected Volatility Share Options Granted Expected volatility Disclosure Of Defined Benefit Plans [Table] Disclosure Of Defined Benefit Plans [Table] Number of Options, Exercised during the year Number of Options, Exercised during the year Number of share options exercised in share-based payment arrangement Level3 Of Fair Value Hierarchy [Member] Level 3 Disposals Disposals, property, plant and equipment Cover [Abstract] Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items] Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items] Capital commitments Total capital commitments *Includes unrealized gains recognized in profit or loss attributable to balances held at the end of the reporting period Unrealised gains recognized in profit or loss. Unrealised Gains Recognized In Profit Or Loss Description Of Accounting Policy For Segment Reporting Explanatory Segment Information Description Of Risk Free Interest Rate Share Options Granted Risk-free interest rate Disclosure Of Cash Flow Statement Explanatory Cash Flow Information Current Assets [Abstract] Current assets Useful Life Measured As Period Of Time Property Plant And Equipment Useful life Cash at bank Cash [abstract] Assets [member] Aggregated Time Bands [Member] Aggregated time bands [member] Key Management Personnel Compensation Shortterm Employee Benefits Wages, salaries and bonuses Significant Unobservable Input Liabilities Significant unobservable input, financial instruments with preferred rights Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets Disclosure of quantitative information about right-of-use assets [text block] Document Transition Report Document Transition Report Net cash from/(used in) operating activities Net cash used in operating activities Net operating cash outflow Net cash flows from (used in) operating activities Cash Flows From Used In Operating Activities Net cash used in operating activities Series Pre-A preferred shares. Series Pre A Preferred Shares [Member] Series Pre-A Preferred Shares Differences of foreign currency translation Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities Proceeds from exercise of options Proceeds From Exercise Of Options Changes in operating assets and liabilities. Changes In Operating Assets And Liabilities [Abstract] Changes in working capital Number of shares outstanding Ordinary shares Number Of Shares Outstanding Balance, shares Balance, shares Expected Dividend As Percentage Share Options Granted Dividend yield Effective Interest Rate Of Financial Assets Reclassified Out Of Financial Assets At Fair Value Through Profit Or Loss Effective interest rate of financial assets reclassified out of financial assets at fair value through profit or loss Connect Union. Connect Union [Member] Connect Union Weighted Average Share Price Share Options Granted2019 Grant date share price Fair value of share based payment on grant date Explanation Of Effect Of Sharebased Payments On Profit Or Loss Summary of Share-Based Compensation Expenses Summary of Other income Disclosure of Other Income Explanatory Disclosure of other income explanatory. Financial Assets At Fair Value [Member] Financial Assets at FVPL Number of treasury shares. Number Of Treasury Shares Number of treasury shares Accrued professional service fee Accrued Professional Service Fee Accrued professional service fee. Property Plant And Equipment [Member] Property, plant and equipment [member] Summary of Property, Plant and Equipment Disclosure Of Detailed Information About Property Plant And Equipment Explanatory Percentage of reasonably possible decrease in unobservable input Payment made by holders of preferred shares upon or in connection with conversion of preferred shares into ordinary shares Payment Made by Holders of Preferred Shares Upon or in Connection With Conversion of Preferred Shares into Ordinary Shares Disclosure Of Classes Of Share Capital [Line Items] Disclosure Of Classes Of Share Capital [Line Items] Current Assets Total current assets Disclosure Of Employee Benefits Explanatory Employee Benefit Expenses Schedule of Other non-current Assets Disclosure Of Other Noncurrent Assets Explanatory Number of Options, Options exercisable at December 31, 2021 Number Of Share Options Exercisable In Sharebased Payment Arrangement Finance income/(cost)-net Finance income/(costs)-net Finance costs - net Finance Income Cost Trade Payables Trade And Other Payables To Trade Suppliers Trade payables Percentage of reasonably possible increase in unobservable input Description Of Accounting Policy For Earnings Per Share Explanatory Loss per share Settlements Fair Value Measurement Assets Settlements Financial instruments with preferred rights. Financial Instruments With Preferred Rights [Member] Financial Instruments with Preferred Rights Closing foreign exchange rate Net foreign exchange gains/(losses) included in other gains/(losses)-net Net foreign exchange gains/(losses) Net foreign exchange gain (loss) Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss Share Premium [Member] Share Premium Net loss Loss for the year Net loss Net operating loss Profit Loss Description Of Accounting Policy For Property Plant And Equipment Explanatory Property, plant and equipment Percentage of reserve fund of registered capital. Percentage Of Reserve Fund Of Registered Capital Percentage of reserve fund of registered capital Aggregate Difference Between Fair Value At Initial Recognition And Amount Determined Using Valuation Technique Yet To Be Recognised Ending balance Beginning balance Business Contact Person Business Contact [Member] Description of accounting policy for basis of preparation explanatory. Description Of Accounting Policy For Basis Of Preparation Explanatory Basis of preparation Amortized period Liability Insurance Amortized Period Liability insurance amortized period Financial Instruments and Risk Management Disclosure of financial risk management [text block] Connect Biopharma Australia PTY LTD Connect AU. Connect A U [Member] Additions Additions to right-of-use assets Share-based Payment equal monthly installments. Share Based Payment Equal Monthly Installments Vest in equal monthly installments Australia Australian Dollar deposit AUSTRALIA Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Total current financial assets at fair value through profit or loss Current Financial Assets At Fair Value Through Profit Or Loss Financial assets at fair value through profit or loss Contributions by and distributions to owners of parent. Contributions By And Distributions To Owners Of Parent Total Transactions with owners Debt outstanding Borrowings Total borrowings Geographical Areas [Axis] Geographical areas [axis] Increase decrease in foreign exchange transactions. Increase Decrease In Foreign Exchange Transactions Increase decrease in foreign exchange transactions Hangzhou Tigermed Consulting Company Limited. Hangzhou Tigermed Consulting Company Limited [Member] Hangzhou Tigermed Consulting Company Limited Deposits. Deposit Deposits Financial Instruments with Preferred Rights Disclosure of financial instruments with preferred rights explanatory. Disclosure Of Financial Instruments With Preferred Rights Explanatory Equipment and improvement. Equipment And Improvement [Member] Equipment and Improvement Entity Shell Company Entity Shell Company Disclosure Of Expenses By Nature Explanatory Expenses by Nature Assets [Abstract] ASSETS Shareholder voting rights Description of shareholder voting rights. Ordinary Shares [Member] Ordinary Shares Share based compensation reserves. Share Based Compensation Reserves Share-based compensation reserves Icfr Auditor Attestation Flag ICFR Auditor Attestation Flag Entity Incorporation State Country Code Entity Incorporation, State or Country Code Issuance of shares to Co-Founders, shares Issuance of shares to Co-founders, shares Increase Decrease In Number Of Ordinary Shares Issued to Co-founders Increase decrease in number of ordinary shares issued to co-founders. Range [axis] Other expenses Other Expense By Nature Others Frontage Laboratories (Suzhou) Company Limited. Frontage Laboratories Suzhou Company Limited [Member] Frontage Laboratories (Suzhou) Company Limited Office Equipment, Furniture and Others Office equipment, furniture and others. Office Equipment Furniture And Others [Member] Operating lease term of contract. Operating Lease Term Of Contract Offices and rental contract lease term Other Comprehensive Income Net Of Tax Exchange Differences On Translation Other Than Translation Of Foreign Operations Exchange differences on translation of foreign operations Amendment Flag Amendment Flag Levels Of Fair Value Hierarchy [Axis] Levels of fair value hierarchy [axis] Disclosure Of Property Plant And Equipment [Abstract] Deferred Tax Assets Deferred income tax assets recognized Deferred tax assets Deferred tax assets Document Registration Statement Document Registration Statement Presentation of leases for lessee [abstract] Increase Decrease Through Amounts Recognised In Profit Or Loss Aggregate Difference Between Fair Value At Initial Recognition And Amount Determined Using Valuation Technique Yet To Be Recognised Change in fair value recognized in profit or loss Payment in relation to listing expenses. Payment In Relation To Listing Expenses Payment in relation to listing expenses Disclosure Of Property Plant And Equipment Explanatory Property, Plant and Equipment New leases Increase through new leases, liabilities arising from financing activities Preference Shares Preference shares [member] Construction payables Construction Payables Construction payables. Summary of Exposure to Foreign Currency Risk Disclosure of effect of changes in foreign exchange rates [text block] Summary of property, plant and equipment useful life Disclosure of property, plant and equipment useful life explanatory Connect Biopharma HongKong Limited Connect HK. Connect H K [Member] Classes Of Financial Instruments [Member] Financial instruments, class [member] Other payables. Other Payables [Member] Other Payables Description Of Accounting Policy For Employee Benefits Explanatory Employee Benefits Financial liabilities measured at fair value Financial liabilities, at fair value Disclosure of reconciliation of liabilities arising from financing activities [line items] Connect Biopharma (Beijing) Co., Ltd Beijing Connect Biopharmaceuticals, Limited [Member] Beijing Connect Biopharmaceuticals, Limited. Research and development expenses. Research And Development Expenses [Member] Research and Development Expenses Disclosure of schedule of other receivables and prepayments. Disclosure Of Schedule Of Other Receivables And Prepayments Schedule of Other Receivables and Prepayments Disclosure Of Events After Reporting Period Explanatory Events After the Reporting Period Additions Purchases, fair value measurement, assets Conversion from preferred shares to ordinary shares after share consolidation Conversion From Preferred Shares To Ordinary Shares After Share Consolidation Conversion from preferred shares to ordinary shares after share consolidation. Other payables and accruals Other payables and accruals. Other Payables And Accruals Other payables and accruals Issued Capital Ordinary Shares Value of share capital Liabilities Arising From Financing Activities [Member] Liabilities arising from financing activities [member] Description Of Accounting Policy For Foreign Currency Translation Explanatory Foreign currency translation Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items] Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items] Share-based compensation to additional Series C preferred shareholder Share based compensation to additional series C preferred shareholder financial instruments with preferred rights. Share Based Compensation To Additional Series C Preferred Shareholder Financial Instruments With Preferred Rights Share-based compensation to additional Series C preferred shareholder Risk-Free interest rate, measurement input. Risk Free Interest Rate Measurement Input [Member] Risk-Free Interest Rate EX-101.DEF 42 cntb-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.PRE 43 cntb-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.CAL 44 cntb-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT XML 45 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page
12 Months Ended
Dec. 31, 2021
shares
Document Information [Line Items]  
Document Type 20-F
Amendment Flag false
Document Period End Date Dec. 31, 2021
Document Fiscal Year Focus 2021
Current Fiscal Year End Date --12-31
Document Fiscal Period Focus FY
Entity Registrant Name Connect Biopharma Holdings Limited
Entity Central Index Key 0001835268
Document Annual Report true
Document Transition Report false
Document Registration Statement false
Document Shell Company Report false
Entity Current Reporting Status Yes
Entity Voluntary Filers No
Entity Interactive Data Current Yes
Entity Well-known Seasoned Issuer No
ICFR Auditor Attestation Flag false
Entity Filer Category Non-accelerated Filer
Entity Common Stock, Shares Outstanding 55,076,319
Entity Shell Company false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Trading Symbol CNTB
Title of 12(b) Security American Depositary Shares, each representing one Ordinary Share, par value $0.000174 per Share
Security Exchange Name NASDAQ
Entity Incorporation, State or Country Code E9
Entity File Number 001-40212
Entity Address, Address Line One Science and Technology Park, East R&D Building, 3rd Floor
Entity Address, Address Line Two 6 Beijing West Road
Entity Address, City or Town Taicang, Jiangsu
Entity Address, Country CN
Entity Address, Postal Zip Code 215400
Document Accounting Standard International Financial Reporting Standards
Auditor Name PricewaterhouseCoopers Zhong Tian LLP
Auditor Location Beijing, the People’s Republic of China
Auditor Firm ID 1424
Business Contact Person  
Document Information [Line Items]  
Contact Personnel Name Dr. Zheng Wei
Entity Address, Address Line One Science and Technology Park, East R&D Building, 3rd Floor
Entity Address, Address Line Two 6 Beijing West Road
Entity Address, City or Town Taicang, Jiangsu
Entity Address, Country CN
Entity Address, Postal Zip Code 215400
City Area Code +86
Local Phone Number 512 5357 7866
Phone Fax Number Description +86 (21) 57940050

XML 46 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Loss
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
¥ / shares
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2020
CNY (¥)
¥ / shares
Dec. 31, 2019
CNY (¥)
¥ / shares
Income Statement [Abstract]        
Research and development expenses ¥ (518,021) $ (81,249) ¥ (150,932) ¥ (106,414)
Administrative expenses (122,445) (19,205) (47,720) (9,713)
Other income 18,996 2,979 6,989 2,836
Other gains/(losses)-net (9,966) (1,563) (6,100) 3,050
Operating loss (631,400) (99,038) (197,763) (110,241)
Finance income 622 98 717 1,066
Finance cost (44) (7) (2,893) (53)
Finance income/(cost)-net 578 91 (2,176) 1,013
Fair value loss of financial instruments with preferred rights (674,269) (105,756) (579,286) (59,397)
Loss before income tax (1,305,127) (204,703) (779,225) (168,625)
Income tax expense (1,697) (266)    
Net loss (1,306,824) (204,969) (779,225) (168,625)
Loss attributable to:        
Owners of the Company ¥ (1,306,824) $ (204,969) ¥ (779,225) ¥ (168,625)
Loss per share        
Basic and diluted | (per share) ¥ (25.0) $ (3.9) ¥ (45.6) ¥ (10.0)
XML 47 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Comprehensive Loss
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Statement Of Comprehensive Income [Abstract]        
Net loss ¥ (1,306,824) $ (204,969) ¥ (779,225) ¥ (168,625)
Items that may be reclassified to profit or loss        
Exchange differences on translation of foreign operations 20,426 3,204 34,655 (6,027)
Items that will not be reclassified to profit or loss        
Exchange differences on translation of foreign operations (57,464) (9,013) 12,377 (466)
Other comprehensive (loss)/income for the year, net of tax (37,038) (5,809) 47,032 (6,493)
Total comprehensive loss for the year (1,343,862) (210,778) (732,193) (175,118)
Total comprehensive loss attributable to:        
Owners of the Company ¥ (1,343,862) $ (210,778) ¥ (732,193) ¥ (175,118)
XML 48 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Non-current assets      
Property, plant and equipment ¥ 59,337 $ 9,307 ¥ 6,939
Right-of-use assets 22,821 3,579 929
Other non-current assets 18,806 2,950 19,860
Intangible assets 560 88 342
Total non-current assets 101,524 15,924 28,070
Current assets      
Other receivable and prepayments 47,255 7,412 33,655
Financial assets at fair value through profit or loss     13,068
Cash and cash equivalents 1,706,880 267,716 1,010,076
Total current assets 1,754,135 275,128 1,056,799
Total assets 1,855,659 291,052 1,084,869
Non-current liabilities      
Lease liabilities 163 26 309
Financial instruments with preferred rights     2,071,508
Deferred income 5,000 784  
Total non-current liabilities 5,163 810 2,071,817
Current liabilities      
Trade payables 81,195 12,735 24,638
Other payables and accruals 32,840 5,152 12,755
Lease liabilities 630 98 604
Total current liabilities 114,665 17,985 37,997
Total liabilities 119,828 18,795 2,109,814
Net (liabilities)/assets 1,735,800 272,257 (1,024,945)
SHAREHOLDERS' (DEFICIT)/EQUITY      
Share capital 66 10 24
Share premium 4,094,434 642,194 41,466
Treasury shares (1,164) (183) (3)
Share-based compensation reserves 61,904 9,709 6,602
Other reserves (41,244) (6,469) (1,693)
Accumulated losses (2,378,165) (373,004) (1,071,341)
Total shareholders' (deficit)/equity 1,735,831 272,257 (1,024,945)
Total liabilities and shareholders' (deficit)/equity ¥ 1,855,659 $ 291,052 ¥ 1,084,869
XML 49 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Changes in Shareholders' (Deficit)/Equity
¥ in Thousands, $ in Thousands
CNY (¥)
USD ($)
Share Capital
CNY (¥)
Share Premium
CNY (¥)
Treasury Shares
CNY (¥)
Share-Based Compensation Reserves
CNY (¥)
Other Reserves
CNY (¥)
Accumulated Losses
CNY (¥)
Balance at Dec. 31, 2018 ¥ (127,093)   ¥ 21 ¥ 38,074 ¥ (1) ¥ 584 ¥ (42,280) ¥ (123,491)
Comprehensive loss                
Net loss (168,625)             (168,625)
Exchange differences (6,493)           (6,493)  
Total comprehensive loss for the year (175,118)           (6,493) (168,625)
Transactions with owners                
Exercise of stock options 49     49   (48) 48  
Share-based compensations 3,875         3,875    
Total Transactions with owners 3,924     49   3,827 48  
Balance at Dec. 31, 2019 (298,287)   21 38,123 (1) 4,411 (48,725) (292,116)
Comprehensive loss                
Net loss (779,225)             (779,225)
Exchange differences 47,032           47,032  
Total comprehensive loss for the year (732,193)           47,032 (779,225)
Transactions with owners                
Issuance of shares to Co-founders     1 3,343   (3,344)    
Issuance of treasury shares     2   (2)      
Share-based compensations 5,535         5,535    
Total Transactions with owners 5,535   3 3,343 (2) 2,191    
Balance at Dec. 31, 2020 (1,024,945)   24 41,466 (3) 6,602 (1,693) (1,071,341)
Comprehensive loss                
Net loss (1,306,824) $ (204,969)           (1,306,824)
Exchange differences (37,038)           (37,038)  
Total comprehensive loss for the year (1,343,862) (210,778)         (37,038) (1,306,824)
Transactions with owners                
Issuance of Ordinary Shares 1,305,819   14 1,305,805        
Conversion from preferred shares 2,743,625   28 2,743,597        
Repurchase of ordinary shares value (3,674)       (1,161)   (2,513)  
Exercise of stock options 1,005     2,149   (1,144)    
Issuance of shares to Co-founders       1,417   (1,417)    
Share-based compensations 57,863         57,863    
Total Transactions with owners 4,104,638   42 4,052,968 (1,161) 55,302 (2,513)  
Balance at Dec. 31, 2021 ¥ 1,735,831 $ 272,257 ¥ 66 ¥ 4,094,434 ¥ (1,164) ¥ 61,904 ¥ (41,244) ¥ (2,378,165)
XML 50 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Cash flows from operating activities        
Cash used in operations ¥ (544,926) $ (85,469) ¥ (167,161) ¥ (90,256)
Net cash used in operating activities (544,900) (85,469) (167,161) (90,256)
Cash flows from investing activities        
Purchase of property, plant and equipment (24,941) (3,912) (14,955) (1,072)
Purchase of financial assets at fair value through profit or loss (114,500) (17,959) (106,600) (163,000)
Proceeds from disposal of financial assets at fair value through profit or loss 128,004 20,076 124,836 160,731
Payment for right-of-use assets (22,284) (3,495)    
Purchase of intangible assets (304) (48) (349)  
Net cash (used in)/ generated from investing activities (34,025) (5,338) 2,932 (3,341)
Cash flows from financing activities        
Proceeds from exercise of options 243 38   49
Proceeds from issuance of ordinary shares 1,431,775 224,567    
Proceeds from issuance of financial instruments with preferred rights     923,247  
Payment for lease liabilities (805) (126) (538) (445)
Payment for repurchase of ordinary shares (3,674) (576)    
Issuance cost of financial instruments with preferred rights     (2,851)  
Payment in relation to listing expenses (111,440) (17,479) (1,097)  
Net cash (used in)/ generated from financing activities 1,316,099 206,424 918,761 (396)
Net (decrease) increase in cash and cash equivalents 737,148 115,617 754,532 (93,993)
Cash and cash equivalents at the beginning of year 1,010,076 158,426 308,972 401,597
Effects of exchange rate changes on cash and cash equivalents (40,344) (6,327) (53,428) 1,368
Cash and cash equivalents at end of year ¥ 1,706,880 $ 267,716 ¥ 1,010,076 ¥ 308,972
XML 51 R7.htm IDEA: XBRL DOCUMENT v3.22.1
General Information, Reorganization and Basis of Presentation
12 Months Ended
Dec. 31, 2021
Disclosure Of General Information Reorganization And Basis Of Presentation [Abstract]  
General Information, Reorganization and Basis of Presentation

1. General Information, Reorganization and Basis of Presentation

1.1 General information

 

Connect Biopharma Holdings Limited (the “Company”) was incorporated on November 23, 2015 in the Cayman Islands as an exempted company with limited liability. The address of the Company’s registered office is P.O. Box 613, Harbour Centre, George Town, Grand Cayman KY1-1107, Cayman Islands. The Company completed its initial public offering (“IPO”) in March 2021 and the Company’s American Depositary Shares (“ADSs”) have been listed on the Nasdaq Global Market (“Nasdaq”) since then. Each ADS of the Company represents one ordinary share, par value USD 0.000174 per share.

 

The Company and its subsidiaries (collectively the “Group”) is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. The Group has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. The Group currently carries out clinical trials on its product candidates in the United States, People’s Republic of China (“PRC”), Australia, Europe, and other jurisdictions.

 

As of December 31, 2021, the Group had direct or indirect interests in the following principal subsidiaries:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Company name

 

Principal activities

 

Place and date of incorporation

 

Attributable equity interest to the Group

 

Directly Held:

 

 

 

 

 

 

 

Connect Biopharma HongKong Limited (“Connect HK”)

 

Investment holding

 

Hong Kong/December 1, 2015

 

 

100

%

Indirectly held:

 

 

 

 

 

 

 

Connect Biopharm LLC (“Connect US”)

 

Pharmaceutical R&D

 

San Diego, United States of America January 24, 2012

 

 

100

%

Connect Biopharma Australia PTY LTD (“Connect AU”)

 

Pharmaceutical R&D

 

Prahran, Australia/July 18, 2014

 

 

100

%

Suzhou Connect Biopharma Co., Ltd. (“Connect SZ”)

 

Pharmaceutical R&D

 

Suzhou, PRC/May 2, 2012

 

 

100

%

Connect Biopharma (Shanghai) Co., Ltd

 

Pharmaceutical R&D

 

Shanghai, PRC/October 23, 2015

 

 

100

%

Connect Biopharma (Beijing) Co., Ltd

 

Pharmaceutical R&D

 

Beijing, PRC/July 9, 2019

 

 

100

%

Connect Biopharma (Shenzhen) Co., Ltd

 

Dormant

 

Shenzhen, PRC/November 15, 2021

 

 

100

%

XML 52 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Disclosure Of Initial Application Of Standards Or Interpretations [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

2.1 Basis of preparation

The Group’s consolidated financial statements were prepared in accordance with International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”). The Group adopted and transitioned to IFRS issued by IASB on January 1, 2018. The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through profit or loss and financial instruments with preferred rights. In preparing its consolidated financial statements prepared under IFRS, the Group early adopted IFRS 9 Financial Instruments (“IFRS 9”) and IFRS 16 Leases (“IFRS 16”) on January 1, 2018.

The Group has applied the following standards and amendments for the first time for their annual reporting period commencing January 1, 2021, which did not have any material impact on the consolidated financial statements:

Amendment to IFRS 16, ‘Leases’ – COVID-19 related rent concessions – Extension of the practical expedient.

The consolidated financial statements for the years ended December 31, 2019, 2020 and 2021 were authorized for issue by the Company’s board of directors (the “Board”) on March 31, 2022.

Liquidity

As of December 31, 2021, the Group had net assets of RMB 1,735.8 million, and accumulated losses of RMB 2,378.2 million. For the year ended December 31, 2021, the Group had net operating loss of RMB 631.4 million and net operating cash outflow of RMB 544.9 million. The principal sources of funding have historically been continuous cash contributions from equity holders and preferred shareholders. The cumulative contributions up through December 31, 2021 approximated USD 440.1 million, among which included USD 219.9 million of proceeds from issuance of ordinary shares in connection with the IPO or RMB 1,431.8 million based on the exchange rate as of the date of the IPO. As of December 31, 2021, the Group had a cash and cash equivalents balance of RMB 1,706.9 million, which it believes to be sufficient available financial resources to meet its obligations becoming due and working capital requirements in the next twelve months from the date of issuance of these financial statements. Accordingly, the Group considers that it is appropriate to prepare the consolidated financial information on a going concern basis.

Impact of COVID-19

In December 2019, a novel strain of coronavirus was reported in Wuhan, China and on March 11, 2020 the WHO declared COVID-19 a pandemic. The COVID-19 pandemic has resulted in a widespread health crisis and numerous disease control measures being taken to limit its spread. As the pandemic continues its impact throughout the world, the healthcare systems of the various countries in which the Group is conducting ongoing clinical trials of CBP-201 and CBP-307 have and may continue to experience great disruption. Enrollment of the Group’s Phase 2 clinical trial of CBP-307 in patients in China was prematurely terminated due to challenges in recruitment caused by the COVID-19 pandemic.

The Group will continue to monitor and assess the impact of the ongoing development of the pandemic on the Group’s clinical trials and for any impact to its financial position and operating results.

2.2 New and amended standards and interpretations not yet adopted by the Group

The Group has not applied the following new and revised IFRSs that have been issued but are not yet effective in the consolidated financial statements.

 

 

 

Effective for annual periods beginning on or after

 

Scope amendments to IFRS 3, IAS 16, IAS 37 and some annual improvements on IFRS 1, IFRS 9, IAS 41 and IFRS 16

 

January 1, 2022

 

Narrow scope amendments to IAS 1, Practice statement 2 and IAS 8

 

January 1, 2023

 

Amendment to IAS 12 – Deferred tax related to assets and liabilities arising from a single transaction

 

 January 1, 2023

 

Amendments to IAS 1, Presentation of financial statements’, on classification of liabilities

 

January 1, 2024

 

 

The Group expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a material impact on disclosures or amounts reported in the Group’s consolidated financial statements in the period of initial application and future reporting periods.

 

2.3 Principles of consolidation

Subsidiaries

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

Intra-group transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group’s accounting policies.

2.4 Separate financial statements

Investments in subsidiaries are accounted for at cost less impairment. Cost includes direct attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividends received and receivable.

Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee’s net assets including goodwill.

2.5 Foreign currency translation

(a) Functional and presentation currency

 

The consolidated financial statements of the Group are presented in RMB as the historical records for its entities were set-up for consolidations in RMB.

 

The functional currency of the Company is USD. Other subsidiaries have functional currencies in USD, RMB and Australian dollars.

 

(b) Transactions and balances

 

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.

 

Since the Group has no borrowings, all foreign exchange gains or losses are presented in the consolidated statements of loss on a net basis within other gains/(losses)-net.

 

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income.

(c) Group companies

 

The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

 

assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;
income and expenses for each statement of loss and comprehensive income/(loss) are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions); and
all resulting currency translation differences are recognized in other comprehensive income/loss.

 

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.

 

(d) Convenience translation

 

Translations of the consolidated balance sheet, the consolidated statement of loss, consolidated statement of comprehensive loss and consolidated statement of cash flows from RMB into USD as of and for the year ended December 31, 2021 are solely for the convenience of the readers and calculated at the rate of USD1.00=RMB 6.3757, representing the exchange rate as of December 31, 2021 set forth in the China Foreign Exchange Trade System. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into USD at that rate, or at any other rate, on December 31, 2021.

 

2.6 Property, plant and equipment

Property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

 

Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

 

The Group’s assets under construction represents buildings and equipment under construction and pending installation, and is stated at cost less accumulated impairment losses, if any. Costs include construction and acquisition costs. No provision for depreciation is made on assets under construction until such time as the assets are completed and ready for its intended use. Once the asset becomes available for use, it is transferred to the appropriate category of assets.

 

Depreciation is calculated using the straight-line method to allocate the cost, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements, the shorter lease term as follows:

 

Assets

 

Useful life

Laboratory equipment

 

5-10 years

Leasehold improvements

 

Shorter of lease term or 5 years

Office equipment and furniture

 

3-5 years

 

The assets’ residual values and useful lives are reviewed and adjusted if appropriate at the end of each reporting period.

 

An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount (Note 2.8).

 

Gains and losses on disposals are determined by comparing proceeds with carrying amount and are recognized within other gains/(losses)—net in the statements of loss.

 

2.7 Intangible assets

 

Software

 

Acquired software licenses are capitalized on the basis of the costs incurred to acquire and bring the specific software into usage. These costs are amortized using the straight-line method over their estimated useful lives of approximately 10 years. Costs associated with maintaining software programs are recognized as expense as incurred.

 

2.8 Impairment of non-financial assets

 

Non-financial assets other than goodwill and intangible assets that have an indefinite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

 

2.9 Investments and other financial assets

 

(a) Classification

 

The Group classifies its financial assets in the following measurement categories:

 

those to be measured subsequently at fair value (either through other comprehensive income (“OCI”) or through profit or loss), and
those to be measured at amortized cost.

 

The classification depends on the entity’s business model for managing the financial assets and the contractual terms of the cash flows.

 

For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through OCI (“FVOCI”).

 

The Group reclassifies debt investments when and only when its business model for managing those assets changes.

 

(b) Recognition and derecognition

 

Regular way purchases and sales of financial assets are recognized on trade date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

 

(c) Measurement

 

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (“FVPL”), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial asset carried at FVPL are expensed in profit or loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

(i)
Debt instruments

 

Subsequent measurement of debt instruments depends on the Group’s business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the Group classifies its debt instruments:

Amortized cost: Assets that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortized cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains/(losses), together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the statements of loss.
FVOCI: Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets’ cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses which are recognized in profit or loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains/(losses). Interest income from these financial assets is included in finance income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains/(losses) and impairment expenses are presented as a separate line item in the statements of loss.
FVPL: Assets that do not meet the criteria for amortized cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured at FVPL is recognized in profit or loss and presented net within other gains/(losses) in the period in which it arises.
(ii)
Equity instruments

 

The Group subsequently measures all equity investments at fair value. Where the Group’s management has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognized in profit or loss as other income when the Group’s right to receive payments is established.

 

Changes in the fair value of financial assets at FVPL are recognized in other gains/(losses) in the statements of loss as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.

 

There were no equity investments during the reporting periods.

 

(d) Impairment

 

The Group assesses on a forward-looking basis the expected credit loss associated with its debt instruments carried at amortized cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk refer to Note 3.1(b) for further details.

 

2.11 Cash and cash equivalents

 

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

 

2.12 Share capital

 

Ordinary shares are classified as equity. Mandatorily redeemable preferred shares are classified as liabilities. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

 

Where any Group company purchases the Company’s equity instruments, for example as the result of a share buy-back or a share-based payment plan, the consideration paid, including any directly attributable incremental costs (net of income taxes), is deducted from equity attributable to the owners of the Group as treasury shares until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the owners of the Group.

 

Shares held by Connect Union, which was established for the purpose of holding shares for the share incentive plans are disclosed as treasury shares and deducted from contributed equity.

 

2.13 Trade and other payables

 

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.

 

2.14 Financial instruments with preferred rights

 

Financial instruments with preferred rights are compound instruments with discretionary dividend right. The Company elected to designate the entire hybrid contracts that include host contract and embedded derivatives as financial liabilities at fair value through profit or loss considering the fact that the instruments also have contingent settlement provisions. They are initially recognized at fair value. Any directly attributable transaction costs are expensed in the consolidated statements of loss.

 

Subsequent to initial recognition, the amount of change in the fair value of the financial instruments with preferred rights that is attributable to changes in the credit risk of that liability shall be presented in OCI with the remaining changes in fair value recognized as “fair value loss of financial instruments with preferred rights” in profit or loss.

 

As of December 31, 2020, management believed that there were no triggering events resulting in redemption in 12 months from the end of the reporting period and so the financial instruments with preferred rights were classified as non-current liabilities unless the Group had an obligation to settle the liabilities within 12 months after the end of the reporting period.

 

Dividends on financial instruments with preferred rights classified as financial liabilities are normally included in financial costs.

 

On March 19, 2021, upon completion of the IPO, all issued and outstanding preferred shares were converted to ordinary share on a one-for-one basis.

 

2.15 Current and deferred income tax

 

The income tax expense or credit for the period is the tax payable on the taxable income of current period based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

 

Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively.

 

(a) Current income tax

 

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

 

Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.

 

(b) Deferred income tax

 

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

 

Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.

 

Deferred tax liabilities and assets are not recognized for temporary differences between the carrying amount and tax bases of investments in foreign operations where the Group is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

 

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.

Investment allowances and similar tax incentives

 

Companies within the Group may be entitled to claim special tax deductions for investments in qualifying assets or in relation to qualifying expenditure (e.g. the research and development tax incentive or other investment allowances). The Group accounts for such allowances as tax credits, which means that the allowance reduces income tax payable and current tax expense. A deferred tax asset is recognized for unclaimed tax credits that are carried forward as deferred tax assets.

 

2.16 Employee benefits

 

(a) Short-term obligations

 

Liabilities for wages and salaries, including non-monetary benefits and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in other payables and accruals in the balance sheet.

 

(b) Defined benefit plans

 

The liability or asset recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method.

 

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms approximating to the terms of the related obligation. In countries where there is no deep market in such bonds, the market rates on government bonds are used.

 

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of loss.

 

Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income. They are included in retained earnings in the statement of changes in equity and in the balance sheet.

 

Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognized immediately in profit or loss as past service costs.

 

(c) Defined contribution plans

 

For defined contribution plans, including those under Section 401(k) of the U.S. Internal Revenue Code, the Group pays contributions to publicly administered pension insurance plans on a mandatory, contractual or voluntary basis. The Group has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.

 

The members of the Group incorporated in the PRC contribute based on a certain percentage of the salaries of their employees to a defined contribution retirement benefit plan organized by relevant government authorities in the PRC on a monthly basis. The government authorities undertake to assume the retirement benefit obligations payable to all existing and further retired employees under these plans and the Group has no further obligation for post-retirement benefits beyond the contributions made. Contributions to these plans are expensed as incurred. Assets of the plans are held and managed by government authorities and are separate from those of the Group.

 

(d) Housing funds and medical insurance

 

The PRC employees of the Group are entitled to participate in various government-supervised housing funds and medical insurance. The Group contributes on a monthly basis to these funds based on a certain percentage of the salaries of the employees, subject to certain ceilings. The Group’s liability in respect of these funds is limited to the contribution payable in each period and recognized as employee benefit expense when they are due.

 

2.17 Share-based compensation

 

The Group operates an equity-settled share-based compensation plan, under which the Group receives services from employees, directors and consultants. The consultants’ work for the Group is under the Group’s direction in the same way as employees and the services rendered by the consultants are similar to those rendered by the Group’s employees.

 

The fair value of options granted under the share incentive plans is recognized as an employee benefits expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:

 

including any market performance conditions (e.g. the entity’s share price);

 

excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the entity over a specified time period); and

 

including the impact of any non-vesting conditions (e.g. the requirement for employees to save or hold shares for a specific period of time).

 

The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. The Group recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.

 

2.18 Research and development expenses

 

The Group incurs costs and efforts on research and development activities. Research expenditures are recorded as an expense in the period the expenditure is incurred. Elements of research and development expenses primarily include (1) expenses related to preclinical testing of the Group’s technologies under development and clinical trials such as payments to CRO investigators and clinical trial sites that conduct the clinical studies; (2) consultant service related to the design of clinical trials and data analysis, (3) payroll and other related expenses of personnel engaged in research and development activities, (4) expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5) other research and development expenses.

 

The Group estimates preclinical and clinical study and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. The Group estimates these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Group will adjust the accrual accordingly. Payments made in advance for the related services are recorded as prepayments in the consolidated balance sheets until the services are rendered.

 

Development costs are recognized as assets if they can be directly attributable to a newly developed service or product and all the following criteria are met or exist:

 

the technical feasibility to complete the development project so that it will be available for use or sale;
the intention to complete the development project to use or sell the product;
the ability to use or sell the product;
the manner in which the development project will generate probable future economic benefits for the Group;
the availability of adequate technical, financial and other resources to complete the development project and use or sell the product; and
the expenditure attributable to the asset during its development can be reliably measured.

 

Research and development expenses are charged to expense as incurred for all periods presented because they have not met all of the criteria stated above.

 

2.19 Administrative expenses

 

Administrative expenses primarily include payroll and related expenses for employees involved in general corporate functions including finance, legal and human resources, rental and depreciation expenses related to facilities and equipment used by these functions, professional service expenses and other general corporate related expenses.

 

2.20 Interest income

 

Interest income from financial assets at FVPL is included in the net fair value gains/(losses) on these assets, see Note 9 below. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset except for financial assets that subsequently become credit-impaired. For credit-impaired financial assets, the effective interest rate is applied to the net carrying amount of the financial asset (after deduction of the loss allowance). Interest income is presented as finance income where it is earned from financial assets that are held for cash management purposes.

 

2.21 Government grants

 

Grants from the government are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group is expected to comply with all required conditions. Government grants received in advance of costs being incurred are deferred until the associated costs are recognized. Grants that compensate the Group for the cost of an asset initially are presented as deferred income and are recognized as income in consolidated statements of loss on a straight-line basis over the useful life of the associated asset.

 

2.22 Leases

 

The Group leases offices and the rental contracts are typically made for fixed periods of approximately 2 to 4 years. All land in the PRC is owned by the mainland PRC government. The PRC government may sell land use rights for a specified period of time. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as right-of-use assets on the balance sheet. The right-of-use assets are amortized over the remaining lease term. In 2021, the Group acquired a land use right from the PRC government for 50 years.

 

Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. However, for leases of real estate for which the Group is a lessee, it has elected not to separate lease and non-lease components and instead accounts for these as a single lease component.

 

Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.

 

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:

 

fixed payments (including in-substance fixed payments), less any lease incentives receivable;
variable lease payment that are based on an index or a rate, initially measured using the index or rate as of the commencement date;
amounts expected to be payable by the Group under residual value guarantees;
the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and
payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option.

 

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

 

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee’s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

 

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

 

Right-of-use assets are measured at cost comprising the following:

 

the amount of the initial measurement of lease liability;

 

any lease payments made at or before the commencement date less any lease incentives received;

 

any initial direct costs; and

 

restoration costs.

 

Right-of-use assets are generally depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset’s useful life.

 

Payments associated with short-term leases and all leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less without a purchase option.

 

2.23 Segment information

 

Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Group are the Co-Founders of the Company. The Group does not divide its operations into different segments and the CODM operates and manages the Group’s entire operations as one segment, which is consistent with the Group’s internal organization and reporting system. The Group does not have any revenue and substantially all non-current assets outside of the country of domicile are in China.

 

2.24 Loss per share

 

(i)
Basic loss per share

 

Basic loss per share is calculated by dividing:

 

the loss attributable to owners of the Company, excluding any costs of servicing equity other than ordinary shares;
by the weighted average number of ordinary shares outstanding during the financial year and excluding treasury shares

 

(ii)
Diluted loss per share

 

Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account:

 

the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and

 

the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares. 
XML 53 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments and Risk Management
12 Months Ended
Dec. 31, 2021
Disclosure Of Financial Instruments [Abstract]  
Financial Instruments and Risk Management

3. Financial Instruments and Risk Management

3.1 Financial risk factors

 

The Group’s activities expose it to a variety of financial risks: market risk (including interest rate risk and exchange risk), credit risk and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group’s financial performance. Risk management is carried out by the senior management of the Group.

(a)
Market risk
(i)
Interest rate risk

The Group’s interest rate risk primarily arises from wealth management products investments measured at fair value through profit or loss (Note 17) and cash and cash equivalents (Note 18). Those carried at variable rates expose the Group to cash flow interest rate risk whereas those at fixed rates expose the Group to fair value interest rate risk. The Group did not have significant interest rate risk during the periods presented.

(ii)
Exchange risk

The Group operates internationally and is exposed to foreign exchange risk, primarily the USD. Foreign exchange risk arises from future commercial transactions and recognized assets and liabilities denominated in a currency that is not the functional currency of the relevant group entity. The Group’s exposure to foreign currency risk at the end of the reporting periods, expressed in RMB, was as follows:

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Cash and cash equivalents

 

 

65,791

 

 

 

150,640

 

 

The aggregate net foreign exchange gains/(losses) recognized in profit or loss were:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Net foreign exchange gains/(losses) included in other gains/(losses)—net

 

 

2,252

 

 

 

(6,772

)

 

 

(3,309

)

 

Most foreign exchange transactions were denominated in USD for the subsidiary that has functional currency in RMB. For the years ended December 31, 2019, 2020 and 2021, if the USD strengthened/weakened by 5% against the RMB with all other variables held constant, net loss for the years then ended would have been RMB 1.6 million lower/higher, RMB 3.3 million lower/higher and RMB 7.5 million lower/higher, respectively.

(b)
Credit risk

Credit risk primarily arises from cash and cash equivalents, financial assets at fair value through profit or loss, and other receivables. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the balance sheets.

The credit risk of cash and cash equivalents and financial assets at fair value through profit or loss is limited because the counterparties are reputable commercial institutions located in the Cayman Islands, the U.S., PRC and Australia.

For other receivables, management makes periodic as well as individual assessments on the recoverability based on historical settlement records and past experience and adjusts for forward looking information based on macroeconomic factors affecting the ability of the debtors to settle the receivables.

The Group applies the expected credit loss model to financial assets measured at amortized cost. Impairment on other receivables is measured as either 12-month expected credit losses or lifetime expected credit losses, depending on whether there has been a significant increase in credit risk since initial recognition. To assess whether there is a significant increase in credit risk, the Group compares the risk of default occurring on the asset as of the reporting date with the risk of default as of the date of initial recognition by considering available, reasonable and supportive forwarding-looking information.

(c)
Liquidity risk

The Group aims to maintain sufficient cash to meet obligations coming due as well as operating and capital requirements.

The table below analyzes the Group’s financial liabilities into relevant maturity groupings based on the remaining period at each year-end date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows except for financial instruments with preferred rights, which are presented on a fair value basis. The maturity dates are determined by the terms in financing agreements presented in Note 24(c) as management considers the other redemption terms are not probable to occur.

 

 

 

As of December 31, 2020

 

 

 

 

 

 

Between

 

 

Between

 

 

More

 

 

 

 

 

 

Less Than

 

 

1 and

 

 

2 and

 

 

Than

 

 

 

 

 

 

1 Year

 

 

2 Years

 

 

5 Years

 

 

5 Years

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Financial instruments with preferred rights

 

 

 

 

 

 

 

 

2,071,508

 

 

 

 

 

 

2,071,508

 

Trade payables

 

 

24,638

 

 

 

 

 

 

 

 

 

 

 

 

24,638

 

Other payables

 

 

8,631

 

 

 

 

 

 

 

 

 

 

 

 

8,631

 

Lease liabilities

 

 

633

 

 

 

225

 

 

 

94

 

 

 

 

 

 

952

 

Total

 

 

33,902

 

 

 

225

 

 

 

2,071,602

 

 

 

 

 

 

2,105,729

 

 

 

 

As of December 31, 2021

 

 

 

 

 

 

Between

 

 

Between

 

 

More

 

 

 

 

 

 

Less Than

 

 

1 and

 

 

2 and

 

 

Than

 

 

 

 

 

 

1 Year

 

 

2 Years

 

 

5 Years

 

 

5 Years

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Trade payables

 

 

81,195

 

 

 

 

 

 

 

 

 

 

 

 

81,195

 

Other payables

 

 

21,456

 

 

 

 

 

 

 

 

 

 

 

 

21,456

 

Lease liabilities

 

 

653

 

 

 

186

 

 

 

 

 

 

 

 

 

839

 

Total

 

 

103,304

 

 

 

186

 

 

 

 

 

 

 

 

 

103,490

 

 

 

 

3.2 Capital management

The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

The Group monitors capital by regularly reviewing the capital structure and the overall capital markets. The Group may seek additional financing or debt at terms satisfactory to the Group in order to maintain adequate resources.

As of December 31, 2020 and 2021, the Group had no debt outstanding.

3.3 Fair value estimation

As of December 31, 2021 the Group does not have any financial instruments measured at fair value. The table below analyzes the Group’s financial instruments carried at fair value as of December 31, 2020 by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorized into three levels within a fair value hierarchy as follows:

(i)
Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).
(ii)
Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).
(iii)
Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Financial assets at fair value through profit or loss

 

 

 

 

 

 

 

 

13,068

 

 

 

13,068

 

Total assets

 

 

 

 

 

 

 

 

13,068

 

 

 

13,068

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Financial instruments with preferred rights

 

 

 

 

 

 

 

 

2,071,508

 

 

 

2,071,508

 

Total liabilities

 

 

 

 

 

 

 

 

2,071,508

 

 

 

2,071,508

 

 

There were no transfers between levels 1, 2 and 3 during the years.

Financial instruments in Level 3

If one or more of the significant inputs are not based on observable market data, the instrument is included in level 3.

Specific valuation techniques used to value financial instruments include:

Quoted market prices or dealer quotes for similar instruments;
A combination of observable and unobservable inputs, including risk-free rate, expected volatility, discount rate for lack of marketability (“DLOM”), etc.

Level 3 instruments within the Group’s assets and liabilities include short-term investment in wealth management products measured at fair value through profit or loss and financial instruments with preferred rights.

The following table presents the changes in level 3 instruments of short-term investment in wealth management products for the years ended December 31, 2019, 2020 and 2021.

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Financial assets at fair value through profit or loss

 

 

 

 

 

 

 

 

 

Opening balance

 

 

27,565

 

 

 

30,632

 

 

 

13,068

 

Additions

 

 

163,000

 

 

 

106,600

 

 

 

114,500

 

Settlements

 

 

(160,731

)

 

 

(124,836

)

 

 

(128,004

)

Investment income credited to profit or loss (Note 8)*

 

 

798

 

 

 

672

 

 

 

436

 

Closing balance

 

 

30,632

 

 

 

13,068

 

 

 

 

*Includes unrealized gains recognized in profit or loss attributable to balances held at the end of the reporting period

 

 

132

 

 

 

68

 

 

 

 

 

The valuation of level 3 instruments of wealth management products and financial instruments with preferred rights is set out in Note 17 and Note 24.

The changes in level 3 instruments with preferred rights for the years ended December 31, 2019, 2020 and 2021 are presented in Note 24.

The carrying amounts of the Group’s other financial assets and liabilities, including cash and cash equivalents, other receivables, trade payable and other payables, approximate their fair values.

XML 54 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Critical Accounting Estimates and Judgements
12 Months Ended
Dec. 31, 2021
Critical Accounting Estimates And Judgements [Abstract]  
Critical Accounting Estimates and Judgements

4. Critical Accounting Estimates and Judgements

The preparation of financial statements requires the use of accounting estimates which, by definition, may not equal the actual results. Management also needs to exercise judgment in applying the Group’s accounting policies. Estimates and judgments are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Group and that are believed to be reasonable under the circumstances.

a) Fair value of financial assets

The fair value of financial assets that are not traded in an active market is determined using valuation techniques. The Group uses its judgement to select a variety of methods and make assumptions that are mainly based on market conditions existing at the end of each reporting period.

b) Fair value of financial instruments with preferred rights

The fair value of financial instruments with preferred rights that are not traded in an active market is determined using valuation techniques. The Group first determined the equity value and then allocated the equity value to each element of the Group’s capital structure using either an option pricing backsolve method (“OPM”), or a hybrid method, which employs the concepts of the OPM and the probability-weighted expected return method (“PWERM”) that merged into a single framework.

Key assumptions such as risk-free interest rate, DLOM and expected volatility are disclosed in Note 24.

c) Recognition of share-based compensation expenses

As mentioned in Note 22, the equity-settled share-based compensation plan was granted to employees and consultants. The Group has used the Binomial option-pricing model to determine the total fair value of the awarded options, which is to be expensed over the vesting period. Significant estimates on assumptions, such as the fair value of underlying shares, risk-free interest rate, expected volatility and dividend yield, are required to be made by the management.

For the details of the key assumptions and estimates used by management in determining the fair values of share based compensation, refer to Note 22.

d)
Current and deferred income taxes

(i) Deferred income tax

The Group recognizes deferred tax assets based on estimates that it is probable to generate sufficient taxable profits in the foreseeable future against which the deductible losses and temporary differences will be utilized. The recognition of deferred tax assets mainly involves management’s judgments and estimations about the timing and the amount of taxable profits of the companies which have tax losses, refer to Note 10 for details.

XML 55 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Expenses by Nature
12 Months Ended
Dec. 31, 2021
Expense By Nature [Abstract]  
Expenses by Nature

5. Expenses by Nature

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Clinical trials related expenses

 

 

82,046

 

 

 

107,440

 

 

 

424,724

 

Employee benefit expenses (Note 6)

 

 

15,098

 

 

 

27,243

 

 

 

120,173

 

Consultancy fee (i)

 

 

12,011

 

 

 

31,784

 

 

 

69,498

 

R&D materials and consumable supplies

 

 

988

 

 

 

2,127

 

 

 

13,718

 

Depreciation and amortization

 

 

790

 

 

 

1,436

 

 

 

4,082

 

Office expenses

 

 

2,424

 

 

 

3,052

 

 

 

3,653

 

Expense related to Series C financing (ii)

 

 

 

 

 

19,655

 

 

 

 

Others

 

 

2,770

 

 

 

5,915

 

 

 

4,618

 

 

 

 

116,127

 

 

 

198,652

 

 

 

640,466

 

 

(i)
The Company exclusively licenses CBP-174 from a third-party licensor. Such license is worldwide and royalty-bearing. As of December 31, 2021, CBP-174 has not yet been commercialized, the Company is only subject to a non-refundable, non-creditable license maintenance fee, which is paid to the third-party licensor on an annual basis and recorded as a consultancy fee within research and development expense.
(ii)
Represents a share-based compensation to additional Series C preferred shareholder, which was recognized as an administrative expense as set forth in Note 22. 
XML 56 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Employee Benefit Expenses
12 Months Ended
Dec. 31, 2021
Classes Of Employee Benefits Expense [Abstract]  
Employee Benefit Expenses

6. Employee Benefit Expenses

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Share-based compensation expenses (Note 22)

 

 

3,875

 

 

 

5,535

 

 

 

57,863

 

Wages, salaries and bonuses

 

 

8,628

 

 

 

19,527

 

 

 

56,122

 

Welfare expenses

 

 

964

 

 

 

520

 

 

 

4,820

 

Housing funds

 

 

491

 

 

 

690

 

 

 

1,368

 

Contributions to defined benefit plan (Note 27(d))

 

 

1,140

 

 

 

971

 

 

 

 

 

 

 

15,098

 

 

 

27,243

 

 

 

120,173

 

 

(i) The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder. The Company does not have any further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk.

 

Employee benefit expenses were charged in the following line items in the consolidated statements of loss:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Research and development expenses

 

 

11,496

 

 

 

18,405

 

 

 

68,225

 

Administrative expenses

 

 

3,602

 

 

 

8,838

 

 

 

51,948

 

 

 

 

15,098

 

 

 

27,243

 

 

 

120,173

 

XML 57 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Other Income
12 Months Ended
Dec. 31, 2021
Other Income Expense [Abstract]  
Other Income

7. Other Income

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Government grants

 

 

2,836

 

 

 

6,989

 

 

 

18,996

 

 

Government grants are mainly related to cash incentives from the China government based on specific milestones or operating expenses incurred in China and tax incentives from the Australian government for conducting clinical research and development activities in Australia. In 2021, the Group received a one-time award of RMB 11.0 million for its successful IPO listing, other subsidies of RMB 6.2 million from China local government, RMB 1.6 million from the Australian government as an incentive for research and development activities.

XML 58 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Other Gains/(losses) Net
12 Months Ended
Dec. 31, 2021
Other Income (Losses) Net [Abstract]  
Other Gains/(losses)-Net

8. Other Gains/(losses)—net

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Net foreign exchange gains/(losses)

 

 

2,252

 

 

 

(6,772

)

 

 

(3,309

)

Investment income from wealth management products

 

 

798

 

 

 

672

 

 

 

436

 

Other loss (i)

 

 

 

 

 

 

 

 

(7,093

)

 

 

 

3,050

 

 

 

(6,100

)

 

 

(9,966

)

 

(i) The Group incurred a loss of RMB 7.0 million (USD 1.1 million) due to a phishing scam experienced in May 2021 which resulted in the Company remitting such amount to an account set up by the phishers rather than to one of the Company’s vendors. No loss of company data nor any loss or compromise of third-party information has been discovered. The Company filed a claim and partially recovered RMB 1.0 million losses from its cyber insurance provider.

XML 59 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Finance Income/(cost) Net
12 Months Ended
Dec. 31, 2021
Profit Loss [Abstract]  
Finance Income/(cost) Net

9. Finance Income/(cost) —net

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Finance income

 

 

 

 

 

 

 

 

 

Interest from bank deposits and term deposits

 

 

1,066

 

 

 

717

 

 

 

622

 

Finance cost

 

 

 

 

 

 

 

 

 

Issuance cost of financial instruments with preferred rights

 

 

 

 

 

(2,851

)

 

 

 

Interest for lease liabilities

 

 

(53

)

 

 

(42

)

 

 

(44

)

 

 

 

(53

)

 

 

(2,893

)

 

 

(44

)

Finance income/(cost)—net

 

 

1,013

 

 

 

(2,176

)

 

 

578

 

XML 60 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Major Components Of Tax Expense Income [Abstract]  
Income Taxes

10. Income Taxes

 

Income tax expense is recognized based on the income tax rates in the following main tax jurisdictions where the Group operates for the years ended December 31, 2019, 2020 and 2021.

a) Cayman Islands

 

The Company is incorporated in the Cayman Islands as an exempted company with limited liabilities under the Companies Law of the Cayman Islands and accordingly, is exempted from Cayman Islands income tax.

b)
Hong Kong

 

Hong Kong profits tax rate was 16.5% as of April 1, 2018 when the two-tiered profits tax regime took effect, under which the tax rate is 8.25% for assessable profits on the first HK$ 2 million and 16.5% for any assessable profits in excess. No Hong Kong profit tax was provided for as there was no estimated assessable profit that was subject to Hong Kong profits tax during the years ended December 31, 2019, 2020 and 2021.

c)
United States

 

Connect US is incorporated in the U.S. and is a single member Limited Liability Company that is disregarded for US income tax purposes wholly owned by Connect SZ (before September 2018) and then Connect HK from a tax perspective. During the years ended December 31, 2019 and 2020, from a U.S. tax perspective, Connect HK is subject to US federal corporate income tax at a rate of 21% and state income tax in California at a rate of 8.84% to the extent of the income apportionable to Connect US. No provision for income taxes was made for the years ended December 31, 2019 and 2020. The provision for income taxes for the year ended December 31, 2021 was RMB 1.7 million.

d)
Australia

 

Connect AU is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is 30%. Connect AU has no taxable income for all periods presented, therefore, no provision for income taxes has been provided.

e)
PRC

 

Provision for PRC corporate income tax is calculated based on the statutory income tax rate of 25% on the assessable income of respective PRC Group entities during the years ended December 31, 2019, 2020 and 2021 in accordance with relevant PRC enterprise income tax rules and regulations.

 

No provision for PRC corporate income tax has been made for the years ended December 31, 2019, 2020 and 2021 as the Group had no such taxable profit for the years then ended.

 

The reconciliation between the Group’s actual tax charge and the amount that is calculated based on the statutory income tax rate of 25% in the PRC is as follows:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Loss from operations in the PRC

 

 

(73,741

)

 

 

(85,788

)

 

 

(233,382

)

Loss from overseas entities

 

 

(94,884

)

 

 

(693,437

)

 

 

(1,071,745

)

Loss before income tax

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,305,127

)

Tax expense at PRC enterprise income tax rate of 25%

 

 

(42,156

)

 

 

(194,806

)

 

 

(326,282

)

Expenses not deductible for income tax purpose

 

 

799

 

 

 

3,185

 

 

 

13,663

 

Super deduction of research and development expenses (i)

 

 

(9,529

)

 

 

(13,341

)

 

 

(35,523

)

Tax losses and deductible temporary differences for which no deferred income tax assets were recognized

 

 

33,956

 

 

 

40,865

 

 

 

114,121

 

Effect of income tax in jurisdictions other than the PRC

 

 

16,930

 

 

 

164,097

 

 

 

235,718

 

Income tax expense

 

 

 

 

 

 

 

 

1,697

 

 

(i)
According to policies promulgated by the State Tax Bureau of the PRC, certain of the Group's subsidiaries are entitled to tax incentives for research and development expenses at 175% of tax-deductible research and development expenses in 2019, 2020 and 2021.

 

For the year ended December 31, 2021, the Group’s income tax expense of RMB 1.7 million is due primarily to income tax expense for Connect US, which is treated for income tax purposes as a service provider for Connect HK and earns service fee income on a cost-plus basis.

 

The Group did not recognize deferred income tax assets for the tax losses and deductible temporary differences that amounted to approximately RMB 284 million, RMB 582 million and RMB 1,327 million as of December 31, 2019, 2020 and 2021, respectively. The balance of research and development tax credits for Connect US as of December 31, 2021 is RMB 13.74 million, which can be carried forward against future tax liabilities.

 

As of December 31, 2019, 2020 and 2021, the Group did not have any significant unrecognized uncertain tax positions.

XML 61 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share

11. Net Loss Per Share

 

Upon approval of shareholders of the Company on March 12, 2021, every 1.74 ordinary shares were consolidated into one ordinary share (the “Share Consolidation”) (Note 19). To calculate net loss per share, the number of shares used reflects such Share Consolidation retrospectively as of January 1, 2019 in the calculation of the weighted average number of ordinary shares outstanding.

Basic and diluted net losses per share reflecting the effect of the issuance of ordinary shares by the Company are presented as follows.

 

Basic net loss per share is calculated by dividing the net loss attributable to owners of the Company by the weighted average number of ordinary shares outstanding.

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

Net loss attributable to owners of the Company (RMB’000)

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,306,824

)

Weighted average number of ordinary shares outstanding (in thousands)

 

 

16,875

 

 

 

17,090

 

 

 

52,177

 

Basic net loss per share (RMB)

 

 

(10.0

)

 

 

(45.6

)

 

 

(25.0

)

 

Share options and preferred shares are considered as potential dilutive shares throughout the reporting period. However, since the Group had incurred losses for the years ended December 31, 2019, 2020 and 2021, the potential dilutive shares have anti-dilutive effect on loss per share if they are converted to ordinary shares. Thus, diluted loss per share is equivalent to the basic loss per share.

XML 62 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant and Equipment
12 Months Ended
Dec. 31, 2021
Disclosure Of Property Plant And Equipment [Abstract]  
Property, Plant and Equipment

12. Property, Plant and Equipment

 

 

 

 

 

 

 

 

 

Office
equipment,

 

 

 

 

 

 

 

 

 

Laboratory
equipment

 

 

Leasehold
improvements

 

 

furniture
and others

 

 

Assets under
construction

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of January 1, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

 

3,059

 

 

 

628

 

 

 

582

 

 

 

 

 

 

4,269

 

Accumulated depreciation

 

 

(1,121

)

 

 

(234

)

 

 

(375

)

 

 

 

 

 

(1,730

)

Net book value

 

 

1,938

 

 

 

394

 

 

 

207

 

 

 

 

 

 

2,539

 

Year ended December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Opening net book value

 

 

1,938

 

 

 

394

 

 

 

207

 

 

 

 

 

 

2,539

 

Additions

 

 

2,613

 

 

 

833

 

 

 

3

 

 

 

1,906

 

 

 

5,355

 

Depreciation

 

 

(339

)

 

 

(574

)

 

 

(42

)

 

 

 

 

 

(955

)

Closing net book value

 

 

4,212

 

 

 

653

 

 

 

168

 

 

 

1,906

 

 

 

6,939

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

 

5,672

 

 

 

1,461

 

 

 

585

 

 

 

1,906

 

 

 

9,624

 

Accumulated depreciation

 

 

(1,460

)

 

 

(808

)

 

 

(417

)

 

 

 

 

 

(2,685

)

Net book value

 

 

4,212

 

 

 

653

 

 

 

168

 

 

 

1,906

 

 

 

6,939

 

Year ended December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Opening net book value

 

 

4,212

 

 

 

653

 

 

 

168

 

 

 

1,906

 

 

 

6,939

 

Additions

 

 

30,440

 

 

 

793

 

 

 

422

 

 

 

24,121

 

 

 

55,776

 

Disposals

 

 

(234

)

 

 

 

 

 

(14

)

 

 

 

 

 

(248

)

Depreciation

 

 

(2,142

)

 

 

(813

)

 

 

(175

)

 

 

 

 

 

(3,130

)

Transfers

 

 

 

 

 

2,449

 

 

 

 

 

 

(2,449

)

 

 

 

Closing net book value

 

 

32,276

 

 

 

3,082

 

 

 

401

 

 

 

23,578

 

 

 

59,337

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

 

35,878

 

 

 

4,703

 

 

 

993

 

 

 

23,578

 

 

 

65,152

 

Accumulated depreciation

 

 

(3,602

)

 

 

(1,621

)

 

 

(592

)

 

 

 

 

 

(5,815

)

Net book value

 

 

32,276

 

 

 

3,082

 

 

 

401

 

 

 

23,578

 

 

 

59,337

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

XML 63 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Other non-current Assets
12 Months Ended
Dec. 31, 2021
Miscellaneous Noncurrent Assets [Abstract]  
Other non-current Assets

13. Other non-current Assets

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Deductible value-added tax

 

 

10,260

 

 

 

18,045

 

Prepayments for purchase of non-current assets (i)

 

 

9,600

 

 

 

341

 

Others

 

 

 

 

 

420

 

 

 

 

19,860

 

 

 

18,806

 

 

(i)
As of December 31, 2020, the Group had prepayment balances of approximately RMB 9.6 million, primarily due to the purchase of laboratory equipment for Connect SZ. 
XML 64 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Leases
12 Months Ended
Dec. 31, 2021
Presentation of leases for lessee [abstract]  
Leases

14. Leases

 

Amounts recognized in the consolidated balance sheets are as follows:

 

(i) Right-of-use assets

 

 

 

Land use rights

 

 

Office rent

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Net book amount-as of January 1, 2019

 

 

 

 

 

1,290

 

 

 

1,290

 

Depreciation

 

 

 

 

 

(407

)

 

 

(407

)

Net book amount-as of December 31, 2019

 

 

 

 

 

883

 

 

 

883

 

Additions

 

 

 

 

 

527

 

 

 

527

 

Depreciation

 

 

 

 

 

(481

)

 

 

(481

)

Net book amount-as of as of December 31, 2020

 

 

 

 

 

929

 

 

 

929

 

Additions

 

 

22,284

 

 

 

517

 

 

 

22,801

 

Depreciation

 

 

(297

)

 

 

(612

)

 

 

(909

)

Net book amount-as of as of December 31, 2021

 

 

21,987

 

 

 

834

 

 

 

22,821

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

Cost

 

 

22,284

 

 

 

2,607

 

 

 

24,891

 

Accumulated depreciation

 

 

(297

)

 

 

(1,773

)

 

 

(2,070

)

Net Book value

 

 

21,987

 

 

 

834

 

 

 

22,821

 

 

During the year ended December 31, 2021, the addition of land use rights was related to payments to acquire long-term interest in the usage of land in the PRC over the period of 50 years as stated in the land use right certificate. The land is expected to be used for the construction of production, research and office facilities.

 

(ii) Lease liabilities

 

 

 

As of December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Non-current

 

 

470

 

 

 

309

 

 

 

163

 

Current

 

 

412

 

 

 

604

 

 

 

630

 

.

 

 

882

 

 

 

913

 

 

 

793

 

 

Amounts recognized in the consolidated statements of loss in addition to depreciation presented above are as follows:

 

 

 

As of December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Interest expense

 

 

53

 

 

 

42

 

 

 

44

 

Expense relating to short-term leases (included in administrative expenses and research and development expenses)

 

 

98

 

 

 

45

 

 

 

12

 

Expense relating to leases of low-value assets that are not shown above as short-term leases (included in administrative expenses and research and development expenses)

 

 

58

 

 

 

30

 

 

 

58

 

 

 

 

209

 

 

 

117

 

 

 

114

 

 

The total cash outflow for leases for the years ended December 31, 2019, 2020 and 2021 was RMB 0.4 million, RMB 0.5 million and RMB 0.8 million, respectively.

XML 65 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments by Category
12 Months Ended
Dec. 31, 2021
Disclosure Of Financial Instruments [Abstract]  
Financial Instruments by Category

15. Financial Instruments by Category

 

 

 

Financial assets

 

 

Financial assets

 

 

 

 

Financial assets

 

at FVPL

 

 

at amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

Other receivables

 

 

 

 

 

5,612

 

 

 

5,612

 

Financial assets at fair value through profit or loss

 

 

13,068

 

 

 

 

 

 

13,068

 

Cash and cash equivalents

 

 

 

 

 

1,010,076

 

 

 

1,010,076

 

 

 

 

13,068

 

 

 

1,015,688

 

 

 

1,028,756

 

 

 

 

Financial assets

 

 

Financial assets

 

 

 

 

Financial assets

 

at FVPL

 

 

at amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

Other receivables

 

 

 

 

 

6,423

 

 

 

6,423

 

Cash and cash equivalents

 

 

 

 

 

1,706,880

 

 

 

1,706,880

 

 

 

 

 

 

 

1,713,303

 

 

 

1,713,303

 

 

 

 

Financial

 

 

Financial

 

 

 

 

 

 

liabilities at

 

 

liabilities at

 

 

 

 

Financial Liabilities

 

FVPL

 

 

amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

Financial instruments with preferred rights

 

 

2,071,508

 

 

 

 

 

 

2,071,508

 

Other payables

 

 

 

 

 

8,631

 

 

 

8,631

 

Trade payables

 

 

 

 

 

24,638

 

 

 

24,638

 

Lease liabilities

 

 

 

 

 

913

 

 

 

913

 

 

 

 

2,071,508

 

 

 

34,182

 

 

 

2,105,690

 

 

 

 

Financial

 

 

Financial

 

 

 

 

 

 

liabilities at

 

 

liabilities at

 

 

 

 

Financial Liabilities

 

FVPL

 

 

amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

Other payables

 

 

 

 

 

21,456

 

 

 

21,456

 

Trade payables

 

 

 

 

 

81,195

 

 

 

81,195

 

Lease liabilities

 

 

 

 

 

793

 

 

 

793

 

.

 

 

 

 

 

103,444

 

 

 

103,444

 

XML 66 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Other Receivables and Prepayments
12 Months Ended
Dec. 31, 2021
Other Receivables And Prepayments [Abstract]  
Other Receivables and Prepayments

16. Other Receivables and Prepayments

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Prepayment for clinical trials related services

 

 

28,043

 

 

 

36,879

 

Deposits(ii)

 

 

3,881

 

 

 

4,312

 

Prepaid expenses(i)

 

 

 

 

 

3,953

 

Others

 

 

1,731

 

 

 

2,111

 

 

 

 

33,655

 

 

 

47,255

 

 

(i)
In March 2021, the Group made payments to purchase director and officer liability insurance. Such expenses are amortized over one year.
(ii)
Deposits held by CRO suppliers are refundable upon the completion of related services. 
XML 67 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Assets at Fair Value Through Profit or Loss
12 Months Ended
Dec. 31, 2021
Financial Assets At Fair Value Through Profit Or Loss [Abstract]  
Financial Assets at Fair Value Through Profit or Loss

17. Financial Assets at Fair Value Through Profit or Loss

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Wealth management products

 

 

13,068

 

 

 

 

 

The returns on these wealth management products were not guaranteed, hence their contractual cash flows did not qualify solely as payments of principal and interest. Therefore, they were measured at fair value through profit or loss. Wealth management products held by the Group with various maturities bear floating interest rates of 1.6%-3.4% and 1.48%-3.44% per annum for the years ended December 31, 2020 and 2021, respectively.

The fair value of wealth management products is based on discounted cash flows using their expected returns. Changes in fair value of these financial assets are recorded in other gains/(losses) – net in the consolidated statements of loss.

XML 68 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Cash and Cash Equivalents
12 Months Ended
Dec. 31, 2021
Cash And Cash Equivalents [Abstract]  
Cash and Cash Equivalents

18. Cash and Cash Equivalents

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Cash at bank

 

 

 

 

 

 

-USD deposits

 

 

975,810

 

 

 

1,645,948

 

-RMB deposits

 

 

28,113

 

 

 

57,595

 

-Australian Dollar deposit

 

 

6,153

 

 

 

3,337

 

 

 

 

1,010,076

 

 

 

1,706,880

 

 

Cash at bank located in the PRC earns interest at floating rates based on daily bank deposit rates, while deposits in banks outside the PRC are with interest rate of nil.

 

Cash at banks denominated in RMB are deposited with banks in the PRC. The conversion of these RMB-denominated balances into foreign currencies and the remittance of funds out of China are subject to the rules and regulations of foreign exchange control promulgated by the Government of the PRC. As of December 31, 2020 and 2021, RMB 932.8 million and RMB 1,501.8 million of cash and cash equivalents were held in banks outside the PRC, respectively.

XML 69 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Share Capital
12 Months Ended
Dec. 31, 2021
Disclosure Of Classes Of Share Capital [Abstract]  
Share Capital

19. Share Capital

Upon approval of shareholders of the Company on March 12, 2021, every 1.74 ordinary shares with a par value of USD 0.0001 each in the authorized share capital of the Company (including all issued and unissued shares) were consolidated into one share with a par value of USD 0.000174 each. Therefore, the authorized share capital of the Company was changed from USD 50,000 into USD 76,560. The authorized share capital of the Company as of December 31, 2021 was USD 76,560. The number of ordinary shares below are presented retrospectively as if such Share Consolidation took place as of January 1, 2019.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number of Ordinary Shares

 

 

Share Capital

 

 

Share Premium(i)

 

 

Total

 

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of January 1, 2019

 

 

17,684,770

 

 

 

21

 

 

 

38,074

 

 

 

38,095

 

Exercise of stock options

 

 

 

 

 

 

 

 

49

 

 

 

49

 

As of December 31, 2019

 

 

17,684,770

 

 

 

21

 

 

 

38,123

 

 

 

38,144

 

Issuance of shares to Co-Founders (iv, Note 22)

 

 

282,526

 

 

 

1

 

 

 

3,343

 

 

 

3,344

 

Issuance of treasury shares

 

 

1,686,495

 

 

 

2

 

 

 

 

 

 

2

 

As of December 31, 2020

 

 

19,653,791

 

 

 

24

 

 

 

41,466

 

 

 

41,490

 

Issuance of ordinary shares (ii)

 

 

12,937,500

 

 

 

14

 

 

 

1,305,805

 

 

 

1,305,819

 

Conversion from preferred shares to ordinary shares (Note 24)

 

 

24,791,804

 

 

 

28

 

 

 

2,743,597

 

 

 

2,743,625

 

Repurchase of ordinary shares (iii)

 

 

(20,765

)

 

 

 

 

 

 

 

 

 

Issuance of shares to Co-Founders (iv, Note 22)

 

 

121,080

 

 

 

 

 

 

1,417

 

 

 

1,417

 

Exercise of stock options

 

 

 

 

 

 

 

 

2,149

 

 

 

2,149

 

As of December 31, 2021

 

 

57,483,410

 

 

 

66

 

 

 

4,094,434

 

 

 

4,094,500

 

 

(i)
Share premium mainly arose from the contributions to the Company by its holders of ordinary shares and the conversion from preferred shares.
(ii)
In March 2021, 12,937,500 ADSs (representing 12,937,500 ordinary shares, including the exercise of the option by the underwriters in full to purchase additional ADSs) were offered by the Company in connection with its listing on Nasdaq, and the proceeds received were USD 219.9 million or RMB 1,431.8 million based on the exchange rate as of the date of the IPO. The Company incurred issuance costs of USD 19.3 million in connection with this offering.
(iii)
In March 2021, at the request of one co-founder the Group repurchased 20,765 ordinary shares from him for a consideration of RMB 2.5 million (USD 0.4 million) for the payment of employee withholding taxes related to share-based awards, then such shares were cancelled accordingly.
(iv)
Pursuant to the Company’s shareholder agreement in effect as of the completion of the Series C financing (see Note 22), each of the Company’s founders is entitled to two or more votes to ensure the Co-Founders control the majority of the votes under certain circumstances.
XML 70 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Treasury Shares
12 Months Ended
Dec. 31, 2021
Treasury Shares [Abstract]  
Treasury shares

20. Treasury Shares

 

Treasury shares were previously held by Connect Union for the purpose of issuing shares under 2019 Stock Incentive Plan in 2019 and 2020. All the Company’s ordinary shares held by Connect Union were surrendered to the Company in September 2021. As of December 31, 2019, 2020 and 2021, there were 877,066, 2,563,563 and 2,407,091 treasury shares, respectively.

XML 71 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Reserves
12 Months Ended
Dec. 31, 2021
Disclosure Of Reserves Within Equity [Abstract]  
Reserves

21. Reserves

(a) Share-based compensation reserves

The share-based compensation reserves represent the fair value of unexercised options granted to employees recognized in accordance with the accounting policy adopted for equity-settled share-based payments described in Note 2.17 to the financial statements.

(b) Other reserves

Other reserves mainly represent the reserve transferred from share-based compensation reserve upon exercise of share options and foreign currency translation reserve described in Note 2.5(c).

(c) Statutory reserves

In accordance with the PRC regulations and the articles of association of the PRC companies now included in the Group, before annual profit distribution, companies registered in the PRC are required to set aside 10% of their net profit for the year after offsetting any prior year losses as determined under relevant PRC accounting standards to the statutory surplus reserve fund. When the balance of such reserve reaches 50% of the entity’s registered capital, any further appropriation is optional. No profit appropriation to the reserve fund was made for those Group entities for the reporting periods as they were in accumulated loss positions.

Under PRC laws and regulations, there are restrictions on the Company’s PRC subsidiaries with respect to transferring certain of their net assets to the Company either in the form of dividends, loans, or advances. Restricted net assets including paid-in capital and statutory reserve funds of the Company’s PRC subsidiaries was RMB 137.7 million as of December 31, 2020 and RMB 288.9 million as of December 31, 2021.

XML 72 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Compensation
12 Months Ended
Dec. 31, 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]  
Share-Based Compensation

22. Share-Based Compensation

 

2019 Stock Incentive Plan

 

The Group adopted the 2019 stock incentive plan ("2019 Plan") and obtained Board’s approval on November 1, 2019, under which the Group may grant various awards such as options, restricted shares or restricted share units to employees, directors, and consultants for services rendered. As of December 31, 2020 and 2021 the Group has reserved 4,460,600 (after the Share Consolidation 2,563,563) and 2,407,091 ordinary shares (after the Share Consolidation).

 

Pursuant to the plan, a grantee has the right to subscribe for the ordinary shares at a price determined by the Board. The options granted can only vest if the service conditions are met. Options granted under the plan are valid and effective for 10 years from the date of grant and vest over a service period which is generally four years; 25% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next 36 months. Some options are vested in equal monthly installments or annual installments over the entire service period or vested immediately upon the grant date in instances where services had already been performed in their entirety.

 

The Chinese grantees are entitled to subscribe for underlying shares only if an IPO is achieved, provided that the service condition is also met. As of each grant date during the year ended December 31, 2020, management believed achievement of the IPO was probable.

 

The grant date of certain grantees occurred after the date they had begun rendering services to satisfy the condition attached to the share option award, the management estimated the grant date fair value in each reporting period for the purpose of recognizing the expense during the period between the service commencement date and the grant date. Once the grant date has been established, the recognized expense is based on the actual grant date fair value of the share option in the period of change.

 

Grantees who leave the Group other than for certain causes will lose their entitlement to the vested options if not exercised within three months of their termination date (or within three months after the IPO kick-off date for certain option holders).

 

2021 Stock Incentive Plan

 

The Group adopted 2021 Stock Incentive Plan (“2021 Plan”) effective on the day of effectiveness of its IPO. Awards granted under the 2021 Plan may be either stock options, stock appreciation rights (“SARs”), restricted stock units (“RSUs”), restricted stock awards (“RSA”) or dividend equivalent right ("DER”).

 

Pursuant to the plan, a grantee has the right to subscribe for the ordinary shares at a price determined by the Board. The options granted can only vest if the service conditions are met. Options granted under the plan are valid and effective for 10 years from the date of grant and vest over a service period which is generally four years; 25% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next 36 months.

 

Grantees who leave the Group other than for certain causes will lose their entitlement to the vested options if not exercised within three months of their termination date.

 

In 2021, the Company granted a total of 2,403,660 options which contain 897,660 options from the 2019 Plan and 1,506,000 options from the 2021 Plan.

 

2021 Employee Share Purchase Plan

 

The Group adopted but have not yet implemented the 2021 Employee Share Purchase Plan (“2021 ESPP”). A total of 600,000 ordinary shares were initially reserved for issuance under the 2021 ESPP Plan. On the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031, the number of shares available for issuance under the 2021 ESPP Plan shall be increased by that number of shares equal to the lesser of 1% of the aggregate number of ordinary shares of the Group outstanding on the final day of the immediately preceding calendar year or such smaller number of shares as determined by the Groups board of directors. No offering has been made under the 2021 ESPP Plan in the period from the adoption of the 2021 ESPP Plan to December 31, 2021.

The options activities under 2019 and 2021 Plans (after the Share Consolidation) for the year ended December 31, 2019, 2020 and 2021 were as follows:

 

 

 

Number of options

 

 

Weighted average
exercise price per
share option

Options outstanding as of January 1, 2019

 

 

 

 

 

Granted

 

 

198,064

 

 

USD 0.9

Forfeited (i)

 

 

(7,302

)

 

USD 0.9

Options outstanding as of December 31, 2019

 

 

190,762

 

 

 

Granted

 

 

1,500,887

 

 

USD 6.6

Forfeited (i)

 

 

(25,766

)

 

USD 0.9

Options outstanding as of December 31, 2020

 

 

1,665,883

 

 

 

Granted

 

 

2,403,660

 

 

USD 13.8

Exercised

 

 

(163,773

)

 

USD 0.9

Forfeited (i)

 

 

(157,381

)

 

USD 14.7

Options outstanding as of December 31, 2021

 

 

3,748,389

 

 

 

Options exercisable as of December 31, 2021

 

 

485,324

 

 

 

 

The weighted average remaining contractual life of options outstanding as of December 31, 2019, 2020 and 2021 was 7.6, 9.3 and 9.2 years, respectively.

 

(i)
The options were forfeited when the employment terminated.

Fair value of options granted

 

Prior to the completion of the IPO, the Group determined its equity value which was estimated using the hybrid method and adopted the allocation model to determine the fair value of its underlying ordinary shares. After the completion of the IPO, the fair value of the share options is estimated based on the fair market value of the Company’s underlying ordinary shares at the grant date.

 

Based on the fair value of underlying ordinary shares, the Group used the Binomial option-pricing model to determine the fair value of options as of the grant date. Key assumptions (after the Share Consolidation) for the options granted are set forth below:

 

 

 

Year Ended December 31

 

 

2019

 

 

2020

 

 

2021

Weighted average exercise price during the year

 

USD 0.9

 

 

USD 6.6

 

 

USD 13.8

Grant date share price

 

USD 1.9~USD 2.1

 

 

USD 2.1~USD 11.1

 

 

USD 4.3~USD 23.3

Risk-free interest rate

 

1.7%~2.1%

 

 

0.8%~1.1%

 

 

1.2%~1.7%

Expected volatility

 

56.6%~77.4%

 

 

61.8%~77.4%

 

 

60.5%~62.2%

Option life

 

10 years

 

 

10 years

 

 

10 years

Expected early exercise multiple

 

 

2.2

 

 

 

2.2

 

 

2.2

Dividend yield

 

Nil

 

 

Nil

 

 

Nil

Forfeiture rate

 

 

9.5

%

 

 

9.5

%

 

*3.0%-9.6%

Weighted average fair value of options granted during the year

 

USD 1.2

 

 

USD 4.2

 

 

USD 10.6

 

* Forfeiture rates for executives and all other employees in the year ended December 31, 2021, were 3.0% and 9.6%,

respectively.

 

The Company adopted the average volatility of the comparable companies as the proxy of the expected volatility of the underlying share. The volatility of each comparable company was based on the historical daily stock prices for a period with length commensurate to the remaining maturity life of the share options.

Share-based compensation to Co-Founders

On December 20, 2018, pursuant to the shareholders agreement entered into among the Company and all its shareholders in connection with its Series B financing, up to 702,278 and 1,140,474 ordinary shares (before Share Consolidation) will be issued to the Co-Founders and Connect Union, respectively, for no consideration, contingent on achieving of various R&D milestones as non-market performance conditions. Under such agreement, the ordinary shares may also be issued in a lump sum immediately after the closing of new financing that meets several requirements including, among others, the pre-money valuation of the Group exceeding USD 600,000,000 (“Financing Condition”). Such shares to be issued to Connect Union were reserved for future issuance of options.

 

Upon achievement of certain R&D milestones, 351,140 ordinary shares (before Share Consolidation) were vested and yet to be issued to the Co-Founders as of December 31, 2019. In January 2020, another 140,456 ordinary shares (before Share Consolidation) were vested to the Co-Founders. Accordingly, the Company issued 491,596 ordinary shares (before Share Consolidation) to the Co-Founders and 798,330 ordinary shares (before Share Consolidation) to Connect Union, respectively, for no consideration in April 2020. The Company recognized the related share-based compensation expenses in the amounts of RMB 2.7 million and RMB 1.2 million for the years ended December 31, 2019 and 2020, respectively. Unless otherwise waived by the Company and the investors party to the shareholders agreement, 210,682 ordinary shares (before Share Consolidation) are potentially issuable to the Co-Founders and 342,144 ordinary shares (before Share Consolidation) are potentially issuable to Connect Union upon achievement of the Financing Condition.

 

Pursuant to the shareholders agreement entered into in connection with the Company’s Series C financing in August and December 2020, upon the issuance of the remaining ordinary shares issuable upon achievement of the Financing Condition (i.e. 210,682 ordinary shares (before Share Consolidation) to be issued to the Co-Founders and 342,144 ordinary shares (before Share Consolidation) to be issued to Connect Union), the Company will be obligated to issue additional Series C preferred shares at par value to each of the Series C shareholders so that the shareholdings of the Series C preferred shares obtained by such Series C shareholders will not be diluted. As of December 31, 2020, the Company has not yet issued the above ordinary shares to Co-Founders and Connect Union, so no additional Series C preferred shares are issued.

 

Pursuant to the shareholders agreement, upon achievement of certain R&D milestones, 210,682 ordinary shares were issued to the Co-Founders for the year ended December 31, 2021. After the Share Consolidation, these have become 121,080 ordinary shares.


In March 2021, based on the anti-dilutive obligation of the Company to issue additional Series C preferred shares, the Company also issued additional
80,457 Series C preferred shares. After the Share Consolidation, these have become 46,232 preferred shares. Upon completion of the IPO, such preferred shares were converted to ordinary shares on a one-for-one basis.

 

The Group determined its equity value which was estimated using the hybrid method and adopted the allocation model to determine the fair value of this share-based payment as USD 0.9 per share before the Share Consolidation (USD 1.57 after the Share Consolidation) on the grant date. Key assumptions included risk-free interest rate of 2.5%, expected volatility of 60.0%, dividend yield of nil and were based on the management’s best estimates.

Share-based compensation to additional Series C preferred shareholder

 

In August 2020, the Company entered into a Series C preferred share purchase agreement with certain investors to issue 18,186,643 shares (10,452,094 after the Share Consolidation) of Series C preferred shares for a cash consideration of USD 115.0 million. Subsequent to the completion of the Series C financing in August 2020, the Company negotiated with another investor for an additional round of Series C financing. On December 1, 2020, the Company issued 3,162,894 (1,817,755 after the Share Consolidation) additional Series C preferred shares to such investor for a cash consideration of USD 20.0 million with the same subscription price and similar terms as Series C preferred shares issued in August 2020 (“Additional Series C Preferred Shares”).

 

According to the relevant guidance under IFRS 2, when the Group receives identifiable consideration that is less than the fair value of the equity instruments granted or liability incurred, the Group measures the identifiable goods or services received. The Group shall measure the unidentifiable goods or services received (or to be received) as the difference between the fair value of the share-based payment and the fair value of any identifiable goods or services received (or to be received) on the grant date.

 

Therefore, the Group recognized the difference between the cash consideration received from and the fair value of the Additional Series C Preferred Shares on the issuance date as a share-based compensation in the amount of approximately RMB 19.7 million for the year ended December 31, 2020.

 

Share-based compensation expenses included in the consolidated statements of loss for the years ended December 31, 2019, 2020 and 2021 is as follows:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Research and development expenses (Note 6)

 

 

3,635

 

 

 

3,523

 

 

 

26,532

 

Administrative expenses (Note 5(ii), Note 6)

 

 

240

 

 

 

21,667

 

 

 

31,331

 

 

 

 

3,875

 

 

 

25,190

 

 

 

57,863

 

 

Upon completion of the IPO, all issued and outstanding Additional Series C Preferred Shares were converted to ordinary share on a one-for-one basis.

XML 73 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Other Payables and Accruals
12 Months Ended
Dec. 31, 2021
Other Payables and Accruals [Abstract]  
Other Payables and Accruals

23. Other Payables and Accruals

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Construction payables

 

 

 

 

 

16,576

 

Payroll, welfare and bonus payables

 

 

4,124

 

 

 

11,384

 

Accrued professional service fee

 

 

8,090

 

 

 

2,318

 

Others

 

 

541

 

 

 

2,562

 

 

 

 

12,755

 

 

 

32,840

 

XML 74 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments with Preferred Rights
12 Months Ended
Dec. 31, 2021
Disclosure Of Financial Instruments [Abstract]  
Financial Instruments with Preferred Rights

24. Financial Instruments with Preferred Rights

The Group has completed a series of financings by issuing preferred shares with the following details:

 

 

 

 

 

 

 

 

Subscription

 

 

 

 

 

Number of

 

 

consideration

 

Date of subscription

 

Round

 

preferred shares

 

 

RMB’000

 

March 3, 2016

 

Series Pre-A

 

 

3,109,000

 

 

 

33,110

 

January 3, 2017

 

Series A

 

 

8,471,200

 

 

 

137,868

 

December 20, 2018

 

Series B

 

 

10,127,579

 

 

 

379,148

 

August 21, 2020/December 1, 2020

 

Series C

 

 

21,349,537

 

 

 

923,247

 

 

 

 

 

 

43,057,316

 

 

 

1,473,373

 

 

After the Share Consolidation, the above number of preferred shares were changed to 24,745,572 and together with additional 46,232 preferred shares as disclosed in the Note 22, the Company’s issued and outstanding preferred shares were 24,791,804 prior to March 19, 2021. Upon completion of the IPO, such preferred shares were converted to ordinary share on a one-for-one basis.

 

The key preferred rights of the preferred shares are summarized as follows:

 

(a) Conversion feature

 

i) Optional conversion

 

Each holder of preferred share shall be entitled to exercise its right to convert any of its preferred shares, at any time after the date of issuance of such shares, and each preferred share may be convertible into a certain number of fully paid and non-assessable ordinary shares at a ratio calculated by dividing the Series Pre-A issue price, the Series A issue price, the Series B issue price, or the Series C issue price, as applicable, by the then applicable conversion price (the “Conversion Price”). The Conversion Price is initially equal to the Series Pre-A issue price, the Series A issue price, the Series B issue price, or the Series C issue price, as applicable, and is subject to adjustment from time to time to reflect stock dividends, stock splits and other events. For the avoidance of doubt, no payment shall

be made by the holders of preferred shares to the Company upon or in connection with the conversion of the preferred shares into ordinary shares.

 

ii) Automatic conversion

 

The preferred shares held by each holder shall be, at the applicable Conversion Price in effect at the time of conversion, without the payment of any additional consideration, converted into fully-paid and non-assessable ordinary shares upon the closing of a Qualified initial public offering (“QIPO”).

 

(b) Liquidation preferences

 

In the event of (i) any liquidation, dissolution or termination event, whether voluntary or involuntary, or (ii) unless waived by the holders of at least a majority of ordinary shares and the holders of at least two thirds of the preferred shares (calculated on a fully-diluted and as-converted basis), any deemed liquidation event as defined in the Company’s shareholders agreement, such as a merger, consolidation, sale, transfer, lease, exclusive license or other disposal of all or substantially all of the assets or intellectual property of the Company or of all of its subsidiaries as a whole (“Deemed Liquidation Event”), all assets and funds legally available for distribution shall be distributed to the holders of preferred shares in preference to the holders of ordinary shares, in an amount per share equal to the applicable series issue price plus any declared but unpaid dividends (the “Preference Amount”).

 

The full preference amount is first paid to the holders of the series of preferred shares that was most recently issued then to the holders of the next level of preference in order (Series C preferred shares, Series B preferred shares, Series A preferred shares, and Series Pre-A preferred shares (ranked pari passu), which are listed in order of highest liquidation preference to lowest).

 

If there are any assets or funds remaining after the aggregate Series Pre-A Preference Amount, Series A Preference Amount, Series B Preference Amount and Series C Preference Amount have been distributed or paid in full to the applicable holders of the preferred shares, the remaining assets and funds of the Company available for distribution shall be distributed ratably among all shareholders (including the preferred shareholders) according to the relative number of ordinary shares of the Company held by such shareholder (on an as-converted basis).

 

If the available funds and assets become insufficient to satisfy the full preferential payment to the holders of a particular series of preferred shares, then such assets shall be distributed among the holders of that particular series of preferred shares, ratably in proportion to the full amounts to which they would otherwise be respectively entitled thereon.

 

(c) Redemption rights

 

Upon the occurrence of any of the following events, any holder of any other series of preferred shares is entitled to request a redemption of any of its shares.

 

(i)
the Company fails to consummate a QIPO on or before December 31, 2024 (the “Target QIPO Date”), such Target QIPO Date shall be postponed reasonably if any force majeure event adversely affects the process of the QIPO of the Company and the postponement arising therefrom is agreed by all the parties (including the preferred shareholders);

 

(ii)
the Company or any of the Co-Founders or the other group companies materially breaches its or his representations, warranties, covenants or obligations under any transaction document.

 

With the written consent of the holder(s) of more than fifty percent (50%) of the voting power of the aggregate number of a particular series of issued and outstanding preferred shares, the Company shall redeem such particular series of preferred shares, out of funds legally available therefor including the capital.

 

The redemption price for each issued and outstanding Series B and Series C preferred share (the “Series B and Series C Redemption Price”) shall be the amount equal to the sum of (i) an amount that would give an internal rate of return that equals to eight percent (8%) per annum on such Series B preferred share and Series C preferred share in respect of the Series B and Series C issue price, respectively, calculated for a period of time commencing from the Series B and Series C issue date and ending on the date that the Series B and Series C Redemption Price is paid in full by the Company, and (ii) any declared but unpaid dividends thereupon.

 

Series A Redemption Price is the amount equal to 150% of the Series A issue Price and any declared but unpaid dividends thereupon.

 

Pre-A shareholders do not have redemption rights, although they have a liquidation preference upon occurrence of any Deemed Liquidation Events.

 

(d) Dividends

 

Dividends are payable when and if declared by the Board out of funds legally available, and such dividends are not cumulative. Holders of the shares shall be entitled to receive out of any funds legally available therefor, when, as and if declared by the Board, non-cumulative dividends, as well as any non-cash dividends when, as and if declared by the Board. In the event the Company shall declare a distribution other than in cash, the holders of shares shall be entitled to a proportionate share of any such distribution when, as and if declared by the Board.

 

The Group designates the entire instruments with preferred rights described above as financial liabilities at fair value through profit or loss with the changes in the fair value recorded in the consolidated statements of loss, except for the changes in the fair value due to own credit risk, which are recorded in other comprehensive income/(loss).

 

Movements of financial instruments with preferred rights during the years ended December 31, 2019, 2020 and 2021 were as follows:

 

 

 

Fair value

 

 

 

RMB’000

 

As of January 1, 2019

 

 

573,499

 

Change in fair value recognized in profit or loss

 

 

59,397

 

Change in fair value due to foreign currency translation recognized in other comprehensive income

 

 

10,112

 

As of December 31, 2019

 

 

643,008

 

Issuance of Series C Preferred Shares

 

 

923,247

 

Change in fair value recognized in profit or loss

 

 

579,286

 

Share-based compensation to additional Series C preferred shareholder

 

 

19,655

 

Change in fair value due to foreign currency translation recognized in other comprehensive income

 

 

(93,688

)

As of December 31, 2020

 

 

2,071,508

 

Change in fair value recognized in profit or loss

 

 

674,269

 

Change in fair value due to foreign currency translation recognized in other comprehensive income

 

 

(2,152

)

Converted to ordinary shares upon IPO

 

 

(2,743,625

)

As of December 31, 2021

 

 

 

 

The Group first determined the equity value and then allocated the equity value to each element of the Group’s capital structure using either the option pricing back-solve method (“OPM”) or a hybrid method.

 

Key valuation assumptions used to determine the fair value of the financial instruments with preferred rights are as follows:

 

 

 

Year ended December 31,

 

 

2019

 

2020

DLOM

 

25.8% ~ 30.7%

 

14.0% ~ 25.8%

Expected volatility

 

55.0% ~ 60.0%

 

64.0% ~ 75.1%

Risk-Free interest rate

 

1.7% ~ 2.3%

 

0.1% ~ 0.2%

 

DLOM was estimated based on OPM. Under OPM, the cost of put option, which can hedge price changes before the privately held shares are sold, was considered as a basis to determine the DLOM.

 

Expected volatility was estimated based on the annualized standard deviation of daily stock price return of comparable companies for periods from respective valuation dates and with similar span as time to exit.

 

Risk-free interest rates were estimated based on the yield of U.S. Treasury strips as of each valuation date.

 

Sensitivity to changes in fair value

 

The Company performed sensitivity test to changes in unobservable inputs in determining the fair value of preferred shares issued by the Company. The changes in unobservable inputs risk-free interest rate and expected volatility will result in a higher or lower fair value measurement. The increase in the fair value of financial instruments with preferred rights would increase the fair value loss in the consolidated statements of loss. When performing the sensitivity test, management applied an increase or decrease to each unobservable input, which represents management’s assessment of reasonably possible change to these unobservable inputs, and effect of those changes to the fair value of financial instruments with preferred rights is as set forth below:

 

If the volatility had increased/decreased 5%, the loss before income tax for the year ended December 31, 2020 would have been approximately RMB 18.0 million lower/RMB 18.1 million higher.

 

If the risk-free interest rate had increased/decreased 1%, the loss before income tax for the year ended December 31, 2020 would have been approximately RMB 887,000 higher/RMB 1,712,000 lower.

 

The Group used the IPO price (USD 17) to determine the fair value of the financial instruments with preferred rights on March 19, 2021. Upon completion of the IPO, such preferred shares were converted to ordinary share on a one-for-one basis.

XML 75 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Cash Flow Information
12 Months Ended
Dec. 31, 2021
Disclosure Of Cash Flow Information [Abstract]  
Cash Flow Information

25. Cash Flow Information

 

(a) Cash used in operations

 

 

 

 

 

Year Ended December 31,

 

 

 

Notes

 

2019

 

 

2020

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Loss before income tax

 

 

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,305,127

)

Adjustments for:

 

 

 

 

 

 

 

 

 

 

 

—Interest for lease liabilities

 

9

 

 

53

 

 

 

42

 

 

 

44

 

—Investment income from wealth management products

 

8

 

 

(798

)

 

 

(672

)

 

 

(436

)

—Amortization of intangible assets

 

 

 

 

 

 

 

7

 

 

 

43

 

—Depreciation of property, plant and equipment

 

12

 

 

383

 

 

 

955

 

 

 

3,130

 

—Depreciation of rights-of-use assets

 

14

 

 

407

 

 

 

481

 

 

 

909

 

—Share-based compensation expenses

 

22

 

 

3,875

 

 

 

25,190

 

 

 

57,863

 

—Net foreign exchange differences

 

 

 

 

(1,368

)

 

 

6,772

 

 

 

3,309

 

—Fair value changes of financial instruments with preferred rights

 

24

 

 

59,397

 

 

 

579,286

 

 

 

674,269

 

—Issuance cost of financial instruments with preferred rights

 

9

 

 

 

 

 

2,851

 

 

 

 

—Loss on disposal of property, plant and equipment

 

 

 

 

 

 

 

 

 

 

250

 

Changes in working capital

 

 

 

 

 

 

 

 

 

 

 

—Other receivables and prepayments

 

 

 

 

(3,026

)

 

 

(9,350

)

 

 

(16,116

)

—Other non-current assets

 

 

 

 

(1,603

)

 

 

(3,906

)

 

 

(8,206

)

—Other payables and accruals

 

 

 

 

1,698

 

 

 

8,558

 

 

 

(11,459

)

—Trade payables

 

 

 

 

19,351

 

 

 

1,850

 

 

 

56,601

 

Net cash used in operations

 

 

 

 

(90,256

)

 

 

(167,161

)

 

 

(544,926

)

 

(b) Non-cash investing and financing activities

 

 

 

 

 

Year Ended December 31,

 

 

 

Notes

 

2019

 

 

2020

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Construction payables

 

 

 

 

 

 

 

 

16,576

 

Fair value changes of financial instruments with preferred rights

 

24

 

 

59,397

 

 

 

579,286

 

 

 

674,269

 

Share-based compensation to additional Series C preferred shareholder

 

22

 

 

 

 

 

19,655

 

 

 

 

 

 

 

 

 

59,397

 

 

 

598,941

 

 

 

690,845

 

 

 

(c) Reconciliation of liabilities arising from financing activities

 

 

 

Financial

 

 

 

 

 

 

instruments with

 

 

 

 

 

 

preferred rights

 

 

Lease liability

 

 

 

RMB’000

 

 

RMB’000

 

At January 1, 2019

 

 

573,499

 

 

 

1,274

 

Cash flows

 

 

 

 

 

(445

)

Interest expenses

 

 

 

 

 

53

 

Differences of foreign currency translation

 

 

10,112

 

 

 

 

Changes in fair value

 

 

59,397

 

 

 

 

At December 31, 2019

 

 

643,008

 

 

 

882

 

Cash flows

 

 

923,247

 

 

 

(538

)

New leases

 

 

 

 

 

527

 

Interest expenses

 

 

 

 

 

42

 

Differences of foreign currency translation

 

 

(93,688

)

 

 

 

Changes in fair value

 

 

579,286

 

 

 

 

Share-based compensation to additional Series C preferred shareholder

 

 

19,655

 

 

 

 

At December 31, 2020

 

 

2,071,508

 

 

 

913

 

Cash flows

 

 

 

 

 

(805

)

New leases

 

 

 

 

 

641

 

Interest expenses

 

 

 

 

 

44

 

Differences of foreign currency translation

 

 

(2,152

)

 

 

 

Changes in fair value

 

 

674,269

 

 

 

 

Conversion to ordinary shares

 

 

(2,743,625

)

 

 

 

At December 31, 2021

 

 

 

 

 

793

 

XML 76 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments
12 Months Ended
Dec. 31, 2021
Capital Commitments [Abstract]  
Commitments

26. Commitments

 

Capital commitments

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Equipment and intangible assets

 

 

 

 

 

 

- Contracted but not provided for

 

 

23,243

 

 

 

146,878

 

 

As of December 31, 2021, the Group had capital commitments of approximately RMB 146.9 million, primarily in connection with the construction of campus in Taicang in the PRC. As of December 31, 2020, the Group had capital commitments of approximately RMB 23.2 million, primarily in connection with the purchase of equipment and improvement of the Group’s laboratory in Suzhou in the PRC.

 

Other commitments

 

In December 2021, the Company entered into the office lease agreement for approximately 3,600 square feet in San Diego, California, and the lease commenced in March 2022. The aggregate lease obligation over the three-year lease term is approximately $0.6 million.
XML 77 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

27. Related Party Transactions

 

Parties are considered to be related if one party has the ability, directly or indirectly, to control or exercise significant influence over the other party. Parties are also considered to be related if they are subject to common control. Members of key management of the Group and their close family members are also considered as related parties.

 

Names of related parties

 

Nature of relationship

Hangzhou Simo Company Limited

 

Entity controlled by a director of the Company

Frontage Laboratories (Suzhou) Company Limited

 

Entity controlled by a director of the Company

Shanghai Tigermed Consulting Company Limited

 

Entity controlled by a director of the Company

Hangzhou Tigermed Consulting Company Limited

 

Entity controlled by a director of the Company

Beijing Medical Development (Suzhou) Company Limited

 

Entity controlled by a director of the Company

 

 

As the former director Xiaoping Ye resigned on February 2, 2021, the above companies were no longer considered as related parties for the year ended December 31, 2021.

 

In addition to other related party transactions and balances disclosed elsewhere in this financial information, the following is a summary of significant transactions and balances with related parties during the years ended December 31, 2019, 2020 and 2021 and at each year end.

 

(a)
Interests in subsidiaries of the Company are set out in Note 1.1.

 

(b)
Significant transactions with related parties

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Purchase of clinical trials related services

 

 

 

 

 

 

 

 

 

Hangzhou Simo Company Limited

 

 

5,601

 

 

 

5,948

 

 

 

 

Frontage Laboratories (Suzhou) Company Limited

 

 

2,346

 

 

 

2,157

 

 

 

 

Hangzhou Tigermed Consulting Company Limited

 

 

810

 

 

 

1,069

 

 

 

 

Beijing Medical Development (Suzhou) Company Limited

 

 

186

 

 

 

301

 

 

 

 

Shanghai Tigermed Consulting Company Limited

 

 

891

 

 

 

34

 

 

 

 

 

(c)
Balances with related parties

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

(i) Prepayments

 

 

 

 

 

 

Hangzhou Tigermed Consulting Company Limited

 

 

850

 

 

 

 

Hangzhou Simo Company Limited

 

 

507

 

 

 

 

 

All the above balances with related parties were unsecured, interest-free and had no fixed repayment terms.

 

(d)
Key management personnel compensation

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Wages, salaries and bonuses

 

 

3,358

 

 

 

8,013

 

 

 

18,100

 

Share-based compensation expenses

 

 

2,749

 

 

 

1,148

 

 

 

28,266

 

Contributions to defined benefit plan (i)

 

 

1,140

 

 

 

971

 

 

 

 

Welfare, housing funds and other

 

 

216

 

 

 

180

 

 

 

308

 

 

 

 

7,463

 

 

 

10,312

 

 

 

46,674

 

 

(i)
The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder following termination. The Company will have no further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk. The benefit obligation was determined using certain assumptions, including life annuity factor and specified interest rate, which were published by the U.S. Internal Revenue Service.

(e) Shares repurchase from key management personnel

 

In March 2021, the Group repurchased 20,765 ordinary shares from one of the co-founders (see Note 19).

XML 78 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Events After the Reporting Period
12 Months Ended
Dec. 31, 2021
Disclosure Of Nonadjusting Events After Reporting Period [Abstract]  
Events After the Reporting Period

28. Events After the Reporting Period

In addition to those disclosed elsewhere in these financial statements, the following events occurring after the reporting periods are noted.

From January to March 2022, the Group granted 2,044,741 ordinary share options to its employees and directors with service based vesting conditions and weighted average exercise price of USD 4.45.

XML 79 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Restricted Net Assets and Parent Company Only Condensed Financial Information
12 Months Ended
Dec. 31, 2021
Restricted Net Assets And Parent Company Condensed Financial Information [Abstract]  
Restricted Net Assets and Parent Company Only Condensed Financial Information

29. Restricted net Assets and Parent Company only Condensed Financial Information

The Company’s ability to pay dividends is primarily dependent on the Company receiving distributions of funds from its subsidiaries. Relevant PRC statutory laws and regulations permit payments of dividends by the Company’s subsidiaries in the PRC only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations.

In accordance with the PRC laws and regulations, statutory reserve funds shall be made and can only be used for specific purposes and are not distributable as cash dividends. As a result of these PRC laws and regulations that require annual appropriation of 10% of net after-tax profits to be set aside prior to payment of dividends as statutory surplus fund, unless such reserve fund reaches 50% of the entity’s registered capital, the Group’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.

The Company performs a test on the restricted net assets of its consolidated subsidiaries (the “Restricted Net Assets”) in accordance with Securities and Exchange Commission Regulation S-X Section 4-08 (e) (3) “General Notes to Financial Statements” and concluded that the condensed financial information for the parent company is required to be presented as of December 31, 2020 and 2021 and for the years ended December 31, 2019, 2020 and 2021.

 

Furthermore, cash transfers from the Company’s PRC subsidiaries to their parent companies outside of China are subject to PRC government control of currency conversion. Shortages in the availability of foreign currency may restrict the ability of the PRC subsidiaries and consolidated affiliated entities to remit sufficient foreign currency to pay dividends or other payments to the Company, or otherwise satisfy their foreign currency denominated obligations.

(a) Condensed balance sheets

 

 

As of December 31,

 

 

2020

 

 

2021

 

 

2021

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

ASSETS

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

 

 

Interest in a subsidiary

 

472,273

 

 

 

1,177,380

 

 

 

184,667

 

Total non-current assets

 

472,273

 

 

 

1,177,380

 

 

 

184,667

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

885,611

 

 

 

1,464,637

 

 

 

229,722

 

Other receivables

 

84,278

 

 

 

86,352

 

 

 

13,544

 

Other current assets

 

1,097

 

 

 

 

 

 

 

Total current assets

 

970,986

 

 

 

1,550,989

 

 

 

243,266

 

Total assets

 

1,443,259

 

 

 

2,728,369

 

 

 

427,933

 

LIABILITIES

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

Financial instruments with preferred rights

 

2,071,508

 

 

 

 

 

 

 

Total non-current liabilities

 

2,071,508

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Trade payables

 

 

 

 

49

 

 

 

7

 

Other payables and accruals

 

6,864

 

 

 

34,190

 

 

 

5,364

 

Total current liabilities

 

6,864

 

 

 

34,239

 

 

 

5,371

 

Total liabilities

 

2,078,372

 

 

 

34,239

 

 

 

5,371

 

Net (liabilities)/assets

 

(635,113

)

 

 

2,694,130

 

 

 

422,562

 

SHAREHOLDERS’ (DEFICIT)/EQUITY

 

 

 

 

 

 

 

 

Share capital

 

24

 

 

 

66

 

 

 

10

 

Share premium

 

41,466

 

 

 

4,094,434

 

 

 

642,194

 

Treasury shares

 

(3

)

 

 

(1,164

)

 

 

(183

)

Other reserves

 

(5,732

)

 

 

(10,359

)

 

 

(1,625

)

Accumulated losses

 

(670,868

)

 

 

(1,388,847

)

 

 

(217,834

)

Total shareholders’ (deficit)/equity

 

(635,113

)

 

 

2,694,130

 

 

 

422,562

 

 

(b) Condensed statements of loss

 

 

Year Ended December 31,

 

 

2019

 

 

2020

 

 

2021

 

 

2021

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

Administrative expenses

 

(23

)

 

 

(29,540

)

 

 

(43,710

)

 

 

(6,856

)

Operating loss

 

(23

)

 

 

(29,540

)

 

 

(43,710

)

 

 

(6,856

)

Finance income/(costs)—net

 

335

 

 

 

(2,758

)

 

 

 

 

 

 

Fair value loss of financial instruments with preferred rights

 

(59,397

)

 

 

(579,286

)

 

 

(674,269

)

 

 

(105,756

)

Loss before income tax

 

(59,085

)

 

 

(611,584

)

 

 

(717,979

)

 

 

(112,612

)

Income tax expense

 

 

 

 

 

 

 

 

 

 

 

Loss for the year

 

(59,085

)

 

 

(611,584

)

 

 

(717,979

)

 

 

(112,612

)

 

(c) Condensed statements of cash flows

 

 

Year Ended December 31,

 

 

2019

 

 

2020

 

 

2021

 

 

2021

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

Net cash from/(used in) operating activities

 

249

 

 

 

(4,766

)

 

 

(31,025

)

 

 

(4,866

)

Net cash used in investing activities

 

(159,057

)

 

 

(204,170

)

 

 

(672,529

)

 

 

(105,483

)

Net cash generated from financing activities

 

99,990

 

 

 

934,284

 

 

 

1,319,418

 

 

 

206,945

 

Net (decrease)/increase in cash and cash equivalents

 

(58,818

)

 

 

725,348

 

 

 

615,864

 

 

 

96,596

 

Cash and cash equivalents at the beginning of year

 

267,665

 

 

 

213,253

 

 

 

885,611

 

 

 

138,904

 

Effects of exchange rate changes on cash and cash equivalents

 

4,406

 

 

 

(52,990

)

 

 

(36,838

)

 

 

(5,778

)

Cash and cash equivalents at end of year

 

213,253

 

 

 

885,611

 

 

 

1,464,637

 

 

 

229,722

 

XML 80 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Disclosure Of Initial Application Of Standards Or Interpretations [Abstract]  
Basis of preparation

2.1 Basis of preparation

The Group’s consolidated financial statements were prepared in accordance with International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”). The Group adopted and transitioned to IFRS issued by IASB on January 1, 2018. The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through profit or loss and financial instruments with preferred rights. In preparing its consolidated financial statements prepared under IFRS, the Group early adopted IFRS 9 Financial Instruments (“IFRS 9”) and IFRS 16 Leases (“IFRS 16”) on January 1, 2018.

The Group has applied the following standards and amendments for the first time for their annual reporting period commencing January 1, 2021, which did not have any material impact on the consolidated financial statements:

Amendment to IFRS 16, ‘Leases’ – COVID-19 related rent concessions – Extension of the practical expedient.

The consolidated financial statements for the years ended December 31, 2019, 2020 and 2021 were authorized for issue by the Company’s board of directors (the “Board”) on March 31, 2022.

Liquidity

As of December 31, 2021, the Group had net assets of RMB 1,735.8 million, and accumulated losses of RMB 2,378.2 million. For the year ended December 31, 2021, the Group had net operating loss of RMB 631.4 million and net operating cash outflow of RMB 544.9 million. The principal sources of funding have historically been continuous cash contributions from equity holders and preferred shareholders. The cumulative contributions up through December 31, 2021 approximated USD 440.1 million, among which included USD 219.9 million of proceeds from issuance of ordinary shares in connection with the IPO or RMB 1,431.8 million based on the exchange rate as of the date of the IPO. As of December 31, 2021, the Group had a cash and cash equivalents balance of RMB 1,706.9 million, which it believes to be sufficient available financial resources to meet its obligations becoming due and working capital requirements in the next twelve months from the date of issuance of these financial statements. Accordingly, the Group considers that it is appropriate to prepare the consolidated financial information on a going concern basis.

Impact of COVID-19

In December 2019, a novel strain of coronavirus was reported in Wuhan, China and on March 11, 2020 the WHO declared COVID-19 a pandemic. The COVID-19 pandemic has resulted in a widespread health crisis and numerous disease control measures being taken to limit its spread. As the pandemic continues its impact throughout the world, the healthcare systems of the various countries in which the Group is conducting ongoing clinical trials of CBP-201 and CBP-307 have and may continue to experience great disruption. Enrollment of the Group’s Phase 2 clinical trial of CBP-307 in patients in China was prematurely terminated due to challenges in recruitment caused by the COVID-19 pandemic.

The Group will continue to monitor and assess the impact of the ongoing development of the pandemic on the Group’s clinical trials and for any impact to its financial position and operating results.

New and amended standards and interpretations not yet adopted by the Group

2.2 New and amended standards and interpretations not yet adopted by the Group

The Group has not applied the following new and revised IFRSs that have been issued but are not yet effective in the consolidated financial statements.

 

 

 

Effective for annual periods beginning on or after

 

Scope amendments to IFRS 3, IAS 16, IAS 37 and some annual improvements on IFRS 1, IFRS 9, IAS 41 and IFRS 16

 

January 1, 2022

 

Narrow scope amendments to IAS 1, Practice statement 2 and IAS 8

 

January 1, 2023

 

Amendment to IAS 12 – Deferred tax related to assets and liabilities arising from a single transaction

 

 January 1, 2023

 

Amendments to IAS 1, Presentation of financial statements’, on classification of liabilities

 

January 1, 2024

 

 

The Group expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a material impact on disclosures or amounts reported in the Group’s consolidated financial statements in the period of initial application and future reporting periods.

Principles of consolidation

2.3 Principles of consolidation

Subsidiaries

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

Intra-group transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group’s accounting policies.

Separate financial statements

2.4 Separate financial statements

Investments in subsidiaries are accounted for at cost less impairment. Cost includes direct attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividends received and receivable.

Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee’s net assets including goodwill.

Foreign currency translation

2.5 Foreign currency translation

(a) Functional and presentation currency

 

The consolidated financial statements of the Group are presented in RMB as the historical records for its entities were set-up for consolidations in RMB.

 

The functional currency of the Company is USD. Other subsidiaries have functional currencies in USD, RMB and Australian dollars.

 

(b) Transactions and balances

 

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.

 

Since the Group has no borrowings, all foreign exchange gains or losses are presented in the consolidated statements of loss on a net basis within other gains/(losses)-net.

 

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income.

(c) Group companies

 

The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

 

assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;
income and expenses for each statement of loss and comprehensive income/(loss) are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions); and
all resulting currency translation differences are recognized in other comprehensive income/loss.

 

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.

 

(d) Convenience translation

 

Translations of the consolidated balance sheet, the consolidated statement of loss, consolidated statement of comprehensive loss and consolidated statement of cash flows from RMB into USD as of and for the year ended December 31, 2021 are solely for the convenience of the readers and calculated at the rate of USD1.00=RMB 6.3757, representing the exchange rate as of December 31, 2021 set forth in the China Foreign Exchange Trade System. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into USD at that rate, or at any other rate, on December 31, 2021.

Property, plant and equipment

2.6 Property, plant and equipment

Property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

 

Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

 

The Group’s assets under construction represents buildings and equipment under construction and pending installation, and is stated at cost less accumulated impairment losses, if any. Costs include construction and acquisition costs. No provision for depreciation is made on assets under construction until such time as the assets are completed and ready for its intended use. Once the asset becomes available for use, it is transferred to the appropriate category of assets.

 

Depreciation is calculated using the straight-line method to allocate the cost, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements, the shorter lease term as follows:

 

Assets

 

Useful life

Laboratory equipment

 

5-10 years

Leasehold improvements

 

Shorter of lease term or 5 years

Office equipment and furniture

 

3-5 years

 

The assets’ residual values and useful lives are reviewed and adjusted if appropriate at the end of each reporting period.

 

An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount (Note 2.8).

 

Gains and losses on disposals are determined by comparing proceeds with carrying amount and are recognized within other gains/(losses)—net in the statements of loss.

Intangible assets

2.7 Intangible assets

 

Software

 

Acquired software licenses are capitalized on the basis of the costs incurred to acquire and bring the specific software into usage. These costs are amortized using the straight-line method over their estimated useful lives of approximately 10 years. Costs associated with maintaining software programs are recognized as expense as incurred.

Impairment of non-financial assets

2.8 Impairment of non-financial assets

 

Non-financial assets other than goodwill and intangible assets that have an indefinite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

Investments and other financial assets

2.9 Investments and other financial assets

 

(a) Classification

 

The Group classifies its financial assets in the following measurement categories:

 

those to be measured subsequently at fair value (either through other comprehensive income (“OCI”) or through profit or loss), and
those to be measured at amortized cost.

 

The classification depends on the entity’s business model for managing the financial assets and the contractual terms of the cash flows.

 

For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through OCI (“FVOCI”).

 

The Group reclassifies debt investments when and only when its business model for managing those assets changes.

 

(b) Recognition and derecognition

 

Regular way purchases and sales of financial assets are recognized on trade date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

 

(c) Measurement

 

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (“FVPL”), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial asset carried at FVPL are expensed in profit or loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

(i)
Debt instruments

 

Subsequent measurement of debt instruments depends on the Group’s business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the Group classifies its debt instruments:

Amortized cost: Assets that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortized cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains/(losses), together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the statements of loss.
FVOCI: Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets’ cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses which are recognized in profit or loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains/(losses). Interest income from these financial assets is included in finance income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains/(losses) and impairment expenses are presented as a separate line item in the statements of loss.
FVPL: Assets that do not meet the criteria for amortized cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured at FVPL is recognized in profit or loss and presented net within other gains/(losses) in the period in which it arises.
(ii)
Equity instruments

 

The Group subsequently measures all equity investments at fair value. Where the Group’s management has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognized in profit or loss as other income when the Group’s right to receive payments is established.

 

Changes in the fair value of financial assets at FVPL are recognized in other gains/(losses) in the statements of loss as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.

 

There were no equity investments during the reporting periods.

 

(d) Impairment

 

The Group assesses on a forward-looking basis the expected credit loss associated with its debt instruments carried at amortized cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk refer to Note 3.1(b) for further details.

Cash and cash equivalents

2.11 Cash and cash equivalents

 

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Share capital

2.12 Share capital

 

Ordinary shares are classified as equity. Mandatorily redeemable preferred shares are classified as liabilities. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

 

Where any Group company purchases the Company’s equity instruments, for example as the result of a share buy-back or a share-based payment plan, the consideration paid, including any directly attributable incremental costs (net of income taxes), is deducted from equity attributable to the owners of the Group as treasury shares until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the owners of the Group.

 

Shares held by Connect Union, which was established for the purpose of holding shares for the share incentive plans are disclosed as treasury shares and deducted from contributed equity.

Trade and other payables

2.13 Trade and other payables

 

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.

Financial instruments with preferred rights

2.14 Financial instruments with preferred rights

 

Financial instruments with preferred rights are compound instruments with discretionary dividend right. The Company elected to designate the entire hybrid contracts that include host contract and embedded derivatives as financial liabilities at fair value through profit or loss considering the fact that the instruments also have contingent settlement provisions. They are initially recognized at fair value. Any directly attributable transaction costs are expensed in the consolidated statements of loss.

 

Subsequent to initial recognition, the amount of change in the fair value of the financial instruments with preferred rights that is attributable to changes in the credit risk of that liability shall be presented in OCI with the remaining changes in fair value recognized as “fair value loss of financial instruments with preferred rights” in profit or loss.

 

As of December 31, 2020, management believed that there were no triggering events resulting in redemption in 12 months from the end of the reporting period and so the financial instruments with preferred rights were classified as non-current liabilities unless the Group had an obligation to settle the liabilities within 12 months after the end of the reporting period.

 

Dividends on financial instruments with preferred rights classified as financial liabilities are normally included in financial costs.

 

On March 19, 2021, upon completion of the IPO, all issued and outstanding preferred shares were converted to ordinary share on a one-for-one basis.

Current and deferred income tax

2.15 Current and deferred income tax

 

The income tax expense or credit for the period is the tax payable on the taxable income of current period based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

 

Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively.

 

(a) Current income tax

 

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

 

Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.

 

(b) Deferred income tax

 

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

 

Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.

 

Deferred tax liabilities and assets are not recognized for temporary differences between the carrying amount and tax bases of investments in foreign operations where the Group is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

 

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.

Investment allowances and similar tax incentives

 

Companies within the Group may be entitled to claim special tax deductions for investments in qualifying assets or in relation to qualifying expenditure (e.g. the research and development tax incentive or other investment allowances). The Group accounts for such allowances as tax credits, which means that the allowance reduces income tax payable and current tax expense. A deferred tax asset is recognized for unclaimed tax credits that are carried forward as deferred tax assets.

Employee Benefits

2.16 Employee benefits

 

(a) Short-term obligations

 

Liabilities for wages and salaries, including non-monetary benefits and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in other payables and accruals in the balance sheet.

 

(b) Defined benefit plans

 

The liability or asset recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method.

 

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms approximating to the terms of the related obligation. In countries where there is no deep market in such bonds, the market rates on government bonds are used.

 

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of loss.

 

Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income. They are included in retained earnings in the statement of changes in equity and in the balance sheet.

 

Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognized immediately in profit or loss as past service costs.

 

(c) Defined contribution plans

 

For defined contribution plans, including those under Section 401(k) of the U.S. Internal Revenue Code, the Group pays contributions to publicly administered pension insurance plans on a mandatory, contractual or voluntary basis. The Group has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.

 

The members of the Group incorporated in the PRC contribute based on a certain percentage of the salaries of their employees to a defined contribution retirement benefit plan organized by relevant government authorities in the PRC on a monthly basis. The government authorities undertake to assume the retirement benefit obligations payable to all existing and further retired employees under these plans and the Group has no further obligation for post-retirement benefits beyond the contributions made. Contributions to these plans are expensed as incurred. Assets of the plans are held and managed by government authorities and are separate from those of the Group.

 

(d) Housing funds and medical insurance

 

The PRC employees of the Group are entitled to participate in various government-supervised housing funds and medical insurance. The Group contributes on a monthly basis to these funds based on a certain percentage of the salaries of the employees, subject to certain ceilings. The Group’s liability in respect of these funds is limited to the contribution payable in each period and recognized as employee benefit expense when they are due.

Share-based compensation

2.17 Share-based compensation

 

The Group operates an equity-settled share-based compensation plan, under which the Group receives services from employees, directors and consultants. The consultants’ work for the Group is under the Group’s direction in the same way as employees and the services rendered by the consultants are similar to those rendered by the Group’s employees.

 

The fair value of options granted under the share incentive plans is recognized as an employee benefits expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:

 

including any market performance conditions (e.g. the entity’s share price);

 

excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the entity over a specified time period); and

 

including the impact of any non-vesting conditions (e.g. the requirement for employees to save or hold shares for a specific period of time).

 

The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. The Group recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.

Research and development expenses

2.18 Research and development expenses

 

The Group incurs costs and efforts on research and development activities. Research expenditures are recorded as an expense in the period the expenditure is incurred. Elements of research and development expenses primarily include (1) expenses related to preclinical testing of the Group’s technologies under development and clinical trials such as payments to CRO investigators and clinical trial sites that conduct the clinical studies; (2) consultant service related to the design of clinical trials and data analysis, (3) payroll and other related expenses of personnel engaged in research and development activities, (4) expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5) other research and development expenses.

 

The Group estimates preclinical and clinical study and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. The Group estimates these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Group will adjust the accrual accordingly. Payments made in advance for the related services are recorded as prepayments in the consolidated balance sheets until the services are rendered.

 

Development costs are recognized as assets if they can be directly attributable to a newly developed service or product and all the following criteria are met or exist:

 

the technical feasibility to complete the development project so that it will be available for use or sale;
the intention to complete the development project to use or sell the product;
the ability to use or sell the product;
the manner in which the development project will generate probable future economic benefits for the Group;
the availability of adequate technical, financial and other resources to complete the development project and use or sell the product; and
the expenditure attributable to the asset during its development can be reliably measured.

 

Research and development expenses are charged to expense as incurred for all periods presented because they have not met all of the criteria stated above.

Administrative expenses

2.19 Administrative expenses

 

Administrative expenses primarily include payroll and related expenses for employees involved in general corporate functions including finance, legal and human resources, rental and depreciation expenses related to facilities and equipment used by these functions, professional service expenses and other general corporate related expenses.

Interest Income

2.20 Interest income

 

Interest income from financial assets at FVPL is included in the net fair value gains/(losses) on these assets, see Note 9 below. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset except for financial assets that subsequently become credit-impaired. For credit-impaired financial assets, the effective interest rate is applied to the net carrying amount of the financial asset (after deduction of the loss allowance). Interest income is presented as finance income where it is earned from financial assets that are held for cash management purposes.

Government grants

2.21 Government grants

 

Grants from the government are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group is expected to comply with all required conditions. Government grants received in advance of costs being incurred are deferred until the associated costs are recognized. Grants that compensate the Group for the cost of an asset initially are presented as deferred income and are recognized as income in consolidated statements of loss on a straight-line basis over the useful life of the associated asset.

Leases

2.22 Leases

 

The Group leases offices and the rental contracts are typically made for fixed periods of approximately 2 to 4 years. All land in the PRC is owned by the mainland PRC government. The PRC government may sell land use rights for a specified period of time. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as right-of-use assets on the balance sheet. The right-of-use assets are amortized over the remaining lease term. In 2021, the Group acquired a land use right from the PRC government for 50 years.

 

Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. However, for leases of real estate for which the Group is a lessee, it has elected not to separate lease and non-lease components and instead accounts for these as a single lease component.

 

Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.

 

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:

 

fixed payments (including in-substance fixed payments), less any lease incentives receivable;
variable lease payment that are based on an index or a rate, initially measured using the index or rate as of the commencement date;
amounts expected to be payable by the Group under residual value guarantees;
the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and
payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option.

 

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

 

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee’s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

 

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

 

Right-of-use assets are measured at cost comprising the following:

 

the amount of the initial measurement of lease liability;

 

any lease payments made at or before the commencement date less any lease incentives received;

 

any initial direct costs; and

 

restoration costs.

 

Right-of-use assets are generally depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset’s useful life.

 

Payments associated with short-term leases and all leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less without a purchase option.

Segment Information

2.23 Segment information

 

Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Group are the Co-Founders of the Company. The Group does not divide its operations into different segments and the CODM operates and manages the Group’s entire operations as one segment, which is consistent with the Group’s internal organization and reporting system. The Group does not have any revenue and substantially all non-current assets outside of the country of domicile are in China.

Loss per share

2.24 Loss per share

 

(i)
Basic loss per share

 

Basic loss per share is calculated by dividing:

 

the loss attributable to owners of the Company, excluding any costs of servicing equity other than ordinary shares;
by the weighted average number of ordinary shares outstanding during the financial year and excluding treasury shares

 

(ii)
Diluted loss per share

 

Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account:

 

the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and

 

the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares. 
XML 81 R37.htm IDEA: XBRL DOCUMENT v3.22.1
General Information, Reorganization and Basis of Presentation (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of General Information Reorganization And Basis Of Presentation [Abstract]  
Summary of Direct or Indirect Interests in Principal Subsidiaries

As of December 31, 2021, the Group had direct or indirect interests in the following principal subsidiaries:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Company name

 

Principal activities

 

Place and date of incorporation

 

Attributable equity interest to the Group

 

Directly Held:

 

 

 

 

 

 

 

Connect Biopharma HongKong Limited (“Connect HK”)

 

Investment holding

 

Hong Kong/December 1, 2015

 

 

100

%

Indirectly held:

 

 

 

 

 

 

 

Connect Biopharm LLC (“Connect US”)

 

Pharmaceutical R&D

 

San Diego, United States of America January 24, 2012

 

 

100

%

Connect Biopharma Australia PTY LTD (“Connect AU”)

 

Pharmaceutical R&D

 

Prahran, Australia/July 18, 2014

 

 

100

%

Suzhou Connect Biopharma Co., Ltd. (“Connect SZ”)

 

Pharmaceutical R&D

 

Suzhou, PRC/May 2, 2012

 

 

100

%

Connect Biopharma (Shanghai) Co., Ltd

 

Pharmaceutical R&D

 

Shanghai, PRC/October 23, 2015

 

 

100

%

Connect Biopharma (Beijing) Co., Ltd

 

Pharmaceutical R&D

 

Beijing, PRC/July 9, 2019

 

 

100

%

Connect Biopharma (Shenzhen) Co., Ltd

 

Dormant

 

Shenzhen, PRC/November 15, 2021

 

 

100

%

XML 82 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of Initial Application Of Standards Or Interpretations [Abstract]  
Summary of property, plant and equipment useful life

Depreciation is calculated using the straight-line method to allocate the cost, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements, the shorter lease term as follows:

 

Assets

 

Useful life

Laboratory equipment

 

5-10 years

Leasehold improvements

 

Shorter of lease term or 5 years

Office equipment and furniture

 

3-5 years

 

XML 83 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments and Risk Management (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of Financial Instruments [Abstract]  
Summary of Exposure to Foreign Currency Risk The Group’s exposure to foreign currency risk at the end of the reporting periods, expressed in RMB, was as follows:

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Cash and cash equivalents

 

 

65,791

 

 

 

150,640

 

Summary of Aggregate Net Foreign Exchange Gains/(Losses) Recognized in Profit or Loss

The aggregate net foreign exchange gains/(losses) recognized in profit or loss were:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Net foreign exchange gains/(losses) included in other gains/(losses)—net

 

 

2,252

 

 

 

(6,772

)

 

 

(3,309

)

Summary of Financial Liabilities into Maturity Groupings Based on Remaining Period to Contractual Maturity Date

The table below analyzes the Group’s financial liabilities into relevant maturity groupings based on the remaining period at each year-end date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows except for financial instruments with preferred rights, which are presented on a fair value basis. The maturity dates are determined by the terms in financing agreements presented in Note 24(c) as management considers the other redemption terms are not probable to occur.

 

 

 

As of December 31, 2020

 

 

 

 

 

 

Between

 

 

Between

 

 

More

 

 

 

 

 

 

Less Than

 

 

1 and

 

 

2 and

 

 

Than

 

 

 

 

 

 

1 Year

 

 

2 Years

 

 

5 Years

 

 

5 Years

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Financial instruments with preferred rights

 

 

 

 

 

 

 

 

2,071,508

 

 

 

 

 

 

2,071,508

 

Trade payables

 

 

24,638

 

 

 

 

 

 

 

 

 

 

 

 

24,638

 

Other payables

 

 

8,631

 

 

 

 

 

 

 

 

 

 

 

 

8,631

 

Lease liabilities

 

 

633

 

 

 

225

 

 

 

94

 

 

 

 

 

 

952

 

Total

 

 

33,902

 

 

 

225

 

 

 

2,071,602

 

 

 

 

 

 

2,105,729

 

 

 

 

As of December 31, 2021

 

 

 

 

 

 

Between

 

 

Between

 

 

More

 

 

 

 

 

 

Less Than

 

 

1 and

 

 

2 and

 

 

Than

 

 

 

 

 

 

1 Year

 

 

2 Years

 

 

5 Years

 

 

5 Years

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Trade payables

 

 

81,195

 

 

 

 

 

 

 

 

 

 

 

 

81,195

 

Other payables

 

 

21,456

 

 

 

 

 

 

 

 

 

 

 

 

21,456

 

Lease liabilities

 

 

653

 

 

 

186

 

 

 

 

 

 

 

 

 

839

 

Total

 

 

103,304

 

 

 

186

 

 

 

 

 

 

 

 

 

103,490

 

 

Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques The table below analyzes the Group’s financial instruments carried at fair value as of December 31, 2020 by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorized into three levels within a fair value hierarchy as follows:
(i)
Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).
(ii)
Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).
(iii)
Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Financial assets at fair value through profit or loss

 

 

 

 

 

 

 

 

13,068

 

 

 

13,068

 

Total assets

 

 

 

 

 

 

 

 

13,068

 

 

 

13,068

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Financial instruments with preferred rights

 

 

 

 

 

 

 

 

2,071,508

 

 

 

2,071,508

 

Total liabilities

 

 

 

 

 

 

 

 

2,071,508

 

 

 

2,071,508

 

Summary of Changes in Level 3 Instruments of Short-term Investment

The following table presents the changes in level 3 instruments of short-term investment in wealth management products for the years ended December 31, 2019, 2020 and 2021.

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Financial assets at fair value through profit or loss

 

 

 

 

 

 

 

 

 

Opening balance

 

 

27,565

 

 

 

30,632

 

 

 

13,068

 

Additions

 

 

163,000

 

 

 

106,600

 

 

 

114,500

 

Settlements

 

 

(160,731

)

 

 

(124,836

)

 

 

(128,004

)

Investment income credited to profit or loss (Note 8)*

 

 

798

 

 

 

672

 

 

 

436

 

Closing balance

 

 

30,632

 

 

 

13,068

 

 

 

 

*Includes unrealized gains recognized in profit or loss attributable to balances held at the end of the reporting period

 

 

132

 

 

 

68

 

 

 

 

XML 84 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Expenses by Nature (Tables)
12 Months Ended
Dec. 31, 2021
Expense By Nature [Abstract]  
Summary of Expenses by Nature

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Clinical trials related expenses

 

 

82,046

 

 

 

107,440

 

 

 

424,724

 

Employee benefit expenses (Note 6)

 

 

15,098

 

 

 

27,243

 

 

 

120,173

 

Consultancy fee (i)

 

 

12,011

 

 

 

31,784

 

 

 

69,498

 

R&D materials and consumable supplies

 

 

988

 

 

 

2,127

 

 

 

13,718

 

Depreciation and amortization

 

 

790

 

 

 

1,436

 

 

 

4,082

 

Office expenses

 

 

2,424

 

 

 

3,052

 

 

 

3,653

 

Expense related to Series C financing (ii)

 

 

 

 

 

19,655

 

 

 

 

Others

 

 

2,770

 

 

 

5,915

 

 

 

4,618

 

 

 

 

116,127

 

 

 

198,652

 

 

 

640,466

 

 

(i)
The Company exclusively licenses CBP-174 from a third-party licensor. Such license is worldwide and royalty-bearing. As of December 31, 2021, CBP-174 has not yet been commercialized, the Company is only subject to a non-refundable, non-creditable license maintenance fee, which is paid to the third-party licensor on an annual basis and recorded as a consultancy fee within research and development expense.
(ii)
Represents a share-based compensation to additional Series C preferred shareholder, which was recognized as an administrative expense as set forth in Note 22. 
XML 85 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Employee Benefit Expenses (Tables)
12 Months Ended
Dec. 31, 2021
Classes Of Employee Benefits Expense [Abstract]  
Schedule of Employee Benefit Expenses

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Share-based compensation expenses (Note 22)

 

 

3,875

 

 

 

5,535

 

 

 

57,863

 

Wages, salaries and bonuses

 

 

8,628

 

 

 

19,527

 

 

 

56,122

 

Welfare expenses

 

 

964

 

 

 

520

 

 

 

4,820

 

Housing funds

 

 

491

 

 

 

690

 

 

 

1,368

 

Contributions to defined benefit plan (Note 27(d))

 

 

1,140

 

 

 

971

 

 

 

 

 

 

 

15,098

 

 

 

27,243

 

 

 

120,173

 

 

(i) The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder. The Company does not have any further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk.

 

Employee benefit expenses were charged in the following line items in the consolidated statements of loss:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Research and development expenses

 

 

11,496

 

 

 

18,405

 

 

 

68,225

 

Administrative expenses

 

 

3,602

 

 

 

8,838

 

 

 

51,948

 

 

 

 

15,098

 

 

 

27,243

 

 

 

120,173

 

XML 86 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Other Income (Tables)
12 Months Ended
Dec. 31, 2021
Other Income Expense [Abstract]  
Summary of Other income

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Government grants

 

 

2,836

 

 

 

6,989

 

 

 

18,996

 

XML 87 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Other Gains/(losses) Net (Tables)
12 Months Ended
Dec. 31, 2021
Other Income (Losses) Net [Abstract]  
Schedule of Other Gains/ (Losses) Net Other Gains/(losses)—net

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Net foreign exchange gains/(losses)

 

 

2,252

 

 

 

(6,772

)

 

 

(3,309

)

Investment income from wealth management products

 

 

798

 

 

 

672

 

 

 

436

 

Other loss (i)

 

 

 

 

 

 

 

 

(7,093

)

 

 

 

3,050

 

 

 

(6,100

)

 

 

(9,966

)

 

(i) The Group incurred a loss of RMB 7.0 million (USD 1.1 million) due to a phishing scam experienced in May 2021 which resulted in the Company remitting such amount to an account set up by the phishers rather than to one of the Company’s vendors. No loss of company data nor any loss or compromise of third-party information has been discovered. The Company filed a claim and partially recovered RMB 1.0 million losses from its cyber insurance provider
XML 88 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Finance Income/(cost) Net (Tables)
12 Months Ended
Dec. 31, 2021
Profit Loss [Abstract]  
Summary of Finance Income/(Cost) Net

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Finance income

 

 

 

 

 

 

 

 

 

Interest from bank deposits and term deposits

 

 

1,066

 

 

 

717

 

 

 

622

 

Finance cost

 

 

 

 

 

 

 

 

 

Issuance cost of financial instruments with preferred rights

 

 

 

 

 

(2,851

)

 

 

 

Interest for lease liabilities

 

 

(53

)

 

 

(42

)

 

 

(44

)

 

 

 

(53

)

 

 

(2,893

)

 

 

(44

)

Finance income/(cost)—net

 

 

1,013

 

 

 

(2,176

)

 

 

578

 

XML 89 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Major Components Of Tax Expense Income [Abstract]  
Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate

The reconciliation between the Group’s actual tax charge and the amount that is calculated based on the statutory income tax rate of 25% in the PRC is as follows:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Loss from operations in the PRC

 

 

(73,741

)

 

 

(85,788

)

 

 

(233,382

)

Loss from overseas entities

 

 

(94,884

)

 

 

(693,437

)

 

 

(1,071,745

)

Loss before income tax

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,305,127

)

Tax expense at PRC enterprise income tax rate of 25%

 

 

(42,156

)

 

 

(194,806

)

 

 

(326,282

)

Expenses not deductible for income tax purpose

 

 

799

 

 

 

3,185

 

 

 

13,663

 

Super deduction of research and development expenses (i)

 

 

(9,529

)

 

 

(13,341

)

 

 

(35,523

)

Tax losses and deductible temporary differences for which no deferred income tax assets were recognized

 

 

33,956

 

 

 

40,865

 

 

 

114,121

 

Effect of income tax in jurisdictions other than the PRC

 

 

16,930

 

 

 

164,097

 

 

 

235,718

 

Income tax expense

 

 

 

 

 

 

 

 

1,697

 

 

(i)
According to policies promulgated by the State Tax Bureau of the PRC, certain of the Group's subsidiaries are entitled to tax incentives for research and development expenses at 175% of tax-deductible research and development expenses in 2019, 2020 and 2021.
XML 90 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share (Tables)
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Net Basic Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to owners of the Company by the weighted average number of ordinary shares outstanding.

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

Net loss attributable to owners of the Company (RMB’000)

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,306,824

)

Weighted average number of ordinary shares outstanding (in thousands)

 

 

16,875

 

 

 

17,090

 

 

 

52,177

 

Basic net loss per share (RMB)

 

 

(10.0

)

 

 

(45.6

)

 

 

(25.0

)

XML 91 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant and Equipment (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of Property Plant And Equipment [Abstract]  
Summary of Property, Plant and Equipment

 

 

 

 

 

 

 

 

 

Office
equipment,

 

 

 

 

 

 

 

 

 

Laboratory
equipment

 

 

Leasehold
improvements

 

 

furniture
and others

 

 

Assets under
construction

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of January 1, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

 

3,059

 

 

 

628

 

 

 

582

 

 

 

 

 

 

4,269

 

Accumulated depreciation

 

 

(1,121

)

 

 

(234

)

 

 

(375

)

 

 

 

 

 

(1,730

)

Net book value

 

 

1,938

 

 

 

394

 

 

 

207

 

 

 

 

 

 

2,539

 

Year ended December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Opening net book value

 

 

1,938

 

 

 

394

 

 

 

207

 

 

 

 

 

 

2,539

 

Additions

 

 

2,613

 

 

 

833

 

 

 

3

 

 

 

1,906

 

 

 

5,355

 

Depreciation

 

 

(339

)

 

 

(574

)

 

 

(42

)

 

 

 

 

 

(955

)

Closing net book value

 

 

4,212

 

 

 

653

 

 

 

168

 

 

 

1,906

 

 

 

6,939

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

 

5,672

 

 

 

1,461

 

 

 

585

 

 

 

1,906

 

 

 

9,624

 

Accumulated depreciation

 

 

(1,460

)

 

 

(808

)

 

 

(417

)

 

 

 

 

 

(2,685

)

Net book value

 

 

4,212

 

 

 

653

 

 

 

168

 

 

 

1,906

 

 

 

6,939

 

Year ended December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Opening net book value

 

 

4,212

 

 

 

653

 

 

 

168

 

 

 

1,906

 

 

 

6,939

 

Additions

 

 

30,440

 

 

 

793

 

 

 

422

 

 

 

24,121

 

 

 

55,776

 

Disposals

 

 

(234

)

 

 

 

 

 

(14

)

 

 

 

 

 

(248

)

Depreciation

 

 

(2,142

)

 

 

(813

)

 

 

(175

)

 

 

 

 

 

(3,130

)

Transfers

 

 

 

 

 

2,449

 

 

 

 

 

 

(2,449

)

 

 

 

Closing net book value

 

 

32,276

 

 

 

3,082

 

 

 

401

 

 

 

23,578

 

 

 

59,337

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

 

35,878

 

 

 

4,703

 

 

 

993

 

 

 

23,578

 

 

 

65,152

 

Accumulated depreciation

 

 

(3,602

)

 

 

(1,621

)

 

 

(592

)

 

 

 

 

 

(5,815

)

Net book value

 

 

32,276

 

 

 

3,082

 

 

 

401

 

 

 

23,578

 

 

 

59,337

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

XML 92 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Other non-current Assets (Tables)
12 Months Ended
Dec. 31, 2021
Miscellaneous Noncurrent Assets [Abstract]  
Schedule of Other non-current Assets

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Deductible value-added tax

 

 

10,260

 

 

 

18,045

 

Prepayments for purchase of non-current assets (i)

 

 

9,600

 

 

 

341

 

Others

 

 

 

 

 

420

 

 

 

 

19,860

 

 

 

18,806

 

 

(i)
As of December 31, 2020, the Group had prepayment balances of approximately RMB 9.6 million, primarily due to the purchase of laboratory equipment for Connect SZ. 
XML 93 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Tables)
12 Months Ended
Dec. 31, 2021
Presentation of leases for lessee [abstract]  
Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets

Amounts recognized in the consolidated balance sheets are as follows:

 

(i) Right-of-use assets

 

 

 

Land use rights

 

 

Office rent

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Net book amount-as of January 1, 2019

 

 

 

 

 

1,290

 

 

 

1,290

 

Depreciation

 

 

 

 

 

(407

)

 

 

(407

)

Net book amount-as of December 31, 2019

 

 

 

 

 

883

 

 

 

883

 

Additions

 

 

 

 

 

527

 

 

 

527

 

Depreciation

 

 

 

 

 

(481

)

 

 

(481

)

Net book amount-as of as of December 31, 2020

 

 

 

 

 

929

 

 

 

929

 

Additions

 

 

22,284

 

 

 

517

 

 

 

22,801

 

Depreciation

 

 

(297

)

 

 

(612

)

 

 

(909

)

Net book amount-as of as of December 31, 2021

 

 

21,987

 

 

 

834

 

 

 

22,821

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

Cost

 

 

22,284

 

 

 

2,607

 

 

 

24,891

 

Accumulated depreciation

 

 

(297

)

 

 

(1,773

)

 

 

(2,070

)

Net Book value

 

 

21,987

 

 

 

834

 

 

 

22,821

 

Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability

(ii) Lease liabilities

 

 

 

As of December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Non-current

 

 

470

 

 

 

309

 

 

 

163

 

Current

 

 

412

 

 

 

604

 

 

 

630

 

.

 

 

882

 

 

 

913

 

 

 

793

 

Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation

Amounts recognized in the consolidated statements of loss in addition to depreciation presented above are as follows:

 

 

 

As of December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Interest expense

 

 

53

 

 

 

42

 

 

 

44

 

Expense relating to short-term leases (included in administrative expenses and research and development expenses)

 

 

98

 

 

 

45

 

 

 

12

 

Expense relating to leases of low-value assets that are not shown above as short-term leases (included in administrative expenses and research and development expenses)

 

 

58

 

 

 

30

 

 

 

58

 

 

 

 

209

 

 

 

117

 

 

 

114

 

XML 94 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments by Category (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of Financial Instruments [Abstract]  
Schedule of Financial Instruments by Category

 

 

 

Financial assets

 

 

Financial assets

 

 

 

 

Financial assets

 

at FVPL

 

 

at amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

Other receivables

 

 

 

 

 

5,612

 

 

 

5,612

 

Financial assets at fair value through profit or loss

 

 

13,068

 

 

 

 

 

 

13,068

 

Cash and cash equivalents

 

 

 

 

 

1,010,076

 

 

 

1,010,076

 

 

 

 

13,068

 

 

 

1,015,688

 

 

 

1,028,756

 

 

 

 

Financial assets

 

 

Financial assets

 

 

 

 

Financial assets

 

at FVPL

 

 

at amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

Other receivables

 

 

 

 

 

6,423

 

 

 

6,423

 

Cash and cash equivalents

 

 

 

 

 

1,706,880

 

 

 

1,706,880

 

 

 

 

 

 

 

1,713,303

 

 

 

1,713,303

 

 

 

 

Financial

 

 

Financial

 

 

 

 

 

 

liabilities at

 

 

liabilities at

 

 

 

 

Financial Liabilities

 

FVPL

 

 

amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

Financial instruments with preferred rights

 

 

2,071,508

 

 

 

 

 

 

2,071,508

 

Other payables

 

 

 

 

 

8,631

 

 

 

8,631

 

Trade payables

 

 

 

 

 

24,638

 

 

 

24,638

 

Lease liabilities

 

 

 

 

 

913

 

 

 

913

 

 

 

 

2,071,508

 

 

 

34,182

 

 

 

2,105,690

 

 

 

 

Financial

 

 

Financial

 

 

 

 

 

 

liabilities at

 

 

liabilities at

 

 

 

 

Financial Liabilities

 

FVPL

 

 

amortized cost

 

 

Total

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

Other payables

 

 

 

 

 

21,456

 

 

 

21,456

 

Trade payables

 

 

 

 

 

81,195

 

 

 

81,195

 

Lease liabilities

 

 

 

 

 

793

 

 

 

793

 

.

 

 

 

 

 

103,444

 

 

 

103,444

 

XML 95 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Other Receivables and Prepayments (Tables)
12 Months Ended
Dec. 31, 2021
Other Receivables And Prepayments [Abstract]  
Schedule of Other Receivables and Prepayments

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Prepayment for clinical trials related services

 

 

28,043

 

 

 

36,879

 

Deposits(ii)

 

 

3,881

 

 

 

4,312

 

Prepaid expenses(i)

 

 

 

 

 

3,953

 

Others

 

 

1,731

 

 

 

2,111

 

 

 

 

33,655

 

 

 

47,255

 

 

(i)
In March 2021, the Group made payments to purchase director and officer liability insurance. Such expenses are amortized over one year.
(ii)
Deposits held by CRO suppliers are refundable upon the completion of related services. 
XML 96 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Assets at Fair Value Through Profit or Loss (Tables)
12 Months Ended
Dec. 31, 2021
Financial Assets At Fair Value Through Profit Or Loss [Abstract]  
Summary of Returns on Wealth Management Products

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Wealth management products

 

 

13,068

 

 

 

 

XML 97 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Cash and Cash Equivalents (Tables)
12 Months Ended
Dec. 31, 2021
Cash And Cash Equivalents [Abstract]  
Summary of Cash and Cash Equivalents

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Cash at bank

 

 

 

 

 

 

-USD deposits

 

 

975,810

 

 

 

1,645,948

 

-RMB deposits

 

 

28,113

 

 

 

57,595

 

-Australian Dollar deposit

 

 

6,153

 

 

 

3,337

 

 

 

 

1,010,076

 

 

 

1,706,880

 

XML 98 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Share Capital (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of Classes Of Share Capital [Abstract]  
Schedule of Share Capital and Share Premium

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number of Ordinary Shares

 

 

Share Capital

 

 

Share Premium(i)

 

 

Total

 

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

As of January 1, 2019

 

 

17,684,770

 

 

 

21

 

 

 

38,074

 

 

 

38,095

 

Exercise of stock options

 

 

 

 

 

 

 

 

49

 

 

 

49

 

As of December 31, 2019

 

 

17,684,770

 

 

 

21

 

 

 

38,123

 

 

 

38,144

 

Issuance of shares to Co-Founders (iv, Note 22)

 

 

282,526

 

 

 

1

 

 

 

3,343

 

 

 

3,344

 

Issuance of treasury shares

 

 

1,686,495

 

 

 

2

 

 

 

 

 

 

2

 

As of December 31, 2020

 

 

19,653,791

 

 

 

24

 

 

 

41,466

 

 

 

41,490

 

Issuance of ordinary shares (ii)

 

 

12,937,500

 

 

 

14

 

 

 

1,305,805

 

 

 

1,305,819

 

Conversion from preferred shares to ordinary shares (Note 24)

 

 

24,791,804

 

 

 

28

 

 

 

2,743,597

 

 

 

2,743,625

 

Repurchase of ordinary shares (iii)

 

 

(20,765

)

 

 

 

 

 

 

 

 

 

Issuance of shares to Co-Founders (iv, Note 22)

 

 

121,080

 

 

 

 

 

 

1,417

 

 

 

1,417

 

Exercise of stock options

 

 

 

 

 

 

 

 

2,149

 

 

 

2,149

 

As of December 31, 2021

 

 

57,483,410

 

 

 

66

 

 

 

4,094,434

 

 

 

4,094,500

 

 

(i)
Share premium mainly arose from the contributions to the Company by its holders of ordinary shares and the conversion from preferred shares.
(ii)
In March 2021, 12,937,500 ADSs (representing 12,937,500 ordinary shares, including the exercise of the option by the underwriters in full to purchase additional ADSs) were offered by the Company in connection with its listing on Nasdaq, and the proceeds received were USD 219.9 million or RMB 1,431.8 million based on the exchange rate as of the date of the IPO. The Company incurred issuance costs of USD 19.3 million in connection with this offering.
(iii)
In March 2021, at the request of one co-founder the Group repurchased 20,765 ordinary shares from him for a consideration of RMB 2.5 million (USD 0.4 million) for the payment of employee withholding taxes related to share-based awards, then such shares were cancelled accordingly.
(iv)
Pursuant to the Company’s shareholder agreement in effect as of the completion of the Series C financing (see Note 22), each of the Company’s founders is entitled to two or more votes to ensure the Co-Founders control the majority of the votes under certain circumstances.
XML 99 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]  
Summary of Options Outstanding

The options activities under 2019 and 2021 Plans (after the Share Consolidation) for the year ended December 31, 2019, 2020 and 2021 were as follows:

 

 

 

Number of options

 

 

Weighted average
exercise price per
share option

Options outstanding as of January 1, 2019

 

 

 

 

 

Granted

 

 

198,064

 

 

USD 0.9

Forfeited (i)

 

 

(7,302

)

 

USD 0.9

Options outstanding as of December 31, 2019

 

 

190,762

 

 

 

Granted

 

 

1,500,887

 

 

USD 6.6

Forfeited (i)

 

 

(25,766

)

 

USD 0.9

Options outstanding as of December 31, 2020

 

 

1,665,883

 

 

 

Granted

 

 

2,403,660

 

 

USD 13.8

Exercised

 

 

(163,773

)

 

USD 0.9

Forfeited (i)

 

 

(157,381

)

 

USD 14.7

Options outstanding as of December 31, 2021

 

 

3,748,389

 

 

 

Options exercisable as of December 31, 2021

 

 

485,324

 

 

 

(i)
The options were forfeited when the employment terminated.
Summary of Key Assumptions for Options Granted

Based on the fair value of underlying ordinary shares, the Group used the Binomial option-pricing model to determine the fair value of options as of the grant date. Key assumptions (after the Share Consolidation) for the options granted are set forth below:

 

 

 

Year Ended December 31

 

 

2019

 

 

2020

 

 

2021

Weighted average exercise price during the year

 

USD 0.9

 

 

USD 6.6

 

 

USD 13.8

Grant date share price

 

USD 1.9~USD 2.1

 

 

USD 2.1~USD 11.1

 

 

USD 4.3~USD 23.3

Risk-free interest rate

 

1.7%~2.1%

 

 

0.8%~1.1%

 

 

1.2%~1.7%

Expected volatility

 

56.6%~77.4%

 

 

61.8%~77.4%

 

 

60.5%~62.2%

Option life

 

10 years

 

 

10 years

 

 

10 years

Expected early exercise multiple

 

 

2.2

 

 

 

2.2

 

 

2.2

Dividend yield

 

Nil

 

 

Nil

 

 

Nil

Forfeiture rate

 

 

9.5

%

 

 

9.5

%

 

*3.0%-9.6%

Weighted average fair value of options granted during the year

 

USD 1.2

 

 

USD 4.2

 

 

USD 10.6

Forfeiture rates for executives and all other employees in the year ended December 31, 2021, were 3.0% and 9.6%,

respectively.

Summary of Share-Based Compensation Expenses

Share-based compensation expenses included in the consolidated statements of loss for the years ended December 31, 2019, 2020 and 2021 is as follows:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Research and development expenses (Note 6)

 

 

3,635

 

 

 

3,523

 

 

 

26,532

 

Administrative expenses (Note 5(ii), Note 6)

 

 

240

 

 

 

21,667

 

 

 

31,331

 

 

 

 

3,875

 

 

 

25,190

 

 

 

57,863

 

XML 100 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Other Payables and Accruals (Tables)
12 Months Ended
Dec. 31, 2021
Trade And Other Payables [Abstract]  
Schedule of Other Payables and Accruals

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Construction payables

 

 

 

 

 

16,576

 

Payroll, welfare and bonus payables

 

 

4,124

 

 

 

11,384

 

Accrued professional service fee

 

 

8,090

 

 

 

2,318

 

Others

 

 

541

 

 

 

2,562

 

 

 

 

12,755

 

 

 

32,840

 

XML 101 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments with Preferred Rights (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of Financial Instruments [Abstract]  
Summary of Series of Financings by Issuing Preferred Shares

The Group has completed a series of financings by issuing preferred shares with the following details:

 

 

 

 

 

 

 

 

Subscription

 

 

 

 

 

Number of

 

 

consideration

 

Date of subscription

 

Round

 

preferred shares

 

 

RMB’000

 

March 3, 2016

 

Series Pre-A

 

 

3,109,000

 

 

 

33,110

 

January 3, 2017

 

Series A

 

 

8,471,200

 

 

 

137,868

 

December 20, 2018

 

Series B

 

 

10,127,579

 

 

 

379,148

 

August 21, 2020/December 1, 2020

 

Series C

 

 

21,349,537

 

 

 

923,247

 

 

 

 

 

 

43,057,316

 

 

 

1,473,373

 

Movements of Financial Instruments with Preferred Rights

Movements of financial instruments with preferred rights during the years ended December 31, 2019, 2020 and 2021 were as follows:

 

 

 

Fair value

 

 

 

RMB’000

 

As of January 1, 2019

 

 

573,499

 

Change in fair value recognized in profit or loss

 

 

59,397

 

Change in fair value due to foreign currency translation recognized in other comprehensive income

 

 

10,112

 

As of December 31, 2019

 

 

643,008

 

Issuance of Series C Preferred Shares

 

 

923,247

 

Change in fair value recognized in profit or loss

 

 

579,286

 

Share-based compensation to additional Series C preferred shareholder

 

 

19,655

 

Change in fair value due to foreign currency translation recognized in other comprehensive income

 

 

(93,688

)

As of December 31, 2020

 

 

2,071,508

 

Change in fair value recognized in profit or loss

 

 

674,269

 

Change in fair value due to foreign currency translation recognized in other comprehensive income

 

 

(2,152

)

Converted to ordinary shares upon IPO

 

 

(2,743,625

)

As of December 31, 2021

 

 

 

Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights

Key valuation assumptions used to determine the fair value of the financial instruments with preferred rights are as follows:

 

 

 

Year ended December 31,

 

 

2019

 

2020

DLOM

 

25.8% ~ 30.7%

 

14.0% ~ 25.8%

Expected volatility

 

55.0% ~ 60.0%

 

64.0% ~ 75.1%

Risk-Free interest rate

 

1.7% ~ 2.3%

 

0.1% ~ 0.2%

XML 102 R58.htm IDEA: XBRL DOCUMENT v3.22.1
Cash Flow Information (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure Of Cash Flow Information [Abstract]  
Summary of Cash Used in Operations

(a) Cash used in operations

 

 

 

 

 

Year Ended December 31,

 

 

 

Notes

 

2019

 

 

2020

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Loss before income tax

 

 

 

 

(168,625

)

 

 

(779,225

)

 

 

(1,305,127

)

Adjustments for:

 

 

 

 

 

 

 

 

 

 

 

—Interest for lease liabilities

 

9

 

 

53

 

 

 

42

 

 

 

44

 

—Investment income from wealth management products

 

8

 

 

(798

)

 

 

(672

)

 

 

(436

)

—Amortization of intangible assets

 

 

 

 

 

 

 

7

 

 

 

43

 

—Depreciation of property, plant and equipment

 

12

 

 

383

 

 

 

955

 

 

 

3,130

 

—Depreciation of rights-of-use assets

 

14

 

 

407

 

 

 

481

 

 

 

909

 

—Share-based compensation expenses

 

22

 

 

3,875

 

 

 

25,190

 

 

 

57,863

 

—Net foreign exchange differences

 

 

 

 

(1,368

)

 

 

6,772

 

 

 

3,309

 

—Fair value changes of financial instruments with preferred rights

 

24

 

 

59,397

 

 

 

579,286

 

 

 

674,269

 

—Issuance cost of financial instruments with preferred rights

 

9

 

 

 

 

 

2,851

 

 

 

 

—Loss on disposal of property, plant and equipment

 

 

 

 

 

 

 

 

 

 

250

 

Changes in working capital

 

 

 

 

 

 

 

 

 

 

 

—Other receivables and prepayments

 

 

 

 

(3,026

)

 

 

(9,350

)

 

 

(16,116

)

—Other non-current assets

 

 

 

 

(1,603

)

 

 

(3,906

)

 

 

(8,206

)

—Other payables and accruals

 

 

 

 

1,698

 

 

 

8,558

 

 

 

(11,459

)

—Trade payables

 

 

 

 

19,351

 

 

 

1,850

 

 

 

56,601

 

Net cash used in operations

 

 

 

 

(90,256

)

 

 

(167,161

)

 

 

(544,926

)

Summary of Non-cash Investing and Financing Activities

(b) Non-cash investing and financing activities

 

 

 

 

 

Year Ended December 31,

 

 

 

Notes

 

2019

 

 

2020

 

 

2021

 

 

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Construction payables

 

 

 

 

 

 

 

 

16,576

 

Fair value changes of financial instruments with preferred rights

 

24

 

 

59,397

 

 

 

579,286

 

 

 

674,269

 

Share-based compensation to additional Series C preferred shareholder

 

22

 

 

 

 

 

19,655

 

 

 

 

 

 

 

 

 

59,397

 

 

 

598,941

 

 

 

690,845

 

Summary of Reconciliation of Liabilities Arising from Financing Activities

(c) Reconciliation of liabilities arising from financing activities

 

 

 

Financial

 

 

 

 

 

 

instruments with

 

 

 

 

 

 

preferred rights

 

 

Lease liability

 

 

 

RMB’000

 

 

RMB’000

 

At January 1, 2019

 

 

573,499

 

 

 

1,274

 

Cash flows

 

 

 

 

 

(445

)

Interest expenses

 

 

 

 

 

53

 

Differences of foreign currency translation

 

 

10,112

 

 

 

 

Changes in fair value

 

 

59,397

 

 

 

 

At December 31, 2019

 

 

643,008

 

 

 

882

 

Cash flows

 

 

923,247

 

 

 

(538

)

New leases

 

 

 

 

 

527

 

Interest expenses

 

 

 

 

 

42

 

Differences of foreign currency translation

 

 

(93,688

)

 

 

 

Changes in fair value

 

 

579,286

 

 

 

 

Share-based compensation to additional Series C preferred shareholder

 

 

19,655

 

 

 

 

At December 31, 2020

 

 

2,071,508

 

 

 

913

 

Cash flows

 

 

 

 

 

(805

)

New leases

 

 

 

 

 

641

 

Interest expenses

 

 

 

 

 

44

 

Differences of foreign currency translation

 

 

(2,152

)

 

 

 

Changes in fair value

 

 

674,269

 

 

 

 

Conversion to ordinary shares

 

 

(2,743,625

)

 

 

 

At December 31, 2021

 

 

 

 

 

793

 

XML 103 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments (Tables)
12 Months Ended
Dec. 31, 2021
Capital Commitments [Abstract]  
Schedule of Capital Commitments

Capital commitments

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

Equipment and intangible assets

 

 

 

 

 

 

- Contracted but not provided for

 

 

23,243

 

 

 

146,878

 

XML 104 R60.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Tables)
12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Schedule of Significant Transactions and Balances with Related Parties
(b)
Significant transactions with related parties

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Purchase of clinical trials related services

 

 

 

 

 

 

 

 

 

Hangzhou Simo Company Limited

 

 

5,601

 

 

 

5,948

 

 

 

 

Frontage Laboratories (Suzhou) Company Limited

 

 

2,346

 

 

 

2,157

 

 

 

 

Hangzhou Tigermed Consulting Company Limited

 

 

810

 

 

 

1,069

 

 

 

 

Beijing Medical Development (Suzhou) Company Limited

 

 

186

 

 

 

301

 

 

 

 

Shanghai Tigermed Consulting Company Limited

 

 

891

 

 

 

34

 

 

 

 

 

(c)
Balances with related parties

 

 

 

As of December 31,

 

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

(i) Prepayments

 

 

 

 

 

 

Hangzhou Tigermed Consulting Company Limited

 

 

850

 

 

 

 

Hangzhou Simo Company Limited

 

 

507

 

 

 

 

Summary of Key Management Personnel Compensation
(d)
Key management personnel compensation

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

Wages, salaries and bonuses

 

 

3,358

 

 

 

8,013

 

 

 

18,100

 

Share-based compensation expenses

 

 

2,749

 

 

 

1,148

 

 

 

28,266

 

Contributions to defined benefit plan (i)

 

 

1,140

 

 

 

971

 

 

 

 

Welfare, housing funds and other

 

 

216

 

 

 

180

 

 

 

308

 

 

 

 

7,463

 

 

 

10,312

 

 

 

46,674

 

 

(i)
The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder following termination. The Company will have no further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk. The benefit obligation was determined using certain assumptions, including life annuity factor and specified interest rate, which were published by the U.S. Internal Revenue Service.
XML 105 R61.htm IDEA: XBRL DOCUMENT v3.22.1
Restricted Net Assets and Parent Company Only Condensed Financial Information (Tables)
12 Months Ended
Dec. 31, 2021
Restricted Net Assets And Parent Company Condensed Financial Information [Abstract]  
Schedule of Condensed Financial Information For the Parent Company

The Company performs a test on the restricted net assets of its consolidated subsidiaries (the “Restricted Net Assets”) in accordance with Securities and Exchange Commission Regulation S-X Section 4-08 (e) (3) “General Notes to Financial Statements” and concluded that the condensed financial information for the parent company is required to be presented as of December 31, 2020 and 2021 and for the years ended December 31, 2019, 2020 and 2021.

 

Furthermore, cash transfers from the Company’s PRC subsidiaries to their parent companies outside of China are subject to PRC government control of currency conversion. Shortages in the availability of foreign currency may restrict the ability of the PRC subsidiaries and consolidated affiliated entities to remit sufficient foreign currency to pay dividends or other payments to the Company, or otherwise satisfy their foreign currency denominated obligations.

(a) Condensed balance sheets

 

 

As of December 31,

 

 

2020

 

 

2021

 

 

2021

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

ASSETS

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

 

 

Interest in a subsidiary

 

472,273

 

 

 

1,177,380

 

 

 

184,667

 

Total non-current assets

 

472,273

 

 

 

1,177,380

 

 

 

184,667

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

885,611

 

 

 

1,464,637

 

 

 

229,722

 

Other receivables

 

84,278

 

 

 

86,352

 

 

 

13,544

 

Other current assets

 

1,097

 

 

 

 

 

 

 

Total current assets

 

970,986

 

 

 

1,550,989

 

 

 

243,266

 

Total assets

 

1,443,259

 

 

 

2,728,369

 

 

 

427,933

 

LIABILITIES

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

Financial instruments with preferred rights

 

2,071,508

 

 

 

 

 

 

 

Total non-current liabilities

 

2,071,508

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Trade payables

 

 

 

 

49

 

 

 

7

 

Other payables and accruals

 

6,864

 

 

 

34,190

 

 

 

5,364

 

Total current liabilities

 

6,864

 

 

 

34,239

 

 

 

5,371

 

Total liabilities

 

2,078,372

 

 

 

34,239

 

 

 

5,371

 

Net (liabilities)/assets

 

(635,113

)

 

 

2,694,130

 

 

 

422,562

 

SHAREHOLDERS’ (DEFICIT)/EQUITY

 

 

 

 

 

 

 

 

Share capital

 

24

 

 

 

66

 

 

 

10

 

Share premium

 

41,466

 

 

 

4,094,434

 

 

 

642,194

 

Treasury shares

 

(3

)

 

 

(1,164

)

 

 

(183

)

Other reserves

 

(5,732

)

 

 

(10,359

)

 

 

(1,625

)

Accumulated losses

 

(670,868

)

 

 

(1,388,847

)

 

 

(217,834

)

Total shareholders’ (deficit)/equity

 

(635,113

)

 

 

2,694,130

 

 

 

422,562

 

 

(b) Condensed statements of loss

 

 

Year Ended December 31,

 

 

2019

 

 

2020

 

 

2021

 

 

2021

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

Administrative expenses

 

(23

)

 

 

(29,540

)

 

 

(43,710

)

 

 

(6,856

)

Operating loss

 

(23

)

 

 

(29,540

)

 

 

(43,710

)

 

 

(6,856

)

Finance income/(costs)—net

 

335

 

 

 

(2,758

)

 

 

 

 

 

 

Fair value loss of financial instruments with preferred rights

 

(59,397

)

 

 

(579,286

)

 

 

(674,269

)

 

 

(105,756

)

Loss before income tax

 

(59,085

)

 

 

(611,584

)

 

 

(717,979

)

 

 

(112,612

)

Income tax expense

 

 

 

 

 

 

 

 

 

 

 

Loss for the year

 

(59,085

)

 

 

(611,584

)

 

 

(717,979

)

 

 

(112,612

)

 

(c) Condensed statements of cash flows

 

 

Year Ended December 31,

 

 

2019

 

 

2020

 

 

2021

 

 

2021

 

 

RMB’000

 

 

RMB’000

 

 

RMB’000

 

 

USD’000

 

Net cash from/(used in) operating activities

 

249

 

 

 

(4,766

)

 

 

(31,025

)

 

 

(4,866

)

Net cash used in investing activities

 

(159,057

)

 

 

(204,170

)

 

 

(672,529

)

 

 

(105,483

)

Net cash generated from financing activities

 

99,990

 

 

 

934,284

 

 

 

1,319,418

 

 

 

206,945

 

Net (decrease)/increase in cash and cash equivalents

 

(58,818

)

 

 

725,348

 

 

 

615,864

 

 

 

96,596

 

Cash and cash equivalents at the beginning of year

 

267,665

 

 

 

213,253

 

 

 

885,611

 

 

 

138,904

 

Effects of exchange rate changes on cash and cash equivalents

 

4,406

 

 

 

(52,990

)

 

 

(36,838

)

 

 

(5,778

)

Cash and cash equivalents at end of year

 

213,253

 

 

 

885,611

 

 

 

1,464,637

 

 

 

229,722

 

XML 106 R62.htm IDEA: XBRL DOCUMENT v3.22.1
General Information, Reorganization and Basis of Presentation - Additional Information (Details) - $ / shares
12 Months Ended
Dec. 31, 2021
Mar. 12, 2021
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]    
Date of incorporation Nov. 23, 2015  
Country of incorporation Cayman Islands  
Address of registered office P.O. Box 613, Harbour Centre, George Town, Grand Cayman KY1-1107, Cayman Islands.  
Par value   $ 0.0001
Ordinary Shares    
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]    
Number of shares represented by one depositary shares 1  
Par value $ 0.000174 $ 0.000174
XML 107 R63.htm IDEA: XBRL DOCUMENT v3.22.1
General Information, Reorganization and Basis of Presentation - Summary of Direct or Indirect Interests in Principal Subsidiaries (Details)
12 Months Ended
Dec. 31, 2021
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]  
Date of incorporation Nov. 23, 2015
Connect Biopharma HongKong Limited  
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]  
Principal activities Investment holding
Place of incorporation Hong Kong
Date of incorporation Dec. 01, 2015
Attributable equity interest to the Group 100.00%
Connect Biopharm LLC  
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]  
Principal activities Pharmaceutical R&D
Place of incorporation San Diego, United States of America
Date of incorporation Jan. 24, 2012
Attributable equity interest to the Group 100.00%
Connect Biopharma Australia PTY LTD  
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]  
Principal activities Pharmaceutical R&D
Place of incorporation Prahran, Australia
Date of incorporation Jul. 18, 2014
Attributable equity interest to the Group 100.00%
Suzhou Connect Biopharma Co., Ltd.  
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]  
Principal activities Pharmaceutical R&D
Place of incorporation Suzhou, PRC
Date of incorporation May 02, 2012
Attributable equity interest to the Group 100.00%
Connect Biopharma (Shanghai) Co., Ltd  
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]  
Principal activities Pharmaceutical R&D
Place of incorporation Shanghai, PRC
Date of incorporation Oct. 23, 2015
Attributable equity interest to the Group 100.00%
Connect Biopharma (Beijing) Co., Ltd  
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]  
Principal activities Pharmaceutical R&D
Place of incorporation Beijing, PRC
Date of incorporation Jul. 09, 2019
Attributable equity interest to the Group 100.00%
Connect Biopharma (Shenzhen) Co., Ltd  
Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]  
Principal activities Dormant
Place of incorporation Shenzhen, PRC
Date of incorporation Nov. 15, 2021
Attributable equity interest to the Group 100.00%
XML 108 R64.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Mar. 19, 2021
Mar. 31, 2021
CNY (¥)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
CNY (¥)
¥ / $
Segment
Dec. 31, 2021
USD ($)
Segment
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Dec. 31, 2021
USD ($)
¥ / $
Dec. 31, 2020
USD ($)
Dec. 31, 2018
CNY (¥)
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]                    
Net assets       ¥ 1,735,800,000   ¥ (1,024,945,000)   $ 272,257    
Accumulated losses       2,378,200,000            
Net operating loss       631,400,000 $ 99,038 197,763,000 ¥ 110,241,000      
Net operating cash outflow       ¥ 544,900,000 85,469 167,161,000 90,256,000      
Cumulative cash contributions | $               $ 440,100    
Closing foreign exchange rate | ¥ / $       6.3757       6.3757    
Cash and cash equivalents       ¥ 1,706,880,000   ¥ 1,010,076,000 ¥ 308,972,000 $ 267,716 $ 158,426 ¥ 401,597,000
Proceeds from issue of ordinary shares   ¥ 1,431,800,000 $ 219,900 ¥ 1,431,775,000 $ 224,567          
Depreciation method       Depreciation is calculated using the straight-line method Depreciation is calculated using the straight-line method          
Equity investment       ¥ 0            
Number of segments | Segment       1 1          
Preferred shares conversion ratio 1                  
China Government                    
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]                    
Offices and rental contract lease term       50 years 50 years          
Bottom of range                    
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]                    
Offices and rental contract lease term       2 years 2 years          
Top of range                    
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]                    
Offices and rental contract lease term       4 years 4 years          
Software                    
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]                    
Intangible assets estimated useful lives       10 years 10 years          
XML 109 R65.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment (Details)
12 Months Ended
Dec. 31, 2021
Bottom of range | Laboratory Equipment  
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]  
Useful life 5 years
Bottom of range | Leasehold Improvements  
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]  
Useful life Shorter of lease term
Bottom of range | Office Equipment and Furniture  
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]  
Useful life 3 years
Top of range | Laboratory Equipment  
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]  
Useful life 10 years
Top of range | Leasehold Improvements  
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]  
Useful life 5 years
Top of range | Office Equipment and Furniture  
Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]  
Useful life 5 years
XML 110 R66.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments and Risk Management - Summary of Exposure to Foreign Currency Risk (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
CNY (¥)
Dec. 31, 2018
CNY (¥)
Disclosure Of Financial Instruments [Line Items]            
Cash and cash equivalents ¥ 1,706,880 $ 267,716 ¥ 1,010,076 $ 158,426 ¥ 308,972 ¥ 401,597
Foreign Currency Risk            
Disclosure Of Financial Instruments [Line Items]            
Cash and cash equivalents ¥ 150,640   ¥ 65,791      
XML 111 R67.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments and Risk Management - Summary of Aggregate Net Foreign Exchange Gains/(Losses) Recognized in Profit or Loss (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Financial Instruments [Abstract]      
Net foreign exchange gains/(losses) included in other gains/(losses)-net ¥ (3,309) ¥ (6,772) ¥ 2,252
XML 112 R68.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments and Risk Management - Additional Information (Details) - CNY (¥)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Financial Instruments [Abstract]      
Percentage of foreign exchange transactions 5.00% 5.00% 5.00%
Increase decrease in foreign exchange transactions ¥ 7,500,000 ¥ 3,300,000 ¥ 1,600,000
Debt outstanding 0 ¥ 0  
Financial assets measured at fair value 0    
Financial liabilities measured at fair value ¥ 0    
XML 113 R69.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments and Risk Management - Summary of Financial Liabilities into Maturity Groupings Based on Remaining Period to Contractual Maturity Date (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Disclosure Of Financial Instruments [Line Items]        
Financial instruments with preferred rights     ¥ 2,071,508  
Trade payables ¥ 81,195 $ 12,735 24,638  
Other payables 2,562   541  
Lease liabilities 793   913 ¥ 882
Total 103,444   2,105,690  
Credit Risk        
Disclosure Of Financial Instruments [Line Items]        
Financial instruments with preferred rights     2,071,508  
Trade payables 81,195   24,638  
Other payables 21,456   8,631  
Lease liabilities 839   952  
Total 103,490   2,105,729  
Credit Risk | Less than 1 Year        
Disclosure Of Financial Instruments [Line Items]        
Trade payables 81,195   24,638  
Other payables 21,456   8,631  
Lease liabilities 653   633  
Total 103,304   33,902  
Credit Risk | Between 1 and 2 Years        
Disclosure Of Financial Instruments [Line Items]        
Lease liabilities 186   225  
Total ¥ 186   225  
Credit Risk | Between 2 and 5 Years        
Disclosure Of Financial Instruments [Line Items]        
Financial instruments with preferred rights     2,071,508  
Lease liabilities     94  
Total     ¥ 2,071,602  
XML 114 R70.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments and Risk Management - Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques (Details) - CNY (¥)
¥ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Disclosure Of Financial Instruments [Line Items]    
Total assets ¥ 1,713,303 ¥ 1,028,756
Financial instruments with preferred rights   2,071,508
Total liabilities ¥ 103,444 2,105,690
Recurring    
Disclosure Of Financial Instruments [Line Items]    
Financial assets at fair value through profit or loss   13,068
Total assets   13,068
Financial instruments with preferred rights   2,071,508
Total liabilities   2,071,508
Recurring | Level 3    
Disclosure Of Financial Instruments [Line Items]    
Financial assets at fair value through profit or loss   13,068
Total assets   13,068
Financial instruments with preferred rights   2,071,508
Total liabilities   ¥ 2,071,508
XML 115 R71.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments and Risk Management - Summary of Changes in Level 3 Instruments of Short-term Investment (Details) - Level 3 - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Assets      
Opening balance ¥ 13,068 ¥ 30,632 ¥ 27,565
Additions 114,500 106,600 163,000
Settlements (128,004) (124,836) (160,731)
Investment income credited to profit or loss (Note 8) ¥ 436 672 798
Closing balance   13,068 30,632
*Includes unrealized gains recognized in profit or loss attributable to balances held at the end of the reporting period   ¥ 68 ¥ 132
XML 116 R72.htm IDEA: XBRL DOCUMENT v3.22.1
Expenses by Nature - Summary of Expenses by Nature (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Attribution Of Expenses By Nature To Their Function [Abstract]      
Clinical trials related expenses ¥ 424,724 ¥ 107,440 ¥ 82,046
Employee benefit expenses (Note 6) 120,173 27,243 15,098
Consultancy fee 69,498 31,784 12,011
R&D materials and consumable supplies 13,718 2,127 988
Depreciation and amortization 4,082 1,436 790
Office expenses 3,653 3,052 2,424
Expense related to Series C financing   19,655  
Others 4,618 5,915 2,770
Total expenses, by nature ¥ 640,466 ¥ 198,652 ¥ 116,127
XML 117 R73.htm IDEA: XBRL DOCUMENT v3.22.1
Employee Benefit Expenses - Schedule of Employee Benefit Expenses (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Classes Of Employee Benefits Expense [Abstract]      
Share-based compensation expenses (Note 22) ¥ 57,863 ¥ 5,535 ¥ 3,875
Wages, salaries and bonuses 56,122 19,527 8,628
Welfare expenses 4,820 520 964
Housing funds 1,368 690 491
Contributions to defined benefit plan (Note 27(d))   971 1,140
Employee benefit expenses ¥ 120,173 ¥ 27,243 ¥ 15,098
XML 118 R74.htm IDEA: XBRL DOCUMENT v3.22.1
Employee Benefit Expenses - Schedule of Employee Benefit Expenses Included in Consolidated Statements of Loss (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Defined Benefit Plans [Line Items]      
Employee benefit expenses ¥ 120,173 ¥ 27,243 ¥ 15,098
Research and Development Expenses      
Disclosure Of Defined Benefit Plans [Line Items]      
Employee benefit expenses 68,225 18,405 11,496
Administrative Expenses      
Disclosure Of Defined Benefit Plans [Line Items]      
Employee benefit expenses ¥ 51,948 ¥ 8,838 ¥ 3,602
XML 119 R75.htm IDEA: XBRL DOCUMENT v3.22.1
Other Income - Summary of Other Income (Details) - CNY (¥)
¥ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Other Income Expense [Abstract]      
Government grants ¥ 18,996 ¥ 6,989 ¥ 2,836
XML 120 R76.htm IDEA: XBRL DOCUMENT v3.22.1
Other Income - Additional Information (Details)
¥ in Millions
12 Months Ended
Dec. 31, 2021
CNY (¥)
Other Income Expense [Abstract]  
Government grants received ¥ 11.0
Grants received from other subsidies 6.2
Revenue from government as an incentive for research and development ¥ 1.6
XML 121 R77.htm IDEA: XBRL DOCUMENT v3.22.1
Other Gains/(losses) Net - Schedule of Other gains/ (losses) - Net (Details)
¥ in Thousands, $ in Thousands
1 Months Ended 12 Months Ended
May 31, 2021
CNY (¥)
May 31, 2021
USD ($)
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Other Income (Losses) Net [Abstract]            
Net foreign exchange gains/(losses)     ¥ (3,309)   ¥ (6,772) ¥ 2,252
Investment income from wealth management products     436   672 798
Other loss ¥ (7,000) $ (1,100) (7,093)      
Other gains/(losses)-net     ¥ (9,966) $ (1,563) ¥ (6,100) ¥ 3,050
XML 122 R78.htm IDEA: XBRL DOCUMENT v3.22.1
Other Gains/(losses)-Net - Other gains/ (losses)-Net (Parenthetical) (Details)
¥ in Thousands, $ in Millions
1 Months Ended 12 Months Ended
May 31, 2021
CNY (¥)
May 31, 2021
USD ($)
Dec. 31, 2021
CNY (¥)
Other Income (Losses) Net [Abstract]      
Other loss ¥ 7,000 $ 1.1 ¥ 7,093
Losses partially recovered from cyber insurance     ¥ 1,000
XML 123 R79.htm IDEA: XBRL DOCUMENT v3.22.1
Finance Income/(cost) Net - Summary of Finance income/(cost) Net (Details)
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Disclosure Of Finance Income Expense [Abstract]        
Interest from bank deposits and term deposits ¥ 622   ¥ 717 ¥ 1,066
Issuance cost of financial instruments with preferred rights     (2,851)  
Interest for lease liabilities (44)   (42) (53)
Finance costs (44) $ (7) (2,893) (53)
Finance income/(cost)-net ¥ 578 $ 91 ¥ (2,176) ¥ 1,013
XML 124 R80.htm IDEA: XBRL DOCUMENT v3.22.1
Income taxes - Additional Information (Details)
$ in Thousands
12 Months Ended
Apr. 01, 2018
CNY (¥)
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
HKD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2020
HKD ($)
Dec. 31, 2019
CNY (¥)
Dec. 31, 2019
HKD ($)
Disclosure Of Income Taxes [Line Items]                
Tax expenses (income)   ¥ (326,282,000)     ¥ (194,806,000)   ¥ (42,156,000)  
Provision for income taxes   1,697,000 $ 266          
Deferred income tax assets recognized   0            
Deductible temporary differences for which no deferred tax asset is recognized   1,327,000,000     582,000,000   284,000,000  
Unrecognized uncertain tax positions   0     0   0  
Research and development tax credits   13,740,000            
Connect Biopharm LLC                
Disclosure Of Income Taxes [Line Items]                
Provision for income taxes   ¥ 1,700,000     ¥ 0   ¥ 0  
Hong Kong                
Disclosure Of Income Taxes [Line Items]                
Tax rate 16.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Assessable profits | $       $ 0   $ 0   $ 0
Hong Kong | Bottom of range                
Disclosure Of Income Taxes [Line Items]                
Percentage of assessable profits 8.25%              
Assessable profits ¥ 2,000,000              
UNITED STATES | Connect Biopharma HongKong Limited                
Disclosure Of Income Taxes [Line Items]                
Corporate income tax rate         21.00% 21.00% 21.00% 21.00%
State Income Tax in California | Connect Biopharm LLC                
Disclosure Of Income Taxes [Line Items]                
State income tax rate   8.84% 8.84% 8.84% 8.84% 8.84% 8.84% 8.84%
Australia | Connect Biopharma Australia PTY LTD                
Disclosure Of Income Taxes [Line Items]                
Tax rate   30.00% 30.00% 30.00%        
Tax expenses (income)   ¥ 0     ¥ 0   ¥ 0  
Provision for income taxes   ¥ 0     ¥ 0   ¥ 0  
PRC                
Disclosure Of Income Taxes [Line Items]                
Tax rate   25.00% 25.00% 25.00% 25.00% 25.00% 25.00% 25.00%
Assessable profits   ¥ 0     ¥ 0   ¥ 0  
Tax expenses (income)   0     0   0  
Provision for income taxes   ¥ 0     ¥ 0   ¥ 0  
XML 125 R81.htm IDEA: XBRL DOCUMENT v3.22.1
Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Details)
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Disclosure Of Income Taxes [Line Items]        
Loss from operations in the PRC ¥ (233,382)   ¥ (85,788) ¥ (73,741)
Profit (loss) from overseas entities (1,071,745)   (693,437) (94,884)
Loss before income tax (1,305,127) $ (204,703) (779,225) (168,625)
Tax expense at PRC enterprise income tax rate of 25% (326,282)   (194,806) (42,156)
Expenses not deductible for income tax purpose 13,663   3,185 799
Super deduction of research and development expenses (35,523)   (13,341) (9,529)
Tax losses and deductible temporary differences for which no deferred income tax assets were recognized 114,121   40,865 33,956
Effect of income tax in jurisdictions other than the PRC (235,718)   ¥ (164,097) ¥ (16,930)
Income tax expense ¥ 1,697 $ 266    
XML 126 R82.htm IDEA: XBRL DOCUMENT v3.22.1
Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Parenthetical) (Details) - PRC
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Income Taxes [Line Items]      
Tax rate 25.00% 25.00% 25.00%
Percentage of tax-deductible research and development expenses 175.00% 175.00% 175.00%
XML 127 R83.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share - Additional Information (Details)
Mar. 12, 2021
shares
Earnings Per Share [Abstract]  
Ordinary shares consolidation 1.74
XML 128 R84.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share - Schedule of Net Basic Loss Per Share (Details)
¥ / shares in Units, ¥ in Thousands, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
¥ / shares
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
CNY (¥)
¥ / shares
shares
Dec. 31, 2019
CNY (¥)
¥ / shares
shares
Earnings Per Share [Abstract]        
Net loss attributable to owners of the Company (RMB'000) ¥ (1,306,824) $ (204,969) ¥ (779,225) ¥ (168,625)
Weighted average number of ordinary shares outstanding (in thousands) | shares 52,177 52,177 17,090 16,875
Basic net loss per share (RMB) | ¥ / shares ¥ (25.0)   ¥ (45.6) ¥ (10.0)
XML 129 R85.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2019
CNY (¥)
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment ¥ 59,337 ¥ 6,939 $ 9,307 ¥ 2,539
Additions 55,776 5,355    
Disposals (248)      
Depreciation (3,130) (955)    
Cost        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment 65,152 9,624   4,269
Accumulated depreciation        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment (5,815) (2,685)   (1,730)
Laboratory Equipment        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment 32,276 4,212   1,938
Additions 30,440 2,613    
Disposals (234)      
Depreciation (2,142) (339)    
Laboratory Equipment | Cost        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment 35,878 5,672   3,059
Laboratory Equipment | Accumulated depreciation        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment (3,602) (1,460)   (1,121)
Leasehold Improvements        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment 3,082 653   394
Additions 793 833    
Depreciation (813) (574)    
Transfers 2,449      
Leasehold Improvements | Cost        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment 4,703 1,461   628
Leasehold Improvements | Accumulated depreciation        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment (1,621) (808)   (234)
Office Equipment, Furniture and Others        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment 401 168   207
Additions 422 3    
Disposals (14)      
Depreciation (175) (42)    
Office Equipment, Furniture and Others | Cost        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment 993 585   582
Office Equipment, Furniture and Others | Accumulated depreciation        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment (592) (417)   ¥ (375)
Assets Under Construction        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment 23,578 1,906    
Additions 24,121 1,906    
Transfers (2,449)      
Assets Under Construction | Cost        
Disclosure Of Property Plant And Equipment [Line Items]        
Property, plant and equipment ¥ 23,578 ¥ 1,906    
XML 130 R86.htm IDEA: XBRL DOCUMENT v3.22.1
Other non-current Assets - Schedule of Other Non-current Assets (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Miscellaneous Noncurrent Assets [Abstract]      
Deductible value-added tax ¥ 18,045   ¥ 10,260
Prepayments for purchase of non-current assets 341   9,600
Others 420    
Other non-current assets ¥ 18,806 $ 2,950 ¥ 19,860
XML 131 R87.htm IDEA: XBRL DOCUMENT v3.22.1
Other non-current Assets - Schedule of Other Non-current Assets (Parenthetical) (Details)
¥ in Millions
Dec. 31, 2020
CNY (¥)
Equipment and Improvement | Suzhou  
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]  
Prepayments ¥ 9.6
XML 132 R88.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets (Details)
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]        
Net book amount. Beginning balance ¥ 929   ¥ 883 ¥ 1,290
Additions 22,801   527  
Depreciation (909)   (481) (407)
Net book amount, Ending balance 22,821 $ 3,579 929 883
Cost 24,891      
Accumulated deprecation (2,070)      
Net Book value 22,821   929 883
Land use Rights        
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]        
Additions 22,284      
Depreciation (297)      
Net book amount, Ending balance 21,987      
Cost 22,284      
Accumulated deprecation (297)      
Net Book value 21,987      
Office Rent        
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]        
Net book amount. Beginning balance 929   883 1,290
Additions 517   527  
Depreciation (612)   (481) (407)
Net book amount, Ending balance 834   929 883
Cost 2,607      
Accumulated deprecation (1,773)      
Net Book value ¥ 834   ¥ 929 ¥ 883
XML 133 R89.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Additional Information (Details) - CNY (¥)
¥ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]      
Total cash outflow for leases ¥ 0.8 ¥ 0.5 ¥ 0.4
Land use Rights      
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]      
Useful life 50 years    
XML 134 R90.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Presentation of leases for lessee [abstract]        
Non-current ¥ 163 $ 26 ¥ 309 ¥ 470
Current 630 $ 98 604 412
Total lease liabilities ¥ 793   ¥ 913 ¥ 882
XML 135 R91.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Presentation of leases for lessee [abstract]      
Interest expense ¥ 44 ¥ 42 ¥ 53
Expense relating to short-term leases (included in administrative expenses and research and development expenses) 12 45 98
Expense relating to leases of low-value assets that are not shown above as short-term leases (included in administrative expenses and research and development expenses) 58 30 58
Total interest expense amount recognized ¥ 114 ¥ 117 ¥ 209
XML 136 R92.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments by Category - Schedule of Financial Instruments by Category (Details) - CNY (¥)
¥ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Disclosure Of Financial Instruments [Line Items]    
Financial Assets ¥ 1,713,303 ¥ 1,028,756
Financial liabilities 103,444 2,105,690
Financial Assets at FVPL    
Disclosure Of Financial Instruments [Line Items]    
Financial Assets   13,068
Financial Assets at Amortized Cost    
Disclosure Of Financial Instruments [Line Items]    
Financial Assets 1,713,303 1,015,688
Other Receivables    
Disclosure Of Financial Instruments [Line Items]    
Financial Assets 6,423 5,612
Other Receivables | Financial Assets at Amortized Cost    
Disclosure Of Financial Instruments [Line Items]    
Financial Assets 6,423 5,612
Financial Assets at Fair Value through Profit or Loss    
Disclosure Of Financial Instruments [Line Items]    
Financial Assets   13,068
Financial Assets at Fair Value through Profit or Loss | Financial Assets at FVPL    
Disclosure Of Financial Instruments [Line Items]    
Financial Assets   13,068
Cash and Cash Equivalents    
Disclosure Of Financial Instruments [Line Items]    
Financial Assets 1,706,880 1,010,076
Cash and Cash Equivalents | Financial Assets at Amortized Cost    
Disclosure Of Financial Instruments [Line Items]    
Financial Assets 1,706,880 1,010,076
Financial Liabilities at FVPL    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities   2,071,508
Financial Liabilities at Amortized Cost    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities 103,444 34,182
Financial Instruments with Preferred Rights    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities   2,071,508
Financial Instruments with Preferred Rights | Financial Liabilities at FVPL    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities   2,071,508
Other Payables    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities 21,456 8,631
Other Payables | Financial Liabilities at Amortized Cost    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities 21,456 8,631
Trade Payables    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities 81,195 24,638
Trade Payables | Financial Liabilities at Amortized Cost    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities 81,195 24,638
Lease Liabilities    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities 793 913
Lease Liabilities | Financial Liabilities at Amortized Cost    
Disclosure Of Financial Instruments [Line Items]    
Financial liabilities ¥ 793 ¥ 913
XML 137 R93.htm IDEA: XBRL DOCUMENT v3.22.1
Other Receivables and Prepayments - Schedule of Other Receivables and Prepayments (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Other Receivables And Prepayments [Abstract]      
Prepayment for clinical trials related services ¥ 36,879   ¥ 28,043
Deposits 4,312   3,881
Prepaid expenses 3,953    
Others 2,111   1,731
Other receivables and prepayments ¥ 47,255 $ 7,412 ¥ 33,655
XML 138 R94.htm IDEA: XBRL DOCUMENT v3.22.1
Other Receivables and Prepayments - Additional Information (Details)
1 Months Ended
Mar. 31, 2021
Other Receivables And Prepayments [Abstract]  
Amortized period 1 year
XML 139 R95.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Assets At Fair Value Through Profit or Loss - Summary of Returns on Wealth Management Products (Details)
¥ in Thousands
Dec. 31, 2020
CNY (¥)
Wealth Management Products  
Disclosure Of Financial Instruments [Line Items]  
Wealth management products ¥ 13,068
XML 140 R96.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Assets At Fair Value Through Profit or Loss - Additional Information (Details)
Dec. 31, 2021
Dec. 31, 2020
Bottom of range    
Disclosure Of Financial Assets [Line Items]    
Effective interest rate of financial assets reclassified out of financial assets at fair value through profit or loss 1.48% 1.60%
Top of range    
Disclosure Of Financial Assets [Line Items]    
Effective interest rate of financial assets reclassified out of financial assets at fair value through profit or loss 3.44% 3.40%
XML 141 R97.htm IDEA: XBRL DOCUMENT v3.22.1
Cash and Cash Equivalents - Schedule of Cash And Cash Equivalents (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
CNY (¥)
Dec. 31, 2018
CNY (¥)
Cash at bank            
Total cash and cash equivalents ¥ 1,706,880 $ 267,716 ¥ 1,010,076 $ 158,426 ¥ 308,972 ¥ 401,597
USD deposits            
Cash at bank            
Total cash and cash equivalents 1,645,948   975,810      
RMB deposits            
Cash at bank            
Total cash and cash equivalents 57,595   28,113      
Australian Dollar deposit            
Cash at bank            
Total cash and cash equivalents ¥ 3,337   ¥ 6,153      
XML 142 R98.htm IDEA: XBRL DOCUMENT v3.22.1
Cash and Cash Equivalents - Additional Information (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
CNY (¥)
Dec. 31, 2018
CNY (¥)
Cash at bank            
Cash and cash equivalents ¥ 1,706,880 $ 267,716 ¥ 1,010,076 $ 158,426 ¥ 308,972 ¥ 401,597
Outside of PRC            
Cash at bank            
Cash and cash equivalents ¥ 1,501,800   ¥ 932,800      
XML 143 R99.htm IDEA: XBRL DOCUMENT v3.22.1
Share Capital - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
Mar. 12, 2021
Dec. 31, 2021
Disclosure Of Classes Of Share Capital [Line Items]    
Ordinary shares consolidation 1.74  
Value of share capital $ 50,000 $ 76,560
Par value per share $ 0.0001  
Ordinary Shares    
Disclosure Of Classes Of Share Capital [Line Items]    
Par value per share $ 0.000174 $ 0.000174
XML 144 R100.htm IDEA: XBRL DOCUMENT v3.22.1
Share Capital - Schedule of Share Capital and Share Premium (Details)
¥ in Thousands, $ in Thousands
1 Months Ended 12 Months Ended
Mar. 31, 2021
shares
Dec. 31, 2021
CNY (¥)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
CNY (¥)
shares
Dec. 31, 2019
CNY (¥)
shares
Disclosure Of Classes Of Share Capital [Line Items]          
Balance   ¥ (1,024,945)   ¥ (298,287) ¥ (127,093)
Issuance of Ordinary Shares   1,305,819      
Conversion from preferred shares to ordinary shares   2,743,625      
Exercise of stock options   1,005     49
Balance   ¥ 1,735,831 $ 272,257 ¥ (1,024,945) ¥ (298,287)
Ordinary Shares          
Disclosure Of Classes Of Share Capital [Line Items]          
Balance, shares | shares   19,653,791 19,653,791 17,684,770 17,684,770
Issuance of Ordinary Shares, shares | shares   12,937,500 12,937,500    
Conversion from preferred shares to ordinary shares, shares | shares   24,791,804 24,791,804    
Repurchase of ordinary shares, shares | shares (20,765) (20,765) (20,765)    
Issuance of shares to Co-Founders, shares | shares   121,080 121,080 282,526  
Issuance of treasury shares, shares | shares       1,686,495  
Balance, shares | shares   57,483,410 57,483,410 19,653,791 17,684,770
Share Capital          
Disclosure Of Classes Of Share Capital [Line Items]          
Balance   ¥ 24   ¥ 21 ¥ 21
Issuance of Ordinary Shares   14      
Conversion from preferred shares to ordinary shares   28      
Issuance of shares to Co-Founders       1  
Issuance of treasury shares       2  
Balance   66   24 21
Share Premium          
Disclosure Of Classes Of Share Capital [Line Items]          
Balance   41,466   38,123 38,074
Issuance of Ordinary Shares   1,305,805      
Conversion from preferred shares to ordinary shares   2,743,597      
Issuance of shares to Co-Founders   1,417   3,343  
Exercise of stock options   2,149     49
Balance   4,094,434   41,466 38,123
Share Capital and Share Premium          
Disclosure Of Classes Of Share Capital [Line Items]          
Balance   41,490   38,144 38,095
Issuance of Ordinary Shares   1,305,819      
Conversion from preferred shares to ordinary shares   2,743,625      
Issuance of shares to Co-Founders   1,417   3,344  
Issuance of treasury shares       2  
Exercise of stock options   2,149     49
Balance   ¥ 4,094,500   ¥ 41,490 ¥ 38,144
XML 145 R101.htm IDEA: XBRL DOCUMENT v3.22.1
Share Capital - Schedule of Share Capital and Share Premium (Parenthetical) (Details)
¥ in Thousands, $ in Thousands
1 Months Ended 12 Months Ended
Mar. 31, 2021
CNY (¥)
shares
Mar. 31, 2021
USD ($)
shares
Dec. 31, 2021
CNY (¥)
shares
Dec. 31, 2021
USD ($)
shares
Disclosure Of Classes Of Share Capital [Line Items]        
Number of ADSs issued 12,937,500 12,937,500    
Proceeds from issuance of ordinary shares ¥ 1,431,800 $ 219,900 ¥ 1,431,775 $ 224,567
Issuance costs | $   $ 19,300    
Repurchase of ordinary shares value | ¥     ¥ (3,674)  
Shareholder voting rights     Pursuant to the Company’s shareholder agreement in effect as of the completion of the Series C financing (see Note 22), each of the Company’s founders is entitled to two or more votes to ensure the Co-Founders control the majority of the votes under certain circumstances. Pursuant to the Company’s shareholder agreement in effect as of the completion of the Series C financing (see Note 22), each of the Company’s founders is entitled to two or more votes to ensure the Co-Founders control the majority of the votes under certain circumstances.
Ordinary Shares [Member]        
Disclosure Of Classes Of Share Capital [Line Items]        
Authorized shares 12,937,500 12,937,500    
Repurchase of ordinary shares, shares 20,765 20,765 20,765 20,765
Repurchase of ordinary shares value ¥ 2,500 $ 400    
XML 146 R102.htm IDEA: XBRL DOCUMENT v3.22.1
Treasury Shares - Additional Information (Details) - shares
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Classes Of Share Capital [Line Items]      
Number of treasury shares 2,407,091 2,563,563 877,066
XML 147 R103.htm IDEA: XBRL DOCUMENT v3.22.1
Reserves - Additional Information (Details) - CNY (¥)
¥ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Disclosure Of Reserves Within Equity [Abstract]    
Percentage of net profit to offset prior losses 10.00%  
Percentage of reserve fund of registered capital 50.00%  
Statutory reserve ¥ 288.9 ¥ 137.7
XML 148 R104.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Compensation - Additional Information (Details)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Dec. 01, 2020
USD ($)
shares
Jan. 20, 2020
shares
Dec. 20, 2018
CNY (¥)
shares
Aug. 31, 2020
USD ($)
shares
Apr. 30, 2020
CNY (¥)
Dec. 31, 2021
$ / shares
shares
Dec. 31, 2021
CNY (¥)
shares
Dec. 31, 2020
CNY (¥)
shares
Dec. 31, 2019
CNY (¥)
shares
Mar. 31, 2021
shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Shares reserved for future issuance under 2019 Stock Incentive plan               4,460,600    
Period of grant of share-based payment arrangement             10 years      
Options granted vesting term             Options granted under the plan are valid and effective for 10 years from the date of grant and vest over a service period which is generally four years; 25% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next 36 months. Some options are vested in equal monthly installments or annual installments over the entire service period or vested immediately upon the grant date in instances where services had already been performed in their entirety.      
Vesting period             4 years      
Vesting rights percentage             25.00%      
Vest in equal monthly installments             36 months      
Share options granted             2,403,660 1,500,887 198,064  
Weighted average remaining contractual life of options outstanding             9 years 2 months 12 days 9 years 3 months 18 days 7 years 7 months 6 days  
Number of shares issued           43,057,316 43,057,316      
Consideration, contingent on achieving of R&D milestones | ¥     ¥ 0   ¥ 0          
Number of shares issued for pre money valuation amount | ¥     ¥ 600,000,000              
Share-based compensation expenses | ¥             ¥ 57,863,000 ¥ 25,190,000 ¥ 3,875,000  
Dividend yield              
Co-Founders                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Share-based compensation expenses | ¥               ¥ 1,200,000 ¥ 2,700,000  
Fair value of share based payment on grant date | $ / shares           $ 0.9        
Fair value of share based payment on grant date at consolidation | $ / shares           $ 1.57        
Risk-free interest rate             2.50%      
Expected volatility             60.00%      
Share Purchase Agreement                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Share-based compensation expenses | ¥               ¥ 19,700,000    
2019 Stock Incentive Plan                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Share options granted             897,660      
2021 Stock Incentive Plan                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Period of grant of share-based payment arrangement             10 years      
Options granted vesting term             Options granted under the plan are valid and effective for 10 years from the date of grant and vest over a service period which is generally four years; 25% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next 36 months.      
Vesting period             4 years      
Vesting rights percentage             25.00%      
Vest in equal monthly installments             36 months      
Share options granted             1,506,000      
After Share Consolidation                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Shares reserved for future issuance under 2019 Stock Incentive plan           2,407,091 2,407,091 2,563,563    
Ordinary Shares                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Number of shares issued at consolidation           121,080 121,080      
Ordinary Shares | Co-Founders                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Shares reserved for future issuance   210,682                
Number of shares issued   491,596       210,682 210,682      
Number of shares vested   140,456             351,140  
Number of shares potentially issuable   210,682                
Ordinary Shares | Connect Union                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Shares reserved for future issuance   342,144                
Number of shares issued   798,330 1,140,474     342,144 342,144      
Number of shares potentially issuable   342,144                
Ordinary Shares | Series B Financing | Co-Founders                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Number of shares issued     702,278              
Series C Preferred Shares                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Number of shares issued           21,349,537 21,349,537 0    
Series C Preferred Shares | Co-Founders                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Number of shares issued                   80,457
Number of shares issued at consolidation                   46,232
Series C Preferred Shares | Share Purchase Agreement                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Number of shares issued 3,162,894     18,186,643            
Number of shares issued at consolidation 1,817,755     10,452,094            
Cash consideration | $ $ 20.0     $ 115.0            
2021 Employee Share Purchase Plan                    
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                    
Shares reserved for future issuance           600,000 600,000      
Percentage of shares equal to lesser of aggregate number of ordinary shares             1.00%      
Number of shares potentially issuable           600,000 600,000      
XML 149 R105.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Compensation - Summary of Options Outstanding (Details)
12 Months Ended
Dec. 31, 2021
shares
$ / shares
Dec. 31, 2020
shares
$ / shares
Dec. 31, 2019
shares
$ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]      
Number of Options, Options outstanding, Beginning Balance 1,665,883 190,762 0
Number of Options, Granted during the year 2,403,660 1,500,887 198,064
Number of Options, Exercised during the year (163,773)    
Number of Options, Forfeited during the year (157,381) (25,766) (7,302)
Number of Options, Options outstanding, Ending Balance 3,748,389 1,665,883 190,762
Number of Options, Options exercisable at December 31, 2021 485,324    
Weighted Average Exercise Price per Share Option, Granted during the year | $ / shares $ 13.8 $ 6.6 $ 0.9
Weighted average exercise price of share options exercised in share-based payment arrangement | $ / shares 0.9    
Weighted Average Exercise Price per Share Option, Forfeited during the year | $ / shares $ 14.7 $ 0.9 $ 0.9
XML 150 R106.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Compensation - Summary of Key Assumptions for Options Granted (Details)
12 Months Ended
Dec. 31, 2021
USD ($)
yr
$ / shares
Dec. 31, 2020
USD ($)
yr
$ / shares
Dec. 31, 2019
USD ($)
yr
$ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]      
Weighted average exercise price during the year $ 13.8 $ 6.6 $ 0.9
Option life | yr 10 10 10
Expected early exercise multiple 2.2 2.2 2.2
Dividend yield
Forfeiture rate   9.50% 9.50%
Weighted average fair value of options granted during the year | $ $ 10.6 $ 4.2 $ 1.2
Bottom of range      
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]      
Grant date share price $ 4.3 $ 2.1 $ 1.9
Risk-free interest rate 1.20% 0.80% 1.70%
Expected volatility 60.50% 61.80% 56.60%
Forfeiture rate 3.00%    
Top of range      
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]      
Grant date share price $ 23.3 $ 11.1 $ 2.1
Risk-free interest rate 1.70% 1.10% 2.10%
Expected volatility 62.20% 77.40% 77.40%
Forfeiture rate 9.60%    
XML 151 R107.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Compensation - Summary of Key Assumptions for Options Granted (Parenthetical) (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]      
Forfeiture rate for executives and all other employees   9.50% 9.50%
Bottom of range      
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]      
Forfeiture rate for executives and all other employees 3.00%    
Top of range      
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]      
Forfeiture rate for executives and all other employees 9.60%    
XML 152 R108.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Compensation - Summary of Share-Based Compensation Expenses (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]      
Share-based compensation expenses ¥ 57,863 ¥ 25,190 ¥ 3,875
Research and Development Expenses      
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]      
Share-based compensation expenses 26,532 3,523 3,635
Administrative Expenses      
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]      
Share-based compensation expenses ¥ 31,331 ¥ 21,667 ¥ 240
XML 153 R109.htm IDEA: XBRL DOCUMENT v3.22.1
Other Payables and Accruals - Schedule of Other Payables and Accruals (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Trade And Other Payables [Abstract]      
Construction payables ¥ 16,576    
Payroll, welfare and bonus payables 11,384   ¥ 4,124
Accrued professional service fee 2,318   8,090
Other payables 2,562   541
Other payables and accruals ¥ 32,840 $ 5,152 ¥ 12,755
XML 154 R110.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments with Preferred Rights - Summary of Series of Financings by Issuing Preferred Shares (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Disclosure Of Financial Instruments [Line Items]    
Number of preferred shares 43,057,316  
Subscription consideration ¥ 1,473,373  
Series Pre-A Preferred Shares    
Disclosure Of Financial Instruments [Line Items]    
Date of subscription Mar. 03, 2016  
Number of preferred shares 3,109,000  
Subscription consideration ¥ 33,110  
Series A Preferred Shares    
Disclosure Of Financial Instruments [Line Items]    
Date of subscription Jan. 03, 2017  
Number of preferred shares 8,471,200  
Subscription consideration ¥ 137,868  
Series B Preferred Shares    
Disclosure Of Financial Instruments [Line Items]    
Date of subscription Dec. 20, 2018  
Number of preferred shares 10,127,579  
Subscription consideration ¥ 379,148  
Series C Preferred Shares    
Disclosure Of Financial Instruments [Line Items]    
Date of subscription Aug. 21, 2020  
Date of subscription Dec. 01, 2020  
Number of preferred shares 21,349,537 0
Subscription consideration ¥ 923,247  
XML 155 R111.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments with Preferred Rights - Additional Information (Details)
12 Months Ended
Mar. 19, 2021
Dec. 31, 2021
CNY (¥)
shares
Dec. 31, 2021
$ / shares
shares
Dec. 31, 2020
CNY (¥)
shares
Mar. 18, 2021
shares
Disclosure Of Financial Instruments [Line Items]          
Number of shares issued   43,057,316 43,057,316    
Preferred Shares Conversion Ratio 1        
Financial Instruments with Preferred Rights          
Disclosure Of Financial Instruments [Line Items]          
Conversion from preferred shares to ordinary shares after share consolidation   24,745,572 24,745,572    
Preference Shares | Financial Instruments with Preferred Rights          
Disclosure Of Financial Instruments [Line Items]          
Number of shares issued at consolidation   46,232 46,232    
Number of shares issued         24,791,804
Number of shares outstanding         24,791,804
Payment made by holders of preferred shares upon or in connection with conversion of preferred shares into ordinary shares | ¥   ¥ 0      
Initial public offering price | $ / shares     $ 17    
Preferred Shares Conversion Ratio   1      
Preference Shares | Financial Instruments with Preferred Rights | Volatility          
Disclosure Of Financial Instruments [Line Items]          
Percentage of reasonably possible increase in unobservable input       5.00%  
Percentage of reasonably possible decrease in unobservable input       5.00%  
Loss before income tax lower due to change in unobservable input | ¥       ¥ 18,000,000.0  
Loss before income tax higher due to change in unobservable input | ¥       ¥ 18,100,000  
Preference Shares | Financial Instruments with Preferred Rights | Risk-Free Interest Rate          
Disclosure Of Financial Instruments [Line Items]          
Percentage of reasonably possible increase in unobservable input       1.00%  
Percentage of reasonably possible decrease in unobservable input       1.00%  
Loss before income tax lower due to change in unobservable input | ¥       ¥ 1,712,000  
Loss before income tax higher due to change in unobservable input | ¥       ¥ 887,000  
Preference Shares | Financial Instruments with Preferred Rights | Bottom of range          
Disclosure Of Financial Instruments [Line Items]          
Percentage of voting equity interests acquired   50.00% 50.00%    
Series A Preferred Shares          
Disclosure Of Financial Instruments [Line Items]          
Number of shares issued   8,471,200 8,471,200    
Series A Preferred Shares | Financial Instruments with Preferred Rights          
Disclosure Of Financial Instruments [Line Items]          
Redemption price percentage   150.00%      
Series B Preferred Shares          
Disclosure Of Financial Instruments [Line Items]          
Number of shares issued   10,127,579 10,127,579    
Series B Preferred Shares | Financial Instruments with Preferred Rights          
Disclosure Of Financial Instruments [Line Items]          
Internal rate of return   8.00%      
Series C Preferred Shares          
Disclosure Of Financial Instruments [Line Items]          
Number of shares issued   21,349,537 21,349,537 0  
Series C Preferred Shares | Financial Instruments with Preferred Rights          
Disclosure Of Financial Instruments [Line Items]          
Internal rate of return   8.00%      
XML 156 R112.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments with Preferred Rights - Movements of Financial Instruments with Preferred Rights (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Financial Instruments [Line Items]      
Share-based compensation to additional Series C preferred shareholder   ¥ 19,655  
Change in fair value due to foreign currency translation recognized in other comprehensive income ¥ (37,038) 47,032 ¥ (6,493)
Financial Instruments with Preferred Rights      
Disclosure Of Financial Instruments [Line Items]      
Beginning balance 2,071,508 643,008 573,499
Issuance of Series C Preferred Shares   923,247  
Change in fair value recognized in profit or loss 674,269 579,286 59,397
Share-based compensation to additional Series C preferred shareholder   19,655  
Change in fair value due to foreign currency translation recognized in other comprehensive income (2,152) (93,688) 10,112
Converted to ordinary shares upon IPO ¥ (2,743,625)    
Ending balance   ¥ 2,071,508 ¥ 643,008
XML 157 R113.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments with Preferred Rights - Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights (Details) - Financial Instruments with Preferred Rights
Dec. 31, 2020
Dec. 31, 2019
DLOM | Bottom of range    
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]    
Significant unobservable input, financial instruments with preferred rights 0.140 0.258
DLOM | Top of range    
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]    
Significant unobservable input, financial instruments with preferred rights 0.258 0.307
Expected Volatility | Bottom of range    
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]    
Significant unobservable input, financial instruments with preferred rights 0.640 0.550
Expected Volatility | Top of range    
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]    
Significant unobservable input, financial instruments with preferred rights 0.751 0.600
Risk-Free Interest Rate | Bottom of range    
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]    
Significant unobservable input, financial instruments with preferred rights 0.001 0.017
Risk-Free Interest Rate | Top of range    
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]    
Significant unobservable input, financial instruments with preferred rights 0.002 0.023
XML 158 R114.htm IDEA: XBRL DOCUMENT v3.22.1
Cash Flow Information - Summary of Cash Used in Operations (Details)
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Disclosure Of Cash Flow Information [Abstract]        
Loss before income tax ¥ (1,305,127) $ (204,703) ¥ (779,225) ¥ (168,625)
Adjustments for:        
Interest for lease liabilities 44   42 53
-Investment income from wealth management products (436)   (672) (798)
-Amortization of intangible assets 43   7  
-Depreciation of property, plant and equipment 3,130   955 383
-Depreciation of rights-of-use assets 909   481 407
-Share-based compensation expenses 57,863   25,190 3,875
-Net foreign exchange differences 3,309   6,772 (1,368)
-Fair value changes of financial instruments with preferred rights 674,269   579,286 59,397
-Issuance cost of financial instruments with preferred rights     2,851  
-Loss on disposal of property, plant and equipment 250      
Changes in working capital        
-Other receivables and prepayments (16,116)   (9,350) (3,026)
-Other non-current assets (8,206)   (3,906) (1,603)
-Other payables and accruals (11,459)   8,558 1,698
-Trade payables 56,601   1,850 19,351
Net cash used in operations ¥ (544,926) $ (85,469) ¥ (167,161) ¥ (90,256)
XML 159 R115.htm IDEA: XBRL DOCUMENT v3.22.1
Cash Flow Information - Summary of Non-cash Investing and Financing Activities (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Cash Flow Information [Abstract]      
Construction payables ¥ 16,576    
Fair value changes of financial instruments with preferred rights 674,269 ¥ 579,286 ¥ 59,397
Share-based compensation to additional Series C preferred shareholder   19,655  
Non-cash investing and financing activities ¥ 690,845 ¥ 598,941 ¥ 59,397
XML 160 R116.htm IDEA: XBRL DOCUMENT v3.22.1
Cash Flow Information - Summary of Reconciliation of Liabilities Arising from Financing Activities (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Financial Instruments with Preferred Rights      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Beginning balance ¥ 2,071,508 ¥ 643,008 ¥ 573,499
Cash flows   923,247  
Differences of foreign currency translation (2,152) (93,688) 10,112
Changes in fair value 674,269 579,286 59,397
Conversion to ordinary shares (2,743,625)    
Share-based compensation to additional Series C preferred shareholder   19,655  
Ending balance   2,071,508 643,008
Lease Liabilities      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Beginning balance 913 882 1,274
Cash flows (805) (538) (445)
New leases 641 527  
Interest expenses 44 42 53
Ending balance ¥ 793 ¥ 913 ¥ 882
XML 161 R117.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments - Schedule of Capital Commitments (Details) - CNY (¥)
¥ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Equipment and Intangible Assets - Contracted but not provided for    
Capital Commitments [Abstract]    
Capital commitments ¥ 146,878 ¥ 23,243
XML 162 R118.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments - Additional Information (Details)
¥ in Millions
1 Months Ended
Dec. 31, 2021
CNY (¥)
ft²
Dec. 31, 2020
CNY (¥)
San Diego, California    
Capital Commitments [Abstract]    
Square feet of operating lease area | ft² 3,600  
Lease term 3 years  
Aggregate lease obligation ¥ 0.6  
Construction in Progress    
Capital Commitments [Abstract]    
Capital commitments ¥ 146.9  
Equipment and Improvement    
Capital Commitments [Abstract]    
Capital commitments   ¥ 23.2
XML 163 R119.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions - Schedule of Significant Transactions with Related Parties (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Hangzhou Simo Company Limited    
Disclosure Of Transactions Between Related Parties [Line Items]    
Purchase of clinical trials related services ¥ 5,948 ¥ 5,601
Frontage Laboratories (Suzhou) Company Limited    
Disclosure Of Transactions Between Related Parties [Line Items]    
Purchase of clinical trials related services 2,157 2,346
Hangzhou Tigermed Consulting Company Limited    
Disclosure Of Transactions Between Related Parties [Line Items]    
Purchase of clinical trials related services 1,069 810
Beijing Medical Development (Suzhou) Company Limited    
Disclosure Of Transactions Between Related Parties [Line Items]    
Purchase of clinical trials related services 301 186
Shanghai Tigermed Consulting Company Limited    
Disclosure Of Transactions Between Related Parties [Line Items]    
Purchase of clinical trials related services ¥ 34 ¥ 891
XML 164 R120.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions - Schedule of Balances with Related Parties (Details) - CNY (¥)
¥ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Disclosure Of Transactions Between Related Parties [Line Items]    
Prepayments ¥ 36,879 ¥ 28,043
Hangzhou Tigermed Consulting Company Limited    
Disclosure Of Transactions Between Related Parties [Line Items]    
Prepayments   850
Hangzhou Simo Company Limited    
Disclosure Of Transactions Between Related Parties [Line Items]    
Prepayments   ¥ 507
XML 165 R121.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions - Summary of Key Management Personnel Compensation (Details) - CNY (¥)
¥ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Related Party Transactions [Abstract]      
Wages, salaries and bonuses ¥ 18,100 ¥ 8,013 ¥ 3,358
Share-based compensation expenses 28,266 1,148 2,749
Contributions to defined benefit plan   971 1,140
Welfare, housing funds and other 308 180 216
Key management personnel compensation ¥ 46,674 ¥ 10,312 ¥ 7,463
XML 166 R122.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions - Additional Information (Details) - shares
1 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2021
Ordinary Shares    
Disclosure Of Transactions Between Related Parties [Line Items]    
Repurchase of ordinary shares 20,765 20,765
XML 167 R123.htm IDEA: XBRL DOCUMENT v3.22.1
Restricted Net Assets and Parent Company Only Condensed Financial Information - Additional Information (Details)
12 Months Ended
Dec. 31, 2021
Restricted Net Assets And Parent Company Condensed Financial Information [Abstract]  
Percentage of annual require net after tax profits 10.00%
Percentage of reserve fund of registered capital 50.00%
XML 168 R124.htm IDEA: XBRL DOCUMENT v3.22.1
Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Balance Sheets (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
CNY (¥)
Dec. 31, 2018
CNY (¥)
Non-current assets            
Total non-current assets ¥ 101,524 $ 15,924 ¥ 28,070      
Current assets            
Cash and cash equivalents 1,706,880 267,716 1,010,076 $ 158,426 ¥ 308,972 ¥ 401,597
Total current assets 1,754,135 275,128 1,056,799      
Total assets 1,855,659 291,052 1,084,869      
Non-current liabilities            
Total non-current liabilities 5,163 810 2,071,817      
Current liabilities            
Trade payables 81,195 12,735 24,638      
Other payables and accruals 32,840 5,152 12,755      
Total current liabilities 114,665 17,985 37,997      
Total liabilities 119,828 18,795 2,109,814      
Net (liabilities)/assets 1,735,800 272,257 (1,024,945)      
SHAREHOLDERS' (DEFICIT)/EQUITY            
Share capital 66 10 24      
Share premium 4,094,434 642,194 41,466      
Treasury shares (1,164) (183) (3)      
Other reserves (41,244) (6,469) (1,693)      
Accumulated losses (2,378,165) (373,004) (1,071,341)      
Parent            
Non-current assets            
Interest in a subsidiary 1,177,380 184,667 472,273      
Total non-current assets 1,177,380 184,667 472,273      
Current assets            
Cash and cash equivalents 1,464,637 229,722 885,611 $ 138,904 ¥ 213,253 ¥ 267,665
Other receivables 86,352 13,544 84,278      
Other current assets     1,097      
Total current assets 1,550,989 243,266 970,986      
Total assets 2,728,369 427,933 1,443,259      
Non-current liabilities            
Financial instruments with preferred rights     2,071,508      
Total non-current liabilities     2,071,508      
Current liabilities            
Trade payables 49 7        
Other payables and accruals 34,190 5,364 6,864      
Total current liabilities 34,239 5,371 6,864      
Total liabilities 34,239 5,371 2,078,372      
Net (liabilities)/assets 2,694,130 422,562 (635,113)      
SHAREHOLDERS' (DEFICIT)/EQUITY            
Share capital 66 10 24      
Share premium 4,094,434 642,194 41,466      
Treasury shares (1,164) (183) (3)      
Other reserves (10,359) (1,625) (5,732)      
Accumulated losses (1,388,847) (217,834) (670,868)      
Total shareholders' (deficit)/equity ¥ 2,694,130 $ 422,562 ¥ (635,113)      
XML 169 R125.htm IDEA: XBRL DOCUMENT v3.22.1
Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Loss (Details)
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Disclosure Of Financial Information [Line Items]        
Administrative expenses ¥ (122,445) $ (19,205) ¥ (47,720) ¥ (9,713)
Operating loss (631,400) (99,038) (197,763) (110,241)
Finance income/(costs)-net 578 91 (2,176) 1,013
Fair value loss of financial instruments with preferred rights (674,269) (105,756) (579,286) (59,397)
Loss before income tax (1,305,127) (204,703) (779,225) (168,625)
Income tax expense (1,697) (266)    
Net loss (1,306,824) (204,969) (779,225) (168,625)
Parent        
Disclosure Of Financial Information [Line Items]        
Administrative expenses (43,710) (6,856) (29,540) (23)
Operating loss (43,710) (6,856) (29,540) (23)
Finance income/(costs)-net     (2,758) 335
Fair value loss of financial instruments with preferred rights (674,269) (105,756) (579,286) (59,397)
Loss before income tax (717,979) (112,612) (611,584) (59,085)
Net loss ¥ (717,979) $ (112,612) ¥ (611,584) ¥ (59,085)
XML 170 R126.htm IDEA: XBRL DOCUMENT v3.22.1
Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Cash Flows (Details)
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
CNY (¥)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Disclosure Of Financial Information [Line Items]        
Net cash from/(used in) operating activities ¥ (544,900) $ (85,469) ¥ (167,161) ¥ (90,256)
Net cash used in investing activities (34,025) (5,338) 2,932 (3,341)
Net cash generated from financing activities 1,316,099 206,424 918,761 (396)
Net (decrease) increase in cash and cash equivalents 737,148 115,617 754,532 (93,993)
Cash and cash equivalents at the beginning of year 1,010,076 158,426 308,972 401,597
Effects of exchange rate changes on cash and cash equivalents (40,344) (6,327) (53,428) 1,368
Cash and cash equivalents at end of year 1,706,880 267,716 1,010,076 308,972
Parent        
Disclosure Of Financial Information [Line Items]        
Net cash from/(used in) operating activities (31,025) (4,866) (4,766) 249
Net cash used in investing activities (672,529) (105,483) (204,170) (159,057)
Net cash generated from financing activities 1,319,418 206,945 934,284 99,990
Net (decrease) increase in cash and cash equivalents 615,864 96,596 725,348 (58,818)
Cash and cash equivalents at the beginning of year 885,611 138,904 213,253 267,665
Effects of exchange rate changes on cash and cash equivalents (36,838) (5,778) (52,990) 4,406
Cash and cash equivalents at end of year ¥ 1,464,637 $ 229,722 ¥ 885,611 ¥ 213,253
XML 171 R127.htm IDEA: XBRL DOCUMENT v3.22.1
Events After the Reporting Period - Additional Information (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2022
shares
$ / shares
Dec. 31, 2021
shares
$ / shares
Dec. 31, 2020
shares
$ / shares
Dec. 31, 2019
shares
$ / shares
Disclosure of non-adjusting events after reporting period [line items]        
Share options granted | shares   2,403,660 1,500,887 198,064
weighted average exercise price | $ / shares   $ 13.8 $ 6.6 $ 0.9
Ordinary Share Options        
Disclosure of non-adjusting events after reporting period [line items]        
Share options granted | shares 2,044,741      
weighted average exercise price | $ / shares $ 4.45      
XML 172 cntb-20211231_htm.xml IDEA: XBRL DOCUMENT 0001835268 ifrs-full:GrossCarryingAmountMember cntb:OfficeEquipmentFurnitureAndOthersMember 2020-12-31 0001835268 ifrs-full:SharePremiumMember 2018-12-31 0001835268 cntb:IssuedCapitalAndSharePremiumMember 2021-01-01 2021-12-31 0001835268 ifrs-full:CurrencyRiskMember 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:TopOfRangeMember cntb:DiscountRateForLackOfMarketabilityMeasurementInputMember 2020-12-31 0001835268 ifrs-full:LeaseLiabilitiesMember 2020-01-01 2020-12-31 0001835268 ifrs-full:ForeignCountriesMember 2020-12-31 0001835268 ifrs-full:ParentMember 2019-01-01 2019-12-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember cntb:OfficeEquipmentFurnitureAndOthersMember 2021-12-31 0001835268 ifrs-full:ConstructionInProgressMember 2021-12-31 0001835268 country:HK 2021-01-01 2021-12-31 0001835268 ifrs-full:FinancialAssetsAtFairValueMember 2020-12-31 0001835268 stpr:CA cntb:ConnectUSMember 2021-01-01 2021-12-31 0001835268 cntb:IssuedCapitalAndSharePremiumMember 2020-01-01 2020-12-31 0001835268 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember ifrs-full:CreditRiskMember 2021-12-31 0001835268 cntb:LandUseRightsMember 2021-12-31 0001835268 cntb:AdministrativeExpensesMember 2021-01-01 2021-12-31 0001835268 2021-03-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember cntb:LaboratoryEquipmentMember 2021-12-31 0001835268 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2020-12-31 0001835268 country:US cntb:ConnectHKMember 2019-01-01 2019-12-31 0001835268 cntb:OtherReceivablesMember 2020-12-31 0001835268 cntb:ShanghaiConnectBiopharmaceuticalsLimitedMember 2021-01-01 2021-12-31 0001835268 ifrs-full:OrdinarySharesMember cntb:ConnectUnionMember 2021-12-31 0001835268 ifrs-full:GrossCarryingAmountMember cntb:LaboratoryEquipmentMember 2021-12-31 0001835268 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001835268 cntb:OtherPayablesMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2021-12-31 0001835268 ifrs-full:CreditRiskMember 2020-12-31 0001835268 ifrs-full:OtherReservesMember 2021-01-01 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:TopOfRangeMember cntb:RiskFreeInterestRateMeasurementInputMember 2020-12-31 0001835268 cntb:WealthManagementProductsMember 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:BottomOfRangeMember ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2019-12-31 0001835268 cntb:SeriesCPreferredSharesMember cntb:SharePurchaseAgreementMember 2020-08-01 2020-08-31 0001835268 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001835268 2021-03-12 2021-03-12 0001835268 cntb:CashAndCashEquivalentMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2021-12-31 0001835268 cntb:HangzhouTigermedConsultingCompanyLimitedMember 2020-01-01 2020-12-31 0001835268 ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2020-12-31 0001835268 cntb:AfterShareConsolidationMember 2021-12-31 0001835268 ifrs-full:ParentMember 2020-01-01 2020-12-31 0001835268 cntb:ConnectUSMember 2019-01-01 2019-12-31 0001835268 cntb:LaboratoryEquipmentMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001835268 stpr:CA 2021-12-31 0001835268 cntb:ResearchAndDevelopmentExpensesMember 2019-01-01 2019-12-31 0001835268 ifrs-full:OrdinarySharesMember cntb:ConnectUnionMember 2018-12-20 0001835268 ifrs-full:GrossCarryingAmountMember cntb:LaboratoryEquipmentMember 2020-12-31 0001835268 cntb:ConnectAUMember 2021-01-01 2021-12-31 0001835268 cntb:SharePurchaseAgreementMember 2020-01-01 2020-12-31 0001835268 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001835268 ifrs-full:CreditRiskMember 2021-12-31 0001835268 ifrs-full:OtherReservesMember 2020-12-31 0001835268 ifrs-full:Level3OfFairValueHierarchyMember 2021-01-01 2021-12-31 0001835268 country:CN 2020-12-31 0001835268 ifrs-full:OrdinarySharesMember cntb:CoFoundersMember 2021-12-31 0001835268 ifrs-full:IssuedCapitalMember 2020-12-31 0001835268 cntb:LaboratoryEquipmentMember 2021-12-31 0001835268 cntb:TwentyTwentyOneStockIncentivePlanMember 2021-01-01 2021-12-31 0001835268 2020-12-31 0001835268 ifrs-full:GrossCarryingAmountMember ifrs-full:ConstructionInProgressMember 2021-12-31 0001835268 country:AU cntb:ConnectAUMember 2020-01-01 2020-12-31 0001835268 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember 2020-12-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2021-12-31 0001835268 cntb:SeriesAPreferredSharesMember 2021-12-31 0001835268 cntb:OfficeEquipmentFurnitureAndOthersMember 2021-01-01 2021-12-31 0001835268 ifrs-full:SharePremiumMember 2019-12-31 0001835268 cntb:SeriesBFinancingMember ifrs-full:OrdinarySharesMember cntb:CoFoundersMember 2018-12-20 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:LeaseholdImprovementsMember 2019-12-31 0001835268 2021-03-12 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:PreferenceSharesMember cntb:RiskFreeInterestRateMeasurementInputMember 2020-01-01 2020-12-31 0001835268 ifrs-full:ConstructionInProgressMember 2020-12-31 0001835268 ifrs-full:ConstructionInProgressMember 2020-01-01 2020-12-31 0001835268 ifrs-full:LeaseLiabilitiesMember 2018-12-31 0001835268 2021-05-01 2021-05-31 0001835268 cntb:TwentyTwentyOneEmployeeSharePurchasePlanMember 2021-01-01 2021-12-31 0001835268 cntb:OfficeRentMember 2020-12-31 0001835268 ifrs-full:BottomOfRangeMember 2019-01-01 2019-12-31 0001835268 cntb:CashAndCashEquivalentMember 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2020-12-31 0001835268 ifrs-full:LeaseLiabilitiesMember 2019-01-01 2019-12-31 0001835268 ifrs-full:TreasurySharesMember 2021-01-01 2021-12-31 0001835268 ifrs-full:ParentMember 2021-01-01 2021-12-31 0001835268 ifrs-full:SharePremiumMember 2021-12-31 0001835268 2021-03-19 2021-03-19 0001835268 ifrs-full:GrossCarryingAmountMember cntb:LaboratoryEquipmentMember 2019-12-31 0001835268 country:CN 2020-01-01 2020-12-31 0001835268 cntb:AdministrativeExpensesMember 2020-01-01 2020-12-31 0001835268 cntb:LaboratoryEquipmentMember 2020-01-01 2020-12-31 0001835268 country:HK 2019-01-01 2019-12-31 0001835268 country:US 2020-12-31 0001835268 ifrs-full:GrossCarryingAmountMember ifrs-full:ConstructionInProgressMember 2020-12-31 0001835268 ifrs-full:FinancialLiabilitiesAtFairValueMember 2020-12-31 0001835268 cntb:HangzhouTigermedConsultingCompanyLimitedMember 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2020-01-01 2020-12-31 0001835268 ifrs-full:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001835268 cntb:OfficeEquipmentAndFurnitureMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001835268 cntb:LaboratoryEquipmentMember 2020-12-31 0001835268 ifrs-full:OrdinarySharesMember 2019-12-31 0001835268 ifrs-full:OtherReservesMember 2020-01-01 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:PreferenceSharesMember cntb:RiskFreeInterestRateMeasurementInputMember 2020-12-31 0001835268 country:HK 2018-04-01 2018-04-01 0001835268 cntb:FrontageLaboratoriesSuzhouCompanyLimitedMember 2020-01-01 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:TopOfRangeMember cntb:DiscountRateForLackOfMarketabilityMeasurementInputMember 2019-12-31 0001835268 ifrs-full:LeaseholdImprovementsMember 2021-12-31 0001835268 ifrs-full:OrdinarySharesMember 2018-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:PreferenceSharesMember ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2020-12-31 0001835268 cntb:SeriesCPreferredSharesMember cntb:SharePurchaseAgreementMember 2020-12-01 0001835268 country:AU 2020-12-31 0001835268 cntb:OtherPayablesMember 2020-12-31 0001835268 2020-01-01 2020-12-31 0001835268 cntb:CoFoundersMember 2020-01-01 2020-12-31 0001835268 cntb:OfficeRentMember 2021-12-31 0001835268 ifrs-full:GrossCarryingAmountMember 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:TopOfRangeMember cntb:RiskFreeInterestRateMeasurementInputMember 2019-12-31 0001835268 stpr:CA 2021-12-01 2021-12-31 0001835268 ifrs-full:LeaseLiabilitiesMember 2021-01-01 2021-12-31 0001835268 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-12-31 0001835268 ifrs-full:IssuedCapitalMember 2020-01-01 2020-12-31 0001835268 ifrs-full:OtherReservesMember 2021-12-31 0001835268 ifrs-full:NotLaterThanOneYearMember ifrs-full:CreditRiskMember 2021-12-31 0001835268 ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember ifrs-full:CreditRiskMember 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2019-12-31 0001835268 ifrs-full:GrossCarryingAmountMember cntb:OfficeEquipmentFurnitureAndOthersMember 2021-12-31 0001835268 cntb:LaboratoryEquipmentMember 2021-01-01 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2021-01-01 2021-12-31 0001835268 ifrs-full:OtherReservesMember 2019-01-01 2019-12-31 0001835268 ifrs-full:BottomOfRangeMember 2021-12-31 0001835268 cntb:SeriesCPreferredSharesMember cntb:SharePurchaseAgreementMember 2020-11-30 2020-12-01 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:FinancialLiabilitiesAtFairValueMember 2020-12-31 0001835268 cntb:OtherPayablesMember 2021-12-31 0001835268 2018-12-31 0001835268 ifrs-full:OrdinarySharesMember 2021-03-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:BottomOfRangeMember cntb:DiscountRateForLackOfMarketabilityMeasurementInputMember 2019-12-31 0001835268 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-12-31 0001835268 cntb:OfficeEquipmentFurnitureAndOthersMember 2020-12-31 0001835268 cntb:SeriesCPreferredSharesMember cntb:CoFoundersMember 2021-03-31 0001835268 ifrs-full:TopOfRangeMember 2021-12-31 0001835268 ifrs-full:RecurringFairValueMeasurementMember 2020-12-31 0001835268 cntb:HangzhouSimoCompanyLimitedMember 2020-12-31 0001835268 cntb:SeriesAPreferredSharesMember 2021-01-01 2021-12-31 0001835268 cntb:BeijingMedicalDevelopmentSuzhouCompanyLimitedMember 2019-01-01 2019-12-31 0001835268 ifrs-full:OrdinarySharesMember cntb:CoFoundersMember 2020-01-20 2020-01-20 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember cntb:OfficeEquipmentFurnitureAndOthersMember 2019-12-31 0001835268 2021-12-31 0001835268 ifrs-full:IssuedCapitalMember 2021-01-01 2021-12-31 0001835268 country:AU 2021-12-31 0001835268 ifrs-full:LeaseholdImprovementsMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001835268 cntb:SeriesPreAPreferredSharesMember 2021-01-01 2021-12-31 0001835268 country:CN 2019-01-01 2019-12-31 0001835268 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:LeaseLiabilitiesMember 2021-12-31 0001835268 ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:PreferenceSharesMember 2021-01-01 2021-12-31 0001835268 cntb:EquipmentAndIntangibleAssetsMember 2020-12-31 0001835268 ifrs-full:ParentMember 2021-12-31 0001835268 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-01-01 2021-12-31 0001835268 cntb:ShanghaiTigermedConsultingCompanyLimitedMember 2019-01-01 2019-12-31 0001835268 cntb:TwoThousandNineteenStockIncentivePlanMember 2021-01-01 2021-12-31 0001835268 ifrs-full:ConstructionInProgressMember 2021-01-01 2021-12-31 0001835268 ifrs-full:OrdinarySharesMember cntb:CoFoundersMember 2019-01-01 2019-12-31 0001835268 ifrs-full:SharePremiumMember 2019-01-01 2019-12-31 0001835268 ifrs-full:OrdinarySharesMember 2021-01-01 2021-12-31 0001835268 ifrs-full:BottomOfRangeMember 2020-12-31 0001835268 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember ifrs-full:CreditRiskMember 2020-12-31 0001835268 ifrs-full:SharePremiumMember 2020-01-01 2020-12-31 0001835268 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-01-01 2020-12-31 0001835268 ifrs-full:ParentMember 2018-12-31 0001835268 ifrs-full:GrossCarryingAmountMember ifrs-full:LeaseholdImprovementsMember 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:TopOfRangeMember ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2020-12-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:LeaseholdImprovementsMember 2020-12-31 0001835268 cntb:TwentyTwentyOneEmployeeSharePurchasePlanMember 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:PreferenceSharesMember 2021-03-18 0001835268 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember ifrs-full:FinancialAssetsAtFairValueMember 2020-12-31 0001835268 ifrs-full:Level3OfFairValueHierarchyMember 2019-01-01 2019-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2020-12-31 0001835268 ifrs-full:TreasurySharesMember 2020-12-31 0001835268 cntb:HangzhouTigermedConsultingCompanyLimitedMember 2019-01-01 2019-12-31 0001835268 cntb:IssuedCapitalAndSharePremiumMember 2019-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2020-01-01 2020-12-31 0001835268 cntb:LaboratoryEquipmentMember 2019-12-31 0001835268 ifrs-full:ParentMember 2019-12-31 0001835268 cntb:IssuedCapitalAndSharePremiumMember 2020-12-31 0001835268 cntb:OfficeEquipmentAndFurnitureMember ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001835268 ifrs-full:TopOfRangeMember 2020-12-31 0001835268 ifrs-full:NotLaterThanOneYearMember ifrs-full:CreditRiskMember 2020-12-31 0001835268 cntb:ResearchAndDevelopmentExpensesMember 2021-01-01 2021-12-31 0001835268 dei:BusinessContactMember 2021-01-01 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:TopOfRangeMember ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2019-12-31 0001835268 ifrs-full:LeaseholdImprovementsMember 2019-12-31 0001835268 ifrs-full:GrossCarryingAmountMember cntb:OfficeEquipmentFurnitureAndOthersMember 2019-12-31 0001835268 cntb:IssuedCapitalAndSharePremiumMember 2021-12-31 0001835268 cntb:TradePayablesMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2020-12-31 0001835268 cntb:SeriesCPreferredSharesMember cntb:SharePurchaseAgreementMember 2020-08-31 0001835268 cntb:EquipmentAndImprovementMember cntb:SuzhouMember 2020-12-31 0001835268 cntb:ConnectUSMember 2020-01-01 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember cntb:SeriesBPreferredSharesMember 2021-01-01 2021-12-31 0001835268 cntb:TradePayablesMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2021-12-31 0001835268 cntb:BeijingConnectBiopharmaceuticalsLimitedMember 2021-01-01 2021-12-31 0001835268 ifrs-full:LeaseLiabilitiesMember 2020-12-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember cntb:OfficeEquipmentFurnitureAndOthersMember 2020-12-31 0001835268 ifrs-full:ReserveOfSharebasedPaymentsMember 2019-01-01 2019-12-31 0001835268 ifrs-full:ReserveOfSharebasedPaymentsMember 2018-12-31 0001835268 ifrs-full:OrdinarySharesMember cntb:CoFoundersMember 2020-01-20 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:BottomOfRangeMember cntb:RiskFreeInterestRateMeasurementInputMember 2019-12-31 0001835268 ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:PreferenceSharesMember 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2019-01-01 2019-12-31 0001835268 stpr:CA cntb:ConnectUSMember 2019-01-01 2019-12-31 0001835268 ifrs-full:TreasurySharesMember 2018-12-31 0001835268 ifrs-full:TopOfRangeMember 2020-01-01 2020-12-31 0001835268 cntb:HangzhouSimoCompanyLimitedMember 2020-01-01 2020-12-31 0001835268 cntb:IssuedCapitalAndSharePremiumMember 2019-01-01 2019-12-31 0001835268 country:AU cntb:ConnectAUMember 2021-01-01 2021-12-31 0001835268 ifrs-full:OtherReservesMember 2018-12-31 0001835268 cntb:SeriesBPreferredSharesMember 2021-01-01 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2018-12-31 0001835268 cntb:TradePayablesMember 2020-12-31 0001835268 cntb:OfficeRentMember 2019-01-01 2019-12-31 0001835268 cntb:OtherReceivablesMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2020-12-31 0001835268 cntb:LaboratoryEquipmentMember ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001835268 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:LeaseLiabilitiesMember 2020-12-31 0001835268 ifrs-full:ComputerSoftwareMember 2021-01-01 2021-12-31 0001835268 ifrs-full:FinancialAssetsAtAmortisedCostMember 2020-12-31 0001835268 cntb:OtherReceivablesMember 2021-12-31 0001835268 ifrs-full:GrossCarryingAmountMember ifrs-full:LeaseholdImprovementsMember 2019-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:BottomOfRangeMember cntb:RiskFreeInterestRateMeasurementInputMember 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2018-12-31 0001835268 cntb:HangzhouSimoCompanyLimitedMember 2019-01-01 2019-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2021-12-31 0001835268 cntb:OfficeEquipmentFurnitureAndOthersMember 2019-12-31 0001835268 cntb:OfficeRentMember 2019-12-31 0001835268 country:HK 2020-01-01 2020-12-31 0001835268 ifrs-full:ParentMember 2020-12-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:LeaseholdImprovementsMember 2021-12-31 0001835268 ifrs-full:LeaseLiabilitiesMember 2019-12-31 0001835268 country:CN 2021-01-01 2021-12-31 0001835268 ifrs-full:IssuedCapitalMember 2021-12-31 0001835268 cntb:AdministrativeExpensesMember 2019-01-01 2019-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:BottomOfRangeMember ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2020-12-31 0001835268 cntb:OfficeEquipmentFurnitureAndOthersMember 2020-01-01 2020-12-31 0001835268 ifrs-full:Level3OfFairValueHierarchyMember 2020-01-01 2020-12-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember cntb:LaboratoryEquipmentMember 2020-12-31 0001835268 cntb:IssuedCapitalAndSharePremiumMember 2018-12-31 0001835268 cntb:SeriesBPreferredSharesMember 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:BottomOfRangeMember cntb:DiscountRateForLackOfMarketabilityMeasurementInputMember 2020-12-31 0001835268 cntb:CashAndCashEquivalentMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2020-12-31 0001835268 ifrs-full:OrdinarySharesMember 2021-03-01 2021-03-31 0001835268 cntb:EquipmentAndImprovementMember 2020-12-31 0001835268 cntb:TradePayablesMember 2021-12-31 0001835268 ifrs-full:OrdinarySharesMember 2020-01-01 2020-12-31 0001835268 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001835268 stpr:CA cntb:ConnectUSMember 2020-01-01 2020-12-31 0001835268 ifrs-full:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001835268 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2021-12-31 0001835268 ifrs-full:TreasurySharesMember 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:PreferenceSharesMember ifrs-full:BottomOfRangeMember 2021-12-31 0001835268 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001835268 country:US cntb:ConnectHKMember 2020-01-01 2020-12-31 0001835268 2019-01-01 2019-12-31 0001835268 cntb:EquipmentAndIntangibleAssetsMember 2021-12-31 0001835268 ifrs-full:FinancialAssetsAtAmortisedCostMember 2021-12-31 0001835268 ifrs-full:OtherReservesMember 2019-12-31 0001835268 ifrs-full:SharePremiumMember 2021-01-01 2021-12-31 0001835268 cntb:SeriesCPreferredSharesMember 2021-12-31 0001835268 2020-04-01 2020-04-30 0001835268 ifrs-full:GrossCarryingAmountMember 2019-12-31 0001835268 ifrs-full:TreasurySharesMember 2020-01-01 2020-12-31 0001835268 cntb:SeriesCPreferredSharesMember 2020-12-31 0001835268 cntb:ShanghaiTigermedConsultingCompanyLimitedMember 2020-01-01 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember cntb:SeriesAPreferredSharesMember 2021-01-01 2021-12-31 0001835268 2021-01-01 2021-12-31 0001835268 cntb:OfficeRentMember 2020-01-01 2020-12-31 0001835268 cntb:OtherPayablesMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2020-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2019-12-31 0001835268 cntb:CashAndCashEquivalentMember 2020-12-31 0001835268 ifrs-full:IssuedCapitalMember 2019-12-31 0001835268 cntb:ConnectUSMember 2021-01-01 2021-12-31 0001835268 country:CN 2021-12-31 0001835268 2021-03-01 2021-03-31 0001835268 country:US 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember cntb:SeriesCPreferredSharesMember 2021-01-01 2021-12-31 0001835268 ifrs-full:Level3OfFairValueHierarchyMember 2020-12-31 0001835268 2018-12-19 2018-12-20 0001835268 cntb:ConnectSzMember 2021-01-01 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2021-01-01 2021-12-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember cntb:LaboratoryEquipmentMember 2019-12-31 0001835268 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001835268 country:AU cntb:ConnectAUMember 2019-01-01 2019-12-31 0001835268 ifrs-full:LeaseholdImprovementsMember 2020-12-31 0001835268 cntb:LandUseRightsMember 2021-01-01 2021-12-31 0001835268 ifrs-full:CurrencyRiskMember 2020-12-31 0001835268 cntb:SeriesCPreferredSharesMember 2021-01-01 2021-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2019-01-01 2019-12-31 0001835268 cntb:OfficeRentMember 2018-12-31 0001835268 cntb:SeriesPreAPreferredSharesMember 2021-12-31 0001835268 ifrs-full:IssuedCapitalMember 2018-12-31 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember ifrs-full:PreferenceSharesMember ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2020-01-01 2020-12-31 0001835268 cntb:OfficeRentMember 2021-01-01 2021-12-31 0001835268 cntb:ConnectHKMember 2021-01-01 2021-12-31 0001835268 ifrs-full:LeaseholdImprovementsMember ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001835268 ifrs-full:BottomOfRangeMember 2020-01-01 2020-12-31 0001835268 cntb:OfficeEquipmentFurnitureAndOthersMember 2021-12-31 0001835268 ifrs-full:ReserveOfSharebasedPaymentsMember 2019-12-31 0001835268 ifrs-full:ForeignCountriesMember 2021-12-31 0001835268 cntb:FrontageLaboratoriesSuzhouCompanyLimitedMember 2019-01-01 2019-12-31 0001835268 ifrs-full:Level3OfFairValueHierarchyMember 2018-12-31 0001835268 country:HK ifrs-full:BottomOfRangeMember 2018-04-01 2018-04-01 0001835268 ifrs-full:OrdinarySharesMember cntb:ConnectUnionMember 2020-01-20 0001835268 cntb:FinancialInstrumentsWithPreferredRightsMember 2020-12-31 0001835268 ifrs-full:LeaseLiabilitiesMember 2021-12-31 0001835268 ifrs-full:GrossCarryingAmountMember 2021-12-31 0001835268 ifrs-full:OrdinarySharesMember 2021-12-31 0001835268 cntb:AfterShareConsolidationMember 2020-12-31 0001835268 cntb:CoFoundersMember 2021-01-01 2021-12-31 0001835268 ifrs-full:MajorOrdinaryShareTransactionsMember 2022-01-01 2022-03-31 0001835268 cntb:ResearchAndDevelopmentExpensesMember 2020-01-01 2020-12-31 0001835268 cntb:BeijingMedicalDevelopmentSuzhouCompanyLimitedMember 2020-01-01 2020-12-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2020-12-31 0001835268 ifrs-full:TopOfRangeMember 2019-01-01 2019-12-31 0001835268 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2019-12-31 0001835268 ifrs-full:Level3OfFairValueHierarchyMember 2019-12-31 0001835268 ifrs-full:TreasurySharesMember 2019-12-31 0001835268 ifrs-full:OrdinarySharesMember 2020-12-31 0001835268 2019-12-31 0001835268 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001835268 ifrs-full:SharePremiumMember 2020-12-31 0001835268 cntb:ConnectUSMember 2021-01-01 2021-12-31 0001835268 cntb:OtherReceivablesMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2021-12-31 0001835268 cntb:ShenzhenConnectBiopharmaceuticalsLimitedMember 2021-01-01 2021-12-31 0001835268 ifrs-full:OrdinarySharesMember 2021-03-12 0001835268 cntb:CoFoundersMember 2019-01-01 2019-12-31 0001835268 ifrs-full:GrossCarryingAmountMember ifrs-full:LeaseholdImprovementsMember 2020-12-31 0001835268 ifrs-full:GovernmentMember 2021-01-01 2021-12-31 pure utr:sqft shares cntb:Segment iso4217:HKD iso4217:CNY iso4217:USD shares iso4217:CNY iso4217:USD utr:Y iso4217:USD iso4217:CNY shares false 0 0 0 0001835268 FY --12-31 0 0 0 20-F false true 2021-12-31 2021 false false 001-40212 Connect Biopharma Holdings Limited E9 Science and Technology Park, East R&D Building, 3rd Floor 6 Beijing West Road Taicang, Jiangsu CN 215400 Dr. Zheng Wei Science and Technology Park, East R&D Building, 3rd Floor 6 Beijing West Road Taicang, Jiangsu 215400 CN +86 512 5357 7866 +86 (21) 57940050 American Depositary Shares, each representing one Ordinary Share, par value $0.000174 per Share CNTB NASDAQ 55076319 No No Yes Yes Non-accelerated Filer true false false International Financial Reporting Standards false 1424 PricewaterhouseCoopers Zhong Tian LLP Beijing, the People’s Republic of China 106414000 150932000 518021000 81249000 9713000 47720000 122445000 19205000 2836000 6989000 18996000 2979000 3050000 -6100000 -9966000 -1563000 -110241000 -197763000 -631436000 -99038000 1066000 717000 622000 98000 53000 2893000 44000 7000 1013000 -2176000 578000 91000 -59397000 -579286000 -674269000 -105756000 -168625000 -779225000 -1305127000 -204703000 1697000 266000 -168625000 -779225000 -1306824000 -204969000 -168625000 -779225000 -1306824000 -204969000 -10.0 -45.6 -25.0 -3.9 -168625000 -779225000 -1306824000 -204969000 -6027000 34655000 20426000 3204000 -466000 12377000 -57464000 -9013000 -6493000 47032000 -37038000 -5809000 -175118000 -732193000 -1343862000 -210778000 -175118000 -732193000 -1343862000 -210778000 6939000 59337000 9307000 929000 22821000 3579000 19860000 18806000 2950000 342000 560000 88000 28070000 101524000 15924000 33655000 47255000 7412000 13068000 1010076000 1706880000 267716000 1056799000 1754135000 275128000 1084869000 1855659000 291052000 309000 163000 26000 2071508000 5000000 784000 2071817000 5163000 810000 24638000 81195000 12735000 12755000 32840000 5152000 604000 630000 98000 37997000 114665000 17985000 2109814000 119828000 18795000 -1024945000 1735831000 272257000 24000 66000 10000 41466000 4094434000 642194000 3000 1164000 183000 6602000 61904000 9709000 -1693000 -41244000 -6469000 -1071341000 -2378165000 -373004000 -1024945000 1735831000 272257000 1084869000 1855659000 291052000 21000 38074000 -1000 584000 -42280000 -123491000 -127093000 -168625000 -168625000 -6493000 -6493000 -6493000 -168625000 -175118000 49000 -48000 48000 49000 3875000 3875000 49000 3827000 48000 3924000 21000 38123000 -1000 4411000 -48725000 -292116000 -298287000 -779225000 -779225000 47032000 47032000 47032000 -779225000 -732193000 1000 3343000 -3344000 2000 -2000 5535000 5535000 3000 3343000 -2000 2191000 5535000 24000 41466000 -3000 6602000 -1693000 -1071341000 -1024945000 24000 41466000 -3000 6602000 -1693000 -1071341000 -1024945000 -1306824000 -1306824000 -37038000 -37038000 -37038000 -1306824000 -1343862000 14000 1305805000 1305819000 28000 2743597000 2743625000 -1161000 -2513000 -3674000 1417000 -1417000 2149000 -1144000 1005000 57863000 57863000 42000 4052968000 -1161000 55302000 -2513000 4104638000 66000 4094434000 -1164000 61904000 -41244000 -2378165000 1735831000 -90256000 -167161000 -544926000 -85469000 -90256000 -167161000 -544926000 -85469000 1072000 14955000 24941000 3912000 163000000 106600000 114500000 17959000 160731000 124836000 128004000 20076000 22284000 3495000 349000 304000 48000 -3341000 2932000 -34025000 -5338000 49000 243000 38000 1431775000 224567000 923247000 445000 538000 805000 126000 3674000 576000 2851000 1097000 111440000 17479000 -396000 918761000 1316099000 206424000 -93993000 754532000 737148000 115617000 401597000 308972000 1010076000 158426000 1368000 -53428000 -40344000 -6327000 308972000 1010076000 1706880000 267716000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. General Information, Reorganization and Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">1.1 General information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma Holdings Limited (the “Company”) was incorporated on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 23, 2015</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cayman Islands</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as an exempted company with limited liability. The address of the Company’s registered office is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">P.O. Box 613, Harbour Centre, George Town, Grand Cayman KY1-1107, Cayman Islands.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company completed its initial public offering (“IPO”) in March 2021 and the Company’s American Depositary Shares (“ADSs”) have been listed on the Nasdaq Global Market (“Nasdaq”) since then. Each ADS of the Company represents </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary share, par value USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.000174</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company and its subsidiaries (collectively the “Group”) is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. The Group has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. The Group currently carries out clinical trials on its product candidates in the United States, People’s Republic of China (“PRC”), Australia, Europe, and other jurisdictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Group had direct or indirect interests in the following principal subsidiaries:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:32.152%;"/> <td style="width:1.002%;"/> <td style="width:20.788%;"/> <td style="width:1.002%;"/> <td style="width:25.158%;"/> <td style="width:1.002%;"/> <td style="width:0.603%;"/> <td style="width:16.289%;"/> <td style="width:2.004%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Company name</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Principal activities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Place and date of incorporation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Attributable equity interest to the Group</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Directly Held:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma HongKong Limited (“Connect HK”)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment holding</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hong Kong</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 1, 2015</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Indirectly held:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharm LLC (“Connect US”)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Diego, United States of America</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 24, 2012</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma Australia PTY LTD (“Connect AU”)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prahran, Australia</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 18, 2014</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Suzhou Connect Biopharma Co., Ltd. (“Connect SZ”)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Suzhou, PRC</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 2, 2012</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma (Shanghai) Co., Ltd</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shanghai, PRC</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 23, 2015</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma (Beijing) Co., Ltd</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beijing, PRC</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 9, 2019</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma (Shenzhen) Co., Ltd</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dormant</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shenzhen, PRC</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 15, 2021</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table></div> 2015-11-23 Cayman Islands P.O. Box 613, Harbour Centre, George Town, Grand Cayman KY1-1107, Cayman Islands. 1 0.000174 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Group had direct or indirect interests in the following principal subsidiaries:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:32.152%;"/> <td style="width:1.002%;"/> <td style="width:20.788%;"/> <td style="width:1.002%;"/> <td style="width:25.158%;"/> <td style="width:1.002%;"/> <td style="width:0.603%;"/> <td style="width:16.289%;"/> <td style="width:2.004%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Company name</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Principal activities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Place and date of incorporation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Attributable equity interest to the Group</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Directly Held:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma HongKong Limited (“Connect HK”)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment holding</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hong Kong</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 1, 2015</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Indirectly held:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharm LLC (“Connect US”)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Diego, United States of America</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 24, 2012</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma Australia PTY LTD (“Connect AU”)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prahran, Australia</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 18, 2014</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Suzhou Connect Biopharma Co., Ltd. (“Connect SZ”)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Suzhou, PRC</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 2, 2012</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma (Shanghai) Co., Ltd</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shanghai, PRC</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 23, 2015</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma (Beijing) Co., Ltd</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical R&amp;D</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beijing, PRC</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 9, 2019</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect Biopharma (Shenzhen) Co., Ltd</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dormant</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shenzhen, PRC</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 15, 2021</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table> Investment holding Hong Kong 2015-12-01 1 Pharmaceutical R&D San Diego, United States of America 2012-01-24 1 Pharmaceutical R&D Prahran, Australia 2014-07-18 1 Pharmaceutical R&D Suzhou, PRC 2012-05-02 1 Pharmaceutical R&D Shanghai, PRC 2015-10-23 1 Pharmaceutical R&D Beijing, PRC 2019-07-09 1 Dormant Shenzhen, PRC 2021-11-15 1 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.1 Basis of preparation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group’s consolidated financial statements were prepared in accordance with International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”). The Group adopted and transitioned to IFRS issued by IASB on January 1, 2018. The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through profit or loss and financial instruments with preferred rights. In preparing its consolidated financial statements prepared under IFRS, the Group early adopted IFRS 9 Financial Instruments (“IFRS 9”) and IFRS 16 Leases (“IFRS 16”) on January 1, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group has applied the following standards and amendments for the first time for their annual reporting period commencing January 1, 2021, which did not have any material impact on the consolidated financial statements:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amendment to IFRS 16, ‘Leases’ – COVID-19 related rent concessions – Extension of the practical expedient.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements for the years ended December 31, 2019, 2020 and 2021 were authorized for issue by the Company’s board of directors (the “Board”) on March 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Group had net assets of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,735.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and accumulated losses of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,378.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. For the year ended December 31, 2021, the Group had net operating loss of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">631.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and net operating cash outflow of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">544.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The principal sources of funding have historically been continuous cash contributions from equity holders and preferred shareholders. The cumulative contributions up through December 31, 2021 approximated USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">440.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, among which included USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">219.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of proceeds from issuance of ordinary shares in connection with the IPO or RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,431.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million based on the exchange rate as of the date of the IPO. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Group had a cash and cash equivalents balance of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,706.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which it believes to be sufficient available financial resources to meet its obligations becoming due and working capital requirements in the next twelve months from the date of issuance of these financial statements. Accordingly, the Group considers that it is appropriate to prepare the consolidated financial information on a going concern basis.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impact of COVID-19</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, a novel strain of coronavirus was reported in Wuhan, China and on March 11, 2020 the WHO declared COVID-19 a pandemic. The COVID-19 pandemic has resulted in a widespread health crisis and numerous disease control measures being taken to limit its spread. As the pandemic continues its impact throughout the world, the healthcare systems of the various countries in which the Group is conducting ongoing clinical trials of CBP-201 and CBP-307 have and may continue to experience great disruption. Enrollment of the Group’s Phase 2 clinical trial of CBP-307 in patients in China was prematurely terminated due to challenges in recruitment caused by the COVID-19 pandemic.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group will continue to monitor and assess the impact of the ongoing development of the pandemic on the Group’s clinical trials and for any impact to its financial position and operating results.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.2 New and amended standards and interpretations not yet adopted by the Group</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group has not applied the following new and revised IFRSs that have been issued but are not yet effective in the consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.235%;"/> <td style="width:1.003%;"/> <td style="width:18.759%;"/> <td style="width:1.003%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Effective for annual periods beginning on or after</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Scope amendments to IFRS 3, IAS 16, IAS 37 and some annual improvements on IFRS 1, IFRS 9, IAS 41 and IFRS 16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:1.000pt solid;background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2022</span></p></td> <td style="border-top:1.000pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Narrow scope amendments to IAS 1, Practice statement 2 and IAS 8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amendment to IAS 12 – Deferred tax related to assets and liabilities arising from a single transaction</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> January 1, 2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amendments to IAS 1, Presentation of financial statements’, on classification of liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2024</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a material impact on disclosures or amounts reported in the Group’s consolidated financial statements in the period of initial application and future reporting periods.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.3 Principles of consolidation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsidiaries</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intra-group transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group’s accounting policies.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.4 Separate financial statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments in subsidiaries are accounted for at cost less impairment. Cost includes direct attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividends received and receivable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee’s net assets including goodwill.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.5 Foreign currency translation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Functional and presentation currency</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements of the Group are presented in RMB as the historical records for its entities were set-up for consolidations in RMB.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The functional currency of the Company is USD. Other subsidiaries have functional currencies in USD, RMB and Australian dollars.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Transactions and balances</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the Group has no borrowings, all foreign exchange gains or losses are presented in the consolidated statements of loss on a net basis within other gains/(losses)-net.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Group companies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">income and expenses for each statement of loss and comprehensive income/(loss) are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions); and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">all resulting currency translation differences are recognized in other comprehensive income/loss.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On consolidation, exchange differences arising from the translation of any net investment in foreign entities are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(d) Convenience translation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Translations of the consolidated balance sheet, the consolidated statement of loss, consolidated statement of comprehensive loss and consolidated statement of cash flows from RMB into USD as of and for the year ended December 31, 2021 are solely for the convenience of the readers and calculated at the rate of USD1.00=RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3757</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, representing the exchange rate as of December 31, 2021 set forth in the China Foreign Exchange Trade System. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into USD at that rate, or at any other rate, on December 31, 2021.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.6 Property, plant and equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group’s assets under construction represents buildings and equipment under construction and pending installation, and is stated at cost less accumulated impairment losses, if any. Costs include construction and acquisition costs. No provision for depreciation is made on assets under construction until such time as the assets are completed and ready for its intended use. Once the asset becomes available for use, it is transferred to the appropriate category of assets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to allocate the cost, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements, the shorter lease term as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:74.49%;"/> <td style="width:1.02%;"/> <td style="width:24.49%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Assets</span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Useful life</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of lease term</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office equipment and furniture</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assets’ residual values and useful lives are reviewed and adjusted if appropriate at the end of each reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount (Note 2.8).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gains and losses on disposals are determined by comparing proceeds with carrying amount and are recognized within other gains/(losses)—net in the statements of loss.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.7 Intangible assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Software</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired software licenses are capitalized on the basis of the costs incurred to acquire and bring the specific software into usage. These costs are amortized using the straight-line method over their estimated useful lives of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Costs associated with maintaining software programs are recognized as expense as incurred.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.8 Impairment of non-financial assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-financial assets other than goodwill and intangible assets that have an indefinite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.9 Investments and other financial assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Classification</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group classifies its financial assets in the following measurement categories:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">those to be measured subsequently at fair value (either through other comprehensive income (“OCI”) or through profit or loss), and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">those to be measured at amortized cost.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The classification depends on the entity’s business model for managing the financial assets and the contractual terms of the cash flows.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through OCI (“FVOCI”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group reclassifies debt investments when and only when its business model for managing those assets changes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Recognition and derecognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regular way purchases and sales of financial assets are recognized on trade date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Measurement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (“FVPL”), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial asset carried at FVPL are expensed in profit or loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.</span></p><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Debt instruments</span></div></div><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent measurement of debt instruments depends on the Group’s business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the Group classifies its debt instruments:</span></p><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortized cost: Assets that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortized cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains/(losses), together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the statements of loss.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FVOCI: Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets’ cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses which are recognized in profit or loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains/(losses). Interest income from these financial assets is included in finance income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains/(losses) and impairment expenses are presented as a separate line item in the statements of loss.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FVPL: Assets that do not meet the criteria for amortized cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured at FVPL is recognized in profit or loss and presented net within other gains/(losses) in the period in which it arises.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity instruments</span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group subsequently measures all equity investments at fair value. Where the Group’s management has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognized in profit or loss as other income when the Group’s right to receive payments is established.</span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the fair value of financial assets at FVPL are recognized in other gains/(losses) in the statements of loss as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> equity investments during the reporting periods.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(d) Impairment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group assesses on a forward-looking basis the expected credit loss associated with its debt instruments carried at amortized cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk refer to Note 3.1(b) for further details.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.11 Cash and cash equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.12 Share capital</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ordinary shares are classified as equity. Mandatorily redeemable preferred shares are classified as liabilities. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Where any Group company purchases the Company’s equity instruments, for example as the result of a share buy-back or a share-based payment plan, the consideration paid, including any directly attributable incremental costs (net of income taxes), is deducted from equity attributable to the owners of the Group as treasury shares until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the owners of the Group.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares held by Connect Union, which was established for the purpose of holding shares for the share incentive plans are disclosed as treasury shares and deducted from contributed equity.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.13 Trade and other payables</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.14 Financial instruments with preferred rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights are compound instruments with discretionary dividend right. The Company elected to designate the entire hybrid contracts that include host contract and embedded derivatives as financial liabilities at fair value through profit or loss considering the fact that the instruments also have contingent settlement provisions. They are initially recognized at fair value. Any directly attributable transaction costs are expensed in the consolidated statements of loss.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent to initial recognition, the amount of change in the fair value of the financial instruments with preferred rights that is attributable to changes in the credit risk of that liability shall be presented in OCI with the remaining changes in fair value recognized as “fair value loss of financial instruments with preferred rights” in profit or loss.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, management believed that there were no triggering events resulting in redemption in 12 months from the end of the reporting period and so the financial instruments with preferred rights were classified as non-current liabilities unless the Group had an obligation to settle the liabilities within 12 months after the end of the reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividends on financial instruments with preferred rights classified as financial liabilities are normally included in financial costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 19, 2021, upon completion of the IPO, all issued and outstanding preferred shares were converted to ordinary share on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-for-one basis.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.15 Current and deferred income tax</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The income tax expense or credit for the period is the tax payable on the taxable income of current period based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Current income tax</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Deferred income tax</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities and assets are not recognized for temporary differences between the carrying amount and tax bases of investments in foreign operations where the Group is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment allowances and similar tax incentives</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Companies within the Group may be entitled to claim special tax deductions for investments in qualifying assets or in relation to qualifying expenditure (e.g. the research and development tax incentive or other investment allowances). The Group accounts for such allowances as tax credits, which means that the allowance reduces income tax payable and current tax expense. A deferred tax asset is recognized for unclaimed tax credits that are carried forward as deferred tax assets.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.16 Employee benefits</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Short-term obligations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Liabilities for wages and salaries, including non-monetary benefits and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in other payables and accruals in the balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Defined benefit plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The liability or asset recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms approximating to the terms of the related obligation. In countries where there is no deep market in such bonds, the market rates on government bonds are used.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of loss.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income. They are included in retained earnings in the statement of changes in equity and in the balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognized immediately in profit or loss as past service costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Defined contribution plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For defined contribution plans, including those under Section 401(k) of the U.S. Internal Revenue Code, the Group pays contributions to publicly administered pension insurance plans on a mandatory, contractual or voluntary basis. The Group has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The members of the Group incorporated in the PRC contribute based on a certain percentage of the salaries of their employees to a defined contribution retirement benefit plan organized by relevant government authorities in the PRC on a monthly basis. The government authorities undertake to assume the retirement benefit obligations payable to all existing and further retired employees under these plans and the Group has no further obligation for post-retirement benefits beyond the contributions made. Contributions to these plans are expensed as incurred. Assets of the plans are held and managed by government authorities and are separate from those of the Group.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(d) Housing funds and medical insurance</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The PRC employees of the Group are entitled to participate in various government-supervised housing funds and medical insurance. The Group contributes on a monthly basis to these funds based on a certain percentage of the salaries of the employees, subject to certain ceilings. The Group’s liability in respect of these funds is limited to the contribution payable in each period and recognized as employee benefit expense when they are due.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.17 Share-based compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group operates an equity-settled share-based compensation plan, under which the Group receives services from employees, directors and consultants. The consultants’ work for the Group is under the Group’s direction in the same way as employees and the services rendered by the consultants are similar to those rendered by the Group’s employees.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of options granted under the share incentive plans is recognized as an employee benefits expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">including any market performance conditions (e.g. the entity’s share price);</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the entity over a specified time period); and</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">including the impact of any non-vesting conditions (e.g. the requirement for employees to save or hold shares for a specific period of time).</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. The Group recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.18 Research and development expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group incurs costs and efforts on research and development activities. Research expenditures are recorded as an expense in the period the expenditure is incurred. Elements of research and development expenses primarily include (1) expenses related to preclinical testing of the Group’s technologies under development and clinical trials such as payments to CRO investigators and clinical trial sites that conduct the clinical studies; (2) consultant service related to the design of clinical trials and data analysis, (3) payroll and other related expenses of personnel engaged in research and development activities, (4) expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5) other research and development expenses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group estimates preclinical and clinical study and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. The Group estimates these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Group will adjust the accrual accordingly. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments made in advance for the related services are recorded as prepayments in the consolidated balance sheets until the services are rendered.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Development costs are recognized as assets if they can be directly attributable to a newly developed service or product and all the following criteria are met or exist:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the technical feasibility to complete the development project so that it will be available for use or sale;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the intention to complete the development project to use or sell the product;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to use or sell the product;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the manner in which the development project will generate probable future economic benefits for the Group;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of adequate technical, financial and other resources to complete the development project and use or sell the product; and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the expenditure attributable to the asset during its development can be reliably measured.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses are charged to expense as incurred for all periods presented because they have not met all of the criteria stated above.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.19 Administrative expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Administrative expenses primarily include payroll and related expenses for employees involved in general corporate functions including finance, legal and human resources, rental and depreciation expenses related to facilities and equipment used by these functions, professional service expenses and other general corporate related expenses.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.20 Interest income</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income from financial assets at FVPL is included in the net fair value gains/(losses) on these assets, see Note 9 below. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset except for financial assets that subsequently become credit-impaired. For credit-impaired financial assets, the effective interest rate is applied to the net carrying amount of the financial asset (after deduction of the loss allowance). Interest income is presented as finance income where it is earned from financial assets that are held for cash management purposes.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.21 Government grants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grants from the government are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group is expected to comply with all required conditions. Government grants received in advance of costs being incurred are deferred until the associated costs are recognized. Grants that compensate the Group for the cost of an asset initially are presented as deferred income and are recognized as income in consolidated statements of loss on a straight-line basis over the useful life of the associated asset.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.22 Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group leases offices and the rental contracts are typically made for fixed periods of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All land in the PRC is owned by the mainland PRC government. The PRC government may sell land use rights for a specified period of time. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as right-of-use assets on the balance sheet. The right-of-use assets are amortized over the remaining lease term. In 2021, the Group acquired a land use right from the PRC government for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. However, for leases of real estate for which the Group is a lessee, it has elected not to separate lease and non-lease components and instead accounts for these as a single lease component.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fixed payments (including in-substance fixed payments), less any lease incentives receivable;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">variable lease payment that are based on an index or a rate, initially measured using the index or rate as of the commencement date;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">amounts expected to be payable by the Group under residual value guarantees;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee’s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets are measured at cost comprising the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount of the initial measurement of lease liability;</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any lease payments made at or before the commencement date less any lease incentives received;</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any initial direct costs; and</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restoration costs.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets are generally depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset’s useful life.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments associated with short-term leases and all leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less without a purchase option.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.23 Segment information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Group are the Co-Founders of the Company. The Group does not divide its operations into different segments and the CODM operates and manages the Group’s entire operations as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> segment, which is consistent with the Group’s internal organization and reporting system. The Group does not have any revenue and substantially all non-current assets outside of the country of domicile are in China.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.24 Loss per share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basic loss per share</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic loss per share is calculated by dividing:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the loss attributable to owners of the Company, excluding any costs of servicing equity other than ordinary shares;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">by the weighted average number of ordinary shares outstanding during the financial year and excluding treasury shares</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diluted loss per share</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.1 Basis of preparation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group’s consolidated financial statements were prepared in accordance with International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”). The Group adopted and transitioned to IFRS issued by IASB on January 1, 2018. The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through profit or loss and financial instruments with preferred rights. In preparing its consolidated financial statements prepared under IFRS, the Group early adopted IFRS 9 Financial Instruments (“IFRS 9”) and IFRS 16 Leases (“IFRS 16”) on January 1, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group has applied the following standards and amendments for the first time for their annual reporting period commencing January 1, 2021, which did not have any material impact on the consolidated financial statements:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amendment to IFRS 16, ‘Leases’ – COVID-19 related rent concessions – Extension of the practical expedient.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements for the years ended December 31, 2019, 2020 and 2021 were authorized for issue by the Company’s board of directors (the “Board”) on March 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Group had net assets of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,735.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and accumulated losses of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,378.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. For the year ended December 31, 2021, the Group had net operating loss of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">631.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and net operating cash outflow of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">544.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The principal sources of funding have historically been continuous cash contributions from equity holders and preferred shareholders. The cumulative contributions up through December 31, 2021 approximated USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">440.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, among which included USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">219.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of proceeds from issuance of ordinary shares in connection with the IPO or RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,431.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million based on the exchange rate as of the date of the IPO. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Group had a cash and cash equivalents balance of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,706.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which it believes to be sufficient available financial resources to meet its obligations becoming due and working capital requirements in the next twelve months from the date of issuance of these financial statements. Accordingly, the Group considers that it is appropriate to prepare the consolidated financial information on a going concern basis.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impact of COVID-19</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, a novel strain of coronavirus was reported in Wuhan, China and on March 11, 2020 the WHO declared COVID-19 a pandemic. The COVID-19 pandemic has resulted in a widespread health crisis and numerous disease control measures being taken to limit its spread. As the pandemic continues its impact throughout the world, the healthcare systems of the various countries in which the Group is conducting ongoing clinical trials of CBP-201 and CBP-307 have and may continue to experience great disruption. Enrollment of the Group’s Phase 2 clinical trial of CBP-307 in patients in China was prematurely terminated due to challenges in recruitment caused by the COVID-19 pandemic.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group will continue to monitor and assess the impact of the ongoing development of the pandemic on the Group’s clinical trials and for any impact to its financial position and operating results.</span></p> 1735800000 -2378200000 -631400000 -544900000 440100000 219900000 1431800000 1706900000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.2 New and amended standards and interpretations not yet adopted by the Group</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group has not applied the following new and revised IFRSs that have been issued but are not yet effective in the consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.235%;"/> <td style="width:1.003%;"/> <td style="width:18.759%;"/> <td style="width:1.003%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Effective for annual periods beginning on or after</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Scope amendments to IFRS 3, IAS 16, IAS 37 and some annual improvements on IFRS 1, IFRS 9, IAS 41 and IFRS 16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:1.000pt solid;background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2022</span></p></td> <td style="border-top:1.000pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Narrow scope amendments to IAS 1, Practice statement 2 and IAS 8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amendment to IAS 12 – Deferred tax related to assets and liabilities arising from a single transaction</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> January 1, 2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amendments to IAS 1, Presentation of financial statements’, on classification of liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2024</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a material impact on disclosures or amounts reported in the Group’s consolidated financial statements in the period of initial application and future reporting periods.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.3 Principles of consolidation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsidiaries</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intra-group transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group’s accounting policies.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.4 Separate financial statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments in subsidiaries are accounted for at cost less impairment. Cost includes direct attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividends received and receivable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee’s net assets including goodwill.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.5 Foreign currency translation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Functional and presentation currency</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements of the Group are presented in RMB as the historical records for its entities were set-up for consolidations in RMB.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The functional currency of the Company is USD. Other subsidiaries have functional currencies in USD, RMB and Australian dollars.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Transactions and balances</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the Group has no borrowings, all foreign exchange gains or losses are presented in the consolidated statements of loss on a net basis within other gains/(losses)-net.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Group companies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">income and expenses for each statement of loss and comprehensive income/(loss) are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions); and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">all resulting currency translation differences are recognized in other comprehensive income/loss.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On consolidation, exchange differences arising from the translation of any net investment in foreign entities are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(d) Convenience translation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Translations of the consolidated balance sheet, the consolidated statement of loss, consolidated statement of comprehensive loss and consolidated statement of cash flows from RMB into USD as of and for the year ended December 31, 2021 are solely for the convenience of the readers and calculated at the rate of USD1.00=RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3757</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, representing the exchange rate as of December 31, 2021 set forth in the China Foreign Exchange Trade System. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into USD at that rate, or at any other rate, on December 31, 2021.</span></p> 6.3757 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.6 Property, plant and equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group’s assets under construction represents buildings and equipment under construction and pending installation, and is stated at cost less accumulated impairment losses, if any. Costs include construction and acquisition costs. No provision for depreciation is made on assets under construction until such time as the assets are completed and ready for its intended use. Once the asset becomes available for use, it is transferred to the appropriate category of assets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to allocate the cost, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements, the shorter lease term as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:74.49%;"/> <td style="width:1.02%;"/> <td style="width:24.49%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Assets</span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Useful life</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of lease term</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office equipment and furniture</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assets’ residual values and useful lives are reviewed and adjusted if appropriate at the end of each reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount (Note 2.8).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gains and losses on disposals are determined by comparing proceeds with carrying amount and are recognized within other gains/(losses)—net in the statements of loss.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to allocate the cost, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements, the shorter lease term as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:74.49%;"/> <td style="width:1.02%;"/> <td style="width:24.49%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Assets</span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Useful life</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of lease term</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office equipment and furniture</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.013888888888888888in;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> Depreciation is calculated using the straight-line method P5Y P10Y Shorter of lease term 5 years P3Y P5Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.7 Intangible assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Software</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired software licenses are capitalized on the basis of the costs incurred to acquire and bring the specific software into usage. These costs are amortized using the straight-line method over their estimated useful lives of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Costs associated with maintaining software programs are recognized as expense as incurred.</span></p> P10Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.8 Impairment of non-financial assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-financial assets other than goodwill and intangible assets that have an indefinite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.9 Investments and other financial assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Classification</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group classifies its financial assets in the following measurement categories:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">those to be measured subsequently at fair value (either through other comprehensive income (“OCI”) or through profit or loss), and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">those to be measured at amortized cost.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The classification depends on the entity’s business model for managing the financial assets and the contractual terms of the cash flows.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through OCI (“FVOCI”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group reclassifies debt investments when and only when its business model for managing those assets changes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Recognition and derecognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regular way purchases and sales of financial assets are recognized on trade date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Measurement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (“FVPL”), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial asset carried at FVPL are expensed in profit or loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.</span></p><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Debt instruments</span></div></div><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent measurement of debt instruments depends on the Group’s business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the Group classifies its debt instruments:</span></p><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortized cost: Assets that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortized cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains/(losses), together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the statements of loss.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FVOCI: Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets’ cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses which are recognized in profit or loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains/(losses). Interest income from these financial assets is included in finance income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains/(losses) and impairment expenses are presented as a separate line item in the statements of loss.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FVPL: Assets that do not meet the criteria for amortized cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured at FVPL is recognized in profit or loss and presented net within other gains/(losses) in the period in which it arises.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity instruments</span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group subsequently measures all equity investments at fair value. Where the Group’s management has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognized in profit or loss as other income when the Group’s right to receive payments is established.</span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the fair value of financial assets at FVPL are recognized in other gains/(losses) in the statements of loss as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> equity investments during the reporting periods.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(d) Impairment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group assesses on a forward-looking basis the expected credit loss associated with its debt instruments carried at amortized cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk refer to Note 3.1(b) for further details.</span></p> 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.11 Cash and cash equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.12 Share capital</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ordinary shares are classified as equity. Mandatorily redeemable preferred shares are classified as liabilities. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Where any Group company purchases the Company’s equity instruments, for example as the result of a share buy-back or a share-based payment plan, the consideration paid, including any directly attributable incremental costs (net of income taxes), is deducted from equity attributable to the owners of the Group as treasury shares until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the owners of the Group.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares held by Connect Union, which was established for the purpose of holding shares for the share incentive plans are disclosed as treasury shares and deducted from contributed equity.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.13 Trade and other payables</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.14 Financial instruments with preferred rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights are compound instruments with discretionary dividend right. The Company elected to designate the entire hybrid contracts that include host contract and embedded derivatives as financial liabilities at fair value through profit or loss considering the fact that the instruments also have contingent settlement provisions. They are initially recognized at fair value. Any directly attributable transaction costs are expensed in the consolidated statements of loss.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent to initial recognition, the amount of change in the fair value of the financial instruments with preferred rights that is attributable to changes in the credit risk of that liability shall be presented in OCI with the remaining changes in fair value recognized as “fair value loss of financial instruments with preferred rights” in profit or loss.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, management believed that there were no triggering events resulting in redemption in 12 months from the end of the reporting period and so the financial instruments with preferred rights were classified as non-current liabilities unless the Group had an obligation to settle the liabilities within 12 months after the end of the reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividends on financial instruments with preferred rights classified as financial liabilities are normally included in financial costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 19, 2021, upon completion of the IPO, all issued and outstanding preferred shares were converted to ordinary share on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-for-one basis.</span></p> 1 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.15 Current and deferred income tax</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The income tax expense or credit for the period is the tax payable on the taxable income of current period based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Current income tax</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Deferred income tax</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities and assets are not recognized for temporary differences between the carrying amount and tax bases of investments in foreign operations where the Group is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment allowances and similar tax incentives</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Companies within the Group may be entitled to claim special tax deductions for investments in qualifying assets or in relation to qualifying expenditure (e.g. the research and development tax incentive or other investment allowances). The Group accounts for such allowances as tax credits, which means that the allowance reduces income tax payable and current tax expense. A deferred tax asset is recognized for unclaimed tax credits that are carried forward as deferred tax assets.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.16 Employee benefits</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Short-term obligations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Liabilities for wages and salaries, including non-monetary benefits and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in other payables and accruals in the balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Defined benefit plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The liability or asset recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms approximating to the terms of the related obligation. In countries where there is no deep market in such bonds, the market rates on government bonds are used.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of loss.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income. They are included in retained earnings in the statement of changes in equity and in the balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognized immediately in profit or loss as past service costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Defined contribution plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For defined contribution plans, including those under Section 401(k) of the U.S. Internal Revenue Code, the Group pays contributions to publicly administered pension insurance plans on a mandatory, contractual or voluntary basis. The Group has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The members of the Group incorporated in the PRC contribute based on a certain percentage of the salaries of their employees to a defined contribution retirement benefit plan organized by relevant government authorities in the PRC on a monthly basis. The government authorities undertake to assume the retirement benefit obligations payable to all existing and further retired employees under these plans and the Group has no further obligation for post-retirement benefits beyond the contributions made. Contributions to these plans are expensed as incurred. Assets of the plans are held and managed by government authorities and are separate from those of the Group.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(d) Housing funds and medical insurance</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The PRC employees of the Group are entitled to participate in various government-supervised housing funds and medical insurance. The Group contributes on a monthly basis to these funds based on a certain percentage of the salaries of the employees, subject to certain ceilings. The Group’s liability in respect of these funds is limited to the contribution payable in each period and recognized as employee benefit expense when they are due.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.17 Share-based compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group operates an equity-settled share-based compensation plan, under which the Group receives services from employees, directors and consultants. The consultants’ work for the Group is under the Group’s direction in the same way as employees and the services rendered by the consultants are similar to those rendered by the Group’s employees.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of options granted under the share incentive plans is recognized as an employee benefits expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">including any market performance conditions (e.g. the entity’s share price);</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the entity over a specified time period); and</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">including the impact of any non-vesting conditions (e.g. the requirement for employees to save or hold shares for a specific period of time).</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. The Group recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.18 Research and development expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group incurs costs and efforts on research and development activities. Research expenditures are recorded as an expense in the period the expenditure is incurred. Elements of research and development expenses primarily include (1) expenses related to preclinical testing of the Group’s technologies under development and clinical trials such as payments to CRO investigators and clinical trial sites that conduct the clinical studies; (2) consultant service related to the design of clinical trials and data analysis, (3) payroll and other related expenses of personnel engaged in research and development activities, (4) expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5) other research and development expenses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group estimates preclinical and clinical study and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. The Group estimates these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Group will adjust the accrual accordingly. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments made in advance for the related services are recorded as prepayments in the consolidated balance sheets until the services are rendered.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Development costs are recognized as assets if they can be directly attributable to a newly developed service or product and all the following criteria are met or exist:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the technical feasibility to complete the development project so that it will be available for use or sale;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the intention to complete the development project to use or sell the product;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to use or sell the product;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the manner in which the development project will generate probable future economic benefits for the Group;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of adequate technical, financial and other resources to complete the development project and use or sell the product; and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the expenditure attributable to the asset during its development can be reliably measured.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses are charged to expense as incurred for all periods presented because they have not met all of the criteria stated above.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.19 Administrative expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Administrative expenses primarily include payroll and related expenses for employees involved in general corporate functions including finance, legal and human resources, rental and depreciation expenses related to facilities and equipment used by these functions, professional service expenses and other general corporate related expenses.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.20 Interest income</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income from financial assets at FVPL is included in the net fair value gains/(losses) on these assets, see Note 9 below. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset except for financial assets that subsequently become credit-impaired. For credit-impaired financial assets, the effective interest rate is applied to the net carrying amount of the financial asset (after deduction of the loss allowance). Interest income is presented as finance income where it is earned from financial assets that are held for cash management purposes.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.21 Government grants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grants from the government are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group is expected to comply with all required conditions. Government grants received in advance of costs being incurred are deferred until the associated costs are recognized. Grants that compensate the Group for the cost of an asset initially are presented as deferred income and are recognized as income in consolidated statements of loss on a straight-line basis over the useful life of the associated asset.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.22 Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group leases offices and the rental contracts are typically made for fixed periods of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All land in the PRC is owned by the mainland PRC government. The PRC government may sell land use rights for a specified period of time. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as right-of-use assets on the balance sheet. The right-of-use assets are amortized over the remaining lease term. In 2021, the Group acquired a land use right from the PRC government for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. However, for leases of real estate for which the Group is a lessee, it has elected not to separate lease and non-lease components and instead accounts for these as a single lease component.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fixed payments (including in-substance fixed payments), less any lease incentives receivable;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">variable lease payment that are based on an index or a rate, initially measured using the index or rate as of the commencement date;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">amounts expected to be payable by the Group under residual value guarantees;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee’s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets are measured at cost comprising the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount of the initial measurement of lease liability;</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any lease payments made at or before the commencement date less any lease incentives received;</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any initial direct costs; and</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restoration costs.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets are generally depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset’s useful life.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments associated with short-term leases and all leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less without a purchase option.</span></p> P2Y P4Y P50Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.23 Segment information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Group are the Co-Founders of the Company. The Group does not divide its operations into different segments and the CODM operates and manages the Group’s entire operations as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> segment, which is consistent with the Group’s internal organization and reporting system. The Group does not have any revenue and substantially all non-current assets outside of the country of domicile are in China.</span></p> 1 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2.24 Loss per share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basic loss per share</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic loss per share is calculated by dividing:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the loss attributable to owners of the Company, excluding any costs of servicing equity other than ordinary shares;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">by the weighted average number of ordinary shares outstanding during the financial year and excluding treasury shares</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diluted loss per share</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and</span></div></div><p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Financial Instruments and Risk Management</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">3.1 Financial risk factors</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group’s activities expose it to a variety of financial risks: market risk (including interest rate risk and exchange risk), credit risk and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group’s financial performance. Risk management is carried out by the senior management of the Group.</span></p><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Market risk</span></div></div><div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest rate risk</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group’s interest rate risk primarily arises from wealth management products investments measured at fair value through profit or loss (Note 17) and cash and cash equivalents (Note 18). Those carried at variable rates expose the Group to cash flow interest rate risk whereas those at fixed rates expose the Group to fair value interest rate risk. The Group did not have significant interest rate risk during the periods presented.</span></p><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exchange risk</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group operates internationally and is exposed to foreign exchange risk, primarily the USD. Foreign exchange risk arises from future commercial transactions and recognized assets and liabilities denominated in a currency that is not the functional currency of the relevant group entity. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group’s exposure to foreign currency risk at the end of the reporting periods, expressed in RMB, was as follows:</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.753%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,791</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150,640</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate net foreign exchange gains/(losses) recognized in profit or loss were:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.086%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.668%;"/> <td style="width:0.603%;"/> <td style="width:1.493%;"/> <td style="width:0.603%;"/> <td style="width:11.482%;"/> <td style="width:0.798%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.482%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net foreign exchange gains/(losses) included in other gains/(losses)—net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,252</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,772</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Most foreign exchange transactions were denominated in USD for the subsidiary that has functional currency in RMB. For the years ended December 31, 2019, 2020 and 2021, if the USD strengthened/weakened by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% against the RMB with all other variables held constant, net loss for the years then ended would have been </span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lower/higher, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lower/higher and RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lower/higher, respectively.</span></p><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(b)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Credit risk</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.164375;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Credit risk primarily arises from cash and cash equivalents, financial assets at fair value through profit or loss, and other receivables. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The credit risk of cash and cash equivalents and financial assets at fair value through profit or loss is limited because the counterparties are reputable commercial institutions located in the Cayman Islands, the U.S., PRC and Australia.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For other receivables, management makes periodic as well as individual assessments on the recoverability based on historical settlement records and past experience and adjusts for forward looking information based on macroeconomic factors affecting the ability of the debtors to settle the receivables.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group applies the expected credit loss model to financial assets measured at amortized cost. Impairment on other receivables is measured as either 12-month expected credit losses or lifetime expected credit losses, depending on whether there has been a significant increase in credit risk since initial recognition. To assess whether there is a significant increase in credit risk, the Group compares the risk of default occurring on the asset as of the reporting date with the risk of default as of the date of initial recognition by considering available, reasonable and supportive forwarding-looking information.</span></p><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(c)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity risk</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group aims to maintain sufficient cash to meet obligations coming due as well as operating and capital requirements.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below analyzes the Group’s financial liabilities into relevant maturity groupings based on the remaining period at each year-end date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows except for financial instruments with preferred rights, which are presented on a fair value basis. The maturity dates are determined by the terms in financing agreements presented in Note 24(c) as management considers the other redemption terms are not probable to occur.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:25.816%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.189%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.189%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.594%;"/> <td style="width:12.208%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.189%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.594%;"/> <td style="width:12.208%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Between</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Between</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">More</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Less Than</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 and</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2 and</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Than</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 Year</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">5 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">5 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,638</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,638</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">633</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">952</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,902</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,602</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,105,729</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:25.802%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Between</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Between</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">More</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Less Than</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 and</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2 and</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Than</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 Year</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">5 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">5 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,456</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,456</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">653</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">839</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,304</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">3.2 Capital management</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.164375;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.164375;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group monitors capital by regularly reviewing the capital structure and the overall capital markets. The Group may seek additional financing or debt at terms satisfactory to the Group in order to maintain adequate resources.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020 and 2021, the Group had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> debt outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">3.3 Fair value estimation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 the Group does </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any financial instruments measured at fair value. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below analyzes the Group’s financial instruments carried at fair value as of December 31, 2020 by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorized into three levels within a fair value hierarchy as follows:</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.164375;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(iii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:49.963%;"/> <td style="width:1.215%;"/> <td style="width:0.603%;"/> <td style="width:10.093%;"/> <td style="width:0.594%;"/> <td style="width:1.215%;"/> <td style="width:0.603%;"/> <td style="width:10.093%;"/> <td style="width:0.594%;"/> <td style="width:1.215%;"/> <td style="width:0.594%;"/> <td style="width:10.111%;"/> <td style="width:0.594%;"/> <td style="width:1.215%;"/> <td style="width:0.594%;"/> <td style="width:10.111%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial assets at fair value through profit or loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were no transfers between levels 1, 2 and 3 during the years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial instruments in Level 3</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If one or more of the significant inputs are not based on observable market data, the instrument is included in level 3.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specific valuation techniques used to value financial instruments include:</span></p><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Quoted market prices or dealer quotes for similar instruments;</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.793752553345275%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A combination of observable and unobservable inputs, including risk-free rate, expected volatility, discount rate for lack of marketability (“DLOM”), etc.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 instruments within the Group’s assets and liabilities include short-term investment in wealth management products measured at fair value through profit or loss and financial instruments with preferred rights.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the changes in level 3 instruments of short-term investment in wealth management products for the years ended December 31, 2019, 2020 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:56.993%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.473%;"/> <td style="width:0.798%;"/> <td style="width:1.605%;"/> <td style="width:0.603%;"/> <td style="width:11.473%;"/> <td style="width:0.798%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.473%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial assets at fair value through profit or loss</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Opening balance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,565</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,632</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">163,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106,600</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Settlements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160,731</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124,836</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128,004</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment income credited to profit or loss (Note 8)*</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">798</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">672</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">436</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Closing balance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,632</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*Includes unrealized gains recognized in profit or loss attributable to balances held at the end of the reporting period</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation of level 3 instruments of wealth management products and financial instruments with preferred rights is set out in Note 17 and Note 24.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The changes in level 3 instruments with preferred rights for the years ended December 31, 2019, 2020 and 2021 are presented in Note 24.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of the Group’s other financial assets and liabilities, including cash and cash equivalents, other receivables, trade payable and other payables, approximate their fair values.</span></p> <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group’s exposure to foreign currency risk at the end of the reporting periods, expressed in RMB, was as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.753%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,791</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150,640</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 65791000 150640000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate net foreign exchange gains/(losses) recognized in profit or loss were:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.086%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.668%;"/> <td style="width:0.603%;"/> <td style="width:1.493%;"/> <td style="width:0.603%;"/> <td style="width:11.482%;"/> <td style="width:0.798%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.482%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net foreign exchange gains/(losses) included in other gains/(losses)—net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,252</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,772</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table> 2252000 -6772000 -3309000 0.05 0.05 0.05 1600000 3300000 7500000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below analyzes the Group’s financial liabilities into relevant maturity groupings based on the remaining period at each year-end date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows except for financial instruments with preferred rights, which are presented on a fair value basis. The maturity dates are determined by the terms in financing agreements presented in Note 24(c) as management considers the other redemption terms are not probable to occur.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:25.816%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.189%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.189%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.594%;"/> <td style="width:12.208%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.189%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.594%;"/> <td style="width:12.208%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Between</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Between</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">More</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Less Than</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 and</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2 and</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Than</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 Year</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">5 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">5 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,638</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,638</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">633</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">952</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,902</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,602</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,105,729</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:25.802%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> <td style="width:1.447%;"/> <td style="width:0.603%;"/> <td style="width:12.196%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Between</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Between</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">More</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Less Than</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 and</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2 and</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Than</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 Year</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">5 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">5 Years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,456</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,456</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">653</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">839</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,304</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 2071508000 2071508000 24638000 24638000 8631000 8631000 633000 225000 94000 952000 33902000 225000 2071602000 2105729000 81195000 81195000 21456000 21456000 653000 186000 839000 103304000 186000 103490000 0 0 0 0 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below analyzes the Group’s financial instruments carried at fair value as of December 31, 2020 by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorized into three levels within a fair value hierarchy as follows:</span><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.164375;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:3.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(iii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:49.963%;"/> <td style="width:1.215%;"/> <td style="width:0.603%;"/> <td style="width:10.093%;"/> <td style="width:0.594%;"/> <td style="width:1.215%;"/> <td style="width:0.603%;"/> <td style="width:10.093%;"/> <td style="width:0.594%;"/> <td style="width:1.215%;"/> <td style="width:0.594%;"/> <td style="width:10.111%;"/> <td style="width:0.594%;"/> <td style="width:1.215%;"/> <td style="width:0.594%;"/> <td style="width:10.111%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial assets at fair value through profit or loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 13068000 13068000 13068000 13068000 2071508000 2071508000 2071508000 2071508000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the changes in level 3 instruments of short-term investment in wealth management products for the years ended December 31, 2019, 2020 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:56.993%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.473%;"/> <td style="width:0.798%;"/> <td style="width:1.605%;"/> <td style="width:0.603%;"/> <td style="width:11.473%;"/> <td style="width:0.798%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.473%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial assets at fair value through profit or loss</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Opening balance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,565</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,632</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">163,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106,600</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Settlements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160,731</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124,836</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128,004</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment income credited to profit or loss (Note 8)*</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">798</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">672</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">436</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Closing balance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,632</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*Includes unrealized gains recognized in profit or loss attributable to balances held at the end of the reporting period</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 27565000 30632000 13068000 163000000 106600000 114500000 160731000 124836000 128004000 798000 672000 436000 30632000 13068000 132000 68000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Critical Accounting Estimates and Judgements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements requires the use of accounting estimates which, by definition, may not equal the actual results. Management also needs to exercise judgment in applying the Group’s accounting policies. Estimates and judgments are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Group and that are believed to be reasonable under the circumstances.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">a) Fair value of financial assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of financial assets that are not traded in an active market is determined using valuation techniques. The Group uses its judgement to select a variety of methods and make assumptions that are mainly based on market conditions existing at the end of each reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">b) Fair value of financial instruments with preferred rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of financial instruments with preferred rights that are not traded in an active market is determined using valuation techniques. The Group first determined the equity value and then allocated the equity value to each element of the Group’s capital structure using either an option pricing backsolve method (“OPM”), or a hybrid method, which employs the concepts of the OPM and the probability-weighted expected return method (“PWERM”) that merged into a single framework.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Key assumptions such as risk-free interest rate, DLOM and expected volatility are disclosed in Note 24.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">c) Recognition of share-based compensation expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As mentioned in Note 22, the equity-settled share-based compensation plan was granted to employees and consultants. The Group has used the Binomial option-pricing model to determine the total fair value of the awarded options, which is to be expensed over the vesting period. Significant estimates on assumptions, such as the fair value of underlying shares, risk-free interest rate, expected volatility and dividend yield, are required to be made by the management.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the details of the key assumptions and estimates used by management in determining the fair values of share based compensation, refer to Note 22.</span></p><div style="margin-left:0.056%;display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.074%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.0751620907708315%;">d)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Current and deferred income taxes</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(i) Deferred income tax</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group recognizes deferred tax assets based on estimates that it is probable to generate sufficient taxable profits in the foreseeable future against which the deductible losses and temporary differences will be utilized. The recognition of deferred tax assets mainly involves management’s judgments and estimations about the timing and the amount of taxable profits of the companies which have tax losses, refer to Note 10 for details.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Expenses by Nature</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.04%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials related expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82,046</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107,440</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">424,724</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee benefit expenses (Note 6)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,098</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,243</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120,173</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consultancy fee (i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,011</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,784</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,498</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D materials and consumable supplies</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">988</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,127</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,718</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">790</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,436</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,082</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,424</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,052</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,653</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expense related to Series C financing (ii)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Others</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,770</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,915</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,618</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116,127</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">198,652</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">640,466</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:1.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.598295276029473%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company exclusively licenses CBP-174 from a third-party licensor. Such license is worldwide and royalty-bearing. As of December 31, 2021, CBP-174 has not yet been commercialized, the Company is only subject to a non-refundable, non-creditable license maintenance fee, which is paid to the third-party licensor on an annual basis and recorded as a consultancy fee within research and development expense.</span></div></div><div style="margin-left:1.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.598295276029473%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Represent</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s a share-based compensation to additional Series C preferred shareholder, which was recognized as an administrative expense as set forth in Note 22.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.04%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials related expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82,046</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107,440</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">424,724</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee benefit expenses (Note 6)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,098</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,243</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120,173</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consultancy fee (i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,011</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,784</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,498</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D materials and consumable supplies</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">988</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,127</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,718</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">790</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,436</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,082</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,424</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,052</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,653</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expense related to Series C financing (ii)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Others</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,770</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,915</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,618</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116,127</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">198,652</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">640,466</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:1.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.598295276029473%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company exclusively licenses CBP-174 from a third-party licensor. Such license is worldwide and royalty-bearing. As of December 31, 2021, CBP-174 has not yet been commercialized, the Company is only subject to a non-refundable, non-creditable license maintenance fee, which is paid to the third-party licensor on an annual basis and recorded as a consultancy fee within research and development expense.</span></div></div><div style="margin-left:1.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.598295276029473%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Represent</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s a share-based compensation to additional Series C preferred shareholder, which was recognized as an administrative expense as set forth in Note 22.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div> 82046000 107440000 424724000 15098000 27243000 120173000 12011000 31784000 69498000 988000 2127000 13718000 790000 1436000 4082000 2424000 3052000 3653000 19655000 2770000 5915000 4618000 116127000 198652000 640466000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Employee Benefit Expenses</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.04%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expenses (Note 22)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,535</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Wages, salaries and bonuses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,628</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,527</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,122</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Welfare expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">964</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">520</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,820</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Housing funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">491</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">690</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,368</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contributions to defined benefit plan (Note 27(d))</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,140</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">971</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,098</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,243</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120,173</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder. The Company does not have any further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee benefit expenses were charged in the following line items in the consolidated statements of loss:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.179%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,496</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,405</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Administrative expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,602</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,838</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,948</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,098</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,243</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120,173</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.04%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.649%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expenses (Note 22)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,535</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Wages, salaries and bonuses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,628</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,527</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,122</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Welfare expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">964</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">520</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,820</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Housing funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">491</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">690</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,368</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contributions to defined benefit plan (Note 27(d))</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,140</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">971</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,098</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,243</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120,173</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder. The Company does not have any further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee benefit expenses were charged in the following line items in the consolidated statements of loss:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.179%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,496</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,405</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Administrative expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,602</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,838</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,948</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,098</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,243</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120,173</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 3875000 5535000 57863000 8628000 19527000 56122000 964000 520000 4820000 491000 690000 1368000 1140000 971000 15098000 27243000 120173000 11496000 18405000 68225000 3602000 8838000 51948000 15098000 27243000 120173000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Other Income</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.54%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Government grants</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,836</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,989</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,996</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Government grants are mainly related to cash incentives from the China government based on specific milestones or operating expenses incurred in China and tax incentives from the Australian government for conducting clinical research and development activities in Australia. In 2021, the Group received a one-time award of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for its successful IPO listing, other subsidies of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from China local government, RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from the Australian government as an incentive for research and development activities.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.54%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Government grants</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,836</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,989</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,996</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 2836000 6989000 18996000 11000000.0 6200000 1600000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Gains/(losses)—net</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.531%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.668%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.491%;"/> <td style="width:0.798%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.491%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net foreign exchange gains/(losses)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,252</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,772</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment income from wealth management products</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">798</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">672</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">436</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other loss (i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,050</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,966</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) The Group incurred a loss of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million) due to a phishing scam experienced in May 2021 which resulted in the Company remitting such amount to an account set up by the phishers rather than to one of the Company’s vendors. No loss of company data nor any loss or compromise of third-party information has been discovered. The Company filed a claim and partially recovered RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million losses from its cyber insurance provider</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p> <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Gains/(losses)—net</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.531%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.668%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.491%;"/> <td style="width:0.798%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.491%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net foreign exchange gains/(losses)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,252</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,772</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment income from wealth management products</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">798</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">672</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">436</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other loss (i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,050</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,966</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) The Group incurred a loss of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million) due to a phishing scam experienced in May 2021 which resulted in the Company remitting such amount to an account set up by the phishers rather than to one of the Company’s vendors. No loss of company data nor any loss or compromise of third-party information has been discovered. The Company filed a claim and partially recovered RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million losses from its cyber insurance provider</span> 2252000 -6772000 -3309000 798000 672000 436000 -7093000 3050000 -6100000 -9966000 -7000000.0 -1100000 1000000.0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Finance Income/(cost) —net</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.131%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.499%;"/> <td style="width:0.797%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.499%;"/> <td style="width:0.797%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.499%;"/> <td style="width:0.797%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Finance income</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest from bank deposits and term deposits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,066</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">717</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">622</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Finance cost</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance cost of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,851</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest for lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,893</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Finance income/(cost)—net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,013</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,176</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">578</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.131%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.499%;"/> <td style="width:0.797%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.499%;"/> <td style="width:0.797%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.499%;"/> <td style="width:0.797%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Finance income</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest from bank deposits and term deposits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,066</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">717</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">622</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Finance cost</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance cost of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,851</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest for lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,893</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Finance income/(cost)—net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,013</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,176</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">578</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1066000 717000 622000 2851000 53000 42000 44000 53000 2893000 44000 1013000 -2176000 578000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax expense is recognized based on the income tax rates in the following main tax jurisdictions where the Group operates for the years ended December 31, 2019, 2020 and 2021.</span></p><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">a) Cayman Islands</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is incorporated in the Cayman Islands as an exempted company with limited liabilities under the Companies Law of the Cayman Islands and accordingly, is exempted from Cayman Islands income tax.</span></p><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">b)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Hong Kong</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hong Kong profits tax rate was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% as of April 1, 2018 when the two-tiered profits tax regime took effect, under which the tax rate is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for assessable profits on the first HK$ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for any assessable profits in excess. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Hong Kong profit tax was provided for as there was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> estimated </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9bca7063-8ec0-4bb9-ad6d-1d53d9b59371;"><span style="-sec-ix-hidden:F_a1bb4e6a-fe69-4e22-8eb7-6f96543230ba;"><span style="-sec-ix-hidden:F_5199ee41-8720-4fa7-a096-2f06402dc2e6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as</span></span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">se</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ea23cd3e-73eb-412e-95ae-5196e9ea67f7;"><span style="-sec-ix-hidden:F_b812b8d5-f047-4367-b01d-3664eb53d96b;"><span style="-sec-ix-hidden:F_a70e3020-4a7f-4ecd-94f1-c0b28235406e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ss</span></span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">able profit that was subject to Hong Kong profits tax during the years ended December 31, 2019, 2020 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">c)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">United States</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect US is incorporated in the U.S. and is a single member Limited Liability Company that is disregarded for US income tax purposes wholly owned by Connect SZ (before September 2018) and then Connect HK from a tax perspective. During the years ended December 31, 2019 and 2020, from a U.S. tax perspective, Connect HK is subject to US federal corporate income tax at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and state income tax in California at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.84</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to the extent of the income apportionable to Connect US. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> provision for income taxes was made for the years ended December 31, 2019 and 2020. The provision for income taxes for the year ended December 31, 2021 was RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">d)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Australia</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Connect AU is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. Connect AU has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> taxable income for all periods presented, therefore, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> provision for income taxes has been provided.</span></p><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">e)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PRC</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for PRC corporate income tax is calculated based on the statutory income tax rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the assessable income of respective PRC Group entities during the years ended December 31, 2019, 2020 and 2021 in accordance with relevant PRC enterprise income tax rules and regulations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> provision for PRC corporate income tax has been made for the years ended December 31, 2019, 2020 and 2021 as the Group had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such taxable profit for the years then ended.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The reconciliation between the Group’s actual tax charge and the amount that is calculated based on the statutory income tax rate of 25% in the PRC is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.516%;"/> <td style="width:1.326%;"/> <td style="width:0.603%;"/> <td style="width:11.509%;"/> <td style="width:0.798%;"/> <td style="width:1.104%;"/> <td style="width:0.603%;"/> <td style="width:11.509%;"/> <td style="width:0.798%;"/> <td style="width:1.326%;"/> <td style="width:0.603%;"/> <td style="width:11.509%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations in the PRC</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,741</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,788</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">233,382</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from overseas entities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94,884</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">693,437</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,071,745</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">779,225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305,127</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax expense at PRC enterprise income tax rate of 25%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,156</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">194,806</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326,282</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses not deductible for income tax purpose</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">799</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,185</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,663</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Super deduction of research and development expenses (i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,529</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,523</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax losses and deductible temporary differences for which no deferred income tax assets were recognized</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,956</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,865</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,121</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effect of income tax in jurisdictions other than the PRC</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,930</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">164,097</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">235,718</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,697</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:2.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7400778769790306%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to policies promulgated by the State Tax Bureau of the PRC, certain of the Group's subsidiaries are entitled to tax incentives for research and development expenses at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of tax-deductible research and development expenses in 2019, 2020 and 2021.</span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, the Group’s income tax expense of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is due primarily to income tax expense for Connect US, which is treated for income tax purposes as a service provider for Connect HK and earns service fee income on a cost-plus basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognize deferred income tax assets for the tax losses and deductible temporary differences that amounted to approximately RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">284</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">582</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,327</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2019, 2020 and 2021, respectively. The balance of research and development tax credits for Connect US as of December 31, 2021 is RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which can be carried forward against future tax liabilities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2019, 2020 and 2021, the Group did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any significant unrecognized uncertain tax positions.</span></p> 0.165 0.0825 2000000 0.165 0 0 0 0 0 0 0.21 0.21 0.0884 0.0884 0.0884 0 0 1700000 0.30 0 0 0 0 0 0 0.25 0.25 0.25 0 0 0 0 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The reconciliation between the Group’s actual tax charge and the amount that is calculated based on the statutory income tax rate of 25% in the PRC is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.516%;"/> <td style="width:1.326%;"/> <td style="width:0.603%;"/> <td style="width:11.509%;"/> <td style="width:0.798%;"/> <td style="width:1.104%;"/> <td style="width:0.603%;"/> <td style="width:11.509%;"/> <td style="width:0.798%;"/> <td style="width:1.326%;"/> <td style="width:0.603%;"/> <td style="width:11.509%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations in the PRC</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,741</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,788</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">233,382</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from overseas entities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94,884</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">693,437</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,071,745</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">779,225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305,127</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax expense at PRC enterprise income tax rate of 25%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,156</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">194,806</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326,282</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses not deductible for income tax purpose</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">799</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,185</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,663</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Super deduction of research and development expenses (i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,529</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,523</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax losses and deductible temporary differences for which no deferred income tax assets were recognized</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,956</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,865</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,121</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effect of income tax in jurisdictions other than the PRC</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,930</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">164,097</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">235,718</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,697</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:2.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7400778769790306%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to policies promulgated by the State Tax Bureau of the PRC, certain of the Group's subsidiaries are entitled to tax incentives for research and development expenses at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of tax-deductible research and development expenses in 2019, 2020 and 2021.</span></div></div> -73741000 -85788000 -233382000 -94884000 -693437000 -1071745000 -168625000 -779225000 -1305127000 -42156000 -194806000 -326282000 799000 3185000 13663000 9529000 13341000 35523000 33956000 40865000 114121000 -16930000 -164097000 -235718000 1697000 1.75 1.75 1.75 1700000 0 284000000 582000000 1327000000 13740000 0 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Net Loss Per Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon approval of shareholders of the Company on March 12, 2021, every </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.74</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares were consolidated into one ordinary share (the “Share Consolidation”) (Note 19). To calculate net loss per share, the number of shares used reflects such Share Consolidation retrospectively as of January 1, 2019 in the calculation of the weighted average number of ordinary shares outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net losses per share reflecting the effect of the issuance of ordinary shares by the Company are presented as follows.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is calculated by dividing the net loss attributable to owners of the Company by the weighted average number of ordinary shares outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.312%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.555%;"/> <td style="width:0.798%;"/> <td style="width:1.029%;"/> <td style="width:0.603%;"/> <td style="width:11.555%;"/> <td style="width:0.798%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.564%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to owners of the Company (RMB’000)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">779,225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,306,824</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average number of ordinary shares outstanding (in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,875</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,090</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,177</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share (RMB)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45.6</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share options and preferred shares are considered as potential dilutive shares throughout the reporting period. However, since the Group had incurred losses for the years ended December 31, 2019, 2020 and 2021, the potential dilutive shares have anti-dilutive effect on loss per share if they are converted to ordinary shares. Thus, diluted loss per share is equivalent to the basic loss per share.</span></p> 1.74 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is calculated by dividing the net loss attributable to owners of the Company by the weighted average number of ordinary shares outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.312%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.555%;"/> <td style="width:0.798%;"/> <td style="width:1.029%;"/> <td style="width:0.603%;"/> <td style="width:11.555%;"/> <td style="width:0.798%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.564%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to owners of the Company (RMB’000)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">779,225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,306,824</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average number of ordinary shares outstanding (in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,875</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,090</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,177</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share (RMB)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45.6</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table> -168625000 -779225000 -1306824000 16875000 17090000 52177000 -10.0 -45.6 -25.0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Property, Plant and Equipment</span></p><div style="font-size:11.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:35.37%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:11.314%;"/> <td style="width:0.723%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:11.333%;"/> <td style="width:0.723%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:9.914%;"/> <td style="width:0.723%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:11.314%;"/> <td style="width:0.723%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:8.513%;"/> <td style="width:0.723%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Office<br/>equipment,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Laboratory <br/>equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Leasehold<br/>improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">furniture<br/>and others</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Assets under <br/>construction</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">As of January 1, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,059</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">628</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">582</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,121</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">234</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">375</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,730</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net book value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,938</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">394</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">207</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,539</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Opening net book value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,938</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">394</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">207</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,539</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,613</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">833</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,355</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">339</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">574</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">955</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Closing net book value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,212</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">653</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">168</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,672</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,461</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">585</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,624</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,460</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">808</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">417</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,685</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net book value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,212</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">653</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">168</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Opening net book value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,212</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">653</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">168</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">30,440</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">422</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">24,121</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,776</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Disposals</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">234</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">248</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,142</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">813</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">175</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,130</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Transfers</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,449</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,449</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Closing net book value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">32,276</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,082</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">401</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,578</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">59,337</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">35,878</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,703</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">993</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,578</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">65,152</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,602</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,621</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">592</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,815</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net book value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">32,276</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,082</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">401</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,578</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">59,337</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:35.37%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:11.314%;"/> <td style="width:0.723%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:11.333%;"/> <td style="width:0.723%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:9.914%;"/> <td style="width:0.723%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:11.314%;"/> <td style="width:0.723%;"/> <td style="width:1.187%;"/> <td style="width:0.538%;"/> <td style="width:8.513%;"/> <td style="width:0.723%;"/> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Office<br/>equipment,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Laboratory <br/>equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Leasehold<br/>improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">furniture<br/>and others</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Assets under <br/>construction</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:7.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">As of January 1, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,059</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">628</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">582</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,121</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">234</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">375</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,730</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net book value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,938</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">394</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">207</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,539</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Opening net book value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,938</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">394</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">207</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,539</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,613</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">833</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,355</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">339</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">574</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">955</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Closing net book value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,212</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">653</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">168</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,672</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,461</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">585</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,624</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,460</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">808</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">417</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,685</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net book value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,212</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">653</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">168</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Opening net book value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,212</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">653</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">168</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">30,440</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">422</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">24,121</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,776</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Disposals</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">234</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">248</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,142</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">813</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">175</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,130</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Transfers</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,449</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,449</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Closing net book value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">32,276</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,082</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">401</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,578</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">59,337</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">35,878</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,703</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">993</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,578</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">65,152</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,602</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,621</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">592</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,815</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net book value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">32,276</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,082</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">401</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23,578</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">59,337</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 3059000 628000 582000 4269000 -1121000 -234000 -375000 -1730000 1938000 394000 207000 2539000 1938000 394000 207000 2539000 2613000 833000 3000 1906000 5355000 339000 574000 42000 955000 4212000 653000 168000 1906000 6939000 5672000 1461000 585000 1906000 9624000 -1460000 -808000 -417000 -2685000 4212000 653000 168000 1906000 6939000 4212000 653000 168000 1906000 6939000 30440000 793000 422000 24121000 55776000 234000 14000 248000 2142000 813000 175000 3130000 2449000 -2449000 32276000 3082000 401000 23578000 59337000 35878000 4703000 993000 23578000 65152000 -3602000 -1621000 -592000 -5815000 32276000 3082000 401000 23578000 59337000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Other non-current Assets</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.756%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.802%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.802%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductible value-added tax</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,260</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,045</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayments for purchase of non-current assets (i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,600</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Others</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">420</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,860</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,806</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of December 31, 2020, the Group had prepayment balances of approximately RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, primarily due to the purchase of laboratory equipment for Connect SZ.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.756%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.802%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.802%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductible value-added tax</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,260</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,045</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayments for purchase of non-current assets (i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,600</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Others</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">420</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,860</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,806</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of December 31, 2020, the Group had prepayment balances of approximately RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, primarily due to the purchase of laboratory equipment for Connect SZ.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div> 10260000 18045000 9600000 341000 420000 19860000 18806000 9600000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts recognized in the consolidated balance sheets are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) Right-of-use assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.438%;"/> <td style="width:1.568%;"/> <td style="width:0.603%;"/> <td style="width:15.019%;"/> <td style="width:0.798%;"/> <td style="width:1.169%;"/> <td style="width:0.603%;"/> <td style="width:15.019%;"/> <td style="width:0.798%;"/> <td style="width:1.568%;"/> <td style="width:0.603%;"/> <td style="width:15.019%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Land use rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Office rent</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net book amount-as of January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,290</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,290</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">407</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">407</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net book amount-as of December 31, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">527</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">527</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">481</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">481</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net book amount-as of as of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">929</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">929</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,284</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">517</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,801</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">297</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">612</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">909</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net book amount-as of as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,987</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">834</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,821</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,284</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,607</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,891</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">297</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,773</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,070</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net Book value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,987</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">834</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,821</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, the addition of land use rights was related to payments to acquire long-term interest in the usage of land in the PRC over the period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as stated in the land use right certificate. The land is expected to be used for the construction of production, research and office facilities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:11.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) Lease liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.457%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.201%;"/> <td style="width:0.603%;"/> <td style="width:1.169%;"/> <td style="width:0.603%;"/> <td style="width:15.201%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.201%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-current</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">470</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">309</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">163</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">412</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">604</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">630</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:1.0pt;font-family:Times New Roman;">.</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">882</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts recognized in the consolidated statements of loss in addition to depreciation presented above are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.48%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.193%;"/> <td style="width:0.603%;"/> <td style="width:1.169%;"/> <td style="width:0.603%;"/> <td style="width:15.193%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.193%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expense relating to short-term leases (included in administrative expenses and research and development expenses)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expense relating to leases of low-value assets that are not shown above as short-term leases (included in administrative expenses and research and development expenses)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">209</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total cash outflow for leases for the years ended December 31, 2019, 2020 and 2021 was RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts recognized in the consolidated balance sheets are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) Right-of-use assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.438%;"/> <td style="width:1.568%;"/> <td style="width:0.603%;"/> <td style="width:15.019%;"/> <td style="width:0.798%;"/> <td style="width:1.169%;"/> <td style="width:0.603%;"/> <td style="width:15.019%;"/> <td style="width:0.798%;"/> <td style="width:1.568%;"/> <td style="width:0.603%;"/> <td style="width:15.019%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Land use rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Office rent</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net book amount-as of January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,290</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,290</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">407</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">407</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net book amount-as of December 31, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">527</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">527</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">481</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">481</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net book amount-as of as of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">929</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">929</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,284</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">517</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,801</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">297</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">612</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">909</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net book amount-as of as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,987</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">834</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,821</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,284</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,607</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,891</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">297</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,773</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,070</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net Book value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,987</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">834</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,821</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1290000 1290000 407000 407000 883000 883000 527000 527000 481000 481000 929000 929000 22284000 517000 22801000 297000 612000 909000 21987000 834000 22821000 22284000 2607000 24891000 297000 1773000 2070000 21987000 834000 22821000 P50Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) Lease liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.457%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.201%;"/> <td style="width:0.603%;"/> <td style="width:1.169%;"/> <td style="width:0.603%;"/> <td style="width:15.201%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.201%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-current</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">470</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">309</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">163</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">412</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">604</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">630</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:1.0pt;font-family:Times New Roman;">.</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">882</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 470000 309000 163000 412000 604000 630000 882000 913000 793000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts recognized in the consolidated statements of loss in addition to depreciation presented above are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.48%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.193%;"/> <td style="width:0.603%;"/> <td style="width:1.169%;"/> <td style="width:0.603%;"/> <td style="width:15.193%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.193%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expense relating to short-term leases (included in administrative expenses and research and development expenses)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expense relating to leases of low-value assets that are not shown above as short-term leases (included in administrative expenses and research and development expenses)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">209</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 53000 42000 44000 98000 45000 12000 58000 30000 58000 209000 117000 114000 400000 500000 800000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Financial Instruments by Category</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.258%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.126%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">at FVPL</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">at amortized cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other receivables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,612</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,612</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial assets at fair value through profit or loss</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,010,076</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,010,076</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,015,688</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,028,756</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.258%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.126%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">at FVPL</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">at amortized cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other receivables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,423</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,423</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,706,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,706,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,713,303</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,713,303</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.258%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.126%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">liabilities at</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">liabilities at</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial Liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">FVPL</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">amortized cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,638</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,638</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,182</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,105,690</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.272%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.127%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.127%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.127%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">liabilities at</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">liabilities at</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial Liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">FVPL</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">amortized cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,456</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,456</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">.</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,444</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,444</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.258%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.126%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">at FVPL</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">at amortized cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other receivables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,612</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,612</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial assets at fair value through profit or loss</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,010,076</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,010,076</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,015,688</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,028,756</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.258%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.126%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">at FVPL</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">at amortized cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other receivables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,423</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,423</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,706,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,706,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,713,303</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,713,303</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.258%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.126%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.135%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">liabilities at</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">liabilities at</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial Liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">FVPL</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">amortized cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,638</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,638</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,182</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,105,690</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.272%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.127%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.127%;"/> <td style="width:0.603%;"/> <td style="width:1.577%;"/> <td style="width:0.603%;"/> <td style="width:15.127%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">liabilities at</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">liabilities at</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial Liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">FVPL</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">amortized cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,456</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,456</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">.</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,444</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,444</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 5612000 5612000 13068000 13068000 1010076000 1010076000 13068000 1015688000 1028756000 6423000 6423000 1706880000 1706880000 1713303000 1713303000 2071508000 2071508000 8631000 8631000 24638000 24638000 913000 913000 2071508000 34182000 2105690000 21456000 21456000 81195000 81195000 793000 793000 103444000 103444000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16. Other Receivables and Prepayments</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.753%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayment for clinical trials related services</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,043</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,879</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits(ii)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,881</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,312</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses(i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,953</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Others</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,731</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,111</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,255</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Group made payments to purchase director and officer liability insurance. Such expenses are amortized over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits held by CRO suppliers are refundable upon the completion of related services.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.753%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayment for clinical trials related services</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,043</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,879</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits(ii)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,881</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,312</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses(i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,953</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Others</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,731</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,111</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,255</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Group made payments to purchase director and officer liability insurance. Such expenses are amortized over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits held by CRO suppliers are refundable upon the completion of related services.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div> 28043000 36879000 3881000 4312000 3953000 1731000 2111000 33655000 47255000 P1Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">17. Financial Assets at Fair Value Through Profit or Loss</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.821%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.626%;"/> <td style="width:0.705%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.811%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Wealth management products</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The returns on these wealth management products were not guaranteed, hence their contractual cash flows did not qualify solely as payments of principal and interest. Therefore, they were measured at fair value through profit or loss. Wealth management products held by the Group with various maturities bear floating interest rates of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%-</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%-</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.44</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum for the years ended December 31, 2020 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of wealth management products is based on discounted cash flows using their expected returns. Changes in fair value of these financial assets are recorded in other gains/(losses) – net in the consolidated statements of loss.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.821%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.626%;"/> <td style="width:0.705%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.811%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Wealth management products</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 13068000 0.016 0.034 0.0148 0.0344 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18. Cash and Cash Equivalents</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.738%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.811%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.811%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash at bank</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-USD deposits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">975,810</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,645,948</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-RMB deposits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,113</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,595</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-Australian Dollar deposit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,153</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,337</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,010,076</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,706,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash at bank located in the PRC earns interest at floating rates based on daily bank deposit rates, while deposits in banks outside the PRC are with interest rate of nil.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash at banks denominated in RMB are deposited with banks in the PRC. The conversion of these RMB-denominated balances into foreign currencies and the remittance of funds out of China are subject to the rules and regulations of foreign exchange control promulgated by the Government of the PRC. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020 and 2021, RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">932.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,501.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of cash and cash equivalents were held in banks outside the PRC, respectively.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.738%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.811%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.811%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash at bank</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-USD deposits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">975,810</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,645,948</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-RMB deposits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,113</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,595</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-Australian Dollar deposit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,153</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,337</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,010,076</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,706,880</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 975810000 1645948000 28113000 57595000 6153000 3337000 1010076000 1706880000 932800000 1501800000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">19. Share Capital</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon approval of shareholders of the Company on March 12, 2021, every </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.74</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares with a par value of USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0001</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> each in the authorized share capital of the Company (including all issued and unissued shares) were consolidated into one share with a par value of USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.000174</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> each. Therefore, the authorized share capital of the Company was changed from USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> into USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,560</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The authorized share capital of the Company as of December 31, 2021 was USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,560</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The number of ordinary shares below are presented retrospectively as if such Share Consolidation took place as of January 1, 2019.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.241%;"/> <td style="width:1.465%;"/> <td style="width:0.603%;"/> <td style="width:13.3%;"/> <td style="width:0.798%;"/> <td style="width:1.465%;"/> <td style="width:0.603%;"/> <td style="width:8.041%;"/> <td style="width:0.603%;"/> <td style="width:1.465%;"/> <td style="width:0.603%;"/> <td style="width:9.488%;"/> <td style="width:0.603%;"/> <td style="width:1.465%;"/> <td style="width:0.603%;"/> <td style="width:8.05%;"/> <td style="width:0.603%;"/> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Ordinary Shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Share Capital</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Share Premium(i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,684,770</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,074</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,095</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,684,770</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,123</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,144</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of shares to Co-Founders (iv, Note 22)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">282,526</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,343</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,344</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of treasury shares</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,686,495</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,653,791</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,466</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of ordinary shares (ii)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,937,500</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305,805</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305,819</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion from preferred shares to ordinary shares (Note 24)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,791,804</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,743,597</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,743,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Repurchase of ordinary shares (iii)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,765</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of shares to Co-Founders (iv, Note 22)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,080</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,417</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,417</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,149</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,149</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,483,410</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,434</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share premium mainly arose from the contributions to the Company by its holders of ordinary shares and the conversion from preferred shares.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,937,500</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ADSs (representing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,937,500</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares, including the exercise of the option by the underwriters in full to purchase additional ADSs) were offered by the Company in connection with its listing on Nasdaq, and the proceeds received were USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">219.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million or RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,431.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million based on the exchange rate as of the date of the IPO. The Company incurred issuance costs of USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in connection with this offering.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(iii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n March 2021, at the request of one co-founder the Group repurchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,765</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares from him for a consideration of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million) for the payment of employee withholding taxes related to share-based awards, then such shares were cancelled accordingly</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(iv)</span><div style="display:inline;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Company’s shareholder agreement in effect as of the completion of the Series C financing (see Note 22), each of the Company’s founders is entitled to two or more votes to ensure the Co-Founders control the majority of the votes under certain circumstances.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/></span></div></div></div> 1.74 0.0001 0.000174 50000000 76560000 76560000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.241%;"/> <td style="width:1.465%;"/> <td style="width:0.603%;"/> <td style="width:13.3%;"/> <td style="width:0.798%;"/> <td style="width:1.465%;"/> <td style="width:0.603%;"/> <td style="width:8.041%;"/> <td style="width:0.603%;"/> <td style="width:1.465%;"/> <td style="width:0.603%;"/> <td style="width:9.488%;"/> <td style="width:0.603%;"/> <td style="width:1.465%;"/> <td style="width:0.603%;"/> <td style="width:8.05%;"/> <td style="width:0.603%;"/> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Ordinary Shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Share Capital</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Share Premium(i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,684,770</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,074</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,095</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,684,770</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,123</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,144</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of shares to Co-Founders (iv, Note 22)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">282,526</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,343</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,344</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of treasury shares</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,686,495</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,653,791</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,466</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of ordinary shares (ii)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,937,500</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305,805</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305,819</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion from preferred shares to ordinary shares (Note 24)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,791,804</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,743,597</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,743,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Repurchase of ordinary shares (iii)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,765</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of shares to Co-Founders (iv, Note 22)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,080</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,417</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,417</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,149</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,149</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,483,410</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,434</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share premium mainly arose from the contributions to the Company by its holders of ordinary shares and the conversion from preferred shares.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,937,500</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ADSs (representing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,937,500</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares, including the exercise of the option by the underwriters in full to purchase additional ADSs) were offered by the Company in connection with its listing on Nasdaq, and the proceeds received were USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">219.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million or RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,431.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million based on the exchange rate as of the date of the IPO. The Company incurred issuance costs of USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in connection with this offering.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(iii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n March 2021, at the request of one co-founder the Group repurchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,765</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares from him for a consideration of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million) for the payment of employee withholding taxes related to share-based awards, then such shares were cancelled accordingly</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(iv)</span><div style="display:inline;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Company’s shareholder agreement in effect as of the completion of the Series C financing (see Note 22), each of the Company’s founders is entitled to two or more votes to ensure the Co-Founders control the majority of the votes under certain circumstances.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/></span></div></div> 17684770 21000 38074000 38095000 49000 49000 17684770 21000 38123000 38144000 282526 1000 3343000 3344000 1686495 2000 2000 19653791 24000 41466000 41490000 12937500 14000 1305805000 1305819000 24791804 28000 2743597000 2743625000 20765 121080 1417000 1417000 2149000 2149000 57483410 66000 4094434000 4094500000 12937500 12937500 219900000 1431800000 19300000 20765 2500000 400000 Pursuant to the Company’s shareholder agreement in effect as of the completion of the Series C financing (see Note 22), each of the Company’s founders is entitled to two or more votes to ensure the Co-Founders control the majority of the votes under certain circumstances. <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">20. Treasury Shares</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treasury shares were previously held by Connect Union for the purpose of issuing shares under 2019 Stock Incentive Plan in 2019 and 2020. All the Company’s ordinary shares held by Connect Union were surrendered to the Company in September 2021. As of December 31, 2019, 2020 and 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">877,066</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,563,563</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,407,091</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> treasury shares, respectively.</span></p> 877066 2563563 2407091 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">21. Reserves</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Share-based compensation reserves</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The share-based compensation reserves represent the fair value of unexercised options granted to employees recognized in accordance with the accounting policy adopted for equity-settled share-based payments described in Note 2.17 to the financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Other reserves</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other reserves mainly represent the reserve transferred from share-based compensation reserve upon exercise of share options and foreign currency translation reserve described in Note 2.5(c).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Statutory reserves</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with the PRC regulations and the articles of association of the PRC companies now included in the Group, before annual profit distribution, companies registered in the PRC are required to set aside </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their net profit for the year after offsetting any prior year losses as determined under relevant PRC accounting standards to the statutory surplus reserve fund. When the balance of such reserve reaches </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the entity’s registered capital, any further appropriation is optional. No profit appropriation to the reserve fund was made for those Group entities for the reporting periods as they were in accumulated loss positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under PRC laws and regulations, there are restrictions on the Company’s PRC subsidiaries with respect to transferring certain of their net assets to the Company either in the form of dividends, loans, or advances. Restricted net assets including paid-in capital and statutory reserve funds of the Company’s PRC subsidiaries was RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2020 and RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">288.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021.</span></p> 0.10 0.50 137700000 288900000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">22. Share-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2019 Stock Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group adopted the 2019 stock incentive plan ("2019 Plan") and obtained Board’s approval on November 1, 2019, under which the Group may grant various awards such as options, restricted shares or restricted share units to employees, directors, and consultants for services rendered. As of December 31, 2020 and 2021 the Group has reserved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,460,600</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (a</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fter the Share Consolidation </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,563,563</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,407,091</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares (a</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fter the Share Consolidation)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the plan, a grantee has the right to subscribe for the ordinary shares at a price determined by the Board. The options granted can only vest if the service conditions are met. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options granted under the plan are valid and effective for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years from the date of grant and vest over a service period which is generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months. Some options are vested in equal monthly installments or annual installments over the entire service period or vested immediately upon the grant date in instances where services had already been performed in their entirety.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Chinese grantees are entitled to subscribe for underlying shares only if an IPO is achieved, provided that the service condition is also met. As of each grant date during the year ended December 31, 2020, management believed achievement of the IPO was probable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The grant date of certain grantees occurred after the date they had begun rendering services to satisfy the condition attached to the share option award, the management estimated the grant date fair value in each reporting period for the purpose of recognizing the expense during the period between the service commencement date and the grant date. Once the grant date has been established, the recognized expense is based on the actual grant date fair value of the share option in the period of change.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantees who leave the Group other than for certain causes will lose their entitlement to the vested options if not exercised within three months of their termination date (or within three months after the IPO kick-off date for certain option holders).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Stock Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group adopted </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 Stock Incentive Plan (“2021 Plan”) effective on the day of effectiveness of its IPO. Awards granted under the 2021 Plan may be either stock options, stock appreciation rights (“SARs”), restricted stock units (“RSUs”), restricted stock awards (“RSA”) or dividend equivalent right ("DER”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the plan, a grantee has the right to subscribe for the ordinary shares at a price determined by the Board. The options granted can only vest if the service conditions are met. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options granted under the plan are valid and effective for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years from the date of grant and vest over a service period which is generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantees who leave the Group other than for certain causes will lose their entitlement to the vested options if not exercised within three months of their termination date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2021, the Company granted a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,403,660</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> options which contain </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">897,660</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> options from the 2019 Plan and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,506,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> options from the 2021 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Share Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group adopted but have not yet implemented the 2021 Employee Share Purchase Plan (“2021 ESPP”). A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares were initially reserved for issuance under the 2021 ESPP Plan. On the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031, the number of shares available for issuance under the 2021 ESPP Plan shall be increased by that number of shares equal to the lesser of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the aggregate number of ordinary shares of the Group outstanding on the final day of the immediately preceding calendar year or such smaller number of shares as determined by the Groups board of directors. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No offering has been made under the 2021 ESPP Plan in the period from the adoption of the 2021 ESPP Plan to December 31, 2021.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The options activities under 2019 and 2021 Plans (after the Share Consolidation) for the year ended December 31, 2019, 2020 and 2021 were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:60.25%;"/> <td style="width:1.698%;"/> <td style="width:0.603%;"/> <td style="width:14.378%;"/> <td style="width:0.798%;"/> <td style="width:1.698%;"/> <td style="width:20.575%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted average<br/>exercise price per<br/>share option</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">198,064</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited (i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,302</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190,762</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,500,887</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited (i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,766</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,665,883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,403,660</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.8</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">163,773</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited (i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">157,381</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.7</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,748,389</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">485,324</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted average remaining contractual life of options outstanding as of December 31, 2019, 2020 and 2021 was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div><div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The options were forfeited when the employment terminated.</span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair value of options granted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the completion of the IPO, the Group determined its equity value which was estimated using the hybrid method and adopted the allocation model to determine the fair value of its underlying ordinary shares. After the completion of the IPO, the fair value of the share options is estimated based on the fair market value of the Company’s underlying ordinary shares at the grant date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the fair value of underlying ordinary shares, the Group used the Binomial option-pricing model to determine the fair value of options as of the grant date. Key assumptions (after the Share Consolidation) for the options granted are set forth below:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:42.13%;"/> <td style="width:1.336%;"/> <td style="width:0.603%;"/> <td style="width:15.258%;"/> <td style="width:1.994%;"/> <td style="width:1.336%;"/> <td style="width:0.603%;"/> <td style="width:15.138%;"/> <td style="width:1.994%;"/> <td style="width:1.336%;"/> <td style="width:18.273%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="9" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average exercise price during the year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.8</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant date share price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">~USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">~USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">~USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.3</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Option life</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected early exercise multiple</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_15a4dbee-7276-4e36-8ad1-42a7322137a1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nil</span></span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c0323612-661d-4824-a424-de733e9953f7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nil</span></span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_efb04996-6ed5-4b71-9631-15ef26b61eac;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nil</span></span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeiture rate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.5</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.5</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%-</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average fair value of options granted during the year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">* </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeiture rates for executives and all other employees in the year ended December 31, 2021, were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%,</span></span></p><div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> respectively.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company adopted the average volatility of the comparable companies as the proxy of the expected volatility of the underlying share. The volatility of each comparable company was based on the historical daily stock prices for a period with length commensurate to the remaining maturity life of the share options.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-based compensation to Co-Founders</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 20, 2018, pursuant to the shareholders agreement entered into among the Company and all its shareholders in connection with its Series B financing, up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">702,278</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,140,474</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares (before Share Consolidation) will be issued to the Co-Founders and Connect Union, respectively, for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> consideration, contingent on achieving of various R&amp;D milestones as non-market performance conditions. Under such agreement, the ordinary shares may also be issued in a lump sum immediately after the closing of new financing that meets several requirements including, among others, the pre-money valuation of the Group exceeding USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“Financing Condition”). Such shares to be issued to Connect Union were reserved for future issuance of options.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon achievement of certain R&amp;D milestones, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">351,140</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares (before Share Consolidation) were vested and yet to be issued to the Co-Founders as of December 31, 2019. In January 2020, another </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140,456</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares (before Share Consolidation) were vested to the Co-Founders. Accordingly, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">491,596</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares (before Share Consolidation) to the Co-Founders and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">798,330</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares (before Share Consolidation) to Connect Union, respectively, for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> consideration in April 2020. The Company recognized the related share-based compensation expenses in the amounts of RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2019 and 2020, respectively. Unless otherwise waived by the Company and the investors party to the shareholders agreement, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">210,682</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares (before Share Consolidation) are potentially issuable to the Co-Founders and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">342,144</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares (before Share Consolidation) are potentially issuable to Connect Union upon achievement of the Financing Condition.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the shareholders agreement entered into in connection with the Company’s Series C financing in August and December 2020, upon the issuance of the remaining ordinary shares issuable upon achievement of the Financing Condition (i.e. 210,682 ordinary shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(before Share Consolidation) </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to be issued to the Co-Founders and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">342,144</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(before Share Consolidation) </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to be issued to Connect Union), the Company will be obligated to issue additional Series C preferred shares at par value to each of the Series C shareholders so that the shareholdings of the Series C preferred shares obtained by such Series C shareholders will not be diluted. As of December 31, 2020, the Company has not yet issued the above ordinary shares to Co-Founders and Connect Union, so </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional Series C preferred shares are issued.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the shareholders agreement, upon achievement of certain R&amp;D milestones, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">210,682</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares were issued to the Co-Founders for the year ended December 31, 2021. After the Share Consolidation, these have become </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,080</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br/>In March 2021, based on the anti-dilutive obligation of the Company to issue additional Series C preferred shares, the Company also issued additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,457</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Series C preferred shares. After the Share Consolidation, these have become </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,232</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> preferred shares. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon completion of the IPO, such preferred shares were converted to ordinary shares on a one-for-one basis.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group determined its equity value which was estimated using the hybrid method and adopted the allocation model to determine the fair value of this share-based payment as USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share before the Share Consolidation (USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.57</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the Share Consolidation) on the grant date. Key assumptions included risk-free interest rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, expected volatility of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, dividend yield of nil and were based on the management’s best estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-based compensation to additional Series C preferred shareholder</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the Company entered into a Series C preferred share purchase agreement with certain investors to issue </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,186,643</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,452,094</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the Share Consolidation) of Series C preferred shares for a cash consideration of USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Subsequent to the completion of the Series C financing in August 2020, the Company negotiated with another investor for an additional round of Series C financing. On December 1, 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,162,894</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,817,755</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the Share Consolidation) additional Series C preferred shares to such investor for a cash consideration of USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million with the same subscription price and similar terms as Series C preferred shares issued in August 2020 (“Additional Series C Preferred Shares”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to the relevant guidance under IFRS 2, when the Group receives identifiable consideration that is less than the fair value of the equity instruments granted or liability incurred, the Group measures the identifiable goods or services received. The Group shall measure the unidentifiable goods or services received (or to be received) as the difference between the fair value of the share-based payment and the fair value of any identifiable goods or services received (or to be received) on the grant date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Therefore, the Group recognized the difference between the cash consideration received from and the fair value of the Additional Series C Preferred Shares on the issuance date as a share-based compensation in the amount of approximately RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expenses included in the consolidated statements of loss for the years ended December 31, 2019, 2020 and 2021 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.373%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.733%;"/> <td style="width:0.603%;"/> <td style="width:1.029%;"/> <td style="width:0.603%;"/> <td style="width:11.733%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.733%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses (Note 6)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,635</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,523</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,532</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Administrative expenses (Note 5(ii), Note 6)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">240</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,667</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,331</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,190</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon completion of the IPO, all issued and outstanding </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional Series C Preferred Shares</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were converted to ordinary share on a one-for-one basis.</span></p> 4460600 2563563 2407091 Options granted under the plan are valid and effective for 10 years from the date of grant and vest over a service period which is generally four years; 25% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next 36 months. Some options are vested in equal monthly installments or annual installments over the entire service period or vested immediately upon the grant date in instances where services had already been performed in their entirety. P10Y P4Y 0.25 P36M Options granted under the plan are valid and effective for 10 years from the date of grant and vest over a service period which is generally four years; 25% of the granted options vest on the first anniversary of the grant date and the remaining options vest in equal monthly installments over next 36 months. P10Y P4Y 0.25 P36M 2403660 897660 1506000 600000 0.01 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The options activities under 2019 and 2021 Plans (after the Share Consolidation) for the year ended December 31, 2019, 2020 and 2021 were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:60.25%;"/> <td style="width:1.698%;"/> <td style="width:0.603%;"/> <td style="width:14.378%;"/> <td style="width:0.798%;"/> <td style="width:1.698%;"/> <td style="width:20.575%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted average<br/>exercise price per<br/>share option</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">198,064</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited (i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,302</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190,762</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,500,887</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited (i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,766</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,665,883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,403,660</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.8</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">163,773</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited (i)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">157,381</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.7</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,748,389</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">485,324</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The options were forfeited when the employment terminated.</span></div></div> 0 198064 0.9 7302 0.9 190762 1500887 6.6 25766 0.9 1665883 2403660 13.8 163773 0.9 157381 14.7 3748389 485324 P7Y7M6D P9Y3M18D P9Y2M12D <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the fair value of underlying ordinary shares, the Group used the Binomial option-pricing model to determine the fair value of options as of the grant date. Key assumptions (after the Share Consolidation) for the options granted are set forth below:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:42.13%;"/> <td style="width:1.336%;"/> <td style="width:0.603%;"/> <td style="width:15.258%;"/> <td style="width:1.994%;"/> <td style="width:1.336%;"/> <td style="width:0.603%;"/> <td style="width:15.138%;"/> <td style="width:1.994%;"/> <td style="width:1.336%;"/> <td style="width:18.273%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="9" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average exercise price during the year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.8</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant date share price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">~USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">~USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">~USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.3</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%~</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Option life</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected early exercise multiple</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_15a4dbee-7276-4e36-8ad1-42a7322137a1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nil</span></span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c0323612-661d-4824-a424-de733e9953f7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nil</span></span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_efb04996-6ed5-4b71-9631-15ef26b61eac;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nil</span></span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeiture rate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.5</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.5</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%-</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average fair value of options granted during the year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6</span></p></td> </tr> </table><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeiture rates for executives and all other employees in the year ended December 31, 2021, were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%,</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> respectively.</span></p> 0.9 6.6 13.8 1.9 2.1 2.1 11.1 4.3 23.3 0.017 0.021 0.008 0.011 0.012 0.017 0.566 0.774 0.618 0.774 0.605 0.622 10 10 10 2.2 2.2 2.2 0.095 0.095 0.030 0.096 1.2 4.2 10.6 0.030 0.096 702278 1140474 0 600000000 351140 140456 491596 798330 0 2700000 1200000 210682 342144 342144 0 210682 121080 80457 46232 0.9 1.57 0.025 0.600 18186643 10452094 115000000.0 3162894 1817755 20000000.0 19700000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expenses included in the consolidated statements of loss for the years ended December 31, 2019, 2020 and 2021 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.373%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.733%;"/> <td style="width:0.603%;"/> <td style="width:1.029%;"/> <td style="width:0.603%;"/> <td style="width:11.733%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.733%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses (Note 6)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,635</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,523</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,532</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Administrative expenses (Note 5(ii), Note 6)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">240</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,667</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,331</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,190</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,863</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 3635000 3523000 26532000 240000 21667000 31331000 3875000 25190000 57863000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">23. Other Payables and Accruals</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:67.087%;"/> <td style="width:1.494%;"/> <td style="width:0.603%;"/> <td style="width:13.757%;"/> <td style="width:0.603%;"/> <td style="width:1.494%;"/> <td style="width:0.603%;"/> <td style="width:13.757%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,576</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll, welfare and bonus payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,124</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,384</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional service fee</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,090</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,318</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Others</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">541</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,562</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,755</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,840</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:67.087%;"/> <td style="width:1.494%;"/> <td style="width:0.603%;"/> <td style="width:13.757%;"/> <td style="width:0.603%;"/> <td style="width:1.494%;"/> <td style="width:0.603%;"/> <td style="width:13.757%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,576</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll, welfare and bonus payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,124</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,384</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional service fee</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,090</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,318</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Others</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">541</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,562</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,755</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,840</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 16576000 4124000 11384000 8090000 2318000 541000 2562000 12755000 32840000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">24. Financial Instruments with Preferred Rights</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group has completed a series of financings by issuing preferred shares with the following details:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.881%;"/> <td style="width:1.596%;"/> <td style="width:14.666%;"/> <td style="width:1.596%;"/> <td style="width:0.603%;"/> <td style="width:13.627%;"/> <td style="width:0.603%;"/> <td style="width:1.596%;"/> <td style="width:0.603%;"/> <td style="width:13.627%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Subscription</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">consideration</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date of subscription</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Round</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">preferred shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 3, 2016</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series Pre-A</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,109,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,110</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 3, 2017</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,471,200</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137,868</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 20, 2018</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,127,579</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">379,148</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 21, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 1, 2020</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series C</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,349,537</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">923,247</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,057,316</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,473,373</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the Share Consolidation, the above number of preferred shares were changed to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,745,572</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and together with additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,232</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> preferred shares as disclosed in the Note 22, the Company’s issued and outstanding preferred shares were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,791,804</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> prior to March 19, 2021. Upon completion of the IPO, such preferred shares were converted to ordinary share on a one-for-one basis.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The key preferred rights of the preferred shares are summarized as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(a) Conversion feature</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">i) Optional conversion</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each holder of preferred share shall be entitled to exercise its right to convert any of its preferred shares, at any time after the date of issuance of such shares, and each preferred share may be convertible into a certain number of fully paid and non-assessable ordinary shares at a ratio calculated by dividing the Series Pre-A issue price, the Series A issue price, the Series B issue price, or the Series C issue price, as applicable, by the then applicable conversion price (the “Conversion Price”). The Conversion Price is initially equal to the Series Pre-A issue price, the Series A issue price, the Series B issue price, or the Series C issue price, as applicable, and is subject to adjustment from time to time to reflect stock dividends, stock splits and other events. For the avoidance of doubt, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> payment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">shall</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">made by the holders of preferred shares to the Company upon or in connection with the conversion of the preferred shares into ordinary shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ii) Automatic conversion</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preferred shares held by each holder shall be, at the applicable Conversion Price in effect at the time of conversion, without the payment of any additional consideration, converted into fully-paid and non-assessable ordinary shares upon the closing of a Qualified initial public offering (“QIPO”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(b) Liquidation preferences</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of (i) any liquidation, dissolution or termination event, whether voluntary or involuntary, or (ii) unless waived by the holders of at least a majority of ordinary shares and the holders of at least two thirds of the preferred shares (calculated on a fully-diluted and as-converted basis), any deemed liquidation event as defined in the Company’s shareholders agreement, such as a merger, consolidation, sale, transfer, lease, exclusive license or other disposal of all or substantially all of the assets or intellectual property of the Company or of all of its subsidiaries as a whole (“Deemed Liquidation Event”), all assets and funds legally available for distribution shall be distributed to the holders of preferred shares in preference to the holders of ordinary shares, in an amount per share equal to the applicable series issue price plus any declared but unpaid dividends (the “Preference Amount”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full preference amount is first paid to the holders of the series of preferred shares that was most recently issued then to the holders of the next level of preference in order (Series C preferred shares, Series B preferred shares, Series A preferred shares, and Series Pre-A preferred shares (ranked pari passu), which are listed in order of highest liquidation preference to lowest).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If there are any assets or funds remaining after the aggregate Series Pre-A Preference Amount, Series A Preference Amount, Series B Preference Amount and Series C Preference Amount have been distributed or paid in full to the applicable holders of the preferred shares, the remaining assets and funds of the Company available for distribution shall be distributed ratably among all shareholders (including the preferred shareholders) according to the relative number of ordinary shares of the Company held by such shareholder (on an as-converted basis).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the available funds and assets become insufficient to satisfy the full preferential payment to the holders of a particular series of preferred shares, then such assets shall be distributed among the holders of that particular series of preferred shares, ratably in proportion to the full amounts to which they would otherwise be respectively entitled thereon.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(c) Redemption rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the occurrence of any of the following events, any holder of any other series of preferred shares is entitled to request a redemption of any of its shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company fails to consummate a QIPO on or before December 31, 2024 (the “Target QIPO Date”), such Target QIPO Date shall be postponed reasonably if any force majeure event adversely affects the process of the QIPO of the Company and the postponement arising therefrom is agreed by all the parties (including the preferred shareholders);</span></div></div><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7589560035999874%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company or any of the Co-Founders or the other group companies materially breaches its or his representations, warranties, covenants or obligations under any transaction document.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With the written consent of the holder(s) of more than fifty percent (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%) of the voting power of the aggregate number of a particular series of issued and outstanding preferred shares, the Company shall redeem such particular series of preferred shares, out of funds legally available therefor including the capital.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The redemption price for each issued and outstanding Series B and Series C preferred share (the “Series B and Series C Redemption Price”) shall be the amount equal to the sum of (i) an amount that would give an internal rate of return that equals to eight percent (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%) per annum on such Series B preferred share and Series C preferred share in respect of the Series B and Series C issue price, respectively, calculated for a period of time commencing from the Series B and Series C issue date and ending on the date that the Series B and Series C Redemption Price is paid in full by the Company, and (ii) any declared but unpaid dividends thereupon.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A Redemption Price is the amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Series A issue Price and any declared but unpaid dividends thereupon.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-A shareholders do not have redemption rights, although they have a liquidation preference upon occurrence of any Deemed Liquidation Events.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(d) Dividends</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividends are payable when and if declared by the Board out of funds legally available, and such dividends are not cumulative. Holders of the shares shall be entitled to receive out of any funds legally available therefor, when, as and if declared by the Board, non-cumulative dividends, as well as any non-cash dividends when, as and if declared by the Board. In the event the Company shall declare a distribution other than in cash, the holders of shares shall be entitled to a proportionate share of any such distribution when, as and if declared by the Board.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group designates the entire instruments with preferred rights described above as financial liabilities at fair value through profit or loss with the changes in the fair value recorded in the consolidated statements of loss, except for the changes in the fair value due to own credit risk, which are recorded in other comprehensive income/(loss).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Movements of financial instruments with preferred rights during the years ended December 31, 2019, 2020 and 2021 were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:81.827%;"/> <td style="width:1.772%;"/> <td style="width:0.603%;"/> <td style="width:15.0%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">573,499</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value recognized in profit or loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value due to foreign currency translation recognized in other comprehensive income</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,112</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">643,008</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of Series C Preferred Shares</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">923,247</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value recognized in profit or loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation to additional Series C preferred shareholder</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value due to foreign currency translation recognized in other comprehensive income</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93,688</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value recognized in profit or loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value due to foreign currency translation recognized in other comprehensive income</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,152</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Converted to ordinary shares upon IPO</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,743,625</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group first determined the equity value and then allocated the equity value to each element of the Group’s capital structure using either </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the option pricing back-solve method (“OPM”) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or a hybrid method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Key valuation assumptions used to determine the fair value of the financial instruments with preferred rights are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:67.276%;"/> <td style="width:1.503%;"/> <td style="width:14.859%;"/> <td style="width:1.503%;"/> <td style="width:14.859%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DLOM</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-Free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DLOM was estimated based on OPM. Under OPM, the cost of put option, which can hedge price changes before the privately held shares are sold, was considered as a basis to determine the DLOM.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility was estimated based on the annualized standard deviation of daily stock price return of comparable companies for periods from respective valuation dates and with similar span as time to exit.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rates were estimated based on the yield of U.S. Treasury strips as of each valuation date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sensitivity to changes in fair value</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company performed sensitivity test to changes in unobservable inputs in determining the fair value of preferred shares issued by the Company. The changes in unobservable inputs risk-free interest rate and expected volatility will result in a higher or lower fair value measurement. The increase in the fair value of financial instruments with preferred rights would increase the fair value loss in the consolidated statements of loss. When performing the sensitivity test, management applied an increase or decrease to each unobservable input, which represents management’s assessment of reasonably possible change to these unobservable inputs, and effect of those changes to the fair value of financial instruments with preferred rights is as set forth below:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the volatility had increased/decreased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, the loss before income tax for the year ended December 31, 2020 would have been approximately RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lower/RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million higher.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the risk-free interest rate had increased/decreased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, the loss before income tax for the year ended December 31, 2020 would have been approximately RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">887,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> higher/RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,712,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lower.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group used the IPO price (USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) to determine the fair value of the financial instruments with preferred rights on March 19, 2021. Upon completion of the IPO, such preferred shares were converted to ordinary share on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-for-one basis.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Group has completed a series of financings by issuing preferred shares with the following details:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.881%;"/> <td style="width:1.596%;"/> <td style="width:14.666%;"/> <td style="width:1.596%;"/> <td style="width:0.603%;"/> <td style="width:13.627%;"/> <td style="width:0.603%;"/> <td style="width:1.596%;"/> <td style="width:0.603%;"/> <td style="width:13.627%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Subscription</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">consideration</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date of subscription</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Round</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">preferred shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 3, 2016</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series Pre-A</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,109,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,110</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 3, 2017</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,471,200</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137,868</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 20, 2018</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,127,579</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">379,148</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 21, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 1, 2020</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series C</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,349,537</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">923,247</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,057,316</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,473,373</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 2016-03-03 3109000 33110000 2017-01-03 8471200 137868000 2018-12-20 10127579 379148000 2020-08-21 2020-12-01 21349537 923247000 43057316 1473373000 24745572 46232 24791804 24791804 0 0.50 0.08 0.08 1.50 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Movements of financial instruments with preferred rights during the years ended December 31, 2019, 2020 and 2021 were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:81.827%;"/> <td style="width:1.772%;"/> <td style="width:0.603%;"/> <td style="width:15.0%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">573,499</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value recognized in profit or loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value due to foreign currency translation recognized in other comprehensive income</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,112</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">643,008</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of Series C Preferred Shares</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">923,247</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value recognized in profit or loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation to additional Series C preferred shareholder</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value due to foreign currency translation recognized in other comprehensive income</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93,688</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value recognized in profit or loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value due to foreign currency translation recognized in other comprehensive income</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,152</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Converted to ordinary shares upon IPO</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,743,625</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 573499000 59397000 10112000 643008000 923247000 579286000 19655000 -93688000 2071508000 674269000 -2152000 2743625000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Key valuation assumptions used to determine the fair value of the financial instruments with preferred rights are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:67.276%;"/> <td style="width:1.503%;"/> <td style="width:14.859%;"/> <td style="width:1.503%;"/> <td style="width:14.859%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DLOM</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-Free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% ~ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table> 0.258 0.307 0.140 0.258 0.550 0.600 0.640 0.751 0.017 0.023 0.001 0.002 0.05 0.05 18000000.0 18100000 0.01 0.01 887000 1712000 17 1 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">25. Cash Flow Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:3.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Cash used in operations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:45.473%;"/> <td style="width:1.373%;"/> <td style="width:7.523%;"/> <td style="width:1.373%;"/> <td style="width:0.594%;"/> <td style="width:12.44%;"/> <td style="width:0.798%;"/> <td style="width:1.373%;"/> <td style="width:0.594%;"/> <td style="width:12.44%;"/> <td style="width:0.798%;"/> <td style="width:1.373%;"/> <td style="width:0.594%;"/> <td style="width:12.458%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">779,225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305,127</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments for:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Interest for lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Investment income from wealth management products</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">798</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">672</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">436</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Amortization of intangible assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Depreciation of property, plant and equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">383</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">955</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,130</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Depreciation of rights-of-use assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">407</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">481</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">909</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Share-based compensation expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,190</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,863</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Net foreign exchange differences</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,368</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,772</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Fair value changes of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Issuance cost of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,851</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Loss on disposal of property, plant and equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in working capital</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Other receivables and prepayments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,026</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,350</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,116</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Other non-current assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,603</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,206</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Other payables and accruals</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,698</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,558</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,459</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Trade payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,351</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,850</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,601</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operations</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90,256</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167,161</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">544,926</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Non-cash investing and financing activities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.468%;"/> <td style="width:1.113%;"/> <td style="width:11.159%;"/> <td style="width:1.113%;"/> <td style="width:0.603%;"/> <td style="width:10.101%;"/> <td style="width:0.603%;"/> <td style="width:1.113%;"/> <td style="width:0.603%;"/> <td style="width:10.101%;"/> <td style="width:0.603%;"/> <td style="width:1.113%;"/> <td style="width:0.603%;"/> <td style="width:10.101%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,576</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value changes of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation to additional Series C preferred shareholder</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">598,941</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">690,845</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Reconciliation of liabilities arising from financing activities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:67.016%;"/> <td style="width:1.493%;"/> <td style="width:0.603%;"/> <td style="width:13.607%;"/> <td style="width:0.798%;"/> <td style="width:1.493%;"/> <td style="width:0.603%;"/> <td style="width:13.589%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">instruments with</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Lease liability</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">At January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">573,499</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,274</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash flows</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">445</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Differences of foreign currency translation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,112</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">643,008</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">882</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash flows</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">923,247</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">538</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New leases</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">527</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Differences of foreign currency translation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93,688</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation to additional Series C preferred shareholder</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash flows</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">805</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New leases</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">641</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Differences of foreign currency translation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,152</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion to ordinary shares</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,743,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Cash used in operations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:45.473%;"/> <td style="width:1.373%;"/> <td style="width:7.523%;"/> <td style="width:1.373%;"/> <td style="width:0.594%;"/> <td style="width:12.44%;"/> <td style="width:0.798%;"/> <td style="width:1.373%;"/> <td style="width:0.594%;"/> <td style="width:12.44%;"/> <td style="width:0.798%;"/> <td style="width:1.373%;"/> <td style="width:0.594%;"/> <td style="width:12.458%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">779,225</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305,127</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments for:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Interest for lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Investment income from wealth management products</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">798</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">672</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">436</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Amortization of intangible assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Depreciation of property, plant and equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">383</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">955</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,130</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Depreciation of rights-of-use assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">407</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">481</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">909</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Share-based compensation expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,190</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,863</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Net foreign exchange differences</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,368</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,772</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Fair value changes of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Issuance cost of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,851</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Loss on disposal of property, plant and equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in working capital</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Other receivables and prepayments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,026</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,350</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,116</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Other non-current assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,603</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,906</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,206</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Other payables and accruals</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,698</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,558</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,459</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—Trade payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,351</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,850</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,601</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operations</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90,256</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167,161</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">544,926</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table> -168625000 -779225000 -1305127000 53000 42000 44000 798000 672000 436000 7000 43000 383000 955000 3130000 407000 481000 909000 3875000 25190000 57863000 -1368000 6772000 3309000 59397000 579286000 674269000 2851000 -250000 -3026000 -9350000 -16116000 -1603000 -3906000 -8206000 1698000 8558000 -11459000 19351000 1850000 56601000 -90256000 -167161000 -544926000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Non-cash investing and financing activities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.468%;"/> <td style="width:1.113%;"/> <td style="width:11.159%;"/> <td style="width:1.113%;"/> <td style="width:0.603%;"/> <td style="width:10.101%;"/> <td style="width:0.603%;"/> <td style="width:1.113%;"/> <td style="width:0.603%;"/> <td style="width:10.101%;"/> <td style="width:0.603%;"/> <td style="width:1.113%;"/> <td style="width:0.603%;"/> <td style="width:10.101%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Notes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction payables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,576</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value changes of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation to additional Series C preferred shareholder</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">598,941</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">690,845</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 16576000 59397000 579286000 674269000 19655000 59397000 598941000 690845000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Reconciliation of liabilities arising from financing activities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:67.016%;"/> <td style="width:1.493%;"/> <td style="width:0.603%;"/> <td style="width:13.607%;"/> <td style="width:0.798%;"/> <td style="width:1.493%;"/> <td style="width:0.603%;"/> <td style="width:13.589%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Financial</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">instruments with</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Lease liability</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">At January 1, 2019</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">573,499</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,274</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash flows</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">445</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Differences of foreign currency translation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,112</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">643,008</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">882</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash flows</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">923,247</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">538</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New leases</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">527</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Differences of foreign currency translation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93,688</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation to additional Series C preferred shareholder</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,655</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash flows</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">805</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New leases</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">641</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Differences of foreign currency translation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,152</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion to ordinary shares</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,743,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 573499000 1274000 -445000 53000 10112000 59397000 643008000 882000 923247000 -538000 527000 42000 -93688000 579286000 19655000 2071508000 913000 -805000 641000 44000 -2152000 674269000 -2743625000 793000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">26. Commitments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:3.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Capital commitments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.753%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equipment and intangible assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- Contracted but not provided for</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,243</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146,878</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Group had capital commitments of approximately RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, primarily in connection with the constru</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ction of campus in Taicang in the PRC. As of December 31, 2020, the Group had capital commitments of approximately RMB </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, primarily in connection with the purchase of equipment and improvement of the Group’s laboratory in Suzhou in the PRC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:18.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other commitments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company entered into the office lease agreement for approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,600</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet in San Diego, California, and the lease commenced in March 2022. The aggregate lease obligation over the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lease term is approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Capital commitments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.753%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> <td style="width:1.614%;"/> <td style="width:0.603%;"/> <td style="width:13.803%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equipment and intangible assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- Contracted but not provided for</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,243</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146,878</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 23243000 146878000 146900000 23200000 3600 P3Y 600000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">27. Related Party Transactions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parties are considered to be related if one party has the ability, directly or indirectly, to control or exercise significant influence over the other party. Parties are also considered to be related if they are subject to common control. Members of key management of the Group and their close family members are also considered as related parties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:56.0%;"/> <td style="width:1.0%;"/> <td style="width:43.0%;"/> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Names of related parties</span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Nature of relationship</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Simo Company Limited</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Entity controlled by a director of the Company</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Frontage Laboratories (Suzhou) Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Entity controlled by a director of the Company</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shanghai Tigermed Consulting Company Limited</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Entity controlled by a director of the Company</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Tigermed Consulting Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Entity controlled by a director of the Company</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beijing Medical Development (Suzhou) Company Limited</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:8.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Entity controlled by a director of the Company</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the former director Xiaoping Ye resigned on February 2, 2021, the above companies were no longer considered as related parties for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.164375;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to other related party transactions and balances disclosed elsewhere in this financial information, the following is a summary of significant transactions and balances with related parties during the years ended December 31, 2019, 2020 and 2021 and at each year end.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:2.667%;display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7400778769790306%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interests in subsidiaries of the Company are set out in Note 1.1.</span></div></div><p style="margin-left:2.667%;text-indent:-2.74%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><div style="margin-left:2.667%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7400778769790306%;">(b)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Significant transactions with related parties</span></div></div><p style="margin-left:2.667%;text-indent:-2.74%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.54%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Purchase of clinical trials related services</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Simo Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,601</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,948</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Frontage Laboratories (Suzhou) Company Limited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,346</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,157</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Tigermed Consulting Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">810</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,069</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beijing Medical Development (Suzhou) Company Limited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">301</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shanghai Tigermed Consulting Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">891</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:2.667%;display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7400778769790306%;">(c)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Balances with related parties</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.824%;"/> <td style="width:1.855%;"/> <td style="width:0.603%;"/> <td style="width:13.721%;"/> <td style="width:0.594%;"/> <td style="width:1.484%;"/> <td style="width:0.603%;"/> <td style="width:13.721%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(i) Prepayments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Tigermed Consulting Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">850</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Simo Company Limited</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">507</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All the above balances with related parties were unsecured, interest-free and had no fixed repayment terms.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><div style="margin-left:2.667%;display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7400778769790306%;">(d)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Key management personnel compensation</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.179%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Wages, salaries and bonuses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,358</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,013</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,749</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,148</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contributions to defined benefit plan (i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,140</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">971</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Welfare, housing funds and other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">216</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">308</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,463</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,312</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,674</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder following termination. The Company will have no further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk. The benefit obligation was determined using certain assumptions, including life annuity factor and specified interest rate, which were published by the U.S. Internal Revenue Service.</span></div></div></div><p style="margin-left:2.667%;text-indent:-2.74%;padding-left:2.667%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(e) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Shares repurchase from key management personnel</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(255,254,254,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n March 2021, the Group repurchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,254,254,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,765</span><span style="background-color:rgba(255,254,254,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary shares from one of the co-founders (see Note 19).</span></p> <div style="margin-left:2.667%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7400778769790306%;">(b)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Significant transactions with related parties</span></div></div><p style="margin-left:2.667%;text-indent:-2.74%;padding-left:2.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.54%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.271%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Purchase of clinical trials related services</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Simo Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,601</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,948</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Frontage Laboratories (Suzhou) Company Limited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,346</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,157</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Tigermed Consulting Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">810</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,069</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beijing Medical Development (Suzhou) Company Limited</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">301</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shanghai Tigermed Consulting Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">891</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:2.667%;display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7400778769790306%;">(c)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Balances with related parties</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.824%;"/> <td style="width:1.855%;"/> <td style="width:0.603%;"/> <td style="width:13.721%;"/> <td style="width:0.594%;"/> <td style="width:1.484%;"/> <td style="width:0.603%;"/> <td style="width:13.721%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(i) Prepayments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Tigermed Consulting Company Limited</span></p></td> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">850</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hangzhou Simo Company Limited</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">507</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 5601000 5948000 2346000 2157000 810000 1069000 186000 301000 891000 34000 850000 507000 <div style="margin-left:2.667%;display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.7400778769790306%;">(d)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Key management personnel compensation</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.179%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> <td style="width:1.391%;"/> <td style="width:0.603%;"/> <td style="width:11.677%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Wages, salaries and bonuses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,358</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,013</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,749</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,148</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contributions to defined benefit plan (i)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,140</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">971</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Welfare, housing funds and other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">216</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">308</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,463</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,312</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,674</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The defined benefit plan was established in 2018 for one founder and subsequently terminated in 2020. The aggregate value of the benefits under this plan was fully funded and rolled over into an individual retirement account for the benefit of the founder following termination. The Company will have no further obligations with respect to such plan and is no longer subject to actuarial risk and investment risk. The benefit obligation was determined using certain assumptions, including life annuity factor and specified interest rate, which were published by the U.S. Internal Revenue Service.</span></div></div> 3358000 8013000 18100000 2749000 1148000 28266000 1140000 971000 216000 180000 308000 7463000 10312000 46674000 20765 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">28. Events After the Reporting Period</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.4279166666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to those disclosed elsewhere in these financial statements, the following events occurring after the reporting periods are noted.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.4279166666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From January to March 2022, the Group granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,044,741</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ordinary share options to its employees and directors with service based vesting conditions and </span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">weighted average exercise price of USD </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.45</span><span style="background-color:rgba(254,254,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 2044741 4.45 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">29. Restricted net Assets and Parent Company only Condensed Financial Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s ability to pay dividends is primarily dependent on the Company receiving distributions of funds from its subsidiaries. Relevant PRC statutory laws and regulations permit payments of dividends by the Company’s subsidiaries in the PRC only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with the PRC laws and regulations, statutory reserve funds shall be made and can only be used for specific purposes and are not distributable as cash dividends. As a result of these PRC laws and regulations that require annual appropriation of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of net after-tax profits to be set aside prior to payment of dividends as statutory surplus fund, unless such reserve fund reaches </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the entity’s registered capital, the Group’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company performs a test on the restricted net assets of its consolidated subsidiaries (the “Restricted Net Assets”) in accordance with Securities and Exchange Commission Regulation S-X Section 4-08 (e) (3) “General Notes to Financial Statements” and concluded that the condensed financial information for the parent company is required to be presented as of December 31, 2020 and 2021 and for the years ended December 31, 2019, 2020 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, cash transfers from the Company’s PRC subsidiaries to their parent companies outside of China are subject to PRC government control of currency conversion. Shortages in the availability of foreign currency may restrict the ability of the PRC subsidiaries and consolidated affiliated entities to remit sufficient foreign currency to pay dividends or other payments to the Company, or otherwise satisfy their foreign currency denominated obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Condensed balance sheets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:58.214%;"/> <td style="width:0.594%;"/> <td style="width:11.678%;"/> <td style="width:0.798%;"/> <td style="width:1.289%;"/> <td style="width:0.594%;"/> <td style="width:11.687%;"/> <td style="width:0.798%;"/> <td style="width:1.289%;"/> <td style="width:0.594%;"/> <td style="width:11.669%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">USD’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ASSETS</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-current assets</span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest in a subsidiary</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">472,273</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,177,380</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">184,667</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total non-current assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">472,273</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,177,380</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">184,667</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Current assets</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">885,611</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,464,637</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">229,722</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other receivables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,278</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86,352</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,544</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,097</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">970,986</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,550,989</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">243,266</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,443,259</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,728,369</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">427,933</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">LIABILITIES</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-current liabilities</span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total non-current liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Current liabilities</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables and accruals</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,864</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,190</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,364</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,864</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,239</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,371</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,078,372</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">34,239</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5,371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net (liabilities)/assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">635,113</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,694,130</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">422,562</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SHAREHOLDERS’ (DEFICIT)/EQUITY</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share capital</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share premium</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,466</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,434</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">642,194</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treasury shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,164</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other reserves</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,732</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,359</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">670,868</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,388,847</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">217,834</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total shareholders’ (deficit)/equity</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">635,113</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,694,130</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">422,562</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Condensed statements of loss</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.496%;"/> <td style="width:0.603%;"/> <td style="width:10.057%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">USD’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Administrative expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,540</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,710</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,856</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">29,540</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">43,710</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,856</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finance income/(costs)—net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">335</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,758</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value loss of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105,756</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">59,085</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">611,584</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">717,979</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">112,612</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax expense</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Loss for the year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">59,085</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">611,584</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">717,979</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">112,612</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Condensed statements of cash flows</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.58%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> <td style="width:1.123%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.084%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">USD’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net cash from/(used in) operating activities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">249</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4,766</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">31,025</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4,866</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">159,057</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">204,170</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">672,529</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">105,483</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net cash generated from financing activities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">99,990</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">934,284</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,319,418</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">206,945</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net (decrease)/increase in cash and cash equivalents</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">58,818</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">725,348</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">615,864</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">96,596</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents at the beginning of year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">267,665</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213,253</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">885,611</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138,904</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effects of exchange rate changes on cash and cash equivalents</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,406</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,990</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,838</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,778</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents at end of year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">213,253</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">885,611</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,464,637</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">229,722</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> 0.10 0.50 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company performs a test on the restricted net assets of its consolidated subsidiaries (the “Restricted Net Assets”) in accordance with Securities and Exchange Commission Regulation S-X Section 4-08 (e) (3) “General Notes to Financial Statements” and concluded that the condensed financial information for the parent company is required to be presented as of December 31, 2020 and 2021 and for the years ended December 31, 2019, 2020 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, cash transfers from the Company’s PRC subsidiaries to their parent companies outside of China are subject to PRC government control of currency conversion. Shortages in the availability of foreign currency may restrict the ability of the PRC subsidiaries and consolidated affiliated entities to remit sufficient foreign currency to pay dividends or other payments to the Company, or otherwise satisfy their foreign currency denominated obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Condensed balance sheets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:58.214%;"/> <td style="width:0.594%;"/> <td style="width:11.678%;"/> <td style="width:0.798%;"/> <td style="width:1.289%;"/> <td style="width:0.594%;"/> <td style="width:11.687%;"/> <td style="width:0.798%;"/> <td style="width:1.289%;"/> <td style="width:0.594%;"/> <td style="width:11.669%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">USD’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ASSETS</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-current assets</span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest in a subsidiary</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">472,273</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,177,380</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">184,667</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total non-current assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">472,273</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,177,380</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">184,667</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Current assets</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">885,611</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,464,637</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">229,722</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other receivables</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,278</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86,352</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,544</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,097</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">970,986</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,550,989</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">243,266</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,443,259</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,728,369</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">427,933</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">LIABILITIES</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-current liabilities</span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total non-current liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,071,508</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Current liabilities</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade payables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other payables and accruals</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,864</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,190</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,364</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,864</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,239</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,371</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,078,372</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">34,239</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5,371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net (liabilities)/assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">635,113</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,694,130</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">422,562</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SHAREHOLDERS’ (DEFICIT)/EQUITY</span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share capital</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share premium</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,466</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,434</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">642,194</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treasury shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,164</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other reserves</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,732</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,359</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,625</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">670,868</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,388,847</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">217,834</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total shareholders’ (deficit)/equity</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">635,113</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,694,130</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">422,562</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b) Condensed statements of loss</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.496%;"/> <td style="width:0.603%;"/> <td style="width:10.057%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">USD’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Administrative expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,540</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,710</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,856</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">29,540</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">43,710</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,856</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finance income/(costs)—net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">335</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,758</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value loss of financial instruments with preferred rights</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,397</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">579,286</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,269</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105,756</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">59,085</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">611,584</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">717,979</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">112,612</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax expense</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Loss for the year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">59,085</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">611,584</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">717,979</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">112,612</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(c) Condensed statements of cash flows</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.58%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> <td style="width:1.123%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.084%;"/> <td style="width:0.798%;"/> <td style="width:1.225%;"/> <td style="width:0.594%;"/> <td style="width:10.066%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RMB’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">USD’000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net cash from/(used in) operating activities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">249</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4,766</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">31,025</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4,866</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">159,057</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">204,170</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">672,529</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">105,483</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net cash generated from financing activities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">99,990</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">934,284</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,319,418</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">206,945</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net (decrease)/increase in cash and cash equivalents</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">58,818</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">725,348</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">615,864</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">96,596</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents at the beginning of year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">267,665</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213,253</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">885,611</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138,904</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effects of exchange rate changes on cash and cash equivalents</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,406</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,990</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,838</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,778</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents at end of year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">213,253</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">885,611</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,464,637</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">229,722</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 472273000 1177380000 184667000 472273000 1177380000 184667000 885611000 1464637000 229722000 84278000 86352000 13544000 1097000 970986000 1550989000 243266000 1443259000 2728369000 427933000 2071508000 2071508000 49000 7000 6864000 34190000 5364000 6864000 34239000 5371000 2078372000 34239000 5371000 -635113000 2694130000 422562000 24000 66000 10000 41466000 4094434000 642194000 3000 1164000 183000 -5732000 -10359000 -1625000 -670868000 -1388847000 -217834000 -635113000 2694130000 422562000 23000 29540000 43710000 6856000 -23000 -29540000 -43710000 -6856000 335000 -2758000 -59397000 -579286000 -674269000 -105756000 -59085000 -611584000 -717979000 -112612000 -59085000 -611584000 -717979000 -112612000 249000 -4766000 -31025000 -4866000 -159057000 -204170000 -672529000 -105483000 99990000 934284000 1319418000 206945000 -58818000 725348000 615864000 96596000 267665000 213253000 885611000 138904000 4406000 -52990000 -36838000 -5778000 213253000 885611000 1464637000 229722000 EXCEL 173 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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c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end XML 174 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 175 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 176 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 331 420 1 false 88 0 false 11 false false R1.htm 100000 - Document - Cover Page Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage Cover Page Cover 1 false false R2.htm 100010 - Statement - Consolidated Statements of Loss Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss Consolidated Statements of Loss Statements 2 false false R3.htm 100040 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 3 false false R4.htm 100050 - Statement - Consolidated Balance Sheets Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 100060 - Statement - Consolidated Statements of Changes in Shareholders' (Deficit)/Equity Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity Consolidated Statements of Changes in Shareholders' (Deficit)/Equity Statements 5 false false R6.htm 100070 - Statement - Consolidated Statements of Cash Flows Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100080 - Disclosure - General Information, Reorganization and Basis of Presentation Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentation General Information, Reorganization and Basis of Presentation Notes 7 false false R8.htm 100090 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100100 - Disclosure - Financial Instruments and Risk Management Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagement Financial Instruments and Risk Management Notes 9 false false R10.htm 100110 - Disclosure - Critical Accounting Estimates and Judgements Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCriticalAccountingEstimatesAndJudgements Critical Accounting Estimates and Judgements Notes 10 false false R11.htm 100120 - Disclosure - Expenses by Nature Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNature Expenses by Nature Notes 11 false false R12.htm 100130 - Disclosure - Employee Benefit Expenses Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitExpenses Employee Benefit Expenses Notes 12 false false R13.htm 100140 - Disclosure - Other Income Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncome1 Other Income Notes 13 false false R14.htm 100150 - Disclosure - Other Gains/(losses) Net Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNet Other Gains/(losses) Net Notes 14 false false R15.htm 100160 - Disclosure - Finance Income/(cost) Net Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNet1 Finance Income/(cost) Net Notes 15 false false R16.htm 100170 - Disclosure - Income Taxes Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 100180 - Disclosure - Net Loss Per Share Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShare1 Net Loss Per Share Notes 17 false false R18.htm 100190 - Disclosure - Property, Plant and Equipment Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment Property, Plant and Equipment Notes 18 false false R19.htm 100200 - Disclosure - Other non-current Assets Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssets Other non-current Assets Notes 19 false false R20.htm 100210 - Disclosure - Leases Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeases1 Leases Notes 20 false false R21.htm 100220 - Disclosure - Financial Instruments by Category Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategory1 Financial Instruments by Category Notes 21 false false R22.htm 100230 - Disclosure - Other Receivables and Prepayments Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepayments Other Receivables and Prepayments Notes 22 false false R23.htm 100240 - Disclosure - Financial Assets at Fair Value Through Profit or Loss Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLoss1 Financial Assets at Fair Value Through Profit or Loss Notes 23 false false R24.htm 100250 - Disclosure - Cash and Cash Equivalents Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalents1 Cash and Cash Equivalents Notes 24 false false R25.htm 100260 - Disclosure - Share Capital Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapital Share Capital Notes 25 false false R26.htm 100270 - Disclosure - Treasury Shares Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureTreasuryShares Treasury Shares Notes 26 false false R27.htm 100280 - Disclosure - Reserves Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureReserves Reserves Notes 27 false false R28.htm 100290 - Disclosure - Share-Based Compensation Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensation Share-Based Compensation Notes 28 false false R29.htm 100300 - Disclosure - Other Payables and Accruals Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccruals Other Payables and Accruals Notes 29 false false R30.htm 100310 - Disclosure - Financial Instruments with Preferred Rights Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRights Financial Instruments with Preferred Rights Notes 30 false false R31.htm 100320 - Disclosure - Cash Flow Information Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformation Cash Flow Information Notes 31 false false R32.htm 100330 - Disclosure - Commitments Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitments Commitments Notes 32 false false R33.htm 100340 - Disclosure - Related Party Transactions Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions Related Party Transactions Notes 33 false false R34.htm 100350 - Disclosure - Events After the Reporting Period Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEventsAfterReportingPeriod Events After the Reporting Period Notes 34 false false R35.htm 100360 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformation Restricted Net Assets and Parent Company Only Condensed Financial Information Notes 35 false false R36.htm 100370 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 36 false false R37.htm 100380 - Disclosure - General Information, Reorganization and Basis of Presentation (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationTables General Information, Reorganization and Basis of Presentation (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentation 37 false false R38.htm 100390 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 38 false false R39.htm 100400 - Disclosure - Financial Instruments and Risk Management (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables Financial Instruments and Risk Management (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagement 39 false false R40.htm 100410 - Disclosure - Expenses by Nature (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureTables Expenses by Nature (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNature 40 false false R41.htm 100420 - Disclosure - Employee Benefit Expenses (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitExpensesTables Employee Benefit Expenses (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitExpenses 41 false false R42.htm 100430 - Disclosure - Other Income (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeTables Other Income (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncome1 42 false false R43.htm 100440 - Disclosure - Other Gains/(losses) Net (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetTables Other Gains/(losses) Net (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNet 43 false false R44.htm 100450 - Disclosure - Finance Income/(cost) Net (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetTables Finance Income/(cost) Net (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNet1 44 false false R45.htm 100460 - Disclosure - Income Taxes (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes 45 false false R46.htm 100470 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShare1 46 false false R47.htm 100480 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment 47 false false R48.htm 100490 - Disclosure - Other non-current Assets (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsTables Other non-current Assets (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssets 48 false false R49.htm 100500 - Disclosure - Leases (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeases1 49 false false R50.htm 100510 - Disclosure - Financial Instruments by Category (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryTables Financial Instruments by Category (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategory1 50 false false R51.htm 100520 - Disclosure - Other Receivables and Prepayments (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsTables Other Receivables and Prepayments (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepayments 51 false false R52.htm 100530 - Disclosure - Financial Assets at Fair Value Through Profit or Loss (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLossTables Financial Assets at Fair Value Through Profit or Loss (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLoss1 52 false false R53.htm 100540 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalents1 53 false false R54.htm 100550 - Disclosure - Share Capital (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalTables Share Capital (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapital 54 false false R55.htm 100560 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationTables Share-Based Compensation (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensation 55 false false R56.htm 100570 - Disclosure - Other Payables and Accruals (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsTables Other Payables and Accruals (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccruals 56 false false R57.htm 100580 - Disclosure - Financial Instruments with Preferred Rights (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsTables Financial Instruments with Preferred Rights (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRights 57 false false R58.htm 100590 - Disclosure - Cash Flow Information (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationTables Cash Flow Information (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformation 58 false false R59.htm 100600 - Disclosure - Commitments (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsTables Commitments (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitments 59 false false R60.htm 100610 - Disclosure - Related Party Transactions (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions 60 false false R61.htm 100620 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information (Tables) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationTables Restricted Net Assets and Parent Company Only Condensed Financial Information (Tables) Tables http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformation 61 false false R62.htm 100630 - Disclosure - General Information, Reorganization and Basis of Presentation - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails General Information, Reorganization and Basis of Presentation - Additional Information (Details) Details 62 false false R63.htm 100640 - Disclosure - General Information, Reorganization and Basis of Presentation - Summary of Direct or Indirect Interests in Principal Subsidiaries (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails General Information, Reorganization and Basis of Presentation - Summary of Direct or Indirect Interests in Principal Subsidiaries (Details) Details 63 false false R64.htm 100650 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 64 false false R65.htm 100660 - Disclosure - Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment (Details) Details 65 false false R66.htm 100670 - Disclosure - Financial Instruments and Risk Management - Summary of Exposure to Foreign Currency Risk (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfExposureToForeignCurrencyRiskDetails Financial Instruments and Risk Management - Summary of Exposure to Foreign Currency Risk (Details) Details 66 false false R67.htm 100680 - Disclosure - Financial Instruments and Risk Management - Summary of Aggregate Net Foreign Exchange Gains/(Losses) Recognized in Profit or Loss (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndRiskManagementSummaryOfAggregateNetForeignExchangeGainslossesRecognizedInProfitOrLossDetails Financial Instruments and Risk Management - Summary of Aggregate Net Foreign Exchange Gains/(Losses) Recognized in Profit or Loss (Details) Details 67 false false R68.htm 100690 - Disclosure - Financial Instruments and Risk Management - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails Financial Instruments and Risk Management - Additional Information (Details) Details 68 false false R69.htm 100700 - Disclosure - Financial Instruments and Risk Management - Summary of Financial Liabilities into Maturity Groupings Based on Remaining Period to Contractual Maturity Date (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails Financial Instruments and Risk Management - Summary of Financial Liabilities into Maturity Groupings Based on Remaining Period to Contractual Maturity Date (Details) Details 69 false false R70.htm 100710 - Disclosure - Financial Instruments and Risk Management - Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails Financial Instruments and Risk Management - Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques (Details) Details 70 false false R71.htm 100720 - Disclosure - Financial Instruments and Risk Management - Summary of Changes in Level 3 Instruments of Short-term Investment (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails Financial Instruments and Risk Management - Summary of Changes in Level 3 Instruments of Short-term Investment (Details) Details 71 false false R72.htm 100730 - Disclosure - Expenses by Nature - Summary of Expenses by Nature (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails Expenses by Nature - Summary of Expenses by Nature (Details) Details 72 false false R73.htm 100740 - Disclosure - Employee Benefit Expenses - Schedule of Employee Benefit Expenses (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails Employee Benefit Expenses - Schedule of Employee Benefit Expenses (Details) Details 73 false false R74.htm 100750 - Disclosure - Employee Benefit Expenses - Schedule of Employee Benefit Expenses Included in Consolidated Statements of Loss (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails Employee Benefit Expenses - Schedule of Employee Benefit Expenses Included in Consolidated Statements of Loss (Details) Details 74 false false R75.htm 100760 - Disclosure - Other Income - Summary of Other Income (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeSummaryOfOtherIncomeDetails Other Income - Summary of Other Income (Details) Details 75 false false R76.htm 100770 - Disclosure - Other Income - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeAdditionalInformationDetails Other Income - Additional Information (Details) Details 76 false false R77.htm 100780 - Disclosure - Other Gains/(losses) Net - Schedule of Other gains/ (losses) - Net (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails Other Gains/(losses) Net - Schedule of Other gains/ (losses) - Net (Details) Details 77 false false R78.htm 100790 - Disclosure - Other Gains/(losses)-Net - Other gains/ (losses)-Net (Parenthetical) (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesnetOtherGainsLossesnetParentheticalDetails Other Gains/(losses)-Net - Other gains/ (losses)-Net (Parenthetical) (Details) Details 78 false false R79.htm 100800 - Disclosure - Finance Income/(cost) Net - Summary of Finance income/(cost) Net (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails Finance Income/(cost) Net - Summary of Finance income/(cost) Net (Details) Details 79 false false R80.htm 100810 - Disclosure - Income taxes - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails Income taxes - Additional Information (Details) Details 80 false false R81.htm 100820 - Disclosure - Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Details) Details 81 false false R82.htm 100830 - Disclosure - Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Parenthetical) (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateParentheticalDetails Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Parenthetical) (Details) Details 82 false false R83.htm 100840 - Disclosure - Net Loss Per Share - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails Net Loss Per Share - Additional Information (Details) Details 83 false false R84.htm 100850 - Disclosure - Net Loss Per Share - Schedule of Net Basic Loss Per Share (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetBasicLossPerShareDetails Net Loss Per Share - Schedule of Net Basic Loss Per Share (Details) Details 84 false false R85.htm 100860 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) Details 85 false false R86.htm 100870 - Disclosure - Other non-current Assets - Schedule of Other Non-current Assets (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails Other non-current Assets - Schedule of Other Non-current Assets (Details) Details 86 false false R87.htm 100880 - Disclosure - Other non-current Assets - Schedule of Other Non-current Assets (Parenthetical) (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails Other non-current Assets - Schedule of Other Non-current Assets (Parenthetical) (Details) Details 87 false false R88.htm 100890 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets (Details) Details 88 false false R89.htm 100900 - Disclosure - Leases - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 89 false false R90.htm 100910 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability (Details) Details 90 false false R91.htm 100920 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails Leases - Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation (Details) Details 91 false false R92.htm 100930 - Disclosure - Financial Instruments by Category - Schedule of Financial Instruments by Category (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails Financial Instruments by Category - Schedule of Financial Instruments by Category (Details) Details 92 false false R93.htm 100940 - Disclosure - Other Receivables and Prepayments - Schedule of Other Receivables and Prepayments (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails Other Receivables and Prepayments - Schedule of Other Receivables and Prepayments (Details) Details 93 false false R94.htm 100950 - Disclosure - Other Receivables and Prepayments - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherReceivablesAndPrepaymentsAdditionalInformationDetails Other Receivables and Prepayments - Additional Information (Details) Details 94 false false R95.htm 100960 - Disclosure - Financial Assets At Fair Value Through Profit or Loss - Summary of Returns on Wealth Management Products (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossSummaryOfReturnsOnWealthManagementProductsDetails Financial Assets At Fair Value Through Profit or Loss - Summary of Returns on Wealth Management Products (Details) Details 95 false false R96.htm 100970 - Disclosure - Financial Assets At Fair Value Through Profit or Loss - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossAdditionalInformationDetails Financial Assets At Fair Value Through Profit or Loss - Additional Information (Details) Details 96 false false R97.htm 100980 - Disclosure - Cash and Cash Equivalents - Schedule of Cash And Cash Equivalents (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails Cash and Cash Equivalents - Schedule of Cash And Cash Equivalents (Details) Details 97 false false R98.htm 100990 - Disclosure - Cash and Cash Equivalents - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails Cash and Cash Equivalents - Additional Information (Details) Details 98 false false R99.htm 101000 - Disclosure - Share Capital - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails Share Capital - Additional Information (Details) Details 99 false false R100.htm 101010 - Disclosure - Share Capital - Schedule of Share Capital and Share Premium (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails Share Capital - Schedule of Share Capital and Share Premium (Details) Details 100 false false R101.htm 101020 - Disclosure - Share Capital - Schedule of Share Capital and Share Premium (Parenthetical) (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails Share Capital - Schedule of Share Capital and Share Premium (Parenthetical) (Details) Details 101 false false R102.htm 101030 - Disclosure - Treasury Shares - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureTreasurySharesAdditionalInformationDetails Treasury Shares - Additional Information (Details) Details 102 false false R103.htm 101040 - Disclosure - Reserves - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureReservesAdditionalInformationDetails Reserves - Additional Information (Details) Details 103 false false R104.htm 101050 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 104 false false R105.htm 101060 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails Share-Based Compensation - Summary of Options Outstanding (Details) Details 105 false false R106.htm 101070 - Disclosure - Share-Based Compensation - Summary of Key Assumptions for Options Granted (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails Share-Based Compensation - Summary of Key Assumptions for Options Granted (Details) Details 106 false false R107.htm 101080 - Disclosure - Share-Based Compensation - Summary of Key Assumptions for Options Granted (Parenthetical) (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails Share-Based Compensation - Summary of Key Assumptions for Options Granted (Parenthetical) (Details) Details 107 false false R108.htm 101090 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expenses (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails Share-Based Compensation - Summary of Share-Based Compensation Expenses (Details) Details 108 false false R109.htm 101100 - Disclosure - Other Payables and Accruals - Schedule of Other Payables and Accruals (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails Other Payables and Accruals - Schedule of Other Payables and Accruals (Details) Details 109 false false R110.htm 101110 - Disclosure - Financial Instruments with Preferred Rights - Summary of Series of Financings by Issuing Preferred Shares (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails Financial Instruments with Preferred Rights - Summary of Series of Financings by Issuing Preferred Shares (Details) Details 110 false false R111.htm 101120 - Disclosure - Financial Instruments with Preferred Rights - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails Financial Instruments with Preferred Rights - Additional Information (Details) Details 111 false false R112.htm 101130 - Disclosure - Financial Instruments with Preferred Rights - Movements of Financial Instruments with Preferred Rights (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails Financial Instruments with Preferred Rights - Movements of Financial Instruments with Preferred Rights (Details) Details 112 false false R113.htm 101140 - Disclosure - Financial Instruments with Preferred Rights - Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails Financial Instruments with Preferred Rights - Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights (Details) Details 113 false false R114.htm 101150 - Disclosure - Cash Flow Information - Summary of Cash Used in Operations (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails Cash Flow Information - Summary of Cash Used in Operations (Details) Details 114 false false R115.htm 101160 - Disclosure - Cash Flow Information - Summary of Non-cash Investing and Financing Activities (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails Cash Flow Information - Summary of Non-cash Investing and Financing Activities (Details) Details 115 false false R116.htm 101170 - Disclosure - Cash Flow Information - Summary of Reconciliation of Liabilities Arising from Financing Activities (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails Cash Flow Information - Summary of Reconciliation of Liabilities Arising from Financing Activities (Details) Details 116 false false R117.htm 101180 - Disclosure - Commitments - Schedule of Capital Commitments (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfCapitalCommitmentsDetails Commitments - Schedule of Capital Commitments (Details) Details 117 false false R118.htm 101190 - Disclosure - Commitments - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails Commitments - Additional Information (Details) Details 118 false false R119.htm 101200 - Disclosure - Related Party Transactions - Schedule of Significant Transactions with Related Parties (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails Related Party Transactions - Schedule of Significant Transactions with Related Parties (Details) Details 119 false false R120.htm 101210 - Disclosure - Related Party Transactions - Schedule of Balances with Related Parties (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfBalancesWithRelatedPartiesDetails Related Party Transactions - Schedule of Balances with Related Parties (Details) Details 120 false false R121.htm 101220 - Disclosure - Related Party Transactions - Summary of Key Management Personnel Compensation (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails Related Party Transactions - Summary of Key Management Personnel Compensation (Details) Details 121 false false R122.htm 101230 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 122 false false R123.htm 101240 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationAdditionalInformationDetails Restricted Net Assets and Parent Company Only Condensed Financial Information - Additional Information (Details) Details 123 false false R124.htm 101250 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Balance Sheets (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Balance Sheets (Details) Details 124 false false R125.htm 101260 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Loss (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Loss (Details) Details 125 false false R126.htm 101270 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Cash Flows (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Cash Flows (Details) Details 126 false false R127.htm 101280 - Disclosure - Events After the Reporting Period - Additional Information (Details) Sheet http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails Events After the Reporting Period - Additional Information (Details) Details 127 false false All Reports Book All Reports cntb-20211231.htm cntb-20211231.xsd cntb-20211231_cal.xml cntb-20211231_def.xml cntb-20211231_lab.xml cntb-20211231_pre.xml cntb-ex12_1.htm cntb-ex12_2.htm cntb-ex13_1.htm cntb-ex13_2.htm cntb-ex15_1.htm cntb-ex1_1.htm cntb-ex2_5.htm cntb-ex4_10.htm cntb-ex4_11.htm cntb-ex4_12.htm cntb-ex4_13.htm cntb-ex4_5.htm cntb-ex8_1.htm img67639792_0.jpg img67639792_1.jpg img67639792_10.jpg img67639792_11.jpg img67639792_12.jpg img67639792_13.jpg img67639792_14.jpg img67639792_15.jpg img67639792_16.jpg img67639792_17.jpg img67639792_18.jpg img67639792_2.jpg img67639792_3.jpg img67639792_4.jpg img67639792_5.jpg img67639792_6.jpg img67639792_7.jpg img67639792_8.jpg img67639792_9.jpg http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full http://xbrl.sec.gov/dei/2021q4 true true JSON 179 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cntb-20211231.htm": { "axisCustom": 0, "axisStandard": 28, "contextCount": 331, "dts": { "calculationLink": { "local": [ "cntb-20211231_cal.xml" ] }, "definitionLink": { "local": [ "cntb-20211231_def.xml" ] }, "inline": { "local": [ "cntb-20211231.htm" ] }, "labelLink": { "local": [ "cntb-20211231_lab.xml" ] }, "presentationLink": { "local": [ "cntb-20211231_pre.xml" ] }, "schema": { "local": [ "cntb-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 665, "entityCount": 1, "hidden": { "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 9, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 13 }, "keyCustom": 128, "keyStandard": 292, "memberCustom": 43, "memberStandard": 39, "nsprefix": "cntb", "nsuri": "http://www.connectbiopharm.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Cover Page", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Critical Accounting Estimates and Judgements", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCriticalAccountingEstimatesAndJudgements", "shortName": "Critical Accounting Estimates and Judgements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_0fbd064c-bfff-40d7-a6a0-3ecc12fbae94", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101010 - Disclosure - Share Capital - Schedule of Share Capital and Share Premium (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "shortName": "Share Capital - Schedule of Share Capital and Share Premium (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_27e4fc27-2cbf-4d82-bb4e-6aa8508dedc4", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_4cb62d4f-6595-4d8f-aa01-596e97b8529d", "decimals": "INF", "first": true, "lang": null, "name": "cntb:NumberOfAmericanDepositarySharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101020 - Disclosure - Share Capital - Schedule of Share Capital and Share Premium (Parenthetical) (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails", "shortName": "Share Capital - Schedule of Share Capital and Share Premium (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_cb4bf0e8-1fc4-41fb-9374-724fb929616e", "decimals": "-5", "lang": null, "name": "ifrs-full:ShareIssueRelatedCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTreasurySharesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "INF", "first": true, "lang": null, "name": "cntb:NumberOfTreasuryShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101030 - Disclosure - Treasury Shares - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureTreasurySharesAdditionalInformationDetails", "shortName": "Treasury Shares - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTreasurySharesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "INF", "first": true, "lang": null, "name": "cntb:NumberOfTreasuryShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfShareCapitalReservesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "2", "first": true, "lang": null, "name": "cntb:PercentageOfEntityProfitToOffsetPriorLosses", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101040 - Disclosure - Reserves - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureReservesAdditionalInformationDetails", "shortName": "Reserves - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfShareCapitalReservesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "2", "first": true, "lang": null, "name": "cntb:PercentageOfEntityProfitToOffsetPriorLosses", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_0fbd064c-bfff-40d7-a6a0-3ecc12fbae94", "decimals": "INF", "first": true, "lang": null, "name": "cntb:SharesReservedForFutureIssuanceUnderTwoThousandNineteenStockIncentivePlan", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101050 - Disclosure - Share-Based Compensation - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "shortName": "Share-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_0fbd064c-bfff-40d7-a6a0-3ecc12fbae94", "decimals": "INF", "first": true, "lang": null, "name": "cntb:SharesReservedForFutureIssuanceUnderTwoThousandNineteenStockIncentivePlan", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_0fbd064c-bfff-40d7-a6a0-3ecc12fbae94", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101060 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails", "shortName": "Share-Based Compensation - Summary of Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_262cc553-d917-49c8-ace1-939be27818ae", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101070 - Disclosure - Share-Based Compensation - Summary of Key Assumptions for Options Granted (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "shortName": "Share-Based Compensation - Summary of Key Assumptions for Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_2abf11c2-e256-474a-a744-8fb5f3cfd3b0", "decimals": "3", "first": true, "lang": null, "name": "cntb:ForfeitureRateShareOptionsGranted", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101080 - Disclosure - Share-Based Compensation - Summary of Key Assumptions for Options Granted (Parenthetical) (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "shortName": "Share-Based Compensation - Summary of Key Assumptions for Options Granted (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R108": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101090 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expenses (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails", "shortName": "Share-Based Compensation - Summary of Share-Based Compensation Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_4bdbc359-be6c-4dca-be98-5125077f532f", "decimals": "-3", "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfScheduleOfOtherPayablesAndAccruals", "div", "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ConstructionPayables", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101100 - Disclosure - Other Payables and Accruals - Schedule of Other Payables and Accruals (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails", "shortName": "Other Payables and Accruals - Schedule of Other Payables and Accruals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfScheduleOfOtherPayablesAndAccruals", "div", "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ConstructionPayables", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Expenses by Nature", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNature", "shortName": "Expenses by Nature", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101110 - Disclosure - Financial Instruments with Preferred Rights - Summary of Series of Financings by Issuing Preferred Shares (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails", "shortName": "Financial Instruments with Preferred Rights - Summary of Series of Financings by Issuing Preferred Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "lang": null, "name": "cntb:PreferredSharesSubscriptionConsideration", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101120 - Disclosure - Financial Instruments with Preferred Rights - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "shortName": "Financial Instruments with Preferred Rights - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_60f481ec-5b2d-496c-9dee-62f1ad2a5e52", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfNonCashInvestingAndFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_2abf11c2-e256-474a-a744-8fb5f3cfd3b0", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ShareBasedCompensationToAdditionalSeriesCPreferredShareholderFinancialInstrumentsWithPreferredRights", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101130 - Disclosure - Financial Instruments with Preferred Rights - Movements of Financial Instruments with Preferred Rights (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails", "shortName": "Financial Instruments with Preferred Rights - Movements of Financial Instruments with Preferred Rights (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_ea0b4048-6e0e-4467-b695-2bb7174f09ac", "decimals": "-3", "lang": null, "name": "ifrs-full:AggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_29794add-4eea-4b1e-b0db-363a642360d6", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101140 - Disclosure - Financial Instruments with Preferred Rights - Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "shortName": "Financial Instruments with Preferred Rights - Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_29794add-4eea-4b1e-b0db-363a642360d6", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101150 - Disclosure - Cash Flow Information - Summary of Cash Used in Operations (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails", "shortName": "Cash Flow Information - Summary of Cash Used in Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfCashUsedInOperationsExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "lang": null, "name": "cntb:AdjustmentsForInvestmentIncomeFromWealthManagementProducts", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfNonCashInvestingAndFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ConstructionPayablesNonCashInvestingAndFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101160 - Disclosure - Cash Flow Information - Summary of Non-cash Investing and Financing Activities (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails", "shortName": "Cash Flow Information - Summary of Non-cash Investing and Financing Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfNonCashInvestingAndFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ConstructionPayablesNonCashInvestingAndFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_fea2c138-3cb9-45a3-9415-7c574b39e570", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101170 - Disclosure - Cash Flow Information - Summary of Reconciliation of Liabilities Arising from Financing Activities (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails", "shortName": "Cash Flow Information - Summary of Reconciliation of Liabilities Arising from Financing Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_2ef51d68-2f24-409f-8129-c4e4f626f8de", "decimals": "-3", "lang": null, "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutScheduleOfCapitalCommitmentsExplanatory", "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_82f3f7ff-bbdd-46c8-b9c4-3945087dfb2d", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CapitalCommitments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101180 - Disclosure - Commitments - Schedule of Capital Commitments (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfCapitalCommitmentsDetails", "shortName": "Commitments - Schedule of Capital Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutScheduleOfCapitalCommitmentsExplanatory", "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_82f3f7ff-bbdd-46c8-b9c4-3945087dfb2d", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CapitalCommitments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_c75c92e3-6248-43fe-a171-67df61435827", "decimals": "INF", "first": true, "lang": null, "name": "cntb:SquareFeetOfOperatingLeaseArea", "reportCount": 1, "unique": true, "unitRef": "U_sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101190 - Disclosure - Commitments - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "shortName": "Commitments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_c75c92e3-6248-43fe-a171-67df61435827", "decimals": "INF", "first": true, "lang": null, "name": "cntb:SquareFeetOfOperatingLeaseArea", "reportCount": 1, "unique": true, "unitRef": "U_sqft", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_362c07db-a026-4fa8-b011-d8a9d385e7c6", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PurchasesOfGoodsRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101200 - Disclosure - Related Party Transactions - Schedule of Significant Transactions with Related Parties (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails", "shortName": "Related Party Transactions - Schedule of Significant Transactions with Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_362c07db-a026-4fa8-b011-d8a9d385e7c6", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PurchasesOfGoodsRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Employee Benefit Expenses", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitExpenses", "shortName": "Employee Benefit Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Prepayments", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101210 - Disclosure - Related Party Transactions - Schedule of Balances with Related Parties (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfBalancesWithRelatedPartiesDetails", "shortName": "Related Party Transactions - Schedule of Balances with Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_20e1a9fb-c58f-433f-af1c-4217be407d1c", "decimals": "-3", "lang": null, "name": "ifrs-full:Prepayments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R121": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101220 - Disclosure - Related Party Transactions - Summary of Key Management Personnel Compensation (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails", "shortName": "Related Party Transactions - Summary of Key Management Personnel Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R122": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_b7f14a78-aaae-445e-8592-635003f83d68", "decimals": "INF", "first": true, "lang": null, "name": "cntb:RepurchaseOfOrdinaryShares", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101230 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R123": { "firstAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "2", "first": true, "lang": null, "name": "cntb:PercentageOfAnnualRequireNetAfterTaxProfits", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101240 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationAdditionalInformationDetails", "shortName": "Restricted Net Assets and Parent Company Only Condensed Financial Information - Additional Information (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "2", "first": true, "lang": null, "name": "cntb:PercentageOfAnnualRequireNetAfterTaxProfits", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R124": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentAssets", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101250 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Balance Sheets (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "shortName": "Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Balance Sheets (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfCondensedFinancialInformationForParentCompanyExplanatory", "div", "cntb:DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_9af7196f-75ab-46f0-9972-28f089300905", "decimals": "-3", "lang": null, "name": "cntb:InterestInSubsidiary", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R125": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdministrativeExpense", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101260 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Loss (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails", "shortName": "Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Loss (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfCondensedFinancialInformationForParentCompanyExplanatory", "div", "cntb:DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_81c59c98-68d8-4a36-97cf-b71bc786f51b", "decimals": "-3", "lang": null, "name": "ifrs-full:AdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R126": { "firstAnchor": { "ancestors": [ "span", "p", "cntb:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101270 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Cash Flows (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "shortName": "Restricted Net Assets and Parent Company Only Condensed Financial Information - Condensed Statements of Cash Flows (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfCondensedFinancialInformationForParentCompanyExplanatory", "div", "cntb:DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_81c59c98-68d8-4a36-97cf-b71bc786f51b", "decimals": "-3", "lang": null, "name": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R127": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101280 - Disclosure - Events After the Reporting Period - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails", "shortName": "Events After the Reporting Period - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_ad0115c7-df94-414d-a7ff-5a0ded84bb4f", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Other Income", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncome1", "shortName": "Other Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Other Gains/(losses) Net", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNet", "shortName": "Other Gains/(losses) Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Finance Income/(cost) Net", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNet1", "shortName": "Finance Income/(cost) Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Income Taxes", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Net Loss Per Share", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShare1", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Property, Plant and Equipment", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Other non-current Assets", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssets", "shortName": "Other non-current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Statements of Loss", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss", "shortName": "Consolidated Statements of Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Leases", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeases1", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Financial Instruments by Category", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategory1", "shortName": "Financial Instruments by Category", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Other Receivables and Prepayments", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepayments", "shortName": "Other Receivables and Prepayments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Financial Assets at Fair Value Through Profit or Loss", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLoss1", "shortName": "Financial Assets at Fair Value Through Profit or Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Cash and Cash Equivalents", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalents1", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Share Capital", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapital", "shortName": "Share Capital", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Treasury Shares", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureTreasuryShares", "shortName": "Treasury Shares", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfShareCapitalReservesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Reserves", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureReserves", "shortName": "Reserves", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfShareCapitalReservesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Share-Based Compensation", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Other Payables and Accruals", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccruals", "shortName": "Other Payables and Accruals", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Financial Instruments with Preferred Rights", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRights", "shortName": "Financial Instruments with Preferred Rights", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Cash Flow Information", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformation", "shortName": "Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Commitments", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Related Party Transactions", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Events After the Reporting Period", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEventsAfterReportingPeriod", "shortName": "Events After the Reporting Period", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformation", "shortName": "Restricted Net Assets and Parent Company Only Condensed Financial Information", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - General Information, Reorganization and Basis of Presentation (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationTables", "shortName": "General Information, Reorganization and Basis of Presentation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfPropertyPlantAndEquipmentUsefulLifeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfPropertyPlantAndEquipmentUsefulLifeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Financial Instruments and Risk Management (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables", "shortName": "Financial Instruments and Risk Management (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Balance Sheets", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "lang": null, "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Expenses by Nature (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureTables", "shortName": "Expenses by Nature (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Employee Benefit Expenses (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitExpensesTables", "shortName": "Employee Benefit Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Other Income (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeTables", "shortName": "Other Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutScheduleOfOtherGainsLossesNetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Other Gains/(losses) Net (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetTables", "shortName": "Other Gains/(losses) Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutScheduleOfOtherGainsLossesNetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutFinanceIncomeCostNet", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Finance Income/(cost) Net (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetTables", "shortName": "Finance Income/(cost) Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutFinanceIncomeCostNet", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Income Taxes (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Other non-current Assets (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsTables", "shortName": "Other non-current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Leases (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_262cc553-d917-49c8-ace1-939be27818ae", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Changes in Shareholders' (Deficit)/Equity", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity", "shortName": "Consolidated Statements of Changes in Shareholders' (Deficit)/Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_f7df0034-5e42-4373-8bc0-2cab7076c47a", "decimals": "-3", "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Financial Instruments by Category (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryTables", "shortName": "Financial Instruments by Category (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Other Receivables and Prepayments (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsTables", "shortName": "Other Receivables and Prepayments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:SummaryOfReturnsOnWealthManagementProductsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Financial Assets at Fair Value Through Profit or Loss (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLossTables", "shortName": "Financial Assets at Fair Value Through Profit or Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:SummaryOfReturnsOnWealthManagementProductsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Cash and Cash Equivalents (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Share Capital (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalTables", "shortName": "Share Capital (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "div", "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfScheduleOfOtherPayablesAndAccruals", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Other Payables and Accruals (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsTables", "shortName": "Other Payables and Accruals (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfScheduleOfOtherPayablesAndAccruals", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Financial Instruments with Preferred Rights (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsTables", "shortName": "Financial Instruments with Preferred Rights (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfCashUsedInOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Cash Flow Information (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationTables", "shortName": "Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfCashUsedInOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutScheduleOfCapitalCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Commitments (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsTables", "shortName": "Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutScheduleOfCapitalCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfCashUsedInOperationsExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashFlowsFromUsedInOperations", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "lang": null, "name": "ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Related Party Transactions (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "div", "cntb:DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfCondensedFinancialInformationForParentCompanyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Restricted Net Assets and Parent Company Only Condensed Financial Information (Tables)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationTables", "shortName": "Restricted Net Assets and Parent Company Only Condensed Financial Information (Tables)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "cntb:DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfCondensedFinancialInformationForParentCompanyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - General Information, Reorganization and Basis of Presentation - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "shortName": "General Information, Reorganization and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "lang": "en-US", "name": "ifrs-full:CountryOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - General Information, Reorganization and Basis of Presentation - Summary of Direct or Indirect Interests in Principal Subsidiaries (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails", "shortName": "General Information, Reorganization and Basis of Presentation - Summary of Direct or Indirect Interests in Principal Subsidiaries (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_28691ad4-535f-455c-937f-4816143eca0c", "decimals": null, "lang": "en-US", "name": "ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "cntb:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:NetAssetsLiabilities", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "cntb:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-5", "lang": null, "name": "ifrs-full:AccumulatedOtherComprehensiveIncome", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfPropertyPlantAndEquipmentUsefulLifeExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_8a018ca0-c1c5-4450-9719-da29243c83cc", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfPropertyPlantAndEquipmentUsefulLifeExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_8a018ca0-c1c5-4450-9719-da29243c83cc", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Financial Instruments and Risk Management - Summary of Exposure to Foreign Currency Risk (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfExposureToForeignCurrencyRiskDetails", "shortName": "Financial Instruments and Risk Management - Summary of Exposure to Foreign Currency Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_951e2369-dd5a-45a9-8cdc-bc808e5ea1f8", "decimals": "-3", "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfAggregateNetForeignExchangeGainsLossesRecognizedInProfitOrLossExplanatory", "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Financial Instruments and Risk Management - Summary of Aggregate Net Foreign Exchange Gains/(Losses) Recognized in Profit or Loss (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndRiskManagementSummaryOfAggregateNetForeignExchangeGainslossesRecognizedInProfitOrLossDetails", "shortName": "Financial Instruments and Risk Management - Summary of Aggregate Net Foreign Exchange Gains/(Losses) Recognized in Profit or Loss (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R68": { "firstAnchor": { "ancestors": [ "cntb:PercentageOfForeignExchangeTransaction", "cntb:PercentageOfForeignExchangeTransaction", "span", "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "2", "first": true, "lang": null, "name": "cntb:PercentageOfForeignExchangeTransaction", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Financial Instruments and Risk Management - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails", "shortName": "Financial Instruments and Risk Management - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "cntb:PercentageOfForeignExchangeTransaction", "cntb:PercentageOfForeignExchangeTransaction", "span", "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "2", "first": true, "lang": null, "name": "cntb:PercentageOfForeignExchangeTransaction", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_0fbd064c-bfff-40d7-a6a0-3ecc12fbae94", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Financial Instruments and Risk Management - Summary of Financial Liabilities into Maturity Groupings Based on Remaining Period to Contractual Maturity Date (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails", "shortName": "Financial Instruments and Risk Management - Summary of Financial Liabilities into Maturity Groupings Based on Remaining Period to Contractual Maturity Date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateExplanatory", "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_02bdcbda-4aac-42a6-8398-78966db691bd", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - General Information, Reorganization and Basis of Presentation", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentation", "shortName": "General Information, Reorganization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Financial Instruments and Risk Management - Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "shortName": "Financial Instruments and Risk Management - Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_56c43211-5f30-4164-b205-163cd3d8a0fd", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesTextBlock", "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_35b74109-ab0e-4114-a41f-e4b64d4f5e68", "decimals": "-3", "first": true, "lang": null, "name": "cntb:FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Financial Instruments and Risk Management - Summary of Changes in Level 3 Instruments of Short-term Investment (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails", "shortName": "Financial Instruments and Risk Management - Summary of Changes in Level 3 Instruments of Short-term Investment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesTextBlock", "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_dfb539ae-d916-4dd4-ab19-1ce0cbd1a5e0", "decimals": "-3", "lang": null, "name": "cntb:FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ClinicalTrialsRelatedExpenses", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Expenses by Nature - Summary of Expenses by Nature (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails", "shortName": "Expenses by Nature - Summary of Expenses by Nature (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ClinicalTrialsRelatedExpenses", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Employee Benefit Expenses - Schedule of Employee Benefit Expenses (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails", "shortName": "Employee Benefit Expenses - Schedule of Employee Benefit Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:EmployeeBenefitsExpense", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Employee Benefit Expenses - Schedule of Employee Benefit Expenses Included in Consolidated Statements of Loss (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "shortName": "Employee Benefit Expenses - Schedule of Employee Benefit Expenses Included in Consolidated Statements of Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_4bdbc359-be6c-4dca-be98-5125077f532f", "decimals": "-3", "lang": null, "name": "ifrs-full:EmployeeBenefitsExpense", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfOtherIncomeExplanatory", "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Other Income - Summary of Other Income (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeSummaryOfOtherIncomeDetails", "shortName": "Other Income - Summary of Other Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfOtherIncomeExplanatory", "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:RevenueFromGovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Other Income - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeAdditionalInformationDetails", "shortName": "Other Income - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:RevenueFromGovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfAggregateNetForeignExchangeGainsLossesRecognizedInProfitOrLossExplanatory", "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Other Gains/(losses) Net - Schedule of Other gains/ (losses) - Net (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails", "shortName": "Other Gains/(losses) Net - Schedule of Other gains/ (losses) - Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "lang": null, "name": "ifrs-full:InvestmentIncome", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_309735c1-dba0-4771-9f88-6eb4b196671c", "decimals": "-5", "first": true, "lang": null, "name": "cntb:OtherNonOperatingIncomesExpenses", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Other Gains/(losses)-Net - Other gains/ (losses)-Net (Parenthetical) (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesnetOtherGainsLossesnetParentheticalDetails", "shortName": "Other Gains/(losses)-Net - Other gains/ (losses)-Net (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-5", "lang": null, "name": "cntb:LossesPartiallyRecoveredFromCyberInsurance", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutFinanceIncomeCostNet", "div", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestIncomeOnDeposits", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100800 - Disclosure - Finance Income/(cost) Net - Summary of Finance income/(cost) Net (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails", "shortName": "Finance Income/(cost) Net - Summary of Finance income/(cost) Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutFinanceIncomeCostNet", "div", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestIncomeOnDeposits", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100810 - Disclosure - Income taxes - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "INF", "lang": null, "name": "ifrs-full:DeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ProfitLossFromContinuingOperationsBeforeTax", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100820 - Disclosure - Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails", "shortName": "Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ProfitLossFromContinuingOperationsBeforeTax", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "ifrs-full:ApplicableTaxRate", "ifrs-full:ApplicableTaxRate", "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_54d7136c-f2f9-434c-a262-26bfbc6ee09f", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100830 - Disclosure - Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Parenthetical) (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateParentheticalDetails", "shortName": "Income taxes - Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "cntb:PercentageOfTaxDeductibleResearchAndDevelopmentExpense", "cntb:PercentageOfTaxDeductibleResearchAndDevelopmentExpense", "span", "div", "div", "cntb:DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_54d7136c-f2f9-434c-a262-26bfbc6ee09f", "decimals": "2", "lang": null, "name": "cntb:PercentageOfTaxDeductibleResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_1c417514-72fc-47d0-8afb-f6e97f1c1c96", "decimals": "2", "first": true, "lang": null, "name": "cntb:ConversionOfOrdinarySharesConverted", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100840 - Disclosure - Net Loss Per Share - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "shortName": "Net Loss Per Share - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R84": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100850 - Disclosure - Net Loss Per Share - Schedule of Net Basic Loss Per Share (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetBasicLossPerShareDetails", "shortName": "Net Loss Per Share - Schedule of Net Basic Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_2abf11c2-e256-474a-a744-8fb5f3cfd3b0", "decimals": "-3", "lang": null, "name": "ifrs-full:WeightedAverageShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100860 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_def7d7eb-72a0-42ec-90ba-244371851fe1", "decimals": "-3", "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentValueAddedTaxReceivables", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100870 - Disclosure - Other non-current Assets - Schedule of Other Non-current Assets (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails", "shortName": "Other non-current Assets - Schedule of Other Non-current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentValueAddedTaxReceivables", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_0a393944-8f46-4f38-9b37-8df6fd193e3a", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:NoncurrentPrepayments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100880 - Disclosure - Other non-current Assets - Schedule of Other Non-current Assets (Parenthetical) (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "shortName": "Other non-current Assets - Schedule of Other Non-current Assets (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_0a393944-8f46-4f38-9b37-8df6fd193e3a", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:NoncurrentPrepayments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_0fbd064c-bfff-40d7-a6a0-3ecc12fbae94", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100890 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails", "shortName": "Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_262cc553-d917-49c8-ace1-939be27818ae", "decimals": "-3", "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:CashOutflowForLeases", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100900 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:CashOutflowForLeases", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Financial Instruments and Risk Management", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagement", "shortName": "Financial Instruments and Risk Management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatoryTextBlock", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentLeaseLiabilities", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100910 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails", "shortName": "Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatoryTextBlock", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_def7d7eb-72a0-42ec-90ba-244371851fe1", "decimals": "-3", "lang": null, "name": "ifrs-full:NoncurrentLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutFinanceIncomeCostNet", "div", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100920 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails", "shortName": "Leases - Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfQuantitativeInformationAboutAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationExplanatoryTextBlock", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_d18373df-5698-4838-a0e8-d0c581ae77c0", "decimals": "-3", "lang": null, "name": "ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100930 - Disclosure - Financial Instruments by Category - Schedule of Financial Instruments by Category (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails", "shortName": "Financial Instruments by Category - Schedule of Financial Instruments by Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_9315fdf9-1a43-479d-8d4b-c1fb865cf684", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Prepayments", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100940 - Disclosure - Other Receivables and Prepayments - Schedule of Other Receivables and Prepayments (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails", "shortName": "Other Receivables and Prepayments - Schedule of Other Receivables and Prepayments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "lang": null, "name": "cntb:Deposit", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "div", "div", "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_cb4bf0e8-1fc4-41fb-9374-724fb929616e", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:LiabilityInsuranceAmortizedPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100950 - Disclosure - Other Receivables and Prepayments - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherReceivablesAndPrepaymentsAdditionalInformationDetails", "shortName": "Other Receivables and Prepayments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_cb4bf0e8-1fc4-41fb-9374-724fb929616e", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:LiabilityInsuranceAmortizedPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:SummaryOfReturnsOnWealthManagementProductsTableTextBlock", "div", "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_159215f5-1e32-4c74-8408-9b263187aa0e", "decimals": "-3", "first": true, "lang": null, "name": "cntb:FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100960 - Disclosure - Financial Assets At Fair Value Through Profit or Loss - Summary of Returns on Wealth Management Products (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossSummaryOfReturnsOnWealthManagementProductsDetails", "shortName": "Financial Assets At Fair Value Through Profit or Loss - Summary of Returns on Wealth Management Products (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:SummaryOfReturnsOnWealthManagementProductsTableTextBlock", "div", "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_159215f5-1e32-4c74-8408-9b263187aa0e", "decimals": "-3", "first": true, "lang": null, "name": "cntb:FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_427487de-1e29-417b-a676-7fd5044b4fe0", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:EffectiveInterestRateOfFinancialAssetsReclassifiedOutOfFinancialAssetsAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100970 - Disclosure - Financial Assets At Fair Value Through Profit or Loss - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossAdditionalInformationDetails", "shortName": "Financial Assets At Fair Value Through Profit or Loss - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_427487de-1e29-417b-a676-7fd5044b4fe0", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:EffectiveInterestRateOfFinancialAssetsReclassifiedOutOfFinancialAssetsAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100980 - Disclosure - Cash and Cash Equivalents - Schedule of Cash And Cash Equivalents (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "shortName": "Cash and Cash Equivalents - Schedule of Cash And Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_4f8059d7-904a-4b81-8965-d4d42b807330", "decimals": "-3", "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_103a3cc1-6781-42c0-a16e-fccf673a739c", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100990 - Disclosure - Cash and Cash Equivalents - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "shortName": "Cash and Cash Equivalents - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_99b7b5e1-35af-4cc6-b926-8de937f25481", "decimals": "-5", "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_1c417514-72fc-47d0-8afb-f6e97f1c1c96", "decimals": "2", "first": true, "lang": null, "name": "cntb:ConversionOfOrdinarySharesConverted", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101000 - Disclosure - Share Capital - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "shortName": "Share Capital - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20211231.htm", "contextRef": "C_b3dc6030-5bae-44f2-b30e-24df6360b1b8", "decimals": "-3", "lang": null, "name": "ifrs-full:IssuedCapitalOrdinaryShares", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } } }, "segmentCount": 88, "tag": { "cntb_AccruedProfessionalServiceFee": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": 0.0, "parentTag": "cntb_OtherPayablesAndAccruals", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued professional service fee.", "label": "Accrued Professional Service Fee", "terseLabel": "Accrued professional service fee" } } }, "localname": "AccruedProfessionalServiceFee", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdjustmentsForDepreciationOfPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation of property, plant and equipment.", "label": "Adjustments For Depreciation Of Property Plant And Equipment", "terseLabel": "-Depreciation of property, plant and equipment" } } }, "localname": "AdjustmentsForDepreciationOfPropertyPlantAndEquipment", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdjustmentsForDepreciationOfRightsOfUseAssets": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation of rights of use assets.", "label": "Adjustments For Depreciation Of Rights Of Use Assets", "terseLabel": "-Depreciation of rights-of-use assets" } } }, "localname": "AdjustmentsForDepreciationOfRightsOfUseAssets", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdjustmentsForInvestmentIncomeFromWealthManagementProducts": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for investment income from wealth management products.", "label": "Adjustments For Investment Income From Wealth Management Products", "negatedLabel": "-Investment income from wealth management products", "terseLabel": "-Investment income from wealth management products" } } }, "localname": "AdjustmentsForInvestmentIncomeFromWealthManagementProducts", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdjustmentsForIssuanceCostOfFinancialInstrumentsWithPreferredRights": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for issuance cost of financial instruments with preferred rights.", "label": "Adjustments For Issuance Cost Of Financial Instruments With Preferred Rights", "terseLabel": "-Issuance cost of financial instruments with preferred rights" } } }, "localname": "AdjustmentsForIssuanceCostOfFinancialInstrumentsWithPreferredRights", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Administrative expenses.", "label": "Administrative Expenses [Member]", "terseLabel": "Administrative Expenses" } } }, "localname": "AdministrativeExpensesMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "cntb_AfterShareConsolidationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "After share consolidation.", "label": "After Share Consolidation [Member]", "terseLabel": "After Share Consolidation" } } }, "localname": "AfterShareConsolidationMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_BasicAndDilutedEarningsLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basic and diluted earnings loss per share.", "label": "Basic And Diluted Earnings Loss Per Share", "terseLabel": "Basic and diluted" } } }, "localname": "BasicAndDilutedEarningsLossPerShare", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "perShareItemType" }, "cntb_BeijingConnectBiopharmaceuticalsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beijing Connect Biopharmaceuticals, Limited.", "label": "Beijing Connect Biopharmaceuticals, Limited [Member]", "terseLabel": "Connect Biopharma (Beijing) Co., Ltd" } } }, "localname": "BeijingConnectBiopharmaceuticalsLimitedMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "cntb_BeijingMedicalDevelopmentSuzhouCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beijing Medical Development (Suzhou) Company Limited.", "label": "Beijing Medical Development Suzhou Company Limited [Member]", "terseLabel": "Beijing Medical Development (Suzhou) Company Limited" } } }, "localname": "BeijingMedicalDevelopmentSuzhouCompanyLimitedMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "cntb_CashAndCashEquivalentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent.", "label": "Cash And Cash Equivalent [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "cntb_ChangesInOperatingAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Changes in operating assets and liabilities.", "label": "Changes In Operating Assets And Liabilities [Abstract]", "terseLabel": "Changes in working capital" } } }, "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "stringItemType" }, "cntb_ClinicalTrialsRelatedExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 0.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical trials related expenses.", "label": "Clinical Trials Related Expenses", "terseLabel": "Clinical trials related expenses" } } }, "localname": "ClinicalTrialsRelatedExpenses", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "cntb_CoFoundersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Co-Founders.", "label": "Co Founders [Member]", "terseLabel": "Co-Founders" } } }, "localname": "CoFoundersMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_ConnectAUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Connect AU.", "label": "Connect A U [Member]", "terseLabel": "Connect Biopharma Australia PTY LTD" } } }, "localname": "ConnectAUMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_ConnectHKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Connect HK.", "label": "Connect H K [Member]", "terseLabel": "Connect Biopharma HongKong Limited" } } }, "localname": "ConnectHKMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_ConnectSzMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Connect SZ [Member]", "label": "Connect SZ [Member]", "terseLabel": "Suzhou Connect Biopharma Co., Ltd." } } }, "localname": "ConnectSzMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "cntb_ConnectUSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Connect US.", "label": "Connect U S [Member]", "terseLabel": "Connect Biopharm LLC" } } }, "localname": "ConnectUSMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_ConnectUnionIncorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Connect Union Incorporation.", "label": "Connect Union Incorporation [Member]", "terseLabel": "Connect Union Inc. (Note)", "verboseLabel": "Connect Union" } } }, "localname": "ConnectUnionIncorporationMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_ConnectUnionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Connect Union.", "label": "Connect Union [Member]", "terseLabel": "Connect Union" } } }, "localname": "ConnectUnionMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_ConsiderationContingentOnAchievingOfResearchAndDevelopmentMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Consideration, contingent on achieving of research and development milestones.", "label": "Consideration Contingent On Achieving Of Research And Development Milestones", "terseLabel": "Consideration, contingent on achieving of R&D milestones" } } }, "localname": "ConsiderationContingentOnAchievingOfResearchAndDevelopmentMilestones", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ConstructionPayables": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": 3.0, "parentTag": "cntb_OtherPayablesAndAccruals", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Construction payables.", "label": "Construction Payables", "terseLabel": "Construction payables" } } }, "localname": "ConstructionPayables", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ConstructionPayablesNonCashInvestingAndFinancingActivities": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails": { "order": 0.0, "parentTag": "cntb_NonCashInvestingAndFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Construction payables non-cash investing and financing activities", "label": "Construction Payables Non-Cash Investing and Financing Activities", "terseLabel": "Construction payables" } } }, "localname": "ConstructionPayablesNonCashInvestingAndFinancingActivities", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ContributionsByAndDistributionsToOwnersOfParent": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contributions by and distributions to owners of parent.", "label": "Contributions By And Distributions To Owners Of Parent", "totalLabel": "Total Transactions with owners" } } }, "localname": "ContributionsByAndDistributionsToOwnersOfParent", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_ConversionFromPreferredSharesToOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion from preferred shares to ordinary shares.", "label": "Conversion from Preferred Shares to Ordinary Shares", "terseLabel": "Conversion from preferred shares to ordinary shares, shares" } } }, "localname": "ConversionFromPreferredSharesToOrdinaryShares", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "cntb_ConversionFromPreferredSharesToOrdinarySharesAfterShareConsolidation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion from preferred shares to ordinary shares after share consolidation.", "label": "Conversion From Preferred Shares To Ordinary Shares After Share Consolidation", "terseLabel": "Conversion from preferred shares to ordinary shares after share consolidation" } } }, "localname": "ConversionFromPreferredSharesToOrdinarySharesAfterShareConsolidation", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_ConversionOfOrdinarySharesConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of ordinary shares converted.", "label": "Conversion Of Ordinary Shares Converted", "terseLabel": "Ordinary shares consolidation" } } }, "localname": "ConversionOfOrdinarySharesConverted", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_CorporateIncomeTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate income tax rate.", "label": "Corporate Income Tax Rate", "terseLabel": "Corporate income tax rate" } } }, "localname": "CorporateIncomeTaxRate", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_CriticalAccountingEstimatesAndJudgementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Critical accounting estimates and judgements.", "label": "Critical Accounting Estimates And Judgements [Abstract]" } } }, "localname": "CriticalAccountingEstimatesAndJudgementsAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_Deposit": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": 1.0, "parentTag": "cntb_OtherReceivablesAndPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits.", "label": "Deposit", "terseLabel": "Deposits" } } }, "localname": "Deposit", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for basis of preparation explanatory.", "label": "Description Of Accounting Policy For Basis Of Preparation Explanatory", "terseLabel": "Basis of preparation" } } }, "localname": "DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cntb_DescriptionOfAccountingPolicyForInvestmentAndOtherFinancialAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for investment and other financial assets explanatory.", "label": "Description Of Accounting Policy For Investment And Other Financial Assets Explanatory", "terseLabel": "Investments and other financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForInvestmentAndOtherFinancialAssetsExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cntb_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for principles of consolidation explanatory.", "label": "Description Of Accounting Policy For Principles Of Consolidation Explanatory", "terseLabel": "Principles of consolidation" } } }, "localname": "DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cntb_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetAdoptedExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for standards issued but not yet adopted explanatory.", "label": "Description Of Accounting Policy For Standards Issued But Not Yet Adopted Explanatory", "terseLabel": "New and amended standards and interpretations not yet adopted by the Group" } } }, "localname": "DescriptionOfAccountingPolicyForStandardsIssuedButNotYetAdoptedExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cntb_DescriptionOfShareholderVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of shareholder voting rights.", "label": "Shareholder voting rights" } } }, "localname": "DescriptionOfShareholderVotingRights", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfAggregateNetForeignExchangeGainsLossesRecognizedInProfitOrLossExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of aggregate net foreign exchange gains/(losses) recognized in profit or loss explanatory.", "label": "Disclosure Of Aggregate Net Foreign Exchange Gains Losses Recognized In Profit Or Loss Explanatory", "terseLabel": "Summary of Aggregate Net Foreign Exchange Gains/(Losses) Recognized in Profit or Loss" } } }, "localname": "DisclosureOfAggregateNetForeignExchangeGainsLossesRecognizedInProfitOrLossExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash flow information.", "label": "Disclosure Of Cash Flow Information [Abstract]" } } }, "localname": "DisclosureOfCashFlowInformationAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_DisclosureOfCashUsedInOperationsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash used in operations.", "label": "Disclosure Of Cash Used In Operations Explanatory", "terseLabel": "Summary of Cash Used in Operations" } } }, "localname": "DisclosureOfCashUsedInOperationsExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfCondensedFinancialInformationForParentCompanyExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of condensed financial information for the parent company.", "label": "Disclosure Of Condensed Financial Information For Parent Company Explanatory", "terseLabel": "Schedule of Condensed Financial Information For the Parent Company" } } }, "localname": "DisclosureOfCondensedFinancialInformationForParentCompanyExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about employee benefit expenses.", "label": "Disclosure Of Detailed Information About Employee Benefit Expenses Explanatory", "terseLabel": "Schedule of Employee Benefit Expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitExpensesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfDetailedInformationAboutFinanceIncomeCostNet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about finance income/(cost) net.", "label": "Disclosure of Detailed Information about Finance Income/(Cost) Net", "terseLabel": "Summary of Finance Income/(Cost) Net" } } }, "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeCostNet", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfDetailedInformationAboutScheduleOfCapitalCommitmentsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about schedule of capital commitments.", "label": "Disclosure Of Detailed Information About Schedule Of Capital Commitments Explanatory", "terseLabel": "Schedule of Capital Commitments" } } }, "localname": "DisclosureOfDetailedInformationAboutScheduleOfCapitalCommitmentsExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about schedule of income tax expense reconciliation.", "label": "Disclosure Of Detailed Information About Schedule Of Income Tax Expense Reconciliation Explanatory", "terseLabel": "Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate" } } }, "localname": "DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfDetailedInformationAboutScheduleOfOtherGainsLossesNetExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about schedule of other gains/(losses) - net.", "label": "Disclosure Of Detailed Information About Schedule Of Other Gains Losses Net Explanatory", "terseLabel": "Schedule of Other Gains/ (Losses) Net" } } }, "localname": "DisclosureOfDetailedInformationAboutScheduleOfOtherGainsLossesNetExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfFinanceIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of finance income expense.", "label": "Disclosure Of Finance Income Expense [Abstract]" } } }, "localname": "DisclosureOfFinanceIncomeExpenseAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_DisclosureOfFinancialInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of financial information.", "label": "Disclosure Of Financial Information [Line Items]", "terseLabel": "Disclosure Of Financial Information [Line Items]" } } }, "localname": "DisclosureOfFinancialInformationLineItems", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfFinancialInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to details of financial information.", "label": "Disclosure Of Financial Information [Table]", "terseLabel": "Disclosure Of Financial Information [Table]" } } }, "localname": "DisclosureOfFinancialInformationTable", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of financial instruments with preferred rights explanatory.", "label": "Disclosure Of Financial Instruments With Preferred Rights Explanatory", "terseLabel": "Financial Instruments with Preferred Rights" } } }, "localname": "DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRights" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of financial liabilities into maturity groupings based on remaining period to contractual maturity date explanatory.", "label": "Disclosure Of Financial Liabilities Into Maturity Groupings Based On Remaining Period To Contractual Maturity Date Explanatory", "terseLabel": "Summary of Financial Liabilities into Maturity Groupings Based on Remaining Period to Contractual Maturity Date" } } }, "localname": "DisclosureOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of general information, reorganization and basis of presentation.", "label": "Disclosure Of General Information Reorganization And Basis Of Presentation [Abstract]" } } }, "localname": "DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of general information, reorganization and basis of presentation.", "label": "Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]", "terseLabel": "Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]" } } }, "localname": "DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationLineItems", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of general information, reorganization and basis of presentation.", "label": "Disclosure Of General Information Reorganization And Basis Of Presentation [Table]", "terseLabel": "Disclosure Of General Information Reorganization And Basis Of Presentation [Table]" } } }, "localname": "DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationTable", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfIncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of income taxes.", "label": "Disclosure Of Income Taxes [Line Items]", "terseLabel": "Disclosure Of Income Taxes [Line Items]" } } }, "localname": "DisclosureOfIncomeTaxesLineItems", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfIncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of income taxes.", "label": "Disclosure Of Income Taxes [Table]", "terseLabel": "Disclosure Of Income Taxes [Table]" } } }, "localname": "DisclosureOfIncomeTaxesTable", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfNonCashInvestingAndFinancingActivitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of non cash investing and financing activities explanatory.", "label": "Disclosure Of Non Cash Investing and Financing Activities Explanatory", "terseLabel": "Summary of Non-cash Investing and Financing Activities" } } }, "localname": "DisclosureOfNonCashInvestingAndFinancingActivitiesExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfOtherIncomeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other income explanatory.", "label": "Disclosure of Other Income Explanatory", "terseLabel": "Summary of Other income" } } }, "localname": "DisclosureOfOtherIncomeExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfOtherIncomeLossesNetExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Other income (losses) net.", "label": "Disclosure of Other income (losses) net explanatory", "terseLabel": "Other Gains/(losses)-Net" } } }, "localname": "DisclosureOfOtherIncomeLossesNetExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNet" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfOtherNonCurrentAssetExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other non-current assets explanatory.", "label": "Disclosure Of Other Non Current Asset Explanatory", "verboseLabel": "Other non-current Assets" } } }, "localname": "DisclosureOfOtherNonCurrentAssetExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssets" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfOtherPayablesAndAccrualsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of other payables and accruals explanatory.", "label": "Disclosure Of Other Payables and Accruals Explanatory", "terseLabel": "Other Payables and Accruals" } } }, "localname": "DisclosureOfOtherPayablesAndAccrualsExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccruals" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfPropertyPlantAndEquipmentUsefulLifeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of property, plant and equipment useful life explanatory", "label": "Summary of property, plant and equipment useful life" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentUsefulLifeExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfQuantitativeInformationAboutAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of quantitative information about amounts recognized in consolidated statements of loss in addition to depreciation explanatory.", "label": "Disclosure of Quantitative Information About Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation Explanatory [Text Block]", "terseLabel": "Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation" } } }, "localname": "DisclosureOfQuantitativeInformationAboutAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationExplanatoryTextBlock", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of quantitative information about lease liabilities explanatory.", "label": "Disclosure of Quantitative Information about Lease Liabilities Explanatory [Text Block]", "terseLabel": "Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability" } } }, "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatoryTextBlock", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of restricted net assets and parent company condensed financial information.", "label": "Disclosure Of Restricted Net Assets And Parent Company Condensed Financial Information Explanatory", "terseLabel": "Restricted Net Assets and Parent Company Only Condensed Financial Information" } } }, "localname": "DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformation" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfScheduleOfOtherPayablesAndAccruals": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of schedule of other payables and accruals.", "label": "Disclosure Of Schedule Of Other Payables And Accruals", "terseLabel": "Schedule of Other Payables and Accruals" } } }, "localname": "DisclosureOfScheduleOfOtherPayablesAndAccruals", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfScheduleOfOtherReceivablesAndPrepayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of schedule of other receivables and prepayments.", "label": "Disclosure Of Schedule Of Other Receivables And Prepayments", "terseLabel": "Schedule of Other Receivables and Prepayments" } } }, "localname": "DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfShareCapitalReservesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of share capital reserves explanatory.", "label": "Disclosure of Share Capital Reserves Explanatory", "terseLabel": "Reserves" } } }, "localname": "DisclosureOfShareCapitalReservesExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureReserves" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities.", "label": "Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities [Text block]", "terseLabel": "Summary of Changes in Level 3 Instruments of Short-term Investment" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesTextBlock", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of summary of cash and cash equivalents explanatory.", "label": "Disclosure of Summary of Cash and Cash Equivalents Explanatory", "terseLabel": "Summary of Cash and Cash Equivalents" } } }, "localname": "DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of summary of financial instruments with preferred rights.", "label": "Disclosure Of Summary of Financial Instruments With Preferred Rights Explanatory", "terseLabel": "Summary of Series of Financings by Issuing Preferred Shares" } } }, "localname": "DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsTables" ], "xbrltype": "textBlockItemType" }, "cntb_DiscountRateForLackOfMarketabilityMeasurementInputMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount rate for lack of marketability, measurement input.", "label": "Discount Rate For Lack Of Marketability Measurement Input [Member]", "terseLabel": "DLOM" } } }, "localname": "DiscountRateForLackOfMarketabilityMeasurementInputMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "cntb_EquipmentAndImprovementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment and improvement.", "label": "Equipment And Improvement [Member]", "terseLabel": "Equipment and Improvement" } } }, "localname": "EquipmentAndImprovementMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_EquipmentAndIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment and intangible assets.", "label": "Equipment And Intangible Assets [Member]", "terseLabel": "Equipment and Intangible Assets - Contracted but not provided for" } } }, "localname": "EquipmentAndIntangibleAssetsMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfCapitalCommitmentsDetails" ], "xbrltype": "domainItemType" }, "cntb_ExpectedEarlyExerciseMultiple": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected early exercise multiple.", "label": "Expected Early Exercise Multiple", "terseLabel": "Expected early exercise multiple" } } }, "localname": "ExpectedEarlyExerciseMultiple", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "pureItemType" }, "cntb_ExpenseRelatedToSeriesCFinancing": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 3.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expense related to Series C financing.", "label": "Expense Related To Series C Financing", "terseLabel": "Expense related to Series C financing" } } }, "localname": "ExpenseRelatedToSeriesCFinancing", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "cntb_FairValueChangesOfFinancialInstrumentsWithPreferredRights": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails": { "order": 1.0, "parentTag": "cntb_NonCashInvestingAndFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value changes of financial instruments with preferred rights.", "label": "Fair Value Changes Of Financial Instruments With Preferred Rights", "terseLabel": "Fair value changes of financial instruments with preferred rights" } } }, "localname": "FairValueChangesOfFinancialInstrumentsWithPreferredRights", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial assets (liabilities) at fair value through profit or loss.", "label": "Financial Assets Liabilities At Fair Value Through Profit Or Loss", "periodEndLabel": "Closing balance", "periodStartLabel": "Opening balance", "terseLabel": "Wealth management products" } } }, "localname": "FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossSummaryOfReturnsOnWealthManagementProductsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "cntb_FinancialInstrumentsWithPreferredRights": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial instruments with preferred rights.", "label": "Financial Instruments With Preferred Rights", "terseLabel": "Financial instruments with preferred rights" } } }, "localname": "FinancialInstrumentsWithPreferredRights", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_FinancialInstrumentsWithPreferredRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instruments with preferred rights.", "label": "Financial Instruments With Preferred Rights [Member]", "terseLabel": "Financial Instruments with Preferred Rights" } } }, "localname": "FinancialInstrumentsWithPreferredRightsMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "cntb_ForfeitureRateShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forfeiture rate, share options granted.", "label": "Forfeiture Rate Share Options Granted", "terseLabel": "Forfeiture rate", "verboseLabel": "Forfeiture rate for executives and all other employees" } } }, "localname": "ForfeitureRateShareOptionsGranted", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails" ], "xbrltype": "percentItemType" }, "cntb_FrontageLaboratoriesSuzhouCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Frontage Laboratories (Suzhou) Company Limited.", "label": "Frontage Laboratories Suzhou Company Limited [Member]", "terseLabel": "Frontage Laboratories (Suzhou) Company Limited" } } }, "localname": "FrontageLaboratoriesSuzhouCompanyLimitedMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "cntb_GainsLossesOnConversionToOrdinarySharesUponInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains losses on conversion to ordinary shares upon initial public offering.", "label": "Gains Losses on Conversion to Ordinary Shares Upon Initial Public Offering", "negatedLabel": "Converted to ordinary shares upon IPO" } } }, "localname": "GainsLossesOnConversionToOrdinarySharesUponInitialPublicOffering", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_HangzhouSimoCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hangzhou Simo Company Limited.", "label": "Hangzhou Simo Company Limited [Member]", "terseLabel": "Hangzhou Simo Company Limited" } } }, "localname": "HangzhouSimoCompanyLimitedMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfBalancesWithRelatedPartiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "cntb_HangzhouTigermedConsultingCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hangzhou Tigermed Consulting Company Limited.", "label": "Hangzhou Tigermed Consulting Company Limited [Member]", "terseLabel": "Hangzhou Tigermed Consulting Company Limited" } } }, "localname": "HangzhouTigermedConsultingCompanyLimitedMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfBalancesWithRelatedPartiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "cntb_HousingFunds": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": 5.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Housing funds.", "label": "Housing Funds", "terseLabel": "Housing funds" } } }, "localname": "HousingFunds", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_IncomeTaxSuperDeductionOfResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails2": { "order": 2.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax super deduction of research and development expenses.", "label": "Income Tax Super Deduction Of Research And Development Expenses", "negatedLabel": "Super deduction of research and development expenses" } } }, "localname": "IncomeTaxSuperDeductionOfResearchAndDevelopmentExpenses", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "cntb_IncreaseDecreaseInForeignExchangeTransactions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in foreign exchange transactions.", "label": "Increase Decrease In Foreign Exchange Transactions", "terseLabel": "Increase decrease in foreign exchange transactions" } } }, "localname": "IncreaseDecreaseInForeignExchangeTransactions", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_IncreaseDecreaseInNumberOfOrdinarySharesIssuedToCoFounders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase decrease in number of ordinary shares issued to co-founders.", "label": "Increase Decrease In Number Of Ordinary Shares Issued to Co-founders", "terseLabel": "Issuance of shares to Co-founders, shares", "verboseLabel": "Issuance of shares to Co-Founders, shares" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedToCoFounders", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "cntb_IncreaseDecreaseInValueOfOrdinarySharesIssued": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 0.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "increase decrease in value of ordinary shares issued.", "label": "Increase Decrease in Value of Ordinary Shares Issued", "verboseLabel": "Issuance of Ordinary Shares" } } }, "localname": "IncreaseDecreaseInValueOfOrdinarySharesIssued", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_IncreaseDecreaseInValueOfOrdinarySharesIssuedToCoFounders": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 7.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in value of ordinary shares issued to co-founders.", "label": "Increase Decrease In Value Of Ordinary Shares Issued To Co-founders", "terseLabel": "Issuance of shares to Co-founders", "verboseLabel": "Issuance of shares to Co-Founders" } } }, "localname": "IncreaseDecreaseInValueOfOrdinarySharesIssuedToCoFounders", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_IncreaseDecreaseThroughConversionToOrdinarySharesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through conversion to ordinary shares, liabilities arising from financing activities.", "label": "Increase (decrease) through Conversion to ordinary shares, liabilities arising from financing activities.", "terseLabel": "Conversion to ordinary shares" } } }, "localname": "IncreaseDecreaseThroughConversionToOrdinarySharesLiabilitiesArisingFromFinancingActivities", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_IncreaseDecreaseThroughInterestExpenseLiabilitiesArisingFromFinancingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through interest expense, liabilities arising from financing activities.", "label": "Increase (decrease) through Interest Expense, liabilities arising from financing activities", "terseLabel": "Interest expenses" } } }, "localname": "IncreaseDecreaseThroughInterestExpenseLiabilitiesArisingFromFinancingActivities", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_IncreaseDecreaseThroughShareBasedCompensationToAdditionalSeriesCPreferredShareholderLiabilitiesArisingFromFinancingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through share-based compensation to additional Series C preferred shareholder, liabilities arising from financing activities.", "label": "Increase (decrease) through Share-based compensation to additional Series C preferred shareholder, liabilities arising from financing activities", "terseLabel": "Share-based compensation to additional Series C preferred shareholder" } } }, "localname": "IncreaseDecreaseThroughShareBasedCompensationToAdditionalSeriesCPreferredShareholderLiabilitiesArisingFromFinancingActivities", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_InitialPublicOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering Price", "label": "Initial Public Offering Price", "terseLabel": "Initial public offering price" } } }, "localname": "InitialPublicOfferingPrice", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "cntb_InterestInSubsidiary": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest in a subsidiary,", "label": "Interest In Subsidiary", "terseLabel": "Interest in a subsidiary" } } }, "localname": "InterestInSubsidiary", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_InternalRateOfReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internal Rate of Return", "label": "Internal Rate of Return", "terseLabel": "Internal rate of return" } } }, "localname": "InternalRateOfReturn", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_IssuanceCostOfFinancialInstrumentsWithPreferredRights": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails": { "order": 0.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance cost of financial instruments with preferred rights.", "label": "Issuance Cost Of Financial Instruments With Preferred Rights", "negatedLabel": "Issuance cost of financial instruments with preferred rights" } } }, "localname": "IssuanceCostOfFinancialInstrumentsWithPreferredRights", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails" ], "xbrltype": "monetaryItemType" }, "cntb_IssuanceOfTreasuryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of treasury shares.", "label": "Issuance Of Treasury Shares", "terseLabel": "Issuance of treasury shares, shares" } } }, "localname": "IssuanceOfTreasuryShares", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "cntb_IssuanceOfValueOfTreasuryShares": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 8.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of value of treasury shares.", "label": "Issuance Of Value Of Treasury Shares", "terseLabel": "Issuance of treasury shares" } } }, "localname": "IssuanceOfValueOfTreasuryShares", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_IssuedCapitalAndSharePremiumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued capital and share premium.", "label": "Issued Capital And Share Premium [Member]", "terseLabel": "Share Capital and Share Premium" } } }, "localname": "IssuedCapitalAndSharePremiumMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "domainItemType" }, "cntb_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cntb_LandUseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Land use rights.", "label": "Land use Rights [Member]", "terseLabel": "Land use Rights" } } }, "localname": "LandUseRightsMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "domainItemType" }, "cntb_LiabilityInsuranceAmortizedPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability insurance amortized period", "label": "Liability Insurance Amortized Period", "terseLabel": "Amortized period" } } }, "localname": "LiabilityInsuranceAmortizedPeriod", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherReceivablesAndPrepaymentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cntb_LossesPartiallyRecoveredFromCyberInsurance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Losses partially recovered from cyber insurance.", "label": "Losses Partially Recovered from Cyber Insurance", "terseLabel": "Losses partially recovered from cyber insurance" } } }, "localname": "LossesPartiallyRecoveredFromCyberInsurance", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesnetOtherGainsLossesnetParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "cntb_NonCashInvestingAndFinancingActivities": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash investing and financing activities.", "label": "Non-cash investing and financing activities", "totalLabel": "Non-cash investing and financing activities" } } }, "localname": "NonCashInvestingAndFinancingActivities", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_NonCurrentDeferredRevenue": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non current deferred revenue.", "label": "Non Current Deferred Revenue", "terseLabel": "Deferred income" } } }, "localname": "NonCurrentDeferredRevenue", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cntb_NumberOfAmericanDepositarySharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of American depositary shares issued.", "label": "Number of American Depositary Shares Issued", "terseLabel": "Number of ADSs issued" } } }, "localname": "NumberOfAmericanDepositarySharesIssued", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails" ], "xbrltype": "sharesItemType" }, "cntb_NumberOfSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of segments.", "label": "Number Of Segments", "terseLabel": "Number of segments" } } }, "localname": "NumberOfSegments", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cntb_NumberOfShareOptionsVestedInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options vested in share-based payment arrangement", "label": "Number Of Share Options Vested In Share Based Payment Arrangement", "terseLabel": "Number of shares vested" } } }, "localname": "NumberOfShareOptionsVestedInShareBasedPaymentArrangement", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_NumberOfSharesIssuedAtConsolidation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued at consolidation.", "label": "Number of shares issued at consolidation" } } }, "localname": "NumberOfSharesIssuedAtConsolidation", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_NumberOfSharesIssuedForPreMoneyValuationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Number of shares issued for pre money valuation amount.", "label": "Number Of Shares Issued For Pre Money Valuation Amount", "terseLabel": "Number of shares issued for pre money valuation amount" } } }, "localname": "NumberOfSharesIssuedForPreMoneyValuationAmount", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_NumberOfSharesRepresentedByOneDepositaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares represented by one depositary shares.", "label": "Number of Shares Represented by One Depositary Shares", "terseLabel": "Number of shares represented by one depositary shares" } } }, "localname": "NumberOfSharesRepresentedByOneDepositaryShares", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_NumberOfTreasuryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares.", "label": "Number Of Treasury Shares", "terseLabel": "Number of treasury shares" } } }, "localname": "NumberOfTreasuryShares", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureTreasurySharesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_OfficeEquipmentAndFurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office equipment and furniture.", "label": "Office Equipment and Furniture" } } }, "localname": "OfficeEquipmentAndFurnitureMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cntb_OfficeEquipmentFurnitureAndOthersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office equipment, furniture and others.", "label": "Office Equipment Furniture And Others [Member]", "terseLabel": "Office Equipment, Furniture and Others" } } }, "localname": "OfficeEquipmentFurnitureAndOthersMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cntb_OfficeExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 5.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Office expenses.", "label": "Office Expenses", "terseLabel": "Office expenses" } } }, "localname": "OfficeExpenses", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "cntb_OfficeRentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office rent.", "label": "Office Rent [Member]", "terseLabel": "Office Rent" } } }, "localname": "OfficeRentMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "domainItemType" }, "cntb_OperatingLeaseCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease costs.", "label": "Operating Lease Costs", "terseLabel": "Aggregate lease obligation" } } }, "localname": "OperatingLeaseCosts", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_OperatingLeasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease period.", "label": "Operating Lease Period", "terseLabel": "Lease term" } } }, "localname": "OperatingLeasePeriod", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cntb_OperatingLeaseTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease term of contract.", "label": "Operating Lease Term Of Contract", "terseLabel": "Offices and rental contract lease term" } } }, "localname": "OperatingLeaseTermOfContract", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cntb_OrdinarySharesReserved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares reserved.", "label": "Ordinary Shares Reserved", "terseLabel": "Ordinary shares reserved" } } }, "localname": "OrdinarySharesReserved", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_OtherIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other income expense.", "label": "Other Income Expense [Abstract]" } } }, "localname": "OtherIncomeExpenseAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_OtherIncomeLossesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other income losses net.", "label": "Other Income (Losses) Net [Abstract]" } } }, "localname": "OtherIncomeLossesNetAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_OtherNonCurrentAssetsOther": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails": { "order": 0.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other non-current assets other.", "label": "Other Non-current Assets Other", "terseLabel": "Others" } } }, "localname": "OtherNonCurrentAssetsOther", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_OtherNonOperatingIncomesExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails": { "order": 3.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other non-operating incomes (expenses).", "label": "Other Non Operating Incomes Expenses", "negatedLabel": "Other loss", "terseLabel": "Other loss" } } }, "localname": "OtherNonOperatingIncomesExpenses", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesnetOtherGainsLossesnetParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "cntb_OtherPayablesAndAccruals": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other payables and accruals.", "label": "Other Payables And Accruals", "terseLabel": "Other payables and accruals", "totalLabel": "Other payables and accruals" } } }, "localname": "OtherPayablesAndAccruals", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cntb_OtherPayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables and accruals.", "label": "Other Payables and Accruals [Abstract]" } } }, "localname": "OtherPayablesAndAccrualsAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_OtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables.", "label": "Other Payables [Member]", "terseLabel": "Other Payables" } } }, "localname": "OtherPayablesMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "cntb_OtherReceivablesAndPrepayments": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other receivables and prepayments.", "label": "Other Receivables And Prepayments", "terseLabel": "Other receivable and prepayments", "totalLabel": "Other receivables and prepayments" } } }, "localname": "OtherReceivablesAndPrepayments", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cntb_OtherReceivablesAndPrepaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other receivables and prepayments.", "label": "Other Receivables And Prepayments [Abstract]" } } }, "localname": "OtherReceivablesAndPrepaymentsAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_OtherReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other receivables.", "label": "Other Receivables [Member]", "terseLabel": "Other Receivables" } } }, "localname": "OtherReceivablesMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "cntb_PaymentForRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment for right of use assets.", "label": "Payment For Right Of Use Assets", "negatedLabel": "Payment for right-of-use assets" } } }, "localname": "PaymentForRightOfUseAssets", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cntb_PaymentInRelationToListingExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment in relation to listing expenses.", "label": "Payment In Relation To Listing Expenses", "negatedLabel": "Payment in relation to listing expenses" } } }, "localname": "PaymentInRelationToListingExpenses", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cntb_PaymentMadeByHoldersOfPreferredSharesUponOrInConnectionWithConversionOfPreferredSharesIntoOrdinaryShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Made by Holders of Preferred Shares Upon or in Connection With Conversion of Preferred Shares into Ordinary Shares", "label": "Payment made by holders of preferred shares upon or in connection with conversion of preferred shares into ordinary shares" } } }, "localname": "PaymentMadeByHoldersOfPreferredSharesUponOrInConnectionWithConversionOfPreferredSharesIntoOrdinaryShares", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_PayrollWelfareAndBonusPayables": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": 2.0, "parentTag": "cntb_OtherPayablesAndAccruals", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payroll, welfare and bonus payables.", "label": "Payroll Welfare And Bonus Payables", "terseLabel": "Payroll, welfare and bonus payables" } } }, "localname": "PayrollWelfareAndBonusPayables", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_PercentageOfAnnualRequireNetAfterTaxProfits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of annual require net after tax profits.", "label": "Percentage Of Annual Require Net After Tax Profits", "terseLabel": "Percentage of annual require net after tax profits" } } }, "localname": "PercentageOfAnnualRequireNetAfterTaxProfits", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_PercentageOfAssessableProfits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of assessable profits", "label": "Percentage of assessable profits" } } }, "localname": "PercentageOfAssessableProfits", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_PercentageOfEntityProfitToOffsetPriorLosses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of entity profit to offset prior losses", "label": "Percentage of Entity Profit to Offset Prior Losses", "terseLabel": "Percentage of net profit to offset prior losses" } } }, "localname": "PercentageOfEntityProfitToOffsetPriorLosses", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureReservesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_PercentageOfEntitysReserveRegisteredCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of entity's reserve registered capital.", "label": "Percentage of Entitys Reserve Registered Capital", "terseLabel": "Percentage of reserve fund of registered capital" } } }, "localname": "PercentageOfEntitysReserveRegisteredCapital", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureReservesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_PercentageOfForeignExchangeTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of foreign exchange transaction.", "label": "Percentage Of Foreign Exchange Transaction", "terseLabel": "Percentage of foreign exchange transactions" } } }, "localname": "PercentageOfForeignExchangeTransaction", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_PercentageOfReserveFundOfRegisteredCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of reserve fund of registered capital.", "label": "Percentage Of Reserve Fund Of Registered Capital", "terseLabel": "Percentage of reserve fund of registered capital" } } }, "localname": "PercentageOfReserveFundOfRegisteredCapital", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_PercentageOfSharesEqualToLesserOfAggregateNumberOfOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares equal to lesser of aggregate number of ordinary shares.", "label": "Percentage of Shares Equal to Lesser of Aggregate Number of Ordinary Shares", "terseLabel": "Percentage of shares equal to lesser of aggregate number of ordinary shares" } } }, "localname": "PercentageOfSharesEqualToLesserOfAggregateNumberOfOrdinaryShares", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_PercentageOfTaxDeductibleResearchAndDevelopmentExpense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of tax deductible research and development expense.", "label": "Percentage Of Tax Deductible Research And Development Expense", "terseLabel": "Percentage of tax-deductible research and development expenses" } } }, "localname": "PercentageOfTaxDeductibleResearchAndDevelopmentExpense", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateParentheticalDetails" ], "xbrltype": "percentItemType" }, "cntb_PeriodOfGrantOfShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of grant of share-based payment arrangement.", "label": "Period Of Grant Of Share Based Payment Arrangement", "terseLabel": "Period of grant of share-based payment arrangement" } } }, "localname": "PeriodOfGrantOfShareBasedPaymentArrangement", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cntb_PreferredSharesConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares conversion ratio.", "label": "Preferred Shares Conversion Ratio", "terseLabel": "Preferred shares conversion ratio" } } }, "localname": "PreferredSharesConversionRatio", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "cntb_PreferredSharesSubscriptionConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred shares, subscription consideration.", "label": "Preferred Shares Subscription Consideration", "terseLabel": "Subscription consideration" } } }, "localname": "PreferredSharesSubscriptionConsideration", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_PreferredSharesSubscriptionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares, subscription date.", "label": "Preferred Shares Subscription Date", "terseLabel": "Date of subscription" } } }, "localname": "PreferredSharesSubscriptionDate", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "dateItemType" }, "cntb_PreferredSharesSubscriptionDateOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Shares Subscription Date One", "label": "Preferred Shares Subscription Date One", "terseLabel": "Date of subscription" } } }, "localname": "PreferredSharesSubscriptionDateOne", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "dateItemType" }, "cntb_PreferredSharesSubscriptionDateTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares subscription date two.", "label": "Preferred Shares Subscription Date Two", "terseLabel": "Date of subscription" } } }, "localname": "PreferredSharesSubscriptionDateTwo", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "dateItemType" }, "cntb_PrepaymentsForPurchaseOfNonCurrentAssets": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepayments for purchase of non-current assets.", "label": "Prepayments For Purchase Of Non Current Assets", "terseLabel": "Prepayments for purchase of non-current assets" } } }, "localname": "PrepaymentsForPurchaseOfNonCurrentAssets", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ProceedsFromIssuanceOfFinancialInstrumentsWithPreferredRights": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of financial instruments with preferred rights.", "label": "Proceeds From Issuance Of Financial Instruments With Preferred Rights", "terseLabel": "Proceeds from issuance of financial instruments with preferred rights" } } }, "localname": "ProceedsFromIssuanceOfFinancialInstrumentsWithPreferredRights", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cntb_ProfitLossFromContinuingOperationsBeforeTax": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Profit (loss) from continuing operations before tax.", "label": "Profit Loss From Continuing Operations Before Tax", "terseLabel": "Loss from operations in the PRC" } } }, "localname": "ProfitLossFromContinuingOperationsBeforeTax", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ProfitLossFromOverseasEntities": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Profit (loss) from overseas entities", "label": "Profit (loss) from overseas entities", "terseLabel": "Loss from overseas entities" } } }, "localname": "ProfitLossFromOverseasEntities", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "cntb_RecoveryFromInsuranceAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Recovery from insurance amount.", "label": "Recovery from Insurance Amount" } } }, "localname": "RecoveryFromInsuranceAmount", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesnetOtherGainsLossesnetParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "cntb_RedemptionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price percentage.", "label": "Redemption price percentage" } } }, "localname": "RedemptionPricePercentage", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_RepurchaseOfOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchase of ordinary shares.", "label": "Repurchase of Ordinary Shares", "negatedLabel": "Repurchase of ordinary shares, shares", "terseLabel": "Repurchase of ordinary shares", "verboseLabel": "Repurchase of ordinary shares, shares" } } }, "localname": "RepurchaseOfOrdinaryShares", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "sharesItemType" }, "cntb_RepurchaseOfOrdinarySharesValue": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 5.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Repurchase of ordinary shares value.", "label": "Repurchase Of Ordinary Shares Value", "terseLabel": "Repurchase of ordinary shares value" } } }, "localname": "RepurchaseOfOrdinarySharesValue", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_ResearchAndDevelopmentExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development expenses.", "label": "Research And Development Expenses [Member]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensesMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "cntb_RestrictedNetAssetsAndParentCompanyCondensedFinancialInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted net assets and parent company condensed financial information.", "label": "Restricted Net Assets And Parent Company Condensed Financial Information [Abstract]" } } }, "localname": "RestrictedNetAssetsAndParentCompanyCondensedFinancialInformationAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_RevenueFromGovernmentAsAnIncentiveForResearchAndDevelopment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from government as an incentive for research and development.", "label": "Revenue from government as an incentive for research and development" } } }, "localname": "RevenueFromGovernmentAsAnIncentiveForResearchAndDevelopment", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_RevenueFromGovernmentGrantsFromOtherSubsidies": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from government grants from other subsidies.", "label": "Grants received from other subsidies" } } }, "localname": "RevenueFromGovernmentGrantsFromOtherSubsidies", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_RightOfUseAssetsAccumulatedDepreciation": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails": { "order": 1.0, "parentTag": "ifrs-full_RightofuseAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Right of use assets accumulated depreciation.", "label": "Right of use Assets Accumulated Depreciation", "negatedTerseLabel": "Accumulated deprecation" } } }, "localname": "RightOfUseAssetsAccumulatedDepreciation", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_RiskFreeInterestRateMeasurementInputMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk-Free interest rate, measurement input.", "label": "Risk Free Interest Rate Measurement Input [Member]", "terseLabel": "Risk-Free Interest Rate" } } }, "localname": "RiskFreeInterestRateMeasurementInputMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "cntb_SeriesAPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A preferred shares.", "label": "Series A Preferred Shares [Member]", "terseLabel": "Series A Preferred Shares" } } }, "localname": "SeriesAPreferredSharesMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "cntb_SeriesBFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B financing.", "label": "Series B Financing [Member]", "terseLabel": "Series B Financing" } } }, "localname": "SeriesBFinancingMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_SeriesBPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B preferred shares.", "label": "Series B Preferred Shares [Member]", "terseLabel": "Series B Preferred Shares" } } }, "localname": "SeriesBPreferredSharesMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "cntb_SeriesCPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series c preferred shares.", "label": "Series C Preferred Shares [Member]", "terseLabel": "Series C Preferred Shares", "verboseLabel": "Series C Preferred Shares" } } }, "localname": "SeriesCPreferredSharesMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "cntb_SeriesPreAPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series Pre-A preferred shares.", "label": "Series Pre A Preferred Shares [Member]", "terseLabel": "Series Pre-A Preferred Shares" } } }, "localname": "SeriesPreAPreferredSharesMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "cntb_ShanghaiConnectBiopharmaceuticalsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Connect Biopharmaceuticals, Limited.", "label": "Shanghai Connect Biopharmaceuticals, Limited [Member]", "terseLabel": "Connect Biopharma (Shanghai) Co., Ltd" } } }, "localname": "ShanghaiConnectBiopharmaceuticalsLimitedMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "cntb_ShanghaiTigermedConsultingCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Tigermed Consulting Company Limited.", "label": "Shanghai Tigermed Consulting Company Limited [Member]", "terseLabel": "Shanghai Tigermed Consulting Company Limited" } } }, "localname": "ShanghaiTigermedConsultingCompanyLimitedMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "cntb_ShareBasedCompensationReserves": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share based compensation reserves.", "label": "Share Based Compensation Reserves", "terseLabel": "Share-based compensation reserves" } } }, "localname": "ShareBasedCompensationReserves", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cntb_ShareBasedCompensationToAdditionalSeriesCPreferredShareholderFinancialInstrumentsWithPreferredRights": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails": { "order": 2.0, "parentTag": "cntb_NonCashInvestingAndFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation to additional series C preferred shareholder financial instruments with preferred rights.", "label": "Share Based Compensation To Additional Series C Preferred Shareholder Financial Instruments With Preferred Rights", "terseLabel": "Share-based compensation to additional Series C preferred shareholder", "verboseLabel": "Share-based compensation to additional Series C preferred shareholder" } } }, "localname": "ShareBasedCompensationToAdditionalSeriesCPreferredShareholderFinancialInstrumentsWithPreferredRights", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfNoncashInvestingAndFinancingActivitiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ShareBasedPaymentAwardVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment award, award vesting period.", "label": "Share Based Payment Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedPaymentAwardVestingPeriod", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cntb_ShareBasedPaymentAwardVestingRightsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment award, vesting rights, percentage.", "label": "Share Based Payment Award Vesting Rights Percentage", "terseLabel": "Vesting rights percentage" } } }, "localname": "ShareBasedPaymentAwardVestingRightsPercentage", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_ShareBasedPaymentEqualMonthlyInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Payment equal monthly installments.", "label": "Share Based Payment Equal Monthly Installments", "terseLabel": "Vest in equal monthly installments" } } }, "localname": "ShareBasedPaymentEqualMonthlyInstallments", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cntb_SharePurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share purchase agreement.", "label": "Share Purchase Agreement [Member]", "terseLabel": "Share Purchase Agreement" } } }, "localname": "SharePurchaseAgreementMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_SharesReservedForFutureIssuanceUnderTwoThousandNineteenStockIncentivePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares reserved for future issuance under 2019 stock incentive plan.", "label": "Shares Reserved for Future Issuance under Two Thousand Nineteen Stock Incentive Plan", "terseLabel": "Shares reserved for future issuance under 2019 Stock Incentive plan" } } }, "localname": "SharesReservedForFutureIssuanceUnderTwoThousandNineteenStockIncentivePlan", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_ShenzhenConnectBiopharmaceuticalsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shenzhen Connect Biopharmaceuticals, Limited.", "label": "Shenzhen Connect Biopharmaceuticals, Limited [Member]", "terseLabel": "Connect Biopharma (Shenzhen) Co., Ltd" } } }, "localname": "ShenzhenConnectBiopharmaceuticalsLimitedMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "cntb_SquareFeetOfOperatingLeaseArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Square feet of operating lease area.", "label": "Square Feet Of Operating Lease Area", "terseLabel": "Square feet of operating lease area" } } }, "localname": "SquareFeetOfOperatingLeaseArea", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "cntb_SummaryOfReturnsOnWealthManagementProductsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of returns on wealth management products.", "label": "Summary Of Returns On Wealth Management Products Table [Text Block]", "terseLabel": "Summary of Returns on Wealth Management Products" } } }, "localname": "SummaryOfReturnsOnWealthManagementProductsTableTextBlock", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLossTables" ], "xbrltype": "textBlockItemType" }, "cntb_SuzhouMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suzhou.", "label": "Suzhou [Member]", "terseLabel": "Suzhou" } } }, "localname": "SuzhouMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails" ], "xbrltype": "domainItemType" }, "cntb_TaxLossesAndDeductibleTemporaryDifferencesForWhichNoDeferredIncomeTaxAssetsRecognized": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails2": { "order": 3.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax losses and deductible temporary differences for which no deferred income tax assets were recognized.", "label": "Tax Losses And Deductible Temporary Differences For Which No Deferred Income Tax Assets Recognized", "terseLabel": "Tax losses and deductible temporary differences for which no deferred income tax assets were recognized" } } }, "localname": "TaxLossesAndDeductibleTemporaryDifferencesForWhichNoDeferredIncomeTaxAssetsRecognized", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "cntb_TradePayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade payables.", "label": "Trade Payables [Member]", "terseLabel": "Trade Payables" } } }, "localname": "TradePayablesMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "cntb_TransactionsWithOwnersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transactions with owners.", "label": "Transactions With Owners [Abstract]", "terseLabel": "Transactions with owners" } } }, "localname": "TransactionsWithOwnersAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "stringItemType" }, "cntb_TreasurySharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury shares.", "label": "Treasury Shares [Abstract]" } } }, "localname": "TreasurySharesAbstract", "nsuri": "http://www.connectbiopharm.com/20211231", "xbrltype": "stringItemType" }, "cntb_TreasurySharesHeldForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury shares held for issuance.", "label": "Treasury Shares held for Issuance", "terseLabel": "Treasury shares held for issuance" } } }, "localname": "TreasurySharesHeldForIssuance", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_TreasurySharesHeldForIssuanceConsolidated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury shares held for issuance consolidated", "label": "Treasury Shares Held For Issuance Consolidated" } } }, "localname": "TreasurySharesHeldForIssuanceConsolidated", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_TwentyTwentyOneEmployeeSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty twenty one employee share purchase plan.", "label": "Twenty Twenty One Employee Share Purchase Plan [Member]", "terseLabel": "2021 Employee Share Purchase Plan" } } }, "localname": "TwentyTwentyOneEmployeeSharePurchasePlanMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_TwentyTwentyOneStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty twenty one stock incentive plan.", "label": "2021 Stock Incentive Plan" } } }, "localname": "TwentyTwentyOneStockIncentivePlanMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_TwoThousandNineteenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Stock Incentive Plan.", "label": "Two Thousand Nineteen Stock Incentive Plan [Member]", "terseLabel": "2019 Stock Incentive Plan" } } }, "localname": "TwoThousandNineteenStockIncentivePlanMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_UnrealisedGainsRecognizedInProfitOrLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrealised gains recognized in profit or loss.", "label": "Unrealised Gains Recognized In Profit Or Loss", "terseLabel": "*Includes unrealized gains recognized in profit or loss attributable to balances held at the end of the reporting period" } } }, "localname": "UnrealisedGainsRecognizedInProfitOrLoss", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "cntb_UnrecognizedUncertainTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized uncertain tax positions.", "label": "Unrecognized uncertain tax positions" } } }, "localname": "UnrecognizedUncertainTaxPositions", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_WealthManagementProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wealth Management Products.", "label": "Wealth Management Products" } } }, "localname": "WealthManagementProductsMember", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossSummaryOfReturnsOnWealthManagementProductsDetails" ], "xbrltype": "domainItemType" }, "cntb_WeightedAverageSharePriceShareOptionsGrantedAtConsolidation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average share price share options granted at consolidation.", "label": "Weighted Average Share Price Share Options Granted At Consolidation", "terseLabel": "Fair value of share based payment on grant date at consolidation" } } }, "localname": "WeightedAverageSharePriceShareOptionsGrantedAtConsolidation", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "cntb_WelfareExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Welfare expenses.", "label": "Welfare Expenses", "terseLabel": "Welfare expenses" } } }, "localname": "WelfareExpenses", "nsuri": "http://www.connectbiopharm.com/20211231", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails" ], "xbrltype": "monetaryItemType" }, "country_AU": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AUSTRALIA", "terseLabel": "Australia", "verboseLabel": "Australian Dollar deposit" } } }, "localname": "AU", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "PRC", "verboseLabel": "RMB deposits" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HONG KONG", "terseLabel": "Hong Kong" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "US Federal Corporate Income Tax", "verboseLabel": "USD deposits" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]", "terseLabel": "Business Contact Person" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name", "terseLabel": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard", "terseLabel": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement", "terseLabel": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report", "terseLabel": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation Date Of Incorporation", "terseLabel": "Date of incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PhoneFaxNumberDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of Phone or Fax Number", "label": "Phone Fax Number Description" } } }, "localname": "PhoneFaxNumberDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AccountingProfit": { "auth_ref": [ "r55", "r56" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Accounting Profit", "terseLabel": "Assessable profits", "verboseLabel": "Loss before income tax" } } }, "localname": "AccountingProfit", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "auth_ref": [ "r63", "r70", "r115", "r122", "r125" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation and amortisation [member]", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationAndAmortisationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated Other Comprehensive Income", "negatedLabel": "Accumulated losses", "terseLabel": "Accumulated losses", "totalLabel": "Total accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Losses" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions Other Than Through Business Combinations Property Plant And Equipment", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r192" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions to right-of-use assets", "terseLabel": "Additions" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AddressOfRegisteredOfficeOfEntity": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The address at which the entity's office is registered." } }, "en-us": { "role": { "label": "Address Of Registered Office Of Entity", "terseLabel": "Address of registered office" } } }, "localname": "AddressOfRegisteredOfficeOfEntity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForAmortisationExpense": { "auth_ref": [ "r135" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Adjustments for amortisation expense", "terseLabel": "-Amortization of intangible assets" } } }, "localname": "AdjustmentsForAmortisationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": { "auth_ref": [ "r135" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 15.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other assets", "terseLabel": "-Other non-current assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": { "auth_ref": [ "r133" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 14.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other operating receivables", "terseLabel": "-Other receivables and prepayments" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "auth_ref": [ "r134" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Fair Value Gains Losses", "terseLabel": "-Fair value changes of financial instruments with preferred rights" } } }, "localname": "AdjustmentsForFairValueGainsLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "auth_ref": [ "r133" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 16.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in other operating payables", "terseLabel": "-Other payables and accruals" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r133" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 20.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Increase Decrease In Trade Account Payable", "terseLabel": "-Trade payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments For Reconcile Profit Loss [Abstract]", "terseLabel": "Adjustments for:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r134" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Sharebased Payments", "terseLabel": "Share-based compensation expenses", "verboseLabel": "-Share-based compensation expenses" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "auth_ref": [ "r134", "r146" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Unrealised Foreign Exchange Losses Gains", "terseLabel": "-Net foreign exchange differences" } } }, "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdministrativeExpense": { "auth_ref": [ "r2", "r49", "r97" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity classifies as being administrative." } }, "en-us": { "role": { "label": "Administrative Expense", "negatedLabel": "Administrative expenses" } } }, "localname": "AdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised": { "auth_ref": [ "r223" ], "lang": { "en": { "role": { "documentation": "The aggregate difference between the fair value at initial recognition and the transaction price for financial instruments that is yet to be recognised in profit or loss. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Aggregate Difference Between Fair Value At Initial Recognition And Amount Determined Using Valuation Technique Yet To Be Recognised", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r120", "r124", "r171" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated Measurement [Member]", "terseLabel": "Aggregated measurement [member]" } } }, "localname": "AggregatedMeasurementMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r25", "r76", "r184", "r196", "r197", "r221", "r241", "r244", "r263", "r264", "r266", "r272" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated Time Bands [Member]", "terseLabel": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r75", "r172" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } }, "en-us": { "role": { "label": "All Levels Of Fair Value Hierarchy [Member]", "terseLabel": "All levels of fair value hierarchy [member]" } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable Tax Rate", "terseLabel": "Tax rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r22", "r171", "r172", "r176", "r252", "r255" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails2": { "order": 1.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets 1", "periodEndLabel": "Assets at end of period", "periodStartLabel": "Assets at beginning of period", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "auth_ref": [ "r3", "r10" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Attribution Of Expenses By Nature To Their Function [Axis]", "terseLabel": "Attribution of expenses by nature to their function [axis]" } } }, "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AverageEffectiveTaxRate": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Average effective tax rate", "terseLabel": "State income tax rate", "totalLabel": "Total average effective tax rate" } } }, "localname": "AverageEffectiveTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r107", "r108" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic Earnings Loss Per Share", "terseLabel": "Basic net loss per share (RMB)", "totalLabel": "Total basic earnings (loss) per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetBasicLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_Borrowings": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } }, "en-us": { "role": { "label": "Borrowings", "terseLabel": "Debt outstanding", "totalLabel": "Total borrowings" } } }, "localname": "Borrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r181", "r182", "r183", "r210", "r237", "r266" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom Of Range [Member]", "terseLabel": "Bottom of range" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalCommitments": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of future capital expenditures that the entity is committed to make." } }, "en-us": { "role": { "label": "Capital commitments", "totalLabel": "Total capital commitments" } } }, "localname": "CapitalCommitments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfCapitalCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CapitalCommitmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Commitments [Abstract]" } } }, "localname": "CapitalCommitmentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfCapitalCommitmentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r63", "r67", "r115", "r116", "r121", "r122", "r123", "r124", "r125", "r217", "r228", "r229", "r280", "r282" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount [Axis]", "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r67", "r116", "r121", "r123", "r124", "r217", "r228", "r229", "r280", "r281" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying Amount [Member]", "terseLabel": "Carrying amount [member]" } } }, "localname": "CarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r144" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Cumulative cash contributions", "totalLabel": "Total cash" } } }, "localname": "Cash", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash [abstract]", "terseLabel": "Cash at bank" } } }, "localname": "CashAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r19", "r144", "r165" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 0.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash And Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at the beginning of year", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfExposureToForeignCurrencyRiskDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r126", "r145" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash Flows From Used In Financing Activities", "netLabel": "Net cash flows from (used in) financing activities", "terseLabel": "Cash flows", "totalLabel": "Net cash (used in)/ generated from financing activities", "verboseLabel": "Net cash generated from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r126", "r145" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash Flows From Used In Investing Activities", "netLabel": "Net cash flows from (used in) investing activities", "terseLabel": "Net cash used in investing activities", "totalLabel": "Net cash (used in)/ generated from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r126", "r145" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails": { "order": 0.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash Flows From Used In Operating Activities", "negatedLabel": "Net operating cash outflow", "netLabel": "Net cash flows from (used in) operating activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities", "verboseLabel": "Net cash from/(used in) operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperations": { "auth_ref": [ "r135", "r146" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } }, "en-us": { "role": { "label": "Cash Flows From Used In Operations", "negatedLabel": "Net operating cash outflow", "netLabel": "Net cash flows from (used in) operations", "terseLabel": "Cash used in operations", "totalLabel": "Net cash used in operations", "verboseLabel": "Net operating cash outflow" } } }, "localname": "CashFlowsFromUsedInOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashOutflowForLeases": { "auth_ref": [ "r191" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for leases." } }, "en-us": { "role": { "label": "Cash outflow for leases", "terseLabel": "Payment for land use rights", "totalLabel": "Total cash outflow for leases", "verboseLabel": "Total cash outflow for leases" } } }, "localname": "CashOutflowForLeases", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories Of Financial Assets [Axis]", "terseLabel": "Categories of financial assets [axis]" } } }, "localname": "CategoriesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories Of Financial Liabilities [Axis]", "terseLabel": "Categories of financial liabilities [axis]" } } }, "localname": "CategoriesOfFinancialLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories Of Related Parties [Axis]", "terseLabel": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfBalancesWithRelatedPartiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r111", "r113", "r179", "r194" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r111", "r179", "r194" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Classes Of Employee Benefits Expense [Abstract]" } } }, "localname": "ClassesOfEmployeeBenefitsExpenseAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r235", "r236", "r262", "r274", "r275", "r276" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Financial Assets [Axis]", "terseLabel": "Classes of financial assets [axis]" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r228", "r230", "r231", "r233" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Financial Instruments [Axis]", "terseLabel": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossSummaryOfReturnsOnWealthManagementProductsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r228", "r230", "r231", "r233" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Classes Of Financial Instruments [Member]", "terseLabel": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossSummaryOfReturnsOnWealthManagementProductsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r235", "r236", "r262", "r275" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Financial Liabilities [Axis]", "terseLabel": "Financial Liabilities at Amortized Cost" } } }, "localname": "ClassesOfFinancialLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r117" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Intangible Assets Other Than Goodwill [Axis]", "terseLabel": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfLiabilitiesAxis": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Liabilities [Axis]", "terseLabel": "Classes of liabilities [axis]" } } }, "localname": "ClassesOfLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r68" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Property Plant And Equipment [Axis]", "terseLabel": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfCapitalCommitmentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Share Capital [Axis]", "terseLabel": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "axisDefault": "Share capital", "label": "Classes Of Share Capital [Member]", "terseLabel": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClosingForeignExchangeRate": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } }, "en-us": { "role": { "label": "Closing foreign exchange rate" } } }, "localname": "ClosingForeignExchangeRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components Of Equity [Axis]", "terseLabel": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax [Abstract]", "terseLabel": "Items that may be reclassified to profit or loss" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax [Abstract]", "terseLabel": "Items that will not be reclassified to profit or loss" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r4", "r40", "r151", "r153", "r159", "r164" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive Income", "totalLabel": "Total comprehensive loss for the year" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income Attributable To [Abstract]", "terseLabel": "Total comprehensive loss attributable to:" } } }, "localname": "ComprehensiveIncomeAttributableToAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "auth_ref": [ "r4", "r42" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } }, "en-us": { "role": { "label": "Comprehensive Income Attributable To Owners Of Parent", "terseLabel": "Owners of the Company", "totalLabel": "Owners of the Company" } } }, "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComputerSoftwareMember": { "auth_ref": [ "r118" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Computer Software [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ConstructionInProgressMember": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Construction in progress [member]", "terseLabel": "Assets Under Construction", "verboseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ContractualCapitalCommitments": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } }, "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Equipment and intangible assets - Contracted but not provided for", "verboseLabel": "Capital commitments" } } }, "localname": "ContractualCapitalCommitments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CountryOfIncorporation": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The country in which the entity is incorporated." } }, "en-us": { "role": { "label": "Country Of Incorporation", "terseLabel": "Country of incorporation", "verboseLabel": "Place of incorporation" } } }, "localname": "CountryOfIncorporation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CreditRiskMember": { "auth_ref": [ "r225", "r267", "r268", "r269" ], "lang": { "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Credit Risk [Member]", "terseLabel": "Credit Risk" } } }, "localname": "CreditRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrencyRiskMember": { "auth_ref": [ "r247", "r267", "r268", "r269", "r270" ], "lang": { "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Currency Risk [Member]", "terseLabel": "Foreign Currency Risk" } } }, "localname": "CurrencyRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfExposureToForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r26", "r159", "r160" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current Assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets [Abstract]", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r238" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets measured at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Current Financial Assets At Fair Value Through Profit Or Loss", "terseLabel": "Financial assets at fair value through profit or loss", "totalLabel": "Total current financial assets at fair value through profit or loss" } } }, "localname": "CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r186" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails": { "order": 1.0, "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current Lease Liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "Current" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r27", "r159", "r162" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current Liabilities", "negatedLabel": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r10" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": 2.0, "parentTag": "cntb_OtherReceivablesAndPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]" } }, "en-us": { "role": { "label": "Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised", "terseLabel": "Deductible temporary differences for which no deferred tax asset is recognized" } } }, "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxAssets": { "auth_ref": [ "r20", "r23", "r58" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Deferred tax assets", "negatedLabel": "Deferred tax assets", "terseLabel": "Deferred income tax assets recognized", "verboseLabel": "Deferred Tax Assets" } } }, "localname": "DeferredTaxAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationAndAmortisationExpense": { "auth_ref": [ "r1", "r3", "r49", "r166", "r250", "r257" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 6.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation and amortisation expense", "negatedLabel": "Depreciation and amortisation expense", "terseLabel": "Depreciation and amortization", "totalLabel": "Total depreciation and amortisation expense" } } }, "localname": "DepreciationAndAmortisationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationMethodPropertyPlantAndEquipment": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The depreciation method used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation method" } } }, "localname": "DepreciationMethodPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r66", "r69" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation Property Plant And Equipment", "negatedLabel": "Depreciation" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r187" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedLabel": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for cash flows." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Cash Flows Explanatory", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DescriptionOfAccountingPolicyForCashFlowsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for earnings per share." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Earnings Per Share Explanatory", "terseLabel": "Loss per share" } } }, "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Employee Benefits Explanatory", "terseLabel": "Employee Benefits" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for expenses." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Expenses Explanatory", "terseLabel": "Administrative expenses" } } }, "localname": "DescriptionOfAccountingPolicyForExpensesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Financial Instruments Explanatory", "terseLabel": "Financial instruments with preferred rights" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for foreign currency translation." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Foreign Currency Translation Explanatory", "terseLabel": "Foreign currency translation" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "auth_ref": [ "r80" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Government Grants", "terseLabel": "Government grants" } } }, "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Impairment Of Nonfinancial Assets Explanatory", "terseLabel": "Impairment of non-financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for income tax." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Income Tax Explanatory", "terseLabel": "Current and deferred income tax" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Intangible Assets Other Than Goodwill Explanatory", "terseLabel": "Intangible assets" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for income and expense arising from interest." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Interest Income And Expense Explanatory", "terseLabel": "Interest Income" } } }, "localname": "DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Issued Capital Explanatory", "terseLabel": "Share capital" } } }, "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Leases Explanatory", "terseLabel": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Property Plant And Equipment Explanatory", "terseLabel": "Property, plant and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Research And Development Expense Explanatory", "terseLabel": "Research and development expenses" } } }, "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for segment reporting." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Segment Reporting Explanatory", "terseLabel": "Segment Information" } } }, "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Sharebased Payment Transactions Explanatory", "terseLabel": "Share-based compensation" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for subsidiaries. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Subsidiaries Explanatory", "terseLabel": "Separate financial statements" } } }, "localname": "DescriptionOfAccountingPolicyForSubsidiariesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Trade And Other Payables Explanatory", "terseLabel": "Trade and other payables" } } }, "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r212" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Description Of Expected Volatility Share Options Granted", "terseLabel": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities": { "auth_ref": [ "r14" ], "lang": { "en": { "role": { "documentation": "The description of the nature of the entity's operations and principal activities." } }, "en-us": { "role": { "label": "Description of nature of entity's operations and principal activities", "terseLabel": "Principal activities" } } }, "localname": "DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r212" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Description Of Option Life Share Options Granted", "terseLabel": "Option life" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r212" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Description Of Risk Free Interest Rate Share Options Granted", "terseLabel": "Risk-free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment": { "auth_ref": [ "r62" ], "lang": { "en": { "role": { "documentation": "Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description Of Useful Life Property Plant And Equipment", "terseLabel": "Useful life" } } }, "localname": "DescriptionOfUsefulLifePropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": { "auth_ref": [ "r201" ], "lang": { "en": { "role": { "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of vesting requirements for share-based payment arrangement", "terseLabel": "Options granted vesting term" } } }, "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Accounting Judgements And Estimates Explanatory", "terseLabel": "Critical Accounting Estimates and Judgements" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCriticalAccountingEstimatesAndJudgements" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Attribution Of Expenses By Nature To Their Function [Abstract]" } } }, "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure Of Cash And Cash Equivalents Explanatory", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalents1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "auth_ref": [ "r148" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } }, "en-us": { "role": { "label": "Disclosure Of Cash Flow Statement Explanatory", "terseLabel": "Cash Flow Information" } } }, "localname": "DisclosureOfCashFlowStatementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital [Abstract]" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital Explanatory", "terseLabel": "Schedule of Share Capital and Share Premium" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital [Line Items]", "terseLabel": "Disclosure Of Classes Of Share Capital [Line Items]" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureTreasurySharesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital [Table]", "terseLabel": "Disclosure Of Classes Of Share Capital [Table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureTreasurySharesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments." } }, "en-us": { "role": { "label": "Disclosure Of Commitments Explanatory", "terseLabel": "Commitments" } } }, "localname": "DisclosureOfCommitmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of credit risk exposure [line items]" } } }, "localname": "DisclosureOfCreditRiskExposureLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfCapitalCommitmentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureTable": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the credit risk exposure." } }, "en-us": { "role": { "label": "Disclosure of credit risk exposure [table]" } } }, "localname": "DisclosureOfCreditRiskExposureTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfCapitalCommitmentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Defined Benefit Plans [Line Items]", "terseLabel": "Disclosure Of Defined Benefit Plans [Line Items]" } } }, "localname": "DisclosureOfDefinedBenefitPlansLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "auth_ref": [ "r74" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } }, "en-us": { "role": { "label": "Disclosure Of Defined Benefit Plans [Table]", "terseLabel": "Disclosure Of Defined Benefit Plans [Table]" } } }, "localname": "DisclosureOfDefinedBenefitPlansTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r224", "r230", "r237" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Detailed Information About Financial Instruments Explanatory", "terseLabel": "Schedule of Financial Instruments by Category" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r68" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disclosure Of Detailed Information About Property Plant And Equipment Explanatory", "terseLabel": "Summary of Property, Plant and Equipment" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r110" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure Of Earnings Per Share Explanatory", "terseLabel": "Net Loss Per Share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShare1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "auth_ref": [ "r84" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } }, "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Summary of Exposure to Foreign Currency Risk" } } }, "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "auth_ref": [ "r79" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for employee benefits." } }, "en-us": { "role": { "label": "Disclosure Of Employee Benefits Explanatory", "terseLabel": "Employee Benefit Expenses" } } }, "localname": "DisclosureOfEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r53" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure Of Events After Reporting Period Explanatory", "terseLabel": "Events After the Reporting Period" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureEventsAfterReportingPeriod" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Disclosure Of Expenses By Nature Explanatory", "terseLabel": "Expenses by Nature" } } }, "localname": "DisclosureOfExpensesByNatureExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNature" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfExpensesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of expenses." } }, "en-us": { "role": { "label": "Disclosure Of Expenses Explanatory", "terseLabel": "Summary of Expenses by Nature" } } }, "localname": "DisclosureOfExpensesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } }, "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques" } } }, "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "Disclosure Of Finance Income Expense Explanatory", "terseLabel": "Finance Income/(cost) Net" } } }, "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNet1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Financial Assets [Line Items]", "terseLabel": "Disclosure Of Financial Assets [Line Items]" } } }, "localname": "DisclosureOfFinancialAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "auth_ref": [ "r237" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } }, "en-us": { "role": { "label": "Disclosure Of Financial Assets [Table]", "terseLabel": "Disclosure Of Financial Assets [Table]" } } }, "localname": "DisclosureOfFinancialAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Financial Instruments [Abstract]" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of financial instruments measured at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Financial Instruments At Fair Value Through Profit Or Loss Explanatory", "terseLabel": "Financial Assets at Fair Value Through Profit or Loss" } } }, "localname": "DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLoss1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r248" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "Disclosure Of Financial Instruments Explanatory", "terseLabel": "Financial Instruments by Category" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategory1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Financial Instruments [Line Items]", "terseLabel": "Disclosure Of Financial Instruments [Line Items]" } } }, "localname": "DisclosureOfFinancialInstrumentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossSummaryOfReturnsOnWealthManagementProductsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfExposureToForeignCurrencyRiskDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "auth_ref": [ "r224", "r230", "r237" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } }, "en-us": { "role": { "label": "Disclosure Of Financial Instruments [Table]", "terseLabel": "Disclosure Of Financial Instruments [Table]" } } }, "localname": "DisclosureOfFinancialInstrumentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossSummaryOfReturnsOnWealthManagementProductsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfExposureToForeignCurrencyRiskDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "auth_ref": [ "r237" ], "lang": { "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Disclosure Of Financial Liabilities Explanatory", "terseLabel": "Movements of Financial Instruments with Preferred Rights" } } }, "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } }, "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Financial Instruments and Risk Management" } } }, "localname": "DisclosureOfFinancialRiskManagementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "auth_ref": [ "r16" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } }, "en-us": { "role": { "label": "Disclosure Of General Information About Financial Statements Explanatory", "terseLabel": "General Information, Reorganization and Basis of Presentation" } } }, "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGovernmentGrantsExplanatory": { "auth_ref": [ "r82" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for government grants." } }, "en-us": { "role": { "label": "Disclosure Of Government Grants Explanatory", "terseLabel": "Other Income" } } }, "localname": "DisclosureOfGovernmentGrantsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncome1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure Of Income Tax Explanatory", "terseLabel": "Income Taxes" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r213" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period Explanatory", "terseLabel": "Summary of Key Assumptions for Options Granted" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Information About Key Management Personnel Explanatory", "terseLabel": "Summary of Key Management Personnel Compensation" } } }, "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Initial Application Of Standards Or Interpretations [Abstract]" } } }, "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]", "terseLabel": "Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]" } } }, "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable": { "auth_ref": [ "r149" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the initial application of standards or interpretations." } }, "en-us": { "role": { "label": "Disclosure Of Initial Application Of Standards Or Interpretations [Table]", "terseLabel": "Disclosure Of Initial Application Of Standards Or Interpretations [Table]" } } }, "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Summary of Direct or Indirect Interests in Principal Subsidiaries" } } }, "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r198", "r199" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "Leases" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeases1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Nonadjusting Events After Reporting Period [Abstract]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "auth_ref": [ "r51" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r208" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Share Options Explanatory", "terseLabel": "Summary of Options Outstanding" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]" } }, "en-us": { "role": { "label": "Disclosure Of Other Noncurrent Assets Explanatory", "terseLabel": "Schedule of Other non-current Assets" } } }, "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]" } }, "en-us": { "role": { "label": "Disclosure Of Prepayments And Other Assets Explanatory", "terseLabel": "Other Receivables and Prepayments" } } }, "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepayments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment [Abstract]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r71" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment Explanatory", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment [Line Items]", "terseLabel": "Disclosure Of Property Plant And Equipment [Line Items]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r68" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment [Table]", "terseLabel": "Disclosure Of Property Plant And Equipment [Table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "auth_ref": [ "r194" ], "lang": { "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [text block]", "terseLabel": "Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]", "terseLabel": "Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "auth_ref": [ "r194" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } }, "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Rightofuse Assets [Table]", "terseLabel": "Disclosure Of Quantitative Information About Rightofuse Assets [Table]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "auth_ref": [ "r117" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } }, "en-us": { "role": { "label": "Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill Explanatory", "terseLabel": "Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights" } } }, "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "auth_ref": [ "r143" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities Explanatory", "terseLabel": "Summary of Reconciliation of Liabilities Arising from Financing Activities" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "auth_ref": [ "r143" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r94" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure Of Related Party Explanatory", "terseLabel": "Related Party Transactions" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReservesWithinEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Reserves Within Equity [Abstract]" } } }, "localname": "DisclosureOfReservesWithinEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r38" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure Of Share Capital Reserves And Other Equity Interest Explanatory", "terseLabel": "Share Capital" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapital" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure Of Sharebased Payment Arrangements Explanatory", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsTable": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to significant unobservable inputs used in the fair value measurement of assets." } }, "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of assets [table]" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]", "terseLabel": "Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to significant unobservable inputs used in the fair value measurement of liabilities." } }, "en-us": { "role": { "label": "Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Table]", "terseLabel": "Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Table]" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure Of Summary Of Significant Accounting Policies Explanatory", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]", "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r211" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]", "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r90" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties Explanatory", "terseLabel": "Schedule of Significant Transactions and Balances with Related Parties" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties [Line Items]", "terseLabel": "Disclosure Of Transactions Between Related Parties [Line Items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfBalancesWithRelatedPartiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties [Table]", "terseLabel": "Disclosure Of Transactions Between Related Parties [Table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfBalancesWithRelatedPartiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTreasurySharesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Disclosure Of Treasury Shares Explanatory", "terseLabel": "Treasury shares" } } }, "localname": "DisclosureOfTreasurySharesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureTreasuryShares" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r65" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disposals, property, plant and equipment", "negatedLabel": "Disposals" } } }, "localname": "DisposalsPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Loss per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r107" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings Per Share Explanatory", "terseLabel": "Schedule of Net Basic Loss Per Share" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r136", "r137" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect Of Exchange Rate Changes On Cash And Cash Equivalents", "terseLabel": "Effects of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EffectiveInterestRateOfFinancialAssetsReclassifiedOutOfFinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r279" ], "lang": { "en": { "role": { "documentation": "The effective interest rate of financial assets reclassified out of the fair value through profit or loss measurement category. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Effective Interest Rate Of Financial Assets Reclassified Out Of Financial Assets At Fair Value Through Profit Or Loss", "terseLabel": "Effective interest rate of financial assets reclassified out of financial assets at fair value through profit or loss" } } }, "localname": "EffectiveInterestRateOfFinancialAssetsReclassifiedOutOfFinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r1", "r3", "r49" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 4.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee Benefits Expense", "negatedLabel": "Employee benefits expense", "terseLabel": "Employee benefit expenses (Note 6)", "totalLabel": "Employee benefit expenses", "verboseLabel": "Employee benefit expenses" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entitys Total For Related Parties [Member]", "terseLabel": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfBalancesWithRelatedPartiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "auth_ref": [ "r101", "r104", "r170" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } } }, "localname": "EntitysTotalForSubsidiariesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r22", "r30", "r150", "r152", "r171", "r172", "r176" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' (deficit)/equity" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract] 1", "terseLabel": "SHAREHOLDERS\u2019 DEFICIT", "verboseLabel": "SHAREHOLDERS' (DEFICIT)/EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r22" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity And Liabilities", "totalLabel": "Total liabilities and shareholders' (deficit)/equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAttributableToOwnersOfParent": { "auth_ref": [ "r21" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } }, "en-us": { "role": { "label": "Equity Attributable To Owners Of Parent", "terseLabel": "Net liabilities", "totalLabel": "Total shareholders' (deficit)/equity" } } }, "localname": "EquityAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } }, "en-us": { "role": { "label": "Equity Attributable To Owners Of Parent [Member]", "terseLabel": "Total" } } }, "localname": "EquityAttributableToOwnersOfParentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [Member]", "terseLabel": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "auth_ref": [ "r212" ], "lang": { "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected Dividend As Percentage Share Options Granted", "terseLabel": "Dividend yield" } } }, "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ExpenseByNature": { "auth_ref": [ "r49" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity." } }, "en-us": { "role": { "label": "Expense By Nature", "terseLabel": "Total expenses by nature", "totalLabel": "Total expenses, by nature" } } }, "localname": "ExpenseByNature", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseByNatureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense By Nature [Abstract]" } } }, "localname": "ExpenseByNatureAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } }, "en-us": { "role": { "label": "Expense From Sharebased Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets", "terseLabel": "Share-based compensation expenses", "totalLabel": "Total expense from share-based payment transactions" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "auth_ref": [ "r10" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense From Sharebased Payment Transactions With Employees", "terseLabel": "Share-based compensation expenses (Note 22)", "verboseLabel": "Share-based compensation expenses" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": { "auth_ref": [ "r190" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails": { "order": 2.0, "parentTag": "ifrs-full_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets." } }, "en-us": { "role": { "label": "Expense relating to leases of low-value assets for which recognition exemption has been used", "terseLabel": "Expense relating to leases of low-value assets that are not shown above as short-term leases (included in administrative expenses and research and development expenses)" } } }, "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "auth_ref": [ "r189" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails": { "order": 1.0, "parentTag": "ifrs-full_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease." } }, "en-us": { "role": { "label": "Expense relating to short-term leases for which recognition exemption has been used", "terseLabel": "Expense relating to short-term leases (included in administrative expenses and research and development expenses)" } } }, "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": { "auth_ref": [ "r214" ], "lang": { "en": { "role": { "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)." } }, "en-us": { "role": { "label": "Explanation Of Effect Of Sharebased Payments On Profit Or Loss", "terseLabel": "Summary of Share-Based Compensation Expenses" } } }, "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r43" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance Costs", "negatedLabel": "Finance cost", "negatedTotalLabel": "Finance costs" } } }, "localname": "FinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r46" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 0.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance Income", "terseLabel": "Finance income" } } }, "localname": "FinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncomeCost": { "auth_ref": [ "r46" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance Income Cost", "terseLabel": "Finance costs - net", "totalLabel": "Finance income/(cost)-net", "verboseLabel": "Finance income/(costs)-net" } } }, "localname": "FinanceIncomeCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssets": { "auth_ref": [ "r222", "r228", "r229", "r231", "r232" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial Assets", "periodEndLabel": "Financial assets at end of period", "periodStartLabel": "Financial assets at beginning of period", "terseLabel": "Financial Assets", "totalLabel": "Total assets", "verboseLabel": "FINANCIAL ASSETS" } } }, "localname": "FinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtAmortisedCostMember": { "auth_ref": [ "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]" } }, "en-us": { "role": { "label": "Financial Assets At Amortised Cost [Member]", "terseLabel": "Financial Assets at Amortized Cost" } } }, "localname": "FinancialAssetsAtAmortisedCostMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsAtFairValue": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Financial assets measured at fair value" } } }, "localname": "FinancialAssetsAtFairValue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueMember": { "auth_ref": [ "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets measured at fair value class. [Refer: Financial assets; At fair value [member]]" } }, "en-us": { "role": { "label": "Financial Assets At Fair Value [Member]", "terseLabel": "Financial Assets at FVPL" } } }, "localname": "FinancialAssetsAtFairValueMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r238" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails": { "order": 0.0, "parentTag": "ifrs-full_FinancialAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial Assets At Fair Value Through Profit Or Loss", "periodEndLabel": "Closing balance", "periodStartLabel": "Opening balance", "terseLabel": "Financial assets at fair value through profit or loss", "totalLabel": "Total financial assets at fair value through profit or loss" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Assets At Fair Value Through Profit Or Loss [Abstract]", "terseLabel": "Assets" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "auth_ref": [ "r238" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Financial Assets At Fair Value Through Profit Or Loss Category [Member]", "terseLabel": "Financial Assets at Fair Value through Profit or Loss" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsCategoryMember": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial Assets Category [Member]", "terseLabel": "Financial assets, category [member]" } } }, "localname": "FinancialAssetsCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r235", "r236", "r262", "r274", "r275", "r276" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial Assets [Member]", "terseLabel": "Financial assets, class [member]" } } }, "localname": "FinancialAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilities": { "auth_ref": [ "r222" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Total", "totalLabel": "Total liabilities", "verboseLabel": "Total liabilities" } } }, "localname": "FinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "auth_ref": [ "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } }, "en-us": { "role": { "label": "Financial Liabilities At Amortised Cost [Member]", "terseLabel": "Financial Liabilities at Amortized Cost" } } }, "localname": "FinancialLiabilitiesAtAmortisedCostMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, at fair value", "terseLabel": "Financial liabilities measured at fair value" } } }, "localname": "FinancialLiabilitiesAtFairValue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValueMember": { "auth_ref": [ "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]" } }, "en-us": { "role": { "label": "Financial Liabilities At Fair Value [Member]", "terseLabel": "Financial Liabilities at Amortized Cost", "verboseLabel": "Financial Liabilities at FVPL" } } }, "localname": "FinancialLiabilitiesAtFairValueMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r239" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails": { "order": 0.0, "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as \u2018an accounting mismatch\u2019) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity\u2019s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial Liabilities At Fair Value Through Profit Or Loss", "terseLabel": "Financial instruments with preferred rights", "totalLabel": "Total financial liabilities at fair value through profit or loss" } } }, "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial Liabilities Category [Member]", "terseLabel": "Financial liabilities, category [member]" } } }, "localname": "FinancialLiabilitiesCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesMember": { "auth_ref": [ "r235", "r236", "r262", "r275" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Financial Liabilities [Member]", "terseLabel": "Financial liabilities, class [member]" } } }, "localname": "FinancialLiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ForeignCountriesMember": { "auth_ref": [ "r258", "r259" ], "lang": { "en": { "role": { "documentation": "This member stands for countries outside the entity's country of domicile. [Refer: Country of domicile [member]]" } }, "en-us": { "role": { "label": "Foreign countries [member]", "terseLabel": "Outside of PRC" } } }, "localname": "ForeignCountriesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": { "auth_ref": [ "r48" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Gains (losses) on disposals of property, plant and equipment", "negatedLabel": "-Loss on disposal of property, plant and equipment", "netLabel": "Net gains (losses) on disposals of property, plant and equipment", "terseLabel": "(Gain)/Loss on disposal of PPE", "verboseLabel": "-(Gain)/Loss on disposal of PPE" } } }, "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": { "auth_ref": [ "r47" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Gains Losses On Exchange Differences On Translation Net Of Tax", "terseLabel": "Exchange differences", "verboseLabel": "Change in fair value due to foreign currency translation recognized in other comprehensive income" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r15", "r83" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails": { "order": 0.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss", "netLabel": "Net foreign exchange gain (loss)", "terseLabel": "Net foreign exchange gains/(losses) included in other gains/(losses)-net", "verboseLabel": "Net foreign exchange gains/(losses)" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndRiskManagementSummaryOfAggregateNetForeignExchangeGainslossesRecognizedInProfitOrLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r219" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Gains Losses On Financial Liabilities At Fair Value Through Profit Or Loss", "terseLabel": "Fair value loss of financial instruments with preferred rights", "totalLabel": "Total gains (losses) on financial liabilities at fair value through profit or loss" } } }, "localname": "GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of assets. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets", "terseLabel": "Investment income credited to profit or loss (Note 8)", "totalLabel": "Total gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets" } } }, "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r73", "r185", "r260", "r273" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical Areas [Axis]", "terseLabel": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r73", "r185", "r260", "r273" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical Areas [Member]", "terseLabel": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GovernmentGrants": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]" } }, "en-us": { "role": { "label": "Government Grants", "terseLabel": "Government grants" } } }, "localname": "GovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeSummaryOfOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GovernmentMember": { "auth_ref": [ "r261" ], "lang": { "en": { "role": { "documentation": "This member stands for a government, government agencies and similar bodies whether local, national or international." } }, "en-us": { "role": { "label": "Government [member]", "terseLabel": "China Government" } } }, "localname": "GovernmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r63", "r115", "r122", "r125", "r217", "r229", "r231", "r232", "r280", "r282" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Gross Carrying Amount [Member]", "terseLabel": "Cost" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "auth_ref": [ "r180" ], "lang": { "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } }, "en-us": { "role": { "label": "Historical Volatility For Shares Measurement Input [Member]", "terseLabel": "Expected Volatility", "verboseLabel": "Volatility" } } }, "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r44", "r54", "r55", "r56", "r98", "r168", "r251" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Income Tax Expense Continuing Operations", "negatedLabel": "Income tax expense", "negatedTerseLabel": "Tax income (expense)", "terseLabel": "Income tax expense", "totalLabel": "Income tax expense", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r144" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes", "netLabel": "Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxEntitysOwnEquityInstruments": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of the entity's own equity instruments, recognised in profit or loss before tax, due to a reasonably possible decrease in an unobservable input. [Refer: Tax income (expense)]" } }, "en-us": { "role": { "label": "Loss before income tax lower due to change in unobservable input" } } }, "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxEntitysOwnEquityInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxEntitysOwnEquityInstruments": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of the entity's own equity instruments, recognised in profit or loss before tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]" } }, "en-us": { "role": { "label": "Loss before income tax higher due to change in unobservable input" } } }, "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxEntitysOwnEquityInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Increase Decrease In Number Of Ordinary Shares Issued", "terseLabel": "Issuance of shares to Co-founders, shares", "verboseLabel": "Issuance of Ordinary Shares, shares" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseThroughAmountsRecognisedInProfitOrLossAggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised": { "auth_ref": [ "r223", "r245" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the aggregate difference between the fair value at initial recognition and the transaction price of financial instruments yet to be recognised in profit or loss resulting from amounts recognised in profit or loss. [Refer: Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Increase Decrease Through Amounts Recognised In Profit Or Loss Aggregate Difference Between Fair Value At Initial Recognition And Amount Determined Using Valuation Technique Yet To Be Recognised", "terseLabel": "Change in fair value recognized in profit or loss" } } }, "localname": "IncreaseDecreaseThroughAmountsRecognisedInProfitOrLossAggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r140" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through changes in fair values, liabilities arising from financing activities", "terseLabel": "Changes in fair value" } } }, "localname": "IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "auth_ref": [ "r7" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 2.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } }, "en-us": { "role": { "label": "Increase (decrease) through conversion of convertible instruments, equity", "terseLabel": "Conversion from preferred shares", "verboseLabel": "Conversion from preferred shares to ordinary shares" } } }, "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r139" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities", "terseLabel": "Differences of foreign currency translation" } } }, "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "auth_ref": [ "r7" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 4.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } }, "en-us": { "role": { "label": "Increase Decrease Through Exercise Of Options", "terseLabel": "Exercise of stock options" } } }, "localname": "IncreaseDecreaseThroughExerciseOfOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r138" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities", "terseLabel": "Cash flows" } } }, "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNewTransactionsAggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised": { "auth_ref": [ "r223", "r245" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the aggregate difference between the fair value at initial recognition and the transaction price of financial instruments yet to be recognised in profit or loss resulting from new transactions. [Refer: Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Increase Decrease Through New Transactions Aggregate Difference Between Fair Value At Initial Recognition And Amount Determined Using Valuation Technique Yet To Be Recognised", "terseLabel": "Issuance of Series C Preferred Shares" } } }, "localname": "IncreaseDecreaseThroughNewTransactionsAggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r6" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 1.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase Decrease Through Sharebased Payment Transactions", "terseLabel": "Share-based compensations", "verboseLabel": "Share based compensation" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]" } }, "en-us": { "role": { "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment", "terseLabel": "Transfers" } } }, "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r141", "r146" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase through new leases, liabilities arising from financing activities", "terseLabel": "New leases" } } }, "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwill": { "auth_ref": [ "r22" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets and goodwill", "periodEndLabel": "Intangible assets and goodwill at end of period", "periodStartLabel": "Intangible assets and goodwill at beginning of period", "terseLabel": "Intangible assets", "totalLabel": "Total intangible assets and goodwill" } } }, "localname": "IntangibleAssetsAndGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r112", "r117", "r194" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible Assets Other Than Goodwill [Member]", "terseLabel": "Intangible assets other than goodwill [member]" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestExpense": { "auth_ref": [ "r167", "r249", "r257" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from interest." } }, "en-us": { "role": { "label": "Interest expense", "totalLabel": "Total interest expense amount recognized" } } }, "localname": "InterestExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r188" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails": { "order": 0.0, "parentTag": "ifrs-full_InterestExpense", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest expense on lease liabilities", "negatedLabel": "Interest for lease liabilities", "terseLabel": "Interest expense", "verboseLabel": "Interest for lease liabilities" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestIncomeOnDeposits": { "auth_ref": [ "r10" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails": { "order": 0.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of interest income on deposits. [Refer: Interest income]" } }, "en-us": { "role": { "label": "Interest income on deposits", "terseLabel": "Interest from bank deposits and term deposits" } } }, "localname": "InterestIncomeOnDeposits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinanceIncomecostNetSummaryOfFinanceIncomecostNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "auth_ref": [ "r18", "r169", "r253" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } }, "en-us": { "role": { "label": "Investments accounted for using equity method", "terseLabel": "Equity investment", "totalLabel": "Total investments accounted for using equity method" } } }, "localname": "InvestmentAccountedForUsingEquityMethod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentIncome": { "auth_ref": [ "r46", "r95" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of investment income, such as interest and dividends." } }, "en-us": { "role": { "label": "Investment income", "terseLabel": "Investment income from wealth management products" } } }, "localname": "InvestmentIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r30" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 0.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued Capital", "terseLabel": "Share capital", "totalLabel": "Total issued capital" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued Capital [Member]", "terseLabel": "Share Capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_IssuedCapitalOrdinaryShares": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Issued Capital Ordinary Shares", "terseLabel": "Value of share capital" } } }, "localname": "IssuedCapitalOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation", "totalLabel": "Key management personnel compensation" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": { "auth_ref": [ "r87" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": 4.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, other long-term employee benefits", "terseLabel": "Welfare, housing funds and other" } } }, "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r86" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": 2.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation Postemployment Benefits", "terseLabel": "Contributions to defined benefit plan" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r88" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": 1.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation Sharebased Payment", "terseLabel": "Share-based compensation expenses" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r85" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": 0.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation Shortterm Employee Benefits", "terseLabel": "Wages, salaries and bonuses" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LaterThanFiveYearsMember": { "auth_ref": [ "r196", "r197", "r241", "r243", "r246", "r272" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than five years." } }, "en-us": { "role": { "label": "Later than five years [member]", "terseLabel": "More than 5 Years" } } }, "localname": "LaterThanFiveYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "auth_ref": [ "r10", "r196", "r197", "r241", "r246", "r272" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } }, "en-us": { "role": { "label": "Later than one year and not later than two years [member]", "terseLabel": "Between 1 and 2 Years" } } }, "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than five years." } }, "en-us": { "role": { "label": "Later than two years and not later than five years [member]", "terseLabel": "Between 2 and 5 Years" } } }, "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r186" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease Liabilities", "terseLabel": "Lease liabilities", "totalLabel": "Total lease liabilities", "verboseLabel": "Aggregate lease obligation over lease term" } } }, "localname": "LeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease liabilities [abstract]" } } }, "localname": "LeaseLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_LeaseLiabilitiesMember": { "auth_ref": [ "r142", "r147" ], "lang": { "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease Liabilities [Member]", "terseLabel": "Lease Liabilities" } } }, "localname": "LeaseLiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseholdImprovementsMember": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } }, "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level1OfFairValueHierarchyMember": { "auth_ref": [ "r75", "r172" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } }, "en-us": { "role": { "label": "Level1 Of Fair Value Hierarchy [Member]", "terseLabel": "Level 1" } } }, "localname": "Level1OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level2OfFairValueHierarchyMember": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } }, "en-us": { "role": { "label": "Level2 Of Fair Value Hierarchy [Member]", "terseLabel": "Level 2" } } }, "localname": "Level2OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level3OfFairValueHierarchyMember": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } }, "en-us": { "role": { "label": "Level3 Of Fair Value Hierarchy [Member]", "terseLabel": "Level 3" } } }, "localname": "Level3OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r75", "r172" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels Of Fair Value Hierarchy [Axis]", "terseLabel": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r22", "r171", "r172", "r176", "r252", "r256" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails2": { "order": 0.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities 1", "negatedLabel": "Liabilities", "periodEndLabel": "At December 31, 2021", "periodStartLabel": "At January 1, 2021", "terseLabel": "Net liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract] 1", "terseLabel": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r143" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } }, "en-us": { "role": { "label": "Liabilities arising from financing activities", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "LiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "auth_ref": [ "r143" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Liabilities Arising From Financing Activities [Axis]", "terseLabel": "Liabilities arising from financing activities [axis]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": { "auth_ref": [ "r143" ], "lang": { "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Liabilities Arising From Financing Activities [Member]", "terseLabel": "Liabilities arising from financing activities [member]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureCashFlowInformationSummaryOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LiabilitiesMember": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } }, "en-us": { "role": { "label": "Liabilities [Member]", "terseLabel": "Liabilities [member]" } } }, "localname": "LiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LineItemsByFunctionMember": { "auth_ref": [ "r3", "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } }, "en-us": { "role": { "label": "Line Items By Function [Member]", "terseLabel": "Line items by function [member]" } } }, "localname": "LineItemsByFunctionMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Components Of Tax Expense Income [Abstract]" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MajorCustomersAxis": { "auth_ref": [ "r261" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Major customers [axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MajorCustomersMember": { "auth_ref": [ "r261" ], "lang": { "en": { "role": { "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used." } }, "en-us": { "role": { "label": "Customers [member]" } } }, "localname": "MajorCustomersMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "auth_ref": [ "r52" ], "lang": { "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Major ordinary share transactions [member]", "terseLabel": "Ordinary Share Options" } } }, "localname": "MajorOrdinaryShareTransactionsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r25", "r76", "r184", "r196", "r197", "r221", "r234", "r241", "r263", "r264", "r266", "r272" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [Axis]", "terseLabel": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r120", "r124", "r171" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [Axis]", "terseLabel": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MiscellaneousNoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Miscellaneous Noncurrent Assets [Abstract]" } } }, "localname": "MiscellaneousNoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_NetAssetsLiabilities": { "auth_ref": [ "r10", "r154" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } }, "en-us": { "role": { "label": "Net Assets Liabilities", "netLabel": "Net assets (liabilities)", "totalLabel": "Net (liabilities)/assets", "verboseLabel": "Net assets" } } }, "localname": "NetAssetsLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r51" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r51" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r26", "r159", "r161" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 0.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Noncurrent Assets 1", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent Assets [Abstract]", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r186" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails": { "order": 0.0, "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Noncurrent Lease Liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "Non-current" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r27", "r159", "r163" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 0.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Noncurrent Liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent Liabilities [Abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentPrepayments": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current prepayments. [Refer: Prepayments]" } }, "en-us": { "role": { "label": "Noncurrent Prepayments", "terseLabel": "Prepayments" } } }, "localname": "NoncurrentPrepayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentValueAddedTaxReceivables": { "auth_ref": [ "r29" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current value added tax receivables. [Refer: Value added tax receivables]" } }, "en-us": { "role": { "label": "Noncurrent Value Added Tax Receivables", "terseLabel": "Deductible value-added tax" } } }, "localname": "NoncurrentValueAddedTaxReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r24", "r196", "r197", "r241", "r246", "r272" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Not later than one year [member]", "terseLabel": "Less than 1 Year" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r202", "r206", "r210" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Outstanding Share Options", "periodEndLabel": "Number of Options, Options outstanding, Ending Balance", "periodStartLabel": "Number of Options, Options outstanding, Beginning Balance" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r207" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Exercisable In Sharebased Payment Arrangement", "terseLabel": "Number of Options, Options exercisable at December 31, 2021" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "auth_ref": [ "r205" ], "lang": { "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "negatedLabel": "Number of Options, Exercised during the year", "terseLabel": "Number of Options, Exercised during the year" } } }, "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r204" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Forfeited In Sharebased Payment Arrangement", "negatedLabel": "Number of Options, Forfeited during the year", "terseLabel": "Forfeited during the year" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r203" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Granted In Sharebased Payment Arrangement", "terseLabel": "Number of Options, Granted during the year", "verboseLabel": "Share options granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number Of Shares Authorised", "terseLabel": "Authorized shares", "verboseLabel": "Authorized share capital" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of preferred shares", "terseLabel": "Number of shares issued", "totalLabel": "Total number of shares issued", "verboseLabel": "NUMBER OF PREFERRED SHARES" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number Of Shares Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "terseLabel": "Ordinary shares", "verboseLabel": "Number of shares outstanding" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r36", "r107" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary Shares [Member]", "terseLabel": "Ordinary Shares" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income [Abstract]", "terseLabel": "Other comprehensive loss", "verboseLabel": "Comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r28", "r47" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other Comprehensive Income Net Of Tax Exchange Differences On Translation", "terseLabel": "Exchange differences on translation of foreign operations", "totalLabel": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations": { "auth_ref": [ "r47" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to exchange differences on translation of the financial statements of a parent company or a stand-alone entity to a different presentation currency. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other Comprehensive Income Net Of Tax Exchange Differences On Translation Other Than Translation Of Foreign Operations", "terseLabel": "Exchange differences on translation of foreign operations" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "auth_ref": [ "r45", "r50" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax", "totalLabel": "Other comprehensive (loss)/income for the year, net of tax" } } }, "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentAssets": { "auth_ref": [ "r22" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Other Current Assets", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r29" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other Current Receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherExpenseByNature": { "auth_ref": [ "r1", "r49" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 9.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Other Expense By Nature", "negatedTerseLabel": "Other expenses", "terseLabel": "Others" } } }, "localname": "OtherExpenseByNature", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherGainsLosses": { "auth_ref": [ "r1", "r2" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Gains Losses", "terseLabel": "Other gains/(losses)-net", "totalLabel": "Other gains/(losses) - net" } } }, "localname": "OtherGainsLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherGainslossesNetScheduleOfOtherGainsLossesNetDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherIncome": { "auth_ref": [ "r1", "r2", "r96" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentAssets": { "auth_ref": [ "r22" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } }, "en-us": { "role": { "label": "Other Noncurrent Assets", "terseLabel": "Other non-current assets", "totalLabel": "Other non-current assets" } } }, "localname": "OtherNoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherPayables": { "auth_ref": [ "r22" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": 4.0, "parentTag": "cntb_OtherPayablesAndAccruals", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Payables", "terseLabel": "Other payables" } } }, "localname": "OtherPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReceivables": { "auth_ref": [ "r29" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": 3.0, "parentTag": "cntb_OtherReceivablesAndPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Receivables", "terseLabel": "Others" } } }, "localname": "OtherReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReserves": { "auth_ref": [ "r30" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 4.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other Reserves", "terseLabel": "Other reserves" } } }, "localname": "OtherReserves", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReservesMember": { "auth_ref": [ "r8", "r37" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other Reserves [Member]", "terseLabel": "Other Reserves" } } }, "localname": "OtherReservesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par Value Per Share", "terseLabel": "Par value per share", "verboseLabel": "Par value" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ParentMember": { "auth_ref": [ "r91" ], "lang": { "en": { "role": { "documentation": "This member stands for an entity that controls one or more entities." } }, "en-us": { "role": { "label": "Parent [Member]", "terseLabel": "Parent" } } }, "localname": "ParentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfCashFlowsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PaymentsForShareIssueCosts": { "auth_ref": [ "r131" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for share issue costs." } }, "en-us": { "role": { "label": "Payments for share issue costs", "negatedLabel": "Issuance cost of financial instruments with preferred rights" } } }, "localname": "PaymentsForShareIssueCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r130" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments Of Lease Liabilities Classified As Financing Activities", "negatedLabel": "Payment for lease liabilities", "negatedTerseLabel": "Payments of lease liabilities" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": { "auth_ref": [ "r129" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to acquire or redeem entity's shares." } }, "en-us": { "role": { "label": "Payments to acquire or redeem entity's shares", "negatedLabel": "Payment for repurchase of ordinary shares" } } }, "localname": "PaymentsToAcquireOrRedeemEntitysShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputEntitysOwnEquityInstruments": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of the entity's own equity instruments." } }, "en-us": { "role": { "label": "Percentage of reasonably possible decrease in unobservable input" } } }, "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputEntitysOwnEquityInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputEntitysOwnEquityInstruments": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of the entity's own equity instruments." } }, "en-us": { "role": { "label": "Percentage of reasonably possible increase in unobservable input" } } }, "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputEntitysOwnEquityInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "auth_ref": [ "r216" ], "lang": { "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Percentage of voting equity interests acquired" } } }, "localname": "PercentageOfVotingEquityInterestsAcquired", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "auth_ref": [ "r72", "r77" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]" } }, "en-us": { "role": { "label": "Post-employment benefit expense in profit or loss, defined benefit plans", "terseLabel": "Contributions to defined benefit plan (Note 27(d))", "totalLabel": "Total post-employment benefit expense in profit or loss, defined benefit plans" } } }, "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PreferenceSharesMember": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Preference shares [member]", "terseLabel": "Preference Shares" } } }, "localname": "PreferenceSharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Prepayments": { "auth_ref": [ "r29" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": 0.0, "parentTag": "cntb_OtherReceivablesAndPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered." } }, "en-us": { "role": { "label": "Prepayments", "terseLabel": "Prepayment for clinical trials related services", "verboseLabel": "Prepayments" } } }, "localname": "Prepayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfBalancesWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Presentation of leases for lessee [abstract]" } } }, "localname": "PresentationOfLeasesForLesseeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary": { "auth_ref": [ "r99", "r102", "r155", "r156" ], "lang": { "en": { "role": { "documentation": "The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Principal place of business of subsidiary", "terseLabel": "Place of incorporation" } } }, "localname": "PrincipalPlaceOfBusinessOfSubsidiary", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets": { "auth_ref": [ "r278" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the disposal or maturity of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } }, "en-us": { "role": { "label": "Proceeds from disposal or maturity of available-for-sale financial assets", "terseLabel": "Proceeds from disposal of financial assets at fair value through profit or loss" } } }, "localname": "ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfOptions": { "auth_ref": [ "r131" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of options." } }, "en-us": { "role": { "label": "Proceeds From Exercise Of Options", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromExerciseOfOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r131" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "terseLabel": "Proceeds from issuance of ordinary shares" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r128" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds From Issuing Shares", "terseLabel": "Cash consideration", "verboseLabel": "Proceeds from issuance of ordinary shares" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfessionalFeesExpense": { "auth_ref": [ "r10" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 1.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } }, "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Consultancy fee" } } }, "localname": "ProfessionalFeesExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r5", "r39", "r132", "r151", "r153", "r159", "r252", "r254", "r265", "r277" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossAttributableToOwnersOfParent", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit Loss", "negatedLabel": "Net operating loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Loss for the year" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit Loss [Abstract]" } } }, "localname": "ProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit Loss Attributable To [Abstract]", "terseLabel": "Loss attributable to:" } } }, "localname": "ProfitLossAttributableToAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r41" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit Loss Attributable To Owners Of Parent", "terseLabel": "Net loss attributable to owners of the Company (RMB'000)", "totalLabel": "Owners of the Company" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetBasicLossPerShareDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r1", "r2", "r218", "r252", "r254" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails": { "order": 0.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 0.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit Loss Before Tax", "terseLabel": "Loss before income tax", "totalLabel": "Loss before income tax", "verboseLabel": "Loss before income tax" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r46", "r106" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit Loss From Operating Activities", "negatedLabel": "Net operating loss", "totalLabel": "Operating loss" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedStatementsOfLossDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r17", "r67" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property Plant And Equipment", "periodEndLabel": "Property, plant and equipment at end of period", "periodStartLabel": "Property, plant and equipment at beginning of period", "terseLabel": "Property, plant and equipment", "totalLabel": "Total property, plant and equipment", "verboseLabel": "Net book value" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r68", "r112", "r194" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property Plant And Equipment [Member]", "terseLabel": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfCapitalCommitmentsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "auth_ref": [ "r100", "r103", "r157" ], "lang": { "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Attributable equity interest to the Group" } } }, "localname": "ProportionOfOwnershipInterestInSubsidiary", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PurchaseOfAvailableforsaleFinancialAssets": { "auth_ref": [ "r278" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } }, "en-us": { "role": { "label": "Purchase of available-for-sale financial assets", "negatedLabel": "Purchase of financial assets at fair value through profit or loss" } } }, "localname": "PurchaseOfAvailableforsaleFinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r127" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase Of Intangible Assets Classified As Investing Activities", "negatedLabel": "Purchase of intangible assets", "negatedTerseLabel": "Purchase of intangible assets" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r127" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase Of Property Plant And Equipment Classified As Investing Activities", "negatedLabel": "Purchase of property, plant and equipment", "negatedTerseLabel": "Purchase of property, plant and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchasesFairValueMeasurementAssets": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase in the fair value measurement of assets resulting from purchases of those assets. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Purchases, fair value measurement, assets", "terseLabel": "Additions" } } }, "localname": "PurchasesFairValueMeasurementAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Purchases of goods, related party transactions", "terseLabel": "Purchase of clinical trials related services" } } }, "localname": "PurchasesOfGoodsRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfSignificantTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r181", "r182", "r183", "r210", "r237", "r266" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r181", "r182", "r183", "r210", "r237", "r266" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RawMaterialsAndConsumablesUsed": { "auth_ref": [ "r1", "r49" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 7.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]" } }, "en-us": { "role": { "label": "Raw materials and consumables used", "negatedLabel": "Raw materials and consumables used", "terseLabel": "R&D materials and consumable supplies" } } }, "localname": "RawMaterialsAndConsumablesUsed", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RecurringFairValueMeasurementMember": { "auth_ref": [ "r171" ], "lang": { "en": { "role": { "documentation": "This member stands for fair value measurements which other IFRSs require or permit in the statement of financial position at the end of each reporting period. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Recurring Fair Value Measurement [Member]", "terseLabel": "Recurring" } } }, "localname": "RecurringFairValueMeasurementMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r119" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research And Development Expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } }, "en-us": { "role": { "label": "Reserve Of Sharebased Payments [Member]", "terseLabel": "Share-Based Compensation Reserves" } } }, "localname": "ReserveOfSharebasedPaymentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r30", "r50" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 5.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained Earnings", "terseLabel": "Accumulated losses", "totalLabel": "Total retained earnings" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromGovernmentGrants": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]" } }, "en-us": { "role": { "label": "Government grants received" } } }, "localname": "RevenueFromGovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureOtherIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r193" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Rightofuse Assets", "periodEndLabel": "Net book amount, Ending balance", "periodStartLabel": "Net book amount. Beginning balance", "terseLabel": "Right-of-use assets", "totalLabel": "Net Book value", "verboseLabel": "Land of use rights" } } }, "localname": "RightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssetsRevaluedAssetsAtCost": { "auth_ref": [ "r195" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails": { "order": 0.0, "parentTag": "ifrs-full_RightofuseAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of right-of-use assets that would have been recognised had the revalued assets been carried under the cost model. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Right-of-use assets, revalued assets, at cost", "terseLabel": "Cost", "verboseLabel": "Aggregate amount paid" } } }, "localname": "RightofuseAssetsRevaluedAssetsAtCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SaleOrIssueOfTreasuryShares": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Sale or issue of treasury shares", "terseLabel": "Issuance of treasury shares" } } }, "localname": "SaleOrIssueOfTreasuryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SettlementsFairValueMeasurementAssets": { "auth_ref": [ "r175" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in the fair value measurement of assets resulting from settlements. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Settlements Fair Value Measurement Assets", "negatedLabel": "Settlements" } } }, "localname": "SettlementsFairValueMeasurementAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfChangesInLevel3InstrumentsOfShortTermInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareIssueRelatedCost": { "auth_ref": [ "r7" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } }, "en-us": { "role": { "label": "Share issue related cost", "terseLabel": "Issuance costs" } } }, "localname": "ShareIssueRelatedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r30" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 2.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share Premium", "terseLabel": "Share premium" } } }, "localname": "SharePremium", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share Premium [Member]", "terseLabel": "Share Premium" } } }, "localname": "SharePremiumMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r211" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Sharebased Payment Arrangements [Member]", "terseLabel": "Share-based payment arrangements [member]" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares." } }, "en-us": { "role": { "label": "Shares Reserved For Issue Under Options And Contracts For Sale Of Shares", "terseLabel": "Number of shares potentially issuable", "verboseLabel": "Shares reserved for future issuance" } } }, "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "auth_ref": [ "r101", "r104", "r170" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Subsidiaries [axis]" } } }, "localname": "SignificantInvestmentsInSubsidiariesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationSummaryOfDirectOrIndirectInterestsInPrincipalSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_SignificantUnobservableInputLiabilities": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } }, "en-us": { "role": { "label": "Significant Unobservable Input Liabilities", "terseLabel": "Significant unobservable input, financial instruments with preferred rights" } } }, "localname": "SignificantUnobservableInputLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Changes In Equity [Abstract]" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement Of Changes In Equity [Line Items]", "terseLabel": "Statement Of Changes In Equity [Line Items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement Of Changes In Equity [Table]", "terseLabel": "Statement Of Changes In Equity [Table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatutoryReserve": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves created based on legal requirements." } }, "en-us": { "role": { "label": "Statutory Reserve", "terseLabel": "Statutory reserve" } } }, "localname": "StatutoryReserve", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureReservesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "auth_ref": [ "r55" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails2": { "order": 1.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax Effect Of Expense Not Deductible In Determining Taxable Profit Tax Loss", "terseLabel": "Expenses not deductible for income tax purpose" } } }, "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfForeignTaxRates": { "auth_ref": [ "r55" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails2": { "order": 4.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax Effect Of Foreign Tax Rates", "terseLabel": "Effect of income tax in jurisdictions other than the PRC" } } }, "localname": "TaxEffectOfForeignTaxRates", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "auth_ref": [ "r55" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails2": { "order": 0.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax Expense Income At Applicable Tax Rate", "negatedLabel": "Tax calculated at statutory tax rate of 25%", "terseLabel": "Tax expenses (income)", "verboseLabel": "Tax expense at PRC enterprise income tax rate of 25%" } } }, "localname": "TaxExpenseIncomeAtApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenActualTaxChargeAndAmountCalculatedBasedOnStatutoryIncomeTaxRateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r181", "r182", "r183", "r210", "r237", "r266" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top Of Range [Member]", "terseLabel": "Top of range" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialAssetsAtFairValueThroughProfitOrLossAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade And Other Payables [Abstract]" } } }, "localname": "TradeAndOtherPayablesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "auth_ref": [ "r31" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 0.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } }, "en-us": { "role": { "label": "Trade And Other Payables To Trade Suppliers", "terseLabel": "Trade payables", "verboseLabel": "Trade Payables" } } }, "localname": "TradeAndOtherPayablesToTradeSuppliers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasuryShares": { "auth_ref": [ "r30", "r105" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails": { "order": 3.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": -1.0 }, "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury Shares", "negatedLabel": "Treasury shares", "terseLabel": "Treasury shares" } } }, "localname": "TreasuryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformationCondensedBalanceSheetsDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasurySharesMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury Shares [Member]", "terseLabel": "Treasury Shares" } } }, "localname": "TreasurySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r220", "r226", "r227", "r267", "r268", "r269", "r271" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types Of Risks [Axis]", "terseLabel": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfExposureToForeignCurrencyRiskDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r220", "r226", "r227", "r267", "r268", "r269", "r271" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Types Of Risks [Member]", "terseLabel": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfExposureToForeignCurrencyRiskDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskManagementSummaryOfFinancialLiabilitiesIntoMaturityGroupingsBasedOnRemainingPeriodToContractualMaturityDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r211" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types Of Sharebased Payment Arrangements [Axis]", "terseLabel": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsAxis": { "auth_ref": [ "r173", "r178" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Unobservable Inputs [Axis]", "terseLabel": "Unobservable inputs [axis]" } } }, "localname": "UnobservableInputsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsMember": { "auth_ref": [ "r173", "r178" ], "lang": { "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } }, "en-us": { "role": { "label": "Unobservable Inputs [Member]", "terseLabel": "Unobservable inputs [member]" } } }, "localname": "UnobservableInputsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]" } }, "en-us": { "role": { "label": "Research and development tax credits" } } }, "localname": "UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill", "terseLabel": "Intangible assets estimated useful lives" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "auth_ref": [ "r62" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Useful Life Measured As Period Of Time Property Plant And Equipment", "terseLabel": "Useful life" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r78" ], "calculation": { "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": 0.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages and salaries", "terseLabel": "Wages, salaries and bonuses" } } }, "localname": "WagesAndSalaries", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "auth_ref": [ "r207" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Exercisable In Sharebased Payment Arrangement2019", "terseLabel": "Options exercisable at December 31, 2021" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r205" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Weighted Average Exercise Price per Share Option, Exercised during the year" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r204" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Forfeited In Sharebased Payment Arrangement2019", "terseLabel": "Weighted Average Exercise Price per Share Option, Forfeited during the year" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r203" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Granted In Sharebased Payment Arrangement2019", "terseLabel": "Weighted Average Exercise Price per Share Option, Granted during the year", "verboseLabel": "weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": { "auth_ref": [ "r209" ], "lang": { "en": { "role": { "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options In Sharebased Payment Arrangement Exercised During Period At Date Of Exercise2019", "terseLabel": "Weighted average exercise price during the year" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r202", "r206" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Outstanding In Sharebased Payment Arrangement2019", "periodEndLabel": "Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period", "periodStartLabel": "Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period", "terseLabel": "Options outstanding at December 31, 2021" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "auth_ref": [ "r213" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Fair Value At Measurement Date Share Options Granted", "terseLabel": "Weighted average fair value of options granted during the year" } } }, "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r210" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life Of Outstanding Share Options2019", "terseLabel": "Weighted average remaining contractual life of options outstanding" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "auth_ref": [ "r212" ], "lang": { "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Share Price Share Options Granted2019", "terseLabel": "Grant date share price", "verboseLabel": "Fair value of share based payment on grant date" } } }, "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r109" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted Average Shares", "terseLabel": "Weighted average number of ordinary shares outstanding (in thousands)" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetBasicLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "San Diego, California", "terseLabel": "State Income Tax in California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.connectbiopharm.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2021-03-24" }, "r102": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r103": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r104": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r106": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r107": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r108": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24" }, "r111": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r113": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2021-03-24" }, "r116": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard", "URIDate": "2021-03-24" }, "r118": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2021-03-24" }, "r119": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2021-03-24" }, "r121": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76&doctype=Standard", "URIDate": "2021-03-24" }, "r122": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2021-03-24" }, "r123": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2021-03-24" }, "r124": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r125": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2021-03-24" }, "r126": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r127": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24" }, "r128": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r129": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "138", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r131": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r132": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r133": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24" }, "r134": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r135": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r136": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r137": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r138": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r139": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "138", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_138_b&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B_d&doctype=Standard", "URIDate": "2021-03-24" }, "r141": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B&doctype=Standard", "URIDate": "2021-03-24" }, "r142": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2021-03-24" }, "r143": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44D", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2021-03-24" }, "r144": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r145": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r146": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24" }, "r147": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2021-03-24" }, "r148": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "Presentation of a statement of cash flows", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI", "URIDate": "2021-03-24" }, "r149": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r151": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r152": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r153": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r154": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "IG63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r155": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_b&doctype=Standard", "URIDate": "2021-03-24" }, "r156": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_b&doctype=Standard", "URIDate": "2021-03-24" }, "r157": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2021-03-24" }, "r158": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "2", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r159": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "51", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_51&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r161": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r162": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r163": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r164": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r165": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r166": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r167": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r168": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r169": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24" }, "r170": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r171": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r172": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r173": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2021-03-24" }, "r174": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r175": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r176": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r177": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r178": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2021-03-24" }, "r179": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_e&doctype=Standard", "URIDate": "2021-03-24" }, "r180": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B36", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r181": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r182": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r183": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r184": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r185": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r186": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r187": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2021-03-24" }, "r188": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2021-03-24" }, "r189": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2021-03-24" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r190": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_d&doctype=Standard", "URIDate": "2021-03-24" }, "r191": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2021-03-24" }, "r192": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2021-03-24" }, "r193": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2021-03-24" }, "r194": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r195": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "57", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_57&doctype=Standard", "URIDate": "2021-03-24" }, "r196": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24" }, "r197": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard", "URIDate": "2021-03-24" }, "r198": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2021-03-24" }, "r199": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2021-03-24" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "o", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2021-03-24" }, "r200": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard", "URIDate": "2021-03-24" }, "r201": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2021-03-24" }, "r202": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r203": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r204": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r205": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r206": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r207": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r208": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2021-03-24" }, "r209": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "r", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2021-03-24" }, "r210": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24" }, "r211": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r212": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r213": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2021-03-24" }, "r214": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r215": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2021-03-24" }, "r216": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r217": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r218": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r219": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r220": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2021-03-24" }, "r221": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r222": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r223": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r224": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r225": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r226": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r227": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r228": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24" }, "r229": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "56", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_56&doctype=Standard", "URIDate": "2021-03-24" }, "r230": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24" }, "r231": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24" }, "r232": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2021-03-24" }, "r233": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard", "URIDate": "2021-03-24" }, "r234": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2021-03-24" }, "r235": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2021-03-24" }, "r236": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard", "URIDate": "2021-03-24" }, "r237": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r238": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2021-03-24" }, "r239": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2021-03-24" }, "r240": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8&doctype=Standard", "URIDate": "2021-03-24" }, "r241": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r242": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B2", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r243": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r244": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r245": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG14", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG14&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r246": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r247": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2021-03-24" }, "r248": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2021-03-24" }, "r249": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard", "URIDate": "2021-03-24" }, "r250": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2021-03-24" }, "r251": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24" }, "r252": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r253": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r254": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r255": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r256": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2021-03-24" }, "r257": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2021-03-24" }, "r258": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r259": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r260": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r261": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r262": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2021-03-24" }, "r263": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard", "URIDate": "2021-03-24" }, "r264": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2021-03-24" }, "r265": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r266": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r267": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard", "URIDate": "2021-03-24" }, "r268": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard", "URIDate": "2021-03-24" }, "r269": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r270": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r271": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2021-03-24" }, "r272": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2021-03-24" }, "r273": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2021-03-24" }, "r274": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2021-03-24" }, "r275": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2021-03-24" }, "r276": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2021-03-24" }, "r277": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r278": { "IssueDate": "2021-01-01", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r279": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "12A", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_12A_f&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r280": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r281": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r282": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r283": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r284": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r285": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r286": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r287": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r288": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r289": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r290": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r291": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r292": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r293": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r3": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r32": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_c&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r51": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r55": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2021-03-24" }, "r6": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_b&doctype=Standard", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2021-03-24" }, "r64": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "135", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "5", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_5&doctype=Standard", "URIDate": "2021-03-24" }, "r78": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard", "URIDate": "2021-03-24" }, "r79": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2021-03-24" }, "r81": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2021-03-24" }, "r82": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "20", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS20_g39-39_TI", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2021-03-24" }, "r84": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2021-03-24" }, "r85": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r87": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19_a&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r93": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "21", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_a&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24" }, "r95": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r97": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r98": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r99": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_ii&doctype=Standard", "URIDate": "2021-03-24" } }, "version": "2.1" } ZIP 180 0000950170-22-005219-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-005219-xbrl.zip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�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�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

J_9%@OQY,MYJ8 &J<^'U/ZI*W;FKL%?4Q:@;O@S MX^%S/,^2KYVJO]=,GKLQTV!(]>C7/_!27'CQS]/*AV ,;(:$39>%5@\.&H#4 MI+*O 8@92/;\-E#WE)MM"S?B )"@>4?(V'[OML^'_()1?9?_"3N<-8W7;;'0 MB9D&&ZH/O8P->>(H?L.!1/R2U&D L].35%W,VR:T8!BF&@"I/N^= &1B"@8< M@>:,V/#?+6_C[KNA#L4U(%&=TREO87^S_M@3 NZ@&=AC#]NW*JBQNNHA3KD: M<^]G!E$>*NRR >G!00. F@"V:_#)@2>-_8K8?$;ADXM=[3#%N#!FBJFW5 H)GMSK, K_JS)M/> M(#PUX%)=M.W 54MEDN[M]4GI4@Q-!84V/F S:%E<(&:9WU[!3(+IY=,BPFW2-9OQL+5JP-@V2W?U6]G% MX8[+)@4I8K;ZAZV5R">53MQ)!K#/ -A!7@;IRE<#NK;YL^M 9[P0+X>GF^ Q M#<9O66( L/6O5(/$M@'9=4C,!*N/S:XN:K#Z#%B%W5WV](.TR_L"\N/5$09.PF&#UUZ MP5=IBLS?Q8!O:*DK?[8AC']K1'5?7AH8JF!FX[UZ5!H'K2T0*!I;1W M>(E4>@ ND % !B_QUZBKW@2T5N;1=LYL_W0=OAZ4@K&S-^; MEPEP]R45+L]+^Z^F&4VGZCE#PL;B0EAR)>4(T%R4(AG?I\ELS#2T?_PEB4\& M!YR>KP9AZN%!:X2E=1M$/2.BI ,Z5(N82%6YVYX'O8A!,ZO4IF+M/)/Q^*]4 KS**/I&(IYI.[HOS5!E< M*BL1RT*YK$RP@G]<=AL8K(X4J]G'0K:\?8.UN58-6E6W^]!HS2E*6?L,7D># MU\:G9E^B8@UJ52?__E!K7IL]%.2F3O^7@:]2NP;#ZC'!(8BJ+%Z7%:V(E=5FB>K^WZXM MOS]^"MWW]F9#06?\*?G!]P,A/?\-?R*><".@$1T_>OCE?&7[2WQ-/0D_\)?9 MH"(?+#Y UX;=YI'EVVORX:AKJ0A$_7#T], \^AX'"7]Y!1T:%3BRPAC(:!2C MG)]8$&]20@HD1Y;X]X8;>,[9N+&(DP!AJ.=A^/B'HXC%P,I.*DS^/FY0FU%^ M!V;J.)@<%P3Z"$( 6G@8_#]C5[A;5,4[EQN=ZM+]@$7%.7-9X];DHU;T4GZ% M-;FTTJ1I,_VH5?U$?.B3\HA[1P*VM'WZN["8CT_DT1 ?&LK'MZ;&V)7CZ)I+ M>A"^!@M-%&-6YSI]Q+Q!H0J:<:I4<3&I4JU&NG&J5I_AMDK!%M2C4[/%1J79 MAUEJB.'XC:ZIRF?DLZ\PWBI(T%&-4*U"/A]%G>JOHU.##RG$Q4RH) SYWN*> ML$?JD$M"4FTT1+)2Z\"'S0C;[J 6]3$51=2DU0(&09*6?1">2U"($=@?-6KK M_B<.19C.9<#D5Q\:'B;,6J%?X8%;IXW1JYO')0_]6T=$^L\67])'J]JT2D6A M0VT-$7N,?XEE!D:AUJ7-KFZ:;AQ&TTY=.Q7>(L62YT$8M;X-4]-B_5B-INFT M$./OVL)H<4&]&*;^CS;S\3+NM?2P;MHRK4B%YF[$)OBO$-7@7YY%^R9_A$=] M]"O,&9@O3([ZT^0*F?.AF>APK(IO#U$WN>X"?Z ?!0AF_M194?((?V&8>TAL MYF".X@OR2+R 3Q8W%-; $2B7-\H@O$;3=OK!!!4&7GPAF.Y\Y,90OQW.ZJ-* M_L]@5OWUFJ86:,MA-"!HTX%@:?S 90G/MGS4"_-?YH'8',"JB^^/I,;I5FPT M+=(*.H\@.W#'94,IA01HQEPP>;K=D!JD2Z'"WH3_]N+S1A<%^,F)R,>;/?XF M!.C>&+6\!FVCUD--JR::+8HZB"\PAZHMT$ Z1A"P30!\$G?UW'ZZ@S]RI:J_ M5BR%'%QZO[ RL#\*0IK[H=,_QS*):F(1;:W_?@$R*$AN8F]B&Z\#'@:(EFK3?SR2_!D(9TLJ^>! M2 )TGJT49+6:Z48S:VJQFF5E2 YT.V]'=V!P0*U4?*9)/N%N?+$I:Z3>Y0]F MT.L*FQ<"R1ZW+I& M7S:!?X5A++9W&S]XU)DMP*C2"+H[G]&,'7I<_!C$_$Y^[+L9_(N_C489;2_/ M5I#W,=1X05RQSZYSL)3]5[V+CZ:%].8&'?%@BUP0\=\K'_H[H4O_XY/#ITCY M&$]JF"Z%#KHY/L?K!\+*^RMT9.-BZCRX#*!7P(!0WS;M.8QOJZ9JDR3%JE*F MO@D:"QTT/!HT:X>.U@P.N)F2M6+]U-DZ)TQ=.PY9P^$W]!4LRT#G=$8:JG7[ MLSW\)N4H.BNG,Y\'>0!WLJ\N^B&%>V0H SR7$ =EKHH%]RVC#LG;LIYBK,>K M:4^[\N^A?NI2,$"N3]6WL6P\6ZS)07Q *FXFTP?+"ZHIWT:ZN]PI+.(/'PB1 M*CA;% /GR@V@?A_A(CB3-5FLZ52J(1N-]?3#:CI9; &14 V4FJ[Q[M+OQ!5W MEU*E6Q#*:J')[VQ/6^+Z0!AX4AIZHDRG:H<0!&;I; MM,(?+S(!-8H91@]21^3&25:PC&,N>VL'+B@IBNH3[']I-3RIK]>UOJ MT1V=IX+?DR6?0\L*Y;_+HE-8=2RA_[[PD)0)*7G8?X)NANF=\X7_K;A),64, M_6QR,'/_\N.;<0NZ)'B;1I51(*U(QXM42>K+@,&"[P8&$BE!_1JO;3;IVE1J M-,-P^Q%*J'9'DKO,Q#W;SGQ2'H&J&T1?:KQ(KUY2UGT='9YA7PT;ZO(!2OG7 MT>!1NRS([HE?H_L%=VFY4E6?QK(4Z*A8<2U?_6V,R_>BI'/"UK,%#Q:5;R(V MTHQ2JX+'.GD,/+=.S=?QC05X!31?-HL@$OYCX9)H#<7A]*1$B0QGXK@X5 9! M+=UHAD7]-%UW?UEWOWD\=FVI8^T5YG87G<>CKQ;'R8X UI'8,H+I$'CZ+?M)!(_FRG0#[/)@-;J$^)MSD58IJBQR,VNGB^XXL85; 0X#D39AZM1N* M'(#:]=%]51HW41^ LHFE,-@5_VAA8EV) U!:3*@??X,Q%]8Z,"!Q__]RR-!_8FC-B42G(F-T MR)16H/GB] YY9VIJJ&3-QG!QK"0O1A&EE_H*R0EJ]&N@/Z#5:;U.%])=5"U9 M ;5X9W6\MD6!9WY;U3CE@6DW_UK7)RLI1ZA=ZC["0[T8I@@8+/E[K05'J:1C M2_JQ]$N]+XH%#B%NB$$U>3A5Q]BZ'9F,QJ?0IK5@+X7;)QZ$Q'/)Q)A 9I.^ MS'Q&%K 8A]6'U#;MBXRF)=J,Y[)>,YR B1WRO9<4OJ2C.B"%D_BS+0>Y%'HG M10LTDAR4JBX1;]SSJ.U\79TK6DLPTL7T'=EDPW7UIJJ)8GQ1#/72\E!8O5() MV6A0J1U[DR! [%N?L)?Y?$,33OTK'P%&'PD>EU3N]/+6V('%:%JJ3?^MT)/O M"<4PC =IR54&&?^="AU2GC=:VT/?;$_'"FC&*P]8_$MR4<#8OVB$W5*U?@"95@$JF$ M#5Z)H%(RGQ:$A[/4_IG@RH6X4]@RPKJ%@Y<[A2KREM5<*-J)1<4R:10)!9* MLG*@H_+S: "N3UNJO'Y6?#_G&E8J*'F>N[1]@<* -H8W779_W:RQ.79F.>H& MRQ8EF 6HH16JZ4:GVM1=4Q_3H-NX]$Z[[@W!T)I4K6::\B#E!FL8\E]:K>H$ MW26]FHE&J=@9H?\!U"1QSF?)L[>V0V+^,B=@;0W5NT5%.Q8:L^(W,&>#R)+W M^C[^';:3R2-H3>IW*SK*1L!T"3!\XG_P!:E'V\/(^(*RC23C5"I+2U?21/E] MI.+S7C7]4I:^]/.8A?_Q7Y7"YS^/6?C[WRN%SW\>L_!??/0#PEI!/%.@S%%: MLM$K5Z_/0:AP7RW__:B%QX4H1F9@ZK/+@%W;SJ^SQ8W-?H4MF$BP=,/],41< M3-O$I4FD?_E1-D?VVB),C%?K#0L>.4%19PW1^!6#C92_1.^J<)Z7D%2-LY6?1JE$DCQ(F@4O8^;SATB**K4@/ 0%,Z%! 1[> M%C:J64\^8F7OE*ZE_CY.\>6\)B4-JCZ-5PDI94F%'A5?1ZE*\PLL1<7:T8Y3 M31K^>LD(27-^X^ZN>1_8I<0H51;AB=/2!:ZBDLTT(U;K+,N66Z60^G7,JK2P M4!W-B-4Z;Z%6'5%"O\-DJQY\QV2?6NH/+3 M.)7X"G]NQ?_.?/)QO?&"+2&%#H0!WB7].I8Z!-75H/9&G>O)1ZILBRC^LL(= MBHQ2Z9^)[46K&]NW19Z96Q9@1'NIL^JH1JF:+IYQCFS;!C\FQ$+13L%N;O1^ MM<7;0/$##YD;;PAD;8/LQ.Y FDP*;JQM!Y5FS,J1+*/+;#%U^.$WWM,+/.IL M+P.66VQCB]H^/FU@N.)N_$S[W9B4QX6(/$5G'@Z0+QSNK=-+/."3>,NYXZ_T MYGN/MNK&\V";[A9Z@4,WL*KCZ>3S(-0>3=:.U\$VU7T$"P>;N9I.&W#PU(HE*>3.E5^?K+B15M>!^F!]$8V($[9<0 M]U!&*#=0[N:YNS!Y" :AX] 8C#7M$ =Y:&I MV7;TUA8Y',5+68S;*-Y4Y' 4KW@]K8WRNF('T0"W+ #^T1;/E="-F$6[PAY] M$<.TL-#U^*X<#J)9_B>V,4<>2G'.X6R!0\*5GV8" MG =R_DBI4>9I$U2U[XN)CN=!--T=P0,F!W""KWV)5*>^ M6_ V-;JF-./"H.P/HD%+.[:&1SN[ECI$];7O>?8K>QA-P1.F" ]2FC]7TUVT M10Y#<0KST((Z,(!^\8,'5 .Y\B#X4+C]+VW*>/)Q*4A>/,K'!PAI;&TVVPK3E.43"9:J'4H?5C-,8R3:2=VHVVP3*L[$L7,#V=^71 6#T51 M.E__\B_>)-\?8XN$,,>L[1_^#U!+ P04 " #S@W]4BX^R%D$H^/F61W MIC*;DJ_$%8_EDC29O&W1)"0Q2X%:D+2M_/H X$T )'A(:FCRLK,6&\?7 /H" MT/CKW][6WN@%D<#U\>>3BW?G)R.$;=]Q\?+SR=?9Z7AV?7]_\K>??O/7WYZ> MCF[N[A]'C^AU-+9#]P7=N('M^4%$T.CWLR]_&/W[:OHP>G#Q+\]6@$8WOAVM M$0Y'IZ-5&&X^G9V]OKZ^7EZ?G[T_?7\PO/GRZ_/CI\H=W'W[\^.&/Y^>?SL\+Q?S-EKC+53CZO?V' M$2M%V\88>=YV=.=B"]NNY8UF::-_&MUC^]UH['FC*2L5C*8H0.0%.>_B.CV* MX).7PG@+W$^!O4)KZ\&W>?<^GQ3PO#T3[YU/EF>7Y^?OS[)22@KVUVE*=LI^ M.KVXI!#?O07.R8B.!@YXVQJ-I.1O OWK>TY]\?'CQS/^-2,-7!DAK?;B[-]? M'F8^IG"[09]/ G>]\=#)V>#0\L5 IY>_1G/K#06, MH4[DH'7D,S!4= M9V>"&:8H],DVJWM*O]Z@T'*]X+*)5P"ZMC?FT[4<$M>F_7M$X3@(4!C0OC]9 MA,^2]<;"VPGVMG3". A3 )F N,<+GZPY"[*/5Y;'UL%LA6@U[;F]O[[LF+UZ MBXU!(FA%>TMUPW!K6%GMP4"7AJ([2&DU.P;5S.V5A9(>;Z(PF/OL M5RZ]YLA>8??7"*422XN'X'J[WR&Z?=LPB1]<;1^I:B4HPU?]T(VG7:O?FPJ_ MI2WX6X2N$*9"(4R[E1LL"@)-=@S>T-X8,PE7B/S=HN8Y_9OV@UH5>5_SCP_I MQ]8,Z=G WA@1+_3$FK7](&0=+4N!\L?6G.C;PM$Z&W!]C<,LQT<*)R+,HH\- M_,IZJ7[NMB3[-;(WACP@JR0^XU$,V)@OL?M?Y-QCI?T[#G@PQE]$ >K(JITV M;P@3>>D'UWJF2RS<[IF%M8U#96 U7'2/QX[C?8D:O86(-N&D=3 &[V'OEW5.TKTQL4N]LXB==HS^K]"W M\JYY0G$6,%G,:CMU::-I^07QUY]/W 4)3A>1Y_W\1/R%&Y9VFWSY]RM$AX.% M(DY&/G$0^7QR?C)Z1V3W[.2;BS4R>N/>L9>0J)#K/G MPJ*M@9#3PL2B8_'7P*LM#A-QPY*K :LJ"0EG@X^BP%A?"A(^I?DC8!(IP>+0 MPP"J_PJ_08%#3@T)CYZ;H("G51@2VK)W4#_Y8B)(O>]M%2L ]ZT7$H]*AK$" M;Y$&7-]+=FX=@")A',<^DP6R]Q_A/N0]F\/[.&T$:MG-RO'Q,6"SK3LH/8CWYX0Z<.-3LI'^[9SC B3*OB):5EO(EE$?VC MY/I?'!>'V$9:7F@64:*$*SYF:ZK&CI6&0TZ/ABG)P/-S._E$F:/UQB<6V=ZX M=#I1M\Q&P9U/OJU<>_7HWR#Z&V$'6Y(&XYW'_%":-,1P!!R3+C3*%PH1)S(F MGRX?=+'_WX;=(UHM-:$ JU,6&M9^VJ"&$;TJ;L\E\2A$/YE>0M:KJL&P[$@4 MBTAWTQ#0F2^(Y^8Y72T"U#_8P\WPPZOH#%K!H9:KY!*![%0%0 -$'UU,UMX^ M/_!"K ,H+$$I,20T.B"@]CV=0*I8:_P9E*C3O LOI'8X_+HN]:D<3VMU$ Z@ MR.+1,PF^^=T7UDNU90> N7.3,_6*LDR[PR4)Y;$%5(FV,G;YA%8BVU'4QCXFPXU5_M=\4C"(X)7XS M "6=;IR/5!XX[(1#*>G W.<_SR*V'T-%LBF@JTEWE$$"*O#"[1.5(2&%SA8O MWX,P!>9M.2%C^:9-$$3(N;8V;D@[:PB@QEDJF\UF0,NG9"/( FDQ:8]!8/75 M8#J%S8@FM!C$'O>#@#.A3J2*@M<,3'62E&?"I:;,VHW6IN!1FFH"239/DYW. MHYBB]49/;JY*DBN9 K&-%I$H$.#H&@4M'T-*E8QT>HQBBEX0CN2W#T'#K%NI MU>R'IJ#3$4)6P,[_L'^8"'ZQO)*S"!Q@G=:8$VJ[163+M8,2U2@@)1"(204*A"LJHY+2>'A*@:BE6:QR4R2 B4T=8&-P:R MAE0$5Q6(Y-2#2:.FJ*@HDAI*0.)T;1A490/7E(&$K1(#K9L](,=&#'FJ=$:5 M$-0)W2'>%3Y4;)HO9Y9@@Y] 9Z>?KUA4]H9ER$M_J;L\EF8Y8.H#W:#XWWO, M#;K)8D(<:NZE6B5V+4TYQG7$URVUH972T#6=KC?C=ES?"5_4$N59G_@O?*X_ M,]WX%$>PB^\M?>>\H76_T++\VD7\_TENE^Q5;-A[Z#MGT.T;(K8;,-&Y*4\8 MD#N;@VB/*=I$A(J60% 87(O(]D$!G1[9OP*=^]?^G1]AIW@GX8>CG1X,-+OF M-%DD/%$<+OIQT&URA:O4$4S1=VI;Q9!IK=I8:6+/VU4 R='X_[5L"#WO:$TJ M0':K#1(_NAF0RIA%A\H,X(:.R=B.)1HU&L 7B:78C@UB!8-IFD:+3M0M344. MHP7+IE9/C5BJ;#@\3>:1I-<-14 %US3S=:5/BP*X!I_UA3W2$K_5+7F'6AE+ MLA%R>%&U+PC_"4!Q85=!H:\Y1F^RG%K?'$+[_S"3\9-5E\%:ZZO@LD%P]BTU\<\/5$TD/ C).R&^* M&;-&6L^4R:)ZM*MHVM7)D+\8:=JU9A 5)7S5< 5=?G;[!_.63P?+MGI^2]?T M_WB,\Z.H9.[Q%,5=GOL/+F>#\"+512L'Z- ;.ZW8(3V_JU$<$N*&")%Z1ZBF M%"1\@UN=C?'P[BU XEN[")+.2H#^OG1#W*LU4&@KH9TNU $J*PX)\1!1/)4 M[%\U3$XU!AL:&=)4 RC- M&K9MC4-+V5JW7REMZTK!.R*2/V$IDS?4SINZP2]?+&PM^9F1&8NVD*U<.EU; MA+#!R>^F7VT?V"NM;"@W$9/0[->8-\A>8??7"*4/7 (X@2)+FB"/F?5(U S\ MCI/"(E+ ;Y7_5QLYP#0<2FDE)8:.YOM,*J)K[$-VY(;)*=(AF0A0I95JUJOM M(W/&4*:?JA_@:)FD9VG'A#V':_JG2[LV)W2 FY+($?8;@"N1FI EKSJ!0H" MWND[A(*D$.S+GOH#F7Q/1G#NSQ!A;DOFJYB2-U=K+&_7&\_?(G2%,**B0QA+ MD/-^R,USX)W3@S2740_W($<*?6 MZQ>Z'KEP99M7/J:5\Y15+-@/^V)H2Z@\@XE *6[:@[;&%4C%S)$5NN'NKM;K M8S$.4%\ $F^5"E@=!I?2#\;K9I4ILKNQ#"2.*]6D:E8KZ(=+\%=1;")_*Q20 MN*FCNA2,U2@*"6F3UE*@;"@&":%<62EP28E!^:D%%[6\A-.%-+-7R(D\1%U5 M.0$@C[5>:)6-CF_6DF?_G%F>14QZ?K -R.0CV["KO2G.]NO2BHVYP-"*$T]^ M0*MB!1CV\A1FJ=HP !5X[?D+>PB.@80G=W->']PX\":D+= M1=@Q\&&5@]E:N\,D2E<%&($0$HJ.XK/>\VM9&R1^M!:B*O^L93V#>1&"&!3= MB"K)8&V79938<.D[4!N1V[,\,X_',_,\HC"W#_./#^E'.+9AM7-R*Z%5TJ$I MLOTE=OG16Q.WT/58$A]@B0^,Q(FUS-CUJ$.7/P/PZ.?GX&-\@6 C:9N $#Q3 M"6*Y5UHDA(1BH"6H@#Y,[9#X):Y/!72!<-C'-VI7DB1:UU0&J :,P[5)XD"; MVC%,!98/FY4_PE&!I=ZQ$YHJ@1_2Q1 DLV2";]#&#]S0&+66P"R=6A6RC;*O M[2]@PT^RHP(O#F^RT"98^+[Q"X2M">&R'D>51RFM:^Q+%NX@1#J^3/B.'/_4SP2SC8D1';9O5 MS6Y#PS%@\KS'\=WM0OK@8J:5A(;%V5@R;A='U+S,+P$7RIIAT+2'/6$)<.D\ MYA?+.JGT0P<:U9!KLF'GM$/>H=.?3J)D;5-\1WT6YT)3-X420"6@]-FT2CBR M^AF.,*M](DX(4I4><^<_FB*]&G'FI#D5/^,_=NB484HH?SK>H#2,>N-+C:I- M?H$ROU)8'?).>?(@Q".A/()8MY#4T2D)-20.ZRP8!;LUB@ZHD'0GN4PU:98% MJJ2X.U'02K'I'22AY?^RT'(QZ?F5Y3%/;+9"[+Y34'U,%X[Z4KT'7#G$7J&: MHA=VL:[0=02,;]&%YXT5E\3D=%NFYQ]3F=UE_YWY1,\"1FI70?-_M3."R M4PMM\0Z9BY=S?[;R24@+KN/90%VD;RO77B63(+XEA-8 M5:E+*."H'V!\I'3C-JT"@HH*L<].'>.[QPB>QL,@NA+%O MU4>(#JUI"V::S@M+8BI4X6 N9'7;"^W1W)72QA[+6N<_47Q3E,6[JO=&617? MD.6%JSS=/IT6#A4Y1K_CVC09RERI2S\*/-MJG\E0W"FL>6M+FIX44O!I%]R( M[T7)'GC^\7BXH%H/0D8;Z;.KQXK^*R94(K), ?0/BC5++1"G&N!9!Z0OL!XK M0[)$_:5\%"D#H(:D!U*8O>Z87[0YX0^<.7F14MZ-]&6Z0$>#7+P_=E,B?Z@V M_9<[/UEF#.G]%^")^W;%E(IBO3@64TO%!O$QX_+<$&))%\!SW^^ (W-B.6AL MV^SX6\*//##:1M<>>I/ER!\\WO^EWN_EQ)(JR-K#CY=$8+O7!FGD--QXQ<@U ME]S1R&D[W4V#IEO17G!(W.5V_1J-=G;U&@<7QINR[:I RYV M?0]5BPW:U9G$$:F'VI$=LKI ;8_K[8RS.X3T<_X\.G:RE[#RI](/O5?.=1M+ M-='<5:T#3;I50=Y1[\.3S+:YYK9]^CML$0]5A@(J#N ME0V&9S^K0X2^EW9!J>W*J;;DF MN4W5W%?YSD-SN>R"9?51)O!7R_;#G4KP"OREM'UP1?KZ4;<,?\?&&N[K/?AX MR9:4P)EAS\GOSAW4YX_@_6D4-0MIC8#LS )UG:;Q1A"//7A2K& M*"HTBRL*>=B9*?+Z8-NAU(1V;6J*/J(DU2>[3VRQ^Z4,F86W$^QMJ>_EL"U8 MIV![9T&G[&,I71P<\U2:!+5RYYTZD>QA;/H/VRAXL3QE_@* !@/KF#6Q@TI$$/ IFG$FM+@Q8%<[)1N.LU] M_O,LVFP\E_+'%-!Z:;TKI_> 8VJ3L-&\?&.*SE<#MCU>R (-6I'#-W]S:!8] M!Z[C6F1K"KAZP=-P"1AR>+W%DI3QP QH&D8 '[V$KNE1!( (:^T;J8( #JBK M6<-]-2I!UVZTAIW"H?/TK'FU B"XK@,Y9WOR$=GR 56\+GA$<)-4. $B+UVR M5Y@%=LK<0XR<6XM@%R]SO-I73@Y]G4#KV17)(QI0^J]P>55 Y.20$.E/13$] M97-12$@KCKL"5)D*4O_5IK0R:SC0E+.:408%.+W2D/ VG;F$)^>T7\@:X'&L M'3Z&H/,. M U4AL*J7O]8!>7MOJRI(6WC5I.-0E82$4R%M52$!*34D/,>4.$64K#400/5<(@\5 $1* M2#AZ2ST%ZK[U?I?6;9:]"8Z)*UXYEF^MQ/+E=K&@+)TLTO0<4XHMN2ZF/LDH MSU=EHJ&X?V;E5PE%9@$WS/;/K+K+U:98;8-S39*2;*@6(/%-5]#4["=K% >. M6"HM]!'+B@-'W'Q9NW7Q6LLD^9W]AUV_^>E_4$L#!!0 ( /.#?U0F%C-K M9$< ,N9!0 5 8VYT8BTR,#(Q,3(S,5]D968N>&UL[7W;=^,VD^?[_!7> MWI>9L]OI2[Y;60YF=F7/C0)2?Q"$0I(NJW\]0N0$L4+0 4 M2!4H/B3=;0-@U0] H6XH_/M_OJZ#BQ=$(A^'/[WY\-W[-Q7-_>?;GX@KY=3-S8?T'7?N0&.$H(NOC7Q\__ M=O'?E[/[BWL__/W9B=#%-7:3-0KCB[<7JSC>_/CNW;=OW[[S%GX8X2")Z0>C M[UR\?G?Q]NUN^"N"'/;SBVLG1A<_?GS_\>/;]]^__?[#_,-??OSXPX\?__[= MQ^^___O_>?_^Q_?O"]WP9DO\Y2J^^%?WWRY8+_KM,$1!L+VX]4,G='TGN'C< M?_3_7MR%[G<7DR"XF+%>T<4,18B\(.^[;,R KMO]I;]Z.V'CY3%[UXC[\T%G8TP M2K^M\)%]<_9;+\X[%!O_]5WVR[QI;>AOWZ=M/_SPPP_OTM_F32.?UY .^N'= M?W^^?TPA>4LG,Z8 HS?_\2\7%QER#G$)#M ,+2YV?WV:W=6I\\/XG>>OW^W: MO'."@'XZ'6%%T$+(_YXEAMU?&6K_N] SWF[03V\B?[T)T)MW1]-$_XY"MC7> M>FCA)$'.'QY/;FD8T]2F@[]=H_4S(FU)Y8UAF,X5'8ZXR3-Z MFP/3DMJ&D40T[PFN4LL^YC(IY\;//MZL'+).I2D5?Q\^?/S^P[O8><4A7F_? MI3S,Z/^^[B7R%:82_\%9HC(;;A@_O]WW3^EM[M4QR8\Q/06R#[,3P_?H/[W\ MA]%T<;5RPB6*[L)'.A1:X<"CY]@U6OBN'Z,_$C_>RO@S^(E>YB\_;S^A$!$G MN L7F*S30VF&Z*IS0O_/]%^3T+MT(I]R\$#HX1;&V4\]SV=_ECI>H]CQ@TAM M*?1 0,= 'LO"8[)>.V0[75S[A'YR2NY"+_W;71@CVBZFB^6!^%3GV#C!8_(< M^9[O$!]%BCA#H:_?]9Q3_>@O0Y]N+R>,)ZZ+DS"FFN@#W9HN)='@^C7W08A MY:T>"*8G3KQ]"%B[T+NA,FO#9%N7J&E_O5\(-$R?8]V%V8A]S MT!/M5DQ?H?650^C)X4WB6\HEQ93;GZOM"'"NP5)O$Y"-T@\Y-V%(@/B'D?ZFE^OY/2[HBF) M>(WFSJM1;4YSU-[658&NP^3-$!W+I:=(2MHEBK\A%$[2LX&VI#N&+!'=49,U M4ZNNG,!- C:-NZ.%S6828[+-QYZI'X*GIVQXT#\X5!N+5RBFVG =QZ:R.Q7 M! BM@JZL%G,?[&WU3NE,D2]T$:2Z?CR)(A07%@CWU\^24SL9L M5T1L#U$;]<_J:7CI!"Q>\;A"E(%)E$: \"*)4,:2-FZ=?KYG$(\YD=N,U1M[ M/*7U1A\IK;:2/1R6=/9(%DZ[-@/,U7U.A=KJCHI!KHE##-,I>G M,T1MW#":AK\A)XA7!\. MO825WF;G808P ;5)F-?[>WS7SE1"MZ1K,_V#G] MX@1LOQQV$__WVIO7R&=.#(H9@=Y^[)Y]XRQ&=^5L_)BN:H.A LUA3\?T87&6 M: Z]])\/!*W]9'T\"&T^T]M&T";T.+79Z.?Z73ES0A6UA.HAC#J31XO^P/VN M#I8[Y5WA-7.:'1T7-S'VB=G/-:5?T)9J \EZD^;)W6(RS?[VB5"S&'F&$&GY M.4M ,B!..ODV%/CXO]Y[L$T#IO6UT\=V?O-CJG>C!2($>5ERZH$5Q+(TB)Z%Z-ZML ?RMLT()7J1BCF2X*F2$3 MXD=4"MX2O,Z%8WIA(OUM*_.[:RKZW0/T+%[[:<"_Y$])S:7"[]JMU7:#GPP M@P>/YJC]LCQ#:8R2JJCQ=D[5U%#JK[Z#>"( &Y"[& MU"-RRE_L372+:#9CZA\S>M^KA1ZLODN)_8)V4=M)N#,4F4GDA-MI&&RO<.@Q MD\@KG,@Y _DO2\'+MFNI)WHLAKEE_M@)21H(V'M-"QKB(KKZRX]\296*!=7@ MYRLZ] :3.,]N-B-2C_Z$" P/+?PP[7U/_UEJC%YC1.'V]D,PK@U?L&-T["D) ML%OZ?,#N$V/.S<=H?QLQ0NYW2_SRSD-^^MT__L+^^C;[:W;_$?GY5PO84%;1 M'5T_.3J!\XR"G]Y(F[\[$<%SYSE :L1F37LE=$Y';2 N_74O!-&-0% 4L0]> MEZ[F%JBJM^F%M,N$FIOTN^RJ U6'/I=NY!;(X[?KA<2;,/;C[0Z?-#*U!VKR MZO.VBJ0#W"G_NK]GW@^)=!-X;"/($F<+8,-.E9OTJ M#\Q!X&?WMR5$UIKV2NA^H:4>YKWYT4 MOWVO)%/3/PAVMI4474[C/C=3)AQS MRR:]IB%6.@3->R3X5QPD5$4CVUL_0$1,:;5=CR2F-0V2+YS%V224,L;DTD+UFLA*[OV>I$=,D9O6S6+DUL21HZM0C\47Q*22V MU*A'XF[6B"PI()\(_A:O9%3R6_=)[NOAJ,^T3S&M]::]$$J_RE;8XW;]C ,. M=>7?]T+2(W+3T@D?/C[/_9CK+ZHUZ96PFUYS7H]+EU,J#YQT-BN MV&4U0D6,)[8_FGOU+-R_) *W4JU)/\9QYL2B^S)**TX*)I[;K'^7U^Z/>S]$ M'V3>KE+;DY+Z48/4CR<@]8K^=4KF5$F3$5IH>0(RLTTKI7'7K'\"'S#5:H+_ MYV\:I1&W<3][G7V=($= 7NG7O1#$ZM$&#RMJ%@BE8JU)+X2E'[QU7K-O7J/( M)7Z:"LBA4-RV7R]27L7LD:G6#N$I9 V-^_&S9_:5X) I_K9/]N@UO@E2?]A/;R*T+#K2=E5EM0HB+PA>*P1O]Q1C2>ST8D/-"*:(_O2& M'JY)1(G!FRR^W@:/]S4\%DX0(6V&N;5\CV,]"]Q:R:XP[K?G41!P!>0XZX!DOE_XVQGD>ZP6*0$/1Z\;-74H)V7,OP\HL!'5)?W+)5HFU MF^7W(SQ^!8%\LWQ_#Y?O6G: 6<[_ H]S<<*!6=;_"H_UAA0&L[S_#1[O_)P( MLVS_'2K;M4P+LWS_ Q[?_/0-LVS_ )?M>E*(88T&,/\ ]3H!%DUAAD'J- UY^H8YA^@5B=)_3$, $#5KBF1R##W8#6\ M2F:28;8!*G@J&4^&40"H[_%2IPS[; !J>HTY68;9!ZCGB7.\#/,.4,NKI(T9 M9AB@6E=/2C/,,T"-CI_O9IAOL)J<)(W., P ];EZ.IYAG@%J5C&N8>H"973O T MS"] +:Z>/VJ89X :7$-JJF'F >IM3 16]V9F_H9HZ4%WU/K]>FB2YEVG/T];Y)07 M"+])J9P\1^D;R'M*=BG96EW;)9#WS2FOF)5Z/WT>ZW75V$^^5HN83K^%=.4( MID&EAS'*[D*7O1&"KE'VYUVX*P@])9X?.ONG0]((636%O\4 D%8-?5DW+WF2)7+%WJ4^^R1@.SOL4^5C<*["V)YT7I$2+@4WV"3"$A.4TB&I?0VM(,U1^ $^RVKB-(7'#D=F-ZFJU;0]K)57^]19,U@42SC,4(?*" MBH^6/3C;5))*EI"\)R0^!>?)S2LBKI].5/9LD.Z!5!\ $M>I^K.;*-E\\MJ> MQO:>XRM\BY/0JQ< /'(P2',S<=UDG:1/>HBT5,F,J8]@;AXIINSUB^EB!WGY M(.'.EJ0+I#G9.3OBF/C/23T+MFMW[V/ZE.!F^]Z@YA42V/-@YS%N;0<#_#K ;0 M$.[1<%HS*-IXDF%B(JV0H!UT*"\5D<\9)AK-I4)4/>EE!,I>7O!\\RJ%',\X M]$(A#:*AV5]?9IGK"[>88PU_.&_NK>9=U=M<9KSHO;6N((R!B9>C9ATJFKJ! M$7^X=2#I2$F>/]QBALUKT84]9C$N[01HRQ"#=<6HVE@<31$+ZP#0D1C\J(;% M++?;&]QPB,4H:&H92EO&NNIL9@7!+AQE'0HZTD A6F5=I3K32B8GI&4=)CIK M@AOCLJYH7^=NR')0S3I\=%:$1F3-N@*'K=:)+&AG'0HZJT$]IF==V4?31X<@VFT4[@FC'A9\99B_%YP_??T*4B=+#]C-$P75"_\_T7Y3M2R?R&9M4 M0E ^LY]ZGI^Q5NAXC6+'#R+]ZT""$.Z!R.FB)9D-ETT,CFXL:'T\3;R[/T:' MAI2NO/-(V$/\'RU7X%'7.[I M3*+4W#!FIL6"Y\9--G\")F3]S2VY;+:#KOM'-]PPT M1X T0U073DW+!T12ZH034FMH4?9<1]II;GD84P,M3KU0.%DKWC^NP@04 =4< M,YG:5(D--6$&'@E)UIDQ**#GH4G3,;LP%170 YVT*7']=* &-Q3EY&J4UF5Q MP#_E[BW.D>ER6P=ZV+0_:R]NN5D1SSAV%#" M8[)>.TQ$7?N$?G)*[D(O_5OZ8@N*XN@N?"!^Z/H;)WA,GB/?\QWBHPA>N &P MJVP,.!BY%9H> M$<4W7X%I/B:I1=!Y7V-'GSD>W=GW_ADL1M @GC1W\9^O3, M=5C1Q1>Z_].DKKNP"%ECY$!Y $A<=[BR0%8,*Y2^G2Z^.'$J)G:L3*G]FPJ MB,J%7/1/V-M=]#BKN4P-#6IZ_ST]2O=?W@32S.38/ 0.4WSW[[Q3!6^_M,1N M=J7.II&>/$F1SIN<:9"I&<#'/Z4 YDU@+56XKQ]\!>[E3L>EV26)Z: 71O;_VJ?4DGA+-$8Q1?HG\?_KALCWA M>@,81!R%?]+_CD%<:X3S"V6)O0-C+$M#N2OF'I9U>*#<*\:Q='7Z2MZN'#[P M\#0'MSK&9XQX22->ZC, $\*3NR^/,^BL"]\8$.X' ]$Z[GORB"M9HM:%L@PL MG8/%:QWWPPS']WL[MNVR.=CYUG'?E\11=BA8%\4\9OWH^BQLOE2J#8ZF6\3F M*Y8M%HZ>Z\6.D'?E"ET>P2X8$8C!Z9:[#R$Q!R-XQ,*FFOME0 M'IQ,+N[?[(M8I)Y*Q@U!\4ZYE[W!86!H2.[G]NPTO]!U[+B0,/KL_!.3JR2* M\9J>II)0)K%RTF)UP8R-M][_-?76 MH&RY!_F"U1<43Z((Q90\Y]D/FO,#N(TA<3-+"V#)GMLH-H)$_26.Z=Z:+E(" M)4SPVD+B):6K430>6H"C6V<%@92 ^?T3*H,HK:PT:K9QTRH^KS<)/6\?\2+^YA"9^!0TA\31'&_4CH): M0TA<*%00$S*FTA<2KX>ZY;>$GLU9T"Y<*B1>RGM"XO/*B5:W ?Z6$OL4(>\N MU&%6L3LTCAOY@44M-5 HEK>8('^9UW^>T7W4<-(+NX#BC$(]"3WV!RM&]^($ MC4^?"II#XHCN?!9ST=/4Q(/%.91S]\]Y?T .:58M$WB1Z0,3'WG0Q]]=(JG<) M$3E^9$@X'1*'=MY_Y%&!],0$T[XX)9OT!OU5K;^QQ-C\V+I/2S\BLDY?HQ"6 MS&ML;[Y^3I;CVEPA9]_&V-:I[WRT$,)$_"L-LL"#5ZA;WV-1T,-Y4D( M2E0IA@A@HJA="$XK(%(M]:[H7@;7XM;/D2B+ M;UOW&%H/L&F%R\T"^,,@ #00,GB6&%Q<]A5P!PVC9;$X) M399LJV5;U$IJ-&CQX:!2S M2\UC,XAL4D4++O<#-QA2%J-PLKA@;V'6,277RC-*57S!1,^T!%(T^2P& YY] M<-]5#JXEN$H$O+Y]#C,EMQ-E0<'RMS)N?.N'3NCZK#0TW71)*GPH.;UTW::XYW*8]7"2$H=+>L/?#0,9=3G0!QXP"@'&T2HM6#O>+> MD/B=TX]2O8*MP>::PK6&4+F0N;#K30?#":6'9L4#4#M_8**AZH05G:=BKH'[ MS50]K&T9'X3[5'QJ5_PXG+/08K:U#\13W&@ZF8/!_'FAX809@,&[)<$K1DA2-8S.?2"3V9B2?N 8FO+SB^IS2F%]FF(?H?Y! )7^(>D/@: M?2.PYN.*(,^/5?P(U8:0N-@?19(7O J-(%%O4(:!]%:=JX^'IVQ-XEO')[\Z M08+F*ZIL+5=9J9DI8<5FA "T& H2$M6#B2JHQ>-J_@VSGTH3B[5&@<3_G#@> MHN2F=],?G"U3HZ(Y3G_\F+!H*2(-1Z%2;TC\UN:D,E6W_@O2FG'%<2!A4)HM M(8?E5I#H;S]9D&2&QUA 2%[SC0.OL&",'ED4.E#QE4D6R4C5<;&/" M!&$,GXSA$]/1@YK]"Y1IY0< +>]#F$C8%7FT&".)T%'TC%BR#I5D5YV/CI$JC0.)_=XE= M6JZOV@X2#P0.9J#%#;D(/RW"9[QIU7E7Z0N(U50$B*B'W MY/Y,+4VJI*V:DX@DW2!Q. D",;6RE:O0]XQX!;E;4Z(_M&!8VA$2EY437?7D M!\5#"OC'MC/5U!$2EV.Z6VG:OF\[WTT=(7$Y)J&,22@=^J[4[$"80/449ZN: MC##!4$Y=X%O H@@^QS0!S[\D?^%( :1Q*!@9U=JC:H8K4 !4=P9:K9J99VH M6$3@86G>,!WA,HQ]I&X15P-I,K/R?+,5:L8H3"CZ43]DNP\F-CULGD9+WV)4 M+$V'LBFEY?0YF/WF1AVUSQH]+.>;"7.VV1]7Z6OGT5V8K8Y"G^GB<85)S-YJ M/3Q["SS%H_!PYE.(GR-$7MA9G.6L/-$U>!?R+)[I(M--:HND,4_ V,<@.2@- M,JB>96+D0Y!0U'+(27.0VHUF[,&DRN?;1BJ.&PO2[(YA\"&%P<\C\/204,*< M"$4\02H)$ZOT-29MGD*"G,"G0O\3U?JB&7(Q/1S^9&> 3+BH=H4T+X\HCK/ M6YN94>L-B=]T9M@LH/W\1-7Y:8'#<:-:'U(UK?:*G1!F5$*+7<1':7;Y2Q3M M52J+H>MOQ;:<))C8MG1,FS3>3NG#'N.&I]^YUK@<>W7M'WT4:&KG%D/5M>C7 MLQPL=OX;7'.*EH?%,0!UIMM@12#CLTIOU)L!;A"Y12#\=W[QNZ-F)HD=W MA;PDH)M8T. N=(/$8\A^QI*3'F/Y_%U-@2 $,(N0/6U88BW:<27VT MR@- ,L:+8OF:K3'D[RZW7U@-'33'\Q7RR6T2NNEIU.22UQX($@KY>KO<[FF4>:R%/0;* MUQ%WT 3NZ1F*$#-@)J%WS8P;G#XENE\Z7#K5^QFCU3W0Q2Y/\<%HL46O>Q:6X1&>*3 1:>E!DVE$%1^0]ID$$RQ5/UG;,[CB M(!++>O#P-.?9=XS/(/+MI2=][MM1.W8M]I"I0]%\MEL,0:=']KUZIC0,9TPE MJ_,NI&W1W'E%T<3S_(S>NW"!R3JMP@70I_+9^2TA6U2S-\Y45I"DV@D3])8YCO)XN4@(E3/#:0N(E MI:O1+7%H 8GN3P@OB;-9^:X33 AR9(M)U+X=3]&>J0BYWRWQRSL7)V%,,I;V M_T@W=+:9LQ]\_?F7ZJX]_ (TN(T+A-\:-#_M%LN1181JB\9#?LK6'W]A?WV; M_34EG?[SZSU:.L%-&/-?Q>.UZ(6L['O7)7.L0%/IU] (,N^!N\ITJ)]_$;NS MJDVZU@YJ[A(%#>$>9+1@PJJ'NTQYH43.G%@<)ZBW[%6N/ST*Y#K]A;'I?D#$ MI8JGLT19]D$4,7ZSH"]WKIL[0)KH.=ZH:5.UAJ8W\M.C="/G30PML2C>D&Q] ML;\=%A?[U]>K2862_4\-,DXVF)KO!Z..L].:6IJ>@LF3= KR)KWN\LF38)?3 M7T#:39,71.BFOUDL*%3^BUQX"MKW"N[5%P&X]!>@P'53POQPF0E2,:K5AI"X MJ+DN8O6S5J4O)%YS:;6CFLH0.BL)G9CI!I'47R6V;90Z0^+V&BT0(ZVO 6*%V6LUF)5Y ]I. MZSPNT^PYMCA*Q_,0M M>DTNH:_K!G$N\LGGNDG-9VX=BUKN]TIF7MW.MCA+1N/ 9CYRZSC5GF@53[UU M*.AHWW57/DQVNSJ8"ZHZ3,8-2.Y#D,0Z%CNTK>\'4?Y40:+G@2GKV&PGSD41 M,ICLFQ5L7+45)N,&!-LA]&CQ17,-G8Q%-*WC]!CE6Q09M?BE:8WI9C%6ZS@] M9KIKL5JSW/\5-/=*,5ZS@/P--"!J@6"SB/P=-"*<8+%9]O\!G'T3,6:SB/T M$#'5*+5A:Q"V(Z]=2-N.ZU[CN,H=#U S^5F9N70H!-.0%>!)8DRV)7-JO#(VB"MCL%/519G5J7:8 MELVB4H&G%ERB!2;L^SQ"=;IW1/.4&C81U?U3([?^BJM*#TCI0@=21< WMX7$ MRSFE6C)Z4]LZ+S+P!<<'+>N.70Q&A-T8#Y>T[2$J0O_!J:-N<&!C^RZ71(\) MW=X[$EA5A>:B +P-V78H8[SLP$%1^B$]73@G/C,<#O4M>9QV\R&@*Y^R@/QE MN-N?2FNZV@429SVG3X^IF4//A=!7N:R+,IK I*[260?#&&PU[73@*L;G%,$Y M@5,;=HSC>)5[^#&1XQ3WX8=(NC0&SBFAS X=_* *->J)W(!+NY%&=YC- M[C @B7GC9=;Q!B=0_^^P[L(=?T-,YY"Q#AX8+F 8IF2EB/8#P52RQ%M6$3RF M\WWS1^*GL_V8K-<.V4X7PA8 C<+B) GIEAJ&>J- TEV5*%=_PTPR!"3.\TKY MX@EK,IH4NT/B6$BIQ/26]3-FP]P[S^S"&B;;9M(DC2%A?N40LO7#9>9)F[AN MLLY<:==H0Y";^=_H+TGL1]G?0^]NO7%\DBZAT/M$ M2A:QUB"0N+^GMCQ:X8"=!@2_9&\-R]Z,;.@#B;?]:S_1-%XA,E\YX>[QZLLD MHEN,2AV\?O;#+,2GO[P-#0\),2J>-CBB9K4^&@I=C6F,T\7"=U$^\&U"J$%, M92K]6CH7#<]UJG8%-2L%B=)B8I1Z0^*7/8 >DRSC)7TH?DGH;I)I2$V=('%W M%[K,@8JN4?;G3FC,B1-&"[H =RFF'&;TY[Z+;UD9\6GE\!&_DB?SF<#TB[=\ MS%7-050&2]7- A,HU3B2GC.IEAS;[)8!"HV*]US1Y93[S!L\0$!14%T@'?N! M*IN.:W:#1["YZN[I(;2XNJF:MZD2ZA5[<"SFOYW_1E%D6QWJ5%\9>IX2BR'1 M.+\4/2DPP>A3(>Q,C,.$UIQ0,F"5W'=U_PP>6A(1;LHE:-TU/K,PJO@)+89( MUWY1]D=:=_G1\+)1[*#?%BI6#M/"9_KG B7BJEWT-"LJU$K>DQQF3U/FA0X T__>THO86@<:(\UCI+FMIT:BT0!%XNROM1J[PES7 M3"QFV)BF4EX;@H,=9N3@M(=/+]>B^[WXVK]R+ ][)"2A18%SVN$ ,SJ@(!T$E')4#$KGYGQ>48'GE)+7> MD(R:T4DW&L99(G.LO)&;^AB^^#1K],'7VD!"MI@!H QM8R=(W%6) MFZ$7)TB0M]N^\16.Q,J24F=C*RG]VG3QM/^:("./M\!4NUKIW-52>,_ N7M* M1T1=0%B,4>-96;@)PU%R@'*MZ[JN*SP"3WX9(?#<2^ZO',4^]+LG0&(_16PM M=KYU)$<;U5F+X3K!6:WAJP0,G-I95#I::G<&3_>'D! 6(QDC(R?D=(R%C),0$3E1NT3_O_07Z3%<]98K*^@=$ M194W7-.$XXO MMU=.C):8; _IE/ (GO MG%))_DZU'4@>[GWGV0^HU$,R6[RA"W3.)O&MXY-?F=N"WA(1X_; I'JYZQU2U)R0^C>I4 M(*4\5XXI3Z9*9TC<\HC4%1?BKF?#J7GIR#,5?_/CU0/MA A!GBR@IS< I)DJ M[A?B1WZX9(4 =_R$RXD;^R_RK:@WBI7\R][RTAQGQ #FB92ZF-7/6T%S2!SQ M!*J6](7)S=Z\V]4Z1QY+>=2U#7F=07.;&[.[\JT/!"_\>$KNTZ+N;2P/K3%! M8E/RK+5:#M(1S-IA#\Y6Q0BK-#-& PL23D*/_<$R#5Z;%-S8S3-B>,A M.2Z\9E:FY^@&M,2AS8; $,Q$ NWXN%(HJ Q0+:)B,11R+X" ]^9X!5!$='-L M&KRFC4O"&A@4;T4>AP/TZY%Z&T64<*8370"*@_)[>4IQA490JNHD>$1D[]^9 MAF2(FX9O0QRN,@K""$ !:'V8"%S0\H/6&D!TCY4C$0&_5XX1K*VQ.0<1:P@< M\ NHK2HOD;B:H0F8X+3,'9?F/%8>CM0+9<"$2E40M8K;M,0+]N)2%D_]0S8( MH=4R.L1YU+5S/>ED5SB.<5&5PC(6XW&,^99EG0UE[B@GR[18M3Z4WD=J-!2KP:KR5#NI8L2VG?%S7@ MY8)P5ER%A^/&@C2+=1%?QJ MXZ?.VY+\>-2!.F9"*KB9CSP"+(9+8^/E0,DD+E X6F>W"$2NS&3A D>&=TT M%U/00(_\G%KL?NUQV-,PQ=KO[/ EDKFHU] P4[6+6;.[0B)RYD3+J77 M0DN-(%%_B>,8KZ>+E$ )$[RVD'A)Z6JT&0\M(-'=L-Q;NI(@UZV_62R0F]7= MC!%!43QSXCKM,^0R7<%?^,B;)G'=4:[CM.KYXY#0GN.-VN:N-1P]";+3"Z8F MKZ2J\@ZM,OO<@P$HQXJ&;^U\J#RA5,($)JO'FFG2NMH%C& BT-Y'IE0PNY_3 MR6(C5RXYZD>.Q>SV.%F2$6'TN+\WQ]EO4?[65TXT7,ZM4GT=NDX MFY3:=RB(H_U/WF:*T8>WNX#:[L?\O"Z13:[8"9+:=QZF]WD93NGRDWF-2HT@ M4?\)X25Q-BO?I2@3Y#0'=_FM(?'#%P;-\U)O#HFC&N82BU'4OAU/N5"/D/O= M$K^\B5D\B0@A/[" M(IM>[Z0^(].]O6U3/D!@0M"Y@2LXAV"BH9;AP-$+.!//.:LL9EIR6*6I'(4C M BBGBHZK1MU)LKRMM<$[.@ T3&UPD+1:_DPQL?@JC@:G3/,9AOO$EHR'\S+ MS\.I8K>;833+S9KE'65*88+\97B5"FZ%1TSXS2%Q9-R]!=LZ-V&.#MI*/TNC M;-BN"5/JJEP, N7?6FMUZ,XI&$9-)<7[D;:GYLW&CRDO%MHS^5V%$B,Z[THW MCP!)>Y%2K6[?-'2WBF,]^U4RA+FG.G#X@@@3/-/%E'A4L)!M^LDH^TU\V,JE M)SL4ND&:'?[.4;H-7.L!GB_5V[^7H$!\9E>!H)_4%HBE_WP@:.TGZ]%]8@_?@W.?7.'U!HBR."2Z M1MF?=V&J;%>=/=F9P@L]Z U@CN[B(5?1G,6%4Q5Z05HQ=6SW*T)A=EH/ QF! MW:7LHE=RYX?TJ0I=**"F#(;ZB!T$^=C#6OG#?MDDS'%C-*+% ,;HGJ%-0MP5 M!:VZT'ZY"?IIVJSY#R:)!DP*,3H"E)B9PN MYHR31!JJ:^IC] QR0E=&57-;2$@+9./-*R*NG^[CU,^F+5SK XR!1ML"C7U% MTP2.)YB@*(?2&MUIE0I%)4<54+Y5'/\\CUM#R ,XQV/0U/J@J04Y%W5/C<41 M4;D X%GM,!D>6C()K-#XF$!@0&(T^!?/+GV@C6_38I!$DE;950KS(&; C.?>(O-P'^M(> MDW3MX7MP2;K0T]@$8=/]T3Q9(T+W4'B--CBBWY+G&BGVA#1'8U*H+4FA0TU+ M+KL%)TF\HN=SU) N)NP B:L'@EV$O(C9U3L%5O$6M[PG)#Y3DE(R9RAP8N1= MX4A\:F*FTM5$$SQ%91^R9 M 1QFQ._G,N7NP=FR#38AA#W7G?Y5)_C;>G"H8EN7(76)WFYD2#@--?XU1F"M MB\#F#RH44HC55J*PIS5\JJ[,AK[&5,A'Q%XMN=Q]*ER*"ZL(6D)"?4X_*A'* MS8M,>0!(7#=2JU)/2=+WC'C]2M54)PD,QM,/:]-.J;4R?!)>56[PR,Y# M0?M.<*'08[+!)#5:U4#B=3%&6]E%\#,*V%+:+R(>9>#9ZA5#J#E"/XC2>8UPX'N.X(4@]D,F2H%0P-^R9 MIO8&YU]!=#5-OGIW8S0_4&F"O>GB$SW>XMVY=\D_]W@TZW3O:I_I8:S6%90F M5(Q3_8JB-#J%_DA\DJF0=+C(<8W-YV01[PKP'Z1%XTG3W,&LE"FM MYF\.\79(92M?*&PDW?JA,8MATD^R!>XLN6>CW@#=T7WS1^($GW$8KX(M\SLX M0<"KMJG9&=(^KFF_:<9&JO3NKKAE1DCJYTYWGY/?%VLH1WC4J)#P*:6'[6A/ MSQ7DW86M)%S[$4V>K[N]L\<\7:MS?(^B*,VI75)U9$G5(_ZU8L&A>]R8D&;] M-\1D#/(F+XA0CF:(A1FIZ-DOV80%#1Q\22 XNB3N'0@-V4$-'4S:<5&/I6$Z;!LTNG\TITS#2?NRD@3B4%@E^?AQ.YT)*N@?"*)'(MJR)*\L"+UF MKX6K3DK#"-U0OMMS3/7(Y;.&*=)Z+$C[^^:5I0P@EN9:.Y_FE.2("BW&V%WX MV\IW5Y\P]J(I>:1GO^\R+[5)$H>TE< M*#3ZHP 2[I6#(O,7$,H11W70.7'D QG;2SI?5I#3QPP':69+5N[,CWZ_)0C= M4:JIH(MG5$?B\*-F,JL.!A8-MM5=2N&O.*#S%OCQMC46:D-!0F)/\;7_0D_R MT)L4S%P=&'3'@81!]5;%7OM5O^%\Z&%]2N>QZ6[B9,^6J6$P\T!;WJ [*CUN M?!59&0?8UR_'J[C::T&6L"98$TWY7T"1T5H;\ORV/+-A# ,Y "W^J*M8AN$E%?(6!5^K K? 53PJL+/&&FRXKFE1I"HO\1QC-=4%6$$2IC@M87$ M2TI78X'J0PM(= ^S1G!O52YN7JFFXD>9:5)V8C1';O8=O>N$Y!'O27Q-M7"F M3F:_U"F3T0,ED.9ACC=J@J/6$!(7-M5,&>N+G "-LZXO4B(_HY,%&%LCT#R$ ML2I">Z!O'!)L]P+TW(]7DBF(G2'-4 M.0IN'9^D;Y1.XL]I2GYZZ%]K2M6C!AWKVIQ'71LE_Q?/9"WCPS4+@7*L6&FB M9AV6.2YC I/5TU]2*X ($Z)3^W]/8)M:?-E9+HCJ-J;%[,(\S^Z[NMMM#;9Z M>[K_7(*!X @A]CV&OL>[FPU(2CP.]. M0971=$R=5P;+ ^T MN-SN:908C^(>QKP]_'(A>VBY]*GW,T;EQ%M3_8.=5*SNIYRZQO9G9X&/B8QC M"8_S-/CT#QZ82*IZ"=H>M&74&@XJH/"H['3I\9N[S]3.1(L]".I0-!^\%D, M\SR]5T^DA.&QF='_%3CFO:OUFQ^O\D>6LNK&!S].^@93_AY7N*0K, D*P8&='J_A=Q;TC\2M\BKO$H[@&>+XD]VM3'F*V7R02Z M_2>"I]GJYIZL"R3<93M SR_7/(*Q.:G ^I@\YQFO+-6+-R>R+GW1-@W;D,=Z M&5[1NLO9V%INA]O\&VZ!&^ME&+=+3=P$[2') 'Z9:,%VYS8VC+'H%4P1QH+V M?:S-4@UDS15:[FN]'U!%Z13;)@W*&TPKOZ4[2:JD"MX(KNM[,&%1]0U)%5D% M' ;@!M)_(KA!%;48!VT]]/ TATP9'(A;R"@JJ1IJ,3#ZVZ:?/0-J=1QW^&HX M_RRY_6MT!Z4&B<7 Z.\@D>4SD/O,RJM#9CA9C(?^HA"9:@.YFFU,9%3LQ"&' M4R9>%EQB[1:8K%.6QX"))5P/+6#R%.)G]K D(^PNW"35QW9K+ H[0.+J9S^B M7V/W> \E,O:O)T>%F\\I Q*&VXP%"8OZA#7&PP3-87/4%DP2P)-!X MW14*+[9>=SU]L+@[WC)E"H6[8ERR?2)H#HDC*T/,5%]_083YL5G";$6QG^/R MZ[Z318RR\[+R9E@]'&1D7$BS._B$E'O?>68Z$?,A*K%5[0")JP)MTLL>U98# MX>,(G4A4HD3-+A9'L?4&,'?9AE.Q4,EVT.T]\-05I>>CZ\2I=!N35\;D%6@8 M3ZEY&3LA5526BD 7>YA+RLG2U3\['KK<_HP#CZI5TT4%S*<-#J?DCKE?F=.3 M;BDF5P]*6*T#E685)8R;U-/7MR&M@D--Q^GB5\P>>[_Y(_'C[?X B"8N_3=I MV'[J(QA;)>G0H1/,TCKC,Q0GA"N,N>T,7FOU4%:5+RVS?,"!>[ *&T-=#3-Z M[./0>0ZV#SB*_-0)Y1+Z0_IGS35U$\9TRJ/IMW _^;G.H[1PC'W,'C2O48]H MMOP8)#3W"^+ 2EX7M%@5-$%SK,7_[K)KA+P[NC?QPH^GY)YVNT0+3-#<>6TS M&R")'+/9%;$&3U-J2#O!0_(<^.YT0967]&HIV0?M M:L8,*(6$[&J/,0W;KC1LI90.64"MC$>KX"I0=!2SL9MCJ&5XQ&""QV#G^>L0 MA-R["!6,L:1E$]-VE[0TF>,GCTA:C$'[%#\S<4&8T(TWFL8;36:1$,1.J_5] M:K$\\.PW*Q)'\C\('4(8H3V4!=<+FUI\44?%_-".R%J,QWA[ZR@=1"G>#!.9 MGE6,FOR%BET![RTL:R..]+=:<1BK20%[LU5N#_*RG@;RZJP=%0^K50%[4/7+_ MF$O>,HOG#X/!LVWZEF%C%7Z$!7A2E.D) >4^Z')".DO",CPA\,UT:1:6843@ M&R)*66!#+K?R&;^D>R_B@\;I,=9BL83KH=5BR=TMW!E2NEPK[&D-GZIU"AKZ MGL_-U7.M2M#AXX?+)4%+)T;7_F*7UG6)XF\('12Z2;S3,(J/>X7>9(T3JN*A M&)$U9A_T>"_@?%^,3M0$CMEJH?A/>O+HK%E@]+!CZPU20!"D.7U \7:L553^OS!XJSF +-(#]=@YZV(H\<<;R_9=7NIYWPHL=T%$Q[MA&.98:F! M"_!<9*WT!KD="B,KUZ80Q2E4MC%]L>_T15 8:<9HP-AG0+,'3S@G\*RIL\M@ MZ]'T.[<\N*,MOG/+;#-D4 XYS/D+VN9B;!)%29;3%3W1^9SC7-[EXG$,AMH< M#'WTZ:FT\%TGC.M9YT_I<+SP[YG9Y+J7#9JI=D;CT6I#D:"Z\?7WA]3/?H M6KNHJ?&=:QCW(--)FC@K$"]$2;4_))[G>*.FF-0:0N+"OB?$0#UC<'[!58-& MF<51H[$V7IUC&VKCM8RT&_=$G.)._5A-%&"]V2.M/Z#HG'F%N %41CM9#D8G M9EEY(2E;*Q8G$<@5E+K]8C&[UI7V/G$IM8X5FK'T6N=PKP/?O+(4;]26Y4X^ 7&-5'B[62RH MBCY=7*79VQ$UPS!!U%C;YW,STZ*[#6CXZQ;@?>!T;^YVA^Y1W^IZWXJ3X+O8 MPB:^UC4B1]U7Z0*TG@BR/O7"G/DN=BX>:^ .)([4%=0:V\=B)%O:OP.+72J& ML5L9G"U7%6S$6OK\S?CD6B)J?5SJB+TJ=QI8C$L?IT$7G@F+XU)]0GZ$"V,@ ME]S-(MR-ZV0@E]Y[EA^F?2T#N4G?\RP@;QNTQ_J??F2 M[,@NJ52EH)"L_3BU7A_=%?*2@,[-[H&XPN\ )HU4]7EIM0AA!TBN\N(6N:)+ MT8]9@A/52M*?J6=HB/I"XK6^S*1SV- %-F<:'('BI'E-U62QYIJ\!YE,E>?V M/A"\023>/@1.&$]"C[W,LV%SI'9/O[D[)(Z%E$HR*V3]C(6)#M"%'C75J-;* MWEN:4)R;,GP4>ED9<)$=?>+0B?!(@>EM5:O^*CU&*JG['.%L,?N:$EJ&Q0$[ MF)BT=,!+="G!Y0[) 0 3(:55HRCQ<]M*10 #A4/WJJ;2J5]Y%U.&IL5!!I.' MS;WZE1[HUO+!>U"XG3&:R2#,DF&9R9\07A)GLV*W.2?,L251RD7MV_$4[9F* MD/O=$K^\B^(-2?E)_Y;JZBG![%]?KR85LO8_!0UHHSG';PV)'SC66X,6L.,J(22JN$4:^P%B;_1/P;'/R9Z]NR/ MQ"'H%K&JZU/Z0:JIA*#JU:!V-TE7E^0%15 MK[ZC)V[7$157..*_+L=K-GKUK/?J2;1>!D:N<0)E4]'QT*B.5IZ9$($"% '# MGBA5==!B-+2=VW#H\B\^IGG(#2U4KRLV M8%KY:C>$@(?*0 M$'?EI-KQ)XR]2+2PQ3$CU0$@<7U%25QBEN//[AT49ZG94=W<#1*'-V%,CYIH MCNF)=8M)F5I)E$RE[QGQ^I6>O$X2M)'I D?VSTZX_'.%DT=_C=D5%"?V-,O[6.NCA[!8>PLT;WSC GK19%X3-BW56G5',$XKG-_B\)(SIQ M[%*R)LJ*(QBC_!+Y_Z0?^4SM)VI'7J,7%.#4@M #OLTPYL)J[.[@RO';HZ\Y M@I5!'5654VQEJZIP0)UVNJY>?3VMXL%3UG!@ M;2B:6GZ%>=YJT/YF(VEJFA:['-N T\K6\+BHC5M,-*U50;JN[]T B=TT>BLA\/EZ*P? MG?7B>QUHXVR;,^6+;2#1/KK<^W>Y#\Y-VKWC?'0CCFY$OANQ*'MA8C)Z"D=/ M(4AKZ[0&.WB_V* =A; \83#L=+F);DLQB=%&&^UWZ:W@M'KJ+GM6=D&_H0\D MWLK%>B5,<1M#XH:+NMJ5[5H/8[;>#&UVD?OIHHP@S\IK:&VE?6?2=#DSJT]! M[I3QX6]FH CHWGD3;6G!14 >9C"1.(6U*P85)D8]>4FD\MH.M;P6/J,6BN]2 MWK^@."ML. D9#E34[\RT:1ALJ3'KL1="O,(#8+G*GO]R%VE[7"$$LGCZ8TPG MF1UBTT7.QP..LI4J"[ I=3:F&!37*P]SGE*MT1&48I80MMITJO4U=('$&14T M'J+;:1JO$'EPM@SZ:([3'S\FFTW@(R)6/]5Z0^)W#'\-Z<9)=@C(JND5&_4F M_41.%LW.D-#>G;TRR5=I!HF#+SAT,[FLR(NP@\%WEK/WS>["Q^0Y\CV?JFN\ M)<-M!PG;*RU@^:U!\>-$*WJTL3]8'8$7)Y \%\)M#HDCK6+#P/66P\;4X:JY ME[F;>VI/$/.VN6I72'/!UGN\E8)?:0:)@[LH2I"WT@\<26.GGPR6+BS:*;1PVKBNB1Q G[U3E%; M2.BF?BTJ&M=^LA9[18J-(%%?=Q%H>!- <5+FPF6&(D1>9'I#W@H2_3,6D B1 M=^.0T ^78A9J#2%QL5/TXYCXSTG,%(@YGGX+$6&E/U-GG,Q&:.IJ91J!3E@G MC^0I!E@L#GG*XRKEP*]BM (F(M) N7Y4;4P"'Y/ -;*<18$3ZQ!H%X$I0U!U M5%L'@BPP4V97'/JPF'%9/"<_2OE1%HLY;XRV5(\%?B##8NZ5%09)F,!B")0" M((>2+ZH1"8L1X8:.%XOY5W,J20*B%O.OH@>5 Z<6 MUZW3]2#R8J[VLZ][\G6CZ?3*N0K+ V!3>6';O:)-*#/\8+)U4.@)\FK,V;H: MFR9FO@J4=2"T\^MU*7LV= M?A25>QQ!O,!Z%U)L4$ZH-"M;APO-XZ7&_M">^*MZ>G A$_LOZ"; MUPT3N$+8^:TA\?- \,*/V2%Q2X_C_"'4B4L);LZSE?>$Q&>VPE!VC+ 77H5\ MU5M"XN,3U:,B!CJ5PF&^;8KF?WSK^.17)TC0?$5PLEQE$S4EK)>0ZV/'A831 M865>(BI.T-QY55C%A[:0>,F6(:5J)SRHCD=W64(WVF['-3WVJ=09$K>'V5"8 M,#M3?"6*[S"R>L</X%"BM%@XLSF4RL# 7UW[K(B E< M..:"=8YS$S@<;6Y8YX WNZL*!HAUGGD32*B9+V:A^9L=T!1MG3%D40Q9L"L( MMP'^!C%N4K4EGG6E93W2YWX4ZKE;%[K X'F-, M8XP)!O6<[7,7OM#3J_7NXW4'SO%.6+;EF-<=$L=4T60I;N@:97_>A?S[C)E" M?K-84)UGNKAY==G+PFA&M]]5^K=&9[JA+T#";7CE*QN0GPJF3"RG6XQE951" M1:T=1FBB8ZM.5=.#"SC9>NY!RQ4=?FSC%JHJOUG&BB).9,2%A\R5AT[5[$7.:GC[1)SJ=,=,5TQ\^4]6( MFF?;-*V*$':D%9U-]0W0>D10N*B)\:;0E<80L#EO*?&^4OW$20)8\_H;8@7K MD#=Y0<19HIM71%P_0@_$=U&+-?OQ_8@8F/Q>! M3R M8?86%J,,+S'>UKFZ.Y1&UL M[+U[=]PXDB?Z_WX*W)ISMNUSK7+9/3NSU3LS>U*296M*5JJE=-7VUKFG#T4B M,]G%)++YD)SUZ2\"#Q(DP5<2H)#N^:.[9(D,1 1 (!"/7_S;__ZZB] 33M*0 MQ/_^W;OO?_@.X=@G01AO_OV[+P]GBX>+Z^OO_O=__+=_^W_.SM#EU?4MNL7/ M:.%GX1.^#%,_(FF>8/3JX?-K]'_.[V_031C_]NBE&%T2/]_A.$-G:)ME^S^] M??O\_/Q]L [CE$1Y1@=,O_?)[BTZ.Q/D+Q+LP>_1I9=A]*?W/[Q_?_;#'\_^ M^&[U[I__]/['/[W_E^_?__.__OC__O##GW[X07F-[ ])N-EFZ)7_&L%;=.PX MQE%T0%=A[,5^Z$7H00[Z!EW'_O=H$47H'MY*T3U.;X^)M'W)-F\??_##W]\6[S5^@3\ZTP^=@:_.GOW MGHKX_=3C7QO//_^1/?WNQQ]_?,O^6CR:AKH'*=EW;__/ MYYL')N<9G:&,:@U_]Q__#2&NCH1$^!ZO$?SWR_UU*W<_OH4GWL9X0Z M<43'9B2V"5[KWXN2I/(:J.5'4,N[?P&U_)..6G;8XW__+@UW^PA_]W8"H]EX M)K,F@YD=YIC<*_IY8K.J;)(TS#+)O,@PRPV28UE>>^DC&S%/SS:>M^>C1D#R MK?B4_ZGS2$V_AF MG,#V*9X#>AW; .>>?]R<;IC!"P69ZGCX:X;C ?LHRZ&)'[EH0BV.))H)XV- M'JZ3E+&0>5])3':'MUS>/YZ]_^>WZSR*_@I/E#^=^23Y:_D(4PG[/7NB/$"6 M:[HIDQU>>5\_?-U'7@QL'"0?3*1__V[$BV]'2^G'V2.;O'?OQ=3!;RHC\<,$ M\P'I:#A.\>(QS1+/SVJLCGO7&+?+A)[<7G)XV'H)3N6YIN.MYB?3=&GV*MN$%R8_>U%>[!B4]6MJCB7,E$['[HTCR+FD$;$_ MWN.(?G3Q9D4>MB3)Z'>XN\'4\$VO2/++-O2W]]@G&YA?$G_XBG=[^.&3EYYC M''])&_N>>?K&OI%;$E]XZ?::+N04.%K$@9@O^C/#ATZ;_^)C0_;%&A1JCK=JS M-J!+6FV:9-4=<=0:ZR1PG-3%52/%_O<;\O0VP"$3^.__##^>\1^94/2??Y4^ MENMX39(=FQ5J^>/K#._J$]W[N+'-C)[':1C@A-&G_X!MB0ZZC!?^-L1/]%_+ M-1B<7N)OZ;*YQ$\X(GO@ZW-(;U 9B?5;G1&ZLTS+(@]"2D?+A.HF;O39%N78+WWJ'K@QWSIDO[TR\8 M7)(X6%"+UMO0BR)._##%=TGHTPV'6;5+9H:DUS'[%S@"@SLNTB))//I)P(_R MQ> R!WOWCEJ])%ADX%B%XY#_\?T/[WYLW>CFY\2E>5C105,A9HM@:>=I.IB M2U+#=[W,LW5$GJD)S&WA#GM!\[!+TMR2[(:NLF2U]>)EC/]"#X:>&W'[&R[) M5;NW+[+BEK?:)B3?;.\2L@ZS90(7Y%Z#YCAJ+NGC(D\2^CG=A-YC&.F.LLY' M79*$^9KHJ2KN*ZUBU)]S288/?\_#K-T[(?[L$L<79+>GMB'=D)=K9C+ +Q*\ MI:H-GX3'ENX(V2]A%-$=XAQ3DR+RTC1LRW(X,7UN>][VJ6EP/E,6:R)'FH/^2.]<81>0C>* MGJ.C_TTK(8DB^('3MHO?L'>L0[W9>32 M>CH^SK""&XN%^ 6GZY2.<.HGX9XS_B7%])-,@>)]GACDXL>)=@MMEE MOETI8PFYI(6+! =A=A^FO_5L-(T'K7RY?\X]V-"\C)U&A;=H\4CRC+OV4N$< M_QT'U^"-24D4!N NI&LOX_>;Y1K.I^MX$03,A[XBJBM1^697^&MV3EG]K6\; M>"FVS.E87:,+WP>6X59,N?0/]-S@7A7A4&6&0^776%KA)Z$[IF_.-XP_P2,H#6/=(\9XV&5>''J,1]J^DN8;9?/,4XZ'9<];\P: M6GC8XB@2MOH]WM.YZ@@L:!YV>N$6OHXCW"-3IZ$[F0Q^4\\E$[_^J^*^:%E% M74^Z-"'JWE<:-G3?8[]KN]&,?]]:,$*[V74]Z9+V[_+$WX+;=KG^2$B0LGP( M\%13:UG=@EK5/YB 04L"'!]@OUTE9,>#@#E$_O8B+IB>8VH6PNU6;U4,?]VE MF:*6&PXWU)ZEYMP 9T3+XRY)= '>+%@X]0VV,T6AZR5C:TS-#@)GVP,&'5X4 M04[=PNI]QR7=%]I3CX?R8!MJP'6^[9*\ZBG1Z@T8[G#I(>&2Y)\AW2G,#IU? M5>4AE[BG1TB Y3U5IA_TNM:[WS)K"4 N! \I\8V(_;+5&M _[9+&[R$VW7>Z M5!YRB?OJ3;HT/\YQ]HQQK%@GX3%7\Q$$7=7*.%_Q./O[6-JSW&9O\,:+>(Q& MLQ?JGG!I"C7!09G?"KO;BG ' 3V:O*3+0SZ6CK'-\AX'(GV:Y0_=X<2G]+V- MUO77_K!+R3+8)QNHO4B!==FB.V^+A&6^= ?6;&S)M% M$"0X3;F+ISWEIO:8<\JE5R)?O1)UJ[GQM$OR]%6&'/=!FSP.CXQ)%T;\=9KF M.#C/LUN2_05GBX#LZ=DU,2(]@KI+LUTN118R'))\VO&*2Y(-EL=I*2!!["HB MS\S1#\6:UW%_S< MA"G5*BA:H^+A;MF)0[BDN2)723D%[D@:#JJ"'?2R2])6G4A!F& _^\SR8*08 M914["S,NDP>'_RXLWO6Y(_ MA#LB$B]NPEU(AVX/3?>^8^6N(+?42M[>,/"4KE==6LGZY.3^^V[W:\9FHU;2 MQY8K<[%I%NXB*Y,GFR6LD\DY-6LRJLSXOO#V8>9%P^+0C3=O_A8" MM\WO]_?Z]SNB+L?<0"[-)N67SA%\M)J=K"\Z/N!=EV05=>E0%5&[SU\4;O5% M.N;N?#Q%E_2B\0"4D!<%RX-LNQ%DYBBYJ."HC*R]J+[KTGR5!5_B>Z-KC-^[ MENM5N,/7<49WI9!>]97D&RCTA\O<A(P?^'HW,N>]UR2\3,] MH7!$CQ9,\K1^XO9^LL/>=DE>D57&P&W"0**=M4^E_G%C>T]Q\ETP0R#5QS*@ ML*78:3@2MVXS.IZ82S,T"F7C./S.430-9O8\X3C'<+I])/0R%,-TL$L_._'8 M7BB*X?57JW$$7)K3BAUPE1O\)$]XLH^@;)+\U:/#XR!%SF6BDOR?XG)(X"V0_#R.M[G/>9[ MR^,N272) T":A$1DO-N3Q$L.ER$ =F-ZD!28S+?D4IAYD-D'EL^UXHCN2#XU M0-PE;2EA7F$97\?B%@(6 MG??UOHETT?6D2W(,A6!A%R^RSE/A"1F>O#&>JDOZ:4M2E@G(TB6N[#C+F!44 M13HGG$'"5FP3)>65^_( ;+! ERU-CRQ>I2,L[!$3<#1=E[ZYVHVJ\'TLU*P=@ K27*Z&7M/&$34> MR8U#:%]"M0#V"@S5']EM>\6EF9.X6Z6C7/BKSO.4?F>0K;Y[I"N3/3,>!LX0 M>9F.-V MG0$4$,!A%T*31=TDT3<[L_:-[^BDN2+=B4,-\\M9ID;IC,%;N.V2=9 M0,LI6% =9]>Q%%W2"W? M,I>EJ9*EYI7($<:[,-^U&[,#WC(7^^! 336O4D>DH^MY*[? C_3<2RI7M'M, M5X<7A[_+-ESG7AK"!T(Y :2$P56X4TB[M,;[RB:'F\?M;QN\W?'+&2YPV#6> MP:XG7=)\W3?7GA99?] E*89'9Y=Y!KW1 WKZSA(-'C>>2SI5D*9Y+@,.J$GS M!5+A919WMB7MKIBA[]O%-5!,T.LX(Q(J[6-"\CWE)#V'V5C2;7/GA7%AB*\( M0$N"O9I[D7P'+(,13KHY6'!IO50NUV-R(=I3[8^FZ))>*K@>/;E@>!(.A240 M/^_KA_4:^U!!R0L$Q#G6T3NM_167)*OT)Z%,ANO0IZNK&6D7]>.:>H#EFI^& MX[P!Q@9S59NM7MEQ>AI QB4-U/(YQV5_NNCG+UL(M\4QVQTA ]XU=O*?X_!O M].#\C /Z345*W]B'',JDAR;!'4/&I?E2/YW^O++A[[DDH^RX!& M:-]/6E]P2:HBJ-/B*^]WN XE,%=+F&5\3%<8>,NE>2GAYH]RA@Y\W=R<%$B; M="'P?G;03SMYPO=X$Z;P(;0X$D>_[M(LJ=EP&H#4$7@K7:];P]3@!E_9P6!, M(DC/Z[.ZVLN2!PD)UN%OUSSLTI*J.%EK52UCC]2N]QUR. _%!H9-T019%8:5>K3>^TA5D#7W5I1NI>YGO\ M!.H-9(4<=/8:[*+6ONR2M%IWX3$.A=:779*VZ>KH^!%> M)BS 7>_VV&Y@=KQC:!)\C@_,6]")?["IX"<)_\5?/_U4/R?*/[BD9'XOZMD= M*@_-:NCV8&5W/NJ2FO7UO'OWC+DDT+$FSLTIS! ECWTTUY[ ,N_-O DKN M?L%>E&T_TTLGCX_>)02**;7%>A.HN327I>NMK9]D][,NR?+9^QM)+NBLT GH MW3NT#UM*O+^':R1<\7%P#J@1PK?>60PZDH)+\R!CVK*F 2+:$M0F'GF8'D/+ MG)^89TS0[[ON(]"ZA=N?=FEV5._USR0KTHQD "A=^/3?24?QV' *5CSV-?A% MI5]=G[.^XTV79NC8>N%QOI#C*+NDIY_P03E=Z2X.M8&L*SNF\\KZJI&4<@V1 M/GA$QOI:U7,T09>T4L>B['71:A]W2:)*@1 [%NFFWY5:FE9SX<8&(J:.X9+N M3+05:U6:$>(N::M2D-'SX>B>=4F6_LVLD1HZ86-LTC))9DT,,!ER+W39=;^EE/RR02B7C#<88T5AI$QEP'HI:%/3[;+ M,,JAZ9B70"8]0R^GGS7[4K09?P->Y;DS/QG:.T; M"/F,AV&P,99+NJPZNF3S*:SD;/7M6\,IN"1W_YG'OM4;$F_HM7=GX'*AI^>2 M3D9<*PS<*([LR]IV#1[Y\JRA,HB,=X3'V)]=6@CW@*T9ER=!>ZY)_4&7I"A. M85T-VK#SN_5-*\O]'M.-,O3I$0R@)SQ=)PXJ,%:=F%-ZW MHR/043YC;!XAP]SGQE-TD*Z$SP >O-?';;M?<$FGP\M\Q9]XIM(,9<7CQG-) MI_6+ ?WX>AMX=+UC$D0[P>>J%I^])/B9=WKA<5OMK7S :R[I7^GJM(RUNWQG M&X+6.9I*UR4=#H8] ;>(JH2I-[S%+YFYI M%S/@A1F352M9/ZS4JS-O:,2++BTIV3GMBG#G$?.E0]IY?[,US2LN23:X'V;G M]6(<%9?D7T01*_I(CZ@6&?*N4[**8D76A5UN%N>'6]CE\8JLMCA,KO*8>?TZ MIWLT(9>TT!8$['4+]K[HDI0ZC!6Z%:UQ:!:W92A-EW0CCLL[+\D.2DY-OV.X M]T6C^'R &]-3B]#]K$LZK[EJH/B8]88+17^+7MT/)F!N#@J$ ='FS--[H;3/ M&>SC-LVOU57^:8RV2RNM+,OM.;X;#[HD16]C<]8M@/[,6N-UV2LQJ%;QB70[&Z-2^Z).7HT,!,W2['C.:2/MLSLZ9VA^\BXY(&SDF6 MT:][?0]SU&,"Z9YU219I6HO]>!G7L[^[0DL];QH[97[!T9I^(5WNVOHC+NFX MMPG-Z':=?41TC.= 9*@R501_A,<16=C/+$W]*UT]=] M=A0%*R7EBSC.O>@>L[)U\-V#)W#E?>7&BMZ.&?&Z2VNF:I!\B>G7'H%?HE8; MSS/46++:0-MF$*D7A7U[UYH\HWO6V$*[\>+@2XI937U'V:+N,9<63OW"W^OS M:7W!):DNZ/UQ0^ (@S"H>IOLSO_O?LTI">G!G4-@@ZRS9[JG]AP5+8^[))$6 MA$'X@B[ISS$.Q"_AW.CPWX^DXY(.U!N9AM=QGI5. @9M7KH-4&,J?Z37H^6: MFHMP5P)7N=X@;7UZ_D,$5HH7_=]P?T$"79U6Q\,N+9K"D]A:>3JLZ*G[=9YSEB18@2?N<%5=4%^)0W5A05++"7[-S M.N9O?9ZIR?3=6KDE]/C@YI.=+QD$4MR%<0C&'&A:!F$Z\BJZGG=)Y[J\BF'9 MF_)AEZ09TX;*:MLIMM_=DC+BRP=(NR)\O>^XI&E]&==B!UBFS'66]N7.#:?@ MDMQ];3S'!K+Z:+@D>]UAJF]%>)GC%;FG_R:Q]Q@=J&F8@AU0OM3 [@=XC$W, M,T74PK\"2H%_+*VN\LI MTEXP,9J2E6MYD3XTW$6KLX)#9/NW+M_&@2U*(PJXX&)+P MJ7W8)6DJ*9)DMPOYICXZNU+_ZJPE_QF&HY-:"9=>YHGV3JU;?^ M)P'>(X:.%7 )6.$=( DDA\L0?/&8GIEP?OZR#?WM+;D47W'17D8VEF/7@]\; M7A2+ \T?'+@ 1(]D19[;P1F:3YJ;KDJ-ZB<U$;#,H-R5'?BQDM6[*9+@#:,8"^J MAAH>_"W=S2+ M0%K0+'R;G$VPGB:3-^E.54C$W2_%YY-B10(+MU!08V65UV2 M5%/JI -N.:)BJHO,+,?>*O$"Z$1]V#V2.@I=\^\N34IOB%8%\S<2\VTCZ))6 MU#V3]U2Z%GY:73/!X>^Y)&-W2VZVH1:7TT*N\;W+CZ)L.YV\5K1G(T'\Z"%F MV;!N"&1O;TF,>;16LVL#%NV>ZW7)(/#KG.$]#<)P+IR?*2^(7> M;A+ I88<;>BCIX$O'/B22]JL-Z'L" ?6'C2(KN,#"LP!OOKKF.Z-<)%L![+H M>MPES3)#^\X[#'#^%4^YQ+]!_-H3AZQ5+Q/C/?;#WC;V-7TB.3M"\SC0;D^5 MO[NDY?($$BA8PX^LV@MN2C7$@:Y_VEQ2U7H=^KC,O(V#JSR)0\!::L_$ZW_) MX$GPA..<-4(N@<$6Z2*F1P[]*7S"K!=,B@'=DWF GW!$=)_?9'*.K:%:X^L> MUV7K"RY)-1!S<#*RH&T44W4+ZC[FJX\:NLSXO/<[$T3^@WU:_+/BO_CKQ6W] M RG_X))*!Z3%"YQ'EAH32[QM0RGWO;2=TI7B2Z@[$?2-H\9Z*,93G3&2=DEV M]&+5&CX3?W9IPO0=W7IKZSI>69&6,]CJ^Q-"C+(263O19 MN/!PBU_$=%LU,)FP8?OIO@W65/^,2W-4R;,I@7\:.;JI"!YH$G[IULG.KVYO MK_&!G-)B[T$B$@W,G$H:8BYI0^&9?76MDC8>=$F*%E=UX84N0FO3H6,L#.62 M)BL+FB-9WH1KK );?H2DTXXRJ1$D7)+\2YS3W8Q^JA<)#L),DX(DDX_*&HA6 M'1Q%S"5M<# 6NI>'^:X]*J@^Y!+W!0!+NLY>,VHX07YJ2U ]"-?-MM< M+15X_)",=96#Z4R0!W1ME9AJ/IJ_(!;FBQPYEJ?-C8[HOD5 MU2B D?3?,@:^Y)*^^UP$G=^!"1_$X &^3X^>*.S-O7/V*G@K%8$ MR!0D2);W_80:N5K>1E(P>\=MZP3.ZT!+<-76>^Q@ N9.IVJ/YF-3J:;1(ZM;N,M4^[)$_?T5DFGC#+8F#_LR&$[( :0TE06H;0^F&,&R^X-#N0;P>5 M/\R/_!SC)-V&^P$])8^A8"CTG6;[A"=SP$]E)@?\ZZ\7BQJC\K=VCHAI@;MJ M'?A@1#Y+HQK3T$5"*?O0?E!^HQ_H(4+O;^SH^\\\X.D1;?F+Q]%PZ:-J:V(I MJWJ*V;$7*YLTEDNZ'-6K:'C(?2 I@P7E7H"E =@!VZ]YS*79$ :&[*+>GYO8 M\KQ+,E6QBXKO1:D [K"^>E\UV!1*[062PKDJS:%+NFY7ST1KB?2_Y=)<%!V> M!^6"ZQYV29K/WM](D46/D,]72;W.,!X)X!A^Z+!PUYW2>*JH34& MYZ3_39?DI$)MLTCH&N=ZEW^A]YV72<::G(#EU&JNW?Z&WA(-!I-(+$K*9$JHJ'C4 M1I5:'W9)IW2AYKN<>2HZ()QZK/%11%R2_E-(;T@)',\_$\H^V,5%^#U5?)W, M%]JCA&-HN:2+2?#S9:_D$\#*M\6L2[.I7@$5D&:9*<$='6/ODH,(F3N'95<1 M!H3(V[MJSU[=^Z)*NV4XCRD=R,ZGG73<%H M# ZN_9";!L";GO_;6' :=!=-HN3J+*YSLX'.G%UO>3CH525@M M[3!ZG?A&B#NE+<7F^8RS+0FF@=;TT9BEYOL!^WE"5^N[]X^K,&N$P;2/6,F0 MX 84E=Z+5N0&T_,F6:X7FTV"-_03*Q+)*I>7OB2*HVB:NQ)[CR1AAV4QIUT= MA]L>=NH34+[I)A@*:[5]CUE>1[SA)_2H;6(D29-9'&$?%)?E7=%!HWAZFOW7'NQL/ MNB0%^UC8;BFN;U!CU"J*_FF7Y+G+$W]+-]F.)DBL"W6X#G&P2#F0Z;#T,P.D M7=+4>!MF>,K9&'JNZJ2[(J]Z[Q_KK#J6MDNZ8K;,ED3!]6Z?D">>H]JWVW>\ MXY)LZER-:)K2^99+\M5ZRE9./)N@LP6-";KFB^R4$CZH](+-MUD'UMJ1=QHMEU9Z#SCI MT8"D;142!4A*NR.B\8Q+^BIQ%F0+WL5^3Y@:- ML9 'OFXK3YQN)D]T#=&O\A[VDP$YXO4W7)J+$OZ;^3<609['W=I:E1#[X.7 /Y1*K/3QAJ*7>\;=Z]-;G[M?+OKGTE$ MS0TO.5S1^U4#Y:O].9,YUD MH"_ -8*22Q]] _R.^<$8YITP!7FLF(5YX![TX$5%.*_;HW8T59?T4X$#Z?9L M%T^96ZG>(2%1] N.UE0Q5&7G),[3EHOKD#=WHHRF2_3R%.8 (.O4ZQGA>-?25JWY9KNAO'&]B"^8VO_78VX"V7YD'7 M7^J"7K0VU*+JF8D!K\YBRBSR(*1TKL)D=UU/*VS^W27E-WU_^H05;0G T61< MTL"4#+(1-?U'479)3S4DP ]?J848IO@N"7U<]; )?+["R=8BXAC86D.C&7=2 M+G88LO3C2WKY3<-L0,7,P#==FODF8.Z 7M:MK\S:.>G+0WT.RC^XI.)JWQZ. M3Y0J $5'U&H/(..2!NINE7[XCK87C'WDU2B9FE3;D5&@^^:/(^32['S$9)-X M^RV#/8(3OLR].!7DB$1Z27ZQOR_,2\PLR MEYTD1'$1#\/A'3L+/WGI.<;QEZ[.%(:'F>5CXU[)Y9J.J V&'4' I9GO0M@H ML++J%SFZ57PD)'@.H]&-X::.X:KN=-[M;G#-L9J;-H)+>BMSXQ9/7AC!;6-- MDM2+< VH=$!V71^%6;'<2US;.NI^==GWY418&FJ6 _!N2V)\Y7WE=PTEO4-S M'+8_Z])R%0YHS9VYSQ+I?_.%EF?SBF1T27:3G[@,UU[ZR"8W3\\VGK?GMS < M9:G\S1F?RG=G0D'BURSC -P@]#]@Z5*+H^,^.? E];DG?4WZA_=^GS MZ')\]'T@0]YU2M;,RP1F;&&X#.Q&/>!5ER2MFV,L% =%%M(HZYG9H>^[)#-/ M)O$/4'S1UUNW^:C!)#B99U3W8/._M'0F&?*:P=UJMZ/TP9[/\B1.EW$;E!MS M)G=".!]-RSS6_O@<%[M9+9:2%"NU;STK7?NP2]+T91 SZ&")\B%#]B:2L'L) MFP7R4A+RZ* *@HEN6?:\X=3\U7OBM-D#1S78&4+,)6U\3.C%_<)+D@.DP>Y@ MS?6Y.UO?F.6^=TG\G,?[XQP:&4$BIN:JIWW,)<6S+V8(MG7C07.'*H8@R7D! M8=MQ&= _Z9(^A[IR9G'8?,0Q3N",+FZL]YA*ZL7A[Q+@[=Q+PY0A0Z60>\@[ M1^LA?HR3=VG>@%%?QK=@A?=";K:_X9)< K,0B@T&IY!UO6.V095T:"XV"<;= M."J=S[ND<5;?#-$=X=#O*GO7/3MC(CC+ZY;)6ZUIX-6G7%*UNAD5JE0;#(X" MJ>FF,*M5<479\B) =;BBO]%EZ+<]:;!#B7H!^H0CF7C=!O7;_8*Y2\%Z'?JX MJR2@]H3)3/^0!/38@YU0K)(1A9%C7G?I(U/:2_%"-7:1J&:X=&YR@PFX)'4# M7:4&NG(5/N%1V"T#Z;BD UVJ[ZB\8*>DZ?-KR W#A(]$1\O8/D1OD44O/@M478;K-89H!_R2L1^Q^^LMH-6MO*_MGJFCJ+FD#ZTEW!<: MZGC')=ED=CN=#JBV[X4G:'O>)9F@IPZ)P:I:KD5PM?/6J7]\SG)W#,6:T74< MX*\_X?:K9_TYEY3>TFGS%C^KS20+4-IR Q#])8L#:4'-XA#ZHRB)G[SU0@Z] M)ZBAN MC''R!7E_P MLW5MC?QN'?5)%WFV)4GG:FE]P4KE//_I:7>H=B08&0D%A*GB0E VNFG/]![\KDN:KCCWZ&<99F ITSL9 M^]WP0L*V=\VEONB2[3J@H#H>=TG_XA8,FV.=\!PO@XN S!8?+GW(O"-0>!*P^=M"?*-A\'+NE=?)&LRF3(;M/VO$LRP=Z. M4TCS\J(KS#PKG<@.;<^[)-/0U0FVQ8?=/B('W#&+QU&S$G=NZZ8W(MMZ"(D9 M/&KCG&E.K:[B0JZMH!D4E6Q]TR4YN=4'AEZUG71O[*_W17O?1LUL&OM==+SN MTLS<>\^?(62_:\YI*$#'I'TO1);WTA:&N=WLO3'CU!=TSUM68B(E MU_ 17-);<< IUNZP$['^@DM2'8.R:199TZ+77GHE Z7[7E]7VXYWG)*M!QF> M)]SS;T]8Q.TR'T'+)5V,;[QW&F >S9G0%UCR/K4\V+1:0^_=Z&:5Q^Q8G*K$4D)JSG"Y.Y[?>:$3>Z8[\S6%(]8R@5LN5AU M/3FCBA9!D$!#R%3\ #D2FK-]P LN[1^"-R@6W(0IH$P%/,U1QCXZ3H2^-UV2 M\[/W-Y)4G"JJZZKGP!_TLDO2:G%.N.D\/#JA?=$E*:FYD>]RU@J-]^PCNWV" MMSA.PR?1\Z'/DAM,P26YZ\'C/N?BF#=-%U_5>C[TEF#IGW=)^VPS4#-=&GU& M^OR#PRFX)+?BU1SA '51DHH-5N:0?XG)(QAAL,^Q_NLI[Z)2I*(K2U5P%>68U"AXOV"%).::("Z[.&9*5S'-,? M,KA%CE@HK2^[)*VN(Y<$]^U!\!V6'322IDNZ8;CR?SP6D+[K19>DI$MV3U(O M2L>[5P:\.E,HXPDG+2=:\^^.*?]H2/*;EE)LT]1=TE<31:W=+=]\U)AA_"5. ML!?!=L;R^47.S^^PNW44H(QZU26M]P5Z'O &%%QT'#,1/.JBZ:QN( WP*L%8 M8GV#Y_1HTVDH,:>TH69&BF:&![P>$OA>(HNZ84%3?I;+2@/.<5]%4]B:,F6LWV*RA NK*!S M+P[Z9&I_PR6Y?L('!>9/YMV KPG'*2N7>=C2,Q$J:62JIKACMAM#4VBZI)LN MY\N0;.:A[[LDLWHD_CGW("[C9LC9RD$1HV*A9J&.:/_83\.?-(!+6E/A/>[I=T47\6-TN*-;+=1J ME5GN#1\/SVI-E\^BSXQ2N]J^G&P,9@ZX@Y\XG[T GQ\^D2C "E&!;T;%Y7M(N"1Y%Q!,VU,N M\:^JO>[E'KN5=KWOJLRR/-Q79VBLX+U$7)*^(Q.-[]*F\]L&4'5)/]Q@%AG+ M%R1ME[GYI$MR:-L.K0C[]4.^WTGKMG7;M#;QP!E^;I@I[/$/QIAH@Z M,CQ:7W%)LE&(R25P:&&?Q+LQW0UK-5A]U29*R!&E E9)3G/?M M_M,\.B:(6P%J%07P5SFUI9228G&IU7H0AK_MTOPZ!-Q\$I#,1R3\G.>4'9RF M G]*NY.U/VPA37%XN91-"87#(/ 8SR/(&K'5T.20:%"-IV M#0-?*_^.OB M2YW9\@]S=FX@NQV)'S+B_]:7/S3P)9=6M'!LFTF'.8J8R;V%@YK"QW9^H,8 MW>7*WZS(\CGFL1PO:7I"CR+ATDR>DR0AS^!^:9T?Y1&7./^(R2;Q]MO0ITL& M_&Z=R(3ZIXVMHB:J6,V7H"+LZ-;0. +&^/Y$2?^^)?DJW%#3%W,0V0BL,"B( M\.+#3;@+&3)@V\$[DH)!:W1/TE#[/ M6!,ZN1ATR/65F5=;EJ;Q,X'-JKVWT:#W7-)S-6&DQ^^I?=C"!4.MKY/@D-VW M"NT;LVPPU_XZ6>3T_D6219;A-&,\7$6>SG+O>'C&W1""T<"\)*Q*_X->> M"Q+HH,R'O&71.))I ]75QR#<@A6Y(%>4C: 9IYY*S:6O]!Z,NDZ3M7S");Y9 M9H X1U(PQKEHO2YMJ:L\ MB4/0C_/)62OZ>:17,<CRP[[&V7Y&VI7^?QY;0M:<:A&/K)"&"Z:N2:7C+Y&;HB M-V$J<-:88Z6CWJ/K+9?6Y:#->ZSCZ>1JI>3B+CMZ\SW%'&[%\91=TA/W/,-7 M/,B'U/*XR1 =.,99[$/FI+?$X9K/N:37BM=V"*3):%?P6*)60B2M^T()?3->GP>V@>AV5^1T^E5?M[+LFH;EE@IE*^HU#>7(9: 3>CZF4-#&/L*S[' MX=]8S)_MB.471<_=>D%27 #6 OJL$;K&K@!FP&>/$_->7I*1>PG:W% M])I.UXX- UX- ):AFU:O(:,^Z]+ZXL%346\RL!M7USLNR3;XF.QK;3*2CDLZ MZ+,LQ;V1I^;Z!R7"9,)N'4;=*7T9[GHUSM S.Z+E[)X5D;4+#$V+#GU1W9YY M^M3 K,?A.4*&QS5G86IZ5RB3Q":QP\X<_G:58Z"!ONXB^E.\^??O<'SVY>&[ MBA"4'*&FP+ .7CPTS3O[R2_TK]%C4-U%DB:[3F Z&0RX?Y4-^?F(C:!2@&D M1#(%^E8/\?Y:$ MK%I((L,QF#AKDBA*&564"+*V9LJ,$&)>"N8Y-23). MT^,+I] #U(]Y29 "\!QE=I]@OEA2HU^1&!HI8\.OB]'1,D&U\:U^8AHG(K_: M7M #=$-W>7YH'BE[01-QHDA21;]RNJ2@6]$+[6#E.LG*O3C5_2C M72.AT,^>ZX<(1BPO[>"'HM$'U1D^E@PF^=65_. ! L:=/'$=%'8TZ"Z4%'= MKQG^FJ%'>KO\S>H!(FQ$KWC&'SBQ$\ "K(04NSH -%#$^T"MZWXCR@*ZF,$9>L*.?&,]W?"KN("FB M%@:SM" P0;:>BEZI(R@/+5F M<=^2&+HU7=.ME*7*+>) XRX=O:P(P 1S7= 1SGPZ!%TO8@RV(M9R%.05PYR4 MC-&W+5[M\!TAYFRGZR(K$!V:);Z6<%)?X!Y9SF\"Y_.81Z!67V)Z2W/YVD)'!:)NVAYS3@]"$4! M^<>$VE@-/E&J%[S4LU0K_W#"U^E6"Z%?/MEK[L!8L>!/K-K'- M[U$M"%&Z6=S(>,^Q8@F22*&)?@6JB)&UY0F "'T8B.(UJ!ND:P5B6?'"WX;X MB?Z+PR,VDV\^AQ$]+$@\^?BIL/ &KGZ"";@(>I(-,.-;SEV6JB'?@QR?+:K*AR@DH5O2#N5;7/P$KK_[]YN_[\NE15C9XL0 M& 4WA#MGCYQZ005),A:GKY[);^GR4)LT.2K:BV%/7L)((YP<$8&E#6.BZXJE M70R+%K8O%/,I0K/+-V8;Q2]^P^K.QC04W66#@"= CL*DW)?C6 L86I%.!A"9 M5 IU=O H]&>Z&-6:1,H&O:Q/9+572G>#%/EB<)DG14KJ(KMD[4+E'Z'+Y)'Z MDGPBP2B2-!%CE07P@#TDN*6[!"KY18)AI'!<4*#G/>,9<:;I+18!V_P&6S+^ M#ST+ZME33(4GI@++J=BSJ0BX-ND"1P=JM=C4VXH^EFHZ>2HJ22=7B4D./A8K.N+QB/T)>15[K-V$X5)=YMH[(,RNC!\?P6-GH M\GPDI73@>T7LP"2<,',TYK^+\-=T_D-!4&8(R'B$ MB([_;C=KKD25LP9ND9I,V2]A%%&3 MAP%, ?9%N X!.E8]8"4JXT2#H^0(KL#<855AJBB(H6PAX N!+7:.DX^0'*5H+R-HS[4'MPO*@)V0 M"P=9_K##R2:,-Q\3\@S-WAFN[+&[$*.()$G$:2)!U'DI*@F ,XNB[%^\%R\[ MCNA=]2%_3,,@])*B4G?2Y/P!$EOAH(.;:ZK0MIU"KRUK4^H^C=:#B3JP#$:8 MHPK,A$!BFMK*#V&&;JRG-Y@62OVDW)%,)(DOU^#+6<0!_ ?,AB" M4.7+%>&QX6=+P)M!-5U;HIOZ4>$R2E3#5N##8]=*.0Q(S0=",!*20R$V%HN: M%Z.=LN3J4A#R1I2^U6M1@H,P8TU1IQB3G P".K/4E$YENY)'5?(^P^'SY]P# MPYL5!2FYJHM'DF=5V.K? 2BE1(#"08&93J^P< ^]CB6$R(JH.=?* ;;"7[-S M*-":9+@(Z#4XN02+J.01:IU4+E'))KS ;OOT$9 M<6]^.E13C!XF4.!W;JG [U3GJ=/(^[LZ7Z$R7QZ;+T_,5U*9+U^=K[0R7Y&8 M+T^9+[6.P;+!.*CQ.4]\%$4=S+=6BP4:M*@5HX!JQRN807O-CA 4_S,8F MS&NYKH$%?.N*TUM1)1.(%,1"<%&:NN;-BR8^$Q+ M@02$A4J7I:+.=>-=)0RN3>!5F(9/D]2EF"^ H69,P$K:I)2+K\=9\VQ$B27 M"Z:969R@188*Z@C(OP1@D!$)];A!0DQ/BOF[$--6-4&EUR ,-,F!7K0QXBF' MB#Q&X<;FI!]HVCIP&-RLQ^I^&/+G M\CFF:\!088U*'#U3ZH@P\J+\^N;Z]7UAX>YK/@R $ M>/:[&W.) M%A"AY4&!! (:6(R ?HT@+2&TF990+S@]SMKM*Y^=JUQVTFVD61YK[_)AD/L* MPFY=!)N?1]$H9;G^2$B0,GPW*!),LH-J3DPJUQ)CL$^$4H!>1RA+Z.:;DP0RLB9MWA!A6-,1$"D(0\0!:G?O[B].3[C"I<929IEX, 8J!T'E*(@/ M WEGIR=IPRO*)'X%,:/7?$K]4F9E=A^YS)GWU6J.D>R; F[\X]-5*_MIG@%. M#7R55I:F:=ZEAVJMS9UJ "L4*1@>@#4X#'3-P/*DBKO(Z CX N2H086Z:@:=G$"I0R M";I065+(5- ^$9%: 8;;YFJ6:[F^>>EQ^U\5?:'<,M3[+@!O_WQW498KOC)& BY #D0%CG[@_-2:'V5L2*-L,19$I;5 M^^H]@%M-N^EQ$K-<[ZHY+:4WZAQGSQC'BD MA"ZEL2Z8^1:THC48*FH0(]:%?YFVD6.JF&X,5ZP>4<1T8[/\\T5U9+C:RZJB M(*I^@S=>Q$O%)YADC H2-?2VS#(#[%;QT$J>;0-3U' H9 \-,*)6A">5T"N MEQQ34Z9 VHBT&+IY@W-_!NP"R[))KZ0.D$0=![Q$0G:XXK"Q3ECLBJDZSY3R MYLXX$.V7&"CM':;/4;MM<^QMNZ0G4&/W!477):@9K1V2V(VP:)P^%KQ9+^6_ M,NFT4H#?WB &KC./E=Y3TF*IE]^0JA]][Y>YS--Y]:)?$VHS0W91V1=E&/8A M:%7C4TU?,'TI4>\?AY>X?1@23IW"JDPKJ[D8QT&(N8G-=N*X;"\ RK;S#B^! MQ];5#DPH140,C6Z*%'!7%J M-FCAFPOX8'#:JP7H2F0YP)D71FF]LV_Q[!P0:<;4T#'3W+91^L'9BE_9DZ[= M7S2SB.57RW9I_@E-BEAP$HYRVLSB#2VQ6X)6+H* /I/RG+.)F)N"%A+$W&5; M [(I"+ZQQWQMB=R2V%?C6%,#<=4XG//L-]=Z,_SFOA"JG_,%A.AKVVK\\JI> MVA\/Z((>[IL9;W66'!<#NM.^/ Y)$9.Y3M,6PAMBU:&-]3=%=!X(.'Q.2[^UV"Y)' ZO@G] 7I)J/ MJJ3,G ;[4<&W/-L),?5G,"5*-LX((,_5E,;N V@$X$*%/BM]287A*=TI1$ZC*:Z4LXV?4/4-=7$7EFM6A?4H!1--"JN+:MTB."X5IO< PE9_2D M8+5H\S0EMB9KT=$KJ\L)G?]$">6K/&60CJ]/75I-CT-&G9=2 GWHKCM/XVW; M0E9JP8H)/4$YE(V\6)S%BGS[,M\C^(DNP$N48.^"!,>Z#"^88XC20$#$/38K M:\@RKVUA5I_:9_0,$&HUIS4(Z9QDGSG(CQ!;EH0) MZ(1E\B &SA.A4"V%+W&/R8>O056>HF;;X?R$SZ KS3?B;[MX-60/=P% _^P M*M,ZQB272&&3K;JRYI#^B_$*D7W)+9+L5-P-JG'H>9*'M V$(G?'WP M/'?^,Q$ZV0B=U->'U1SX A6&:>+"VX?T%FP&XX;/N" Y)\#-5%%:T&WX;/E2 M'NNUYA^],$XA.1/+QBW,U:&F;2H %84E.SV+06EH(5I_G5+Z)[V M/U]_,YH0"YF-R=' 8_W>U34B^V=(3@F[G*6N0 MM$PHTY[LB##8;S1I4RJ&AP^2" :L=4]P3!.1W*4X(^A5(%AZC3+.%.I4T)MQ M?C5;MPQW%%HS6;H4ZY^ 8JD&8^QG7QX,-#?DI-!Y2/94Q!VZN;$%Z3F1Z]H< M2L:_/#BJY:BJX"_H898Z2;CG9H=IG=\9">>YK60&"Y9GJ-@TE S<2 -&[USF MNFGYS)$^VW!6%1DUMS@3J*D?A"W5- 1_KQN"YB,3988/!%0ECJMD"3&>WKZZ M$=9AM0OG76$=WEBI$7-'>9V.3Z]084Q5N!8J+"SD#5=AS<#^76M@SY'$ZH(^ MM7[6(4L1<9;4A7@=UTL\9RH!ICS0W0-L/,WU;/J)4) _,1FB&OMJS$Z-YLUQ M.M]Q[R[TS*TEM%T4U:Z+U$C2U(9!YJJ=!,38+$M@SA0X^T+7<.BEH/0;;B0I MHG),:B;,GD\U]P*HSCV+\\\Z]YJ\*^XJK AG(GZD298K1E(F=\8XF3VY]?ES M_-H<%D+;3#+KZ\P*\9 P$/T/IIF&2EM67Z5Z8D*-:ZA;D?0%.NM.$E7NPYTM M=B_LSF7Y*=*OC_[W)EQ+4X)NL#SA9KE>A3M\3>0 M4CA.?#XN@H&EG<&.')'L Y@?='14#E]!D04,D1A)%KXI_53C1H7TLDL\W;QV M+&^L"L%.Q MN'E>L'M^JJ^\AN:SQ0%WS[#+)EH$2DX0]S TX&)ZL--LF0FS*43,MW(_%R.V MEZ:SYL.EH7%O"41N7CVT9(H=MRIF@9!L=)85D4G5/2?Q$@S!98K=N-KW10Q; M=\#)H>?%U;2O%#U.A=",5]%,5M6,71_Y/7["<8[A[OL1ZG)C6)\L5X[=AYD% M"9>!,#C>R\/)B1ZKLL**M2Q@-RE&^A3%:P#=LK&X>)MB-)[YEVJEMIK\5W'7 M%R@*_YD'&^9%3:%3CK#@346'+I(P8VU/%7R)8@R6-UP._PV(KH]%E**7 _)F M084F[)>/K)[IL ?^_\L8/V3$_^TZ!MQE^@E"_Z))>_O[']Z_0XPF*HBRKDBG M)4WM ^;T4<;_0V*,4B9B6(@(LV;UFZVE,G_XBA,_3'DVLTA]K>8S7\?LERPC M7;B.%TD"U@?\^/Z'=S].*UA_KF\= SP8 [8L]!UR"F=1;J$$3PZ&Y&BH'&ZNBCR[ HNE,$90V^5Z=@6NA$-&2&W7 MN9@D!XAE[< LF9;/)T@A3FN6.YH)]JL.42&#)V2PEC;7R)FY9-#"L."=[2*KKVHUO5A8I!ZN;.P'9:"7Z!%A M7.1&3H*GD=1J'#,FCRE.G@#1Y#K>YY.B=RHQQ*G-$+(S(X(Z$Q4Y0B&']?#< M)3T;_ RBNBOZ<9/$2PZ795W6%4E^V8;^]I9<"E"8((1%ZN8YY?<+-Q,Z9%00A&6RB=T59_7 S3UM, M"P)6C+67E%)6_H@:,'"0U_*.ZD5KALHZD7E% MI98#B5^=HK3-@K6QTT_NR-DLZ;!C"2@YS;;Z_0'#B66& M53/VS[D'+2R\C+6NJMYP6/"=K/-4)*Z9:W:CCJJY^I4#%SE#]IO$S*J5]B8Y M+JJFKDJWO*(02[7NES%2QO^6=%,ISG5G ML33\34H+*%X;1Q5BR*W U\7'2OWBF96.>;:E:IXJ1#:4%/ Y17TF;!)X5H^A M85D[W8*M,MN*3:V>R6I+\M2+@UMZ[7,9K(DEUBH= D'KTKOU"+OBDD.!DY T50=MZHSUS::8L)#E$0K)NJDF9, M8BF2I+Y7^L*'FH=W=)Z MJE,%G2BF8X/UDX!+'!@Y[BBI9KP5H$6QO52A;QLORI! D68J MJH+8MEP,"Z2#'2ND^I[#;%H%V5P$ >NT4-:$BA*'\SREEAFTJ-T]TOV?/7.7 MP#TT.X#]E$&N]-_S< \+[%@WJ1Q<+9B5!2"2 :1R@"0+S(;+>/JTY.+;TY.Z M/ H.9LLOT"'KFO/ MF,&S^MI-2=FNTMU?EFA-\\#X.6$V4'ZFFZ]H[N/2U*E MRPZ(N>4"TCJHG/M3,#R%@2KF2=#!;1E MJ^B<9A,+T?FQ)AS?!>0=>,!MEJ ;EZ8V416/'W?X6?+W*:"8U5S'5"0[3C/I M/[2E+9Z )&J$ZB3ET*)K M]Q+50KLEL1?\+6>06!^>6)WFFG)ZC^G=*ROZA=U,3"2K>DT!R;48%&$V*O)@ M6)3(<:&T"W" ?HT@^RJTGF,F4#141/")J&NR([8"KC,/[R(&Y/RD][HR?ODE)C:5I,V25@_4" MZME$+CP$Q7@L4"&QZ=&K,)8H]6$LRN>)'%?5CGVD[D66)>%CSOIPKLCR.::S MM5QSM_AT2&EF"V])%%"J?P!P_G7HA]GKMYB-?5K2R1.2)ZVJE-&*($X;[LB< M^FG)IGZC8.!;W8/@FGPIC'+1+3,.+H_/5Y2TBC:6=$>YM)(#:(SSBK-E-O;+ M%<1OP,*/,_TS%W==T6?*6<;%>N$TI!?+66YK9;=E'R];S5U49A=Q(#K.X5V8 M[XQ$<*XKJX0=_+*S'!O$6M<:XX)I%Q)SY\OV@8RX[7".><&::^Y"F:V*<+9* MV3' .E[4,O?-0!,PTLAO).I;PR$P*$OARF8R7#1++&Q##!B4I>K?;A'H!.2H M^N/FED1U,GS$U/JKY-C<8\JK%X>_\\S[.#CWTA#L0TI2?A)'Q8DZT[4VG \U M1>L-O<^HK+"=Y!&8@1?V"CMS9&W-J*BF9P8ZM L%J;E(50[8,<)X8)<)A0M[ M\;:75%-[W-%-7>F]?#HD3G.K1H\]>JHBML_XS'**G!B>!2/*)PS4H!44990I MLU:49E""J,Z\"/S9*P$TR'PC5ZQE!JQ&^>J5;=/,B1LX)^D)":5J]I%TI_*N M^@3 @71.R&\\H=)EKO?2AZ-P_@B<((!<_0=02_/C;&2@5Q%(BSRB(A==U6(8\S^><31) M$3I#7LDD*/JQ^-SAGL4X^(=1=;FESZ!HS _J?Q@51S7-#L5"59AZ*3Q4Q37/ MVI0Q;7!H:QQ0+M/^6+8RS+9E492(BA6$QT@G*(SW=!?44>9(^BVGGK&$Z MC^>B'1OC!,74A+1>5N*&1Z:X&BM9)]=Q1CY[&$=\&2(P2R;9, M3Z+/^R7GY;L!W.YF;@_LX!STN(O4W"C@%,EA4<$K8LP"<$7!KHQ$KPA2."[? M9<6"\]:3.JCZE@;B>N6'G2L MY-8450)BQ!?!TY]-]*@B]?'@^/;;)0GWXZ2N4-)EZBRWS79-TD%JDV7 (EJO ML9_179P# @DG[R3_"B<)7Y+BXJ7WM;_1SR@-0E]4#'35YWQ;*"R=N5N M#R(Z(7RM"9_9GH,OT$709'] _OV]03[4%5ML5:$D_OOTIII'4*K5!ILWK?)+ M&4#4%)Z*.*T.$$\1B;2"2)Z8F%%SNMK!'D],M@KK-@NJ?E@<_>< MFD%V=44?,^US63>VNOO,T[''FDPM#K)"JL<#N@6OEMU*EYBR@=.,[ZG+^!+O M21I.B^U+FASV_=&+?T.!(,NR6^E?=\5O3D&XJ":7N%*3>!8I"@R;ECKPJ77" M)7Q-:W6[?42+6L(YM&?VDY YPL"CNXRGI5&"1QXNQPK9DQ%$S%.CHD$ES6,. ME/C)2%4S6UY*NO(SXYW7 4[%:N4H]+OWU.)8Z(+!BV,!:WZ+BU/ZU?WG\S_\ M\,,/5J$8[$A=+%G6S!ZHOVA!L*6I5=L(Z&;0UK>($\ Z]C9@AD SAT-ZC\'- MA^_Q)DSAC#)14UD. V(E? 2TSGDV3U(,9;GLTJ*TD4Y0,082@Z!R%'L5L;8% MK>^U%8$Q&^L/:3'%S:FUFA:N-M=JWO(G&C?5UEJZCA76+9MZ5T<>$%@6/1^L M08-#;T?I[2];3,R"_6U63.WEC[6NA$$@/%H.,S>.MUE)6ZZ$I:RA*JM= >1 M0!;&FP?(2O22HUL^2@"'DB*2)%T700M$,8L<>K?#1_*$DQBX8,D!IM::"F5X M@J)H-XB2/D^DF'MK.*Y&U!"*XS]$V?%$V\!D->TLN&HWX--]MUP7R02?0LIR MXF\/DWSGG"S+H"C['Q2D9XFFFI9,W=L8;62AC(:M8E;'M%Q_D3512F3I$M// MR _'H>=6PZ>KEIA5P$C;1 0V+9>F;$U6;XJHO2J?.L1I"5C;ARN"BL0:KS&1 MH:V-MKUV[QZSW)] ")]=D'1BANIBLTG8JA4%E6COA5;M(ALB5>O44ZM>*1O\ MJ]]7M;H2#GQ.O_@%P]ZV*Z,V1]UXVELEIU\F =W,G\9E2L(A"! SB]E,;)QD M:10',=>A)<) _E;KE<)2V(^LG-])7N!$F2I_Q#, M$50%$-Z)2"-]WQ[T^DLX^N@LTC"W6'+XZZ>?CF3YT_+V(_J)_I]+O*F+XQ.) M-^@G^G]6PY4L'#GI?!5]&^H)59]$,<&,0 M!UC$ ?P'4O:I.0_UU]-SF5FH"!R [ =J('!=M MDZ%@:=BN@#0IF0KKTBD;9$Y40%E.0\J**33?A]3PH1< 6O2L/>95^(3!SC=P>_Y,J"RL O5_ ML*N#U1W;E R<@+D./-K2"F!#6N>BJT+;LWRQ56TJ9WFP+V+/+_XV N:[DLA M30!.3'X7)R1 U>G,I9AS&H:UX%I\#8^USF[']-ORZ#BVMN5JAZ,2+(EOI%<) MV?V"O2C;?O9BCT,KW"4DR/T15H&V_O&L'$H>I:PVXIF-AG;%<&@OQCM=!>C: M6OWCB5^SINJMKL*Q"K%E=,VGD<+G7&J"CHB4I2',&1@4\5%1.2RZL[8T=(GB MYYA.$QAM$U&*(?7]D=%2;&C'19 ^)"5[G],"2]-QWBN9'Z>H?-4[,[\ G[V_ MD>2"?J!TK(G&<4'%HD&L:5Y]CT7R&@[.#\L8BYH_ST1HH-'$.BD'@W)-$F-9 M$>C9=+/;ESJJ"RRJLNZK M.14#F4W7XN=@7N:U<^9*;M]L@6R$FRSST@'%VP MG])E;-276B(JR;$8G!(2HP$4XHNX6V?00!-!BZ7#8JD'UC/!%WH@\9R.]>)B@%W),^_H(OYB$1O?L!CU.JWZ MK%03":UN-VHUVL\D*_"#90U\NO#IOQ-\;%%(M0;MB60*:' HQT">&&2&DCN! M'B.H#C-;I&-1YDI0;8086&ZQ '*\)]D,L$G(>WF%Y' M)CHAEQIPRU< 8_/ZK0Q=D*3 97^#8LSN*98=E2^AE4A5B!9, D9',#P]Q9#* M "#>"'_Z,N$N=4 #HA^599=ZI0>ZR6[N7)-TU8K9.1J)&-/_/6(+%ZK^EA'F_"QTAX&=FE 3*//Q(2 M/-,;PH1T2@6QMQQ&NA+Y[01&0G(HNLW;R:F<2^[*I KA68)L(;R UE#Z&6T* MX6TFE (M7R9?3 5SQ]&8#'F@(^!L!B$8\G2 M9)T$;2>+\ADS).>LIO,0)24TSGN8M8D[727J::[?VGE_6VL"/XAL0;Z+M@(I+U M"X[6=&]\@[:$-WL&4&C>VH$=P-^ N(I[34W&+]QKJJ/IC3 [(CKF&>MM@64? MA<<98IG&(GISQ_*,AO%4YNVF&VL!GY0@_\VQ^00#^X4K()ZS-O4V(:(V"EEB M6E7@%&YLID38%7,(?M=\LJH &(#T-!7T FBXQZ46J=D.JPJ$'\X\R.&05X?I M4!R)H%C<\EQF7ZP,2::XOKG,\]QM #4^DF(34$XM,^Z@C<(?;I<;G$F8#KC@ ,7B9XO]+X90-0Q MT!THMEH]) 5?+/M"XLQ2>WS/<:!\T5+(E]R]G#WQ@CK46A\E/RPC0X(1QX'H M2U2T8RJX:CG$YT67?T$UJM^F7GM>4WO+..I5H=W*3+SGN083 UH*(4?YC4Z% MT4JA1$&&I9/YE CK8TI7EQ=!^1T_I0%G%7+\+'UAT.[0YZ[@Z""S"C_G41;N MI^'V2,)@UM$/ Y2Y8F4L"N> MJ[OBLY<$/^.TQ 2;FN>JI.Y*Z\^#0=[P_Z G/IB8/FO9K^8%%5L,/RK/J\6%J8MP=3]_^?*[-C\N#YZ8MCRHK642(+0"WXF/X!;H ! M7O:"T]< _5 Z4**J5VH-3;18IY4B!6#/P]PD85[&;TA18IFS41$?%N!!]!Z[ M1:8V&!.CUZIBOB'=5%R8Y9I@25NU@!XDA/!L@>/+" M""XT:Y+0/^%:^Z-I[B ^-,^9"L3@U>]&6D(OO.7.K*6H6T$)VHF105F>'/N, M#GX&HS?T]P()>O):OER+R_'4K#M)OSA4"J?%LBC7/44YJQY$(1)@DF7$_PT1 M6X(QV_%">&!7S %[S_VO'T1)W42[7]*N>W=EQ9XM0]^H3$7T5$J"2\@S)R0X>(^ M"3FTS*AAE=H0A9]HW13-MZ QI4-FL@%YM5!U' V:F7*B3Q<(/E>^Z"()(7\7 M+!=AE<2;A9^%3U-34BK7/CX(KRPKAD'E.#/DIUB5N2T/U1.",PMM70CN*8); M*DU2TMVCB/6_3HUW#:>4$2?]HIW#+0A8R1"C4D9<2MB,RGO&MI1RAG8?BZR MC@+\4WX2GQ]NP=3'*[+:XC"YRF-65#+ALU6&X?"O?"!T?D!\*( Q88,A.=H, M'Z]MX2OSK6B ;\*#3P>4,PUD!' NJ$:6!<:L/X5MX'='%NK4LUHJ2+9V+XN MFY:E$FO50!6=FCR1*HH69&B>0JD*W+:XOU+K9XW##"JTNT+F$R$0"NAM,>H; M5(R+@CR!,U2B39VZ K1HZXT4BU+\W@2+;T0A%=_Y2TR^N%#?>4EV4(!DIU9" M2N< HZO"X]HM?V0> WFUFMI=N.;+Z6B7;,N-8TH2Z4:4$@ :F^U(AE$!!K:M M?C-#K*"6FXR3)YS^0F_I8;7?Z8AD'H M34[DER2A%-Q#:4'VC<,B%.YWP3J<2@4QA_FNY:YI]6Z)_:GI^L=^/K75=N]X MHCT3AU\$P(7 MIVH[E(Q?ZH%:>7XYK!H<>2/:J%BU]G#J)^&>N^2X(VZYYF&NM,1N@ZV;WMC\ M<.]%I8M]6EJ((*=XT;\5.:6E6PX)DRR\CN"+9,/^(560[/C)/8M.>+-0:-G+ MKBH JT2B,&!\&'"SLU[ I]9)7T*@D0],M@&O#4J3+UO+1.*QR=]E;HM"[#: MY8\#@%^1Y"[!GTF,#Q#?X9;>#AIEF^[R%W*,A(B V%BK$0'^PD)>[LW#EHIBV)S7S[W)DOPEE&@@4B/"!( MVO>&F!.C]EER<41S"1&"L]OLKD!_@[2 I80KGGR6J_!V+/VA(*VD/YR48)7& M((4P,Z38&A)C .BV;6&J"(2-J,G$Z^+9"[1#L">;-*UJ )+-&-A)2?7"W2LF ME$OWQ?FF%DOW59_O"PN;\_6F>Z* 3>HMJ*O.$R@KT@CU3F31Y9+IX\7>& MBI[J*C#G"2>WP[Y7$O*F648]R/;U/,27[89A0NX&_KW2JJ \X^;QGIR3+*/' M]?H>EM.DNS6GQ$)_0&N6S$(#W%?0P+D(@-8%!"V7HK/8EK#*EW&];>(T$Z,( MG<'E*6*^RFB>_HG&!=-&!,7)>QJ"Z+/HOYT9BO23 Q78,PC&[KD"[MI$<8T@ M9;LUV42.HRJSEBN9)C);\QW4-3Q;1^X" I-[8GF30=-@A0K49Z69X4LT8S4M M<.56Y&]QD$?,>JT*"A$/_IN[!._"?#>7N&JRWCG.GC&.E21!NOO<& 7%KN0& MBO&0FC[(#-:;^5NKV]-#.VJVL\H078'I#^$F#M>A#^U$?!]\QX"P0J+0IZR9 MW@5D+V+XL1P7E0,C.?)+[ O6==+2EKE'%99.KYIK$L+SU"QA(>*)]BCS&O-[ MFZ#*0\"G(DO5!\X[1I^R/#5#XV7D:G-*RNP4F3URS=N@3 ?B../!F)C$9WZ> ML"0X^[@1%F73>)3ADB1S;="K,)99-] TD EO2^ &J/,MB<%GF7SWN>AA6] M:.N9<#!$PG2$VO," M?_;1BZ!FZ83E*K%HZ4^G+I+X8D:!6%BK]]&F79>(IFK+OQ59!$$(/WG1 YT6 MG%[FNJ'WL11P^^8K^[FB'K^Q2QPD**&C$2#HN@;;9 MWBQB**"J9&\BM8"2F3>O8"K?%0Q;RKR]C *V,:V>Z=P>^/\O8_Q!M+9EV\P= M?6E+/VUHHSU=&.B"@21]&>01(R 8XB0EE,N,D4?B/W283DEMEXS8%;EV/ B9 M,_X?0D4O^B/SS+2]%!VNJK:J*^BVY -/&TPOS'&<>]$]7&,3#)7&4.6R\KYR MG^YDSW Q$H/@96.AA _&RZY944WF?14HQ=: ,BS*++W[I:S@'>&RBD%X#363 ME8XC@-ZM^?KMB5HI0!P]M_/YR;_$U/:*(+.3_@.'F_C#5_I9T9.!8]XS^/M) MH0"8SS4GC;"@C8)P30TV'%MIRC:GJ)K( /CVRJ&0& O)P63' S:<3>A8:NW3 M9U+QGYLPQN^F0>$*2L5_&4G'):B 85?$>%.1 PY72YO,C1<'7U)\S^!F#32M M!X=J3L^]>TOXM::8CK3\VC92##!>.YD+ 3A@L-4813WQ<6(B^TT]V1']ZLV3 MK9[A#8'+.> ZJ7D^4SI6%T0YFE,MD<=^NVJC0E7C)(5DK"\SEVPO);/NQ0M+W+HDA26V6^[$9$2HN64'):HDB23-^K8']YAS'F!I_(J?U MDOX:/5BMTJ5<%H%#J.*]HPL/4 Y75[( MZ+PD454(3A%)DKR U7DA&I&=685IW!=A2_6B_QON+TAP=+_RZI67DT24)@*B MK@O1=>NU+HIBE,EBC[L$JDBS VPUV2(. 'IU/S%#1ZEJD>395I8QZ,5BA#DN M!E;$K+97XK)"3V(QQAMV"F[W$W8V]Z)XUK+K'69Y,ZE0EZ:%$M*Q*&$F' MN8]JC-\+QN]=9UR'-#V; *HQ_.?<@Y.+\@'-,12P7I)G=3>9\GFL\-?L/"+^ M;Z8J"3F,&+3H\\DF#G_G$!@E:!Y8TCQ[#SUL,4-&3A%WO$D.Y\CWGEM=S:L4 MU97*1 7:V ,V:EJIY<2C7X$7Q)BQ=0-Y285UYLO_755R\!+I+]0GR'S59?\/#&F=D?08Q#JMFP2+8A7$( M\0=8Y[)VWPSD:(6T]9ZP)B41DU*3H&BC9AL'UJ D%7!>O3BSM1H2P*#3 $_9 M?6L^U' 3 E11=VZ_?#[_<(^65^CN_L/5A_O[#Y?HX=/B_L.#ZW(T'=>Q'HW5 M>4'Z 65M!\9J3>8F!/;J;>4$+,1RK?4/];H@(*RK:QCTQ+I 52AMK]$OHO%)*]DH;5 M:ZNWCJ(_CIH*D]&;>)*%K*HEG=8$INR_4^DYG:%B" 1CS)*Y8$W62CM$K<"> M%/AW(?!<@4Z=S*9+\_4BOP"TC6%A*\6^Y GSI%.RKC25JC6]+^J\K"4-MK>^ MN8Z+%MM*;?)ECE?DGOZ;Q-YC=+BC^S^XI:P_SC[/A/^-09_R MG.QE JFTYQBRBU?>5]EAY5DT#YS>58>!Z3PR^A)8'G*T(_),-\@@9VV=15)O M&*-FA*P/0&S;%Y8S9R=(PVSW@]< M=):'/65%IL):Z_J"JR.@%9D+SMJ6J-4ZQY8;GZ?*G)$_S06[,#&9N_+)R5E" M%BHPC')?J5VX7IQ?WUROKFWXGX0[4ZWXD>V-P;95=@[%,H!>P(5UQ(VC2=5. M14-E'^X/E[QA_OPXN_6.=B**;+22%@)B[K*MR:2SSKOB?R:QP$^D M$[V?U@ZGI(448LYS7VWD.0O?K#*35VDN8WJ3WY/4B[K2^Z:Y;\_8-9/>+@(Q M5&^:WVD*K^\\]0H&?/U6IX.[NP\G+:FZ=+]A,<7^PL;AR+8X?:T*V9^W>IKR M%U^SA*B#4O>-4VIH9#T5.-L#;1H+B-M8WK,+3*D4/1Z8V<.K!*1)\V IX/Z2 M2M&ZJA7MC+#U9@:4G5%)G:ER::FLE[TVE%L,BYC=8Q^'S/D[+:2HT'&9YT8, MURJWW*-/=^DI;9L:R0 5?+BX AZ7_@%PZ=:A'V:OWV(VNNORR1L6(\6*8!1B ML_5W(;M=R"^SQMO8E*1?I'.-$1?\2C;M_J[0 M1$ 4":KNRZ&YT,\G#(=1\[YRV7)5S'?NN"OKBJ(ABA[L,O!SDU(>MGA!16 MY"YO0=A:.,>FL&I44H!BG!^N\IAU>)L&459 7Z#S Y(D9\G^,R9*)UO;.:<-/Q8ESCSP@A,EFK-IZSY7:Z9.T-Q&]_BS$*'4N[M8<.\ M1:]NA+^8CO4-ZD![GY=,5 J%&1NHT-.RHB=I5X.??5[GY]P*Z_2 !E)QS4+A M5%E@O T=BT>\+>(19X W/%O%,+U)B$1V]D]1H&"JZI;="CR>P#YK&:X9L:). MB43#BQG:RAN4K+?0^]0%;'4E!R\M9'%&0[>6+RQ+7M.S96H&:7EFPS (QJ'; MM[[?X4R9I%;E;G2S6S/A9^SS Y?Q5>)!E["'P^Z11$=?51D-Q(DXR&?%\V.9 MV1'(3*Q =WJ?^C'7%CYFT;S>D>N+*4TTVIXAG].TQ>\6)CBS 8Z]]*09?K<47GD;6;>5G@LMH=3 MB:@\2S-'.6:!0O-MBAQ):=O[^!6:$+PXW35Q+KV-Z(,8UE:2&RT-;PCT =R2 M&',\DZ.K:UGC/Z"#."$WV:VX76?@69= ;ZZ*3"D#T!>4G8Q %6 =$I])L:)Y MLI[@.F@ CX92<8U+Y;+O&FN5^WB^RR..+L;ZR_MJAPM+1P?T]9)Y U]B'R>9 M%\;0)(ZDK"GML8>H2A?EDC#O""=)GXI(M?-MB&A6'=+7,=3L T='@DA53#M) M2^:5L,/W&7M1MD4[:EOS:G_(\X=L%2(I^$@J: ['5?C-J74A4G+,3Q&''[&>QWWF%Z^KHDXBRW3?"Q M_0PLZU&>"F0<<051<6VFVQ9Z' LO0VLZ+'J"<8N;1K7ESVEK0JS'5I O& NQ MP9 83;29A92ZFY,77X_[]0+H _H(G.FZPTIXL:L3R.D(^ )XV>QH^T1RYN?( MXV#2JA-T(/,LL&6V3N$UJK)YY2B;-?.@HE6KUD!Y3>?IW.9<#B*7?6YOPS0Q MVAP-MK#2>_PE1AT_SG.OP8&>R]?#P5;7Z]#'92>G.+C*DSC,\HEM4CE=I4\5 M!$P*TJPHP@\M;0^CC!>\C^@BZ4. E),$OJ MO:@A/O*0J\*RL!X!GY8WEQ_N'_Z 7EU^N+J^N%Z]?OOASU^N5W]Q5PHQ-3)' M82:4O&D\5Y(N%+W_]W_ZG^_?_>O_0D+YUATJ%ZJM-,D'=%&Q]MQFO.D.LFW> ML=4J!8I1>?KF\7+YI+)^+Z ODT M#D3.P7R],7E:@<2 !3>):/_M2K:A>0UI4W3LMS%1,[7J*5H_XHW];+D69](MR4J\C.OX$D,CA#"F MQQE]%B*+/)HC\#4FP(KP<6%+EZ MR\2V[ZF"I!ANXI .Z\59H\M-*DK8-"USJ)W,]N\I%2LU*,62$4WWFA3E*6]V MK>0+[$I^@() U/DULU\,TGMA$ A$L]VA"H F9ZY,TS50S:\4?A#FHFV@*=D4 M59&.'0[33#A]&R>7^1<+45UYC([+/-<-S31E6PE/+)JUXYC(H2E*-8H2X5FJ M?\HRX6];YDAZ4MK+5\J:%+]0RHN7 +5LJ+RIV4VXQJPH5?0X^\A;G)DY2#A- M!&-PP# D.ZF)84Y3V&9K.#K%:ZL^M2\QF";TJ+N@9U*8:0 ))11AV37PZ%"O M/E+)KA(^']YJA2],T!VUN,)\=VR9,EMK@H:KO#;+PO?V&;Y+J#T0[KWH+O)\ M:IF?0X85/;D [?PQ#8/0FV9",;)@)X/9D0!DI6UOBPV)Q#(J2$/K B[6HZ#. M<=DE?4LW/XYO"-]C\H0!X_ JAZP2B73(O%JK9[+:DCRE'^LMY2S#.'[(B/]; MD?P 29F3EV;*\A> "^9;6#,^2AC$G/G7WO_P[D?$!D?%Z*SIP[>FGJBBF7M5 M,YR%$@V3:X9R@20;2/+14-7=-ZBJFO-AY&)*F8;"RF*RE5/5[.++W!'4=$@" M:J9)M%$."K(B%^2*,$Y'FY'5JUJQ4F!#X=K)"+H@9Y+\J8M;"4*V";O^1H2M M7Q'D@."GYO478!6+026&KD"_67U3FFBK^9=W)O"R<0<; /=)C8A%$7*-0+/I M4B-6O96_8"@)P<&"?IW>!M]CB #"K1)*;.GE+(?RE37H*<_2C&Z1@/JDW"1@ MNSIRL[QJ*\8D MR]!EUW&.5TJ5A\JV54W?)<3'.&#(D:+['#_OIVU0DJPHXU:,O-K!?A*R136A M&.ZG[-5GJT.?!3D:+GIH5D"W4OLN&34N!_D)L ^&,4BRW(OAIZ^XIS %QVLU MU<'NU!B5J[8=U+K ")%>"1BLURGGF]@)^170$8;;$N+>;SS M2MGJ29$ %N5H2 R'U/%.7?Z&"_ZL.<=S= INZP,A;%;^>8$A?(NGU8'5.P)C MD7#T]A50?^D^(2;$%4NZFI&F[0GB*6B[WYX>CFWUL1;Z"(4^?*8/V]T]:FZO M27>*AJO/_G7""/N=;KB8H8+JW+B*ZPV] @0\$5Y*+9BS; 5?D62-6>7]/34! M#&1Z5,_:DCRBM@E/L\9?L9]#<(JW;/2B2+2AP;M]1 [8&DR#<5EKGV5-V#=\ M4@NWZH8/8BL:9URZJ#&%0'BNK"0[,E5PKZK3]9)IN9UVT$S)RCW6H2L9S+94 M-<1ZG"WY'\87/G61@0 -=UGI.<<14'#(C9:!\H];AD_DV*SXEQ>^"]0$%;1] M[F+06;333#6[L-^!A(D@19I6;,,FJYB_.;J4&F"^B;,@Z5F%?&'66&L0=JP0 M',WE0RS=*;>%L2<(OBD.3\7:>X,^<*OOW(O 9#\Y@1\R+\E&BGR.-V$O23X&3-LM7N&3WR'$TA\]3:C:U]U6;?B!K 7 MMR$/AGN#GOB A'Y#:"WB3%MK6BK@D>JC7M>N?ZQ89 8!_&!4#G2*4JKKN:? M*Q.IS*,M9X;$V>8EVK-@>_\R8].)685L&IU+>DV'Z7RT94J^@'SE+>*"[O#? MCG32M5@@SPO4F9<'X9]5#77_<:$.D=[Y2BF#?3VH*8/5N,XB $P6 + $[_VT MCN956C+5Q5WNM9D2-2'LM7(<[AXM\7R9A_QH^W:(Q[@E-J^.+](E=Q2!M/,*N*?8[I( MMN&^!)XT4P*\R'A3.B84YA[VHJWG_]_>NS5'CB-K@N_[*_BRL]5CF:=/5=L\ MG)VU,0M)J4R=4BJRI5"E]=3#,2J(4+"*04;S(J7RUZ\[;@1(\!8D"$;V/'27 M4@(<[@ (./SR>9[ 64_@"TN*XUE**C:FI$\- V*$4M PMIH?G.7']+\N5Z>^ MC_S8NPK)<_+.N_2C<)>D<>@OALE:36X5>@CFU2;+=1O$..BJ%>B\I=JS(=_R MBRC9_CE1I)0H4@Z3T)&;6'!+6^*VXVGEJ;:EFWJ,@7R6W@I28WL0Y:'!SB"<+K^ MLPB8V>'DNCJ5R1+#H159:*1$#$AE_D,.>:XB\T]0BJHHWW(@:EE'BC.?= !RZJ^3DNZ3B^[ MM!Y+PM02J3@**'&/4;=EZQ)3R%(#T#(B3)-7<)!N7I-1!S8^WSE6FB![-H)( M6X_89!RP1R7M40F!^-E(5;5'2NEXUH:Z5%Z TN6OB=TR=22O^:;&Y+ "/=W; M]-<9"I=.((.>;8)2+)QOZ4?*:SSK"[!8"2I1>"0W.&]M,O_9_R-)+^'X3PYP M:JZ^A:>R3@EY6T')^]T'6G-47U2L_9N$F=K7.U"^QU98X+'YFC=ADWAL!-3^ MV1BS1(/;$E5311/+\?CJ2PU!@D&EBEAQ]?6N]PM_^JI4.BOX&RUN0GW:2WZ\ MU>Q/>QA%LQF@S2+SE"IV/"YOU W P_W4DG5VP_VFE:*B9S=+8U6W-A<75"O^G;@Z MCJH)VI1,?4.@>&J@J13/;@HE#QHF\7?XWR6.N,TOPN0(3[.#OR4%=:* IGL( M^?=YK;2H>U*R7>I&,2K22J' 1G90+9MEW8% MKL7\]Q?/ M[J29 0BG%;1B@^+$,8#*9^0]*BP.X!$ZPO^3S2"E;@5='3 (BAV&)X;0:@9@ M1N^[? K40&+/2C2#?1=WJ*]0G@.4#%ZHU)H,=R3=@R=O06&5!D+,%+IDKK6J M)+YP*\ ]SCZ2);->P;KTK04#T&N)>1>HN]2/HC=\7P(#), GY.4;W$0W,;P] M,4]CS!*P4;RC& :.+CX.>]MO<21T\+"ASD[62!-3CN#=ZV+20;R;LQ6SHF4, M7%5;WNRF]-"17M:6K%"K_E8K,E7+P,Z?RSRH]L1T554JY3;.43B^'^M@F*$H M*U*7DY<5.4=Q*ULU/*%VB-4G32668XR9@5K]9:[5.^_IS8LIT07S+QPTU1B4 M!;-<<[3(*;O)"X&!<'IUBP0P0^KZ-1;(B#(<=,1SW7NB M])4J(MX^?,;748#(! D/146ELY[#-%?XP9>4<.0>B0[) I6F#B]0!E* ,GE0 ME -\3!N"FY 9MR1\*9_"RJBVGO>LOD7\?(M?PQ<*D#+*OD8?1ICHN6"&A5U% MD/(8UXS8@OFNVDXD_Q'EG\';V'URLJ./OEW@"M'3:L;%V3'*'GL6H490RZ"9 M(\)N>OFTBU\XR.C;F_L)F91'(>4,^IYZL$E\'.46NPUC]W*LJV*V.- AIA;Y); 2R==[U;/SRF-=Y*HWYJ3951DA(9&Q5TH!(?'EV]$&: X'(*%YG(_ M/\CL1*:)X4:R#V)B;N7$R-$]!2=^%H_CW!/3BF,V:N?8TD9@CR:&VJ5V. M]4(H)ES\S*P,DRH]ZI >&].C@WIR5&Y'L1^:\H &T;T?.HI/9X//$)]N4TJA M'/%!EA&?;E/@.B9];\$MG*VH,3*CT%<21;_&R6O\0'T5)* Q*^.L:1X2]2A5 M3Y!E\3CI&8A2-YQ1>=[_.8\\;"^"(I&2:T)R4%LT"^XJ)?ZH]#A*V=L!::J* M5&RY\#=;L)+3RA1IXB!56K"C8EI?G8LXU>.A>Y7L5GT%O18-' ]^1',S1Y4M M0%KOO(R3H@ZFIR0N+(-KCQ4A4KBG/ L!;(44\IC-]8Z'$FY2:B.;YKFB1H3* MV,&#H/_[<^#+T!M7 =DW\0/X6CZR[)Y6\WKPG^=@)GH$ * M_)F>:K]XE.S92B;?]?@6S(&M;6B;L7QKMF3*/)QF*6/>.BX//8.IOERQJ#NI"8]/6C %83_WCF,88M-3A]+B,_R\)=2()5QA#9 M3T/0U?.@-ZI)7TE_/G(VWGD8+)73$X',82V;<28J=GLA/8UE8T-[=&SJ,2QM MGN7PWBKS) ,S00LYVRE+VB3#3:H3X2>#T'$2OR\-JH095'UJ4$VE0?7(#:KY MK##*5R3WPPBC8'=)>F A\$])D9NB:*;"#%)J89JC:)[>O$O8/\\SAG[.- ]& M<[L8VU,&]^CH#?,S4V@LM:_LDRBX.AO0F%JH; U MB>;:M73TJ;Y+1NQL6#>>M-1B!QLJMUD=I0G%HYZK0-^TTEXI$JQ'H9:TY%*? MOZ1\3:L@)J&A9D,8\Q+9I;GV. .T>A?&WCW)X,6[W8-R=855DA*JV/",TIFP M!P4/5 E5N!"U(I>"1VAKKM3O1V5_#3.DH^L,U6Y02G2+!B+8;7P30-^93* M\;&-QH'=K\C9[&@!>\V;PU8*-8\>HP:5-94\PVKCJ)C7RYN7 ;=C,ZQEM!BU M_L.=P@)]7^C0M+ZBJ:Q].?Z93P?_)/@TB/!FCX_HL2'A">(9B]W_,-.@[OW* MEA![P:J.17,-AS)=K^?.$RA]T(#)K&4^3:- &7!]I)] G?V@AF/ M-'Y_7AZ#=? 76\"&K+Q?<@TW5$!.]2Y5*Q8F[P4]:P4)1W+,=\!EX@DZMN/F MQG*L!SS*";;JX/*_<9V>E=9=Y:OC$3086MK _X9I2^.0"+!4+U?G\=3XXUP>LU3*G-B:2L'/HI)J;/B%T@?U>.Y/7MV MA-348+&HHGSRC[&.U0I>5$2Y6?_J/9,8K8H"6G0>H4TUV.!9#Y==!@K1/:I% MXU[SE>)K6TD;;XQPIJIR(R6*JL+P=+F2K'=_-L)TE<>KKI#=RGA)S%'F:*#E M*@A(@-?>Z C%DC"/':6DV9TW3[C?]*+I (E86H4"Q]-HW_<^E0\T,9L)&#+Z MD@<0/* *>.H2\=2+,HI41"4PJLN7PY!',I\P9@_G!S]%TTLFD-DG,LKB=46A MQ&9!QK; SD@*WG9'CQQYG-0O8E*XVAVPGZP=1FI<",P):6" MW3H9DX*,X)0$I6+?-17G/1/B45W. *;WP0PH3YNN#^.L)Z 9I@CVP?L!^\!^ MRDJ&@J40/#O>*,Y@T"LB!<7H/?B0!>\;Y6+B5)>5CT]BA78&E M#&C:BYWZ0HXDCS21Q: T'H@.Z]%Q970$!X=C0S.8:^,? E1( -XK5VFD\HE+DU&U.-4Z7% Z4Q/N(7]7!7-1U_06KEIJ\Y=:=&^#1DH>$@RD6,[:M%*T[U"6:;OSG* M3"^;^AF6 D8E^7?>5DIH#=L$+=NK(@CS)+T.T\/-J250. T/B7@W5_.6:S+C M 5NNN_IN!A0GNZ*6MNI*%=:;V"O3-.8JPSJ7U$W@7-S&D"=PY;W?\9CE.19Y M3!V"B? C1A0AV,P*)3'+_#079%GN)'TEZ+,EP0K.+_^9?/A&TFV8D2]IN"5Z M4M-UDNY(6.8U-,.%&RP![YTG&O*!(,90F MWS/Y!9,MRYMSJ0+ V9'Q%CDD6YA,>TZ4A>'7U M("IBGY4T44T03MXKZ<]2Y]R.>(VIKE+,H!1SOKKFE_X1AHPND\,A9% /(R'L M.4%/H6@7G1ZSL=.W_WI\&*?&/CY', [Q-LI#Z"#SRO&%QFQ"ZEB5-SL;!GQXSX8.>ZPF%7SF\X"(A\R56,",9YK[KCFG0,SXF M2? :1M'4Z7@Z#Q3_CG'!D ZJWGG4> 0KLR%,NILR]83XE;S1R!F.W)QEQ8%; M@2DP!)RE5P1O)JP-KX39-.)?O\Z3^&:>1U/NVRJ7P3F;?9H4SWM0=W=AOD[Q MN3K1+)9S42* *;/%!_;8R&C[P+%_R%DQ?H[FK;)JFZ,UFZ.YOL:RSL#JQ0\C M]*O!/9+Y$9&\#SRP.\L)E"F3OMPS.YP/IJ[D?#Z.G!3?1/!2PI)VZ'WZ0LQ!**,LY-QNN;XDGEL9I.+IIVF%.Z8 MX?Q>)@?<>6R+VDN6.N'3K?N0+5PF!K_RCR?\F"/?Y'A?VB$_Z61-<;!O^:1M M2XXL'.5%]O[9]X\41 \C\^ _Z)0 Y7B2@(N,I5/1'Q2Z]OU^#\7W?5),4QN> MDK)EQQK#:"3<_DC"=O+#&$;U( 6D8SWEN2' ;]REWAZE-\^M;D&Z^KW>6,9@ MGDJM^*RBPRE&.CP^\K>1)Y(D7#%6,N)6CR4U0EXW-]*,;2R]*XR.H_9HW>[* M,L)Q@-+\.L=.M22GE@)039'B)9]H=>%G*>P,6Y9A"6[?L$KO.*AX3HB6%YYE MG<:SKAEIDY2$S[&GR6$-ZUZ@GU:S2]A?\G'.9YD\4X*M6J]O8T$DL;%*J%A# M8I"D?CYRU:I!2/E ?4[J:\=&L:?(T>!+=#/E11IGZ_@K\:-\_QG>$.SN_)(F MB!*4T7R2#?F67V#\X6CM5,9\IFQ@M$N^TJ&]@QP;#=QT\',77^J\3&SJA61B MKV./#>F58WIB4(^.ZOV.XWH7EN(^9YV(AL#?^W(3-,^&)='GP4:]=@^%:A?\ MU#W6J27YS+Y6*O9W$\$NIBSKUW.A; &5'OV>B%1*V=-1PW#,)LP]2 MP2G#+0^3 *$)TE2F8TG[/ 12RI!4!D<2,\3 M!$6HRRP9'5-)HA,Q M0K8L, 1S?"_X"S-^GL8+3(EZ%R* ,GZV9DF;A'UA)Q-L2W+6_<23L*_I&349 M9L&*6WI%Y7-ZM;;_7P\&%C =%ANKENR0U8,-OU>NS7AB#U MF2NS3R)36:+=)-%LQ=JG":2WOZ-J86H?:5'12(E2NR? FQ^'WUG,6AS =#B'W4N&-H[G2.* 5!RXOV.O'B4&5N7LA[Y*_S -0,YE4 MD;H^$J=FOB*:]^2%Q 7!"M;38^8SZ'EN8[46X$'G2"2?K9Y30@UCT[R]Z#=R M%(EMOB!N[04VH2CB'49%D+EYDJCUU]B$HM1LOP9YK,:I1:A+POW$L[2_A:=^ M')P239'DR/$^4+.$^_*!EHJD]2$%Z/BI(!RLZ"0E)1'4%\NTH5RF;<[-C@*Y M<>BNY9D>(R.)=95&;"@)\BI27FQ&%*OVW6M@QX_^ ;?P-?SF9.566'<9.0_I M>93@HKDW&JAG$(&>L'H(QB<2B2)K"$T^22P&CV#< VD*NV*OG-[T D4561XJ MLMR[<$LFJN_*B%FOUSJ.9^%!8+Q:KK,[CE7-W:3/K:TJ M;]2>!N][5//Y'7=A]HJ/+R6/36ELQ\KW%9T5Q!994W M^T53#,#YB5JI:3MP;:TF@(7/<;A#[/'\)GXA'(1+1PL>H?\_:%C EE1_I7X9 MZ+LT\6GSFJ ^@K%&=TDN?WT-SW+Z^_'OL@N.9/(+M"!8HASF-4_G&'T(WLKW,D?9GJ2HWV-BA%I);.>]T8>$[,J[HV M,K]TAG4_[:SSW160++2EF>*SQ7!+B<>>0'QU-Z[,4+26%(Q[(BRKU0PKE;^Y);=5MC$\9?4XC !KE\L1:%-R;_!@3:/$$J61AGVO8X_?-M2R)RK<+K?QOXU[V#!8'BS)H'SR 7[V"9K7*;C(5H"+Y.7HHM+ =U;/@64O;I/#,25[ MT)]1DV9@F6<_7WQ?JZ'TB'X@AO.4\?#WRH@>#$E+H=HM>3;++.AE0KCH03G( M+*$(JD>YXW#=^=D3%8%C[BEK^5)T9&RWG$TO1$A5)(8?NP2/\^V*V4:&?2442E(LJ,5Z5 0 MZ^%@ES BC<8.R+=?R$_9<_7>_( M*]5)_"VMR[)Z?DYI38E2:^&N-?GF7>4W6-8*LVIEA:M5'+!49EG.)7A$NX.L M_;(AVWT<_K,@_R#Y)KD@O._I=;F$.)Z01UIR0")/%&E=!X53ZEM(P7T0$)OD\ 7BGD_UG8@?B6/)0(CR:>!GFI M@$#90NEA@0=ILB4DR# H7?!A+G,S/<:7&-O;P> RH$JOY^(,_6O6B>&?N9P0 M'%1&S357_9D3+6S6^=!B5J;8)3:/)%;*@C](LE61[Y-TQ%G/*V.(QQ6A.SMF^2]6Z7D?Q+ M&B;I>(B,'<OAFXK(A(D\\^HJ@6,G!,(8J[W=SA,",S[$2Z'@_;Q05JM^TQ4J^UMJ M\O+^]O,[[Y=__V79K*NN46#^/_VXP%"&9;.N'L!HH9\IJNM\(O^XGBEA]*Z3 MM*RC>)?$#&P^GZ3*L3(,3>=00V/B)'[/?$^YY?K&MH25[XE22(RHDYF\YTK>596RL'C5)ZC>M'(6!WEO\@4CBMCZ["241AO*&(EBV,[\GE$0S MEXL%J=;TLOGI\/A:-##40#]5X]Y-_'4?;O=87R9;IP\D?0FW)+OGP =7(68F M_+WPHW"'4;NJ>2^;"NU+%.&D)@E3!DVN\/LO.6?"=<$GBAJT#.BJFNGZ)O8H ME[2 48;1B8)13W#J :MP=>4>9Y9>:YK].IL!&FRQL]Y4XVNKUNZT%VE>K3:4 MWZ*)?K)D"$[T#/B.-(8]2LZ;Z0D[D0CJ5F+\S_1>0<,(R;#"CQ]=$YIN@=MU MG/LNM\GXKYT"$AJR'DF/MXEG&YHY_]P.$;)&QFWO3I/*N\G M."B)]\LO5M&S9I%;/]&;E.XEJ?*]*J4 M%T&]6HQPGL+57Z28*-4LY-6KX,62*3,)44BX7+\20/$NK&98R-MH4EC$!DEYC(,H, M(:%3BZ:]#TJD0'-,B7WT$.8.1@_P*L_3\*F@IMQ-,A+ CONZ*<:I2AAC]N:I M@SVU8-J[%,7R5;'RY/^=2\&H^"]&*!?ZP<[T*-5K,1LR^<1RM:B)->^3"Q5Q M.DE;,=:3VH+R?%>[NJ&".^R_?D;T'#C54!VFUI #U54?1P9XW?\W_W#\GU?> M09!G7APY@)<5QV-DV6 TK7A"(_%?&Z7*O,)R,-Y$(IF58:>288I2@3O^GF0D M?3G5,";)>)S.DGFNIF@QQE-;C&,2!^R8'"[7+S!R$LE&.B-U".ZI7#GO=<&$]U9VO?A9IUGH(C-!B95,\-"G714G9R$88]9F2\LW*F>#QT=5L9)F>]90D?]I" MUFW&6KB)C>'FV05!Q#8&H+/>"90N!-%A*&^C JY1W)\"SL%?$-R(W01AS+(% M#&D#5F_#^2=%OO=S94KD/&ASTSPE<),@/QR,B*:&"C0U1"3RV,\_V,QU@:B M-M&4N)%YC V/\4'AC\2$(2O>I:T)8WD=:*WB[-.'ZK.4VS\:WZ-550/.ZMF,IJ M),B=GQ3"4JAY977D0C'*S&[HB05M=4-K\!7"^V3;":T7F600'>-0T)".QP@M MD]V&@IC6>#:4P#LUMJ:]]IVM>V(:WODNJ=8@M%V:DZWP*@B@30;TH6)!Z=M6HJ74/HVA?KL_Y&D6@RKFD\Q7H74 W*]]=%Z7JL-B?@> MI*0K8;E:ONXLYF)5"ZA47)@()$ +UN5>SM\WE@ "[ FFE?UU+MUJ"S=D@;7H M AI">*DBS]]0X.5Q+IF2/H^4U$;PV!#SN&ALB:J=F(J\M@"X-(N09BQ)&3<+-F!;$,%$O)*8DDV225SJ'6[U0 "/M*KM3RL+71LI0A8RU M;7B84A;-8M4DD'6-0P4>W_C?>-8J.^Q&/DR8VJ$#JL,0HLJA/-GG3LJ8+K]D M'M8U\TE90/@Q3I[0HH$:P$U\+'(:*7U3XCTK<09:R,YTVI;"C:>RXS%^/&0( M3^3 MDQ,J,8]B**\<2W^I>7RX\Q9>+P7$17Z1(\SUI5R1'0+#7Y 8?LC1N3OA&<*) M>YPZ=<#/?A9,)6'SI^U,3 TDFF_'#]](N@WI$5?#P5BE*;KY!GGMC?'9'-4; MLYO9J.\\.:X7%"F&^, KBY8U/_<),.&=_NN)'U4E9Y:FA!_)1(H?QD8(.;\< MVBH\+'DAT=_6.WF[?PI)ZJ?;_=NH1PDC2\TTY?4L2<]BP)A:,AT1"VA[?[-\ M(A^3S(^R\7%$QA-)TC\3(6K7)B/\;NZP.Y:G]D+2D4\G2L/!HVE#T@-/*@TH MV*"HI==P[MW"37V3D\.IIB/]YJ>CLX ;.;ZL=:%C0BD\>+\C%QYEX\>;J&8] M:>&SQ2,7+I/#(61AVR?#Y[*HA&U):=E\UX-_MW.(0,UNCW%*_ A5!UJ!]5X6 MQ+V)IRK-_=]OXFU4!)@/S@;#^B?/M!*M7G]7+\Y=Q>(0Y[&_9LHSY<-ZQ/ODO1 OX/9I$1<_>N4 MD)L8PRRR'*-RK9G8<# /1_/$<"P*V*V9S=(4:%&?,,3['0H>"L%M5[#52BCX MV?XZ2EYI96/<:E/#$=&P;QS!DT/,]LU:DK,&Y$_%F^D3U4IZC'TA:?A7,SV5 M)A% 6X+9:H\\9@3^>QONA(>%0FZP,>G[ M!4;U7&63S38=ZFKS.8E@5+LOF&P_R>:D^4(Y*.KQGTOE-U)8_=V?Y0P0T [L M%!@7T<4/KSE2T&7V.V[O"S\.1K)>9M/3#YE2G!D>8*0D#> .8KSQ,2986%^ M)6^?X3)GUAF)176I +X_[$$OQYK3 O:<>\9.?:C!B%XYI()_I0[JR5$EVKKP MR%F]IV:<#G7]O\*(B(SL1SZ-+T([\5,2%Y:##MLB*\:7&&D/DIBKYH@E&;6G MIB)HH0H:XB#OEE(,6E7J_U[XF%( .QH#9J7ZO7I*BIS6Q4YVL/DFA792 7=8 M*7O-1A/&:$C.DB@,Z#EXP>QSDV^@.$7)]D]+N457W+Y(4Q^H\9_9;TZ5F)/S M2GK<4+5L]C7WR(PRZ-HK/J)I6#4+AEO#T\$?!V98AW6@2?L88?W7GPH6&? 7 M+Q$#>?XL^(5V9*W6OJ62CGJ-D>6V3XB L&>!' MVZKJ0?K^:.<-C,I&$ MGB]%\5:.$CTF$\F0Z\&6:,Y\CRH:S6:?)L7S7L#.<'B7F_@Z20D\/508FDQ% M_$S##+X4_#AY/N)4U^15"*RDA+K/L3 )X\-C-02V;RQE-;)NT%_D//&/XL8 M@I0S_A2@(PYMA">;F$0-^RA[IX&M^HQ3=KGM!*\S76EJ_IZ(2UWON#MONNQ$ M$7Q*<_CL9W-/*E54$8C>SH(JK3!B2R"&$B0V?'D+,U=1'*C;?1H$CLMRZRJ7 M,GM_HOE*V;?64)RLRBN4+2ZGKE\Q.=%?I",[VW,!S""QYGTIE_*L\31DC)%#PQ#'?]\X'F M#XVR++:NFW.1WT(2V16*JK'4(E[&>-605>[)5A87@5U;^_LJETDP7'^?(!A4 MLE:)B3-!LZ@,XH%D;+3*U60ASNB,0:5+G&LMZ55.N!:+IY>MY-IAJDXXNC!, MC?S%5N9P(V'<%UI:96 MR;K-S_$K0:\;"5:@9XHC_$L:;DV'^2___O-_G+@48AB/C\,O+CJ2^1+#PBT0BH/P MS%9CEX']3!7S40K((.-"2OUL9(F$3JT&9#!)."B2@]K HZ7J41*8K=-L98"; M]=11JDR'&C]'N.C4DJE?5TT\4)JO?_MR:VDC"@N$#HH\:AKOA0;C3&@9FQZ ME(763+JYLE9+FSIBZ/L9'#)/T=L7>*1AP>FRME,M#X#!ZV?KUQAYSM]NRC#] M4P^'TME $?<%,]Z1<^.)L!#TL-:3!BP=\?P)^]D/R,7;IR0*8+>O=Y7(J<ZGQ7;FY?:O-=ZTGG7ZS7,EL ATR;5LD:WD\)'*=6^]0).+@"BII6W&07*N=!: M3OPDR?R+Y=8 [#1;_KZZMZJ)CU-K&;6$3Q>H%Q,*J?E)*[)9-.^:Y:(6Q+LD MWJH[T4*&'S.2QDG\?CO;UV533N-.94*6HP@[W$S[M04QEJFV,T+FKG7L6*K) M^CG6,Z5O1>]O/[_S?OGW7W[^8>:C9@'4_;'*N!@ZVHZ*:-\ S0M%7";9J&+B MG!AW#_SUIRW0^\O[F"Q;@HK;U2!#MGPAZH9_XE'6O??>TGF/=+:YZPPIV61[ MD\)S9A6S$E'PU>&WF&T2^NN'XGB,0IC2<7N)TO($[;,3)E*E0),-N] $>6^3 M>.QOQUORLQKCJV430F^CG@,-:DIHOA??XHH7W]!=0+QV1E< ]4G]0:V M7UI.)JD.F-,Q33_.#!B16(S2>U3X'TAT_5A@L/-L< Q<%L-[*EP"_%[AP"M9 MF!>DGH>VDT-8',:!?_",!$IIEK"7\:QK-FN5_WGJFHX%Q+&3^C0%I_HI2%\5 MFD+-\2RG-J6';BJLR"0EWKE!7-]4L: M*AH'#';WBB!\-1:Y?<1G+':@>W=#MOLX_&=!_D'R37)!2MUT+$B[H@%[G%75 M0K?"*CV474_AEYZ-C&.O9-FC/'N2:4]R[0';Z+&X((I6_:^]#E6XD@\4,$24 M/OL_F'.)#Z0D9X#'+@@7+.9CS3\P0 M;9D.C']6AIXCY7;.^= ^9<,&L"2CP(M#%W.1XG$')V^:(Q8_JT0T*AE/D+); M/'-R&?C>E'0]2=@K1?IR5B)5SJ%2M%"*YEM?+7.,IO0/826_LNS*1-^2V?N$ M;TU:,;$<[WS%%4>IEL!?0BFE*.>A++5CMRR$BN>S>IP.S.K0,_70JOY$^WROO<9Y"6@&O&KY)JB541ET] M@NR9\!Y5V,;:U(::+K;@T]']<:%$1'_X9^%'GT$?WT M1@^ )CB4=V!CT>@/,9@U_'M;TFK.L M-2CJ$Q\?PU$'.34CU*_L-$?["N&4- M+4B':CA>#N$26Q*#N.),LQMY5$D5^Z@7DF&2A#=OXR2R+<^OQ87._ MNKU9V3$WL'C8R^0 6^PA!\5E*BAB1MACE#U*>A908CM":2EF=S8RWS-,< M[:*/-F9#+@1+=-[I$$H+)$V35\Q%& 4F0)[R MN8HQG,ZQ<%=( LMDL[XQGF;A^"-)GE/_N ^W<*QC)M'J6WAR#*5"RZ/$O-^1 MG%5+Q"0":,C%JA0^D\*W(P4]<:J%L&HEK]038N3U(@M;J0!&M7#?7!G0UM5B M56J^'Z6T8A ,T^7#E &^ZD#G**RZ=X>OKR6)/T&G[_NDV(3/)#V0 *M#%Q'Z MX1 ?V8_?;L-#F)-@$B.M&,P3HWGE6G55GYTRI=@YD M;X4PW_5/*9TENF;6F1&?H@94-"3[U'YXC8PGAZ?QS>&8)B_D=-C:RDXH@^G1 M[!&6U&VM[J3""..T% +M& I5VS?RI,)H1FEM6132-BWL#WL21?QV'^W0\0$Y?;3SL1&< 1.)Z6V<$*X)R&< MU3@&9H4?5R&7>QAL%K^=BF/-$?SP\&'S,$<$*76^,2SCWQ)\L7S MN"8).N(EU;9J32V>OS5#G-$44JG?O6>H$";HGH4PM=S[]RWK8T?3NMGNTE41 MA'!5K_*<9&R[7$?^J;$D2-#C%#V%I(2_(VZMB/K/]68BU7%2PV;F5.SGXN^GA>8PG%7:EHXH5R3K;EG%C5H._1-3C"^4_[6_.4 M*ZHRHI+QA[9XOI^(Q;)1-68*=D9F /0?)4#EJ4*9YK1*B\K2N<^K\VX-"C-- M*.P#C(7W;)*&)'LHT)=HP0LM!O/4T;R?V'A_F/F7U)$J\=9C:M< VNT5=!R[:PWI'0VM/L/M6 MUZZ$3:-Z%&*-H JUY>2MK=J$(HFEDJ)0FAX2I86Y.-DSD*1^<+ T;0R.QK0. M3E99*^O:"1[$*=F#AA*^\+H7=R1?[S;^MRY04=I_ TW4W^UXL!Z?MM/C$9FZ MIK$GRFD@'B 6HO:_]4(>99204?W7.QG>6#+[+SC?ND^.3V>@3"?,5:[,&X:= M\'E++,X;VI96<)(%]-0_W60I:5@T[8WBLY(1:9G=DA<29;"!1%[2IQ!6 M,]WNWT8\;!E1^FV5.5B2\ P1[M-*I96.8*+A]B^SJ_:E:-8?\ZI/OA&X!KJ@/YY"7+T\IBA3M]8[O603LX[J^?EY2 "3_E+ M&3C<=[LP@*.EB2J"E!(LDVTC&O$LW..M0;OJ;A61A3Q$S0]E:@GJ9Z! M(-H7,;N,QP*[.FF@++!\1L]+R(9'$N86O- N\'QWS]41=? ]YBCQU,^RI5NO(N MQ3_,DC;/X6MNXGO"'EF;Y!;.,Y@ $20Y%JJ;0_2$&''"WW%YXD5L$.G)L8;0 M/;E\XJ3DFIQ3)J&CU7S?F;8^JPYT54#K LN+E* !/8 M5P6>XXSG9_L=>66*C(#.#$FV2D-:4BQ-#CRU)GY>;?/PA?YU7 625Z[9_% B M5I4+@;\22W'?P1\'JVX?3,S-TX*FEHLBP"-A1"4]B[5_)^,],K!MK\#T9&S708CJLVXU M^$C+S0$M>YNO=TR3S6I8"5C[<:K,VX?B<,"HJX0F)K';&M01X41AN%?;-PHZ M_*/(7]=/0'I"!Z5N5#:L$3@"2V1FTZ!F8=O%2/[TJPU@ZD])_/QK@CYXJX$[(V5HP*7^ M]*ME7.I3^8WTZ?[D_3I+(M5EY-/RH<9<_7&2,,K-"?EG*IX9B$+!7GCG;7%4 MVZHC#040"LPT05XT2,*B_C(5WWR',7X%*>L16N/YKL7Q6M1U^Q= _' X1LD; M(1&'T8B1BW2O9M/*E6910<'\ *,< ]C7WO5;1B3FYP<3G;.:XIMJK%! MG9%#;%?>[S \\4+DQ];9?$'"/RB0&E6>I*JZ)46.J)399"'M=6WX)SXVQK/_ MVSOO-K>E#UN5D2\\'\.KB2E'>3=7FH)5<2N*SP"Q;6E%F&&.062(GXQ!9HEP M+E#WSB12BB$81'8YB'77GPW9^(:5,E$(;$4FB2QC>9O:D$T]<+1%,PDX@U'E M8;LG01'!3U1IA6N)A"]4;06I:5G MRFJYNBW3L8'I5%=.RW'I;!S+D>< ML[,U"T;WIQB,IO]2Z97QZ&971CQCX37;LK+B=9E]VS(W&)=?<+35+D>ACU@Y M$%X*K-#PU$!?="2/#N7)L7C]12>87S9$UUY$JL2PX#6IK?H-X:][&K$G7@R? MV1.&1E"?1V$V"S((1ZB@_$X-BSJ4U-_9K=0&FM@+S":BO,"[0J)V,A?O)M&Q M!^@&HC^B(PZ>\0&]44;J^7Q\]K ID51+0(HJ!(%/]S']!Z9QE8S\0',4U:8' MQU9@53E$!=8?J:!6L,^+9K''8A#F=IL6\.094Y!#MR33 MN]OG9!MA-I+3D./S6(JZM7RF#:5$CE%4F4O_&,+>UD^,4V/" M&$X-)UD]),]$%JTV)M4,!%*3MV7TK:;W]36#CK(L**-X?!AVU\F!O)5BXYS! MEVE9;BW/<9B!UYJCL[_3AL?\B D)3UZ)G=6+01*S3-?B&?+RB1IOB$^"5LQ M"4K2^%S/U@=@(-R%6S_.'^/D";$U\=*XB8]%GCW2;!73RY#&>O$>>7*0D#"F,(07U>_P=F?-N++E3%CBG6K;?V4YL"[KL)A'6 C]Z M( B2=*D_5Q@Z=,]J&N.2HQM1:N&IXDLN/<:F=UE]TC!._X5FKR\(LSY]6>OT M#2GI,B^HL]NYCI0M:H*&WB3>RK!%*\8)/L<#BL3\"TUQ+\#J!1P%&%]^G1*X M@8!CDN48XZT<[?3\G\9I"@.]QY'@4V1#T:#N=ZHM%/X$PUGSGEH35?A080"/ MBBB&\' ,[:JDHUCWI5J35/.HRA75Q&V5:95N-2G\="N&AQ\[.. M_HI1-.28 MOV?3SKOCJZI)ZV+04!052FKGIJ1XMXN)J3! :=O?UI.9\"?H@RV(+X>9,\ M[),T1^0-"63S=1]N]PI"QX=OY$"-2Y_\[(*0&)_7YCF9B+C+C^8NB2_];'\# MFYM"+:SBP&!JK7T:_;HY7WUUTZ[R/ V?"G8T5PN];9+-GH3I=1'3[-;^Y_XI M5)U/RZ6?IF^X4A2(9K6%IT 1(1K'%8$[:LLBH.&/:1ZRMQ"K' E?/2\C^3&% M4[%"Y5N8F:?+UFC.I[&K!FS_7=36VY&8*IK93;Q+T@-=&VG>5(7J:NOR@,- MAS#@X*V(9@Q["&VV\6J[#\D+_ LS$$S1K9_#" ZW)#8I25O[L>O6J* 8G7EFGDW+Z\FJ-0VU\5/;KYOP$_4K0?$>"%:C6_C.\>$FZ M#3/R)0VWA->E7%-M*;N)Z;^HF8Z#1:W2%-$'6" ZZQA<%:D,WUSE5W#+X*W, M_OC+O__\'^:C>'8VG$_\!NAG7+0&8;+F&[UO;^=BXL>]+O)=E+Q2Q$I4RIN4 ME'I+Y^S?)?DM[!V*A+Z.R3_@/FE[F3*';=B&M7;.61?F8_ZX,?-=:>2<:01$R1LL&>QOSEE$;QCH@7!4\FP3 M0[T$^)+SKV$4P9=-@4 1<"'V]+4^6Y@O&4;C"Z&"^BA>(('1NBG,LZM82]W=5N*2T2Z:Y0( MF597B*G#4H3AJ%#K'6H-H%KC?_!4>?&C%EOJ"#+.M^?IKHX-OC^F]I]0HNXG M18U#+)&W&L&Y&F9A(!7G8E^F) AS]"^WG4S55DOY=O]>^'AFPC[".T_:JE9/ M29'KB-_?,=ZOS),A@43;APL4;\&;6,2P;!+5EJE\N!OR+;] 1+S6@\ 13TZ7 MI".&EYEDN &8:BL5Q;_UD)V0N,M)JF1SX>TNY$*;0DWNCO;.3PYUSV]2&O+" M?:B#W(^-79T+6'N<:JK;X8V+EFF_,%>&$>]B2*^'N%I9 W^6#J+9?W94BSS5 SCR-1BNS]L^\? MM?0DPU9J:>9\#=0SM%3/!,"Q\5DVN/.2?"7U\[:EF?/5D5@$Z]W') DR&E6" MIG5X!*AGDWEY^O9VJ\Z@!0FU5,SH8V[3 GVELK;F!4%L:7CT&U2;WGV=KZ3( M/T.UL\N 8V[K7(0ZH"P_AYNC/%IZN-QT:HP6FC%YLH%T\]9V6E<'YVO3@0C9 M2\MLZ^I/$PORM^;M26SAG%VZ20):CE]@'K5Z'UB[. MM04, &$N-W9:T5^:-09C4^&5\Q2M)1QL%.A/ M;5'3,,SR/4!+/Y&PPY?N+7GV(^;2JAZ(AC\[7T6#_U2$ ^,IMTF8"0$N(3]M M-/\/).+RQ+PG 0]>IY%17TBZQ0S"Y[HALK&E\S4S:4!#-::EG*5=,!@GI7F, M(^I^4C1@\?(-/.@N:>CH7+@A$1SSQHN<0;!(6^2]GG$Y+!>JGSM>0;D@VZ>8U4AHXCTY:!4%*LHP9>1K"DO0VRYA?>/)LU2=/RTQ7 MFSH7H"N]YH2/?&FW7B]?M]3X&3#>19'?)?D_2+X*DB/<<6/M3.TK\-C_A(/\)3XETE JL>[ M^C?GJS!)W9V>IM=Q])U/E8RL4H[_+TD6=N<']^GI7#S=4A2$*=GF&J:=DN1/ M/8KK](&D+_":SYCOE$<9\<2HCZD?YWKBTT X%\LLN+RC/_GQ\_=]4CR$AX2' M96AU?6HW;U>'I;PJQ,&L!2WVP+EIZ>?\PS '8W<\E5O[N%RM2FHC_5ZH3<[P MY:QR#16^MH(C:+E?5>&>9NCW#+ZYAS>[VMRY( HH#8\)IOJ0:G!I+I-A%G84 M29>;&Y[W& I*K@C[+\\ ;(;JZ:V"U/:^O:$ZU M)D0I+9RSV\]^LA#32>V27CT_I^095-D[DO,PI0_?MGMT)]=/C._5$Z-O$M1D MHSA?;> 1EA$_=,-AV>JA[^[H7#B>X8]9)A7+PJ4T^Z^RWB_ZD\DYGPB#+:*$ M#Y%L=JN+_6DL- -%P\"I?>)].SI?SS+CCG]TL._8XW&]VX0'1&F%LRA\BH@2 M]H,("_@B?0VCR+S$H\DZGQ@.[!@.BP)M[^1F!RO /#>VU0;^=KKBG$TM'VGT4@ MP)3BX -H!P=8G&&.RP'$G*;JO0)C;^S_US%YR)/MG_#BAG^&+P1#MQO>ISW[ M.5_?_@!CW'S6CC,V!9)9[X%<[HL'/+SW?K@)GTEZP%S8."LBW,Z]S.C#NCO? M)3K$:2NX@J'E4LP&5R3WPPAWE@YD\.%PC)(W0BY(3."Z$>I&7SO!Z62=KVO5 M\]$;,>9$$LX%KA?/:GXQF-LZ%^&*! @5BA'8Y'!,4C]]NPH1UYU 9PGL?9=< M<>41XQM1O;I13.@-2SD!9>?3H[BXN8)]$S/3ZVU[@D*/CHX-XOVK*9O,Y?U[ M.U]#GAB"&]'_=E_!$VEIYISQOM Y]$&7[(J,VUAZQJT,)NE\0IJBLT7DM3"H M*^?,.E;*8IKG9"S5I2@D2B0P M3;W[+F45X6P-4+,+3#'I<&NR]"BNU_==WE.).O_B*^\\:=%9J0%4B/ED>/+U M>CD.HK@$%W8<8A6>;9*B2H7,=;BT&]H[7UD!WU9Z!+B5[J+(X%/%#('#$^Q6 MVF8@U. TM)U/D?8%FP)U>E[TS7T=AA(_H#,886KY[7KG'VHAQ:8V3HL(%?CI M\'GDV0!=P60]^CA'!ZA<_.W5%AH:._]:*@:2K!7'NZ&Q_0$02=3T8=)+XCW*"QO7-15G3>J5L"U"T17">" M[6YB^F5)7$$%M*OI@CN1G/.)8#:0X? !W?T6@%S(@_'CH(I:VMC(^7JP"XGK M!.:IUYHX#8-5&0%-C0=FDT-8'!JTX.XN3MT^IH+@37!^;8V7\GC]"-=IJCTN M[PD0]./PNZAX=^%G(7ZSP+LHR]V=GSV"KO,OK"N_MJ<2W]C5[:.4/2N)K&)0 MM:^V-'.^,E4CIWD1JJVJ8<><&P!0QK&>L=NN0%FA:E& M6M3T-5J%!TQ,-PWG(E=B9@>$UR[%C5"6V6[RXS:84+H[NKR_+TCX!]R GTD M'U:D%%9^*#!AOE=8X DTG*^G^OUTA,[U[N1<*%$UDFVK=7Q%C@B3T7"$-+5V M+H;T(S58SSNLLSU[+S0-C!8WC@?7(H(NSM>MK"DPW.[:KZ_3-9.@J["U6)E( M+$F?OI![\AQF^"V9[)M#^SI?136BT("EVQ>IIZ7O4MZK&/'+],:RZD7O2)?V MO@MP$I2I*@)7KLE34&_I?!-J1ME*OM&@:[JE\U*VX6E&YUZX0.-(.]\%MZA* M_JS@5GT*09QTNV_-S^OJY30)#ZV_*" M*Q"(5$DL8M?/_&WJZ5P\H[5QL"&CJ:=S\>IFE;;OK*FUP[N/@_YN8("K!(V[ MU2NOUF I6,;\/[@7?JDRW=C0)4(GBX&YAFWM1_\@?MH0C=#4SOE>?_ CLDZI MW[Y: ;5!MVWNX.I&X=C6GW[5[@OY6^=SS!YM;6>(VF(!.G,;F'M;.^;?_^+K\ICE]N/"U'(Y:0KW^ Y%&P()+A \ MA+L3FK-[AW5WOD["&2^21- 5+\"0XB'W[PF$G-J]6>P'G E5(T3=S-W8U/GJ MJ1;XWY)<1E ))UBVVL*_TZ9LOM[=E^*AJ$!_*M4<6YT3S=V4###,G MD74^,;^2-^5.AIL!,S(C]+\06#Q:-##)@%/TAF(3X0\US\>IU)Q/0Q7XM-U$ M;&KK7 0MB8K>CG 5M$7&9GKDWB#/R,@!G$_6%"7TS+,T!67GTZ-EI+1]"X:& MSIGO/H1JL:FGGF8U0NX3=59#$G7,C9VO(/MB9#Q >]A 0V/G0AAPI4MO?[-Q MK;&+>X%$;%0G7'*/4AZ]:#B-;?2S< L7W%48%5@_ST\QV)\BX,-10#^7VD?5 MHX_S56RHG4&5=3@*Z-;#Q/\\+:CJ3B'^G]%K-!#?PL) SB=/-W.)FFI$B3]K M/:IZ=WRKP$C,^23T?0\LY"G0JV"P\4$[K.<"7&WH M@F]RK^'?G&^=>P1(CC9EP_6XU9NZ+>6+N"=POH9;N)L1 M%(8%!\6!!BS6BD+6-\!SPG&<[PE:D8 5B&GRB\@&+M<9(_2W3.N*WH0=XC,B M3!\-CN#6UL[GO']",_\3"Z.RG3T]:##GDUA]8L 7V%XFIJ6#8]SUE%RH$_WJ MI\%OK$(1\R37G_?=?9ROCU)1;!T;;X[6XACF-1Q)U/FD] DF6T3\F.87WQ(2 MT <=7(+')/.C=2IRX->[U8L?1GAFP/4&?R*5"-9&9_L8HLXGI>'U*P[7]8X? MJ8/>SK7>3F%5X!>8LKE)8=:S>T+CR4TUCKI;.X^CU:*/:$9<<_!2_U[.-Z$H M['>=,.,3M=9C+'Q'(^>B]*[@VOQ*&43"N<"K***Y*-G0#)8>'=T+Q],T MT?0CDZ$OWN[P>">;9+,G87I=Q-0NV+R@0ZDX%[O)-]AN->SJY5PL$PX,'"$[ M$DX(+-.3H//)X%<;O/7S-R4"IL,RW-7+-:(A0N&T93JT-G2^)A73#*9.TVJ# M(:]VTKXV?7L[72,)Q\#KZ/D&"Y6ID=NB@N.L9(U9K%,1=KYQRP3DMAN_VLHY MVPW/ETM9D8<6>X"?:>4E!2MRT&NHFYSSB;@B$F=CO6-ZB<1P*#W[N#?3$#;A M$9ZO';6ZQU!TFFN ^0\,VE]%E6^(3FEMO9RH=1;]A*5)4O(YBN^$,C]%N"25!3B'LALM=[.1=K ML"MBCN*L X9R/H'-$62:@:,= VL0#>6-GJKV;BZOCJ\DVL%GTF@*KOS=^1IT5B$:5A"V@\*BQ%5-#1_]*>UJ"EX* X''S.0%838$M/J"^B>VW @NN-@DF[1!#5=!U]4 M<);0%T5H^'C;FSM?V5XU9]K\C@,(+"6HZ2ZAB9\LZ1KOZ#@P.#7ZABX-IN9\ MS;4G<>4[>X-%E/I,]T=\ B7GXBMHU-Y4 M6[G<^IM7F,@W]O_KF @P95;8JDBW>]APK161AW1?2M;\*HX+/[HG-)@QAB,D0I-()>6?!=[1&+P^ZE4?.LYC@^K0>3^; MPX$,#5UNS5L_#AXS0J$'FK) #6V<;[6J*:/=6-74VKD8E_#R?4[PZD2OL?H. M;LFC:.WC7B30$ ITS"2[_!6.XK;;R-S6N0A&^ ENB;J"GV,2\%_B_=+D'AA& MQ+G0ZO/.P-\ &T];;[>J-GS\H+053_!26^] 4<5G&YKR#7IP4].EW#2XO?SH M?X?'RR2H9;DUMW2^S:3ELS%_MT<&66M?YR)V&0@ZL]I'FR"&C. \( E>C_Y$5:!X\R-5J*5:T-SJFJ="ASOB'?\HLHV?[9:F0;2WP!'T*)&]^O0FE; M#[<@F(V:@ V%[R\ M*L@FN8=_)['_%+V!AIFALE%VJA5N0!B3YYC%QZBIE!(D5T0GOL8"]G)@O.<2 M.'6^?)IBR!-YN;VP,:"K,]%B)%'GDZ(:3 9"5O3HZ5X\0]*/5N"N(Y"K;W?G M@O8W]RW&TF>"/>?Y+WC#:1@Z\A3!M!'I2&-65X...9JF5F.@%/C$V="Z A'XB4^3:+BEFXP626\F"745<]/Y*^ 3$C MZ#K?$_2I 6H/":D6U+"?JZVW-9I6(+_C9ULB-%)L/P(OA@VY("(#>G;58CN M (T\.;]N@^W^[ODBG_>NQPN$7TEW22O#9@8 MM69.UUM+0_Y$HD#3J$1FF6D-^_9T?MC<"O_;Q9O .F@'JVQH[ER0+L\'M8N/ MC^&LD7$NN%KW6@28]J^47>VQ%'7L"K$M(SS1=/?&PW8/9V*$&$:H=BCJYAW) M^^ID8XD[7W/5&P+7!#>."NQ'- -W>U',_9R+9D@?,V'L#$U!:Z'A\&[W=R+E1[ MV79Z-,K7JY1EV(/D)+(+#+^OI$Y.'E!_*GV'A]AM@@'O^R0FS#%J?W>^ MW4L#7&_#<6L7YP+A?==\$[K\BC!$6[Q!'Z%IBHCE&)B.]16K );]>CB?[6IY MTB8OI-[*+5+2%C%^WO#LN(GA0,9G: /&2$M;YS-/M?(O_EN7,5(T<<[P5+#$ M9XA$K#XU!OH0>G5U^3U]2@IZ%1=Q4#_ U#\Z7X7RWN(X9CUO.;WU@L3H-.D; MFSH-\-KMPBTI Y'CX+I(XQ"AMQK"!#M[N+U+7DASBOD9;PV T9J71=H:Q'Q6H]Q0-+-:[+9)T7FQ\$=,)\3$C_D MR?9/::E V5-"YF,\I(\H3?3HS#+8S:4 M .3&!U=S%^<",=K7SGH MV[Y/8U.7J\>KI\&D(]9*QUND7P_GZ]%E#VC]E$9;&_I2=S]-JD5)P:07I] M>/A)L5ZC"#D_3HS 5@VV:E-3YP)T7==E> I57_I4U^M!93'0TYCBE)4.O@ZP MZ6IKYZN'08*8R41-WJ\Q2;-]>.RJ:7I"=T>"9ODQ_:_+EH8,]*/C-B??#XA0@F[)CF /M92F:K6SCGK/%Q:@\IC:N5ZQXK(MUF+^O9V M+J9Z;V!4!=R/$]ZWZ*#[(13C.)^VKH,P^*UT6MV3B/F\K3]2OPHWRLA MSFF"$:=-=WE[<^>K:8[65FNAF1>NNY];NQV)O\/_+I&K;7X1)D>XYP[^EA3T M@0$WQ2$$I;!AS89U=[Z&HGSY)EEM*7;M.KTG 2$'CN?;ZDGOU=>YB+H"UALN MIK.;<\'@1J2J)'Q"=*J;5DEOY;2N%M5WZ7/*CZ(WGFY- KRZ+M_@>Y!)U[7O MJG]7YX#V!D=$H]FBJ\/9Q+[5)!O4V_FW5'EU]GJ:.O7Y)3'/[A-!OCR?M.[\ M:VKI?,YAKQ>'@EI86K"YVMX+0R@X%_=3" ^U%'6 WQ)@&95W&0R1*59::L5M MD_H$0LZ%'U67H"PAOO0*"I8X=;Y\ZDM4 >X6@2K,A#+H/=N'BM.;7%28H:"7 MK*1Q_?8V-'*^5GP?;9+ZSG_Y)>N^+4816M0J;TAZP","'M2LK'K&@^8:"JNT M>Q>FH.Q^>A1=YS/)]TDP F2H@X##C/L'LBU2V*0___*T"?.H5@NC^O>E1)0P M10QFT(\VR2V!6RU=[U;/SREYA@]1!A)JSZ#6H)-3"#I]YOM/24IO<+F-&HMH M-[1T_XTI!T4=P(;6F+\G-'(F?F87?_^#9Q@]QT&,\?/>#T\VA@[I[ASK8V=KI:<$*DY)J0'+.?5=5T!:^2^NJT-G?^!7Z% MLP^OYP<_HCX<\W=5;>748,936]<[;NK22R'4363M[9VO@ HBU:\23KVQ4WPMZT/HT$DG N\ ?J@R=Z'V9\ML0/55L[9 MIGN>GJ'\X8FY:V;>C4V="_"E2+=[.#Q;ZGW14NWA+B3!*F,8N3WB]\;3=3XU MPY6?GC%[ X@M:A+:DS=UF\0@L]J)A)U/#E4[]DD4W!R.:?+"8G5;S^3F#LZ% M41>D;^F=MB[.!:K4U:Q9R.G=+U7(=I#JTV@YGX*N:",S4NM46)%]J3LU6W;( MP)%P(E0[+F49,!9/T5RY: *BB\C-5')%,8L/3^AZCI^YYO0H0LX_G#:46K?( MM#1M1,+L-)@PJ@V)\B'*4J^.1_@::+2L_PUM_0T:?W='Y\(9BE?UUI/[ M]5U0L#V<5R^PK^!+OL=9(OZW) (UR$_? MKN&IES;LRTHCQX&$#)[JH0"]GJ,LHT+7JM8:(?1.H;,4OR P7B),M[+EQWZ.Y\YGO_;WU[.)N+ M\7 *6><34X'$_/ -M,$P(U_2<$MTBR!'GI1&P0:Q>B,R3S/4$@RPJP/!E(GX M"M[I69AW92_UZ^9\9]31H[N*PS>U=UP>[/%!6P+Y6^K8K!8F8*+-32/ MOYN&MW'J$8[MP11U,Z DZ@X7[V/)'E._>.>@F'AM=^F MK34T=J^BW?F'6KRW\B?GL\Q?@33^"$N$) 8]U5^'PWLYW1AMHB\1QV/ANZ_C:;;A.WTG8T147V_MGWCS1N TTR\!_4HD&S:7K' M]NOA- .G^+Y/BJ9L*.6/SK^W-IM-ZQ?7HZ-[X7(_YXC'4B/J4^R]NY]ST:J* M'7478A:*4._:UJYG9^="LIB:[1MFI[06KJZU?=R> M9X<#<(0/C;Q(XVP=-V$24DMY,WKYJ8064=IB8%#1LL.(E(!0+=NP[3LSM73. M?E=H.$7"%M@R(@YA="1^%U7GZ'-*'"6PJ<#LU/9I>W/WZUNMDM6D= ROM]6# MDG/Q/Z9)EEWZ:?J&\MEMRFY@Z?I5?)MF!1#G&!UF)XBQF?/Y[F7#6JBEZB.)28IWO7Q[WQ,@Z,?A M=P%&>.%G848ASS(,XF1EZ0TX55/3=KZNR-Q6. CQ(VF'JFUL[EP0#IF)F27] MXNY:.C@O2B>,P:OGE) 6<)ZVQLY7A*:\HS.,^S<:@0X,#9T'\-.0?!$55[T1 M#4V-=T!?YQ^]4F6.)5+2 M-Y(>M]1\[O;M[5S,&HY/!=[G.GPA_2&"^A%Q+K0I3+M#[5Y2A:0N*XTX)D:; M>PR$7!X]\#Z6GGS=7$R#&&K'34=[Y^M8>=/U+QE\(@GG JNP6ZT6UUH[YTKK MAV^T0B(-,*OC8;>U=PAC$CQB:3[L0 ^$#=GNX_"?!>B"^2:Y(&51B":' M_3*Y=8NBDFP)"2C,2XF@>JJS=A0UY[M90X7*5D6^3]+FW=34>BD ">S$8/K: M)H$'/RAT7T"!2.M>F*%]G:]4YSO+_?-*@ X)#S#"J\G70UE&JB%*OV]'YRNA M&2/A4PYSU++A@4=_US.1M*&CT_ C4U1D$ZI9R]K:?)&AH[%P)/?))A )T?71-JJ&E&]&AH[%R(OGL.59 /AV.4O)&F=3J)U%)\ MZ4W5,/L&PO?HOTSKW0##G?/-*DT#QHRJ;C]L4S?G@C'E$?5%O0)]NV^SJ]>B MOJV*,C;HNVKNZWSE[OW7S^AI";%R+D7WR(H#/02:LVO;^S@7B<)(XN3R#*<& M)UNEE4.;$&*NP7:7]=Q-&=RF-LYGNGRJ5-,C1I9K&$C.^41T^<)N#D<_3%EZ M#!P&.]WQ,MK5UIN\\XF25YFB"/>X^"JMG8LQ&!9V>5"PBIU?V$ #I:9E:^WH MY@[NA>FHD<"2$-@GQ-7=!B&'$W(N_,!:ELM%8JE/MSEQE56 9AZJ]4[X%-%+ MQ9,0^_D&3B;O.&<.*P,^?&^$W]?^OA1E6O6*"JS6OLIT1U_G;CV,/&6> K-' MK_S[34^TEF;.YW@5!"G6<L4)" M,HY&>2MJ#_J>Q^9D0[F?0-6:@]MS"\?F;PG&/0*;;RI2,,UU:#+##J?C7G0- M>FF'<5,7)(8?J-"=PH#O GGN$'0TCZ'PR:.&!OYU4KJ"E MEW.Q8",>D\R/LH'&ENY^3CT0+R0UW42U/RYA_D_&I+\UI8Y/3-KY!-4!ZQJ, MZ[5V+G78QS@E?H3'&DT3X$$_W_&4:TID&=+/^:ITN7 >R#.N@:R%-]HGU$)P M69.!D8#7*2$"WAW-JZ?I0#TIN1=?C8;DI3%?#?VW G'A3!*A-9R)OP0 9J ">371VWHE>RUJ(J M2)4.5MP7%WX4K(88T1O;.U^MAN1'$R;DN\BP'A0FX[F&!59L[%T18_*_@FPA( MS!X3/*FS]_MY(!'W0@LP O6-7_.IWY.M#!B&):O]_12PE#E&7D XV6,,R]T> M4:8T<;X?*D4W&>XB5MPT;-[>I3L[J3@76RBUS/7'K]9Z'9=UH^UT)*FE!!/2 M8!/FVA^4D%/KXGQ%F\^)7B6C&WJY7"=Q<^IQA+6U,3=S6G(/4Q]AYRL9KSQ' M^9K4<<):6SO?5HTVQ;9=U=')N5!]"C@URC#(T#"&NO-I4C$^[N'C@JWY%+U] M@>,;$ZO*V/>:/8E%DF;K5U[!1\DV;=@P%D9RBN3!+KW/?D NWCXE44!2!A2N M/O4?CW!CPDW"M2+8&I@8?JE4I:ET ,4QZN2B#4)!+V-#F,,B)23N?(&Y])8>P.'16T]7:.6>]S-9I-*SP MOSMGM>M4'V$_F8#R4F!5>9+Y=0%*DY)RR]^8]>=[[Z[.UW\I,,W_,@#,&-US M40"/),LXF%/]=&MLY-3ATO%!EW7TCGY*)[_5%S.&FLMI$,$,J.T7*;X*80>F M.>8:U&LZ].OA_!0PYJ73DN RR'*0':2;Q@)D%FWKUJ+$N?^L< M+06SNY+X(4^V?[8&//7KX?R+X(;R"<)Y3J'D^.QB$*GX>5^\@?X#YV[YFTVR M?HV9L\A/B:%ZWL#^SE?Z(DG3Y!7M2N;U*__NG-6/)'E._>,^W,(V0I-A,Z"A ML:G+;55'0JO83%0(GMJF&M3;I9B?@)GO^Z38A,_P6B ,LC9"O1-31_SX[38\ MA!3/T*@8#.ON5E<_)EE8__SY[Y<2M]73^M@WIFLX.9<3(0T>< C?'(YI\M)6 M2KJUM7/]XF%/HHA_!&9]0FWA_*C6O-.\/N7%VYV?%WT<(?TZ.Q>R3\+M(C)M MZ_8 JG'N:=S+;PF>KPVEI_ITLA-FRG;U'(9#S8ULU(@;K:\TDS-'9Y1 M-]M=NBK@39RDJSPG64X9NX[\VMNGN:7S(Q9C#])CPFQA--'_DKTO+Y.@!A/? MH\NRU$T11:)_ A1B+]@DE\DU,!Y4(AI&DG)^,-RC:MS\2)!_=LXH#13A5YVX MZ1I.,$-+I\[Q-*%^F%O_"3^#!-,U'PK4X7LI_,.ZNQ24H;]*)?&Z2.,0)U^$ M^33Y_WOVDE;,0D&F]HV8,4Q9B6^-E?$<&3%11Y+C+5T_[;Z")^KL= M?VMSR1OS3F<:W.$]N8(='-!=;+C9M3\ZWPD4WBXSP=LUWP?M?9R+I#Z+&GW[ M[:^1023<"\R-"O#MM#EC:LT6 #_!XA 4O; :WMO9V/GL?P&=#F,LV#%$3WLL MT'&+*.\=\,"]NCH7L % @84[9$UA6TN)YS@7[A>07G0#3V1VG6Z2VS#C('W4 MK%2/+.KLXGS?]CK$!QG9%API5M_P97UY=K!,!*-R,EGG$\.,[_@I=QO S&T= M^UO1E4!=5R)5PN14K35R/N^:F;H/ZLXPP_= BDOQ.#6>)24J8U]OTS!2"PAX M^O1K>\"3^+OSK=M:Z+87C&-S1Z>6##7AJLD@4V_C?#TZ4W\&9X>>3M#Y9,BM MI5[!9;R06>".3LZ%4L\U5(Z!UR@4#Z2^JL9M_USM\6.X_(XO2/@'#?J@Q^9% MF!Q!6SGX6U+D&-&3M1N5!_5V*29Z[M"^A$%B:'M*A-)-'QH-TO7IM!1EX&&[ M)T$1B<1MV)0DI-F="%I'(\_?S/&HIQ!9U#?^X0596NUR9)@CP[-8]&%:8!\R MS@47]:0'YW[VZ.A8K>-0'WA85L ^-A6H#[I(#!D#7BMPT0;TZ#7I@J.)+D;' M0L,0XC+!J=JN:"D-G6]7YJGF"6)]BM*U=' N3.^+O;48T# BSH7N4F_Y6YG% MGF_?%(?::,VY%VGW$S1Q0;DPRTO.&N3B.0?BC\'S%[J9S@+D.L9*=LS MQ&O:09VJO(;2,0.?_K_P=0 M2P,$% @ \X-_5'5SEZ?8<0 3"H) !4 !C;G1B+3(P,C$Q,C,Q7W!R M92YX;6SMO6N7VS;6)OI]?H5/SI>9=8[C.$FGV[W>GEFJFU.3*KD][_GB MQ9(@B0E%*KR42_GU!P!)B1=<29#< KE6=VQ7 2#V ^R-?GM[.GR]O:[__4__]M__%]OW[ZYNKF] M?W./OKV9+6/W!5VYT=(+HB1$;_[[TZ?_\>;_7#S>O;ES_3^>G0B]N0J6R0[Y M\9NW;[9QO/_GNW??OGW[?K5V_2CPDAA_,/I^&>S>O7G[-AO^,D0.^?F;*R=& M;_[YXP\__OCVAY_>_O1^\?[G?_[XX9\__O+]AW]\^.'_^>&'?_[P0Z%;L#^$ M[F8;O_GOR__QAO3"W_9]Y'F'-S>N[_A+U_'>/.4?_7_?W/K+[]_,/._-(^D5 MO7E$$0I?T.K[=$P/4_!/+R?C-7+_&2VW:.?OO\1D_C]:[3Z[@U>#3^BWU;X2-[\M=;^VT^T M]?L/'SZ\H[\]-HU<5D,\[/MW_^?3W1.E\RU>H1BCAK[[G__MS9L4CC#PT"-: MOR%_?GZ\+0VR)& OXVR\!GZP.[PC/=\]XO]\ MS3?&98 WWH.S(830CVQ#M/[7=TL_?GZ;]R>P_-_B7O%AC_[U7>3N]A[Z[ETW M4WZ*\8Y,OTYVK[O"_UP=?QC-UW=!%"F1H342"-(N@]T^1%OD1YCES=')'78P MHB\_67P?ACIY2CPA+=L=W_Z+_ MFOEX7T8NGNA#B$\[/Z8_51.\AC[2+R!/R6[GA(?Y^LG=^"[>A(X?SY;+(/%C MK-L\X"5(3TJ([P@CV[TQR?'Q^R2NO>WQ*HNCB<._$^-^: MB\CKWC,1^#/! :$++$/6;IQ/2I<6\2B];<%YO$4A-B."'7JOOLU8O?J=\D<' MZ_;XWQBS>R25!DJ=>R,@%48HQ6\91#&>A ;XPN[]\D(ZAX7SJKW_&3U[PQ_C M1=3T!Q12!4\#>E[/?E%_"(,]"N/#@T=.;7]UC772?8-#43I.ORQ]'_C+) SQ M]V>8,W5./6'WWHBX0PX6*!J[J=*A9_E35H8N#I=82=@$X4%;$DD'ZI<[Z&9X M1$ODOCC/'M5[L!*_=PY*JE2CP?I?N72+S^(;QPW_[7@)6FS#(-EL,4MC;6(> M$BG59"&UQNU/3\8F*4:>_$%DU(OC$?0UZ),,T+-!1XZ.2V?OQHZG:[8QNO8[ M^46(A582'NA,=+F)W;E? C(7N>[4J]UZV_L4*^(D7Q$_(S82E/P=JOT'$,T/ MSB$7I=A*#1/':R24!<,,[Z[XXL989*(UPOK(*HW-&'!8"$;ME^3<15CPGVF2 M)QBA9U*"W. MB=JU#T+JCD2A&ZQT'2S2@7H_=^+076*DL1&9J5D^09VZXG=[QS_,?>]P&?@K MX@E:%01 4R8S^4F(/N].?=\]^\#;QB86]#!45PM,? 7BGE##P<#0PRL9M?A% M(]H;C#QLT* 1E>)!0 00FM&E,M80P01=><3M.F18H1$1HB$'H4B,?8[!@ M0R->X?8?*O"@NR#"[D!"$(U61G&T8<,1C82!>)">0Q.Z%+!Z 0E2-)-E:J-! M"E=(6&&+AHOK_[@ PWOHK^K=;/T:X71S=^@^A MBS?+WO&>DN?(7;E.Z*)($6X?\U]$")0QU9&!N_:67K(AF(ZK$T1M\C:8S1(K* MD3,*/]-&26^\(:HO:U^85XG9B4^ *Q2>BZ= MV@6*OR'DSZBQA%MB%3+<(!+6W!%_V*7C+1,OK8)$;2UR@"5Q$!Z.8S^J6X7# MS\P^Z-N),A#3'"KQT(Q*T�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

  •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

    N MHI@(&/1[8H%]BXYY\T(=+X%MT 3Y'M6 3%JPNECE0'0&3A3[L3?MKE.!*\\@ MP^"S\)-/#WQ7J*JA3TV*KU'-88U\B9;T/Z8/)0;"7#UB!_4?DP:;4.%'$C>_ M.4.NS6 JY'R<8BQE3( MN@MIMV68 ,J=Z,@T^X.3[XIP2>8#D[/[GU=X[NZN\W"RQFZ"2)(:&0;_@ E& MN4)[[@59J-/XCU%7.[GUAV-L;)&/BT]5V-#-,S>O[?UT\&-DZ6@LH:I:(^67 M-/NXI4TR8ZXBM,E )QK8XD';U%5:-6TX57/WABL8B#=H\7F)#'?#[:^MM"\L MC'LU4J]K"%QQ#PZ9I@<-\!4'.A?9&8.DYT)O4/U!PIGD*E;U7&T]*Q#Q\'C> M=^*HJB@//D'>3RD1+<8^0GE'AHDU._4:C@D=D=I[@';9$04!L7_WWO#4LG]M M\;@\W&(+9%Q:8/8*(_)$DV6@^(L-,7QP!=)C)>$W804!(8*MGBU8_!H3DQ QDKUPK M*6]%SQO@#XHEJ3,\IM8>K(VM18EL:^NU@@:+KZ-M/%PEOX(Y31[!#=0W#UM" MYC$;'7U&" FH"/(O]K*Y9A:T;_$$V+'B6V>U=UP/YNNZ%-6_-NF+KJC.!?4F M6A'\BUOSAP,&G-A%T2$_//QKW;.,YCMOFMD5-35.50]Z[Q&?$%((\8LX M5"(&M"?EK94^GB.J4@E=>'.8+.))MBZ@RLYF9+^(H>TU)L/T&;Q!<>F=O $7 M!QV?A^@^OTGS/'##2$0\P;=]U3!LSU5;:JL8H">%,S8$#BPF&*_H-I,"[A<^ M#NZYWK2FSNOV"L.[A;LJ,C18EK"#> /M(VXUWHA2+\KD O$6UV,A<]ZF+'9Z M*?RP.MKE=!W=J2?\A-":Y-RYNC1L4E"BUH.H5[D(T\:2U@T]'(2LN;S0>3!E(K]:" #6Y;* ME#P?'4SQ9?2JM@7JJC1\,3/9A8/G0^"EAE>37=8W<>V-D91U1_SVK&#F)&YLMG()23^=7E?DBJT4R#Z,.@T4-E8,Q14EA?, M<_6T5Z9S=YSW'.BOF2D>G.OZ_B5\^^J],8R_K_X^V7G!YY#Z?#LN]]J'!P:T M4W6S[@.+;.:-,7]:9NTG?FY9*#06^?>U=Q$ZJ0E9_@I?B0L7#39'3XG*]MZ\ MVFM@UJ#WSQY,VT&-@Q)K#B'DN,TN%>.-YV+X>O[O)QN']+]ANKO"F^_3PUZQW?EG"W:\S<:/%R0<.[YWW%!9^S?WNU[;G9)3GTWNN'1'&7I1TVTJVD_'D MB6K&B5]QO#[:9WS/BA'MU6^]>.!TRD_>]QP'W+\5U[:==":2VXN"5X?R5"51 M2 >ABI3Z$\&;M^KXGH8><+AKV8:4[*GA?02L*4<;=OD+="X?,5$*D(R[;W_) MWMQ!VPJ;PE=@2_&:H\*0.IK>*OGON'H = :2 57:=@JVM8:_L0#2SL0K04?P MVC4-D ?EAEF.\<,+TY=X1_Y(CHNV.*J[6:YUW0 W\8Q*/&>/@+7AY6\99KVP M@A3[X+'YO%OIO=3[KYE'E@)F+BSX3E!/" X0XF'R'RW7VHS=RV-;7>Y]S[GH M2NQ6U\[,GXK33 75G=PYL9?D$AGWQL\%"H>Q6IT5 %< MS<)*,LN>,AL4'OZ;>2^,7RB6M.O\/^!\%_PQV\('[YQM*FQ=2-5AOZEC#BII MOAU)KPK7QQQK.Z:Q>1VI-$ 7BW1_(68G1^\&2A.TI2S\ZW$F+=8Z:KJ_O]\_ M,N= S^<$G]>=+P^.V.9_%>F$?@@8SGLMISI%XGDC)=H6#LX?/,VI6?6!!:7! M/P?/_D[!NR0MS;9Z/N-[>GT:\#@UQR^Q*%[3_@/[+?3HEH.KEM;UII;/_[ED M7!?]C:Q/#85U[8@ZA][-3%GO/_%ZX. / C7G:CM^B*$?.<=*Q.^B?>7+TS90 M!I'U)NN')E0FM\[8OWR=U39(;"BOXD ;F%.Y!Z8_O=0(\3PL^N#])39>-$A; M3PV'PZ$G?'=@)1S_@?0:;'LV8)YPV=NWNJ'3#'.HNJ'+\\2#EPY:-]]^6JNG M.KOQ50D=0IDI!X_'[G40Y[R?+C$F1704OJ@)=(UZ\"J0T#2BER6\-M'QH>C= MA]-=]^*>]NK]\.=Y&M&6C(@M6'@GJ@NS5PBMW7@MBG^U'X.-A.7YD[1-G495 MVT-@.[-4!>Y'4;2]^%0\M')RYV-.0LVN\@'UE'47.5NKB:G#FN!,RTPB6UF: M950EPR1X*7/@$SY"AOHD&\_^,I79Q-E@QIBJ!D<7/"Q&6Y9&4R2&Y?_9K@[[ M7 MM\)ZFWP1Y5*YEB6U^/GR>A7*\($=6-'Q','Q3-=/+ )]-+KP>J'E2,ZI*J3N>E]3H^-*-PI@'%RI\; M2K@-V[@WG/'W?7<%NWT_],IF9NUYUJ;[>16]1PH^^IO_^W">]X8![R"V$OL_ MV,".WF);JFNE])$ .EV8+.!K.A7X]UB04JEK7]S2:L'OV;5"<_A6TW5\3+7^ MF@&U>^.;%87D\=5?2O]5/O9T^L[:A#G1G6L8>08WAOR^2*(B6C!&%<'T'Y"\ M$-=FDDQ82W7)AWV;\2:0_.WI,([*1&0F_?+/!H>G0/,?Q=$W_32)22E>VSI. M9)/#5?3S5.^&.ZB>OZ85,N]W9^N38L:#4[M&,,?.AHM8ZN\6IY.0%/ AI'HY M_F".>..W;[V[(NI<4]E&&1^($:X/L@C9#9-=YO<%%KUE-3M8G2M!77+Z9#7J(BJ85OUZ!$6-_TV?RDS:[=&6X;6Q6[)%P-FH+'VX_<'3R26O;VL.=K2KX.CF%0[6:S7D[_)3 MHO*NPKT?(1/%[U^)&3*,[R6FPB(KRK+>T';UB>IUXMK9]QE>MWNG(R0JI(5SF4T$I1D9QL]$ MI $XF^Q5TQ-JY!6>@M:"H>T\6!OR$2*G_RL>LGZYS=3L2. M^AZY;#ZVV,;L3QXQX35M9&YB;X)]VD@9F\_Z+U7_S.BA;:[<7J?;2S7NDLB#$>^9G*I'W1:'@Z; M6;UV/W3$HS'[>X!1A$-]1*=[,&TFFW*722F_,_+*1._]_5!+\=\_3EP]7F2R MO=AI++LB(F#\U5 )TQGI)K_DO>$,<+@6;0]$[0K^"\C.N@[)">\G\(S32SG7 M+C,=7QNRH@SC/W$AM#3H=&=?_G/]<50A;V2^_\)%PB_Z$0HBUQ[,8? MI#IH6M?&EEJ%E/H+W_H1UH4%F M\S<"I#N!K+WZE!V\-.LKD5?GU2?)M5?:52_D.,4O_/8ZL,^UQVBHM*JRVZ"B M3EQ-8+XJBH.3;U_%KL@=N9AI6%A0]^ ^J=[(Q;U,7- G*6,B?RH\@5EM.!6J MXDAN5-.P%D1:KD%L,-(HPW!1=CTK$OJFF*T$RF68VBHF%O#^-N9+ .^@+V_[ M,A4HE_-68")]N4!BGCX,B QE&$7X7H@*)?V-+JX:_0C9!8YY04FA,%HBF.OW M"QI]N -*I2.,WQE6IV4856S"#<(O,V YR>:D!FO-\D%Y6AON3_86BDDKN1IY M( C9Z(Y\)E=F;M>]D]9:9XJ;0,?N;SB:ZFPO.5V$&UYB+.R$[8-&I/M;O$Q ?@M9 MFY(N8#\OI>1Q!;UTB4V^OZN%9RY=X@* =R8BG4N9\+%PC@+0[/*4R^\>V.!=O/>'PX'GG;Z#XS/NWI65XY% MD^D:GTYPK4)N_@M!J7_7N:1X'MKQSK,_H(!6)O:K(:03E"D+**CF$6!&,76# M#!,?#[<6C+$57W;0M"F59SH8\1*L $BP8-<-:T/R$J,0+4H^LIZI#)RG'")= M'[XNP[1ZSN+4RF:E>(3'W-1@^-]RCK?"DB>9\-\T-3@$Y4\H@U&X_H@J^B[= M*_H*[S<=F=+=6A-AYY9R?]O]BZ:_M>_Y6WYLFUZJ-W%TDSX0L=+("GA-]P U MQ!(B+6RKI?^LBB:X-51UA ^=U6G$UJ<0\#O@T!H0 SB/ H>&NV-=.]2+(%5V6@JP_R$P"!+C) M^"6'ANNIY8)O,LS&Y23J8G9B!T*@C HX\2B',9+)FSC^UI8G99BXQR,?;8^" MWYDQDN4BR*-TO!:JLX!F,R$1?G8#'>#AT-^C'%6I2]9GKF_?92^/K'.L&/\= M-5T9#76%TT^&%YW?67L50Y4C@_ M'@ZDO_+ /+^XY_9%H]'W]\M^NS?41E479OG=*S][L4U"XIWIEI:>#-YSMIRQ M_VK5R9ILSX)\TM"<=5M)]W]"MC14UW#B Z.R QES8H]!*Z P:E2&Z4U[ RZ^C6/W<]L&,B5#,SR^X:>\N+A MT,&\J+3]\Z61()#$_'..G*A96%Z$SG#H,SBB!;\9#,[U#BKHYT]^]5_"UZ.3 MQ\0JL9( 89@#Q*8:H&A3E"0Y)##N4^7V(Q\7E];EJ2,MD/QR(AU)9$1HQ5UN M '\T2DM\I0QT@DP2E6($,W QYUL.0Q7X-\^"J4*IMZZ8F1Q'Z>2W5*Q5<+NB MKG>4S?S!GIW 5MWH]+RA8\1;.C'?KKUT?7PFRU TR>G?I?7!@S5-5@?\R5^! M9I.%DG;8WFS:,!5G QG$M]T"A,5HC-+%6&27"7QLN>K?FU$N;0.O]+HRK3T# MZ _UJRLK*9IP#^*E5&,W:NT55(0]EI:/\%5@]!OKK4X1$V68;VAHW[Y)X;91 M1P\N#D_TC@<.C1=%7^]ZO8G;F Z8$&?)D3^C5?]?U:-^;YU=B 1+1R7Z,LPY MJ#U^NH%03!Y'U- 5$FJSG/;S3\><"7Q88OL(CG+];P*6/@?,0BGH^'H9YN%3 MQ+>(OA!92;>%:NF"WN7#NB42>^\7,DRAWT!A28&;#',A<%@?,J>C 00N2K;9 M'_Y$M9E$L7Y-_UM]K,+.CV%9BZQ+K$&GRV)#_^"WA_P 0S&G;'(&'Q/O=RGE M;)/Y (W)@&687ZJH-)GH7V:@45!.D_W\_*^F:HK!NWG4TH4%]D QO D)QM\]7UI%SF.(5T> MM A73V=@;:&[E(W"_:\N&6;W!2!OWF,Z8X/G MV3Y;L]=?C*;#Q.(2/!,RZ-F/M@I)Y.D-MO.3#.)=@31S9GY6,!W8@C_T"K]% MT[S/+-OR@Z?+:?&EQU*.M%RZG)B*14<-,@.8@SS=-R14F*R;V (= M925N02-GNBQHGJDPH0TK(-MKF7W(/L@@47ZA5G+Z#/*U/8%(;T^6803R[9'^ MPCG_PAJRI3^_>KK\TYBWZZ+7<]:7I?,EW4DSDD,C)ZX6M0MQ&S]*TP6#"CYA MLU_-ER8QYN?N-H\H%:7D/=2S%$+PWZN5*%.!25=2I_]]<(\4X6D4,NG"7'M? M6$F]L*?O((=VXH0K;7[@;/' N_I!N\5#!"SL2(*LW]&=Z5+U;U^'O4(+^D=\ M8[[D[7]C(#?,+@9K8^: M8-3E;>=KA]6,U_$:/PP>&V5$B92G^P]R(JE*L@P M?ZA(<\P\22? -F;X#<&TX9%D)Z,R\H="^P+?%CN>>/N_64G?J$D MW*>P[M[3%&5R>HUMT MW*V-9"5?E;)-XQ7;S=/._?C7TOJA L,2_/-!^_];\)J\!^G@EV=.S8M=_&_Q M1/)<\KK)I>[;VXVTVJ[!$8[X QT,B1.J-"["R2;/%3<:EQ3'/BK9N!WJ>Z:O MN13U?Z_C\>V"\@1!"@C@7F+@A/CW/(UDH7>AN\95S/:R_]$^92/&\FGOLO1K M!E#E8=B>%%F8FQ^ 5P3U)P6#!'DWV$/0U L(]#U7_NQYBWZ"6*IX.=,"83<[ M;XQ-B9] K2$;#[%0X7P3_?N-D]Z"&$*NN2,E*[RI Z?$U='FI"WQ9==,@PH_ M RUOUK5="9U=%XE>AC#@*%!K\@RU_VP5(21.??0Y8W&H:VXR3&WQ7ZK#\X E MXSO\_F.\?\(#/^):<+]6V(7 Z7R51Y@BG.A [A.D Y"C[:&HO:%MZPJICK9O M0@S ;\#Y+P>&Q_#;&CL]PQZ7!,EY="U4-N'1"#< M\+5_D 7N'3F%X!_(F9Y6:.Z@B%M(!]@X O@?2F5SGB'L)L*IF!6U2'%GY1%5 M^BVJS1/X'QW?5J_]0<-*;[[N>?3SCR3&I,N"=8^5IY#8WRZ@U8IJ:Z,!EXX_ MYOG],W'?Y(C1CJ="L'07@[?N7\@TR_O H@V> M05*@SEHEX2_MQ^?*?YLLI)P]6Y&SRKM=_:#_I_&"]]-!.EW?2?41[H3J3%X4 M< OY4ZQ*CR4(SL.9+3U9F;DC,9=[K^/ V\;8E/GV]2N/66QJ#AN]G%+S(M__ MY&G@#C,%MXYZ>D0J_P:G# A4I4S$0K*I<]F>+_LAE%8_Y/'B"V3?Y MZ(Z5H8 C/_80O0$JR@,,EG2CL>%2].7:P3(9AK#_]UE4KJ_]7@Q/NDB+K%1? M*!HVT[1!^5:L/(4I),4C.-AYC,(X#3L*0@M72!\63RSMU,5UA)DH!_KBC1 ] M$4J)1\#]-X$G9_Y7%7'V<6DR<$D1N^ $XU )ZJI)B*_R=#8<\G7KWMU@&.S\ M\**TNOA 69B6$\D=-SC 3A3,5$W;7U]5'G[61W'^!?G7GN5?A$$>DFOE\+=2 M_.MI!<0J&)@R%X9("9.JGWNM_WK.>^Z?%9=2N^E;=$V_6?@ W]?2^<]O+[5OG5IIIV3>]%YYO(N?P_S0&*J[ M!;H4*PC<::88^XML$A/=[!3OO]]^U3GB:3HGS1YB0<< ?)'9EH( MJ>9 %=#F""C[UYHC:@V:A-8MA13D2LO #=CVM?1C'^8+?YDE!B<^\ MS5[;: 5:#-,,5"4MLGUNY.W\5!=R][[NQL_+JOCF]+_):>_D$385G=$.0+VU?"K.;U0\0BHC!$:9*-LWB0_]N\1^]45UE5 MTW/W.S2'?_8U4,[9%K\4)2$>- OD(T[#E*5"Z5H(@ZAL?9# 922S%2VB2T?C MK10+X?HS4-FC,*R*'[*5N-HXS>KH(_@L;HJEE*X=BZBDHQ)H*WM%G[W ZT!G M>XFCOMLE3=:7_!,6:?1]]_Q;RX(]ZQ9=ZW\!C;"""WV'GWAMBIC+5.8(R*AY283D MZ39DU'0!&EA%!ES$2T*"%#D"74CISUL MI@7OG_[,&0@P\GQM%E68?>VZA\D3PH]S,LPK$^3;Y)/_57$=H1,>9GQ@,:/9 M7L#^_T_U1<^U8Y%ST[W@8MGR\P,86DRQ(IPMPQ"76L-,5[3"C!9-WWA3+6F( MZZO:EYUAR2[1S[V\SKFU7I +_K!IQ6&,BL?/N7=OY2!'89%DH\@M2[C$.P8" MB:AYBXI6DF%<=;>!4IY$WVM+!6J6[W3,\>'C#=;Y8PR3^",IYG?U*W15KUUQ MD,;"I?FUB8@F/'FXJLNY,KR40O*JJ.G(= W2FHZ8*;P;6"##!&PF].M>.F;" M&+IU(7@_^2V!$0ZD,5=4-8:V+$4D-1R*@CR$2E566!%QG>0*:LUO7UO\ZS+* MQ2$KGE \#(Z0NO;TEP:-S:CMZ-M M$]HU$;XHE6* D2>ZIB][SD.7BH2,1+P%^(6INON%J32P5?=0KSI1)*<:O]^. =SCKS QZ;80.])1?XP8B.O$B-.\E:,[DOX, K6'I M0#Z[>6:*E%&[A*\MH"0[?CG1MB;(TJ-SKD@Q-NW4K;5Z<"=,&-'Q:$*485L1 M$8=T#9GG]7\%)I[X-,P_N/1._PKO>NWZ/-UF0, MF=)6R[Q2SW7@-X_KZH+WZQC36#!4N!YJ920"@HMP]E_@S^?@Z!FHY_D" M#\HK$N+6894HW-;-N:ZS.P6?MY^XM"_)38$FINK!;@)R[/ *<.:F%>YBZG[N M@%UNB.K4(QT2B>UDT=,9'7*ZNWEU3WACN$VTBY?WZP)?HZIO)E67MLI31U?% MPC3J.:5CA2NOV:CKVE:^GUQK'2F>:B]]+C31#'1B.X5_NKGQ M#[O#YB&[AMW?3>19H6'P%U4)3A0Q<931?^!DB$Y\!=$3PDV4_1:NZ^X\P ?C M/&&&EV9[JA$5?_BBS;/)S>6_CVW+%),1E6"YZ ?B/6^^*C?HL@0E' M<-E;/\ _"D,9S=\9QM?N/_G2.$W>5U,;V5_=5=*MMT1,I3H*M">Y VY*;F33 M-'_UBU<#PCKIKYX7Y_UB[.J<)$65#3"]O*_&Z@IR1B3\PIEQ\B'J16D.7E=R MH39MU*/+V)2YT9UAZ "UQP.55>W:?E;S'9(CEY_>:YD7[;: LI;L%:2_:(\9 MLZ8-2FGV(X&+VC2/F_^^_!EOCEV[7;0]QZ7G0%7&8H=?SY!1Z.\/*])X%^&X MA&9AP=IM%W>\MG,?F'3T= O(&TV0J,&&(S,Q[-7EH,FM\QS-RVH6ETPL5?=,NWATSU\KFJ[K4AF^\)^S(SMT#HBO?FI*D6$RR>-,KFDPX^ B M#Q)'1RZEWVG_4K<3+9=R*@W--0@L1): MA!<36_#^#N^=WHD[@PI_2D-HK6[&6VO3W JE7UREQ.#(NVG]T^-+G1VBG<&+ M+FV;7W/N?&W'Y2O'+(7.FWF-6MS^T;]WP1* EZS.C\W*,"K<'-\OLSS,A1]U MFC\W[^+:+6S=FG73U-_LAGR#Q@6/RJ09P5!G5IG>3[TMPR1WYH15Z M=:%^VL?%$W>\ZWHL(]NCV[1ZU=RYI[<45DA*D,Y(9B)B1OT;?B[2B1!6TV_B MMXWCE"0N()>7<9V&!4-2&K O_ 8&*2%NRT?2@)<:] 0U]Y,\S9D$CF#'GWEZ M?4F8T[C> _5/_(:W=Y@1L92T-J[[Y^IZCVG#4YWAAJ<;7WX)FSX5G3'Y]Y=2 M]3WG! TUT[575IU+AQW$Y]&%@6LP*W8/Y"L3+@S).X/T-&,SXKK 161UN<'Q M\AXS'?5[^4[=9JB449XK'S!],>91565ROJF!I&&H(?%H3=LH--[,/3=Q\0QG M8=WJBO-7KE6-80@D)CTRC$^-'+N5?+:'>U[CN_]I":I[\1/^OO? M"!X23KVN.B9A2[,N([NIY].;\Q3 A6J!M2V/@ G7P0F0NVAG!>WTOF&XB(MR M]-(CB)XJGZ3.BK,9X.RZ:;4;T;F$-_SZG3'O"QD*B72\,D5WL,4B]_U1GQ]] M_LK#1@4]S[T+-=9TMA65*&)IKP9V&!7HIY4N5GNL7*MT0&(CWHW\2U!O4 !9 MO+Q]4&T<6]XC:'?S6,( '6J[ MQV''IKX\S?>-;(M)W'_9J,/M7UBT&$;%(#?KME'(DTG\CGKFX<[V MA+EZ8CRFC*\!WXX?.::WO9 PQ9-A5C'!/WBWV8<" M^)6<-[]]NZGF+ZB'P<9V.G7#H_$EK\?YJJA.JF&SUR(#H"^]NKFHQ39&D"Y, M&=4?29+PI'EAN%0FZ#*CVBH8VB_DI;#_E)C!0:1E&N38NNYG;XMM:7G)0P9U0'?] (,.D MFO.5&G"@[9M( IV]$5U?)D+&:CA4L-A&W 3SWL@PX'WJ)N0-I [:M^T542F# M+;KHE1-'Z0X@4[(];[6!/MH.#Z^FJX6A-4U_J^JF:2[R >Y;";GO!D( L>.& M@MIDFB;<[M@5U+"AK,_#=G7JN;!&C#\'9'B-UT6M'R!)CO\G]F9899722I:6 M73?KU/+V,,)D("L9P +G$^T5#&JNL.XX%&KMG\KO8?)L^\NY(KZOPG>E+-)GM_607@;M.P%=#RP]IV MFV(5!V"NRTM-6J7PK=6A H;JQ/55U))BRNT85D[*J&+;GFBVH;1QCKS!9H2_ M:M#Q"?481&HV9"@'R O+'$9N%28_730B[SG8(UKSQ4% M;4#AXC7L7R^B=J?<'>^%GL>=^?PC3*#.)WU053-2G0E)CLC_K?DE97)'<;6! ML>.UG0[M&1\,+1$QU3Z"9!>IDMC)6 M 'H\,D+@.D9N*AZ!DN)HT\=$JM)3G4B MIA)_6 Z=A5 !T/2!F:2KW8$844*%'(F3E3WJJ'%Q,HPP&QQ-H&J-I!K(,,98 MV!9])Q-D24[EQ7/\."%D>#LI!@AH7VN]>)-0SL91/2N@\_ G\@;^4& -HM,; M3O\<7HH[:5%=F'+UR>0U'4 <;N4MF%%4///NTNHUH94H1)S']EM,+IR#H]?1 M+*'2]E9F*FU+U:^&&Q#I3$U=[:OZBHKSIJS5%."J@1W(H^_@'"2VC MIO<,?B67ID[W!5X^V%FY^?QIA6-]Z^S?7^&'<[*F?9"UYE!E&T%'<@BL/ ;^ M]QS&;68ECEL/;"@M:N70>_4J_ZH&_YQ4TW#C;+L.=*_O3#MS M\HW=/">^9%7VV@>7S$C/2]-0+4_60'!A&%-F3!C;!X#: ..U#&/ V"[-!BX2 M;LLP%46WIU%TJB?VY-\("UDWEI7!*8.SO2!=UK,^RK7/O*_6/?_^Q4].@ZX_ MI9[9M>TA1P?)MVF&R'M->HN3YWRC7NL"HLX6'[B;[WBC:/RZ##,PD)&:S] = M=0QRZ[[.F)[1\O#J>+TI-JOU* M&\RV,08;S!>PF?8@DEFL$T;YF$L]) C!PAH1?VA E]++X)>"AF/O.:XP1Y Z MFH1L'A_>S(:VC(?\DM1K M&2R<['E1E2IWO(OJZ?_,:[P6O^.+<;AGZ-'N:JM)"S8'C?3#X?1F9#QQI!1=E#,;FT)J1,+UFL:(LH"$.IKL(JFGQ\(H+O,Q]1/< 0'MX@]F1]+9Q8ZE\WM/#PQD^PB=KNO!;Y82[HZ7_>6N2<^/2:[&EY&*W MZ/-/-6%:9<'9,4UK)+78"U4;RM03!1/L/4,%HA;\&K*%$<75W@%D,Q3']._MCQ?:J0XB>FY=&V'1'V'<9YAM0HAT].F4MO/]9 M8O,G]1C8FCR1I\=&ERY!LK6NMH^M%=S;GB@OV7+'GF^"G6J$B]ABTZ=:P(B@"FO>L+B,(2[A_;(\!]41*=-;80&YO"[!^=48Z.Y9@PZ-PA*!ZU=CYQ<.:RI"%_V95%\8:+'QX[?^$ MPWHWFK)^Z??:P!O^TAMY_D)BOTG;@#W7/\R2G)@5E+KPL#1 \V-9 8IV(^(# M_U&Z&<;$ZNA=734)@ ]6"-<]"U&]M,A(L&\5()LIF>_G@)A*-YX@5#[15!H\ MR%WT4N/4-314RS /\]]$+MY$T7!+;\-_MW6!6JM+5LHE0+-;+V+G3)CP6](3 M%DU)(=M6"X,6V)AF%$A\3&$B*AZY>*[8IZ6'T*]IE;4TL>0<^VOTNR?6%:JE M?TW9<1I\Z-FDA;/LEQA"C'B)R8LS_A&HE.1 \@ES8C$+VP_/MKF[/I!AMJ6W MY%E!6,DI ^0P$W*DT!%E1-1Z]CKKR5O(F%W-Y#\YT>5(2YU\/7MC6 M[N[8[ ML_'B$Z?)@D:"<>X'=^:;P=\;$87=4^? M2T0 ED)%S3]=L(5O]AP$!(P4*W.AD9<.B?PEO'Y%43)9R8.YM"90?3DP$>59 MONURXB9W>"V*UK>;E@^^&2 J_"6=P-Q.X!(Y&3&_U?S)1(>X(#64[H:KX ]M MME/N;5;FZ"S\1E"Q4^RR?!I.8MC%A%EM!,$>] )GYQ9++1<3;>ZU26YINN NC[YZROR] M1;E;F186[/\0EE<\SF*&O/W^YJ)Z2I.!Z^>DVHP,2=B@I!HX >\71.P M-XOQ^0!CSF\-[GSEYJNUL>E=Q4O8[+OD'4#37WC+KQ)Y>#_P;+=K1N2E1A]6 M4<+_(>[=HZ'J_S_0\4B*-*D08BJ52IHN1)IFZO&@DB8)N4ZE<@L)&1FSDQB7 M-)4'3RJC).0RE5LQ3(Q+*KGS(,;,5.[9NQB;F=ESMN]9YZQS?K_?6>NLL\Y9 MYX^QEK'M_=GO]^?]>K]>G_W9[S?J_U6^O14UZTO;3))WEA<\U=X9BE??WLOY M4]<[MK3%YN3]L'.FC5M()1^=1^\UKI\>6AF9>>#]\,J'PR,U*Q78<4 )3%M M2+V=J$7;4B8Q'8F78WSXB9X:L(/_I0/*0;?" D)L<*O+[)Z>U*#A0_M5'O]< M#2>^OVN#8WG_N[,I83=5NA*W#OSW<>CF9]W]M]Y<]TAQFW<9:N)?-)?FWG[= M=Y*D&WV7I)C>'?.W6TD*)_1Z264ZIS3(UG4 V#ZDVFZJBM>'=[6^KRR:NRO= M+I10,#3='H);$)B$K&&NIZZ4G*6HPRFURK90>6*!4,W+?T;<_FEH9ES9!P3A?3U M@9?[G56LEVTN\:ZGXY!:O@('#U4YP'."96%)VNPRA3S\K8!I#I/1XVG88=(( M"J"KX/BSK-Z3F2K+P[>=^-DX:4J_N6W@+>:OHR_SEBY3,<=<'^&NQWU **CR M2X4MU?_Q"M%^)\K9FOK\J[N#:]\LL+5PNH_^29B;\!#0$;RYHVD?)XX(W;B< MZ%-,]\;%C;&O+^^K*6K83GR7N7ZQSBJJ;3P-YE689[L#0@/VRC'.G-^K.VU? MNC1<,X\\I.O8K; D-&CRTH5]7ZBDD]T+_;1FXK@<0\\5/<(UCTPU M0&IRC!\^WG,_]%Q_&QPL6"Q&7D=?5E8&*DWUWJ'9%'@JLD>10R Q5S!%$X%E 3[Q]["7X,H*L]C%=Z1GF:,CTM4W^$V>)MVSTXG] &-F>AEM M,^1]>[I,C\0;4B^%%*DA[S/W4U9A5U*9 FJOU#MO._2B,JS:L-Y5CJE7.TJ] M& N==PK2,)_7':?TXY'EW1(2TH5]3CL,NT0)6J/Y6C-X[;/^Y3A-CN+PE(K$ M28<9E^X$@D@W.$]8+M3^Y_W^H:(OV%[L-4:MATF8:FJ1RLY74_; M+P25P3%.E5K]Y=5Y_LYV!1/]XKRF6!34K4=?U>K&]W_&;'DD"0JS>9%6/1/E MVAOI'QH+-T$V/)PBJN!LX ;A/R_T=>#SPZPUU%Z*![$W3-;S2-"R;;S7VTXA M^L+'.XEG:S8?X,6BRFV7"%'1DF.4MK_FPL822W?I81@X#Z:+&$R"0^$$2<64 MN13E.39>H/>P'"-MUE?K!H2I(#G>E*6ACRQ"S3>L1E@#<(JE6[-NE*)=HTG] M)&#&2[.?PYTVR,??S2K&IG_431_K7KHV;<^$[8O];)& M^%,3:7D0LAI^,(">/X9S":SIE7C5A7NJ+4)B@^P#,ZA(J!N MC5#-OXX+I@(-)#EF[_LF"GQ\QQDO7-P>SP3\I_:H1N-W!\L'1@<"V(\(!N@9 MWW/[@0;]O>W(!GHGI52.F5*'#!J(&Q#46.\C2;<10F\I*H=6/BWT^4\_ 0:R M&H<%ZIQ1:)5CQ"/239P;(N18&7!* TR+ENST*Z=O>\>J]S3P<*A=++@-&S:Z MFC$*2:6%H5P5"GR1>C5Y'V_AY%5%.'>Q_GB"J7CCS?-OMZ_0^MG_5"FD'?C M>PG\J\O#+81"6T)-6U'J;[ R7XXY%[0"&.NL_UOAOST'V"4E9RREVXF9P ?Y'0Z5N=W:#>N],BT%YK_EFQ6B^-B'S M'U'^6*)4*JOB7C8FB9-@KW.ATRIC0UL@!F]ZM>\0L6WFH.3^"\-D"N]Z1LN_ M,&WATV[)%F9\2].#'])C@J+/R1M^W:3*,1:0&2-DY29!\_"O^6,GC1ZEJ>5N M+O(I+1S\R4F=&:4S!-YKSIE3$GV]0G3.C,1]QL?\_>*9+)VT0_SZ&GSZNUU_ M:^K0M+<4#?Y:9#_46X=+X*K0C6C'0>!.J1I>@J=PNXUG\;H^1".(6\]<2_TY M+=FPN-HCF&8@&E=\Z&I@+H-&6'K3F4<"4UZ#25>B4W]PU: ;756K7J)^[ZCRWEL_=^L[!;^'YPB%R$51E*C@Q8%'K M_&$/X-ED87_WBO#!L^*N![&IC^YRU6;*!OQ/CF(.B^X$9R1GQ2)2>Z[DH^Y\ MC#O^KC3X&>U@NQQ3/LLE3?9IEHO%O,?#-T+-W[>:X_Z!'S7R2V.9]8?<>&G M\II-?3[]3J\#@/.RUY=>^I# 5!=_E,&0P #)BMK&!%EJC'"+?5+;_F^K M ;^_-YJ\R]8>\-Z<,SK+YUZF;WC$K/L:I4NYO[ D=,+0&^\?.'1>>:OIYBG% M;NKLO)W[&2M=1T=G21;FD$4HNX79YR7^M?C6/C>!!.9-;FZ37A(6X7DU&R$M MIBF3L69B:#.86U=M68 M=Q:C!4_^]PJBQ8F%G_]K:#G_]VYU/G^\TUZBSXBA) .@ [:/:]O-)JA)G/MI M9C'"[I'W168-FL@&T*XXU;^ &O>;AVPYS,RGAI[;UD78'V:0?Q3'@JUQ]E\/ ML/OV2O%Z4\.[MBG4]F\/ND?^#UA9N*>3?$-_7U-ZYU;H:56T<(K M5=JI%YX]ZBG):"\HVA5),ZO_YZ?6E]W:-4J>IQY:O4L.+5T M+N5&WT2 &&@D34Y)UDK=9&\)=M#*L?33H%EM2U#]C:BBS\WLZFP?5^+K%WXO M0^O6JA?Z>TF,>#?+;SJ>H:;LK#UBL,"090 7N7&DDJ5)D;[#QZ2.Q7[IE?0G M.8/PHZ;,34'J<":JOMY[X.TL>,6"[(T[[9=V*"C]_?C*0F;_LNQ$N\P_8]IX MF#_WD@U5EG\ANR//'^T)W7",<_=[,/\N]I#Y%R +=[#.4^\BS5")8+R,$\6> MTCDVWO.E?RMG:*Z:62*:UJ0F,8VV).;+6&E-:7N:!=O-:QPU6@Q+OW]YEY9@ MU#]HR\L2K0^=$3]+-)HQ^+VJ^#)N7CM(CIE4S0;&!LX69_S7LITW+?RV/;NY MP]V-%XE+V1L4/XMCL(E#LTQQ?NCO-Y+5_]XD"2^N#(YMDIZH;;2(?NR5M>'Z MZ&C6,J_[6YFTL[5BO:H;43OX8%.'?:3G5C9T056[LFF/&5+JXL1&:W2^7^!X?X).>9O1V?$ M<,A9RBM:#_1^R<,BV4^PO>R0-D4_WZ<5=SZ9W-KV7MLKNG=T>;,H^NRM'P&' M+WR>UR3@RF8EIS8\'OO'4)*K?//8>[T0@@5A$]GBI^]T3M-2T3J,]RN,%Z18 M?M!I$.-0?E?7G!9_X5? \#K%E/DP0WZ*\V+GX\4/V*HM#8:CAL4=4UN[EY85 M3.ADYF2[4@$>KJ^_^!5>:F$CAO=?-%(4?&\$OZWB^9XFGO]%DJY-G!,_1B.S M#L#"(G%8FP@JCAUFKEDL-@-U"C*3J:%<7?BWP*?\>N\403WTL%E&W(#_&]K! M:#EF^9& Z'^VF:&EJ:>]9 M=5 2LP 0R^9S)#9R3.W>&FVDC4YZ#R)D55QM,#? IOX MXAH].+>>N L.1OF"IF^_\YT:<]KA3E,)=$G(TIM MA W[%C>^(JVCLRH.:<< MRQ4&[CW9W83RTCH6JCU UN@#]T%=H&P@F7@J -L2D3O^\61J?A0SK:-BV^;\ MUD'CN??/I)5#7RL7W"B_E ;#)JKEF-:GW_AO2)/A8+;8%([*A[4$J:W)IA=[ M9JU[:39"('YH6Y FE4_I.;DGK "^N2.]<25&\<&-^_?G"R0H*M=NX!A#BG_U MTC?0/\W1-X(V]1)@.7#.C4I"UK1J\\?TM[]JGY6TJH]9K+PWM U.K%2.<[A> M4/#,9V>"P%DK^F_JN4L%T\Q^K/@;3 :QSEQPJ#K7']G<.VG8%K!K!D"9USD] MAZG*LM?=)O>TW- \3@W3G6_:#"S?5&TCJ)C:!Y8(B?E:C% Y9HW/0E#RKH K M^!G^LO&,+^F^0N,_Z^9.(MUVMK8=I'+MLJ15+[X_+%3<],AE[Y^;4GY-W'E[ M_87?K_"'#9>W-Q(>/$BZYN1>V?]EO*=[+(",O.=]ZIUUZ^^91QI_I9 M[@'+U+RRK1WM+B\>':-U$L\L5CBA?T(]9?R,&B-,;\0Q/#&P,\02FC)B.<9L M*EXPJ>.4_\(%CGR?'.Z5X[> O,Y.M?-WA^B 8-/Y.**F[ID_6H27HJ;A;< 4 M15!8% /7$?<3W<#CE8MQ5S_B*N\M4"^NS'7&53+P-TK!*T MTB/+.E0,7KZR"K.DO-!HI%;Q]'%0:VP97QE.MZOHX9@)HPQ.@375+[[*,7G< M#M-8"VNV'U4T=S&&Y;ELL_HL+N'WB-"9!R1G+H5K!22<]"(2 M1Z4,,^O5+DQ(C!PY7:;,^75ATZM@ .6'#V+D&"U=9/MO.6;M_A#!:PJ%1I*] ME)J"OVLSL#=G6U=3S9J&B!4]5F5B]K",?*1#JGYYZ& WYU@A'):P.5GWKR5J MF.!W1PV##Y$R^?THIT6I61Q!]DIZ2&).T^KAJ(.285)#B^Y[5)73CD&*XF1H M';1%QJK'ZM-.0;N8K"7J@@L<)M9[L:V)-FX^#1W(\LNT*_X_N9.X/HK0IHZ[ M2KH>I%<, \O=?,,!, EF"E#:'>FAZ 3A$FL(P(<*@2R2]Q7X$(*L+J[9C9O= M3L?@VBINT7QSJ*(_8UP[F2F/XLHJR]^VLKSI^V/\J!,IM:(-X,&[:<@/(^K6 M-!?:VV'M3(?H#[5-[BN"QVX=GDX$<7U\@4=3'39NP8Q11EX%CS0,;:\L?=5- MOI_)KG72Z6QG3A/.":LKALI[)=V\[@;+2GA*)J\QL]T1GUN:0N\9? M3$9V6OS(N//$G%MF4LJT*ACX]'F4MV-O0Z?C9M'RDSNN\=.,&XZ[%GMH]'>6 M2TC?JQ 5&PG9PQ_0DEXJ&M,W-D,PH(QQDV8+3C@3ET#,!(ZZ"#?I)22O@ =J MIPI],HQ00-E-(V3D0?$0)ARL2%3X5[M\I$Z.\49JN67>=TR9=RJUZB2D1 OO MAB EN%@!.!\\+%._@NB3\]5,5W)JEG%AB=#K._7, MOJ7L))(OZQ909C/Y3FCG90_5@K*F6B!!GP V,@$1CJ%C)K9[$2T(ZV@L#C4V MXL5L5I?%%/QQQ&#% 5ZB[.ABDP*DV=4PND:?&B1D)O#MH3.:_2.)8 M=65L]GCF6MA7E'2(WV]XHOV44DWOER*AYF^<[^)*EN.9_G5";NH;0D'2/IPZ M4N*FZK;KCI^M1L:$V[[:,(>O5-4M!"<^?6B?JI1V M:75B[I23;[/2CI3O]AG? J=R]? !#T@^1SXH=RG:6FG(W/16.Y]LQK_#3_P M-F1:%<&*?_6@BI+ZO^_,% RV&DHW1*SF^ M.B_(AC]./[I[>#Z) F^'YNKW7QMS@%LUM?370=;IA0ET0[A1"U3PY0=$]IBVV Q].@% MU:O.4QEL:&'I# M(+(<:5NHB4R_6W_B:*6RM=]/#NT/$HO "/5SC68H*;M)# MF>=JL.LF<1T6?BZ-%+?1SAT&_R5NDZD\B_8(I_1*+22M7U@:TO6R/-.! CTG M7@,15]IC0E;R)RJ75S\2HL(IV76>^V8F&(W@>]W2?8(CJ,KME6ZF;P>G&6%R MC,;H!NKS5;N?1T>7$Y=);Y16=!MSC(3BCH#B,/):"GSM]VF8!:WWJU3HEEX. MBS)RZ)9CA-8V]3@XYPBX,$K<9PZ^K;4^WQ(U9Z5(W 3'@*VB)?H*7:44%?AY M:<_"EZ?Y_[K#Z4)2O<-+ES%>;;\U2>BGS2T/$44>WBWD=5**M?.MNFNK9<24OK['9[T=,EG7L#:T- ;> M3+4FSV(9R+JN;QT$-Q'^U5D8D"B?+8$?O5PL-7@$Y4FQTZ\+_)#=("M>6=KB MN1Y,OQV!3OI[B3+5J[M/'A"Q&EGW;JSRU7VZ@/ONXKDP-#<1R?]Q0]T^T=[I M6*B$VQ(UFM5HZO25VFA--E2\/RL"Q\W9/W2;^*7KY9A2G'1M:^W"4 R]EZ@" MGR_R(^J!-O=L_N662)=GP>DNT,JJ:=23:6^#IP7V@KW7CK%[N/ V.68*&PPJ MBH-Z?X8>[ P0-\XOL-IJM$> P\K.U"?YTR!%.8E##5\Q&%%XB.O4')SF= MMLVU"QT%/$FJF])P?\"1K7*,1[!/(-F\4;CTD 3[=(YM7>Q55R['>(%?8@+D M&.*")VNAGYG+IA^:R&6WOIC/,8P: (Q8KZP)K^\$^%L9N?:\Z1_$)@"^K>ND M]B"EUBC 04"Y3:"(BBYOZG=IYQB_]"'J+KDO8SZ78_SAVQ,URZ&5S*?)%[-: M8\["N9@=M[65?\6(8V3%'$?)H4$J21@^I8SE29ZL WRH^UP@)#\$LCP&-3Q$ M:HDZ2"V$9912&/K[=;8R1*3X/M2U9&15Z[P. R6'AG&E^'6P(J).4>\[\A*E MK+*'Y)U /J_@S=\U2.\?,Q)".=E+2Y M'D4_E* #,7.L<@7V2NNK\Q([ #B8FD1 M0F--\0A/A\L,!991F8TA WXEL+.@\5&1M@;!2\2:C-QZG[83G]9ZY++2OEU% MYVK?!5,\^ET&?'O*>ZX'+PLH*D): H+:E-S7ATQ$/S@Z?M+">9\(MYSJW52S MKI>F)=);S:NGKX&L[^?Y$ W:3&V#*GQO-#(+@:?CE1[]K-34QN_GN[P-5BAN M4_YAR)M>7*W;T2G="&GRA.EQG&->PB<^5(I-M?Y&'6?>0;XJO$2.J4>!Y^[1 M$63-)B)%^?ZB]#"\'0RIU+2 AHTX]->UM"!JC7[G%3S'*L??T+I3ZDQ,SE&, M!&0W36^9/'$S<+]NL2OO\(55F(8CE'\J?MM!?$% MRS$QA>0$1%%*:I=C+AN[B<)YNH,V]3>THK7J7;62$:.)F,:AC<@ E%E)N'H$ MTK2DYO+._YVZ@=4W_2][^ =#2-&8X)8^@RDBPYB?'(?S@HA0'^(V#RJO5@O9 MT+7TYM$N&]Y^?3U501!V-'-1_-C4,>KMFR5E*2KK"K8IC\O6VA_^?VO%4-GR M6'2K8B8G;&&AH_WP"I67NU3C*Z9-3=[_H>'=-[7-?Q!C"1T_-#DQ/]BK_V3T;I&:>(EGCJ40;?!^= MNFT?!__;2')F##&%8UYBX[A_ )>!?B_!7!.9L9 ;.T4S$#VAB-'4'^/3_P%I MTM&*IP6C4(_#XACZ*\ \],Z!.NKP7?@'EYVQ3?%;4)^6V ?4FJP%&4= LUN< M+2]@&X?N4)EA/04EH"6S'@YG/,*%=D./66#&1%]/&7O5N_">?T1J92>/J/W* M6/B1N$WQ_[C(\VY$CKDGY8I7=')G)B(\U# A_5I2*DK1_PVJYR\ /49/_X>- M[QA[J[68?_1C?JTM19WP'T?\U\V[H=V?+%%7..7(,1?$#U'#4U:U*3M8K3VE M\#]^-.:3H1A$Y1!(>F_1^/!9@S!);:6>I15D7?T,YC=F[*I2OA76F9UG_X)* M/P%'S*;K],!S!LSTX[0']7MOTA^!(B[E]\0$I9DEU2@8]N!.RC$22^DZ.'8X M1H3K$XG/0\7I@A!(E\=_P^>Q)K-%K8DZ-O578,9IZ"U8E\MH?,M=2;.2<0B4 MO.*I&ATE9J(N+Z[F,WQ CE$*1.ESB4L'+:!H3.>K*ZF1K$H].0J3ZVY3PY%5 M@/HOT_8'M".R"D&=@D'J^>PG'Z_UR61"E!-^&$/H#\4OBC/*YSJ[L#\,A]E3 M$9*#2/<#4BU+88R_FN1SC*-U/E=J EIQ,O97YU"=&UR):%CMF5ZU6)O;6;F. MD2O=JK]/&X4]N$*?_S9S#=C*8_<9BFFVA_99@HVQSZEFO(E\^!9>:<1Z9U@.;:*_$3@RC'QRG#Q"&$I$)U/@SF M=>^R0UYK,6:B\)9(>]?Q:%E.?K+VJCWOS;V5_BZY^6>:1C.JP!RRI%[@UM?@ MG'M-=VF!\7$/XH(>Y7#7TE34&'=37KKZ6SB5Y R^W/_I6T^ P55I'&Z[_7W6 MP=UG\\]!!8I!4\K+KQTR;@D*_UD9.&A6/F)-V6G8NQNK^7W]'_E87WY*QJ[K MD4.]O1YTC4B#^1VR5SBA5B-32WH-?K*X_;*'*6S9YP:.=:?4S;$T34E_P 7# MO'VX='DF@ M*8 E#?0_P,!\4>L*&@FZ.+0'4M(V,'C) \(Q 9#. M^P<.?'XGDR^NE44C!/JGO7YRC#H*$+HP3^1=QUHCI?QG6^6U";7G%?$S@[BS MBW6)G74"7_8;QEX]!>?Y6OSQH$!PJV:S;IK9!UP>"[1M[7.NTU=IXSA+_B(/ MJY%KVVA^02LF$ 60I6L(7H[=GY?X0K!NFZ7TI+4L+ OSY^&/0\J2T\/D?A;B.CJS32+NT8& MC9V?7[U+7O9]5?/ \1RSV;.U+8UTF7!ZZU>WTTZ!"ZS\3 +,!B6"RS?#^/$U M^':"X<6=[#+5X"*_A8#8!N'8_A?B45^G+WW55U^&Y^\4Q._,OMKZH0< [4G1 MSH#&<]@V/"3XV?@UOQIL^U28FL,94-KF=X-Q=Y8/6\]$HS3B@G^F@3)B&*%M MN ZC>._8O"6B\D0P';^:0EU37QDF?O)<2@"G8PGV!?!T0\WN]MDIRUKED^"/ M'*\B3^K!AIJ-[;LS%<"F^!F'0JV *,+1S!TA3S?K M,KSO+11$@O[Z+4L^27AU._S;;<>YOBV1\V/LAU*28N6R'/ANTXGNF>@OWX_HK8@Y>KK)1_''@5-7(U3.CF"*G.!UA5PI;W_"VKN28Y.UII'16XD M\)[O$4Q[J9V)"RU'>O2B')/P3K&N.9-$+))C@G":U*8F-#H(9B"^P0EE%&%X M5=CLK,2]TO/I4Z!.O5AZ2HY)#)(8UM8L(QJ.2,*1K8OD$-C ^E)SL8?D0XZE M:X!!4]CAL9K5TE.P;;;?XB/SV[GUF'W*B+ZSP/ M(QMQD#5V_N$V;VSY[F$'N M#BT?JDHYVZFKT*@7_7[#Y>I3-FN/;XS;)M);B\E2Z,U:N#$[QQYQ1I:_9B-= M_')R/9G!*INNU]M7RRH9F83 DL7'ES%4LSKZ4C2?<>&6/*".,&DZO6K0_R). MC>I/7%U_SOGW?O*Z//%K"]YGK-'N^?SCM3/.%;R6YV$W1N.FO]K0OGF_V+UO M;)J"YEB4[4_-"_!]&B9L;#\U2AH,&=577EDHOR]HJ/38U637.3FRK5_,?9E* M](B6&*THT#0X%IRZ1'&!Z$B]=RVB=N;G@;F)Q@,_N ^8L-%?#YHEWM1R[FA$>8%IX MNJ\*B1#NBDS^<$TK\9/LJZ4?H:^AN48.>:O3P*\#(:8VQ.2 M;%]#&K>_TEFZ28Z!3@-U5OQ<:1*O(C$Y?/<82WEC6;F$7O"H(,GA?%B$MZP: MB2.]HAV38];\_#;! E/1Z?45Z#LT02D'\CC&6D'YQ_KZ)!T]K92R[Z. .<"6 MGC<$NJJ*D_^(&/L(]YX,2'#J.&=O%U@!\SSURS/=!F\6NY+*GW-%4Z7;2 M60X*["U6=( GQZBD+2DRYL+3.@G@]:FBR4%20P=8]U63X8XQ.2;0-W2.,C@6Q&V?1\=VR%!*Y(GCT"]=P'1$1JV28S)N2-_VG(?#O+EM9_OU[73.-0?/S7E7!_.@HB0H=2 VX>;70^Q8H$W(7),9;7?6]W8T""E M7>GNG9*:O=S>GWOL\+.,\L?W>P5OY)@. (4"2ZQ4DR>:1P=T"62"91"#*[/3 MEV.RID^B-_*O%)T6SYQ!%@)###D&?TB.^:)$#_99(-6=#;-EJ<$I;A5(;8?4 M1JSFW9!!$K/%>:_:9S8*7K.ID4@,!7P(%\@QQI35P1E-)9UT#>9J?TVMWU%I MO"E70&PZ\@X,2B )-AHB.PKEF&;KQ6:TJ =_$>[+,P%#6#)E> -\!%-I*D5>Q6/5L>H&S"GUI&YP>+41.C*/$#U6KU M!I>8/97B*OA5(D[E56';( &XYB"3X#RF)=UQPQ612U< MLJM3XN79%&\J))QX22J'4(N JC?W"%YA1!HC+ 6$X ]@:"Z "*LVFJ'_#@C. M!KR AL-ATPM8H.[8Q "B_O-)A-3H>.L)V#;?STR.&0@7+P1)4R38UZ.HA55* MT&R C5OY=02^R.O-)\.*NV2LV6=)-767'.$8YE(&D =>1I2L-Y[^ MB0W4,TXA[Q<94ST151?T%3\C40#YDTU?1WBC[=V-<3+EJ%#@$]#[N?9$O?RDC[33F2=S A4EFHV-973-W3T"LEU^!7- M@F-'R[NP,:9J]-;Z_52,VHGETX2 Q[IO3M8>[!@83FH=5=J#)G5#NE# M(S%ENE%!/$_#3A.9EU77U!,V4B>Z M0:OGS;F%4/8G@I5@1;8A[]SK/M?O/][X9Z=\KY&83+>,+[#*8,=&EY[P?T1[ MI;TZKZ6)8Z6EGC\'KY3W?[(C=]EGCSL]((O53NM&'OAI]_GZKS%6P.YO*S4J MMBNW??.ZHX^.I6\1"(_8X>28)97IB^#:IG@/F]>B,:\@&6N5I=>S9M:B>ART MS0=^V]O\]X/M#Z__[^=8&_5__C\/I;4*_T_/I4%\E)N3_L2D)*(W'5?]CO4" MR,)@#YM/U1XT.:7@_CAC?V!.34E7T.0*V&PI=K+3^_KA]UN.I[#$28K-LZ8] MZ"E;Q8&H"+(DHAK^9@UZVN]ZN+[*)MF*A5SD#QB%Q;_#.O\_/^J@Q,@%#4'6 M&3GFO9TR>IQIA_WA=:Z!Z0$O"EY%%.,-E:?,TG'0_'4; _,F1<6LJ9X*GVSN]]2WOGKD@*+!@<$[O[_L")H<]$+BHAQ05*>A MV?.CQ5A>UDIOB=G9_^U:%"P:7'>9_W\<5NR[$%#^9.U;WY^!WMKOWKW]\6OR MKH+A]ZGWBE#3TO*\K#\2M_V/GY5&C?T4,?9[ MYYU3[:?UPRO?;EBJK2&-@ N$0?73<41-B-$HQZR7;H$!%)50EJ6]!TRW!DF, MV2?*/!:8"&>?[>4*=/_3$B%2B)5^S&UPATL:M:7^DB/L6A:\PVPR!PST 33 M4P:08>WB<_%84_#KA#-%*PL."@G+R>\R!>:UI.=%02JC?EKUW\.F)W/T=YD# MJDJ;O_W1I0 _ LV&68U/< )@DE] *=B+:_1-#YHM/ MYC8 'RIDT9 7:XDLY7T07,$>IN"E7S5CP&W?U[N1QS3__9TCR-BM7 &^VKG#72 M))JN+!/PH0QCB]D*0I\#5'JPVO6@T#T M3T*P\(FA)1AUEY$UVDORZBC5,^(M;#7Y@.:#09>3/RY\<;8Z<^*FF_9Q7-,8K34.+$R8I)\WR[O(8#Q_HVEP4N&&WAYWZ-&GCEM?W#S&BD MV!QY4N4HM_;R@Q3;_EEE_'(#S6OT:58_KY@@H&?0_R&:>'Z,!,%W H6L#7H>$A>O)+ M:E*#$S< _2:W_,%B,UQW[U10O#1+ 1_C8RXR8"K_ M,#"[/[K89\B@8ZHL8.7/H3G;=[AWF1LP31CFB079M97FN&;\I+'$F4IL'68R M.&H%-.M>HC'U=O\X40U.AD1UX9Y[H2:45*)A*,Q!\?85(-#O*1$J/H5WRT@" M#53JN@?!9QUEJO2/Z,2C[1/B55WA310-.*8^D]C^LQ8RC#>U4W;L8":$)7N? M0*/F?MC&9 T"27#3Y$]5ZH$$R#FV:VUW]R>4C3H*@ZP_2GO<>\HFV8&]0XWN M'6^2OU]ZTYMZ:/]85#DQ#_'SR9(+#VT!OXLPTE_/">U*-?:Z7X"C79KO0/C7L/ M[UQYXQ=UW9)08LWCZVP>#C963BP[2%HB50:!V$#:J4P\I(Q*E!"K3H)&>/Z8 MY\:NGZ%.G29)K7#&V6_%B29X]?'HYOF3+T,Q>^XX?X:<(A(^O%EQ_5(L\^#M MP.R *W\[%RV,%2_\NQ"X[$.O.F1-N?^1_D7[[ZY+#L]7N[>4SQS_V%S]R.,* M\Q5!3W**SN,O072I%P;08$_@Z U/*_F9N<:Q!$PEV*#NQFA-58_%> TE>N:0 MFO1(9D!%6L>;J.NQ37U#JE K@Q/UC%=,]3^3Y-#I^D/,FUKU S\SM6,L;9R? MZK[*TOM!EM'ZQ[V0J<@HB:Q-N]A!,#K_%W.63(D-Q-L"J@ M[89VW1?AU:C3A]M*6]5+_X&!8NEID!M/^TM*'0XDJTW]Y7WD!W!\,3F[=")K M+U=Y+[TOB]5C)M[6B7U7([G@1S?4V94@*V+WURRW(-:L?-QNF ^\>]+TZXL* M1-HK/"%13K]P=;F-7FK^]H+^O;$5'OI,ZY0;;C8ALUQUCLZGM_BXU]I#NF8+ M7:)'UBL?!9/3G(XU-%FG'"OC[NCV> Z3!VS(< *H.=U$64W70UJ(&V59)GI! M4_Q5H5[#:EJV-5 %C[G>]X#^AAW\7V;E"<)-*SG.O+=7PYB:FJ?TEDNMRF%E MR!M1T98*-S&\YNXNH3@@LGAM:#YI -@^ MX*I/H#*1 M[$_YM6^DKI(L-1A:#3'^I)D)-E+Z3QWX48.';21!],\L7:(1=628Q6,FI-T8 MJ0]2L#/O"8V8,AU8$VJ\SF4X3.<:-A49A[7D:1:!*^D.J#;N)V/$Z%773BM2YQO[8H=PBZHV]IG;7 MT:RYX!ME6#O]:]BGHYE-BD_HY^/CWBQUB:$?IJV#LR7^TD,='%7\;2(!KN*Q M5F1!/Y\*^J9)KYV;#!U &W%ZPEK?2L^4(N9J*F!%5#M2050#]ZM0@WSGKQE- MHZ)B1W@^%D:4#$<)2A1,=2 M5E%BZT'S__XF]GJ>BB875]JJX'^=I1X6M(RJU<0OG4ZBD8*%A\R0M3;)Q40# M_ZEA_RKUK!A1@+(C:.^(?&VC7>2#]V :]3T[$?OGVO6]4!,NV#H"J1;F"X)3 MKXV?U?Y3,RG=V(I:M+I],,2\SS^TN! (@BF\ [J@2,T6%\V[[!BBY&#ZX_%Y MJGG!MN;6H=.);QX$>%C]*O !*, ;4A+!123'1'MJ0F9W3",X-@5^.HR$J>'> MZ= $J\RL^JYKX6X*'O,-2TWQ]>%8=6=<7#GL?5;K@<&I7].OR;'6)! IZ#Y M0V0=$7)[6DF.&=\P*]N%M&3\W=_['HAUK>^W8S)^AI&5J-[V[]I-J@^55AGO MFUHX_<'8V*0PYGE];.*F6_NCO\?<;_IMA>JYRR)Q%U0A2T!4Y9BN(Q,2?NV! MXQ%WW;8W?[G6G/+WX/3V8_8I@7/AX>,_@0SNT-J^HNIC6H:+[S.;$D6 M3AD(=2^2XV7\OJDP)GRT<%)Z:9BO/IY-W ORI0:#7&&8'+.6'1]&'V&MO/Z# M4R6H>22PLVU(T]3?O1]52'+,I2Z2Z#=*1&^'',>1V72EZSJD6W0]?YVH6!@Z MU4XJ6_D4842(\$M%1[I(%2AG L4Q0KQD/<*%;,_121WP79; ^U>@?K_G8#BJ MS]]+EUG'@(W^E%6UY_<_#0%R)BP L9FXZ0Y'6]#B]/LD4MLJQN(@LAS3AJIH M#88V+MG'Q8>T_')%N81>$1P2D#-(S9YR3DMW79GZI#687[%8!2ST5-M4VN#3E,,!S7* M:AQY7H=S" DY*Z;KPE[8@[KKT@ 2B>%&N41$27'R"HR)'44->F>SK )536C>D9#3Z^.6;U" MH:S$I8UV($?-T@8,DAK0]>681 9*]9ZV-GCJ0]AX@B%K/I5V3+#KX&D_3UW8 M5O8:R/%U'7J:[^;6/ZZU8"J ]&.\DP]UC3B^BD@LW],CAD%_#IF@Z:F+.LSYA)(@L7N[I&2-152!S[X#U"' M8X$'>UEJB$;?X%G+$)$D\GZP?Q[E?[4(2@SC[M+^8Q#X*/#3$YR+/V0^TV+3 M@V,-HA1HGLT!G'XA7'#C0E,+7/!&E34WC ']6>W$3:UVE#3"O$>F8_FPR_6N0OR:@5#:VDX1Z_;4Q MMY18&^:;/>AC85^RN$;0Z((,+=J=!>?0+ N"Y9C3_[8$(YM!_DV20(L+;4W( M\\/YHC&WH"R-"]5S/MX;IN;5Z+EET? X",V+]7^C0S%ZCOXXLB!Q9,%_(GJ6 MN6Z45F%QC2+25UE2 MV-D6,,R&*L-(';B:S!!L%_1:J,"4!R:-9X+BEW:YP,PC-=U!IMCY]+#%5_\-$,/JD-9J,DB8GO"GXX'Q@:DPBEM. M8$5'KRXJZF_D)DN, MIQH@WJSYAX?>_OL&CAR&:2Z%5.=Z^H&*S@ :J1#VY)WM4>J)N0L('T%8-#^B M; 15*%^#_[,&Z2:<=J=THUQJ'#>%G22O]DLG]=$7WQ[Z,OY;@EX"&'=#?S$! M+L@QGT/^TY R?G9Q%S)R;+3 L13AFS]C-P?O$%I*P73'1L/W,6%T4MLX /1(I$C8K..W)_ M0T@F =+D"G#*$_H;VPA*0F:BQ<\G?G;L6S1<^/ 4OO[&PL->&>X8$*^_'6QE MJ-_]H2R)K.^_%M#Z1?4<0,1UJ_?=P'\8)[8*R0NJHWSXY#A7VF4O!M110*18 MHW8,=Y1C?CRK,9&Q2%>2#XK8=5@M:407?:W4!M8#J^H6O!/+4H3,A'0Y1G4Z MJ[<4^,//<$QK>56-)#5J&B\Z\@U1M&CMO/8W^#%^2!+I2VX @ MJ35L "6)HV!*'LVBJ\:82A&9-422E_Y+,ZF$(W/N1\KR18"Z3Z81I"/=TJL< M.VN'KU<^#!=F:EZVIR\=N<,H8Q2*>]NMQJ?@B0[9">)K1N<0/THK18XY)*W: M-S5M6,^=T6CG@H^[N//Y63RAO1RSQT,+ G\\)\WYL%OEF"0 /,WO:Q4PXF98 M.CX6CUGKI#@VS02&H+V=]3@54]8R:LIQB=GD-P+*CY;7Q' E88YEKVC!.0KK M#AQ^^D:UT?DM/"?QEEK(,FOP]!9@.D$;7 ME"GY#_C:9VK7$Y=E.B@(24,$U0K:A-IWS^^,7*98Q=1+:B9H+7TN6R=G/;HK MPLL3^L6XGMV]@Z&CZ?[5D6L@9D- P�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�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lj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�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end

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

  •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�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�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